<SEC-DOCUMENT>0001274737-25-000019.txt : 20250311
<SEC-HEADER>0001274737-25-000019.hdr.sgml : 20250311
<ACCEPTANCE-DATETIME>20250311092138
ACCESSION NUMBER:		0001274737-25-000019
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		90
CONFORMED PERIOD OF REPORT:	20241231
FILED AS OF DATE:		20250311
DATE AS OF CHANGE:		20250311

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			EXAGEN INC.
		CENTRAL INDEX KEY:			0001274737
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MEDICAL LABORATORIES [8071]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39049
		FILM NUMBER:		25726047

	BUSINESS ADDRESS:	
		STREET 1:		1261 LIBERTY WAY
		CITY:			VISTA
		STATE:			CA
		ZIP:			92081
		BUSINESS PHONE:		(760) 560-1501

	MAIL ADDRESS:	
		STREET 1:		1261 LIBERTY WAY
		CITY:			VISTA
		STATE:			CA
		ZIP:			92081

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EXAGEN DIAGNOSTICS INC
		DATE OF NAME CHANGE:	20031230
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>exdx-20241231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:7095620a-7684-4e36-937b-24fd606ed1ea,g:3f375e3f-dda6-40cc-be01-a2493780a401,d:9ecffbbbc3a143a09815a7575cabd836-->
<html xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns="http://www.w3.org/1999/xhtml" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:cyd="http://xbrl.sec.gov/cyd/2024" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:srt="http://fasb.org/srt/2024" xmlns:exdx="http://www.exagen.com/20241231" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>exdx-20241231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalYearFocus" id="f-32">2024</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalPeriodFocus" id="f-33">FY</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-34">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-35">0001274737</ix:nonNumeric><ix:nonNumeric contextRef="c-47" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="f-296">P3Y</ix:nonNumeric><ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="f-334">one</ix:nonFraction><ix:nonFraction unitRef="unit" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfReportingUnits" format="ixt-sec:numwordsen" scale="0" id="f-335">one</ix:nonFraction><ix:nonNumeric contextRef="c-47" name="us-gaap:LesseeFinanceLeaseTermOfContract1" id="f-420">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="c-5" name="us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="f-425">http://fasb.org/us-gaap/2024#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</ix:nonNumeric><ix:nonNumeric contextRef="c-6" name="us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="f-426">http://fasb.org/us-gaap/2024#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</ix:nonNumeric><ix:nonNumeric contextRef="c-5" name="us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="f-431">http://fasb.org/us-gaap/2024#AccruedLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-6" name="us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="f-432">http://fasb.org/us-gaap/2024#AccruedLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-5" name="us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="f-437">http://fasb.org/us-gaap/2024#OperatingLeaseLiabilityNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-6" name="us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="f-438">http://fasb.org/us-gaap/2024#OperatingLeaseLiabilityNoncurrent</ix:nonNumeric><ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfOperatingSegments" scale="0" id="f-729">1</ix:nonFraction></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="exdx-20241231.xsd"/></ix:references><ix:resources><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="installment"><xbrli:measure>exdx:installment</xbrli:measure></xbrli:unit><xbrli:unit id="segment"><xbrli:measure>exdx:segment</xbrli:measure></xbrli:unit><xbrli:unit id="unit"><xbrli:measure>exdx:unit</xbrli:measure></xbrli:unit><xbrli:unit id="supplier"><xbrli:measure>exdx:supplier</xbrli:measure></xbrli:unit><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-03-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:MedicareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:MedicareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:MedicareAdvantageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:MedicareAdvantageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:UnitedHealthcareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:MedicareAdvantageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:MedicareAdvantageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:MedicareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:MedicareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exdx:AVISECTDTestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exdx:AVISECTDTestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">exdx:SupplierOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">exdx:SupplierTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">exdx:SupplierOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">exdx:SupplierTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:CommercialMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:CommercialMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:Government1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:Government1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:ClientMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:ClientMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">us-gaap:OtherCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">us-gaap:OtherCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ShippingAndHandlingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ShippingAndHandlingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exdx:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exdx:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exdx:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exdx:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-10-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:AmendedLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-09-01</xbrli:startDate><xbrli:endDate>2017-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:AmendedLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:AmendedLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-28</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:AmendedLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:AmendedLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:AmendedLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:AmendedLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:PaymentInKindPIKNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:AmendedLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:PaymentInKindPIKNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:AmendedLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:PaymentInKindPIKNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:Term2017Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:EquipmentNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:EquipmentNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:EquipmentNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:EquipmentNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">exdx:OfficeAndLaboratoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">exdx:OfficeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">exdx:OfficeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-08-01</xbrli:startDate><xbrli:endDate>2024-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">exdx:AlleghenyHealthNetworkResearchInstituteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exdx:AHNCollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exdx:AHNCollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">exdx:USDepartmentOfJusticeCaseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:AmendedLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:A2017TermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-100"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">exdx:ShelfRegistrationStatementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-11-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">exdx:ShelfRegistrationStatementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">exdx:CowenEquityDistributionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-15</xbrli:startDate><xbrli:endDate>2022-09-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">exdx:ExpirationJan192026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">exdx:ExpirationMar312026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">exdx:ExpirationApr12026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">exdx:ExpirationDec72025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">exdx:NoExpirationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">exdx:IncentiveAwardPlan2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">exdx:IncentiveAwardPlan2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">exdx:CommonSharesAvailableForGrantUnderThe2019PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">exdx:IncentiveAwardPlan2019Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-124"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-132"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">exdx:TaxYearsThroughDecember312017Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-133"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">exdx:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-134"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">exdx:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-135"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">exdx:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-136"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">exdx:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i9ecffbbbc3a143a09815a7575cabd836_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:16pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:16pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:16pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">10-K</ix:nonNumeric></span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">(Mark One) </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"/><td style="width:2.917%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.883%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentAnnualReport" format="ixt:fixed-true" id="f-2">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">For the fiscal year ended <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-4"><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="f-3">December 31</ix:nonNumeric>, 2024</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="f-5">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the transition period from     to     .</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Commission File Number: </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-6">001-39049</ix:nonNumeric></span></div><div style="text-align:center"><img src="exdx-20241231_g1.jpg" alt="Image_0.jpg" style="height:56px;margin-bottom:5pt;vertical-align:text-bottom;width:153px"/></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:22pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-7">EXAGEN INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.719%"><tr><td style="width:0.1%"/><td style="width:1.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.066%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.066%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.733%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.066%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.737%"/><td style="width:0.1%"/></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-8">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-9">20-0434866</ix:nonNumeric></span></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(I.R.S. Employer<br/>Identification No.)</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-10">1261 Liberty Way</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-11">Vista</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-12">California</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-13">92081</ix:nonNumeric></span></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Address of Principal Executive Offices)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Zip Code)</span></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:39.766%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-14">(760)</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-15">560-1501</ix:nonNumeric></span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Registrant's Telephone Number, Including Area Code)</span></td></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.999%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:36.329%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-16">Common Stock, par value $0.001 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-17">XGN</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-18">The Nasdaq Global Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(g) of the Act: None</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes &#9744; <ix:nonNumeric contextRef="c-1" name="dei:EntityWellKnownSeasonedIssuer" id="f-19">No</ix:nonNumeric> &#9746;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes &#9744; <ix:nonNumeric contextRef="c-1" name="dei:EntityVoluntaryFilers" id="f-20">No</ix:nonNumeric> &#9746;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="c-1" name="dei:EntityCurrentReportingStatus" id="f-21">Yes</ix:nonNumeric> &#9746; No &#9744; </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). <ix:nonNumeric contextRef="c-1" name="dei:EntityInteractiveDataCurrent" id="f-22">Yes</ix:nonNumeric> &#9746; No &#9744; </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">"emerging growth company" in Rule 12b-2 of the Securities Exchange Act of 1934. </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.959%"><tr><td style="width:1.0%"/><td style="width:20.521%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.521%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.962%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.973%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.523%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Large accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="f-23">Non-accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntitySmallBusiness" format="ixt:fixed-true" id="f-24">&#9746;</ix:nonNumeric></span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-25">&#9744;</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on the attestation to its management's assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:IcfrAuditorAttestationFlag" format="ixt:fixed-false" id="f-26">&#9744;</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentFinStmtErrorCorrectionFlag" format="ixt:fixed-false" id="f-27">&#9744;</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b).&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">No</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="c-1" name="dei:EntityShellCompany" format="ixt:fixed-false" id="f-28">&#9746;</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">As of June 30, 2024 (the last business day of the registrant's most recently completed second fiscal quarter), the aggregate market value of the registrant's common stock held by non-affiliates of the registrant was approximately $<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-5" name="dei:EntityPublicFloat" scale="6" id="f-29">27.0</ix:nonFraction> million, based on the closing price of the registrant's common stock on the Nasdaq Global Market of $1.82 per share.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total shares of common stock outstanding as of the close of business on March&#160;7, 2025 was <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-30">17,898,098</ix:nonFraction>.</span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">DOCUMENTS INCORPORATED BY REFERENCE</span></div><ix:nonNumeric contextRef="c-1" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="f-31" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Certain information required to be disclosed in Part III of this report is incorporated by reference from the registrant's definitive Proxy Statement for the 2025 Annual Meeting of Stockholders, which proxy statement will be filed not later than 120 days after the end of the fiscal year covered by this Form 10-K.</span></div></ix:nonNumeric><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i9ecffbbbc3a143a09815a7575cabd836_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:10.303%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:76.092%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.305%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Part I</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9ecffbbbc3a143a09815a7575cabd836_13">Business.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9ecffbbbc3a143a09815a7575cabd836_13">2</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9ecffbbbc3a143a09815a7575cabd836_16">Risk Factors.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9ecffbbbc3a143a09815a7575cabd836_16">32</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1B.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9ecffbbbc3a143a09815a7575cabd836_19">Unresolved Staff Comments.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9ecffbbbc3a143a09815a7575cabd836_19">67</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1C.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9ecffbbbc3a143a09815a7575cabd836_22">Cybersecurity.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9ecffbbbc3a143a09815a7575cabd836_22">67</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9ecffbbbc3a143a09815a7575cabd836_25">Properties.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9ecffbbbc3a143a09815a7575cabd836_25">70</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9ecffbbbc3a143a09815a7575cabd836_28">Legal Proceedings.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9ecffbbbc3a143a09815a7575cabd836_28">70</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9ecffbbbc3a143a09815a7575cabd836_31">Mine Safety Disclosures.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9ecffbbbc3a143a09815a7575cabd836_31">70</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Part II</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 5.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9ecffbbbc3a143a09815a7575cabd836_37">Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9ecffbbbc3a143a09815a7575cabd836_37">71</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 6.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9ecffbbbc3a143a09815a7575cabd836_40">[Reserved].</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9ecffbbbc3a143a09815a7575cabd836_40">71</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 7.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9ecffbbbc3a143a09815a7575cabd836_43">Management's Discussion and Analysis of Financial Condition and Results of Operations.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9ecffbbbc3a143a09815a7575cabd836_43">72</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 7A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9ecffbbbc3a143a09815a7575cabd836_58">Quantitative and Qualitative Disclosures About Market Risk.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9ecffbbbc3a143a09815a7575cabd836_58">81</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 8.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9ecffbbbc3a143a09815a7575cabd836_61">Financial Statements and Supplementary Data.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9ecffbbbc3a143a09815a7575cabd836_61">81</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 9.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9ecffbbbc3a143a09815a7575cabd836_64">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9ecffbbbc3a143a09815a7575cabd836_64">81</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 9A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9ecffbbbc3a143a09815a7575cabd836_67">Controls and Procedures.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9ecffbbbc3a143a09815a7575cabd836_67">81</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 9B.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9ecffbbbc3a143a09815a7575cabd836_70">Other Information.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9ecffbbbc3a143a09815a7575cabd836_70">83</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 9C.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9ecffbbbc3a143a09815a7575cabd836_73">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9ecffbbbc3a143a09815a7575cabd836_73">83</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Part III</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 10.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9ecffbbbc3a143a09815a7575cabd836_79">Directors, Executive Officers and Corporate Governance.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9ecffbbbc3a143a09815a7575cabd836_79">84</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 11.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9ecffbbbc3a143a09815a7575cabd836_82">Executive Compensation.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9ecffbbbc3a143a09815a7575cabd836_82">84</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 12.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9ecffbbbc3a143a09815a7575cabd836_85">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9ecffbbbc3a143a09815a7575cabd836_85">84</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 13.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9ecffbbbc3a143a09815a7575cabd836_88">Certain Relationships and Related Transactions, and Director Independence.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9ecffbbbc3a143a09815a7575cabd836_88">84</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 14.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9ecffbbbc3a143a09815a7575cabd836_91">Principal Accountant Fees and Services.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9ecffbbbc3a143a09815a7575cabd836_91">84</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Part IV</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 15.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9ecffbbbc3a143a09815a7575cabd836_97">Exhibits and Financial Statement Schedules.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9ecffbbbc3a143a09815a7575cabd836_97">85</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 16.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9ecffbbbc3a143a09815a7575cabd836_100">Form 10-K Summary.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9ecffbbbc3a143a09815a7575cabd836_100">85</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9ecffbbbc3a143a09815a7575cabd836_106">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9ecffbbbc3a143a09815a7575cabd836_106">90</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9ecffbbbc3a143a09815a7575cabd836_109">Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9ecffbbbc3a143a09815a7575cabd836_109">F-1</a></span></div></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:17pt;margin-top:17pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="i9ecffbbbc3a143a09815a7575cabd836_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Part I</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Forward-Looking Statements and Market Data</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">This Annual Report on Form 10-K (the Annual Report), contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the Exchange Act). All statements other than statements of historical facts contained in this Annual Report, including statements regarding our future results of operations and financial position, business strategy, current and future product offerings, reimbursement and coverage, the expected benefits from our commercial arrangements with third parties, research and development costs, timing and likelihood of success, plans and objectives of management for future operations, our studies or clinical validations being predictive of actual use, our pipeline and potential growth, and profitability are forward-looking statements.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In some cases, you can identify forward-looking statements by terms such as "believe," "may," "will," "should," "predict," "goal," "strategy," "aim," "potentially," "possible," "probable," "estimate," "continue," "anticipate," "intend," "could," "would," "project," "plan," "expect," "likely," "seek," and similar expressions that convey uncertainty of future events or outcomes, are intended to identify forward-looking statements.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The forward-looking statements in this Annual Report are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. These forward-looking statements speak only as of the date of this Annual Report and are subject to a number of risks, uncertainties and assumptions described under the sections &#8220;Risk Factors&#8221; and elsewhere in this Annual Report. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond our control, you should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in an evolving environment. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties. Except as required by applicable law, we undertake no obligation to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In this Annual Report, we use the metrics of Adjusted EBITDA, which is not calculated in accordance with generally accepted accounting principles in the United States and is a non-GAAP financial measure. Adjusted EBITDA excludes from net loss interest income (expense), depreciation and amortization expense, and stock-based compensation expense.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">This Annual Report also contains estimates and other statistical data made by independent parties and by us relating to market size and growth and other data about our industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. In addition, projections, assumptions and estimates of our future performance and the future performance of the markets in which we operate are necessarily subject to a high degree of uncertainty and risk.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We use our trademarks in this Annual Report as well as trademarks, tradenames and service marks that are the property of other organizations. Solely for convenience, certain trademarks and tradenames referred to in this Annual Report may appear without the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> and &#8482; symbols, but those references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or that the applicable owner will not assert its rights, to these trademarks and tradenames. </span></div><div style="margin-top:9pt;text-align:justify"><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="i9ecffbbbc3a143a09815a7575cabd836_13"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:21pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item 1. Business.</span></div><div style="margin-top:21pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Overview </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are a medical technology company primarily focused on the design, development and commercialization of a next-generation portfolio of innovative testing products under our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> brand, which allow for the differential diagnosis, prognosis and monitoring of complex rheumatic, autoimmune and autoimmune-related disease including, among others, systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). We believe our strong focus and extensive background in the field of rheumatology, combined with our commitment to exceptional customer service and support, position us well to respond to the needs of rheumatologists, primary care physicians, other specialists, and the patients they serve.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our tests are used in a variety of clinical settings to provide clarity in autoimmune disease decision-making with the goal of improving patients' clinical outcomes. We commercially launched our flagship testing product, AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD, in 2012. AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD enables differential diagnosis for patients presenting with symptoms indicative of a wide variety of connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. Traditional screening methods often lack accuracy, resulting in repeat testing and delayed diagnosis. With significant increases in autoimmune incidence in recent years, AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD provides unique biomarkers that empower clinicians to confidently and quickly diagnose various CTDs.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Since launching AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD, we have produced an extensive body of peer-reviewed literature supporting the test&#8217;s clinical validity and utility, demonstrating the importance of AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD in patient care.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Beginning in late 2022, w</span><span style="background-color:#ffffff;color:#080808;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">e revitalized our organization with the addition of key members to our senior leadership team, including our Chief Executive Officer, Chief Financial Officer, Vice President of Sales, Chief Medical Officer, and Medical and Laboratory Director.</span><span style="color:#080808;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">By leveraging our team&#8217;s extensive experience to create clinically distinct solutions that improve patient lives, we </span><span style="background-color:#ffffff;color:#080808;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">have created a strong foundation for growth and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">believe that we are well-positioned </span><span style="background-color:#ffffff;color:#080808;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">to positively impact patient care and address unmet clinical needs in autoimmune disease</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. We strive to become a partner of choice for doctors, hospitals, healthcare systems, and payors. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under the leadership of our Chief Executive Officer, John Aballi, who joined Exagen in October 2022, we have been executing an operational turnaround of the business, which has resulted in a return to revenue growth and gross margin expansion while significantly reducing operating expenses and cash burn. Comparing our financial results in fiscal 2024 to fiscal 2022, we have grown revenue by over 20%, expanded our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD trailing twelve-month average selling price by over 40%, improved gross margin by over 1,200 basis points, reduced operating expenses by over 30% and reduced net loss by nearly 70%. At the same time, we have nearly doubled our salesforce productivity and brought an intense focus to our Research and Development (R&amp;D) investments - resulting in a 45% reduction in related expenses and prioritization of near-term pipeline opportunities.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We believe we are well positioned to deliver revenue growth and positive Adjusted EBITDA in the near term.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Recent Developments </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In December 2024, we announced the completion of our 1,000,000</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">th</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD test, marking a significant milestone that underscores our dedication to supporting patients and clinicians managing CTDs and other rheumatic and autoimmune conditions.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In January 2025, we announced conditional approval by the New York State Department of Health (NYSDOH), and commercial launch, of our new SLE and RA biomarker assays on the AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD platform. Collectively, we believe these new biomarkers will further improve the clinical utility of AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD and provide clinicians with the information they need to definitively diagnose patients and shorten their autoimmune diagnostic journeys. We expect that the addition of these new biomarkers will lead to improvements in our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD average selling price, gross margin expansion and increased demand while positioning us for profitability.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Our Current Market </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our testing products allow for the differential diagnosis, prognosis and monitoring of complex autoimmune and autoimmune-related diseases, including SLE and RA. We leverage our sales channel to primarily target the approximately 6,000 rheumatologists across the United States to promote use of our product portfolio.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The National Institute of Environmental Health Sciences estimates that there are over 40 million patients in the United States with suspected cases of autoimmune diseases. Autoimmune diseases encompass a broad range of serious, chronic and debilitating conditions in which a person&#8217;s immune system creates antibodies that mistakenly </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">react against normal healthy tissues, causing inflammation and irreversible tissue damage. Detection of these antibodies through blood tests can help diagnose, prognose and monitor the course of autoimmune diseases. However, knowing when to test and which autoantibody to test for is challenging due to the vagueness of symptoms, unexplained flaring and remission of symptoms, and many conditions which can mimic autoimmune disease. Early and accurate diagnosis of the conditions causing these overlapping symptoms is critical, as an incorrect diagnosis can lead to toxicity from inappropriate medications, irreversible tissue damage and other comorbidities associated with uncontrolled disease. There is no known cause or cure for these chronic conditions and current treatment interventions are targeted at managing symptoms and limiting disease progression. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our flagship product, AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD, enables clinicians to more effectively diagnose complex autoimmune conditions such as lupus, rheumatoid arthritis, and Sj&#246;gren&#8217;s syndrome earlier and with greater accuracy, as compared to the current standard of care. Our laboratory specializes in the testing of rheumatic diseases, delivering precise and timely results through our full suite of AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">-branded tests for disease diagnosis, prognosis, and monitoring. With a focus on research, innovation, education, and patient-centered care, we are dedicated to addressing the ongoing challenges of autoimmune disease management. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Connective Tissue Diseases</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">CTDs are a sub-category of autoimmune diseases involving inflammation of the joints, tissues and internal organs. Persons with CTDs often present to their rheumatologist with complaints of joint pain, fatigue, unexplained fever, inflammation, rash, stiffness and muscle aches. These symptoms overlap among numerous CTDs, including SLE, one of the most severe CTDs, which historically has been difficult to rule out, as well as other autoimmune-related diseases and other disorders that mimic these diseases, such as fibromyalgia. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Systemic Lupus Erythematosus </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">SLE, the most common and severe form of lupus, is a chronic, inflammatory disorder that can damage any part of the body, including the skin, joints and internal organs. The blood of a person afflicted with SLE contains autoantibodies, which are the cause of the inflammation and organ damage and are one indicator of immune system abnormalities. SLE is characterized by a rise in symptoms and/or abnormal laboratory test results. SLE varies in severity, from mild cases to those in which significant, and potentially fatal, damage occurs to vital organs such as the brain, heart, kidneys and lungs. Detection of these autoantibodies can assist rheumatologists in the diagnosis of SLE. Diagnosis of SLE allows rheumatologists to initiate the most appropriate therapy to minimize irreversible organ damage and reduce morbidity and mortality. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Standard laboratory tests for diagnosing SLE include measuring immunological biomarkers, such as antinuclear antibody (ANA), anti-double stranded DNA (anti-dsDNA) and other autoantibody tests. ANA are a group of autoantibodies produced by a person&#8217;s immune system when it fails to adequately distinguish between self and non-self. The ANA test detects these autoantibodies in the blood and is a useful screening tool for SLE and other autoimmune and autoimmune-related diseases. The vast majority of SLE patients test positive for ANA. However, the high sensitivity of ANA for SLE is counterbalanced by somewhat poor specificity. According to a study published in 2022 by Dinse et al., which investigated the increasing prevalence of ANA in the United States using data from the National Health and Nutrition Examination Survey, approximately 0.7%&#8211;2.4% of individuals with a positive ANA test have SLE. This lack of specificity leads to many inappropriate non-autoimmune referrals to the rheumatologist from primary care physicians. For example, it has been reported that 30% of fibromyalgia patients may test positive for ANA, potentially generating as many as four million inappropriate rheumatology referrals. In addition, the Dinse et al. study reported the estimated prevalence of a positive ANA test in the normal, healthy, U.S. population to be 16.1% (approximately 41.5 million people), indicating a significant need for a highly specific test for this disease.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Anti-dsDNA are autoantibodies that target a person&#8217;s double-stranded DNA. The anti-dsDNA antibody test is a very specific test for SLE, as anti-dsDNA antibodies are rarely found in autoimmune diseases other than SLE. A strongly positive anti-dsDNA antibody test makes it very likely that a person has SLE, although if the test is negative it does not necessarily rule out SLE. Many people with SLE have a negative anti-dsDNA antibody test, reaffirming the need for an effective testing product which adds clarity to the rheumatologist&#8217;s clinical assessment.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Rheumatoid Arthritis </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">RA is a chronic, systemic autoimmune disease in which the immune system attacks the joints and can also affect other organ systems. The annual incidence and prevalence of RA in the United States is estimated to be approximately 135,000 and 2 million, respectively. Patients suffering from RA develop joint damage that is associated with painful inflammation and often progresses to irreversible damage of cartilage and bone, leading to significant disability and a reduction in quality of life and the ability to work. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Diagnosis of RA involves performing a complete medical history review with physical and/or radiographic examination of the number and distribution of swollen, tender and painful joints that have persisted for more than six weeks. Laboratory testing for rheumatoid factor (RF), anti-cyclic citrullinated peptide (CCP) antibodies and testing for general, nonspecific inflammation with erythrocyte sedimentation rate (ESR) and C-reactive protein tests are used to assist in the diagnosis. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Early diagnosis and effective treatment of RA is critically important to prevent erosive bone or joint damage and disability. In effect, rheumatologists are compelled to reach a definitive diagnosis quickly and administer effective treatment. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Our Strategy </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We address the unmet needs of those suffering from debilitating and chronic autoimmune disorders through aiding in differential diagnosis, prognosis and monitoring, to ultimately improve clinical outcomes for patients.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We aim to become the standard of care in autoimmune disease testing. The key tenets of our business strategy include:</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.46pt;text-decoration:underline">Expand adoption of our flagship product, AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;text-decoration:underline;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;text-decoration:underline"> CTD</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> We have demonstrated a solid track record of commercial growth of our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD test. We believe we are uniquely positioned to continue expanding our commercial presence within the autoimmune disease market by leveraging our specialized sales force and expansive network of relationships with rheumatologists across the United States. Using our specialty laboratory focused on rheumatology, we plan to build upon industry-leading quality, service and technology to support strong AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD adoption while continuing to expand and improve our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD offering, grow our ordering physician base, and enhance our average reimbursement rates. </span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.46pt;text-decoration:underline">Continue to develop innovative testing products, using clear criteria for R&amp;D projects and commercialization milestones</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We intend to leverage our protein and molecular assay development capabilities, bioinformatic team and proprietary technologies to pursue the development of additional testing products designed to have superior clinical utility for rheumatic conditions. We undertake research projects that have the potential for impactful results and address the top consumer needs in the rheumatology space. The research projects we support are those that we believe will have a competitive advantage (such as using proprietary technology), a pathway for reimbursement and an established evidence development plan with sufficient market size. Criteria for developing products that we ultimately commercialize include Medicare coverage (specific to patient population), proprietary value-based pricing, published clinical utility and a strategy for medical guideline inclusion.</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.46pt;text-decoration:underline">Deliver sustainable profitable growth</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We seek to establish a solid foundation for growth and path to sustained profitability through continued gross margin expansion and improved operating expense efficiencies through the implementation of certain internal initiatives, such as leveraging validation, utility and reimbursement-oriented clinical studies to facilitate payor coverage of our testing products. We center our efforts on long-term reimbursement and average sales price (ASP) growth. This strategy includes optimizing revenue cycle practices, focusing managed care efforts on medical policy expansion and continuing to educate insurance payors on the published, real-world evidence of the clinical utility of our testing products, demonstrating healthcare cost savings and reductions in time to diagnosis.</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We also seek to improve our per-test costs by focusing on profitable, core test offerings, minimizing fixed costs and overhead, and focusing our laboratory resources on AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD optimization. Additionally, we employ a streamlined salesforce covering territories which are designed to achieve the most efficient and effective reach and frequency for the promotion of AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD.</span></div><div><span><br/></span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Our Proprietary Technologies</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We believe the competitive advantage for our testing products is supported by two core proprietary technologies: our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus platform, which incorporate Cell-Bound Complement Activation Products (CB-CAPs) for diagnosing SLE and a set of three biomarkers, the t-cell based CB-CAP TC4d, along with two t-cell antibodies, TIgG, and TIgM (the T-Cell Biomarkers), all of which are incorporated into our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD product. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> Lupus </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.47pt;font-weight:400;line-height:115%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus platform, which we offer as a stand-alone test and as part of our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.47pt;font-weight:400;line-height:115%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD test platform, is a proprietary, patent-protected and clinically validated method to aid in the diagnosis of SLE that provides a significant improvement in sensitivity, relative to the current standard of care. The AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.47pt;font-weight:400;line-height:115%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus platform leverages CB-CAPs </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">technology, which determines the blood levels of complement activated proteins permanently deposited on hematopoietic cells. Rheumatologists measure components of the complement system, including serum levels of C3 and C4, to help diagnose SLE and monitor SLE disease activity. C3 and C4 are the most commonly determined complement proteins in the blood and the precursors to activation of complement proteins into biologically active breakdown products. However, there are limitations with measuring C3 and C4 blood levels as indicators of complement activation. For example, increased synthesis of C3 and C4 by the liver can offset increased C3 and C4 breakdown during activation of the complement cascade, resulting in no change in serum levels. While the limitations and drawbacks of measuring standard components of the complement system, such as C3 and C4, are well recognized by the medical community, these laboratory biomarkers are part of international guidelines for the classification of SLE.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We believe the availability of complement biomarkers combined with our proprietary algorithmic interpretations, as a support or replacement of standard C3 and C4 measures, is of great value for rheumatologists and their patients. CB-CAPs technology directly measures protein products of complement activation, such as C4d, the product of C4 activation. These complement activation products become stably attached to surfaces of circulating blood cells to become CB-CAPs. As such, the determination of CB-CAPs in the blood provides benefits when compared to the traditional complement measurement. These include the stable, accurate and unequivocal information of complement activation that enable consistent measurement and an improved ability to assess and monitor changes in biological activity related to activation of the complement system. In a clinical validation study published in 2014 by Chaim Putterman, et al. (the 2014 Study), EC4d and BC4d showed 22% higher sensitivity (66%) than C3 and C4 (44%) in diagnosing SLE, with specificity fixed at 91%.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our proprietary AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus platform integrates EC4d and BC4d with eight autoantibodies to yield a quantitative and qualitative assessment of SLE risk. The AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus platform was designed to improve upon the diagnostic sensitivity of conventional biomarkers used to diagnose SLE while maintaining a high degree of specificity. In the 2014 Study, the AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus platform demonstrated 80% sensitivity for SLE (meaning eight out of ten diagnosed SLE patients tested positive) and 86% specificity for SLE (meaning 86% of non-SLE control subjects with other rheumatic conditions tested negative). A later study published in 2022 by Tyler O&#8217;Malley, et al., compared the clinical utility of the AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus platform to the conventional biomarker strategy in the diagnosis of SLE, demonstrating six-fold increased odds of SLE diagnosis and three-fold increased odds of treatment initiation with a positive AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus result. We believe this patent-protected platform gives us a significant advantage over our competitors.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our CB-CAPs technology for diagnosing SLE has patent protection through March 2034.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">T-Cell Biomarkers</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our collaborative efforts with the Allegheny Health Network Research Institute (AHN) have resulted in further development of the T-Cell Biomarkers, for which we obtained an exclusive, worldwide license from AHN in May 2021 and launched commercially in January 2025 as part of the AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD test. These biomarkers have been clinically validated, exhibit a high degree of specificity for lupus, are more sensitive for lupus compared to conventional biomarkers and serve as an enhancement to the AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus profile also included in the test. The TC4d test is patent protected through 2035, representing a proprietary expansion of CB-CAPs, involving a biochemical process wherein complement activation products are measured on T-cells.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Our Tests </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We offer 10 commercialized tests under our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> brand, offering next-generation insights to aid the diagnosis, prognosis and monitoring of autoimmune conditions. Our flagship product, AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD, represents approximately 90% of our current annual revenue.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> CTD (Including AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> Lupus)</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our flagship testing product, AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.47pt;font-weight:400;line-height:115%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD, is a comprehensive test that aids in distinguishing overlapping symptoms and the differential diagnosis of a wide variety of CTDs and other diseases in one convenient blood draw. These diseases include SLE, RA, Sj&#246;gren&#8217;s syndrome, APS, other autoimmune-related diseases and other disorders that mimic these diseases, such as fibromyalgia. These conditions are often challenging to diagnose as a result of overlapping symptoms. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Rheumatologists choose to order the comprehensive AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD test or the more focused AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus test based on medical necessity, which is determined by each patient&#8217;s symptoms and medical history. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD includes our proprietary AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.47pt;font-weight:400;line-height:115%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus platform, the cornerstone of the SLE assessment. AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus begins by quantifying the level of CB-CAPs biomarkers (EC4d and BC4d) in the patient&#8217;s blood. These biomarkers are elevated in patients with SLE compared to patients with other CTDs. Next, the AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">platform integrates these cell-bound complement products with 8 autoantibodies to yield a quantitative and qualitative assessment of SLE risk. In January 2025, we added three new unique T-Cell Biomarkers which provide enhanced sensitivity for SLE as compared to conventional SLE biomarkers and serve as a complement to the AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus profile. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In a recent scientific abstract presented at the 2024 American College of Rheumatology (ACR) annual meeting, the combined T-Cell Biomarker panel was shown to capture a unique subset of SLE subjects otherwise testing negative for all conventional SLE biomarkers and the CB-CAPs biomarkers (EC4d and BC4d) already included in the AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD test. The data, which showed that up to 50% of SLE subjects testing negative by conventional SLE biomarkers are identified as positive by one or more T-Cell Biomarker, has subsequently been published </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Frontiers in Immunology </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(February 26, 2025).</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In cases of early inflammatory arthritis, differential diagnosis is broad, including conditions like reactive arthritis, crystal arthropathy, spondyloarthropathy, and other systemic rheumatic diseases such as SLE and Sjogren&#8217;s syndrome, alongside RA. Approximately 70% of RA patients show serological evidence of RA, identified by key biomarkers: anti-CCP and RF. The remaining 30% of patients, despite lacking these serological markers, are clinically diagnosed with RA (the Seronegative RA Subgroup); this subgroup is referred to as &#8220;seronegative RA.&#8221; These seronegative RA patients often face delays in diagnosis due to the absence of serological evidence. In January 2025, we added three unique biomarkers specific to seronegative RA&#8212;Anti-RA33 IgA, Anti-RA33 IgG and Anti-RA33 IgM (the RA Sub-Profile Biomarkers)&#8212;that help bridge this diagnostic gap and enable AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD to correctly identify a greater proportion of the traditional Seronegative RA Subgroup, allowing for more timely and targeted treatment plans for these patients.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Other AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> Tests</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We offer the following additional tests under our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">brand.</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.666%"><tr><td style="width:1.0%"/><td style="width:22.663%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:63.014%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.023%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt;padding-left:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Test</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt;padding-left:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Test Description</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt;padding-left:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Type</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt;padding-left:4.5pt;padding-right:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"> APS</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt;padding-left:4.5pt;padding-right:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"> APS aids in both the diagnosis and management of APS, a hyper-coagulation state leading to thrombosis, pregnancy complications and even death. Rheumatologists would typically request the AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"> APS test in patients who initially tested positive for one or more APS biomarkers contained in AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"> CTD, or in the management of patients experiencing a high-risk pregnancy.</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt;padding-left:4.5pt;padding-right:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Diagnostic</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt;padding-left:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"> Vasculitis AAV</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt;padding-left:4.5pt;padding-right:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"> Vasculitis AAV utilizes a testing panel of individual analytes designed to provide physicians with rapid and reliable results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis (AAV). AAV is a group of autoimmune diseases characterized by vascular inflammation and damage. Early signs and symptoms vary greatly and are not always indicative of the severity of the disease. Rapid and accurate testing is essential to prevent death and long-term disability.</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt;padding-left:4.5pt;padding-right:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Diagnostic</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt;padding-left:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"> Anti-Histone</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"> Anti-Histone is a test for autoantibodies to histone proteins commonly found in drug induced lupus and SLE patients.</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt;padding-left:4.5pt;padding-right:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Diagnostic</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt;padding-left:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"> SLE Prognostic</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt;padding-left:4.5pt;padding-right:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"> SLE Prognostic is a panel of autoantibodies that have established predictive value for assessing the potential for complications affecting the kidney, brain and cardiovascular system, including lupus nephritis, lupus psychosis, strokes and heart attacks related to lupus. Rheumatologists rely on insights from the AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"> SLE Prognostic test to help tailor their treatment approach.</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt;padding-left:4.5pt;padding-right:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Prognostic</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt;padding-left:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"> Anti-CarP</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt;padding-left:4.5pt;padding-right:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"> Anti-CarP, is a biomarker-driven RA prognostic test, offered through a distribution agreement with Werfen USA, LLC to help identify RA patients with an increased risk for joint damage.</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt;padding-left:4.5pt;padding-right:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Prognostic</span></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt;padding-left:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"> SLE Monitor</span></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt;padding-left:4.5pt;padding-right:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"> SLE Monitor is a blood test that employs CB-CAPs technology and is intended to assess the condition of a patient that has been diagnosed with SLE. AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"> SLE Monitor offers additional insight into a patient&#8217;s disease activity as well as possible adverse events. AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"> SLE Monitor may be utilized by patients multiple times a year and throughout their lives.</span></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt;padding-left:4.5pt;padding-right:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Monitoring</span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.666%"><tr><td style="width:1.0%"/><td style="width:22.663%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:63.014%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.023%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt;padding-left:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"> MTX</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt;padding-left:4.5pt;padding-right:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">MTX is a patented and validated blood test that precisely measures blood levels of methotrexate polyglutamates (MTXPG), the active metabolite of methotrexate linked to disease control in RA patients. Methotrexate is the most widely prescribed drug by rheumatologists in the treatment of RA. Measuring MTXPGs allows rheumatologists to identify patients presenting with inadequate exposure to methotrexate, enabling them to optimize dosing and achieve therapeutic levels commensurate with adequate disease control.</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt;padding-left:4.5pt;padding-right:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Monitoring</span></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt;padding-left:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"> HCQ</span></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt;padding-left:4.5pt;padding-right:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"> HCQ is a blood test designed to help rheumatologists objectively monitor levels of hydroxychloroquine (HCQ), in whole blood as they treat patients with SLE and other CTDs, including RA. HCQ is typically prescribed to patients to control SLE disease activity and prevent flares.</span></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt;padding-left:4.5pt;padding-right:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Monitoring</span></div></td></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Test Reports</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> portfolio of testing products deliver meaningful insights to healthcare providers around the diagnosis, prognosis, and monitoring of CTDs. Our flagship product, AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD, delivers a comprehensive assessment of CTDs via some of the most specific and sensitive biomarkers in the industry. This information is delivered within an easy-to-understand test report, typically provided to rheumatologists within five business days of specimen receipt. As shown below, AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD displays a graphical representation of the AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus index results, along with an accompanying interpretation describing the likelihood of the presence of lupus. Subsequent pages contain results for other biomarkers spanning across a broad number of disease states, conveniently grouped to assist providers in making confident, accurate and timely treatment decisions. The AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD test report facilitates discussion of results with patients due to its intuitive structure and content. A sample of the full AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD report is shown below:</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">CTD Report</span></div><div style="margin-top:9pt;text-align:center"><img src="exdx-20241231_g2.jpg" alt="CTD Report Screenshot 1v1.1.jpg" style="height:834px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"/></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-align:center"><img src="exdx-20241231_g3.jpg" alt="CTD Report Screenshot 2v1.jpg" style="height:839px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"/></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-align:center"><img src="exdx-20241231_g4.jpg" alt="CTD Report Screenshot 3v1.jpg" style="height:839px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"/></div><div style="margin-top:9pt;text-align:center"><span><br/></span></div><div style="margin-top:9pt;text-align:center"><span><br/></span></div><div style="margin-top:9pt;text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Our Pipeline and Growth Opportunities</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We regularly confer with national experts in the clinical management of rheumatic autoimmune diseases to help guide the organization&#8217;s leadership team on the design and execution of research projects, as well as weigh-in on known and anticipated advances in technologies affecting clinical management of rheumatic and other autoimmune diseases. We believe there is significant potential to capitalize on our proprietary technologies by integrating with commercially validated biomarkers to develop testing products with superior clinical utility, on our own or through collaboration with partners.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have prioritized the following pipeline opportunities:</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">PAD4 Biomarkers</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Citrullination is a post-translation modification in which the amino acid arginine is converted to citrulline, altering protein structure and increasing the potential for autoimmunity. This process is central to the pathogenesis of RA, where an aberrant immune response against citrullinated proteins contributes to chronic inflammation and joint damage. Peptidyl arginine deiminase 4 (PAD4) is a key enzyme in this process, and autoantibodies targeting PAD4 (anti-PAD4 IgG and IgA) have been increasingly recognized for their potential clinical relevance in RA.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">While anti-citrullinated protein antibodies (ACPA) and RF are the primary serologic markers for RA, a subset of patients classified as seronegative RA lack these conventional biomarkers, reflecting an unmet need for a test that captures the Seronegative RA Subgroup. Emerging evidence suggests that anti-PAD4 antibodies may serve as novel diagnostic biomarkers for RA, particularly in these unique seronegative cases. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Beyond the potential diagnostic utility, anti-PAD4 autoantibodies have been associated with more severe disease phenotypes, including greater joint erosion and extra-articular involvement, further underscoring their relevance in RA pathogenesis. Ongoing research aims to better define their role in early detection, disease activity stratification, and prognosis, particularly in distinguishing RA from other autoimmune and inflammatory arthritides.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">SLE Disease Activity</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are leveraging clinical and laboratory data collected across multiple longitudinal SLE cohorts to identify a set of biomarkers that can inform an AI-developed algorithm aimed at guiding ongoing treatment decisions throughout the course of a lupus patient&#8217;s journey.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">SLE is characterized by a chronic, systemic inflammatory burden, and disease progression is defined by the accumulation of irreversible organ damage typically resulting from chronic inflammation and/or chronic corticosteroid use. Among the challenges for rheumatologists responsible for the care of lupus patients is the unpredictability of the disease course defined by periods of waxing and waning episodes of inflammation. The unpredictable nature of SLE and the lack of reliable conventional biomarkers indicative of present and near-term disease activity results in a significant unmet need for a surrogate method to monitor disease activity. Our goal is to leverage clinical and laboratory data collected across multiple longitudinal SLE cohorts to identify a set of biomarkers that can inform an AI-developed algorithm aimed at guiding ongoing treatment decisions throughout the course of a lupus patient&#8217;s journey.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">RA Disease Activity</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are leveraging our extensive biorepository containing clinically annotated serum collected from RA patients to screen for a host of protein antibody markers in an effort to develop an algorithmic solution that accurately predicts RA disease activity in a manner that outperforms conventional RA biomarkers.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">RA is a chronic inflammatory disorder typically affecting multiple peripheral joints in a symmetrical pattern leading to progressive changes in bone and cartilage that causes pain, swelling, and eventually loss of joint function. RA is thought to affect 1% of the general population and is typically diagnosed in a person&#8217;s 40s and 50s. The management of RA involves routine follow up visits where physical signs and symptoms are evaluated and typically inflammatory biomarkers (C-reactive protein or erythrocyte sedimentation rate) are performed as a general indicator of inflammatory load. The conventional approach to inflammatory assessment is non-specific and therefore suffers from both a lack of sensitivity and specificity which limits their utility for gauging actively treatable inflammation or assessing treatment response. Accordingly, there is an unmet need for an objective surrogate of on-target RA disease activity that can be used to inform clinical decision-making in the form of treatment escalation or escalation based on risk of disease activity assessed at regular intervals.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Lupus Nephritis Biomarkers</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are leveraging our intellectual property licensed from Johns Hopkins University (JHU) to develop a test for detecting protein analytes in urine that can aid rheumatologists in the ongoing management and risk stratification of patients suffering from Lupus Nephritis (LN).</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">LN is an autoimmune disease and a frequent complication in people who have SLE. It causes the immune system to produce proteins called autoantibodies that attack the body's own tissues and organs, including the kidneys. If left untreated, LN can lead to significant health problems, permanent kidney damage and even death. Early diagnosis and treatment are key to managing LN and to preventing it from escalating. Although early onset of LN is not typically noticeable by patients, nearly 40% of SLE patients go on to develop LN. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Currently, urinary protein to creatine ratio measurement is the standard means of assessing kidney involvement. However, it is not necessarily indicative of kidney prognosis or treatment response. At the 2024 ACR annual meeting, data was presented by our academic collaborators at JHU demonstrating meaningful progress towards the development of a non-invasive urinary protein biomarker panel. In advance of the 2024 ACR annual meeting a provisional patent application was filed to patent methods of using a multitude of urinary protein biomarkers to predict LN treatment response at 12 months post-treatment, inflammatory kidney activity, kidney damage, and long-term kidney function.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Kidney Damage Biomarkers </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The kidneys are affected in up to 40% of SLE patients. Nephritis is a major contributor to SLE morbidity and prevention and minimization of kidney damage is one of the most important goals of early anti-inflammatory therapy in these patients. Current methods for assessment of kidney involvement/damage are limited to serum creatinine, its derivative, estimated GRF (eGFR), measurement of the protein to creatinine ratio in urine (UPCR) and histologic examination of kidney biopsies. eGFR is insensitive for early-stage disease, UPCR lacks specificity and biopsies are regionally variable and highly invasive with attendant risks. We have developed a four-protein blood-based panel, which sensitively detects kidney damage in early LN and diabetic nephropathy which significantly outperforms creatinine and eGFR. A provisional patent application was filed in November 2024 for methods of detecting kidney damage using the blood-based panel. We expect to make this panel available through Pharma collaborations in early 2025 prior to releasing commercially through our clinical lab.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Sales and Marketing </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We employ a specialized sales force focused on targeting the approximately 6,000 rheumatologists across the United States. Our sales representatives generally have extensive experience in healthcare sales with backgrounds in rheumatology, diagnostics and/or pharmaceutical sales. In addition, our sales representatives complete a comprehensive disease-level sales training program and are required to participate in regular, ongoing training activities and certifications. Our goal is for our sales representative to be viewed as a collaborative resource to the rheumatologists and their practice.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our field-based sales force is organized into 40 territories within the following five regions: West, Central, Northeast, Southeast and Mid-Atlantic. We anticipate adding new territories during 2025, in a measured fashion. We also maintain an inside sales force that helps further our access to rheumatologists located in rural and outlying areas of the United States and works to increase our brand awareness with healthcare providers in these areas. We continually evaluate our sales force's reach and frequency of interactions with rheumatologists, including as we launch our pipeline products. Our specialized sales force and marketing activities are further augmented by our centralized, dedicated client services department. Our client services department uses its high level of technical training to enhance sales efficiency and customer satisfaction by providing personalized customer support.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Adoption and Growth through Quality Testing and Service</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our focus on quality allows for a dedicated sales approach based on a commitment to understanding the needs of both provider and patient. By raising awareness of the benefits AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing provides, our sales team is able to deliver quality testing and support services to providers, and ultimately, their patients. To ensure our marketing and sales efforts are reaching those that we believe could benefit most from AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, we emphasize execution in three core areas: targeting, messaging and call frequency. We strategically target the highest-potential practices by utilizing various data sources (e.g., market analytics, demographic data, historical therapeutic usage and diagnostic product trends). Furthermore, we believe the increased access afforded by our testing products will allow for patient-focused messaging</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">and the increased accuracy of our testing products over current standard of care diagnostic methodologies. Finally, we execute a high-frequency promotional strategy for our top-targeted rheumatologists and their office personnel to build knowledge, understanding and retention of the benefits of our testing products. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We plan to leverage core channels for building awareness and adoption, including our participation with multiple patient advocacy organizations and medical societies, such as the ACR. We have also established strong relationships with multiple rheumatology care management organizations (Super Groups), which can be key in influencing favorable reimbursement. Our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> MTX testing product has been included in the clinical guidelines for two of these groups. We believe our experience with advancing a testing product from initial development through clinical adoption differentiates us and uniquely positions us to replicate success with our other testing products. Beyond working with these Super Groups, we intend to continue to augment field selling activity with a balanced marketing mix, including print and digital advertising, direct marketing, continuing medical education programs and working with key opinion leaders to support peer-to-peer educational events.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Reimbursement, Clinical Validation and Clinical Utility </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Reimbursement </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The primary source of revenue for our products is reimbursement from third-party payors and client bill arrangements. Third-party payors include government payors (such as Medicare and Medicaid) and commercial payors (such as insurance companies). Achieving and maintaining broad coverage and reimbursement from third-party payors, including Medicare, for our commercialized and pipeline products is a key determinant of our revenue, financial results and future growth.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are actively engaged in efforts to achieve broad commercial coverage and reimbursement for our current and future products, including contracting with commercial payors. Achieving positive coverage reduces the need for appeals and reduces failures to collect from the patient&#8217;s insurance. Additionally, achieving in-network contracts with commercial payors can shorten the time required to receive payments. Our approach to commercial payment is centered on working toward inclusion in clinical guidelines and individual payor medical policies. We seek to accomplish this through continued evidence development and publication, medical director engagement and individual claim-based appeal efforts, detailed as follows: </span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.46pt;text-decoration:underline">Meet the evidence standards necessary to be consistent with leading clinical guidelines</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We believe inclusion in leading clinical guidelines plays a critical role in payors&#8217; coverage decisions. In order to change clinical guidelines, tests must carry a high level of published evidence demonstrating analytical validity, clinical validity, clinical utility and cost-effectiveness. When studies with such evidence are published in peer-reviewed journals and demonstrate performance superior to standard of care testing, the authors of clinical guidelines may assess the level of evidence and determine whether modifying existing guidelines to include new technology is warranted.</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.46pt;text-decoration:underline">Execute an internal managed care policy and claims adjudication function as part of our core business operations</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> We employ a team of in-house claims processing and reimbursement specialists who work with patients and payors to obtain maximum reimbursement. In parallel, a managed care team collaborates with our reimbursement specialists to ensure our payor outreach strategy reacts to and anticipates the changing needs of our customer base. Overall, we work to address payors at the national level in addition to high-claim-volume regional payors we have identified based on our current territory coverage.</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.46pt;text-decoration:underline">Cultivate a network of key opinion leaders</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Key opinion leaders are able to influence clinical practice by publishing research and determining whether new tests should be integrated into clinical guidelines. We collaborate with key opinion leaders early in the development process to ensure our clinical studies are designed and executed in a way that clearly demonstrates the benefits of our testing products to healthcare providers and payors.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">While we have contracts for reimbursement with a limited number of commercial payors, we are actively pursuing favorable medical policies and additional commercial payor contracts. When we contract to serve as a participating provider, reimbursements are made pursuant to a percentage of our charges or a negotiated fee schedule amount. For in-network and out-of-network claims for which we are not reimbursed in full (or receive a claim denial), we may elect to appeal the insurer&#8217;s underpayment (or denial of payment) or seek payment from the patient.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Clinical Validation </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We demonstrated the clinical validity of AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus in a study of 794 patients conducted from 2010 to 2014 across multiple leading academic centers. The primary endpoint of the study was the specificity and sensitivity of AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus compared to common autoantibodies used to diagnose SLE and other CTDs, such as ANA and anti-dsDNA. The final results of this study showed that AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus demonstrated 86% specificity and 80% sensitivity in distinguishing SLE from other CTDs and fibromyalgia. Additionally, the results showed that AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus was </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">33% more specific than ANA (53% specificity/89% sensitivity) and 48% more sensitive than anti-dsDNA (32% sensitivity/97% specificity). </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We further demonstrated the clinical validity of AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus for detection of probable SLE (pSLE) in a 246 subject, multi-center, prospective, cross-sectional study, first published in the Arthritis &amp; Rheumatology Journal in September 2019. The objective of this study was to evaluate the frequency of AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus and CB-CAPs as a marker of complement activation in patients with pSLE and the usefulness of the AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus platform as a predictor of the evolution of pSLE into classified SLE by the ACR criteria. Of the 92 pSLE patients, more pSLE were positive for CB-CAPs (28%) or AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus (40%) than for low complement (9%) at the enrollment visit (p=0.0001, for each) and an AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus index score &gt;0.08 prospectively associated with the development from pSLE to SLE by ACR classification criteria within 18 months (hazard ratio = 3.11, p&lt;0.01).</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">With the addition of the novel T-Cell SLE biomarker panel to our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD panel, we demonstrated the clinical validity of T Cell-bound autoantibodies (TIgG and TIgM) and C4d-bound CD3+ T Cells (TC4d) in a multi-center clinical validation study of 400 clinically characterized patients. The study aimed to evaluate the panel&#8217;s performance in differentiating SLE from non-SLE autoimmune rheumatic diseases (ARDs) and healthy individuals. At 94&#8211;95% clinical specificity for SLE vs. healthy individuals, the sensitivity (95% CI) for SLE was 58.1% (48.1&#8211;67.7%) for TC4d, 31.4% (22.7&#8211;41.2%) for TIgG, and 29.5% (21.0&#8211;39.2%) for TIgM. Notably, the T Cell biomarkers identified 19% of diagnosed SLE patients who were negative for all conventional SLE biomarkers and our CB-CAPs (EC4d and BC4d). Compared to conventional SLE biomarkers (anti-dsDNA, anti-Smith, and serum complement proteins C3 &amp; C4), the novel T Cell biomarkers demonstrated significantly greater sensitivity for SLE (64% vs. 41%; p &lt; 0.001, g = 0.6), with an associated odds ratio of 3.7 (95% CI: 4.9&#8211;98.8). These findings support the added clinical value of T Cell biomarkers in enhancing the sensitivity of the AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD panel for SLE.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The addition of anti-RA33 autoantibodies to the AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD panel was supported by clinical validation data demonstrating their added sensitivity in seronegative rheumatoid arthritis (RA)&#8212;patients clinically diagnosed with RA but testing negative for anti-CCP and Rheumatoid Factor (IgA/IgM). A study involving 651 clinically characterized subjects (290 RA patients, 261 ARD controls, and 100 healthy subjects) with diagnostic cutoffs established at 98% specificity for RA vs. healthy individuals and 95% specificity vs. ARDs, resulted in sensitivities for anti-RA33 IgA, IgG, and IgM of 6.0%, 6.2%, and 17.7%, respectively. Notably, 12% (13/109) of seronegative RA patients were positive for at least one anti-RA33 isotype, demonstrating their additive clinical value.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In an internal validation study of 377 clinically characterized subjects (101 seronegative RA, 60 seropositive RA, 143 ARDs, and 73 healthy controls), we established cutoffs at 95%, 96%, and 99% specificity for IgA, IgM, and IgG, respectively. The combined sensitivity in seronegative RA was 16%, with specificity exceeding 90% for RA vs. ARD controls, except for IgG in RA vs. SLE (85%) and IgA/IgM in RA vs. psoriatic arthritis (86%). Collectively, these findings support the inclusion of anti-RA33 autoantibodies in the RA sub-panel of the AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD comprehensive report.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Clinical Utility </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have collaborated with both academic and community clinicians to demonstrate the clinical utility of AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus versus standard diagnostic tests in physician diagnosis, impact on patient management decisions, patient reported outcomes and health economics.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We sponsored a longitudinal, case-control, retrospective review of medical charts in 2016 to assess the value and clinical utility of AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus to rheumatologists. The results of this study were published in the Open Rheumatology Journal in 2016 and suggested that a positive AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus test aids in the diagnosis of SLE versus standard diagnostic tests.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In early 2018, we initiated CARE for Lupus, a prospective, randomized, multi-site study to assess the performance of AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus versus standard diagnostic laboratory tests (SDLT). A total of 145 patients were enrolled across 32 sites between July 2017 and December 2018, with 73 patients enrolled in the SDLT group and 72 patients in the AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus group. The CARE study was published in September 2019 in Lupus Science &amp; Medicine. Results among patients who tested positive for AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus (n=9) showed 44% in the AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus group had a higher likelihood of SLE, compared with 9% in the SDLT group (p=0.127). Among patients who tested negative for AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus (n=63), 60% in the AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus group had a lower likelihood of SLE, compared with 37% in the SDLT group (p=0.012). In the group of patients randomized to the AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus group, positive test results associated significantly with initiation of prednisone (p=0.03) and a similar trend was observed with HCQ therapy (p=0.11). Finally, in the group of patients randomized to the AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus group, a positive test result associated with an increase in patient-reported outcomes measuring health-related quality of life using five-level EQ-5D (EQ5D-5L index score) from enrollment to visit two (p=0.028), and greater improvements were detectable when compared to the group of patients positive for AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus and randomized to the SDLT arm (p=0.049).</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In July 2021, a real-world retrospective analysis of patients tested with the AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus test was published in the journal Lupus Science &amp; Medicine, titled "A multianalyte assay panel with cell-bound complement activation products demonstrates clinical utility in systemic lupus erythematosus clinical utility study summary." A cohort of 161 AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus tested patients from 12 rheumatology centers across the United States provided clinical outcome data on diagnosis and treatment decisions following AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus testing. The study findings revealed a seven to 15-fold increased risk of Lupus diagnosis in AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus Positive and anti-dsDNA negative patients relative to patients negative for both tests. In addition, AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus positive and anti-dsDNA negative patients were at three to four-fold increased odds, relative to patients testing negative for both tests, of starting a new HCQ (cornerstone therapy for Lupus) prescription following AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus testing. Collectively, the study results affirm earlier study findings demonstrating the superior clinical utility and actionability of AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus vs. standard diagnostic testing for the differential diagnosis of Lupus.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In July 2022, we announced new, real-world evidence illustrating that AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing can enable decisive clinical action in the differential diagnosis of lupus. The "Complement Activation Products vs Standard ANA Testing: Treatment Outcomes, Diagnosis, and Economic Impact in Systemic Lupus Erythematosus" (CAPSTONE) study was the largest comparative utility study in lupus diagnostics and was published in the Journal of Managed Care &amp; Specialty Pharmacy. The study leveraged multiple databases encompassing electronic health records and linked insurance claims data on nearly 50,000 patients tested with AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> or standard of care labs from hundreds of rheumatologists across the United States, comparing diagnosis, treatment and cost of care outcomes for new patients tested with AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus and those tested with a traditional ANA (tANA) approach, including specific autoantibodies. The CAPSTONE study supports that the AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus test is more clinically effective, both for patients who test positive and those who test negative, as compared to the current standard of care. Important key findings of the CAPSTONE study included, among other things, a: (i) 2x decrease in diagnostic testing costs in the first six-month follow-up period for AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus [-] vs. tANA[-]; (ii) 3.5x less frequent repeat testing overall when using AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus vs. tANA; (iii) 6x increased odds of establishing a new SLE diagnosis with AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus [+] vs. tANA[+]; and (iv) 3x increased odds of initiating one or more SLE treatments with AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus [+] vs. tANA[+]. The CAPSTONE study exemplifies the advantages of the AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus test for patients, providers and payors. Delayed diagnosis leads to increased disease burden and diminished quality of life for the patient relative to the current standard of care. By receiving conclusive results, providers are able to initiate treatment early, reducing the need for more aggressive approaches down the road that can lead to irreversible consequences for the patient. Additionally, a conclusive negative test allows providers to lower the number of repeat tests and follow-up visits which is a critical step for achieving diagnostic clarity for the patient.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Healthcare Economics</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In October 2020, a study in collaboration with leading health economic experts was published in the journal ACR Open Rheumatology, titled "Evaluation of the Economic Benefit of Earlier SLE Diagnosis using a Multivariate Assay Panel (MAP)." This was the first ever evaluation of the economics of diagnosing SLE with AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus (MAP) compared to standard diagnostic laboratory tests in a hypothetical cohort of 1,000 suspected SLE patients. Over the four-year time horizon, AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus demonstrated an estimated total direct cost savings of approximately $2.0 million ($1,991 per patient). In addition, the study findings from the economic model estimated a $0.7 million dollar savings in total cost of care with AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus versus a conventional SLE biomarker testing approach, as a result of the increased diagnostic sensitivity of the AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus test leading to fewer in-patient hospitalization costs. On a per tested basis, the AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus test is estimated to reduce total cost of care by $655 per eligible patient in the first year.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Laboratory Operations </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We perform all of our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> tests in our approximately 13,000 square-foot laboratory located in Vista, California. Our laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and accredited by the College of American Pathologists (CAP). Our laboratory is certified for performance of high-complexity testing by the Centers for Medicare &amp; Medicaid Services (CMS) in accordance with CLIA and is licensed by California and all states requiring out-of-state licensure, including the NYSDOH. Our clinical laboratory typically reports AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing results within five business days. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We believe that our existing laboratory facility is adequate to meet our business needs for at least the next 12 months and that additional laboratory space will be available on commercially reasonable terms, if required.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Quality Assurance </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our quality assurance function oversees the quality of our laboratory operations. We have established oversight for systems implementation and maintenance procedures, document control processes, supplier qualification, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">preventive and/or corrective actions and employee training processes that we believe achieve excellence in operations. We continuously monitor and improve our processes and procedures and believe this high-quality service leads to customer satisfaction and retention.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Competition </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The traditional methods used by healthcare providers to test patients with CTD-like symptoms are the main competitors of our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products. Such traditional methods include testing for a broad range of diagnostic, immunology and chemistry biomarkers, such as ANA and anti-dsDNA, and serum complement biomarkers, such as C3 and C4. We also face competition from commercial laboratories, such as ARUP Laboratories, Inc.; Laboratory Corporation of America Holdings; the Mayo Clinic; and Quest Diagnostics Incorporated, all of which have existing infrastructures to support the commercialization of diagnostic services. Large, multispecialty group medical clinics, health systems and academic medical university-based clinics may provide in-house clinical laboratories offering autoimmune and autoimmune-related disease testing services. Additionally, we compete against regional clinical laboratories providing testing in the autoimmune and autoimmune-related disease field, including Aqtual, Inc. Other potential competitors include companies that might develop diagnostic, disease or drug monitoring products, such as AMPEL BioSolutions, LLC; DxTerity Diagnostics, Inc.; Genalyte Inc.; Immunovia AB; Oncimmune Holdings plc; and Progentec Diagnostics Inc. In the future, we may also face competition from companies developing new products or technologies. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We believe the principal competitive factors in our target market include: quality and strength of clinical and analytical validation data; confidence in diagnostic results; sales and marketing capabilities; the extent of reimbursement; inclusion in clinical guidelines; cost-effectiveness; and ease of use. We rely upon independent sources for phlebotomy to obtain patient samples; interruptions to this capability could dramatically impact patient access to our tests.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Many of our potential competitors have widespread brand recognition and substantially greater financial, technical and research and development resources; in addition to greater selling and marketing capabilities. Others may develop products with prices lower than ours or have preferred network status that could be viewed by rheumatologists and payors as functionally equivalent to our solution or offer solutions at prices designed to promote market penetration. If we are unable to change clinical practice in a meaningful way or compete successfully against current and future competitors, we may be unable to increase market acceptance and sales of our products, which could prevent us from increasing our revenue or achieving profitability. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Human Capital</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December&#160;31, 2024, we had a total of 209 employees: 203 full-time employees and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> part-time employees. This includes 57 in laboratory operations, 13 in research and development, 59 in sales and marketing and 74 in general and administrative functions. All of our employees are located in the United States, none of which are represented by a labor union or covered by a collective bargaining agreement. We consider relations with our employees to be good.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We recognize that attracting, motivating and retaining talent at all levels is vital to our continued success. Our employees are a significant asset and we aim to create an equitable, inclusive and empowering environment in which our employees can grow and advance their careers, with the overall goal of developing, retaining and expanding our workforce, as needed, to support our current pipeline and future business goals. By focusing on employee retention and engagement, we improve our ability to support our business operations and protect the long-term interests of our securityholders. Our success also depends on our ability to attract, engage and retain a diverse group of employees. Our efforts to recruit and retain a diverse and passionate workforce include providing competitive compensation and benefits packages and efforts to ensure our employees' voices are heard.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We value innovation, passion, data-driven decision making, persistence and honesty, and are building a diverse environment where our employees can thrive and be inspired to make exceptional contributions to bring novel testing products to patients.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our human capital resources objectives include, as applicable, identifying, recruiting, retaining, motivating and integrating our existing and future employees. The principal purposes of our equity incentive plans are to attract, retain and motivate selected employees and directors through grants of stock-based compensation awards and payments of cash-based performance bonus awards, in order to increase stockholder value and the success of our company by motivating our employees to perform to the best of their abilities and achieve our objectives. We are committed to providing a competitive and comprehensive benefits package to our employees. Our benefits package provides a balance of protection along with the flexibility to meet the individual health and wellness needs of our </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">employees. We plan to continue to refine our efforts related to optimizing our use of human capital as we grow, including improvements in the way we hire, develop, motivate and retain employees.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Intellectual Property Overview </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We strive to protect and enhance the proprietary technologies that we believe are important to our business and seek to obtain and maintain patents for any patentable aspects of our testing products or other inventions that are important to the development of our business. Our success will depend on our ability to obtain and maintain patent and other proprietary protection for commercially important technology, inventions and know-how related to our business. It will also depend on our ability to defend and enforce our patents, maintain our licenses to use intellectual property owned by third parties, preserve the confidentiality of our trade secrets and operate without infringing the valid and enforceable patents and other proprietary rights of third parties. We also rely on continuing technological innovation and in-licensing opportunities to develop, strengthen, and maintain our proprietary position in the fields targeted by our testing products and services. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are the owner or licensee of a portfolio of patents and patent applications and possess substantial know-how and trade secrets which protect various aspects of our business. The patent families comprising our patent portfolio are primarily focused on our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products for the diagnosis, prognosis and monitoring of autoimmune and autoimmune-related diseases. We intend to leverage the intellectual property surrounding our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products as an important component of our business strategy.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Patent Protection for our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"> Testing Products</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our portfolio of patents and patent applications related to our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products generally relates to three aspects: the AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Lupus platform, the AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD platform and the AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">MTX test. As of February 21, 2025, our portfolio primarily consisted of the following:</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> Lupus Platform</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We own five issued U.S. patents (US 10,132,813, US 11,360,099, US 11,531,033, US 11,761,965, and US 11,885,812), three U.S. nonprovisional patent applications, and six foreign patents that relate to our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus platform. The foreign patents have issued in Europe (EP2972365), China (CN105229470), and Japan (JP6453299). These patents cover the AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus algorithm. The patents expire between 2032 and 2034.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">TC4d, TIgG and TIgM Biomarkers</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We licensed one issued patent (US 9,709,564) that relates to our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD product. A foreign patent application has been filed in Brazil (BR112017002575 2). These patents cover a method of specifically diagnosing SLE through the combined use of a CB-CAP bound to a t-cell along with t-cell autoantibodies. The U.S. patent expires in 2035.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">MTX Exposure Assessment Products and Services</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We own two patents that relate to our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> MTX product and methods for monitoring methotrexate therapy using red blood cell MTXPG exposure assessments. These patents include U.S. Patent Nos. 7,582,282 and 7,695,908, which are expected to expire in 2026 and 2027, respectively.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Proprietary Rights and Processes</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We may rely, in some circumstances, on proprietary technology and processes, including trade secrets, to protect our technology. However, these can be difficult to protect. We seek to protect our proprietary technology and processes, in part, by entering into confidentiality agreements with those who have access to our confidential information, including our employees, consultants, scientific advisors and contractors. We also seek to preserve the integrity and confidentiality of our proprietary technology and processes by maintaining physical security of our premises and physical and electronic security of our information technology systems. While we have confidence in these individuals, organizations and systems, agreements or security measures may be breached, and we may not have adequate remedies for any such breach. In addition, our proprietary technology and processes may otherwise become known or be independently discovered by competitors. To the extent that our employees, consultants, scientific advisors, contractors or any future collaborators use intellectual property owned by others in their work for us, disputes may arise as to the rights in related or resulting know-how and inventions. For this and more comprehensive risks related to our proprietary technology and processes, please see &#8220;Risk Factors&#8212;Risks Related to our Intellectual Property.&#8221;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">License Agreements </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Amended and Restated Exclusive License Agreement with the University of Pittsburgh</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In August 2011, we entered into an amended and restated exclusive license agreement (the UPitt License Agreement) with the University of Pittsburgh (UPitt), through which we obtained an exclusive license to UPitt&#8217;s patent rights in certain inventions (the UPitt Patent Rights) related to the use of CB-CAPs technology in the diagnosis, prognosis and monitoring of diseases, including certain patents related to our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.47pt;font-weight:400;line-height:115%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under the agreement, we were required to pay UPitt a low single-digit royalty on net sales of products or services that utilized the UPitt Patent Rights sold by us or our affiliates, subject to minimum annual royalty payments and other adjustment in certain circumstances. The UPitt License Agreement terminated on March 23, 2024, which was the date of the expiration of the last licensed patent covering the applicable licensed product or service, and our royalty obligations for cash collections related to each licensed product or service ended on such date.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Amended and Restated Exclusive License Agreement with Allegheny Health Network Research Institute </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In May 2021, we entered into an exclusive license agreement with AHN, as amended in January 2025, under which we obtained an exclusive, worldwide license to AHN's patent rights in certain inventions (the AHN Patent Rights) related to diagnostics for autoimmune rheumatic diseases.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under the agreement, we are permitted to make, use and sell products and services utilizing the AHN Patent Rights and to sublicense such rights; provided, however, that any such sublicenses may only be granted with AHN's consent. AHN retained the right to practice under the AHN Patent Rights and to use such rights for teaching, research, education, public service, clinical and other research-related purposes. In addition, the agreement is subject to the rights of the U.S. government with respect to the AHN Patent Rights, including under a funding agreement between AHN and the U.S. government and under the Bayh-Dole Act of 1980 (Bayh-Dole Act) (35 U.S.C. &#167;200, et seq.). Pursuant to the Bayh-Dole Act, the U.S. government may acquire a nonexclusive, nontransferable, paid-up license to practice or have practiced for or on behalf of the U.S. government the inventions described in the AHN Patent Rights throughout the world.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In consideration for the rights granted to us under the agreement, we paid an initial license fee to AHN to cover past patent expenses and agreed to pay future direct patent costs related to AHN Patent Rights. We were also required to pay AHN a low single-digit royalty on net sales of products utilizing the AHN Patent Rights through the first quarter of 2024 sold by us or our affiliates, subject to adjustment in certain circumstances. Beginning in the second quarter of 2024, we are required to pay AHN an increased low single-digit royalty or a flat annual minimum royalty amount, which royalty obligations continue for each licensed product on a country-by-country basis until the expiration of the last licensed patent covering the applicable licensed product in such country, pending approvals and commercialization, or the earlier termination of the agreement (excluding payment obligations accruing prior to such termination).</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the event we sublicense any of the AHN Patent Rights, we are obligated to pay AHN a mid-double-digit percentage of any sublicense income, whether in the form of royalties or sub-license fees.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The agreement requires that we diligently develop and commercialize products that are covered by the AHN Patent Rights. If we elect not to pursue intellectual property rights or expand commercialization to certain territories within a commercially reasonable period, AHN may pursue other licenses and terminate our exclusive license with respect to such territories upon 30 days prior written notice.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We may terminate the agreement upon 60-day written notice to AHN provided we pay a specified termination fee. AHN may terminate the agreement in the event of our nonperformance of any of our material obligations under the agreement if such nonperformance remains uncured for a certain period of time following our receipt of written notice of such nonperformance or in the event of insolvency. Absent early termination, the agreement will continue until expiration date of the longest-lived patent right included in the AHN Patent Rights.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In January 2025, we amended the amended and restated exclusive license agreement with AHN to include additional terms regarding the sale by us of certain combination products under the AHN Patent Rights. Under the amendment, we are required to pay AHN a nominal royalty on net sales of combination products utilizing the T-Cell Biomarkers under the AHN Patent Rights.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Exclusive License Agreement Johns Hopkins University</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In November 2023, we entered into an exclusive license agreement with JHU, under which we obtained an exclusive, worldwide license to JHU&#8217;s patent rights in certain inventions (the JHU Patent Rights) related to methods </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">of using urinary protein biomarkers as a means of risk stratifying lupus nephritis patients and predicting treatment response.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under the agreement, we are permitted to make, use, import, export, offer and sell products and services utilizing the JHU Patent Rights and to sublicense such rights, subject to certain limitations. JHU retained the right to practice under the JHU Patent Rights and to use such rights for teaching, research, education, public service, clinical and other research related purposes; in addition to make, use and sell products and services to a qualified humanitarian organization for humanitarian purposes in so-called &#8220;least developed countries,&#8221; as defined by the United Nations Country Classification.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In consideration for the rights granted to us under the agreement, we paid an initial license fee and past patent expenses and agreed to pay future direct patent costs related to the JHU Patent Rights. Under the terms of the exclusive license agreement, we are required to pay royalties in the low single-digits on net sales of products using the assigned patents, subject to annual minimums, as well as certain milestone payments.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the event we sublicense any of the JHU Patent Rights, we are obligated to pay JHU a double-digit percentage of sublicensing income; however, royalties we receive on sales made by sublicensees will be treated as if we made the sale.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The agreement requires that we diligently develop and commercialize products that are covered by the JHU Patent Rights, and we have agreed to meet certain development and commercial milestones. JHU may terminate the agreement if we fail to develop, commercialize and sell the licensed products. Additionally, JHU may terminate the agreement for cause upon 60-day written notice in the event of our nonperformance of any of our material obligations under the agreement if such nonperformance remains uncured for a certain period of time following our receipt of written notice of such nonperformance or in the event of insolvency. JHU may terminate the agreement immediately upon written notice to Exagen in the event of a material breach that is incapable of cure. Absent early termination, the agreement will continue for the longer of (i) expiration of the last to expire patent included in the license agreement, (ii) 10 years after the first commercial sale of any licensed product utilizing the JHU Patent Rights, or (iii) if no patents issue, 20 years from the effective date of the agreement (November 8, 2023). We may terminate the agreement upon 90 days&#8217; advance written notice to JHU.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Exclusive License Agreement and Collaboration Agreement with Queen Mary University of London </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In November 2021, we entered into an exclusive license agreement with Queen Mary University of London (QMUL), under which we obtained an exclusive license to QMUL's patent-pending inventions (the QMUL Patent Rights), related to diagnosis and/or development of diagnostic or companion diagnostics for RA. We terminated this agreement with QMUL in September 2024.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Regulations </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Clinical Laboratory Improvement Amendments of 1988 </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As a clinical laboratory, we are required to hold certain federal, state and local licenses, certifications and permits to conduct our business. Under CLIA, we are required to hold a certificate applicable to the categories of laboratory tests we perform and to comply with standards applicable to our operations, including test processes, personnel, facilities administration, equipment maintenance, recordkeeping, quality systems and proficiency testing. We must maintain CLIA certification to be eligible to bill for diagnostic services provided to Medicare beneficiaries. Many commercial third-party payors also require CLIA certification as a condition of payment. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our Vista facility holds a current CLIA certificate. To renew our CLIA certificate, we are subject to survey and inspection every two years to assess compliance with program standards. We elect to participate in the accreditation program of CAP. CMS has deemed CAP standards to be equally or more stringent than CLIA regulations and has approved CAP as a recognized accrediting organization. Inspection by CAP is performed in lieu of inspection by CMS for CAP-accredited laboratories. Because we are accredited by the CAP Laboratory Accreditation Program, we are deemed to also comply with CLIA. The regulatory and compliance standards applicable to the testing we perform may change over time, and any such changes could have a material effect on our business. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Penalties for non-compliance with CLIA or CAP requirements include suspension, limitation or revocation of the laboratory&#8217;s CLIA or CAP certificate, as well as a directed plan of correction, state on-site monitoring, civil money penalties, civil injunctive suit or criminal penalties, as applicable. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">State Laboratory Licensing </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our Vista facility also holds a state license issued by the California Department of Public Health (DPH). California law and regulations establish standards for the day-to-day operation of a clinical laboratory, including the training and skills required of laboratory personnel and quality control. In addition, California laws and regulations also mandate proficiency testing, which involves testing of specimens that have been specifically prepared for the laboratory for quality control purposes. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Because we receive specimens from New York, our Vista facility is also required to be licensed by the NYSDOH New York laws and regulations establish standards in a variety of operational areas, including:</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.46pt">day-to-day operation of the laboratory, including training, supervision and skill levels required of laboratory personnel;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.46pt">physical requirements of a facility;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.46pt">equipment; and</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.46pt">validation and quality control.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">New York law also mandates proficiency testing for laboratories licensed under New York state law, regardless of whether such laboratories are located in or outside of New York. If a laboratory is out of compliance with New York's statutory or regulatory standards, the NYSDOH, may suspend, limit, revoke or annul the laboratory&#8217;s New York license, censure the holder of the license or assess civil money penalties. Statutory or regulatory noncompliance may result in a laboratory&#8217;s operator being found guilty of a misdemeanor under New York law. New York's law and regulations are more stringent than CLIA in certain respects. For example, NYSDOH must approve a laboratory developed test (LDT) before it is offered in New York. We have received written approval from NYSDOH to offer our products in New York.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition to New York and California, other states, including Maryland, Pennsylvania and Rhode Island, require licensing of out-of-state laboratories under certain circumstances. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Federal Oversight of Laboratory Developed Tests and Certain Devices</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The laws and regulations governing the marketing of diagnostic products are evolving, extremely complex, and in many instances, there are no significant regulatory or judicial interpretations of these laws and regulations. We perform our tests like AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD, AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> SLE Prognostic and AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> MTX assays in our Vista, California clinical laboratory, and although the performance of such tests is primarily regulated under CLIA, as administered by CMS, as well as by applicable state laws, as described above, the FDA has in recently promulgated regulations asserted its authority over the safety and efficacy of such laboratory developed tests (LDTs), including through pre-market review, and the controls necessary to maintain assay quality. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The U.S. Food and Drug Administration (FDA) regulates any diagnostic tests that meet the definition of a medical device, except under specific, narrow circumstances. The Federal Food, Drug and Cosmetic Act (FDCA) defines a medical device as "an instrument, apparatus, implement, machine, contrivance, implant, in vitro reagent, or other similar or related article, including a component part, or accessory, which is, among other things: intended for use in the diagnosis of disease or other conditions, or in the cure, mitigation, treatment, or prevention of disease, in man or other animals and which does not achieve its primary intended purposes through chemical action within or on the body of man or other animals and which is not dependent upon being metabolized for the achievement of any of its primary intended purposes." By this definition, in vitro reagents and diagnostic tests are considered medical devices. Specifically, the FDA defines an in vitro diagnostic test (IVD) as "reagents, instruments, and systems intended for use in the diagnosis of disease or other conditions, including a determination of the state of health, in order to cure, mitigate, treat, or prevent disease or its sequelae." Therefore, the FDA generally considers diagnostic testing products like ours to be IVDs subject to the agency's regulatory requirements.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Among other things, pursuant to the FDCA and its implementing regulations, the FDA regulates the research, testing, manufacturing, safety, labeling, storage, recordkeeping, pre-market clearance or approval, marketing and promotion and sales and distribution of medical devices, including IVDs, in the United States to ensure that medical products distributed domestically are safe and effective for their intended uses. In addition, the FDA regulates the export of medical devices manufactured in the United States to international markets. Many of the instruments, reagents, kits or other consumable products used within our laboratories are regulated as medical devices and therefore must comply with FDA quality system regulations and certain other device requirements. We have policies and procedures in place to ensure that we source such materials from suppliers that are in compliance with any applicable medical device regulatory requirements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The FDCA classifies medical devices into one of three categories based on the risks associated with the device and the level of control necessary to provide reasonable assurance of safety and effectiveness. Devices deemed by the FDA to pose the greatest risk, such as life-sustaining, life-supporting or implantable devices or devices deemed not substantially equivalent to a previously 510(k) cleared device, are categorized as Class III. These devices typically require submission and approval of a premarket approval application (PMA). Devices deemed to pose lower risk are categorized as either Class I or II. For most Class II devices, a manufacturer must submit to the FDA a 510(k) premarket notification submission requesting clearance of the device for commercial distribution in the United States. Some low-risk Class II devices are exempted from this requirement. When a 510(k) premarket notification submission is required, the manufacturer must submit to the FDA a premarket notification submission demonstrating that the device is "substantially equivalent" to a predicate device, which is: (i) a device that was legally marketed prior to May 28, 1976, for which PMA approval is not required, (ii) a legally marketed device that has been reclassified from Class III to Class II or Class I, or (iii) another legally marketed, similar device that has been cleared through the 510(k) clearance process. Class II devices may also be subject to special controls such as performance standards, post-market surveillance, FDA guidelines, or particularized labeling. Most Class I devices are exempt from 510(k) premarket notification requirements, but like Class II and Class III devices, are subject to general controls, such as registration and listing, quality system, labeling, and reporting requirements.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">After the FDA permits a device to enter commercial distribution, numerous regulatory requirements apply. These include: the Quality System Regulation, which requires manufacturers to follow elaborate design, testing, control, documentation and other quality assurance procedures during the manufacturing process; labeling regulations; the FDA&#8217;s general prohibition against promoting products for unapproved or "off-label" uses; and the medical device reporting regulation, which requires that manufacturers report to the FDA if their device may have caused or contributed to a death or serious injury or malfunctioned in a way that would likely cause or contribute to a death or serious injury if the malfunction were to recur. The FDA has broad post-market and regulatory and enforcement powers, including facility inspections and market surveillance. Failure to comply with the applicable U.S. medical device regulatory requirements could result in, among other things, warning letters, fines, injunctions, consent decrees, civil penalties, repairs, replacements, refunds, recalls or seizures of products, total or partial suspension of production, the FDA&#8217;s refusal to grant future premarket clearances or approvals, withdrawals or suspensions of current product applications, and criminal prosecution.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Although the FDA had historically statutory authority to assure that medical devices, including IVDs, are safe and effective for their intended uses, the FDA has generally exercised its enforcement discretion and not enforced applicable device regulations with respect to LDTs, which are IVDs that are designed, manufactured and used within a single high-complexity CLIA-certified laboratory. We believe that all of our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> test products are LDTs, as are our near-term pipeline candidate tests. However, in May 2024, the FDA issued a final rule aimed at regulating LDTs under the current medical device framework and phasing out its existing enforcement discretion policy for this category of diagnostic tests; the final rule became effective on July 5, 2024. The LDT enforcement policy phase-out process will occur in gradual stages over a total period of four years, with pre-market approval applications for high-risk tests to be submitted by the 3.5-year mark. Moderate-risk and low-risk tests are expected to be in compliance at the 4-year mark, although FDA has stated it will continue to exercise enforcement discretion with respect to tests that are the subject of pre-market submissions that are pending review. The FDA&#8217;s final rule and proposed phase-out process is complex and, concurrently, the agency announced several exceptions from the requirement to comply with full medical device regulatory controls, depending upon the specific nature of the LDT and the clinical laboratory that is offering such LDT for use by healthcare providers. We have begun the process of evaluating the final rule&#8217;s potential impact on our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> test products, our operations, and our business more generally. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Publication of the LDT final rule prompted the American Clinical Laboratory Association (ACLA) and one of its members, on May 29, 2024, as well as the Association for Molecular Pathology (AMP) and one of its members, on August 19, 2024, to file complaints against the FDA in the Eastern District of Texas and the Southern District of Texas, respectively. Both complaints allege that the agency does not have authority to promulgate the LDT final rule and seek to vacate the FDA&#8217;s action; the two cases were subsequently consolidated into a single action pending in the Eastern District of Texas. Briefing is ongoing in the consolidated case and the outcome is uncertain. The ongoing litigation could potentially affect the FDA&#8217;s plans to implement these new LDT requirements, making the implementation timeline somewhat uncertain although no preliminary injunction has been issued to date. Accordingly, the agency has continued its implementation efforts by actively providing guidance and training to clinical laboratories on how to comply with medical device general controls. Following the transition to the new Trump administration, it is unclear whether the Executive Branch of the U.S. government will continue to defend the FDA&#8217;s rulemaking action in the consolidated litigation in Texas or if it will take steps to rescind or modify the LDT final rule. Affected stakeholders also continue to press for a comprehensive legislative solution to create a harmonized paradigm for oversight of LDTs by both the FDA and CMS, instead of implementation of the FDA&#8217;s final rule, which may be disruptive to the industry and to patient access to certain diagnostic tests. However, this FDA rulemaking was initiated after years of failed congressional attempts to harmonize the regulatory paradigms </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">applicable to LDTs and other IVDs, making it unclear whether any legislative efforts would be successful going forward. The outcome of the November 2024 elections on the composition of the 2025-2026 Congress, with both the Senate and House transitions to Republican control, also creates uncertainties for the diagnostic industry.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Even though we presently commercialize our tests as LDTs, the FDA may disagree that our marketed tests are within the scope of its current enforcement discretion criteria for LDTs, our tests may in the future become subject to more onerous regulation by the FDA. If and when the FDA begins to actively enforce its premarket submission regulations with respect to LDTs generally or to our tests in particular, whether as a result of new legislative authority or under the May 2024 LDT final rule, depending upon the risk classification of each individual test, we may be required to obtain premarket clearance for our diagnostic assays under Section 510(k) of the FDCA or approval of a PMA. The process for submitting a 510(k) premarket notification and receiving FDA clearance usually takes from three to 12 months, but it can take significantly longer, and clearance is never guaranteed. The process for submitting and obtaining FDA approval of a PMA generally takes from one to three years or even longer, and approval is not guaranteed. PMA approval typically requires extensive clinical data and can be significantly longer, more expensive and more uncertain than the 510(k) clearance process. If premarket review is required for some or all of our tests, the FDA could require that we stop selling our tests and testing services pending clearance or approval and conduct clinical testing prior to making submissions to FDA to obtain premarket clearance or approval. The FDA could also require that we label our tests as investigational or limit the labeling claims we are permitted to make.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Regulation of Clinical Trials</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have also conducted and may in the future conduct research studies for our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> tests and our other tests in development that involve clinical investigators and human subjects (or stored specimens from human subjects) at sites in the United States. We may need to conduct additional clinical trials for the AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> tests, as well as other tests we may offer in the future, to drive test adoption in the marketplace and reimbursement. Should we not be able to perform these studies, or should their results not provide clinically meaningful data and value for clinicians, adoption of our tests could be impaired and we may not be able to obtain reimbursement for them.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The conduct of clinical trials is also subject to extensive federal and institutional regulations intended to assure that the data and reported results are credible and accurate and that the rights, safety, and welfare of study participants are protected. Most studies involving human participants must be reviewed and approved by, and conducted under the auspices of, a duly-constituted institutional review board (IRB), which is a multi-disciplinary committee responsible for reviewing and evaluating the risks and benefits of a clinical trial for participating subjects and monitoring the trial on an ongoing basis. Companies sponsoring the clinical trials and investigators also must comply with, as applicable, regulations, guidelines and IRB requirements for obtaining informed consent from the study subjects, following the protocol and investigational plan, adequately monitoring the clinical trial, and timely reporting of adverse events. The sponsoring company or the IRB may suspend or terminate a clinical trial at any time on various grounds, including a finding that the subjects are being exposed to an unacceptable health risk. In addition, trials involving human subjects often require significant time and cash resources to complete and are subject to a high degree of risk, including risks of experiencing delays, failing to complete the trial or obtaining unexpected or negative results.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If the investigational device presents a &#8220;significant risk,&#8221; as defined by the FDA, the agency requires the device sponsor to submit an investigational device exemption application (IDE) to the FDA. The exemption must become effective prior to commencing human clinical studies. A significant risk device is one that presents a potential for serious risk to the health, safety or welfare of a patient and either is implanted, used in supporting or sustaining human life, substantially important in diagnosing, curing, mitigating or treating disease or otherwise preventing impairment of human health, or otherwise presents a potential for serious risk to a patient. An IDE must be supported by appropriate non-clinical data, such as animal and laboratory test results, showing that the device has a safety profile appropriate for human testing and that the trial protocol is scientifically sound. The IDE will automatically become effective 30 days after receipt by the FDA, unless the FDA expressly approves or denies the application in writing or notifies the sponsor that the investigation is on hold and may not begin until the sponsor provides supplemental information about the investigation that satisfies the agency&#8217;s concerns. If the FDA determines that there are deficiencies or other concerns with an IDE that require modification of the trial, the FDA may permit a clinical trial to proceed under a conditional approval or the sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. If the device presents a non-significant risk to the patient according to criteria established by FDA as part of the IDE regulations, a sponsor may begin the clinical trial after obtaining approval for the trial by one or more IRBs without separate authorization from the FDA, but must still comply with abbreviated IDE requirements, such as monitoring the investigation, ensuring that the investigators obtain informed consent, and labeling and record-keeping requirements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the Consolidated Appropriations Act for 2023, Congress amended the FDCA to require the sponsor of any pivotal clinical trial that will be used to demonstrate the safety and effectiveness of a medical device marketing authorization submission to develop a diversity action plan for such trial, and if submission of an IDE application is required, to submit such diversity action plan to the FDA. The action plan must include the sponsor&#8217;s diversity goals for enrollment, as well as a rationale for the goals and a description of how the sponsor will meet them. The FDA may grant a waiver for some or all of the requirements for a diversity action plan. It is unknown at this time how the diversity action plan may affect device pivotal clinical trial planning and timing, but if FDA objects to a sponsor&#8217;s diversity action plan and requires the sponsor to amend the plan or take other actions, it may delay trial initiation.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Advertising of Laboratory Services or LDTs</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Advertising for laboratory services and diagnostic testing products is subject to federal truth-in-advertising laws enforced by the Federal Trade Commission (FTC), as well as comparable state consumer protection laws, whether or not such services are regulated by the FDA as Class I or Class II devices or not directly subject to enforcement discretion with respect to the FDA&#8217;s device requirements as LDTs. Under the Federal Trade Commission Act (the FTC Act), the FTC is empowered, among other things, to (a) prevent unfair methods of competition and unfair or deceptive acts or practices in or affecting commerce; (b) seek monetary redress and other relief for conduct injurious to consumers; and (c) gather and compile information and conduct investigations relating to the organization, business, practices, and management of entities engaged in commerce. The FTC has very broad enforcement authority, and failure to abide by the substantive requirements of the FTC Act and other consumer protection laws can result in administrative or judicial penalties, including civil penalties, injunctions affecting the manner in which we would be able to market services or products in the future, or criminal prosecution.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Federal and State Physician Self-Referral Prohibitions</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are subject to the federal physician self-referral prohibitions, commonly known as the Stark Law, and to similar state law restrictions, such as California&#8217;s Physician Ownership and Referral Act of 1933 (PORA), and other comparable state laws. The Stark Law generally prohibits us from billing Medicare or Medicaid for certain designated health services, including clinical laboratory services, when the physician ordering the service, or any member of such physician&#8217;s immediate family, has a financial relationship with us, unless the arrangement meets an exception to the prohibition. A financial relationship can be a compensation arrangement or an ownership or investment interest.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Sanctions for a Stark Law violation include the following:</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.46pt">denial of payment for the services provided in violation of the prohibition;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.46pt">refunds of amounts collected in violation of the Stark Law;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.46pt">significant civil penalties for each bill or claim for a service arising out of the prohibited referral, and additional penalties for each arrangement or scheme that the parties know (or should know) has the principal purpose of circumventing the Stark Law's prohibition;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.46pt">the imposition of penalties of up to three times the amounts assessed for each item or service wrongfully claimed; and</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.46pt">possible exclusion from federal healthcare programs, including Medicare and Medicaid.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Stark Law applies regardless of any intent by the parties to induce or reward referrals or the reasons for the financial relationship and the referral. In addition, violations of the Stark Law may also serve as the basis for liability under the federal False Claims Act, which can result in additional civil penalties. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Similarly, PORA makes it unlawful for a physician or certain other healing arts licensees to refer a person for certain healthcare services, including clinical laboratory services, if the licensee has a financial interest with the person or entity that receives the referral, unless an exemption is met. Unlike the Stark Law, PORA applies regardless of the source of payment. PORA also prohibits the submission of claims for services provided pursuant to a prohibited referral, and violation of this prohibition constitutes a public offense and is punishable upon conviction by a fine not exceeding fifteen thousand dollars ($15,000) for each violation and appropriate disciplinary action. Other states also have self-referral restrictions with which we have to comply, some of which differ from those imposed by the Stark Law or PORA. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Federal and State Anti-Kickback Laws </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Federal Anti-Kickback Statute makes it a felony for a person or entity, including a clinical laboratory, to knowingly and willfully offer, pay, solicit or receive any remuneration, directly or indirectly, overtly or covertly, in cash or in kind, in order to induce or in return for the referral of an individual for the furnishing of, or the recommending or arranging for the furnishing of, purchasing, leasing, ordering or arranging for or recommending purchasing, leasing or ordering of any item or service that is reimbursable in whole or in part, under any federal healthcare program. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. Courts have broadly interpreted the scope of the Anti-Kickback Statute and generally have held that the statute may be violated if merely one purpose of a payment arrangement is to induce referrals. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition to statutory exceptions to the Anti-Kickback Statute, regulations provide for a number of safe harbors. If an arrangement meets the provisions of a safe harbor or exception, it is deemed to comply with the Anti-Kickback Statute, and the parties are immune from prosecution. An arrangement must fully comply with each element of an applicable safe harbor in order to qualify for protection. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Failure to meet the requirements of an exception or a safe harbor does not render an arrangement illegal. Rather, the government may evaluate such arrangements on a case-by-case basis, taking into account all facts and circumstances. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A violation of the Anti-Kickback Statute may result in imprisonment for up to ten years and significant fines for each violation and additional administrative civil money penalties, plus up to three times the amount of the remuneration paid. Convictions under the Anti-Kickback Statute result in mandatory exclusion from federal healthcare programs for a minimum of five years. In addition, a violation of the Anti-Kickback Statute can serve as the basis of liability under the federal False Claims Act, which is discussed in greater detail below.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Although the Anti-Kickback Statute applies only to items and services reimbursable under any federal healthcare program, a number of states, including California, have passed statutes substantially similar to the Anti-Kickback Statute that apply to all third-party payors, including commercial insurers, and, in some states, to patients without insurance. The California Attorney General and courts have interpreted the California anti-kickback and fee-splitting laws in substantially the same way as the courts have interpreted the Anti-Kickback Statute. Penalties under such state laws include imprisonment and significant monetary fines. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, in October 2018, the Eliminating Kickbacks in Recovery Act of 2018 (EKRA) was enacted as part of the Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act. EKRA is an all-payor anti-kickback law that makes it a criminal offense to pay any remuneration to induce referrals to, or in exchange for, patients using the services of a recovery home, a substance use clinical treatment facility, or laboratory. However, unlike the Anti-Kickback Statute, EKRA is not limited to services covered by federal healthcare programs but applies more broadly to services covered by &#8220;healthcare benefit programs,&#8221; including commercial third-party payors. Although EKRA apparently was intended to reach patient brokering and similar arrangements to induce patronage of substance use recovery and treatment, the language in EKRA is broadly written. Further, certain of EKRA&#8217;s exceptions are inconsistent with the Anti-Kickback Statute and regulations. EKRA permits the U.S. Department of Justice to issue regulations clarifying EKRA&#8217;s exceptions or adding additional exceptions, but such regulations have not yet been issued.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Other Federal and State Healthcare Laws </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition to the requirements discussed above, several other healthcare fraud and abuse laws could have an effect on our business. For example, federal law permits the U.S. Department of Health and Human Services (HHS) Office of Inspector General (OIG), to exclude an individual or entity from Medicare or Medicaid for charging federal healthcare programs, including Medicare or Medicaid, substantially in excess of its usual charges for its items or services absent a finding of good cause. The terms &#8220;usual charge&#8221; and &#8220;substantially in excess&#8221; are subject to varying interpretations, and the HHS OIG has withdrawn multiple versions of a proposed rule intended to implement the statute. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The federal False Claims Act prohibits, among other things, a person from knowingly presenting, or causing to be presented, a false or fraudulent claim for payment to the federal government. In addition to actions initiated by the government itself, the statute authorizes actions to be brought on behalf of the federal government by a private party having knowledge of the alleged fraud pursuant to its </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">qui tam</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> provisions. Because the complaint in a </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">qui tam</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> action is initially filed under seal, the action may be pending for some time before the defendant is even aware of the action. Regardless of whether the government intervenes in the action, the relator, if successful, will receive a percentage of the recovery. In addition, providers and suppliers must report and return any overpayments received from the Medicare and Medicaid programs within 60 days of identification, and failure to identify and return such overpayments exposes the provider or supplier to federal False Claims Act liability. Violation of the federal False Claims Act may result payment of up to three times the actual damages sustained by the government, plus </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">significant per-claim civil penalties, as well as mandatory exclusion from government healthcare programs. Several states, including California, have enacted comparable false claims laws that may apply regardless of payor.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The federal civil monetary penalties law (the CMP Law) prohibits, among other things, (1) the offering or transfer of remuneration (including a waiver of copayments and deductible amounts) to a Medicare or Medicaid beneficiary if the person knows or should know it is likely to influence the beneficiary&#8217;s selection of a particular provider, practitioner, or supplier of services reimbursable by Medicare or Medicaid, unless an exception applies; (2) employing or contracting with an individual or entity that the provider knows or should know is excluded from participation in a federal healthcare program; (3) billing for services requested by an unlicensed physician or an excluded provider; (4) billing for medically unnecessary services; and (5) presenting or causing to be presented a claim to a federal healthcare program that the person knows or should know is for an item or service that was not provided as claimed or is false or fraudulent. The penalties for violating the CMP Law may include exclusion, substantial fines, and payment of up to three times the amount billed, depending on the nature of the offense. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As noted, a person who offers or provides to a Medicare or Medicaid beneficiary any remuneration, including waivers of co-payments, co-insurance and deductible amounts (or any part thereof), that the person knows or should know is likely to influence the beneficiary&#8217;s selection of a particular provider, practitioner or supplier of Medicare or Medicaid payable items or services may be held liable under the CMP Law. Moreover, in certain cases, providers who routinely waive amounts owed by federal healthcare program beneficiaries can also be held liable under the Anti-Kickback Statute and the federal False Claims Act. One of the exceptions to the prohibition under the CMP Law covers non-routine, unadvertised waivers of copayments or deductible amounts based on individualized determinations of financial need or exhaustion of reasonable collection efforts, and the Anti-Kickback Statute has a safe harbor. The HHS OIG has emphasized in guidance documents that this exception should only be used on a case-by-case basis to address the financial needs of each particular patient. Although this prohibition applies only to federal healthcare program beneficiaries, applicable state laws related to, among other things, unlawful schemes to defraud, excessive fees for services, tortious interference with patient contracts and statutory or common law fraud, may also be implicated for similar practices offered to patients covered by commercial payors.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Federal criminal statutes prohibit, among other actions, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, including those administered by commercial payors, and knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services. Like the Anti-Kickback Statute, this federal criminal statute requires a showing of intent, but a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Physician Payments Sunshine Act imposes annual reporting requirements on manufacturers of certain devices, drugs and biologics for certain payments and transfers of value by them and in some cases their distributors to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), certain other advanced non-physician healthcare practitioners (such as nurse practitioners), and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members. Any failure to comply with these reporting requirements could result in significant fines and penalties. Because we manufacture our own in vitro diagnostic tests solely for use by or within our own laboratory, we believe that we are exempt from these reporting requirements. We may become subject to such reporting requirements under the terms of current CMS regulations, however, if the FDA requires us to obtain marketing authorizations for our diagnostic tests as medical devices (whether because the agency determines that one or more of such tests do not fall within the scope of the agency&#8217;s existing LDT definition or because of its recently issued final rule to exercise authority over LDTs as medical devices) or Congress enacts legislative reforms to the federal oversight of LDTs to subject them to FDA regulation and/or the reporting requirements of the Sunshine Act. It is presently unknown how CMS will respond to the recently finalized FDA policy change to effectively render all LDTs medical device products under federal law, and whether or when it will assert that the Sunshine Act&#8217;s reporting requirements will begin to apply to the manufacturers of such LDTs. Given that litigation is ongoing between members of the clinical laboratory industry and FDA/HHS in relation to the May 2024 LDT final rule, it may be many months or even years before we have clarity on the applicability of state and federal Sunshine Act laws to our business. Certain states also require medical device manufacturers to maintain compliance programs and/or be licensed as manufacturers or distributors by a state professional board or health department. Because the FDA&#8217;s now-in-effect final rule renders a clinical laboratory like ours a &#8220;medical device manufacturer,&#8221; we have begun the process of evaluating whether and to what extent those kinds of medical device-specific state requirements may be applicable to our operations. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are also subject to applicable state restrictions on laboratory billing. These laws vary from state to state but generally are intended to prevent a provider who ordered but did not perform the service from billing for that service at a markup. For example, California has an anti-markup statute with which we must comply, which prohibits a provider from charging for any laboratory test that it did not perform unless the provider (a) notifies the patient, client </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">or customer of the name, address and charges of the laboratory performing the test, and (b) charges no more than what the provider was charged by the clinical laboratory that performed the test except for any other service actually rendered to the patient by the provider (for example, specimen collection, processing and handling). This provision applies, with certain limited exceptions, to licensed persons such as physicians and clinical laboratories regulated under California&#8217;s Business and Professions Code. A violation of this provision can lead to imprisonment and/or a fine of up to $10,000. Other states have similar anti-markup and other client billing restrictions with which we must comply. Many states also have "direct-bill" laws, that require the party that performed the service to bill for the service, with certain exceptions.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If our operations are found to be in violation of any of the fraud and abuse laws described above or any other healthcare regulatory laws that apply to us, we may be subject to penalties, including potentially significant criminal and civil and/or administrative penalties, damages, fines, disgorgement, imprisonment, exclusion from participation in government healthcare programs, contractual damages, reputational harm, administrative burdens, diminished profits and future earnings, and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">International Regulations </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If we market our testing products outside of the United States, we may be subject to foreign regulatory requirements governing human clinical testing, prohibitions on the import of tissue necessary for us to perform our testing products or restrictions on the export of tissue imposed by countries outside of the United States or the import of tissue into the United States, and marketing approval. These requirements vary by jurisdiction, differ from those in the United States and may in some cases require us to perform additional pre-clinical or clinical testing. In many countries outside of the United States, coverage, pricing and reimbursement approvals are also required. Additionally, many countries in which we may offer any of our testing products in the future have anti-kickback regulations prohibiting providers from offering, paying, soliciting or receiving remuneration, directly or indirectly, in order to induce business that is reimbursable under any national healthcare program.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Privacy and Security Laws </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">U.S. Data Privacy and Security Laws</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">The Administrative Simplification provisions of the federal Health Insurance Portability and Accountability Act of 1996 (HIPAA), as amended by the federal Health Information Technology for Economic and Clinical Health Act (HITECH) the U.S. Department of HHS has issued regulations that established comprehensive federal standards for the privacy and security of health information. HITECH, among other things, expanded and strengthened HIPAA, created new targets for enforcement, imposed new penalties for noncompliance, and established new breach notification requirements. HIPAA applies to health plans, healthcare clearing houses, and healthcare providers that conduct certain healthcare transactions electronically (collectively, Covered Entities), as well as individuals or entities that perform services for them involving the use, or disclosure of, individually identifiable health information or "protected health information" (PHI) under HIPAA (Business Associates). HIPAA also regulates and standardizes the codes, formats and identifiers used in certain healthcare transactions and standardization of identifiers for health plans and providers, for example insurance billing. Any non-compliance with HIPAA and HITECH and related penalties, could adversely impact our business. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">The HIPAA security standards require the adoption of administrative, physical, and technical safeguards and the adoption of written security policies and procedures to maintain the security of PHI. Also, federal agencies are increasing their focus on the importance of cybersecurity in protecting health information. For example, HHS outlined its cybersecurity strategy for the health care sector on December 6, 2023, which builds on a national strategy published by the White House on March 1, 2023, and on February 16, 2024, the HHS Office for Civil Rights (OCR) and the National Institute of Standards and Technology (NIST) announced the publication of a cybersecurity resource guide for implementing HIPAA.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">The HIPAA privacy regulations address the privacy of PHI by limiting the use and release of such information. They also set forth certain rights that an individual has with respect to an individual&#8217;s PHI maintained by a covered entity, including the right to access or amend certain records containing PHI, request an accounting of disclosures of PHI, and to request restrictions on the use or disclosure of PHI. The HIPAA breach notification regulations impose certain reporting requirements on Covered Entities and their Business Associates in the event of a breach of PHI. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">Covered Entities must report breaches of PHI that has not been encrypted or otherwise secured in accordance with guidance from the Secretary of HHS (the Secretary). Breaches must be reported as soon as reasonably practicable, but no later than sixty days following discovery of the breach. Reports must be made to affected individuals, the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">Secretary, and depending on the size of the breach, the local and national media. Covered Entities like us are also subject to the HHS HIPAA audit program and may be investigated in connection with a privacy or data security complaint.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">Significant civil and criminal fines and other penalties may be imposed for violating HIPAA directly, and in connection with acts or omissions of any agents, including downstream business associates, as determined according to the federal common law of agency. Penalties for failure to comply with a requirement of HIPAA and HITECH vary significantly depending on the failure and include civil monetary penalties of up to approximately $2.1 million per violation of the same requirement per calendar year (as of August 8, 2024, subject to annual inflation adjustments). A single breach incident can violate multiple requirements, resulting in potential penalties in excess of $2.1 million. Additionally, a person who knowingly obtains or discloses individually identifiable health information in violation of HIPAA may face a criminal penalty of up to $50,000 and up to one year of imprisonment. These criminal penalties increase if the wrongful conduct involves false pretenses or the intent to sell, transfer or use identifiable health information for commercial advantage, personal gain, or malicious harm. Covered Entities are also subject to enforcement by state Attorneys General who were given authority to enforce HIPAA.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">Additionally, while HIPAA does not create a private right of action allowing individuals to file suit against us in civil court for violations of HIPAA, its standards have been used as the basis for duty of care cases in state civil suits such as those for negligence or recklessness in the misuse or breach of PHI.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">Further, to the extent that we submit electronic healthcare claims and payment transactions that do not comply with the transaction standards established under HIPAA and HITECH, payments to us may be delayed or denied.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">Even when HIPAA does not apply, according to the FTC, failing to take appropriate steps to keep consumers&#8217; personal information secure constitutes unfair or deceptive acts or practices in or affecting commerce in violation of Section 5(a) of the FTC Act. The FTC expects a company&#8217;s data security measures to be reasonable and appropriate in light of the sensitivity and volume of consumer information it holds, the size and complexity of its business, and the cost of available tools to improve security and reduce vulnerabilities. Individually identifiable health information is considered sensitive data that merits stronger safeguards. The FTC and states' Attorneys General have also brought enforcement actions and prosecuted some data breach cases as unfair and/or deceptive acts or practices under the FTC Act and comparable state laws.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">The HIPAA privacy and security regulations establish a uniform federal "floor" and do not preempt state laws that are more stringent or provide individuals with greater rights with respect to the privacy or security of, and access to, their records containing PHI or insofar as such state laws apply to personal information that is broader in scope than PHI. Certain state laws govern the privacy and security of health-related and other personal information in certain circumstances, some of which are more stringent than HIPAA and many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. Failure to comply with these laws, where applicable, can result in the imposition of significant civil and/or criminal penalties and private litigation. The State of California, for example, has implemented comprehensive laws and regulations. The California Confidentiality of Medical Information Act (CMIA) imposes restrictive requirements regulating the use and disclosure of health information and other personally identifiable information. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">In addition to the CMIA, California adopted the California Consumer Privacy Act of 2018 (CCPA), which went into effect January 1, 2020. The CCPA, among other things, created new data privacy obligations for covered companies and provides new privacy rights to California residents, including the right to opt out of certain disclosures of their information. It also created individual privacy rights for California consumers and increased the privacy and security obligations of entities handling certain categories of personal information. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. Although the law includes limited exceptions, including for PHI maintained by a Covered Entity or Business Associate under HIPAA and medical information maintained by healthcare providers under the CMIA, it may regulate or impact our processing of personal information depending on the context. Further, the California Privacy Rights Act (CPRA) went into effect January 1, 2023, strengthening the CCPA. The CPRA imposes additional data protection obligations on covered businesses, including additional consumer rights processes, limitations on data uses, new audit requirements for higher risk data, and opt outs for certain uses of sensitive data and expands the application of the CCPA to all human resources personal information of our California-based employees. It also created a new California data protection agency authorized to issue substantive regulations and is expected to result in increased privacy and information security enforcement. Various states such as Colorado, Connecticut, Delaware, Florida, Indiana, Iowa, Kentucky, Maryland, Montana, Nebraska, New Hampshire, New Jersey, Oregon, Rhode Island, Tennessee, Texas, Utah, and Virginia have enacted their own omnibus consumer </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">privacy laws similar to the CCPA, and other states are considering proposals for such laws, all of which increases the complexity of compliance and the risk of failures to comply.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">Numerous other federal and state laws, including consumer protection laws and regulations, govern the collection, dissemination, use, access to, confidentiality and security of patient health information. For example, Washington state recently enacted the &#8220;My Health My Data&#8221; Act which regulates a broad category called &#8220;consumer health data,&#8221; defined as &#8220;personal information that is linked or reasonably linkable to a consumer and that identifies a consumer&#8217;s past, present, or future physical or mental health.&#8221; Notably, the &#8220;My Health My Data&#8221; Act contains a private right of action, which is expected to increase litigation. In addition, Congress and some states are considering new laws and regulations that further protect the privacy and security of medical records or medical information. With the recent increase in publicity regarding data breaches resulting in improper dissemination of consumer information, all 50 states have passed laws regulating the actions that a business must take if it experiences a data breach, as defined by state law, including prompt disclosure within a specified amount of time to affected individuals. In addition to data breach notification laws, some states have enacted statutes and rules requiring businesses to reasonably protect certain types of personal information they hold or to otherwise comply with certain specified data security requirements for personal information. Congress has also been considering similar federal legislation relating to data privacy and data protection. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">Many states have also implemented genetic testing and privacy laws imposing specific patient consent requirements and requirements for protecting test results. The interplay of federal and state laws regulating genetic information may be subject to varying interpretations by courts and government agencies, creating complex compliance issues for us and potentially exposing us to additional expense, adverse publicity and liability. Further, as regulatory focus on genetic privacy issues continues to increase and laws and regulations concerning the protection of personal information expand and become more complex, these potential risks to our business could intensify. In addition, the interpretation and application of consumer, health-related, and data protection laws are often uncertain, contradictory, and in flux. For example, increasing concerns about health information privacy have recently prompted the federal government to issue guidance, taking a newly expansive view of the scope of the laws and regulations that they enforce. The applicability and requirements of these laws and penalties for violations vary widely. Failure to maintain compliance, or changes in state or federal laws regarding privacy or security, could result in civil and/or criminal penalties and damages and could have a material adverse effect on our business.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">Also, more than thirty states regulate artificial intelligence (AI) or are considering proposed legislation that would regulate AI. Generally, such regulations aim to protect individuals such as consumers, employees, and/or job applicants from bias, discrimination, and invasion of privacy and to promote transparency with respect to use of AI by companies.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Information Blocking Rules</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Office of the National Coordinator for Health Information Technology (ONC) coordinates the ongoing development of standards to enable interoperable health information technology infrastructure nationwide in the healthcare sector. In May 2020, ONC released the final Information Blocking Rule to implement the interoperability and patient access provisions of the 21st Century Cures Act, which took effect in 2021. We need to continually review our practices for conduct that could be considered as likely to interfere with access, exchange or use of electronic health information, as those practices are prohibited by the Information Blocking Rule, unless one of the exceptions outlined in the Information Blocking Rule applies. Among other things, the Information Blocking Rule requires us to provide patients with on-demand access to laboratory test results. These requirements can be inconsistent with our obligations as a laboratory under state law and/or medical or ethical standards. It is currently unclear how the ONC will approach delays in providing patient access in these situations. Healthcare providers including laboratories will be subject "disincentives" for violations of the Information Blocking Rule. HHS and ONC released a final rule establishing disincentives for health care providers that have committed information blocking on June 24, 2024, potentially affecting certain providers&#8217; eligibility in the Medicare Promoting Interoperability Program and Medicare Shared Savings Program. HHS indicated it may establish additional health care provider disincentives in future rulemaking.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">GDPR and Foreign Laws </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are also subject to foreign privacy laws in the foreign jurisdictions in which we sell our testing products. The interpretation, application and interplay of consumer and health-related data protection laws in the United States, Europe and elsewhere are often uncertain, contradictory and in flux. In Europe, the General Data Protection Regulation (GDPR) went into full effect in May 2018. The GDPR implements stringent operational requirements for processors and controllers of personal data, including, for example, expanded disclosures about how personal information is collected and used, limitations on retention of information, increased requirements pertaining to health </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">data and pseudonymized (i.e., key-coded) data, mandatory data breach notification requirements, more robust rights for individuals in regard to their personal data and higher standards for controllers to demonstrate that they have obtained valid consent for certain data processing activities. It provides that European Union (EU), and European Economic Area (EEA), member states may make their own further laws and regulations, which may impose further limitations, including in relation to the processing of biometric or health data, which may result in differences between member state laws, limit our ability to use and share personal data, cause our costs to increase and/or harm our business and/or financial condition.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Among other requirements, the GDPR also regulates transfers of personal data subject to the GDPR to third countries that have not been found to provide adequate protection to such personal data, including the United States, and the efficacy and longevity of current transfer mechanisms between the EU and the United States remains uncertain. For example, in 2016, the EU and the United States agreed to a transfer framework for data transferred from the EU to the United States, called the Privacy Shield, but the Court of Justice of the EU invalidated the Privacy Shield when it decided the case Maximilian Schrems vs. Facebook (Case C-311-18), known as &#8220;Schrems II.&#8221; However, on July 10, 2023, the European Commission adopted an adequacy decision for a new mechanism for transferring data from the EU to the United States &#8211; the EU-U.S. Data Privacy Framework, which provides EU individuals with several new rights, including the right to obtain access to their data, or obtain correction or deletion of incorrect or unlawfully handled data. The adequacy decision followed the signing of an executive order introducing new binding safeguards to address the points raised in the Schrems II decision. Notably, the new obligations were geared to ensure that data can be accessed by U.S. intelligence agencies only to the extent necessary and proportionate and to establish an independent and impartial redress mechanism to handle complaints from Europeans concerning the collection of their data for national security purposes. The European Commission will continually review developments in the United States along with its adequacy decision. Adequacy decisions can be adapted or even withdrawn in the event of developments affecting the level of protection in the applicable jurisdiction, and uncertainty surrounding the continuing independence of the redress mechanism in the United States could lead the EU to revisit or withdraw its adequacy decision. Future actions of EU data protection authorities are difficult to predict. Some customers or other service providers may respond to these evolving laws and regulations by asking us to make certain privacy or data-related contractual commitments that we are unable or unwilling to make. This could lead to the loss of current or prospective customers or other business relationships.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Relatedly, following the United Kingdom&#8217;s withdrawal from the EU, the GDPR was implemented in the United Kingdom as the U.K. GDPR with the U.K. GDPR sits alongside the amended U.K. Data Protection Act 2018, retains the GDPR in U.K. national law. Under the U.K. GDPR, companies not established in the United Kingdom but who process personal data in relation to the offering of goods or services to individuals in the United Kingdom, or to monitor their behavior will be subject to the U.K. GDPR&#8212;the requirements of which are (at this time) largely aligned with those under the EU GDPR and as such, may lead to similar compliance and operational costs with potential fines of up to &#163;17.5 million or 4% of global turnover. In June of 2021, the European Commission issued a decision, which will sunset on June 27, 2025 without further action, that the United Kingdom ensures an adequate level of protection for personal data transferred under the EU GDPR from the EU to the United Kingdom.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Billing and Government Reimbursement for Clinical Laboratory Services </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Medicare</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Medicare coverage is limited to items and services within the scope of a Medicare benefit category that are reasonable and necessary for the diagnosis or treatment of an illness or injury. With respect to Medicare coverage, Palmetto GBA, the Medicare Administrative Contractor (MAC) responsible for administering Medicare&#8217;s molecular diagnostic services program (MolDX Program), issued a Local Coverage Determination (LCD) that provides coverage for our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> MTX test. The MAC responsible for administering Medicare claims submitted by our laboratory, Noridian Healthcare Solutions (Noridian), has adopted Palmetto&#8217;s positive coverage policy, along with a related local coverage article that identifies a unique billing identifier for this test. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under Medicare, payment for our laboratory tests is generally made under the Clinical Laboratory Fee Schedule (CLFS) with payment amounts assigned to specific procedure billing codes. In April 2014, Congress passed the Protecting Access to Medicare Act (PAMA), which substantially changed the way in which Medicare sets the payment amounts for clinical laboratory services. Under PAMA, laboratories that receive the majority of their Medicare revenue from payments made under the CLFS or the Physician Fee Schedule (PFS) are required to report to CMS, beginning in 2017 and every three years thereafter (or annually for "advanced diagnostic laboratory tests" (ADLTs)), private payor payment rates and volumes for their tests. Laboratories that fail to report the required payment information may be subject to substantial civil monetary penalties. As required under PAMA, CMS uses the rates and volumes reported by laboratories to develop Medicare payment rates for laboratory tests equal to the volume-weighted median of the private payor payment rates for the tests. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On June 23, 2016, CMS published the final rule implementing the reporting and rate-setting requirements under PAMA. For tests furnished on or after January 1, 2018, Medicare payments for clinical diagnostic laboratory tests (CDLTs) are based upon these reported private payor rates. For CDLTs assigned a new or substantially revised Current Procedural Terminology (CPT), because there is no comparable existing CDLT, CMS will set the initial payment rates using the gap-fill methodology, as under prior law. Initial payment rates for new ADLTs will be based on the actual list charge. Any reductions to payment rates resulting from the new methodology are limited to up to 10% per test per year in each of the years 2018 through 2020. As noted below, federal law has delayed implementation of further reductions until 2025, at which time the reduction cap will rise to 15% per test per year. PAMA did not impact Medicare reimbursement for AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD in 2024 compared to levels experienced in 2023. Additionally, we do not expect PAMA and changes to the PFS will not have a significant impact to Medicare reimbursement for AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD in 2025 compared to levels experienced in 2024.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Since December 2019, Congress has passed a series of laws to modify PAMA&#8217;s statutory requirements related to the data reporting period and phase-in of payment reductions under the CLFS or CDLTs that are not ADLTs. Most recently, on September 26, 2024, Section 221 of the Continuing Appropriations and Extensions Act, 2025, was passed, and it delayed data reporting requirements for CDLTs that are not ADLTs as well as the phase-in of payment reductions. The next data reporting period for CDLTs that are not ADLTs will be January 1, 2026 through March 31, 2026, and will be based on the original data collection period of January 1, 2019 through June 30, 2019. After this data reporting period, the three-year data reporting cycle for these tests will resume (e.g., 2028, 2031, etc.).</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The same series of laws modified the phase-in of payment reductions resulting from private payor rate implementation so that a 0.0% reduction limit was applied for calendar years (CYs) 2021 through 2024, as compared to the payment amounts for a test the preceding year. The Further Continuing Appropriations and Other Extensions Act, 2025, further applied a 0.0% reduction limit for CY 2025. Consequently, payment may not be reduced by more than 15% per year for CYs 2026 through 2028 as compared to the payment amounts established for a test the prior year.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">PAMA also authorized the adoption of new, temporary billing codes and unique test identifiers for FDA-cleared or approved tests, as well as ADLTs. The American Medical Association's (AMA) CPT Editorial Panel approved a proposal to create a new section of billing codes called Proprietary Laboratory Analyses (PLA) codes, to facilitate implementation of this section of PAMA. The AMA publishes approved codes on a quarterly basis.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Billing for diagnostic testing can be complicated. Depending on the billing arrangement and applicable law, we must bill various parties, such as commercial payors, Medicare, Medicaid, physicians, hospitals, employer groups and patients, all of which have different billing requirements. Additionally, compliance with applicable laws and regulations as well as internal compliance policies and procedures adds further complexity to the billing process. Changes in laws and regulations could negatively impact our ability to bill our clients or increase our costs. CMS also establishes new procedures and continuously evaluates and implements changes to the reimbursement process for billing government healthcare programs. Missing or incorrect information on test requisitions adds complexity to and slows the billing process, creates backlogs of unbilled tests, and generally increases the aging of accounts receivable and bad debt expense. Failing to bill timely or correctly may have negative consequences for us, such as not being reimbursed for our services or experiencing an increase in the aging of our accounts receivable, which could adversely impact our results of operations and cash flows. Failure to comply with applicable laws relating to billing federal healthcare programs could also lead to various penalties, including:</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.46pt">overpayments and recoupments of reimbursement received;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.46pt">exclusion from participation in Medicare/Medicaid programs;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.46pt">asset forfeitures;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.46pt">civil and criminal fines and penalties; and</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.46pt">the loss of various licenses, certificates and authorizations necessary to operate our business.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Any of these penalties or sanctions could have a material adverse effect on our results of operations or cash flows. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Environmental and Other Regulatory Requirements</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our laboratory is subject on an ongoing basis to federal, state and local laws and regulations governing the use, storage, handling and disposal of regulated medical waste, hazardous waste and biohazardous waste, including chemicals, biological agents and compounds and blood and other tissue specimens. Typically, we use licensed or otherwise qualified outside vendors to dispose of this waste. However, many of these laws and regulations provide </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">for strict liability, holding a party potentially liable without regard to fault or negligence. As a result, we could be held liable for damages and fines if our, or others', business operations or other actions result in contamination of the environment or personal injury due to exposure to hazardous materials. Our costs for complying with these laws and regulations cannot be estimated or predicted and depends on a number of factors, including the amount and nature of waste we produce (which depends in part on the number of tests we perform) and the terms we negotiate with our waste disposal vendors. Since inception, we have disposed of all hazardous and/or medical waste that we produced across our entire business through environmentally sound methods.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our operations are also subject to extensive requirements established by the U.S. Occupational Safety and Health Administration relating to workplace safety for healthcare employees, including requirements to develop and implement programs to protect workers from exposure to blood-borne pathogens by preventing or minimizing any exposure through needle stick or similar penetrating injuries.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Information About Our Directors and Executive Officers</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following persons currently serve as the directors and executive officers of Exagen:</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.502%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:66.298%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Directors and Executive Officers</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Position</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Executive Officers</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">John Aballi</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President, Chief Executive Officer and Director</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jeffrey G. Black</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer and Corporate Secretary</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tina Nova, Ph.D.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Chairman of the Board of Directors</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Directors</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ana Hooker</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President, Chief Laboratory Officer, Exact Sciences Corporation</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Scott Kahn, Ph.D.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director, Rady Children's Institute for Genomic Medicine</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Paul Kim</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer, Fulgent Genetics, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bruce Robertson, Ph.D.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Managing Director, H.I.G Capital, LLC</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Frank Stokes</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer, Castle Biosciences, Inc.</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Environmental, Social and Governance Matters</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In 2022, we created our Environmental, Social and Governance Committee (ESG Committee) with the purpose, duties and responsibility of reviewing and recommending our programs, policies and practices relating to ESG issues. The ESG Committee meets formally at least annually and plans to make recommendations to our President and Chief Executive Officer to be presented to the audit committee of our board of directors (the Audit Committee) when warranted. For more information regarding our ESG initiatives, please refer to www.exagen.com/investors.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Suppliers </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We rely on sole suppliers for the critical supply of reagents, equipment and other materials that we use to perform the tests that comprise our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products. We also purchase components used in our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing product transportation kits from sole-source suppliers. Some of these items are unique to these suppliers and vendors. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Financial Information </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We manage our operations and allocate resources as a single reporting segment. Financial information regarding our operations, assets and liabilities, including our net loss for the years ended December 31, 2024 and 2023 and our total assets as of December 31, 2024 and 2023, is included in our Financial Statements in Item 8 of this Annual Report.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Corporate Information</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We were incorporated under the laws of the state of New Mexico in 2002, under the name Exagen Corporation. In 2003, we changed our state of incorporation from New Mexico to Delaware by merging with and into Exagen Diagnostics, Inc., pursuant to which we changed our name to Exagen Diagnostics, Inc. In January 2019, we changed our name to Exagen Inc. Our principal executive offices are located at 1261 Liberty Way, Vista, California </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">92081. Our telephone number is (760) 560-1501. Our website address is www.exagen.com. The information contained in, or accessible through, our website is not part of, and is not incorporated by reference into, this Annual Report. Investors should not rely on any such information in deciding whether to purchase our common stock.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Available Information</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We file Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, proxy and information statements and other information with the Securities and Exchange Commission (SEC). Our filings with the SEC are available free of charge on the SEC&#8217;s website and on the "Investors" section of our website as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC. The SEC maintains a website that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC at www.sec.gov.</span></div><div id="i9ecffbbbc3a143a09815a7575cabd836_16"></div><div style="margin-top:21pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item 1A. Risk Factors.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Investing in our common stock involves a high degree of risk. You should consider carefully the risks and uncertainties described below, together with all of the other information included in this Annual Report, including our financial statements and related notes and "Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations," before making an investment decision to purchase or sell shares of our common stock. If any of the following risks are realized, our business, financial condition, results of operations and prospects could be materially and adversely affected. In that event, the trading price of our common stock could decline, and you could lose part or all of your investment. The risks described below are not the only ones that we may face, and additional risks or uncertainties not known to us or that we currently deem immaterial may also impair our business and future prospects.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Summary Risk Factors</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The risk factors described below are a summary of the principal risk factors associated with an investment in us. These are not the only risks we face. You should carefully consider these risk factors, together with the risk factors set forth in this Item 1A:</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:12.84pt">Our operating results may fluctuate significantly, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations or any guidance we may provide. We have a history of losses and we may not be able to generate sufficient revenue to achieve and maintain profitability. Our estimates regarding profitability and the time in which we may achieve profitability may ultimately be incorrect;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">If third-party payors do not provide coverage and adequate reimbursement for our testing products, or they breach, rescind or modify their contracts or reimbursement policies or delay payments for our testing products, or if we or our partners are unable to successfully negotiate payor contracts, our commercial success could be materially compromised;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">In the near-term, we expect that our financial results will depend primarily on sales of our testing products, and we will need to generate sufficient revenue from these testing products to grow our business;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">We may be unable to manage our growth effectively, which could make it difficult to execute our business strategy;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Our commercial success depends on attaining and maintaining significant market acceptance of our testing products among rheumatologists, patients, third-party payors and others in the medical community; </span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">We rely on sole suppliers for some of the reagents, equipment and other materials used in our testing products, and a sole third-party fulfillment center used to supply healthcare providers with our testing products, and we may not be able to fund replacements or transition to alternative suppliers or fulfillment centers;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">If we are unable to support demand for our current testing products or any of our future testing products or solutions, our business could suffer;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">If we are unable to compete successfully, we may be unable to increase or sustain our revenue or achieve profitability;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Developing new testing products involves a lengthy and complex process, and we may not be able to commercialize on a timely basis, or at all, other testing products we are developing;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">If our sole clinical laboratory facility becomes damaged or inoperable, we are required to vacate our existing facility or we are unable to expand our existing facility as needed, we will be unable to perform our testing services and our business will be harmed;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">We may require substantial additional capital to finance our planned operations, which may not be available to us on acceptable terms or at all. Our failure to obtain additional financing when needed on acceptable terms, or at all, could force us to delay, limit, reduce or eliminate our product development programs, commercialization efforts or other operations;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">We conduct business in a heavily regulated industry. Complying with the numerous statutes and regulations pertaining to our business is expensive and time-consuming, and any failure by us, our consultants or commercial partners to comply could result in substantial penalties;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">We have previously and may again in the future be required to modify our business practices, pay fines, incur significant expenses or experience losses due to litigation or governmental investigations;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">The FDA may disagree with our assessment that our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> test products and any other tests we may develop are LDTs eligible for enforcement discretion and determine that such test products are fully subject to active compliance enforcement under the FDCA and FDA regulations;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">If we are unable to maintain intellectual property protection, our competitive position could be harmed; and</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">If we fail to comply with our obligations in the agreements under which we license intellectual property rights from third parties or otherwise experience disruptions to our business relationships with our licensors, we could lose license rights that are important to our business.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Risks Related to Our Business and Strategy </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We have a history of losses, we expect to incur net losses in the future and we may not be able to generate sufficient revenue to achieve and maintain profitability. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have incurred net losses since our inception. For the years ended December&#160;31, 2024 and 2023, we incurred net losses of $15.1 million and $23.7 million, respectively, and we expect to incur additional losses in 2025 and in future periods. As of December&#160;31, 2024, we had an accumulated deficit of $294.3 million. We also expect to continue to devote substantial resources to increase adoption of, and reimbursement for, our testing products and to develop future testing products. Over the next several years, we expect to continue to devote substantially all of our resources to increase adoption of, and reimbursement for, our testing products and to develop future testing products. We may not be able to generate sufficient revenue to achieve and maintain profitability. Our failure to achieve and maintain profitability in the future could cause the market price of our common stock to decline and materially and adversely affect our prospects and business. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">If third-party payors do not provide coverage and adequate reimbursement for our testing products, or they breach, rescind or modify their contracts or reimbursement policies or delay payments for our testing products, or if we or our partners are unable to successfully negotiate payor contracts, our commercial success could be materially compromised. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Successful commercialization, or continued commercialization, of our testing products depends, in large part, on the availability of coverage and adequate reimbursement from third-party payors, including government payors, such as Medicare and Medicaid and commercial payors. For the testing products that we develop and commercialize, each third-party payor decides whether to cover the product, the amount it will reimburse for a covered product and the specific conditions for reimbursement. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Reimbursement by third-party payors may depend on a number of factors, including the payor&#8217;s determination that tests using our technologies are: </span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">not experimental or investigational; </span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">medically necessary; </span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">demonstrated to lead to improved patient outcomes; </span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">appropriate for the specific patient; </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">cost-saving or cost-effective; </span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">supported by peer-reviewed medical journals; and </span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">included in clinical guidelines. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If we are unable to provide third-party payors with sufficient evidence of the clinical utility and validity of our tests, they may not provide coverage, or may provide limited coverage, which may materially and adversely affect our revenue and our ability to succeed. In addition, clinicians may be less likely to order a test unless third-party payors pay a substantial portion of the test price. Therefore, coverage determinations and reimbursement levels and conditions are critical to commercial success, and if we are not able to secure positive coverage determinations and reimbursement levels, our business may be materially adversely affected.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Third-party payors and other entities also conduct technology assessments of new medical tests and devices and provide and/or sell the results of their assessments to other parties. These assessments may be and have been used by third-party payors and healthcare providers as grounds to deny coverage for or refuse to use a test or procedure, including our tests. In addition, third-party payors have increased their efforts to control the cost, utilization and delivery of healthcare services. These measures have resulted in reduced payment rates and decreased utilization for the diagnostics industry. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Effective April 25, 2012, Palmetto GBA, the Medicare MolDx Program, assigned the AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> MTX assay a unique identifier and determined that the test meets the applicable Medicare coverage criteria to support dose optimization and therapeutic decision making for patients diagnosed with RA on methotrexate. Our current Medicare Administrative Contractor, Noridian, has adopted this coverage policy. In addition, and effective April 1, 2022, CMS agreed to recognize a new PLA code for our protein-based test, AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus. Noridian priced this PLA code at $1,085 per test. To determine pricing beyond 2022, CMS recommended crosswalking AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus (0312U) to Vectra (81490) at a rate of $840.65 per test. This pricing was finalized on the 2023 CLFS and is effective from January 1, 2023 through December 31, 2025. A pricing determination is not synonymous with a coverage determination. Having a price associated with the PLA code for any particular test does not secure coverage or reimbursement for that PLA code from Medicare or any other third-party payor. So, in an effort to improve transparency regarding Medicare support of AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus, we submitted a formal request to Noridian for coverage of our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus test under the new PLA Code. On September 27, 2022, we received notice that Noridian has deemed our application for an LCD to be valid, but our application is still pending. Ultimately receiving a favorable LCD is uncertain and may be time-consuming, resource intensive and require multiple quarterly or annual periods to complete. We have faced and may again face or continue to face challenges relating to commercial payor claim processing and revenue with our tests.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other third-party payors make their own decisions as to whether to establish a policy to reimburse our testing products. Because approvals must be sought on a payor-by-payor basis, establishing broad coverage is a time-consuming and costly process. There are many third-party payors who have not yet established a coverage policy applicable to our testing products. In addition, several commercial payors issued non-coverage policies with respect to AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus, determining that AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus does not meet the medical criteria for coverage and is considered investigational and/or experimental. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">While our testing products are reimbursed by a number of third-party payors, we do not currently have contracts with significant private payors. We have in the past, and will likely in the future, experience delays and temporary interruptions in the receipt of payments from third-party payors due to changes in their internal processes, documentation requirements and other issues, which could cause our revenue to fluctuate from period to period. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If we are not successful in reversing existing non-coverage policies, or if other third-party payors issue negative coverage policies, these policies could have a material adverse effect on our business and operations. Even if many third-party payors currently reimburse for our testing products, such payors have in the past and may again withdraw coverage at any time, review and adjust the rate of reimbursement, require co-payments from patients or stop paying for our testing products altogether, any of which could materially reduce our revenue. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Our operating results may fluctuate significantly, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations or any guidance we may provide. Our estimates regarding profitability and the time in which we may achieve profitability may ultimately be incorrect.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our quarterly and annual operating results may fluctuate significantly, which makes it difficult for us to predict our future operating results. The estimated time in which we may achieve positive Adjusted EBITDA and profitability and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">fluctuations in our operating results may vary from period to period due to a variety of factors, many of which are beyond our control. These factors include, but are not limited to: </span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">our ability to successfully market and sell our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">our ability to increase the average selling price for our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">our ability to successfully commercialize new testing products and to do so in the timelines in which we expect, including the January 2025 launch of AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD incorporating our new T-Cell Biomarkers and RA Sub-Profile Biomarkers; </span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the extent to which the T-Cell Biomarkers and RA Sub-Profile Biomarkers are reimbursed by third-party payors; </span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the extent to which our current testing and future testing products, if any, are eligible for coverage and reimbursement from third-party payors;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the timing and cost of, and level of investment in, research, development, regulatory approval and commercialization activities relating to our testing products, which may change from time to time</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the cost of supplies, equipment and materials used for our testing products and laboratory operations, which may vary depending on the quantity of production and the terms of our agreements with third-party suppliers and manufacturers; </span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">expenditures that we may incur to acquire, develop or commercialize additional testing products and technologies; </span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the level of demand for our testing products, which may vary significantly; </span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the receipt, timing and mix of revenue for our testing products; </span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">future accounting pronouncements or changes in our accounting policies;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">our ability to collect timely reimbursement for our tests;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the rate and extent to which payors make an overpayment determination and require us to return all or some portion of payments which we received in a prior period; and</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the timing and success or failure of competing products, or any other change in the competitive landscape of our industry, including consolidation among our competitors or partners. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The cumulative effects of these factors could result in large fluctuations and unpredictability in our quarterly and annual operating results and could cause our estimates regarding positive Adjusted EBITDA profitability to ultimately be incorrect. For instance during 2024, our quarterly operating results varied due, in part, to our efforts regarding revenue cycle management. As a result, comparing our operating results on a period-to-period basis may not be meaningful. Investors should not rely on our past results as an indication of our future performance. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">This variability and unpredictability could also result in our failing to meet the expectations of industry or financial analysts or investors for any period. If our revenue, Adjusted EBITDA, profitability estimates or operating results fall below the expectations of analysts or investors or below any forecasts we may provide to the market, this could have a material adverse effect on our business, financial condition and results of operations and/or cause the market price of our common stock to decline. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">In the near-term, we expect that our financial results will depend primarily on sales of our testing products, and we will need to generate sufficient revenue from these testing products to grow our business. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A significant majority of our historical revenue has been derived from the sale of our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD testing product, which we commercially launched in 2012. In the near term, we expect to continue to derive a majority of our revenue from sales of AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD. We are in various stages of commercialization and research and development with respect to other testing products that we may offer, but there can be no assurance that we will be able to successfully develop or commercialize these testing products. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The demand for our testing products may decrease or may not continue to increase at historical rates for a number of reasons. In addition, at any point in time we may decide to no longer commercialize any of our testing products for any number of reasons. While we have experienced revenue growth from the sale of our testing products, we </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">may not be able to sustain this growth or maintain existing revenue levels. Further, we cannot ensure the continued availability of our testing products in commercial quantities at acceptable costs. If we are unable to increase sales of our testing products, expand reimbursement for our testing products, or successfully develop and commercialize additional testing products, our revenue and our ability to achieve and sustain profitability would be impaired, and the market price of our common stock could decline.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Business disruptions could seriously harm our future revenue and financial condition and increase our costs and expenses. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our operations could be subject to earthquakes, power shortages, telecommunications failures, water shortages, floods, hurricanes, typhoons, fires, extreme weather conditions, medical epidemics, political instability, acts of war, including the current conflicts in Ukraine and the Middle East, and other natural or manmade disasters (which may be exacerbated due to climate change) or business interruptions, for which we are predominantly self-insured. We rely on third-party manufacturers to produce our testing products. Our ability to obtain clinical supplies of our testing products could be disrupted if the operations of these suppliers were affected by a man-made or natural disaster or other business interruption. In addition, our corporate headquarters is located in Vista, California near major earthquake faults and fire zones, and the ultimate impact on us of being located near major earthquake faults and fire zones and being consolidated in a certain geographical area is unknown. The occurrence of any of these business disruptions could seriously harm our operations and financial condition and increase our costs and expenses.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">If we fail to maintain proper and effective internal control over financial reporting, our ability to produce accurate and timely financial statements could be impaired, investors may lose confidence in our financial reporting and the trading price of our common stock may decline.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Pursuant to Section 404 of Sarbanes-Oxley, our management is required to report upon the effectiveness of our internal control over financial reporting. When we reach an accelerated filer threshold, our independent registered public accounting firm will be required to attest to the effectiveness of our internal control over financial reporting. The rules governing the standards that must be met for management to assess our internal control over financial reporting are complex and require significant documentation, testing and possible remediation. To comply with the requirements of being a reporting company under the Exchange Act, we may need to upgrade our information technology systems; implement additional financial and management controls, reporting systems and procedures; and/or hire additional accounting and finance staff as we grow. If we or, if required, our auditors are unable to conclude that our internal control over financial reporting is effective, investors may lose confidence in our financial reporting and the trading price of our common stock may decline.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our management has previously identified material weaknesses in our internal controls that we believe have been remediated, however we cannot assure you that there will not be material weaknesses or significant deficiencies in our internal control over financial reporting in the future. Any failure to maintain internal control over financial reporting could severely inhibit our ability to accurately report our financial condition, results of operations or cash flows. If we are unable to conclude that our internal control over financial reporting is effective, or if our independent registered public accounting firm determines we have a material weakness or significant deficiency in our internal control over financial reporting once that firm begin its Section 404 reviews, investors may lose confidence in the accuracy and completeness of our financial reports, the market price of our common stock could decline, and we could be subject to sanctions or investigations by the Nasdaq Stock Market LLC, the SEC or other regulatory authorities. Failure to remedy any material weakness in our internal control over financial reporting, or to implement or maintain other effective control systems required of public companies, could also restrict our future access to the capital markets.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We may be unable to manage our growth effectively, which could make it difficult to execute our business strategy. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition to the need to scale our testing capacity, our future growth plans may also impose significant added responsibilities on management, including the need to identify, recruit, train and integrate additional employees and the need to manage additional relationships with various partners, suppliers and other third parties. In addition, if we were to experience rapid and significant growth, our administrative and operational infrastructure may be strained, requiring us to expand our financial, development, regulatory, manufacturing, marketing and sales capabilities or contract with third parties to provide these capabilities for us. Our ability to manage our business and growth, as well as function as a public company, will require us to continue to improve our operational, financial and management controls, reporting systems and procedures. The time and resources required to optimize these systems is uncertain, and failure to complete optimization in a timely and efficient manner could adversely affect our operations. If we are unable to manage our ongoing and future growth effectively, it may be difficult for us to execute our business strategy and our business could be harmed. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our commercial success depends upon attaining and maintaining significant market acceptance of our testing products among rheumatologists, patients, third-party payors and others in the medical community. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our success depends on our ability to continue to develop and market testing products that are recognized and accepted as safe, effective, reliable and cost effective, and any testing product that we offer may not gain or maintain market acceptance among rheumatologists, third-party payors, patients or the medical community. Market acceptance of our testing products depends on a number of factors, including: </span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the perceived accuracy of our test results by rheumatologists and patients;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the potential and perceived advantages of our testing products over alternative products;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the demonstration of the performance and clinical validity of our testing products in clinical studies, the results of which, may not replicate the positive results from earlier studies; </span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the introduction of new tests that compete with our testing products;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the product cost in relation to alternative products;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">publicity concerning our testing products or competing products and treatments;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the availability of coverage and adequate reimbursement by third-party payors, including government authorities;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">relative convenience and ease of administration; and</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the effectiveness of our sales and marketing efforts.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, if we or our future partners have to withdraw a product from the market, it could harm our business and/or impact market acceptance of our other testing products. Further, our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products consist of various biomarkers, any of which could independently encounter issues with manufacturing, supply or overall quality. If any of the biomarkers in our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD test were to encounter any issues, we may experience an impact in the overall success of AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">CTD as a whole, including a reduction in ASP or overall revenue, until such time as it can be remedied. Moreover, if our testing products do not achieve an adequate level of acceptance by rheumatologists, hospitals, third-party payors or patients, we may not generate sufficient revenue from that testing product and may not become or remain profitable. Our efforts to educate the medical community and third-party payors regarding the benefits of our testing products may require significant resources and may never be successful. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We may experience limits on our revenue if healthcare providers decide not to order our testing products or if we are otherwise unable to create or maintain demand for our testing products. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If we are unable to create or maintain demand for our testing products in sufficient volume, we may not generate sufficient revenue to become profitable. To generate increased demand, we will need to continue to educate healthcare providers about the benefits of our testing products through publications in peer-reviewed medical journals, presentations at medical conferences and other similar means. For example, in the fourth quarter of 2024, we were featured in five scientific presentations at the 2024 ACR annual meeting. We will also need to generate demand for our testing products through one-on-one education by our sales force. We also plan to focus on educating patients about the benefits of these testing products, which we believe will be necessary to generate further demand. In addition, our inability to obtain and maintain coverage and adequate reimbursement from third-party payors may limit adoption by healthcare providers, as well as third-party payors exerting pressure on healthcare providers to order in-network testing products which could adversely affect our revenue.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Healthcare providers may rely on guidelines issued by industry groups regarding the diagnosis, prognosis, treatment and monitoring of autoimmune and autoimmune-related diseases, and the monitoring of the effectiveness of therapeutic drugs used to treat such diseases before utilizing any diagnostic test or monitoring solution. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">The sizes of the markets for our testing products have not been established with precision and may be smaller than we estimate. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our estimates of the annual total addressable markets for our current and potential future testing products are based on a number of internal and third-party estimates. These include, without limitation, the number of patients with autoimmune and autoimmune-related diseases and the assumed prices at which we can sell testing products and our partners can sell therapeutics in markets that have not been established. While we believe our assumptions and the data underlying our estimates are reasonable, these assumptions and estimates may not be correct and the conditions supporting our assumptions or estimates may change at any time, thereby reducing the predictive </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">accuracy of these underlying factors. As a result, our estimates of the annual total addressable market for our current and potential future testing products may prove to be incorrect. If the actual number of patients who would benefit from our testing products, the price at which we and our partners can sell future testing products, or the annual total addressable market for our testing products is smaller than we have estimated, it may impair our sales growth and have an adverse impact on our business. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We may expend our limited resources to pursue a particular testing product and fail to capitalize on other testing products that may be more profitable or for which there is a greater likelihood of success. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Because we have limited financial and managerial resources, we focus on specific testing products. As a result, we may forego or delay pursuit of opportunities with others that could have had greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. In addition, our spending on current and future research and development programs for testing products may not yield any commercially viable testing products. If we do not accurately evaluate the commercial potential or target market for a potential testing product, we may forego other similar arrangements which would have been more advantageous for us to pursue.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We rely on sole suppliers for some of the reagents, equipment and other materials used in our testing products, and a sole third-party fulfillment center used to supply healthcare providers with our testing products, and we may not be able to find replacements or transition to alternative suppliers or fulfillment centers.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We rely on sole suppliers for critical supply of reagents, equipment and other materials that we use to perform the tests that comprise our testing products. We also purchase components used in our specimen collection and transportation kits from sole-source suppliers. Some of these items are unique to these suppliers and vendors. While we have developed alternate sourcing strategies for many of these materials and vendors, we cannot be certain whether these strategies will be effective or the alternative sources will be available when we need them. We are not a major customer of some of our suppliers, and these suppliers may therefore give other customers&#8217; needs higher priority than ours. If our suppliers can no longer provide us with the materials we need to perform the tests that comprise our testing products, if the materials do not meet our quality specifications, or if we cannot obtain acceptable substitute materials, an interruption in test processing could occur and, in certain circumstances, we may be required to amend or cancel test results we have issued. Additionally, if we are unable to remedy future potential quality issues with unique reagent suppliers, or otherwise find a supplier for future biomarkers with issues, we may experience difficulties obtaining market acceptance for our products. Moreover, any issues with quality may result in a change from time to time of the composition of our tests, including our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">CTD test, which could impact the average selling price and revenues received from sales of such test.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, if we should encounter delays or difficulties in securing the quality and quantity of equipment we require for our testing products, we may need to reconfigure our test processes, which could result in an interruption in sales. Any such interruption may significantly affect our future revenue and harm our customer relations and reputation. In addition, in order to mitigate these risks, we may need to maintain inventories of these supplies at higher levels than would be the case if multiple sources of supply were available.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We rely on a third-party as our sole fulfillment center in Georgia to supply healthcare providers with our testing products. Our sole fulfillment center could be harmed or rendered inoperable by natural or man-made disasters, including fire, earthquake, hurricane, flooding, pandemics or other disease outbreaks and power outages, which may render it difficult or impossible for us to supply healthcare providers with our testing products for some period of time. The inability to supply healthcare providers with our testing products or the backlog of tests that could develop if our sole fulfillment center is inoperable for even a short period of time, may result in the loss of customers or harm to our reputation or business relationships, and we may be unable to regain those customers or repair our reputation in the future. Furthermore, our sole fulfillment center could be costly and time-consuming to repair or replace. If our sole fulfillment center is destroyed or otherwise rendered inoperable, we may have difficulty replacing this fulfillment center and there can be no assurance we could do so in a timely manner, on terms favorable to us or at all.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">If we are unable to support demand for our current testing products or any of our future testing products or solutions, our business could suffer. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If demand for our testing products or any of our future testing products or solutions grows, we will need to continue to scale our testing capacity and processing technology, expand customer service, billing and systems processes and enhance our internal quality assurance program. We may also need additional certified laboratory scientists and other scientific and technical personnel to process higher volumes of our testing products. We cannot assure you that any increases in scale, related improvements and quality assurance will be successfully implemented or </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">that appropriate personnel will be available. We will also need to purchase additional equipment, some of which can take several months or more to procure, setup and validate, and increase our software and computing capacity to meet increased demand. Failure to implement necessary procedures, transition to new processes, hire the necessary personnel, obtain any necessary additional equipment and increase software and computing capacity could result in higher costs of processing tests or inability to meet demand. There can be no assurance that we will be able to perform our testing on a timely basis at a level consistent with demand, or that our efforts to scale our operations, expand our personnel, equipment, software and computing capacities, or implement process enhancements will be successfully implemented and will not negatively affect the quality of test results. In addition, there can be no assurance that we will have adequate space in our laboratory facility to accommodate such required expansion. If we encounter difficulty meeting market demand or quality standards, our reputation could be harmed and our future prospects and our business could suffer. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Billing for our testing products is complex, and we must dedicate substantial time and resources to the billing process to be paid for our testing products. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Billing for our testing products is complex, time consuming and expensive. Depending on the billing arrangement and applicable law, we bill various third-party payors, including Medicare and Medicaid, and commercial payors, as well as patients, all of which have different billing requirements. We generally bill third-party payors for our testing products and pursue reimbursement on a case-by-case basis where pricing contracts are not in place. We may also face increased risk in our collection efforts, including long collection cycles and potential delays in claims processing, which could adversely affect our business, results of operations and financial condition. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Several factors contribute to the complexity of the billing process, including: </span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">differences between the list price for our testing products and the reimbursement rates of third-party payors; </span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">compliance with complex federal and state regulations related to billing Medicare and Medicaid; </span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">disputes among third-party payors as to which party is responsible for payment; </span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">differences in coverage among third-party payors; </span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the effect of patient deductibles, co-payments or co-insurance; </span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">differences in information and billing requirements among third-party payors; </span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">changes to billing codes used for our testing products; </span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">risk of government audits related to billing; </span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">incorrect or missing billing information; and </span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the resources required to manage the billing and claims appeals process. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We use standard industry billing codes, known as CPT codes, to bill for our testing products. If these codes were to change, there is risk that errors could be made in the claim adjudication process. Such errors can occur with claims submission, third-party transmission or in the processing of the claim by the payor. Claim adjudication errors may result in a delay in payment processing or a reduction in the amount of the payment received. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As we introduce new testing products, we will need to add new codes to our billing process as well as our financial reporting systems. Failure or delays in effecting these changes in external billing and internal systems and processes could negatively affect our collection rates, revenue and cost of collecting. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our billing activities require us to implement compliance procedures and oversight, train and monitor our employees, and undertake internal audits to evaluate compliance with applicable laws and regulations as well as internal compliance policies and procedures. Payors also conduct external audits to evaluate payments, which add further complexity to the billing process. If the payor makes an overpayment determination, there is a risk that we may be required to return all or some portion of prior payments we have received. Additionally, providers and suppliers must report and return overpayments received from the Medicare and Medicaid programs within 60 days of identification. Failure to identify and return such overpayments exposes the provider or supplier to liability under the federal False Claims Act. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additionally, from time to time, third-party payors change processes that may affect timely payment. These changes have in the past and may again result in uneven cash flow or impact the timing of revenue recognized with these payors. With respect to payments received from government healthcare programs, factors such as a prolonged </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">government shutdown could cause significant regulatory delays or could result in attempts to reduce payments made to us by federal healthcare programs. In addition, third-party payors may refuse to ultimately make payment if their processes and requirements have not been met on a timely basis. These billing complexities, and the related uncertainty in obtaining payment for our testing products could negatively affect our revenue and cash flow, our ability to achieve profitability, and the consistency and comparability of our results of operations.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In 2024, Noridian posted the calendar year 2025 Medicare Physician Fee Schedule (MPFS), and CLFS, which establishes the reimbursement rates to be paid by Medicare for our jurisdiction for services performed on or after January 1, 2025. PAMA and changes to the MPFS and CLFS are not expected to have a significant impact to Medicare reimbursement for AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD in 2025 compared to levels experienced in 2024. Revenue from Medicare comprised 25% and 34% of our revenue for the years ended December&#160;31, 2024 and 2023, respectively. Revenue from the sale of our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD test comprised 91% and 88% of our revenue for the years ended December&#160;31, 2024 and 2023, respectively. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We also rely on a third-party provider to provide revenue cycle management software systems for certain processing and collection functions. In the past, we have experienced delays in claims processing as a result of our third-party provider making changes to its invoicing system, as well as not submitting claims to payors within the timeframe required. If claims for our testing products are not submitted to payors on a timely basis, or if we are required to switch to a different systems provider, it could have an adverse effect on our revenue and our business. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">At times, we share our proprietary technology and confidential information, including trade secrets, with third parties that conduct studies and other services on our behalf. We seek to protect our proprietary technology, in part, by entering into confidentiality agreements, consulting agreements or other similar agreements with our advisors, employees and consultants prior to beginning research or disclosing proprietary information. These agreements typically limit the rights of the third parties to use or disclose our confidential information. Despite the contractual provisions employed when working with third parties, the need to share trade secrets and other confidential information increases the risk that such trade secrets become known by our competitors, are intentionally or inadvertently incorporated into the technology of others or are disclosed or used in violation of these agreements. Given that our proprietary position is based, in part, on our know-how and trade secrets and despite our efforts to protect our trade secrets, a competitor&#8217;s discovery of our proprietary technology and confidential information or other unauthorized use or disclosure would impair our competitive position and may have a material adverse effect on our business, financial condition, results of operations and prospects. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">If we are unable to maintain or expand our sales and marketing force, as needed, to adequately address our customers&#8217; and future partners&#8217; needs, our business may be adversely affected. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We sell our testing products through our own specialized sales force. Our testing products compete in a concentrated specialty market of autoimmune and autoimmune-related diseases, and utilizing a specialized sales force is integral to our strategy. As such, we believe it is necessary to maintain a sales force that includes sales representatives with specific technical backgrounds and industry expertise and expect to continue to evaluate the reach and frequency with rheumatologists, including as we launch our pipeline products. We may be required to expand our specialized sales force as our company grows. Training of additional sales representatives can be costly and time consuming, particularly given the level of experience and sophistication we seek in our sales force. If we are unable to effectively retain, train and integrate additional sales representatives, as needed, it may adversely affect our ability to effectively market and sell our testing products. In addition, competition for highly specialized sales personnel is intense, and we may not be able to attract and retain personnel or be able to maintain an efficient and effective sales and marketing force. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our future sales will depend in large part on our ability to maintain an effective sales force. If we are unsuccessful in this regard, it could negatively impact our revenue growth and potential profitability. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">If we are unable to compete successfully, we may be unable to increase or sustain our revenue or achieve profitability. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our principal competition for our testing products is traditional methods used by healthcare providers to test patients with CTD-like symptoms. Such traditional methods include testing for a broad range of diagnostic, immunology and chemistry biomarkers, such as ANA and anti-dsDNA and serum complement biomarkers, such as C3 and C4. We also face competition from commercial laboratories, such as ARUP Laboratories, Inc.; Laboratory Corporation of America Holdings; the Mayo Clinic; and Quest Diagnostics Incorporated, all of which have existing infrastructures to support the commercialization of diagnostic services. Large, multispecialty group medical clinics, health systems </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">and academic medical university-based clinics may provide in-house clinical laboratories offering autoimmune and autoimmune-related disease testing services. Additionally, we compete against regional clinical laboratories providing testing in the autoimmune and autoimmune-related disease field, including Aqtual, Inc. Other potential competitors include companies that might develop diagnostic or disease or drug monitoring products, such as AMPEL BioSolutions, LLC; DxTerity Diagnostics Inc.; Genalyte Inc.; Immunovia AB; Oncimmune Holdings plc; and Progentec Diagnostics Inc. In the future, we may also face competition from companies developing new products or technologies.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We believe the principal competitive factors in our target market include: quality and strength of clinical and analytical validation data; confidence in diagnostic results; sales and marketing capabilities; the extent of reimbursement; inclusion in clinical guidelines; cost-effectiveness; and ease of use. We rely upon independent sources for phlebotomy to obtain patient samples; interruptions to this capability could dramatically impact patient access to our tests.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Many of our potential competitors have widespread brand recognition and substantially greater financial, technical and research and development resources and selling and marketing capabilities than we do. Others may develop products with prices lower than ours that could be viewed by rheumatologists and payors as functionally equivalent to our solution or offer solutions at prices designed to promote market penetration, which could force us to lower the list price of our products and affect our ability to achieve profitability. If we are unable to change clinical practice in a meaningful way or compete successfully against current and future competitors, we may be unable to increase market acceptance and sales of our products, which could prevent us from increasing our revenue or achieving profitability and could cause the market price of our common stock to decline. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">To compete successfully we must be able to demonstrate, among other things, that our testing products are accurate and cost effective. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Developing new testing products involves a lengthy and complex process, and we may not be able to commercialize on a timely basis, or at all, other testing products we are developing. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We may not be able to develop testing products with the clinical utility necessary to be useful and commercially successful. There are certain products for which a commercial launch would trigger additional payment obligations to licensors of the technology. In these cases, if the economic projections of the product do not outweigh the additional obligations, we may not launch these products. In order to develop and commercialize testing products, we need to: </span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">expend significant funds to conduct substantial research and development; </span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">conduct successful verification, validation and utility studies; </span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">develop and scale our laboratory processes to accommodate different tests; </span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">achieve and maintain required regulatory certifications, including the hiring of appropriately licensed laboratory personnel; </span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">develop and scale our infrastructure to be able to analyze increasingly large amounts of data; and</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">build the commercial infrastructure to market and sell new testing products. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our testing product development process involves a high degree of risk and may take several years. Our testing product development efforts may fail for many reasons, including: </span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">failure to identify additional biomarkers to incorporate into our testing products; </span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">failure or sub-optimal performance of the testing product at the research or development stage;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">obtaining patient consent inclusive of genetic analysis;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">difficulty in accessing archival patient specimens, especially specimens with known clinical results; or </span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">failure of clinical validation, utility and outcome studies to support the effectiveness of the test. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Typically, few research and development projects result in commercial products, and success in early clinical studies often is not replicated in later studies. At any point, we may abandon development of a testing product candidate or we may be required to expend considerable resources repeating clinical studies, which would </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">adversely affect the timing for generating potential revenue from a new testing product and our ability to invest in other products in our pipeline. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, as we develop testing products, we may have to make significant investments in product development, marketing and selling resources. If a clinical validation study fails to demonstrate the prospectively defined endpoints of the study, we might choose to abandon the development of the testing product or product feature that was the subject of the clinical study, which could harm our business. Additionally, competitors may develop and commercialize competing products or technologies faster than us or at a lower cost. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Developing new testing products and enhancements to our existing technologies is expensive and time consuming, and there is no assurance that such activities will result in significant new marketable testing products, enhancements to our current technologies, design improvements, cost savings, revenue or other expected benefits. If we spend significant resources on research and development and are unable to generate an adequate return on our investment or divert resources away from other, more attractive growth opportunities, our business and results of operations may be materially and adversely affected. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">If we cannot enter into new clinical study collaborations, our product development and subsequent commercialization could be delayed. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the past, we have entered into clinical study collaborations, and our success in the future depends in part on our ability to enter into additional collaborations with highly regarded institutions. This can be difficult due to internal and external constraints placed on these organizations. Some organizations may limit the number of collaborations they have with any one company so as to not be perceived as biased or conflicted. Organizations may also have insufficient administrative and related infrastructure to enable collaborations with many companies at once, which can extend the time it takes to develop, negotiate and implement a collaboration. Additionally, organizations often insist on retaining the rights to publish the clinical data resulting from the collaboration. The publication of clinical data in peer-reviewed medical journals is a crucial step in commercializing and obtaining reimbursement for testing products such as ours, and our inability to control when and if results are published may delay or limit our ability to derive sufficient revenue from any solution. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We may acquire businesses or assets, form joint ventures or make investments in other companies or technologies that could harm our operating results, dilute our stockholders&#8217; ownership, increase our debt or cause us to incur significant expense. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As part of our business strategy, we may pursue acquisitions of complementary businesses or assets, as well as technology licensing arrangements and other strategic transactions or collaborations with third parties. We also may pursue strategic alliances that leverage our core technology and industry experience to expand our offerings or distribution, make investments in other companies or acquire ownership rights to therapeutics that are synergistic with our testing products. To date, other than our acquisition of the medical diagnostics division of Cypress Bioscience, Inc. in 2010, we have not acquired other companies or therapeutics and we have limited experience with respect to the formation of strategic alliances and joint ventures. If we make any acquisitions, we may not be able to integrate these acquisitions successfully into our existing business, and we could assume unknown or contingent liabilities. Any future acquisitions by us also could result in significant write-offs or the incurrence of debt and contingent liabilities, any of which could harm our operating results. Integration of an acquired company, business or assets also may require management resources that otherwise would be available for ongoing development of our existing business. We may not identify or complete these transactions in a timely manner, on a cost-effective basis, or at all, and we may not realize the anticipated benefits of any acquisition, technology license, strategic alliance, joint venture or investment. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">To finance any acquisitions or investments, we may choose to issue shares of our stock, or stock equivalents, as consideration, which would dilute the ownership of our stockholders. If the price of our common stock is low or volatile, we may not be able to acquire other companies for stock. Alternatively, it may be necessary for us to raise additional funds for these activities through public or private financings or through the issuance of debt. Additional funds may not be available on terms that are favorable to us, or at all, and any debt financing may involve covenants limiting or restricting our ability to take certain actions. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Also, the anticipated benefit of any strategic alliance, joint venture or acquisition may not materialize or such strategic alliance, joint venture or acquisition may be prohibited. In addition, our loan agreement restricts our ability to pursue certain mergers, acquisitions, amalgamations or consolidations that we may believe to be in our best interest. Additionally, future acquisitions or dispositions could result in potentially dilutive issuances of our equity securities, the incurrence of debt, contingent liabilities or amortization expenses or write-offs of goodwill, any of which could harm our financial condition. We cannot predict the number, timing or size of future joint ventures or acquisitions, or the effect that any such transactions might have on our operating results. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">The diagnostic industry is subject to rapidly changing technology, which could make our current and future testing products obsolete. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our industry is characterized by rapid technological changes, frequent new product introductions and enhancements and evolving industry standards. These advances require us to continuously develop our technology and work to develop new solutions to keep pace with evolving standards of care. Our testing products could become obsolete unless we continually innovate and expand our testing product offerings to include new clinical applications. If we are unable to develop new testing products or to demonstrate the applicability of our testing products for other diseases, our sales could decline and our competitive position could be harmed. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our failure to maintain relationships or build new relationships with key opinion leaders could materially adversely impact our business and prospects. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Key opinion leaders are able to influence clinical practice by publishing research and determining whether new tests should be integrated into clinical guidelines. We rely on key opinion leaders early in the development process to help ensure our clinical studies are designed and executed in a way that clearly demonstrates the benefits of our testing products to healthcare providers and payors. Our failure to maintain or build new relationships with such key opinion leaders could affect rheumatologist and patient perception of our testing products and result in a loss of existing and future customers and therefore materially adversely impact our business and prospects. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">If we are sued for errors and omissions or professional liability, we could face substantial liabilities that exceed our resources. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The marketing, sale and use of our testing products could lead to liability claims if someone were to allege that any such testing product failed to perform as it was designed. We may also be subject to liability for errors in the results we provide to rheumatologists or for a misunderstanding of, or inappropriate reliance upon, the information we provide. We may also be subject to similar types of claims related to testing products we may develop in the future. Any errors or omissions or professional liability claim could result in substantial damages and be costly and time consuming for us to defend. Although we maintain professional liability insurance, we cannot assure you that our insurance would fully protect us from the financial impact of defending against these types of claims or any judgments, fines or settlement costs arising out of any such claims. Any errors or omissions or professional liability claim brought against us, with or without merit, could materially increase our insurance rates or prevent us from securing insurance coverage in the future. Additionally, any product liability lawsuit could cause material injury to our reputation or cause us to suspend sales of our testing products. Similarly, any product liability lawsuit affecting our partners could also cause injury to our reputation. We may also initiate a correction or removal for one of our testing products, issue a safety alert or undertake a field action or recall to reduce a risk to health posed by potential failure of our products to perform as designed, which could lead to increased costs and lead to increased scrutiny by regulatory authorities and our customers regarding the quality and safety of our testing products and to negative publicity, including safety alerts, press releases or administrative or judicial actions. The occurrence of any of these events could have an adverse effect on our business and results of operations. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">The loss of members of our senior management team or our inability to attract and retain highly skilled scientists, technicians and salespeople could adversely affect our business. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our success depends largely on the skills, experience and performance of key members of our executive management team, including John Aballi, our President and Chief Executive Officer, and others in key management positions. The efforts of each of these persons will be critical to us as we continue to develop our technologies and test processes and focus on our growth. If we were to lose one or more of these key employees, we may experience difficulties in competing effectively, developing our technologies and implementing our business strategy. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, our research and development programs and commercial laboratory operations depend on our ability to attract and retain highly skilled scientists, including licensed clinical laboratory scientists and biostatisticians. We may not be able to attract or retain qualified scientists and technicians in the future due to the intense competition for qualified personnel among life science businesses, particularly in Southern California. Because it is expected that there will be a shortage of clinical laboratory scientists in coming years, it may become more difficult to hire sufficient numbers of qualified personnel. We also face competition from universities and public and private research institutions in recruiting and retaining highly qualified scientific personnel. Additionally, our success depends on our ability to attract and retain qualified and highly-specialized salespeople. We may have difficulties locating, recruiting or retaining qualified salespeople, which could cause a delay or decline in the rate of adoption of our testing products. If we are not able to attract and retain the necessary personnel to accomplish our business objectives, we may experience constraints that could adversely affect our ability to support our research and development, clinical laboratory and sales efforts. All of our employees are at-will, which means that either we or the employee may terminate their employment at any time.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">If our sole clinical laboratory facility becomes damaged or inoperable, we are required to vacate our existing facility or we are unable to expand our existing facility as needed, we will be unable to perform our testing services and our business will be harmed.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We currently derive all of our revenue from tests conducted at a single laboratory facility located in Vista, California. Vista is situated on or near earthquake fault lines. Our facility and equipment could be harmed or rendered inoperable by natural or man-made disasters which may be exacerbated due to climate change, including earthquake, fire, flood, power loss, communications failure or terrorism, or public health crises. In particular, we store all of our flow cytometers, the instrument we use to detect CB-CAPs on cells, at our Vista facility. If all of our flow cytometers were rendered inoperable simultaneously pursuant to a natural or man-made disaster, we would be unable to perform these key tests as we do in the ordinary course of our business. The inability to perform the tests contained in our testing products or to reduce the backlog of analyses that could develop if our facility is inoperable, for even a short period of time, may result in the loss of customers or harm to our reputation, and we may be unable to regain those customers or repair our reputation in the future. Additionally, we store our bio-repository of specimens, which were collected in collaboration with leading academic institutions and help us to further validate our testing products, at our Vista facility. If these specimens were destroyed pursuant to a natural or man-made disaster or otherwise become unavailable, our ability to develop new testing products may be delayed. Furthermore, our facility and the equipment we use to perform our research and development work could be unavailable or costly and time-consuming to repair or replace. It would be difficult, time-consuming and expensive to rebuild our facility or license or transfer our proprietary technology to a third party, particularly in light of the licensure and accreditation requirements for a commercial laboratory like ours. Even in the unlikely event we are able to find a third party with such qualifications to enable us to conduct the tests contained in our testing products, we may be unable to negotiate commercially reasonable terms. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In order to rely on a third party to perform the tests contained in our testing products (even assuming we are able to do so in compliance with applicable regulations), we would need to engage another facility with established state licensure and CLIA certification under the scope of which tests could be performed following validation and other required procedures. We cannot assure you that we would be able to find another CLIA-certified facility willing to comply with the required procedures, that any such facility would be willing to perform the tests contained in our testing products for us on commercially reasonable terms, or that it would be able to meet our quality standards. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In order to establish additional clinical reference laboratory facilities, we have to spend considerable time and money securing adequate space, which may include constructing additional facilities, recruiting and training employees, and establishing the additional operational and administrative infrastructure necessary to support a second facility. We may not be able, or it may take considerable time, to replicate our testing processes or results in any new or converted facility. Additionally, any new clinical reference laboratory facility opened by us would be subject to certification under CLIA and licensing by several states, including, as applicable, California and New York, which could take a significant amount of time and result in delays in our ability to begin operations. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We believe we have the capacity to meet our projected needs for at least the next 12 months, although we may grow at a rate that is faster than we expect. We may need to further expand our laboratory space in the future. Any future expansion could disrupt laboratory operations, resulting in an inability to meet customer turnaround time expectations, and could be delayed, resulting in slower realization of laboratory efficiencies anticipated from the use of the expanded facilities. Adverse consequences resulting from a delay in the laboratory expansion could harm our relationships with our customers and our reputation, and could affect our ability to generate revenue. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We carry insurance for damage to our property and the disruption of our business, but this insurance may not cover all the risks associated with damage or disruption to our business, provide coverage in amounts sufficient to cover our potential losses or continue to be available to us on acceptable terms, if at all. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our testing process involves the use of sophisticated state-of-the-art equipment that requires precise calibration, and issues affecting such equipment may delay delivery or impact the quality of the test results to rheumatologists or otherwise adversely affect our operations. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As part of our process of determining CB-CAPs, the key biomarker detection and measurement technology incorporated into our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus and AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD products, we utilize a number of flow cytometers that require calibration and performance validation according to the requirements of the CAP at specified time intervals. While we believe we have implemented appropriate controls and metrics in our laboratory to meet such requirements, we cannot provide any assurance that our instruments will not fall out of specification, in which case we would be required to re-calibrate them. Failure to timely re-calibrate our instruments could negatively impact the test results, which could result in liability and harm our reputation. Patient specimens degrade and become unusable generally within 48 hours of collection. Therefore, if we do not have other sufficient properly functioning flow cytometers due to </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">failure to meet specifications or they otherwise become inoperable, our ability to process patient specimens in the required timeframe would be compromised and our business could be harmed. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Failure in our information technology, telephone or other systems could significantly disrupt our operations and adversely affect our business and financial condition. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Information technology and telephone systems are used extensively in virtually all aspects of our business, including laboratory testing, sales, billing, customer service, logistics and management of medical data. The success of our business depends on the ability to obtain, process, analyze, maintain and manage this data. Our management relies on our information systems because: </span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">patient specimens must be received, tracked and processed on a timely basis; </span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">test results must be reported on a timely basis; </span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">billings and collections for all customers must be managed efficiently and accurately; </span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">third-party ancillary billing services require proper tracking and reporting; </span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">pricing and other information related to our services is needed by our sales force and other personnel in a timely manner to conduct business; </span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">patient-identifiable health information must be securely held and kept confidential; </span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">regulatory compliance requires proper tracking and reporting; and </span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">proper recordkeeping is required for operating our business, managing employee compensation and other personnel matters. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our business, results of operations and financial condition may be materially and adversely affected if, among other things: </span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">our information technology, telephone or other systems fail or are interrupted for any extended length of time; </span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">services relating to our information technology, telephone or other systems are not kept current; </span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">our information technology, telephone or other systems do not have the capacity to support expanded operations and increased levels of business; </span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">data is lost or unable to be restored or processed; or </span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">data is corrupted due to a breach of security. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Despite the precautionary measures we have taken to prevent breakdowns in our information technology, telephone and other systems, sustained or repeated system failures that interrupt our ability to process test orders, deliver test results or perform testing in a timely manner or that cause us to inadvertently disclose or lose patient information could adversely affect our business, results of operations and financial condition. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Security breaches, loss of data and other disruptions to us, our third-party service providers or our partners could compromise sensitive information related to our business or prevent us from accessing critical information and expose us to liability, which could materially and adversely affect our business and our reputation. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the ordinary course of our business, we and our partners, and our respective third-party service providers collect and store sensitive data, such as PHI (including test results), personally identifiable information, and credit card information. We also store business and financial information, intellectual property, research and development information, trade secrets, and other proprietary and business critical information, including that of our customers, payors and third-party partners. We manage and maintain our applications and data utilizing a combination of on-site and vendor-owned systems. We face a number of risks related to our protection of, and our service providers&#8217; protection of, this critical information, including loss of access, unauthorized disclosure and unauthorized access, as well as risks associated with our ability to identify and audit such events and risks associated with the need to reconstruct any lost or stolen data. In addition, we have limited control over the storage of sensitive data by our third-party partners as well as risks related to the transfer and sale of de-identified data files to such partners. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The secure processing, storage, maintenance, and transmission of this critical information is vital to our operations and business strategy, and we devote significant resources to protecting such information. Although we take measures to protect sensitive information from unauthorized access or disclosure, our information technology and infrastructure, and that of our third-party billing and collections provider, may be vulnerable to attacks by hackers or viruses, or otherwise breached due to employee error, malfeasance or other activities. Attacks upon information technology systems are increasing in their frequency, levels of persistence, sophistication and intensity, and are being conducted by sophisticated and organized groups and individuals with a wide range of motives and expertise. Additionally, the adoption of AI technologies may further heighten the risk of cyber-attacks. Leveraging AI capabilities to potentially improve internal functions and operations presents further risks and challenges, including the possibility of creating new attack methods for adversaries. The use of AI to support business operations carries inherent risks related to data privacy, IP, and security, such as intended, unintended, or inadvertent transmission of proprietary, confidential, or sensitive information, as well as challenges related to implementing and maintaining AI tools, such as developing and maintaining appropriate datasets for such support. If we fail to implement adequate safeguards, the use of AI may introduce additional operational vulnerabilities by producing inaccurate outcomes based on flaws in the underlying data or methodologies, or unintended results. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additionally, most of our employees have the ability to work remotely, which may increase the risk of security breaches, loss of data and other disruptions as a consequence of more employees accessing sensitive and critical information from remote locations. Because the techniques used to obtain unauthorized access to, or to sabotage, systems change frequently and often are not recognized until launched against a target, we may be unable to anticipate these techniques or implement adequate preventative measures. We may also experience security breaches that may remain undetected for an extended period. While we do not believe that we have experienced any such attack or breach, if such an event were to occur, our networks would be compromised and the information we store on those networks could be accessed by unauthorized parties, publicly disclosed, lost or stolen. A security breach or privacy violation that leads to unauthorized access, disclosure or modification of, or prevents access to, patient information, including PHI, could implicate state and federal breach notification laws. Any such access, disclosure or other loss of information could also result in legal claims or proceedings, and liability under laws that protect the privacy of personal information, such as HIPAA, as amended by the HITECH Act, and their implementing regulations and similar state data privacy and security laws and regulations including civil and criminal penalties. Unauthorized access, loss or dissemination could also disrupt our operations, including our ability to process tests, provide test results, bill payors or patients, process claims and appeals, provide customer assistance services, conduct research and development activities, collect, process and prepare company financial information, provide information about our products and other patient and rheumatologist education and outreach efforts through our website and manage the administrative aspects of our business and could damage our reputation, any of which could materially and adversely affect our business. Any breach could also result in the compromise of our trade secrets and other proprietary information, which could materially and adversely affect our competitive position.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, the interpretation and application of federal and state consumer, health-related and data protection laws in the United States are often uncertain, contradictory and in flux. It is possible that these laws may be interpreted and applied in a manner that is inconsistent with our practices. If so, this could result in government-imposed fines or orders requiring that we change our practices, as well as private litigation, which could adversely affect our business. Moreover, these laws and their interpretations are constantly evolving and may become more stringent or inclusive over time. For example, increasing concerns about health information privacy have recently prompted the federal government to issue guidance taking a newly expansive view of the scope of the laws and regulations that they enforce. Complying with these various laws could cause us to incur substantial costs or require us to change our business practices, systems and compliance procedures in a manner adverse to our business.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If we are unable to prevent such security breaches or privacy violations or implement satisfactory remedial measures in connection with security incidents, we may suffer material loss of reputation, financial loss, civil or criminal fines or other penalties. In addition, these breaches and other forms of inappropriate access can be difficult to detect, and any delay in identifying them may lead to increased harm of the type described above.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our financial condition, commercialization efforts and results of operations have been and may again in the future be adversely affected by outbreaks of contagious diseases.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Any outbreak of a contagious disease, or other adverse public health developments, could have a material and adverse effect on our business operations. Such adverse effects could include disruptions or restrictions on the ability of our, our collaborators&#8217;, or our suppliers&#8217; personnel to travel, and could result in temporary closures of our facilities or the facilities of our collaborators or suppliers, including our sole laboratory. While the impact of the COVID-19 pandemic on our business, financial condition, results of operations and cash flows has subsided, the extent to which any potential pandemics or health epidemics will affect our operations in the future will depend on future developments, which are highly uncertain and cannot be predicted with confidence.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Performance issues, service interruptions or price increases by our shipping carrier could adversely affect our business, results of operations and financial condition, and harm our reputation and ability to provide testing services on a timely basis. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Expedited, reliable shipping is essential to our operations. We have been utilizing both United Parcel Service (UPS) and Federal Express Corporation (Federal Express) for reliable and secure point-to-point transport of patient specimens to our laboratory and enhanced tracking of these patient specimens. Should Federal Express, UPS, or any other carrier we may use in the future, encounter delivery performance issues such as loss, damage or destruction of a specimen, it may be difficult to replace our patient specimens in a timely manner and such occurrences may damage our reputation and lead to decreased utilization from rheumatologists for our testing services and increased cost and expense to our business. In addition, any significant increase in shipping time or disruption to delivery service, whether due to bad weather, natural disaster (which may be exacerbated due to climate change), public health epidemics or pandemics, terrorist attacks or threats, labor strikes, work stoppages or boycotts, or for other reasons, could adversely affect our ability to receive and process patient specimens on a timely basis. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If we, Federal Express, or UPS were to terminate our relationship, we would be required to find another party to provide expedited, reliable point-to-point transport of our patient specimens. There are only a few other providers of such nationwide transport services, and there can be no assurance that we will be able to enter into arrangements with such other providers on acceptable terms, if at all. Finding a new provider of transport services would be time-consuming and costly and result in delays in our ability to provide our testing services. Even if we were to enter into an arrangement with any such provider, there can be no assurance that they will provide the same level of quality in transport services currently provided to us by Federal Express and UPS. If any new provider does not provide, or if Federal Express or UPS does not continue to provide, the required quality and reliability of transport services at the same or similar costs, it could materially and adversely affect our business, reputation, results of operations and financial condition. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Inflation could adversely affect our business and financial results.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The current inflationary environment has resulted in higher prices, which have impacted our costs incurred to generate revenue from our laboratory testing services, costs to attract and retain personnel, and other operating costs. The severity and duration of the current inflationary environment remains uncertain and may continue to impact our financial condition and results of operations. Inflation may continue to adversely affect us by increasing the costs of products, materials (including reagents and laboratory supplies), and labor needed to operate our business in future periods. Actions by the government to stimulate the economy may increase the risk of significant inflation, which may have an adverse impact on our business or financial results. Moreover, we may not be able to pass those costs along in the products we sell. As such, inflationary pressures could have a material adverse effect on our performance and financial statements.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We maintain cash deposits in excess of federally insured limits. Adverse developments affecting financial institutions, including bank failures, could adversely affect our liquidity and financial performance.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We maintain our cash, cash equivalents, and marketable securities with high quality, accredited financial institutions. However, some of these accounts exceed the Federal Deposit Insurance Corporation (FDIC) insurance limit of $250,000 and, while we believe we are not exposed to significant credit risk due to the financial strength of these depository institutions or investments, if any such depository institution fails to return our deposits, or if a depository institution is subject to other adverse conditions in the financial or credit markets, this could further impact access to our invested cash or cash equivalents and could adversely impact our operating liquidity and financial performance. Further, the failure or collapse of one or more of these depository institutions or default on these investments could materially adversely affect our ability to recover these assets and/or materially harm our financial condition.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our ability to utilize our net operating loss carryforwards and certain other tax attributes may be limited. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended (the Code), if a corporation undergoes an &#8220;ownership change&#8221; (generally defined as a greater than 50 percentage-point change (by value) in its equity ownership by &#8220;5-percent shareholders,&#8221; as defined in the Code, over a rolling three-year period), the corporation&#8217;s ability to use its pre-change net operating loss (NOL), carryforwards and other pre-change tax attributes to offset its post-change federal taxable income and taxes, as applicable, may be limited. We previously completed a study to assess whether an ownership change, as defined by Section 382 of the Code, had occurred from our formation through December 31, 2019. Based upon this study, we determined that ownership changes had occurred in 2003, 2008, 2012, 2017 and 2019, and that our ability to use a significant portion of our NOL carryforwards is subject to limitation under Section 382 of the Code as a result of a prior ownership change. If we undergo an ownership change as a result of subsequent shifts in our stock ownership, our ability to utilize our NOL </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">carryforwards and other pre-change tax attributes could be further limited by Sections 382 and 383 of the Code. Similar provisions of state tax law may also apply. In addition, federal NOL carryforwards generated in periods after December 31, 2017, may be carried forward indefinitely but, in taxable years beginning after December 31, 2020, may only be used to offset 80% of our taxable income. As a result of the foregoing, if we earn net taxable income, our ability to use NOL carryforwards and other tax attributes to offset taxable income and taxes, as applicable, may be limited. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our term loan contains restrictions that limit our flexibility in operating our business, and if we fail to comply with the covenants and other obligations under our loan agreement, the lenders may be able to accelerate amounts owed under the facility and may foreclose upon the assets securing our obligations. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In September 2017, we entered into the loan and security agreement (the 2017 Term Loan) with Innovatus Life Sciences Lending Fund I, LP (Innovatus), which we subsequently amended in November 2019, November 2021, April 2023 and April 2024 (the Amended Loan Agreement). The Amended Loan Agreement is collateralized by substantially all of our personal property, including our intellectual property. The Amended Loan Agreement also subjects us to certain affirmative and negative covenants, including limitations on our ability to transfer or dispose of assets, merge with or acquire other companies, make investments, pay dividends, incur additional indebtedness and liens and conduct transactions with affiliates. We are also subject to certain covenants that require us to maintain a minimum liquidity of at least $2.0 million, achieve certain minimum amounts of annual revenue, as measured on a rolling twelve-month basis, periodically deliver financial statements to Innovatus with an unqualified opinion (including no &#8220;going concern&#8221;) from our independent certified public accounting firm, and are required under certain conditions to make mandatory prepayments of outstanding principal. As a result of these covenants, we have certain limitations on the manner in which we can conduct our business, and we may be restricted from engaging in favorable business activities or financing future operations or capital needs until our current debt obligations are paid in full or we obtain the consent of Innovatus, which we may not be able to obtain. As of December&#160;31, 2024, there was $15.0 million in principal outstanding under the term loan and an additional $3.5 million outstanding representing interest payable in-kind by adding the paid in-kind interest amount to the outstanding principal balance of the term loans. Under the Amended Loan Agreement, we are required to repay any outstanding principal and capitalized interest in monthly installments over a ten-month period commencing on April 1, 2026. At December&#160;31, 2024, we were in compliance with all covenants of the Amended Loan Agreement. We cannot be certain that we will be able to generate sufficient cash flow or revenue to meet the financial covenants or pay the principal and accrued interest on our debt. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, upon the occurrence of an event of default, Innovatus, among other things, can declare all indebtedness due and payable immediately, which would adversely impact our liquidity and reduce the availability of our cash flows to fund working capital needs, capital expenditures and other general corporate purposes. An event of default includes, but is not limited to, our failure to pay any amount due and payable under the Amended Loan Agreement, the occurrence of a material adverse change in our business as defined in the Amended Loan Agreement, our breach of any representation or warranty in the Amended Loan Agreement, our breach of any covenant in the Amended Loan Agreement (subject to a cure period in some cases), a change in control as defined in the Amended Loan Agreement, our default on any debt payments to a third party in an amount exceeding $0.5 million or any voluntary or involuntary insolvency proceeding. If an event of default occurs and we are unable to repay amounts due under the Amended Loan Agreement, Innovatus could foreclose on substantially all of our personal property, including our intellectual property. We cannot be certain that future working capital, borrowings or equity financings will be available to repay or refinance our debt to Innovatus or any other debt we may incur in the future. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We may require substantial additional capital to finance our planned operations, which may not be available to us on acceptable terms or at all. Our failure to obtain additional financing when needed on acceptable terms, or at all, could force us to delay, limit, reduce or eliminate our product development programs, commercialization efforts or other operations. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We believe, based on our current plan, that our current cash and cash equivalents and anticipated future revenue, will be sufficient to meet our anticipated cash requirements for at least the next 12 months. We have based this estimate on assumptions that may prove to be wrong, and we could use our capital resources sooner than we currently expect. Our operating plans and other demands on our cash resources may change as a result of many factors currently unknown to us and we may need to seek additional funds sooner than planned, through public or private equity or debt financings or other sources, such as strategic collaborations. If our available cash balances and anticipated future revenue are insufficient to satisfy our liquidity requirements, including because of lower demand for our testing products or lower-than-expected rates of reimbursement from commercial payors and government payors, or other risks described in this &#8220;Risk Factors&#8221; section, we may seek to raise additional capital through equity offerings, debt financings, collaborations or licensing arrangements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On November 17, 2023, we filed a shelf registration statement on Form S-3, as amended by Amendment No. 1 to Form S-3 filed on November 27, 2023, that provides for aggregate offerings of up to $150.0 million of our securities subject to various limitations. We filed a prospectus on November 29, 2023 pursuant to this registration statement, registering sales of our common stock in an amount not to exceed $50.0 million, pursuant to a sales agreement by and between us and TD Securities (USA) LLC (as successor in interest to Cowen and Company, LLC) (TD Cowen), as amended by Amendment No. 1 to Sales Agreement dated November 17, 2023 (the Amended Sales Agreement). Using a shelf registration statement to raise capital generally takes less time and is less expensive than other means, such as conducting an offering under a registration statement on Form S-1 and companies may be able to receive more favorable terms by raising capital pursuant to a shelf registration statement on Form S-3. Our ability to raise capital under our current shelf registration statement (and any future registration statement on Form S-3) has in the past, and may again in the future be, limited by, among other things, current and future SEC rules and regulations impacting the eligibility of smaller companies to use Form S-3 without restrictions. We have previously been subject to the "baby shelf rules" and if we were to become subject to the "baby shelf rules" again, we would be unable to use our shelf registration statement on Form S-3 or the Amended Sales Agreement to raise additional funds to the extent the aggregate market value of securities sold by us or on our behalf pursuant to Instruction I.B.6. of Form S-3 during the 12 calendar months immediately prior to, and including, any intended sale would exceed one-third of the aggregate market value of our public float, calculated in accordance with the instructions to Form S-3. As of the date of this Annual Report, we are not subject to the "baby shelf rules" because the market value of our outstanding shares of common stock held by non-affiliates calculated in accordance with Instruction I.B.6. of Form S-3, or public float, was greater than $75.0 million as of the date of this Annual Report.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the case of the incurrence of further indebtedness, the Amended Loan Agreement, subject to certain customary exceptions, restricts our ability to incur additional indebtedness or encumber any of our property without the prior consent of Innovatus. Under the Amended Loan Agreement, we are required to make monthly interest payments at a rate equal to the sum (the Basic Rate) of (a) the greater of 8.0% or The Wall Street Journal prime rate (the Prime Rate), plus (b) 2.0% (provided that 1.5% of the Basic Rate is payable in-kind by adding the amount to the outstanding principal balance of the term loans). We may also consider raising additional capital in the future to expand our business, pursue strategic investments, take advantage of financing opportunities, or for other reasons. In addition, we may seek additional capital due to favorable market conditions or strategic considerations, even if we believe we have sufficient funds for our current or future operating plans. The timing and amounts of our future capital requirements are difficult to forecast and will depend on numerous factors, including: our ability to maintain and grow sales of our testing products, as well as the costs associated with conducting clinical studies to demonstrate the utility of our testing products and support reimbursement efforts; fluctuations in working capital; the costs to expand our sales and marketing capabilities; the costs of developing our product pipeline, including the costs associated with conducting our ongoing and future validation studies; the additional costs we may incur as a result of operating as a public company and the extent to which we in-license, acquire or invest in complementary businesses or products.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additional funding may not be available to us on acceptable terms, or at all. If we raise funds by issuing equity securities, including as a result of our existing sales agreement with TD Cowen, dilution to our stockholders could result, and the market price of our common stock could decline. Any equity securities issued also may provide for rights, preferences or privileges senior to those of holders of our common stock. The incurrence of additional indebtedness or the issuance of certain equity securities could result in increased fixed payment obligations and could also result in restrictive covenants (similar to our current obligations pursuant to the Amended Loan Agreement), such as limitations on our ability to incur additional debt or issue additional equity, limitations on our ability to acquire or license intellectual property rights, and other operating restrictions that could adversely affect our ability to conduct our business. In addition, our Amended Loan Agreement restricts our ability to incur additional indebtedness or encumber any of our property without the prior consent of Innovatus, subject to certain exceptions. In the event that we enter into collaborations or licensing arrangements to raise capital, we may be required to accept unfavorable terms. These agreements may require that we relinquish or license to a third party on unfavorable terms our rights to technologies or product candidates that we otherwise would seek to develop or commercialize ourselves or reserve certain opportunities for future potential arrangements when we might be able to achieve more favorable terms. If we are not able to secure additional funding when needed, we may have to delay, reduce the scope of or eliminate one or more research and development programs or selling and marketing initiatives. In addition, we may have to work with a partner on one or more of our testing products or market development programs, which could lower the economic value of those products or programs to our company.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We are a smaller reporting company and the reduced disclosure requirements applicable to smaller reporting companies may make our common stock less attractive to investors. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are a &#8220;smaller reporting company&#8221; as defined in the Exchange Act. We may take advantage of certain of the scaled disclosures available to smaller reporting companies and will be able to take advantage of these scaled </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">disclosures for so long as our voting and non-voting common stock held by non-affiliates is less than $250.0 million measured on the last business day of our second fiscal quarter, or our annual revenue is less than $100.0 million during the most recently completed fiscal year and our voting and non-voting common stock held by non-affiliates is less than $700.0 million measured on the last business day of our second fiscal quarter. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Risks Related to Regulatory and Compliance Matters </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Healthcare policy changes could cause significant harm to our business, operations and financial condition. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The ACA made a number of substantial changes to the way healthcare is financed both by governmental and commercial payors. The ACA also introduced mechanisms to reduce the per capita rate of growth in Medicare spending if expenditures exceed certain targets. Any such reductions could affect reimbursement payments for our tests.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In April 2014, Congress passed PAMA, which included substantial changes to the way in which clinical laboratory services are paid under the CLFS. Under PAMA, certain clinical laboratories are required to periodically report to CMS private payor payment rates and volumes for their tests, and laboratories that fail to report the required payment information may be subject to substantial civil monetary penalties. Since December 2019, Congress has passed a series of laws to modify PAMA&#8217;s statutory requirements related to the data reporting period and phase-in of payment reductions under the CLFS for CDLTs that are not ADLTs. Most recently, on September 26, 2024, Section 221 of the Continuing Appropriations and Extensions Act, 2025, was passed, and it delayed data reporting requirements for CDLTs that are not ADLTs as well as the phase-in of payment reductions until 2026. Medicare reimbursement for CDLTs is based on the weighted-median of the payments made by private payors for these tests, rendering private payor payment levels even more significant than in the past. As a result, future Medicare payments may fluctuate more often and become subject to the willingness of private payors to recognize the value of diagnostic tests generally and any given test individually. The impact of this payment system on rates for our tests, including any current or future tests we may develop, is uncertain.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We cannot predict whether or when these or other recently enacted healthcare initiatives will be implemented at the federal or state level or how any such legislation or regulation may affect us. For instance, the payment reductions imposed by the ACA and the changes to reimbursement amounts paid by Medicare for tests such as ours based on the procedure set forth in PAMA, could limit the prices we will be able to charge or the amount of available reimbursement for our tests, which would reduce our revenue. Additionally, these healthcare laws, regulations and policies could be amended or additional healthcare initiatives could be implemented in the future.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Further, the impact on our business of the expansion of the federal and state governments&#8217; role in the U.S. healthcare industry generally, including the social, governmental and other pressures to reduce healthcare costs while expanding individual benefits, is uncertain. Any future changes or initiatives could have a materially adverse effect on our business, financial condition, results of operations and cash flows.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Complying with numerous regulations pertaining to our business is an expensive and time-consuming process, and any failure to comply could result in substantial penalties. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are subject to CLIA, a federal law that regulates clinical laboratories that perform testing on specimens derived from humans for the purpose of providing information for the diagnosis, prevention or treatment of disease. CLIA regulations mandate specific standards in the areas of personnel qualifications, administration and participation in proficiency testing, patient test management, quality control, quality assurance and inspections. We have a current certificate of accreditation under CLIA because we are accredited to perform testing by CAP. To renew this certificate, we are subject to survey and inspection every two years. Moreover, inspectors from CMS or CAP may make random inspections of our clinical reference laboratory. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Although we are required to hold a certificate of accreditation or compliance under CLIA that allows us to perform high complexity testing, we are not required to hold a certificate of accreditation through CAP. We could alternatively maintain a certificate of accreditation from another accrediting organization or a certificate of compliance through inspection by surveyors acting on behalf of the CLIA program. If our accreditation under CAP were to terminate, either voluntarily or involuntarily, we would need to convert our certification under CLIA to a certificate of compliance (or to a certificate of accreditation with another accreditation organization) in order to maintain our ability to perform clinical testing and to continue commercial operations. Whether we would be able to successfully maintain operations through either of these alternatives would depend upon the facts and circumstances surrounding termination of our CAP accreditation, such as whether any deficiencies were identified by CAP as the basis for termination and, if so, whether these were addressed to the satisfaction of the surveyors for the CLIA program (or another accrediting organization). </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The failure to comply with CLIA requirements can result in enforcement actions, including the revocation, suspension, or limitation of our CLIA certificate of accreditation, as well as a directed plan of correction, state on-site monitoring, civil money penalties, civil injunctive suit and/or criminal penalties. We must maintain CLIA compliance and certification to be eligible to bill for tests provided to Medicare beneficiaries and to some patients covered by commercial payors. If we were to be found out of compliance with CLIA program requirements and subjected to sanctions, our business and reputation could be harmed. Even if it were possible for us to bring our laboratory back into compliance, we could incur significant expenses and potentially lose revenue in doing so. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are also required to maintain a license to conduct testing in California. California laws establish standards for day-to-day operation of our clinical reference laboratory, including the training and skills required of personnel and quality control. In addition, our clinical reference laboratory is licensed on a product-specific basis by New York as an out of state laboratory and our testing products, as LDTs, must be approved by the NYSDOH on a product-by-product basis before they are offered in New York. We are also subject to periodic inspection by the NYSDOH and required to demonstrate ongoing compliance with NYSDOH regulations and standards. To the extent NYSDOH identified any non-compliance and we are unable to implement satisfactory corrective actions to remedy such non-compliance, the State of New York could withdraw approval for our testing products. New York law also mandates proficiency testing for laboratories licensed under New York state law, regardless of whether or not such laboratories are located in New York. Moreover, several other states require that we hold licenses to test specimens from patients in those states. Other states may have similar requirements or may adopt similar requirements in the future. Although we have obtained licenses from states where we believe we are required to be licensed, we may become aware of other states that require out-of-state laboratories to obtain licensure in order to accept specimens from the state, and it is possible that other states currently have such requirements or will have such requirements in the future. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If we were to lose our CLIA accreditation or California license, whether as a result of a revocation, suspension or limitation, we would no longer be able to sell our testing products, which would limit our revenue and harm our business. If we were to lose our license or fail to obtain or maintain NYSDOH approval for our laboratory developed tests in New York or if we were to lose our license in other states where we are required to hold licenses, we would not be able to test specimens from those states, which would limit our revenue.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We conduct business in a heavily regulated industry. Complying with the numerous statutes and regulations pertaining to our business is expensive and time-consuming, and any failure by us, our consultants or commercial partners to comply could result in substantial penalties. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our industry and our operations are heavily regulated by various federal, state, local and foreign laws and regulations, and the regulatory environment in which we operate could change significantly and adversely in the future. These laws and regulations currently include, among others:</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">CLIA&#8217;s and CAP&#8217;s regulation of our laboratory activities, as well as state licensure laws and regulations;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">FDA laws and regulations that apply to medical devices such as our companion diagnostics and other IVDs as well as LDTs, following the July 2024 effective date of the agency&#8217;s LDT final rule;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">federal and state laws and standards affecting reimbursement by government payors, including certain coding requirements to obtain reimbursement and certain payment mechanisms for clinical laboratory services resulting from PAMA;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">HIPAA and HITECH, which establish comprehensive federal standards with respect to the privacy and security of PHI, and requirements for the use of certain standardized electronic transactions with respect to transmission of such information, as well as similar laws protecting other types of personal information;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">state laws governing the maintenance of personally identifiable information of state residents, including medical information, and which impose varying breach notification requirements, some of which allow private rights of action by individuals for violations and also impose penalties for such violations;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the federal Anti-Kickback Statute, which generally prohibits knowingly and willfully offering, paying, soliciting or receiving remuneration, directly or indirectly, in return for or to induce a person to refer to an individual any good, facility, item or service that is reimbursable under a federal healthcare program;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the federal Stark Law, which generally prohibits a physician from making a referral for certain designated health services covered by Medicare or Medicaid, including laboratory and pathology services, if the physician or an immediate family member has a financial relationship with the entity providing the designated health services;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the federal False Claims Act, which imposes up to treble damages and per-claim civil penalties, and provides for civil whistleblower or </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">qui tam</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> actions, against individuals or entities for knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the CMP Law, which generally prohibits, among other things, the offering or transfer of remuneration to a Medicare or Medicaid beneficiary if it is likely to influence the beneficiary&#8217;s selection of a particular provider, practitioner or supplier of services reimbursable by Medicare or Medicaid; </span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">EKRA, which imposes criminal penalties for knowing and willful payment or offer, or solicitation or receipt, of any remuneration, whether directly or indirectly, overtly or covertly, in cash or in kind, in exchange for the referral or inducement of laboratory testing (among other healthcare services) covered by healthcare benefit programs (including commercial insurers) unless a specific exception applies;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the ACA, which, among other things, establishes a requirement for providers and suppliers to report and return any overpayments received from the Medicare and Medicaid programs;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">other federal and state fraud and abuse laws, such as anti-kickback laws, prohibitions on self-referral, fee-splitting restrictions, insurance fraud laws, anti-markup laws, prohibitions on the provision of tests at no or discounted cost to induce physician or patient adoption and false claims acts, some of which may extend to services reimbursable by any third-party payor, including private payors;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the prohibition on reassignment of Medicare claims and other Medicare and Medicaid billing and coverage requirements;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">state laws that prohibit other specified healthcare practices, such as billing physicians for tests that they order, waiving coinsurance, copayments, deductibles and other amounts owed by patients, business corporations practicing medicine or employing or engaging physicians to practice medicine and billing a state Medicaid program at a price that is higher than what is charged to one or more other payors;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the FCPA, and applicable foreign anti-bribery laws;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">federal, state and local regulations relating to the handling and disposal of regulated medical waste, hazardous waste and biohazardous waste and workplace safety for healthcare employees;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">laws and regulations relating to health and safety, labor and employment, public reporting, taxation and other areas applicable to businesses generally, all of which are subject to change; and</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">similar foreign laws and regulations that apply to us in the countries in which we operate or may operate in the future.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Various federal and state laws, such as the Sunshine Act and state gift bans, that apply to medical device manufacturers could extend to our clinical reference laboratory now that FDA will actively regulate LDTs as medical devices pursuant to the 2024 final rule, and clinical laboratories offering and furnishing LDTs are considered to be device manufacturers as a result. We are in the process of evaluating whether and to what extent those kinds of medical device-specific state requirements may be applicable to our operations.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Any future growth of our business, including, in particular, continued reliance on consultants, commercial partners and other third parties, may increase the potential for violating these laws. In some cases, our risk of violating these or other laws and regulations is further increased because of the lack of their complete interpretation by applicable regulatory authorities or courts, and their provisions are thus open to a variety of interpretations. We have adopted policies and procedures designed to comply with these laws and regulations and, in the ordinary course of our business, we conduct internal reviews of our compliance with these laws. Our compliance is also subject to review by applicable government agencies. However, these laws and regulations are subject to change and additional interpretation and guidance from regulatory authorities.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">It is possible that some of our business activities could be subject to challenge under one or more of such laws. Such a challenge, regardless of the outcome, could have a material adverse effect on our business, business relationships, reputation, financial condition and results of operations. Although an effective compliance program can mitigate the risk of investigation and prosecution for violations of these laws, the risks cannot be entirely eliminated. Given the complexity of these existing and changing rules and regulations, it is not always possible to identify and deter misconduct by employees, distributors, consultants and commercial partners and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">or in protecting us from government investigations or other actions or lawsuits stemming from a failure to comply with applicable laws or regulations. Additionally, we are subject to the risk that a person or government could allege such fraud or other misconduct, even if none occurred. For additional information see the risk factor below entitled &#8220;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">We have previously and may again in the future be required to modify our business practices, pay fines, incur significant expenses or experience losses due to litigation or governmental investigations.&#8221; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management&#8217;s attention from the operation of our business. Moreover, achieving and sustaining compliance with these laws may prove costly. If we or our operations, or any of the rheumatologists or entities with whom we do business are found to be in violation of any of the laws described above or any other governmental regulations that apply to us, we may be subject to significant penalties, including administrative, civil and/or criminal penalties, damages, fines, disgorgement, individual imprisonment, exclusion from participation in U.S. federal or state healthcare programs, such as Medicare and Medicaid, and similar programs outside the United States, a corporate integrity agreement or other agreement to resolve allegations of non-compliance with these laws, and the curtailment or restructuring of our operations, any of which could materially adversely affect our ability to operate our business and our financial results. To the extent that any of our testing products are sold in a foreign country, we may be subject to similar foreign laws and regulations, which may include, for instance, applicable post-marketing requirements, including safety surveillance, anti-fraud and abuse laws, and implementation of corporate compliance programs and reporting of payments or transfers of value to healthcare professionals. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">If we use hazardous materials in a manner that causes contamination or injury, we could be liable for resulting damages. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are subject to federal, state and local laws, rules and regulations governing the use, discharge, storage, handling and disposal of biological material, chemicals and waste. We cannot eliminate the risk of accidental contamination or injury to employees or third parties from the use, storage, handling or disposal of these materials. In the event of contamination or injury, we could be held liable for any resulting damages, remediation costs and any related penalties or fines, and any liability could exceed our resources or any applicable insurance coverage we may have. The cost of compliance with these laws and regulations may become significant, and our failure to comply may result in substantial fines or other consequences, either of which could negatively affect our operating results.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We have previously and may again in the future be required to modify our business practices, pay fines, incur significant expenses or experience losses due to litigation or governmental investigations.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">From time to time and in the ordinary course of our business, we have been and may be subject to litigation or governmental investigation on a variety of matters in the United States or foreign jurisdictions, including, without limitation, regulatory, intellectual property, product liability, antitrust, consumer, false claims, whistleblower, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">qui tam</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, privacy, anti-kickback, anti-bribery, environmental, commercial, securities and employment litigation and claims and other legal proceedings that may arise from the conduct of our business. Our activities relating to our products and services are subject to extensive regulation in the United States and foreign jurisdictions. Like many companies in our industry, we have in the ordinary course of business received inquiries, subpoenas, civil investigative demands, and other types of information requests from government authorities. In addition, any litigation or government investigation generally, diverts the attention of our management team and resources from our core business and limits the time and attention of our management team otherwise available to devote to our business. Government investigation and litigation in general may cause us to incur significant expenses, to experience significant losses, and, as a result of such matters, we may also be required to materially alter the conduct of our operations or pay significant penalties. For example, pursuant to a settlement agreement, we made a single lump-sum remittance to the government in the amount of $0.7&#160;million plus interest in October 2023, the U.S. Attorney&#8217;s Office dismissed this &#8220;covered conduct&#8221; in the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">qui tam</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> with prejudice, while non-covered conduct was dismissed without prejudice. The Department of Justice excused itself from the case in connection with the settlement. In November 2023, the complaint was unsealed and served on Exagen. Exagen filed a motion to dismiss the complaint. In February 2024, the relator filed a motion for leave to amend the complaint. Exagen opposed this motion, and all motions are still pending. While we cannot predict when these matters will be resolved, the Company intends to vigorously defend against the claims being asserted in the complaint.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Any of these circumstances may adversely affect our business, prospects, reputation and results of operations.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We are subject to U.S. and certain foreign export and import controls, sanctions, embargoes, anti-corruption laws and anti-money laundering laws and regulations. Compliance with these legal standards could impair our ability to compete in domestic and international markets. We can face criminal liability and other serious consequences for violations, which can harm our business. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are subject to export control and import laws and regulations, including the U.S. Export Administration Regulations, U.S. Customs regulations, various economic and trade sanctions regulations administered by the U.S. Treasury Department&#8217;s Office of Foreign Assets Controls, the FCPA, the U.S. domestic bribery statute contained in 18 U.S.C. &#167; 201, the U.S. Travel Act, the USA PATRIOT Act, and other state and national anti-bribery and anti-money laundering laws in the countries in which we conduct activities. Anti-corruption laws are interpreted broadly and prohibit companies and their employees, agents, contractors and other collaborators from authorizing, promising, offering, or providing, directly or indirectly, improper payments or anything else of value to recipients in the public or private sector. We may engage third parties to sell our testing products outside the United States, to conduct clinical trials, and/or to obtain necessary permits, licenses, patent registrations and other regulatory approvals. We have direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities and other organizations. We can be held liable for the corrupt or other illegal activities of our employees, agents, contractors, and other collaborators, even if we do not explicitly authorize or have actual knowledge of such activities. Any violations of the laws and regulations described above may result in substantial civil and criminal fines and penalties, imprisonment, the loss of export or import privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm and other consequences.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">The FDA may disagree with our assessment that our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"> test products and any other tests we may develop are LDTs eligible for enforcement discretion and determine that such test products are fully subject to active compliance enforcement under the FDCA and FDA regulations.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The FDA regulates any diagnostic test that meets the definition of a medical device, except under specific, narrow circumstances. The FDCA defines a medical device as &#8220;an instrument, apparatus, implement, machine, contrivance, implant, in vitro reagent, or other similar or related article, including a component part, or accessory which is , among other things: intended for use in the diagnosis of disease or other conditions, or in the cure, mitigation, treatment, or prevention of disease, in man or other animals and which does not achieve its primary intended purposes through chemical action within or on the body of man or other animals and which is not dependent upon being metabolized for the achievement of any of its primary intended purposes.&#8221; By this definition, in vitro reagents and diagnostic tests are considered medical devices. Specifically, the FDA defines an IVD as &#8220;reagents, instruments, and systems intended for use in the diagnosis of disease or other conditions, including a determination of the state of health, in order to cure, mitigate, treat, or prevent disease or its sequelae.&#8221; Therefore, the FDA generally considers diagnostic testing products to be IVDs subject to the agency&#8217;s regulatory requirements for IVDs. Historically, the FDA had generally exercised its enforcement discretion and not enforced applicable regulations with respect to LDTs, which are IVDs that are designed, manufactured, and used within a single high-complexity CLIA-certified laboratory. We believe that all of our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> test products are LDTs, as are our near-term pipeline candidate tests.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If the FDA were to disagree with our conclusion that our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> test products fall within the scope of the agency&#8217;s LDT definition and determines that the AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> tests are thus subject to FDA&#8217;s medical device authorities and implementing regulations, we would become immediately subject to extensive regulatory requirements and may be required to stop selling our existing tests or refrain from launching any other tests we may develop. In particular, the FDA may require us to obtain marketing authorization for each of our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> tests in order for use to commercialize them. The premarket review process for diagnostic testing products can be lengthy, expensive, time-consuming, and unpredictable. As part of the process to prepare regulatory submissions for FDA review, we may be required to conduct formal clinical trials before applying for commercial marketing authorization. Performing additional, new nonclinical studies or clinical trials in order to obtain product approval from the FDA, if any were to become necessary, would take a significant amount of time and would substantially delay our ability to commercialize our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> tests, all of which would adversely impact our business. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">While we believe that we are currently in material compliance with applicable laws and regulations as historically enforced by the FDA with respect to LDTs, we cannot assure you that the FDA will agree with our determination. Any finding by the FDA or another regulatory authority that we have violated these laws and regulations, or a public announcement that we are being investigated for possible violations, could adversely affect our business, prospects, results of operations or financial condition.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Planned changes in the way that the FDA regulates tests designed and performed by laboratories like ours could result in delay or additional expense in offering our current tests and tests that we may develop in the future.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We currently market our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> tests as LDTs and may, in the future, market other tests as LDTs. Historically, the FDA had exercised enforcement discretion with respect to most LDTs and generally had not required laboratories that furnish LDTs to comply with the agency&#8217;s requirements for medical devices (e.g., establishment registration, device listing, quality system regulations, premarket clearance or approval, and post-market controls). However, in </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">May 2024, the FDA issued a final rule to regulate LDTs under the current medical device framework and phasing out its existing enforcement discretion policy for this category of diagnostic tests over several years. The effective date of the agency&#8217;s final rule was July 5, 2024. The agency&#8217;s final rule provides that the LDT enforcement policy phase-out process will occur in gradual stages over a total period of four years, with premarket approval applications for high-risk tests to be submitted by the 3.5-year mark. Moderate-risk and low-risks tests are expected to be in compliance at the four-year mark, although FDA has stated that if premarket submissions are pending review it will continue to exercise enforcement discretion with respect to those tests. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The FDA&#8217;s final rule is complex and, concurrently, the agency announced several exceptions from the requirement to comply with full medical device regulatory controls, depending upon the specific nature of the LDT and the clinical laboratory that is offering such LDT for use by health care providers. Of potential relevance is the agency&#8217;s position on LDTs that were marketed prior to the official publication date of the final rule. Such &#8220;currently marketed&#8221; tests are subject to many of the device regulatory controls but are exempted from the premarket review and FDA authorization requirements (unless or until significant modifications are made to such &#8220;currently marketed&#8221; tests). Similarly, FDA has created a partial enforcement discretion policy for tests approved by the New York State Clinical Laboratory Evaluation Program whereby such tests also do not need to undergo FDA premarket review but must come into compliance with all other device general controls in a stagged fashion between 2025 and 2027. We have begun the process of evaluating the final rule&#8217;s potential impact on our tests, as well as our operations and business more generally.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On May 29, 2024, the American Clinical Laboratory Association (ACLA) and one of its members filed a complaint against the FDA in the Eastern District of Texas, alleging that the agency does not have authority to promulgate the LDT final rule and seeking to vacate the FDA&#8217;s action. A second lawsuit was also filed against FDA by the Association for Molecular Pathology (AMP) on August 19, 2024 in the Southern District of Texas, and subsequently the two cases were consolidated into a single action pending in the Eastern District of Texas. Briefing is ongoing in the consolidated case, and the outcome of such litigation is uncertain. The litigation could potentially affect FDA&#8217;s plans to implement these new LDT requirements, making the potential implementation timeline somewhat uncertain, although no preliminary injunction has been issued to date. Accordingly, the agency has continued its implementation efforts by actively providing guidance and training to clinical laboratories on how to comply with medical device general controls.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Affected stakeholders also continue to press for a comprehensive legislative solution to create a harmonized paradigm for oversight of LDTs by both the FDA and CMS, instead of implementation of the FDA&#8217;s final rule, which may be disruptive to the industry and to patient access to certain diagnostic tests. However, this FDA rulemaking was initiated after years of failed congressional attempts to harmonize the regulatory paradigms applicable to LDTs and other IVDs, making it unclear whether any legislative efforts would be successful going forward.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If the FDA prevails in the Texas litigation and is able to fully implement the multi-year phase-in plan for the LDT final rule or Congress enacts comprehensive legislation to regulate in vitro diagnostics that moots the need for the LDT final rule, it could have a materially adverse impact on our results of operations. Failure to comply with any applicable FDA requirements could trigger a range of enforcement actions by the FDA, including warning letters, civil monetary penalties, injunctions, criminal prosecution, recall or seizure, operating restrictions, partial suspension or total shutdown of operations and denial of or challenges to applications for clearance or approval, as well as significant adverse publicity.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">The FTC and/or state enforcement or regulatory agencies may object to the methods and materials we use to promote our tests and initiate enforcement against us, which could adversely affect our business and financial condition.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The FTC and/or state enforcement or regulatory agencies (including but not limited to the offices of state attorneys general) may object to the materials and methods we use to promote our current tests or other LDTs we may develop in the future, including with respect to the product claims in our promotional materials, and may initiate enforcement actions against us. Enforcement actions by the FTC may include, among others, injunctions, civil penalties and equitable monetary relief.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Actual or perceived failures to comply with applicable data protection, privacy and security laws, regulations, standards and other requirements could materially and adversely affect our business, results of operations and financial condition.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Any failure or perceived failure by us to comply with federal or state laws or regulations, our internal policies and procedures or our contracts governing our use and disclosures of personal information could result in negative publicity, government investigations and enforcement actions including significant penalties, claims by third parties, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">and damage to our reputation, any of which could have a material adverse effect on our operations, financial performance and business.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Failure to comply with HIPAA, the HITECH Act, their implementing regulations and similar comparable state laws and regulations affecting the transmission, security and privacy of health information could result in significant penalties or private litigation. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Numerous federal, state and foreign laws and regulations, including HIPAA and the HITECH Act in the United States, govern the collection, dissemination, disclosure, security, use and confidentiality of individually identifiable health information and, in many cases, other personal information. HIPAA and the HITECH Act require us to comply with standards for the use and disclosure of PHI within our company and with respect to third parties. The privacy, security and breach notification rules promulgated under HIPAA, as amended by the HITECH Act, Standards for Privacy of Individually Identifiable Health Information (Privacy Standards) and the Security Standards for the Protection of Electronic Protected Health Information (Security Standards) under HIPAA establish a set of basic national privacy and security standards for the protection of individually identifiable health information by Covered Entities and their Business Associates. HIPAA requires Covered Entities, such as us, to develop and maintain policies and procedures with respect to individually identifiable health information that is used or disclosed, including the adoption of administrative, physical and technical safeguards to protect the privacy and security of such information. HIPAA also requires us to provide individuals with certain rights with respect to their PHI. If we engage a Business Associate to help us carry out healthcare activities and functions, we must have a written Business Associate contract or other arrangement with the Business Associate that establishes specifically what the Business Associate has been engaged to do and obligates the Business Associate to comply with HIPAA requirements. Further, in the event of a breach of unsecured PHI we must notify each individual whose PHI is breached as well as federal regulators and in some cases, must publicize the breach in local or national media.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">HIPAA also includes standards for common healthcare electronic transactions and code sets, such as claims information, plan eligibility, payment information and the use of electronic signatures, and privacy and electronic security of individually identifiable health information. Covered Entities, such as certain healthcare providers, are required to conform to such transaction set standards, known as the Standards for Electronic Transactions, pursuant to HIPAA. Submission of electronic healthcare claims and payment transactions that do not comply with the HIPAA electronic data transmission standards could result in delayed or denied payments.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the conduct of our business, we process, maintain, and transmit sensitive data, including PHI. There can be no assurance that a material breach of privacy or security will not occur. If there is a breach, we could be subject to various lawsuits, penalties and damages and may be required to incur costs to mitigate the impact of the breach on affected individuals such that our business may be materially and adversely affected.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Penalties for failure to comply with HIPAA requirements are substantial and could include corrective action plans and/or the imposition of civil or criminal penalties. HIPAA also authorizes state attorneys general to file suit under HIPAA on behalf of state residents. Courts can award damages, costs and attorneys&#8217; fees related to violations of HIPAA in such cases. While HIPAA does not create a private right of action allowing individuals to sue us in civil court for HIPAA violations, its standards have been used as the basis for a duty of care claim in state civil suits such as those for negligence or recklessness in the misuse or breach of PHI.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additionally, certain states have adopted comparable privacy and security laws and regulations, some of which may apply more broadly or be more stringent than HIPAA. For example, the CCPA, which went into effect on January 1, 2020, gives California residents expanded rights to access and delete their personal information, opt out of certain personal information sharing, and receive detailed information about how their personal information is used. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. Further, the CPRA went into effect in California amending the CCPA and may increase our compliance costs and potential liability, imposes additional data protection obligations on covered businesses, including additional consumer rights processes, limitations on data uses, new audit requirements for higher risk data and adds opt outs for certain uses of sensitive data. It also created a new regulatory authority, the California Privacy Protection Agency (CPPA), which is authorized to issue substantive regulations and could result in increased privacy and information security enforcement. In the event that we are subject to or affected by HIPAA, the CCPA, the CPRA or other domestic privacy and data protection laws (for example Virginia's Consumer Data Protection Act and other similar laws that recently went into effect in in other states, such as Utah, Colorado, Connecticut, Delaware, Florida, Indiana, Iowa, Montana, Oregon, Tennessee, and Texas or Washington's "My Health My Data" Act), any liability from failure to comply with the requirements of these laws could adversely affect our financial condition.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In Europe, the GDPR went into effect in May 2018 and imposes strict requirements for processing the personal data of individuals within the EEA. Companies that must comply with the GDPR face increased compliance obligations </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">and risk, including more robust regulatory enforcement of data protection requirements and potential fines for noncompliance of up to &#8364;20 million or 4% of the annual global revenues of the noncompliant company, whichever is greater. Among other requirements, the GDPR regulates transfers of personal data subject to the GDPR to countries outside of the EEA that have not been found to provide adequate protection to such personal data. In 2016, the EU and United States agreed to a transfer framework for data transferred from the EU to the United States, called the Privacy Shield, but the Privacy Shield was invalidated in July 2020 by the Court of Justice of the EU. In July 2023, however, the European Commission adopted an adequacy decision for a new mechanism for transferring data from the EU to the United States &#8211; the EU-US Data Privacy Framework, which provides EU individuals with several new rights, including the right to obtain access to their data, or obtain correction or deletion of incorrect or unlawfully handled data. The adequacy decision followed the signing of an executive order introducing new binding safeguards addressing the reasons behind the Court of Justice of the EU&#8217;s invalidation of the original Privacy Shield. The European Commission will continually review developments in the United States along with its adequacy decision, and the adequacy decision could be altered or withdrawn. Future actions of EU data protection authorities and the potential impacts on data transfers are difficult to predict.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Relatedly, following the United Kingdom&#8217;s withdrawal from the EU, the GDPR was implemented in the United Kingdom as the U.K. GDPR. The U.K. GDPR sits alongside the amended U.K. Data Protection Act 2018, which implements certain derogations in the EU GDPR into U.K. law. The U.K. GDPR mirrors the fines under the GDPR, i.e., fines up to the greater of &#8364;20 million (&#163;17.5 million) or 4% of annual global turnover. In June of 2021, the European Commission issued a decision, which will sunset on June 27, 2025 without further action, that the United Kingdom ensures an adequate level of protection for personal data transferred under the EU GDPR from the EU to the United Kingdom.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The regulatory framework governing the collection, storage, use and sharing of certain information, particularly financial and other personal information, is rapidly evolving and is likely to continue to be subject to uncertainty and varying interpretations. Additionally, increasing concerns about health information privacy have recently prompted the federal government to issue guidance taking a newly expansive view of the scope of the laws and regulations that they enforce. It is possible that these laws may be interpreted and applied in a manner that is inconsistent with our existing practices. Any failure or perceived failure by us, or any third parties with which we do business, to comply with our privacy policies, changing expectations, evolving laws, rules and regulations, industry standards or contractual obligations to which we or such third parties are or may become subject, may result in actions or other claims against us by governmental entities or private actors, the expenditure of substantial costs, time and other resources or the incurrence of significant fines, penalties or other liabilities. In addition, any such action, particularly to the extent we were found to be guilty of violations or otherwise liable for damages, would damage our reputation and adversely affect our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Although we work to comply with applicable laws, regulations and standards, our contractual obligations and other legal obligations, these requirements are evolving and may be modified, interpreted and applied in an inconsistent manner from one jurisdiction to another and may conflict with one another or other legal obligations with which we must comply. Any failure or perceived failure by us or our employees, representatives, contractors, consultants, collaborators, or other third parties to comply with such requirements or adequately address privacy and security concerns, even if unfounded, could result in additional cost and liability to us, damage our reputation and adversely affect our business and results of operations.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our future growth may depend, in part, on our ability to operate in foreign markets, where we would be subject to additional regulatory burdens and other risks and uncertainties. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our future growth may depend, in part, on our ability to develop and commercialize our testing products in foreign markets. We are not permitted to market or promote any of our testing products before we receive regulatory approval from applicable regulatory authorities in foreign markets, and we may never receive such regulatory approvals for any of our testing products. To obtain separate regulatory approval in many other countries, we and our collaborators and service providers must comply with numerous and varying regulatory requirements regarding safety and efficacy and governing, among other things, clinical trials, commercial sales, pricing and distribution of our testing products. If we obtain regulatory approval of our testing products and ultimately commercialize our testing products in foreign markets, we would be subject to additional risks and uncertainties, including any or all of the following: </span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">different regulatory requirements for approval of IVDs in foreign countries; </span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">reduced protection for intellectual property rights; </span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the existence of additional third-party patent rights of potential relevance to our business; </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">changes in tariffs, trade barriers and regulatory requirements; </span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">economic weakness, including inflation, or political instability in particular foreign economies and markets; </span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad; </span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">foreign currency fluctuations, which could result in increased operating expenses and reduced revenue and other obligations incident to doing business in another country; </span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">inflationary pressures, such as those the global market is currently experiencing, which have and may increase costs for materials, supplies, and services;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">foreign reimbursement, pricing and insurance regimes; </span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">workforce uncertainty in countries where labor unrest is common; </span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and </span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">business interruptions resulting from geopolitical actions, including war and terrorism, such as current conflicts in Ukraine and the Middle East; natural disasters which may be exacerbated due to climate change, including earthquakes, typhoons, floods and fires; outbreak of disease; boycotts; or other business restrictions. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Risks Related to our Intellectual Property </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">If we are unable to maintain intellectual property protection, our competitive position could be harmed. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our ability to protect our technologies, such as the AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus platform, affects our ability to compete and to achieve sustained profitability. We rely on a combination of U.S. and foreign patents and patent applications, copyrights, trademarks and trademark applications, and contractual restrictions to protect our intellectual property rights. We cannot be certain that the claims in our granted patents and pending patent applications covering our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products will be considered patentable or enforceable by the United States Patent and Trademark Office (the USPTO) courts in the United States, or by patent offices and courts in foreign countries. If we fail to protect our intellectual property, third parties may be able to compete more effectively against us and we may incur substantial litigation costs in our attempts to recover or restrict use of our intellectual property. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We apply for patents covering our testing products and technologies and uses thereof, as we deem appropriate, however we may fail to apply for patents on important testing products and technologies in a timely fashion or at all, or we may fail to apply for patents in potentially relevant jurisdictions, or we may cease our prosecution and maintenance of patents in potentially relevant jurisdictions. Currently, we have an exclusive license to two issued U.S. patents, one U.S. patent application, and certain corresponding foreign counterpart patents, relevant to our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products. We own five issued U.S. patents, three pending U.S. patent applications, and certain corresponding foreign counterpart patents relevant to our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products. While we intend to pursue additional patent applications, it is possible that our pending patent applications and any future applications may not result in issued patents. Even if such patents do successfully issue, third parties may challenge the validity, enforceability or scope thereof, which may result in such patents being narrowed, invalidated or held unenforceable. Any successful opposition to our patents could deprive us of exclusive rights necessary for the further development of our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products. Furthermore, even if they are unchallenged, our patents may not adequately protect our intellectual property, provide exclusivity for our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products or prevent others from designing around our claims. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We might not have been the first to make the inventions covered by each of our pending patent applications and we might not have been the first to file patent applications for these inventions. To determine the priority of these inventions, we may have to participate in interference proceedings, derivation proceedings or other post-grant proceedings declared by the USPTO that could result in substantial cost to us. No assurance can be given that our patent applications will have priority over other patent applications. In addition, recent changes to the patent laws of the United States allow for various post-grant opposition proceedings that have not been extensively tested, and their outcome is therefore uncertain. Furthermore, if third parties bring these proceedings against our patents, we could experience significant costs and management distraction. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We previously held licenses to five patent families related to CB-CAPs technology from UPitt. We have terminated these license agreements (related to U.S. Patent Nos. 7,361,517; 7,390,631; 7,585,640; 7,588,905; 8,080,382; </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">8,126,654, and foreign equivalents thereof), effective March 22, 2024, and as a result may face increased competition with respect to the portion of our testing products previously protected by these patents.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition to the protection afforded by patents, we rely on trade secret protection and confidentiality agreements to protect proprietary know-how that is not patentable, or that we elect not to patent, processes for which patents are difficult to enforce and any other elements of our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products and development processes that involve proprietary know-how, information or technology that is not covered by patents. However, trade secrets can be difficult to protect. While we use commercially reasonable efforts to protect our trade secrets, our licensors, employees, consultants, contractors and other advisors may unintentionally or willfully disclose such trade secret information to third parties and competitors. We attempt to protect our proprietary technology in large part by entering into confidentiality and non-disclosure agreements with our employees, consultants and other contractors. We cannot assure you, however, that these agreements will not be breached, that we will have adequate remedies for any breach or that competitors will not know of, or independently discover, our trade secrets. We cannot assure you that others will not independently develop substantially equivalent proprietary information or be issued patents that may prevent the sale of our testing products, technologies, services or know-how or require licensing and the payment of significant fees or royalties by us in order to produce our testing products, technologies or services. Further, we cannot be certain that the steps we have taken will prevent the misappropriation of our trade secrets and other confidential information. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Monitoring unauthorized disclosure is difficult, and we do not know whether the steps we have taken to prevent such disclosure are, or will be, adequate. If we were to enforce a claim that a third party had illegally obtained and was using our trade secrets, it would be expensive and time consuming, and the outcome would be unpredictable. In addition, courts outside the United States may be less willing to protect trade secrets. If we are unable to prevent unauthorized material disclosure of our trade secrets and other confidential information to third parties, and in particular in jurisdictions where we have not filed for patent protection, we may not be able to establish or maintain a competitive advantage in our market, which could materially adversely affect our business, operating results and financial condition. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Certain of our testing products utilize unpatented technology that is publicly available and can be used by our competitors. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Certain of our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products, such as AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD, utilize both patented technology and publicly available technology that is not protected by patents or other intellectual property rights. We believe that using certain publicly available technology allows us to offer a better and more comprehensive testing product. However, the publicly available technology which we rely upon is also used in, and may continue to be used in, products which compete with our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products. Our competitors may independently develop competing diagnostic products and services that do not infringe our intellectual property. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"> testing products. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our success is heavily dependent on intellectual property, particularly on obtaining and enforcing patents. Obtaining and enforcing patents in the diagnostics industry involves both technological and legal complexity, and is therefore costly, time-consuming and inherently uncertain. The United States has enacted and is currently implementing wide-ranging patent reform legislation. Recent Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the U.S. Congress, the federal courts and the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. We cannot predict the breadth of claims that may be allowed or enforced in our patents or in third-party patents. We may not develop additional proprietary products, methods and technologies that are patentable. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Some of our intellectual property has been discovered through government funded programs and thus may be subject to federal regulations such as &#8220;march-in&#8221; rights, certain reporting requirements and a preference for U.S.-based companies. Compliance with such regulations may limit our exclusive rights, and limit our ability to contract with non-U.S. manufacturers. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Some of the intellectual property rights we have acquired or licensed or may acquire or license in the future may have been generated through the use of U.S. government funding and may therefore be subject to certain federal regulations. For example, some of the research and development work related to our CB-CAPs technology was funded by government research grants. As a result, the U.S. government may have certain rights to intellectual </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">property embodied in our testing products pursuant to the Bayh-Dole Act. These U.S. government rights include a non-exclusive, non-transferable, irrevocable worldwide license to use inventions for any governmental purpose. In addition, the U.S. government has the right, under certain limited circumstances, to require us to grant exclusive, partially exclusive or non-exclusive licenses to any of these inventions to a third party if it determines that: (i) adequate steps have not been taken to commercialize the invention; (ii) government action is necessary to meet public health or safety needs; or (iii) government action is necessary to meet requirements for public use under federal regulations (also referred to as &#8220;march-in rights&#8221;). The U.S. government also has the right to take title to these inventions if the grant recipient fails to disclose the invention to the government or fails to file an application to register the intellectual property within specified time limits. Intellectual property generated under a government funded program is also subject to certain reporting requirements, compliance with which may require us to expend substantial resources. In addition, the U.S. government requires that any products embodying any of these inventions or produced through the use of any of these inventions be manufactured substantially in the United States. This preference for U.S. industry may be waived by the federal agency that provided the funding if the owner or assignee of the intellectual property can show that reasonable but unsuccessful efforts have been made to grant licenses on similar terms to potential licensees that would be likely to manufacture substantially in the United States or that under the circumstances domestic manufacture is not commercially feasible. This preference for U.S. industry may limit our ability to contract with non-U.S. product manufacturers for products covered by such intellectual property. To the extent any of our future intellectual property is also generated through the use of U.S. government funding, the provisions of the Bayh-Dole Act may similarly apply. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We may not be able to protect our intellectual property rights throughout the world. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Filing, prosecuting and defending patents on our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products in all countries throughout the world would be prohibitively expensive. Moreover, we believe that obtaining foreign patents may be more difficult than obtaining domestic patents because of differences in patent laws and, accordingly, our patent position may be stronger in the United States than abroad. In addition, the laws of some foreign countries do not protect intellectual property rights in the same manner and to the same extent as laws in the United States. Various countries limit the subject matter that can be patented and limit the ability of a patent owner to enforce patents in the medical and other related fields. This may limit our ability to obtain or utilize those patents internationally. In order to manage our foreign patent costs and focus on the U.S. market, we made the decision to cease the prosecution and maintenance of certain of our foreign patents and patent applications related to our CB-CAPs technology, which is used in our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and further, may export otherwise infringing products to territories where we have patent protection, but enforcement of such patent protection is not as strong as that in the United States. These products may compete with our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property protection, particularly those relating to biotechnology products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly, and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">The patent protection and patent prosecution for some of our testing products may be dependent on third parties. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We or our licensors may fail to identify patentable aspects of inventions made in the course of development and commercialization activities before it is too late to obtain patent protection on them. Therefore, we may miss potential opportunities to strengthen our patent position. It is possible that defects of form in the preparation or filing of our patents or patent applications may exist, or may arise in the future, for example with respect to proper priority claims, inventorship, claim scope or requests for patent term adjustments. If we or our licensors, whether current or future, fail to establish, maintain or protect such patents and other intellectual property rights, such rights may be reduced or eliminated. If our licensors are not fully cooperative or disagree with us as to the prosecution, maintenance or enforcement of any patent rights, such patent rights could be compromised. If there are material defects in the form, preparation, prosecution or enforcement of our patents or patent applications, such patents may </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">be invalid and/or unenforceable, and such applications may never result in valid, enforceable patents. Any of these outcomes could impair our ability to prevent competition from third parties, which may have an adverse impact on our business. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As a licensee of third parties, we rely on third parties to file and prosecute patent applications and maintain patents and otherwise protect the licensed intellectual property under some of our license agreements. We have not had and do not have primary control over these activities for certain of our patents or patent applications and other intellectual property rights. We cannot be certain that such activities by third parties have been or will be conducted in compliance with applicable laws and regulations or will result in valid and enforceable patents or other intellectual property rights. Pursuant to the terms of the license agreements with some of our licensors, the licensors may have the right to control enforcement of our licensed patents or defense of any claims asserting the invalidity of these patents and even if we are permitted to pursue such enforcement or defense, we will require the cooperation of our licensors. We cannot be certain that our licensors will allocate sufficient resources or prioritize their or our enforcement of such patents or defense of such claims to protect our interests in the licensed patents. Even if we are not a party to these legal actions, an adverse outcome could harm our business because it may permit other parties to compete with us. If any of our licensors or any of our future licensors or future collaborators fail to appropriately prosecute and maintain patent protection for patents covering any of our testing products, our ability to develop and commercialize those testing products may be adversely affected and we may not be able to prevent competitors from making, using and selling competing products. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, even where we have the right to control patent prosecution of patents and patent applications we have acquired or licensed from third parties, we may still be adversely affected or prejudiced by actions or inactions of our predecessors or licensors and their counsel that took place prior to us assuming control over patent prosecution. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our technology acquired or licensed from various third parties may be subject to retained rights. Our predecessors or licensors often retain certain rights under their agreements with us, including the right to use the underlying technology for noncommercial academic and research use, to publish general scientific findings from research related to the technology and to make customary scientific and scholarly disclosures of information relating to the technology. It is difficult to monitor whether our predecessors or licensors limit their use of the technology to these uses, and we could incur substantial expenses to enforce our rights to our licensed technology in the event of misuse. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If we are limited in our ability to utilize acquired or licensed technologies, or if we lose our rights to critical in-licensed technology, we may be unable to successfully develop, out-license, market and sell our testing products, which could adversely affect our business. Our business strategy depends on the successful development of licensed and acquired technologies into commercial products. Therefore, any limitations on our ability to utilize these technologies may impair our ability to develop, out-license or market and sell our testing products.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">If we fail to comply with our obligations in the agreements under which we license intellectual property rights from third parties or otherwise experience disruptions to our business relationships with our licensors, we could lose license rights that are important to our business. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are a party to a number of license agreements under which we are granted intellectual property rights that are important to our business. For example, we license certain patent rights from AHN and JHU. Our existing license agreements impose various regulatory and/or commercial diligence obligations, payment of milestones and/or royalties and other obligations. If we fail to comply with our obligations under a license agreement, the license agreement may be terminated, in which event we would not be able to further develop or market certain AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products. Additionally, we may not always have the first right to maintain, enforce or defend our licensed intellectual property rights and, although we would likely have the right to assume the maintenance, enforcement and defense of such intellectual property rights if our licensors do not, our ability to do so may be compromised by our licensors&#8217; acts or omissions.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Licensing of intellectual property rights is of critical importance to our business and involves complex legal, business and scientific issues. Disputes may arise between us and our licensors regarding intellectual property rights subject to a license agreement, including the scope of rights granted under the license agreement and other interpretation-related issues, and whether and the extent to which our technology and processes infringe on intellectual property rights of the licensor that are not subject to the licensing agreement. If disputes over intellectual property rights that we have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, our business, results of operations, financial condition and prospects may be adversely affected. We may enter into additional licenses in the future and if we fail to comply with obligations under those agreements, we could suffer adverse consequences.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent process. Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on any issued patents and/or applications are due to be paid to the USPTO and foreign patent agencies in several stages over the lifetime of the patents and/or applications. Our outside counsel has systems in place to monitor deadlines to pay these fees and to remind us of these fees, and our outside counsel employs an outside firm to pay these fees due to the USPTO and to foreign patent agencies based on our instructions. In the aggregate, these fees can be cost prohibitive for an early-stage company. Accordingly, we made a financially-driven decision to prioritize our payment of these fees and to allow certain of our applications to lapse, particularly with respect to our ex-U.S. rights licensed from UPitt related to our CB-CAPs technology. The permanent lapse of certain of these ex-U.S. rights may result in our patent position being stronger in the United States than abroad, such as in countries that are part of the European Patent Convention, and third parties may be able to compete more effectively against us in countries outside the United States, including in those countries that belong to the European Patent Convention. Additionally, while an inadvertent lapse may sometimes be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, our competitors might be able to enter the market earlier than should otherwise have been the case, which would have a material adverse effect on our business. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We may not be successful in obtaining or maintaining necessary rights to product components and processes for our development pipeline through acquisitions and in-licenses. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Presently we have intellectual property rights, through licenses from third parties and under patents that we own, related to our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products. Because our programs may involve additional products that require the use of proprietary rights held by third parties, the growth of our business will likely depend in part on our ability to acquire, in-license or use these proprietary rights. We may be unable to acquire or in-license proprietary rights that we identify as being necessary for our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products. Even if we are able to obtain a license to such proprietary rights, it may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. In that event, we may be required to expend significant time and resources to develop or license replacement technology. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The licensing and acquisition of third-party proprietary rights is a competitive area, and companies, which may be more established, or have greater resources than we do, may also be pursuing strategies to license or acquire third-party proprietary rights that we may consider necessary or attractive in order to further develop our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products. More established companies may have a competitive advantage over us due to their size, cash resources and greater clinical development and commercialization capabilities. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us, either on reasonable terms, or at all. We also may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment, or at all. If we are unable to successfully obtain rights to required third-party intellectual property rights on commercially reasonable terms, our ability to further develop our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products and our business, financial condition and prospects for growth could suffer. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Third-party claims alleging intellectual property infringement may prevent or delay our development efforts. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our commercial success depends in part on our avoiding infringement of the patents and proprietary rights of third parties. There is a substantial amount of litigation, both within and outside the United States, involving patents and other intellectual property rights in the diagnostics industry, as well as administrative proceedings for challenging patents, including interference and reexamination proceedings before the USPTO or oppositions and other comparable proceedings in foreign jurisdictions. The Leahy-Smith America Invents Act introduced new procedures including inter partes review and post grant review. The implementation of these procedures brings the possibility of third-party challenges to our patents and the outcome of such challenges could result in a loss or narrowing of our patent rights. In such an event, our competitors might be able to enter the market earlier than should otherwise have been the case, which would have a material adverse effect on our business. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are developing our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products. As the diagnostics industry expands and more patents are issued, the risk increases that our activities related to our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products may give rise to claims of infringement of the patent rights of others. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We cannot assure you that any of our current or future AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products will not infringe existing or future patents. Although we are not aware of any issued patents that will prevent us from marketing our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products, there may be third-party patents of which we are currently unaware with claims to materials or methods of manufacture related to the use or manufacture of our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products. If a third party that owns such a patent asserts it successfully against one of our current or future AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products, we may be unable to market our product, which could materially harm our business and because patent applications can take many years to issue and may be confidential for 18 months or more after filing, there may be currently pending third-party patent applications which may later result in issued patents that our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products or our technologies may infringe, or which such third parties claim are infringed by the use of our technologies. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Parties making claims against us for infringement or misappropriation of their intellectual property rights may seek and obtain injunctive or other equitable relief, which could effectively block our ability to further develop one or more of our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products. Defense of these claims, regardless of their merit, would involve substantial expenses and would be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees if we are found to be willfully infringing a third party&#8217;s patents, obtain one or more licenses from third parties, pay royalties or redesign our infringing products, which may be impossible or require substantial time and monetary expenditure. We cannot predict whether any such license would be available at all or whether it would be available on commercially reasonable terms. Furthermore, even in the absence of litigation, we may need to obtain licenses from third parties to advance our research or development of our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all. In that event, we would be unable to further develop our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products, which could harm our business significantly. Even if we were able to obtain a license, the rights may be nonexclusive, which may give our competitors access to the same intellectual property. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition to infringement claims against us, if third parties have prepared and filed patent applications in the United States that also claim technology to which we have rights, we may have to participate in interference proceedings in the USPTO to determine the priority of invention. Third parties may also attempt to initiate reexamination, post grant review or inter partes review of our patents in the USPTO. We may also become involved in similar proceedings in the patent offices in other jurisdictions regarding our intellectual property rights with respect to our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products and technology. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We may be involved in proceedings to protect or enforce our patents or the patents of our licensors, which could be expensive, time-consuming and unsuccessful. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Third parties may infringe, misappropriate or otherwise violate our existing patents, patents that may be issued to us in the future, or the patents of our licensors that are licensed to us. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming. We may not be able to prevent, alone or with our licensors, misappropriation of our intellectual property rights, particularly in countries where the laws may not protect those rights as fully as in the United States. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, if we or one of our licensors initiated legal proceedings against a third party to enforce a patent covering one of our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products, the defendant could counterclaim that the patent covering such AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing product is invalid and/or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace, and there are numerous grounds upon which a third party can assert invalidity or unenforceability of a patent. Such proceedings could result in an invalidation of our patents. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the patent protection on our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products. Such a loss of patent protection could have a material adverse impact on our business. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Litigation proceedings may fail and, even if successful, may result in substantial costs and distract our management and other employees. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Because of the expense and uncertainty of litigation, we may not be in a position to enforce our intellectual property rights against third parties. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Because of the expense and uncertainty of litigation, we may conclude that even if a third party is infringing our patents or other intellectual property rights, the risk-adjusted cost of bringing and enforcing such a claim or action may be too high or not in the best interest of our company or our stockholders. We are not aware of any third-party infringement of our intellectual property rights that would have a materially adverse impact on our business. In addition, there can be no assurance that our licensors will be willing to bring and enforce claims to prevent third parties from infringing intellectual property that is licensed to us, particularly if the affected intellectual property is less important to the licensor&#8217;s business than to ours. In such cases, we may decide that the more prudent course of action is to simply monitor the situation or initiate or seek some other non-litigious action or solution. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have received confidential and proprietary information from third parties. In addition, we employ individuals who were previously employed at other companies in our industry. We may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise improperly used or disclosed confidential information of these third parties or our employees&#8217; former employers. Further, we may be subject to ownership disputes in the future arising, for example, from conflicting obligations of consultants or others who are involved in developing our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products. We may also be subject to claims that former employees, collaborators or other third parties have an ownership interest in our patents or other intellectual property. Litigation may be necessary to defend against these and other claims challenging our right to and use of confidential and proprietary information. If we fail in defending any such claims, in addition to paying monetary damages, we may lose our rights therein. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against these claims, litigation could result in substantial cost and be a distraction to our management and employees. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Risks Related to Our Common Stock </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our stock price may be volatile, and you may not be able to sell shares of our common stock at or above the price you paid. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The public trading price for our common stock is affected by a number of factors, including: </span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">actual or anticipated variations in our and our competitors&#8217; financial condition and results of operations; </span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">announcements by us or our competitors of new products, strategic partnerships or capital commitments; </span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">changes in reimbursement by current or potential third-party payors; </span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">issuance of new securities analysts&#8217; reports or changed recommendations for our stock; </span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">actual or anticipated changes in regulatory oversight of our testing products; </span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">developments or disputes concerning our intellectual property or other proprietary rights; </span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">commencement of, or our involvement in, litigation; </span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">announced or completed acquisitions of businesses or technologies by us or our competitors; </span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">any major change in our management; </span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">changes in accounting principles; </span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">announcement or expectation of additional financing efforts; </span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">future sales of our common stock by our executive officers, directors and other stockholders; and </span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">general economic conditions and slow or negative growth of our markets, including as a result of the current conflicts in the Ukraine and the Middle East. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, the stock market in general, and the market for stock of life sciences companies in particular, has experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of those companies. Broad market and industry factors, as well as general economic, political and market conditions such as recessions or interest rate changes, may seriously affect the market price of our common stock, regardless of our actual operating performance. As a result of this volatility, you may not realize any return on your investment in us and may lose some or all of your investment. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, in the past, following periods of volatility in the overall market and the market price of a particular company&#8217;s securities, securities class action litigation has often been instituted against these companies. This litigation, if instituted against us, could result in substantial costs and a diversion of our management&#8217;s attention and resources. Any adverse determination in any such litigation or any amounts paid to settle any such actual or threatened litigation could require that we make significant payments. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Future sales of shares by existing stockholders could cause our stock price to decline. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Sales of a substantial number of shares of our common stock in the public market or the perception that these sales might occur could significantly reduce the trading price of our common stock and impair our ability to raise adequate capital through the sale of additional equity securities.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">At December 31, 2024, our employees and members of our board of directors collectively hold options to acquire up to 489,296 shares of our common stock and restricted stock units representing the contingent right to receive up to 1,710,373 shares of our common stock. These shares are registered pursuant to our previously filed registration statements on Form S-8 and are generally freely-tradeable. Future sales of substantial amounts of our common stock in the public market, including sales by our directors, employees, or other significant holders, shares issued upon exercise of then outstanding options or warrants, or the perception that such sales may occur, could adversely affect the market price of our common stock and cause significant dilution to our existing stockholders.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, our directors and executive officers have and may continue to establish programmed selling plans under Rule 10b5-1 of the Exchange Act for the purpose of effecting sales of our common stock. Any sales of securities by directors and executive officers, or the perception that those sales may occur, including the entry into such programmed selling plans, could have a material adverse effect on the trading price of our common stock, particularly if the trading volume of our common stock is relatively low at the time of these sales.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Provisions in our charter documents and under Delaware law could discourage a takeover that stockholders may consider favorable and may lead to entrenchment of management. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our amended and restated certificate of incorporation and amended and restated bylaws contain provisions that could significantly reduce the value of our shares to a potential acquiror or delay or prevent changes in control or changes in our management without the consent of our board of directors. The provisions in our charter documents include the following: </span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">a classified board of directors with three-year staggered terms, which may delay the ability of stockholders to change the membership of a majority of our board of directors; </span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">no cumulative voting in the election of directors, which limits the ability of minority stockholders to elect director candidates; </span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the exclusive right of our board of directors, unless the board of directors grants such right to the stockholders, to elect a director to fill a vacancy created by the expansion of the board of directors or the resignation, death or removal of a director, which prevents stockholders from being able to fill vacancies on our board of directors; </span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the required approval of at least 66-2/3% of the shares entitled to vote to remove a director for cause, and the prohibition on removal of directors without cause; </span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the ability of our board of directors to authorize the issuance of shares of preferred stock and to determine the price and other terms of those shares, including preferences and voting rights, without stockholder approval, which could be used to significantly dilute the ownership of a hostile acquiror; </span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the ability of our board of directors to alter our amended and restated bylaws without obtaining stockholder approval; </span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the required approval of at least 66-2/3% of the shares entitled to vote to adopt, amend or repeal our amended and restated bylaws or repeal the provisions of our amended and restated certificate of incorporation regarding the election and removal of directors; </span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">a prohibition on stockholder action by written consent, which forces stockholder action to be taken at an annual or special meeting of our stockholders; </span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">an exclusive forum provision providing that the Court of Chancery of the State of Delaware will be the exclusive forum for certain actions and proceedings; </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the requirement that a special meeting of stockholders may be called only by the board of directors, which may delay the ability of our stockholders to force consideration of a proposal or to take action, including the removal of directors; and </span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">advance notice procedures that stockholders must comply with in order to nominate candidates to our board of directors or to propose matters to be acted upon at a stockholders&#8217; meeting, which may discourage or deter a potential acquiror from conducting a solicitation of proxies to elect the acquiror&#8217;s own slate of directors or otherwise attempting to obtain control of us. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are also subject to the anti-takeover provisions contained in Section 203 of the Delaware General Corporation Law. Under Section 203, a corporation may not, in general, engage in a business combination with any holder of 15% or more of its capital stock unless the holder has held the stock for three years or, among other exceptions, the board of directors has approved the transaction. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware will be the exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our amended and restated certificate of incorporation provide that the Court of Chancery of the State of Delaware is the exclusive forum for any derivative action or proceeding brought on our behalf, any action asserting a breach of fiduciary duty, any action asserting a claim against us arising pursuant to the Delaware General Corporation Law, our amended and restated certificate of incorporation, or any action asserting a claim against us that is governed by the internal affairs doctrine; provided, that, this provision would not apply to suits brought to enforce a duty or liability created by the Securities Act or the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction. To the extent that any such claims may be based upon federal law claims, Section 27 of the Exchange Act creates exclusive federal jurisdiction over all suits brought to enforce any duty or liability created by the Exchange Act or the rules and regulations thereunder. Furthermore, Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all suits brought to enforce any duty or liability created by the Securities Act or the rules and regulations thereunder. These choice of forum provisions may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage such lawsuits against us and our directors, officers and other employees. By agreeing to this provision, however, the stockholders will not be deemed to have waived our compliance with the Federal Securities laws and rules and regulations thereunder. Furthermore, the enforceability of similar choice of forum provisions in other companies&#8217; certificates of incorporation has been challenged in legal proceedings, and it is possible that a court could find these types of provisions to be inapplicable or unenforceable. If a court were to find the choice of forum provisions in our amended and restated certificate of incorporation to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could adversely affect our business and financial condition. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our executive officers, directors and principal stockholders, if they choose to act together, have the ability to control or significantly influence all matters submitted to stockholders for approval. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Based on their most recent publicly filed beneficial ownership reports, our greater than 5% stockholders collectively own approximately 50% of our outstanding capital stock and our greater than 5% stockholders, directors and executive officers collectively own (without duplication) approximately 52% of our outstanding capital stock as of February 15, 2025. As a result, such persons, acting together, have the ability to control or significantly influence all matters submitted to our stockholders for approval, including the election and removal of directors and approval of any significant transaction, as well as our management and business affairs. This concentration of ownership may have the effect of delaying, deferring or preventing a change in control, impeding a merger, consolidation, takeover or other business combination involving us, or discouraging a potential acquiror from making a tender offer or otherwise attempting to obtain control of our business, even if such a transaction would benefit other stockholders. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We have never paid dividends on our capital stock, and we do not anticipate paying dividends in the foreseeable future. Your ability to achieve a return on your investment will depend on appreciation, if any, in the price of our common stock. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have never declared or paid any cash dividends on our common stock and do not intend to pay any cash dividends in the foreseeable future. We currently intend to retain any future earnings to fund the growth of our business. In addition, our Amended Loan Agreement restricts our ability to pay cash dividends on our common stock and we may also enter into credit agreements or other borrowing arrangements in the future that will restrict our ability to declare or pay cash dividends on our common stock. Any determination to pay dividends in the future will be at the discretion of our board of directors and will depend on our financial condition, operating results, capital </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">requirements, general business conditions and other factors that our board of directors may deem relevant. As a result, capital appreciation, if any, of our common stock will be the sole source of gain for the foreseeable future. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">An active, liquid trading market for our common stock may not be maintained.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Prior to our initial public offering, there had been no public market for our common stock. While our common stock now trades on The Nasdaq Global Market (Nasdaq), we can provide no assurance that we will be able to develop and sustain an active trading market for our common stock. Even if an active trading market is developed, it may not be sustained. The lack of an active market may impair your ability to sell your shares at the time you wish to sell them or at a price that you consider reasonable. An inactive market may also impair our ability to raise capital by selling shares and may impair our ability to acquire other businesses or technologies using our shares as consideration, which, in turn, could materially adversely affect our business. During 2024, our average daily trading volume has been approximately 56,732 shares.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our failure to meet the continued listing requirements of Nasdaq or The Nasdaq Stock Market LLC could result in a delisting of our common stock. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If we fail to satisfy the continued listing requirements of Nasdaq, such as the corporate governance requirements or the minimum closing bid price requirement, Nasdaq may take steps to delist our common stock. Such a delisting would likely have a negative effect on the price of our common stock and would impair your ability to sell or purchase our common stock when you wish to do so. In the event of a delisting, we can provide no assurance that any action taken by us to restore compliance with listing requirements would allow our common stock to become listed again, stabilize the market price or improve the liquidity of our common stock, prevent our common stock from dropping below the Nasdaq minimum bid price requirement or prevent future non-compliance with Nasdaq&#8217;s listing requirements.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">If securities or industry analysts downgrade our common stock or otherwise issue adverse opinions or commentary regarding our stock or do not publish research or reports about our company, our stock price and trading volume could decline. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The trading market for our common stock depends in part on the research and reports that equity research analysts publish about us and our business. Currently, we have limited analyst coverage and we do not have any control over such analysts or the content and opinions included in their reports. Securities analysts may elect not to provide research coverage of our company, and such lack of research coverage may adversely affect the market price of our common stock. The price of our common stock could also decline if one or more equity research analysts downgrade our common stock or if those analysts issue other unfavorable commentary or cease publishing reports about us or our business. If one or more equity research analysts cease coverage of our company, we could lose visibility in the market, which in turn could cause our stock price to decline. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We could be subject to securities class action litigation. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the past, securities class action litigation has often been brought against a company following a decline in the market price of its securities. This risk is especially relevant for us because life sciences and diagnostics companies have experienced significant stock price volatility in recent years. If we face such litigation, it could result in substantial costs and a diversion of management&#8217;s attention and resources, which could harm our business.</span></div><div id="i9ecffbbbc3a143a09815a7575cabd836_19"></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item 1B. Unresolved Staff Comments.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Not applicable.</span></div><div><span><br/></span></div><div id="i9ecffbbbc3a143a09815a7575cabd836_22"></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" format="ixt:fixed-false" id="f-36">Item 1C. Cybersecurity.</ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" id="f-37" continuedAt="f-37-1" escape="true"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We recognize the critical importance of maintaining the trust and confidence of physicians, patients, business partners and employees toward our business and are committed to protecting the confidentiality, integrity and availability of our business operations and systems. Our board of directors is actively involved in oversight of our risk management activities, and cybersecurity represents an important element of our overall approach to risk management. Our cybersecurity policies, standards, processes and practices are based on recognized frameworks established by NIST and other applicable industry standards, as well as the HIPAA Security Rule and other recognized frameworks. In general, we seek to address cybersecurity risks through a comprehensive, cross-functional approach that is focused on preserving the confidentiality, security and availability of the information that we collect and store by identifying, preventing and mitigating cybersecurity threats and effectively responding to cybersecurity incidents when they occur.</span></div></ix:nonNumeric><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-37-1" continuedAt="f-37-2"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Cybersecurity Risk Management and Strategy; Effect of Risk</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We face risks related to cybersecurity such as unauthorized access, cybersecurity attacks and other security incidents, including as perpetrated by hackers and unintentional damage or disruption to hardware and software systems, loss of data, and misappropriation of confidential information. To identify and assess material risks from cybersecurity threats, we maintain a comprehensive cybersecurity program to ensure our systems are effective and prepared for information security risks, including regular oversight of our programs for security monitoring for internal and external threats to ensure the confidentiality and integrity of our information assets. We consider risks from cybersecurity threats in addition to other company risks as part of our overall risk assessment process. We employ a range of tools and services, including regular network and endpoint monitoring, audits, vulnerability assessments, and penetration testing to inform our risk identification and assessment. As discussed in more detail under &#8220;Cybersecurity Governance&#8221; below, our Audit Committee provides oversight of our cybersecurity risk management and strategy processes, which are led by our Vice President of Information Services.</span></div><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock" id="f-38" escape="true"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementProcessesIntegratedFlag" format="ixt:fixed-true" id="f-39">We also identify our cybersecurity threat risks by comparing our processes to standards set by NIST, as well as performing intrusion detection and prevention.</ix:nonNumeric> To provide for the availability of critical data and systems, maintain regulatory compliance, manage our material risks from cybersecurity threats, and protect against and respond to cybersecurity incidents, we undertake the following activities:</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">a.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:9.67pt">monitor emerging data protection laws and implement changes to our processes that are designed to comply with such laws;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">b.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:9.67pt">through our policies, practices and contracts (as applicable), require employees, as well as third parties that provide services on our behalf, to treat confidential information and data with care;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">c.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10.23pt">employ technical safeguards that are designed to protect our information systems from cybersecurity threats, including firewalls, intrusion prevention and detection systems, anti-malware functionality and access controls, which are evaluated and improved through vulnerability assessments and cybersecurity threat intelligence;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">d.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:9.67pt">provide regular, mandatory training for our employees regarding cybersecurity threats as a means to equip them with effective tools to address cybersecurity threats, and to communicate our evolving information security policies, standards, processes and practices;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">e.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:9.67pt">conduct regular phishing email simulations for all employees with access to our email systems to enhance awareness and responsiveness to possible threats;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">f.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:12.46pt">conduct monthly cybersecurity management and incident training for employees involved in our systems and processes that handle sensitive data;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">g.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:9.67pt">leverage internal and external resources to help us identify, protect, detect, respond and recover when there is an actual or potential cybersecurity incident; and</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">h.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:9.67pt">carry information security risk insurance that provides protection against the potential losses arising from a cybersecurity incident</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" id="f-40" escape="true"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our incident response plan coordinates the activities we take to prepare for, detect, respond to and recover from cybersecurity incidents, which include processes to triage, assess severity for, escalate, contain, investigate and remediate the incident, as well as to comply with potentially applicable legal obligations and mitigate damage to our business and reputation. As part of the above processes, we rely on internal resources rather than consultants, auditors or other third parties, to review our cybersecurity program.</span></div></ix:nonNumeric><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" format="ixt:fixed-true" id="f-41"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementThirdPartyEngagedFlag" format="ixt:fixed-true" id="f-42">Our processes also address cybersecurity threat risks associated with our use of third-party service providers, including our suppliers and manufacturers or who have access to patient and employee data or our systems.</ix:nonNumeric></ix:nonNumeric> In addition, cybersecurity considerations affect the selection and oversight of our third-party service providers. We perform diligence on third parties that have access to our systems, data or facilities that house such systems or data.</span></div></ix:continuation><div style="margin-top:9pt;text-align:justify"><ix:continuation id="f-37-2" continuedAt="f-37-3"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We describe whether and how risks from identified cybersecurity threats, including as a result of any previous cybersecurity incidents, have materially affected or are reasonably likely to materially affect us, including our business strategy, results of operations, or financial condition, under the heading &#8220;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Failure in our information technology, telephone or other systems could significantly disrupt our operations and adversely affect our business and financial condition</span></ix:continuation><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="f-37-3">,&#8221; which disclosures are incorporated by reference herein.</ix:continuation> </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock" id="f-43" escape="true"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Cybersecurity Governance; Management</span></div><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskRoleOfManagementTextBlock" id="f-44" continuedAt="f-44-1" escape="true"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" id="f-46" escape="true"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" id="f-45" escape="true">Cybersecurity is an important part of our risk management processes and an area of focus for our board of directors and management. In general, our board of directors oversees risk management activities designed and implemented by our management, and considers specific risks, including, for example, risks associated with our strategic plan, business operations, and capital structure. Our <ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" format="ixt:fixed-true" id="f-47">board of directors</ix:nonNumeric> executes its oversight responsibility for risk management both directly and through delegating oversight of certain of these risks to its committees, and our board of directors has authorized our <ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" format="ixt:fixed-true" id="f-48">Audit Committee</ix:nonNumeric> to oversee risks from cybersecurity threats.</ix:nonNumeric></ix:nonNumeric> </span></div></ix:nonNumeric><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="f-44-1">Upon detection of a material cybersecurity threat, our Audit Committee receives an update from management of the cybersecurity threat, risk management and strategy processes, as well as the steps management has taken to respond to such risks. <ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" id="f-49" escape="true">In such sessions, our Audit Committee generally receives materials that include cybersecurity materials discussing current material cybersecurity threat risks, and describing our ability to mitigate those risks, and discusses such matters with our Chief Executive Officer. Our Audit Committee and board of directors receive prompt and timely information regarding any cybersecurity incident that meets established reporting thresholds.</ix:nonNumeric></ix:continuation> </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" id="f-50" escape="true">Our cybersecurity risk management and strategy processes, which are discussed in greater detail above, are led by our Vice President of Information Services, with support from our entire Information Services department. Such individuals have collectively over 10 years of prior work experience in various roles involving managing information security, developing cybersecurity strategy, implementing effective information and cybersecurity programs, as well as several relevant degrees and certifications.</ix:nonNumeric> These Information Services team members are informed about and monitor the prevention, mitigation, detection, and remediation of cybersecurity incidents through their management of, and participation in, the cybersecurity risk management and strategy processes described above, including the operation of our incident response plan. As discussed above, these Information Services team members report to our Chief Executive Officer, and ultimately to the Audit Committee of our board of directors about material cybersecurity threats.</span></div></ix:nonNumeric><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><div id="i9ecffbbbc3a143a09815a7575cabd836_25"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item 2. Properties.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our corporate headquarters are located in Vista, California, where we lease approximately 27,000 square feet of office and laboratory space under a lease that expires in 2027, with an option to extend a portion of the lease for an additional five-year period. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We also lease approximately 28,000 square feet of additional office space in Carlsbad, California, under a sublease that is co-terminus with our other lease expiring in 2027. We believe that our current facilities are adequate for our current needs and that suitable additional or alternative spaces will be available in the future on commercially reasonable terms, if required.</span></div><div id="i9ecffbbbc3a143a09815a7575cabd836_28"></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item 3. Legal Proceedings.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">From time to time, we may be involved in legal proceedings or subject to claims incident to the ordinary course of business. Regardless of the outcome, such proceedings or claims can have an adverse impact on us because of defense and settlement costs, diversion of resources and other factors, and there can be no assurances that favorable outcomes will be obtained.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In October 2023, we resolved an investigation with the U.S. Attorney&#8217;s Office for the District of Massachusetts that was initiated by a </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">qui tam</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> lawsuit. Pursuant to a Settlement Agreement, we made a single lump-sum remittance to the government in the amount of $0.7 million plus interest in connection with specimen processing arrangements that we historically had with physicians. The U.S. Attorney&#8217;s Office dismissed this &#8220;covered conduct&#8221; in the qui tam with prejudice, while non-covered conduct was dismissed without prejudice. The Department of Justice excused itself from the case in connection with the settlement. In November 2023, the complaint was unsealed and served on us. We filed a motion to dismiss the complaint. In February 2024, the relator filed a motion for leave to amend the complaint. We opposed this motion, and all motions are still pending. While we cannot predict when these matters will be resolved, the Company intends to vigorously defend against the claims being asserted in the complaint.</span></div><div id="i9ecffbbbc3a143a09815a7575cabd836_31"></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Items 4. Mine Safety Disclosures.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><div id="i9ecffbbbc3a143a09815a7575cabd836_34"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Part II</span></div><div style="text-align:center"><span><br/></span></div><div id="i9ecffbbbc3a143a09815a7575cabd836_37"></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Market Information</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our common stock began trading on The Nasdaq Global Market on September 19, 2019 under the symbol "XGN." Prior to September 19, 2019, there was no public market for our common stock.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Holders of Record</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of March&#160;7, 2025, there were approximately 23 stockholders of record of our common stock. This number was derived from our shareholder records and does not include beneficial owners of our common stock whose shares are held in "street" name with various dealers, clearing agencies, banks, brokers and other fiduciaries.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Dividend Policy</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have never declared or paid any cash dividends on our capital stock. We intend to retain future earnings, if any, to finance the operation of our business and do not anticipate paying any cash dividends in the foreseeable future. Any future determination related to dividend policy will be made at the discretion of our board of directors after considering our financial condition, results of operations, capital requirements, business prospects and other factors the board of directors deems relevant, and subject to the restrictions contained in any future financing instruments. In addition, our ability to pay cash dividends is currently prohibited by the terms of our Amended Loan Agreement.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Securities Authorized for Issuance under Equity Compensation Plans</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">See Part III, Item 12 of this Annual Report under the section titled "Security Ownership of Certain Beneficial Owners and Management" for information about our equity compensation plans, which is incorporated by reference herein.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Performance Graph</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Not applicable.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Recent Sales of Unregistered Securities</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">None.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Purchases of Equity Securities by the Issuer</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">None.</span></div><div style="margin-top:9pt"><span><br/></span></div><div id="i9ecffbbbc3a143a09815a7575cabd836_40"></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6. [</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reserved.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">]</span></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><div id="i9ecffbbbc3a143a09815a7575cabd836_43"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">You should read the following discussion of our financial condition and results of operations in conjunction with the financial statements and the notes thereto included elsewhere in this Annual Report. Some of the information contained in this discussion and analysis or set forth elsewhere in this Annual Report, including information with respect to our plans and strategy for our business and financial performance, includes forward-looking statements that are based on current beliefs, plans and expectations and involve risks, uncertainties and assumptions. You should read the "Special note regarding forward-looking statements" and "Risk Factors" section of this Annual Report for a discussion of important factors that could cause our actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.</span></div><div id="i9ecffbbbc3a143a09815a7575cabd836_46"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Overview</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are a medical technology company primarily focused on the design, development and commercialization of a next-generation portfolio of innovative testing products under our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> brand, which allow for the differential diagnosis, prognosis and monitoring of complex rheumatic, autoimmune and autoimmune-related disease including, among others, SLE and RA. We believe our strong focus and extensive background in the field of rheumatology, combined with our commitment to exceptional customer service and support, position us well to respond to the needs of rheumatologists, primary care physicians, other specialists, and the patients they serve.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our tests are used in a variety of clinical settings to provide clarity in autoimmune disease decision-making with the goal of improving patients' clinical outcomes. We commercially launched our flagship testing product, AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD, in 2012. AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.47pt;font-weight:400;line-height:115%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD enables differential diagnosis for patients presenting with symptoms indicative of a wide variety of CDTs and other related diseases with overlapping symptoms. Traditional screening methods often lack accuracy, resulting in repeat testing and delayed diagnosis. With significant increases in autoimmune incidence in recent years, AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.47pt;font-weight:400;line-height:115%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD provides unique biomarkers that empower clinicians to confidently and quickly diagnose various CTDs. Beginning in late 2022, w</span><span style="background-color:#ffffff;color:#080808;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">e revitalized our organization with the addition of key members to our senior leadership team, including our Chief Executive Officer, Chief Financial Officer, Vice President of Sales, Chief Medical Officer, and Medical and Laboratory Director.</span><span style="color:#080808;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">By leveraging our team&#8217;s extensive experience to create clinically distinct solutions that improve patient lives, we </span><span style="background-color:#ffffff;color:#080808;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">have created a strong foundation for growth and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">believe that we are well-positioned </span><span style="background-color:#ffffff;color:#080808;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">to positively impact patient care and address unmet clinical needs in autoimmune disease</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. We strive to become a partner of choice for doctors, hospitals, healthcare systems, and payors.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under the leadership of our Chief Executive Officer, John Aballi, who joined Exagen in October 2022, we are executing an operational turnaround of the business, resulting in a return to revenue growth and gross margin expansion while significantly reducing operating expenses and cash burn.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">All of our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> tests are performed in our approximately 13,000 square foot laboratory located in Vista, California, which is certified under the CLIA and accredited by CAP. Our laboratory is certified for performance of high-complexity testing by CMS in accordance with CLIA and is licensed by all states requiring out-of-state licensure. Our clinical laboratory typically reports all AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">testing product results within five business days.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Reimbursement for our testing services comes from several sources, including commercial payors (such as insurance companies and health maintenance organizations), government payors (such as Medicare and Medicaid), client payors (such as hospitals, other laboratories, etc.) and patients. Reimbursement rates vary by product and payor.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Since launching AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.47pt;font-weight:400;line-height:115%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD, we have produced an extensive body of peer-reviewed literature supporting the test&#8217;s clinical validity and utility, demonstrating the importance of AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.47pt;font-weight:400;line-height:115%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD in patient care. Revenue from this product comprised 91% and 88% of our revenue for the years ended December&#160;31, 2024 and 2023, respectively. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition to providing diagnostic testing, we are leveraging our clinical laboratory to enter into agreements in the normal course of business with leading pharmaceutical companies and contract research organizations for the use of our testing products and/or the de-identified data generated from such tests. We believe the quality of our testing, proprietary offerings and specialized knowledge give us an advantage in this space. We plan to continue to pursue additional partnerships with leading pharmaceutical companies and academic research centers that are synergistic with our evolving portfolio of testing products, as more of these organizations realize the extent of the service we can provide.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We market our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products using our specialized sales force covering 40 territories in the United States. Many diagnostic sales forces are trained only to understand the comparative benefits of the tests they promote. In contrast, the specialized backgrounds of our sales personnel, coupled with our comprehensive training, enables our sales representatives to interpret results from our de-identified patient test reports and provide unique </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">insights in a highly tailored discussion with rheumatologists. We believe our focus on and experience in the field of rheumatology, combined with our commitment to excellent customer service and support, position us very well to respond to the needs of rheumatologists and the patients they serve.</span></div><div id="i9ecffbbbc3a143a09815a7575cabd836_49"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Factors Affecting Our Performance</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We believe there are several important factors that have impacted, and that we expect will impact, our operating performance and results of operations, including:</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.46pt;text-decoration:underline">Commercial Launch of AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;text-decoration:underline;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;text-decoration:underline"> CTD Enhancements</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. Our flagship product, AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD, enables clinicians to more effectively diagnose complex autoimmune conditions such as lupus, rheumatoid arthritis, and Sj&#246;gren&#8217;s syndrome earlier and with greater accuracy, as compared to the current standard of care. Our laboratory specializes in the testing of rheumatic diseases, delivering precise and timely results, supported by a full suite of AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">-branded tests for disease diagnosis, prognosis, and monitoring. With a focus on research, innovation, education, and patient-centered care, we are dedicated to addressing the ongoing challenges of autoimmune disease management.</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In January 2025, we announced conditional approval by NYSDOH and commercial launch of our new SLE and RA biomarker assays on the AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD platform. Collectively, we believe these new biomarkers will further improve the clinical utility of AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD, providing clinicians with the information they need to definitively diagnose patients and shorten their autoimmune diagnostic journeys. We expect the addition of these new biomarkers will drive gains in our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD average selling price, gross margin expansion and increase demand while positioning us for profitability.</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.46pt;text-decoration:underline">Reimbursement for Our Testing Products</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. Our revenue depends on achieving broad coverage and reimbursement for our tests from third-party payors, including both commercial payors and government payors. Payment from third-party payors differs depending on whether we are considered a "participating provider" (have entered into a contract with the payors as a participating provider) or a "non-participating provider" (do not have a contract and are considered a "non-participating provider"). Payors will often reimburse non-participating providers at a lower amount than participating providers, if at all. We have received a substantial portion of our revenue from a limited number of commercial payors, most of which have not contracted with us to be a participating provider. Historically, we have experienced situations where commercial payors proactively reduced the amounts they were willing to reimburse for our tests, and in other situations, commercial payors have determined that the amounts they previously paid were too high and have sought to recover those perceived excess payments by deducting such amounts from payments otherwise being made. When we contract to serve as a participating provider, reimbursements are made pursuant to a negotiated fee schedule and are limited to only covered indications.&#160;If we are not able to obtain or maintain coverage and adequate reimbursement from third-party payors, we may not be able to effectively increase our testing volume and revenue as expected. Additionally, changes in our estimated reimbursements for tests performed in prior periods can positively or negatively impact our revenue in the current period and cause our financial results to fluctuate. In addition, in connection with our revenue cycle management initiatives, we held claims in the first half of the year which resulted in increases in our accounts receivable and an accelerated decrease in our cash in the first half of the year. As expected, this trend reversed in the second half of the year, as cash was collected on billed tests.</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.46pt;text-decoration:underline">Expanding Adoption of AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:115%;position:relative;text-decoration:underline;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;text-decoration:underline"> CTD</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Since the launch of AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD in 2012 and through December&#160;31, 2024, we have delivered approximately 1,009,812 of these tests. 122,883 AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD tests were delivered in the year ended December&#160;31, 2024, representing approximately 11% decline over the same period in 2023. The number of ordering healthcare providers in the quarter ended December&#160;31, 2024 was 2,370, representing an approximate 1% decrease over the same period in 2023. Revenue growth for our testing products will depend, in part, on our ability to continue to expand our base of ordering healthcare providers and increase our penetration with existing healthcare providers.</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.46pt;text-decoration:underline">Development of Innovative Testing Products</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We expect to continue to invest in research and development in order to develop additional testing products. Our success in developing new testing products will be important in our efforts to grow our business by expanding the potential market for our products and diversifying our sources of revenue. We intend to leverage our protein and molecular assay development capabilities, bioinformatic team and proprietary technologies to pursue the development of additional testing products designed to have superior clinical utility for rheumatic conditions. </span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.46pt;text-decoration:underline">Deliver Sustainable Profitable Growth</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We seek to establish a solid foundation for growth and path to sustained profitability through continued gross margin enhancements and improved operating expense efficiencies through the implementation of certain internal initiatives, such as leveraging validation, utility </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">and reimbursement-oriented clinical studies to facilitate payor coverage of our testing products. We center our efforts around long-term reimbursement and ASP growth. This strategy includes optimizing revenue cycle practices, focusing managed care efforts on medical policy expansion and continuing to educate insurance payors on the published, real-world evidence of the clinical utility of our testing products, demonstrating healthcare cost savings and reductions in time to diagnosis.</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.46pt;text-decoration:underline">Timing of Our Research and Development Expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. We conduct clinical studies to validate our new testing products, as well as ongoing clinical and outcome studies to further expand the published evidence that supports our commercialized AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products. We also expend funds to secure clinical samples that can be used in discovery, product development, clinical validation, utility and outcome studies. Our spending on experiments and clinical studies may vary substantially from quarter to quarter, and the timing of these research and development activities is difficult to predict. If a substantial number of clinical samples are obtained in a given quarter or if a high-cost experiment is conducted in one quarter versus the next, the timing of these expenses will affect our financial results.</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.46pt;text-decoration:underline">How We Recognize Revenue</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. We record revenue on an accrual basis, using an estimate of the amount that we will ultimately realize, as determined based on a historical analysis of amounts collected by test and by payor, among other factors. Changes to such estimates may increase or decrease revenue recognized in future periods.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">While each of these areas present significant opportunities for us, they also pose significant risks and challenges that we must address. We discuss many of these risks, uncertainties and other factors in the section entitled "Risk Factors."</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Seasonality</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Based on our experience to date, we expect some seasonal variations in our financial results due to a variety of factors, such as: the year-end holiday period and other major holidays, vacation patterns of both patients and healthcare providers (including medical conferences), climate and weather conditions in our markets (for example, excess sun exposure can cause flares in SLE), seasonal conditions that may affect medical practices and provider activity (for example, influenza outbreaks that may reduce the percentage of patients that can be seen) and other factors relating to the timing of patient benefit changes, as well as patient deductibles and co-insurance limits.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Inflationary Environment</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The current inflationary environment has resulted in higher prices, which have impacted our costs incurred to generate revenue from our laboratory testing services, costs to attract and retain personnel, and other operating costs. The severity and duration of the current inflationary environment remains uncertain and may continue to impact our financial condition and results of operations.</span></div><div id="i9ecffbbbc3a143a09815a7575cabd836_52"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Financial Overview</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Revenue</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We recognize revenue in accordance with the provisions of ASC Topic 606, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Revenue from Contracts with Customers.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> We record revenue on an accrual basis, using an estimate of the amount we will ultimately receive, as determined based on a historical analysis of amounts collected by test and by payor, among other factors. These assessments require significant judgment by management.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">To date, we have derived nearly all of our revenue from the sale of our testing products, most of which is attributable to our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD test. Revenue from the sale of our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD test comprised 91% and 88% of our revenue for the years ended December&#160;31, 2024 and 2023, respectively. We primarily market our testing products to rheumatologists and their physician assistants in the United States. The healthcare professionals who order our testing products, and to whom results are reported, are generally not responsible for payment for these products. The parties that pay for these services (payors) consist of commercial payors (insurance companies, health maintenance organizations, etc.), government payors (primarily Medicare and Medicaid), client payors (hospitals, other laboratories, etc.), and patient self-pay. Our service is completed upon the delivery of test results to the prescribing rheumatologists which triggers billing for the service.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our ability to increase our revenue will depend on the success of the commercial launch of the T-Cell Biomarker and RA Sub-Profile Biomarkers enhancements to our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD test, in addition to our ability to further penetrate the market for our current and future testing products and increase our ASP for tests delivered.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In April 2022, we were granted a PLA code for our protein-based test, AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus, which is offered standalone or as part of our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD test. Noridian, our MAC, has set the current pricing for this PLA code at $840.65 per test through December 31, 2025. The process for obtaining and maintaining consistent reimbursement for new tests can be uncertain, lengthy and time consuming. A pricing determination is not synonymous with a coverage determination. Having a price associated with the PLA code for any particular test does not secure coverage or reimbursement for that PLA code from Medicare or any other third-party payor.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We submitted a formal request to Noridian for coverage of our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus test under the new PLA Code and on September 27, 2022, we received notice that Noridian deemed our application for an LCD to be valid, but our application is still pending. Ultimately receiving a favorable LCD is uncertain and may be time-consuming, resource intensive and require multiple quarterly or annual periods to complete and is subject to risks and uncertainties described in the section entitled </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">"Risk Factors"</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> in this Annual Report. In the meantime, we have continued to submit Medicare claims for AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus, appeal denials and respond to requests for additional information. On January 31, 2024, CMS released a coverage article under which all multi-analyte proteomic testing will be considered within the scope of MolDX and reviewed through their technology assessment process. The article listed several such tests, including the AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus test, and requires all laboratories furnishing multi-analyte proteomics testing in MolDX jurisdictions to register with the DEX</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Diagnostics Exchange Registry and obtain a Z-Code</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> identifier. We were issued a Z-Code</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> identifier in May 2024. To determine if the submitted tests are compliant with relevant policy requirements, these tests will undergo technical assessment by Palmetto GBA as part of the MolDX program.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We face consistent challenges relating to commercial payor claim processing and revenue. While collectability has improved with certain plans year-over-year, we continue to experience denials due to unfavorable medical policy with certain plans, and we expect this situation to persist.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the year ended December 31, 2023, we implemented several revenue cycle management initiatives, including among others, withholding the submission of commercial payor claims for reimbursement until subsequent quarters, increasing appeals efforts, adjusting the documentation required of physicians when ordering our tests and implementing increases to our patient payment rates. Additionally, in November 2023, we increased the list price billed for our tests. These ongoing revenue cycle management initiatives aim to optimize our appeals process and the potential for cash collections. We've experienced moderate declines in test volume since the second half of 2023, as rheumatologists and patients adjust to these changes. We delivered 122,883 tests for our flagship product, AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD, in the year ended December&#160;31, 2024 as compared to 137,650 tests for the year ended December&#160;31, 2023 resulting from the expected impacts of revenue cycle management initiatives and the reduction of sales territories which began in 2022.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Costs of Revenue</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Costs of revenue represents the expenses associated with obtaining and testing patient specimens. The components of our costs of revenue include materials costs, direct labor, equipment, infrastructure expenses, shipping charges to transport specimens, blood specimen collections fees, royalties, depreciation and allocated overhead (including rent and utilities).</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Each payor, whether commercial, government, or individual, reimburses us at different amounts. These differences can be significant. As a result, our costs of revenue as a percentage of revenue may vary significantly from period to period due to the composition of payors for each period's billings. We expect that our costs of revenue will increase year-over-year in the near-term as a result of costs associated with the addition of the T-Cell Biomarkers and RA Sub-Profile Biomarkers to our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD test.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Operating Expenses</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Selling, General and Administrative Expenses</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Selling, general and administrative expenses consist of personnel costs (including stock-based compensation expense), direct marketing expenses, accounting and legal expenses, consulting costs, and allocated overhead (including rent, information technology, depreciation and utilities). We expect that our selling, general and administrative expenses will increase year-over-year in the near-term as a result of increased headcount.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Research and Development Expenses</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Research and development expenses include costs incurred to develop our technology, test products and product candidates, in addition to costs incurred to collect clinical specimens and conduct clinical studies to develop and support those products and product candidates. These costs consist of personnel-related expenses (including stock-based compensation expense), materials, laboratory supplies, consulting costs, costs associated with setting </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">up and conducting clinical studies and allocated overhead (including rent and utilities). We expense all research and development costs in the periods in which they are incurred. We expect that our research and development expenses will remain relatively consistent year-over-year in the near-term.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Interest Expense</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Interest expense consists of cash and non-cash interest expense associated with our financing arrangements, including the borrowings under our Amended Loan Agreement with Innovatus. We expect interest expense to remain relatively consistent in the year ending December 31, 2025 as compared to the year ended December 31, 2024.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Interest Income</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Interest income consists of interest income earned on our cash and cash equivalents.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Income Tax Expense</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Income taxes include federal and state income taxes in the United States.</span></div><div id="i9ecffbbbc3a143a09815a7575cabd836_55"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the Years Ended December&#160;31, 2024 and 2023:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.284%"/><td style="width:0.1%"/></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55,641&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52,548&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,093&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Costs of revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,529&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23,092&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(563)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross margin</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33,112&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29,456&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,656&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41,373&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47,428&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6,055)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,375&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,865&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">510&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46,748&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52,293&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,545)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13,636)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(22,837)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,201&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,234)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,335)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">767&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,516&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(749)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(15,103)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(23,656)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,553&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(15,115)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(23,689)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,574&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Revenue</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Revenue increased $3.1&#160;million, or 5.9%, for the year ended December&#160;31, 2024 compared to the year ended December&#160;31, 2023, primarily due to improved ASP (including cash collected related to tests performed in prior periods), partially offset by decreased AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD year-over-year volume resulting from the expected impacts of revenue cycle management initiatives and the reduction of sales territories which began in 2022. The number of AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD tests delivered decreased to 122,883 in the year ended December&#160;31, 2024 compared to 137,650 tests delivered in the same 2023 period. The AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD test accounted for 91% and 88% of revenue for the years ended December&#160;31, 2024 and 2023, respectively. The number of ordering healthcare providers decreased to 2,370 for the three months ended December&#160;31, 2024 compared to 2,383 in the same 2023 period.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Costs of Revenue</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Costs of revenue decreased $0.6&#160;million, or 2.4%, for the year ended December&#160;31, 2024 compared to the year ended December&#160;31, 2023. This decrease was primarily due to decreases of $1.0 million in materials and supplies expenses and additional decreases in facilities and allocated overhead expenses, royalties expenses and phlebotomy expenses. These decreases were partially offset by an increase of $0.7 million in shipping and handling </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">costs resulting from increased cost-per-shipment, offset in-part by reduced shipping volume; and an increase of $0.7 million in direct labor. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Gross Margin</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Gross margin as a percentage of revenue increased to 59.5% for the year ended December&#160;31, 2024 compared to 56.1% for the year ended December&#160;31, 2023, primarily due to improved ASP (including cash collected related to tests performed in prior periods) and decreases in materials and supplies expenses, facilities and allocated overhead expenses, royalties expenses and phlebotomy expenses; partially offset by increases in shipping and handling costs resulting from increased cost-per shipment, and increases in direct labor.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Selling, General and Administrative Expenses</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Selling, general and administrative expenses decreased $6.1&#160;million, or 12.8%, for the year ended December&#160;31, 2024 compared to the year ended December&#160;31, 2023. This decrease was primarily due to a decrease of $1.8 million in stock-based compensation expense and a decrease of $1.5 million in asset disposal costs related to the assignment of a lease in 2023; in addition to decreases in professional service expenses, legal expenses, insurance expenses, facilities and allocated overhead expenses, personnel costs and audit and tax services. These decreases were partially offset by an increase in commissions.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Research and Development Expenses</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Research and development expenses increased $0.5 million, or 10.5%, for the year ended December&#160;31, 2024 compared to the year ended December&#160;31, 2023. This increase was primarily due to increases of $0.7 million of personnel costs (including salaries, benefits and stock-based compensation) resulting from increased allocation of labor to research and development for laboratory personnel working on the validation of the T-Cell Biomarkers and RA Sub-Profile Biomarkers; and increases in professional service fees and laboratory expenses. These increases were partially offset by decreases of $0.3 million of clinical trial expenses and decreases in facilities and allocated overhead expenses.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Interest Expense</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Interest expense remained substantially consistent for the year ended December&#160;31, 2024 compared to the year ended December&#160;31, 2023.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Interest Income</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Interest income decreased $0.7 million for the year ended December&#160;31, 2024 compared to the year ended December&#160;31, 2023, primarily due to lower cash and cash equivalents balances of interest-earning accounts.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Income Tax Expense</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Income tax expense remained substantially consistent for the year ended December&#160;31, 2024 compared to the year ended December&#160;31, 2023.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Liquidity and Capital Resources</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have incurred net losses since our inception. For the years ended December&#160;31, 2024 and 2023, we incurred a net loss of $15.1 million and $23.7&#160;million, respectively, and we expect to incur additional losses in future periods. To date, we have generated only limited revenue, and despite any estimates we may make regarding our ability to become profitable, we may never achieve revenue sufficient to offset our expenses. As of December&#160;31, 2024, we had an accumulated deficit of $294.3&#160;million and cash and cash equivalents of $22.0 million. Cash in excess of immediate requirements is invested in accordance with our investment policy, primarily with a view to liquidity and capital preservation. Currently, our funds are held in cash and money market funds.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Since becoming a public company, our primary sources of capital have been cash inflows from product sales, sales of our common stock and, to a lesser extent, borrowings under our 2017 Term Loan. Our obligations under the Amended Loan Agreement are secured by a security interest in substantially all of our assets, including our intellectual property. The Amended Loan Agreement contains customary conditions to borrowing, events of default, and covenants, including covenants requiring us to maintain minimum liquidity of $2.0 million, covenants to achieve certain minimum amounts of revenue, and covenants limiting our ability to dispose of assets, undergo a change in control, merge with or acquire other entities, incur debt, incur liens, pay dividends or other distributions to holders of our capital stock, repurchase stock and make investments, in each case subject to certain exceptions. Per the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Amended Loan Agreement, we are not required to comply with the revenue covenant for any quarter during which we maintain a minimum aggregate cash balance equal to fifty percent of the aggregate principal amount of the 2017 Term Loan funded (excluding any capitalized interest paid-in-kind) at all times during such quarter. The consequences of failing to achieve the performance covenants, when applicable, will be cured if (i) within thirty days of failing to achieve the performance covenant, we submit a new financial plan approved by our board of directors to Innovatus under which we are expected to break even on a cash flow basis prior to the maturity date, and (ii) within thirty days of the submission of such financial plan, we issue additional equity securities or subordinated debt with net proceeds sufficient to fund any cash flow deficiency generated from operations, as defined in the Amended Loan Agreement. In addition, upon the occurrence of an event of default, Innovatus, among other things, can declare all indebtedness due and payable immediately, which would adversely impact our liquidity and reduce the availability of our cash flows to fund working capital needs, capital expenditures and other general corporate purposes. As of December&#160;31, 2024, we were in compliance with all covenants of the Amended Loan Agreement with Innovatus. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On November 17, 2023, we filed a registration statement on Form S-3 (Shelf Registration Statement) covering the offering, from time to time, of up to $150.0 million of common stock, preferred stock, debt securities, warrants and units, all of which remain available for sale at December 31, 2023.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On September 15, 2022, we entered into a sales agreement, as amended on November 17, 2023 (the Sales Agreement) with TD Securities (USA) LLC, as sales agent, pursuant to which the Company may offer and sell, from time to time, shares of Company common stock having an aggregate offering price of up to $50.0 million. The Company is not obligated to sell any shares of Company common stock in the offering and, as of December&#160;31, 2024, the Company has not sold any shares of its common stock pursuant to the Sales Agreement.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Funding Requirements</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our primary use of cash is to fund our operations as we continue to grow our business. We expect to continue to incur operating losses in the near term. In the short-term, we expect increases in costs of revenue as a result of costs associated with the addition of the T-Cell Biomarkers and RA Sub-Profile Biomarkers to our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD test. We also anticipate increases in our selling, general and administrative expenses due to increased headcount. We expect research and development expenses to remain relatively consistent in the short-term. We believe we have sufficient laboratory capacity to support increased test volume. Cash used to fund operating expenses is impacted by the timing of when we pay expenses, as reflected in the change in our outstanding accounts payable and accrued expenses.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We expect that our near- and longer-term liquidity requirements will continue to consist of working capital and general corporate expenses associated with the growth of our business, including payments we may be required to make upon the achievement of previously negotiated milestones associated with intellectual property we have licensed, payments related to non-cancelable purchase obligations for reagents, payments related to our principal and interest under our long term borrowing arrangements, payments for operating leases related to our office and laboratory space in Vista, CA and our office space in Carlsbad, CA, and payments for finance leases related to our laboratory equipment (see Note 4, "Borrowings," and Note 6, "Commitments and Contingencies," to our audited financial statements included in this Annual Report). Based on our current business plan, we believe that our existing cash and cash equivalents and our anticipated future revenue, will be sufficient to meet our anticipated cash requirements for at least the next 12&#160;months from the date of this filing.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our estimate of the period of time through which our financial resources will be adequate to support our operations is a forward-looking statement and involves risks and uncertainties. Actual results could vary as a result of a number of factors, including:</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">our ability to improve AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">CTD ASP as a result of the launch of the T-Cell Biomarkers and RA Sub-Profile Biomarkers, in addition to our ability to achieve adequate reimbursement for these additions to our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD test offering;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">our ability to achieve sufficient market acceptance, coverage and adequate reimbursement from third-party payors and adequate market share and revenue for our testing products;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">our ability to maintain and grow sales of our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;testing products, as well as the costs associated with conducting clinical studies to demonstrate the utility of our products and support reimbursement efforts;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.46pt">fluctuations in working capital;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.46pt">the costs of developing our product pipeline, including the costs associated with conducting our ongoing and future validation, utility and outcome studies as well as the success of our development and commercialization efforts; and</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.46pt">the extent to which we establish additional partnerships or in-license, acquire or invest in complementary businesses or products as well as the success of our existing partnerships and/or in-licenses.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Until such time, if ever, as we can generate revenue to support our costs structure, we expect to finance our operations as needed through equity offerings, debt financings or other capital sources, including potentially collaborations, licenses and other similar arrangements. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our stockholders may be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. If additional funding is required or desired, there can be no assurance that additional funds will be available to us on acceptable terms on a timely basis, if at all, or that we will generate sufficient cash from operations to adequately fund our operating needs or achieve or sustain profitability. If we are unable to raise additional capital or generate sufficient cash from operations to adequately fund our operations, we will need to delay, reduce or eliminate some or all of our research and development programs, product portfolio expansion plans or commercialization efforts. Doing so will likely have an unfavorable effect on our ability to execute on our business plan and could have a negative impact on our commercial and strategic relationships. If we cannot expand our operations or otherwise capitalize on our business opportunities because we lack sufficient capital, our business, financial condition, and results of operations could be adversely affected.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Cash Flows</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table summarizes our cash flows for the periods indicated:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.999%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash provided by (used in):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;Operating activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13,279)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14,462)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;Investing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(515)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(804)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;Financing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(663)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10,632)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net change in cash, cash equivalents and restricted cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14,457)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(25,898)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Cash Flows from Operating Activities</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Net cash used in operating activities for the year ended December&#160;31, 2024 was $13.3 million and primarily resulted from (i) our net loss of $15.1 million adjusted for non-cash charges of $4.9 million primarily related to stock-based compensation, depreciation, amortization, non-cash lease expenses and non-cash interest and (ii) changes in our net operating assets of $3.1&#160;million primarily related to net increases in prepaid expenses and other current assets and accounts receivable, and net decreases in operating lease liabilities, partially offset by net increases in accounts payable. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Net cash used in operating activities for the year ended December 31, 2023 was $14.5 million and primarily resulted from (i) our net loss of $23.7 million adjusted for non-cash charges of $8.9 million primarily related to stock-based compensation, depreciation, amortization, loss on disposal of assets primarily related to the assignment of a lease, non-cash lease expenses and non-cash interest and (ii) changes in our net operating assets of $0.3 million primarily related to net increases in prepaid expenses and other current assets and accounts receivable, and net decreases in operating lease liabilities, partially offset by net increases in accrued and other current liabilities.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Cash Flows from Investing Activities</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Net cash used in investing activities for the year ended December&#160;31, 2024 and 2023 was $0.5&#160;million and $0.8 million, respectively, and was primarily due to net purchases of property and equipment.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Cash Flows from Financing Activities</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Net cash used in financing activities for the year ended December&#160;31, 2024 was $0.7 million, primarily consisting of principal payments on finance lease obligations and notes payable, partially offset by the proceeds from the Exagen Inc. 2019 Employee Stock Purchase Plan (the ESPP) purchases.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Net cash used in financing activities for the year ended December 31, 2023 was $10.6 million, primarily consisting of principal payments on the Amended Loan Agreement, finance lease obligations and notes payable, partially offset by the proceeds from the ESPP purchases.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Critical Accounting Estimates</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our management&#8217;s discussion and analysis of our financial condition and results of operations is based on our audited financial statements, which have been prepared in accordance with accounting principles generally accepted in United States of America (GAAP). The preparation of these audited financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the audited financial statements, as well as the reported revenue generated and expenses incurred during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions and any such differences may be material. We believe the following accounting estimates are the most critical to us, in that they require our most difficult, subjective or complex judgments in the preparation of our financial statements. For further information, see Note 2, "Summary of Significant Accounting Policies," to our Financial Statements, which outlines our application of significant accounting policies. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Revenue Recognition</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">To date, substantially all of our revenue has been derived from sales of our testing products. We primarily market our testing products to rheumatologists and their physician assistants in the United States. The healthcare professionals who order our services and to whom test results are reported are generally not responsible for payment for these services. The parties that pay for these services consist of commercial payors, government payors (primarily Medicare and Medicaid), client payors (hospitals, other laboratories, etc.) and patient self-pays.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Payors are billed at our list price. Net revenues recognized consist of amounts billed net of allowances for differences between amounts billed and the estimated consideration we expect to receive from such payors. We follow a standard process, which considers historical denial and collection experience, insurance reimbursement policies and other factors, to estimate allowances and implicit price concessions, recording adjustments in the current period as changes in estimates. Further adjustments to the allowances, based on actual receipts, are recorded upon settlement. The transaction price is estimated using an expected value method on a portfolio basis. Our portfolios are grouped per payor (each individual third-party insurance, Medicare, Medicaid, client payors, patient self-pay, etc.) and per test basis.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Collection of our net revenues from payors is normally a function of providing complete and correct billing information to the healthcare insurers and generally occurs within 30 to 90 days of billing.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The process for estimating revenues and the ultimate collection of accounts receivable involves significant judgment and estimation by management. We continually assess the state of our cash collections in order to identify areas of risk and opportunity that allow us to appropriately estimate receivables and revenue. Should we later determine the judgements underlying estimated collections change, our financial results could be impacted in future periods. Included in revenues for the years ended December&#160;31, 2024 and 2023 were net revenue increases of $6.6 million and $3.4 million, respectively, associated with changes in estimated variable consideration related to performance obligations satisfied in previous periods.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Recent Accounting Pronouncements</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">See Note 2, "Recent Accounting Pronouncements, of our annual financial statements."</span></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><div id="i9ecffbbbc3a143a09815a7575cabd836_58"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 7A. Quantitative and Qualitative Disclosures About Market Risk.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Not applicable.</span></div><div id="i9ecffbbbc3a143a09815a7575cabd836_61"></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 8. Financial Statements and Supplementary Data.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial statements and supplemental data required by this item are set forth at the pages indicated in Part IV, Item 15(a)(1) of this Annual Report.</span></div><div><span><br/></span></div><div id="i9ecffbbbc3a143a09815a7575cabd836_64"></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">None.</span></div><div id="i9ecffbbbc3a143a09815a7575cabd836_67"></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item 9A. Controls and Procedures.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms, and that the information we are required to disclose in such reports is accumulated and communicated to our management, including our principal executive officer and principal financial officer, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable and not absolute assurance of achieving the desired control objectives. In reaching a reasonable level of assurance, management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. In addition, the design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our management, with the participation of our principal executive officer and our principal financial officer, evaluated, as of the end of the period covered by this Annual Report on Form 10-K, the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act). Based on that evaluation, our principal executive officer and principal financial officer have concluded that as of December&#160;31, 2024, our disclosure controls and procedures were effective at a reasonable level of assurance.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Management's Report on Internal Control over Financial Reporting</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act. Internal control over financial reporting is a process designed under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP. Our internal control over financial reporting includes those policies and procedures that: (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of our assets, (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with GAAP, and that our receipts and expenditures are being made only in accordance with authorizations of our management and directors, and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on the financial statements. Because of its inherent limitations, internal controls over financial reporting may not prevent or detect all misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December&#160;31, 2024, our management assessed the effectiveness of our internal control over financial reporting using the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Internal Control-Integrated Framework (2013)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. Based on this assessment, our management concluded that, as of December&#160;31, 2024, our internal control over financial reporting was effective.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Changes in Internal Control Over Financial Reporting</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">There have been no changes in our internal control over financial reporting during the three months ended December&#160;31, 2024 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Inherent Limitations on Effectiveness of Controls and Procedures</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and our management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div></div></div><div id="i9ecffbbbc3a143a09815a7575cabd836_70"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9B. Other Information.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Rule 10b5-1 trading arrangements</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the twelve months ended December&#160;31, 2024, none of our directors or officers <ix:nonNumeric contextRef="c-4" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-51"><ix:nonNumeric contextRef="c-4" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-52">adopted</ix:nonNumeric></ix:nonNumeric> or <ix:nonNumeric contextRef="c-4" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-53"><ix:nonNumeric contextRef="c-4" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-54">terminated</ix:nonNumeric></ix:nonNumeric> a "Rule 10b5-1 trading arrangement" or "non-Rule 10b5-1 trading arrangement," as each term is defined in Item 408 of Regulation S-K.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Insider Trading Policy</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We maintain an <ix:nonNumeric contextRef="c-1" name="ecd:InsiderTrdPoliciesProcAdoptedFlag" format="ixt:fixed-true" id="f-55">Insider Trading Policy</ix:nonNumeric> that, among other things, prohibits all officers, directors, and other employees with access to sensitive Company information from engaging in &#8220;hedging&#8221; transactions with respect to our shares. This includes short sales, hedging of share ownership positions, and transactions involving derivative securities relating to our shares. The Insider Trading Policy also generally prohibits borrowing or other arrangements involving the non-recourse pledge of our shares. This policy is included as Exhibit 19 to this Annual Report.</span></div><div style="margin-top:9pt"><span><br/></span></div><div id="i9ecffbbbc3a143a09815a7575cabd836_73"></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Not applicable.</span></div><div style="margin-top:9pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83</span></div></div></div><div id="i9ecffbbbc3a143a09815a7575cabd836_76"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Part III</span></div><div style="text-align:center"><span><br/></span></div><div id="i9ecffbbbc3a143a09815a7575cabd836_79"></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 10. Directors, Executive Officers and Corporate Governance.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The information required by this item is incorporated herein by reference to our Proxy Statement with respect to our 2025 Annual Meeting of Stockholders to be filed with the SEC within 120 days of the end of the fiscal year covered by this Annual Report.</span></div><div id="i9ecffbbbc3a143a09815a7575cabd836_82"></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 11. Executive Compensation.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The information required by this item is incorporated herein by reference to our Proxy Statement with respect to our 2025 Annual Meeting of Stockholders to be filed with the SEC within 120 days of the end of the fiscal year covered by this Annual Report.</span></div><div id="i9ecffbbbc3a143a09815a7575cabd836_85"></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The information required by this item is incorporated herein by reference to our Proxy Statement with respect to our 2025 Annual Meeting of Stockholders to be filed with the SEC within 120 days of the end of the fiscal year covered by this Annual Report.</span></div><div id="i9ecffbbbc3a143a09815a7575cabd836_88"></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 13. Certain Relationships and Related Transactions, and Director Independence.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The information required by this item is incorporated herein by reference to our Proxy Statement with respect to our 2025 Annual Meeting of Stockholders to be filed with the SEC within 120 days of the end of the fiscal year covered by this Annual Report.</span></div><div id="i9ecffbbbc3a143a09815a7575cabd836_91"></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 14. Principal Accountant Fees and Services.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our independent registered public accounting firm is BDO USA, P.C., San Diego, California, PCAOB ID #<ix:nonNumeric contextRef="c-1" name="dei:AuditorFirmId" id="f-56">243</ix:nonNumeric>.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The information required by this item is incorporated herein by reference to our Proxy Statement with respect to our 2025 Annual Meeting of Stockholders to be filed with the SEC within 120 days of the end of the fiscal year covered by this Annual Report.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</span></div></div></div><div id="i9ecffbbbc3a143a09815a7575cabd836_94"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Part IV</span></div><div style="text-align:center"><span><br/></span></div><div id="i9ecffbbbc3a143a09815a7575cabd836_97"></div><div style="-sec-extract:summary;margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item 15. Exhibits and Financial Statement Schedules.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Financial Statements and Financial Statement Schedules</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(1) Exhibits</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A list of exhibits is set forth on the Exhibit Index immediately preceding the signature page of this Annual Report and is incorporated herein by reference.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(2) All financial statements</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The financial statements of Exagen Inc., together with the report thereon of BDO USA, P.C., an independent registered public accounting firm, are included in this Annual Report beginning on page F-2.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(3) Financial statement schedules</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">All schedules have been omitted because the information required to be set forth therein is not applicable or is shown in the financial statements or notes thereto.</span></div><div id="i9ecffbbbc3a143a09815a7575cabd836_100"></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 16. Form 10-K Summary.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">None.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85</span></div></div></div><div id="i9ecffbbbc3a143a09815a7575cabd836_103"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Index to Exhibits</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.109%"><tr><td style="width:1.0%"/><td style="width:7.407%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.286%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.691%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.543%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.049%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.296%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.028%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Incorporated by Reference</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit Number</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit Description</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Form</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">File No.</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit Filing Date</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Filed/Furnished Herewith</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1274737/000119312519252366/d769261dex31.htm">Amended and Restated Certificate of Incorporation.</a></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">001-39049</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/23/2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1274737/000127473721000017/ex31-amendedandrestatedbyl.htm">Amended and Restated Bylaws.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">001-39049</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3/22/2021</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1274737/000127473723000004/exhibit-exagenxamendmentto.htm">Amendment to Amended and Restated Bylaws, dated January 19, 2023.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">001-39049</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1/23/2023</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1274737/000119312519240403/d692844dex41.htm">Specimen stock certificate evidencing the shares of common stock.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233446</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/9/2019</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex44.htm">Form of Common Stock Purchase Warrant issued to investors by the Company in connection with private placement financings.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233446</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.4</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/9/2019</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex48.htm">Form of Common Stock Purchase Warrant to purchase common stock issued to investors by the Company in 2016.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233446</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.8</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/9/2019</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.4</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex49.htm">Form of Warrant to Purchase Stock issued to Innovatus Life Sciences Lending Fund I, LP in connection with the Company's 2018 loan agreement.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233446</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.9</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/9/2019</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.5</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1274737/000127473721000094/ex45-formofprexfundedwarra.htm">Form of Exchange Warrant.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">001-39049</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.5</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8/9/2021</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.6</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1274737/000127473724000022/xgn-descriptionofsecurities.htm">Description of Securities</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">001-39049</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.8</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3/18/2024</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.1#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex102.htm">Exagen Diagnostics, Inc. 2013 Stock Option Plan, as amended, and form of option agreement thereunder.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233446</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/9/2019</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.2#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1274737/000119312519240403/d692844dex103.htm">Exagen Inc. 2019 Incentive Award Plan.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233446</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/9/2019</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.3#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1274737/000119312519240403/d692844dex104.htm">Form of Option Agreement under Exagen Inc. 2019 Incentive Award Plan.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233446</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.4</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/9/2019</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.4#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1274737/000127473721000015/ex105-formofrsuagreement20.htm">Form of Restricted Stock Unit Agreement under Exagen Inc. 2019 Incentive Award Plan.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">001-39049</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.5</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3/16/2021</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.5#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1274737/000119312519240403/d692844dex105.htm">Exagen Inc. 2019 Employee Stock Purchase Plan.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233446</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.5</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/9/2019</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.6&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex1010.htm">Asset Purchase Agreement, dated October 8, 2010, by and between Cypress Bioscience, Inc., Proprius, Inc. and the Company.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233446</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.11</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/9/2019</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.7&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex1011.htm">Amendment No. One to Asset Purchase Agreement, dated March 10, 2011, by and between Cypress Bioscience, Inc., Proprius, Inc. and the Company.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233446</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.12</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/9/2019</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.8</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex1012.htm">Amendment No. Two to Asset Purchase Agreement, dated August 21, 2012, by and between Royalty Pharma Collection Trust, Proprius, Inc. and the Company.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233446</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.13</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/9/2019</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.9&#8224;&#x5E;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex1013.htm">Amendment No. Three to Asset Purchase Agreement, dated February 6, 2013, by and between Royalty Pharma Collection Trust, Proprius, Inc. and the Company.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233446</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.14</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/9/2019</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.10</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex1014.htm">Amendment No. Four to Asset Purchase Agreement</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex1014.htm"> and Consent</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex1014.htm">, dated October 8, 2013, by and between Royalty Pharma Collection Trust, Proprius, Inc. and the Company.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233446</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.15</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/9/2019</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.11</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex1015.htm">Amendment No. Five to Asset Purchase Agreement, dated January 26, 2016, by and between Royalty Pharma Collection Trust, Proprius, Inc. and the Company.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233446</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.16</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/9/2019</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.12&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex1016.htm">Amendment No. Six to Asset Purchase Agreement, dated February 16, 2017, by and between Royalty Pharma Collection Trust, Proprius, Inc. and the Company.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233446</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.17</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/9/2019</span></td><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.109%"><tr><td style="width:1.0%"/><td style="width:7.407%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.286%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.691%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.543%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.049%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.296%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.028%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.13&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex1017.htm">Amended and Restated Exclusive License Agreement, dated August 2, 2011, by and between the University of Pittsburgh-Of the Commonwealth System of Higher Education and the Company.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233446</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.18</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/9/2019</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.14&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex1018.htm">First Amendment to Amended and Restated Exclusive License Agreement, dated May 17, 2012, by and between the University of Pittsburgh-Of the Commonwealth System of Higher Education and the Company.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233446</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.19</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/9/2019</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.15&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex1019.htm">Second Amendment to Amended and Restated Exclusive License Agreement, dated September 30, 2013, by and between the University of Pittsburgh-Of the Commonwealth System of Higher Education and the Company.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233446</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.20</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/9/2019</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.16</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex1020.htm">Third Amendment to Amended and Restated Exclusive License Agreement, dated June 24, 2016, by and between the University of Pittsburgh-Of the Commonwealth System of Higher Education and the Company.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233446</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.21</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/9/2019</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.17&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex1021.htm">Exclusive License Agreement, dated September 30, 2013, by and between the University of Pittsburgh-Of the Commonwealth System of Higher Education and the Company.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233446</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.22</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/9/2019</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.18&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex1022.htm">Exclusive License Agreement, dated September 5, 2011, by and between Thierry Dervieux, Ph.D. and the Company.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233446</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.23</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/9/2019</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.19</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex1024.htm">Standard Industrial/Commercial Multi-Tenant Lease, dated January 13, 2012, by and between RGS Properties and the Company.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">001-39049</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7/28/2020</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.20</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex1025.htm">First Amendment to Standard Industrial/Commercial Multi-Tenant Lease, dated December 1, 2013, by and between RGS Properties and the Company.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">001-39049</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7/28/2020</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.21</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1274737/000127473720000026/secondamend1261suitebc.htm">Second A</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1274737/000127473720000026/secondamend1261suitebc.htm">ddendum</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1274737/000127473720000026/secondamend1261suitebc.htm"> to Standard Industrial/Commercial Multi-Tenant Lease, dated April 29, 2016, by and between RGS Properties and the Company.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">001-39049</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.27</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3/25/2020</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.22</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1274737/000127473720000026/thirdamend1261suitebc.htm">Third A</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1274737/000127473720000026/thirdamend1261suitebc.htm">ddendum</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1274737/000127473720000026/thirdamend1261suitebc.htm"> to Standard Industrial/Commercial Multi-Tenant Lease, dated June 16, 2017, by and between RGS Properties and the Company.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">001-39049</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.28</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3/25/2020</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.23</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1274737/000127473720000026/fourthamendmenttolease.htm">Fourth A</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1274737/000127473720000026/fourthamendmenttolease.htm">ddendum</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1274737/000127473720000026/fourthamendmenttolease.htm"> to Standard Industrial/Commercial Multi-Tenant Lease, dated March 16, 2020, by and between RGS Properties and the Company.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">001-39049</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.29</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3/25/2020</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.24</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1274737/000127473721000115/ex103-fifthaddendumtolease.htm">Fifth A</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1274737/000127473721000115/ex103-fifthaddendumtolease.htm">ddendum</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1274737/000127473721000115/ex103-fifthaddendumtolease.htm"> to Standard Industrial/Commercial Multi-Tenant Lease, dated October 19, 2021, by and between RGS Properties and the Company.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">001-39049</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11/10/2021</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.25</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex1030.htm">Standard Industrial/Commercial Single-Tenant Lease, dated September 4, 2014, by and between Geiger Court, LLC and the Company.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233446</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/9/2019</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.26</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1274737/000127473720000026/firstamend1221lease.htm">First A</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1274737/000127473720000026/firstamend1221lease.htm">ddendum</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1274737/000127473720000026/firstamend1221lease.htm"> to Standard Industrial/Commercial Single-Tenant Lease, dated August 2, 2017, by and between Geiger Court, LLC and the Company.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">001-39049</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3/25/2020</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.27</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1274737/000127473720000026/a1221libertyway-leasea.htm">Extension of Lease to Standard Industrial/Commercial Single-Tenant Lease, dated March 12, 2020, by and between Liberty Vista and the Company.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">001-39049</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.32</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3/25/2020</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.28</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1274737/000127473721000015/ex1034-amend1to1221liberty.htm">First Amendment to Standard Industrial/Commercial Single-Tenant Lease, dated January 6, 2021, by and between Liberty Vista and the Company.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">001-39049</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.34</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3/16/2021</span></td><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.109%"><tr><td style="width:1.0%"/><td style="width:7.407%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.286%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.691%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.543%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.049%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.296%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.028%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.29</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1274737/000127473721000115/ex102-amend2to1221libertyw.htm">Second Amendment to Standard Industrial/Commercial Single-Tenant Lease, dated October 11, 2021, by and between Liberty Vista and the Company.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">001-39049</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11/10/2021</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.30</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1274737/000127473720000026/ex10331261suitealeasev2.htm">Standard Industrial/Commercial Multi-Tenant Lease, dated March 17, 2020 by and between RGS Properties and the Company.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">001-39049</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.33</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3/25/2020</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.31</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1274737/000127473721000115/ex104-firstaddendumtolease.htm">First A</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1274737/000127473721000115/ex104-firstaddendumtolease.htm">ddendum</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1274737/000127473721000115/ex104-firstaddendumtolease.htm"> to Standard Industrial/Commercial Multi-Tenant Lease, dated October 19, 2021, by and between RGS Properties and the Company.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">001-39049</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.4</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11/10/2021</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.32&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1274737/000127473721000115/ex101-subleaseagreement819.htm">Sublease Agreement, dated August 19, 2021, by and between Plum Healthcare Group, LLC and the Company.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">001-39049</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11/10/2021</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.33</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex1031.htm">Master Lease Agreement, dated February 1, 2018, by and between Celtic Commercial Finance, a division of MB Equipment Finance, LLC and the Company.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233446</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.32</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/9/2019</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.34</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex1032.htm">Loan and Security Agreement, dated September 7, 2017, by and between Innovatus Life Sciences Lending Fund I, LP and the Company.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233446</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.33</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/9/2019</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.35</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1274737/000127473720000026/ex1036-innovatusxexage.htm">First Amendment to Loan and Security Agreement, dated November 19, 2019, by and between Innovatus Life Sciences Lending I, LP and the Company.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">001-39049</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.36</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3/25/2020</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.36</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1274737/000127473720000097/ex101-innovatusacknowl.htm">Acknowledgement Letter to Loan and Security Agreement, dated October 7, 2020, by and between Innovatus Life Sciences Lending Fund I, LP and the Company.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">001-39049</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11/10/2020</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.37</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1274737/000127473721000115/ex105-secondamendmentloana.htm">Second Amendment to Loan and Security Agreement, dated November 1, 2021, by and among Innovatus Life Sciences Lending Fund I, LP, other lenders and the Company.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">001-39049</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.5</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11/10/2021</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.38</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex1034.htm">Form of Indemnification Agreement for Directors and Officers.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233446</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.35</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/9/2019</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.39#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1274737/000119312519240403/d692844dex1038.htm">Non-Employee Director Compensation Program.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233446</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.38</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/9/2019</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.40#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1274737/000127473721000015/ex1046-executivecicseveran.htm">Exagen Inc. Amended and Restated Executive Change in Control and Severance Plan.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">001-39049</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8/5/2024</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.41#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1274737/000127473722000067/johnaballiceoemploymentagr.htm">Employment Agreement, dated as of October 16, 2022, by and between the Company and John Aballi</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">001-39049</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10/16/2022</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.42#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1274737/000127473724000071/exagencfoemploymentagreeme.htm">Employment Agreement, dated as of September 1, 2024, by and between the Company and Jeff Black.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">001-39049</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8/2/2024</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.43</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1274737/000127473722000064/ex11-xgnxsalesagreement.htm">Sales Agreement, dated as of September 15, 2022, by and between the Company and TD Securities (USA) LLC</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">001-39049</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/15/2022</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.44&#x5E;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1274737/000127473723000041/exhibit101to042823thirdame.htm">Third Amendment to Loan and Security Agreement dated April 28, 2023, by and among Innovatus Life Sciences Lending I, LP, other lenders and the Company.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">001-39049</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5/4/2023</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.45</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1274737/000127473724000048/innovatusfourthamendmentto.htm">Fourth Amendment to Loan and Security Agreement, dated April 12, 2024, by and among Innovatus Life Sciences Lending I, LP, other lenders, and the Company.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">001-39049</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5/13/2024</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.46</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1274737/000127473723000103/a1221libertywayassignmenta.htm">Assignment and Assumption Agreement, by and among Liberty Vista, L.P., Mindera Corporation and the Company.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">001-39049</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11/13/2023</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.47</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1274737/000127473723000116/exagen-hazeltinexconsultin.htm">Consulting Agreement, dated as of December 6, 2023, by and between the Company and Mark Hazeltine.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">001-39049</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12/11/2023</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="exagen-boardbookxtab18xins.htm">Insider Trading Policies and Procedures.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex231-2024bdoconsent.htm">Consent of Independent Registered Public Accounting Firm.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.109%"><tr><td style="width:1.0%"/><td style="width:7.407%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.286%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.691%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.543%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.049%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.296%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.028%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9ecffbbbc3a143a09815a7575cabd836_106">Power of Attorney (included on signature page).</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="xgn311-123124.htm">Certificate of Principal Executive Officer, pursuant to Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="xgn312-123124.htm">Certificate of Principal Financial Officer, pursuant to Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32.1*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="xgn321-123124.htm">Certifications Pursuant to U.S.C. Section 1350, As Adopted Pursuant to Section 906 of the Public Company Accounting Reform and Investor Protection Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97.1#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1274737/000127473723000103/exagen-clawbackpolicy.htm">Exagen Inc. Clawback Policy.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">001-39049</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11/13/2023</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Schema Document.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Calculation Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Definition Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Labels Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Presentation Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The cover page from the Company's Annual Report on Form 10-K for the year ended December 31, 2021, has been formatted in Inline XBRL.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="padding-left:76.5pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">* &#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This certification is deemed not filed for purpose of Section 18 of the Exchange Act or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act.</span></div><div style="padding-left:76.5pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">#&#160;&#160;&#160;&#160;Indicates management contract or compensatory plan.</span></div><div style="padding-left:76.5pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8224;&#160;&#160;&#160;&#160;Portions of this exhibit (indicated by asterisks) have been omitted for confidentiality purposes.</span></div><div style="padding-left:76.5pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#x5E;&#160;&#160;&#160;&#160;Certain schedules to this exhibit have been omitted pursuant to Item 601(a)(5) of Regulation S-K. Copies of the omitted schedules will be furnished to the SEC upon request.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89</span></div></div></div><div id="i9ecffbbbc3a143a09815a7575cabd836_106"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Signatures</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.760%"><tr><td style="width:1.0%"/><td style="width:56.762%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:35.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EXAGEN INC.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: March&#160;11, 2025</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">by:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ John Aballi</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">John Aballi</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</span></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Power of Attorney</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints John Aballi and Jeffrey G. Black as his or her true and lawful attorneys-in-fact, and each of them, with full power of substitution, for him or her in any and all capacities, to sign any amendments to this Annual Report on Form 10-K and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact, and either of them, or his or their substitute or substitutes may do or cause to be done by virtue hereof.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Pursuant to the requirements of the Securities Exchange Act of 1934, this Annual Report on Form 10-K has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</span></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.871%"><tr><td style="width:1.0%"/><td style="width:5.507%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.007%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.514%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.007%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.473%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Signature</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Title</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Date</span></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="6" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/ John Aballi</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">President, Chief Executive Officer and Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March&#160;11, 2025</span></div></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">John Aballi</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Principal Executive Officer)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="6" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/ Jeffrey G. Black</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Chief Financial Officer and Corporate Secretary</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March&#160;11, 2025</span></div></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Jeffrey G. Black</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Principal Financial and Accounting Officer)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="6" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/ Tina S. Nova, Ph.D.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Executive Chairman of the Board</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March&#160;11, 2025</span></div></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tina S. Nova, Ph.D.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="6" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/ Ana Hooker</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March&#160;11, 2025</span></div></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ana Hooker</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="6" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/ Scott Kahn, Ph.D.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March&#160;11, 2025</span></div></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Scott Kahn, Ph.D.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="6" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/ Paul Kim</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March&#160;11, 2025</span></div></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Paul Kim</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="6" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/ Bruce C. Robertson, Ph.D.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March&#160;11, 2025</span></div></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Bruce C. Robertson, Ph.D.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="6" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/ Frank Stokes</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March&#160;11, 2025</span></div></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Frank Stokes</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90</span></div></div></div><div id="i9ecffbbbc3a143a09815a7575cabd836_109"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exagen Inc.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:79.016%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.784%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Index to Financial Statements</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9ecffbbbc3a143a09815a7575cabd836_112">Report of Independent Registered Public Accounting Firm</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (PCAOB ID No. 243)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#3051f2;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="color:#3051f2;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9ecffbbbc3a143a09815a7575cabd836_112">2</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9ecffbbbc3a143a09815a7575cabd836_115">Balance Sheets as of December 31, 202</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9ecffbbbc3a143a09815a7575cabd836_115">4</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9ecffbbbc3a143a09815a7575cabd836_115"> and 202</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9ecffbbbc3a143a09815a7575cabd836_115">3</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#3051f2;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="color:#3051f2;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9ecffbbbc3a143a09815a7575cabd836_115">4</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9ecffbbbc3a143a09815a7575cabd836_118">Statements of Operations for the Years Ended December 31, 202</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9ecffbbbc3a143a09815a7575cabd836_118">4</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9ecffbbbc3a143a09815a7575cabd836_118"> and 20</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9ecffbbbc3a143a09815a7575cabd836_118">23</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#3051f2;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="color:#3051f2;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9ecffbbbc3a143a09815a7575cabd836_118">5</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9ecffbbbc3a143a09815a7575cabd836_121">Statements of Stockholders' Equity for the Years Ended December 31, 202</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9ecffbbbc3a143a09815a7575cabd836_121">4</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9ecffbbbc3a143a09815a7575cabd836_121"> and 202</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9ecffbbbc3a143a09815a7575cabd836_121">3</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#3051f2;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="color:#3051f2;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9ecffbbbc3a143a09815a7575cabd836_121">6</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9ecffbbbc3a143a09815a7575cabd836_124">Statements of Cash Flows for the Years Ended December 31, 202</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9ecffbbbc3a143a09815a7575cabd836_124">4</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9ecffbbbc3a143a09815a7575cabd836_124"> and 202</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9ecffbbbc3a143a09815a7575cabd836_124">3</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#3051f2;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="color:#3051f2;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9ecffbbbc3a143a09815a7575cabd836_124">7</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9ecffbbbc3a143a09815a7575cabd836_127">Notes to Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#3051f2;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="color:#3051f2;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9ecffbbbc3a143a09815a7575cabd836_127">8</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-1</span></div></div></div><div id="i9ecffbbbc3a143a09815a7575cabd836_112"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Report of Independent Registered Public Accounting Firm</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Shareholders and Board of Directors</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Exagen Inc.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Vista, California</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Opinion on the Financial Statements </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have audited the accompanying balance sheets of Exagen Inc. (the "Company&#8221;) as of December 31, 2024 and 2023, the related statements of operations, stockholders&#8217; equity, and cash flows for the years then ended, and the related notes (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2024 and 2023, and the results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States of America.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Basis for Opinion</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Critical Audit Matter</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of the critical audit matter does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Revenue Recognition &#8211; Estimation of Transaction Price</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As described in Note 2 to the financial statements, the Company&#8217;s revenue was $55.6 million for the year ended December 31, 2024, substantially all of which has been derived from sales of its testing products. Net revenues recognized consist of amounts billed net of allowances for differences between amounts billed and the estimated consideration the Company expects to receive from payors. The process for estimating revenues involves significant judgment and estimation. The Company considers historical denial and collection experience and insurance reimbursement policies and other factors, to estimate allowances and implicit price concessions. The transaction price is estimated using an expected value method on a portfolio basis. The Company's portfolios are grouped per payor (i.e., each individual commercial payor, Medicare, Medicaid, client payors, patient self-pay, etc.) and per test. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We identified the estimation of the transaction price using an expected value method for certain portfolios as a critical audit matter. Significant judgment is used in considering historical denial and collection experience and insurance reimbursement policies to determine the estimated consideration the Company expects to receive. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Auditing these elements involved especially subjective auditor judgment due to the nature and extent of audit effort required to address these matters. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The primary procedures we performed to address this critical audit matter included:</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Testing the Company&#8217;s process to estimate transaction price using an expected value method for certain portfolios by evaluating the reasonableness of the Company&#8217;s assumptions regarding historical denial and collection experience and insurance reimbursement policies by developing an expectation of those assumptions using historical data inputs.</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Testing the completeness and accuracy of a sample of tests used by management as data inputs in their analysis to monitor historical denial and collection experience and insurance reimbursement policies by comparing the data to physician test requisition forms, evidence of test delivery and cash collection activity.</span></div><div style="margin-top:9pt;text-align:justify"><span><br/></span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">/s/ <ix:nonNumeric contextRef="c-1" name="dei:AuditorName" id="f-57">BDO USA, P.C.</ix:nonNumeric></span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have served as the Company&#8217;s auditor since 2017.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:AuditorLocation" id="f-58">San Diego, California</ix:nonNumeric></span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">March&#160;11, 2025</span></div><div style="margin-top:9pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-3</span></div></div></div><div id="i9ecffbbbc3a143a09815a7575cabd836_115"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exagen Inc.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance Sheets</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:75.800%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.868%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-59">22,036</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-60">36,493</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-61">7,835</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-62">6,551</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="f-63">6,584</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="f-64">4,797</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-65">36,455</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-66">47,841</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-67">5,283</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-68">5,201</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-69">2,401</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-70">3,286</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="f-71">550</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="f-72">616</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-73">44,689</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-74">56,944</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liabilities and Stockholders' Equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-75">4,137</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-76">3,131</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-77">1,096</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="f-78">976</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Borrowings-current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LongTermDebtCurrent" scale="3" id="f-79">423</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:LongTermDebtCurrent" scale="3" id="f-80">264</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-81">7,850</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-82">7,531</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-83">13,506</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-84">11,902</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Borrowings-non-current portion, net of discounts and debt issuance costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-85">19,822</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-86">19,231</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-87">1,664</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-88">2,760</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other non-current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="f-89">157</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="f-90">357</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-91">35,149</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-92">34,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commitments and contingencies (Note 6)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-5" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-93"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-6" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-94"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stockholders' equity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-95"><ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-96">0.001</ix:nonFraction></ix:nonFraction> par value per share; <ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-97"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-98">10,000,000</ix:nonFraction></ix:nonFraction> shares authorized, <ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="f-99"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-100"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="f-101"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-102">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued or outstanding at December 31, 2024 and December 31, 2023</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="f-103">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="f-104">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-105"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-106">0.001</ix:nonFraction></ix:nonFraction> par value per share; <ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-107"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-108">200,000,000</ix:nonFraction></ix:nonFraction> shares authorized at December 31, 2024 and December 31, 2023; <ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-109"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-110">17,640,328</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-111"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-112">17,045,954</ix:nonFraction></ix:nonFraction> shares issued and outstanding at December 31, 2024 and December 31, 2023, respectively</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-113">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-114">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Additional paid-in capital</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="f-115">303,853</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="f-116">301,893</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-117">294,331</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-118">279,216</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total stockholders' equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-119">9,540</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-120">22,694</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total liabilities and stockholders' equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-121">44,689</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-122">56,944</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these financial statements</span></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-4</span></div></div></div><div id="i9ecffbbbc3a143a09815a7575cabd836_118"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exagen Inc.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Statements of Operations</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.876%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.184%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="12" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-123">55,641</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-124">52,548</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Costs of revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="f-125">22,529</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="f-126">23,092</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross margin</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="f-127">33,112</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="f-128">29,456</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-129">41,373</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-130">47,428</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-131">5,375</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-132">4,865</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="f-133">46,748</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="f-134">52,293</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-135">13,636</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-136">22,837</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestExpenseNonoperating" format="ixt:num-dot-decimal" scale="3" id="f-137">2,234</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:InterestExpenseNonoperating" format="ixt:num-dot-decimal" scale="3" id="f-138">2,335</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="f-139">767</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:InvestmentIncomeInterest" format="ixt:num-dot-decimal" scale="3" id="f-140">1,516</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeLossAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-141">15,103</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:IncomeLossAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-142">23,656</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-143">12</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-144">33</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-145">15,115</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-146">23,689</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss per share, basic and diluted (Note 2)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-147"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-148">0.83</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-149"><ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-150">1.34</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average number of shares used to compute net loss per share, basic and diluted (Note 2)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-151"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-152">18,203,044</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-153"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-154">17,679,467</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these financial statements</span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-5</span></div></div></div><div id="i9ecffbbbc3a143a09815a7575cabd836_121"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exagen Inc.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Statements of Stockholders' Equity</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share amounts)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.358%"/><td style="width:0.1%"/></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total<br/>Stockholders'<br/>Equity</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balances at December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-8" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-155">16,549,984</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-156">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-157">297,970</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-158">255,527</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-159">42,460</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of stock from vested restricted stock units</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-12" decimals="INF" name="exdx:IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesShares" format="ixt:num-dot-decimal" scale="0" id="f-160">273,042</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise of stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-12" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-161">93,335</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-162">27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-163">27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of stock under Employee Stock Purchase Plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-12" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="f-164">129,593</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="f-165">279</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="f-166">279</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-167">3,617</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-168">3,617</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-169">23,689</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-170">23,689</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balances at December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-15" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-171">17,045,954</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-172">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-173">301,893</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-174">279,216</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-175">22,694</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of stock from vested restricted stock units</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-18" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-176">413,202</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise of stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-18" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-177">85,124</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-178">22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-179">22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of stock under Employee Stock Purchase Plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-18" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="f-180">96,048</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="f-181">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="f-182">175</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="f-183">176</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-184">1,763</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-185">1,763</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-186">15,115</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-187">15,115</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balances at December 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-21" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-188">17,640,328</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-189">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-190">303,853</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-191">294,331</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-192">9,540</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these financial statements</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-6</span></div></div></div><div id="i9ecffbbbc3a143a09815a7575cabd836_124"></div><hr style="page-break-after:always"/><div style="min-height:24.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exagen Inc.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Statements of Cash Flows</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.950%"><tr><td style="width:1.0%"/><td style="width:75.190%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.497%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.057%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.497%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.059%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-193">15,115</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-194">23,689</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-195">1,724</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-196">2,168</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of debt discount and debt issuance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="f-197">154</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="f-198">156</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-cash interest expense</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaidInKindInterest" scale="3" id="f-199">276</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:PaidInKindInterest" scale="3" id="f-200">363</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss on disposal of assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:GainLossOnDispositionOfAssets1" scale="3" id="f-201">111</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:GainLossOnDispositionOfAssets1" scale="3" id="f-202">189</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss on lease assignment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="exdx:GainLossOnDispositionOfLeaseAssignment" format="ixt:fixed-zero" scale="3" id="f-203">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="exdx:GainLossOnDispositionOfLeaseAssignment" format="ixt:num-dot-decimal" scale="3" id="f-204">1,470</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-cash lease expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="exdx:NonCashLeaseExpense" scale="3" id="f-205">884</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="exdx:NonCashLeaseExpense" scale="3" id="f-206">939</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-207">1,763</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-208">3,617</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes in assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="f-209">1,284</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="f-210">474</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="exdx:IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets" format="ixt:num-dot-decimal" scale="3" id="f-211">1,787</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="exdx:IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets" scale="3" id="f-212">654</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="3" id="f-213">63</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="3" id="f-214">101</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="f-215">976</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-216">1,010</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="f-217">308</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="f-218">67</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" scale="3" id="f-219">600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-220">2,497</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-221">13,279</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-222">14,462</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="f-223">515</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="f-224">828</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from disposal of property and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="f-225">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="3" id="f-226">24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="f-227">515</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="f-228">804</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from exercise of stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="f-229">22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="f-230">27</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from common stock issued under Employee Stock Purchase Plan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromStockPlans" scale="3" id="f-231">176</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ProceedsFromStockPlans" scale="3" id="f-232">279</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Principal payment on finance lease obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="f-233">490</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="f-234">697</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Principal payment on note payable obligations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RepaymentsOfNotesPayable" scale="3" id="f-235">371</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:RepaymentsOfNotesPayable" scale="3" id="f-236">241</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Principal payment on long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:fixed-zero" scale="3" id="f-237">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-238">10,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash used in financing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="f-239">663</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-240">10,632</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net change in cash, cash equivalents and restricted cash</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-241">14,457</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-242">25,898</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash, beginning of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-243">36,693</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-244">62,591</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash, end of year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-245">22,236</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-246">36,693</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Supplemental disclosure of cash flow information:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash paid for interest expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="f-247">1,719</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="f-248">1,737</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Supplemental disclosure of non-cash items:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equipment purchased under notes payable obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="exdx:EquipmentPurchasedUnderNotesPayableObligations" scale="3" id="f-249">706</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="exdx:EquipmentPurchasedUnderNotesPayableObligations" scale="3" id="f-250">250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Costs incurred, but not paid, in connection with capital expenditures</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="f-251">717</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="f-252">66</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these financial statements</span></div><div style="height:24.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-7</span></div></div></div><div id="i9ecffbbbc3a143a09815a7575cabd836_127"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div id="i9ecffbbbc3a143a09815a7575cabd836_130"></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Exagen Inc.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Notes to Financial Statements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Note 1. <ix:nonNumeric contextRef="c-1" name="us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" id="f-253" continuedAt="f-253-1" escape="true">Organization</ix:nonNumeric></span></div><ix:continuation id="f-253-1"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Description of Business</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Exagen Inc. (the Company) is a medical technology company primarily focused on the design, development and commercialization of a next-generation portfolio of testing products under our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> brand, which allow for the differential diagnosis, prognosis and monitoring of complex rheumatic, autoimmune and autoimmune-related disease including, among others, systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Liquidity</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company has incurred recurring losses and negative cash flows from operating activities since inception. The Company anticipates that it will continue to incur net losses in future periods. At December&#160;31, 2024, the Company had cash and cash equivalents of $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="f-254">22.0</ix:nonFraction> million and had an accumulated deficit of $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="f-255">294.3</ix:nonFraction> million. Since inception, the Company has financed its operations primarily through a combination of equity financings, debt financing arrangements, and revenue from sales of the Company's products. Based on the Company's current business plan, management believes that its existing capital resources will be sufficient to fund the Company's obligations for at least twelve months following the issuance of these financial statements.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">To execute its business plans, the Company may need additional funding to support its continuing operations and pursue its growth strategy. Until such time as the Company can achieve significant cash flows from operations, if ever, it may need to finance its operations through the sale of its stock, debt financings or other strategic transactions. Although the Company has been successful in raising capital in the past, there is no assurance that it will be successful in obtaining such additional financing on terms acceptable to the Company, if at all. The terms of any financing may adversely affect the holdings or the rights of the Company's stockholders. If the Company is unable to obtain funding, the Company could be forced to delay, reduce or eliminate some or all of its programs, product portfolio expansion plans or commercialization efforts, which could have a material adverse effect on the Company's business, operating results and financial condition and the Company's ability to achieve its intended business objectives.</span></div></ix:continuation><div id="i9ecffbbbc3a143a09815a7575cabd836_133"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Note 2. <ix:nonNumeric contextRef="c-1" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="f-256" continuedAt="f-256-1" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="f-256-1" continuedAt="f-256-2"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Basis of Presentation and Use of Estimates</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company's financial statements are prepared in accordance with accounting principles generally accepted in the United States of America (GAAP). The preparation of the accompanying financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities as of the date of the financial statements, and the reported amounts of revenue and expenses during the reporting period. Actual results could materially differ from those estimates.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Significant estimates and assumptions made in the accompanying financial statements include, but are not limited to revenue recognition, the estimated incremental borrowing rate for the determination of the Company's operating lease right-of-use (ROU) assets and the recoverability of its long-lived assets and net deferred tax assets (and related valuation allowance). The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could materially differ from those estimates.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ConcentrationRiskCreditRisk" id="f-257" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Concentration of Credit Risk and Other Risk and Uncertainties</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Financial instruments that potentially subject the Company to credit risk consist principally of cash, cash equivalents and accounts receivable. Substantially all the Company's cash and cash equivalents are held at one financial institution that management believes is of high credit quality. Such deposits may, at times, exceed federally insured limits. The Company has not experienced any losses on its cash or cash equivalents.</span></div></ix:nonNumeric><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Significant payors and customers are those which represent more than 10% of the Company's total revenue or accounts receivable balance at each respective balance sheet date. <ix:nonNumeric contextRef="c-1" name="us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" id="f-258" continuedAt="f-258-1" escape="true">For each significant payor and customer, </ix:nonNumeric></span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-256-2" continuedAt="f-256-3"><ix:continuation id="f-258-1"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">revenue as a percentage of total revenue and accounts receivable as a percentage of total accounts receivable are as follows:</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.707%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.768%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Revenue</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-24" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-259">25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-25" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-260">34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medicare Advantage</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-26" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-261">20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-27" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-262">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United Healthcare</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-28" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-263">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">*</span></td></tr></table></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:2.847%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.724%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:90.129%"/><td style="width:0.1%"/></tr><tr style="height:8pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less than 10%.</span></td></tr></table></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.707%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.768%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accounts Receivable</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medicare Advantage</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-29" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-264">25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-30" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-265">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-31" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-266">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-32" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-267">42</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:continuation><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For the years ended December&#160;31, 2024 and 2023, approximately <ix:nonFraction unitRef="number" contextRef="c-33" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-268">91</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="c-34" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-269">88</ix:nonFraction>%, respectively, of the Company's revenue was related to the AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD test.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company is dependent on key suppliers for certain laboratory materials. For the year ended December&#160;31, 2024, approximately <ix:nonFraction unitRef="number" contextRef="c-35" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-270">71</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="c-36" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-271">26</ix:nonFraction>%</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">of the Company's diagnostic testing supplies were purchased from two suppliers, respectively. For the year ended December 31, 2023, approximately <ix:nonFraction unitRef="number" contextRef="c-37" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-272">66</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="c-38" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-273">30</ix:nonFraction>%</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">of the Company's diagnostic testing supplies were purchased from two suppliers, respectively. An interruption in the supply of these materials would impact the Company's ability to perform testing services.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Disaggregation of Revenue</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="f-274" escape="true"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table includes the Company's revenues as disaggregated by payor and customer category (in&#160;thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.707%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.768%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-275">29,600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-276">23,985</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-277">14,323</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-278">18,002</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Client(1)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-279">11,360</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-280">9,949</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other(2)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="f-281">358</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="f-282">612</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-283">55,641</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-284">52,548</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.24pt">Includes hospitals, other laboratories, etc.</span></div><div style="padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.24pt">Includes patient self-pay.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="f-285" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Cash, Cash Equivalents and Restricted Cash</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company considers all highly-liquid investments purchased with a remaining maturity date of three months or less upon acquisition to be cash equivalents. These investments are stated at cost, which approximates fair value.</span></div></ix:nonNumeric><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company has an arrangement with a financial institution with which it has an existing banking relationship, whereby in exchange for the issuance of corporate credit cards, the Company agreed to obtain a certificate of deposit with this financial institution in the amount of $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:RestrictedCash" scale="6" id="f-286">0.2</ix:nonFraction> million as collateral for the balances borrowed on these cards. The Company has classified the value of this certificate of deposit (including all interest earned thereon) within other assets in the accompanying balance sheets. The Company has the right to terminate the credit card program at any time. Upon termination of the credit card program and repayment of all outstanding balances owed, the Company may redeem the certificate of deposit (and all interest earned thereon).</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-256-3" continuedAt="f-256-4"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" id="f-288" escape="true"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" id="f-287" escape="true"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cash, cash equivalents and restricted cash presented in the accompanying statements of cash flows consist of the following (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.707%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.768%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-289">22,036</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-290">36,493</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:RestrictedCash" scale="3" id="f-291">200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:RestrictedCash" scale="3" id="f-292">200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-293">22,236</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-294">36,693</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="f-295" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Property and Equipment</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Property and equipment are stated at cost, net of depreciation and amortization. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally between <span style="-sec-ix-hidden:f-296">three</span> and <ix:nonNumeric contextRef="c-48" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen" id="f-297">five years</ix:nonNumeric>. Leasehold improvements are amortized on a straight-line basis over the lesser of the estimated useful life or the remaining term of the related lease. Maintenance and repairs are charged to expense as incurred, and improvements and betterments are capitalized. When assets are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the balance sheet and any resulting gain or loss is reflected in operating expenses in the statements of operations in the period realized.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="f-298" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Long-lived Assets</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company&#8217;s long-lived assets are comprised principally of its property and equipment and operating lease assets. The Company amortizes all finite lived intangible assets over their respective estimated useful lives. Operating lease assets are amortized over the term of the leases. In considering whether long-lived assets are impaired, the Company combines its long-lived assets into groupings, a determination which is made principally on the basis of whether the assets are specific to a particular test offered or technology being developed. If the Company identifies a change in the circumstances related to its long-lived assets that indicates the carrying value of any such asset may not be recoverable, the Company will perform an impairment analysis. A long-lived asset is deemed to be impaired when the undiscounted cash flows expected to be generated by the asset (or asset group) are less than the asset&#8217;s carrying amount. Management&#8217;s estimates of future cash flows are impacted by projected test volume and levels of reimbursement, as well as expectations related to the future cost structure of the entity. Any required impairment loss would be measured as the amount by which the asset&#8217;s carrying value exceeds its fair value, and would be recorded as a reduction in the carrying value of the related asset and a charge to operating expense.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeLeasesPolicyTextBlock" id="f-299" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Leases</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company categorizes leases at their commencement as either operating or finance leases. The Company recognizes operating lease ROU assets and operating lease liabilities for each lease arrangement identified. Lease liabilities are recorded at the present value of future lease payments discounted using the Company's incremental borrowing rate for the lease established at the commencement date. The incremental borrowing rate is the rate of interest the Company would have to pay to borrow, on a collateralized basis over a similar term and in a similar economic environment, an amount equal to the total lease payments. The Company primarily considers industry data, its credit rating and the lease term to determine its incremental borrowing rate. ROU assets are measured at the amount of the lease liability plus any initial direct costs, less any lease incentives received before commencement. Lease expense is recognized as a single lease cost over the lease term on a straight-line basis. The Company has elected not to apply the recognition requirements to short-term leases and not to separate non-lease components from lease components for its leases.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="exdx:ClinicalStudyPolicyPolicyTextBlock" id="f-300" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Clinical Studies</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">From time to time, the Company engages in efforts to scientifically measure and document the application and efficacy of its various testing products. These arrangements typically require the Company to pay a fee to a third-party scientific investigator (usually a physician or research institution) for each subject enrolled in a clinical study, and the Company accrues expenses based on estimated progress of services performed, including actual level of subjects enrolled and progress of the clinical studies. Payments made prior to the completion of clinical study services are capitalized as a prepaid expense. The prepaid amounts are expensed as the related goods are delivered or the services are performed, or when it is no longer expected that the goods will be delivered or the services rendered. Expenses associated with clinical study activities are recorded in research and development expenses in the accompanying statement of operations.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-256-4" continuedAt="f-256-5"><ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueRecognitionPolicyTextBlock" id="f-301" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Revenue Recognition</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Substantially all of the Company's revenue has been derived from sales of its testing products and is primarily comprised of a high volume of relatively low-dollar transactions. The Company primarily markets its testing products to rheumatologists and their physician assistants in the United States. The healthcare professionals who order the Company's testing products and to whom test results are reported are generally not responsible for payment for these products. The parties that pay for these services (each, a payor) consist of commercial payors (healthcare insurers), government payors (primarily Medicare and Medicaid), client payors (hospitals, other laboratories, etc.) and patient self-pay. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company recognizes revenue in accordance with Accounting Standards Codification Topic 606, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> and follows a five-step process to determine the amount and timing of revenue recognized: (1) identify the contract with the customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to performance obligations in the contract, and (5) recognize revenue when (or as) the performance obligation is satisfied. The Company's service is a single performance obligation that is completed upon the delivery of test results to the prescribing physician which triggers revenue recognition.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Payors are generally billed at the Company's list price, unless a separate pricing contract is in place. Net revenues recognized consist of amounts billed net of allowances for differences between amounts billed and the estimated consideration the Company expects to receive from such payors. The process for estimating revenues and the ultimate collection of accounts receivable involves significant judgment and estimation. The Company follows a standard process, which considers historical denial and collection experience, insurance reimbursement policies and other factors, to estimate allowances and implicit price concessions. Adjustments are recorded in the current period as changes in estimates occur. Further adjustments to the allowances, based on actual receipts, are recorded upon settlement. Included in revenues for the years ended December&#160;31, 2024 and 2023 were net revenue increases of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" id="f-302">6.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" id="f-303">3.4</ix:nonFraction> million, respectively, associated with changes in estimated variable consideration related to performance obligations satisfied in previous periods. The transaction price is estimated using an expected value method on a portfolio basis.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Variable consideration is included in the transaction price only to the extent it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainties with respect to the amount are resolved. The Company's portfolios are grouped per payor (i.e. each individual commercial payor, Medicare, Medicaid, client payors, patient self-pay, etc.) and per test. Consideration may be constrained and excluded from the transaction price in situations where there is no contractually agreed upon reimbursement coverage or in absence of a predictable pattern and history of collectability with a payor. Accordingly, in such situations revenues are recognized on the basis of actual cash collections. Additionally, from time to time, the Company may issue refunds to payors for overpayments or amounts billed in error. Any refunds are accounted for as reductions in revenues in the statement of operations as an element of variable consideration. The estimated expected refunds are accrued as a liability on the Company&#8217;s balance sheet.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Collection of the Company's net revenues from payors is normally a function of providing complete and correct billing information, along with any requested medical or other claims-related information to the healthcare insurers. This generally occurs within 30 to 90 days of billing, however, the amount and timing of any reimbursements or collections for the Company's billed tests may vary by payor and other circumstances. Contracts do not contain significant financing components based on the typical period of time between performance of services and collection of consideration.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ReceivablesPolicyTextBlock" id="f-304" continuedAt="f-304-1" escape="true"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Accounts Receivable and Allowance for Credit Losses</span></div></ix:nonNumeric><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="f-304-1">We accrue an allowance for credit losses against our accounts receivable based on management&#8217;s current estimate of amounts that will not be collected. Management&#8217;s estimates are typically based on historical loss information adjusted for current conditions. We generally do not perform evaluations of the financial condition of our customers and generally do not require collateral. The allowance for credit losses was <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:FinancingReceivableAllowanceForCreditLossExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="f-305"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:FinancingReceivableAllowanceForCreditLossExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="f-306">zero</ix:nonFraction></ix:nonFraction> as of each of December&#160;31, 2024 and 2023. Adjustments for implicit price concessions attributable to variable consideration, as discussed above, are incorporated into the measurement of the accounts receivable balances and are not part of the allowance for credit losses.</ix:continuation> Accounts receivable was $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="f-307">7.8</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="f-308">6.6</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="f-309">6.1</ix:nonFraction> million for the years ended December&#160;31, 2024, 2023 and 2022, respectively. </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="f-310" continuedAt="f-310-1" escape="true"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Research and Development</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Costs associated with research and development activities are expensed as incurred and include, but are not limited to, personnel-related expenses, including stock-based compensation expense; materials; laboratory </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-256-5" continuedAt="f-256-6"><ix:continuation id="f-310-1"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">supplies; consulting costs; costs associated with setting up and conducting clinical studies; depreciation; amortization and allocated overhead, including rent and utilities.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:AdvertisingCostsPolicyTextBlock" id="f-311" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Advertising and Marketing Costs</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Costs associated with advertising and marketing activities are expensed as incurred. Total advertising and marketing costs were approximately $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:AdvertisingExpense" scale="6" id="f-312">1.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:AdvertisingExpense" scale="6" id="f-313">1.5</ix:nonFraction> million for the years ended December&#160;31, 2024 and 2023, respectively, and are included in selling, general and administrative expenses in the accompanying statements of operations.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:CostOfSalesPolicyTextBlock" id="f-314" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Shipping and Handling Costs</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Costs incurred for shipping and handling are included in costs of revenue in the accompanying statements of operations and were approximately $<ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-5" name="us-gaap:CostOfRevenue" scale="6" id="f-315">3.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-5" name="us-gaap:CostOfRevenue" scale="6" id="f-316">2.5</ix:nonFraction> million for the years ended December&#160;31, 2024 and 2023, respectively.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:EmployeeStockOwnershipPlanESOPPolicy" id="f-317" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Stock-Based Compensation</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company recognizes compensation expense for all stock-based awards to employees and directors based on the grant-date estimated fair values over the requisite service period of the awards (usually the vesting period) on a straight-line basis. Equity award forfeitures are recorded as they occur.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The fair value of each restricted stock unit (RSU) is determined on the grant date using the closing price of the Company's common stock on that date. The Company's RSUs generally vest in equal annual installments over <ix:nonFraction unitRef="installment" contextRef="c-1" decimals="INF" name="exdx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments" format="ixt-sec:numwordsen" scale="0" id="f-318">four</ix:nonFraction> years from the date of grant or, for grants to new hires, date of hire. Vesting of the RSU is subject to the holder's continued service with the Company. The Company issues new shares of common stock to satisfy the RSUs upon vesting.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="f-319" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Comprehensive Loss</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Comprehensive loss is defined as a change in equity of a business enterprise during a period, resulting from transactions from nonowner sources. There have been no items qualifying as other comprehensive loss and, therefore, for all periods presented, the Company's comprehensive loss was the same as its reported net loss.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxPolicyTextBlock" id="f-320" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Income Taxes</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized as an expense in the period that includes the enactment date. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company recognizes net deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If management determines that the Company would be able to realize its deferred tax assets in the future in excess of their net recorded amount, management would adjust the deferred tax asset valuation allowance, which would reduce the provision for income taxes. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company records uncertain tax positions on the basis of a two-step process whereby (i) management determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (ii) for those tax positions that meet the more-likely-than-not recognition threshold, management recognizes the largest amount of tax benefit that is more than 50% likely to be realized upon ultimate settlement with the related tax authority. The Company recognizes interest and penalties related to unrecognized tax benefits within income tax expense. Any accrued interest and penalties are included within the related tax liability.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerSharePolicyTextBlock" id="f-321" continuedAt="f-321-1" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Net Loss Per Share</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Basic net loss per share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common stock outstanding during the period. Diluted net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-256-6"><ix:continuation id="f-321-1"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">stockholders by the weighted-average number of common stock equivalents outstanding for the period determined using the treasury-stock and if-converted methods. The weighted-average number of shares used to compute basic and diluted shares includes shares issuable upon the exercise of pre-funded warrants at a nominal price. Potentially dilutive common stock equivalents are comprised of warrants for the purchase of common stock, stock options, RSUs outstanding under the Company's 2019 Incentive Award Plan (the 2019 Plan) and shares of the Company's common stock pursuant to the Exagen Inc. 2019 Employee Stock Purchase Plan (ESPP). For each of the years ended December&#160;31, 2024 and 2023, there is no difference in the number of shares used to calculate basic and diluted shares outstanding as the inclusion of the potentially dilutive securities would be antidilutive.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="f-322" escape="true"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Potentially dilutive securities not included in the calculation of diluted net loss per share, because to do so would be anti-dilutive, are as follows (in common stock equivalent shares):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.707%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.768%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Warrants to purchase common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-51" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-323">325,330</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-52" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-324">409,108</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-53" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-325">489,296</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-54" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-326">986,819</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-55" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-327">1,710,373</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-56" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-328">1,387,459</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock purchase plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-57" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-329">57,461</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-58" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-330">44,700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-331">2,582,460</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-332">2,828,086</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="f-333" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Recent Accounting Pronouncements</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB), or other standard setting bodies and adopted by the Company as of the specified effective date. Unless otherwise discussed, Accounting Standards Updates (ASU) not included in the Company&#8217;s disclosures were assessed and determined to be either not applicable or are not expected to have a material impact on the Company&#8217;s financial statements or disclosures.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">In December 2023, the FASB issued ASU 2023-09,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%"> Income Taxes (Topic 740): Improvements to Income Tax Disclosures</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> (ASU 2023-09), which requires additional income tax disclosures in the rate reconciliation table for federal, state and foreign income taxes, in addition to more details about the reconciling items in some categories when items meet a certain quantitative threshold. ASU 2023-09 is effective for annual periods beginning after December 15, 2024 with early adoption permitted. This update will result in enhanced income tax disclosures, and the Company does not expect any impact to income tax expense.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">In November 2024, the FASB issued ASU 2024-03, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%">Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> (&#8220;ASU 2024-03&#8221;). This update requires entities to include more detailed information about the types of expenses, including purchases of inventory, employee compensation, depreciation, amortization, and depletion, in commonly presented expense captions such as cost of sales, research and development, and selling, general and administrative expenses. ASU 2024-03 is effective for annual periods beginning after December 15, 2026, with early adoption permitted. The company is currently evaluating the impact of this standard on its financial statement presentation and disclosures.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:107%">Recently Adopted Accounting Standards</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In November 2023, the FASB issued ASU No. 2023-07, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (ASU 2023-07), which requires public entities to disclose significant segment expenses that are regularly provided to the Chief Operating Decision Maker (CODM) and details of how the CODM uses financial reporting to assess the performance of a segment. The Company adopted this pronouncement in 2024 and retrospectively to all prior periods using the significant segment expense categories identified. The impact of the adoption of the amendments in this update was not material to the Company&#8217;s financial position and results of operations, as the requirements impact only segment reporting disclosures in the footnotes to the Company&#8217;s financial statements.</span></div></ix:nonNumeric></ix:continuation><div id="i9ecffbbbc3a143a09815a7575cabd836_139"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Note 3. <ix:nonNumeric contextRef="c-1" name="exdx:PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock" id="f-336" continuedAt="f-336-1" escape="true">Other Financial Information</ix:nonNumeric></span></div><ix:continuation id="f-336-1" continuedAt="f-336-2"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Prepaid Expenses and Other Current Assets</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" id="f-337" continuedAt="f-337-1" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Prepaid expenses and other current assets consist of the following (in thousands):</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-336-2"><ix:continuation id="f-337-1"><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.707%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.768%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Diagnostic&#160;testing&#160;supplies</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-338">5,725</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-339">2,871</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherPrepaidExpenseCurrent" scale="3" id="f-340">859</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OtherPrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="f-341">1,926</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-342">6,584</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-343">4,797</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Property and Equipment, net</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="f-344" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Property and equipment consist of the following (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.707%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.768%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Furniture&#160;and&#160;fixtures</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="3" id="f-345">105</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="3" id="f-346">98</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-347">4,248</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-348">5,312</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-349">2,113</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-350">2,185</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-351">3,286</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-352">3,316</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-353">1,543</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="3" id="f-354">59</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-355">11,295</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-356">10,970</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: accumulated depreciation and amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-357">6,012</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-358">5,769</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-359">5,283</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-360">5,201</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Depreciation and amortization expense for the years ended December&#160;31, 2024 and 2023, was approximately $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="f-361">1.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="f-362">2.2</ix:nonFraction> million, respectively. At December&#160;31, 2024 and 2023, the gross book value of assets under finance leases was $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" scale="6" id="f-363">2.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" scale="6" id="f-364">2.5</ix:nonFraction> million, respectively.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Loss on Lease Assignment</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On October 24, 2023, the Company entered into an assignment and assumption (the Assignment and Assumption Agreement) of the Company&#8217;s previously executed lease agreement with Liberty Vista, LP (formerly known as Geiger Court, LLC) and Mindera Corporation (Mindera), pursuant to which the Company assigned to Mindera the lease of a building located adjacent to the Company's headquarters in Vista, CA. Under the terms of the Assignment and Assumption Agreement, Mindera assumed all obligations under the lease, effective October 31, 2023. As a result of the lease assignment, the Company derecognized the remaining balances related to the associated operating lease ROU asset of $<ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="6" id="f-365">0.7</ix:nonFraction>&#160;million, operating lease liability of $<ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-5" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="f-366">0.8</ix:nonFraction>&#160;million and leasehold improvements of $<ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-5" name="us-gaap:LeaseholdImprovementsGross" format="ixt:num-dot-decimal" scale="6" id="f-367">1.6</ix:nonFraction>&#160;million, resulting in a $<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" sign="-" name="exdx:GainLossOnDispositionOfLeaseAssignment" scale="6" id="f-368">1.5</ix:nonFraction> million loss on lease assignment. The loss was classified within selling, general and administrative expenses in the accompanying statements of operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Accrued and Other Current Liabilities</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="f-369" escape="true"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Accrued and other current liabilities consist of the following (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.707%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.768%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued&#160;payroll&#160;and&#160;related&#160;expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccruedSalariesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-370">5,046</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AccruedSalariesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-371">4,738</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-372">2,804</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-373">2,793</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-374">7,850</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-375">7,531</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div id="i9ecffbbbc3a143a09815a7575cabd836_142"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Note 4. <ix:nonNumeric contextRef="c-1" name="us-gaap:DebtDisclosureTextBlock" id="f-376" continuedAt="f-376-1" escape="true">Borrowings</ix:nonNumeric></span></div><ix:continuation id="f-376-1" continuedAt="f-376-2"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">2017 Term Loan</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In September 2017, the Company executed a term loan agreement (the 2017 Term Loan) with Innovatus Life Sciences Lending Fund I, LP (Innovatus), as amended (the Amended Loan Agreement), pursuant to which the Company borrowed $<ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="f-377">25.0</ix:nonFraction>&#160;million. At December&#160;31, 2024, <ix:nonFraction unitRef="usd" contextRef="c-71" decimals="0" name="us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity" format="ixt:fixed-zero" scale="0" id="f-378">no</ix:nonFraction> additional amounts remained available to borrow under the Amended Loan Agreement.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On April 28, 2023, the Company entered into the Amended Loan Agreement. The Amended Loan Agreement was treated as a modification. In connection with the Amended Loan Agreement, the Company repaid $<ix:nonFraction unitRef="usd" contextRef="c-72" decimals="-5" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="f-379">10.0</ix:nonFraction>&#160;million of </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-376-2" continuedAt="f-376-3"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">the principal balance outstanding, for which the prepayment premium was waived. Pursuant to the Amended Loan Agreement, the interest rate on all borrowings under the Amended Loan Agreement is the sum (the Basic Rate) of (a) the greater of <ix:nonFraction unitRef="number" contextRef="c-72" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-380">8.0</ix:nonFraction>% or The Wall Street Journal prime rate (the Prime Rate), plus (b) <ix:nonFraction unitRef="number" contextRef="c-73" decimals="2" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-381">2.0</ix:nonFraction>%, which is paid-in-kind in the form of additional term loans (PIK Loans). Under the Amended Loan Agreement, an amount equal to <ix:nonFraction unitRef="number" contextRef="c-73" decimals="3" name="exdx:DebtInstrumentStatedInterestRatePaidInKind" scale="-2" id="f-382">1.5</ix:nonFraction>% of the Basic Rate will be payable in-kind and capitalized to the principal amount of the outstanding term loan on a monthly basis until April 1, 2026, after which interest is scheduled to accrue at the Basic Rate. The maturity date of the loan was extended to December 31, 2026. The Company estimated the effective interest rate of this loan to be approximately <ix:nonFraction unitRef="number" contextRef="c-71" decimals="3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-383">10.6</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="c-74" decimals="3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-384">11.0</ix:nonFraction>% as of December&#160;31, 2024 and 2023, respectively. Accrued interest is due and payable monthly, unless the Company elects to pay paid-in-kind interest. The outstanding principal and accrued interest under the Amended Loan Agreement is to be repaid in <ix:nonFraction unitRef="installment" contextRef="c-75" decimals="INF" name="exdx:DebtInstrumentNumberOfMonthlyInstallments" format="ixt-sec:numwordsen" scale="0" id="f-385">ten</ix:nonFraction> equal monthly installments commencing in April 2026. Upon repayment of the final installment under the Amended Loan Agreement, the Company is required to pay an additional fee of $<ix:nonFraction unitRef="usd" contextRef="c-71" decimals="-5" name="us-gaap:DebtInstrumentFeeAmount" format="ixt:num-dot-decimal" scale="6" id="f-386">1.0</ix:nonFraction>&#160;million. This obligation is being accreted into interest expense over the term of the loan using the effective interest method. For the years ended December&#160;31, 2024 and 2023, the Company issued PIK Loans totaling $<ix:nonFraction unitRef="usd" contextRef="c-76" decimals="-5" name="exdx:DebtInstrumentPaidInKindLoansIssued" scale="6" id="f-387">0.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-5" name="exdx:DebtInstrumentPaidInKindLoansIssued" scale="6" id="f-388">0.4</ix:nonFraction> million, respectively. At December&#160;31, 2024, $<ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-5" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="f-389">18.5</ix:nonFraction> million in principal and PIK loans are outstanding, all of which is included in borrowings-non-current portion on the accompanying balance sheet.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Amended Loan Agreement is collateralized by a first priority security interest in substantially all of the Company's assets, including intellectual property. The affirmative covenants of the Amended Loan Agreement require that the Company timely file taxes, maintain good standing and government compliance, maintain liability and other insurance, provide prompt notification of significant corporate events, and furnish audited financial statements within 150 days of fiscal year end without qualification as to the scope of the audit or as to going concern and without any other similar qualification.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The affirmative covenants require that the Company achieve a specified level of revenue, as measured quarterly on a rolling <ix:nonNumeric contextRef="c-75" name="exdx:DebtInstrumentCovenantRevenuePerformancePeriod" format="ixt-sec:durwordsen" id="f-390">twelve-month</ix:nonNumeric> basis, however the Company is not required to comply with the revenue covenant for any quarter during which it maintains a minimum aggregate cash balance equal to <ix:nonFraction unitRef="number" contextRef="c-75" decimals="2" name="exdx:DebtInstrumentMinimumCashBalanceRequiredNotRequiredToComplyWithCovenant" format="ixt-sec:numwordsen" scale="-2" id="f-391">fifty</ix:nonFraction> percent of the aggregate principal amount of the Amended Loan Agreement (excluding any capitalized interest paid-in-kind) at all times during such quarter. The consequences of failing to achieve the performance covenants, when applicable, will be cured if, (i) within <ix:nonNumeric contextRef="c-75" name="exdx:DebtInstrumentCovenantNumberOfDaysToCureIfPerformanceMeasureIsNotMet" format="ixt-sec:durwordsen" id="f-392">thirty days</ix:nonNumeric> of failing to achieve the performance covenant, the Company submits a new financial plan approved by the Company's board of directors (the Board) to Innovatus under which the Company is expected to break even on a cash flow basis prior to the maturity date, and (ii) within <ix:nonNumeric contextRef="c-75" name="exdx:DebtInstrumentCovenantNumberOfDaysToCureIfPerformanceMeasureIsNotMet" format="ixt-sec:durwordsen" id="f-393">thirty days</ix:nonNumeric> of the submission of such financial plan, the Company issues additional equity securities or subordinated debt with net proceeds sufficient to fund any cash flow deficiency generated from operations, as defined in the Amended Loan Agreement. The Amended Loan Agreement requires that the Company maintain certain levels of minimum liquidity and maintains an unrestricted cash balance of $<ix:nonFraction unitRef="usd" contextRef="c-71" decimals="-5" name="exdx:DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance" scale="6" id="f-394">2.0</ix:nonFraction> million.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The negative covenants provide, among other things, that without the prior consent of Innovatus, subject to certain exceptions, the Company may not dispose of certain assets, engage in certain business combinations or acquisitions, incur additional indebtedness or encumber any of the Company's property, pay dividends on the Company's capital stock or make prohibited investments. The Amended Loan Agreement provides that an event of default will occur if, among other triggers, (i)&#160;the Company defaults in the payment of any amount payable under the agreement when due, (ii)&#160;there occurs any circumstance(s) that could reasonably be expected to result in a material adverse effect on the Company's business, operations or condition, or on the Company's ability to perform its obligations under the agreement, (iii)&#160;the Company becomes insolvent, (iv)&#160;the Company undergoes a change in control or (v)&#160;the Company breaches any negative covenants or certain affirmative covenants in the agreement or, subject to a cure period, otherwise neglects to perform or observe any material item in the agreement.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2024, the Company was in compliance with all covenants of the Amended Loan Agreement.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon an event of default in any of the Amended Loan Agreement covenants, the repayment of the 2017 Term Loan may be accelerated, and the applicable interest rate will be increased by <ix:nonFraction unitRef="number" contextRef="c-79" decimals="3" name="exdx:DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease" scale="-2" id="f-395">4.0</ix:nonFraction>% until the default is cured. Although repayment of the 2017 Term Loan can be accelerated under certain circumstances, the Company believes acceleration of this loan is not probable as of the date of these financial statements. Accordingly, the Company has reflected the amounts of the Amended Loan Agreement due beyond twelve months of the balance sheet date as non-current.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Equipment Notes Payable</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company has purchased laboratory equipment in the normal course of business using notes payable. At December&#160;31, 2024, the total notes payable balance related to the financed equipment was $<ix:nonFraction unitRef="usd" contextRef="c-80" decimals="-5" name="us-gaap:NotesPayable" format="ixt:num-dot-decimal" scale="6" id="f-396">1.1</ix:nonFraction>&#160;million, with </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-376-3"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$<ix:nonFraction unitRef="usd" contextRef="c-80" decimals="-5" name="us-gaap:NotesPayableCurrent" format="ixt:num-dot-decimal" scale="6" id="f-397">0.4</ix:nonFraction>&#160;million classified within borrowings-current portion and $<ix:nonFraction unitRef="usd" contextRef="c-80" decimals="-5" name="us-gaap:LongTermNotesPayable" format="ixt:num-dot-decimal" scale="6" id="f-398">0.7</ix:nonFraction>&#160;million within borrowings-non-current portion, net of discounts and debt issuance costs in the accompanying balance sheets. At December 31, 2023, the total notes payable balance related to this financed equipment was $<ix:nonFraction unitRef="usd" contextRef="c-81" decimals="-5" name="us-gaap:NotesPayable" format="ixt:num-dot-decimal" scale="6" id="f-399">0.8</ix:nonFraction>&#160;million, with $<ix:nonFraction unitRef="usd" contextRef="c-81" decimals="-5" name="us-gaap:NotesPayableCurrent" format="ixt:num-dot-decimal" scale="6" id="f-400">0.3</ix:nonFraction>&#160;million classified within borrowings-current portion and $<ix:nonFraction unitRef="usd" contextRef="c-81" decimals="-5" name="us-gaap:LongTermNotesPayable" format="ixt:num-dot-decimal" scale="6" id="f-401">0.5</ix:nonFraction>&#160;million within borrowings-non-current portion, net of discounts and debt issuance costs in the accompanying balance sheets. The financed equipment is subject to effective interest rates between <ix:nonFraction unitRef="number" contextRef="c-82" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-402">5.28</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="c-83" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-403">10.50</ix:nonFraction>%, and will mature between October 1, 2026 and April 1, 2028.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Future Minimum Payments on Outstanding Borrowings</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="f-404" escape="true"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December&#160;31, 2024, future minimum aggregate payments, including interest, for outstanding borrowings are as follows (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.303%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.767%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ending December 31,</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="f-405">2,076</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" format="ixt:num-dot-decimal" scale="3" id="f-406">21,400</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" scale="3" id="f-407">215</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" scale="3" id="f-408">67</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="exdx:LongTermDebtIncludingUndiscountedInterest" format="ixt:num-dot-decimal" scale="3" id="f-409">23,758</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unamortized debt discount and issuance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" scale="3" id="f-410">70</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="exdx:LongTermDebtUndiscountedInterestAmount" format="ixt:num-dot-decimal" scale="3" id="f-411">3,443</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total borrowings, net of discounts and debt issuance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-412">20,245</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: Borrowings-current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LongTermDebtCurrent" scale="3" id="f-413">423</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Borrowings-non-current portion, net of discounts and debt issuance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-414">19,822</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div id="i9ecffbbbc3a143a09815a7575cabd836_145"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Note 5. <ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeasesTextBlock" id="f-416" continuedAt="f-416-1" escape="true"><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeFinanceLeasesTextBlock" id="f-415" continuedAt="f-415-1" escape="true">Leases</ix:nonNumeric></ix:nonNumeric></span></div><ix:continuation id="f-416-1" continuedAt="f-416-2"><ix:continuation id="f-415-1" continuedAt="f-415-2"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Leases</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Operating Leases</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company leases office and laboratory space located in Vista, California. The lease expires in April 2027, with an option to extend portions of the lease for additional <ix:nonNumeric contextRef="c-84" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="f-417">5-year</ix:nonNumeric> periods. The Company has not included the optional renewal periods in the measurement of the lease liability, because it is not reasonably certain that the Company will exercise these renewal options. The Company's payments under the lease are subject to escalation clauses.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company leases additional office space in Carlsbad, California, under a sublease which commenced in October 2021 and expires in April 2027. Monthly base rent under the sublease agreement is $<ix:nonFraction unitRef="usd" contextRef="c-85" decimals="0" name="exdx:OperatingLeaseMonthlyBaseRent" format="ixt:num-dot-decimal" scale="0" id="f-418">72,143</ix:nonFraction>. The monthly base rent increases by approximately <ix:nonFraction unitRef="number" contextRef="c-86" decimals="2" name="exdx:OperatingLeaseAnnualIncreaseInBaseRentPaymentPercent" scale="-2" id="f-419">3</ix:nonFraction>% annually, each October 1, through the remainder of the lease term.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Finance Leases</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company has entered into various finance lease agreements to obtain laboratory equipment. The terms of the Company's finance leases generally range from <span style="-sec-ix-hidden:f-420">three</span> to <ix:nonNumeric contextRef="c-48" name="us-gaap:LesseeFinanceLeaseTermOfContract1" format="ixt-sec:durwordsen" id="f-421">five years</ix:nonNumeric> and are typically secured by the underlying equipment. The portion of the future payments designated as principal repayments were classified as finance lease liabilities on the Company's balance sheet.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Operating and Finance Leases Balances and Costs</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:LeaseCostTableTextBlock" id="f-422" continuedAt="f-422-1" escape="true"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Operating and finance leases consist of the following (in thousands):</span></div></ix:nonNumeric></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-416-2" continuedAt="f-416-3"><ix:continuation id="f-415-2" continuedAt="f-415-3"><ix:continuation id="f-422-1"><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:25.361%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.163%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.783%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.786%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Lease Balance</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Lease Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-423">2,401</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-424">3,286</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-425"><span style="-sec-ix-hidden:f-426">Property and equipment, net</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAsset" scale="3" id="f-427">486</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAsset" scale="3" id="f-428">810</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Lease Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-429">1,096</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="f-430">976</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-431"><span style="-sec-ix-hidden:f-432">Accrued and other current liabilities</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="f-433">201</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="f-434">490</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-435">1,664</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-436">2,760</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-437"><span style="-sec-ix-hidden:f-438">Other non-current liabilities</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" id="f-439">157</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" id="f-440">358</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Costs associated with the Company's leases were included in the statements of operations as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.794%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.783%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.785%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Lease Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease cost</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-441">1,345</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-442">1,463</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finance lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of lease assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" id="f-443">280</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" id="f-444">556</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest on finance lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:FinanceLeaseInterestExpense" scale="3" id="f-445">84</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:FinanceLeaseInterestExpense" scale="3" id="f-446">128</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total lease cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-447">1,709</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-448">2,147</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">(1) Includes variable lease cost of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:VariableLeaseCost" format="ixt:num-dot-decimal" scale="0" id="f-449">196,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:VariableLeaseCost" format="ixt:num-dot-decimal" scale="0" id="f-450">129,000</ix:nonFraction> for the years ended December&#160;31, 2024 and 2023, respectively.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Supplemental cash flow information on leases is as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.794%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.783%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.785%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating cash out flows from operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="f-451">1,240</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="f-452">1,405</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating cash out flows from interest paid on finance leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" scale="3" id="f-453">84</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" scale="3" id="f-454">128</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Financing cash out flows from finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="f-455">490</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="f-456">697</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Information regarding the weighted-average lease term and weighted average discount rate are as follows:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.783%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.785%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average remaining lease term (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-5" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-457">2.3</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-6" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-458">3.3</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-5" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-459">1.76</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-6" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-460">2.06</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-5" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-461">8.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-6" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-462">8.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-5" decimals="3" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-463">17.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-6" decimals="3" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-464">12.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="f-466" continuedAt="f-466-1" escape="true"><ix:nonNumeric contextRef="c-1" name="us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock" id="f-465" continuedAt="f-465-1" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Future payments under operating and finance leases as of December&#160;31, 2024 are as follows (in thousands):</span></div></ix:nonNumeric></ix:nonNumeric></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-466-1"><ix:continuation id="f-465-1"><ix:continuation id="f-416-3"><ix:continuation id="f-415-3"><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.917%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.783%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.784%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Finance Leases</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="f-467">1,277</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="f-468">248</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="3" id="f-469">1,315</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo" scale="3" id="f-470">147</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="f-471">445</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree" scale="3" id="f-472">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total minimum lease payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="f-473">3,037</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDue" scale="3" id="f-474">423</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="f-475">277</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount" scale="3" id="f-476">65</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-477">2,760</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:FinanceLeaseLiability" scale="3" id="f-478">358</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-479">1,096</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="f-480">201</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Lease obligations, net of current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-481">1,664</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" id="f-482">157</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:continuation></ix:continuation></ix:continuation><div id="i9ecffbbbc3a143a09815a7575cabd836_148"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Note 6. <ix:nonNumeric contextRef="c-1" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="f-483" continuedAt="f-483-1" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="f-483-1" continuedAt="f-483-2"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Licensing Agreements</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company has licensed technology for use in its diagnostic tests. In addition to the milestone payments required by these agreements, individual license agreements generally provide for ongoing royalty payments ranging from <ix:nonFraction unitRef="number" contextRef="c-87" decimals="INF" name="exdx:RoyaltyObligationPercentageOfSales" scale="-2" id="f-484">2.0</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="c-88" decimals="INF" name="exdx:RoyaltyObligationPercentageOfSales" scale="-2" id="f-485">7.0</ix:nonFraction>% on net sales of products which incorporate licensed technology, as defined in such agreements. Royalties are accrued when incurred and recorded in costs of revenue in the accompanying statements of operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Supply Agreements</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In August 2024, the Company amended a supply agreement with <ix:nonFraction unitRef="supplier" contextRef="c-89" decimals="INF" name="exdx:PurchaseObligationAmendedSupplyAgreementNumberOfSuppliers" format="ixt-sec:numwordsen" scale="0" id="f-486">one</ix:nonFraction> supplier for reagents, which includes pricing terms and minimum purchase commitments, through December 31, 2025, for new consumable products related to the Company's launch of the Anti-RA33 IgA, Anti-RA33 IgG and Anti-RA33 IgM biomarkers. The aggregate minimum annual purchase commitment related to such agreement for the year ending December 31, 2025 is $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:PurchaseObligationDueInNextTwelveMonths" scale="6" id="f-487">10.4</ix:nonFraction> million.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Collaboration Obligations</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In May 2021, the Company entered into an exclusive license agreement with Allegheny Health Network Research Institute (AHN), pursuant to which the Company is required to pay AHN a collaboration fee of $<ix:nonFraction unitRef="usd" contextRef="c-90" decimals="-5" name="exdx:CollaborationAgreementAnnualCollaborationFee" scale="6" id="f-488">0.4</ix:nonFraction> million per year. Collaboration expenses under the master research collaboration agreement were $<ix:nonFraction unitRef="usd" contextRef="c-91" decimals="-5" name="exdx:CollaborationAgreementCollaborationExpenses" scale="6" id="f-489"><ix:nonFraction unitRef="usd" contextRef="c-92" decimals="-5" name="exdx:CollaborationAgreementCollaborationExpenses" scale="6" id="f-490">0.3</ix:nonFraction></ix:nonFraction> million for each of the years ended December&#160;31, 2024 and 2023. Collaboration expenses under the AHN collaboration are included in research and development expenses in the accompanying statements of operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Contingencies</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnifications; including for subpoenas and other civil investigative demands, from governmental agencies, Medicare or Medicaid and managed care organizations reviewing billing practices or requesting comment on allegations of billing irregularities that are brought to their attention through billing audits or third parties. The Company's exposure under these agreements is unknown because it involves claims that may be made against the Company in the future, but have not yet been made or that the Company believes to be immaterial. The Company accrues a liability for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Litigation</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">From time to time, the Company may be subject to various legal proceedings that arise in the ordinary course of business activities. The Company does not believe the outcome of any such matters as of December&#160;31, 2024 will have a material effect on its financial position or results of operations.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In October 2023, the Company resolved an investigation with the U.S. Attorney&#8217;s Office for the District of Massachusetts that was initiated by a </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">qui tam </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">lawsuit (the October 2023 Lawsuit). Pursuant to a settlement agreement entered into by and between the Company and the U.S. Department of Justice (the Settlement Agreement), the Company made a single lump-sum remittance to the government in the amount of $<ix:nonFraction unitRef="usd" contextRef="c-93" decimals="-5" name="us-gaap:PaymentsForLegalSettlements" format="ixt:num-dot-decimal" scale="6" id="f-491">0.7</ix:nonFraction>&#160;million, including interest, in connection with specimen processing arrangements that Exagen historically had with </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-483-2"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">physicians. The U.S. Attorney&#8217;s Office dismissed this &#8220;covered conduct&#8221; in the October 2023 Lawsuit with prejudice, while non-covered conduct was dismissed without prejudice. The Department of Justice excused itself from the case in connection with the settlement. In November 2023, the complaint was unsealed by the court and served on Exagen by the relator. Exagen filed a motion to dismiss the complaint. In December 2023, the Company's insurance carrier provided reimbursement for certain defense costs the Company incurred in the October 2023</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Lawsuit. In February 2024, the relator filed a motion for leave to amend the complaint. Exagen opposed this motion, and all motions are still pending. The Company cannot predict when these matters will be resolved, the outcome of these matters, or their potential impact, which may materially and adversely affect the Company's business, prospects, and financial condition. The Company intends to vigorously defend against the claims being asserted in the complaint.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company's participation in federal healthcare programs is not affected by the Settlement Agreement.</span></div></ix:continuation><div style="text-indent:24.75pt"><span><br/></span></div><div id="i9ecffbbbc3a143a09815a7575cabd836_151"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Note 7. <ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueDisclosuresTextBlock" id="f-492" continuedAt="f-492-1" escape="true">Fair Value Measurements</ix:nonNumeric></span></div><ix:continuation id="f-492-1" continuedAt="f-492-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="f-493" escape="true"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The carrying values of the Company's cash, cash equivalents and restricted cash, accounts receivable, prepaid expenses and other current assets, accounts payable and accrued and other current liabilities are determined to be a Level 1 measurement. The carrying values of these items approximate their fair values due to their short-term nature. The estimated fair value of the Company's long-term borrowings is determined by Level 2 inputs and based primarily on quoted market prices for similar issues. As of December&#160;31, 2024, the Amended Loan Agreement had a carrying value of $<ix:nonFraction unitRef="usd" contextRef="c-94" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="f-494">19.1</ix:nonFraction> million and a fair value of $<ix:nonFraction unitRef="usd" contextRef="c-94" decimals="-5" name="us-gaap:DebtInstrumentFairValue" scale="6" id="f-495">19.2</ix:nonFraction> million. As of December 31, 2023, the Amended Loan Agreement had a carrying value of $<ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="f-496">18.7</ix:nonFraction>&#160;million and a fair value of $<ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-5" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="6" id="f-497">19.7</ix:nonFraction>&#160;million. The estimated fair value of the Amended Loan Agreement was determined based on a discounted cash flow approach using available market information on discount and borrowing rates with similar terms, maturities, and credit ratings. The aggregate carrying value of the Company's other long-term borrowings as of December&#160;31, 2024 was $<ix:nonFraction unitRef="usd" contextRef="c-80" decimals="-5" name="us-gaap:NotesPayable" format="ixt:num-dot-decimal" scale="6" id="f-498">1.1</ix:nonFraction>&#160;million and approximated its fair value.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Fair value is defined as the exchange price that would be received for an asset or an exit price paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The three-levels of the valuation hierarchy for disclosure of fair value measurements are defined as follows:</span></div><div style="margin-top:9pt;padding-left:94.5pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Level 1 -&#160;&#160;&#160;&#160;Unadjusted quoted prices in active markets for identical assets or liabilities;</span></div><div style="margin-top:9pt;padding-left:94.5pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Level 2 -&#160;&#160;&#160;&#160;Inputs other than quoted prices included within Level 1 that are observable, unadjusted quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and</span></div><div style="margin-top:9pt;padding-left:94.5pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Level 3 -&#160;&#160;&#160;&#160;Unobservable inputs that are supported by little or no market activity for the related assets or liabilities.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The categorization of a financial instrument within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="f-499" escape="true"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table sets forth the Company's financial instruments that were measured at fair value on a recurring basis within the fair value hierarchy (in thousands):</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.432%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Money market funds, included in cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-500">15,144</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-501">15,144</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-502">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-503">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.285%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.579%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Money market funds, included in cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-100" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-504">14,386</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-505">14,386</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-506">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-507">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-492-2"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The fair value of the Company's money market funds is based on quoted market prices.</span></div></ix:continuation><div id="i9ecffbbbc3a143a09815a7575cabd836_154"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Note 8. <ix:nonNumeric contextRef="c-1" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="f-508" continuedAt="f-508-1" escape="true">Stockholders' Equity</ix:nonNumeric></span></div><ix:continuation id="f-508-1"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Common Stock</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Shelf Registration Statement</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On November 17, 2023, the Company filed a registration statement on Form S-3, as amended (the 2023 Shelf Registration Statement), covering the offering, from time to time, of up to $<ix:nonFraction unitRef="usd" contextRef="c-104" decimals="-3" name="exdx:SaleOfStockAuthorizedAmount" scale="6" id="f-509">150.0</ix:nonFraction> million of common stock, preferred stock, debt securities, warrants and units. The 2023 Shelf Registration Statement became effective on November 29, 2023, and all $<ix:nonFraction unitRef="usd" contextRef="c-105" decimals="-3" name="exdx:SaleOfStockRemainingAuthorizedAmount" format="ixt:num-dot-decimal" scale="6" id="f-510">150.0</ix:nonFraction>&#160;million remain available for sale as of December&#160;31, 2024.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">At The Market Sales Agreement</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On September 15, 2022, the Company entered into a sales agreement, as amended on November 17, 2023 (the Sales Agreement) with TD Securities (USA) LLC as sales agent, pursuant to which the Company may offer and sell, from time to time, shares of Company common stock having an aggregate offering price of up to $<ix:nonFraction unitRef="usd" contextRef="c-106" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="f-511">50.0</ix:nonFraction>&#160;million. The Company is not obligated to sell any shares of Company common stock in the offering. As of December&#160;31, 2024, the Company has not sold any shares of its common stock pursuant to the Sales Agreement</span><span style="color:#008080;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Outstanding Warrants</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" id="f-512" escape="true"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following equity classified warrants to purchase common stock were outstanding as of December&#160;31, 2024:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.432%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.783%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.788%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Issuance date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Expiration date</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-107" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-513">237,169</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-107" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-514">1.84</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">January 19, 2016</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">January 19, 2026</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-108" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-515">67,086</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-108" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-516">1.84</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31, 2016</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31, 2026</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-109" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="f-517">131</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-109" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-518">1.84</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 1, 2016</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 1, 2026</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-110" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-519">20,944</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-110" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-520">14.32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 7, 2018</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 7, 2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock warrants (Exchange Warrants)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-111" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-521">804,951</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-111" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-522">0.001</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 22, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">None</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-523">1,130,281</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="exdx:StockIssuedDuringPeriodSharesWarrantsExercisedNet" format="ixt:fixed-zero" scale="0" id="f-524"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="INF" name="exdx:StockIssuedDuringPeriodSharesWarrantsExercisedNet" format="ixt:fixed-zero" scale="0" id="f-525">No</ix:nonFraction></ix:nonFraction> warrants to purchase common stock were exercised during the years ended December&#160;31, 2024 and 2023.</span></div></ix:continuation><div id="i9ecffbbbc3a143a09815a7575cabd836_160"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Note 9. <ix:nonNumeric contextRef="c-1" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="f-526" continuedAt="f-526-1" escape="true">Stock Option Plan</ix:nonNumeric></span></div><ix:continuation id="f-526-1" continuedAt="f-526-2"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">2019 Incentive Award Plan</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In September 2019, the Board adopted, and the Company's stockholders approved, the 2019 Plan. Under the 2019 Plan, which expires in September 2029, the Company may grant stock options, stock appreciation rights, restricted stock, RSUs and other awards to individuals who are then employees, officers, non-employee directors or consultants of the Company or its subsidiaries. The options generally expire <ix:nonNumeric contextRef="c-112" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" id="f-527">ten years</ix:nonNumeric> after the date of grant and are exercisable to the extent vested. Vesting is established by the Board and is generally <ix:nonNumeric contextRef="c-112" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-528">four years</ix:nonNumeric> from the date of grant or, for grants to new hires, date of hire. The 2019 Plan contains an "evergreen provision" that allows annual increases in the number of shares available for issuance on the first day of each calendar year through January 1, 2029 in an amount equal to the lesser of: (i) <ix:nonFraction unitRef="number" contextRef="c-113" decimals="2" name="exdx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage" scale="-2" id="f-529">4</ix:nonFraction>% of the outstanding capital stock on each December 31st, or (ii) such lesser amount determined by the Board. As of December&#160;31, 2024, <ix:nonFraction unitRef="shares" contextRef="c-114" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-530">2,189,228</ix:nonFraction> shares of common stock remained available for future awards. Pursuant to the evergreen provision, on January 1, 2025, an additional <ix:nonFraction unitRef="shares" contextRef="c-115" decimals="INF" name="exdx:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-531">705,613</ix:nonFraction> shares of common stock became available for issuance under the 2019 Plan.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Restricted Stock Units</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" id="f-532" continuedAt="f-532-1" escape="true"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">RSU activity under the Company's 2019 Plan is set forth below:</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-526-2" continuedAt="f-526-3"><ix:continuation id="f-532-1"><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.163%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.378%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Grant Date Fair Value Per Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Value</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding, December&#160;31, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-116" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-533">1,387,459</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-116" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-534">4.24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-116" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-535">2,761</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Awards granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-117" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-536">1,324,275</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-117" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-537">2.11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Awards released</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-117" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-538">413,202</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-117" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-539">4.87</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Awards canceled</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-117" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-540">588,159</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-117" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="f-541">4.11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding, December&#160;31, 2024</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-118" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-542">1,710,373</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-118" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-543">2.48</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-118" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-544">7,013</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December&#160;31, 2024, all of the outstanding RSUs are unvested. The fair value of RSUs vested in the years ended December&#160;31, 2024 and 2023 was $<ix:nonFraction unitRef="usd" contextRef="c-117" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" scale="6" id="f-545">0.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-119" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" format="ixt:num-dot-decimal" scale="6" id="f-546">0.6</ix:nonFraction>&#160;million, respectively. The weighted average grant date fair value per share for RSUs granted during the years ended December&#160;31, 2024 and 2023 was $<ix:nonFraction unitRef="usdPerShare" contextRef="c-117" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-547">2.11</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="c-119" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-548">2.39</ix:nonFraction>, respectively. As of December&#160;31, 2024, total unrecognized compensation cost related to RSUs was $<ix:nonFraction unitRef="usd" contextRef="c-118" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="f-549">3.4</ix:nonFraction> million, which is expected to be recognized over a remaining weighted-average vesting period of <ix:nonNumeric contextRef="c-117" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-550">2.8</ix:nonNumeric> years.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Stock Options</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="f-551" escape="true"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Stock option activity under the 2019 Plan is set forth below:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.367%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.888%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.918%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of<br/>Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise&#160;Price Per Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term&#160;(Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Value</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding, December 31, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-552">986,819</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-553">11.87</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-7" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-554">6.44</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="f-555">228</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="f-556">55,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="f-557">1.99</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-558">85,124</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="f-559">0.26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-560">9,623</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="f-561">16.70</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-562">458,276</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="f-563">16.46</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding, December&#160;31, 2024</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-564">489,296</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-565">8.39</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-566">6.53</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="f-567">370</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested and expected to vest, December&#160;31, 2024</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-568">489,296</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="f-569">8.39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-570">6.53</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" scale="3" id="f-571">370</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Options exercisable, December&#160;31, 2024</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="f-572">468,706</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" scale="0" id="f-573">8.65</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-574">6.42</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" scale="3" id="f-575">332</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The weighted-average grant date fair value per share of options granted during the years ended December&#160;31, 2024 and 2023 was $<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-576">1.44</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-577">2.17</ix:nonFraction>, respectively. The aggregate intrinsic value of options exercised during the years ended December&#160;31, 2024 and 2023 was $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="6" id="f-578">0.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="6" id="f-579">0.2</ix:nonFraction> million, respectively. The intrinsic value is calculated as the difference between the fair value of the Company's common stock and the exercise price of the stock options. The fair value of the Company's common stock was $<ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-580">4.10</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-581">1.99</ix:nonFraction> per share at December&#160;31, 2024 and 2023, respectively. As of December&#160;31, 2024, total unrecognized compensation cost related to option awards was negligible.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">2019 Employee Stock Purchase Plan</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In September 2019, the Board adopted, and the Company's stockholders approved, the ESPP. The ESPP became effective on the day the ESPP was adopted by the Board. The ESPP permits participants to purchase common stock through payroll deductions of up to <ix:nonFraction unitRef="number" contextRef="c-120" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" scale="-2" id="f-582">20</ix:nonFraction>% of their eligible compensation. The number of shares of common stock available for issuance under the ESPP will be annually increased on the first day of each calendar year during the term of the ESPP through January 1, 2029 in an amount equal to the lesser of (i) 1% of the outstanding capital stock on each December 31st, or (ii) such lesser amount determined by the Board. During the year ended December&#160;31, 2024, the Company issued <ix:nonFraction unitRef="shares" contextRef="c-121" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="f-583">96,048</ix:nonFraction> shares of common stock pursuant to scheduled purchases under the ESPP. As of December&#160;31, 2024, <ix:nonFraction unitRef="shares" contextRef="c-120" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-584">523,744</ix:nonFraction> shares of common stock remained available for issuance. Pursuant to the evergreen provision, on January 1, 2025, an additional <ix:nonFraction unitRef="shares" contextRef="c-122" decimals="INF" name="exdx:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-585">176,403</ix:nonFraction> shares became available for issuance under the ESPP.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Stock-based compensation expense related to the ESPP for each of the years ended December&#160;31, 2024 and 2023 was less than $<ix:nonFraction unitRef="usd" contextRef="c-123" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-586"><ix:nonFraction unitRef="usd" contextRef="c-121" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-587">0.1</ix:nonFraction></ix:nonFraction> million. As of December&#160;31, 2024, total unrecognized compensation cost related to stock purchase rights granted under the ESPP was less than $<ix:nonFraction unitRef="usd" contextRef="c-120" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" scale="6" id="f-588">0.1</ix:nonFraction> million, which is expected to be recognized over a remaining weighted-average vesting period of <ix:nonNumeric contextRef="c-121" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-589">0.2</ix:nonNumeric> years.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Stock-Based Compensation Expense</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-526-3"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="f-590" escape="true"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total non-cash stock-based compensation expense recorded related to options granted, RSUs granted and stock purchase rights granted under the ESPP in the statement of operations is as follows (in thousands):</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.075%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-124" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-591">159</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-125" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-592">191</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-593">1,374</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-127" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-594">3,174</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-128" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-595">230</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-129" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-596">252</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-597">1,763</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-598">3,617</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" id="f-599" escape="true"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Common stock reserved for future issuance consists of the following at December&#160;31, 2024:</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:77.408%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.784%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Warrants to purchase common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-130" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-600">1,130,281</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock option grants issued and outstanding</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-131" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-601">489,296</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock reserved for issuance upon vesting of outstanding restricted stock units</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-118" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-602">1,710,373</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock available for grant under the 2019 Plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-114" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-603">2,189,228</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock available for future issuance under ESPP</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-120" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-604">523,744</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-605">6,042,922</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div id="i9ecffbbbc3a143a09815a7575cabd836_163"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Note 10. <ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxDisclosureTextBlock" id="f-606" continuedAt="f-606-1" escape="true">Income Taxes</ix:nonNumeric></span></div><ix:continuation id="f-606-1" continuedAt="f-606-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="f-607" escape="true"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The provision for income taxes consists of the following (in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.545%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-608">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-609">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="f-610">12</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="f-611">33</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" id="f-612">12</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" id="f-613">33</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-614">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-615">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-616">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-617">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total deferred</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-618">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-619">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-620">12</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-621">33</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="f-622" escape="true"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The effective tax rate of our provision for income taxes differs from the federal statutory rate as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.660%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Federal statutory tax rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="f-623">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-7" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="f-624">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State income taxes, net of federal tax benefits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="f-625">2.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-7" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="f-626">2.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development tax credits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" id="f-627">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-7" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" id="f-628">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" id="f-629">5.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-7" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" id="f-630">3.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-deductible expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" scale="-2" id="f-631">2.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-7" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" scale="-2" id="f-632">1.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="f-633">15.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-7" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="f-634">18.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" format="ixt:fixed-zero" scale="-2" id="f-635">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-7" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" scale="-2" id="f-636">0.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-637">0.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-7" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-638">0.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Significant components of the Company&#8217;s deferred tax assets at December&#160;31, 2024 and 2023 are shown below (in thousands). A valuation allowance has been established as realization of the Company&#8217;s deferred tax assets has not met the more likely-than-not threshold requirement. <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="f-639" continuedAt="f-639-1" escape="true">If the Company&#8217;s judgment changes and it is determined </ix:nonNumeric></span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-606-2" continuedAt="f-606-3"><ix:continuation id="f-639-1"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">that the Company will be able to realize these deferred tax assets, the tax benefits relating to any reversal of the valuation allowance on deferred tax assets will be accounted for as a reduction to income tax expense (in thousands).</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.545%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-640">35,348</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-641">32,479</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development tax credits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" format="ixt:num-dot-decimal" scale="3" id="f-642">2,360</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" format="ixt:num-dot-decimal" scale="3" id="f-643">2,353</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accruals, reserves and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves" scale="3" id="f-644">955</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves" format="ixt:num-dot-decimal" scale="3" id="f-645">1,119</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" format="ixt:num-dot-decimal" scale="3" id="f-646">2,785</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" format="ixt:num-dot-decimal" scale="3" id="f-647">2,547</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Indefinite lived assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" scale="3" id="f-648">276</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" scale="3" id="f-649">300</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="3" id="f-650">598</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="f-651">1,391</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Lease liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="exdx:DeferredTaxAssetsLeaseLiability" scale="3" id="f-652">681</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="exdx:DeferredTaxAssetsLeaseLiability" scale="3" id="f-653">925</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Capitalization of research and experimentation costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="exdx:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCapitalizationOfResearchAndExperimentationCosts" format="ixt:num-dot-decimal" scale="3" id="f-654">2,942</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="exdx:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCapitalizationOfResearchAndExperimentationCosts" format="ixt:num-dot-decimal" scale="3" id="f-655">2,929</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total gross deferred tax assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-656">45,945</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-657">44,043</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: valuation allowance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-658">45,237</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-659">42,942</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred tax assets, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" scale="3" id="f-660">708</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-661">1,101</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Right of use assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="exdx:DeferredTaxLiabilitiesRightOfUseAssets" scale="3" id="f-662">592</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="exdx:DeferredTaxLiabilitiesRightOfUseAssets" scale="3" id="f-663">814</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Basis differences in fixed and intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="exdx:DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets" scale="3" id="f-664">116</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="exdx:DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets" scale="3" id="f-665">287</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" scale="3" id="f-666">708</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-667">1,101</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:fixed-zero" scale="3" id="f-668">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:fixed-zero" scale="3" id="f-669">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:SummaryOfValuationAllowanceTextBlock" id="f-670" escape="true"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Changes in the valuation allowance for deferred tax assets during the years ended December&#160;31, 2024 and 2023, which related primarily to increases in net operating loss (NOL) carryforwards, research and development tax credits, and capitalization of research and experimentation costs were as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.545%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Valuation allowance at the beginning of the year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-671">42,942</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-672">38,567</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Increases recorded to income tax provision</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" format="ixt:num-dot-decimal" scale="3" id="f-673">2,295</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" format="ixt:num-dot-decimal" scale="3" id="f-674">4,375</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Valuation allowance at the end of the year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-675">45,237</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-676">42,942</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">At December&#160;31, 2024 and 2023, the Company had federal NOL carryforwards of approximately $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic" scale="6" id="f-677">141.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic" scale="6" id="f-678">129.8</ix:nonFraction> million, respectively. At December&#160;31, 2024 and 2023, the Company had state NOL carryforwards of $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" scale="6" id="f-679">98.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" scale="6" id="f-680">91.0</ix:nonFraction> million, respectively. Approximately $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" scale="6" id="f-681">43.5</ix:nonFraction> million of the federal tax loss carryforwards will begin to expire in 2025, unless previously utilized. The federal NOL carryforwards generated after December 31, 2017 of $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" scale="6" id="f-682">98.0</ix:nonFraction> million will carryforward indefinitely. The Company&#8217;s state tax loss carryforwards will begin to expire in 2030, unless previously utilized.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">At December&#160;31, 2024, the Company's deferred tax assets are primarily comprised of federal and state tax NOL carryforwards. The Company completed a formal study through the year ended December 31, 2019 and determined ownership changes within the meaning of Internal Revenue Code (IRC), Section 382 had occurred in 2003, 2008, 2012, 2017 and 2019. Based on the analysis, $<ix:nonFraction unitRef="usd" contextRef="c-132" decimals="-5" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" scale="6" id="f-683">58.4</ix:nonFraction> million of the Company's tax attribute carryforwards through December 31, 2017 cannot be utilized under IRC Section 382. The Company's ability to utilize NOL carryforwards generated after December 31, 2017 will not expire under the Tax Cuts and Jobs Act of 2017. The Company adjusted tax attribute carry forwards and deferred tax assets accordingly. As the deferred tax assets associated with the tax attribute carry forwards were fully offset by a valuation allowance, a corresponding reduction in the Company's valuation allowance was also recorded, resulting in no income tax impact.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-606-3"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company is subject to taxation in the United States and in various state jurisdictions. The Company&#8217;s tax years for 2004 and forward are subject to examination by the U.S. and state tax authorities due to the carryforward of unutilized NOLs and research and development credits. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company recognizes interest and/or penalties related to income tax matters in its provision for income taxes. The Company does not have any material accruals for, and did not recognize any, material interest or penalties in these financial statements in any period presented. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Uncertain Tax Positions </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">At December&#160;31, 2024 and 2023, the Company had <ix:nonFraction unitRef="usd" contextRef="c-6" decimals="INF" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:fixed-zero" scale="0" id="f-684"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="INF" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:fixed-zero" scale="0" id="f-685">no</ix:nonFraction></ix:nonFraction> unrecognized tax benefits. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company does not believe that the balance of unrecognized tax benefits will materially change within the next twelve months.</span></div></ix:continuation><div id="i9ecffbbbc3a143a09815a7575cabd836_166"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Note 11. <ix:nonNumeric contextRef="c-1" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="f-686" continuedAt="f-686-1" escape="true">401(k) Plan</ix:nonNumeric></span></div><ix:continuation id="f-686-1"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company sponsors an employee savings plan that qualifies as a deferred salary arrangement under Section 401(k) of the Code. Participating employees may defer up to the Internal Revenue Service annual contribution limit. Additionally, the Company may elect to make contributions into the savings plan at its sole discretion. For each of the years ended December&#160;31, 2024 and 2023, the Company made contributions to the 401(k) Plan at <ix:nonFraction unitRef="number" contextRef="c-1" decimals="2" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" scale="-2" id="f-687"><ix:nonFraction unitRef="number" contextRef="c-7" decimals="2" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" scale="-2" id="f-688">4</ix:nonFraction></ix:nonFraction>% of qualified employee compensation. For each of the years ended December&#160;31, 2024 and 2023, these contributions totaled approximately $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:DefinedContributionPlanCostRecognized" scale="6" id="f-689"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:DefinedContributionPlanCostRecognized" scale="6" id="f-690">0.8</ix:nonFraction></ix:nonFraction> million.</span></div></ix:continuation><div id="i9ecffbbbc3a143a09815a7575cabd836_736"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Note 12. <ix:nonNumeric contextRef="c-1" name="us-gaap:SegmentReportingDisclosureTextBlock" id="f-691" continuedAt="f-691-1" escape="true">Segment Reporting</ix:nonNumeric></span></div><ix:continuation id="f-691-1" continuedAt="f-691-2"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the CODM in making decisions regarding resource allocation and assessing performance. The Company operates in a single operating segment focused on the design, development and commercialization of testing products which allow for the differential diagnosis, prognosis and monitoring of complex rheumatic, autoimmune and autoimmune-related disease. Segment revenue is primarily derived from the sale of the Company&#8217;s testing products, most of which is attributable to its AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD test.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company&#8217;s CODM is its Chief Executive Officer. The CODM assesses performance for the segment and decides how to allocate resources based on revenue and net loss as reported on the Statement of Operations, after taking into account the Company&#8217;s strategic priorities, its cash balance and its expected use of cash. The CODM considers budget/forecast versus actual results on a quarterly basis when making decisions about the allocation of resources. The measure of segment assets is reported on the balance sheet as total assets and were $<ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-5" name="us-gaap:Assets" scale="6" id="f-692">44.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-134" decimals="-5" name="us-gaap:Assets" scale="6" id="f-693">56.9</ix:nonFraction> million for the years ended December&#160;31, 2024 and 2023, respectively. </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" id="f-694" continuedAt="f-694-1" escape="true"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Segment revenue and net loss, including significant segment expenses regularly provided to the CODM are as follows (in thousands):</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-694-1"><ix:continuation id="f-691-2"><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.876%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.184%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="12" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-135" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-695">55,641</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-136" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-696">52,548</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Costs of revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-135" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="f-697">22,529</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-136" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="f-698">23,092</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross margin</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-135" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="f-699">33,112</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-136" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="f-700">29,456</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Segment operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-135" decimals="-3" name="us-gaap:LaborAndRelatedExpense" format="ixt:num-dot-decimal" scale="3" id="f-701">27,753</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-136" decimals="-3" name="us-gaap:LaborAndRelatedExpense" format="ixt:num-dot-decimal" scale="3" id="f-702">27,070</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outside services</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-135" decimals="-3" name="exdx:OutsideServicesExpense" format="ixt:num-dot-decimal" scale="3" id="f-703">4,253</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-136" decimals="-3" name="exdx:OutsideServicesExpense" format="ixt:num-dot-decimal" scale="3" id="f-704">5,920</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Facilities related</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-135" decimals="-3" name="us-gaap:OccupancyNet" format="ixt:num-dot-decimal" scale="3" id="f-705">3,674</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-136" decimals="-3" name="us-gaap:OccupancyNet" format="ixt:num-dot-decimal" scale="3" id="f-706">5,125</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Travel &amp; entertainment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-135" decimals="-3" name="us-gaap:TravelAndEntertainmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-707">2,440</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-136" decimals="-3" name="us-gaap:TravelAndEntertainmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-708">2,469</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-135" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-709">1,604</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-136" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-710">3,426</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-135" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-711">1,041</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-136" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-712">1,426</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">1</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-135" decimals="-3" name="us-gaap:SegmentReportingOtherItemAmount" format="ixt:num-dot-decimal" scale="3" id="f-713">5,983</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-136" decimals="-3" name="us-gaap:SegmentReportingOtherItemAmount" format="ixt:num-dot-decimal" scale="3" id="f-714">6,857</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total segment operating expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-135" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-715">46,748</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-136" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-716">52,293</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-135" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-717">13,636</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-136" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-718">22,837</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-135" decimals="-3" name="us-gaap:InterestExpenseNonoperating" format="ixt:num-dot-decimal" scale="3" id="f-719">2,234</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-136" decimals="-3" name="us-gaap:InterestExpenseNonoperating" format="ixt:num-dot-decimal" scale="3" id="f-720">2,335</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-135" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="f-721">767</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-136" decimals="-3" name="us-gaap:InvestmentIncomeInterest" format="ixt:num-dot-decimal" scale="3" id="f-722">1,516</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-135" decimals="-3" sign="-" name="us-gaap:IncomeLossAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-723">15,103</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-136" decimals="-3" sign="-" name="us-gaap:IncomeLossAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-724">23,656</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-135" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-725">12</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-136" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-726">33</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Segment net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-135" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-727">15,115</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-136" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-728">23,689</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"> Other segment items included in Segment net loss include insurance expenses, trade show and conference expenses, fulfillment expenses, board compensation, clinical trial expenses, collaboration expenses and bank fees, among others.</span></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-25</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-19
<SEQUENCE>2
<FILENAME>exagen-boardbookxtab18xins.htm
<DESCRIPTION>EX-19
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i34d779e96d03453f958ed7fff2a8bca0_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">EXAGEN INC.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">AMENDED AND RESTATED INSIDER TRADING COMPLIANCE POLICY</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This Insider Trading Compliance Policy (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Policy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) consists of seven sections&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.8pt">Section I provides an overview&#59; </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.8pt">Section II sets forth the policies of Exagen Inc. prohibiting insider trading&#59; </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.8pt">Section III explains insider trading&#59; </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.8pt">Section IV consists of procedures that have been put in place by Exagen Inc. to prevent insider trading&#59; </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.8pt">Section V sets forth additional transactions that are prohibited by this Policy&#59; </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.8pt">Section VI explains Rule 10b5-1 trading plans and provides information about Section 16 and Rule 144&#59; and</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.8pt">Section VII refers to the execution and return of a certificate of compliance.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">I.   </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:20.01pt">SUMMARY</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Preventing insider trading is necessary to comply with securities laws and to preserve the reputation and integrity of Exagen Inc. (together with its subsidiaries, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) as well as that of all persons affiliated with the Company.  &#8220;Insider trading&#8221; occurs when any person purchases or sells a security while in possession of inside information relating to the security.  As explained in Section III below, &#8220;inside information&#8221; is information that is both &#8220;material&#8221; and &#8220;non-public.&#8221;  Insider trading is a crime.  The penalties for violating insider trading laws include imprisonment, disgorgement of profits, civil fines, and criminal fines of up to $5 million for individuals and $25 million for corporations.  Insider trading is also prohibited by this Policy, and violation of this Policy may result in Company-imposed sanctions, including removal or dismissal for cause.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This Policy applies to all officers, directors, employees of the Company, and certain consultants specified by management (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">specified consultants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  Individuals subject to this Policy are responsible for ensuring that members of their households also comply with this Policy.  This Policy also applies to any entities controlled by individuals subject to the Policy, including any corporations, partnerships or trusts, and transactions by these entities should be treated for the purposes of this Policy and applicable securities laws as if they were for the individual&#8217;s own account. This Policy extends to all activities within and outside an individual&#8217;s Company duties.  Every officer, director, employee and specified consultant must review this Policy.  Questions regarding the Policy should be directed to the Company&#8217;s Chief Financial Officer.</font></div><div style="height:76.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#124;US-DOCS&#92;109678706.2&#124;&#124;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">II.   </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.02pt">STATEMENT OF POLICIES PROHIBITING INSIDER TRADING</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">No officer, director or employee shall purchase or sell any type of security while in possession of material, non-public information relating to the security, whether the issuer of such security is the Company or any other company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Additionally, no officer, director, employee or specified consultant listed on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule I</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (as amended from time to time) shall purchase or sell any security of the Company during the period beginning on the 14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> calendar day before the end of any fiscal quarter of the Company and ending upon the completion of the second full trading day after the public release of earnings data for such fiscal quarter or during any other trading suspension period declared by the Company.  For the purposes of this Policy, a &#8220;trading day&#8221; is a day on which national stock exchanges are open for trading.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">These prohibitions do not apply to&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">purchases of the Company&#8217;s securities from the Company or sales of the Company&#8217;s securities to the Company&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">exercises of stock options or other equity awards or the surrender of shares to the Company in payment of the exercise price or in satisfaction of any tax withholding obligations in a manner permitted by the applicable equity award agreement, or vesting of equity-based awards, that in each case do not involve a market sale of the Company&#8217;s securities (the &#8220;cashless exercise&#8221; of a Company stock option through a broker </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">does</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> involve a market sale of the Company&#8217;s securities, and therefore would not qualify under this exception)&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">periodic contributions to, or the acquisition of Company securities under an &#8220;employee stock purchase plan&#8221; (within the meaning of the Internal Revenue Code of 1986) maintained by the Company (&#8220;ESPP&#8221;), in each case, pursuant to the terms and conditions of the applicable plan or the employees&#8217; advance instructions&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.8pt">bona fide</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> gifts of the Company&#8217;s securities&#59; or</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">purchases or sales of the Company&#8217;s securities made pursuant to any binding contract, specific instruction or written plan entered into outside of a black-out period and while the purchaser or seller, as applicable, was unaware of any material, non-public information and which contract, instruction or plan (i) meets all of the requirements of the affirmative defense provided by Rule 10b5-1 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Rule 10b5-1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) promulgated under the Securities Exchange Act of 1934, as amended (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">1934 Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), (ii) was pre-cleared in advance pursuant to this Policy and (iii) has not been amended or modified in any respect after such initial pre-clearance without such amendment or modification being pre-cleared in advance pursuant to this Policy.  For more information about Rule 10b5-1 trading plans, see Section VI below.</font></div><div style="height:76.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#124;US-DOCS&#92;109678706.2&#124;&#124;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">No officer, director, employee or specified consultant shall directly or indirectly communicate (or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">tip</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) material, non-public information to anyone outside of the Company (except in accordance with the Company&#8217;s policies regarding the protection or authorized external disclosure of Company information) or to anyone within the Company other than on a need-to-know basis.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">III.   </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12.03pt">EXPLANATION OF INSIDER TRADING</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Insider trading</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> refers to the purchase or sale of a security while in possession of &#8220;material,&#8221; &#8220;non-public&#8221; information relating to the security or its issuer.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Securities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> includes stocks, bonds, notes, debentures, options, warrants and other convertible securities, as well as derivative instruments.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Purchase</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">sale</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> are defined broadly under the federal securities law.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Purchase</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> includes not only the actual purchase of a security, but any contract to purchase or otherwise acquire a security.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Sale</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> includes not only the actual sale of a security, but any contract to sell or otherwise dispose of a security.  These definitions extend to a broad range of transactions, including conventional cash-for-stock transactions, conversions, the exercise of stock options, and acquisitions and exercises of warrants or puts, calls or other derivative securities.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">It is generally understood that insider trading includes the following&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.8pt">trading by insiders while in possession of material, non-public information&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.8pt">trading by persons other than insiders while in possession of material, non-public information, if the information either was given in breach of an insider&#8217;s fiduciary duty to keep it confidential or was misappropriated&#59; and</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.8pt">communicating or tipping material, non-public information to others, including recommending the purchase or sale of a security while in possession of such information.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">What Facts are Material&#63;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The materiality of a fact depends upon the circumstances.  A fact is considered &#8220;material&#8221; if there is a substantial likelihood that a reasonable investor would consider it important in making a decision to buy, sell or hold a security, or if the fact is likely to have a significant effect on the market price of the security.  Material information can be positive or negative and can relate to virtually any aspect of a company&#8217;s business or to any type of security, debt or equity.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Examples of material information include (but are not limited to) information about&#58; information concerning product developments or technological developments, the results of clinical trials or clinical studies&#59; communications sent to or received from the U.S. Food and Drug Administration or foreign regulatory agencies&#59; dividends&#59; corporate earnings or earnings forecasts&#59; possible mergers, acquisitions, tender offers or dispositions&#59; major new products, product developments or geographies&#59; important business developments such as trial results, </font></div><div style="height:76.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#124;US-DOCS&#92;109678706.2&#124;&#124;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">developments regarding strategic collaborators or the status of regulatory submissions&#59; management or control changes&#59; significant borrowing or financing developments including pending public sales or offerings of debt or equity securities&#59; defaults on borrowings&#59; bankruptcies&#59; and significant litigation or regulatory actions.  Moreover, material information does not have to be related to a company&#8217;s business.  For example, the contents of a forthcoming newspaper column that is expected to affect the market price of a security can be material.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A good general rule of thumb&#58;  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">When in doubt, do not trade.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">What is Non-Public&#63;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Information is &#8220;non-public&#8221; if it is not available to the general public.  In order for information to be considered public, it must be widely disseminated in a manner making it generally available to investors through such media as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Dow Jones</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Business Wire</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Reuters</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">The Wall Street Journal</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Associated Press</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">United Press International</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, a broadcast on widely available radio or television programs, publication in a widely available newspaper, magazine or news web site, a Regulation FD-compliant conference call, or public disclosure documents filed with the Securities and Exchange Commission (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">SEC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) that are available on the SEC&#8217;s web site.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The circulation of rumors, even if accurate and reported in the media, does not constitute effective public dissemination.  In addition, even after a public announcement, a reasonable period of time must lapse in order for the market to react to the information.  </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Who is an Insider&#63;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;Insiders&#8221; include officers, directors, employees and certain consultants of a company and anyone else who has material inside information about a company.  Insiders have independent fiduciary duties to their company and its stockholders not to trade on material, non-public information relating to the company&#8217;s securities.  All officers, directors, employees and certain consultants of the Company should consider themselves insiders with respect to material, non-public information about the Company&#8217;s business, activities and securities.  Officers, directors, employees and certain consultants may not trade in the Company&#8217;s securities while in possession of material, non-public information relating to the Company, nor may they tip such information to anyone outside the Company (except in accordance with the Company&#8217;s policies regarding the protection or authorized external disclosure of Company information) or to anyone within the Company other than on a need-to-know basis.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Individuals subject to this Policy are responsible for ensuring that members of their households also comply with this Policy.  This Policy also applies to any entities controlled by individuals subject to the Policy, including any corporations, partnerships or trusts, and transactions by these entities should be treated for the purposes of this Policy and applicable securities laws as if they were for the individual&#8217;s own account.</font></div><div style="height:76.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#124;US-DOCS&#92;109678706.2&#124;&#124;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Trading by Persons Other than Insiders</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Insiders may be liable for communicating or tipping material, non-public information to a third party (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">tippee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), and insider trading violations are not limited to trading or tipping by insiders.  Persons other than insiders also can be liable for insider trading, including tippees who trade on material, non-public information tipped to them or individuals who trade on material, non-public information that has been misappropriated.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Tippees inherit an insider&#8217;s duties and are liable for trading on material, non-public information illegally tipped to them by an insider.  Similarly, just as insiders are liable for the insider trading of their tippees, so are tippees who pass the information along to others who trade.  In other words, a tippee&#8217;s liability for insider trading is no different from that of an insider.  Tippees can obtain material, non-public information by receiving overt tips from others or through, among other things, conversations at social, business, or other gatherings.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Penalties for Engaging in Insider Trading</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Penalties for trading on or tipping material, non-public information can extend significantly beyond any profits made or losses avoided, both for individuals engaging in such unlawful conduct and their employers.  The SEC and Department of Justice have made the civil and criminal prosecution of insider trading violations a top priority.  Enforcement remedies available to the government or private plaintiffs under the federal securities laws include&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.8pt">SEC administrative sanctions&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.8pt">securities industry self-regulatory organization sanctions&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.8pt">civil injunctions&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.8pt">damage awards to private plaintiffs&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.8pt">disgorgement of all profits&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.8pt">civil fines for the violator of up to three times the amount of profit gained or loss avoided&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.8pt">civil fines for the employer or other controlling person of a violator (i.e., where the violator is an employee or other controlled person) of up to the greater of $1,425,000 or three times the amount of profit gained or loss avoided by the violator&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.8pt">criminal fines for individual violators of up to $5,000,000 ($25,000,000 for an entity)&#59; and</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.8pt">jail sentences of up to 20 years.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In addition, insider trading could result in serious sanctions by the Company, including dismissal.  Insider trading violations are not limited to violations of the federal securities laws.  Other federal and state civil or criminal laws, such as the laws prohibiting mail and wire fraud </font></div><div style="height:76.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#124;US-DOCS&#92;109678706.2&#124;&#124;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">and the Racketeer Influenced and Corrupt Organizations Act (RICO), also may be violated in connection with insider trading.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Size of Transaction and Reason for Transaction Do Not Matter</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The size of the transaction or the amount of profit received does not have to be significant to result in prosecution.  The SEC has the ability to monitor even the smallest trades, and the SEC performs routine market surveillance.  Brokers and dealers are required by law to inform the SEC of any possible violations by people who may have material, non-public information.  The SEC aggressively investigates even small insider trading violations.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Examples of Insider Trading</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Examples of insider trading cases include actions brought against corporate officers, directors, employees and consultants who traded in a company&#8217;s securities after learning of significant confidential corporate developments&#59; friends, business associates, family members and other tippees of such officers, directors, employees and consultants who traded in the securities after receiving such information&#59; government employees who learned of such information in the course of their employment&#59; and other persons who misappropriated, and took advantage of, confidential information from their employers.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The following are illustrations of insider trading violations.  These illustrations are hypothetical and, consequently, not intended to reflect on the actual activities or business of the Company or any other entity.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Trading by Insider</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">An officer of X Corporation learns that earnings to be reported by X Corporation will increase dramatically.  Prior to the public announcement of such earnings, the officer purchases X Corporation&#8217;s stock.  The officer, an insider, is liable for all profits as well as penalties of up to three times the amount of all profits.  The officer also is subject to, among other things, criminal prosecution, including up to $5,000,000 in additional fines and 20 years in jail.  Depending upon the circumstances, X Corporation and the individual to whom the officer reports also could be liable as controlling persons.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Trading by Tippee</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">An officer of X Corporation tells a friend that X Corporation is about to publicly announce that it has concluded an agreement for a major acquisition.  This tip causes the friend to purchase X Corporation&#8217;s stock in advance of the announcement.  The officer is jointly liable with his friend for all of the friend&#8217;s profits, and each is liable for all civil penalties of up to three times the amount of the friend&#8217;s profits.  The officer and his friend are also subject to criminal prosecution and other remedies and sanctions, as described above.</font></div><div style="height:76.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#124;US-DOCS&#92;109678706.2&#124;&#124;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Prohibition of Records Falsification and False Statements</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 13(b)(2) of the 1934 Act requires companies subject to the Act to maintain proper internal books and records and to devise and maintain an adequate system of internal accounting controls.  The SEC has supplemented the statutory requirements by adopting rules that prohibit (1) any person from falsifying records or accounts subject to the above requirements and (2) officers or directors from making any materially false, misleading, or incomplete statement to any accountant in connection with any audit or filing with the SEC.  These provisions reflect the SEC&#8217;s intent to discourage officers, directors and other persons with access to the Company&#8217;s books and records from taking action that might result in the communication of materially misleading financial information to the investing public.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">IV.   </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:11.35pt">STATEMENT OF PROCEDURES PREVENTING INSIDER TRADING</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The following procedures have been established, and will be maintained and enforced, by the Company to prevent insider trading.  Every officer, director and employee is required to follow these procedures.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Pre-Clearance of All Trades by All Officers, Directors and Employees</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">To provide assistance in preventing inadvertent violations of applicable securities laws and to avoid the appearance of impropriety in connection with the purchase and sale of the Company&#8217;s securities, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">all transactions in the Company&#8217;s securities (including without limitation, acquisitions and dispositions of Company stock, the exercise of stock options and the sale of Company stock issued upon exercise of stock options) by officers, directors and such other employees and specified consultants as are designated from time to time by the Board of Directors, the Chief Executive Officer or the Chief Financial Officer as being subject to this pre-clearance process and as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Schedule I</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> (as amended from time to time) (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Pre-Clearance Person</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8221;) must be pre-cleared</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> by the Company&#8217;s Chief Financial Officer.  Pre-clearance does not relieve anyone of his or her responsibility under SEC rules.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A request for pre-clearance may be oral or in writing (including without limitation by e-mail), should be made at least two business days in advance of the proposed transaction and should include the identity of the Pre-Clearance Person, the type of proposed transaction (for example, an open market purchase, a privately negotiated sale, an option exercise, etc.), the proposed date of the transaction and the number of shares or other securities to be involved.  In addition, the Pre-Clearance Person must execute a certification (in the form approved by the Chief Financial Officer) that he, she or it is not aware of material, nonpublic information about the Company.  The Chief Financial Officer shall have sole discretion to decide whether to clear any contemplated transaction (or the Chief Executive Officer shall have sole discretion to decide whether to clear transactions by the Chief Financial Officer).  All trades that are pre-cleared must be effected within five business days of receipt of the pre-clearance unless a specific exception has been granted by the Chief Financial Officer (or the Chief Executive Officer in the case of the Chief Financial Officer).  A pre-cleared trade (or any portion of a pre-cleared trade) that has not been effected during the five business day period must be pre-cleared again prior to execution.  Notwithstanding receipt of pre-clearance, if the Pre-Clearance Person becomes aware of </font></div><div style="height:76.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">7</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#124;US-DOCS&#92;109678706.2&#124;&#124;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">material, non-public information or becomes subject to a black-out period before the transaction is effected, the transaction may not be completed. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Black-Out Periods</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Additionally, no officer, director, employee or specified consultant listed on Schedule I (as amended from time to time) shall purchase or sell any security of the Company during the period beginning on the 14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:700;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> calendar day before the end of any fiscal quarter of the Company and ending upon the completion of the second full trading day after the public release of earnings data for such fiscal quarter or during any other trading suspension period declared by the Company,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> except for purchases and sales made pursuant to the permitted transactions described in Section II.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">From time to time, the Company, through the Board of Directors, the Company&#8217;s disclosure committee or the Chief Financial Officer may recommend that officers, directors, employees, specified consultants or others suspend trading in the Company&#8217;s securities because of developments that have not yet been disclosed to the public.  Subject to the permitted transactions described in Section II above, all of those affected should not trade in the Company&#8217;s securities while the suspension is in effect, and should not disclose to others that the Company has suspended trading.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Exceptions to the black-out period policy may be approved only by the Chief Financial Officer (or, in the case of an exception for the Chief Financial Officer, the Chief Executive Officer).</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Post-Termination Transactions</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">With the exception of the pre-clearance requirement, this Policy continues to apply to transactions in the Company&#8217;s securities even after termination of service to the Company.  If an individual is in possession of material, non-public information when his or her service terminates, that individual may not trade in the Company&#8217;s securities until that information has become public or is no longer material.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Information Relating to the Company</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.    </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">Access to Information</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Access to material, non-public information about the Company, including the Company&#8217;s business, earnings or prospects, should be limited to officers, directors and employees of the Company on a need-to-know basis.  In addition, such information should not be communicated to anyone outside the Company under any circumstances (except in accordance with the Company&#8217;s policies regarding the protection or authorized external disclosure of Company information) or to anyone within the Company on an other than need-to-know basis.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In communicating material, non-public information to employees of the Company, all officers, directors and employees must take care to emphasize the need for confidential treatment </font></div><div style="height:76.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#124;US-DOCS&#92;109678706.2&#124;&#124;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">of such information and adherence to the Company&#8217;s policies with regard to confidential information.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.    </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">Inquiries From Third Parties</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Inquiries from third parties, such as industry analysts or members of the media, about the Company should be directed to the Chief Financial Officer.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Limitations on Access to Company Information</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The following procedures are designed to maintain confidentiality with respect to the Company&#8217;s business operations and activities.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">All officers, directors, employees and consultants should take all steps and precautions necessary to restrict access to, and secure, material, non-public information by, among other things&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.8pt">maintaining the confidentiality of Company-related transactions&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.8pt">conducting their business and social activities so as not to risk inadvertent disclosure of confidential information.  Review of confidential documents in public places should be conducted so as to prevent access by unauthorized persons&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.8pt">restricting access to documents and files (including computer files) containing material, non-public information to individuals on a need-to-know basis (including maintaining control over the distribution of documents and drafts of documents)&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.8pt">promptly removing and cleaning up all confidential documents and other materials from conference rooms following the conclusion of any meetings (including erasing any whiteboards or other viewable information)&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.8pt">disposing of all confidential documents and other papers, after there is no longer any business or other legally required need, through shredders when appropriate&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.8pt">restricting access to areas likely to contain confidential documents or material, non-public information&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.8pt">safeguarding laptop computers, mobile devices, tablets, memory sticks, CDs and other items that contain confidential information&#59; and</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.8pt">avoiding the discussion of material, non-public information in places where the information could be overheard by others such as in elevators, restrooms, hallways, restaurants, airplanes or taxicabs.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Personnel involved with material, non-public information, to the extent feasible, should conduct their business and activities in areas separate from other Company activities.</font></div><div style="height:76.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">9</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#124;US-DOCS&#92;109678706.2&#124;&#124;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">V.   </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15.34pt">ADDITIONAL PROHIBITED TRANSACTIONS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Company has determined that there is a heightened legal risk and&#47;or the appearance of improper or inappropriate conduct if the persons subject to this Policy engage in certain types of transactions.  Therefore, officers, directors, employees and specified consultants shall comply with the following policies with respect to certain transactions in the Company securities&#58;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Short Sales</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Short sales of the Company&#8217;s securities evidence an expectation on the part of the seller that the securities will decline in value, and therefore signal to the market that the seller has no confidence in the Company or its short-term prospects.  In addition, short sales may reduce the seller&#8217;s incentive to improve the Company&#8217;s performance.  For these reasons, short sales of the Company&#8217;s securities are prohibited by this Policy.  In addition, as noted below, Section 16(c) of the 1934 Act absolutely prohibits Section 16 reporting persons from making short sales of the Company&#8217;s equity securities, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">i.e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, sales of shares that the insider does not own at the time of sale, or sales of shares against which the insider does not deliver the shares within 20 days after the sale.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Publicly Traded Options</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A transaction in options is, in effect, a bet on the short-term movement of the Company&#8217;s stock and therefore creates the appearance that an officer, director, employee or consultant is trading based on inside information.  Transactions in options also may focus an officer&#8217;s, director&#8217;s, employee&#8217;s or consultant&#8217;s attention on short-term performance at the expense of the Company&#8217;s long-term objectives.  Accordingly, transactions in puts, calls or other derivative securities involving the Company&#8217;s equity securities, on an exchange or in any other organized market, are prohibited by this Policy.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Hedging Transactions</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Certain forms of hedging or monetization transactions, such as zero-cost collars and forward sale contracts, allow an officer, director, employee or consultant to lock in much of the value of his or her stock holdings, often in exchange for all or part of the potential for upside appreciation in the stock.  These transactions allow the officer, director, employee or consultant to continue to own the covered securities, but without the full risks and rewards of ownership.  When that occurs, the officer, director, employee or consultant may no longer have the same objectives as the Company&#8217;s other stockholders.  Therefore, all hedging transactions involving the Company&#8217;s equity securities are prohibited by this Policy.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Purchases of the Company&#8217;s Securities on Margin&#59; Pledging the Company&#8217;s Securities to Secure Margin or Other Loans</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Purchasing on margin means borrowing from a brokerage firm, bank or other entity in order to purchase the Company&#8217;s securities (other than in connection with a cashless exercise of stock options under the Company&#8217;s equity plans).  Margin purchases of the Company&#8217;s securities </font></div><div style="height:76.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">10</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#124;US-DOCS&#92;109678706.2&#124;&#124;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">are prohibited by this Policy.  Pledging the Company&#8217;s securities as collateral to secure loans is also prohibited.  This prohibition means, among other things, that you cannot hold the Company&#8217;s securities in a &#8220;margin account&#8221; (which would allow you to borrow against your holdings to buy securities).</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Director and Executive Officer Cashless Exercises</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Company will not arrange with brokers to administer cashless exercises on behalf of directors and executive officers of the Company.  Directors and executive officers of the Company may use the cashless exercise feature of their equity awards only if (i) the director or officer retains a broker independently of the Company, (ii) the Company&#8217;s involvement is limited to confirming that it will deliver the stock promptly upon payment of the exercise price, (iii) the director or officer uses a &#8220;T+2&#8221; cashless exercise arrangement, in which the Company agrees to deliver stock against the payment of the purchase price on the same day the sale of the stock underlying the equity award settles and (iv) the director or officer otherwise complies with this Policy.  Under a T+2 cashless exercise, a broker, the issuer, and the issuer&#8217;s transfer agent work together to make all transactions settle simultaneously.  This approach is to avoid any inference that the Company has &#8220;extended credit&#8221; in the form of a personal loan to the director or executive officer.  Questions about cashless exercises should be directed to the Chief Financial Officer.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Partnership Distributions</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Nothing in this Policy is intended to limit the ability of a venture capital partnership or other similar entity with which a director is affiliated to distribute Company securities to its partners, members or other similar persons.  It is the responsibility of each affected director and the affiliated entity, in consultation with their own counsel (as appropriate), to determine the timing of any distributions, based on all relevant facts and circumstances and applicable securities laws.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Employee Stock Purchase Plan</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The trading prohibitions and restrictions set forth in this Policy do not apply to periodic contributions to, or the acquisition of Company securities under an ESPP, in each case, pursuant to the terms and conditions of the applicable plan or the employees&#8217; advance instructions. However, no insider may initiate or alter his or her instructions regarding the purchase or sale of Company securities in the ESPP&#58; (i) while aware of material nonpublic information&#59; and (ii) in the case of Pre-Clearance Persons, (a) prior to being precleared by the Chief Financial Officer and (b) while any applicable trading window is closed or special blackout period applicable to such person is in effect (provided, however, that with respect to subclause (b) any such initiation or alteration may be made solely to the extent effective following the expiration of such closed trading window and&#47;or special blackout period).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="height:76.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">11</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#124;US-DOCS&#92;109678706.2&#124;&#124;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">VI.   </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:11.35pt">RULE 10B5-1 TRADING PLANS, SECTION 16 AND RULE 144</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Rule 10b5-1 Trading Plans</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.    </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">Overview</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Rule 10b5-1 will protect directors, officers, employees and consultants from insider trading liability under Rule 10b5-1 for transactions under a previously established contract, plan or instruction to trade in the Company&#8217;s stock (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Trading Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) provided that the individual has entered into the Trading Plan in good faith and has acted in good faith with respect to the Trading Plan and in accordance with the terms of Rule 10b5-1 and all applicable state laws and will be exempt from the trading restrictions set forth in this Policy.  The initiation of, and any modification to, any such Trading Plan will be deemed to be a transaction in the Company&#8217;s securities, and such initiation or modification is subject to all limitations and prohibitions relating to transactions in the Company&#8217;s securities.  Each such Trading Plan, and any modification thereof, must be submitted to and pre-approved by the Company&#8217;s Chief Financial Officer, or such other person as the Board of Directors may designate from time to time (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Authorizing Officer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), who may impose such conditions on the implementation and operation of the Trading Plan as the Authorizing Officer deems necessary or advisable.  However, compliance of the Trading Plan to the terms of Rule 10b5-1 and the execution of transactions pursuant to the Trading Plan are the sole responsibility of the person initiating the Trading Plan, not the Company or the Authorizing Officer.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Trading Plans do not exempt individuals from complying with Section 16 short-swing profit rules or liability.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Rule 10b5-1 presents an opportunity for insiders to establish arrangements to sell (or purchase) Company stock without the restrictions of trading windows and black-out periods, even when there is undisclosed material information.  A Trading Plan may also help reduce negative publicity that may result when key executives sell the Company&#8217;s stock.  Rule 10b5-1 only provides an &#8220;affirmative defense&#8221; in the event there is an insider trading lawsuit.  It does not prevent someone from bringing a lawsuit.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A director, officer, employee or consultant may enter into a Trading Plan only when he or she is not in possession of material, non-public information, and only during a trading window period outside of the trading black-out period.  Although transactions effected under a Trading Plan will not require further pre-clearance at the time of the trade, any transaction (including the quantity and price) made pursuant to a Trading Plan of a Section 16 reporting person must be reported to the Company promptly on the day of each trade to permit the Company&#8217;s filing coordinator to assist in the preparation and filing of a required Form 4.  Such reporting may be oral or in writing (including by e-mail) and should include the identity of the reporting person, the type of transaction, the date of the transaction, the number of shares involved and the purchase or sale price.  However, the ultimate responsibility, and liability, for timely filing remains with the Section 16 reporting person.</font></div><div style="height:76.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">12</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#124;US-DOCS&#92;109678706.2&#124;&#124;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Company reserves the right from time to time to suspend, discontinue or otherwise prohibit any transaction in the Company&#8217;s securities, even pursuant to a previously approved Trading Plan, if the Authorizing Officer or the Board of Directors, in its discretion, determines that such suspension, discontinuation or other prohibition is in the best interests of the Company.  Any Trading Plan submitted for approval hereunder should explicitly acknowledge the Company&#8217;s right to prohibit transactions in the Company&#8217;s securities.  Failure to discontinue purchases and sales as directed shall constitute a violation of the terms of this Section VI and result in a loss of the exemption set forth herein. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Officers, directors, employees and consultants may adopt Trading Plans with brokers that outline a pre-set plan for trading of the Company&#8217;s stock, including the exercise of options.  When adopting a new or modified Trading Plan, officers and directors will be required to include in the plan written representations certifying that he or she (i) is not aware of material nonpublic information about the issuer or its securities and (ii) is adopting or modifying the plan in good faith and not as part of a plan or scheme to evade the prohibitions of Exchange Act Rule 10b-5. Trades pursuant to a Trading Plan generally may occur at any time.  However, the Company requires a cooling-off period of 30 days between the establishment or modification of a Trading Plan and commencement of any transactions under such plan for employees that are not officers or directors and for consultants.  For officers and directors, the Company requires a cooling-off period which is the later of (i) 90 days between the establishment or modification of a Trading Plan or (ii) 2 business days following the filing of the Form 10-Q or Form 10-K for the fiscal quarter in which the plan was adopted or modified and commencement of any transaction under such plan.  In any event, the required colling-off period is not to exceed 120 days following adoption or modification of the Trading Plan. For elimination of doubt, Trading Plans for officers and directors may allow for trading day 2 because the cooling off period expires at the beginning of the business day. An individual will be prohibited from having more than one Trading Plan during any consecutive 12-month period.  This prohibition does not apply where an individual transacts directly with the Company, such as participation in the Company&#8217;s employee stock purchase plan (&#8220;ESPP&#8221;), which are not executed on the open market. Furthermore, this prohibition does not apply to Trading Plans authorizing an agent to sell only enough securities as are necessary to satisfy tax withholding obligations arising exclusively from the vesting of a compensatory award, such as on the vesting and settlement of restricted stock units, provided that the award holder is not permitted to exercise control over the timing of such sales. Such prohibition does not apply in the event that an individual has a series of separate contracts with different broker-dealers to execute trades pursuant to a single Trading Plan. A Trading Plan will not be treated as a single-trade plan if it gives the individual&#8217;s agent discretion over whether to execute the plan as a single transaction, or provides that the agent&#8217;s future acts will depend on events or data not known at the time the plan is entered into and it is reasonably foreseeable at the time the plan is entered into that the plan might result in multiple trades. Please review the following description of how a Trading Plan works. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Pursuant to Rule 10b5-1, an individual&#8217;s purchase or sale of securities will not be &#8220;on the basis of&#8221; material, non-public information if&#58;</font></div><div style="height:76.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">13</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#124;US-DOCS&#92;109678706.2&#124;&#124;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:31.8pt">First, before becoming aware of the information, the individual enters into a binding contract to purchase or sell the securities, provides instructions to another person to sell the securities or adopts a written plan for trading the securities (i.e., the Trading Plan).&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:31.8pt">Second, the Trading Plan must either&#58;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:31.8pt">specify the amount of securities to be purchased or sold, the price at which the securities are to be purchased or sold and the date on which the securities are to be purchased or sold&#59;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:31.8pt">include a written formula or computer program for determining the amount, price and date of the transactions&#59; or</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:31.8pt">prohibit the individual from exercising any subsequent influence over the purchase or sale of the Company&#8217;s stock under the Trading Plan in question.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:31.8pt">Third, the purchase or sale must occur pursuant to the Trading Plan and the individual must not enter into a corresponding hedging transaction or alter or deviate from the Trading Plan.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.    </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">Revocation of and Amendments to Trading Plans</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Revocation of Trading Plans should occur only in unusual circumstances.  Effectiveness of any revocation or amendment of a Trading Plan will be subject to the prior review and approval of the Authorizing Officer.  Revocation is effected upon written notice to the broker.  Once a Trading Plan has been revoked, the participant should wait at least 30 days before trading outside of a Trading Plan and 180 days before establishing a new Trading Plan.  You should note that revocation of a Trading Plan can result in the loss of an affirmative defense for past or future transactions under a Trading Plan.  You should consult with your own legal counsel before deciding to revoke a Trading Plan. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A person acting in good faith may amend a prior Trading Plan so long as such amendments are made outside of a quarterly trading black-out period, at a time when the Trading Plan participant does not possess material, non-public information and if made in compliance with the cooling-off periods described above.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Under certain circumstances, a Trading Plan </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">must</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> be revoked.  This may include circumstances such as the announcement of a merger or the occurrence of an event that would cause the transaction either to violate the law or to have an adverse effect on the Company.  The Authorizing Officer or administrator of the Company&#8217;s stock plans is authorized to notify the broker in such circumstances, thereby insulating the insider in the event of revocation.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.    </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">Discretionary Plans</font></div><div style="height:76.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">14</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#124;US-DOCS&#92;109678706.2&#124;&#124;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Although non-discretionary Trading Plans are preferred, discretionary Trading Plans, where the discretion or control over trading is transferred to a broker, are permitted if pre-approved by the Authorizing Officer.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Authorizing Officer of the Company must pre-approve any Trading Plan, arrangement or trading instructions, etc., involving potential sales or purchases of the Company&#8217;s stock or option exercises, including but not limited to, blind trusts, discretionary accounts with banks or brokers, or limit orders.  The actual transactions effected pursuant to a pre-approved Trading Plan will not be subject to further pre-clearance for transactions in the Company&#8217;s stock once the Trading Plan or other arrangement has been pre-approved.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.    </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">Reporting (if Required)</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">If required, an SEC Form 144 will be filled out and filed by the individual&#47;brokerage firm in accordance with the existing rules regarding Form 144 filings.  A footnote at the bottom of the Form 144 should indicate that the trades &#8220;are in accordance with a Trading Plan that complies with Rule 10b5-1 and expires ____.&#8221;  For Section 16 reporting persons, Form 4s should be filed before the end of the second business day following the date that the broker, dealer or plan administrator informs the individual that a transaction was executed, provided that the date of such notification is not later than the third business day following the trade date.  A similar footnote should be placed at the bottom of the Form 4 as outlined above.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.    </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">Options</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Exercises of options for cash may be executed at any time.  &#8220;Cashless exercise&#8221; option exercises through a broker are subject to trading windows.  However, the Company will permit same day sales under Trading Plans.  If a broker is required to execute a cashless exercise in accordance with a Trading Plan, then the Company must have exercise forms attached to the Trading Plan that are signed, undated and with the number of shares to be exercised left blank.  Once a broker determines that the time is right to exercise the option and dispose of the shares in accordance with the Trading Plan, the broker will notify the Company in writing and the administrator of the Company&#8217;s stock plans will fill in the number of shares and the date of exercise on the previously signed exercise form.  The insider should not be involved with this part of the exercise.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.    </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">Trades Outside of a Trading Plan</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">During an open trading window, trades differing from Trading Plan instructions that are already in place are allowed as long as the Trading Plan continues to be followed.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.    </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">Public Announcements</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Company may make a public announcement that Trading Plans are being implemented in accordance with Rule 10b5-1.  It will consider in each case whether a public announcement of a particular Trading Plan should be made.  It may also make public announcements or respond to inquiries from the media as transactions are made under a Trading Plan.</font></div><div style="height:76.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">15</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#124;US-DOCS&#92;109678706.2&#124;&#124;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.    </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">Prohibited Transactions</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The transactions prohibited under Section V of this Policy, including among others short sales and hedging transactions, may not be carried out through a Trading Plan or other arrangement or trading instruction involving potential sales or purchases of the Company&#8217;s securities.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.    </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">No Section 16 Protection</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The use of Trading Plans does not exempt participants from complying with the Section 16 reporting rules or liability for short swing trades.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10.    </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">Limitation on Liability</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">None of the Company, the Chief Financial Officer, the Authorizing Officer or the Company&#8217;s other employees will have any liability for any delay in reviewing, or refusal of, a Trading Plan submitted pursuant to this Section VI or a request for pre-clearance submitted pursuant to Section IV of this Policy.  Notwithstanding any review of a Trading Plan pursuant to this Section VI or pre-clearance of a transaction pursuant to Section IV of this Policy, none of the Company, the Chief Financial Officer, the Authorizing Officer or the Company&#8217;s other employees assumes any liability for the legality or consequences of such Trading Plan or transaction to the person engaging in or adopting such Trading Plan or transaction.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 16&#58;  Insider Reporting Requirements, Short-Swing Profits and Short Sales</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11.    </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">Reporting Obligations Under Section 16(a)&#58;  SEC Forms 3, 4 and 5</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 16(a) of the 1934 Act generally requires all officers, directors and 10% stockholders (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">insiders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), within 10 days after the insider becomes an officer, director or 10% stockholder, to file with the SEC an &#8220;Initial Statement of Beneficial Ownership of Securities&#8221; on SEC Form 3 listing the amount of the Company&#8217;s stock, options and warrants which the insider beneficially owns.  Following the initial filing on SEC Form 3, changes in beneficial ownership of the Company&#8217;s stock, options and warrants or, in the case of Section 16 officers, gifts of equity in the Company, must be reported on SEC Form 4, generally within two business days after the date on which such change or grant occurs, or in certain cases on Form 5, within 45 days after fiscal year end.  The two day Form 4 deadline begins to run from the trade date rather than the settlement date.  A Form 4 must be filed even if, as a result of balancing transactions, there has been no net change in holdings.  In certain situations, purchases or sales of Company stock made within six months </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">prior</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> to the filing of a Form 3 must be reported on Form 4.  Similarly, certain purchases or sales of Company stock made within six months </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">after</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> an officer or director ceases to be an insider must be reported on Form 4.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12.    </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">Recovery of Profits Under Section 16(b)</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">For the purpose of preventing the unfair use of information which may have been obtained by an insider, any profits realized by any officer, director or 10% stockholder from any &#8220;purchase&#8221; and &#8220;sale&#8221; of Company stock during a six-month period, so called &#8220;short-swing </font></div><div style="height:76.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">16</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#124;US-DOCS&#92;109678706.2&#124;&#124;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">profits,&#8221; may be recovered by the Company.  When such a purchase and sale occurs, good faith is no defense.  The insider is liable even if compelled to sell for personal reasons, and even if the sale takes place after full disclosure and without the use of any inside information.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The liability of an insider under Section 16(b) of the 1934 Act is only to the Company itself.  The Company, however, cannot waive its right to short swing profits, and any Company stockholder can bring suit in the name of the Company.  Reports of ownership filed with the SEC on Form 3, Form 4 or Form 5 pursuant to Section 16(a) (discussed above) are readily available to the public, and certain attorneys carefully monitor these reports for potential Section 16(b) violations.  In addition, liabilities under Section 16(b) may require separate disclosure in the Company&#8217;s annual report to the SEC on Form 10-K or its proxy statement for its annual meeting of stockholders.  No suit may be brought more than two years after the date the profit was realized.  However, if the insider fails to file a report of the transaction under Section 16(a), as required, the two-year limitation period does not begin to run until after the transactions giving rise to the profit have been disclosed.  Failure to report transactions and late filing of reports require separate disclosure in the Company&#8217;s proxy statement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Officers and directors should consult the attached &#8220;Short-Swing Profit Rule Section 16(b) Checklist&#8221; attached hereto as &#8220;Attachment A&#8221; in addition to consulting the Chief Financial Officer prior to engaging in any transactions involving the Company&#8217;s securities, including without limitation, the Company&#8217;s stock, options or warrants.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13.    </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">Short Sales Prohibited Under Section 16(c)</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 16(c) of the 1934 Act prohibits insiders absolutely from making short sales of the Company&#8217;s equity securities.  Short sales include sales of stock which the insider does not own at the time of sale, or sales of stock against which the insider does not deliver the shares within 20 days after the sale.  Under certain circumstances, the purchase or sale of put or call options, or the writing of such options, can result in a violation of Section 16(c).  Insiders violating Section 16(c) face criminal liability.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Chief Financial Officer should be consulted if you have any questions regarding reporting obligations, short-swing profits or short sales under Section 16.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Rule 144 (Applicable to Officers, Directors and 10% Stockholders)</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Rule 144 provides a safe harbor exemption to the registration requirements of the Securities Act of 1933, as amended, for certain resales of &#8220;restricted securities&#8221; and &#8220;control securities.&#8221;  &#8220;Restricted securities&#8221; are securities acquired from an issuer, or an affiliate of an issuer, in a transaction or chain of transactions not involving a public offering.  &#8220;Control securities&#8221; are </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">any</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> securities owned by directors, executive officers or other &#8220;affiliates&#8221; of the issuer, including stock purchased in the open market and stock received upon exercise of stock options.  Sales of Company restricted and control securities must comply with the requirements of Rule 144, which are summarized below&#58;</font></div><div style="height:76.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">17</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#124;US-DOCS&#92;109678706.2&#124;&#124;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%;padding-left:31.8pt">Holding Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Restricted securities must be held for at least six months before they may be sold in the market.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%;padding-left:31.8pt">Current Public Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  The Company must have filed all SEC-required reports during the last 12 months or such shorter period that the Company was required to file such reports.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%;padding-left:31.8pt">Volume Limitations.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  For affiliates, total sales of Company common stock for any three-month period may not exceed the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">greater</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of&#58; (i)&#160;1% of the total number of outstanding shares of Company common stock, as reflected in the most recent report or statement published by the Company, or (ii)&#160;the average weekly reported volume of such shares traded during the four calendar weeks preceding the filing of the requisite Form 144.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%;padding-left:31.8pt">Method of Sale.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  For affiliates, the shares must be sold either in a &#8220;broker&#8217;s transaction&#8221; or in a transaction directly with a &#8220;market maker.&#8221;  A &#8220;broker&#8217;s transaction&#8221; is one in which the broker does no more than execute the sale order and receive the usual and customary commission.  Neither the broker nor the selling person can solicit or arrange for the sale order.  In addition, the selling person or Board member must not pay any fee or commission other than to the broker.  A &#8220;market maker&#8221; includes a specialist permitted to act as a dealer, a dealer acting in the position of a block positioner, and a dealer who holds himself out as being willing to buy and sell Company common stock for his own account on a regular and continuous basis. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%;padding-left:31.8pt">Notice of Proposed Sale.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  For affiliates, a notice of the sale (a Form 144) may be required to be filed with the SEC at the time of the sale.  Brokers generally have internal procedures for executing sales under Rule 144 and will assist you in completing the Form 144 and in complying with the other requirements of Rule 144.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">If you are subject to Rule 144, you must instruct your broker who handles trades in Company securities to follow the brokerage firm&#8217;s Rule 144 compliance procedures in connection with all trades.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">VII.   </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:7.36pt">EXECUTION AND RETURN OF CERTIFICATION OF COMPLIANCE</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">After reading this Policy, all officers, directors and employees should execute and return to the Chief Financial Officer the Certification of Compliance form attached hereto as &#8220;Attachment B.&#8221;</font></div><div style="height:76.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">18</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#124;US-DOCS&#92;109678706.2&#124;&#124;</font></div></div></div><div id="i34d779e96d03453f958ed7fff2a8bca0_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">SCHEDULE I</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">INDIVIDUALS SUBJECT TO QUARTERLY TRADING BLACK-OUTS </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">All officers of the Company </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">All members of the Company&#8217;s Board of Directors</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">All employees of the Company</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">Certain consultants specified by Company management</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">INDIVIDUALS SUBJECT TO PRE-CLEARANCE </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">All officers of the Company </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">All members of the Company&#8217;s Board of Directors</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">All employees of the Company in the finance, accounting and legal departments</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">All employees of the Company with a vice president level or higher title</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">Certain consultants specified by Company management</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#124;US-DOCS&#92;109678706.2&#124;&#124;</font></div></div></div><div id="i34d779e96d03453f958ed7fff2a8bca0_7"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">ATTACHMENT A</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">SHORT-SWING PROFIT RULE SECTION&#160;16(B) CHECKLIST</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Note&#58;  ANY combination of PURCHASE AND SALE or SALE AND PURCHASE within six months of each other by an officer, director or 10% stockholder (or any family member living in the same household or certain affiliated entities) results in a violation of Section&#160;16(b), and the &#8220;profit&#8221; must be recovered by Exagen Inc. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  It makes no difference how long the shares being sold have been held or, for officers and directors, that you were an insider for only one of the two matching transactions.  The highest priced sale will be matched with the lowest priced purchase within the six-month period.</font></div><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Sales</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;If a sale is to be made by an officer, director or 10% stockholder (or any family member living in the same household or certain affiliated entities)&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;1.&#160;&#160;&#160;&#160;Have there been any purchases by the insider (or family members living in the same household or certain affiliated entities) within the past six months&#63;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;2.&#160;&#160;&#160;&#160;Have there been any option grants or exercises not exempt under Rule 16b-3 within the past six months&#63;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;3.&#160;&#160;&#160;&#160;Are any purchases (or non-exempt option exercises) anticipated or required within the next six months&#63;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;4.&#160;&#160;&#160;&#160;Has a Form 4 been prepared&#63;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Note&#58;  If a sale is to be made by an affiliate of the Company, has a Form 144 been prepared and has the broker been reminded to sell pursuant to Rule 144&#63;</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Purchases And Option Exercises</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;If a purchase or option exercise for Company stock is to be made&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;1.&#160;&#160;&#160;&#160;Have there been any sales by the insider (or family members living in the same household or certain affiliated entities) within the past six months&#63;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;2.&#160;&#160;&#160;&#160;Are any sales anticipated or required within the next six months (such as tax-related or year-end transactions)&#63;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;3.&#160;&#160;&#160;&#160;Has a Form 4 been prepared&#63;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;Before proceeding with a purchase or sale, consider whether you are aware of material, non-public information which could affect the price of the Company stock.  All transactions in the Company&#8217;s securities by officers and directors must be </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">pre-cleared</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> by contacting the Company&#8217;s Chief Financial Officer.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#124;US-DOCS&#92;109678706.2&#124;&#124;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#124;US-DOCS&#92;109678706.2&#124;&#124;</font></div></div></div><div id="i34d779e96d03453f958ed7fff2a8bca0_10"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">ATTACHMENT B</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">CERTIFICATION OF COMPLIANCE</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">RETURN BY &#91;_________&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#91;insert return deadline&#93;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">TO&#58;&#160;&#160;&#160;&#160;__________________, Chief Financial Officer</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">FROM&#58;&#160;&#160;&#160;&#160;__________________________</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">RE&#58;&#160;&#160;&#160;&#160;INSIDER TRADING COMPLIANCE POLICY OF EXAGEN INC.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">I have received, reviewed and understand the above-referenced Insider Trading Compliance Policy and undertake, as a condition to my present and continued employment with (or, if I am not an employee, affiliation with) Exagen Inc., to comply fully with the policies and procedures contained therein.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">I hereby certify, to the best of my knowledge, that during the calendar year ending December 31, 20__, I have complied fully with all policies and procedures set forth in the above-referenced Insider Trading Compliance Policy.</font></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.416%"><tr><td style="width:1.0%"></td><td style="width:22.164%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.164%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.164%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.167%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SIGNATURE</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">DATE</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">TITLE</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#124;US-DOCS&#92;109678706.2&#124;&#124;</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>ex231-2024bdoconsent.htm
<DESCRIPTION>EX-23.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="ieb3e6489be3c4bbbbbe97862912ce702_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 23.1</font></div><div style="margin-top:12pt;text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Consent of Independent Registered Public Accounting Firm</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (No. 333-275632) and Form S-8 (Nos. 333-233878, 333-256014, 333-264867, 333-272038 and 333-279356) of Exagen Inc. of our report dated March&#160;11, 2025, relating to the financial statements, which appear in this Annual Report on Form 10-K. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; BDO USA, P.C.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">San Diego, California</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;11, 2025</font></div><div style="margin-top:12pt;text-align:justify"><font><br></font></div><div style="margin-top:12pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-right:-4.3pt;text-align:justify"><font><br></font></div><div style="padding-right:-4.3pt"><font><br></font></div><div style="text-align:justify"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>xgn311-123124.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="iaed8be6133fc427db5060b0dee795062_1"></div><div style="min-height:43pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:242%">Exhibit 31.1</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:139%">EXAGEN INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:242%">CERTIFICATION OF CHIEF EXECUTIVE OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:167%">PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="text-align:center"><font><br></font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">I, John Aballi, certify that&#58;</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">I have reviewed this Annual Report on Form 10-K of Exagen Inc.&#59;</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:168%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:168%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:168%"> Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:168%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:168%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:168%"> Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:168%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:168%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:168%"> Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">5.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="height:43pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:43pt;width:100%"><div><font><br></font></div></div><div style="margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:9pt;text-indent:18pt"><font><br></font></div><div style="margin-bottom:21pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.648%"><tr><td style="width:1.0%"></td><td style="width:49.226%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.574%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; March&#160;11, 2025</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; John Aballi</font></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><font><br></font></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">John Aballi</font></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td></tr></table></div><div style="margin-top:3pt"><font><br></font></div><div style="height:43pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>xgn312-123124.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="iec5e4f65e6e842718af4390c45814f43_1"></div><div style="min-height:43pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:242%">Exhibit 31.2</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:139%">EXAGEN INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:242%">CERTIFICATION OF CHIEF FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:167%">PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">I, Jeffrey G. Black, certify that&#58;</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">I have reviewed this Annual Report on Form 10-K of Exagen Inc.&#59;</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%"> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">5.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="height:43pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:43pt;width:100%"><div><font><br></font></div></div><div style="margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:9pt;text-indent:18pt"><font><br></font></div><div style="margin-bottom:21pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.648%"><tr><td style="width:1.0%"></td><td style="width:49.226%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.574%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; March&#160;11, 2025</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Jeffrey G. Black</font></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><font><br></font></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jeffrey G. Black</font></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial and Accounting Officer)</font></td></tr></table></div><div style="margin-top:3pt"><font><br></font></div><div style="height:43pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>xgn321-123124.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i7ece92209b274e0c9daff8cfb5c950a0_1"></div><div style="min-height:43pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:201%">Exhibit 32.1</font></div><div style="text-align:right"><font><br></font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:167%">CERTIFICATION OF CHIEF EXECUTIVE OFFICER</font></div><div style="text-align:center"><font><br></font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">Pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of Exagen Inc. (the &#34;Company&#34;) hereby certifies, to such officer's knowledge, that&#58;</font></div><div style="margin-top:9pt;padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> The accompanying annual report on Form 10-K of the Company for the fiscal year ended December 31, 2024 (the &#34;Report&#34;) fully complies with the requirements of Section&#160;13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="margin-top:9pt;padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company for the periods presented therein.</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Dated&#58; March&#160;11, 2025</font></div><div style="text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.066%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; John Aballi</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">John Aballi</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;padding-right:2pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">President and Chief Executive Officer</font></div><div style="margin-bottom:2pt;padding-right:2pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Principal Executive Officer)</font></div></td></tr></table></div><div style="margin-top:16pt"><font><br></font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:167%">CERTIFICATION OF CHIEF FINANCIAL OFFICER</font></div><div style="text-align:center"><font><br></font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">Pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of Exagen Inc. (the &#34;Company&#34;) hereby certifies, to such officer's knowledge, that&#58;</font></div><div style="margin-top:9pt;padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> The accompanying annual report on Form 10-K of the Company for the fiscal year ended December 31, 2024 (the &#34;Report&#34;) fully complies with the requirements of Section&#160;13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="margin-top:9pt;padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company for the periods presented therein.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Dated&#58; March&#160;11, 2025</font></div><div style="text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.066%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Jeffrey G. Black</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jeffrey G. Black</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;padding-right:2pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Financial Officer (Principal Financial and Accounting Officer)</font></div></td></tr></table></div><div style="margin-top:16pt"><font><br></font></div><div style="height:43pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>exdx-20241231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:7095620a-7684-4e36-937b-24fd606ed1ea,g:3f375e3f-dda6-40cc-be01-a2493780a401-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:exdx="http://www.exagen.com/20241231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types1="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.exagen.com/20241231">
  <xs:import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/cyd-af-sub/2024" schemaLocation="https://xbrl.sec.gov/cyd/2024/cyd-af-sub-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="exdx-20241231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="exdx-20241231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="exdx-20241231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="exdx-20241231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.exagen.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://www.exagen.com/role/AuditInformation">
        <link:definition>0000002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheets" roleURI="http://www.exagen.com/role/BalanceSheets">
        <link:definition>9952151 - Statement - Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetsParenthetical" roleURI="http://www.exagen.com/role/BalanceSheetsParenthetical">
        <link:definition>9952152 - Statement - Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StatementsofOperations" roleURI="http://www.exagen.com/role/StatementsofOperations">
        <link:definition>9952153 - Statement - Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StatementsofStockholdersEquity" roleURI="http://www.exagen.com/role/StatementsofStockholdersEquity">
        <link:definition>9952154 - Statement - Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StatementsofCashFlows" roleURI="http://www.exagen.com/role/StatementsofCashFlows">
        <link:definition>9952155 - Statement - Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Organization" roleURI="http://www.exagen.com/role/Organization">
        <link:definition>9952156 - Disclosure - Organization</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>9952157 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherFinancialInformation" roleURI="http://www.exagen.com/role/OtherFinancialInformation">
        <link:definition>9952158 - Disclosure - Other Financial Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Borrowings" roleURI="http://www.exagen.com/role/Borrowings">
        <link:definition>9952159 - Disclosure - Borrowings</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.exagen.com/role/Leases">
        <link:definition>9952160 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.exagen.com/role/CommitmentsandContingencies">
        <link:definition>9952161 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.exagen.com/role/FairValueMeasurements">
        <link:definition>9952162 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://www.exagen.com/role/StockholdersEquity">
        <link:definition>9952163 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockOptionPlan" roleURI="http://www.exagen.com/role/StockOptionPlan">
        <link:definition>9952164 - Disclosure - Stock Option Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.exagen.com/role/IncomeTaxes">
        <link:definition>9952165 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="A401kPlan" roleURI="http://www.exagen.com/role/A401kPlan">
        <link:definition>9952166 - Disclosure - 401(k) Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReporting" roleURI="http://www.exagen.com/role/SegmentReporting">
        <link:definition>9952167 - Disclosure - Segment Reporting</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>9955511 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesTables" roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesTables">
        <link:definition>9955512 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherFinancialInformationTables" roleURI="http://www.exagen.com/role/OtherFinancialInformationTables">
        <link:definition>9955513 - Disclosure - Other Financial Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BorrowingsTables" roleURI="http://www.exagen.com/role/BorrowingsTables">
        <link:definition>9955514 - Disclosure - Borrowings (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.exagen.com/role/LeasesTables">
        <link:definition>9955515 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.exagen.com/role/FairValueMeasurementsTables">
        <link:definition>9955516 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityTables" roleURI="http://www.exagen.com/role/StockholdersEquityTables">
        <link:definition>9955517 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockOptionPlanTables" roleURI="http://www.exagen.com/role/StockOptionPlanTables">
        <link:definition>9955518 - Disclosure - Stock Option Plan (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.exagen.com/role/IncomeTaxesTables">
        <link:definition>9955519 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingTables" roleURI="http://www.exagen.com/role/SegmentReportingTables">
        <link:definition>9955520 - Disclosure - Segment Reporting (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationDetails" roleURI="http://www.exagen.com/role/OrganizationDetails">
        <link:definition>9955521 - Disclosure - Organization (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails" roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails">
        <link:definition>9955522 - Disclosure - Summary of Significant Accounting Policies - Revenue by Major Payers (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesNarrativeDetails" roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails">
        <link:definition>9955523 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails" roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails">
        <link:definition>9955524 - Disclosure - Summary of Significant Accounting Policies - Disaggregation of Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails" roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails">
        <link:definition>9955525 - Disclosure - Summary of Significant Accounting Policies - Cash, Cash Equivalents and Restricted Cash (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesSecuritiesDetails" roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesSecuritiesDetails">
        <link:definition>9955526 - Disclosure - Summary of Significant Accounting Policies - Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherFinancialInformationPrepaidExpensesDetails" roleURI="http://www.exagen.com/role/OtherFinancialInformationPrepaidExpensesDetails">
        <link:definition>9955527 - Disclosure - Other Financial Information - Prepaid Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherFinancialInformationPropertyandEquipmentNetDetails" roleURI="http://www.exagen.com/role/OtherFinancialInformationPropertyandEquipmentNetDetails">
        <link:definition>9955528 - Disclosure - Other Financial Information - Property and Equipment Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherFinancialInformationNarrativeDetails" roleURI="http://www.exagen.com/role/OtherFinancialInformationNarrativeDetails">
        <link:definition>9955529 - Disclosure - Other Financial Information - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherFinancialInformationAccruedLiabilitiesDetails" roleURI="http://www.exagen.com/role/OtherFinancialInformationAccruedLiabilitiesDetails">
        <link:definition>9955530 - Disclosure - Other Financial Information - Accrued Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BorrowingsNarrativeDetails" roleURI="http://www.exagen.com/role/BorrowingsNarrativeDetails">
        <link:definition>9955531 - Disclosure - Borrowings - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BorrowingsFutureMinimumPaymentsDetails" roleURI="http://www.exagen.com/role/BorrowingsFutureMinimumPaymentsDetails">
        <link:definition>9955532 - Disclosure - Borrowings - Future Minimum Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesNarrativeDetails" roleURI="http://www.exagen.com/role/LeasesNarrativeDetails">
        <link:definition>9955533 - Disclosure - Leases - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesLeaseBalancesDetails" roleURI="http://www.exagen.com/role/LeasesLeaseBalancesDetails">
        <link:definition>9955534 - Disclosure - Leases - Lease Balances (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesCostsAssociatedwiththeCompanysLeasesDetails" roleURI="http://www.exagen.com/role/LeasesCostsAssociatedwiththeCompanysLeasesDetails">
        <link:definition>9955535 - Disclosure - Leases - Costs Associated with the Company's Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesSupplementalCashFlowInformationOnLeasesAndWeightedAverageLeaseTermDetails" roleURI="http://www.exagen.com/role/LeasesSupplementalCashFlowInformationOnLeasesAndWeightedAverageLeaseTermDetails">
        <link:definition>9955536 - Disclosure - Leases - Supplemental Cash Flow Information On Leases And Weighted-Average Lease Term (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesFuturePaymentsUnderOperatingAndFinanceLeasesDetails" roleURI="http://www.exagen.com/role/LeasesFuturePaymentsUnderOperatingAndFinanceLeasesDetails">
        <link:definition>9955537 - Disclosure - Leases - Future Payments Under Operating And Finance Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesFuturePaymentsUnderOperatingAndFinanceLeasesDetails_1" roleURI="http://www.exagen.com/role/LeasesFuturePaymentsUnderOperatingAndFinanceLeasesDetails_1">
        <link:definition>9955537 - Disclosure - Leases - Future Payments Under Operating And Finance Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesNarrativeDetails" roleURI="http://www.exagen.com/role/CommitmentsandContingenciesNarrativeDetails">
        <link:definition>9955538 - Disclosure - Commitments and Contingencies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetails" roleURI="http://www.exagen.com/role/FairValueMeasurementsDetails">
        <link:definition>9955539 - Disclosure - Fair Value Measurements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityNarrativeDetails" roleURI="http://www.exagen.com/role/StockholdersEquityNarrativeDetails">
        <link:definition>9955540 - Disclosure - Stockholders' Equity - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityWarrantstoPurchaseCommonStockOutstandingDetails" roleURI="http://www.exagen.com/role/StockholdersEquityWarrantstoPurchaseCommonStockOutstandingDetails">
        <link:definition>9955541 - Disclosure - Stockholders' Equity - Warrants to Purchase Common Stock Outstanding (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockOptionPlanNarrativeDetails" roleURI="http://www.exagen.com/role/StockOptionPlanNarrativeDetails">
        <link:definition>9955542 - Disclosure - Stock Option Plan - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockOptionPlanRestrictedStockUnitsDetails" roleURI="http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails">
        <link:definition>9955543 - Disclosure - Stock Option Plan - Restricted Stock Units (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockOptionPlanStockOptionActivityDetails" roleURI="http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails">
        <link:definition>9955544 - Disclosure - Stock Option Plan - Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockOptionPlanStockBasedCompensationExpenseDetails" roleURI="http://www.exagen.com/role/StockOptionPlanStockBasedCompensationExpenseDetails">
        <link:definition>9955545 - Disclosure - Stock Option Plan - Stock-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockOptionPlanCommonStockReservedForFutureIssuanceDetails" roleURI="http://www.exagen.com/role/StockOptionPlanCommonStockReservedForFutureIssuanceDetails">
        <link:definition>9955546 - Disclosure - Stock Option Plan - Common Stock Reserved For Future Issuance (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails" roleURI="http://www.exagen.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails">
        <link:definition>9955547 - Disclosure - Income Taxes - Components of Income Tax Expense (Benefit) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails" roleURI="http://www.exagen.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails">
        <link:definition>9955548 - Disclosure - Income Taxes - Reconciliation of Effective Income Tax Rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails" roleURI="http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails">
        <link:definition>9955549 - Disclosure - Income Taxes - Reconciliation of Deferred Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesChangeInValuationAllowanceDetails" roleURI="http://www.exagen.com/role/IncomeTaxesChangeInValuationAllowanceDetails">
        <link:definition>9955550 - Disclosure - Income Taxes - Change In Valuation Allowance (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesNarrativeDetails" roleURI="http://www.exagen.com/role/IncomeTaxesNarrativeDetails">
        <link:definition>9955551 - Disclosure - Income Taxes - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="A401kPlanDetails" roleURI="http://www.exagen.com/role/A401kPlanDetails">
        <link:definition>9955552 - Disclosure - 401(k) Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingNarrativeDetails" roleURI="http://www.exagen.com/role/SegmentReportingNarrativeDetails">
        <link:definition>9955553 - Disclosure - Segment Reporting - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingDetails" roleURI="http://www.exagen.com/role/SegmentReportingDetails">
        <link:definition>9955554 - Disclosure - Segment Reporting (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="exdx_AuditInformationAbstract" abstract="true" name="AuditInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="exdx_IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesShares" abstract="false" name="IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="exdx_GainLossOnDispositionOfLeaseAssignment" abstract="false" name="GainLossOnDispositionOfLeaseAssignment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_NonCashLeaseExpense" abstract="false" name="NonCashLeaseExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets" abstract="false" name="IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_EquipmentPurchasedUnderNotesPayableObligations" abstract="false" name="EquipmentPurchasedUnderNotesPayableObligations" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_OtherFinancialInformationAbstract" abstract="true" name="OtherFinancialInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock" abstract="false" name="PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="exdx_ClinicalStudyPolicyPolicyTextBlock" abstract="false" name="ClinicalStudyPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="exdx_MedicareMember" abstract="true" name="MedicareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="exdx_MedicareAdvantageMember" abstract="true" name="MedicareAdvantageMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="exdx_UnitedHealthcareMember" abstract="true" name="UnitedHealthcareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="exdx_AVISECTDTestMember" abstract="true" name="AVISECTDTestMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="exdx_SupplierOneMember" abstract="true" name="SupplierOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exdx_SupplierTwoMember" abstract="true" name="SupplierTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="exdx_CommercialMember" abstract="true" name="CommercialMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="exdx_Government1Member" abstract="true" name="Government1Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="exdx_ClientMember" abstract="true" name="ClientMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="exdx_LaboratoryEquipmentMember" abstract="true" name="LaboratoryEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="exdx_ComputerEquipmentAndSoftwareMember" abstract="true" name="ComputerEquipmentAndSoftwareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="exdx_AmendedLoanAgreementMember" abstract="true" name="AmendedLoanAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exdx_Term2017Member" abstract="true" name="Term2017Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="exdx_EquipmentNotesPayableMember" abstract="true" name="EquipmentNotesPayableMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="exdx_InnovatusLifeSciencesLendingFundMember" abstract="true" name="InnovatusLifeSciencesLendingFundMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="exdx_DebtInstrumentStatedInterestRatePaidInKind" abstract="false" name="DebtInstrumentStatedInterestRatePaidInKind" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="exdx_DebtInstrumentNumberOfMonthlyInstallments" abstract="false" name="DebtInstrumentNumberOfMonthlyInstallments" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="exdx_DebtInstrumentPaidInKindLoansIssued" abstract="false" name="DebtInstrumentPaidInKindLoansIssued" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_DebtInstrumentCovenantRevenuePerformancePeriod" abstract="false" name="DebtInstrumentCovenantRevenuePerformancePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="exdx_DebtInstrumentMinimumCashBalanceRequiredNotRequiredToComplyWithCovenant" abstract="false" name="DebtInstrumentMinimumCashBalanceRequiredNotRequiredToComplyWithCovenant" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="exdx_DebtInstrumentCovenantNumberOfDaysToCureIfPerformanceMeasureIsNotMet" abstract="false" name="DebtInstrumentCovenantNumberOfDaysToCureIfPerformanceMeasureIsNotMet" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance" abstract="false" name="DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease" abstract="false" name="DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="exdx_LongTermDebtIncludingUndiscountedInterest" abstract="false" name="LongTermDebtIncludingUndiscountedInterest" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_LongTermDebtUndiscountedInterestAmount" abstract="false" name="LongTermDebtUndiscountedInterestAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_RentalPropertyByTypeAxis" abstract="true" name="RentalPropertyByTypeAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="exdx_RentalPropertyByTypeDomain" abstract="true" name="RentalPropertyByTypeDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="exdx_OfficeAndLaboratoryMember" abstract="true" name="OfficeAndLaboratoryMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="exdx_OfficeMember" abstract="true" name="OfficeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="exdx_OperatingLeaseMonthlyBaseRent" abstract="false" name="OperatingLeaseMonthlyBaseRent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_OperatingLeaseAnnualIncreaseInBaseRentPaymentPercent" abstract="false" name="OperatingLeaseAnnualIncreaseInBaseRentPaymentPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="exdx_CashFlowInformationOperatingAndFinanceLeasePaymentsAbstract" abstract="true" name="CashFlowInformationOperatingAndFinanceLeasePaymentsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="exdx_WeightedAverageRemainingLeaseTermAbstract" abstract="true" name="WeightedAverageRemainingLeaseTermAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="exdx_WeightedAverageDiscountRateAbstract" abstract="true" name="WeightedAverageDiscountRateAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="exdx_AlleghenyHealthNetworkResearchInstituteMember" abstract="true" name="AlleghenyHealthNetworkResearchInstituteMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="exdx_AHNCollaborationMember" abstract="true" name="AHNCollaborationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="exdx_USDepartmentOfJusticeCaseMember" abstract="true" name="USDepartmentOfJusticeCaseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exdx_RoyaltyObligationPercentageOfSales" abstract="false" name="RoyaltyObligationPercentageOfSales" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="exdx_PurchaseObligationAmendedSupplyAgreementNumberOfSuppliers" abstract="false" name="PurchaseObligationAmendedSupplyAgreementNumberOfSuppliers" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="exdx_CollaborationAgreementAnnualCollaborationFee" abstract="false" name="CollaborationAgreementAnnualCollaborationFee" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_CollaborationAgreementCollaborationExpenses" abstract="false" name="CollaborationAgreementCollaborationExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_A2017TermLoanMember" abstract="true" name="A2017TermLoanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exdx_ShelfRegistrationStatementMember" abstract="true" name="ShelfRegistrationStatementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exdx_CowenEquityDistributionAgreementMember" abstract="true" name="CowenEquityDistributionAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="exdx_SaleOfStockAuthorizedAmount" abstract="false" name="SaleOfStockAuthorizedAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_SaleOfStockRemainingAuthorizedAmount" abstract="false" name="SaleOfStockRemainingAuthorizedAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet" abstract="false" name="StockIssuedDuringPeriodSharesWarrantsExercisedNet" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="exdx_ExpirationJan192026Member" abstract="true" name="ExpirationJan192026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="exdx_ExpirationMar312026Member" abstract="true" name="ExpirationMar312026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="exdx_ExpirationApr12026Member" abstract="true" name="ExpirationApr12026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="exdx_ExpirationDec72025Member" abstract="true" name="ExpirationDec72025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="exdx_NoExpirationMember" abstract="true" name="NoExpirationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="exdx_IncentiveAwardPlan2019Member" abstract="true" name="IncentiveAwardPlan2019Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesAuthorized" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesAuthorized" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="exdx_CommonSharesAvailableForGrantUnderThe2019PlanMember" abstract="true" name="CommonSharesAvailableForGrantUnderThe2019PlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="exdx_DeferredTaxAssetsLeaseLiability" abstract="false" name="DeferredTaxAssetsLeaseLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCapitalizationOfResearchAndExperimentationCosts" abstract="false" name="DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCapitalizationOfResearchAndExperimentationCosts" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_DeferredTaxLiabilitiesRightOfUseAssets" abstract="false" name="DeferredTaxLiabilitiesRightOfUseAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets" abstract="false" name="DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_ChangesInTheValuationAllowanceForDeferredTaxAssetsRollForward" abstract="true" name="ChangesInTheValuationAllowanceForDeferredTaxAssetsRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="exdx_TaxYearsThroughDecember312017Member" abstract="true" name="TaxYearsThroughDecember312017Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exdx_ReportableSegmentMember" abstract="true" name="ReportableSegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exdx_OutsideServicesExpense" abstract="false" name="OutsideServicesExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>exdx-20241231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:7095620a-7684-4e36-937b-24fd606ed1ea,g:3f375e3f-dda6-40cc-be01-a2493780a401-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.exagen.com/role/BalanceSheets" xlink:type="simple" xlink:href="exdx-20241231.xsd#BalanceSheets"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/BalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_60cf3daa-feec-49ad-b985-5bfab74140b6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_7cf5c948-912c-46ad-9885-f6f17af2b3ad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_60cf3daa-feec-49ad-b985-5bfab74140b6" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_7cf5c948-912c-46ad-9885-f6f17af2b3ad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_ee02ecf7-09b1-41fe-8401-0b203ac6e33f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_60cf3daa-feec-49ad-b985-5bfab74140b6" xlink:to="loc_us-gaap_AssetsCurrent_ee02ecf7-09b1-41fe-8401-0b203ac6e33f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_875e9955-c102-45cf-8856-8e83927f67dd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_60cf3daa-feec-49ad-b985-5bfab74140b6" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_875e9955-c102-45cf-8856-8e83927f67dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_23c09002-6da1-48e9-a6f4-3c40e8f13dff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_60cf3daa-feec-49ad-b985-5bfab74140b6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_23c09002-6da1-48e9-a6f4-3c40e8f13dff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_7ee8660e-e8e5-4d31-a5b1-24bb3a4dda45" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_d751fdec-41ab-4eca-9961-6010ebb0566b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_7ee8660e-e8e5-4d31-a5b1-24bb3a4dda45" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_d751fdec-41ab-4eca-9961-6010ebb0566b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_6aa808f1-c31d-4ab9-a909-dea45ccc73ab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_7ee8660e-e8e5-4d31-a5b1-24bb3a4dda45" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_6aa808f1-c31d-4ab9-a909-dea45ccc73ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssets_6a0b2c00-bcce-4552-8da5-09e2f61b6040" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_7ee8660e-e8e5-4d31-a5b1-24bb3a4dda45" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssets_6a0b2c00-bcce-4552-8da5-09e2f61b6040" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_9245961a-06c2-4fe5-8d19-1576c8167486" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_380566eb-4c3a-4265-b7c4-45a40fe519e1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_9245961a-06c2-4fe5-8d19-1576c8167486" xlink:to="loc_us-gaap_PreferredStockValue_380566eb-4c3a-4265-b7c4-45a40fe519e1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_cd8e58b3-b7f7-44f8-b70f-e9696f249456" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_9245961a-06c2-4fe5-8d19-1576c8167486" xlink:to="loc_us-gaap_AdditionalPaidInCapital_cd8e58b3-b7f7-44f8-b70f-e9696f249456" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_04e28599-98b6-4afb-97f5-d228c2998b5a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_9245961a-06c2-4fe5-8d19-1576c8167486" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_04e28599-98b6-4afb-97f5-d228c2998b5a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_021f05ce-5108-4b82-8a7d-ba2fc486e025" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_9245961a-06c2-4fe5-8d19-1576c8167486" xlink:to="loc_us-gaap_CommonStockValue_021f05ce-5108-4b82-8a7d-ba2fc486e025" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_0231a0ac-b4e6-41ad-b3bd-8ea12abfb3ee" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_77c98247-b911-4f56-b457-e21ae0637242" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_0231a0ac-b4e6-41ad-b3bd-8ea12abfb3ee" xlink:to="loc_us-gaap_StockholdersEquity_77c98247-b911-4f56-b457-e21ae0637242" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_477003d1-7767-4506-9091-83ae03163056" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_0231a0ac-b4e6-41ad-b3bd-8ea12abfb3ee" xlink:to="loc_us-gaap_Liabilities_477003d1-7767-4506-9091-83ae03163056" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_b19e14df-4399-48bf-83b1-c4f550f36b3e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_0231a0ac-b4e6-41ad-b3bd-8ea12abfb3ee" xlink:to="loc_us-gaap_CommitmentsAndContingencies_b19e14df-4399-48bf-83b1-c4f550f36b3e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_c0c81df3-91c2-48a2-b486-1d55e338369c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_72ac3889-8d27-4c59-8461-e729598ae517" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_c0c81df3-91c2-48a2-b486-1d55e338369c" xlink:to="loc_us-gaap_AccountsPayableCurrent_72ac3889-8d27-4c59-8461-e729598ae517" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_75b54f27-2792-4416-bc7e-7af4d27464af" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_c0c81df3-91c2-48a2-b486-1d55e338369c" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_75b54f27-2792-4416-bc7e-7af4d27464af" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_872a1f19-febb-4586-bf63-8a1d644426a2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_c0c81df3-91c2-48a2-b486-1d55e338369c" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_872a1f19-febb-4586-bf63-8a1d644426a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_9fce8fa9-ea2a-48a4-82f3-54147878f285" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_c0c81df3-91c2-48a2-b486-1d55e338369c" xlink:to="loc_us-gaap_LongTermDebtCurrent_9fce8fa9-ea2a-48a4-82f3-54147878f285" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_fbb338a6-4d2a-467e-a71a-c37942e4ca2c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_1a500fb6-63c5-4f99-acc6-e75d62f1a117" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_fbb338a6-4d2a-467e-a71a-c37942e4ca2c" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_1a500fb6-63c5-4f99-acc6-e75d62f1a117" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_7c630366-b2c4-4650-8659-34ec250125e3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_fbb338a6-4d2a-467e-a71a-c37942e4ca2c" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_7c630366-b2c4-4650-8659-34ec250125e3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_44d4b8a6-4322-4749-b717-8732fe1334c0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_fbb338a6-4d2a-467e-a71a-c37942e4ca2c" xlink:to="loc_us-gaap_LiabilitiesCurrent_44d4b8a6-4322-4749-b717-8732fe1334c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_6ff7344a-28f4-45da-b24c-dc2c29477384" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_fbb338a6-4d2a-467e-a71a-c37942e4ca2c" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_6ff7344a-28f4-45da-b24c-dc2c29477384" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StatementsofOperations" xlink:type="simple" xlink:href="exdx-20241231.xsd#StatementsofOperations"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/StatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent_d3519543-b713-4da5-9909-acc2f2bae951" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_d5c64ca2-17b3-4d16-8986-b587bc996429" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossAttributableToParent_d3519543-b713-4da5-9909-acc2f2bae951" xlink:to="loc_us-gaap_OperatingIncomeLoss_d5c64ca2-17b3-4d16-8986-b587bc996429" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating_54612f6a-d76b-4cca-a836-01b9d18c5d55" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossAttributableToParent_d3519543-b713-4da5-9909-acc2f2bae951" xlink:to="loc_us-gaap_InterestExpenseNonoperating_54612f6a-d76b-4cca-a836-01b9d18c5d55" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_64378123-2b52-4cc5-b294-b04826ee4f08" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossAttributableToParent_d3519543-b713-4da5-9909-acc2f2bae951" xlink:to="loc_us-gaap_InvestmentIncomeInterest_64378123-2b52-4cc5-b294-b04826ee4f08" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_cdba1a09-4146-48f9-87f7-17b3a8c92536" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_15cdb572-14ce-48c5-a609-8fbe337e00c9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_cdba1a09-4146-48f9-87f7-17b3a8c92536" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_15cdb572-14ce-48c5-a609-8fbe337e00c9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_9b3c5010-c97b-43db-8ae7-a71b78ddd6d4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_cdba1a09-4146-48f9-87f7-17b3a8c92536" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_9b3c5010-c97b-43db-8ae7-a71b78ddd6d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_2c0e6cbe-4283-4ae6-a862-56e949b0adc5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent_05585722-a128-42cd-8107-1fa7cab716b9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_2c0e6cbe-4283-4ae6-a862-56e949b0adc5" xlink:to="loc_us-gaap_IncomeLossAttributableToParent_05585722-a128-42cd-8107-1fa7cab716b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_7feed195-3770-47f6-a6da-6bc61cab5db9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_2c0e6cbe-4283-4ae6-a862-56e949b0adc5" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_7feed195-3770-47f6-a6da-6bc61cab5db9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_afb57c1e-2664-4000-bd30-66fa8962253d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_7cbba3df-5035-4b9f-b704-08580997e4be" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_afb57c1e-2664-4000-bd30-66fa8962253d" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_7cbba3df-5035-4b9f-b704-08580997e4be" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_1c36217e-3043-411b-ba86-34bb3a04c0da" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_afb57c1e-2664-4000-bd30-66fa8962253d" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_1c36217e-3043-411b-ba86-34bb3a04c0da" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_04d359ad-7ac9-43a3-8f1d-32b8dea37cf3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_cd84eb2e-26fb-4f37-9316-9f3f17092526" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_04d359ad-7ac9-43a3-8f1d-32b8dea37cf3" xlink:to="loc_us-gaap_GrossProfit_cd84eb2e-26fb-4f37-9316-9f3f17092526" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_0f1a5fc8-90c2-47b7-97a6-a73b1b87cedd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_04d359ad-7ac9-43a3-8f1d-32b8dea37cf3" xlink:to="loc_us-gaap_CostsAndExpenses_0f1a5fc8-90c2-47b7-97a6-a73b1b87cedd" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StatementsofCashFlows" xlink:type="simple" xlink:href="exdx-20241231.xsd#StatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/StatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c6c06942-bb3a-4ae6-b61a-19b4a21a41c3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_6cce6129-1064-48b3-8941-b682bf71c73a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c6c06942-bb3a-4ae6-b61a-19b4a21a41c3" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_6cce6129-1064-48b3-8941-b682bf71c73a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_97b06b92-2bfa-4c55-8698-964a85d5bce6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c6c06942-bb3a-4ae6-b61a-19b4a21a41c3" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_97b06b92-2bfa-4c55-8698-964a85d5bce6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8e4ebdce-5cb2-4841-bc04-c5345bf94c18" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_7055350d-905a-45d1-bfe1-e7ed4c72a508" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8e4ebdce-5cb2-4841-bc04-c5345bf94c18" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_7055350d-905a-45d1-bfe1-e7ed4c72a508" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaidInKindInterest_f91cb139-5f82-461d-9a42-7b9d1b05e42a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaidInKindInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8e4ebdce-5cb2-4841-bc04-c5345bf94c18" xlink:to="loc_us-gaap_PaidInKindInterest_f91cb139-5f82-461d-9a42-7b9d1b05e42a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_a0b54e76-d4e2-4ff0-bd78-67b31fc5b247" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8e4ebdce-5cb2-4841-bc04-c5345bf94c18" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_a0b54e76-d4e2-4ff0-bd78-67b31fc5b247" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_453b1c31-66a7-4b5e-bea7-afaf90b6dfcf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8e4ebdce-5cb2-4841-bc04-c5345bf94c18" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_453b1c31-66a7-4b5e-bea7-afaf90b6dfcf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_d0edad07-0baf-4e21-9c31-3362f7ae0b03" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8e4ebdce-5cb2-4841-bc04-c5345bf94c18" xlink:to="loc_us-gaap_ShareBasedCompensation_d0edad07-0baf-4e21-9c31-3362f7ae0b03" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_0a6f67e7-6e2d-4600-89fa-f0f468549065" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8e4ebdce-5cb2-4841-bc04-c5345bf94c18" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_0a6f67e7-6e2d-4600-89fa-f0f468549065" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ef4f7c42-1600-4e97-accb-00b13bea1e06" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8e4ebdce-5cb2-4841-bc04-c5345bf94c18" xlink:to="loc_us-gaap_NetIncomeLoss_ef4f7c42-1600-4e97-accb-00b13bea1e06" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_8435eff1-7c46-4e0c-ad7f-4773a8bb0d9f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8e4ebdce-5cb2-4841-bc04-c5345bf94c18" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_8435eff1-7c46-4e0c-ad7f-4773a8bb0d9f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets_2f724d3b-cc3c-4b48-bd0c-004f93a74957" xlink:href="exdx-20241231.xsd#exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8e4ebdce-5cb2-4841-bc04-c5345bf94c18" xlink:to="loc_exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets_2f724d3b-cc3c-4b48-bd0c-004f93a74957" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_f4fdd25c-64d1-4529-a37e-f5bfbbd69f02" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8e4ebdce-5cb2-4841-bc04-c5345bf94c18" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_f4fdd25c-64d1-4529-a37e-f5bfbbd69f02" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization_ad804d2e-68e0-4a61-a93a-b5966e69fd42" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8e4ebdce-5cb2-4841-bc04-c5345bf94c18" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization_ad804d2e-68e0-4a61-a93a-b5966e69fd42" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_NonCashLeaseExpense_8c82f866-3675-495a-9314-477cdb37c5b7" xlink:href="exdx-20241231.xsd#exdx_NonCashLeaseExpense"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8e4ebdce-5cb2-4841-bc04-c5345bf94c18" xlink:to="loc_exdx_NonCashLeaseExpense_8c82f866-3675-495a-9314-477cdb37c5b7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_a75cf92b-2130-479e-9fb5-5aef16130793" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8e4ebdce-5cb2-4841-bc04-c5345bf94c18" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_a75cf92b-2130-479e-9fb5-5aef16130793" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_GainLossOnDispositionOfLeaseAssignment_7291e247-1658-4d9e-add5-16fb14c37720" xlink:href="exdx-20241231.xsd#exdx_GainLossOnDispositionOfLeaseAssignment"/>
    <link:calculationArc order="14" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8e4ebdce-5cb2-4841-bc04-c5345bf94c18" xlink:to="loc_exdx_GainLossOnDispositionOfLeaseAssignment_7291e247-1658-4d9e-add5-16fb14c37720" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_078ec18d-ae87-480b-9fcd-989663102582" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_43bf93c3-9707-4083-ab4c-760ed6a6d540" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_078ec18d-ae87-480b-9fcd-989663102582" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_43bf93c3-9707-4083-ab4c-760ed6a6d540" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_2ea3b2bb-96e0-4d1c-87f5-fe57ef57c224" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_078ec18d-ae87-480b-9fcd-989663102582" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_2ea3b2bb-96e0-4d1c-87f5-fe57ef57c224" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_296e8913-2272-46db-9f4b-77c6a908f1ca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_078ec18d-ae87-480b-9fcd-989663102582" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_296e8913-2272-46db-9f4b-77c6a908f1ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_c8e313f8-fa85-4c0a-9536-66c7f5656c27" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_078ec18d-ae87-480b-9fcd-989663102582" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_c8e313f8-fa85-4c0a-9536-66c7f5656c27" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans_bb98ce51-3085-4c9c-be8a-48663b090f76" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_078ec18d-ae87-480b-9fcd-989663102582" xlink:to="loc_us-gaap_ProceedsFromStockPlans_bb98ce51-3085-4c9c-be8a-48663b090f76" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_92a5198e-92aa-4573-a817-42faeb16dc64" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4985fafa-8b48-4e5e-bf23-6cae7564b4db" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_92a5198e-92aa-4573-a817-42faeb16dc64" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4985fafa-8b48-4e5e-bf23-6cae7564b4db" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_81238070-1d24-4d0c-ad99-0c3bc2d1c86f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_92a5198e-92aa-4573-a817-42faeb16dc64" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_81238070-1d24-4d0c-ad99-0c3bc2d1c86f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2a203c3c-2530-498e-a90e-2fa0878ff553" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_92a5198e-92aa-4573-a817-42faeb16dc64" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2a203c3c-2530-498e-a90e-2fa0878ff553" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails" xlink:type="simple" xlink:href="exdx-20241231.xsd#SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c4c7bed3-d101-431f-a354-af40bbb79ba1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_9b7440ba-0e53-4a22-acf3-be1ac7693549" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCash"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c4c7bed3-d101-431f-a354-af40bbb79ba1" xlink:to="loc_us-gaap_RestrictedCash_9b7440ba-0e53-4a22-acf3-be1ac7693549" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_fe33523f-8901-4756-aa7d-a7f24cafb081" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c4c7bed3-d101-431f-a354-af40bbb79ba1" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_fe33523f-8901-4756-aa7d-a7f24cafb081" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/OtherFinancialInformationPrepaidExpensesDetails" xlink:type="simple" xlink:href="exdx-20241231.xsd#OtherFinancialInformationPrepaidExpensesDetails"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/OtherFinancialInformationPrepaidExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_e5db77a6-93ad-4a58-906d-47ae27c33e33" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_f54891ad-19b9-4298-ae59-e878de6f7500" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_e5db77a6-93ad-4a58-906d-47ae27c33e33" xlink:to="loc_us-gaap_OtherAssetsCurrent_f54891ad-19b9-4298-ae59-e878de6f7500" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent_81b5cbe4-6ed3-4b37-a927-666ecb298845" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_e5db77a6-93ad-4a58-906d-47ae27c33e33" xlink:to="loc_us-gaap_OtherPrepaidExpenseCurrent_81b5cbe4-6ed3-4b37-a927-666ecb298845" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/OtherFinancialInformationPropertyandEquipmentNetDetails" xlink:type="simple" xlink:href="exdx-20241231.xsd#OtherFinancialInformationPropertyandEquipmentNetDetails"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/OtherFinancialInformationPropertyandEquipmentNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_beab4473-9411-4c03-8294-05d3c831b121" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_accde679-8362-45c2-85bc-84684fae0b54" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_beab4473-9411-4c03-8294-05d3c831b121" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_accde679-8362-45c2-85bc-84684fae0b54" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_43cc05e2-c3c6-48e4-9c2a-763b2324678f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_beab4473-9411-4c03-8294-05d3c831b121" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_43cc05e2-c3c6-48e4-9c2a-763b2324678f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/OtherFinancialInformationAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="exdx-20241231.xsd#OtherFinancialInformationAccruedLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/OtherFinancialInformationAccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_e13fc769-3545-4546-ae8b-222d16f08f40" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalariesCurrent_96e4357a-b4ae-475b-a257-d86de2b4057a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedSalariesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_e13fc769-3545-4546-ae8b-222d16f08f40" xlink:to="loc_us-gaap_AccruedSalariesCurrent_96e4357a-b4ae-475b-a257-d86de2b4057a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_42cf2c1e-46b3-4b90-abee-40339ae39d1e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_e13fc769-3545-4546-ae8b-222d16f08f40" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_42cf2c1e-46b3-4b90-abee-40339ae39d1e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/BorrowingsFutureMinimumPaymentsDetails" xlink:type="simple" xlink:href="exdx-20241231.xsd#BorrowingsFutureMinimumPaymentsDetails"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/BorrowingsFutureMinimumPaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_exdx_LongTermDebtIncludingUndiscountedInterest_c02d83eb-0ab2-4fe9-a25b-06dca5883714" xlink:href="exdx-20241231.xsd#exdx_LongTermDebtIncludingUndiscountedInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_fb55ad05-fd71-4333-810d-46410bfadb9f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exdx_LongTermDebtIncludingUndiscountedInterest_c02d83eb-0ab2-4fe9-a25b-06dca5883714" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_fb55ad05-fd71-4333-810d-46410bfadb9f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_920a154e-c3db-49f4-81b4-aefc201b661f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exdx_LongTermDebtIncludingUndiscountedInterest_c02d83eb-0ab2-4fe9-a25b-06dca5883714" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_920a154e-c3db-49f4-81b4-aefc201b661f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_652a3356-2d32-49ab-868b-f97bd0031d3f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exdx_LongTermDebtIncludingUndiscountedInterest_c02d83eb-0ab2-4fe9-a25b-06dca5883714" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_652a3356-2d32-49ab-868b-f97bd0031d3f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_821136f4-fb3b-4d37-808b-a4a236694f15" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exdx_LongTermDebtIncludingUndiscountedInterest_c02d83eb-0ab2-4fe9-a25b-06dca5883714" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_821136f4-fb3b-4d37-808b-a4a236694f15" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_033b7adc-6315-4eb8-ae6a-2f0245d975e3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_acaf8214-91b2-4650-bb5f-eeac379b589b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_033b7adc-6315-4eb8-ae6a-2f0245d975e3" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_acaf8214-91b2-4650-bb5f-eeac379b589b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_LongTermDebtUndiscountedInterestAmount_24357ff4-eb4e-444c-8acf-c82a56d0cc0f" xlink:href="exdx-20241231.xsd#exdx_LongTermDebtUndiscountedInterestAmount"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_033b7adc-6315-4eb8-ae6a-2f0245d975e3" xlink:to="loc_exdx_LongTermDebtUndiscountedInterestAmount_24357ff4-eb4e-444c-8acf-c82a56d0cc0f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_LongTermDebtIncludingUndiscountedInterest_734e18af-54b2-41f1-a9e5-a2bde5d6677e" xlink:href="exdx-20241231.xsd#exdx_LongTermDebtIncludingUndiscountedInterest"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_033b7adc-6315-4eb8-ae6a-2f0245d975e3" xlink:to="loc_exdx_LongTermDebtIncludingUndiscountedInterest_734e18af-54b2-41f1-a9e5-a2bde5d6677e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/LeasesCostsAssociatedwiththeCompanysLeasesDetails" xlink:type="simple" xlink:href="exdx-20241231.xsd#LeasesCostsAssociatedwiththeCompanysLeasesDetails"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/LeasesCostsAssociatedwiththeCompanysLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_6ab5ae54-9b80-42a5-ae33-dc8639ec49e2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_e06ae2dd-f90f-417a-ab79-9f9b99d27d24" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_6ab5ae54-9b80-42a5-ae33-dc8639ec49e2" xlink:to="loc_us-gaap_OperatingLeaseCost_e06ae2dd-f90f-417a-ab79-9f9b99d27d24" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_658a6582-8cde-430f-844a-722456241f51" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_6ab5ae54-9b80-42a5-ae33-dc8639ec49e2" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_658a6582-8cde-430f-844a-722456241f51" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense_771ea3e7-9ba7-4dff-9cdf-3f0d45102b3a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_6ab5ae54-9b80-42a5-ae33-dc8639ec49e2" xlink:to="loc_us-gaap_FinanceLeaseInterestExpense_771ea3e7-9ba7-4dff-9cdf-3f0d45102b3a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/LeasesFuturePaymentsUnderOperatingAndFinanceLeasesDetails" xlink:type="simple" xlink:href="exdx-20241231.xsd#LeasesFuturePaymentsUnderOperatingAndFinanceLeasesDetails"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/LeasesFuturePaymentsUnderOperatingAndFinanceLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b5773466-12e2-4b60-9cfd-1a70f2308379" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_f9f1375b-19df-4968-98ef-fd59e6b3139d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b5773466-12e2-4b60-9cfd-1a70f2308379" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_f9f1375b-19df-4968-98ef-fd59e6b3139d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_a94840c3-971c-4275-948a-63a692423d0a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b5773466-12e2-4b60-9cfd-1a70f2308379" xlink:to="loc_us-gaap_OperatingLeaseLiability_a94840c3-971c-4275-948a-63a692423d0a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_9daf2775-97cb-49e2-a74c-1bcf3ae6ae7a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_c897eb04-4a41-4ea0-bc54-6dc45d6f36d5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_9daf2775-97cb-49e2-a74c-1bcf3ae6ae7a" xlink:to="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_c897eb04-4a41-4ea0-bc54-6dc45d6f36d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_3241a17f-061c-4816-8b37-b240f3e92107" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_9daf2775-97cb-49e2-a74c-1bcf3ae6ae7a" xlink:to="loc_us-gaap_FinanceLeaseLiability_3241a17f-061c-4816-8b37-b240f3e92107" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_b819bea5-45a6-4ac8-ade5-ebf7fa58e40d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_2c8f8b9e-ff35-466e-8943-c587b7456b80" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiability_b819bea5-45a6-4ac8-ade5-ebf7fa58e40d" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_2c8f8b9e-ff35-466e-8943-c587b7456b80" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_3425932c-03cc-44cb-a2ef-dd248e11deee" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiability_b819bea5-45a6-4ac8-ade5-ebf7fa58e40d" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_3425932c-03cc-44cb-a2ef-dd248e11deee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_5c1f7806-1fa1-49b8-95b8-b2435c38f391" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_5e5b4486-50d4-452c-ae1d-cb67d3f44944" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_5c1f7806-1fa1-49b8-95b8-b2435c38f391" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_5e5b4486-50d4-452c-ae1d-cb67d3f44944" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_800a4c4d-476e-4335-84ff-a02fc435b66c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_5c1f7806-1fa1-49b8-95b8-b2435c38f391" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_800a4c4d-476e-4335-84ff-a02fc435b66c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/LeasesFuturePaymentsUnderOperatingAndFinanceLeasesDetails_1" xlink:type="simple" xlink:href="exdx-20241231.xsd#LeasesFuturePaymentsUnderOperatingAndFinanceLeasesDetails_1"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/LeasesFuturePaymentsUnderOperatingAndFinanceLeasesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_e6e53211-a2e9-498f-bb4d-ec068351c744" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_f43e1bc1-57d8-4919-b827-3e3fa76c9991" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_e6e53211-a2e9-498f-bb4d-ec068351c744" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_f43e1bc1-57d8-4919-b827-3e3fa76c9991" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_776efd1c-4898-46e7-b8a8-293d54d06c03" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_e6e53211-a2e9-498f-bb4d-ec068351c744" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_776efd1c-4898-46e7-b8a8-293d54d06c03" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_77b1778b-21b1-49bf-bc31-3d429281d3a7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_e6e53211-a2e9-498f-bb4d-ec068351c744" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_77b1778b-21b1-49bf-bc31-3d429281d3a7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_8eba3d41-fdf4-4160-a6f1-da985f09916f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_cdf7e96b-f366-48ff-be71-907f4421f39a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_8eba3d41-fdf4-4160-a6f1-da985f09916f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_cdf7e96b-f366-48ff-be71-907f4421f39a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_8787f290-19f5-4db5-8c03-0fdfb59eb31c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_8eba3d41-fdf4-4160-a6f1-da985f09916f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_8787f290-19f5-4db5-8c03-0fdfb59eb31c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_7f2165f8-d9ef-4bda-b6df-b0d5d9287517" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_8eba3d41-fdf4-4160-a6f1-da985f09916f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_7f2165f8-d9ef-4bda-b6df-b0d5d9287517" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails" xlink:type="simple" xlink:href="exdx-20241231.xsd#IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_eacb7bd1-e97d-41b4-91fb-2e6fba9741ec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_e31f76a5-9265-4faf-8a94-870a7edf53ef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_eacb7bd1-e97d-41b4-91fb-2e6fba9741ec" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_e31f76a5-9265-4faf-8a94-870a7edf53ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_26917d95-f230-4ec8-ade8-825b2e7a26cd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_eacb7bd1-e97d-41b4-91fb-2e6fba9741ec" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_26917d95-f230-4ec8-ade8-825b2e7a26cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_a4467f10-c991-4434-871e-668d155be2df" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_a7e53c02-ac7d-4df3-87ad-6869a5b20d16" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_a4467f10-c991-4434-871e-668d155be2df" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_a7e53c02-ac7d-4df3-87ad-6869a5b20d16" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_ff375b61-5cde-4f73-a95a-4fce0a640b91" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_a4467f10-c991-4434-871e-668d155be2df" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_ff375b61-5cde-4f73-a95a-4fce0a640b91" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_7aed7cf2-5a43-4737-aca4-d2b68a39d58e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_4f82d227-b9bf-450e-b231-cb3454981b7c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_7aed7cf2-5a43-4737-aca4-d2b68a39d58e" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_4f82d227-b9bf-450e-b231-cb3454981b7c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_b86a3e46-84fe-4e55-8cd1-86eb5126f0bb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_7aed7cf2-5a43-4737-aca4-d2b68a39d58e" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_b86a3e46-84fe-4e55-8cd1-86eb5126f0bb" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails" xlink:type="simple" xlink:href="exdx-20241231.xsd#IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_4887d244-ca23-4eda-8bb7-1c2037ed45e3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_e1f3715e-4f82-4cfa-a284-248faeebc6c6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_4887d244-ca23-4eda-8bb7-1c2037ed45e3" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_e1f3715e-4f82-4cfa-a284-248faeebc6c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_27eb8a61-bcea-4992-8e17-50e7d3741f68" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_4887d244-ca23-4eda-8bb7-1c2037ed45e3" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_27eb8a61-bcea-4992-8e17-50e7d3741f68" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_dde4d286-ba16-434c-9349-cd7b3cb0bebe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_4887d244-ca23-4eda-8bb7-1c2037ed45e3" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_dde4d286-ba16-434c-9349-cd7b3cb0bebe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_cd8a86b8-b1f8-4382-bcff-ad970b36e1a7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_4887d244-ca23-4eda-8bb7-1c2037ed45e3" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_cd8a86b8-b1f8-4382-bcff-ad970b36e1a7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_d77c24d2-068b-4c0b-a13b-55b1e5131298" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_4887d244-ca23-4eda-8bb7-1c2037ed45e3" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_d77c24d2-068b-4c0b-a13b-55b1e5131298" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_f3a94980-b654-4f75-a3ee-d2402445423a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_4887d244-ca23-4eda-8bb7-1c2037ed45e3" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_f3a94980-b654-4f75-a3ee-d2402445423a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_7a575643-062f-4b44-971e-ce62f9e8369b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_4887d244-ca23-4eda-8bb7-1c2037ed45e3" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_7a575643-062f-4b44-971e-ce62f9e8369b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="exdx-20241231.xsd#IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_ab462b42-b031-4132-9353-2259ac8493a4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves_2cf9979b-7996-4591-94cc-2d52972f7140" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_ab462b42-b031-4132-9353-2259ac8493a4" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves_2cf9979b-7996-4591-94cc-2d52972f7140" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_d5624445-7fc2-4181-9c68-12f544330d89" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_ab462b42-b031-4132-9353-2259ac8493a4" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_d5624445-7fc2-4181-9c68-12f544330d89" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCapitalizationOfResearchAndExperimentationCosts_21745431-3d26-4ed7-8b82-2b13a21ae72a" xlink:href="exdx-20241231.xsd#exdx_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCapitalizationOfResearchAndExperimentationCosts"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_ab462b42-b031-4132-9353-2259ac8493a4" xlink:to="loc_exdx_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCapitalizationOfResearchAndExperimentationCosts_21745431-3d26-4ed7-8b82-2b13a21ae72a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_1cdf121d-757e-40c2-b451-6a0d932b5bf8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_ab462b42-b031-4132-9353-2259ac8493a4" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_1cdf121d-757e-40c2-b451-6a0d932b5bf8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_36d628d2-7bc6-4fe5-988a-cf9abfd13024" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_ab462b42-b031-4132-9353-2259ac8493a4" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_36d628d2-7bc6-4fe5-988a-cf9abfd13024" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_5732288a-0461-46a7-9a04-f297fa32416d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_ab462b42-b031-4132-9353-2259ac8493a4" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_5732288a-0461-46a7-9a04-f297fa32416d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_85d009a2-4871-49bb-a35e-fc98dd5c8ff0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_ab462b42-b031-4132-9353-2259ac8493a4" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_85d009a2-4871-49bb-a35e-fc98dd5c8ff0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DeferredTaxAssetsLeaseLiability_8957e709-8799-4143-9088-edf5f0886adb" xlink:href="exdx-20241231.xsd#exdx_DeferredTaxAssetsLeaseLiability"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_ab462b42-b031-4132-9353-2259ac8493a4" xlink:to="loc_exdx_DeferredTaxAssetsLeaseLiability_8957e709-8799-4143-9088-edf5f0886adb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_1c37f785-6676-4c4e-b2b8-ea137739d959" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_997b4711-d05d-4a17-9b7d-509fd728e47a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_1c37f785-6676-4c4e-b2b8-ea137739d959" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_997b4711-d05d-4a17-9b7d-509fd728e47a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_71263e04-33f4-44f4-ac32-318b1ec7b36a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_1c37f785-6676-4c4e-b2b8-ea137739d959" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_71263e04-33f4-44f4-ac32-318b1ec7b36a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_5baae9f7-915c-4144-acba-3a03dd8787d3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_0428d6ee-ec75-4a5f-9703-ee538bb0ba06" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_5baae9f7-915c-4144-acba-3a03dd8787d3" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_0428d6ee-ec75-4a5f-9703-ee538bb0ba06" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_f553d4a3-7aca-40c8-90bc-0203754205ef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_5baae9f7-915c-4144-acba-3a03dd8787d3" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_f553d4a3-7aca-40c8-90bc-0203754205ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_ae7d6d2d-40ec-41a5-b27a-b8446029e71f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets_15a1b467-43f8-417d-ac38-65111503ff7c" xlink:href="exdx-20241231.xsd#exdx_DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_ae7d6d2d-40ec-41a5-b27a-b8446029e71f" xlink:to="loc_exdx_DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets_15a1b467-43f8-417d-ac38-65111503ff7c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DeferredTaxLiabilitiesRightOfUseAssets_8d7a4453-f7c7-49f1-8a2d-ff254b670d80" xlink:href="exdx-20241231.xsd#exdx_DeferredTaxLiabilitiesRightOfUseAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_ae7d6d2d-40ec-41a5-b27a-b8446029e71f" xlink:to="loc_exdx_DeferredTaxLiabilitiesRightOfUseAssets_8d7a4453-f7c7-49f1-8a2d-ff254b670d80" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/SegmentReportingDetails" xlink:type="simple" xlink:href="exdx-20241231.xsd#SegmentReportingDetails"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/SegmentReportingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_5e38ef4c-a09c-4350-9ee1-439bb1cd5943" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LaborAndRelatedExpense_5af4d516-5531-4b85-a810-08694916a7a3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LaborAndRelatedExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_5e38ef4c-a09c-4350-9ee1-439bb1cd5943" xlink:to="loc_us-gaap_LaborAndRelatedExpense_5af4d516-5531-4b85-a810-08694916a7a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OutsideServicesExpense_8f6e573a-d470-4511-8efe-0a3e9c520634" xlink:href="exdx-20241231.xsd#exdx_OutsideServicesExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_5e38ef4c-a09c-4350-9ee1-439bb1cd5943" xlink:to="loc_exdx_OutsideServicesExpense_8f6e573a-d470-4511-8efe-0a3e9c520634" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OccupancyNet_e62188a0-026f-4064-badf-f4e3fbab22c0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OccupancyNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_5e38ef4c-a09c-4350-9ee1-439bb1cd5943" xlink:to="loc_us-gaap_OccupancyNet_e62188a0-026f-4064-badf-f4e3fbab22c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TravelAndEntertainmentExpense_a29b09da-c71a-4939-917a-00eca5116679" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TravelAndEntertainmentExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_5e38ef4c-a09c-4350-9ee1-439bb1cd5943" xlink:to="loc_us-gaap_TravelAndEntertainmentExpense_a29b09da-c71a-4939-917a-00eca5116679" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_aeacefb0-f9c7-4369-bc74-e8e5909ab27c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_5e38ef4c-a09c-4350-9ee1-439bb1cd5943" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_aeacefb0-f9c7-4369-bc74-e8e5909ab27c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_32f6d899-4baa-4f08-aced-5d420b83fbb2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_5e38ef4c-a09c-4350-9ee1-439bb1cd5943" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_32f6d899-4baa-4f08-aced-5d420b83fbb2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingOtherItemAmount_68633b18-bee0-47b4-832d-cf17aea2f4e5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingOtherItemAmount"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_5e38ef4c-a09c-4350-9ee1-439bb1cd5943" xlink:to="loc_us-gaap_SegmentReportingOtherItemAmount_68633b18-bee0-47b4-832d-cf17aea2f4e5" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>exdx-20241231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:7095620a-7684-4e36-937b-24fd606ed1ea,g:3f375e3f-dda6-40cc-be01-a2493780a401-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.exagen.com/role/StatementsofStockholdersEquity" xlink:type="simple" xlink:href="exdx-20241231.xsd#StatementsofStockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/StatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_e19312a0-4012-4475-9a88-fc70f15c6851" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_767a4f22-9062-4191-a10e-5154fac42302" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_e19312a0-4012-4475-9a88-fc70f15c6851" xlink:to="loc_us-gaap_StatementTable_767a4f22-9062-4191-a10e-5154fac42302" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_18926d3a-6710-4598-abf0-ee40e537714f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_767a4f22-9062-4191-a10e-5154fac42302" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_18926d3a-6710-4598-abf0-ee40e537714f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_18926d3a-6710-4598-abf0-ee40e537714f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_18926d3a-6710-4598-abf0-ee40e537714f" xlink:to="loc_us-gaap_EquityComponentDomain_18926d3a-6710-4598-abf0-ee40e537714f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_532dec69-2378-4141-b7e4-421a2a53103e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_18926d3a-6710-4598-abf0-ee40e537714f" xlink:to="loc_us-gaap_EquityComponentDomain_532dec69-2378-4141-b7e4-421a2a53103e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_c24caff9-5b76-4b57-b6fd-673ba8ee78b8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_532dec69-2378-4141-b7e4-421a2a53103e" xlink:to="loc_us-gaap_CommonStockMember_c24caff9-5b76-4b57-b6fd-673ba8ee78b8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_aa273674-57e7-4ce1-abc5-ac5f45d90d53" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_532dec69-2378-4141-b7e4-421a2a53103e" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_aa273674-57e7-4ce1-abc5-ac5f45d90d53" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_f1a167af-b408-43be-90ca-f81f4e803e2e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_532dec69-2378-4141-b7e4-421a2a53103e" xlink:to="loc_us-gaap_RetainedEarningsMember_f1a167af-b408-43be-90ca-f81f4e803e2e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3e0ec477-12c3-4815-b5f8-0cf4619f1d88" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e19312a0-4012-4475-9a88-fc70f15c6851" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3e0ec477-12c3-4815-b5f8-0cf4619f1d88" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_87444e71-b9a3-4479-be92-6cd303374d65" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3e0ec477-12c3-4815-b5f8-0cf4619f1d88" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_87444e71-b9a3-4479-be92-6cd303374d65" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_c81e425e-1794-408c-950e-ed5d6643957b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3e0ec477-12c3-4815-b5f8-0cf4619f1d88" xlink:to="loc_us-gaap_StockholdersEquity_c81e425e-1794-408c-950e-ed5d6643957b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesShares_9a77191f-0fc7-44ed-88d4-ad5f76fcbeeb" xlink:href="exdx-20241231.xsd#exdx_IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3e0ec477-12c3-4815-b5f8-0cf4619f1d88" xlink:to="loc_exdx_IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesShares_9a77191f-0fc7-44ed-88d4-ad5f76fcbeeb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_ddc6fd82-db6b-424a-b25c-bf027229cc23" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3e0ec477-12c3-4815-b5f8-0cf4619f1d88" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_ddc6fd82-db6b-424a-b25c-bf027229cc23" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_32fef974-41bb-402e-9b97-6d328f6651fb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3e0ec477-12c3-4815-b5f8-0cf4619f1d88" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_32fef974-41bb-402e-9b97-6d328f6651fb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_8ef83387-0704-4689-a777-5c2c8e90efa9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3e0ec477-12c3-4815-b5f8-0cf4619f1d88" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_8ef83387-0704-4689-a777-5c2c8e90efa9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_3819a5b2-f400-4c3e-b9c9-dd739d50163c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3e0ec477-12c3-4815-b5f8-0cf4619f1d88" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_3819a5b2-f400-4c3e-b9c9-dd739d50163c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_19405dba-bb1a-4c2d-a9fa-799606bf7c60" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3e0ec477-12c3-4815-b5f8-0cf4619f1d88" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_19405dba-bb1a-4c2d-a9fa-799606bf7c60" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_ec8ed788-d1b7-437e-bd92-9bead6282157" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3e0ec477-12c3-4815-b5f8-0cf4619f1d88" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_ec8ed788-d1b7-437e-bd92-9bead6282157" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_2d782a93-69ec-4ed0-8acf-d47fadb378bd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3e0ec477-12c3-4815-b5f8-0cf4619f1d88" xlink:to="loc_us-gaap_NetIncomeLoss_2d782a93-69ec-4ed0-8acf-d47fadb378bd" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_5c9a63e4-362c-4f31-8698-42bfca5e9cbe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_ac9e22c9-60ac-4010-aab9-c9caae16ac28" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails" xlink:type="simple" xlink:href="exdx-20241231.xsd#SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_9a1f1a53-48df-4ce8-83fb-75b279c7c75b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_dacb8bb9-5afe-4b61-b7b4-9d9e08568e0b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9a1f1a53-48df-4ce8-83fb-75b279c7c75b" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_dacb8bb9-5afe-4b61-b7b4-9d9e08568e0b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_53e7d71c-85da-4491-b2e7-f1e11dfa1c0f" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_dacb8bb9-5afe-4b61-b7b4-9d9e08568e0b" xlink:to="loc_srt_MajorCustomersAxis_53e7d71c-85da-4491-b2e7-f1e11dfa1c0f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_53e7d71c-85da-4491-b2e7-f1e11dfa1c0f_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_53e7d71c-85da-4491-b2e7-f1e11dfa1c0f" xlink:to="loc_srt_NameOfMajorCustomerDomain_53e7d71c-85da-4491-b2e7-f1e11dfa1c0f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_ac3de328-2fe0-44ce-897f-fcaeb9640972" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_53e7d71c-85da-4491-b2e7-f1e11dfa1c0f" xlink:to="loc_srt_NameOfMajorCustomerDomain_ac3de328-2fe0-44ce-897f-fcaeb9640972" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_MedicareMember_80605c37-d111-4d76-90b7-e6d8a37da148" xlink:href="exdx-20241231.xsd#exdx_MedicareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_ac3de328-2fe0-44ce-897f-fcaeb9640972" xlink:to="loc_exdx_MedicareMember_80605c37-d111-4d76-90b7-e6d8a37da148" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_MedicareAdvantageMember_7e6224b5-f5de-4b75-9023-b5cb8d5b88ce" xlink:href="exdx-20241231.xsd#exdx_MedicareAdvantageMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_ac3de328-2fe0-44ce-897f-fcaeb9640972" xlink:to="loc_exdx_MedicareAdvantageMember_7e6224b5-f5de-4b75-9023-b5cb8d5b88ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_UnitedHealthcareMember_b16610de-8063-4e36-a4e1-524c52b5d0fe" xlink:href="exdx-20241231.xsd#exdx_UnitedHealthcareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_ac3de328-2fe0-44ce-897f-fcaeb9640972" xlink:to="loc_exdx_UnitedHealthcareMember_b16610de-8063-4e36-a4e1-524c52b5d0fe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_4c1f2ecc-95f7-4671-9ceb-cad066c41c24" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_dacb8bb9-5afe-4b61-b7b4-9d9e08568e0b" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_4c1f2ecc-95f7-4671-9ceb-cad066c41c24" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_4c1f2ecc-95f7-4671-9ceb-cad066c41c24_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_4c1f2ecc-95f7-4671-9ceb-cad066c41c24" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_4c1f2ecc-95f7-4671-9ceb-cad066c41c24_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_904ade9d-8e00-4eae-88a5-351bafad6d0c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_4c1f2ecc-95f7-4671-9ceb-cad066c41c24" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_904ade9d-8e00-4eae-88a5-351bafad6d0c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_3195a757-dea7-4fdd-9e4f-ff3a98498c91" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_904ade9d-8e00-4eae-88a5-351bafad6d0c" xlink:to="loc_us-gaap_SalesRevenueNetMember_3195a757-dea7-4fdd-9e4f-ff3a98498c91" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_af331243-1c63-438f-ba4b-09328fabe212" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_904ade9d-8e00-4eae-88a5-351bafad6d0c" xlink:to="loc_us-gaap_AccountsReceivableMember_af331243-1c63-438f-ba4b-09328fabe212" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_acd92da5-9f2a-4a93-8d87-6627b0003691" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_dacb8bb9-5afe-4b61-b7b4-9d9e08568e0b" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_acd92da5-9f2a-4a93-8d87-6627b0003691" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_acd92da5-9f2a-4a93-8d87-6627b0003691_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_acd92da5-9f2a-4a93-8d87-6627b0003691" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_acd92da5-9f2a-4a93-8d87-6627b0003691_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_a6e77280-bf44-447f-8ace-71b16a5c8bbd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_acd92da5-9f2a-4a93-8d87-6627b0003691" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_a6e77280-bf44-447f-8ace-71b16a5c8bbd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_818437f3-4834-4b00-b48e-3a4c487574c9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_a6e77280-bf44-447f-8ace-71b16a5c8bbd" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_818437f3-4834-4b00-b48e-3a4c487574c9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_ba612f07-2533-41a7-b897-5b28f07a34f8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9a1f1a53-48df-4ce8-83fb-75b279c7c75b" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_ba612f07-2533-41a7-b897-5b28f07a34f8" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="exdx-20241231.xsd#SummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_bb77835e-452f-4fe6-a120-c8e0539e3886" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_9455c93b-8cc9-431d-b69b-ca1eaccb8f98" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_bb77835e-452f-4fe6-a120-c8e0539e3886" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_9455c93b-8cc9-431d-b69b-ca1eaccb8f98" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a688464d-3311-4b42-b284-9fed0ca79b65" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_9455c93b-8cc9-431d-b69b-ca1eaccb8f98" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a688464d-3311-4b42-b284-9fed0ca79b65" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_a688464d-3311-4b42-b284-9fed0ca79b65_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a688464d-3311-4b42-b284-9fed0ca79b65" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_a688464d-3311-4b42-b284-9fed0ca79b65_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_bcd12684-c0a6-4b46-8b88-35f50b7c6b90" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a688464d-3311-4b42-b284-9fed0ca79b65" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_bcd12684-c0a6-4b46-8b88-35f50b7c6b90" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_4e1d5cdd-fa42-46c6-a301-bed233d7b4a3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_bcd12684-c0a6-4b46-8b88-35f50b7c6b90" xlink:to="loc_us-gaap_SalesRevenueNetMember_4e1d5cdd-fa42-46c6-a301-bed233d7b4a3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_ddf3febc-564d-4199-b420-5a83b5baa424" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_9455c93b-8cc9-431d-b69b-ca1eaccb8f98" xlink:to="loc_srt_ProductOrServiceAxis_ddf3febc-564d-4199-b420-5a83b5baa424" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ddf3febc-564d-4199-b420-5a83b5baa424_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_ddf3febc-564d-4199-b420-5a83b5baa424" xlink:to="loc_srt_ProductsAndServicesDomain_ddf3febc-564d-4199-b420-5a83b5baa424_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_727aabe5-bcbf-4498-bd27-193cf395e887" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_ddf3febc-564d-4199-b420-5a83b5baa424" xlink:to="loc_srt_ProductsAndServicesDomain_727aabe5-bcbf-4498-bd27-193cf395e887" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AVISECTDTestMember_4237daf3-630e-4a2c-befa-23ced963c907" xlink:href="exdx-20241231.xsd#exdx_AVISECTDTestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_727aabe5-bcbf-4498-bd27-193cf395e887" xlink:to="loc_exdx_AVISECTDTestMember_4237daf3-630e-4a2c-befa-23ced963c907" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShippingAndHandlingMember_194ef6ba-cc88-4a07-88da-fab27b62abc3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShippingAndHandlingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_727aabe5-bcbf-4498-bd27-193cf395e887" xlink:to="loc_us-gaap_ShippingAndHandlingMember_194ef6ba-cc88-4a07-88da-fab27b62abc3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_0affd1bf-6b29-488d-8fd0-b0405fc8bfe6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_9455c93b-8cc9-431d-b69b-ca1eaccb8f98" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_0affd1bf-6b29-488d-8fd0-b0405fc8bfe6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_0affd1bf-6b29-488d-8fd0-b0405fc8bfe6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_0affd1bf-6b29-488d-8fd0-b0405fc8bfe6" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_0affd1bf-6b29-488d-8fd0-b0405fc8bfe6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_4e585fdf-b598-4de3-b569-badc1799c59f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_0affd1bf-6b29-488d-8fd0-b0405fc8bfe6" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_4e585fdf-b598-4de3-b569-badc1799c59f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember_e64adf5a-b136-4a50-90e8-2140285c57a8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_4e585fdf-b598-4de3-b569-badc1799c59f" xlink:to="loc_us-gaap_ProductConcentrationRiskMember_e64adf5a-b136-4a50-90e8-2140285c57a8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplierConcentrationRiskMember_2663d25e-63c8-4465-82ca-7bad127b3257" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplierConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_4e585fdf-b598-4de3-b569-badc1799c59f" xlink:to="loc_us-gaap_SupplierConcentrationRiskMember_2663d25e-63c8-4465-82ca-7bad127b3257" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_1d6535a2-7079-4447-9453-10fe3f783dde" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_9455c93b-8cc9-431d-b69b-ca1eaccb8f98" xlink:to="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_1d6535a2-7079-4447-9453-10fe3f783dde" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_1d6535a2-7079-4447-9453-10fe3f783dde_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_1d6535a2-7079-4447-9453-10fe3f783dde" xlink:to="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_1d6535a2-7079-4447-9453-10fe3f783dde_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_a4113f74-85a0-4d02-b13e-edaa8dec7ac4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_1d6535a2-7079-4447-9453-10fe3f783dde" xlink:to="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_a4113f74-85a0-4d02-b13e-edaa8dec7ac4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_SupplierOneMember_9064a1e9-8d55-4263-be97-cd517db42152" xlink:href="exdx-20241231.xsd#exdx_SupplierOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_a4113f74-85a0-4d02-b13e-edaa8dec7ac4" xlink:to="loc_exdx_SupplierOneMember_9064a1e9-8d55-4263-be97-cd517db42152" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_SupplierTwoMember_5d286bc7-1d94-415b-90d1-4914140b5668" xlink:href="exdx-20241231.xsd#exdx_SupplierTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_a4113f74-85a0-4d02-b13e-edaa8dec7ac4" xlink:to="loc_exdx_SupplierTwoMember_5d286bc7-1d94-415b-90d1-4914140b5668" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_b67ce9bd-cd69-494f-a5e5-96099397d312" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_9455c93b-8cc9-431d-b69b-ca1eaccb8f98" xlink:to="loc_srt_RangeAxis_b67ce9bd-cd69-494f-a5e5-96099397d312" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b67ce9bd-cd69-494f-a5e5-96099397d312_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_b67ce9bd-cd69-494f-a5e5-96099397d312" xlink:to="loc_srt_RangeMember_b67ce9bd-cd69-494f-a5e5-96099397d312_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d14128f9-29f5-4d2a-8244-9048f97fd5a2" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_b67ce9bd-cd69-494f-a5e5-96099397d312" xlink:to="loc_srt_RangeMember_d14128f9-29f5-4d2a-8244-9048f97fd5a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_bc0d9dd6-6050-4d10-8975-a59b6f825ccd" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_d14128f9-29f5-4d2a-8244-9048f97fd5a2" xlink:to="loc_srt_MinimumMember_bc0d9dd6-6050-4d10-8975-a59b6f825ccd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_4ad4aab6-e9e3-4537-a85b-9af4f30c663f" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_d14128f9-29f5-4d2a-8244-9048f97fd5a2" xlink:to="loc_srt_MaximumMember_4ad4aab6-e9e3-4537-a85b-9af4f30c663f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_49fb9621-a89f-4436-b0bc-6124c195ede6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_bb77835e-452f-4fe6-a120-c8e0539e3886" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_49fb9621-a89f-4436-b0bc-6124c195ede6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_85f61537-4c3d-43b3-a57c-54b9e10ea29e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_bb77835e-452f-4fe6-a120-c8e0539e3886" xlink:to="loc_us-gaap_RestrictedCash_85f61537-4c3d-43b3-a57c-54b9e10ea29e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_ea1ba37b-3f78-4301-90dd-e5999b4249cd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_bb77835e-452f-4fe6-a120-c8e0539e3886" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_ea1ba37b-3f78-4301-90dd-e5999b4249cd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_30e8dc9d-6d79-4180-b6a2-d6ef874d6d2b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_bb77835e-452f-4fe6-a120-c8e0539e3886" xlink:to="loc_us-gaap_NumberOfOperatingSegments_30e8dc9d-6d79-4180-b6a2-d6ef874d6d2b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportingUnits_51247100-e974-4f17-9c52-e18f991b9467" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportingUnits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_bb77835e-452f-4fe6-a120-c8e0539e3886" xlink:to="loc_us-gaap_NumberOfReportingUnits_51247100-e974-4f17-9c52-e18f991b9467" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_d9c6ed24-a0b4-4155-ae2a-12c11f7a7e93" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_bb77835e-452f-4fe6-a120-c8e0539e3886" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_d9c6ed24-a0b4-4155-ae2a-12c11f7a7e93" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivableAllowanceForCreditLossExcludingAccruedInterest_a9880fa7-952b-4d55-8206-0be535dd30fc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancingReceivableAllowanceForCreditLossExcludingAccruedInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_bb77835e-452f-4fe6-a120-c8e0539e3886" xlink:to="loc_us-gaap_FinancingReceivableAllowanceForCreditLossExcludingAccruedInterest_a9880fa7-952b-4d55-8206-0be535dd30fc" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_4732d7de-cd19-4598-ba66-7ad82afd9c6d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_bb77835e-452f-4fe6-a120-c8e0539e3886" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_4732d7de-cd19-4598-ba66-7ad82afd9c6d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense_c12a6dae-0305-4f5f-8f2e-46090b72bdbd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdvertisingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_bb77835e-452f-4fe6-a120-c8e0539e3886" xlink:to="loc_us-gaap_AdvertisingExpense_c12a6dae-0305-4f5f-8f2e-46090b72bdbd" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_f361f130-060c-4720-95d8-b0be556614ae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_bb77835e-452f-4fe6-a120-c8e0539e3886" xlink:to="loc_us-gaap_CostOfRevenue_f361f130-060c-4720-95d8-b0be556614ae" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments_b9034c21-ff7f-4d31-920b-a8c3aaf3368c" xlink:href="exdx-20241231.xsd#exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_bb77835e-452f-4fe6-a120-c8e0539e3886" xlink:to="loc_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments_b9034c21-ff7f-4d31-920b-a8c3aaf3368c" xlink:type="arc" order="10"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails" xlink:type="simple" xlink:href="exdx-20241231.xsd#SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_da7c2885-e4af-44d6-8ea5-3d161a934e64" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_5c5970f8-7bb6-4811-8e53-595c1c8cb806" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_da7c2885-e4af-44d6-8ea5-3d161a934e64" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_5c5970f8-7bb6-4811-8e53-595c1c8cb806" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_262f6643-a941-458b-8022-b2ebf41406cf" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_5c5970f8-7bb6-4811-8e53-595c1c8cb806" xlink:to="loc_srt_MajorCustomersAxis_262f6643-a941-458b-8022-b2ebf41406cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_262f6643-a941-458b-8022-b2ebf41406cf_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_262f6643-a941-458b-8022-b2ebf41406cf" xlink:to="loc_srt_NameOfMajorCustomerDomain_262f6643-a941-458b-8022-b2ebf41406cf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_beb95adb-ca85-4311-8df1-721c82da213a" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_262f6643-a941-458b-8022-b2ebf41406cf" xlink:to="loc_srt_NameOfMajorCustomerDomain_beb95adb-ca85-4311-8df1-721c82da213a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_CommercialMember_8c881c1d-4cf0-4e20-9a42-ab4ff9e2c5f3" xlink:href="exdx-20241231.xsd#exdx_CommercialMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_beb95adb-ca85-4311-8df1-721c82da213a" xlink:to="loc_exdx_CommercialMember_8c881c1d-4cf0-4e20-9a42-ab4ff9e2c5f3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_Government1Member_172f08be-9ec5-4adb-b3ce-93186c5b7a07" xlink:href="exdx-20241231.xsd#exdx_Government1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_beb95adb-ca85-4311-8df1-721c82da213a" xlink:to="loc_exdx_Government1Member_172f08be-9ec5-4adb-b3ce-93186c5b7a07" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ClientMember_b9d8865d-cad9-4669-a09b-404a9a564276" xlink:href="exdx-20241231.xsd#exdx_ClientMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_beb95adb-ca85-4311-8df1-721c82da213a" xlink:to="loc_exdx_ClientMember_b9d8865d-cad9-4669-a09b-404a9a564276" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCustomerMember_29f2804e-c4b5-4473-a116-b160fb96afa4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCustomerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_beb95adb-ca85-4311-8df1-721c82da213a" xlink:to="loc_us-gaap_OtherCustomerMember_29f2804e-c4b5-4473-a116-b160fb96afa4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f7ccebc0-9bbb-449b-9da8-fbd35d5500d3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_da7c2885-e4af-44d6-8ea5-3d161a934e64" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f7ccebc0-9bbb-449b-9da8-fbd35d5500d3" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesSecuritiesDetails" xlink:type="simple" xlink:href="exdx-20241231.xsd#SummaryofSignificantAccountingPoliciesSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_21012c7c-63ff-434e-826f-6e6d5388aca1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_930c8bd2-ccdf-4628-a200-e91d78596421" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_21012c7c-63ff-434e-826f-6e6d5388aca1" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_930c8bd2-ccdf-4628-a200-e91d78596421" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_44641418-315c-4166-910b-6a7128b13cda" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_930c8bd2-ccdf-4628-a200-e91d78596421" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_44641418-315c-4166-910b-6a7128b13cda" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_44641418-315c-4166-910b-6a7128b13cda_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_44641418-315c-4166-910b-6a7128b13cda" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_44641418-315c-4166-910b-6a7128b13cda_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_15596d88-ce7b-433d-809a-62f34a7b66b3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_44641418-315c-4166-910b-6a7128b13cda" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_15596d88-ce7b-433d-809a-62f34a7b66b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_005f4e83-3f7e-4b5b-abfd-65ee08ea7b47" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_15596d88-ce7b-433d-809a-62f34a7b66b3" xlink:to="loc_us-gaap_WarrantMember_005f4e83-3f7e-4b5b-abfd-65ee08ea7b47" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember_de2f811f-f3b6-40e0-bd3c-1b3c1ec7a1b8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_15596d88-ce7b-433d-809a-62f34a7b66b3" xlink:to="loc_us-gaap_StockOptionMember_de2f811f-f3b6-40e0-bd3c-1b3c1ec7a1b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_2451bc1e-8fe4-4cb4-869f-59b674610067" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_15596d88-ce7b-433d-809a-62f34a7b66b3" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_2451bc1e-8fe4-4cb4-869f-59b674610067" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_8152f953-2072-4271-a9db-d31ac922a5f5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_15596d88-ce7b-433d-809a-62f34a7b66b3" xlink:to="loc_us-gaap_EmployeeStockMember_8152f953-2072-4271-a9db-d31ac922a5f5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_53f1b2e6-fb82-426c-b56b-22c036d7fbcd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_21012c7c-63ff-434e-826f-6e6d5388aca1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_53f1b2e6-fb82-426c-b56b-22c036d7fbcd" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/OtherFinancialInformationPropertyandEquipmentNetDetails" xlink:type="simple" xlink:href="exdx-20241231.xsd#OtherFinancialInformationPropertyandEquipmentNetDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/OtherFinancialInformationPropertyandEquipmentNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_01c1ef8c-8fda-41ab-90f3-60c85bd51805" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_41cf2598-5072-4f37-b2f1-e6836b171896" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_01c1ef8c-8fda-41ab-90f3-60c85bd51805" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_41cf2598-5072-4f37-b2f1-e6836b171896" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_7f6f51e8-6a84-4fe9-8acb-7dffb87bc19e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_41cf2598-5072-4f37-b2f1-e6836b171896" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_7f6f51e8-6a84-4fe9-8acb-7dffb87bc19e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7f6f51e8-6a84-4fe9-8acb-7dffb87bc19e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_7f6f51e8-6a84-4fe9-8acb-7dffb87bc19e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7f6f51e8-6a84-4fe9-8acb-7dffb87bc19e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9214cf6b-fd1d-453c-a8f9-102c66198074" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_7f6f51e8-6a84-4fe9-8acb-7dffb87bc19e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9214cf6b-fd1d-453c-a8f9-102c66198074" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_3daddaaa-c1c8-4a46-892a-f036296f10a8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9214cf6b-fd1d-453c-a8f9-102c66198074" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_3daddaaa-c1c8-4a46-892a-f036296f10a8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_LaboratoryEquipmentMember_ea7926a1-4495-4db0-ae6b-c06f31e48669" xlink:href="exdx-20241231.xsd#exdx_LaboratoryEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9214cf6b-fd1d-453c-a8f9-102c66198074" xlink:to="loc_exdx_LaboratoryEquipmentMember_ea7926a1-4495-4db0-ae6b-c06f31e48669" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ComputerEquipmentAndSoftwareMember_3fe084d4-81cd-4483-b746-ecc07d8777c7" xlink:href="exdx-20241231.xsd#exdx_ComputerEquipmentAndSoftwareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9214cf6b-fd1d-453c-a8f9-102c66198074" xlink:to="loc_exdx_ComputerEquipmentAndSoftwareMember_3fe084d4-81cd-4483-b746-ecc07d8777c7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_d0e63e7c-5903-46d1-b676-f4f4469f343c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9214cf6b-fd1d-453c-a8f9-102c66198074" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_d0e63e7c-5903-46d1-b676-f4f4469f343c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_75ff2140-946a-4a32-8a4e-4645c4f263b1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9214cf6b-fd1d-453c-a8f9-102c66198074" xlink:to="loc_us-gaap_ConstructionInProgressMember_75ff2140-946a-4a32-8a4e-4645c4f263b1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_51efd51e-44c5-4cbd-a6eb-cef8cc965326" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_01c1ef8c-8fda-41ab-90f3-60c85bd51805" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_51efd51e-44c5-4cbd-a6eb-cef8cc965326" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_e7314019-1e83-467b-b756-723cb8f3f771" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_01c1ef8c-8fda-41ab-90f3-60c85bd51805" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_e7314019-1e83-467b-b756-723cb8f3f771" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_483047f1-3778-42ee-9a52-55c915542680" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_01c1ef8c-8fda-41ab-90f3-60c85bd51805" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_483047f1-3778-42ee-9a52-55c915542680" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/OtherFinancialInformationNarrativeDetails" xlink:type="simple" xlink:href="exdx-20241231.xsd#OtherFinancialInformationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/OtherFinancialInformationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c240ee88-1ee6-45ef-b0e0-a6015c7daff8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_73074f1e-24be-4ac3-aa89-611a6de2d67c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c240ee88-1ee6-45ef-b0e0-a6015c7daff8" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_73074f1e-24be-4ac3-aa89-611a6de2d67c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c8e207cc-6f01-4ed8-9451-b95a2909c184" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_73074f1e-24be-4ac3-aa89-611a6de2d67c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c8e207cc-6f01-4ed8-9451-b95a2909c184" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c8e207cc-6f01-4ed8-9451-b95a2909c184_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c8e207cc-6f01-4ed8-9451-b95a2909c184" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c8e207cc-6f01-4ed8-9451-b95a2909c184_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0b2b354e-0779-4331-aedc-08a1fb3e30e9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c8e207cc-6f01-4ed8-9451-b95a2909c184" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0b2b354e-0779-4331-aedc-08a1fb3e30e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_20de3730-58e7-4172-848c-c98f6dcd6159" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BuildingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0b2b354e-0779-4331-aedc-08a1fb3e30e9" xlink:to="loc_us-gaap_BuildingMember_20de3730-58e7-4172-848c-c98f6dcd6159" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_a4b5e6a1-efad-4f27-8a73-aac4401ab26c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c240ee88-1ee6-45ef-b0e0-a6015c7daff8" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_a4b5e6a1-efad-4f27-8a73-aac4401ab26c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_cd24c26b-aa2d-4ee0-bcee-23cbcb56d4d5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c240ee88-1ee6-45ef-b0e0-a6015c7daff8" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_cd24c26b-aa2d-4ee0-bcee-23cbcb56d4d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_01e2576f-3b1d-4288-a965-a6b840150b12" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c240ee88-1ee6-45ef-b0e0-a6015c7daff8" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_01e2576f-3b1d-4288-a965-a6b840150b12" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_b32bf8ce-a34f-43ab-b719-1834b810915c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c240ee88-1ee6-45ef-b0e0-a6015c7daff8" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_b32bf8ce-a34f-43ab-b719-1834b810915c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsGross_d3204a3a-a34d-4524-a28c-32a3b1dd479e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c240ee88-1ee6-45ef-b0e0-a6015c7daff8" xlink:to="loc_us-gaap_LeaseholdImprovementsGross_d3204a3a-a34d-4524-a28c-32a3b1dd479e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_GainLossOnDispositionOfLeaseAssignment_731a57ac-355b-4cb4-9b44-65d8c788976f" xlink:href="exdx-20241231.xsd#exdx_GainLossOnDispositionOfLeaseAssignment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c240ee88-1ee6-45ef-b0e0-a6015c7daff8" xlink:to="loc_exdx_GainLossOnDispositionOfLeaseAssignment_731a57ac-355b-4cb4-9b44-65d8c788976f" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/BorrowingsNarrativeDetails" xlink:type="simple" xlink:href="exdx-20241231.xsd#BorrowingsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/BorrowingsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_13604e5c-ba24-4350-a12a-c93d0fe7e852" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_93f75f41-96cd-45c2-a8e4-372b88874308" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_13604e5c-ba24-4350-a12a-c93d0fe7e852" xlink:to="loc_us-gaap_DebtInstrumentTable_93f75f41-96cd-45c2-a8e4-372b88874308" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_d1e89647-8be8-4a80-8d22-4679e03562ec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_93f75f41-96cd-45c2-a8e4-372b88874308" xlink:to="loc_us-gaap_DebtInstrumentAxis_d1e89647-8be8-4a80-8d22-4679e03562ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_d1e89647-8be8-4a80-8d22-4679e03562ec_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_d1e89647-8be8-4a80-8d22-4679e03562ec" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_d1e89647-8be8-4a80-8d22-4679e03562ec_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_e4b9e374-4085-4777-a278-925a9898070d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_d1e89647-8be8-4a80-8d22-4679e03562ec" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_e4b9e374-4085-4777-a278-925a9898070d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AmendedLoanAgreementMember_d44151e8-5274-4ee9-b3f8-8d9c3001a969" xlink:href="exdx-20241231.xsd#exdx_AmendedLoanAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e4b9e374-4085-4777-a278-925a9898070d" xlink:to="loc_exdx_AmendedLoanAgreementMember_d44151e8-5274-4ee9-b3f8-8d9c3001a969" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_Term2017Member_5e3d2754-d679-4e14-92bb-ce1d952cf720" xlink:href="exdx-20241231.xsd#exdx_Term2017Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e4b9e374-4085-4777-a278-925a9898070d" xlink:to="loc_exdx_Term2017Member_5e3d2754-d679-4e14-92bb-ce1d952cf720" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_EquipmentNotesPayableMember_6d20a9e6-ec12-45f5-9c83-e3a8a19961bb" xlink:href="exdx-20241231.xsd#exdx_EquipmentNotesPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e4b9e374-4085-4777-a278-925a9898070d" xlink:to="loc_exdx_EquipmentNotesPayableMember_6d20a9e6-ec12-45f5-9c83-e3a8a19961bb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_c6716e1b-2395-4f1d-bf29-963b64533ed0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_93f75f41-96cd-45c2-a8e4-372b88874308" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_c6716e1b-2395-4f1d-bf29-963b64533ed0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_c6716e1b-2395-4f1d-bf29-963b64533ed0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_c6716e1b-2395-4f1d-bf29-963b64533ed0" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_c6716e1b-2395-4f1d-bf29-963b64533ed0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_2ea646bf-1725-46a5-9d39-bd4a2492f003" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_c6716e1b-2395-4f1d-bf29-963b64533ed0" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_2ea646bf-1725-46a5-9d39-bd4a2492f003" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_InnovatusLifeSciencesLendingFundMember_f1d82b30-4b5d-4b89-b9cc-0b9366c73c4a" xlink:href="exdx-20241231.xsd#exdx_InnovatusLifeSciencesLendingFundMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_2ea646bf-1725-46a5-9d39-bd4a2492f003" xlink:to="loc_exdx_InnovatusLifeSciencesLendingFundMember_f1d82b30-4b5d-4b89-b9cc-0b9366c73c4a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_1f1f3ee7-b1b4-4dad-bf91-0629bf9f60a7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_93f75f41-96cd-45c2-a8e4-372b88874308" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_1f1f3ee7-b1b4-4dad-bf91-0629bf9f60a7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1f1f3ee7-b1b4-4dad-bf91-0629bf9f60a7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1f1f3ee7-b1b4-4dad-bf91-0629bf9f60a7" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1f1f3ee7-b1b4-4dad-bf91-0629bf9f60a7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_5047184c-227c-422a-872f-07ebd8cabdb2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1f1f3ee7-b1b4-4dad-bf91-0629bf9f60a7" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_5047184c-227c-422a-872f-07ebd8cabdb2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_2eccaf28-c9c2-4653-aa9b-4d4ecaffe2ee" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LoansPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_5047184c-227c-422a-872f-07ebd8cabdb2" xlink:to="loc_us-gaap_LoansPayableMember_2eccaf28-c9c2-4653-aa9b-4d4ecaffe2ee" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentInKindPIKNoteMember_ad1f28aa-ad30-4b99-acbb-da94f8ae64a3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentInKindPIKNoteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_5047184c-227c-422a-872f-07ebd8cabdb2" xlink:to="loc_us-gaap_PaymentInKindPIKNoteMember_ad1f28aa-ad30-4b99-acbb-da94f8ae64a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_347edc90-fe0b-43a0-8332-1b3770312b5c" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_93f75f41-96cd-45c2-a8e4-372b88874308" xlink:to="loc_srt_RangeAxis_347edc90-fe0b-43a0-8332-1b3770312b5c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_347edc90-fe0b-43a0-8332-1b3770312b5c_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_347edc90-fe0b-43a0-8332-1b3770312b5c" xlink:to="loc_srt_RangeMember_347edc90-fe0b-43a0-8332-1b3770312b5c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_748d7d8d-71ce-4a13-ae44-ebdad8e728c9" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_347edc90-fe0b-43a0-8332-1b3770312b5c" xlink:to="loc_srt_RangeMember_748d7d8d-71ce-4a13-ae44-ebdad8e728c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_71d5296f-20e1-4652-a100-f3c4f4908f47" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_748d7d8d-71ce-4a13-ae44-ebdad8e728c9" xlink:to="loc_srt_MinimumMember_71d5296f-20e1-4652-a100-f3c4f4908f47" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_26658818-1b2b-4c5e-b7ba-966b7126de37" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_748d7d8d-71ce-4a13-ae44-ebdad8e728c9" xlink:to="loc_srt_MaximumMember_26658818-1b2b-4c5e-b7ba-966b7126de37" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_67787900-acd6-4e98-8ea0-24201f4e75aa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_13604e5c-ba24-4350-a12a-c93d0fe7e852" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_67787900-acd6-4e98-8ea0-24201f4e75aa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_ca30f983-5148-4edc-9c33-cd4ee1423c93" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_13604e5c-ba24-4350-a12a-c93d0fe7e852" xlink:to="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_ca30f983-5148-4edc-9c33-cd4ee1423c93" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_31b34403-d1d4-4398-a456-78cd5de1265c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_13604e5c-ba24-4350-a12a-c93d0fe7e852" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_31b34403-d1d4-4398-a456-78cd5de1265c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_1f2be627-7aca-4ef3-9695-5567278175bc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_13604e5c-ba24-4350-a12a-c93d0fe7e852" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_1f2be627-7aca-4ef3-9695-5567278175bc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_991d1205-97f8-4c43-8c20-3d149a8d1d10" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_13604e5c-ba24-4350-a12a-c93d0fe7e852" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_991d1205-97f8-4c43-8c20-3d149a8d1d10" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentStatedInterestRatePaidInKind_318ee729-c112-4254-8562-d36444bac8b5" xlink:href="exdx-20241231.xsd#exdx_DebtInstrumentStatedInterestRatePaidInKind"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_13604e5c-ba24-4350-a12a-c93d0fe7e852" xlink:to="loc_exdx_DebtInstrumentStatedInterestRatePaidInKind_318ee729-c112-4254-8562-d36444bac8b5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_fd65a865-0d0d-40be-80d6-b00380e4bdeb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_13604e5c-ba24-4350-a12a-c93d0fe7e852" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_fd65a865-0d0d-40be-80d6-b00380e4bdeb" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentNumberOfMonthlyInstallments_d8945a5b-dbb9-45ae-9923-940df2f16320" xlink:href="exdx-20241231.xsd#exdx_DebtInstrumentNumberOfMonthlyInstallments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_13604e5c-ba24-4350-a12a-c93d0fe7e852" xlink:to="loc_exdx_DebtInstrumentNumberOfMonthlyInstallments_d8945a5b-dbb9-45ae-9923-940df2f16320" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFeeAmount_87c2f09e-1120-4f74-8430-5a965480a99f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFeeAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_13604e5c-ba24-4350-a12a-c93d0fe7e852" xlink:to="loc_us-gaap_DebtInstrumentFeeAmount_87c2f09e-1120-4f74-8430-5a965480a99f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentPaidInKindLoansIssued_5c20aec3-1b8d-4f15-8832-f3e6915b0e22" xlink:href="exdx-20241231.xsd#exdx_DebtInstrumentPaidInKindLoansIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_13604e5c-ba24-4350-a12a-c93d0fe7e852" xlink:to="loc_exdx_DebtInstrumentPaidInKindLoansIssued_5c20aec3-1b8d-4f15-8832-f3e6915b0e22" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_7c940d47-1d07-4ab3-8a8b-950f7831745e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_13604e5c-ba24-4350-a12a-c93d0fe7e852" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_7c940d47-1d07-4ab3-8a8b-950f7831745e" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentCovenantRevenuePerformancePeriod_003434be-899d-422b-94a0-f528e8bc1146" xlink:href="exdx-20241231.xsd#exdx_DebtInstrumentCovenantRevenuePerformancePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_13604e5c-ba24-4350-a12a-c93d0fe7e852" xlink:to="loc_exdx_DebtInstrumentCovenantRevenuePerformancePeriod_003434be-899d-422b-94a0-f528e8bc1146" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentMinimumCashBalanceRequiredNotRequiredToComplyWithCovenant_b7a1bf82-2c79-414d-a45e-da532c2830a0" xlink:href="exdx-20241231.xsd#exdx_DebtInstrumentMinimumCashBalanceRequiredNotRequiredToComplyWithCovenant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_13604e5c-ba24-4350-a12a-c93d0fe7e852" xlink:to="loc_exdx_DebtInstrumentMinimumCashBalanceRequiredNotRequiredToComplyWithCovenant_b7a1bf82-2c79-414d-a45e-da532c2830a0" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentCovenantNumberOfDaysToCureIfPerformanceMeasureIsNotMet_b6be242e-d85f-4e3d-b69d-e5a839f385cb" xlink:href="exdx-20241231.xsd#exdx_DebtInstrumentCovenantNumberOfDaysToCureIfPerformanceMeasureIsNotMet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_13604e5c-ba24-4350-a12a-c93d0fe7e852" xlink:to="loc_exdx_DebtInstrumentCovenantNumberOfDaysToCureIfPerformanceMeasureIsNotMet_b6be242e-d85f-4e3d-b69d-e5a839f385cb" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance_76064651-81c0-45ea-bb1c-0ae617d086e9" xlink:href="exdx-20241231.xsd#exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_13604e5c-ba24-4350-a12a-c93d0fe7e852" xlink:to="loc_exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance_76064651-81c0-45ea-bb1c-0ae617d086e9" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease_a82d8ae2-97d8-47e6-b8c9-e25666649f60" xlink:href="exdx-20241231.xsd#exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_13604e5c-ba24-4350-a12a-c93d0fe7e852" xlink:to="loc_exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease_a82d8ae2-97d8-47e6-b8c9-e25666649f60" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayable_cf7adaf1-40ad-4ad8-a3a8-def3b5a17aab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_13604e5c-ba24-4350-a12a-c93d0fe7e852" xlink:to="loc_us-gaap_NotesPayable_cf7adaf1-40ad-4ad8-a3a8-def3b5a17aab" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableCurrent_8d801b43-779b-48d6-91c4-8f9136c648cc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_13604e5c-ba24-4350-a12a-c93d0fe7e852" xlink:to="loc_us-gaap_NotesPayableCurrent_8d801b43-779b-48d6-91c4-8f9136c648cc" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermNotesPayable_4780bfcb-10fc-4214-b55c-030df8a0a75e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermNotesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_13604e5c-ba24-4350-a12a-c93d0fe7e852" xlink:to="loc_us-gaap_LongTermNotesPayable_4780bfcb-10fc-4214-b55c-030df8a0a75e" xlink:type="arc" order="18"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="exdx-20241231.xsd#LeasesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_1a2758ac-0b33-4e17-b608-ab383cc2c996" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_1acc01fa-cf26-4d35-9276-2d150bf11634" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_1a2758ac-0b33-4e17-b608-ab383cc2c996" xlink:to="loc_us-gaap_LossContingenciesTable_1acc01fa-cf26-4d35-9276-2d150bf11634" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_RentalPropertyByTypeAxis_83b58195-1e78-47cc-93c7-56703b53813f" xlink:href="exdx-20241231.xsd#exdx_RentalPropertyByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_1acc01fa-cf26-4d35-9276-2d150bf11634" xlink:to="loc_exdx_RentalPropertyByTypeAxis_83b58195-1e78-47cc-93c7-56703b53813f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_RentalPropertyByTypeDomain_83b58195-1e78-47cc-93c7-56703b53813f_default" xlink:href="exdx-20241231.xsd#exdx_RentalPropertyByTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_exdx_RentalPropertyByTypeAxis_83b58195-1e78-47cc-93c7-56703b53813f" xlink:to="loc_exdx_RentalPropertyByTypeDomain_83b58195-1e78-47cc-93c7-56703b53813f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_RentalPropertyByTypeDomain_9f97b6bb-c945-401a-9bdf-592ba21b59c0" xlink:href="exdx-20241231.xsd#exdx_RentalPropertyByTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_exdx_RentalPropertyByTypeAxis_83b58195-1e78-47cc-93c7-56703b53813f" xlink:to="loc_exdx_RentalPropertyByTypeDomain_9f97b6bb-c945-401a-9bdf-592ba21b59c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OfficeAndLaboratoryMember_41cca622-4235-4e9b-aee9-e4c864c885c3" xlink:href="exdx-20241231.xsd#exdx_OfficeAndLaboratoryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exdx_RentalPropertyByTypeDomain_9f97b6bb-c945-401a-9bdf-592ba21b59c0" xlink:to="loc_exdx_OfficeAndLaboratoryMember_41cca622-4235-4e9b-aee9-e4c864c885c3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OfficeMember_002173e5-7b98-4feb-b5d1-03e31c1e7fb7" xlink:href="exdx-20241231.xsd#exdx_OfficeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exdx_RentalPropertyByTypeDomain_9f97b6bb-c945-401a-9bdf-592ba21b59c0" xlink:to="loc_exdx_OfficeMember_002173e5-7b98-4feb-b5d1-03e31c1e7fb7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_171e9c36-f183-4479-9cf1-717c119a5d96" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_1acc01fa-cf26-4d35-9276-2d150bf11634" xlink:to="loc_srt_RangeAxis_171e9c36-f183-4479-9cf1-717c119a5d96" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_171e9c36-f183-4479-9cf1-717c119a5d96_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_171e9c36-f183-4479-9cf1-717c119a5d96" xlink:to="loc_srt_RangeMember_171e9c36-f183-4479-9cf1-717c119a5d96_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_818e98c6-c0ec-483e-a44d-523590d43b85" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_171e9c36-f183-4479-9cf1-717c119a5d96" xlink:to="loc_srt_RangeMember_818e98c6-c0ec-483e-a44d-523590d43b85" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_5441d373-04ce-44e5-921a-d0a5c6c4dead" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_818e98c6-c0ec-483e-a44d-523590d43b85" xlink:to="loc_srt_MinimumMember_5441d373-04ce-44e5-921a-d0a5c6c4dead" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_c98e9e5b-7ccc-4f8c-99e0-4df3cbbdaac6" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_818e98c6-c0ec-483e-a44d-523590d43b85" xlink:to="loc_srt_MaximumMember_c98e9e5b-7ccc-4f8c-99e0-4df3cbbdaac6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermAxis_7cde32a0-90f2-40e5-8f2a-55f252e76002" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_1acc01fa-cf26-4d35-9276-2d150bf11634" xlink:to="loc_us-gaap_LeaseContractualTermAxis_7cde32a0-90f2-40e5-8f2a-55f252e76002" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain_7cde32a0-90f2-40e5-8f2a-55f252e76002_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LeaseContractualTermAxis_7cde32a0-90f2-40e5-8f2a-55f252e76002" xlink:to="loc_us-gaap_LeaseContractualTermDomain_7cde32a0-90f2-40e5-8f2a-55f252e76002_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain_e669d415-7bdd-4f48-9a90-262198d8f953" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LeaseContractualTermAxis_7cde32a0-90f2-40e5-8f2a-55f252e76002" xlink:to="loc_us-gaap_LeaseContractualTermDomain_e669d415-7bdd-4f48-9a90-262198d8f953" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OfficeAndLaboratoryMember_0fd245b3-bbd7-4b73-a1df-56d0e4ac8d16" xlink:href="exdx-20241231.xsd#exdx_OfficeAndLaboratoryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseContractualTermDomain_e669d415-7bdd-4f48-9a90-262198d8f953" xlink:to="loc_exdx_OfficeAndLaboratoryMember_0fd245b3-bbd7-4b73-a1df-56d0e4ac8d16" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OfficeMember_342c9cfa-f0ab-4963-9725-06a17da9ceab" xlink:href="exdx-20241231.xsd#exdx_OfficeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseContractualTermDomain_e669d415-7bdd-4f48-9a90-262198d8f953" xlink:to="loc_exdx_OfficeMember_342c9cfa-f0ab-4963-9725-06a17da9ceab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_896369f4-b747-4790-8232-ee01e7e7dd41" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_1a2758ac-0b33-4e17-b608-ab383cc2c996" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_896369f4-b747-4790-8232-ee01e7e7dd41" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OperatingLeaseMonthlyBaseRent_14ce94d3-9beb-4249-9d15-c4cccf1a5a71" xlink:href="exdx-20241231.xsd#exdx_OperatingLeaseMonthlyBaseRent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_1a2758ac-0b33-4e17-b608-ab383cc2c996" xlink:to="loc_exdx_OperatingLeaseMonthlyBaseRent_14ce94d3-9beb-4249-9d15-c4cccf1a5a71" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OperatingLeaseAnnualIncreaseInBaseRentPaymentPercent_1f98aa59-c741-4619-ab4f-b36ecd6ac604" xlink:href="exdx-20241231.xsd#exdx_OperatingLeaseAnnualIncreaseInBaseRentPaymentPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_1a2758ac-0b33-4e17-b608-ab383cc2c996" xlink:to="loc_exdx_OperatingLeaseAnnualIncreaseInBaseRentPaymentPercent_1f98aa59-c741-4619-ab4f-b36ecd6ac604" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeaseTermOfContract1_aa7c1da3-4919-4234-97ff-da03eb6bc775" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeFinanceLeaseTermOfContract1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_1a2758ac-0b33-4e17-b608-ab383cc2c996" xlink:to="loc_us-gaap_LesseeFinanceLeaseTermOfContract1_aa7c1da3-4919-4234-97ff-da03eb6bc775" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="simple" xlink:href="exdx-20241231.xsd#CommitmentsandContingenciesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_06a8cc59-a100-4b3a-ac1b-2a0cda05483a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable_78980664-c077-4086-b89b-212f02b4edc3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_06a8cc59-a100-4b3a-ac1b-2a0cda05483a" xlink:to="loc_us-gaap_OtherCommitmentsTable_78980664-c077-4086-b89b-212f02b4edc3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_2c3c8f5e-d61d-4c94-9501-b0b84402b502" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_78980664-c077-4086-b89b-212f02b4edc3" xlink:to="loc_srt_CounterpartyNameAxis_2c3c8f5e-d61d-4c94-9501-b0b84402b502" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2c3c8f5e-d61d-4c94-9501-b0b84402b502_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_2c3c8f5e-d61d-4c94-9501-b0b84402b502" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2c3c8f5e-d61d-4c94-9501-b0b84402b502_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8fe3f523-37d1-4981-a25b-a4308b43b9cb" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_2c3c8f5e-d61d-4c94-9501-b0b84402b502" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8fe3f523-37d1-4981-a25b-a4308b43b9cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AlleghenyHealthNetworkResearchInstituteMember_8dcfc057-9064-42f5-8ae9-19b807be0d74" xlink:href="exdx-20241231.xsd#exdx_AlleghenyHealthNetworkResearchInstituteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8fe3f523-37d1-4981-a25b-a4308b43b9cb" xlink:to="loc_exdx_AlleghenyHealthNetworkResearchInstituteMember_8dcfc057-9064-42f5-8ae9-19b807be0d74" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_73931140-1917-47d1-b290-e26d25d6e026" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_78980664-c077-4086-b89b-212f02b4edc3" xlink:to="loc_srt_RangeAxis_73931140-1917-47d1-b290-e26d25d6e026" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_73931140-1917-47d1-b290-e26d25d6e026_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_73931140-1917-47d1-b290-e26d25d6e026" xlink:to="loc_srt_RangeMember_73931140-1917-47d1-b290-e26d25d6e026_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5e6a8a03-ee0d-4e0e-8758-7a82ae9adb4e" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_73931140-1917-47d1-b290-e26d25d6e026" xlink:to="loc_srt_RangeMember_5e6a8a03-ee0d-4e0e-8758-7a82ae9adb4e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_da02ac1c-7e8e-40d1-b354-11cd4a5c7d68" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_5e6a8a03-ee0d-4e0e-8758-7a82ae9adb4e" xlink:to="loc_srt_MinimumMember_da02ac1c-7e8e-40d1-b354-11cd4a5c7d68" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f730933b-5600-4bb4-919c-052ab51cd0e1" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_5e6a8a03-ee0d-4e0e-8758-7a82ae9adb4e" xlink:to="loc_srt_MaximumMember_f730933b-5600-4bb4-919c-052ab51cd0e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_d3f8528f-dcc6-4765-9706-144d2ffc1267" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_78980664-c077-4086-b89b-212f02b4edc3" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_d3f8528f-dcc6-4765-9706-144d2ffc1267" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_d3f8528f-dcc6-4765-9706-144d2ffc1267_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_d3f8528f-dcc6-4765-9706-144d2ffc1267" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_d3f8528f-dcc6-4765-9706-144d2ffc1267_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_bf01fb30-7d48-4b1f-9554-5b326e70a0ca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_d3f8528f-dcc6-4765-9706-144d2ffc1267" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_bf01fb30-7d48-4b1f-9554-5b326e70a0ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseAgreementTermsMember_005ce117-40c6-4737-bc3d-0d8307ce28fa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LicenseAgreementTermsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_bf01fb30-7d48-4b1f-9554-5b326e70a0ca" xlink:to="loc_us-gaap_LicenseAgreementTermsMember_005ce117-40c6-4737-bc3d-0d8307ce28fa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_e6294cd5-e11d-41f1-ad3e-631fcb11ab3f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_78980664-c077-4086-b89b-212f02b4edc3" xlink:to="loc_us-gaap_TypeOfArrangementAxis_e6294cd5-e11d-41f1-ad3e-631fcb11ab3f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e6294cd5-e11d-41f1-ad3e-631fcb11ab3f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_e6294cd5-e11d-41f1-ad3e-631fcb11ab3f" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e6294cd5-e11d-41f1-ad3e-631fcb11ab3f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_963e54ac-14a1-4fee-851b-af4c8850846f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_e6294cd5-e11d-41f1-ad3e-631fcb11ab3f" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_963e54ac-14a1-4fee-851b-af4c8850846f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AHNCollaborationMember_36963cf6-5e1a-4688-9685-5a53643ebbe1" xlink:href="exdx-20241231.xsd#exdx_AHNCollaborationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_963e54ac-14a1-4fee-851b-af4c8850846f" xlink:to="loc_exdx_AHNCollaborationMember_36963cf6-5e1a-4688-9685-5a53643ebbe1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_a3bb1c0a-2ad0-470e-ab54-839bdeae3845" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_78980664-c077-4086-b89b-212f02b4edc3" xlink:to="loc_srt_LitigationCaseAxis_a3bb1c0a-2ad0-470e-ab54-839bdeae3845" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_a3bb1c0a-2ad0-470e-ab54-839bdeae3845_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_a3bb1c0a-2ad0-470e-ab54-839bdeae3845" xlink:to="loc_srt_LitigationCaseTypeDomain_a3bb1c0a-2ad0-470e-ab54-839bdeae3845_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_6e6774a1-fd6f-467a-b894-954e50fa4ae0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_a3bb1c0a-2ad0-470e-ab54-839bdeae3845" xlink:to="loc_srt_LitigationCaseTypeDomain_6e6774a1-fd6f-467a-b894-954e50fa4ae0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_USDepartmentOfJusticeCaseMember_752b1835-7c8a-4799-85f6-7a55c2613474" xlink:href="exdx-20241231.xsd#exdx_USDepartmentOfJusticeCaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_6e6774a1-fd6f-467a-b894-954e50fa4ae0" xlink:to="loc_exdx_USDepartmentOfJusticeCaseMember_752b1835-7c8a-4799-85f6-7a55c2613474" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_9eb7a499-84fa-426f-bfa1-7dfed4d691ae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LitigationStatusAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_78980664-c077-4086-b89b-212f02b4edc3" xlink:to="loc_us-gaap_LitigationStatusAxis_9eb7a499-84fa-426f-bfa1-7dfed4d691ae" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_9eb7a499-84fa-426f-bfa1-7dfed4d691ae_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LitigationStatusAxis_9eb7a499-84fa-426f-bfa1-7dfed4d691ae" xlink:to="loc_us-gaap_LitigationStatusDomain_9eb7a499-84fa-426f-bfa1-7dfed4d691ae_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_c3871671-7c4c-4bfd-b337-301304462746" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LitigationStatusAxis_9eb7a499-84fa-426f-bfa1-7dfed4d691ae" xlink:to="loc_us-gaap_LitigationStatusDomain_c3871671-7c4c-4bfd-b337-301304462746" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SettledLitigationMember_0ab11f45-3584-47eb-a1de-d8ce47885503" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SettledLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_c3871671-7c4c-4bfd-b337-301304462746" xlink:to="loc_us-gaap_SettledLitigationMember_0ab11f45-3584-47eb-a1de-d8ce47885503" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_RoyaltyObligationPercentageOfSales_820b8106-b774-4b8e-81df-165970555fea" xlink:href="exdx-20241231.xsd#exdx_RoyaltyObligationPercentageOfSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_06a8cc59-a100-4b3a-ac1b-2a0cda05483a" xlink:to="loc_exdx_RoyaltyObligationPercentageOfSales_820b8106-b774-4b8e-81df-165970555fea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_PurchaseObligationAmendedSupplyAgreementNumberOfSuppliers_99552c5c-2a15-4487-8cd9-fdef07311795" xlink:href="exdx-20241231.xsd#exdx_PurchaseObligationAmendedSupplyAgreementNumberOfSuppliers"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_06a8cc59-a100-4b3a-ac1b-2a0cda05483a" xlink:to="loc_exdx_PurchaseObligationAmendedSupplyAgreementNumberOfSuppliers_99552c5c-2a15-4487-8cd9-fdef07311795" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInNextTwelveMonths_eb9448e4-9076-48ec-bc9d-47dadc1108d0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PurchaseObligationDueInNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_06a8cc59-a100-4b3a-ac1b-2a0cda05483a" xlink:to="loc_us-gaap_PurchaseObligationDueInNextTwelveMonths_eb9448e4-9076-48ec-bc9d-47dadc1108d0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_CollaborationAgreementAnnualCollaborationFee_0379856b-5378-484f-a5ab-04db47ee8678" xlink:href="exdx-20241231.xsd#exdx_CollaborationAgreementAnnualCollaborationFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_06a8cc59-a100-4b3a-ac1b-2a0cda05483a" xlink:to="loc_exdx_CollaborationAgreementAnnualCollaborationFee_0379856b-5378-484f-a5ab-04db47ee8678" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_CollaborationAgreementCollaborationExpenses_d5cc270a-5c8b-490f-89cc-81da2f7449a7" xlink:href="exdx-20241231.xsd#exdx_CollaborationAgreementCollaborationExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_06a8cc59-a100-4b3a-ac1b-2a0cda05483a" xlink:to="loc_exdx_CollaborationAgreementCollaborationExpenses_d5cc270a-5c8b-490f-89cc-81da2f7449a7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements_94ff5a49-701c-4079-9d0a-95a71c43de57" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_06a8cc59-a100-4b3a-ac1b-2a0cda05483a" xlink:to="loc_us-gaap_PaymentsForLegalSettlements_94ff5a49-701c-4079-9d0a-95a71c43de57" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="exdx-20241231.xsd#FairValueMeasurementsDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_31f2545c-9e35-46a8-b575-9fa99a5911ba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_dfc45ae5-c055-493e-bb03-3c87c92e7f21" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_31f2545c-9e35-46a8-b575-9fa99a5911ba" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_dfc45ae5-c055-493e-bb03-3c87c92e7f21" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_3260cd62-a674-43e6-bf92-4dabb85ab498" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_dfc45ae5-c055-493e-bb03-3c87c92e7f21" xlink:to="loc_us-gaap_DebtInstrumentAxis_3260cd62-a674-43e6-bf92-4dabb85ab498" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_3260cd62-a674-43e6-bf92-4dabb85ab498_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_3260cd62-a674-43e6-bf92-4dabb85ab498" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_3260cd62-a674-43e6-bf92-4dabb85ab498_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_b31c618d-525c-4c52-99b5-c22d620c6990" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_3260cd62-a674-43e6-bf92-4dabb85ab498" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_b31c618d-525c-4c52-99b5-c22d620c6990" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AmendedLoanAgreementMember_095822a3-f6fb-4575-a66a-4ed7d80107ad" xlink:href="exdx-20241231.xsd#exdx_AmendedLoanAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b31c618d-525c-4c52-99b5-c22d620c6990" xlink:to="loc_exdx_AmendedLoanAgreementMember_095822a3-f6fb-4575-a66a-4ed7d80107ad" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_A2017TermLoanMember_50b6aea1-e9d8-4616-83a7-632280af5681" xlink:href="exdx-20241231.xsd#exdx_A2017TermLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b31c618d-525c-4c52-99b5-c22d620c6990" xlink:to="loc_exdx_A2017TermLoanMember_50b6aea1-e9d8-4616-83a7-632280af5681" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_4cc42a59-2d10-4fba-9a47-542ded3c0cee" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_dfc45ae5-c055-493e-bb03-3c87c92e7f21" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_4cc42a59-2d10-4fba-9a47-542ded3c0cee" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_4cc42a59-2d10-4fba-9a47-542ded3c0cee_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_4cc42a59-2d10-4fba-9a47-542ded3c0cee" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_4cc42a59-2d10-4fba-9a47-542ded3c0cee_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_5590e571-75ee-4b88-901f-5ca81d6aa600" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_4cc42a59-2d10-4fba-9a47-542ded3c0cee" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_5590e571-75ee-4b88-901f-5ca81d6aa600" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_c429ec8d-bb2e-49bd-896e-c95b6ceb84c7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_5590e571-75ee-4b88-901f-5ca81d6aa600" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_c429ec8d-bb2e-49bd-896e-c95b6ceb84c7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c143fd92-d086-44c2-b021-53c26beff59c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_dfc45ae5-c055-493e-bb03-3c87c92e7f21" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c143fd92-d086-44c2-b021-53c26beff59c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c143fd92-d086-44c2-b021-53c26beff59c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c143fd92-d086-44c2-b021-53c26beff59c" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c143fd92-d086-44c2-b021-53c26beff59c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7e041c74-d055-4327-a564-ca82a17011dd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c143fd92-d086-44c2-b021-53c26beff59c" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7e041c74-d055-4327-a564-ca82a17011dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_5954d157-1634-41c0-bd5b-8ab4b82ad35e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7e041c74-d055-4327-a564-ca82a17011dd" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_5954d157-1634-41c0-bd5b-8ab4b82ad35e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_ddeacfd2-8772-4421-9215-89d9774c3798" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7e041c74-d055-4327-a564-ca82a17011dd" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_ddeacfd2-8772-4421-9215-89d9774c3798" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_24b803f6-7181-459b-a7ca-7d4866e4cde3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7e041c74-d055-4327-a564-ca82a17011dd" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_24b803f6-7181-459b-a7ca-7d4866e4cde3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_1e62b21c-db4c-4c13-a26d-e2154e6a9d91" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_dfc45ae5-c055-493e-bb03-3c87c92e7f21" xlink:to="loc_us-gaap_FinancialInstrumentAxis_1e62b21c-db4c-4c13-a26d-e2154e6a9d91" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1e62b21c-db4c-4c13-a26d-e2154e6a9d91_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_1e62b21c-db4c-4c13-a26d-e2154e6a9d91" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1e62b21c-db4c-4c13-a26d-e2154e6a9d91_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_861984b4-0cb3-4d4f-a5de-61dc0ffbf6a4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_1e62b21c-db4c-4c13-a26d-e2154e6a9d91" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_861984b4-0cb3-4d4f-a5de-61dc0ffbf6a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_4aa28869-f827-4639-8338-7d497d077b9c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_861984b4-0cb3-4d4f-a5de-61dc0ffbf6a4" xlink:to="loc_us-gaap_MoneyMarketFundsMember_4aa28869-f827-4639-8338-7d497d077b9c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_d6a290e7-e0b9-4321-b874-ad6ffc628bc0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_31f2545c-9e35-46a8-b575-9fa99a5911ba" xlink:to="loc_us-gaap_LongTermDebt_d6a290e7-e0b9-4321-b874-ad6ffc628bc0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_c5801dc3-a9b9-4785-8f26-efe37ddc6a85" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_31f2545c-9e35-46a8-b575-9fa99a5911ba" xlink:to="loc_us-gaap_DebtInstrumentFairValue_c5801dc3-a9b9-4785-8f26-efe37ddc6a85" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_bb3f19fc-60b4-4191-a3b3-e35401496b4c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_31f2545c-9e35-46a8-b575-9fa99a5911ba" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_bb3f19fc-60b4-4191-a3b3-e35401496b4c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_794f9e5b-dd45-402e-8a06-9731d2d65984" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_bb3f19fc-60b4-4191-a3b3-e35401496b4c" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_794f9e5b-dd45-402e-8a06-9731d2d65984" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StockholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="exdx-20241231.xsd#StockholdersEquityNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_12401f2c-23b7-4269-8bc4-a023fbc4c145" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_d08d6781-5021-4e7f-8230-29266f982c6a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_12401f2c-23b7-4269-8bc4-a023fbc4c145" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_d08d6781-5021-4e7f-8230-29266f982c6a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_755ed5b3-d538-42e4-a1ac-3974fe61bae0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_d08d6781-5021-4e7f-8230-29266f982c6a" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_755ed5b3-d538-42e4-a1ac-3974fe61bae0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_755ed5b3-d538-42e4-a1ac-3974fe61bae0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_755ed5b3-d538-42e4-a1ac-3974fe61bae0" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_755ed5b3-d538-42e4-a1ac-3974fe61bae0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_90cfa396-6cc5-4fe2-ab8e-95c2aa3c5573" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_755ed5b3-d538-42e4-a1ac-3974fe61bae0" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_90cfa396-6cc5-4fe2-ab8e-95c2aa3c5573" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ShelfRegistrationStatementMember_b0f57b5a-49ae-4fab-8e76-33f6fd4aa557" xlink:href="exdx-20241231.xsd#exdx_ShelfRegistrationStatementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_90cfa396-6cc5-4fe2-ab8e-95c2aa3c5573" xlink:to="loc_exdx_ShelfRegistrationStatementMember_b0f57b5a-49ae-4fab-8e76-33f6fd4aa557" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_CowenEquityDistributionAgreementMember_eb9def5a-346a-489b-8a4f-1065ef25acc1" xlink:href="exdx-20241231.xsd#exdx_CowenEquityDistributionAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_90cfa396-6cc5-4fe2-ab8e-95c2aa3c5573" xlink:to="loc_exdx_CowenEquityDistributionAgreementMember_eb9def5a-346a-489b-8a4f-1065ef25acc1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_SaleOfStockAuthorizedAmount_6ee9f109-83be-4eae-a16d-e60294f98505" xlink:href="exdx-20241231.xsd#exdx_SaleOfStockAuthorizedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_12401f2c-23b7-4269-8bc4-a023fbc4c145" xlink:to="loc_exdx_SaleOfStockAuthorizedAmount_6ee9f109-83be-4eae-a16d-e60294f98505" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_SaleOfStockRemainingAuthorizedAmount_c4fa382c-f197-4474-926d-81cd6be2429f" xlink:href="exdx-20241231.xsd#exdx_SaleOfStockRemainingAuthorizedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_12401f2c-23b7-4269-8bc4-a023fbc4c145" xlink:to="loc_exdx_SaleOfStockRemainingAuthorizedAmount_c4fa382c-f197-4474-926d-81cd6be2429f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_95e37d2e-e856-4d71-85d3-59527a701b23" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_12401f2c-23b7-4269-8bc4-a023fbc4c145" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_95e37d2e-e856-4d71-85d3-59527a701b23" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet_cec63097-2023-456e-92ca-4adcc5ca029e" xlink:href="exdx-20241231.xsd#exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_12401f2c-23b7-4269-8bc4-a023fbc4c145" xlink:to="loc_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet_cec63097-2023-456e-92ca-4adcc5ca029e" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StockholdersEquityWarrantstoPurchaseCommonStockOutstandingDetails" xlink:type="simple" xlink:href="exdx-20241231.xsd#StockholdersEquityWarrantstoPurchaseCommonStockOutstandingDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/StockholdersEquityWarrantstoPurchaseCommonStockOutstandingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_2b7333c5-1cbd-463b-b49f-84066756510c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_bb79c1f8-ef8b-44c1-8b5b-47e33e660809" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_2b7333c5-1cbd-463b-b49f-84066756510c" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_bb79c1f8-ef8b-44c1-8b5b-47e33e660809" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_030e3064-aa8c-428d-a09e-c6d8d86ec445" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_bb79c1f8-ef8b-44c1-8b5b-47e33e660809" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_030e3064-aa8c-428d-a09e-c6d8d86ec445" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_030e3064-aa8c-428d-a09e-c6d8d86ec445_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_030e3064-aa8c-428d-a09e-c6d8d86ec445" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_030e3064-aa8c-428d-a09e-c6d8d86ec445_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_3debffbc-3e2b-423e-ae21-4ff03f72bf1b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_030e3064-aa8c-428d-a09e-c6d8d86ec445" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_3debffbc-3e2b-423e-ae21-4ff03f72bf1b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ExpirationJan192026Member_fedcd497-199e-4028-b764-4612472d5b8c" xlink:href="exdx-20241231.xsd#exdx_ExpirationJan192026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_3debffbc-3e2b-423e-ae21-4ff03f72bf1b" xlink:to="loc_exdx_ExpirationJan192026Member_fedcd497-199e-4028-b764-4612472d5b8c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ExpirationMar312026Member_54600e7e-6a2a-4dca-a34c-cdb4f1992fdf" xlink:href="exdx-20241231.xsd#exdx_ExpirationMar312026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_3debffbc-3e2b-423e-ae21-4ff03f72bf1b" xlink:to="loc_exdx_ExpirationMar312026Member_54600e7e-6a2a-4dca-a34c-cdb4f1992fdf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ExpirationApr12026Member_de754752-1c5d-4960-aac4-d690442f2463" xlink:href="exdx-20241231.xsd#exdx_ExpirationApr12026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_3debffbc-3e2b-423e-ae21-4ff03f72bf1b" xlink:to="loc_exdx_ExpirationApr12026Member_de754752-1c5d-4960-aac4-d690442f2463" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ExpirationDec72025Member_3b5bf2bc-24ce-4e77-b995-401841772cfe" xlink:href="exdx-20241231.xsd#exdx_ExpirationDec72025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_3debffbc-3e2b-423e-ae21-4ff03f72bf1b" xlink:to="loc_exdx_ExpirationDec72025Member_3b5bf2bc-24ce-4e77-b995-401841772cfe" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_NoExpirationMember_3412a393-3dab-4b6f-8447-9290f6bf486c" xlink:href="exdx-20241231.xsd#exdx_NoExpirationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_3debffbc-3e2b-423e-ae21-4ff03f72bf1b" xlink:to="loc_exdx_NoExpirationMember_3412a393-3dab-4b6f-8447-9290f6bf486c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_9d087781-520e-4284-b9b0-626be3f35883" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_2b7333c5-1cbd-463b-b49f-84066756510c" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_9d087781-520e-4284-b9b0-626be3f35883" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_97a961bf-be09-4a2b-8918-4547cbe86d60" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_2b7333c5-1cbd-463b-b49f-84066756510c" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_97a961bf-be09-4a2b-8918-4547cbe86d60" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StockOptionPlanNarrativeDetails" xlink:type="simple" xlink:href="exdx-20241231.xsd#StockOptionPlanNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/StockOptionPlanNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f7d72acc-f452-444a-b1de-66d2a8cad114" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_73db9ec1-7eed-40b1-af8a-0b8fd8aa4060" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f7d72acc-f452-444a-b1de-66d2a8cad114" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_73db9ec1-7eed-40b1-af8a-0b8fd8aa4060" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_ff79aecb-9a65-485f-b95c-97e5fa2f424d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_73db9ec1-7eed-40b1-af8a-0b8fd8aa4060" xlink:to="loc_us-gaap_PlanNameAxis_ff79aecb-9a65-485f-b95c-97e5fa2f424d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_ff79aecb-9a65-485f-b95c-97e5fa2f424d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_ff79aecb-9a65-485f-b95c-97e5fa2f424d" xlink:to="loc_us-gaap_PlanNameDomain_ff79aecb-9a65-485f-b95c-97e5fa2f424d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_f388c05c-e52e-44c5-aa30-27fe98c66c9f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_ff79aecb-9a65-485f-b95c-97e5fa2f424d" xlink:to="loc_us-gaap_PlanNameDomain_f388c05c-e52e-44c5-aa30-27fe98c66c9f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_IncentiveAwardPlan2019Member_762f8a83-c75f-467e-b07c-f89eb79aed51" xlink:href="exdx-20241231.xsd#exdx_IncentiveAwardPlan2019Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_f388c05c-e52e-44c5-aa30-27fe98c66c9f" xlink:to="loc_exdx_IncentiveAwardPlan2019Member_762f8a83-c75f-467e-b07c-f89eb79aed51" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_80ec3212-503e-4a37-938b-24a7f5a9420c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_73db9ec1-7eed-40b1-af8a-0b8fd8aa4060" xlink:to="loc_us-gaap_AwardTypeAxis_80ec3212-503e-4a37-938b-24a7f5a9420c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_80ec3212-503e-4a37-938b-24a7f5a9420c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_80ec3212-503e-4a37-938b-24a7f5a9420c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_80ec3212-503e-4a37-938b-24a7f5a9420c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b7b5c92f-7f53-44df-9314-38cbdcb8ea24" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_80ec3212-503e-4a37-938b-24a7f5a9420c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b7b5c92f-7f53-44df-9314-38cbdcb8ea24" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_c5d7ce79-9e82-4837-82d5-7e3ffa6dd3b3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b7b5c92f-7f53-44df-9314-38cbdcb8ea24" xlink:to="loc_us-gaap_EmployeeStockOptionMember_c5d7ce79-9e82-4837-82d5-7e3ffa6dd3b3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_45b6f429-ce9d-44e7-aede-3e81b29ebd86" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b7b5c92f-7f53-44df-9314-38cbdcb8ea24" xlink:to="loc_us-gaap_EmployeeStockMember_45b6f429-ce9d-44e7-aede-3e81b29ebd86" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_ff2cdd6f-e6fb-41f3-9db0-754d1123d6d5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b7b5c92f-7f53-44df-9314-38cbdcb8ea24" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_ff2cdd6f-e6fb-41f3-9db0-754d1123d6d5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_8d75d4d1-d66c-435a-bd59-b44e090083b2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_73db9ec1-7eed-40b1-af8a-0b8fd8aa4060" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_8d75d4d1-d66c-435a-bd59-b44e090083b2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_8d75d4d1-d66c-435a-bd59-b44e090083b2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_8d75d4d1-d66c-435a-bd59-b44e090083b2" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_8d75d4d1-d66c-435a-bd59-b44e090083b2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_64dc9e01-fc16-4f59-b3b7-08615492552a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_8d75d4d1-d66c-435a-bd59-b44e090083b2" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_64dc9e01-fc16-4f59-b3b7-08615492552a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_390f2de1-17b9-4199-8921-81f8aac7f3e5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_64dc9e01-fc16-4f59-b3b7-08615492552a" xlink:to="loc_us-gaap_SubsequentEventMember_390f2de1-17b9-4199-8921-81f8aac7f3e5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_5f019f11-4234-496e-9830-ea60b7cf2999" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f7d72acc-f452-444a-b1de-66d2a8cad114" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_5f019f11-4234-496e-9830-ea60b7cf2999" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_9b64141c-0623-459a-aebe-952765b873d4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f7d72acc-f452-444a-b1de-66d2a8cad114" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_9b64141c-0623-459a-aebe-952765b873d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage_b31a519d-d0d2-40c1-9ec4-dc1987b8068e" xlink:href="exdx-20241231.xsd#exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f7d72acc-f452-444a-b1de-66d2a8cad114" xlink:to="loc_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage_b31a519d-d0d2-40c1-9ec4-dc1987b8068e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_487107ec-129c-4cfe-a132-36abe42ed98c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f7d72acc-f452-444a-b1de-66d2a8cad114" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_487107ec-129c-4cfe-a132-36abe42ed98c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesAuthorized_b6fcb9ba-9a7a-43da-a62f-496bfce0d362" xlink:href="exdx-20241231.xsd#exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f7d72acc-f452-444a-b1de-66d2a8cad114" xlink:to="loc_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesAuthorized_b6fcb9ba-9a7a-43da-a62f-496bfce0d362" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_09bef7ae-1249-49e8-8560-199b39756c72" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f7d72acc-f452-444a-b1de-66d2a8cad114" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_09bef7ae-1249-49e8-8560-199b39756c72" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_f86cbfd6-19ad-498d-935d-c2d3a36b765f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f7d72acc-f452-444a-b1de-66d2a8cad114" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_f86cbfd6-19ad-498d-935d-c2d3a36b765f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_7cbabd07-124d-450a-8aff-22931bf9fa62" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f7d72acc-f452-444a-b1de-66d2a8cad114" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_7cbabd07-124d-450a-8aff-22931bf9fa62" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_57db4626-bce9-4b4a-bdc7-e555bcc85e54" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f7d72acc-f452-444a-b1de-66d2a8cad114" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_57db4626-bce9-4b4a-bdc7-e555bcc85e54" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7c51dbc9-cd86-492f-95e0-570476e5c1ce" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f7d72acc-f452-444a-b1de-66d2a8cad114" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7c51dbc9-cd86-492f-95e0-570476e5c1ce" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_d36d5919-0db6-4640-8e47-ad5e207ab92d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f7d72acc-f452-444a-b1de-66d2a8cad114" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_d36d5919-0db6-4640-8e47-ad5e207ab92d" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_b299e9b5-8065-4f3d-afe8-3bfbdca2ccf0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f7d72acc-f452-444a-b1de-66d2a8cad114" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_b299e9b5-8065-4f3d-afe8-3bfbdca2ccf0" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_51a42ab4-b23d-462e-ab21-7360c03c9eca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f7d72acc-f452-444a-b1de-66d2a8cad114" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_51a42ab4-b23d-462e-ab21-7360c03c9eca" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_f547deea-98f3-491b-8cae-f10eadeaaeb7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f7d72acc-f452-444a-b1de-66d2a8cad114" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_f547deea-98f3-491b-8cae-f10eadeaaeb7" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_9fda12bb-1857-4eff-ab46-6fc68cf72df5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f7d72acc-f452-444a-b1de-66d2a8cad114" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_9fda12bb-1857-4eff-ab46-6fc68cf72df5" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_810fdd02-66b2-497e-979e-12b2c228ffd8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f7d72acc-f452-444a-b1de-66d2a8cad114" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_810fdd02-66b2-497e-979e-12b2c228ffd8" xlink:type="arc" order="15"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails" xlink:type="simple" xlink:href="exdx-20241231.xsd#StockOptionPlanRestrictedStockUnitsDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_765e5e79-1f75-4413-9c56-59b866725123" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8d34ba81-62cd-44f6-8044-a68ea2080577" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_765e5e79-1f75-4413-9c56-59b866725123" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8d34ba81-62cd-44f6-8044-a68ea2080577" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_e15c6684-fb47-441d-b9f7-387a1b91fe3d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8d34ba81-62cd-44f6-8044-a68ea2080577" xlink:to="loc_us-gaap_AwardTypeAxis_e15c6684-fb47-441d-b9f7-387a1b91fe3d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e15c6684-fb47-441d-b9f7-387a1b91fe3d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_e15c6684-fb47-441d-b9f7-387a1b91fe3d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e15c6684-fb47-441d-b9f7-387a1b91fe3d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7d9a61ae-aa4a-4cb3-85b7-d1ae1dd11b4d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_e15c6684-fb47-441d-b9f7-387a1b91fe3d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7d9a61ae-aa4a-4cb3-85b7-d1ae1dd11b4d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_69864395-8bee-41e2-bbe7-0ae0b68387c6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7d9a61ae-aa4a-4cb3-85b7-d1ae1dd11b4d" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_69864395-8bee-41e2-bbe7-0ae0b68387c6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_7bc1a639-516d-484c-84e3-e1ebde9224ba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_765e5e79-1f75-4413-9c56-59b866725123" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_7bc1a639-516d-484c-84e3-e1ebde9224ba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_b2c52135-95a9-4a12-8a34-6a5aeeb9fd4c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_7bc1a639-516d-484c-84e3-e1ebde9224ba" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_b2c52135-95a9-4a12-8a34-6a5aeeb9fd4c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_f9bf268f-8a89-4350-a7da-80feccc596d9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_7bc1a639-516d-484c-84e3-e1ebde9224ba" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_f9bf268f-8a89-4350-a7da-80feccc596d9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_4bfb638e-537f-4fad-a359-7d93a29048e0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_7bc1a639-516d-484c-84e3-e1ebde9224ba" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_4bfb638e-537f-4fad-a359-7d93a29048e0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_cd2a2a18-10e5-4ff0-817d-d4146a59eed2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_7bc1a639-516d-484c-84e3-e1ebde9224ba" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_cd2a2a18-10e5-4ff0-817d-d4146a59eed2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_b626866d-1c34-4247-9a15-7c7323268cca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_f43b716f-517a-406a-8cd5-c2db37da2891" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_765e5e79-1f75-4413-9c56-59b866725123" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_f43b716f-517a-406a-8cd5-c2db37da2891" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_ab476d5a-9304-43eb-ae1c-44898d94670b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_f43b716f-517a-406a-8cd5-c2db37da2891" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_ab476d5a-9304-43eb-ae1c-44898d94670b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_96ee3746-21d7-4a5b-903d-1c9eef146a68" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_f43b716f-517a-406a-8cd5-c2db37da2891" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_96ee3746-21d7-4a5b-903d-1c9eef146a68" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_56344457-9844-46e5-b460-e4045fc719b4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_f43b716f-517a-406a-8cd5-c2db37da2891" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_56344457-9844-46e5-b460-e4045fc719b4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c2131b06-8f02-4268-88f2-897894cd5d78" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_f43b716f-517a-406a-8cd5-c2db37da2891" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c2131b06-8f02-4268-88f2-897894cd5d78" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3b8bbb8a-dcf6-47dc-9a6e-9dbf6fa33f19" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_82b2d4e1-d6ea-4bff-b4b4-7478d7da5399" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_765e5e79-1f75-4413-9c56-59b866725123" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_82b2d4e1-d6ea-4bff-b4b4-7478d7da5399" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_1b352fb9-ee29-49a7-ac86-b86db870c666" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_82b2d4e1-d6ea-4bff-b4b4-7478d7da5399" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_1b352fb9-ee29-49a7-ac86-b86db870c666" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StockOptionPlanStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="exdx-20241231.xsd#StockOptionPlanStockBasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/StockOptionPlanStockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c2916ad2-1929-4140-87a2-89d257b2c569" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a52061ba-4e80-43b7-b6b7-ee07a1cbceed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c2916ad2-1929-4140-87a2-89d257b2c569" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a52061ba-4e80-43b7-b6b7-ee07a1cbceed" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_573e493b-fea6-486a-a748-0e335a680ad5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a52061ba-4e80-43b7-b6b7-ee07a1cbceed" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_573e493b-fea6-486a-a748-0e335a680ad5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_573e493b-fea6-486a-a748-0e335a680ad5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_573e493b-fea6-486a-a748-0e335a680ad5" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_573e493b-fea6-486a-a748-0e335a680ad5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_afd28972-fdb7-4b09-882f-a05e11ea92e6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_573e493b-fea6-486a-a748-0e335a680ad5" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_afd28972-fdb7-4b09-882f-a05e11ea92e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_8bfd53b0-ae40-4d76-b6ae-40466438f7cc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_afd28972-fdb7-4b09-882f-a05e11ea92e6" xlink:to="loc_us-gaap_CostOfSalesMember_8bfd53b0-ae40-4d76-b6ae-40466438f7cc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_fd0a373f-0149-464a-85e0-6d48e71fd362" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_afd28972-fdb7-4b09-882f-a05e11ea92e6" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_fd0a373f-0149-464a-85e0-6d48e71fd362" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_ccfb353a-552e-4716-b6cf-08c905a8a5a9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_afd28972-fdb7-4b09-882f-a05e11ea92e6" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_ccfb353a-552e-4716-b6cf-08c905a8a5a9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_7dabee08-1819-4b0a-98a0-3f8175745bdf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c2916ad2-1929-4140-87a2-89d257b2c569" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_7dabee08-1819-4b0a-98a0-3f8175745bdf" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StockOptionPlanCommonStockReservedForFutureIssuanceDetails" xlink:type="simple" xlink:href="exdx-20241231.xsd#StockOptionPlanCommonStockReservedForFutureIssuanceDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/StockOptionPlanCommonStockReservedForFutureIssuanceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5a48927e-d094-4543-a06c-08ff9e52a74a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_32da293e-89e9-4ca8-8f10-5649c047eb4e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5a48927e-d094-4543-a06c-08ff9e52a74a" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_32da293e-89e9-4ca8-8f10-5649c047eb4e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_863188ab-e44a-41f3-a983-c026543d2d39" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_32da293e-89e9-4ca8-8f10-5649c047eb4e" xlink:to="loc_us-gaap_AwardTypeAxis_863188ab-e44a-41f3-a983-c026543d2d39" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_863188ab-e44a-41f3-a983-c026543d2d39_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_863188ab-e44a-41f3-a983-c026543d2d39" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_863188ab-e44a-41f3-a983-c026543d2d39_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_214599ac-f24d-41c8-a48c-df9bcf66cb44" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_863188ab-e44a-41f3-a983-c026543d2d39" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_214599ac-f24d-41c8-a48c-df9bcf66cb44" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_4b298fcb-19c7-4399-a3f8-3d6e2b86ed1a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_214599ac-f24d-41c8-a48c-df9bcf66cb44" xlink:to="loc_us-gaap_WarrantMember_4b298fcb-19c7-4399-a3f8-3d6e2b86ed1a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_45d0dce3-c234-4ddd-b46a-922551489016" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_214599ac-f24d-41c8-a48c-df9bcf66cb44" xlink:to="loc_us-gaap_EmployeeStockOptionMember_45d0dce3-c234-4ddd-b46a-922551489016" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_e492b6d8-f6bd-4cc6-8621-59b0dbebb179" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_214599ac-f24d-41c8-a48c-df9bcf66cb44" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_e492b6d8-f6bd-4cc6-8621-59b0dbebb179" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_CommonSharesAvailableForGrantUnderThe2019PlanMember_b968b866-ba56-41f1-a07d-763b1f1935d0" xlink:href="exdx-20241231.xsd#exdx_CommonSharesAvailableForGrantUnderThe2019PlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_214599ac-f24d-41c8-a48c-df9bcf66cb44" xlink:to="loc_exdx_CommonSharesAvailableForGrantUnderThe2019PlanMember_b968b866-ba56-41f1-a07d-763b1f1935d0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_f7b60789-b665-4b17-81c9-d9c05f878b5a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_214599ac-f24d-41c8-a48c-df9bcf66cb44" xlink:to="loc_us-gaap_EmployeeStockMember_f7b60789-b665-4b17-81c9-d9c05f878b5a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_39cc1292-d8b3-4b1c-96d0-3480d2a0f693" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5a48927e-d094-4543-a06c-08ff9e52a74a" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_39cc1292-d8b3-4b1c-96d0-3480d2a0f693" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="exdx-20241231.xsd#IncomeTaxesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardLineItems_75aa7071-f14b-401a-b6fa-c35ffb02d7f8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardTable_338c483e-8524-49bd-b36b-5035fd7fe0cf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_75aa7071-f14b-401a-b6fa-c35ffb02d7f8" xlink:to="loc_us-gaap_TaxCreditCarryforwardTable_338c483e-8524-49bd-b36b-5035fd7fe0cf" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodAxis_8cfa3ad7-fa70-472f-9526-0056cd078e49" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_338c483e-8524-49bd-b36b-5035fd7fe0cf" xlink:to="loc_us-gaap_TaxPeriodAxis_8cfa3ad7-fa70-472f-9526-0056cd078e49" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain_8cfa3ad7-fa70-472f-9526-0056cd078e49_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxPeriodAxis_8cfa3ad7-fa70-472f-9526-0056cd078e49" xlink:to="loc_us-gaap_TaxPeriodDomain_8cfa3ad7-fa70-472f-9526-0056cd078e49_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain_c0e0eeea-cf1b-44be-aee8-f0dacca7855f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxPeriodAxis_8cfa3ad7-fa70-472f-9526-0056cd078e49" xlink:to="loc_us-gaap_TaxPeriodDomain_c0e0eeea-cf1b-44be-aee8-f0dacca7855f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_TaxYearsThroughDecember312017Member_4438e1c3-7d8d-4ba4-8fbe-87766340cc73" xlink:href="exdx-20241231.xsd#exdx_TaxYearsThroughDecember312017Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_c0e0eeea-cf1b-44be-aee8-f0dacca7855f" xlink:to="loc_exdx_TaxYearsThroughDecember312017Member_4438e1c3-7d8d-4ba4-8fbe-87766340cc73" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_6958cd0e-32e6-48fe-9a93-ed79572bb6fa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_75aa7071-f14b-401a-b6fa-c35ffb02d7f8" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_6958cd0e-32e6-48fe-9a93-ed79572bb6fa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_6b1fb19b-9e84-45c7-9087-b23cfcca2fbc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_75aa7071-f14b-401a-b6fa-c35ffb02d7f8" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_6b1fb19b-9e84-45c7-9087-b23cfcca2fbc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_e2f2159e-5844-4895-b0e6-53c9baf8e715" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_75aa7071-f14b-401a-b6fa-c35ffb02d7f8" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_e2f2159e-5844-4895-b0e6-53c9baf8e715" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_1f585c21-6995-48e6-8051-6a624afd9518" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_75aa7071-f14b-401a-b6fa-c35ffb02d7f8" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_1f585c21-6995-48e6-8051-6a624afd9518" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_fe80efec-2d45-4cec-bf7a-f43adb6dc939" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_75aa7071-f14b-401a-b6fa-c35ffb02d7f8" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_fe80efec-2d45-4cec-bf7a-f43adb6dc939" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/SegmentReportingNarrativeDetails" xlink:type="simple" xlink:href="exdx-20241231.xsd#SegmentReportingNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/SegmentReportingNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_b559027b-ef1a-4cb1-9fa4-c199a9d9da1d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_b0f3cad1-a488-4b0c-864f-497c2a9f6ea6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_b559027b-ef1a-4cb1-9fa4-c199a9d9da1d" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_b0f3cad1-a488-4b0c-864f-497c2a9f6ea6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_17b1314f-5434-4568-b3f0-5dff34ebbe53" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_b0f3cad1-a488-4b0c-864f-497c2a9f6ea6" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_17b1314f-5434-4568-b3f0-5dff34ebbe53" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_17b1314f-5434-4568-b3f0-5dff34ebbe53_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_17b1314f-5434-4568-b3f0-5dff34ebbe53" xlink:to="loc_us-gaap_SegmentDomain_17b1314f-5434-4568-b3f0-5dff34ebbe53_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_f5263fac-e8f1-437b-a24a-33d894b47858" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_17b1314f-5434-4568-b3f0-5dff34ebbe53" xlink:to="loc_us-gaap_SegmentDomain_f5263fac-e8f1-437b-a24a-33d894b47858" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ReportableSegmentMember_cc74d210-578a-433d-bae1-728877e6eb97" xlink:href="exdx-20241231.xsd#exdx_ReportableSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_f5263fac-e8f1-437b-a24a-33d894b47858" xlink:to="loc_exdx_ReportableSegmentMember_cc74d210-578a-433d-bae1-728877e6eb97" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_a69bc961-a80f-4a6f-97d5-c15e2d70b4ae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_b559027b-ef1a-4cb1-9fa4-c199a9d9da1d" xlink:to="loc_us-gaap_NumberOfOperatingSegments_a69bc961-a80f-4a6f-97d5-c15e2d70b4ae" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_437e93a5-bae6-4700-8cbe-8add5b5325e6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_b559027b-ef1a-4cb1-9fa4-c199a9d9da1d" xlink:to="loc_us-gaap_Assets_437e93a5-bae6-4700-8cbe-8add5b5325e6" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/SegmentReportingDetails" xlink:type="simple" xlink:href="exdx-20241231.xsd#SegmentReportingDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/SegmentReportingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_a4d648b3-f934-47ec-9a49-a10cae9e2445" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_138644d9-1bb5-40d1-8a64-efd06f763448" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_a4d648b3-f934-47ec-9a49-a10cae9e2445" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_138644d9-1bb5-40d1-8a64-efd06f763448" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_8bc7bcbf-d6f6-4a11-a1ab-49bf6009316d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_138644d9-1bb5-40d1-8a64-efd06f763448" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_8bc7bcbf-d6f6-4a11-a1ab-49bf6009316d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_8bc7bcbf-d6f6-4a11-a1ab-49bf6009316d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_8bc7bcbf-d6f6-4a11-a1ab-49bf6009316d" xlink:to="loc_us-gaap_SegmentDomain_8bc7bcbf-d6f6-4a11-a1ab-49bf6009316d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_2bb20a0d-4a2b-49a6-9a89-4a51662aa682" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_8bc7bcbf-d6f6-4a11-a1ab-49bf6009316d" xlink:to="loc_us-gaap_SegmentDomain_2bb20a0d-4a2b-49a6-9a89-4a51662aa682" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ReportableSegmentMember_132d92ed-f5f8-469f-a9f6-2d9ff55d49ec" xlink:href="exdx-20241231.xsd#exdx_ReportableSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_2bb20a0d-4a2b-49a6-9a89-4a51662aa682" xlink:to="loc_exdx_ReportableSegmentMember_132d92ed-f5f8-469f-a9f6-2d9ff55d49ec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_28ca31d4-4cb2-4755-93a2-8f70ed6342fe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_a4d648b3-f934-47ec-9a49-a10cae9e2445" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_28ca31d4-4cb2-4755-93a2-8f70ed6342fe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_92254e6b-3248-4d9a-9e92-22215458348f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_a4d648b3-f934-47ec-9a49-a10cae9e2445" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_92254e6b-3248-4d9a-9e92-22215458348f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_f9df8820-bca0-4789-87cb-040a9d6f3f66" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_a4d648b3-f934-47ec-9a49-a10cae9e2445" xlink:to="loc_us-gaap_GrossProfit_f9df8820-bca0-4789-87cb-040a9d6f3f66" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LaborAndRelatedExpense_d0648953-7860-4ed3-b5a1-e458c23705a8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LaborAndRelatedExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_a4d648b3-f934-47ec-9a49-a10cae9e2445" xlink:to="loc_us-gaap_LaborAndRelatedExpense_d0648953-7860-4ed3-b5a1-e458c23705a8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OutsideServicesExpense_874bb7ce-5c71-4067-a14a-0967a8696508" xlink:href="exdx-20241231.xsd#exdx_OutsideServicesExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_a4d648b3-f934-47ec-9a49-a10cae9e2445" xlink:to="loc_exdx_OutsideServicesExpense_874bb7ce-5c71-4067-a14a-0967a8696508" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OccupancyNet_41cd9463-d21e-4355-a837-f7f6b3a0e49d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OccupancyNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_a4d648b3-f934-47ec-9a49-a10cae9e2445" xlink:to="loc_us-gaap_OccupancyNet_41cd9463-d21e-4355-a837-f7f6b3a0e49d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TravelAndEntertainmentExpense_aa911582-732f-4d8a-93d1-e78e17820b97" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TravelAndEntertainmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_a4d648b3-f934-47ec-9a49-a10cae9e2445" xlink:to="loc_us-gaap_TravelAndEntertainmentExpense_aa911582-732f-4d8a-93d1-e78e17820b97" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_d388c035-03f2-4bc9-baf7-53bbb2b145a8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_a4d648b3-f934-47ec-9a49-a10cae9e2445" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_d388c035-03f2-4bc9-baf7-53bbb2b145a8" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_8841cb22-6f84-4343-8ea7-48eabb60fcfd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_a4d648b3-f934-47ec-9a49-a10cae9e2445" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_8841cb22-6f84-4343-8ea7-48eabb60fcfd" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingOtherItemAmount_5853c2d5-5ece-43b5-b626-1576e95c6118" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingOtherItemAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_a4d648b3-f934-47ec-9a49-a10cae9e2445" xlink:to="loc_us-gaap_SegmentReportingOtherItemAmount_5853c2d5-5ece-43b5-b626-1576e95c6118" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_286c8669-b949-4f56-bd01-35d3b849825d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_a4d648b3-f934-47ec-9a49-a10cae9e2445" xlink:to="loc_us-gaap_OperatingExpenses_286c8669-b949-4f56-bd01-35d3b849825d" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_410cb0e7-0ecf-45f4-9892-28226632deed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_a4d648b3-f934-47ec-9a49-a10cae9e2445" xlink:to="loc_us-gaap_OperatingIncomeLoss_410cb0e7-0ecf-45f4-9892-28226632deed" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating_7d6d6b4f-9958-4a3e-8af1-461047c7702d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_a4d648b3-f934-47ec-9a49-a10cae9e2445" xlink:to="loc_us-gaap_InterestExpenseNonoperating_7d6d6b4f-9958-4a3e-8af1-461047c7702d" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_ee874065-0a7b-4bd0-be6c-071c2a6e9cf1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_a4d648b3-f934-47ec-9a49-a10cae9e2445" xlink:to="loc_us-gaap_InvestmentIncomeInterest_ee874065-0a7b-4bd0-be6c-071c2a6e9cf1" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent_5fc852d5-a83e-44dd-9f79-df4cf5295f73" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_a4d648b3-f934-47ec-9a49-a10cae9e2445" xlink:to="loc_us-gaap_IncomeLossAttributableToParent_5fc852d5-a83e-44dd-9f79-df4cf5295f73" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_5093e513-987b-4859-a1de-1fd333fbae88" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_a4d648b3-f934-47ec-9a49-a10cae9e2445" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_5093e513-987b-4859-a1de-1fd333fbae88" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_2e002de6-f223-4e10-a4f7-3633f7029830" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_a4d648b3-f934-47ec-9a49-a10cae9e2445" xlink:to="loc_us-gaap_NetIncomeLoss_2e002de6-f223-4e10-a4f7-3633f7029830" xlink:type="arc" order="16"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd#eedm"/>
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:type="arc" order="101"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="41"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>exdx-20241231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:7095620a-7684-4e36-937b-24fd606ed1ea,g:3f375e3f-dda6-40cc-be01-a2493780a401-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_c0379e48-ba12-442c-b3df-83861984d22f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_a70866b0-caab-4fac-80a2-85b6a0a9d578_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested and expected to vest, Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_561daf9e-6663-415d-92bd-8293841aa7ec_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum employee payroll deduction percentage</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_07c1d500-1ef4-4e3e-93ef-6aae042a0775_verboseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_6f2ad47f-69fb-426e-b852-2d2818049d33_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_a5738acf-559c-46ae-af24-a4662083a7d9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Principal payment on long-term debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_31891bca-b9fa-4100-a0ed-0ecc83bcf9f1_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepayment of principal</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_35e020df-e3d5-4f60-b6fb-5edabab39db9_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Lease Costs</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_a2ddb064-7aed-4ce3-b50a-be091c66c9d3_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Prepaid Expenses and Other Current Assets</link:label>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_ac93b746-d722-425d-8cc2-ace1926bb90e_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net change in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayableCurrent_ca9785da-ac78-46a1-89a6-40991c79402b_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes payable current</link:label>
    <link:label id="lab_us-gaap_NotesPayableCurrent_label_en-US" xlink:label="lab_us-gaap_NotesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableCurrent" xlink:to="lab_us-gaap_NotesPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_InnovatusLifeSciencesLendingFundMember_f78abf65-2fdd-415e-9ba2-0d79aa365d6c_terseLabel_en-US" xlink:label="lab_exdx_InnovatusLifeSciencesLendingFundMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Innovatus Life Sciences Lending Fund</link:label>
    <link:label id="lab_exdx_InnovatusLifeSciencesLendingFundMember_label_en-US" xlink:label="lab_exdx_InnovatusLifeSciencesLendingFundMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Innovatus Life Sciences Lending Fund [Member]</link:label>
    <link:label id="lab_exdx_InnovatusLifeSciencesLendingFundMember_documentation_en-US" xlink:label="lab_exdx_InnovatusLifeSciencesLendingFundMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Innovatus Life Sciences Lending Fund</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_InnovatusLifeSciencesLendingFundMember" xlink:href="exdx-20241231.xsd#exdx_InnovatusLifeSciencesLendingFundMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_InnovatusLifeSciencesLendingFundMember" xlink:to="lab_exdx_InnovatusLifeSciencesLendingFundMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_c0cc08fb-1f5c-4e5d-850e-dba7d8084ccd_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Lessee, Operating Lease, Liability, Maturity</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_RentalPropertyByTypeAxis_c22dd54c-021e-4d2f-ba99-7f2ccc2a9618_terseLabel_en-US" xlink:label="lab_exdx_RentalPropertyByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rental Property, by Type [Axis]</link:label>
    <link:label id="lab_exdx_RentalPropertyByTypeAxis_label_en-US" xlink:label="lab_exdx_RentalPropertyByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rental Property, by Type [Axis]</link:label>
    <link:label id="lab_exdx_RentalPropertyByTypeAxis_documentation_en-US" xlink:label="lab_exdx_RentalPropertyByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Rental Property, by Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_RentalPropertyByTypeAxis" xlink:href="exdx-20241231.xsd#exdx_RentalPropertyByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_RentalPropertyByTypeAxis" xlink:to="lab_exdx_RentalPropertyByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_81b76b7e-4b36-431f-9fda-9fee5a1a9a56_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_b6c4e4ad-b042-43af-a8ea-98c0810aaca2_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllTradingArrangementsMember_terseLabel_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Trading Arrangements</link:label>
    <link:label id="lab_ecd_AllTradingArrangementsMember_label_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Trading Arrangements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllTradingArrangementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="lab_ecd_AllTradingArrangementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_DebtInstrumentNumberOfMonthlyInstallments_2642e673-7a24-4c52-8f79-bea39aed6037_terseLabel_en-US" xlink:label="lab_exdx_DebtInstrumentNumberOfMonthlyInstallments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of monthly installments</link:label>
    <link:label id="lab_exdx_DebtInstrumentNumberOfMonthlyInstallments_label_en-US" xlink:label="lab_exdx_DebtInstrumentNumberOfMonthlyInstallments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Number Of Monthly Installments</link:label>
    <link:label id="lab_exdx_DebtInstrumentNumberOfMonthlyInstallments_documentation_en-US" xlink:label="lab_exdx_DebtInstrumentNumberOfMonthlyInstallments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Number Of Monthly Installments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentNumberOfMonthlyInstallments" xlink:href="exdx-20241231.xsd#exdx_DebtInstrumentNumberOfMonthlyInstallments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_DebtInstrumentNumberOfMonthlyInstallments" xlink:to="lab_exdx_DebtInstrumentNumberOfMonthlyInstallments" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonNeosMember_terseLabel_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-NEOs</link:label>
    <link:label id="lab_ecd_NonNeosMember_label_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-NEOs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonNeosMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonNeosMember" xlink:to="lab_ecd_NonNeosMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_1f4dccb7-23ec-4908-8f51-326f37cf5997_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options, vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:to="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsLineItems_c74a394e-3ca8-46ac-813d-e9c7c9ab19ad_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Commitments [Line Items]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsLineItems_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Commitments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsLineItems" xlink:to="lab_us-gaap_OtherCommitmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PayVsPerformanceDisclosureLineItems_label_en-US" xlink:label="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets_03f2b106-b9cb-482e-875c-f332d29e14f1_negatedLabel_en-US" xlink:label="lab_exdx_DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Basis differences in fixed and intangible assets</link:label>
    <link:label id="lab_exdx_DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets_label_en-US" xlink:label="lab_exdx_DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Fixed Assets And Intangible Assets</link:label>
    <link:label id="lab_exdx_DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets_documentation_en-US" xlink:label="lab_exdx_DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Fixed Assets And Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets" xlink:href="exdx-20241231.xsd#exdx_DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets" xlink:to="lab_exdx_DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_05afeb9d-0170-4079-b8c7-09e5412e9ca5_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_38cb3597-959e-446b-a774-59ef9f76e7de_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_099244de-6b16-499e-90bf-c22f8c52db6d_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicenseAgreementTermsMember_e3dd1516-9eb0-4225-a900-f1809429cc1a_terseLabel_en-US" xlink:label="lab_us-gaap_LicenseAgreementTermsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Licensing Agreements</link:label>
    <link:label id="lab_us-gaap_LicenseAgreementTermsMember_label_en-US" xlink:label="lab_us-gaap_LicenseAgreementTermsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License Agreement Terms [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseAgreementTermsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LicenseAgreementTermsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseAgreementTermsMember" xlink:to="lab_us-gaap_LicenseAgreementTermsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:to="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_523bf31a-364d-44e5-84a3-3af6080b2c3b_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred:</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_95841bb7-d4f2-4999-93bf-06a5f6818725_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_e4086ae1-bc5e-41b4-aa08-d8c2966a4467_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgDiscLineItems_label_en-US" xlink:label="lab_ecd_AwardTmgDiscLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Disclosures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="lab_ecd_AwardTmgDiscLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_bb2a8a3b-3e31-4840-8a00-e4b52f2b9fc1_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Number of Shares, Par Value and Other Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_label_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OtherPerfMeasureAmt" xlink:to="lab_ecd_OtherPerfMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_RoyaltyObligationPercentageOfSales_f5d5bf7a-2afe-4f3e-aa26-f8cb432881d7_terseLabel_en-US" xlink:label="lab_exdx_RoyaltyObligationPercentageOfSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty obligation, percent of net sales</link:label>
    <link:label id="lab_exdx_RoyaltyObligationPercentageOfSales_label_en-US" xlink:label="lab_exdx_RoyaltyObligationPercentageOfSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Obligation, Percentage of Sales</link:label>
    <link:label id="lab_exdx_RoyaltyObligationPercentageOfSales_documentation_en-US" xlink:label="lab_exdx_RoyaltyObligationPercentageOfSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Royalty Obligation, Percentage of Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_RoyaltyObligationPercentageOfSales" xlink:href="exdx-20241231.xsd#exdx_RoyaltyObligationPercentageOfSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_RoyaltyObligationPercentageOfSales" xlink:to="lab_exdx_RoyaltyObligationPercentageOfSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TravelAndEntertainmentExpense_349cf449-ed65-47dc-994e-b3ce996a7914_terseLabel_en-US" xlink:label="lab_us-gaap_TravelAndEntertainmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Travel &amp; entertainment</link:label>
    <link:label id="lab_us-gaap_TravelAndEntertainmentExpense_label_en-US" xlink:label="lab_us-gaap_TravelAndEntertainmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Travel and Entertainment Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TravelAndEntertainmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TravelAndEntertainmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TravelAndEntertainmentExpense" xlink:to="lab_us-gaap_TravelAndEntertainmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_ffa79bbd-441f-44a0-9d84-c4fbb2b4f058_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_9dd98915-4bf0-4be9-89ad-ce23baaf4f96_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_7a530c86-07aa-4d2d-80c2-879bd06b7ec3_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_bb501e01-35c9-4486-9149-86f54db7dece_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_aa3fa695-8b3e-487c-b106-e744bb753684_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_dce85f62-56c5-4069-b165-471a41f1b284_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCustomerMember_3e4c6fc9-283e-43fc-9417-d498f243fe32_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCustomerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherCustomerMember_label_en-US" xlink:label="lab_us-gaap_OtherCustomerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Customer [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCustomerMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCustomerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCustomerMember" xlink:to="lab_us-gaap_OtherCustomerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_b0057d51-74a8-48a6-8520-0a548cc29c7d_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross book value of assets under finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Right-of-Use Asset, before Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_384c43f9-73d9-4c32-a903-06d2ec3410f6_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_96fe6c8a-f643-42c8-af23-31badb1c0e2b_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-current operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_7f9a5af6-4796-4699-a28a-f6d2f05c3c8b_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Lease obligations, net of current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_5d3b6227-d63e-438b-b5df-3d48a1c68257_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_3e2fb561-b3af-46fe-82dd-b1cd21b6838e_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseInterestExpense_9d830e35-ba53-4602-a2f0-e4f27d474cad_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest on finance lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseInterestExpense_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseInterestExpense" xlink:to="lab_us-gaap_FinanceLeaseInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_1495215f-3c20-44d3-959f-132ec3e85401_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LoansPayableMember_1730a50e-b8dd-4760-a30d-0e6027d49840_terseLabel_en-US" xlink:label="lab_us-gaap_LoansPayableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loan payable</link:label>
    <link:label id="lab_us-gaap_LoansPayableMember_label_en-US" xlink:label="lab_us-gaap_LoansPayableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loans Payable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LoansPayableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LoansPayableMember" xlink:to="lab_us-gaap_LoansPayableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_774323c7-e93b-444b-afe9-0f899b87924f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_d10d26c1-3414-480b-923c-23fb299013fb_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_SupplierTwoMember_ccc73a45-f807-42d1-bdce-1823fa6a23cd_terseLabel_en-US" xlink:label="lab_exdx_SupplierTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplier Two</link:label>
    <link:label id="lab_exdx_SupplierTwoMember_label_en-US" xlink:label="lab_exdx_SupplierTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplier Two [Member]</link:label>
    <link:label id="lab_exdx_SupplierTwoMember_documentation_en-US" xlink:label="lab_exdx_SupplierTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Supplier Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_SupplierTwoMember" xlink:href="exdx-20241231.xsd#exdx_SupplierTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_SupplierTwoMember" xlink:to="lab_exdx_SupplierTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForLegalSettlements_e498e70a-66b3-4607-b40d-73452ca89004_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForLegalSettlements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Settlement payment</link:label>
    <link:label id="lab_us-gaap_PaymentsForLegalSettlements_label_en-US" xlink:label="lab_us-gaap_PaymentsForLegalSettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for Legal Settlements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForLegalSettlements" xlink:to="lab_us-gaap_PaymentsForLegalSettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_720a3ce9-734c-427e-8ad4-b2512cb95ea8_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_44e5e0ab-9510-4232-99bf-f67ad1b10810_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development tax credits</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_1c2edb08-9768-4817-af66-79fd3bcddcac_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Money market funds, included in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_860cafee-d5da-4d92-a9b2-22bedb1c8f40_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_621f197c-f998-428a-abe8-b31df51a7be3_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Reconciling Items, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_e46d09d7-0114-43c6-b68e-15c0674cc1c3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplier [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplier [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:to="lab_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_808a9fd3-86e4-4b4d-a389-b8d806f1f7ec_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_2719cf7e-5b83-4bb6-a2de-9d34e4f3204d_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consideration received on transaction</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_20baac3f-e2bd-436e-b778-3ecbbe8c78f7_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, State and Local</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_efa9b315-31de-42b4-8c69-8b629dfd0d3f_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_72db1217-ea78-4124-aca9-91670a1a7999_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue_6b825481-db92-43ed-a15b-85ca88bf1d9d_totalLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total minimum lease payments</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_f2d3e52c-8c33-4f0f-844d-50104c4f3133_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diagnostic&#160;testing&#160;supplies</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Method</link:label>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMethodTextBlock" xlink:to="lab_ecd_AwardTmgMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_ae90e724-f80d-45ee-97e5-09c566da2b78_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrByIndTable_terseLabel_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual</link:label>
    <link:label id="lab_ecd_TradingArrByIndTable_label_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrByIndTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="lab_ecd_TradingArrByIndTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_e7e5d48b-1ff2-4c24-b872-2e918ff75175_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options exercisable (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_d0c37528-6aff-4a74-9515-2c14882447cc_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_0c167ddf-fbe1-4778-900e-766f1848b737_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_0be7101f-b424-4a5b-b585-f3d7a5b6a4b0_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingPoliciesProcLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_3ab848d3-fd7c-45dd-8ec5-ee238062654a_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_RentalPropertyByTypeDomain_bd9e98e6-0acc-4dd4-9bfb-a8627344e907_terseLabel_en-US" xlink:label="lab_exdx_RentalPropertyByTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rental Property, by Type [Domain]</link:label>
    <link:label id="lab_exdx_RentalPropertyByTypeDomain_label_en-US" xlink:label="lab_exdx_RentalPropertyByTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rental Property, by Type [Domain]</link:label>
    <link:label id="lab_exdx_RentalPropertyByTypeDomain_documentation_en-US" xlink:label="lab_exdx_RentalPropertyByTypeDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Rental Property, by Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_RentalPropertyByTypeDomain" xlink:href="exdx-20241231.xsd#exdx_RentalPropertyByTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_RentalPropertyByTypeDomain" xlink:to="lab_exdx_RentalPropertyByTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation, Amount</link:label>
    <link:label id="lab_ecd_AdjToCompAmt_label_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAmt" xlink:to="lab_ecd_AdjToCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3807947b-f76b-4f71-87fb-63a9b58ab308_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding, Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryCompAmt" xlink:to="lab_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_DebtInstrumentPaidInKindLoansIssued_67769c4b-f509-463f-94be-3ed2645d3524_terseLabel_en-US" xlink:label="lab_exdx_DebtInstrumentPaidInKindLoansIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term loan, paid in-kind loans issued</link:label>
    <link:label id="lab_exdx_DebtInstrumentPaidInKindLoansIssued_label_en-US" xlink:label="lab_exdx_DebtInstrumentPaidInKindLoansIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Paid In Kind Loans Issued</link:label>
    <link:label id="lab_exdx_DebtInstrumentPaidInKindLoansIssued_documentation_en-US" xlink:label="lab_exdx_DebtInstrumentPaidInKindLoansIssued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Paid In Kind Loans Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentPaidInKindLoansIssued" xlink:href="exdx-20241231.xsd#exdx_DebtInstrumentPaidInKindLoansIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_DebtInstrumentPaidInKindLoansIssued" xlink:to="lab_exdx_DebtInstrumentPaidInKindLoansIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember_terseLabel_en-US" xlink:label="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table</link:label>
    <link:label id="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember_label_en-US" xlink:label="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:to="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_1794be14-61a9-439f-a702-e859fff0e041_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureAmt" xlink:to="lab_ecd_CoSelectedMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_5e200737-54e2-4ac2-a3dd-df69af82dcf4_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Intrinsic Value (in thousands)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TabularListTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tabular List, Table</link:label>
    <link:label id="lab_ecd_TabularListTableTextBlock_label_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tabular List [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TabularListTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TabularListTableTextBlock" xlink:to="lab_ecd_TabularListTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_b7e4f646-89e9-445e-a980-6b1948441e80_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_8c53c698-2a3d-47c8-84a7-bd82e8e1725d_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increases recorded to income tax provision</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_b939f76a-94c5-47b0-ae8b-e4308c4977e4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level&#160;3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8ff70d80-478c-4728-a60d-1cead030be7a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_b8338a61-d732-4a2b-8165-d7096e5a1d85_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table</link:label>
    <link:label id="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:to="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_TaxYearsThroughDecember312017Member_9aaa97bb-e0f6-44c2-a9ca-392368ae8b4c_terseLabel_en-US" xlink:label="lab_exdx_TaxYearsThroughDecember312017Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Years Through December 31, 2017</link:label>
    <link:label id="lab_exdx_TaxYearsThroughDecember312017Member_label_en-US" xlink:label="lab_exdx_TaxYearsThroughDecember312017Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Years Through December 31, 2017 [Member]</link:label>
    <link:label id="lab_exdx_TaxYearsThroughDecember312017Member_documentation_en-US" xlink:label="lab_exdx_TaxYearsThroughDecember312017Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tax Years Through December 31, 2017</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_TaxYearsThroughDecember312017Member" xlink:href="exdx-20241231.xsd#exdx_TaxYearsThroughDecember312017Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_TaxYearsThroughDecember312017Member" xlink:to="lab_exdx_TaxYearsThroughDecember312017Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_0b1ba3a0-90ff-4cc7-b9e0-aeb77de00fff_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of stock under Employee Stock Purchase Plan (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_dd79d4d0-1d5d-4ad1-844a-8bb0c60a502a_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_73187288-3987-46ef-9fbf-83eb243e4a5c_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Accrued and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_f472425e-c5c6-4d7a-864e-c457a289415e_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Anti-dilutive securities excluded from computation (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_OfficeMember_1e5c8f42-24f8-4c0f-86e9-f18dc0fec37e_terseLabel_en-US" xlink:label="lab_exdx_OfficeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Office</link:label>
    <link:label id="lab_exdx_OfficeMember_label_en-US" xlink:label="lab_exdx_OfficeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Office [Member]</link:label>
    <link:label id="lab_exdx_OfficeMember_documentation_en-US" xlink:label="lab_exdx_OfficeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Office</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OfficeMember" xlink:href="exdx-20241231.xsd#exdx_OfficeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_OfficeMember" xlink:to="lab_exdx_OfficeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_a0207b02-68c6-406f-b9e4-5a8df33c20e2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less: imputed interest</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_781f780a-1f93-4f52-9ab3-482191ec8bd2_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-lived Assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_ExpirationMar312026Member_0e45b473-976f-41c4-b8e1-b8db1b85b380_terseLabel_en-US" xlink:label="lab_exdx_ExpirationMar312026Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant expiration March 31, 2026</link:label>
    <link:label id="lab_exdx_ExpirationMar312026Member_label_en-US" xlink:label="lab_exdx_ExpirationMar312026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expiration Mar 31, 2026 [Member]</link:label>
    <link:label id="lab_exdx_ExpirationMar312026Member_documentation_en-US" xlink:label="lab_exdx_ExpirationMar312026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Expiration Mar 31, 2026</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ExpirationMar312026Member" xlink:href="exdx-20241231.xsd#exdx_ExpirationMar312026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_ExpirationMar312026Member" xlink:to="lab_exdx_ExpirationMar312026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesPolicyTextBlock_4c26bb42-95d0-476e-ae40-aec17f0cc450_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shipping and Handling Costs</link:label>
    <link:label id="lab_us-gaap_CostOfSalesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Goods and Service [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesPolicyTextBlock" xlink:to="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2e0b2dbd-a4eb-45f4-8f82-8a4afc763d43_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents and restricted cash, beginning of year</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_cb3e7491-f316-4778-a89e-daa4efd388ae_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents and restricted cash, end of year</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_dea99b15-ca57-4106-a046-082a9b7b71a0_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_2dfccba2-77b3-47cb-bd08-87078152df51_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options, unrecognized compensation cost</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_0751d2bc-55ae-49ee-8c96-6bb42042b5dd_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_MedicareMember_17bbc654-df8b-46b2-84c1-79d2bcce9539_terseLabel_en-US" xlink:label="lab_exdx_MedicareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Medicare</link:label>
    <link:label id="lab_exdx_MedicareMember_label_en-US" xlink:label="lab_exdx_MedicareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Medicare [Member]</link:label>
    <link:label id="lab_exdx_MedicareMember_documentation_en-US" xlink:label="lab_exdx_MedicareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Medicare</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_MedicareMember" xlink:href="exdx-20241231.xsd#exdx_MedicareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_MedicareMember" xlink:to="lab_exdx_MedicareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_5a9910ea-52ef-4416-bef5-6fb5ffa88663_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_dc2d71d2-a208-418a-bd08-4b1e08608409_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current:</link:label>
    <link:label id="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_label_en-US" xlink:label="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Federal, State and Local, Tax Expense (Benefit) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_83055cb8-2fbf-4b05-b548-9feda376549c_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_1fbb7542-28b5-4358-ac8a-30e5b9eb01e3_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock option grants issued and outstanding</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_28ed9982-4365-47aa-9136-51de6d0b03ec_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards released (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_7abe4e3b-1bb1-4f30-ae65-b0ddaf12210e_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_78479d40-e54e-4fb2-9ec2-87f71b2fa5c9_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_f0c3f48e-9dc0-4248-a760-2c6c6a9d1d4c_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_7f1c46a9-0509-4c8e-a04d-adc7c5e02d74_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants to purchase common stock</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_3d5c558d-2681-4373-aad2-953fb5beab3f_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_e4a68096-e2d4-467c-96ce-d29ee06e5f68_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_262a91d8-69c8-4925-8a0a-3fb722ccceaf_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaidInKindInterest_ec049ae1-bc91-4f40-8067-8897bc451ff3_terseLabel_en-US" xlink:label="lab_us-gaap_PaidInKindInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash interest expense</link:label>
    <link:label id="lab_us-gaap_PaidInKindInterest_label_en-US" xlink:label="lab_us-gaap_PaidInKindInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Paid-in-Kind Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaidInKindInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaidInKindInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaidInKindInterest" xlink:to="lab_us-gaap_PaidInKindInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_ClinicalStudyPolicyPolicyTextBlock_34bbb66b-489a-46ee-b502-f6ed2591d49a_terseLabel_en-US" xlink:label="lab_exdx_ClinicalStudyPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Clinical Studies</link:label>
    <link:label id="lab_exdx_ClinicalStudyPolicyPolicyTextBlock_label_en-US" xlink:label="lab_exdx_ClinicalStudyPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Clinical Study, Policy [Policy Text Block]</link:label>
    <link:label id="lab_exdx_ClinicalStudyPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_exdx_ClinicalStudyPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Clinical Study, Policy</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ClinicalStudyPolicyPolicyTextBlock" xlink:href="exdx-20241231.xsd#exdx_ClinicalStudyPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_ClinicalStudyPolicyPolicyTextBlock" xlink:to="lab_exdx_ClinicalStudyPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_7bec98e8-41f0-498c-8d80-2752c28a9c8b_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_ExpirationDec72025Member_03b76877-ecdb-4031-b87e-586fd30d2d91_terseLabel_en-US" xlink:label="lab_exdx_ExpirationDec72025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant expiration December 7, 2025</link:label>
    <link:label id="lab_exdx_ExpirationDec72025Member_label_en-US" xlink:label="lab_exdx_ExpirationDec72025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expiration Dec 7, 2025 [Member]</link:label>
    <link:label id="lab_exdx_ExpirationDec72025Member_documentation_en-US" xlink:label="lab_exdx_ExpirationDec72025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Expiration Dec 7, 2025</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ExpirationDec72025Member" xlink:href="exdx-20241231.xsd#exdx_ExpirationDec72025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_ExpirationDec72025Member" xlink:to="lab_exdx_ExpirationDec72025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_WeightedAverageRemainingLeaseTermAbstract_ca869586-66ee-43b1-b942-8630471ec4d0_terseLabel_en-US" xlink:label="lab_exdx_WeightedAverageRemainingLeaseTermAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average remaining lease term (years)</link:label>
    <link:label id="lab_exdx_WeightedAverageRemainingLeaseTermAbstract_label_en-US" xlink:label="lab_exdx_WeightedAverageRemainingLeaseTermAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted-Average Remaining Lease Term [Abstract]</link:label>
    <link:label id="lab_exdx_WeightedAverageRemainingLeaseTermAbstract_documentation_en-US" xlink:label="lab_exdx_WeightedAverageRemainingLeaseTermAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Weighted-Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_WeightedAverageRemainingLeaseTermAbstract" xlink:href="exdx-20241231.xsd#exdx_WeightedAverageRemainingLeaseTermAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_WeightedAverageRemainingLeaseTermAbstract" xlink:to="lab_exdx_WeightedAverageRemainingLeaseTermAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_268164d2-af48-4605-8c69-ef47e518f516_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_5a1f455b-3158-4eed-b2dd-e5cead5c0b33_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number&#160;of Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseContractualTermDomain_98775eb1-9684-49eb-a75c-5d733b756630_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseContractualTermDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease Contractual Term [Domain]</link:label>
    <link:label id="lab_us-gaap_LeaseContractualTermDomain_label_en-US" xlink:label="lab_us-gaap_LeaseContractualTermDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Contractual Term [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseContractualTermDomain" xlink:to="lab_us-gaap_LeaseContractualTermDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_611567fa-a0a1-4bd4-aa9c-2402996d743f_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_fe5a5d90-3d47-4605-8681-0416c72e50ff_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SettledLitigationMember_8e86378f-c02d-4c08-b71d-a382a423f8c6_terseLabel_en-US" xlink:label="lab_us-gaap_SettledLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Settled Litigation</link:label>
    <link:label id="lab_us-gaap_SettledLitigationMember_label_en-US" xlink:label="lab_us-gaap_SettledLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Settled Litigation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SettledLitigationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SettledLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SettledLitigationMember" xlink:to="lab_us-gaap_SettledLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_c80101ed-2fc8-45c3-9fec-ea3ca9a65af1_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets_609797ed-13f5-46da-b8f0-9f7182eebcd4_negatedLabel_en-US" xlink:label="lab_exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets_label_en-US" xlink:label="lab_exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Prepaid Expense And Current Other Assets</link:label>
    <link:label id="lab_exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets_documentation_en-US" xlink:label="lab_exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Prepaid Expense And Current Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets" xlink:href="exdx-20241231.xsd#exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets" xlink:to="lab_exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LaborAndRelatedExpense_99f543aa-c53f-48db-b60f-b8e0a6259c49_terseLabel_en-US" xlink:label="lab_us-gaap_LaborAndRelatedExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee expense</link:label>
    <link:label id="lab_us-gaap_LaborAndRelatedExpense_label_en-US" xlink:label="lab_us-gaap_LaborAndRelatedExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Labor and Related Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LaborAndRelatedExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LaborAndRelatedExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LaborAndRelatedExpense" xlink:to="lab_us-gaap_LaborAndRelatedExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_09cc8d83-378c-4e5a-9757-3e1d16f6c369_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportingUnits_d4b33594-2626-426c-a853-5dd88231067f_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportingUnits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of reporting units</link:label>
    <link:label id="lab_us-gaap_NumberOfReportingUnits_label_en-US" xlink:label="lab_us-gaap_NumberOfReportingUnits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Reporting Units</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportingUnits" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportingUnits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportingUnits" xlink:to="lab_us-gaap_NumberOfReportingUnits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_b9ecfede-0373-4dec-807a-3938a1f023bf_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_26367fe8-c359-4fec-95c4-c0d0b0b68dc9_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_364622c3-87db-4bf6-8872-ed413b3d8b7c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrExpirationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrExpirationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expiration Date</link:label>
    <link:label id="lab_ecd_TrdArrExpirationDate_label_en-US" xlink:label="lab_ecd_TrdArrExpirationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Expiration Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrExpirationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrExpirationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrExpirationDate" xlink:to="lab_ecd_TrdArrExpirationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_UnitedHealthcareMember_1d6c8784-a7f7-47f5-9bc7-905b25fbb06a_terseLabel_en-US" xlink:label="lab_exdx_UnitedHealthcareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">United Healthcare</link:label>
    <link:label id="lab_exdx_UnitedHealthcareMember_label_en-US" xlink:label="lab_exdx_UnitedHealthcareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">United Healthcare [Member]</link:label>
    <link:label id="lab_exdx_UnitedHealthcareMember_documentation_en-US" xlink:label="lab_exdx_UnitedHealthcareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">United Healthcare</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_UnitedHealthcareMember" xlink:href="exdx-20241231.xsd#exdx_UnitedHealthcareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_UnitedHealthcareMember" xlink:to="lab_exdx_UnitedHealthcareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_37fd87fb-e191-411e-a2ff-37eb1a6ccdd3_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_c512a7cd-f424-478f-ac13-ef52cd927b7a_negatedLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnAmt" xlink:to="lab_ecd_TotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_d852ccd3-e8c7-4f58-b3f0-a367fb333425_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Footnote</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjFnTextBlock_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:to="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_bd170fac-ad09-4dd3-b3df-8f9b1ac8a933_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration risk percentage</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_46e991ee-3ba0-44b7-ab45-b1b6d0e6ce37_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_d362d7d4-3335-40f7-8d3e-7e08f232b1b6_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise of stock options (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_4b949334-6c4d-4764-8b1c-4638bade7078_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_SaleOfStockRemainingAuthorizedAmount_9db50902-a0fd-40d9-9a19-52890c38dffd_terseLabel_en-US" xlink:label="lab_exdx_SaleOfStockRemainingAuthorizedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock offering, remaining authorized amount</link:label>
    <link:label id="lab_exdx_SaleOfStockRemainingAuthorizedAmount_label_en-US" xlink:label="lab_exdx_SaleOfStockRemainingAuthorizedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Remaining Authorized Amount</link:label>
    <link:label id="lab_exdx_SaleOfStockRemainingAuthorizedAmount_documentation_en-US" xlink:label="lab_exdx_SaleOfStockRemainingAuthorizedAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Remaining Authorized Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_SaleOfStockRemainingAuthorizedAmount" xlink:href="exdx-20241231.xsd#exdx_SaleOfStockRemainingAuthorizedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_SaleOfStockRemainingAuthorizedAmount" xlink:to="lab_exdx_SaleOfStockRemainingAuthorizedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_440bcff2-f357-4ab6-a524-3832031ec23a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote</link:label>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_label_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_cf64cdeb-c281-4f97-a1be-c4c1139291c9_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_44b2716f-b793-4f20-91ca-91f36c552a74_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted- Average Exercise&#160;Price Per Share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_d9e8b47a-420d-448f-93b1-61efab4c1ebe_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_DebtInstrumentMinimumCashBalanceRequiredNotRequiredToComplyWithCovenant_804d723a-8e34-44e6-9635-9146a5de9f33_terseLabel_en-US" xlink:label="lab_exdx_DebtInstrumentMinimumCashBalanceRequiredNotRequiredToComplyWithCovenant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, minimum cash balance</link:label>
    <link:label id="lab_exdx_DebtInstrumentMinimumCashBalanceRequiredNotRequiredToComplyWithCovenant_label_en-US" xlink:label="lab_exdx_DebtInstrumentMinimumCashBalanceRequiredNotRequiredToComplyWithCovenant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Minimum Cash Balance Required, Not Required To Comply With Covenant</link:label>
    <link:label id="lab_exdx_DebtInstrumentMinimumCashBalanceRequiredNotRequiredToComplyWithCovenant_documentation_en-US" xlink:label="lab_exdx_DebtInstrumentMinimumCashBalanceRequiredNotRequiredToComplyWithCovenant" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Minimum Cash Balance Required, Not Required To Comply With Covenant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentMinimumCashBalanceRequiredNotRequiredToComplyWithCovenant" xlink:href="exdx-20241231.xsd#exdx_DebtInstrumentMinimumCashBalanceRequiredNotRequiredToComplyWithCovenant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_DebtInstrumentMinimumCashBalanceRequiredNotRequiredToComplyWithCovenant" xlink:to="lab_exdx_DebtInstrumentMinimumCashBalanceRequiredNotRequiredToComplyWithCovenant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_5c30e8a7-245f-4bdd-8dcb-981232846174_negatedLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, Accumulated Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_9a1d9ecb-d78c-4c35-bbf4-8cb1e7237dea_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average number of shares used to compute net loss per share, diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_e86aaea1-cdf5-4ac2-ab47-1def07f1bd0d_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite lived assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Goodwill and Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_terseLabel_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value</link:label>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_label_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:to="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseObligationDueInNextTwelveMonths_fcf37ce7-ee9b-4f59-8ccc-5cc1223b78c1_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase obligation, due in next twelve months</link:label>
    <link:label id="lab_us-gaap_PurchaseObligationDueInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase Obligation, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PurchaseObligationDueInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:to="lab_us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_46e6854e-58c7-4fc7-80ee-16a4df8c8422_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_53050cba-03ba-4b17-a654-6648dfd61f09_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_6d91c702-2713-4476-8db6-76dd5210df04_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_ba18df8f-7027-4de2-b6e7-4d219a163497_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_c7e94d18-60b0-4b9e-8496-82b4ebb74487_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total gross deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_85a99394-cbc5-427c-a37e-57a4aed99cbc_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_5aea4f2a-e028-4843-801e-8099778dccc3_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease, renewal term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseAxis_8cb22295-961b-45d8-ad9e-df1bcb855f6d_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_label_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis" xlink:to="lab_srt_LitigationCaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_11ef4688-f317-4104-880d-c7c2e84e12d3_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseNonoperating_017d8d35-146b-4f65-8948-fc47449a74a1_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseNonoperating" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseNonoperating_40160706-5a9a-4390-bff8-6080862aed60_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseNonoperating" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseNonoperating_label_en-US" xlink:label="lab_us-gaap_InterestExpenseNonoperating" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense, Nonoperating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseNonoperating" xlink:to="lab_us-gaap_InterestExpenseNonoperating" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_6bc95078-2dc7-4dec-b388-0fd856df3dc4_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Total deferred</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedSalariesCurrent_9cf65672-9c8d-4b06-bb06-e34a087146f6_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedSalariesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued&#160;payroll&#160;and&#160;related&#160;expenses</link:label>
    <link:label id="lab_us-gaap_AccruedSalariesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedSalariesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Salaries, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalariesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedSalariesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedSalariesCurrent" xlink:to="lab_us-gaap_AccruedSalariesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_d15082a5-1673-440e-8ec4-e2fc8fa94924_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_SaleOfStockAuthorizedAmount_50b7f26e-7090-4296-919b-962605f0f4aa_terseLabel_en-US" xlink:label="lab_exdx_SaleOfStockAuthorizedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock offering, authorized amount</link:label>
    <link:label id="lab_exdx_SaleOfStockAuthorizedAmount_label_en-US" xlink:label="lab_exdx_SaleOfStockAuthorizedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Authorized Amount</link:label>
    <link:label id="lab_exdx_SaleOfStockAuthorizedAmount_documentation_en-US" xlink:label="lab_exdx_SaleOfStockAuthorizedAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Authorized Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_SaleOfStockAuthorizedAmount" xlink:href="exdx-20241231.xsd#exdx_SaleOfStockAuthorizedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_SaleOfStockAuthorizedAmount" xlink:to="lab_exdx_SaleOfStockAuthorizedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_209e7394-3c69-401b-b949-7a0785aad4c8_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Standards Update and change in Accounting Principle [Table]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_42440046-a6f2-4a99-9d0a-f57e1350070b_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative expenses</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_cd216037-ba80-46ae-87b5-ac224b0d017e_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Qualified employee compensation contribution, amount</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:to="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_IncentiveAwardPlan2019Member_a8c321f4-fb8f-4350-91ea-18dfbc7bd2a1_terseLabel_en-US" xlink:label="lab_exdx_IncentiveAwardPlan2019Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2019 Incentive Award Plan</link:label>
    <link:label id="lab_exdx_IncentiveAwardPlan2019Member_label_en-US" xlink:label="lab_exdx_IncentiveAwardPlan2019Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Incentive Award Plan, 2019 [Member]</link:label>
    <link:label id="lab_exdx_IncentiveAwardPlan2019Member_documentation_en-US" xlink:label="lab_exdx_IncentiveAwardPlan2019Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Incentive Award Plan, 2019</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_IncentiveAwardPlan2019Member" xlink:href="exdx-20241231.xsd#exdx_IncentiveAwardPlan2019Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_IncentiveAwardPlan2019Member" xlink:to="lab_exdx_IncentiveAwardPlan2019Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_2d358820-5867-4bd4-8632-998f631c6f63_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_48b5248e-f1ff-41aa-bff1-94b439cba403_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesMember_bb095779-81c1-4f45-9dd0-bbfe98686133_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of revenue</link:label>
    <link:label id="lab_us-gaap_CostOfSalesMember_label_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesMember" xlink:to="lab_us-gaap_CostOfSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_9260ee88-2634-45ba-94d6-defc8e3e937b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_ccc47b55-b02d-44f9-9b4f-7e1c37e3ab81_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_45455809-1736-433d-8bf0-4feebbf92cfa_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total borrowings, net of discounts and debt issuance costs</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_593fe8ce-b4ca-4b80-8e19-a16634229fd7_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total borrowings, net of discounts and debt issuance costs</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnAdjsPrrSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Adjustments Prior Service Cost</link:label>
    <link:label id="lab_ecd_PnsnAdjsPrrSvcCstMember_label_en-US" xlink:label="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Adjustments Prior Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsPrrSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:to="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_LongTermDebtUndiscountedInterestAmount_99d4244b-bf4e-41e8-a12a-341c587f0c49_negatedLabel_en-US" xlink:label="lab_exdx_LongTermDebtUndiscountedInterestAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Interest</link:label>
    <link:label id="lab_exdx_LongTermDebtUndiscountedInterestAmount_label_en-US" xlink:label="lab_exdx_LongTermDebtUndiscountedInterestAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Undiscounted Interest Amount</link:label>
    <link:label id="lab_exdx_LongTermDebtUndiscountedInterestAmount_documentation_en-US" xlink:label="lab_exdx_LongTermDebtUndiscountedInterestAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Long-term Debt, Undiscounted Interest Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_LongTermDebtUndiscountedInterestAmount" xlink:href="exdx-20241231.xsd#exdx_LongTermDebtUndiscountedInterestAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_LongTermDebtUndiscountedInterestAmount" xlink:to="lab_exdx_LongTermDebtUndiscountedInterestAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_56a35b57-b1e2-42a8-acc0-a94a27aeacbc_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_a57adf68-23ff-4805-9bdc-b3b4b4cb9ed5_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2028</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Maturity, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_terseLabel_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Executive Categories</link:label>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_label_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Executive Categories [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="lab_ecd_AllExecutiveCategoriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_label_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:to="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_e9922809-ef4c-469c-91a9-2722a6777684_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_5233abca-0a4a-4dae-a163-a4013cdbc591_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_USDepartmentOfJusticeCaseMember_db88b020-b09d-449c-a801-4ffb149e373e_terseLabel_en-US" xlink:label="lab_exdx_USDepartmentOfJusticeCaseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. Department Of Justice Case</link:label>
    <link:label id="lab_exdx_USDepartmentOfJusticeCaseMember_label_en-US" xlink:label="lab_exdx_USDepartmentOfJusticeCaseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">U.S. Department Of Justice Case [Member]</link:label>
    <link:label id="lab_exdx_USDepartmentOfJusticeCaseMember_documentation_en-US" xlink:label="lab_exdx_USDepartmentOfJusticeCaseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">U.S. Department Of Justice Case</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_USDepartmentOfJusticeCaseMember" xlink:href="exdx-20241231.xsd#exdx_USDepartmentOfJusticeCaseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_USDepartmentOfJusticeCaseMember" xlink:to="lab_exdx_USDepartmentOfJusticeCaseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_34ddcf82-bcf9-486a-a9ab-5579e5e823ea_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_6ebf347c-9ddc-4b60-b2b5-0d9db7a5457f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term loan, effective interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnBnftsAdjFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Benefits Adjustments, Footnote</link:label>
    <link:label id="lab_ecd_PnsnBnftsAdjFnTextBlock_label_en-US" xlink:label="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Benefits Adjustments, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnBnftsAdjFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:to="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_f43b69a1-2ff1-4ca1-ae1f-dce2149eac55_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_CashFlowInformationOperatingAndFinanceLeasePaymentsAbstract_403943c9-f7d6-4c11-a06b-0dcacafb6b8f_terseLabel_en-US" xlink:label="lab_exdx_CashFlowInformationOperatingAndFinanceLeasePaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities</link:label>
    <link:label id="lab_exdx_CashFlowInformationOperatingAndFinanceLeasePaymentsAbstract_label_en-US" xlink:label="lab_exdx_CashFlowInformationOperatingAndFinanceLeasePaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Flow Information, Operating and Finance Lease Payments [Abstract]</link:label>
    <link:label id="lab_exdx_CashFlowInformationOperatingAndFinanceLeasePaymentsAbstract_documentation_en-US" xlink:label="lab_exdx_CashFlowInformationOperatingAndFinanceLeasePaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash Flow Information, Operating and Finance Lease Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_CashFlowInformationOperatingAndFinanceLeasePaymentsAbstract" xlink:href="exdx-20241231.xsd#exdx_CashFlowInformationOperatingAndFinanceLeasePaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_CashFlowInformationOperatingAndFinanceLeasePaymentsAbstract" xlink:to="lab_exdx_CashFlowInformationOperatingAndFinanceLeasePaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_a0ed8749-648f-4ea3-a97e-69608eca0354_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_DebtInstrumentStatedInterestRatePaidInKind_b2c99ce6-2d22-4454-8fb5-1863ced393b1_terseLabel_en-US" xlink:label="lab_exdx_DebtInstrumentStatedInterestRatePaidInKind" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term loan, paid in-kind, interest rate</link:label>
    <link:label id="lab_exdx_DebtInstrumentStatedInterestRatePaidInKind_label_en-US" xlink:label="lab_exdx_DebtInstrumentStatedInterestRatePaidInKind" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Stated Interest Rate, Paid In-Kind</link:label>
    <link:label id="lab_exdx_DebtInstrumentStatedInterestRatePaidInKind_documentation_en-US" xlink:label="lab_exdx_DebtInstrumentStatedInterestRatePaidInKind" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Stated Interest Rate, Paid In-Kind</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentStatedInterestRatePaidInKind" xlink:href="exdx-20241231.xsd#exdx_DebtInstrumentStatedInterestRatePaidInKind"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_DebtInstrumentStatedInterestRatePaidInKind" xlink:to="lab_exdx_DebtInstrumentStatedInterestRatePaidInKind" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesShares_c89d60c8-5b70-4ae9-b657-b45a6e29e5c6_terseLabel_en-US" xlink:label="lab_exdx_IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of stock from vested restricted stock units and payment of employees' taxes (in shares)</link:label>
    <link:label id="lab_exdx_IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesShares_label_en-US" xlink:label="lab_exdx_IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance Of Stock From Vested Restricted Stock Units And Payment Of Employees Taxes, Shares</link:label>
    <link:label id="lab_exdx_IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesShares_documentation_en-US" xlink:label="lab_exdx_IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Issuance Of Stock From Vested Restricted Stock Units And Payment Of Employees Taxes, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesShares" xlink:href="exdx-20241231.xsd#exdx_IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesShares" xlink:to="lab_exdx_IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_e860868f-8a0a-4774-abfe-6bb027cee67b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of stock from vested restricted stock units (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_69398340-182c-4d50-9b2f-640aabfba565_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Awards released (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_6fc6f030-374b-47a4-a8aa-9af6d78ee89c_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_94d939e1-5403-41b0-a0df-8e9a4060ef66_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_label_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_22dff600-0532-4a4f-992c-095731478f22_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Furniture&#160;and&#160;fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1b338e60-f94e-4cd6-80ce-8df5a3571605_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_9a768141-9f14-4f18-9a51-3b79a6779372_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_a915f4db-9b32-489d-8fc2-4b52c1a2e1b5_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_2960216f-742b-47a8-ba86-f4b4cf7bcf18_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expired (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_4c4bdfce-b975-4d45-8401-b557d19889a5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_59bc7939-9d9f-4533-b98b-b0228186477d_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_9705774b-7440-42bc-ace8-c26221bb3acc_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less: imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_ffcc29cb-4708-407a-8586-0b35d9bf145f_totalLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total lease cost</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_df13304d-3bdc-4441-b4c8-65133b1497dc_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoName_terseLabel_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:label id="lab_ecd_PeoName_label_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoName" xlink:to="lab_ecd_PeoName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_aebd9c75-aa98-4328-9cfa-a444d3f60497_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants issued to purchase redeemable convertible preferred stock (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:to="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_620489e4-2331-456f-a05f-4cc8037213b8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryIndName" xlink:to="lab_ecd_OutstandingRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SummaryOfValuationAllowanceTextBlock_5dbf0e91-d441-4a95-baff-f202266ae69c_terseLabel_en-US" xlink:label="lab_us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Valuation Allowance</link:label>
    <link:label id="lab_us-gaap_SummaryOfValuationAllowanceTextBlock_label_en-US" xlink:label="lab_us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary of Valuation Allowance [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:to="lab_us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_3ca09d57-90fc-443c-b475-9ee033c7d598_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_c34aee86-a708-4c9a-866e-e6c85f32d7d7_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableLeaseCost_e6245f79-f43e-4a28-b7bf-53f7e78f6d97_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable lease cost</link:label>
    <link:label id="lab_us-gaap_VariableLeaseCost_label_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost" xlink:to="lab_us-gaap_VariableLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_c5a6aebf-9697-42cd-a8df-c29bf2db0529_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplierConcentrationRiskMember_90e06b39-69bf-46bb-96b3-6409418c446e_terseLabel_en-US" xlink:label="lab_us-gaap_SupplierConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplier Concentration Risk</link:label>
    <link:label id="lab_us-gaap_SupplierConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_SupplierConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplier Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplierConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplierConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplierConcentrationRiskMember" xlink:to="lab_us-gaap_SupplierConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoMember_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO</link:label>
    <link:label id="lab_ecd_NonPeoNeoMember_label_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoMember" xlink:to="lab_ecd_NonPeoNeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_853dcbff-5295-43ad-87c9-b36c27e1adfc_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_62d9e19c-661c-450e-87ff-b60e591afa1c_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease obligations, net of current portion</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined</link:label>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_label_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgPredtrmndFlag" xlink:to="lab_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_2717693b-d0fb-42b9-97d3-80015dc212f8_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayable_14da20f3-956c-4a3a-a943-9a00c953a858_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes payable</link:label>
    <link:label id="lab_us-gaap_NotesPayable_label_en-US" xlink:label="lab_us-gaap_NotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayable" xlink:to="lab_us-gaap_NotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_66b69e75-6dc9-40ff-a6d4-2708001d9a56_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">401(k) Plan</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retirement Benefits [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_f784e441-f065-4907-8164-a52d4cb6187e_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_3eb91cb6-b5c7-42c4-94d6-cbae82714b23_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recent Accounting Pronouncements and Recently Adopted Accounting Standards</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_b1d5642c-f480-4857-95d2-3e46a7030fa6_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss per share, diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_CollaborationAgreementCollaborationExpenses_6831aa96-ece4-4501-ba34-712258c5dc10_terseLabel_en-US" xlink:label="lab_exdx_CollaborationAgreementCollaborationExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration agreement, collaboration expenses</link:label>
    <link:label id="lab_exdx_CollaborationAgreementCollaborationExpenses_label_en-US" xlink:label="lab_exdx_CollaborationAgreementCollaborationExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Agreement, Collaboration Expenses</link:label>
    <link:label id="lab_exdx_CollaborationAgreementCollaborationExpenses_documentation_en-US" xlink:label="lab_exdx_CollaborationAgreementCollaborationExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration Agreement, Collaboration Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_CollaborationAgreementCollaborationExpenses" xlink:href="exdx-20241231.xsd#exdx_CollaborationAgreementCollaborationExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_CollaborationAgreementCollaborationExpenses" xlink:to="lab_exdx_CollaborationAgreementCollaborationExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_2acc358d-8a93-4514-a07f-b727fa6223c4_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureName_terseLabel_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_MeasureName_label_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureName" xlink:to="lab_ecd_MeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_cad96c1b-64ea-4588-9608-248b152e86d7_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_886c72d5-88cd-42ab-b8c4-1b826376e838_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Total current</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesAuthorized_c2e882e9-f74e-4f0a-a99d-50c208826d54_terseLabel_en-US" xlink:label="lab_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (decrease) in number of shares authorized (in shares)</link:label>
    <link:label id="lab_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesAuthorized_label_en-US" xlink:label="lab_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Increase (Decrease) In Number Of Shares Authorized</link:label>
    <link:label id="lab_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesAuthorized_documentation_en-US" xlink:label="lab_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Increase (Decrease) In Number Of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesAuthorized" xlink:href="exdx-20241231.xsd#exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesAuthorized" xlink:to="lab_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_terseLabel_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement does not require Recovery</link:label>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_label_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Does Not Require Recovery [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_1fba5d91-21a3-411e-b203-689fa00ed9d8_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_ab505a62-4031-4b44-9507-6651f026d804_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Outstanding Warrants</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_b64184cc-dfc4-41a8-bdcc-c2d4ebdb7c71_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_c9416dba-d18e-4fa4-a66c-3a94e0888368_verboseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_e8d4981a-9199-44bc-b488-8f31fb57bb65_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Qualified employee compensation, employer matching contribution, percent of employees' gross pay</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesAbstract_fc9d7a34-4721-47a3-b186-2868ae3578cd_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liabilities:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Gross [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_OfficeAndLaboratoryMember_1e4d65b0-85a6-4429-9f16-e89dfb910c01_terseLabel_en-US" xlink:label="lab_exdx_OfficeAndLaboratoryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Office and Laboratory</link:label>
    <link:label id="lab_exdx_OfficeAndLaboratoryMember_label_en-US" xlink:label="lab_exdx_OfficeAndLaboratoryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Office and Laboratory [Member]</link:label>
    <link:label id="lab_exdx_OfficeAndLaboratoryMember_documentation_en-US" xlink:label="lab_exdx_OfficeAndLaboratoryMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Office and Laboratory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OfficeAndLaboratoryMember" xlink:href="exdx-20241231.xsd#exdx_OfficeAndLaboratoryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_OfficeAndLaboratoryMember" xlink:to="lab_exdx_OfficeAndLaboratoryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_eeda948d-b336-4350-a1dd-b9aa5ed8cd94_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_35247136-f0ad-426d-9bad-564b78846fa6_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_8c541784-a0db-4bfc-ab21-d414778ea8f9_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_a4993d83-0355-43c5-ae4e-8f6e7deaef0f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value, Financial Instrument Measured on a Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_3b3bf1c1-71f1-4be8-bcd0-4fdcd5e47b76_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_079406ce-2092-4eaa-ad9a-7507439b013c_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermNotesPayable_af5664be-a8ea-415c-ac0b-a33002056d92_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermNotesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes payable noncurrent</link:label>
    <link:label id="lab_us-gaap_LongTermNotesPayable_label_en-US" xlink:label="lab_us-gaap_LongTermNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes Payable, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermNotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermNotesPayable" xlink:to="lab_us-gaap_LongTermNotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_de1dfcb5-e2eb-4fe4-a1f3-288572058544_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_68e1b946-a767-462a-ad9e-8854a8fb27b3_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Deferred tax assets, net</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_2cd785d0-c6f7-40a6-b670-6e0507a7f2bb_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from disposal of property and equipment</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale of Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_7347fe63-739b-4f93-9a1a-aa93f06782ee_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_468577de-cc34-44e0-9775-cc8e2de86c18_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_496ae688-b433-4ecd-be8d-d40a5e025fdb_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term loan, interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_e5c72383-56d4-4a42-9fac-12c4a8d73fd6_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Grant date fair value of RSUs vested</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_9330d10b-90a4-4d1b-b12a-e953551a7d55_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental disclosure of cash flow information:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_45897d55-c900-4c6c-86f3-09192f7ca736_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options, cost not yet recognized, remaining weighted average vesting period</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet_b2276448-5f08-4850-bbb0-9a0bec08e243_terseLabel_en-US" xlink:label="lab_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise of common stock warrants (in shares)</link:label>
    <link:label id="lab_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet_label_en-US" xlink:label="lab_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Warrants Exercised, Net</link:label>
    <link:label id="lab_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet_documentation_en-US" xlink:label="lab_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Warrants Exercised, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet" xlink:href="exdx-20241231.xsd#exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet" xlink:to="lab_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d3bb9b5e-240c-4f53-92a7-c7b3162eb2cf_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_OperatingLeaseAnnualIncreaseInBaseRentPaymentPercent_169e4659-ff29-484e-87ce-34812b41d319_terseLabel_en-US" xlink:label="lab_exdx_OperatingLeaseAnnualIncreaseInBaseRentPaymentPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease, annual increase in base rent payment percentage</link:label>
    <link:label id="lab_exdx_OperatingLeaseAnnualIncreaseInBaseRentPaymentPercent_label_en-US" xlink:label="lab_exdx_OperatingLeaseAnnualIncreaseInBaseRentPaymentPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Annual Increase In Base Rent Payment, Percent</link:label>
    <link:label id="lab_exdx_OperatingLeaseAnnualIncreaseInBaseRentPaymentPercent_documentation_en-US" xlink:label="lab_exdx_OperatingLeaseAnnualIncreaseInBaseRentPaymentPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Lease, Annual Increase In Base Rent Payment, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OperatingLeaseAnnualIncreaseInBaseRentPaymentPercent" xlink:href="exdx-20241231.xsd#exdx_OperatingLeaseAnnualIncreaseInBaseRentPaymentPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_OperatingLeaseAnnualIncreaseInBaseRentPaymentPercent" xlink:to="lab_exdx_OperatingLeaseAnnualIncreaseInBaseRentPaymentPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_658ec12b-23a8-4574-87e7-5fd2fb9d176a_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_4a4ce6bb-fcce-4575-a670-e3b16e1646d7_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finance lease, liability, noncurrent, statement of financial position</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_f8e6fd9a-6cb8-46cf-bc93-a778fd43ce7e_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_99965318-11fa-46ee-bcd9-802cc67eb11f_totalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Effective tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_b1950b45-d985-48bb-98df-92fc6de26004_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_928af818-9afe-4a1c-a02e-5612ab5c829e_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_9df0f333-7941-4077-a122-b8ad1680cf90_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_fc00d610-7e2a-4cc9-abdb-ecfbe47649d4_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock compensation</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_e3a53ce3-7544-4bbe-bf72-b7bccab063f8_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and stockholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:to="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllAdjToCompMember_terseLabel_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation</link:label>
    <link:label id="lab_ecd_AllAdjToCompMember_label_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllAdjToCompMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="lab_ecd_AllAdjToCompMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_47cb4207-a946-43d1-8dfb-74672d6ac718_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_519648a0-a329-48a7-8203-a61648378768_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_ComputerEquipmentAndSoftwareMember_02ae86ab-4bb4-41ba-b58d-019e7fc09161_terseLabel_en-US" xlink:label="lab_exdx_ComputerEquipmentAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Computer equipment and software</link:label>
    <link:label id="lab_exdx_ComputerEquipmentAndSoftwareMember_label_en-US" xlink:label="lab_exdx_ComputerEquipmentAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Computer Equipment and Software [Member]</link:label>
    <link:label id="lab_exdx_ComputerEquipmentAndSoftwareMember_documentation_en-US" xlink:label="lab_exdx_ComputerEquipmentAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Computer Equipment and Software</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ComputerEquipmentAndSoftwareMember" xlink:href="exdx-20241231.xsd#exdx_ComputerEquipmentAndSoftwareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_ComputerEquipmentAndSoftwareMember" xlink:to="lab_exdx_ComputerEquipmentAndSoftwareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_AuditInformationAbstract_label_en-US" xlink:label="lab_exdx_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:label id="lab_exdx_AuditInformationAbstract_documentation_en-US" xlink:label="lab_exdx_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AuditInformationAbstract" xlink:href="exdx-20241231.xsd#exdx_AuditInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_AuditInformationAbstract" xlink:to="lab_exdx_AuditInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_7b4de48e-3f40-45c7-98a5-cb37737a12d0_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_12a3d101-b99f-4bcb-b480-abbb0285637d_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_DeferredTaxAssetsLeaseLiability_216b270e-39e5-44be-9b5b-8690d6f3b8b0_terseLabel_en-US" xlink:label="lab_exdx_DeferredTaxAssetsLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease liability</link:label>
    <link:label id="lab_exdx_DeferredTaxAssetsLeaseLiability_label_en-US" xlink:label="lab_exdx_DeferredTaxAssetsLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Lease Liability</link:label>
    <link:label id="lab_exdx_DeferredTaxAssetsLeaseLiability_documentation_en-US" xlink:label="lab_exdx_DeferredTaxAssetsLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DeferredTaxAssetsLeaseLiability" xlink:href="exdx-20241231.xsd#exdx_DeferredTaxAssetsLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_DeferredTaxAssetsLeaseLiability" xlink:to="lab_exdx_DeferredTaxAssetsLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShippingAndHandlingMember_fea02b96-77f8-4bec-86e1-8138ebbbb558_terseLabel_en-US" xlink:label="lab_us-gaap_ShippingAndHandlingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shipping and Handling</link:label>
    <link:label id="lab_us-gaap_ShippingAndHandlingMember_label_en-US" xlink:label="lab_us-gaap_ShippingAndHandlingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shipping and Handling [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShippingAndHandlingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShippingAndHandlingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShippingAndHandlingMember" xlink:to="lab_us-gaap_ShippingAndHandlingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_aa454916-091e-4def-9246-c19a9951caba_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Future Minimum Aggregate Payments for Outstanding Borrowings</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Maturities of Long-Term Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_b75c54d1-317b-4eb0-8842-69465f491a50_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Organization</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_terseLabel_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change</link:label>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_label_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:to="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_IndividualAxis_terseLabel_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Individual:</link:label>
    <link:label id="lab_ecd_IndividualAxis_label_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_IndividualAxis" xlink:to="lab_ecd_IndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_9cb48751-c2fb-4f0b-b77e-5088da7dc871_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCash_d2442b05-2367-45d5-8669-bdb5766a73a1_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCash_label_en-US" xlink:label="lab_us-gaap_RestrictedCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCash" xlink:to="lab_us-gaap_RestrictedCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_0747021b-76f9-414a-b5b5-4eca3b52037b_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_24713134-fb73-4dea-a522-99953b2c5a53_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_7f0a8112-7970-46ee-9511-aa14f1593554_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_cdebb5d2-c511-41e9-944e-5c21e3c5709a_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_0c55f909-5dcd-4840-8d3d-82639661e765_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_label_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompAnalysisTextBlock" xlink:to="lab_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_b5b00432-91db-480b-812b-a9e264b8ba38_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Reconciliation of Profit or Loss</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:to="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_AlleghenyHealthNetworkResearchInstituteMember_85cc20dd-617b-486f-9e76-96264fd31bf2_terseLabel_en-US" xlink:label="lab_exdx_AlleghenyHealthNetworkResearchInstituteMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Allegheny Health Network Research Institute</link:label>
    <link:label id="lab_exdx_AlleghenyHealthNetworkResearchInstituteMember_label_en-US" xlink:label="lab_exdx_AlleghenyHealthNetworkResearchInstituteMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Allegheny Health Network Research Institute [Member]</link:label>
    <link:label id="lab_exdx_AlleghenyHealthNetworkResearchInstituteMember_documentation_en-US" xlink:label="lab_exdx_AlleghenyHealthNetworkResearchInstituteMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Allegheny Health Network Research Institute</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AlleghenyHealthNetworkResearchInstituteMember" xlink:href="exdx-20241231.xsd#exdx_AlleghenyHealthNetworkResearchInstituteMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_AlleghenyHealthNetworkResearchInstituteMember" xlink:to="lab_exdx_AlleghenyHealthNetworkResearchInstituteMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_bc54ab14-9e55-4889-bbf7-7247c1b65025_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6bc2bc21-0d2a-4571-911a-dd65e7eefe5a_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_WeightedAverageDiscountRateAbstract_75e7dd97-fd2e-4610-9fd1-68baecbd40ed_terseLabel_en-US" xlink:label="lab_exdx_WeightedAverageDiscountRateAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average discount rate</link:label>
    <link:label id="lab_exdx_WeightedAverageDiscountRateAbstract_label_en-US" xlink:label="lab_exdx_WeightedAverageDiscountRateAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted-Average Discount Rate [Abstract]</link:label>
    <link:label id="lab_exdx_WeightedAverageDiscountRateAbstract_documentation_en-US" xlink:label="lab_exdx_WeightedAverageDiscountRateAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Weighted-Average Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_WeightedAverageDiscountRateAbstract" xlink:href="exdx-20241231.xsd#exdx_WeightedAverageDiscountRateAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_WeightedAverageDiscountRateAbstract" xlink:to="lab_exdx_WeightedAverageDiscountRateAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6eccb3c7-bf78-417e-8f85-a4fa16694480_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, fair value per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_ae0cd9a4-8d88-4e73-ae13-c776b685b1e1_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding, beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_97190161-9c67-49c9-bdc1-34a9a8805cb4_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding, ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b5e38b99-2aea-4d04-8382-2a059d5ba6fb_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities and Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_1fd9ef07-fa47-4db1-ba6f-77ec99795984_negatedLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Unamortized debt discount and issuance costs</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_1a1a4087-eb70-4036-b1a8-99bfd70b7d5e_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_6fa560ed-024b-48af-8821-368e24797a59_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDeterminationDate_terseLabel_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:label id="lab_ecd_RestatementDeterminationDate_label_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDeterminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDeterminationDate" xlink:to="lab_ecd_RestatementDeterminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_3eeb5617-b653-4162-b04f-571cd4d948f5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested and expected to vest (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_CommercialMember_7dd7d464-f7a2-4c91-b157-5defd5f83121_terseLabel_en-US" xlink:label="lab_exdx_CommercialMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commercial</link:label>
    <link:label id="lab_exdx_CommercialMember_label_en-US" xlink:label="lab_exdx_CommercialMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commercial [Member]</link:label>
    <link:label id="lab_exdx_CommercialMember_documentation_en-US" xlink:label="lab_exdx_CommercialMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Commercial</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_CommercialMember" xlink:href="exdx-20241231.xsd#exdx_CommercialMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_CommercialMember" xlink:to="lab_exdx_CommercialMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_Term2017Member_fe7aa4f2-90fd-43e3-b661-94f4bd8cba9b_terseLabel_en-US" xlink:label="lab_exdx_Term2017Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2017 Term loan</link:label>
    <link:label id="lab_exdx_Term2017Member_label_en-US" xlink:label="lab_exdx_Term2017Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Term 2017 [Member]</link:label>
    <link:label id="lab_exdx_Term2017Member_documentation_en-US" xlink:label="lab_exdx_Term2017Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Term 2017</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_Term2017Member" xlink:href="exdx-20241231.xsd#exdx_Term2017Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_Term2017Member" xlink:to="lab_exdx_Term2017Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrAdoptionDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adoption Date</link:label>
    <link:label id="lab_ecd_TrdArrAdoptionDate_label_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Adoption Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrAdoptionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrAdoptionDate" xlink:to="lab_ecd_TrdArrAdoptionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTable_terseLabel_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure</link:label>
    <link:label id="lab_ecd_PvpTable_label_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTable" xlink:to="lab_ecd_PvpTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_e7602424-34ca-4564-93cd-5a36316f7a81_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_8d7884df-acf4-4ff7-82be-cc61c61f35b0_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding, beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_e3d4b3a0-9b98-4f6b-b044-16015a49b3f2_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding, ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_10ff89a2-25db-428a-aefb-3932ebb20854_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompRecoveryTable_terseLabel_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery</link:label>
    <link:label id="lab_ecd_ErrCompRecoveryTable_label_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompRecoveryTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="lab_ecd_ErrCompRecoveryTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c7a61fc7-075b-42b0-8a84-5faab5026a2b_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_573224e8-ecf9-40ad-a5a0-f516f248df20_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_5413ab51-d704-4c42-afd6-524ecc80f63a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year</link:label>
    <link:label id="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_label_en-US" xlink:label="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:to="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxPeriodAxis_c01f6441-5006-4cfc-a582-2a1e44b76dbc_terseLabel_en-US" xlink:label="lab_us-gaap_TaxPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Period [Axis]</link:label>
    <link:label id="lab_us-gaap_TaxPeriodAxis_label_en-US" xlink:label="lab_us-gaap_TaxPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxPeriodAxis" xlink:to="lab_us-gaap_TaxPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_e5f63eb1-bc64-48ea-a75b-610a28d2b06f_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Common Stock Reserved For Future Issuance</link:label>
    <link:label id="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:to="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_128becaa-79d7-4bbb-b240-605eb5c3e92f_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Federal statutory tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardExrcPrice_terseLabel_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise Price</link:label>
    <link:label id="lab_ecd_AwardExrcPrice_label_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardExrcPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardExrcPrice" xlink:to="lab_ecd_AwardExrcPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseContractualTermAxis_ff19a99d-f024-4f00-bf08-88fb1b23e287_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseContractualTermAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease Contractual Term [Axis]</link:label>
    <link:label id="lab_us-gaap_LeaseContractualTermAxis_label_en-US" xlink:label="lab_us-gaap_LeaseContractualTermAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Contractual Term [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseContractualTermAxis" xlink:to="lab_us-gaap_LeaseContractualTermAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_1ecc829c-1054-4e85-9d5d-858c21904cac_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_DebtInstrumentCovenantNumberOfDaysToCureIfPerformanceMeasureIsNotMet_9104ca5a-e44e-4008-af34-0ae5280e8835_terseLabel_en-US" xlink:label="lab_exdx_DebtInstrumentCovenantNumberOfDaysToCureIfPerformanceMeasureIsNotMet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term loan, covenant, number of days to cure covenant if performance measure is not met</link:label>
    <link:label id="lab_exdx_DebtInstrumentCovenantNumberOfDaysToCureIfPerformanceMeasureIsNotMet_label_en-US" xlink:label="lab_exdx_DebtInstrumentCovenantNumberOfDaysToCureIfPerformanceMeasureIsNotMet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Covenant, Number Of Days To Cure If Performance Measure Is Not Met</link:label>
    <link:label id="lab_exdx_DebtInstrumentCovenantNumberOfDaysToCureIfPerformanceMeasureIsNotMet_documentation_en-US" xlink:label="lab_exdx_DebtInstrumentCovenantNumberOfDaysToCureIfPerformanceMeasureIsNotMet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Covenant, Number Of Days To Cure If Performance Measure Is Not Met</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentCovenantNumberOfDaysToCureIfPerformanceMeasureIsNotMet" xlink:href="exdx-20241231.xsd#exdx_DebtInstrumentCovenantNumberOfDaysToCureIfPerformanceMeasureIsNotMet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_DebtInstrumentCovenantNumberOfDaysToCureIfPerformanceMeasureIsNotMet" xlink:to="lab_exdx_DebtInstrumentCovenantNumberOfDaysToCureIfPerformanceMeasureIsNotMet" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrDuration_terseLabel_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Arrangement Duration</link:label>
    <link:label id="lab_ecd_TrdArrDuration_label_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Duration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrDuration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrDuration" xlink:to="lab_ecd_TrdArrDuration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_5f28aab3-9821-4ccb-ad71-bb53d4b2ce3e_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of stock under Employee Stock Purchase Plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_ebcb694f-9a27-4377-a138-79af6f01b3ff_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeFinanceLeasesTextBlock_c144e23d-ba0f-4c05-a7b8-566aa79121f9_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeFinanceLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Finance Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeFinanceLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeFinanceLeasesTextBlock" xlink:to="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_1eed9399-2a75-4013-ab64-4ad348378e76_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise of stock options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_2ef75416-4867-4512-81a2-fcfbdc745948_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_530cf70e-9d44-4318-a7ac-4d46ddfd6cbf_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Research and development tax credits</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_76fa7ebc-24a4-4b65-8101-f91df50f9209_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves_9efa140c-5c94-4831-b20a-ba93ee9fb82d_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accruals, reserves and other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Loss Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_41a1215f-0137-46b1-807b-10a530f75b74_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_90edf510-9762-4bad-97ca-0da00e4ebd03_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_label_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:to="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_6be8dd14-61bc-406e-adaf-16d53243cc8a_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsGross_18cc3076-3ac5-4b11-9997-3ef99098181e_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsGross_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leasehold Improvements, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsGross" xlink:to="lab_us-gaap_LeaseholdImprovementsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_0b7370d2-b4c4-476c-ab8b-bd38fbc9d66f_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Finance Lease, Liability, Maturity</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_terseLabel_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_label_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_47725c9e-b793-44ed-821e-63e113ec7d52_totalLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiability" xlink:to="lab_us-gaap_FinanceLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllIndividualsMember_terseLabel_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Individuals</link:label>
    <link:label id="lab_ecd_AllIndividualsMember_label_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Individuals [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="lab_ecd_AllIndividualsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_PurchaseObligationAmendedSupplyAgreementNumberOfSuppliers_9d055f30-fc41-4399-a329-9f181f81d814_terseLabel_en-US" xlink:label="lab_exdx_PurchaseObligationAmendedSupplyAgreementNumberOfSuppliers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of suppliers in amended supply agreement</link:label>
    <link:label id="lab_exdx_PurchaseObligationAmendedSupplyAgreementNumberOfSuppliers_label_en-US" xlink:label="lab_exdx_PurchaseObligationAmendedSupplyAgreementNumberOfSuppliers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase Obligation, Amended Supply Agreement, Number Of Suppliers</link:label>
    <link:label id="lab_exdx_PurchaseObligationAmendedSupplyAgreementNumberOfSuppliers_documentation_en-US" xlink:label="lab_exdx_PurchaseObligationAmendedSupplyAgreementNumberOfSuppliers" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Purchase Obligation, Amended Supply Agreement, Number Of Suppliers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_PurchaseObligationAmendedSupplyAgreementNumberOfSuppliers" xlink:href="exdx-20241231.xsd#exdx_PurchaseObligationAmendedSupplyAgreementNumberOfSuppliers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_PurchaseObligationAmendedSupplyAgreementNumberOfSuppliers" xlink:to="lab_exdx_PurchaseObligationAmendedSupplyAgreementNumberOfSuppliers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BuildingMember_9f7fef33-862a-4954-b63f-20d529e5c8cb_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Building</link:label>
    <link:label id="lab_us-gaap_BuildingMember_label_en-US" xlink:label="lab_us-gaap_BuildingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Building [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BuildingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingMember" xlink:to="lab_us-gaap_BuildingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoMember_terseLabel_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO</link:label>
    <link:label id="lab_ecd_PeoMember_label_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoMember" xlink:to="lab_ecd_PeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_1fc2fc2f-2eb8-4e52-92dc-8d3d7f59e67c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, fair value</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFairValue" xlink:to="lab_us-gaap_DebtInstrumentFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndName_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_TrdArrIndName_label_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndName" xlink:to="lab_ecd_TrdArrIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_28ead634-0c28-4959-bcd9-6a4ffcca6667_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ab51b7c1-d081-4de8-b2ea-812d0a0896a0_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_dd70a5a4-bf1f-40c6-b0e6-feb664d2b550_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_d8978c73-bc95-4234-8224-7ff3e86d790f_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_4a5bc2c4-7e37-4801-ba81-ce207a455147_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized compensation cost related to stock purchase</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_3b80767f-0b5a-45ca-8a34-dcde97eceb81_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options exercisable (in Shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_AHNCollaborationMember_cc132ffa-6f61-481d-8715-cbec552e004c_terseLabel_en-US" xlink:label="lab_exdx_AHNCollaborationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AHN Collaboration</link:label>
    <link:label id="lab_exdx_AHNCollaborationMember_label_en-US" xlink:label="lab_exdx_AHNCollaborationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AHN Collaboration [Member]</link:label>
    <link:label id="lab_exdx_AHNCollaborationMember_documentation_en-US" xlink:label="lab_exdx_AHNCollaborationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">AHN Collaboration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AHNCollaborationMember" xlink:href="exdx-20241231.xsd#exdx_AHNCollaborationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_AHNCollaborationMember" xlink:to="lab_exdx_AHNCollaborationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_2f819f2c-cad3-4f30-8c7d-4ff809ecb6b0_terseLabel_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Concentration of Risk, by Risk Factor and Significant Payer</link:label>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_label_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedules of Concentration of Risk, by Risk Factor [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:to="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_ReportableSegmentMember_a48e8cec-3066-458c-bebb-325d84aad4e6_terseLabel_en-US" xlink:label="lab_exdx_ReportableSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reportable Segment</link:label>
    <link:label id="lab_exdx_ReportableSegmentMember_label_en-US" xlink:label="lab_exdx_ReportableSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reportable Segment [Member]</link:label>
    <link:label id="lab_exdx_ReportableSegmentMember_documentation_en-US" xlink:label="lab_exdx_ReportableSegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reportable Segment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ReportableSegmentMember" xlink:href="exdx-20241231.xsd#exdx_ReportableSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_ReportableSegmentMember" xlink:to="lab_exdx_ReportableSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityAxis_a3a767a1-a3f4-459c-ba89-39234bcc0caa_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lender Name [Axis]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lender Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis" xlink:to="lab_us-gaap_LineOfCreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_fc0328ab-00ac-4f83-bc5d-38640a08944c_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_49f682f3-22af-45a4-ae74-476cc9d89d48_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock reserved for future issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year</link:label>
    <link:label id="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember_label_en-US" xlink:label="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:to="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_360837b9-3ce9-4aa6-990d-113d2eceacfa_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal net operating loss carryforwards, carryforward indefinitely</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_322995dc-1083-4bd5-ab9b-c9b3c22155d4_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Money market funds, included in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_AggtErrCompAmt_label_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompAmt" xlink:to="lab_ecd_AggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization_08f208e0-841d-415e-a7ee-a7cfa74ec8aa_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost, Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_9a14e90c-665a-4152-9467-9faf245a9067_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_b6db791e-2df7-4647-a46e-53277924cd4c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplier [Axis]</link:label>
    <link:label id="lab_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_label_en-US" xlink:label="lab_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplier [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:to="lab_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_d1450fa8-7e89-4caa-9023-4fa3054eabe9_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_da2a691e-43f1-470c-8da4-270468d2a600_periodStartLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Valuation allowance at the beginning of the year</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_8573e45b-b3e4-40d5-b90a-87c7d79680d4_periodEndLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Valuation allowance at the end of the year</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_label_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_5f2f5b0a-9b98-4810-b976-a0b8ce8e4b24_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total segment operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance_73502c24-70bf-4202-b504-acb1d3996935_terseLabel_en-US" xlink:label="lab_exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term loan covenant, minimum unrestricted cash balance</link:label>
    <link:label id="lab_exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance_label_en-US" xlink:label="lab_exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Covenant Compliance, Minimum Unrestricted Cash Balance</link:label>
    <link:label id="lab_exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance_documentation_en-US" xlink:label="lab_exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Covenant Compliance, Minimum Unrestricted Cash Balance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance" xlink:href="exdx-20241231.xsd#exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance" xlink:to="lab_exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardLineItems_49d7bf93-19a5-41a3-b29a-a7338a4f695c_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Line Items]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardLineItems_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems" xlink:to="lab_us-gaap_TaxCreditCarryforwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_6084ef15-b061-4109-8e58-131c510a4134_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Payment Arrangement, Restricted Stock Unit, Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_b826a5e8-6d55-4479-ae7c-99438b30920a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_eff0f84a-e9a8-4a38-9bd4-091111cbd9d8_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_SupplierOneMember_af9a81ca-13f5-4f96-acf4-11a46cc02ecc_terseLabel_en-US" xlink:label="lab_exdx_SupplierOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplier One</link:label>
    <link:label id="lab_exdx_SupplierOneMember_label_en-US" xlink:label="lab_exdx_SupplierOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplier One [Member]</link:label>
    <link:label id="lab_exdx_SupplierOneMember_documentation_en-US" xlink:label="lab_exdx_SupplierOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Supplier One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_SupplierOneMember" xlink:href="exdx-20241231.xsd#exdx_SupplierOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_SupplierOneMember" xlink:to="lab_exdx_SupplierOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoTotalCompAmt_label_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoTotalCompAmt" xlink:to="lab_ecd_PeoTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OccupancyNet_d81ffe61-f650-4bb9-9ea4-e821367121f1_terseLabel_en-US" xlink:label="lab_us-gaap_OccupancyNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Facilities related</link:label>
    <link:label id="lab_us-gaap_OccupancyNet_label_en-US" xlink:label="lab_us-gaap_OccupancyNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Occupancy, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OccupancyNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OccupancyNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OccupancyNet" xlink:to="lab_us-gaap_OccupancyNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_37cbaac5-8c2b-47a2-8e60-c414c4da3678_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_803cea81-dd55-49fb-9f2c-103dbd837219_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_710399c4-4662-4801-94a9-cf19c95823a3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Accrued and Other Current Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_311fdd26-73da-43e3-9ca5-cdae42210759_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_47188204-7c4e-465c-a1f6-44e541e91916_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested and expected to vest (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_dc66b2d4-ed68-4fc6-b6bf-b92b567cd79e_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_13bc607b-dd4b-4078-9607-65b822d62165_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_ad33162f-27fb-4ecc-9eee-825aaae0a647_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureAxis_terseLabel_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measure:</link:label>
    <link:label id="lab_ecd_MeasureAxis_label_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureAxis" xlink:to="lab_ecd_MeasureAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_Government1Member_e3f09d55-71c7-4523-9d9e-6353145f4fe7_terseLabel_en-US" xlink:label="lab_exdx_Government1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Government</link:label>
    <link:label id="lab_exdx_Government1Member_label_en-US" xlink:label="lab_exdx_Government1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Government1 [Member]</link:label>
    <link:label id="lab_exdx_Government1Member_documentation_en-US" xlink:label="lab_exdx_Government1Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Government1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_Government1Member" xlink:href="exdx-20241231.xsd#exdx_Government1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_Government1Member" xlink:to="lab_exdx_Government1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_9ca1c6b3-24c6-4869-a41c-380787cfe6f3_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding, Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_77efbec0-eb6a-4cd8-ae39-6b0c781b0027_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_e470e9c0-3ce9-42bb-839a-205acdbdab22_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_EquipmentPurchasedUnderNotesPayableObligations_821e5545-1438-4d3d-94af-596d0dbb644d_terseLabel_en-US" xlink:label="lab_exdx_EquipmentPurchasedUnderNotesPayableObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equipment purchased under notes payable obligations</link:label>
    <link:label id="lab_exdx_EquipmentPurchasedUnderNotesPayableObligations_label_en-US" xlink:label="lab_exdx_EquipmentPurchasedUnderNotesPayableObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equipment Purchased Under Notes Payable Obligations</link:label>
    <link:label id="lab_exdx_EquipmentPurchasedUnderNotesPayableObligations_documentation_en-US" xlink:label="lab_exdx_EquipmentPurchasedUnderNotesPayableObligations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equipment Purchased Under Notes Payable Obligations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_EquipmentPurchasedUnderNotesPayableObligations" xlink:href="exdx-20241231.xsd#exdx_EquipmentPurchasedUnderNotesPayableObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_EquipmentPurchasedUnderNotesPayableObligations" xlink:to="lab_exdx_EquipmentPurchasedUnderNotesPayableObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_473b0503-dd6e-4f59-94f4-27a0ff7b5a64_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingOtherItemAmount_4d0272a8-cccf-45c5-b49f-58f2189800a1_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingOtherItemAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_SegmentReportingOtherItemAmount_label_en-US" xlink:label="lab_us-gaap_SegmentReportingOtherItemAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting, Other Segment Item, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingOtherItemAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingOtherItemAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingOtherItemAmount" xlink:to="lab_us-gaap_SegmentReportingOtherItemAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description</link:label>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_label_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_GainLossOnDispositionOfLeaseAssignment_9c7f0842-74ac-4a37-8a8c-aba2f2b0f6c6_negatedTerseLabel_en-US" xlink:label="lab_exdx_GainLossOnDispositionOfLeaseAssignment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Loss on lease assignment</link:label>
    <link:label id="lab_exdx_GainLossOnDispositionOfLeaseAssignment_label_en-US" xlink:label="lab_exdx_GainLossOnDispositionOfLeaseAssignment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) On Disposition Of Lease Assignment</link:label>
    <link:label id="lab_exdx_GainLossOnDispositionOfLeaseAssignment_documentation_en-US" xlink:label="lab_exdx_GainLossOnDispositionOfLeaseAssignment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Gain (Loss) On Disposition Of Lease Assignment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_GainLossOnDispositionOfLeaseAssignment" xlink:href="exdx-20241231.xsd#exdx_GainLossOnDispositionOfLeaseAssignment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_GainLossOnDispositionOfLeaseAssignment" xlink:to="lab_exdx_GainLossOnDispositionOfLeaseAssignment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAsset_ce0e5bac-a563-4cd1-a1dc-ec947e7a22e2_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finance lease, right-of-use asset, after accumulated amortization</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Right-of-Use Asset, after Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAsset" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock_8d46a911-4ef1-49ff-88ae-7eaeb4d6ec92_terseLabel_en-US" xlink:label="lab_exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Financial Information</link:label>
    <link:label id="lab_exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock_label_en-US" xlink:label="lab_exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expenses and Other Current Assets; Property, Plant and Equipment; and Accrued Liabilities [Text Block]</link:label>
    <link:label id="lab_exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock_documentation_en-US" xlink:label="lab_exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Prepaid Expenses and Other Current Assets; Property, Plant and Equipment; and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock" xlink:href="exdx-20241231.xsd#exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock" xlink:to="lab_exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_39e0f66f-48f8-4993-8d58-dd0b3a277dc6_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_dad974c9-6d65-4334-803a-5359474b44ac_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_d01460c7-9688-469f-ac1e-8fa21f88cdfa_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_5124fe0c-6492-4de8-991c-0625cafad790_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_c8c09f30-a72b-45f8-9cd8-b4ae0268d2a8_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Reporting</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_a271a9f4-93da-4aed-8cc8-67f93d0f4157_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Borrowings-current portion</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_0e029498-fbba-4aea-a765-b8484763bed5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Borrowings-current portion</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent" xlink:to="lab_us-gaap_LongTermDebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_label_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Additional402vDisclosureTextBlock" xlink:to="lab_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_ShelfRegistrationStatementMember_c3b1471c-1667-4875-8106-a5b5e761c4cb_terseLabel_en-US" xlink:label="lab_exdx_ShelfRegistrationStatementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shelf Registration Statement</link:label>
    <link:label id="lab_exdx_ShelfRegistrationStatementMember_label_en-US" xlink:label="lab_exdx_ShelfRegistrationStatementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shelf Registration Statement [Member]</link:label>
    <link:label id="lab_exdx_ShelfRegistrationStatementMember_documentation_en-US" xlink:label="lab_exdx_ShelfRegistrationStatementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Shelf Registration Statement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ShelfRegistrationStatementMember" xlink:href="exdx-20241231.xsd#exdx_ShelfRegistrationStatementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_ShelfRegistrationStatementMember" xlink:to="lab_exdx_ShelfRegistrationStatementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_919bf1d3-45d6-45e5-93f4-e9f7820b2db6_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_3d9f3a83-9207-4f71-9476-d9d4ec23c01c_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_a605f06b-175f-4ed7-881e-bb986d40643c_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_8619eaac-b916-4f82-b416-f6940514db56_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndTitle_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title</link:label>
    <link:label id="lab_ecd_TrdArrIndTitle_label_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Title</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndTitle" xlink:to="lab_ecd_TrdArrIndTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_48ee51de-b4b5-4e9e-ae15-aecd22b4397f_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_c7a399f9-6e70-46ea-bf2e-937f1ac43498_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_54535fc6-d11b-4e1e-8cb2-bb2b6d91159f_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOwnershipPlanESOPPolicy_08b60db6-ac71-4ec0-b8d7-abafa3ca021e_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOwnershipPlanESOPPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOwnershipPlanESOPPolicy_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOwnershipPlanESOPPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Ownership Plan (ESOP), Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOwnershipPlanESOPPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOwnershipPlanESOPPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPPolicy" xlink:to="lab_us-gaap_EmployeeStockOwnershipPlanESOPPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_df4773aa-cdfc-4751-a755-6d7cb480f57a_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_b92fdb95-2025-4504-9951-f137e2d753f2_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_MedicareAdvantageMember_501bc3fe-771f-4661-9d5e-088f04247fab_terseLabel_en-US" xlink:label="lab_exdx_MedicareAdvantageMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Medicare Advantage</link:label>
    <link:label id="lab_exdx_MedicareAdvantageMember_label_en-US" xlink:label="lab_exdx_MedicareAdvantageMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Medicare Advantage [Member]</link:label>
    <link:label id="lab_exdx_MedicareAdvantageMember_documentation_en-US" xlink:label="lab_exdx_MedicareAdvantageMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Medicare Advantage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_MedicareAdvantageMember" xlink:href="exdx-20241231.xsd#exdx_MedicareAdvantageMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_MedicareAdvantageMember" xlink:to="lab_exdx_MedicareAdvantageMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_c889bedf-1744-433d-acfb-265863c06b30_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_8e4b2752-ce3e-4129-892f-3b2f708fdafe_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_bdc47625-6657-49ec-a930-5cf3f9666163_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_CommonSharesAvailableForGrantUnderThe2019PlanMember_bf0c7ff7-f55c-4f39-ba1d-1927204a3aae_terseLabel_en-US" xlink:label="lab_exdx_CommonSharesAvailableForGrantUnderThe2019PlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock available for grant under the 2019 Plan</link:label>
    <link:label id="lab_exdx_CommonSharesAvailableForGrantUnderThe2019PlanMember_label_en-US" xlink:label="lab_exdx_CommonSharesAvailableForGrantUnderThe2019PlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Shares Available For Grant Under The 2019 Plan [Member]</link:label>
    <link:label id="lab_exdx_CommonSharesAvailableForGrantUnderThe2019PlanMember_documentation_en-US" xlink:label="lab_exdx_CommonSharesAvailableForGrantUnderThe2019PlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common Shares Available For Grant Under The 2019 Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_CommonSharesAvailableForGrantUnderThe2019PlanMember" xlink:href="exdx-20241231.xsd#exdx_CommonSharesAvailableForGrantUnderThe2019PlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_CommonSharesAvailableForGrantUnderThe2019PlanMember" xlink:to="lab_exdx_CommonSharesAvailableForGrantUnderThe2019PlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_DebtInstrumentCovenantRevenuePerformancePeriod_a829c396-8329-4c66-9bd0-e1a5ad147f48_terseLabel_en-US" xlink:label="lab_exdx_DebtInstrumentCovenantRevenuePerformancePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term loan, covenant, revenue performance period</link:label>
    <link:label id="lab_exdx_DebtInstrumentCovenantRevenuePerformancePeriod_label_en-US" xlink:label="lab_exdx_DebtInstrumentCovenantRevenuePerformancePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Covenant, Revenue Performance Period</link:label>
    <link:label id="lab_exdx_DebtInstrumentCovenantRevenuePerformancePeriod_documentation_en-US" xlink:label="lab_exdx_DebtInstrumentCovenantRevenuePerformancePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Covenant, Revenue Performance Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentCovenantRevenuePerformancePeriod" xlink:href="exdx-20241231.xsd#exdx_DebtInstrumentCovenantRevenuePerformancePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_DebtInstrumentCovenantRevenuePerformancePeriod" xlink:to="lab_exdx_DebtInstrumentCovenantRevenuePerformancePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_f624e801-07bd-439f-883b-e911c37a2811_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for interest expense</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_dd4ea799-22ea-48f4-a7ca-b8ef5f812f67_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, before Accumulated Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_46d888c1-434f-4e0b-aea6-b461231d62fc_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_1fd27f95-200b-431e-a884-20e94bc98d22_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level&#160;1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_a25bc865-31b6-4b19-8f27-e95b5ea8d873_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets1_20e9e4d5-3c34-4613-8db6-8bd6c23683cb_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Loss on disposal of assets</link:label>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets1_label_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Disposition of Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDispositionOfAssets1" xlink:to="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_d209c5ae-f25b-4a37-8823-b2184e766da9_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_22d9fa48-8a9b-4c16-857f-46ef62a618d3_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxPeriodDomain_255cac52-d0e3-4068-8859-135d68716b20_terseLabel_en-US" xlink:label="lab_us-gaap_TaxPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Period [Domain]</link:label>
    <link:label id="lab_us-gaap_TaxPeriodDomain_label_en-US" xlink:label="lab_us-gaap_TaxPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxPeriodDomain" xlink:to="lab_us-gaap_TaxPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_a355de49-85f5-4481-a1c1-3abb4cadc3be_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Remaining borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Remaining Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_d36d2dea-4949-4d85-9614-4ed53b30ff33_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Maturity, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_b3d64017-4f0d-4fb4-bf51-bd2f14425613_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_45d8958a-4296-4e4b-8589-2df020749305_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Borrowings-non-current portion, net of discounts and debt issuance costs</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_77866ebc-a9cb-4c0a-9738-46362dbac2f3_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Borrowings-non-current portion, net of discounts and debt issuance costs</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesPolicyTextBlock_5221fa68-b3bb-413c-b931-0ea5d591de0c_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts Receivable and Allowance for Credit Losses</link:label>
    <link:label id="lab_us-gaap_ReceivablesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ReceivablesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Receivable [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesPolicyTextBlock" xlink:to="lab_us-gaap_ReceivablesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_3330ff72-ec65-4d99-a9e8-9abd242c89ad_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e86043be-c1b7-491a-aed7-cc4163691ded_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted- Average Grant Date Fair Value Per Share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_df631ebb-d56e-403a-b184-1c3842aae081_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee options, weighted-average grant date fair value per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_0a34017a-141e-4472-96b7-7cf1ad2d5c6c_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_6c837e04-9c00-428a-96f8-48fd48b205c2_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_147c843d-c5c3-4d88-a764-fc2df0dc6258_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_b390eea3-f173-4c40-afd8-59251b08fc85_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_3dc5aaba-d35d-426b-9b6d-2d26b7c49951_negatedLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_8ee8ac6e-9759-4ab8-a297-c06f7cae9535_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finance lease, right-of-use asset, statement of financial position</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_AmendedLoanAgreementMember_e788a3c2-8555-4a94-8c81-4710d1484f67_terseLabel_en-US" xlink:label="lab_exdx_AmendedLoanAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amended Loan Agreement</link:label>
    <link:label id="lab_exdx_AmendedLoanAgreementMember_label_en-US" xlink:label="lab_exdx_AmendedLoanAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amended Loan Agreement [Member]</link:label>
    <link:label id="lab_exdx_AmendedLoanAgreementMember_documentation_en-US" xlink:label="lab_exdx_AmendedLoanAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amended Loan Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AmendedLoanAgreementMember" xlink:href="exdx-20241231.xsd#exdx_AmendedLoanAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_AmendedLoanAgreementMember" xlink:to="lab_exdx_AmendedLoanAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments_cd664c0d-0bc8-488b-84f1-2f742dcbbced_terseLabel_en-US" xlink:label="lab_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of annual vesting installments</link:label>
    <link:label id="lab_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments_label_en-US" xlink:label="lab_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Annual Installments</link:label>
    <link:label id="lab_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments_documentation_en-US" xlink:label="lab_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Annual Installments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments" xlink:href="exdx-20241231.xsd#exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments" xlink:to="lab_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_0a41d44e-6c6c-46f9-8dcb-f7a2467fa1be_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowElementsAbstract_5378471a-92f7-456d-a45f-4e83a09792d2_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowElementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental disclosure of non-cash items:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowElementsAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowElementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Elements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowElementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_a0bf022f-ae12-4429-8136-01d083626843_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Maturity, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_terseLabel_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Available</link:label>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_label_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Securities Aggregate Available Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:to="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjsMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjsMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="lab_ecd_EqtyAwrdsAdjsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_e8511373-f874-4a3c-9a24-ec613d2d67db_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_044d32b8-4a5a-4e81-8bf1-01c69c513277_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_NonCashLeaseExpense_8e4db520-1355-4847-b810-01ac9d661f50_terseLabel_en-US" xlink:label="lab_exdx_NonCashLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash lease expense</link:label>
    <link:label id="lab_exdx_NonCashLeaseExpense_label_en-US" xlink:label="lab_exdx_NonCashLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Cash Lease Expense</link:label>
    <link:label id="lab_exdx_NonCashLeaseExpense_documentation_en-US" xlink:label="lab_exdx_NonCashLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Non-Cash Lease Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_NonCashLeaseExpense" xlink:href="exdx-20241231.xsd#exdx_NonCashLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_NonCashLeaseExpense" xlink:to="lab_exdx_NonCashLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFeeAmount_4c7844bc-6acc-4872-9b89-a6b35e55cd99_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFeeAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term loan, fee incurred upon payment of final installment</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFeeAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFeeAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Fee Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFeeAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFeeAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFeeAmount" xlink:to="lab_us-gaap_DebtInstrumentFeeAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_f695e64d-231b-439b-a281-f0b5066adbbb_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_terseLabel_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Securities</link:label>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_label_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Underlying Securities Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:to="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_e0ece76f-1611-4587-983d-bc1dfe774568_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Number of Shares, Par Value and Other Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_0bce434d-90c5-4490-9e32-4da20b42d72d_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_AVISECTDTestMember_c5eda77a-1d41-4c81-8f41-b14ce8e2cda6_terseLabel_en-US" xlink:label="lab_exdx_AVISECTDTestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AVISE CTD Test</link:label>
    <link:label id="lab_exdx_AVISECTDTestMember_label_en-US" xlink:label="lab_exdx_AVISECTDTestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AVISE CTD Test [Member]</link:label>
    <link:label id="lab_exdx_AVISECTDTestMember_documentation_en-US" xlink:label="lab_exdx_AVISECTDTestMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">AVISE CTD Test</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AVISECTDTestMember" xlink:href="exdx-20241231.xsd#exdx_AVISECTDTestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_AVISECTDTestMember" xlink:to="lab_exdx_AVISECTDTestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_8943d05c-579b-4e0b-bb20-887ba26a2440_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_84e59e63-2c0c-4184-8fc8-f7d0de235fd1_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_terseLabel_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs)</link:label>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_label_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:to="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_f3c8aa54-3915-4e02-a14d-906fefaf7640_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrossProfit_1f566214-be19-46ea-ae4a-dfae5282691e_totalLabel_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Gross margin</link:label>
    <link:label id="lab_us-gaap_GrossProfit_label_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gross Profit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrossProfit" xlink:to="lab_us-gaap_GrossProfit" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_LaboratoryEquipmentMember_250810da-a519-46d8-abcb-12705f8ce84f_terseLabel_en-US" xlink:label="lab_exdx_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Laboratory equipment</link:label>
    <link:label id="lab_exdx_LaboratoryEquipmentMember_label_en-US" xlink:label="lab_exdx_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Laboratory Equipment [Member]</link:label>
    <link:label id="lab_exdx_LaboratoryEquipmentMember_documentation_en-US" xlink:label="lab_exdx_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Laboratory Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_LaboratoryEquipmentMember" xlink:href="exdx-20241231.xsd#exdx_LaboratoryEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_LaboratoryEquipmentMember" xlink:to="lab_exdx_LaboratoryEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_0b138e2c-0b45-40c7-80e7-e3b4d69972a4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Restricted Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restrictions on Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_a37de6bb-f620-4b08-9c0b-4b68d598ab80_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardGrantDateFairValue_terseLabel_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value as of Grant Date</link:label>
    <link:label id="lab_ecd_AwardGrantDateFairValue_label_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardGrantDateFairValue" xlink:to="lab_ecd_AwardGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_ea117130-f013-4cd7-befc-4739c12e764f_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of lease assets</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_fe6cdb0a-c64b-49b5-921b-f6e0f7bdae3e_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_49a0555f-9372-4782-bff5-56dc886f5481_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested and expected to vest, Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_ExpirationJan192026Member_ed48907a-67a6-4894-ac15-9ae3b65060e7_terseLabel_en-US" xlink:label="lab_exdx_ExpirationJan192026Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant expiration January 19, 2026</link:label>
    <link:label id="lab_exdx_ExpirationJan192026Member_label_en-US" xlink:label="lab_exdx_ExpirationJan192026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expiration Jan 19, 2026 [Member]</link:label>
    <link:label id="lab_exdx_ExpirationJan192026Member_documentation_en-US" xlink:label="lab_exdx_ExpirationJan192026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Expiration Jan 19, 2026</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ExpirationJan192026Member" xlink:href="exdx-20241231.xsd#exdx_ExpirationJan192026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_ExpirationJan192026Member" xlink:to="lab_exdx_ExpirationJan192026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_e6388784-f2b5-4e80-b15b-0a5783ef2e3b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level&#160;2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_ae25791d-9c2e-490e-bb21-56a912868d7c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Borrowings</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_55bd85b1-795b-41cf-a67d-cbe883ec240e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RecoveryOfErrCompDisclosureLineItems_label_en-US" xlink:label="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Recovery of Erroneously Awarded Compensation Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_8bae9564-62d3-45a1-b876-722ea9ed4119_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Disaggregation of Revenue</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssets_6f3c7be4-f099-4e36-8a91-6341b94bce02_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssets" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_22ae69c0-ff1a-45e4-b322-c15b02d8d4b6_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_cc852c6a-b29c-4364-a4d5-df76afc2698d_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdvertisingExpense_a3c665f2-8088-42e5-9942-ce3cb8f0d513_terseLabel_en-US" xlink:label="lab_us-gaap_AdvertisingExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Advertising and marketing costs</link:label>
    <link:label id="lab_us-gaap_AdvertisingExpense_label_en-US" xlink:label="lab_us-gaap_AdvertisingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Advertising Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdvertisingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingExpense" xlink:to="lab_us-gaap_AdvertisingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_fe62370f-0ed0-471b-ae7d-a7eff36d0c0e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Non-cash Stock-based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDateAxis_terseLabel_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date:</link:label>
    <link:label id="lab_ecd_RestatementDateAxis_label_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDateAxis" xlink:to="lab_ecd_RestatementDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_49173338-4af2-4c18-a4a0-0157321b7933_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_a729deff-9c31-4c63-be27-1a238d2a1fc3_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_0aeb7918-b845-435b-9419-4c0728eb1d2f_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_2106589d-29cc-455c-b26b-f24df25b193f_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, $0.001 par value per share; 200,000,000 shares authorized at December 31, 2024 and December 31, 2023; 17,640,328 and 17,045,954 shares issued and outstanding at December 31, 2024 and December 31, 2023, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFinStmtErrorCorrectionFlag_b9abd269-68a0-47fa-8aae-05f6e5db84fd_terseLabel_en-US" xlink:label="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Financial Statement Error Correction</link:label>
    <link:label id="lab_dei_DocumentFinStmtErrorCorrectionFlag_label_en-US" xlink:label="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability_d9744d5b-2aad-4bda-a945-26884f609d11_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating cash out flows from interest paid on finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Interest Payment on Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:to="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_EquipmentNotesPayableMember_17382632-8717-44ea-8a9b-3ae43bbc9e47_terseLabel_en-US" xlink:label="lab_exdx_EquipmentNotesPayableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equipment Notes Payable</link:label>
    <link:label id="lab_exdx_EquipmentNotesPayableMember_label_en-US" xlink:label="lab_exdx_EquipmentNotesPayableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equipment Notes Payable [Member]</link:label>
    <link:label id="lab_exdx_EquipmentNotesPayableMember_documentation_en-US" xlink:label="lab_exdx_EquipmentNotesPayableMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equipment Notes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_EquipmentNotesPayableMember" xlink:href="exdx-20241231.xsd#exdx_EquipmentNotesPayableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_EquipmentNotesPayableMember" xlink:to="lab_exdx_EquipmentNotesPayableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_3a388852-3586-496c-b73b-f08ce107f3e7_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finance lease, liability, current, statement of financial position</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_1dd68307-b440-439b-b484-e6ff8a7cd577_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_e0595eef-be97-49c6-a337-77abbf2a7f86_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossAttributableToParent_8530eb25-0663-4255-9913-dcfb5bec0c18_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossAttributableToParent_label_en-US" xlink:label="lab_us-gaap_IncomeLossAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) Attributable to Parent, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossAttributableToParent" xlink:to="lab_us-gaap_IncomeLossAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationStatusAxis_93c7f209-f8b0-4399-bdd4-a74ea393e496_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationStatusAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation Status [Axis]</link:label>
    <link:label id="lab_us-gaap_LitigationStatusAxis_label_en-US" xlink:label="lab_us-gaap_LitigationStatusAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Status [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LitigationStatusAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationStatusAxis" xlink:to="lab_us-gaap_LitigationStatusAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_e4dada42-2146-44bc-b327-e6160e5e7f9e_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">State income taxes, net of federal tax benefits</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_terseLabel_en-US" xlink:label="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested</link:label>
    <link:label id="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_label_en-US" xlink:label="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:to="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_5125464e-0a33-49db-a78b-0d1cc278b96d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options exercisable, Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_9c328620-3f38-494f-a1d4-78c2fc5cd21c_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_542d6fba-3eee-4539-abb5-f7978b200487_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_ef76f4ad-1fa7-4124-b44d-2c002885990b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards canceled (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease_ddd9031f-a35b-4db6-8397-5e05c42fc039_terseLabel_en-US" xlink:label="lab_exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term loan covenant, increase to interest rate</link:label>
    <link:label id="lab_exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease_label_en-US" xlink:label="lab_exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Covenant Non-Compliance, Interest Rate, Increase (Decrease)</link:label>
    <link:label id="lab_exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease_documentation_en-US" xlink:label="lab_exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Covenant Non-Compliance, Interest Rate, Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease" xlink:href="exdx-20241231.xsd#exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease" xlink:to="lab_exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_terseLabel_en-US" xlink:label="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested</link:label>
    <link:label id="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_label_en-US" xlink:label="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:to="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_DeferredTaxLiabilitiesRightOfUseAssets_a1f81967-ecfa-4703-adfa-c806a2ce8244_negatedTerseLabel_en-US" xlink:label="lab_exdx_DeferredTaxLiabilitiesRightOfUseAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Right of use assets</link:label>
    <link:label id="lab_exdx_DeferredTaxLiabilitiesRightOfUseAssets_label_en-US" xlink:label="lab_exdx_DeferredTaxLiabilitiesRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Right Of Use Assets</link:label>
    <link:label id="lab_exdx_DeferredTaxLiabilitiesRightOfUseAssets_documentation_en-US" xlink:label="lab_exdx_DeferredTaxLiabilitiesRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Right Of Use Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DeferredTaxLiabilitiesRightOfUseAssets" xlink:href="exdx-20241231.xsd#exdx_DeferredTaxLiabilitiesRightOfUseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_DeferredTaxLiabilitiesRightOfUseAssets" xlink:to="lab_exdx_DeferredTaxLiabilitiesRightOfUseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_950d8f72-6ef8-4c75-b8bf-2e800b8804ef_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, $0.001 par value per share; 10,000,000 shares authorized, no shares issued or outstanding at December 31, 2024 and December 31, 2023</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_1145c924-547e-4a2b-b262-faaa5c6ee44d_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment, useful life</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ecf08462-2870-4af6-a5f9-af8e11b7c903_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number&#160;of Options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtByMaturityAbstract_978ef96b-8f0c-4174-82ec-1d1f479062e1_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtByMaturityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Fiscal Year Maturity [Abstract]</link:label>
    <link:label id="lab_us-gaap_LongTermDebtByMaturityAbstract_label_en-US" xlink:label="lab_us-gaap_LongTermDebtByMaturityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtByMaturityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtByMaturityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract" xlink:to="lab_us-gaap_LongTermDebtByMaturityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_OutsideServicesExpense_ea141c44-d436-485f-9170-4a778cb1f25e_terseLabel_en-US" xlink:label="lab_exdx_OutsideServicesExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outside services</link:label>
    <link:label id="lab_exdx_OutsideServicesExpense_label_en-US" xlink:label="lab_exdx_OutsideServicesExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outside Services Expense</link:label>
    <link:label id="lab_exdx_OutsideServicesExpense_documentation_en-US" xlink:label="lab_exdx_OutsideServicesExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Outside Services Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OutsideServicesExpense" xlink:href="exdx-20241231.xsd#exdx_OutsideServicesExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_OutsideServicesExpense" xlink:to="lab_exdx_OutsideServicesExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_67f13408-db5b-4c6f-9c7c-0522a131f063_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_0375b65b-1de4-4366-8b06-6b4506a68b68_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_fc4c494b-b710-4d17-9814-c65901ae785f_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock available for future issuance under ESPP</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_NoExpirationMember_165f8457-7c95-4d07-906a-187a9a00bc7e_terseLabel_en-US" xlink:label="lab_exdx_NoExpirationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">No expiration</link:label>
    <link:label id="lab_exdx_NoExpirationMember_label_en-US" xlink:label="lab_exdx_NoExpirationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">No expiration [Member]</link:label>
    <link:label id="lab_exdx_NoExpirationMember_documentation_en-US" xlink:label="lab_exdx_NoExpirationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">No expiration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_NoExpirationMember" xlink:href="exdx-20241231.xsd#exdx_NoExpirationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_NoExpirationMember" xlink:to="lab_exdx_NoExpirationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_75c2e792-962a-454e-b722-a7c69d6ff473_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss per share, basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentInKindPIKNoteMember_85525612-2d39-4634-8f54-27840df8ac29_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentInKindPIKNoteMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Paid in-kind note</link:label>
    <link:label id="lab_us-gaap_PaymentInKindPIKNoteMember_label_en-US" xlink:label="lab_us-gaap_PaymentInKindPIKNoteMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment in Kind (PIK) Note [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentInKindPIKNoteMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentInKindPIKNoteMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentInKindPIKNoteMember" xlink:to="lab_us-gaap_PaymentInKindPIKNoteMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_ClientMember_b783eac6-e064-45f0-844d-d7b0788281a8_terseLabel_en-US" xlink:label="lab_exdx_ClientMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Client</link:label>
    <link:label id="lab_exdx_ClientMember_label_en-US" xlink:label="lab_exdx_ClientMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Client [Member]</link:label>
    <link:label id="lab_exdx_ClientMember_documentation_en-US" xlink:label="lab_exdx_ClientMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Client</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ClientMember" xlink:href="exdx-20241231.xsd#exdx_ClientMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_ClientMember" xlink:to="lab_exdx_ClientMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_40e15c53-c8c7-48d9-8fa7-b41fcd5955fb_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_619a3590-125c-4de2-acd7-55e589054b3d_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from common stock issued under Employee Stock Purchase Plan</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Stock Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockPlans" xlink:to="lab_us-gaap_ProceedsFromStockPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_b59774a7-000d-4abc-8642-89bc2ee916ca_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating cash out flows from operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote</link:label>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToPeoCompFnTextBlock" xlink:to="lab_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:to="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_ab96031b-1ea7-4f23-8bb3-62ca927ecfb3_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options, expiration period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockOptionMember_a765544d-269c-4212-80c4-05a769796107_terseLabel_en-US" xlink:label="lab_us-gaap_StockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock options</link:label>
    <link:label id="lab_us-gaap_StockOptionMember_label_en-US" xlink:label="lab_us-gaap_StockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockOptionMember" xlink:to="lab_us-gaap_StockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_e8358c57-61c1-4782-85bd-089df0efa198_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_12bd4da0-9d9a-4329-b188-a9952867dd3c_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherPrepaidExpenseCurrent_40b3a71f-3aad-432d-8a16-13dd3c6ce812_terseLabel_en-US" xlink:label="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_OtherPrepaidExpenseCurrent_label_en-US" xlink:label="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Prepaid Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPrepaidExpenseCurrent" xlink:to="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_1b71123a-dde4-45dc-83dd-04febbd35374_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Domestic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_4506a6cf-bfe1-4ae4-ad45-e443fb12f749_negatedLabel_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Principal payment on finance lease obligations</link:label>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_3e795386-9e3d-4a4d-8f78-4b57336e6c54_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financing cash out flows from finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_label_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Principal Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:to="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardTable_9e092016-645f-4974-b381-da332c200634_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Table]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardTable_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable" xlink:to="lab_us-gaap_TaxCreditCarryforwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_4267065d-db27-4485-a8c3-1a108a00599d_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Costs incurred, but not paid, in connection with capital expenditures</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtPnsnAdjsSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Pension Adjustments Service Cost</link:label>
    <link:label id="lab_ecd_AggtPnsnAdjsSvcCstMember_label_en-US" xlink:label="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Pension Adjustments Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtPnsnAdjsSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCapitalizationOfResearchAndExperimentationCosts_f459cde2-c578-4197-aa44-960e55e5d691_terseLabel_en-US" xlink:label="lab_exdx_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCapitalizationOfResearchAndExperimentationCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capitalization of research and experimentation costs</link:label>
    <link:label id="lab_exdx_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCapitalizationOfResearchAndExperimentationCosts_label_en-US" xlink:label="lab_exdx_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCapitalizationOfResearchAndExperimentationCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Capitalization Of Research And Experimentation Costs</link:label>
    <link:label id="lab_exdx_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCapitalizationOfResearchAndExperimentationCosts_documentation_en-US" xlink:label="lab_exdx_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCapitalizationOfResearchAndExperimentationCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Capitalization Of Research And Experimentation Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCapitalizationOfResearchAndExperimentationCosts" xlink:href="exdx-20241231.xsd#exdx_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCapitalizationOfResearchAndExperimentationCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCapitalizationOfResearchAndExperimentationCosts" xlink:to="lab_exdx_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCapitalizationOfResearchAndExperimentationCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_46be1f9a-b931-4f9f-84a5-98acaf954d61_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-deductible expenses</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_b3cd7dac-5755-4773-8032-868f5ac3757c_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_A2017TermLoanMember_36d606d2-3881-44bc-b3ab-894e1d64cbe8_terseLabel_en-US" xlink:label="lab_exdx_A2017TermLoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2017 Term Loan</link:label>
    <link:label id="lab_exdx_A2017TermLoanMember_label_en-US" xlink:label="lab_exdx_A2017TermLoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2017 Term Loan [Member]</link:label>
    <link:label id="lab_exdx_A2017TermLoanMember_documentation_en-US" xlink:label="lab_exdx_A2017TermLoanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2017 Term Loan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_A2017TermLoanMember" xlink:href="exdx-20241231.xsd#exdx_A2017TermLoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_A2017TermLoanMember" xlink:to="lab_exdx_A2017TermLoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_32e38690-2884-4930-a95d-dc8ebc3a4c86_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock, Class of Stock [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock, Class of Stock [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_229d15b7-6dd8-4aeb-a467-57f57f8db39a_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year</link:label>
    <link:label id="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember_label_en-US" xlink:label="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:to="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_a414019f-fa50-4e08-864e-7e1f17b3b369_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_2ee11a9c-65e8-4e0b-a703-e06b5bbdfaf5_terseLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_b5eab6ef-35d1-434c-8d25-c62dfac457e9_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration of Credit Risk and Other Risk and Uncertainties</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_030230cf-7480-4c1e-bcc2-391828e082cf_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Costs of revenue</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdvertisingCostsPolicyTextBlock_2e3c8bcb-26a3-4953-b2ac-5a68f59f2d0b_terseLabel_en-US" xlink:label="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Advertising and Marketing Costs</link:label>
    <link:label id="lab_us-gaap_AdvertisingCostsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Advertising Cost [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdvertisingCostsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:to="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_ChangesInTheValuationAllowanceForDeferredTaxAssetsRollForward_7755d931-ff1e-4a8d-9ee1-5df167d6cb54_terseLabel_en-US" xlink:label="lab_exdx_ChangesInTheValuationAllowanceForDeferredTaxAssetsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes In The Valuation Allowance For Deferred Tax Assets [Roll Forward]</link:label>
    <link:label id="lab_exdx_ChangesInTheValuationAllowanceForDeferredTaxAssetsRollForward_label_en-US" xlink:label="lab_exdx_ChangesInTheValuationAllowanceForDeferredTaxAssetsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changes In The Valuation Allowance For Deferred Tax Assets [Roll Forward]</link:label>
    <link:label id="lab_exdx_ChangesInTheValuationAllowanceForDeferredTaxAssetsRollForward_documentation_en-US" xlink:label="lab_exdx_ChangesInTheValuationAllowanceForDeferredTaxAssetsRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Changes In The Valuation Allowance For Deferred Tax Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ChangesInTheValuationAllowanceForDeferredTaxAssetsRollForward" xlink:href="exdx-20241231.xsd#exdx_ChangesInTheValuationAllowanceForDeferredTaxAssetsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_ChangesInTheValuationAllowanceForDeferredTaxAssetsRollForward" xlink:to="lab_exdx_ChangesInTheValuationAllowanceForDeferredTaxAssetsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_f533f48f-9dc7-4ce0-86d5-958d2b8ad7ac_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_OperatingLeaseMonthlyBaseRent_9caf8a40-cd0c-4494-9003-51bfaa270575_terseLabel_en-US" xlink:label="lab_exdx_OperatingLeaseMonthlyBaseRent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease, monthly base rent</link:label>
    <link:label id="lab_exdx_OperatingLeaseMonthlyBaseRent_label_en-US" xlink:label="lab_exdx_OperatingLeaseMonthlyBaseRent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Monthly Base Rent</link:label>
    <link:label id="lab_exdx_OperatingLeaseMonthlyBaseRent_documentation_en-US" xlink:label="lab_exdx_OperatingLeaseMonthlyBaseRent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Lease, Monthly Base Rent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OperatingLeaseMonthlyBaseRent" xlink:href="exdx-20241231.xsd#exdx_OperatingLeaseMonthlyBaseRent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_OperatingLeaseMonthlyBaseRent" xlink:to="lab_exdx_OperatingLeaseMonthlyBaseRent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfNotesPayable_5d0c2d1b-cb50-4de3-af8c-681c9d670fb1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfNotesPayable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Principal payment on note payable obligations</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfNotesPayable_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Notes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfNotesPayable" xlink:to="lab_us-gaap_RepaymentsOfNotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_8deadde2-6b04-45f0-abc6-f0d3d37c448a_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_651c5d14-d9a1-4ae0-bb66-a2015249cdee_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other non-current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_LongTermDebtIncludingUndiscountedInterest_14b9257d-5c3f-4588-996e-5bbf268dd89e_totalLabel_en-US" xlink:label="lab_exdx_LongTermDebtIncludingUndiscountedInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_exdx_LongTermDebtIncludingUndiscountedInterest_label_en-US" xlink:label="lab_exdx_LongTermDebtIncludingUndiscountedInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Including Undiscounted Interest</link:label>
    <link:label id="lab_exdx_LongTermDebtIncludingUndiscountedInterest_documentation_en-US" xlink:label="lab_exdx_LongTermDebtIncludingUndiscountedInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Long-term Debt, Including Undiscounted Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_LongTermDebtIncludingUndiscountedInterest" xlink:href="exdx-20241231.xsd#exdx_LongTermDebtIncludingUndiscountedInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_LongTermDebtIncludingUndiscountedInterest" xlink:to="lab_exdx_LongTermDebtIncludingUndiscountedInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_d3b82806-521e-4d3b-ae71-09c2267ddad4_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and contingencies (Note 6)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_9aaf654a-4ba9-48d5-ac5e-eeecbd9b2cdd_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrTerminationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Termination Date</link:label>
    <link:label id="lab_ecd_TrdArrTerminationDate_label_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Termination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrTerminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrTerminationDate" xlink:to="lab_ecd_TrdArrTerminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_CollaborationAgreementAnnualCollaborationFee_5b8023f2-a43b-4beb-9f54-82a8d53d388f_terseLabel_en-US" xlink:label="lab_exdx_CollaborationAgreementAnnualCollaborationFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration fee</link:label>
    <link:label id="lab_exdx_CollaborationAgreementAnnualCollaborationFee_label_en-US" xlink:label="lab_exdx_CollaborationAgreementAnnualCollaborationFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Agreement, Annual Collaboration Fee</link:label>
    <link:label id="lab_exdx_CollaborationAgreementAnnualCollaborationFee_documentation_en-US" xlink:label="lab_exdx_CollaborationAgreementAnnualCollaborationFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration Agreement, Annual Collaboration Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_CollaborationAgreementAnnualCollaborationFee" xlink:href="exdx-20241231.xsd#exdx_CollaborationAgreementAnnualCollaborationFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_CollaborationAgreementAnnualCollaborationFee" xlink:to="lab_exdx_CollaborationAgreementAnnualCollaborationFee" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_OtherFinancialInformationAbstract_label_en-US" xlink:label="lab_exdx_OtherFinancialInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Financial Information [Abstract]</link:label>
    <link:label id="lab_exdx_OtherFinancialInformationAbstract_documentation_en-US" xlink:label="lab_exdx_OtherFinancialInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Financial Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OtherFinancialInformationAbstract" xlink:href="exdx-20241231.xsd#exdx_OtherFinancialInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_OtherFinancialInformationAbstract" xlink:to="lab_exdx_OtherFinancialInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_e09aaee2-e467-4716-95ec-c92717c0bf81_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_ef36f7e3-76a9-43c5-a245-d1d9c2f0263f_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of warrant or right, exercise price of warrants or rights (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_b704da5c-e6a6-4ee9-b4a2-6856644b224f_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_75566eb9-41de-4b20-b8a6-ed1a2d7d8f04_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Maturity, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_04ab50ba-1085-487e-9270-199addd7c433_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Option Plan</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_995f4d79-cca9-4c16-9a41-3c917f17d7cc_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_d5c962c0-e776-4dc2-a4dd-faea6a968cd1_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term loan borrowings</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGrossAbstract_6de7de80-41a0-4eba-85d8-1321f906d7bb_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax assets:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGrossAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Gross [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGrossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_8aa91962-89af-46c1-8e22-92f8ddbde293_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_1807672f-f4c1-42ea-b500-a5d81cefe121_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_8dbe6da2-c087-4a07-a30f-a0e7093bd7b1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancingReceivableAllowanceForCreditLossExcludingAccruedInterest_9fd4649e-31b5-4b33-ab62-a42995c9a678_terseLabel_en-US" xlink:label="lab_us-gaap_FinancingReceivableAllowanceForCreditLossExcludingAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Allowance for credit loss</link:label>
    <link:label id="lab_us-gaap_FinancingReceivableAllowanceForCreditLossExcludingAccruedInterest_label_en-US" xlink:label="lab_us-gaap_FinancingReceivableAllowanceForCreditLossExcludingAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financing Receivable, Allowance for Credit Loss, Excluding Accrued Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivableAllowanceForCreditLossExcludingAccruedInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancingReceivableAllowanceForCreditLossExcludingAccruedInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancingReceivableAllowanceForCreditLossExcludingAccruedInterest" xlink:to="lab_us-gaap_FinancingReceivableAllowanceForCreditLossExcludingAccruedInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_997f5c82-a4db-4697-904b-637ef47837f3_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock compensation</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_6b217137-b7d3-47e8-9e7d-c89e9e2e9190_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_df6db1a9-d79d-4f1d-8474-c172718236ab_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_9ed3bc19-1eb2-4aab-be0f-47641615d0bc_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrAxis_terseLabel_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangement:</link:label>
    <link:label id="lab_ecd_TradingArrAxis_label_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrAxis" xlink:to="lab_ecd_TradingArrAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_86ed7eac-f81a-4883-96e6-ff31669aecad_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsTable_11a6689f-3233-48b9-aaa2-e47a2b754b84_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Commitments [Table]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsTable_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Commitments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsTable" xlink:to="lab_us-gaap_OtherCommitmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure, Table</link:label>
    <link:label id="lab_ecd_PvpTableTextBlock_label_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTableTextBlock" xlink:to="lab_ecd_PvpTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_d41b1877-a4ce-4e0d-9f65-b7a022474fef_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Awards canceled (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_edd77746-c931-4ade-b99d-b0c4003990ce_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Excluding Value Reported in Compensation Table</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year</link:label>
    <link:label id="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember_label_en-US" xlink:label="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:to="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_3f8dbf6c-eb72-4ef1-8c22-7df9a7692dec_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_a790810b-7082-4f23-9367-7df1ed8efb59_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finance Leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_aa2a24ee-054f-4b1c-b3c8-175dec0aee9d_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_CowenEquityDistributionAgreementMember_e99c4c3d-6d55-48ba-9030-4121ec1dc1d2_terseLabel_en-US" xlink:label="lab_exdx_CowenEquityDistributionAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cowen Equity Distribution Agreement</link:label>
    <link:label id="lab_exdx_CowenEquityDistributionAgreementMember_label_en-US" xlink:label="lab_exdx_CowenEquityDistributionAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cowen Equity Distribution Agreement [Member]</link:label>
    <link:label id="lab_exdx_CowenEquityDistributionAgreementMember_documentation_en-US" xlink:label="lab_exdx_CowenEquityDistributionAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cowen Equity Distribution Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_CowenEquityDistributionAgreementMember" xlink:href="exdx-20241231.xsd#exdx_CowenEquityDistributionAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_CowenEquityDistributionAgreementMember" xlink:to="lab_exdx_CowenEquityDistributionAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_1dcb0cf1-1c9b-4c6b-8132-dc47f567feba_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_11f59879-85dd-4919-8de5-e1eeb9e5ffae_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductConcentrationRiskMember_7e5711d6-06ae-4ee3-a212-6836d37ec102_terseLabel_en-US" xlink:label="lab_us-gaap_ProductConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product Concentration Risk</link:label>
    <link:label id="lab_us-gaap_ProductConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_ProductConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductConcentrationRiskMember" xlink:to="lab_us-gaap_ProductConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_bc5f9029-730e-46a5-b8e1-de59f53489fb_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_e3929037-7f23-4610-92d2-d753a3faa30c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_b25a594c-5749-4433-b6a1-b8f45bbabb17_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other accrued liabilities</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_1d5a237d-e68a-4188-aa17-552c630a261f_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued and other current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryIndName" xlink:to="lab_ecd_ForgoneRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_82ffb048-3368-45d0-ad5b-988d575c06bd_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intrinsic value of options exercised</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage_7d961b4d-90ca-4a4e-ae51-e1a289261e8a_terseLabel_en-US" xlink:label="lab_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Annual percentage increase in shares available for issuance under the Plan</link:label>
    <link:label id="lab_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage_label_en-US" xlink:label="lab_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Additional Shares Authorized, Percentage</link:label>
    <link:label id="lab_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage_documentation_en-US" xlink:label="lab_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Additional Shares Authorized, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage" xlink:href="exdx-20241231.xsd#exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage" xlink:to="lab_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_1c7363d7-b2eb-40fc-8958-e98ebe0988aa_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_79f9bf02-9f88-49d5-b1b3-3ddac8f2b3d8_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_32fb4e8f-2061-4a3f-8704-7394f6896b82_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_5c818b92-8577-49e9-9220-3c0bf3907d85_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finance lease obligations, current portion</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_a5520978-9220-40b1-a9c3-7b05fb6f3a00_negatedLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: current portion</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_faab7852-fdb1-470d-b625-5108b2c731cf_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total minimum lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_91b70d82-1c8d-424d-b2ba-8d68ebf0a4ac_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_a759c070-7e53-47bf-8bae-4b0f91d3af3c_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_97881bca-27ee-4c3d-a297-6a231db6c96f_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Expired (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLenderDomain_1d0ab563-670e-4820-91e6-a8d9691cdc1a_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Lender [Domain]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLenderDomain_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Lender [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingArrLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingArrLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Arrangements [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="lab_ecd_InsiderTradingArrLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_ExpirationApr12026Member_dec564df-18d1-461d-9592-d8563d5ed9c2_terseLabel_en-US" xlink:label="lab_exdx_ExpirationApr12026Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant expiration April 1, 2026</link:label>
    <link:label id="lab_exdx_ExpirationApr12026Member_label_en-US" xlink:label="lab_exdx_ExpirationApr12026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expiration Apr 1, 2026 [Member]</link:label>
    <link:label id="lab_exdx_ExpirationApr12026Member_documentation_en-US" xlink:label="lab_exdx_ExpirationApr12026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Expiration Apr 1, 2026</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ExpirationApr12026Member" xlink:href="exdx-20241231.xsd#exdx_ExpirationApr12026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_ExpirationApr12026Member" xlink:to="lab_exdx_ExpirationApr12026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeFinanceLeaseTermOfContract1_ebc7d123-1fea-4931-862f-0c2bd27af681_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finance lease, term of contract</link:label>
    <link:label id="lab_us-gaap_LesseeFinanceLeaseTermOfContract1_label_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Finance Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeFinanceLeaseTermOfContract1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:to="lab_us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingAggtErrCompAmt" xlink:to="lab_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_dba759ac-1d86-45f6-a60b-87d22421f6df_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_label_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoActuallyPaidCompAmt" xlink:to="lab_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfRevenue_4ce0de8f-a86f-44f2-8127-a723fbde9cbc_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of revenue</link:label>
    <link:label id="lab_us-gaap_CostOfRevenue_label_en-US" xlink:label="lab_us-gaap_CostOfRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfRevenue" xlink:to="lab_us-gaap_CostOfRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_a88f8930-e8e1-459a-aa5a-4617a4775f86_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (decrease) in revenue recognized</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAxis_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation:</link:label>
    <link:label id="lab_ecd_AdjToCompAxis_label_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="lab_ecd_AdjToCompAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_892467e4-99cd-4120-ad90-5892d95d1171_totalLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableMember_314f6138-ebdf-43cd-ad41-465f8c0acf18_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_4c63c305-be52-4ee7-bc92-88abb87903c4_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock, Type [Table]</link:label>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_label_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock, Type [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_9b403c68-1de2-4039-beef-186ab172de3d_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseTypeDomain_d0696226-d3cf-4099-83f9-f05d27d4ffec_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain" xlink:to="lab_srt_LitigationCaseTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_3777e917-526b-44eb-aacd-48f7a15e54fe_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_dd8f3d94-84f9-4020-a7f4-fd09240bf550_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_93f36d3e-5b8e-4a82-a1f8-7aa7eaaa86d4_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnAdjsSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_PnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Adjustments Service Cost</link:label>
    <link:label id="lab_ecd_PnsnAdjsSvcCstMember_label_en-US" xlink:label="lab_ecd_PnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Adjustments Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnAdjsSvcCstMember" xlink:to="lab_ecd_PnsnAdjsSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationStatusDomain_626d3c02-a4a9-4b58-8d74-f01b663f1b06_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationStatusDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation Status [Domain]</link:label>
    <link:label id="lab_us-gaap_LitigationStatusDomain_label_en-US" xlink:label="lab_us-gaap_LitigationStatusDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Status [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LitigationStatusDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationStatusDomain" xlink:to="lab_us-gaap_LitigationStatusDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_96ffd1de-2f4f-4f82-a968-b6e7fcb89539_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average number of shares used to compute net loss per share, basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_label_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_80694cc1-aba4-4fb2-b1f4-246c6227a1dc_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_053d79d5-1128-4ef5-bfeb-873da13126eb_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted stock units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_31260046-e405-4bb7-b793-1c6cfe11ca85_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock reserved for issuance upon vesting of outstanding restricted stock units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_a0942a56-3ebe-4156-bb0d-667d4f489ef8_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of debt discount and debt issuance costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_855b15fb-03c5-4fdb-b34c-4e951023794b_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_terseLabel_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Executive Category:</link:label>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_label_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Executive Category [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="lab_ecd_ExecutiveCategoryAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:to="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_26cdf11f-64b6-4b82-ac81-3962157d508d_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember" xlink:to="lab_us-gaap_ConstructionInProgressMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_c0ae51f9-30e1-4c72-8aed-af19567a77a4_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_label_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNetMember" xlink:to="lab_us-gaap_SalesRevenueNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_060accfa-b1c7-41fe-aa36-b22ed471ba68_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_663b59d0-2067-4dbf-a81d-4981f1cbd90a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_e7693522-56f6-423d-bca2-9ac4aeb2c25f_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_357dc752-abaa-4576-92e0-953793659b04_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal tax loss carryforwards, subject to expiration</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_863377da-bdde-4018-a4c3-73e5fcfc49bf_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_daa21f20-ba58-4972-8eae-7c6a31cad68e_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureName_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureName_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureName" xlink:to="lab_ecd_CoSelectedMeasureName" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>exdx-20241231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:7095620a-7684-4e36-937b-24fd606ed1ea,g:3f375e3f-dda6-40cc-be01-a2493780a401-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.exagen.com/role/Cover" xlink:type="simple" xlink:href="exdx-20241231.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_ad9b54cf-e14d-49f1-b773-32a087d603fe" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_ab885d49-6ee3-457d-98e7-409de332c0b5" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ad9b54cf-e14d-49f1-b773-32a087d603fe" xlink:to="loc_dei_DocumentType_ab885d49-6ee3-457d-98e7-409de332c0b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_f2cec445-07c3-42be-87be-e5552853bba2" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ad9b54cf-e14d-49f1-b773-32a087d603fe" xlink:to="loc_dei_DocumentAnnualReport_f2cec445-07c3-42be-87be-e5552853bba2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_5586c9eb-8fed-489d-a089-8e39bd5577da" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ad9b54cf-e14d-49f1-b773-32a087d603fe" xlink:to="loc_dei_DocumentPeriodEndDate_5586c9eb-8fed-489d-a089-8e39bd5577da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_4a2e4347-e80c-4a69-b938-64b205848e93" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ad9b54cf-e14d-49f1-b773-32a087d603fe" xlink:to="loc_dei_CurrentFiscalYearEndDate_4a2e4347-e80c-4a69-b938-64b205848e93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_0459c35b-6214-49a4-a473-990fa111c092" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ad9b54cf-e14d-49f1-b773-32a087d603fe" xlink:to="loc_dei_DocumentTransitionReport_0459c35b-6214-49a4-a473-990fa111c092" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_71131966-ad1c-4d35-9630-36a48293d123" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ad9b54cf-e14d-49f1-b773-32a087d603fe" xlink:to="loc_dei_EntityFileNumber_71131966-ad1c-4d35-9630-36a48293d123" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_6cb13e39-91a9-424a-9c8c-ce98edecd4dd" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ad9b54cf-e14d-49f1-b773-32a087d603fe" xlink:to="loc_dei_EntityRegistrantName_6cb13e39-91a9-424a-9c8c-ce98edecd4dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_e017a28f-cebf-4354-9bf8-2c29fc865d67" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ad9b54cf-e14d-49f1-b773-32a087d603fe" xlink:to="loc_dei_EntityIncorporationStateCountryCode_e017a28f-cebf-4354-9bf8-2c29fc865d67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_c35e3df5-5688-4830-ad4c-84052fae049c" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ad9b54cf-e14d-49f1-b773-32a087d603fe" xlink:to="loc_dei_EntityTaxIdentificationNumber_c35e3df5-5688-4830-ad4c-84052fae049c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_ac280d0d-1360-44a7-b6e4-b76df307402d" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ad9b54cf-e14d-49f1-b773-32a087d603fe" xlink:to="loc_dei_EntityAddressAddressLine1_ac280d0d-1360-44a7-b6e4-b76df307402d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_8bbbbefc-871c-4bff-bd8a-a85acfe8a0ee" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ad9b54cf-e14d-49f1-b773-32a087d603fe" xlink:to="loc_dei_EntityAddressCityOrTown_8bbbbefc-871c-4bff-bd8a-a85acfe8a0ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_2923876e-0c72-4c1f-9b1b-cda681993ab2" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ad9b54cf-e14d-49f1-b773-32a087d603fe" xlink:to="loc_dei_EntityAddressStateOrProvince_2923876e-0c72-4c1f-9b1b-cda681993ab2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_29c4cec9-2a27-472a-a718-1f866820725e" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ad9b54cf-e14d-49f1-b773-32a087d603fe" xlink:to="loc_dei_EntityAddressPostalZipCode_29c4cec9-2a27-472a-a718-1f866820725e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_ab7df9a9-d49c-41d7-99f3-7121aac5d753" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ad9b54cf-e14d-49f1-b773-32a087d603fe" xlink:to="loc_dei_CityAreaCode_ab7df9a9-d49c-41d7-99f3-7121aac5d753" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_396bc24d-cac0-4ca0-89b6-290e1bf8fbfa" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ad9b54cf-e14d-49f1-b773-32a087d603fe" xlink:to="loc_dei_LocalPhoneNumber_396bc24d-cac0-4ca0-89b6-290e1bf8fbfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_fca93314-effa-4096-8b8a-e3744d54a781" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ad9b54cf-e14d-49f1-b773-32a087d603fe" xlink:to="loc_dei_Security12bTitle_fca93314-effa-4096-8b8a-e3744d54a781" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_c5fdc913-1a02-42a6-ab7c-ee3a80919948" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ad9b54cf-e14d-49f1-b773-32a087d603fe" xlink:to="loc_dei_TradingSymbol_c5fdc913-1a02-42a6-ab7c-ee3a80919948" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_71cde404-e840-4814-93b6-1d1e8adca318" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ad9b54cf-e14d-49f1-b773-32a087d603fe" xlink:to="loc_dei_SecurityExchangeName_71cde404-e840-4814-93b6-1d1e8adca318" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_dc472901-d254-45b8-8ca7-d45a90e64f02" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ad9b54cf-e14d-49f1-b773-32a087d603fe" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_dc472901-d254-45b8-8ca7-d45a90e64f02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_662d4560-4565-4e92-9fa5-4d9ec09bb024" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ad9b54cf-e14d-49f1-b773-32a087d603fe" xlink:to="loc_dei_EntityVoluntaryFilers_662d4560-4565-4e92-9fa5-4d9ec09bb024" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_9c5c165b-ca6c-4e90-a54a-475281813d11" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ad9b54cf-e14d-49f1-b773-32a087d603fe" xlink:to="loc_dei_EntityCurrentReportingStatus_9c5c165b-ca6c-4e90-a54a-475281813d11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_28a83845-0448-4a5d-8b26-03d456c4365a" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ad9b54cf-e14d-49f1-b773-32a087d603fe" xlink:to="loc_dei_EntityInteractiveDataCurrent_28a83845-0448-4a5d-8b26-03d456c4365a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_415a1f13-a511-49eb-af89-a7ae6413ce3c" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ad9b54cf-e14d-49f1-b773-32a087d603fe" xlink:to="loc_dei_EntityFilerCategory_415a1f13-a511-49eb-af89-a7ae6413ce3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_41d78fc5-5066-414e-897b-34e83212b7cd" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ad9b54cf-e14d-49f1-b773-32a087d603fe" xlink:to="loc_dei_EntitySmallBusiness_41d78fc5-5066-414e-897b-34e83212b7cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_d4e7a22c-ea90-4a29-989d-d55f0d70f07c" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ad9b54cf-e14d-49f1-b773-32a087d603fe" xlink:to="loc_dei_EntityEmergingGrowthCompany_d4e7a22c-ea90-4a29-989d-d55f0d70f07c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_8eda0e20-ea5d-4071-9690-bfcbbe89127f" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ad9b54cf-e14d-49f1-b773-32a087d603fe" xlink:to="loc_dei_IcfrAuditorAttestationFlag_8eda0e20-ea5d-4071-9690-bfcbbe89127f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag_bd7cb8fe-fcf8-4be4-9088-594cbf3fb8ac" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ad9b54cf-e14d-49f1-b773-32a087d603fe" xlink:to="loc_dei_DocumentFinStmtErrorCorrectionFlag_bd7cb8fe-fcf8-4be4-9088-594cbf3fb8ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_471e2ab0-0c26-4ad9-b37d-7281df355060" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ad9b54cf-e14d-49f1-b773-32a087d603fe" xlink:to="loc_dei_EntityShellCompany_471e2ab0-0c26-4ad9-b37d-7281df355060" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_37168b13-fe5f-4d8e-adf1-a38b6cd54088" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ad9b54cf-e14d-49f1-b773-32a087d603fe" xlink:to="loc_dei_EntityPublicFloat_37168b13-fe5f-4d8e-adf1-a38b6cd54088" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_ef1e4e78-8942-461d-9e85-9b0b8d91970e" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ad9b54cf-e14d-49f1-b773-32a087d603fe" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_ef1e4e78-8942-461d-9e85-9b0b8d91970e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_5e1023c4-d8e0-478c-a89e-a48a5a9f277d" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ad9b54cf-e14d-49f1-b773-32a087d603fe" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_5e1023c4-d8e0-478c-a89e-a48a5a9f277d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_ae57e99d-0c3d-425c-9c64-bb3f9b9f7103" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ad9b54cf-e14d-49f1-b773-32a087d603fe" xlink:to="loc_dei_DocumentFiscalYearFocus_ae57e99d-0c3d-425c-9c64-bb3f9b9f7103" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_69c5cea3-92d5-4ac2-ba37-e2579c65c924" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ad9b54cf-e14d-49f1-b773-32a087d603fe" xlink:to="loc_dei_DocumentFiscalPeriodFocus_69c5cea3-92d5-4ac2-ba37-e2579c65c924" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_8ff7aee4-8004-44ae-b58a-d788459d4809" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ad9b54cf-e14d-49f1-b773-32a087d603fe" xlink:to="loc_dei_AmendmentFlag_8ff7aee4-8004-44ae-b58a-d788459d4809" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_3c591df6-5519-4dfc-a3bf-779d7ee69b7f" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ad9b54cf-e14d-49f1-b773-32a087d603fe" xlink:to="loc_dei_EntityCentralIndexKey_3c591df6-5519-4dfc-a3bf-779d7ee69b7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/AuditInformation" xlink:type="simple" xlink:href="exdx-20241231.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AuditInformationAbstract_c51dc416-5c2e-4f01-87fa-1492e46f7e50" xlink:href="exdx-20241231.xsd#exdx_AuditInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_26a83cc3-07e7-4d63-b529-2873424957d7" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_AuditInformationAbstract_c51dc416-5c2e-4f01-87fa-1492e46f7e50" xlink:to="loc_dei_AuditorName_26a83cc3-07e7-4d63-b529-2873424957d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_53979c08-3926-4b0c-8122-8c351ea4d26b" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_AuditInformationAbstract_c51dc416-5c2e-4f01-87fa-1492e46f7e50" xlink:to="loc_dei_AuditorLocation_53979c08-3926-4b0c-8122-8c351ea4d26b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_e9920ce0-1489-4ef2-a1cc-d8834cafbbc8" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_AuditInformationAbstract_c51dc416-5c2e-4f01-87fa-1492e46f7e50" xlink:to="loc_dei_AuditorFirmId_e9920ce0-1489-4ef2-a1cc-d8834cafbbc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/BalanceSheets" xlink:type="simple" xlink:href="exdx-20241231.xsd#BalanceSheets"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/BalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_1622d225-9936-4107-9221-f20d221ad537" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_e9d3d5f6-a769-44e2-a13f-7525443d70b6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1622d225-9936-4107-9221-f20d221ad537" xlink:to="loc_us-gaap_AssetsAbstract_e9d3d5f6-a769-44e2-a13f-7525443d70b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_b72bcb3f-f9e8-4872-b43b-9b3ff4b09c84" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_e9d3d5f6-a769-44e2-a13f-7525443d70b6" xlink:to="loc_us-gaap_AssetsCurrentAbstract_b72bcb3f-f9e8-4872-b43b-9b3ff4b09c84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_0bee03cd-c53b-4ddd-8b49-8c37777b291b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_b72bcb3f-f9e8-4872-b43b-9b3ff4b09c84" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_0bee03cd-c53b-4ddd-8b49-8c37777b291b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_d4bad0a1-c98d-4924-99eb-f73f675ad426" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_b72bcb3f-f9e8-4872-b43b-9b3ff4b09c84" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_d4bad0a1-c98d-4924-99eb-f73f675ad426" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssets_03ecb970-36c4-4dbc-8e45-30a9c8401989" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_b72bcb3f-f9e8-4872-b43b-9b3ff4b09c84" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssets_03ecb970-36c4-4dbc-8e45-30a9c8401989" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_12ad3466-847e-4201-89dc-caf5aeb71ee0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_b72bcb3f-f9e8-4872-b43b-9b3ff4b09c84" xlink:to="loc_us-gaap_AssetsCurrent_12ad3466-847e-4201-89dc-caf5aeb71ee0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_d2198ba3-6ad3-4ff7-9612-f378ac1d31f8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_e9d3d5f6-a769-44e2-a13f-7525443d70b6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_d2198ba3-6ad3-4ff7-9612-f378ac1d31f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_b2fdd80b-c79e-4cb5-b610-995d9e6eb867" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_e9d3d5f6-a769-44e2-a13f-7525443d70b6" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_b2fdd80b-c79e-4cb5-b610-995d9e6eb867" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_306d5163-4451-4abd-b06d-7a178acd774e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_e9d3d5f6-a769-44e2-a13f-7525443d70b6" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_306d5163-4451-4abd-b06d-7a178acd774e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_6aee7de8-2adb-43fa-aae8-f1368919a0bf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_e9d3d5f6-a769-44e2-a13f-7525443d70b6" xlink:to="loc_us-gaap_Assets_6aee7de8-2adb-43fa-aae8-f1368919a0bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1b861023-d3e5-4791-8213-0884a65664f4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1622d225-9936-4107-9221-f20d221ad537" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1b861023-d3e5-4791-8213-0884a65664f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_ade0727d-ad8d-4c38-ae35-10fba517471c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1b861023-d3e5-4791-8213-0884a65664f4" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_ade0727d-ad8d-4c38-ae35-10fba517471c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_be46bb0a-f331-4f98-8e8a-ef264fc14ca7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_ade0727d-ad8d-4c38-ae35-10fba517471c" xlink:to="loc_us-gaap_AccountsPayableCurrent_be46bb0a-f331-4f98-8e8a-ef264fc14ca7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_74dc22bc-d1f5-46e8-98bc-075f6771eea8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_ade0727d-ad8d-4c38-ae35-10fba517471c" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_74dc22bc-d1f5-46e8-98bc-075f6771eea8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_ffd52086-5cb2-4e7c-a9a7-1d955dadbc1f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_ade0727d-ad8d-4c38-ae35-10fba517471c" xlink:to="loc_us-gaap_LongTermDebtCurrent_ffd52086-5cb2-4e7c-a9a7-1d955dadbc1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_c9d9f11a-476d-4f06-a99e-39bcc39f903d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_ade0727d-ad8d-4c38-ae35-10fba517471c" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_c9d9f11a-476d-4f06-a99e-39bcc39f903d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_7417c150-2139-4577-b3a5-32e31ee59b8c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_ade0727d-ad8d-4c38-ae35-10fba517471c" xlink:to="loc_us-gaap_LiabilitiesCurrent_7417c150-2139-4577-b3a5-32e31ee59b8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_aa144f5f-67ee-4753-8acb-73082f232f0c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1b861023-d3e5-4791-8213-0884a65664f4" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_aa144f5f-67ee-4753-8acb-73082f232f0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_2fa10447-503d-4680-ad59-0ab314d88b30" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1b861023-d3e5-4791-8213-0884a65664f4" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_2fa10447-503d-4680-ad59-0ab314d88b30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_8cda9a72-8e12-40fa-a59a-c52e8dd1313a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1b861023-d3e5-4791-8213-0884a65664f4" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_8cda9a72-8e12-40fa-a59a-c52e8dd1313a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_11755255-8b9f-4df7-b6d4-155a2198ba77" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1b861023-d3e5-4791-8213-0884a65664f4" xlink:to="loc_us-gaap_Liabilities_11755255-8b9f-4df7-b6d4-155a2198ba77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_f79c6db1-22b2-4b29-a839-b556c8b1f057" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1b861023-d3e5-4791-8213-0884a65664f4" xlink:to="loc_us-gaap_CommitmentsAndContingencies_f79c6db1-22b2-4b29-a839-b556c8b1f057" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_120ee128-2709-4648-90b7-5dc1579a5e05" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1b861023-d3e5-4791-8213-0884a65664f4" xlink:to="loc_us-gaap_StockholdersEquityAbstract_120ee128-2709-4648-90b7-5dc1579a5e05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_52aa4b24-4f1f-4446-a1fe-bf5a76978f73" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_120ee128-2709-4648-90b7-5dc1579a5e05" xlink:to="loc_us-gaap_PreferredStockValue_52aa4b24-4f1f-4446-a1fe-bf5a76978f73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_b8113b2f-5e19-4181-8d56-7e551f225fa4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_120ee128-2709-4648-90b7-5dc1579a5e05" xlink:to="loc_us-gaap_CommonStockValue_b8113b2f-5e19-4181-8d56-7e551f225fa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_8b209ff2-b82f-45c4-977d-971aec2ffdfd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_120ee128-2709-4648-90b7-5dc1579a5e05" xlink:to="loc_us-gaap_AdditionalPaidInCapital_8b209ff2-b82f-45c4-977d-971aec2ffdfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_791781fa-4a2b-4fdb-bebe-8d442bbdf575" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_120ee128-2709-4648-90b7-5dc1579a5e05" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_791781fa-4a2b-4fdb-bebe-8d442bbdf575" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_8a0b20a3-ae78-495e-bee4-626d72261b6e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_120ee128-2709-4648-90b7-5dc1579a5e05" xlink:to="loc_us-gaap_StockholdersEquity_8a0b20a3-ae78-495e-bee4-626d72261b6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_589f746c-90ce-4e70-ab47-3aca1956d069" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1b861023-d3e5-4791-8213-0884a65664f4" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_589f746c-90ce-4e70-ab47-3aca1956d069" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/BalanceSheetsParenthetical" xlink:type="simple" xlink:href="exdx-20241231.xsd#BalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/BalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_8eaccb68-674f-49c6-b055-8d1cd0a433ce" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_d023be2f-dc5d-44b3-a3fa-b262ae79c4e0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_8eaccb68-674f-49c6-b055-8d1cd0a433ce" xlink:to="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_d023be2f-dc5d-44b3-a3fa-b262ae79c4e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_c8771a6e-44d7-45ef-995a-4e0999880f0e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_d023be2f-dc5d-44b3-a3fa-b262ae79c4e0" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_c8771a6e-44d7-45ef-995a-4e0999880f0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_4498e89d-d32c-4330-9bf7-333289000c37" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_d023be2f-dc5d-44b3-a3fa-b262ae79c4e0" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_4498e89d-d32c-4330-9bf7-333289000c37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_4832d9d8-a26a-4787-984f-99a3445d2ecd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_d023be2f-dc5d-44b3-a3fa-b262ae79c4e0" xlink:to="loc_us-gaap_PreferredStockSharesIssued_4832d9d8-a26a-4787-984f-99a3445d2ecd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_c0a18de2-e063-4fb9-b4fb-ed3db39a3874" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_d023be2f-dc5d-44b3-a3fa-b262ae79c4e0" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_c0a18de2-e063-4fb9-b4fb-ed3db39a3874" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_1709d408-8485-4403-ae66-e63724053788" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_8eaccb68-674f-49c6-b055-8d1cd0a433ce" xlink:to="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_1709d408-8485-4403-ae66-e63724053788" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_f8b14b35-215b-46f0-9bcf-cd429b35bfd9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_1709d408-8485-4403-ae66-e63724053788" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_f8b14b35-215b-46f0-9bcf-cd429b35bfd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_a0f991e5-768a-4902-97c2-b0508e7aaffd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_1709d408-8485-4403-ae66-e63724053788" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_a0f991e5-768a-4902-97c2-b0508e7aaffd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_a67cb1c7-d457-4936-ae5a-9dea0ed6c3a3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_1709d408-8485-4403-ae66-e63724053788" xlink:to="loc_us-gaap_CommonStockSharesIssued_a67cb1c7-d457-4936-ae5a-9dea0ed6c3a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_7a73fa57-d918-44a0-ab8e-2d259be17d02" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_1709d408-8485-4403-ae66-e63724053788" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_7a73fa57-d918-44a0-ab8e-2d259be17d02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StatementsofOperations" xlink:type="simple" xlink:href="exdx-20241231.xsd#StatementsofOperations"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/StatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_17e1591e-dc5a-4919-8c11-ec4d665f07ce" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_dc639bf6-be0d-49bf-ab09-b4316cbe3a3c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_17e1591e-dc5a-4919-8c11-ec4d665f07ce" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_dc639bf6-be0d-49bf-ab09-b4316cbe3a3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_83226490-9f83-4332-b8b3-12420bf20c96" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_17e1591e-dc5a-4919-8c11-ec4d665f07ce" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_83226490-9f83-4332-b8b3-12420bf20c96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_7cd04dae-45d6-44b6-b559-1ce387916b9b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_17e1591e-dc5a-4919-8c11-ec4d665f07ce" xlink:to="loc_us-gaap_GrossProfit_7cd04dae-45d6-44b6-b559-1ce387916b9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_d31f4388-6143-441d-a2fb-3643ca668aab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_17e1591e-dc5a-4919-8c11-ec4d665f07ce" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_d31f4388-6143-441d-a2fb-3643ca668aab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_09f21ef7-88d7-4deb-96c6-4596c849a6d9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_d31f4388-6143-441d-a2fb-3643ca668aab" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_09f21ef7-88d7-4deb-96c6-4596c849a6d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_5aa23480-6ef1-471f-bd75-8e8e39acb658" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_d31f4388-6143-441d-a2fb-3643ca668aab" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_5aa23480-6ef1-471f-bd75-8e8e39acb658" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_a1890169-00dd-4c1e-8a22-031fd099b8c3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_d31f4388-6143-441d-a2fb-3643ca668aab" xlink:to="loc_us-gaap_CostsAndExpenses_a1890169-00dd-4c1e-8a22-031fd099b8c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_e7e527d0-695d-414c-9ed1-4510017425b4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_17e1591e-dc5a-4919-8c11-ec4d665f07ce" xlink:to="loc_us-gaap_OperatingIncomeLoss_e7e527d0-695d-414c-9ed1-4510017425b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating_1efe83d8-5bc7-4a55-a9f3-2cd2f2ecca01" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_17e1591e-dc5a-4919-8c11-ec4d665f07ce" xlink:to="loc_us-gaap_InterestExpenseNonoperating_1efe83d8-5bc7-4a55-a9f3-2cd2f2ecca01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_d1f94a7a-2b19-4ad1-8fcb-6ac0fecd2900" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_17e1591e-dc5a-4919-8c11-ec4d665f07ce" xlink:to="loc_us-gaap_InvestmentIncomeInterest_d1f94a7a-2b19-4ad1-8fcb-6ac0fecd2900" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent_90b65ad5-625d-4afc-bc4f-9850dcdaea7a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_17e1591e-dc5a-4919-8c11-ec4d665f07ce" xlink:to="loc_us-gaap_IncomeLossAttributableToParent_90b65ad5-625d-4afc-bc4f-9850dcdaea7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_470646cf-fac7-46e5-8302-3ea282d36c12" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_17e1591e-dc5a-4919-8c11-ec4d665f07ce" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_470646cf-fac7-46e5-8302-3ea282d36c12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_7a95a1a2-f7ef-4f42-970f-9093333c1589" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_17e1591e-dc5a-4919-8c11-ec4d665f07ce" xlink:to="loc_us-gaap_NetIncomeLoss_7a95a1a2-f7ef-4f42-970f-9093333c1589" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_695f8f37-96cb-41af-b58a-7349bd252916" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_17e1591e-dc5a-4919-8c11-ec4d665f07ce" xlink:to="loc_us-gaap_EarningsPerShareBasic_695f8f37-96cb-41af-b58a-7349bd252916" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_5320d0ba-11a2-4430-ab6a-258f5534a98d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_17e1591e-dc5a-4919-8c11-ec4d665f07ce" xlink:to="loc_us-gaap_EarningsPerShareDiluted_5320d0ba-11a2-4430-ab6a-258f5534a98d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_f12fde52-b381-4522-9427-7b0e4ebd6d39" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_17e1591e-dc5a-4919-8c11-ec4d665f07ce" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_f12fde52-b381-4522-9427-7b0e4ebd6d39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4558d915-6388-47d2-b33d-48243abf2906" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_17e1591e-dc5a-4919-8c11-ec4d665f07ce" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4558d915-6388-47d2-b33d-48243abf2906" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StatementsofStockholdersEquity" xlink:type="simple" xlink:href="exdx-20241231.xsd#StatementsofStockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/StatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_31d25576-28fe-4bcd-b7ff-76813de272bf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_767a4f22-9062-4191-a10e-5154fac42302" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_31d25576-28fe-4bcd-b7ff-76813de272bf" xlink:to="loc_us-gaap_StatementTable_767a4f22-9062-4191-a10e-5154fac42302" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_18926d3a-6710-4598-abf0-ee40e537714f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_767a4f22-9062-4191-a10e-5154fac42302" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_18926d3a-6710-4598-abf0-ee40e537714f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_532dec69-2378-4141-b7e4-421a2a53103e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_18926d3a-6710-4598-abf0-ee40e537714f" xlink:to="loc_us-gaap_EquityComponentDomain_532dec69-2378-4141-b7e4-421a2a53103e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_c24caff9-5b76-4b57-b6fd-673ba8ee78b8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_532dec69-2378-4141-b7e4-421a2a53103e" xlink:to="loc_us-gaap_CommonStockMember_c24caff9-5b76-4b57-b6fd-673ba8ee78b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_aa273674-57e7-4ce1-abc5-ac5f45d90d53" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_532dec69-2378-4141-b7e4-421a2a53103e" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_aa273674-57e7-4ce1-abc5-ac5f45d90d53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_f1a167af-b408-43be-90ca-f81f4e803e2e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_532dec69-2378-4141-b7e4-421a2a53103e" xlink:to="loc_us-gaap_RetainedEarningsMember_f1a167af-b408-43be-90ca-f81f4e803e2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_e19312a0-4012-4475-9a88-fc70f15c6851" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_767a4f22-9062-4191-a10e-5154fac42302" xlink:to="loc_us-gaap_StatementLineItems_e19312a0-4012-4475-9a88-fc70f15c6851" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3e0ec477-12c3-4815-b5f8-0cf4619f1d88" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e19312a0-4012-4475-9a88-fc70f15c6851" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3e0ec477-12c3-4815-b5f8-0cf4619f1d88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_87444e71-b9a3-4479-be92-6cd303374d65" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3e0ec477-12c3-4815-b5f8-0cf4619f1d88" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_87444e71-b9a3-4479-be92-6cd303374d65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_c81e425e-1794-408c-950e-ed5d6643957b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3e0ec477-12c3-4815-b5f8-0cf4619f1d88" xlink:to="loc_us-gaap_StockholdersEquity_c81e425e-1794-408c-950e-ed5d6643957b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesShares_9a77191f-0fc7-44ed-88d4-ad5f76fcbeeb" xlink:href="exdx-20241231.xsd#exdx_IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesShares"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3e0ec477-12c3-4815-b5f8-0cf4619f1d88" xlink:to="loc_exdx_IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesShares_9a77191f-0fc7-44ed-88d4-ad5f76fcbeeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_ddc6fd82-db6b-424a-b25c-bf027229cc23" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3e0ec477-12c3-4815-b5f8-0cf4619f1d88" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_ddc6fd82-db6b-424a-b25c-bf027229cc23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_32fef974-41bb-402e-9b97-6d328f6651fb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3e0ec477-12c3-4815-b5f8-0cf4619f1d88" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_32fef974-41bb-402e-9b97-6d328f6651fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_8ef83387-0704-4689-a777-5c2c8e90efa9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3e0ec477-12c3-4815-b5f8-0cf4619f1d88" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_8ef83387-0704-4689-a777-5c2c8e90efa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_3819a5b2-f400-4c3e-b9c9-dd739d50163c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3e0ec477-12c3-4815-b5f8-0cf4619f1d88" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_3819a5b2-f400-4c3e-b9c9-dd739d50163c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_19405dba-bb1a-4c2d-a9fa-799606bf7c60" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3e0ec477-12c3-4815-b5f8-0cf4619f1d88" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_19405dba-bb1a-4c2d-a9fa-799606bf7c60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_ec8ed788-d1b7-437e-bd92-9bead6282157" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3e0ec477-12c3-4815-b5f8-0cf4619f1d88" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_ec8ed788-d1b7-437e-bd92-9bead6282157" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_2d782a93-69ec-4ed0-8acf-d47fadb378bd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3e0ec477-12c3-4815-b5f8-0cf4619f1d88" xlink:to="loc_us-gaap_NetIncomeLoss_2d782a93-69ec-4ed0-8acf-d47fadb378bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_5c9a63e4-362c-4f31-8698-42bfca5e9cbe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3e0ec477-12c3-4815-b5f8-0cf4619f1d88" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_5c9a63e4-362c-4f31-8698-42bfca5e9cbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_ac9e22c9-60ac-4010-aab9-c9caae16ac28" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3e0ec477-12c3-4815-b5f8-0cf4619f1d88" xlink:to="loc_us-gaap_StockholdersEquity_ac9e22c9-60ac-4010-aab9-c9caae16ac28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StatementsofCashFlows" xlink:type="simple" xlink:href="exdx-20241231.xsd#StatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/StatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_8412cc84-880f-48f3-b6d6-9afb05d88a28" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_88c421f3-4386-4df1-be1a-a9e418144a14" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_8412cc84-880f-48f3-b6d6-9afb05d88a28" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_88c421f3-4386-4df1-be1a-a9e418144a14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_3b8896e9-485e-437e-a419-3033a964f278" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_88c421f3-4386-4df1-be1a-a9e418144a14" xlink:to="loc_us-gaap_NetIncomeLoss_3b8896e9-485e-437e-a419-3033a964f278" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_729d4b28-7d71-40f6-bcd4-8e1cf90a2929" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_88c421f3-4386-4df1-be1a-a9e418144a14" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_729d4b28-7d71-40f6-bcd4-8e1cf90a2929" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization_0cad3c31-f473-498f-85ac-30de47ba8ec0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_729d4b28-7d71-40f6-bcd4-8e1cf90a2929" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization_0cad3c31-f473-498f-85ac-30de47ba8ec0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_642003bb-7148-4202-afad-924cedcd948b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_729d4b28-7d71-40f6-bcd4-8e1cf90a2929" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_642003bb-7148-4202-afad-924cedcd948b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaidInKindInterest_91ed712f-0e1c-4fb4-9611-8989a30f1580" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaidInKindInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_729d4b28-7d71-40f6-bcd4-8e1cf90a2929" xlink:to="loc_us-gaap_PaidInKindInterest_91ed712f-0e1c-4fb4-9611-8989a30f1580" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_0b406bad-efe6-4e18-97e3-23afdac264e1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_729d4b28-7d71-40f6-bcd4-8e1cf90a2929" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_0b406bad-efe6-4e18-97e3-23afdac264e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_GainLossOnDispositionOfLeaseAssignment_e07549c5-030e-43bc-bc9e-b45303ec0ee3" xlink:href="exdx-20241231.xsd#exdx_GainLossOnDispositionOfLeaseAssignment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_729d4b28-7d71-40f6-bcd4-8e1cf90a2929" xlink:to="loc_exdx_GainLossOnDispositionOfLeaseAssignment_e07549c5-030e-43bc-bc9e-b45303ec0ee3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_NonCashLeaseExpense_93c0a3f2-b0d9-4b97-b06a-35e993e9d191" xlink:href="exdx-20241231.xsd#exdx_NonCashLeaseExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_729d4b28-7d71-40f6-bcd4-8e1cf90a2929" xlink:to="loc_exdx_NonCashLeaseExpense_93c0a3f2-b0d9-4b97-b06a-35e993e9d191" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_10129b84-aa56-4f5e-9bce-4bddce074e0a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_729d4b28-7d71-40f6-bcd4-8e1cf90a2929" xlink:to="loc_us-gaap_ShareBasedCompensation_10129b84-aa56-4f5e-9bce-4bddce074e0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c6bcf572-8a9d-45cf-b6a3-34ffad95f084" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_729d4b28-7d71-40f6-bcd4-8e1cf90a2929" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c6bcf572-8a9d-45cf-b6a3-34ffad95f084" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_71b271d7-0322-4e6d-aad1-31f7a10a2ee8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c6bcf572-8a9d-45cf-b6a3-34ffad95f084" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_71b271d7-0322-4e6d-aad1-31f7a10a2ee8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets_ab2cfcd7-b11a-4d69-b07e-b5089e4ed739" xlink:href="exdx-20241231.xsd#exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c6bcf572-8a9d-45cf-b6a3-34ffad95f084" xlink:to="loc_exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets_ab2cfcd7-b11a-4d69-b07e-b5089e4ed739" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_1487cca8-3146-4278-b739-3d61887d40a2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c6bcf572-8a9d-45cf-b6a3-34ffad95f084" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_1487cca8-3146-4278-b739-3d61887d40a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_7c7bba42-af8e-4aa9-9450-fc7dba68f39b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c6bcf572-8a9d-45cf-b6a3-34ffad95f084" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_7c7bba42-af8e-4aa9-9450-fc7dba68f39b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_52d213c6-97d0-4b68-8359-f419060fd6ad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c6bcf572-8a9d-45cf-b6a3-34ffad95f084" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_52d213c6-97d0-4b68-8359-f419060fd6ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_86f4df85-ef82-4b49-8da0-ef8bc0bec869" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c6bcf572-8a9d-45cf-b6a3-34ffad95f084" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_86f4df85-ef82-4b49-8da0-ef8bc0bec869" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d675e2fe-169e-4711-8a54-c20345f0c72b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_88c421f3-4386-4df1-be1a-a9e418144a14" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d675e2fe-169e-4711-8a54-c20345f0c72b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_6019545c-6a83-40df-9376-35d29ca4c3f2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_8412cc84-880f-48f3-b6d6-9afb05d88a28" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_6019545c-6a83-40df-9376-35d29ca4c3f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_b3e46406-6f10-4141-83c0-03190a934014" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_6019545c-6a83-40df-9376-35d29ca4c3f2" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_b3e46406-6f10-4141-83c0-03190a934014" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_f2e35432-e63f-4697-ad15-350291089e9b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_6019545c-6a83-40df-9376-35d29ca4c3f2" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_f2e35432-e63f-4697-ad15-350291089e9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_3f2d5275-0c0a-4419-9703-514e3362ca21" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_6019545c-6a83-40df-9376-35d29ca4c3f2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_3f2d5275-0c0a-4419-9703-514e3362ca21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_0f9ceacc-3d63-468d-b57b-4621ad876bbc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_8412cc84-880f-48f3-b6d6-9afb05d88a28" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_0f9ceacc-3d63-468d-b57b-4621ad876bbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_98d355b9-1ea7-405c-a190-a413e1b8c9e7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_0f9ceacc-3d63-468d-b57b-4621ad876bbc" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_98d355b9-1ea7-405c-a190-a413e1b8c9e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans_f456c299-f6a7-41c8-977c-2463a1512769" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_0f9ceacc-3d63-468d-b57b-4621ad876bbc" xlink:to="loc_us-gaap_ProceedsFromStockPlans_f456c299-f6a7-41c8-977c-2463a1512769" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_e0de458d-4ebc-4c5e-9c22-95b323c9dbaf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_0f9ceacc-3d63-468d-b57b-4621ad876bbc" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_e0de458d-4ebc-4c5e-9c22-95b323c9dbaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_fb9f1125-d8d4-4606-90f3-f9a886a0d65a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_0f9ceacc-3d63-468d-b57b-4621ad876bbc" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_fb9f1125-d8d4-4606-90f3-f9a886a0d65a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_e3eabc04-6a73-466f-b2d0-fefd598c9b02" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_0f9ceacc-3d63-468d-b57b-4621ad876bbc" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_e3eabc04-6a73-466f-b2d0-fefd598c9b02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b859d5e8-163d-4b03-815a-ee11b81ca2dc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_0f9ceacc-3d63-468d-b57b-4621ad876bbc" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b859d5e8-163d-4b03-815a-ee11b81ca2dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_b9eed8ed-8ce7-4b0d-8170-846865b94d17" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_8412cc84-880f-48f3-b6d6-9afb05d88a28" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_b9eed8ed-8ce7-4b0d-8170-846865b94d17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1597e203-d3d8-4030-b981-29b07ea0d953" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_8412cc84-880f-48f3-b6d6-9afb05d88a28" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1597e203-d3d8-4030-b981-29b07ea0d953" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3318226c-e144-456f-bd92-8e31030cfc17" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_8412cc84-880f-48f3-b6d6-9afb05d88a28" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3318226c-e144-456f-bd92-8e31030cfc17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_70b3e947-eac0-497d-b568-27e60e3be9c8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_8412cc84-880f-48f3-b6d6-9afb05d88a28" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_70b3e947-eac0-497d-b568-27e60e3be9c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_9fd2345a-0133-4d6a-8834-384b16b93e8f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_70b3e947-eac0-497d-b568-27e60e3be9c8" xlink:to="loc_us-gaap_InterestPaidNet_9fd2345a-0133-4d6a-8834-384b16b93e8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract_558a1d38-8740-4337-b7a2-525d914ade95" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_8412cc84-880f-48f3-b6d6-9afb05d88a28" xlink:to="loc_us-gaap_SupplementalCashFlowElementsAbstract_558a1d38-8740-4337-b7a2-525d914ade95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_EquipmentPurchasedUnderNotesPayableObligations_fccd576a-3d90-4b26-9360-190a430d9275" xlink:href="exdx-20241231.xsd#exdx_EquipmentPurchasedUnderNotesPayableObligations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_558a1d38-8740-4337-b7a2-525d914ade95" xlink:to="loc_exdx_EquipmentPurchasedUnderNotesPayableObligations_fccd576a-3d90-4b26-9360-190a430d9275" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_1c9f6274-1707-4a56-90e1-011e10ef2094" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_558a1d38-8740-4337-b7a2-525d914ade95" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_1c9f6274-1707-4a56-90e1-011e10ef2094" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/Organization" xlink:type="simple" xlink:href="exdx-20241231.xsd#Organization"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/Organization" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a39c9358-ae24-449f-9006-93ebb1c0d2e5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_293cf249-a454-45d6-8dff-0b65a864899f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a39c9358-ae24-449f-9006-93ebb1c0d2e5" xlink:to="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_293cf249-a454-45d6-8dff-0b65a864899f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="exdx-20241231.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_ffee5974-ef8d-40a8-b5c3-1a233f91e27b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_edd236c0-4e78-424b-a1a9-83d0eed0b996" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ffee5974-ef8d-40a8-b5c3-1a233f91e27b" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_edd236c0-4e78-424b-a1a9-83d0eed0b996" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/OtherFinancialInformation" xlink:type="simple" xlink:href="exdx-20241231.xsd#OtherFinancialInformation"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/OtherFinancialInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OtherFinancialInformationAbstract_c9bfcc65-63f7-40a7-bc9d-407804804629" xlink:href="exdx-20241231.xsd#exdx_OtherFinancialInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock_79bf299c-3a37-482f-8108-2b6f203994bc" xlink:href="exdx-20241231.xsd#exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_c9bfcc65-63f7-40a7-bc9d-407804804629" xlink:to="loc_exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock_79bf299c-3a37-482f-8108-2b6f203994bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/Borrowings" xlink:type="simple" xlink:href="exdx-20241231.xsd#Borrowings"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/Borrowings" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_a54ddbc5-d9be-40f1-adcd-d8539de89f9c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_59b452df-9865-4da3-90db-a23300f5a31f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_a54ddbc5-d9be-40f1-adcd-d8539de89f9c" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_59b452df-9865-4da3-90db-a23300f5a31f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/Leases" xlink:type="simple" xlink:href="exdx-20241231.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_32e183ce-b05b-499b-8091-0b9501534993" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_50316878-6434-488b-b071-a6f0f824d900" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_32e183ce-b05b-499b-8091-0b9501534993" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_50316878-6434-488b-b071-a6f0f824d900" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeasesTextBlock_7c323441-de62-46dc-a29c-7165e013951c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeFinanceLeasesTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_32e183ce-b05b-499b-8091-0b9501534993" xlink:to="loc_us-gaap_LesseeFinanceLeasesTextBlock_7c323441-de62-46dc-a29c-7165e013951c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="exdx-20241231.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0f71de35-33c7-4d21-aa16-6b1393e4875e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_6e679d3d-71c3-4cfe-b3a2-701c5348db2f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0f71de35-33c7-4d21-aa16-6b1393e4875e" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_6e679d3d-71c3-4cfe-b3a2-701c5348db2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="exdx-20241231.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_3f262846-0c1e-45eb-b7d2-de4a599cf7cb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_3fcda0e1-8678-4df5-93bc-a3f5bad57c66" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_3f262846-0c1e-45eb-b7d2-de4a599cf7cb" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_3fcda0e1-8678-4df5-93bc-a3f5bad57c66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StockholdersEquity" xlink:type="simple" xlink:href="exdx-20241231.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_b120fb0b-51e4-4dfa-9e02-c3cadbcbb416" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_3466b80f-a2aa-495f-bfd3-f0be6e3fc6d0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_b120fb0b-51e4-4dfa-9e02-c3cadbcbb416" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_3466b80f-a2aa-495f-bfd3-f0be6e3fc6d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StockOptionPlan" xlink:type="simple" xlink:href="exdx-20241231.xsd#StockOptionPlan"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/StockOptionPlan" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_62cdbb5d-2e68-4ff4-ab4a-f369068bc06c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_8a4df2d2-7d33-4017-8047-2eead6678866" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_62cdbb5d-2e68-4ff4-ab4a-f369068bc06c" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_8a4df2d2-7d33-4017-8047-2eead6678866" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/IncomeTaxes" xlink:type="simple" xlink:href="exdx-20241231.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_8529efe7-1cd5-4813-be0f-6fded17be50b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_f363292e-4075-4c70-9723-57ae7fde2ac6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_8529efe7-1cd5-4813-be0f-6fded17be50b" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_f363292e-4075-4c70-9723-57ae7fde2ac6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/A401kPlan" xlink:type="simple" xlink:href="exdx-20241231.xsd#A401kPlan"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/A401kPlan" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_37513150-b152-4423-b562-4a8d39b93a5e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_e3a38fcd-9999-470f-b036-58dc11f169f1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_37513150-b152-4423-b562-4a8d39b93a5e" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_e3a38fcd-9999-470f-b036-58dc11f169f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/SegmentReporting" xlink:type="simple" xlink:href="exdx-20241231.xsd#SegmentReporting"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/SegmentReporting" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_d861ac18-2ea4-4500-8414-5bd255cf84f9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_15dd6fa1-a68c-4b15-9d39-7f1ecffa555e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_d861ac18-2ea4-4500-8414-5bd255cf84f9" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_15dd6fa1-a68c-4b15-9d39-7f1ecffa555e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="exdx-20241231.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_6c0eeab9-2e5e-495a-9a1d-c1e4229cbbe2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_d8bcfd5b-b0d2-43f6-92dc-1cba0752e7f6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6c0eeab9-2e5e-495a-9a1d-c1e4229cbbe2" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_d8bcfd5b-b0d2-43f6-92dc-1cba0752e7f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_18652cad-6bdf-4977-8b42-3ea50a0c15cc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6c0eeab9-2e5e-495a-9a1d-c1e4229cbbe2" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_18652cad-6bdf-4977-8b42-3ea50a0c15cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_0e640408-3299-42fb-acd6-0247c57e2fba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6c0eeab9-2e5e-495a-9a1d-c1e4229cbbe2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_0e640408-3299-42fb-acd6-0247c57e2fba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_758741bd-bbc5-4c45-bfd8-d9539c4657c9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6c0eeab9-2e5e-495a-9a1d-c1e4229cbbe2" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_758741bd-bbc5-4c45-bfd8-d9539c4657c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_f6b0ef60-8a26-497d-9714-ae61abfc4600" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6c0eeab9-2e5e-495a-9a1d-c1e4229cbbe2" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_f6b0ef60-8a26-497d-9714-ae61abfc4600" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ClinicalStudyPolicyPolicyTextBlock_a3f35ddf-abd8-43bd-84a9-077118d385fd" xlink:href="exdx-20241231.xsd#exdx_ClinicalStudyPolicyPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6c0eeab9-2e5e-495a-9a1d-c1e4229cbbe2" xlink:to="loc_exdx_ClinicalStudyPolicyPolicyTextBlock_a3f35ddf-abd8-43bd-84a9-077118d385fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_2d827481-dc79-4e57-ab09-f78a44db2c62" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6c0eeab9-2e5e-495a-9a1d-c1e4229cbbe2" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_2d827481-dc79-4e57-ab09-f78a44db2c62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesPolicyTextBlock_a5ea7e5a-8a60-4625-bfb5-23955ab710f9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6c0eeab9-2e5e-495a-9a1d-c1e4229cbbe2" xlink:to="loc_us-gaap_ReceivablesPolicyTextBlock_a5ea7e5a-8a60-4625-bfb5-23955ab710f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_91c0498c-3e64-4e2c-8cb4-4f3315eadf72" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6c0eeab9-2e5e-495a-9a1d-c1e4229cbbe2" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_91c0498c-3e64-4e2c-8cb4-4f3315eadf72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingCostsPolicyTextBlock_2b147954-58c2-4eac-91f1-fe743d84447e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdvertisingCostsPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6c0eeab9-2e5e-495a-9a1d-c1e4229cbbe2" xlink:to="loc_us-gaap_AdvertisingCostsPolicyTextBlock_2b147954-58c2-4eac-91f1-fe743d84447e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesPolicyTextBlock_b6922c63-5ba6-4785-83c6-3cd9d8445429" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6c0eeab9-2e5e-495a-9a1d-c1e4229cbbe2" xlink:to="loc_us-gaap_CostOfSalesPolicyTextBlock_b6922c63-5ba6-4785-83c6-3cd9d8445429" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOwnershipPlanESOPPolicy_ee3dccf6-8d13-4225-a857-b78242c7696c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOwnershipPlanESOPPolicy"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6c0eeab9-2e5e-495a-9a1d-c1e4229cbbe2" xlink:to="loc_us-gaap_EmployeeStockOwnershipPlanESOPPolicy_ee3dccf6-8d13-4225-a857-b78242c7696c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_5bf0a632-a7d1-4405-b9f8-ca8290cde0bc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6c0eeab9-2e5e-495a-9a1d-c1e4229cbbe2" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_5bf0a632-a7d1-4405-b9f8-ca8290cde0bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_70f2b248-b3e5-45b6-b28c-165dd30a82f0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6c0eeab9-2e5e-495a-9a1d-c1e4229cbbe2" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_70f2b248-b3e5-45b6-b28c-165dd30a82f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_eb6b56ae-3a10-4058-8339-68eec7c2eb8a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6c0eeab9-2e5e-495a-9a1d-c1e4229cbbe2" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_eb6b56ae-3a10-4058-8339-68eec7c2eb8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_07915fa6-91a9-4ae2-82b7-f926ea4c5894" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6c0eeab9-2e5e-495a-9a1d-c1e4229cbbe2" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_07915fa6-91a9-4ae2-82b7-f926ea4c5894" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_82aa1f9c-d608-4af5-beea-eec678c5ee90" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6c0eeab9-2e5e-495a-9a1d-c1e4229cbbe2" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_82aa1f9c-d608-4af5-beea-eec678c5ee90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="exdx-20241231.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_7038d721-c4c5-4e3b-9515-55cc458bc203" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_c23b25e3-a443-47a0-9937-4e6dc619ceda" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7038d721-c4c5-4e3b-9515-55cc458bc203" xlink:to="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_c23b25e3-a443-47a0-9937-4e6dc619ceda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_47eff6e2-a094-4190-8ce1-3a2659b16edc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7038d721-c4c5-4e3b-9515-55cc458bc203" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_47eff6e2-a094-4190-8ce1-3a2659b16edc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_2a3f9327-c597-4a33-b8de-63ff663da8e2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7038d721-c4c5-4e3b-9515-55cc458bc203" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_2a3f9327-c597-4a33-b8de-63ff663da8e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_922d87d7-9ecf-4f52-9b13-72b17afe8b0d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7038d721-c4c5-4e3b-9515-55cc458bc203" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_922d87d7-9ecf-4f52-9b13-72b17afe8b0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_0f2537e8-f86b-44ea-bf4b-a317aa5496f8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7038d721-c4c5-4e3b-9515-55cc458bc203" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_0f2537e8-f86b-44ea-bf4b-a317aa5496f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/OtherFinancialInformationTables" xlink:type="simple" xlink:href="exdx-20241231.xsd#OtherFinancialInformationTables"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/OtherFinancialInformationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OtherFinancialInformationAbstract_a14158e1-e876-4918-ba66-a569ed195a20" xlink:href="exdx-20241231.xsd#exdx_OtherFinancialInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_82b5d22d-944d-494d-80fc-2dca8886b0fe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_a14158e1-e876-4918-ba66-a569ed195a20" xlink:to="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_82b5d22d-944d-494d-80fc-2dca8886b0fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_0785015c-4f23-4f1e-9bce-4e41221f4304" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_a14158e1-e876-4918-ba66-a569ed195a20" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_0785015c-4f23-4f1e-9bce-4e41221f4304" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_60f591df-bf8e-4139-ba3b-5cf3dbe48a14" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_a14158e1-e876-4918-ba66-a569ed195a20" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_60f591df-bf8e-4139-ba3b-5cf3dbe48a14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/BorrowingsTables" xlink:type="simple" xlink:href="exdx-20241231.xsd#BorrowingsTables"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/BorrowingsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_af36c3dc-42fc-49b8-b8d9-b9ca48b42f79" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_7bf25f1f-c1bc-44ee-a2fd-df995da4b795" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_af36c3dc-42fc-49b8-b8d9-b9ca48b42f79" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_7bf25f1f-c1bc-44ee-a2fd-df995da4b795" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/LeasesTables" xlink:type="simple" xlink:href="exdx-20241231.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_ea983588-1e43-4d14-a629-55d03c2f2f7e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_36805d80-8d55-4f22-8c3b-608894459d86" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ea983588-1e43-4d14-a629-55d03c2f2f7e" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_36805d80-8d55-4f22-8c3b-608894459d86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_5e4e5ad3-076f-472f-8143-fa1ad406bc50" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ea983588-1e43-4d14-a629-55d03c2f2f7e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_5e4e5ad3-076f-472f-8143-fa1ad406bc50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_588e82a1-fbfc-4a63-8ed1-a8b85cab466f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ea983588-1e43-4d14-a629-55d03c2f2f7e" xlink:to="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_588e82a1-fbfc-4a63-8ed1-a8b85cab466f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="exdx-20241231.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_8ed04e59-2345-49d8-bce7-ce81490336bd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_b19df6c3-1326-47cc-a76c-99591942f947" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_8ed04e59-2345-49d8-bce7-ce81490336bd" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_b19df6c3-1326-47cc-a76c-99591942f947" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="exdx-20241231.xsd#StockholdersEquityTables"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/StockholdersEquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_2453411f-8c35-43f0-98fb-60ce73b0c890" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_a7bd2ec3-b8ea-47dd-bf73-0f79b4c84c3e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_2453411f-8c35-43f0-98fb-60ce73b0c890" xlink:to="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_a7bd2ec3-b8ea-47dd-bf73-0f79b4c84c3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StockOptionPlanTables" xlink:type="simple" xlink:href="exdx-20241231.xsd#StockOptionPlanTables"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/StockOptionPlanTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1092b581-7016-4cdb-ba57-3f2250215b78" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_f9d1baa7-94cb-4bcc-961d-022bb21a5d83" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1092b581-7016-4cdb-ba57-3f2250215b78" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_f9d1baa7-94cb-4bcc-961d-022bb21a5d83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_aaccbd84-a946-4f42-858d-c368e2c774f3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1092b581-7016-4cdb-ba57-3f2250215b78" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_aaccbd84-a946-4f42-858d-c368e2c774f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_db59b24e-dd49-42a6-85d5-7be7b7295e6c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1092b581-7016-4cdb-ba57-3f2250215b78" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_db59b24e-dd49-42a6-85d5-7be7b7295e6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_2edfc7d5-e03c-42e7-a452-193a39134c2b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1092b581-7016-4cdb-ba57-3f2250215b78" xlink:to="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_2edfc7d5-e03c-42e7-a452-193a39134c2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="exdx-20241231.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_83e057da-54d1-47c8-ac34-5f70ad3c5aef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_5b30aaf9-5fa0-41a0-ae7f-41a6b4893827" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_83e057da-54d1-47c8-ac34-5f70ad3c5aef" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_5b30aaf9-5fa0-41a0-ae7f-41a6b4893827" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_79bc103f-3761-4f60-aa41-de9a45c34e46" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_83e057da-54d1-47c8-ac34-5f70ad3c5aef" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_79bc103f-3761-4f60-aa41-de9a45c34e46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_198775a5-7f0f-4694-9e32-52db31f8cf61" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_83e057da-54d1-47c8-ac34-5f70ad3c5aef" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_198775a5-7f0f-4694-9e32-52db31f8cf61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfValuationAllowanceTextBlock_501c28a5-e7de-4343-aaf3-2243a7d40592" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_83e057da-54d1-47c8-ac34-5f70ad3c5aef" xlink:to="loc_us-gaap_SummaryOfValuationAllowanceTextBlock_501c28a5-e7de-4343-aaf3-2243a7d40592" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/SegmentReportingTables" xlink:type="simple" xlink:href="exdx-20241231.xsd#SegmentReportingTables"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/SegmentReportingTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_515819ea-dfd2-497f-9752-83ac8656161d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_98747854-0c36-4c89-a47c-6957f2134904" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_515819ea-dfd2-497f-9752-83ac8656161d" xlink:to="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_98747854-0c36-4c89-a47c-6957f2134904" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/OrganizationDetails" xlink:type="simple" xlink:href="exdx-20241231.xsd#OrganizationDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/OrganizationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_462045fa-d570-4746-bb34-270ed590ebda" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_929315da-3eb5-44d4-b75b-84b83536e5e3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_462045fa-d570-4746-bb34-270ed590ebda" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_929315da-3eb5-44d4-b75b-84b83536e5e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_1919cdd6-2252-4c42-9437-4110ac0d8d6f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_462045fa-d570-4746-bb34-270ed590ebda" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_1919cdd6-2252-4c42-9437-4110ac0d8d6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails" xlink:type="simple" xlink:href="exdx-20241231.xsd#SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_dcb4b723-fc4d-48eb-aff9-4bf459ea9f1a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_dacb8bb9-5afe-4b61-b7b4-9d9e08568e0b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_dcb4b723-fc4d-48eb-aff9-4bf459ea9f1a" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_dacb8bb9-5afe-4b61-b7b4-9d9e08568e0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_53e7d71c-85da-4491-b2e7-f1e11dfa1c0f" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_dacb8bb9-5afe-4b61-b7b4-9d9e08568e0b" xlink:to="loc_srt_MajorCustomersAxis_53e7d71c-85da-4491-b2e7-f1e11dfa1c0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_ac3de328-2fe0-44ce-897f-fcaeb9640972" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_53e7d71c-85da-4491-b2e7-f1e11dfa1c0f" xlink:to="loc_srt_NameOfMajorCustomerDomain_ac3de328-2fe0-44ce-897f-fcaeb9640972" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_MedicareMember_80605c37-d111-4d76-90b7-e6d8a37da148" xlink:href="exdx-20241231.xsd#exdx_MedicareMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_ac3de328-2fe0-44ce-897f-fcaeb9640972" xlink:to="loc_exdx_MedicareMember_80605c37-d111-4d76-90b7-e6d8a37da148" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_MedicareAdvantageMember_7e6224b5-f5de-4b75-9023-b5cb8d5b88ce" xlink:href="exdx-20241231.xsd#exdx_MedicareAdvantageMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_ac3de328-2fe0-44ce-897f-fcaeb9640972" xlink:to="loc_exdx_MedicareAdvantageMember_7e6224b5-f5de-4b75-9023-b5cb8d5b88ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_UnitedHealthcareMember_b16610de-8063-4e36-a4e1-524c52b5d0fe" xlink:href="exdx-20241231.xsd#exdx_UnitedHealthcareMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_ac3de328-2fe0-44ce-897f-fcaeb9640972" xlink:to="loc_exdx_UnitedHealthcareMember_b16610de-8063-4e36-a4e1-524c52b5d0fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_4c1f2ecc-95f7-4671-9ceb-cad066c41c24" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_dacb8bb9-5afe-4b61-b7b4-9d9e08568e0b" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_4c1f2ecc-95f7-4671-9ceb-cad066c41c24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_904ade9d-8e00-4eae-88a5-351bafad6d0c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_4c1f2ecc-95f7-4671-9ceb-cad066c41c24" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_904ade9d-8e00-4eae-88a5-351bafad6d0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_3195a757-dea7-4fdd-9e4f-ff3a98498c91" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_904ade9d-8e00-4eae-88a5-351bafad6d0c" xlink:to="loc_us-gaap_SalesRevenueNetMember_3195a757-dea7-4fdd-9e4f-ff3a98498c91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_af331243-1c63-438f-ba4b-09328fabe212" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_904ade9d-8e00-4eae-88a5-351bafad6d0c" xlink:to="loc_us-gaap_AccountsReceivableMember_af331243-1c63-438f-ba4b-09328fabe212" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_acd92da5-9f2a-4a93-8d87-6627b0003691" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_dacb8bb9-5afe-4b61-b7b4-9d9e08568e0b" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_acd92da5-9f2a-4a93-8d87-6627b0003691" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_a6e77280-bf44-447f-8ace-71b16a5c8bbd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_acd92da5-9f2a-4a93-8d87-6627b0003691" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_a6e77280-bf44-447f-8ace-71b16a5c8bbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_818437f3-4834-4b00-b48e-3a4c487574c9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_a6e77280-bf44-447f-8ace-71b16a5c8bbd" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_818437f3-4834-4b00-b48e-3a4c487574c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_9a1f1a53-48df-4ce8-83fb-75b279c7c75b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_dacb8bb9-5afe-4b61-b7b4-9d9e08568e0b" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_9a1f1a53-48df-4ce8-83fb-75b279c7c75b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_ba612f07-2533-41a7-b897-5b28f07a34f8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9a1f1a53-48df-4ce8-83fb-75b279c7c75b" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_ba612f07-2533-41a7-b897-5b28f07a34f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="exdx-20241231.xsd#SummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_ad15c3e2-bffb-409e-ace2-5092b17b7d20" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_9455c93b-8cc9-431d-b69b-ca1eaccb8f98" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ad15c3e2-bffb-409e-ace2-5092b17b7d20" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_9455c93b-8cc9-431d-b69b-ca1eaccb8f98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a688464d-3311-4b42-b284-9fed0ca79b65" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_9455c93b-8cc9-431d-b69b-ca1eaccb8f98" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a688464d-3311-4b42-b284-9fed0ca79b65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_bcd12684-c0a6-4b46-8b88-35f50b7c6b90" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a688464d-3311-4b42-b284-9fed0ca79b65" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_bcd12684-c0a6-4b46-8b88-35f50b7c6b90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_4e1d5cdd-fa42-46c6-a301-bed233d7b4a3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_bcd12684-c0a6-4b46-8b88-35f50b7c6b90" xlink:to="loc_us-gaap_SalesRevenueNetMember_4e1d5cdd-fa42-46c6-a301-bed233d7b4a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_ddf3febc-564d-4199-b420-5a83b5baa424" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_9455c93b-8cc9-431d-b69b-ca1eaccb8f98" xlink:to="loc_srt_ProductOrServiceAxis_ddf3febc-564d-4199-b420-5a83b5baa424" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_727aabe5-bcbf-4498-bd27-193cf395e887" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_ddf3febc-564d-4199-b420-5a83b5baa424" xlink:to="loc_srt_ProductsAndServicesDomain_727aabe5-bcbf-4498-bd27-193cf395e887" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AVISECTDTestMember_4237daf3-630e-4a2c-befa-23ced963c907" xlink:href="exdx-20241231.xsd#exdx_AVISECTDTestMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_727aabe5-bcbf-4498-bd27-193cf395e887" xlink:to="loc_exdx_AVISECTDTestMember_4237daf3-630e-4a2c-befa-23ced963c907" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShippingAndHandlingMember_194ef6ba-cc88-4a07-88da-fab27b62abc3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShippingAndHandlingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_727aabe5-bcbf-4498-bd27-193cf395e887" xlink:to="loc_us-gaap_ShippingAndHandlingMember_194ef6ba-cc88-4a07-88da-fab27b62abc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_0affd1bf-6b29-488d-8fd0-b0405fc8bfe6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_9455c93b-8cc9-431d-b69b-ca1eaccb8f98" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_0affd1bf-6b29-488d-8fd0-b0405fc8bfe6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_4e585fdf-b598-4de3-b569-badc1799c59f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_0affd1bf-6b29-488d-8fd0-b0405fc8bfe6" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_4e585fdf-b598-4de3-b569-badc1799c59f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember_e64adf5a-b136-4a50-90e8-2140285c57a8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_4e585fdf-b598-4de3-b569-badc1799c59f" xlink:to="loc_us-gaap_ProductConcentrationRiskMember_e64adf5a-b136-4a50-90e8-2140285c57a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplierConcentrationRiskMember_2663d25e-63c8-4465-82ca-7bad127b3257" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplierConcentrationRiskMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_4e585fdf-b598-4de3-b569-badc1799c59f" xlink:to="loc_us-gaap_SupplierConcentrationRiskMember_2663d25e-63c8-4465-82ca-7bad127b3257" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_1d6535a2-7079-4447-9453-10fe3f783dde" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_9455c93b-8cc9-431d-b69b-ca1eaccb8f98" xlink:to="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_1d6535a2-7079-4447-9453-10fe3f783dde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_a4113f74-85a0-4d02-b13e-edaa8dec7ac4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_1d6535a2-7079-4447-9453-10fe3f783dde" xlink:to="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_a4113f74-85a0-4d02-b13e-edaa8dec7ac4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_SupplierOneMember_9064a1e9-8d55-4263-be97-cd517db42152" xlink:href="exdx-20241231.xsd#exdx_SupplierOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_a4113f74-85a0-4d02-b13e-edaa8dec7ac4" xlink:to="loc_exdx_SupplierOneMember_9064a1e9-8d55-4263-be97-cd517db42152" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_SupplierTwoMember_5d286bc7-1d94-415b-90d1-4914140b5668" xlink:href="exdx-20241231.xsd#exdx_SupplierTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_a4113f74-85a0-4d02-b13e-edaa8dec7ac4" xlink:to="loc_exdx_SupplierTwoMember_5d286bc7-1d94-415b-90d1-4914140b5668" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_b67ce9bd-cd69-494f-a5e5-96099397d312" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_9455c93b-8cc9-431d-b69b-ca1eaccb8f98" xlink:to="loc_srt_RangeAxis_b67ce9bd-cd69-494f-a5e5-96099397d312" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d14128f9-29f5-4d2a-8244-9048f97fd5a2" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_b67ce9bd-cd69-494f-a5e5-96099397d312" xlink:to="loc_srt_RangeMember_d14128f9-29f5-4d2a-8244-9048f97fd5a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_bc0d9dd6-6050-4d10-8975-a59b6f825ccd" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_d14128f9-29f5-4d2a-8244-9048f97fd5a2" xlink:to="loc_srt_MinimumMember_bc0d9dd6-6050-4d10-8975-a59b6f825ccd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_4ad4aab6-e9e3-4537-a85b-9af4f30c663f" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_d14128f9-29f5-4d2a-8244-9048f97fd5a2" xlink:to="loc_srt_MaximumMember_4ad4aab6-e9e3-4537-a85b-9af4f30c663f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_bb77835e-452f-4fe6-a120-c8e0539e3886" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_9455c93b-8cc9-431d-b69b-ca1eaccb8f98" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_bb77835e-452f-4fe6-a120-c8e0539e3886" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_49fb9621-a89f-4436-b0bc-6124c195ede6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_bb77835e-452f-4fe6-a120-c8e0539e3886" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_49fb9621-a89f-4436-b0bc-6124c195ede6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_85f61537-4c3d-43b3-a57c-54b9e10ea29e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCash"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_bb77835e-452f-4fe6-a120-c8e0539e3886" xlink:to="loc_us-gaap_RestrictedCash_85f61537-4c3d-43b3-a57c-54b9e10ea29e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_ea1ba37b-3f78-4301-90dd-e5999b4249cd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_bb77835e-452f-4fe6-a120-c8e0539e3886" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_ea1ba37b-3f78-4301-90dd-e5999b4249cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_30e8dc9d-6d79-4180-b6a2-d6ef874d6d2b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_bb77835e-452f-4fe6-a120-c8e0539e3886" xlink:to="loc_us-gaap_NumberOfOperatingSegments_30e8dc9d-6d79-4180-b6a2-d6ef874d6d2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportingUnits_51247100-e974-4f17-9c52-e18f991b9467" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportingUnits"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_bb77835e-452f-4fe6-a120-c8e0539e3886" xlink:to="loc_us-gaap_NumberOfReportingUnits_51247100-e974-4f17-9c52-e18f991b9467" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_d9c6ed24-a0b4-4155-ae2a-12c11f7a7e93" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_bb77835e-452f-4fe6-a120-c8e0539e3886" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_d9c6ed24-a0b4-4155-ae2a-12c11f7a7e93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivableAllowanceForCreditLossExcludingAccruedInterest_a9880fa7-952b-4d55-8206-0be535dd30fc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancingReceivableAllowanceForCreditLossExcludingAccruedInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_bb77835e-452f-4fe6-a120-c8e0539e3886" xlink:to="loc_us-gaap_FinancingReceivableAllowanceForCreditLossExcludingAccruedInterest_a9880fa7-952b-4d55-8206-0be535dd30fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_4732d7de-cd19-4598-ba66-7ad82afd9c6d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_bb77835e-452f-4fe6-a120-c8e0539e3886" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_4732d7de-cd19-4598-ba66-7ad82afd9c6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense_c12a6dae-0305-4f5f-8f2e-46090b72bdbd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdvertisingExpense"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_bb77835e-452f-4fe6-a120-c8e0539e3886" xlink:to="loc_us-gaap_AdvertisingExpense_c12a6dae-0305-4f5f-8f2e-46090b72bdbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_f361f130-060c-4720-95d8-b0be556614ae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfRevenue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_bb77835e-452f-4fe6-a120-c8e0539e3886" xlink:to="loc_us-gaap_CostOfRevenue_f361f130-060c-4720-95d8-b0be556614ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments_b9034c21-ff7f-4d31-920b-a8c3aaf3368c" xlink:href="exdx-20241231.xsd#exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_bb77835e-452f-4fe6-a120-c8e0539e3886" xlink:to="loc_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments_b9034c21-ff7f-4d31-920b-a8c3aaf3368c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails" xlink:type="simple" xlink:href="exdx-20241231.xsd#SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_6c1aca63-195a-42be-9ab8-bd668854e932" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_5c5970f8-7bb6-4811-8e53-595c1c8cb806" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6c1aca63-195a-42be-9ab8-bd668854e932" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_5c5970f8-7bb6-4811-8e53-595c1c8cb806" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_262f6643-a941-458b-8022-b2ebf41406cf" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_5c5970f8-7bb6-4811-8e53-595c1c8cb806" xlink:to="loc_srt_MajorCustomersAxis_262f6643-a941-458b-8022-b2ebf41406cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_beb95adb-ca85-4311-8df1-721c82da213a" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_262f6643-a941-458b-8022-b2ebf41406cf" xlink:to="loc_srt_NameOfMajorCustomerDomain_beb95adb-ca85-4311-8df1-721c82da213a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_CommercialMember_8c881c1d-4cf0-4e20-9a42-ab4ff9e2c5f3" xlink:href="exdx-20241231.xsd#exdx_CommercialMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_beb95adb-ca85-4311-8df1-721c82da213a" xlink:to="loc_exdx_CommercialMember_8c881c1d-4cf0-4e20-9a42-ab4ff9e2c5f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_Government1Member_172f08be-9ec5-4adb-b3ce-93186c5b7a07" xlink:href="exdx-20241231.xsd#exdx_Government1Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_beb95adb-ca85-4311-8df1-721c82da213a" xlink:to="loc_exdx_Government1Member_172f08be-9ec5-4adb-b3ce-93186c5b7a07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ClientMember_b9d8865d-cad9-4669-a09b-404a9a564276" xlink:href="exdx-20241231.xsd#exdx_ClientMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_beb95adb-ca85-4311-8df1-721c82da213a" xlink:to="loc_exdx_ClientMember_b9d8865d-cad9-4669-a09b-404a9a564276" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCustomerMember_29f2804e-c4b5-4473-a116-b160fb96afa4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCustomerMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_beb95adb-ca85-4311-8df1-721c82da213a" xlink:to="loc_us-gaap_OtherCustomerMember_29f2804e-c4b5-4473-a116-b160fb96afa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_da7c2885-e4af-44d6-8ea5-3d161a934e64" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_5c5970f8-7bb6-4811-8e53-595c1c8cb806" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_da7c2885-e4af-44d6-8ea5-3d161a934e64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f7ccebc0-9bbb-449b-9da8-fbd35d5500d3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_da7c2885-e4af-44d6-8ea5-3d161a934e64" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f7ccebc0-9bbb-449b-9da8-fbd35d5500d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails" xlink:type="simple" xlink:href="exdx-20241231.xsd#SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_88072cf8-344a-4e9b-abe9-7114cbaa17dc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_004c85be-2db0-4024-9c64-5e86121b1e9f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_88072cf8-344a-4e9b-abe9-7114cbaa17dc" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_004c85be-2db0-4024-9c64-5e86121b1e9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_f244970c-2e46-41b4-a537-d99125713225" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCash"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_88072cf8-344a-4e9b-abe9-7114cbaa17dc" xlink:to="loc_us-gaap_RestrictedCash_f244970c-2e46-41b4-a537-d99125713225" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_99c5ff91-7260-475e-aaab-6ace8bbfb84b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_88072cf8-344a-4e9b-abe9-7114cbaa17dc" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_99c5ff91-7260-475e-aaab-6ace8bbfb84b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesSecuritiesDetails" xlink:type="simple" xlink:href="exdx-20241231.xsd#SummaryofSignificantAccountingPoliciesSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_d7c08c7f-26cf-45dd-a4db-cc72d9eaf765" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_930c8bd2-ccdf-4628-a200-e91d78596421" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d7c08c7f-26cf-45dd-a4db-cc72d9eaf765" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_930c8bd2-ccdf-4628-a200-e91d78596421" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_44641418-315c-4166-910b-6a7128b13cda" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_930c8bd2-ccdf-4628-a200-e91d78596421" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_44641418-315c-4166-910b-6a7128b13cda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_15596d88-ce7b-433d-809a-62f34a7b66b3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_44641418-315c-4166-910b-6a7128b13cda" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_15596d88-ce7b-433d-809a-62f34a7b66b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_005f4e83-3f7e-4b5b-abfd-65ee08ea7b47" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_15596d88-ce7b-433d-809a-62f34a7b66b3" xlink:to="loc_us-gaap_WarrantMember_005f4e83-3f7e-4b5b-abfd-65ee08ea7b47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember_de2f811f-f3b6-40e0-bd3c-1b3c1ec7a1b8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_15596d88-ce7b-433d-809a-62f34a7b66b3" xlink:to="loc_us-gaap_StockOptionMember_de2f811f-f3b6-40e0-bd3c-1b3c1ec7a1b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_2451bc1e-8fe4-4cb4-869f-59b674610067" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_15596d88-ce7b-433d-809a-62f34a7b66b3" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_2451bc1e-8fe4-4cb4-869f-59b674610067" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_8152f953-2072-4271-a9db-d31ac922a5f5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_15596d88-ce7b-433d-809a-62f34a7b66b3" xlink:to="loc_us-gaap_EmployeeStockMember_8152f953-2072-4271-a9db-d31ac922a5f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_21012c7c-63ff-434e-826f-6e6d5388aca1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_930c8bd2-ccdf-4628-a200-e91d78596421" xlink:to="loc_us-gaap_ClassOfStockLineItems_21012c7c-63ff-434e-826f-6e6d5388aca1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_53f1b2e6-fb82-426c-b56b-22c036d7fbcd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_21012c7c-63ff-434e-826f-6e6d5388aca1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_53f1b2e6-fb82-426c-b56b-22c036d7fbcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/OtherFinancialInformationPrepaidExpensesDetails" xlink:type="simple" xlink:href="exdx-20241231.xsd#OtherFinancialInformationPrepaidExpensesDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/OtherFinancialInformationPrepaidExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OtherFinancialInformationAbstract_dbbf49c2-40ff-4c68-8d67-676d4af88623" xlink:href="exdx-20241231.xsd#exdx_OtherFinancialInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_efe20132-53cd-4b94-b2ec-e9446b5ed927" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_dbbf49c2-40ff-4c68-8d67-676d4af88623" xlink:to="loc_us-gaap_OtherAssetsCurrent_efe20132-53cd-4b94-b2ec-e9446b5ed927" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent_81421916-ca1c-4f83-9f9b-c2d344a51715" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_dbbf49c2-40ff-4c68-8d67-676d4af88623" xlink:to="loc_us-gaap_OtherPrepaidExpenseCurrent_81421916-ca1c-4f83-9f9b-c2d344a51715" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_7b1448f7-7e60-4af7-9d4a-78f4ba6447d6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_dbbf49c2-40ff-4c68-8d67-676d4af88623" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_7b1448f7-7e60-4af7-9d4a-78f4ba6447d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/OtherFinancialInformationPropertyandEquipmentNetDetails" xlink:type="simple" xlink:href="exdx-20241231.xsd#OtherFinancialInformationPropertyandEquipmentNetDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/OtherFinancialInformationPropertyandEquipmentNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OtherFinancialInformationAbstract_c728efaf-d788-4684-a795-d6c084401e48" xlink:href="exdx-20241231.xsd#exdx_OtherFinancialInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_41cf2598-5072-4f37-b2f1-e6836b171896" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_c728efaf-d788-4684-a795-d6c084401e48" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_41cf2598-5072-4f37-b2f1-e6836b171896" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_7f6f51e8-6a84-4fe9-8acb-7dffb87bc19e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_41cf2598-5072-4f37-b2f1-e6836b171896" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_7f6f51e8-6a84-4fe9-8acb-7dffb87bc19e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9214cf6b-fd1d-453c-a8f9-102c66198074" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_7f6f51e8-6a84-4fe9-8acb-7dffb87bc19e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9214cf6b-fd1d-453c-a8f9-102c66198074" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_3daddaaa-c1c8-4a46-892a-f036296f10a8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9214cf6b-fd1d-453c-a8f9-102c66198074" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_3daddaaa-c1c8-4a46-892a-f036296f10a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_LaboratoryEquipmentMember_ea7926a1-4495-4db0-ae6b-c06f31e48669" xlink:href="exdx-20241231.xsd#exdx_LaboratoryEquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9214cf6b-fd1d-453c-a8f9-102c66198074" xlink:to="loc_exdx_LaboratoryEquipmentMember_ea7926a1-4495-4db0-ae6b-c06f31e48669" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ComputerEquipmentAndSoftwareMember_3fe084d4-81cd-4483-b746-ecc07d8777c7" xlink:href="exdx-20241231.xsd#exdx_ComputerEquipmentAndSoftwareMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9214cf6b-fd1d-453c-a8f9-102c66198074" xlink:to="loc_exdx_ComputerEquipmentAndSoftwareMember_3fe084d4-81cd-4483-b746-ecc07d8777c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_d0e63e7c-5903-46d1-b676-f4f4469f343c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9214cf6b-fd1d-453c-a8f9-102c66198074" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_d0e63e7c-5903-46d1-b676-f4f4469f343c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_75ff2140-946a-4a32-8a4e-4645c4f263b1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9214cf6b-fd1d-453c-a8f9-102c66198074" xlink:to="loc_us-gaap_ConstructionInProgressMember_75ff2140-946a-4a32-8a4e-4645c4f263b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_01c1ef8c-8fda-41ab-90f3-60c85bd51805" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_41cf2598-5072-4f37-b2f1-e6836b171896" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_01c1ef8c-8fda-41ab-90f3-60c85bd51805" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_51efd51e-44c5-4cbd-a6eb-cef8cc965326" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_01c1ef8c-8fda-41ab-90f3-60c85bd51805" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_51efd51e-44c5-4cbd-a6eb-cef8cc965326" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_e7314019-1e83-467b-b756-723cb8f3f771" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_01c1ef8c-8fda-41ab-90f3-60c85bd51805" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_e7314019-1e83-467b-b756-723cb8f3f771" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_483047f1-3778-42ee-9a52-55c915542680" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_01c1ef8c-8fda-41ab-90f3-60c85bd51805" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_483047f1-3778-42ee-9a52-55c915542680" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/OtherFinancialInformationNarrativeDetails" xlink:type="simple" xlink:href="exdx-20241231.xsd#OtherFinancialInformationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/OtherFinancialInformationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OtherFinancialInformationAbstract_5d865a68-a2c1-49ba-9a84-0db24154ceb0" xlink:href="exdx-20241231.xsd#exdx_OtherFinancialInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_73074f1e-24be-4ac3-aa89-611a6de2d67c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_5d865a68-a2c1-49ba-9a84-0db24154ceb0" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_73074f1e-24be-4ac3-aa89-611a6de2d67c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c8e207cc-6f01-4ed8-9451-b95a2909c184" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_73074f1e-24be-4ac3-aa89-611a6de2d67c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c8e207cc-6f01-4ed8-9451-b95a2909c184" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0b2b354e-0779-4331-aedc-08a1fb3e30e9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c8e207cc-6f01-4ed8-9451-b95a2909c184" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0b2b354e-0779-4331-aedc-08a1fb3e30e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_20de3730-58e7-4172-848c-c98f6dcd6159" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BuildingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0b2b354e-0779-4331-aedc-08a1fb3e30e9" xlink:to="loc_us-gaap_BuildingMember_20de3730-58e7-4172-848c-c98f6dcd6159" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c240ee88-1ee6-45ef-b0e0-a6015c7daff8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_73074f1e-24be-4ac3-aa89-611a6de2d67c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c240ee88-1ee6-45ef-b0e0-a6015c7daff8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_a4b5e6a1-efad-4f27-8a73-aac4401ab26c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c240ee88-1ee6-45ef-b0e0-a6015c7daff8" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_a4b5e6a1-efad-4f27-8a73-aac4401ab26c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_cd24c26b-aa2d-4ee0-bcee-23cbcb56d4d5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c240ee88-1ee6-45ef-b0e0-a6015c7daff8" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_cd24c26b-aa2d-4ee0-bcee-23cbcb56d4d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_01e2576f-3b1d-4288-a965-a6b840150b12" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c240ee88-1ee6-45ef-b0e0-a6015c7daff8" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_01e2576f-3b1d-4288-a965-a6b840150b12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_b32bf8ce-a34f-43ab-b719-1834b810915c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c240ee88-1ee6-45ef-b0e0-a6015c7daff8" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_b32bf8ce-a34f-43ab-b719-1834b810915c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsGross_d3204a3a-a34d-4524-a28c-32a3b1dd479e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsGross"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c240ee88-1ee6-45ef-b0e0-a6015c7daff8" xlink:to="loc_us-gaap_LeaseholdImprovementsGross_d3204a3a-a34d-4524-a28c-32a3b1dd479e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_GainLossOnDispositionOfLeaseAssignment_731a57ac-355b-4cb4-9b44-65d8c788976f" xlink:href="exdx-20241231.xsd#exdx_GainLossOnDispositionOfLeaseAssignment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c240ee88-1ee6-45ef-b0e0-a6015c7daff8" xlink:to="loc_exdx_GainLossOnDispositionOfLeaseAssignment_731a57ac-355b-4cb4-9b44-65d8c788976f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/OtherFinancialInformationAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="exdx-20241231.xsd#OtherFinancialInformationAccruedLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/OtherFinancialInformationAccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OtherFinancialInformationAbstract_10aa14f2-a8ba-4d6e-87e0-9216c0aee964" xlink:href="exdx-20241231.xsd#exdx_OtherFinancialInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalariesCurrent_e26b9a28-7ae4-4145-be18-3c0757c0e933" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedSalariesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_10aa14f2-a8ba-4d6e-87e0-9216c0aee964" xlink:to="loc_us-gaap_AccruedSalariesCurrent_e26b9a28-7ae4-4145-be18-3c0757c0e933" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_745ca45a-47da-45f5-b949-3498d68f0530" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_10aa14f2-a8ba-4d6e-87e0-9216c0aee964" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_745ca45a-47da-45f5-b949-3498d68f0530" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_3ccce432-3611-4e60-93f5-b4c2fec8cf71" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_10aa14f2-a8ba-4d6e-87e0-9216c0aee964" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_3ccce432-3611-4e60-93f5-b4c2fec8cf71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/BorrowingsNarrativeDetails" xlink:type="simple" xlink:href="exdx-20241231.xsd#BorrowingsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/BorrowingsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_9a728281-99c9-413d-a994-10657f3681c9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_93f75f41-96cd-45c2-a8e4-372b88874308" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_9a728281-99c9-413d-a994-10657f3681c9" xlink:to="loc_us-gaap_DebtInstrumentTable_93f75f41-96cd-45c2-a8e4-372b88874308" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_d1e89647-8be8-4a80-8d22-4679e03562ec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_93f75f41-96cd-45c2-a8e4-372b88874308" xlink:to="loc_us-gaap_DebtInstrumentAxis_d1e89647-8be8-4a80-8d22-4679e03562ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_e4b9e374-4085-4777-a278-925a9898070d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_d1e89647-8be8-4a80-8d22-4679e03562ec" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_e4b9e374-4085-4777-a278-925a9898070d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AmendedLoanAgreementMember_d44151e8-5274-4ee9-b3f8-8d9c3001a969" xlink:href="exdx-20241231.xsd#exdx_AmendedLoanAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e4b9e374-4085-4777-a278-925a9898070d" xlink:to="loc_exdx_AmendedLoanAgreementMember_d44151e8-5274-4ee9-b3f8-8d9c3001a969" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_Term2017Member_5e3d2754-d679-4e14-92bb-ce1d952cf720" xlink:href="exdx-20241231.xsd#exdx_Term2017Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e4b9e374-4085-4777-a278-925a9898070d" xlink:to="loc_exdx_Term2017Member_5e3d2754-d679-4e14-92bb-ce1d952cf720" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_EquipmentNotesPayableMember_6d20a9e6-ec12-45f5-9c83-e3a8a19961bb" xlink:href="exdx-20241231.xsd#exdx_EquipmentNotesPayableMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e4b9e374-4085-4777-a278-925a9898070d" xlink:to="loc_exdx_EquipmentNotesPayableMember_6d20a9e6-ec12-45f5-9c83-e3a8a19961bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_c6716e1b-2395-4f1d-bf29-963b64533ed0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_93f75f41-96cd-45c2-a8e4-372b88874308" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_c6716e1b-2395-4f1d-bf29-963b64533ed0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_2ea646bf-1725-46a5-9d39-bd4a2492f003" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_c6716e1b-2395-4f1d-bf29-963b64533ed0" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_2ea646bf-1725-46a5-9d39-bd4a2492f003" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_InnovatusLifeSciencesLendingFundMember_f1d82b30-4b5d-4b89-b9cc-0b9366c73c4a" xlink:href="exdx-20241231.xsd#exdx_InnovatusLifeSciencesLendingFundMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_2ea646bf-1725-46a5-9d39-bd4a2492f003" xlink:to="loc_exdx_InnovatusLifeSciencesLendingFundMember_f1d82b30-4b5d-4b89-b9cc-0b9366c73c4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_1f1f3ee7-b1b4-4dad-bf91-0629bf9f60a7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_93f75f41-96cd-45c2-a8e4-372b88874308" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_1f1f3ee7-b1b4-4dad-bf91-0629bf9f60a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_5047184c-227c-422a-872f-07ebd8cabdb2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1f1f3ee7-b1b4-4dad-bf91-0629bf9f60a7" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_5047184c-227c-422a-872f-07ebd8cabdb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_2eccaf28-c9c2-4653-aa9b-4d4ecaffe2ee" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LoansPayableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_5047184c-227c-422a-872f-07ebd8cabdb2" xlink:to="loc_us-gaap_LoansPayableMember_2eccaf28-c9c2-4653-aa9b-4d4ecaffe2ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentInKindPIKNoteMember_ad1f28aa-ad30-4b99-acbb-da94f8ae64a3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentInKindPIKNoteMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_5047184c-227c-422a-872f-07ebd8cabdb2" xlink:to="loc_us-gaap_PaymentInKindPIKNoteMember_ad1f28aa-ad30-4b99-acbb-da94f8ae64a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_347edc90-fe0b-43a0-8332-1b3770312b5c" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_93f75f41-96cd-45c2-a8e4-372b88874308" xlink:to="loc_srt_RangeAxis_347edc90-fe0b-43a0-8332-1b3770312b5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_748d7d8d-71ce-4a13-ae44-ebdad8e728c9" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_347edc90-fe0b-43a0-8332-1b3770312b5c" xlink:to="loc_srt_RangeMember_748d7d8d-71ce-4a13-ae44-ebdad8e728c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_71d5296f-20e1-4652-a100-f3c4f4908f47" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_748d7d8d-71ce-4a13-ae44-ebdad8e728c9" xlink:to="loc_srt_MinimumMember_71d5296f-20e1-4652-a100-f3c4f4908f47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_26658818-1b2b-4c5e-b7ba-966b7126de37" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_748d7d8d-71ce-4a13-ae44-ebdad8e728c9" xlink:to="loc_srt_MaximumMember_26658818-1b2b-4c5e-b7ba-966b7126de37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_13604e5c-ba24-4350-a12a-c93d0fe7e852" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_93f75f41-96cd-45c2-a8e4-372b88874308" xlink:to="loc_us-gaap_DebtInstrumentLineItems_13604e5c-ba24-4350-a12a-c93d0fe7e852" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_67787900-acd6-4e98-8ea0-24201f4e75aa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_13604e5c-ba24-4350-a12a-c93d0fe7e852" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_67787900-acd6-4e98-8ea0-24201f4e75aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_ca30f983-5148-4edc-9c33-cd4ee1423c93" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_13604e5c-ba24-4350-a12a-c93d0fe7e852" xlink:to="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_ca30f983-5148-4edc-9c33-cd4ee1423c93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_31b34403-d1d4-4398-a456-78cd5de1265c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_13604e5c-ba24-4350-a12a-c93d0fe7e852" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_31b34403-d1d4-4398-a456-78cd5de1265c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_1f2be627-7aca-4ef3-9695-5567278175bc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_13604e5c-ba24-4350-a12a-c93d0fe7e852" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_1f2be627-7aca-4ef3-9695-5567278175bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_991d1205-97f8-4c43-8c20-3d149a8d1d10" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_13604e5c-ba24-4350-a12a-c93d0fe7e852" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_991d1205-97f8-4c43-8c20-3d149a8d1d10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentStatedInterestRatePaidInKind_318ee729-c112-4254-8562-d36444bac8b5" xlink:href="exdx-20241231.xsd#exdx_DebtInstrumentStatedInterestRatePaidInKind"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_13604e5c-ba24-4350-a12a-c93d0fe7e852" xlink:to="loc_exdx_DebtInstrumentStatedInterestRatePaidInKind_318ee729-c112-4254-8562-d36444bac8b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_fd65a865-0d0d-40be-80d6-b00380e4bdeb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_13604e5c-ba24-4350-a12a-c93d0fe7e852" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_fd65a865-0d0d-40be-80d6-b00380e4bdeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentNumberOfMonthlyInstallments_d8945a5b-dbb9-45ae-9923-940df2f16320" xlink:href="exdx-20241231.xsd#exdx_DebtInstrumentNumberOfMonthlyInstallments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_13604e5c-ba24-4350-a12a-c93d0fe7e852" xlink:to="loc_exdx_DebtInstrumentNumberOfMonthlyInstallments_d8945a5b-dbb9-45ae-9923-940df2f16320" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFeeAmount_87c2f09e-1120-4f74-8430-5a965480a99f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFeeAmount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_13604e5c-ba24-4350-a12a-c93d0fe7e852" xlink:to="loc_us-gaap_DebtInstrumentFeeAmount_87c2f09e-1120-4f74-8430-5a965480a99f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentPaidInKindLoansIssued_5c20aec3-1b8d-4f15-8832-f3e6915b0e22" xlink:href="exdx-20241231.xsd#exdx_DebtInstrumentPaidInKindLoansIssued"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_13604e5c-ba24-4350-a12a-c93d0fe7e852" xlink:to="loc_exdx_DebtInstrumentPaidInKindLoansIssued_5c20aec3-1b8d-4f15-8832-f3e6915b0e22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_7c940d47-1d07-4ab3-8a8b-950f7831745e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_13604e5c-ba24-4350-a12a-c93d0fe7e852" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_7c940d47-1d07-4ab3-8a8b-950f7831745e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentCovenantRevenuePerformancePeriod_003434be-899d-422b-94a0-f528e8bc1146" xlink:href="exdx-20241231.xsd#exdx_DebtInstrumentCovenantRevenuePerformancePeriod"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_13604e5c-ba24-4350-a12a-c93d0fe7e852" xlink:to="loc_exdx_DebtInstrumentCovenantRevenuePerformancePeriod_003434be-899d-422b-94a0-f528e8bc1146" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentMinimumCashBalanceRequiredNotRequiredToComplyWithCovenant_b7a1bf82-2c79-414d-a45e-da532c2830a0" xlink:href="exdx-20241231.xsd#exdx_DebtInstrumentMinimumCashBalanceRequiredNotRequiredToComplyWithCovenant"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_13604e5c-ba24-4350-a12a-c93d0fe7e852" xlink:to="loc_exdx_DebtInstrumentMinimumCashBalanceRequiredNotRequiredToComplyWithCovenant_b7a1bf82-2c79-414d-a45e-da532c2830a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentCovenantNumberOfDaysToCureIfPerformanceMeasureIsNotMet_b6be242e-d85f-4e3d-b69d-e5a839f385cb" xlink:href="exdx-20241231.xsd#exdx_DebtInstrumentCovenantNumberOfDaysToCureIfPerformanceMeasureIsNotMet"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_13604e5c-ba24-4350-a12a-c93d0fe7e852" xlink:to="loc_exdx_DebtInstrumentCovenantNumberOfDaysToCureIfPerformanceMeasureIsNotMet_b6be242e-d85f-4e3d-b69d-e5a839f385cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance_76064651-81c0-45ea-bb1c-0ae617d086e9" xlink:href="exdx-20241231.xsd#exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_13604e5c-ba24-4350-a12a-c93d0fe7e852" xlink:to="loc_exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance_76064651-81c0-45ea-bb1c-0ae617d086e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease_a82d8ae2-97d8-47e6-b8c9-e25666649f60" xlink:href="exdx-20241231.xsd#exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_13604e5c-ba24-4350-a12a-c93d0fe7e852" xlink:to="loc_exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease_a82d8ae2-97d8-47e6-b8c9-e25666649f60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayable_cf7adaf1-40ad-4ad8-a3a8-def3b5a17aab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayable"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_13604e5c-ba24-4350-a12a-c93d0fe7e852" xlink:to="loc_us-gaap_NotesPayable_cf7adaf1-40ad-4ad8-a3a8-def3b5a17aab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableCurrent_8d801b43-779b-48d6-91c4-8f9136c648cc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayableCurrent"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_13604e5c-ba24-4350-a12a-c93d0fe7e852" xlink:to="loc_us-gaap_NotesPayableCurrent_8d801b43-779b-48d6-91c4-8f9136c648cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermNotesPayable_4780bfcb-10fc-4214-b55c-030df8a0a75e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermNotesPayable"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_13604e5c-ba24-4350-a12a-c93d0fe7e852" xlink:to="loc_us-gaap_LongTermNotesPayable_4780bfcb-10fc-4214-b55c-030df8a0a75e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/BorrowingsFutureMinimumPaymentsDetails" xlink:type="simple" xlink:href="exdx-20241231.xsd#BorrowingsFutureMinimumPaymentsDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/BorrowingsFutureMinimumPaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_a1f67ebb-6bf2-458b-bf65-fc9bd585a0cd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtByMaturityAbstract_5cc85470-adfe-44fc-9e6d-5b4bab05ed46" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtByMaturityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_a1f67ebb-6bf2-458b-bf65-fc9bd585a0cd" xlink:to="loc_us-gaap_LongTermDebtByMaturityAbstract_5cc85470-adfe-44fc-9e6d-5b4bab05ed46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_50d48555-b656-457b-bcae-d1450cb9d697" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_5cc85470-adfe-44fc-9e6d-5b4bab05ed46" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_50d48555-b656-457b-bcae-d1450cb9d697" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_1486d2df-f333-4da9-8e0b-aee0d57a738f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_5cc85470-adfe-44fc-9e6d-5b4bab05ed46" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_1486d2df-f333-4da9-8e0b-aee0d57a738f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_c614eade-4550-48a5-ad59-d35568f72772" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_5cc85470-adfe-44fc-9e6d-5b4bab05ed46" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_c614eade-4550-48a5-ad59-d35568f72772" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_8725112b-6b38-48b8-b700-08e5dfb33b9d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_5cc85470-adfe-44fc-9e6d-5b4bab05ed46" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_8725112b-6b38-48b8-b700-08e5dfb33b9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_LongTermDebtIncludingUndiscountedInterest_ad73312f-03a8-4b46-b431-ba0591dceeb8" xlink:href="exdx-20241231.xsd#exdx_LongTermDebtIncludingUndiscountedInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_5cc85470-adfe-44fc-9e6d-5b4bab05ed46" xlink:to="loc_exdx_LongTermDebtIncludingUndiscountedInterest_ad73312f-03a8-4b46-b431-ba0591dceeb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_4236c60c-31d3-4478-a3c0-b723046b1100" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_5cc85470-adfe-44fc-9e6d-5b4bab05ed46" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_4236c60c-31d3-4478-a3c0-b723046b1100" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_LongTermDebtUndiscountedInterestAmount_40f43383-4165-4409-90e9-a66b163eadea" xlink:href="exdx-20241231.xsd#exdx_LongTermDebtUndiscountedInterestAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_5cc85470-adfe-44fc-9e6d-5b4bab05ed46" xlink:to="loc_exdx_LongTermDebtUndiscountedInterestAmount_40f43383-4165-4409-90e9-a66b163eadea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_7b14c3d2-dcf1-455b-ba3f-71ea0f108aa7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_5cc85470-adfe-44fc-9e6d-5b4bab05ed46" xlink:to="loc_us-gaap_LongTermDebt_7b14c3d2-dcf1-455b-ba3f-71ea0f108aa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_5bfcf4f4-69e1-469f-bf9d-f0dd44be1773" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_5cc85470-adfe-44fc-9e6d-5b4bab05ed46" xlink:to="loc_us-gaap_LongTermDebtCurrent_5bfcf4f4-69e1-469f-bf9d-f0dd44be1773" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_5b0535d9-306e-436b-acdc-7eea034c6c4f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_5cc85470-adfe-44fc-9e6d-5b4bab05ed46" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_5b0535d9-306e-436b-acdc-7eea034c6c4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="exdx-20241231.xsd#LeasesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_0b2d49df-5d34-4a62-a47e-0d46757d78c2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_1acc01fa-cf26-4d35-9276-2d150bf11634" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0b2d49df-5d34-4a62-a47e-0d46757d78c2" xlink:to="loc_us-gaap_LossContingenciesTable_1acc01fa-cf26-4d35-9276-2d150bf11634" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_RentalPropertyByTypeAxis_83b58195-1e78-47cc-93c7-56703b53813f" xlink:href="exdx-20241231.xsd#exdx_RentalPropertyByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_1acc01fa-cf26-4d35-9276-2d150bf11634" xlink:to="loc_exdx_RentalPropertyByTypeAxis_83b58195-1e78-47cc-93c7-56703b53813f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_RentalPropertyByTypeDomain_9f97b6bb-c945-401a-9bdf-592ba21b59c0" xlink:href="exdx-20241231.xsd#exdx_RentalPropertyByTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_RentalPropertyByTypeAxis_83b58195-1e78-47cc-93c7-56703b53813f" xlink:to="loc_exdx_RentalPropertyByTypeDomain_9f97b6bb-c945-401a-9bdf-592ba21b59c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OfficeAndLaboratoryMember_41cca622-4235-4e9b-aee9-e4c864c885c3" xlink:href="exdx-20241231.xsd#exdx_OfficeAndLaboratoryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_RentalPropertyByTypeDomain_9f97b6bb-c945-401a-9bdf-592ba21b59c0" xlink:to="loc_exdx_OfficeAndLaboratoryMember_41cca622-4235-4e9b-aee9-e4c864c885c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OfficeMember_002173e5-7b98-4feb-b5d1-03e31c1e7fb7" xlink:href="exdx-20241231.xsd#exdx_OfficeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_RentalPropertyByTypeDomain_9f97b6bb-c945-401a-9bdf-592ba21b59c0" xlink:to="loc_exdx_OfficeMember_002173e5-7b98-4feb-b5d1-03e31c1e7fb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_171e9c36-f183-4479-9cf1-717c119a5d96" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_1acc01fa-cf26-4d35-9276-2d150bf11634" xlink:to="loc_srt_RangeAxis_171e9c36-f183-4479-9cf1-717c119a5d96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_818e98c6-c0ec-483e-a44d-523590d43b85" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_171e9c36-f183-4479-9cf1-717c119a5d96" xlink:to="loc_srt_RangeMember_818e98c6-c0ec-483e-a44d-523590d43b85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_5441d373-04ce-44e5-921a-d0a5c6c4dead" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_818e98c6-c0ec-483e-a44d-523590d43b85" xlink:to="loc_srt_MinimumMember_5441d373-04ce-44e5-921a-d0a5c6c4dead" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_c98e9e5b-7ccc-4f8c-99e0-4df3cbbdaac6" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_818e98c6-c0ec-483e-a44d-523590d43b85" xlink:to="loc_srt_MaximumMember_c98e9e5b-7ccc-4f8c-99e0-4df3cbbdaac6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermAxis_7cde32a0-90f2-40e5-8f2a-55f252e76002" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_1acc01fa-cf26-4d35-9276-2d150bf11634" xlink:to="loc_us-gaap_LeaseContractualTermAxis_7cde32a0-90f2-40e5-8f2a-55f252e76002" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain_e669d415-7bdd-4f48-9a90-262198d8f953" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermAxis_7cde32a0-90f2-40e5-8f2a-55f252e76002" xlink:to="loc_us-gaap_LeaseContractualTermDomain_e669d415-7bdd-4f48-9a90-262198d8f953" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OfficeAndLaboratoryMember_0fd245b3-bbd7-4b73-a1df-56d0e4ac8d16" xlink:href="exdx-20241231.xsd#exdx_OfficeAndLaboratoryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermDomain_e669d415-7bdd-4f48-9a90-262198d8f953" xlink:to="loc_exdx_OfficeAndLaboratoryMember_0fd245b3-bbd7-4b73-a1df-56d0e4ac8d16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OfficeMember_342c9cfa-f0ab-4963-9725-06a17da9ceab" xlink:href="exdx-20241231.xsd#exdx_OfficeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermDomain_e669d415-7bdd-4f48-9a90-262198d8f953" xlink:to="loc_exdx_OfficeMember_342c9cfa-f0ab-4963-9725-06a17da9ceab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_1a2758ac-0b33-4e17-b608-ab383cc2c996" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_1acc01fa-cf26-4d35-9276-2d150bf11634" xlink:to="loc_us-gaap_LossContingenciesLineItems_1a2758ac-0b33-4e17-b608-ab383cc2c996" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_896369f4-b747-4790-8232-ee01e7e7dd41" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_1a2758ac-0b33-4e17-b608-ab383cc2c996" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_896369f4-b747-4790-8232-ee01e7e7dd41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OperatingLeaseMonthlyBaseRent_14ce94d3-9beb-4249-9d15-c4cccf1a5a71" xlink:href="exdx-20241231.xsd#exdx_OperatingLeaseMonthlyBaseRent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_1a2758ac-0b33-4e17-b608-ab383cc2c996" xlink:to="loc_exdx_OperatingLeaseMonthlyBaseRent_14ce94d3-9beb-4249-9d15-c4cccf1a5a71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OperatingLeaseAnnualIncreaseInBaseRentPaymentPercent_1f98aa59-c741-4619-ab4f-b36ecd6ac604" xlink:href="exdx-20241231.xsd#exdx_OperatingLeaseAnnualIncreaseInBaseRentPaymentPercent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_1a2758ac-0b33-4e17-b608-ab383cc2c996" xlink:to="loc_exdx_OperatingLeaseAnnualIncreaseInBaseRentPaymentPercent_1f98aa59-c741-4619-ab4f-b36ecd6ac604" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeaseTermOfContract1_aa7c1da3-4919-4234-97ff-da03eb6bc775" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeFinanceLeaseTermOfContract1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_1a2758ac-0b33-4e17-b608-ab383cc2c996" xlink:to="loc_us-gaap_LesseeFinanceLeaseTermOfContract1_aa7c1da3-4919-4234-97ff-da03eb6bc775" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/LeasesLeaseBalancesDetails" xlink:type="simple" xlink:href="exdx-20241231.xsd#LeasesLeaseBalancesDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/LeasesLeaseBalancesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_83c3a48f-276e-41af-8f22-259e6556c53d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_5382d645-83df-4bbc-b384-342e8c4551d6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_83c3a48f-276e-41af-8f22-259e6556c53d" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_5382d645-83df-4bbc-b384-342e8c4551d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_bd080c32-9e64-44fc-b170-0d0d25e7ae4e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_83c3a48f-276e-41af-8f22-259e6556c53d" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_bd080c32-9e64-44fc-b170-0d0d25e7ae4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_ae077d83-21f1-4850-8608-3a0ddda684d5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_83c3a48f-276e-41af-8f22-259e6556c53d" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_ae077d83-21f1-4850-8608-3a0ddda684d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_b201ea40-2399-4a00-a8a8-78ecfe131c8e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_83c3a48f-276e-41af-8f22-259e6556c53d" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_b201ea40-2399-4a00-a8a8-78ecfe131c8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_e74c7a89-a470-4afe-8463-aaa6ae572470" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_83c3a48f-276e-41af-8f22-259e6556c53d" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_e74c7a89-a470-4afe-8463-aaa6ae572470" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_0b27066e-4c35-41a0-99ba-9226c1af2692" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_83c3a48f-276e-41af-8f22-259e6556c53d" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_0b27066e-4c35-41a0-99ba-9226c1af2692" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_cb1abb07-b33f-4ad8-8121-d467b2db716f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_83c3a48f-276e-41af-8f22-259e6556c53d" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_cb1abb07-b33f-4ad8-8121-d467b2db716f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_24a3fcf4-f7e6-46cf-b08a-b434b80971c1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_83c3a48f-276e-41af-8f22-259e6556c53d" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_24a3fcf4-f7e6-46cf-b08a-b434b80971c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_ff3dc9ae-57a7-4c67-8ca6-eb3f9f9563b5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_83c3a48f-276e-41af-8f22-259e6556c53d" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_ff3dc9ae-57a7-4c67-8ca6-eb3f9f9563b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/LeasesCostsAssociatedwiththeCompanysLeasesDetails" xlink:type="simple" xlink:href="exdx-20241231.xsd#LeasesCostsAssociatedwiththeCompanysLeasesDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/LeasesCostsAssociatedwiththeCompanysLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_42ac1bb1-8d8f-456c-b845-5eedc9279a58" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_9ab5e519-cc9c-4e17-b8bf-ab3a513054df" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_42ac1bb1-8d8f-456c-b845-5eedc9279a58" xlink:to="loc_us-gaap_OperatingLeaseCost_9ab5e519-cc9c-4e17-b8bf-ab3a513054df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_bb69d44f-ec83-4f51-93f6-d6b8539bfe3d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_42ac1bb1-8d8f-456c-b845-5eedc9279a58" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_bb69d44f-ec83-4f51-93f6-d6b8539bfe3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense_eb6947be-6c90-467b-8338-80c5e040e01a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_42ac1bb1-8d8f-456c-b845-5eedc9279a58" xlink:to="loc_us-gaap_FinanceLeaseInterestExpense_eb6947be-6c90-467b-8338-80c5e040e01a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_1bca5347-3033-4a42-acae-3167d3a61d58" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_42ac1bb1-8d8f-456c-b845-5eedc9279a58" xlink:to="loc_us-gaap_LeaseCost_1bca5347-3033-4a42-acae-3167d3a61d58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_92dc073f-437d-4e5c-b0b4-6717e10f5c66" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableLeaseCost"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_42ac1bb1-8d8f-456c-b845-5eedc9279a58" xlink:to="loc_us-gaap_VariableLeaseCost_92dc073f-437d-4e5c-b0b4-6717e10f5c66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/LeasesSupplementalCashFlowInformationOnLeasesAndWeightedAverageLeaseTermDetails" xlink:type="simple" xlink:href="exdx-20241231.xsd#LeasesSupplementalCashFlowInformationOnLeasesAndWeightedAverageLeaseTermDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/LeasesSupplementalCashFlowInformationOnLeasesAndWeightedAverageLeaseTermDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_4fb9b96d-2c12-402e-804c-e395cef96352" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_CashFlowInformationOperatingAndFinanceLeasePaymentsAbstract_d0a7a0bb-7f2b-4d03-9323-3eb82f07d128" xlink:href="exdx-20241231.xsd#exdx_CashFlowInformationOperatingAndFinanceLeasePaymentsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_4fb9b96d-2c12-402e-804c-e395cef96352" xlink:to="loc_exdx_CashFlowInformationOperatingAndFinanceLeasePaymentsAbstract_d0a7a0bb-7f2b-4d03-9323-3eb82f07d128" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_19c9780b-746e-4f41-825f-daba335aae42" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_CashFlowInformationOperatingAndFinanceLeasePaymentsAbstract_d0a7a0bb-7f2b-4d03-9323-3eb82f07d128" xlink:to="loc_us-gaap_OperatingLeasePayments_19c9780b-746e-4f41-825f-daba335aae42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability_cec20f58-6c92-4898-bc3d-eef9723bb276" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_CashFlowInformationOperatingAndFinanceLeasePaymentsAbstract_d0a7a0bb-7f2b-4d03-9323-3eb82f07d128" xlink:to="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability_cec20f58-6c92-4898-bc3d-eef9723bb276" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_5a1f4418-f51f-46bd-8d38-88887e0028ad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_CashFlowInformationOperatingAndFinanceLeasePaymentsAbstract_d0a7a0bb-7f2b-4d03-9323-3eb82f07d128" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_5a1f4418-f51f-46bd-8d38-88887e0028ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_WeightedAverageRemainingLeaseTermAbstract_c87e05f1-cd85-4452-bc6c-fa9421e8a77b" xlink:href="exdx-20241231.xsd#exdx_WeightedAverageRemainingLeaseTermAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_4fb9b96d-2c12-402e-804c-e395cef96352" xlink:to="loc_exdx_WeightedAverageRemainingLeaseTermAbstract_c87e05f1-cd85-4452-bc6c-fa9421e8a77b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_633dac03-0df2-4cdf-a1ef-6a17f22d4ea4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_WeightedAverageRemainingLeaseTermAbstract_c87e05f1-cd85-4452-bc6c-fa9421e8a77b" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_633dac03-0df2-4cdf-a1ef-6a17f22d4ea4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_a1b2089e-8c26-49d5-b6af-a4fb0deb2226" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_WeightedAverageRemainingLeaseTermAbstract_c87e05f1-cd85-4452-bc6c-fa9421e8a77b" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_a1b2089e-8c26-49d5-b6af-a4fb0deb2226" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_WeightedAverageDiscountRateAbstract_acfe0313-da3d-40ae-b410-a62ba2fc1d9d" xlink:href="exdx-20241231.xsd#exdx_WeightedAverageDiscountRateAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_4fb9b96d-2c12-402e-804c-e395cef96352" xlink:to="loc_exdx_WeightedAverageDiscountRateAbstract_acfe0313-da3d-40ae-b410-a62ba2fc1d9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_cd80dd36-b695-43e8-92db-9eab3c8adc87" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_WeightedAverageDiscountRateAbstract_acfe0313-da3d-40ae-b410-a62ba2fc1d9d" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_cd80dd36-b695-43e8-92db-9eab3c8adc87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_469d3ff8-d3b7-4820-8b53-43b4ff4fc661" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_WeightedAverageDiscountRateAbstract_acfe0313-da3d-40ae-b410-a62ba2fc1d9d" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_469d3ff8-d3b7-4820-8b53-43b4ff4fc661" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/LeasesFuturePaymentsUnderOperatingAndFinanceLeasesDetails" xlink:type="simple" xlink:href="exdx-20241231.xsd#LeasesFuturePaymentsUnderOperatingAndFinanceLeasesDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/LeasesFuturePaymentsUnderOperatingAndFinanceLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_d43be51d-cd79-4c9b-8d98-f4e522a11a81" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_4a8599db-88f2-4c23-9916-c9cb3b9787ca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d43be51d-cd79-4c9b-8d98-f4e522a11a81" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_4a8599db-88f2-4c23-9916-c9cb3b9787ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_a95bd95a-6f60-4848-a7bf-1a85fd3ca762" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_4a8599db-88f2-4c23-9916-c9cb3b9787ca" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_a95bd95a-6f60-4848-a7bf-1a85fd3ca762" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_51f962f7-90ae-47f7-b406-dae954ed529a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_4a8599db-88f2-4c23-9916-c9cb3b9787ca" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_51f962f7-90ae-47f7-b406-dae954ed529a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_0c777de1-b4c1-43ff-836b-f7868bfb43ef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_4a8599db-88f2-4c23-9916-c9cb3b9787ca" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_0c777de1-b4c1-43ff-836b-f7868bfb43ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b5270699-4db3-4a5e-926b-47fc21b3c4f8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_4a8599db-88f2-4c23-9916-c9cb3b9787ca" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b5270699-4db3-4a5e-926b-47fc21b3c4f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_bee19cdc-2880-4ea8-8863-11bbdeddf6c9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_4a8599db-88f2-4c23-9916-c9cb3b9787ca" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_bee19cdc-2880-4ea8-8863-11bbdeddf6c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_fda0962b-5a83-42bd-a244-a38522f60a43" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_4a8599db-88f2-4c23-9916-c9cb3b9787ca" xlink:to="loc_us-gaap_OperatingLeaseLiability_fda0962b-5a83-42bd-a244-a38522f60a43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_0279fa50-12a1-4f57-8ea4-358efb2830f0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_4a8599db-88f2-4c23-9916-c9cb3b9787ca" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_0279fa50-12a1-4f57-8ea4-358efb2830f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_51952bee-d9b8-48b3-98da-96fbfd29c947" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_4a8599db-88f2-4c23-9916-c9cb3b9787ca" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_51952bee-d9b8-48b3-98da-96fbfd29c947" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_d5cfa921-3841-42ff-bc04-e1a3e7cd08bd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d43be51d-cd79-4c9b-8d98-f4e522a11a81" xlink:to="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_d5cfa921-3841-42ff-bc04-e1a3e7cd08bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_c908c2ef-5ade-4540-9f41-6c301b63ea68" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_d5cfa921-3841-42ff-bc04-e1a3e7cd08bd" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_c908c2ef-5ade-4540-9f41-6c301b63ea68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_582b05ef-1518-433c-b561-4e78fb47db76" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_d5cfa921-3841-42ff-bc04-e1a3e7cd08bd" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_582b05ef-1518-433c-b561-4e78fb47db76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_b88356df-6ea2-4187-8a22-be78bb928144" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_d5cfa921-3841-42ff-bc04-e1a3e7cd08bd" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_b88356df-6ea2-4187-8a22-be78bb928144" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_d8440d0d-24dc-46cc-9357-c4d30d105dd7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_d5cfa921-3841-42ff-bc04-e1a3e7cd08bd" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_d8440d0d-24dc-46cc-9357-c4d30d105dd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_868d9491-ae6b-4eab-9064-657b9849079a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_d5cfa921-3841-42ff-bc04-e1a3e7cd08bd" xlink:to="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_868d9491-ae6b-4eab-9064-657b9849079a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_2b14a060-df8c-4573-b149-fbc8ce17a976" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_d5cfa921-3841-42ff-bc04-e1a3e7cd08bd" xlink:to="loc_us-gaap_FinanceLeaseLiability_2b14a060-df8c-4573-b149-fbc8ce17a976" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_d7bb7b76-0d4d-42e5-9801-92b0ec65287d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_d5cfa921-3841-42ff-bc04-e1a3e7cd08bd" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_d7bb7b76-0d4d-42e5-9801-92b0ec65287d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_c82a6d83-956f-4046-9f8a-146f1d492e07" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_d5cfa921-3841-42ff-bc04-e1a3e7cd08bd" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_c82a6d83-956f-4046-9f8a-146f1d492e07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="simple" xlink:href="exdx-20241231.xsd#CommitmentsandContingenciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_714da389-5826-43e2-82f0-7befca099477" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable_78980664-c077-4086-b89b-212f02b4edc3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_714da389-5826-43e2-82f0-7befca099477" xlink:to="loc_us-gaap_OtherCommitmentsTable_78980664-c077-4086-b89b-212f02b4edc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_2c3c8f5e-d61d-4c94-9501-b0b84402b502" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_78980664-c077-4086-b89b-212f02b4edc3" xlink:to="loc_srt_CounterpartyNameAxis_2c3c8f5e-d61d-4c94-9501-b0b84402b502" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8fe3f523-37d1-4981-a25b-a4308b43b9cb" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_2c3c8f5e-d61d-4c94-9501-b0b84402b502" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8fe3f523-37d1-4981-a25b-a4308b43b9cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AlleghenyHealthNetworkResearchInstituteMember_8dcfc057-9064-42f5-8ae9-19b807be0d74" xlink:href="exdx-20241231.xsd#exdx_AlleghenyHealthNetworkResearchInstituteMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8fe3f523-37d1-4981-a25b-a4308b43b9cb" xlink:to="loc_exdx_AlleghenyHealthNetworkResearchInstituteMember_8dcfc057-9064-42f5-8ae9-19b807be0d74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_73931140-1917-47d1-b290-e26d25d6e026" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_78980664-c077-4086-b89b-212f02b4edc3" xlink:to="loc_srt_RangeAxis_73931140-1917-47d1-b290-e26d25d6e026" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5e6a8a03-ee0d-4e0e-8758-7a82ae9adb4e" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_73931140-1917-47d1-b290-e26d25d6e026" xlink:to="loc_srt_RangeMember_5e6a8a03-ee0d-4e0e-8758-7a82ae9adb4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_da02ac1c-7e8e-40d1-b354-11cd4a5c7d68" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_5e6a8a03-ee0d-4e0e-8758-7a82ae9adb4e" xlink:to="loc_srt_MinimumMember_da02ac1c-7e8e-40d1-b354-11cd4a5c7d68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f730933b-5600-4bb4-919c-052ab51cd0e1" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_5e6a8a03-ee0d-4e0e-8758-7a82ae9adb4e" xlink:to="loc_srt_MaximumMember_f730933b-5600-4bb4-919c-052ab51cd0e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_d3f8528f-dcc6-4765-9706-144d2ffc1267" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_78980664-c077-4086-b89b-212f02b4edc3" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_d3f8528f-dcc6-4765-9706-144d2ffc1267" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_bf01fb30-7d48-4b1f-9554-5b326e70a0ca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_d3f8528f-dcc6-4765-9706-144d2ffc1267" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_bf01fb30-7d48-4b1f-9554-5b326e70a0ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseAgreementTermsMember_005ce117-40c6-4737-bc3d-0d8307ce28fa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LicenseAgreementTermsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_bf01fb30-7d48-4b1f-9554-5b326e70a0ca" xlink:to="loc_us-gaap_LicenseAgreementTermsMember_005ce117-40c6-4737-bc3d-0d8307ce28fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_e6294cd5-e11d-41f1-ad3e-631fcb11ab3f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_78980664-c077-4086-b89b-212f02b4edc3" xlink:to="loc_us-gaap_TypeOfArrangementAxis_e6294cd5-e11d-41f1-ad3e-631fcb11ab3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_963e54ac-14a1-4fee-851b-af4c8850846f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_e6294cd5-e11d-41f1-ad3e-631fcb11ab3f" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_963e54ac-14a1-4fee-851b-af4c8850846f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AHNCollaborationMember_36963cf6-5e1a-4688-9685-5a53643ebbe1" xlink:href="exdx-20241231.xsd#exdx_AHNCollaborationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_963e54ac-14a1-4fee-851b-af4c8850846f" xlink:to="loc_exdx_AHNCollaborationMember_36963cf6-5e1a-4688-9685-5a53643ebbe1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_a3bb1c0a-2ad0-470e-ab54-839bdeae3845" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_78980664-c077-4086-b89b-212f02b4edc3" xlink:to="loc_srt_LitigationCaseAxis_a3bb1c0a-2ad0-470e-ab54-839bdeae3845" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_6e6774a1-fd6f-467a-b894-954e50fa4ae0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_a3bb1c0a-2ad0-470e-ab54-839bdeae3845" xlink:to="loc_srt_LitigationCaseTypeDomain_6e6774a1-fd6f-467a-b894-954e50fa4ae0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_USDepartmentOfJusticeCaseMember_752b1835-7c8a-4799-85f6-7a55c2613474" xlink:href="exdx-20241231.xsd#exdx_USDepartmentOfJusticeCaseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_6e6774a1-fd6f-467a-b894-954e50fa4ae0" xlink:to="loc_exdx_USDepartmentOfJusticeCaseMember_752b1835-7c8a-4799-85f6-7a55c2613474" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_9eb7a499-84fa-426f-bfa1-7dfed4d691ae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LitigationStatusAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_78980664-c077-4086-b89b-212f02b4edc3" xlink:to="loc_us-gaap_LitigationStatusAxis_9eb7a499-84fa-426f-bfa1-7dfed4d691ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_c3871671-7c4c-4bfd-b337-301304462746" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LitigationStatusDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusAxis_9eb7a499-84fa-426f-bfa1-7dfed4d691ae" xlink:to="loc_us-gaap_LitigationStatusDomain_c3871671-7c4c-4bfd-b337-301304462746" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SettledLitigationMember_0ab11f45-3584-47eb-a1de-d8ce47885503" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SettledLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_c3871671-7c4c-4bfd-b337-301304462746" xlink:to="loc_us-gaap_SettledLitigationMember_0ab11f45-3584-47eb-a1de-d8ce47885503" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_06a8cc59-a100-4b3a-ac1b-2a0cda05483a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_78980664-c077-4086-b89b-212f02b4edc3" xlink:to="loc_us-gaap_OtherCommitmentsLineItems_06a8cc59-a100-4b3a-ac1b-2a0cda05483a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_RoyaltyObligationPercentageOfSales_820b8106-b774-4b8e-81df-165970555fea" xlink:href="exdx-20241231.xsd#exdx_RoyaltyObligationPercentageOfSales"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_06a8cc59-a100-4b3a-ac1b-2a0cda05483a" xlink:to="loc_exdx_RoyaltyObligationPercentageOfSales_820b8106-b774-4b8e-81df-165970555fea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_PurchaseObligationAmendedSupplyAgreementNumberOfSuppliers_99552c5c-2a15-4487-8cd9-fdef07311795" xlink:href="exdx-20241231.xsd#exdx_PurchaseObligationAmendedSupplyAgreementNumberOfSuppliers"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_06a8cc59-a100-4b3a-ac1b-2a0cda05483a" xlink:to="loc_exdx_PurchaseObligationAmendedSupplyAgreementNumberOfSuppliers_99552c5c-2a15-4487-8cd9-fdef07311795" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInNextTwelveMonths_eb9448e4-9076-48ec-bc9d-47dadc1108d0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PurchaseObligationDueInNextTwelveMonths"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_06a8cc59-a100-4b3a-ac1b-2a0cda05483a" xlink:to="loc_us-gaap_PurchaseObligationDueInNextTwelveMonths_eb9448e4-9076-48ec-bc9d-47dadc1108d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_CollaborationAgreementAnnualCollaborationFee_0379856b-5378-484f-a5ab-04db47ee8678" xlink:href="exdx-20241231.xsd#exdx_CollaborationAgreementAnnualCollaborationFee"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_06a8cc59-a100-4b3a-ac1b-2a0cda05483a" xlink:to="loc_exdx_CollaborationAgreementAnnualCollaborationFee_0379856b-5378-484f-a5ab-04db47ee8678" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_CollaborationAgreementCollaborationExpenses_d5cc270a-5c8b-490f-89cc-81da2f7449a7" xlink:href="exdx-20241231.xsd#exdx_CollaborationAgreementCollaborationExpenses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_06a8cc59-a100-4b3a-ac1b-2a0cda05483a" xlink:to="loc_exdx_CollaborationAgreementCollaborationExpenses_d5cc270a-5c8b-490f-89cc-81da2f7449a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements_94ff5a49-701c-4079-9d0a-95a71c43de57" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_06a8cc59-a100-4b3a-ac1b-2a0cda05483a" xlink:to="loc_us-gaap_PaymentsForLegalSettlements_94ff5a49-701c-4079-9d0a-95a71c43de57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="exdx-20241231.xsd#FairValueMeasurementsDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_e44bd7e2-e0cf-46fd-9720-5717e988ea19" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_dfc45ae5-c055-493e-bb03-3c87c92e7f21" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_e44bd7e2-e0cf-46fd-9720-5717e988ea19" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_dfc45ae5-c055-493e-bb03-3c87c92e7f21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_3260cd62-a674-43e6-bf92-4dabb85ab498" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_dfc45ae5-c055-493e-bb03-3c87c92e7f21" xlink:to="loc_us-gaap_DebtInstrumentAxis_3260cd62-a674-43e6-bf92-4dabb85ab498" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_b31c618d-525c-4c52-99b5-c22d620c6990" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_3260cd62-a674-43e6-bf92-4dabb85ab498" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_b31c618d-525c-4c52-99b5-c22d620c6990" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AmendedLoanAgreementMember_095822a3-f6fb-4575-a66a-4ed7d80107ad" xlink:href="exdx-20241231.xsd#exdx_AmendedLoanAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b31c618d-525c-4c52-99b5-c22d620c6990" xlink:to="loc_exdx_AmendedLoanAgreementMember_095822a3-f6fb-4575-a66a-4ed7d80107ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_A2017TermLoanMember_50b6aea1-e9d8-4616-83a7-632280af5681" xlink:href="exdx-20241231.xsd#exdx_A2017TermLoanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b31c618d-525c-4c52-99b5-c22d620c6990" xlink:to="loc_exdx_A2017TermLoanMember_50b6aea1-e9d8-4616-83a7-632280af5681" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_4cc42a59-2d10-4fba-9a47-542ded3c0cee" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_dfc45ae5-c055-493e-bb03-3c87c92e7f21" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_4cc42a59-2d10-4fba-9a47-542ded3c0cee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_5590e571-75ee-4b88-901f-5ca81d6aa600" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_4cc42a59-2d10-4fba-9a47-542ded3c0cee" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_5590e571-75ee-4b88-901f-5ca81d6aa600" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_c429ec8d-bb2e-49bd-896e-c95b6ceb84c7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_5590e571-75ee-4b88-901f-5ca81d6aa600" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_c429ec8d-bb2e-49bd-896e-c95b6ceb84c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c143fd92-d086-44c2-b021-53c26beff59c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_dfc45ae5-c055-493e-bb03-3c87c92e7f21" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c143fd92-d086-44c2-b021-53c26beff59c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7e041c74-d055-4327-a564-ca82a17011dd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c143fd92-d086-44c2-b021-53c26beff59c" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7e041c74-d055-4327-a564-ca82a17011dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_5954d157-1634-41c0-bd5b-8ab4b82ad35e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7e041c74-d055-4327-a564-ca82a17011dd" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_5954d157-1634-41c0-bd5b-8ab4b82ad35e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_ddeacfd2-8772-4421-9215-89d9774c3798" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7e041c74-d055-4327-a564-ca82a17011dd" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_ddeacfd2-8772-4421-9215-89d9774c3798" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_24b803f6-7181-459b-a7ca-7d4866e4cde3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7e041c74-d055-4327-a564-ca82a17011dd" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_24b803f6-7181-459b-a7ca-7d4866e4cde3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_1e62b21c-db4c-4c13-a26d-e2154e6a9d91" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_dfc45ae5-c055-493e-bb03-3c87c92e7f21" xlink:to="loc_us-gaap_FinancialInstrumentAxis_1e62b21c-db4c-4c13-a26d-e2154e6a9d91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_861984b4-0cb3-4d4f-a5de-61dc0ffbf6a4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_1e62b21c-db4c-4c13-a26d-e2154e6a9d91" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_861984b4-0cb3-4d4f-a5de-61dc0ffbf6a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_4aa28869-f827-4639-8338-7d497d077b9c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_861984b4-0cb3-4d4f-a5de-61dc0ffbf6a4" xlink:to="loc_us-gaap_MoneyMarketFundsMember_4aa28869-f827-4639-8338-7d497d077b9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_31f2545c-9e35-46a8-b575-9fa99a5911ba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_dfc45ae5-c055-493e-bb03-3c87c92e7f21" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_31f2545c-9e35-46a8-b575-9fa99a5911ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_d6a290e7-e0b9-4321-b874-ad6ffc628bc0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_31f2545c-9e35-46a8-b575-9fa99a5911ba" xlink:to="loc_us-gaap_LongTermDebt_d6a290e7-e0b9-4321-b874-ad6ffc628bc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_c5801dc3-a9b9-4785-8f26-efe37ddc6a85" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_31f2545c-9e35-46a8-b575-9fa99a5911ba" xlink:to="loc_us-gaap_DebtInstrumentFairValue_c5801dc3-a9b9-4785-8f26-efe37ddc6a85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_bb3f19fc-60b4-4191-a3b3-e35401496b4c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_31f2545c-9e35-46a8-b575-9fa99a5911ba" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_bb3f19fc-60b4-4191-a3b3-e35401496b4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_794f9e5b-dd45-402e-8a06-9731d2d65984" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_bb3f19fc-60b4-4191-a3b3-e35401496b4c" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_794f9e5b-dd45-402e-8a06-9731d2d65984" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StockholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="exdx-20241231.xsd#StockholdersEquityNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_dc68f4da-37b1-43a3-a4a8-e07d17370acc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_d08d6781-5021-4e7f-8230-29266f982c6a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_dc68f4da-37b1-43a3-a4a8-e07d17370acc" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_d08d6781-5021-4e7f-8230-29266f982c6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_755ed5b3-d538-42e4-a1ac-3974fe61bae0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_d08d6781-5021-4e7f-8230-29266f982c6a" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_755ed5b3-d538-42e4-a1ac-3974fe61bae0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_90cfa396-6cc5-4fe2-ab8e-95c2aa3c5573" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_755ed5b3-d538-42e4-a1ac-3974fe61bae0" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_90cfa396-6cc5-4fe2-ab8e-95c2aa3c5573" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ShelfRegistrationStatementMember_b0f57b5a-49ae-4fab-8e76-33f6fd4aa557" xlink:href="exdx-20241231.xsd#exdx_ShelfRegistrationStatementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_90cfa396-6cc5-4fe2-ab8e-95c2aa3c5573" xlink:to="loc_exdx_ShelfRegistrationStatementMember_b0f57b5a-49ae-4fab-8e76-33f6fd4aa557" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_CowenEquityDistributionAgreementMember_eb9def5a-346a-489b-8a4f-1065ef25acc1" xlink:href="exdx-20241231.xsd#exdx_CowenEquityDistributionAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_90cfa396-6cc5-4fe2-ab8e-95c2aa3c5573" xlink:to="loc_exdx_CowenEquityDistributionAgreementMember_eb9def5a-346a-489b-8a4f-1065ef25acc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_12401f2c-23b7-4269-8bc4-a023fbc4c145" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_d08d6781-5021-4e7f-8230-29266f982c6a" xlink:to="loc_us-gaap_SubsidiarySaleOfStockLineItems_12401f2c-23b7-4269-8bc4-a023fbc4c145" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_SaleOfStockAuthorizedAmount_6ee9f109-83be-4eae-a16d-e60294f98505" xlink:href="exdx-20241231.xsd#exdx_SaleOfStockAuthorizedAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_12401f2c-23b7-4269-8bc4-a023fbc4c145" xlink:to="loc_exdx_SaleOfStockAuthorizedAmount_6ee9f109-83be-4eae-a16d-e60294f98505" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_SaleOfStockRemainingAuthorizedAmount_c4fa382c-f197-4474-926d-81cd6be2429f" xlink:href="exdx-20241231.xsd#exdx_SaleOfStockRemainingAuthorizedAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_12401f2c-23b7-4269-8bc4-a023fbc4c145" xlink:to="loc_exdx_SaleOfStockRemainingAuthorizedAmount_c4fa382c-f197-4474-926d-81cd6be2429f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_95e37d2e-e856-4d71-85d3-59527a701b23" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_12401f2c-23b7-4269-8bc4-a023fbc4c145" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_95e37d2e-e856-4d71-85d3-59527a701b23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet_cec63097-2023-456e-92ca-4adcc5ca029e" xlink:href="exdx-20241231.xsd#exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_12401f2c-23b7-4269-8bc4-a023fbc4c145" xlink:to="loc_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet_cec63097-2023-456e-92ca-4adcc5ca029e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StockholdersEquityWarrantstoPurchaseCommonStockOutstandingDetails" xlink:type="simple" xlink:href="exdx-20241231.xsd#StockholdersEquityWarrantstoPurchaseCommonStockOutstandingDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/StockholdersEquityWarrantstoPurchaseCommonStockOutstandingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_82cf1bf2-e6b9-418f-981a-77a5434711d1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_bb79c1f8-ef8b-44c1-8b5b-47e33e660809" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_82cf1bf2-e6b9-418f-981a-77a5434711d1" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_bb79c1f8-ef8b-44c1-8b5b-47e33e660809" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_030e3064-aa8c-428d-a09e-c6d8d86ec445" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_bb79c1f8-ef8b-44c1-8b5b-47e33e660809" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_030e3064-aa8c-428d-a09e-c6d8d86ec445" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_3debffbc-3e2b-423e-ae21-4ff03f72bf1b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_030e3064-aa8c-428d-a09e-c6d8d86ec445" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_3debffbc-3e2b-423e-ae21-4ff03f72bf1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ExpirationJan192026Member_fedcd497-199e-4028-b764-4612472d5b8c" xlink:href="exdx-20241231.xsd#exdx_ExpirationJan192026Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_3debffbc-3e2b-423e-ae21-4ff03f72bf1b" xlink:to="loc_exdx_ExpirationJan192026Member_fedcd497-199e-4028-b764-4612472d5b8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ExpirationMar312026Member_54600e7e-6a2a-4dca-a34c-cdb4f1992fdf" xlink:href="exdx-20241231.xsd#exdx_ExpirationMar312026Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_3debffbc-3e2b-423e-ae21-4ff03f72bf1b" xlink:to="loc_exdx_ExpirationMar312026Member_54600e7e-6a2a-4dca-a34c-cdb4f1992fdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ExpirationApr12026Member_de754752-1c5d-4960-aac4-d690442f2463" xlink:href="exdx-20241231.xsd#exdx_ExpirationApr12026Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_3debffbc-3e2b-423e-ae21-4ff03f72bf1b" xlink:to="loc_exdx_ExpirationApr12026Member_de754752-1c5d-4960-aac4-d690442f2463" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ExpirationDec72025Member_3b5bf2bc-24ce-4e77-b995-401841772cfe" xlink:href="exdx-20241231.xsd#exdx_ExpirationDec72025Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_3debffbc-3e2b-423e-ae21-4ff03f72bf1b" xlink:to="loc_exdx_ExpirationDec72025Member_3b5bf2bc-24ce-4e77-b995-401841772cfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_NoExpirationMember_3412a393-3dab-4b6f-8447-9290f6bf486c" xlink:href="exdx-20241231.xsd#exdx_NoExpirationMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_3debffbc-3e2b-423e-ae21-4ff03f72bf1b" xlink:to="loc_exdx_NoExpirationMember_3412a393-3dab-4b6f-8447-9290f6bf486c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_2b7333c5-1cbd-463b-b49f-84066756510c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_bb79c1f8-ef8b-44c1-8b5b-47e33e660809" xlink:to="loc_us-gaap_ClassOfStockLineItems_2b7333c5-1cbd-463b-b49f-84066756510c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_9d087781-520e-4284-b9b0-626be3f35883" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_2b7333c5-1cbd-463b-b49f-84066756510c" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_9d087781-520e-4284-b9b0-626be3f35883" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_97a961bf-be09-4a2b-8918-4547cbe86d60" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_2b7333c5-1cbd-463b-b49f-84066756510c" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_97a961bf-be09-4a2b-8918-4547cbe86d60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StockOptionPlanNarrativeDetails" xlink:type="simple" xlink:href="exdx-20241231.xsd#StockOptionPlanNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/StockOptionPlanNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_02dc869f-b33a-48b5-a950-95697c0418c4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_73db9ec1-7eed-40b1-af8a-0b8fd8aa4060" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_02dc869f-b33a-48b5-a950-95697c0418c4" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_73db9ec1-7eed-40b1-af8a-0b8fd8aa4060" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_ff79aecb-9a65-485f-b95c-97e5fa2f424d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_73db9ec1-7eed-40b1-af8a-0b8fd8aa4060" xlink:to="loc_us-gaap_PlanNameAxis_ff79aecb-9a65-485f-b95c-97e5fa2f424d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_f388c05c-e52e-44c5-aa30-27fe98c66c9f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_ff79aecb-9a65-485f-b95c-97e5fa2f424d" xlink:to="loc_us-gaap_PlanNameDomain_f388c05c-e52e-44c5-aa30-27fe98c66c9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_IncentiveAwardPlan2019Member_762f8a83-c75f-467e-b07c-f89eb79aed51" xlink:href="exdx-20241231.xsd#exdx_IncentiveAwardPlan2019Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_f388c05c-e52e-44c5-aa30-27fe98c66c9f" xlink:to="loc_exdx_IncentiveAwardPlan2019Member_762f8a83-c75f-467e-b07c-f89eb79aed51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_80ec3212-503e-4a37-938b-24a7f5a9420c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_73db9ec1-7eed-40b1-af8a-0b8fd8aa4060" xlink:to="loc_us-gaap_AwardTypeAxis_80ec3212-503e-4a37-938b-24a7f5a9420c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b7b5c92f-7f53-44df-9314-38cbdcb8ea24" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_80ec3212-503e-4a37-938b-24a7f5a9420c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b7b5c92f-7f53-44df-9314-38cbdcb8ea24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_c5d7ce79-9e82-4837-82d5-7e3ffa6dd3b3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b7b5c92f-7f53-44df-9314-38cbdcb8ea24" xlink:to="loc_us-gaap_EmployeeStockOptionMember_c5d7ce79-9e82-4837-82d5-7e3ffa6dd3b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_45b6f429-ce9d-44e7-aede-3e81b29ebd86" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b7b5c92f-7f53-44df-9314-38cbdcb8ea24" xlink:to="loc_us-gaap_EmployeeStockMember_45b6f429-ce9d-44e7-aede-3e81b29ebd86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_ff2cdd6f-e6fb-41f3-9db0-754d1123d6d5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b7b5c92f-7f53-44df-9314-38cbdcb8ea24" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_ff2cdd6f-e6fb-41f3-9db0-754d1123d6d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_8d75d4d1-d66c-435a-bd59-b44e090083b2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_73db9ec1-7eed-40b1-af8a-0b8fd8aa4060" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_8d75d4d1-d66c-435a-bd59-b44e090083b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_64dc9e01-fc16-4f59-b3b7-08615492552a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_8d75d4d1-d66c-435a-bd59-b44e090083b2" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_64dc9e01-fc16-4f59-b3b7-08615492552a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_390f2de1-17b9-4199-8921-81f8aac7f3e5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_64dc9e01-fc16-4f59-b3b7-08615492552a" xlink:to="loc_us-gaap_SubsequentEventMember_390f2de1-17b9-4199-8921-81f8aac7f3e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f7d72acc-f452-444a-b1de-66d2a8cad114" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_73db9ec1-7eed-40b1-af8a-0b8fd8aa4060" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f7d72acc-f452-444a-b1de-66d2a8cad114" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_5f019f11-4234-496e-9830-ea60b7cf2999" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f7d72acc-f452-444a-b1de-66d2a8cad114" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_5f019f11-4234-496e-9830-ea60b7cf2999" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_9b64141c-0623-459a-aebe-952765b873d4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f7d72acc-f452-444a-b1de-66d2a8cad114" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_9b64141c-0623-459a-aebe-952765b873d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage_b31a519d-d0d2-40c1-9ec4-dc1987b8068e" xlink:href="exdx-20241231.xsd#exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f7d72acc-f452-444a-b1de-66d2a8cad114" xlink:to="loc_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage_b31a519d-d0d2-40c1-9ec4-dc1987b8068e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_487107ec-129c-4cfe-a132-36abe42ed98c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f7d72acc-f452-444a-b1de-66d2a8cad114" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_487107ec-129c-4cfe-a132-36abe42ed98c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesAuthorized_b6fcb9ba-9a7a-43da-a62f-496bfce0d362" xlink:href="exdx-20241231.xsd#exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesAuthorized"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f7d72acc-f452-444a-b1de-66d2a8cad114" xlink:to="loc_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesAuthorized_b6fcb9ba-9a7a-43da-a62f-496bfce0d362" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_09bef7ae-1249-49e8-8560-199b39756c72" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f7d72acc-f452-444a-b1de-66d2a8cad114" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_09bef7ae-1249-49e8-8560-199b39756c72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_f86cbfd6-19ad-498d-935d-c2d3a36b765f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f7d72acc-f452-444a-b1de-66d2a8cad114" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_f86cbfd6-19ad-498d-935d-c2d3a36b765f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_7cbabd07-124d-450a-8aff-22931bf9fa62" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f7d72acc-f452-444a-b1de-66d2a8cad114" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_7cbabd07-124d-450a-8aff-22931bf9fa62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_57db4626-bce9-4b4a-bdc7-e555bcc85e54" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f7d72acc-f452-444a-b1de-66d2a8cad114" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_57db4626-bce9-4b4a-bdc7-e555bcc85e54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7c51dbc9-cd86-492f-95e0-570476e5c1ce" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f7d72acc-f452-444a-b1de-66d2a8cad114" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7c51dbc9-cd86-492f-95e0-570476e5c1ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_d36d5919-0db6-4640-8e47-ad5e207ab92d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f7d72acc-f452-444a-b1de-66d2a8cad114" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_d36d5919-0db6-4640-8e47-ad5e207ab92d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_b299e9b5-8065-4f3d-afe8-3bfbdca2ccf0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f7d72acc-f452-444a-b1de-66d2a8cad114" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_b299e9b5-8065-4f3d-afe8-3bfbdca2ccf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_51a42ab4-b23d-462e-ab21-7360c03c9eca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f7d72acc-f452-444a-b1de-66d2a8cad114" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_51a42ab4-b23d-462e-ab21-7360c03c9eca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_f547deea-98f3-491b-8cae-f10eadeaaeb7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f7d72acc-f452-444a-b1de-66d2a8cad114" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_f547deea-98f3-491b-8cae-f10eadeaaeb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_9fda12bb-1857-4eff-ab46-6fc68cf72df5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f7d72acc-f452-444a-b1de-66d2a8cad114" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_9fda12bb-1857-4eff-ab46-6fc68cf72df5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_810fdd02-66b2-497e-979e-12b2c228ffd8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f7d72acc-f452-444a-b1de-66d2a8cad114" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_810fdd02-66b2-497e-979e-12b2c228ffd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails" xlink:type="simple" xlink:href="exdx-20241231.xsd#StockOptionPlanRestrictedStockUnitsDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2ce4cc0a-2490-43b1-9fdb-e72f925c563c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8d34ba81-62cd-44f6-8044-a68ea2080577" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2ce4cc0a-2490-43b1-9fdb-e72f925c563c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8d34ba81-62cd-44f6-8044-a68ea2080577" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_e15c6684-fb47-441d-b9f7-387a1b91fe3d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8d34ba81-62cd-44f6-8044-a68ea2080577" xlink:to="loc_us-gaap_AwardTypeAxis_e15c6684-fb47-441d-b9f7-387a1b91fe3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7d9a61ae-aa4a-4cb3-85b7-d1ae1dd11b4d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_e15c6684-fb47-441d-b9f7-387a1b91fe3d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7d9a61ae-aa4a-4cb3-85b7-d1ae1dd11b4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_69864395-8bee-41e2-bbe7-0ae0b68387c6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7d9a61ae-aa4a-4cb3-85b7-d1ae1dd11b4d" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_69864395-8bee-41e2-bbe7-0ae0b68387c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_765e5e79-1f75-4413-9c56-59b866725123" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8d34ba81-62cd-44f6-8044-a68ea2080577" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_765e5e79-1f75-4413-9c56-59b866725123" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_7bc1a639-516d-484c-84e3-e1ebde9224ba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_765e5e79-1f75-4413-9c56-59b866725123" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_7bc1a639-516d-484c-84e3-e1ebde9224ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_b2c52135-95a9-4a12-8a34-6a5aeeb9fd4c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_7bc1a639-516d-484c-84e3-e1ebde9224ba" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_b2c52135-95a9-4a12-8a34-6a5aeeb9fd4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_f9bf268f-8a89-4350-a7da-80feccc596d9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_7bc1a639-516d-484c-84e3-e1ebde9224ba" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_f9bf268f-8a89-4350-a7da-80feccc596d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_4bfb638e-537f-4fad-a359-7d93a29048e0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_7bc1a639-516d-484c-84e3-e1ebde9224ba" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_4bfb638e-537f-4fad-a359-7d93a29048e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_cd2a2a18-10e5-4ff0-817d-d4146a59eed2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_7bc1a639-516d-484c-84e3-e1ebde9224ba" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_cd2a2a18-10e5-4ff0-817d-d4146a59eed2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_b626866d-1c34-4247-9a15-7c7323268cca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_7bc1a639-516d-484c-84e3-e1ebde9224ba" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_b626866d-1c34-4247-9a15-7c7323268cca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_f43b716f-517a-406a-8cd5-c2db37da2891" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_765e5e79-1f75-4413-9c56-59b866725123" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_f43b716f-517a-406a-8cd5-c2db37da2891" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_ab476d5a-9304-43eb-ae1c-44898d94670b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_f43b716f-517a-406a-8cd5-c2db37da2891" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_ab476d5a-9304-43eb-ae1c-44898d94670b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_96ee3746-21d7-4a5b-903d-1c9eef146a68" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_f43b716f-517a-406a-8cd5-c2db37da2891" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_96ee3746-21d7-4a5b-903d-1c9eef146a68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_56344457-9844-46e5-b460-e4045fc719b4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_f43b716f-517a-406a-8cd5-c2db37da2891" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_56344457-9844-46e5-b460-e4045fc719b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c2131b06-8f02-4268-88f2-897894cd5d78" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_f43b716f-517a-406a-8cd5-c2db37da2891" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c2131b06-8f02-4268-88f2-897894cd5d78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3b8bbb8a-dcf6-47dc-9a6e-9dbf6fa33f19" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_f43b716f-517a-406a-8cd5-c2db37da2891" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3b8bbb8a-dcf6-47dc-9a6e-9dbf6fa33f19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_82b2d4e1-d6ea-4bff-b4b4-7478d7da5399" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_765e5e79-1f75-4413-9c56-59b866725123" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_82b2d4e1-d6ea-4bff-b4b4-7478d7da5399" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_1b352fb9-ee29-49a7-ac86-b86db870c666" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_82b2d4e1-d6ea-4bff-b4b4-7478d7da5399" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_1b352fb9-ee29-49a7-ac86-b86db870c666" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails" xlink:type="simple" xlink:href="exdx-20241231.xsd#StockOptionPlanStockOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7a171c37-50d8-4336-bd2d-2fd905600035" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5e4bb621-a1a5-4f67-a03d-0c1787325e8c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7a171c37-50d8-4336-bd2d-2fd905600035" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5e4bb621-a1a5-4f67-a03d-0c1787325e8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_d4b9610b-61d1-45c6-83a6-f213a0357b49" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5e4bb621-a1a5-4f67-a03d-0c1787325e8c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_d4b9610b-61d1-45c6-83a6-f213a0357b49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c9ec956e-ed06-4c09-81ba-eda7a1cc9313" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5e4bb621-a1a5-4f67-a03d-0c1787325e8c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c9ec956e-ed06-4c09-81ba-eda7a1cc9313" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2f4adbec-714a-4d76-bffe-26ef82e29fa9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5e4bb621-a1a5-4f67-a03d-0c1787325e8c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2f4adbec-714a-4d76-bffe-26ef82e29fa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_4c337bbd-b85b-4887-86f2-18570b6c84c9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5e4bb621-a1a5-4f67-a03d-0c1787325e8c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_4c337bbd-b85b-4887-86f2-18570b6c84c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_290ba4d9-316b-4440-8067-5dd3aa4b3288" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5e4bb621-a1a5-4f67-a03d-0c1787325e8c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_290ba4d9-316b-4440-8067-5dd3aa4b3288" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_fc54c179-00cf-494a-95a9-9e0b3a8a2367" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5e4bb621-a1a5-4f67-a03d-0c1787325e8c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_fc54c179-00cf-494a-95a9-9e0b3a8a2367" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_a8c57039-7827-473f-bfe8-8268c63d956c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7a171c37-50d8-4336-bd2d-2fd905600035" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_a8c57039-7827-473f-bfe8-8268c63d956c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_3adb20c3-45df-428b-bcff-e9e83ed64d54" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7a171c37-50d8-4336-bd2d-2fd905600035" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_3adb20c3-45df-428b-bcff-e9e83ed64d54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_fe848c1b-c431-4a1a-ab2f-373d7126906c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7a171c37-50d8-4336-bd2d-2fd905600035" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_fe848c1b-c431-4a1a-ab2f-373d7126906c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_9dc6ec73-3195-4990-9f55-e23b30b523f5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_fe848c1b-c431-4a1a-ab2f-373d7126906c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_9dc6ec73-3195-4990-9f55-e23b30b523f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_a4ce4793-145c-482b-8a7e-d0639eea8721" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_fe848c1b-c431-4a1a-ab2f-373d7126906c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_a4ce4793-145c-482b-8a7e-d0639eea8721" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_1c353ea9-d7b5-42ac-9446-7f344fc57df7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_fe848c1b-c431-4a1a-ab2f-373d7126906c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_1c353ea9-d7b5-42ac-9446-7f344fc57df7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_49dcbe4e-ea43-4709-8600-f124e9e6b576" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_fe848c1b-c431-4a1a-ab2f-373d7126906c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_49dcbe4e-ea43-4709-8600-f124e9e6b576" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_3a38a2d6-31fa-4f4a-b1a8-cc276976237c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_fe848c1b-c431-4a1a-ab2f-373d7126906c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_3a38a2d6-31fa-4f4a-b1a8-cc276976237c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_41a57e80-aec2-4b44-85bb-ef62cda8b1fd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_fe848c1b-c431-4a1a-ab2f-373d7126906c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_41a57e80-aec2-4b44-85bb-ef62cda8b1fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_c52242af-6152-4f87-b8b8-2a1d87c5801b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7a171c37-50d8-4336-bd2d-2fd905600035" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_c52242af-6152-4f87-b8b8-2a1d87c5801b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_1fe33fb6-3d71-4732-9bdc-321c83456c4f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7a171c37-50d8-4336-bd2d-2fd905600035" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_1fe33fb6-3d71-4732-9bdc-321c83456c4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_aed2a5de-4333-4498-b034-090270cb1469" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7a171c37-50d8-4336-bd2d-2fd905600035" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_aed2a5de-4333-4498-b034-090270cb1469" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_2dfd485b-b7b5-4c4e-a361-e8e194fcfee8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_aed2a5de-4333-4498-b034-090270cb1469" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_2dfd485b-b7b5-4c4e-a361-e8e194fcfee8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_75cb27a4-7781-4899-92f6-a562f88dacdf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_aed2a5de-4333-4498-b034-090270cb1469" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_75cb27a4-7781-4899-92f6-a562f88dacdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_37d820f9-51c7-448c-b0c1-acf2a51ad256" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_aed2a5de-4333-4498-b034-090270cb1469" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_37d820f9-51c7-448c-b0c1-acf2a51ad256" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_ae0d7343-c39d-4f10-8ff7-fc2952ed01eb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_aed2a5de-4333-4498-b034-090270cb1469" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_ae0d7343-c39d-4f10-8ff7-fc2952ed01eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_4f128f98-3a41-4c7b-b2fa-8b5d112b032d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_aed2a5de-4333-4498-b034-090270cb1469" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_4f128f98-3a41-4c7b-b2fa-8b5d112b032d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_c906065e-9c76-4faf-b0b3-61518813d779" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_aed2a5de-4333-4498-b034-090270cb1469" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_c906065e-9c76-4faf-b0b3-61518813d779" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StockOptionPlanStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="exdx-20241231.xsd#StockOptionPlanStockBasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/StockOptionPlanStockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f38f7753-f33c-48ac-8b6e-b13b555fdb7d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a52061ba-4e80-43b7-b6b7-ee07a1cbceed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f38f7753-f33c-48ac-8b6e-b13b555fdb7d" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a52061ba-4e80-43b7-b6b7-ee07a1cbceed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_573e493b-fea6-486a-a748-0e335a680ad5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a52061ba-4e80-43b7-b6b7-ee07a1cbceed" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_573e493b-fea6-486a-a748-0e335a680ad5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_afd28972-fdb7-4b09-882f-a05e11ea92e6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_573e493b-fea6-486a-a748-0e335a680ad5" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_afd28972-fdb7-4b09-882f-a05e11ea92e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_8bfd53b0-ae40-4d76-b6ae-40466438f7cc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_afd28972-fdb7-4b09-882f-a05e11ea92e6" xlink:to="loc_us-gaap_CostOfSalesMember_8bfd53b0-ae40-4d76-b6ae-40466438f7cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_fd0a373f-0149-464a-85e0-6d48e71fd362" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_afd28972-fdb7-4b09-882f-a05e11ea92e6" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_fd0a373f-0149-464a-85e0-6d48e71fd362" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_ccfb353a-552e-4716-b6cf-08c905a8a5a9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_afd28972-fdb7-4b09-882f-a05e11ea92e6" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_ccfb353a-552e-4716-b6cf-08c905a8a5a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c2916ad2-1929-4140-87a2-89d257b2c569" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a52061ba-4e80-43b7-b6b7-ee07a1cbceed" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c2916ad2-1929-4140-87a2-89d257b2c569" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_7dabee08-1819-4b0a-98a0-3f8175745bdf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c2916ad2-1929-4140-87a2-89d257b2c569" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_7dabee08-1819-4b0a-98a0-3f8175745bdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StockOptionPlanCommonStockReservedForFutureIssuanceDetails" xlink:type="simple" xlink:href="exdx-20241231.xsd#StockOptionPlanCommonStockReservedForFutureIssuanceDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/StockOptionPlanCommonStockReservedForFutureIssuanceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_777759fb-56ce-430d-bb4e-d8c1a01e462b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_32da293e-89e9-4ca8-8f10-5649c047eb4e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_777759fb-56ce-430d-bb4e-d8c1a01e462b" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_32da293e-89e9-4ca8-8f10-5649c047eb4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_863188ab-e44a-41f3-a983-c026543d2d39" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_32da293e-89e9-4ca8-8f10-5649c047eb4e" xlink:to="loc_us-gaap_AwardTypeAxis_863188ab-e44a-41f3-a983-c026543d2d39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_214599ac-f24d-41c8-a48c-df9bcf66cb44" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_863188ab-e44a-41f3-a983-c026543d2d39" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_214599ac-f24d-41c8-a48c-df9bcf66cb44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_4b298fcb-19c7-4399-a3f8-3d6e2b86ed1a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_214599ac-f24d-41c8-a48c-df9bcf66cb44" xlink:to="loc_us-gaap_WarrantMember_4b298fcb-19c7-4399-a3f8-3d6e2b86ed1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_45d0dce3-c234-4ddd-b46a-922551489016" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_214599ac-f24d-41c8-a48c-df9bcf66cb44" xlink:to="loc_us-gaap_EmployeeStockOptionMember_45d0dce3-c234-4ddd-b46a-922551489016" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_e492b6d8-f6bd-4cc6-8621-59b0dbebb179" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_214599ac-f24d-41c8-a48c-df9bcf66cb44" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_e492b6d8-f6bd-4cc6-8621-59b0dbebb179" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_CommonSharesAvailableForGrantUnderThe2019PlanMember_b968b866-ba56-41f1-a07d-763b1f1935d0" xlink:href="exdx-20241231.xsd#exdx_CommonSharesAvailableForGrantUnderThe2019PlanMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_214599ac-f24d-41c8-a48c-df9bcf66cb44" xlink:to="loc_exdx_CommonSharesAvailableForGrantUnderThe2019PlanMember_b968b866-ba56-41f1-a07d-763b1f1935d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_f7b60789-b665-4b17-81c9-d9c05f878b5a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_214599ac-f24d-41c8-a48c-df9bcf66cb44" xlink:to="loc_us-gaap_EmployeeStockMember_f7b60789-b665-4b17-81c9-d9c05f878b5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5a48927e-d094-4543-a06c-08ff9e52a74a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_32da293e-89e9-4ca8-8f10-5649c047eb4e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5a48927e-d094-4543-a06c-08ff9e52a74a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_39cc1292-d8b3-4b1c-96d0-3480d2a0f693" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5a48927e-d094-4543-a06c-08ff9e52a74a" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_39cc1292-d8b3-4b1c-96d0-3480d2a0f693" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails" xlink:type="simple" xlink:href="exdx-20241231.xsd#IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0d147572-2b0b-43ce-96e1-0ac2568300ae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_30b98dc2-e65a-4ca2-aec3-5521e279a347" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0d147572-2b0b-43ce-96e1-0ac2568300ae" xlink:to="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_30b98dc2-e65a-4ca2-aec3-5521e279a347" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_df4d5af9-915d-472c-8248-beceec963bb9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_30b98dc2-e65a-4ca2-aec3-5521e279a347" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_df4d5af9-915d-472c-8248-beceec963bb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_cae64c59-8022-485d-b5de-983f72200ca5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_30b98dc2-e65a-4ca2-aec3-5521e279a347" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_cae64c59-8022-485d-b5de-983f72200ca5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_28feaeea-d45f-4cfc-a60c-86091d93af76" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_30b98dc2-e65a-4ca2-aec3-5521e279a347" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_28feaeea-d45f-4cfc-a60c-86091d93af76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_ac802ac5-0268-4ce6-9093-1c06e554172c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0d147572-2b0b-43ce-96e1-0ac2568300ae" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_ac802ac5-0268-4ce6-9093-1c06e554172c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_98dd1762-cd09-4691-9745-6b9acb4e26aa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_ac802ac5-0268-4ce6-9093-1c06e554172c" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_98dd1762-cd09-4691-9745-6b9acb4e26aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_4553a8d8-befc-4337-9484-520a584fac16" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_ac802ac5-0268-4ce6-9093-1c06e554172c" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_4553a8d8-befc-4337-9484-520a584fac16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_9ee032c6-f145-4086-8f90-a948600a3443" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_ac802ac5-0268-4ce6-9093-1c06e554172c" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_9ee032c6-f145-4086-8f90-a948600a3443" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_d90dbfdf-24f4-4499-9646-f8a2b2dcc2a5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0d147572-2b0b-43ce-96e1-0ac2568300ae" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_d90dbfdf-24f4-4499-9646-f8a2b2dcc2a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails" xlink:type="simple" xlink:href="exdx-20241231.xsd#IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_547e8f50-b087-4363-9672-cfe32f98fe05" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_e99741c5-3e45-4594-9b0e-2932373892db" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_547e8f50-b087-4363-9672-cfe32f98fe05" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_e99741c5-3e45-4594-9b0e-2932373892db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_f8ee7d04-0cd0-40e3-a135-fef67a601368" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_547e8f50-b087-4363-9672-cfe32f98fe05" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_f8ee7d04-0cd0-40e3-a135-fef67a601368" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_f9d51c0b-acc3-46f9-8cb5-0981cbe04858" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_547e8f50-b087-4363-9672-cfe32f98fe05" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_f9d51c0b-acc3-46f9-8cb5-0981cbe04858" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_7107f962-6423-4c72-9931-403d39623ddb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_547e8f50-b087-4363-9672-cfe32f98fe05" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_7107f962-6423-4c72-9931-403d39623ddb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_c12c1e92-5dcd-4c6b-8e68-a6462b8d962e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_547e8f50-b087-4363-9672-cfe32f98fe05" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_c12c1e92-5dcd-4c6b-8e68-a6462b8d962e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_9da92ab8-f869-4737-ba2e-c7e40ec6b0b5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_547e8f50-b087-4363-9672-cfe32f98fe05" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_9da92ab8-f869-4737-ba2e-c7e40ec6b0b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_bb2e6f71-87ba-4902-bc19-e33ad2b5618e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_547e8f50-b087-4363-9672-cfe32f98fe05" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_bb2e6f71-87ba-4902-bc19-e33ad2b5618e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_48369733-46bc-4fa8-b2d9-d1f8a505bb52" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_547e8f50-b087-4363-9672-cfe32f98fe05" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_48369733-46bc-4fa8-b2d9-d1f8a505bb52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="exdx-20241231.xsd#IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_91c9433e-1b1f-424a-bcb7-41c1c4928d98" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGrossAbstract_0c73dfce-df8a-41c4-9c8a-684258f35ce9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGrossAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_91c9433e-1b1f-424a-bcb7-41c1c4928d98" xlink:to="loc_us-gaap_DeferredTaxAssetsGrossAbstract_0c73dfce-df8a-41c4-9c8a-684258f35ce9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_7749d03a-a733-406b-be15-6cb5aa628661" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_0c73dfce-df8a-41c4-9c8a-684258f35ce9" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_7749d03a-a733-406b-be15-6cb5aa628661" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_e1a80e37-e0ca-4eb4-b341-80101c9c545b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_0c73dfce-df8a-41c4-9c8a-684258f35ce9" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_e1a80e37-e0ca-4eb4-b341-80101c9c545b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves_044c79b5-a8b5-41be-8b13-5926f2212e55" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_0c73dfce-df8a-41c4-9c8a-684258f35ce9" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves_044c79b5-a8b5-41be-8b13-5926f2212e55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_7d292435-bcec-4f9a-85b9-6e3687305040" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_0c73dfce-df8a-41c4-9c8a-684258f35ce9" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_7d292435-bcec-4f9a-85b9-6e3687305040" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_5108e8bb-89db-40f5-872d-dd7d1fc57a05" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_0c73dfce-df8a-41c4-9c8a-684258f35ce9" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_5108e8bb-89db-40f5-872d-dd7d1fc57a05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_27fc04d4-b16c-43ca-8dba-a199c214b849" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_0c73dfce-df8a-41c4-9c8a-684258f35ce9" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_27fc04d4-b16c-43ca-8dba-a199c214b849" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DeferredTaxAssetsLeaseLiability_74dc559a-fa2a-4620-846b-2714080cb6c5" xlink:href="exdx-20241231.xsd#exdx_DeferredTaxAssetsLeaseLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_0c73dfce-df8a-41c4-9c8a-684258f35ce9" xlink:to="loc_exdx_DeferredTaxAssetsLeaseLiability_74dc559a-fa2a-4620-846b-2714080cb6c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCapitalizationOfResearchAndExperimentationCosts_9f4a1a98-ff07-4006-a4fa-eba4ff44da53" xlink:href="exdx-20241231.xsd#exdx_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCapitalizationOfResearchAndExperimentationCosts"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_0c73dfce-df8a-41c4-9c8a-684258f35ce9" xlink:to="loc_exdx_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCapitalizationOfResearchAndExperimentationCosts_9f4a1a98-ff07-4006-a4fa-eba4ff44da53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_eefe569a-5bdb-47bb-9f87-e28327fcb990" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_0c73dfce-df8a-41c4-9c8a-684258f35ce9" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_eefe569a-5bdb-47bb-9f87-e28327fcb990" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_571399e6-53cc-419e-b0a6-e83a41f6b928" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_0c73dfce-df8a-41c4-9c8a-684258f35ce9" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_571399e6-53cc-419e-b0a6-e83a41f6b928" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_5648436d-53c7-43b0-ae2c-8383b212a85c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_0c73dfce-df8a-41c4-9c8a-684258f35ce9" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_5648436d-53c7-43b0-ae2c-8383b212a85c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract_09023a0e-fab9-455e-b465-ef01f5536903" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_91c9433e-1b1f-424a-bcb7-41c1c4928d98" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesAbstract_09023a0e-fab9-455e-b465-ef01f5536903" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DeferredTaxLiabilitiesRightOfUseAssets_3e8c9538-e476-4a04-9295-4dac82505b04" xlink:href="exdx-20241231.xsd#exdx_DeferredTaxLiabilitiesRightOfUseAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_09023a0e-fab9-455e-b465-ef01f5536903" xlink:to="loc_exdx_DeferredTaxLiabilitiesRightOfUseAssets_3e8c9538-e476-4a04-9295-4dac82505b04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets_9fe95c1c-5084-4ddc-a863-361cf08c7571" xlink:href="exdx-20241231.xsd#exdx_DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_09023a0e-fab9-455e-b465-ef01f5536903" xlink:to="loc_exdx_DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets_9fe95c1c-5084-4ddc-a863-361cf08c7571" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_9ceef82c-0111-40cd-9dee-90756e364cfb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_09023a0e-fab9-455e-b465-ef01f5536903" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_9ceef82c-0111-40cd-9dee-90756e364cfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_1f596136-5c33-415c-adc7-a230e230b7d8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_91c9433e-1b1f-424a-bcb7-41c1c4928d98" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_1f596136-5c33-415c-adc7-a230e230b7d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/IncomeTaxesChangeInValuationAllowanceDetails" xlink:type="simple" xlink:href="exdx-20241231.xsd#IncomeTaxesChangeInValuationAllowanceDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/IncomeTaxesChangeInValuationAllowanceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_666a3463-7ef8-4ce0-b4c2-42df2364ae93" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ChangesInTheValuationAllowanceForDeferredTaxAssetsRollForward_83b3ff3b-730c-4d48-999f-8644472e04e8" xlink:href="exdx-20241231.xsd#exdx_ChangesInTheValuationAllowanceForDeferredTaxAssetsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_666a3463-7ef8-4ce0-b4c2-42df2364ae93" xlink:to="loc_exdx_ChangesInTheValuationAllowanceForDeferredTaxAssetsRollForward_83b3ff3b-730c-4d48-999f-8644472e04e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_2f94952a-296d-4462-8c59-ec4cb8b38017" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_ChangesInTheValuationAllowanceForDeferredTaxAssetsRollForward_83b3ff3b-730c-4d48-999f-8644472e04e8" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_2f94952a-296d-4462-8c59-ec4cb8b38017" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_811c1d70-65ac-4fe1-8762-f3120b645e94" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_ChangesInTheValuationAllowanceForDeferredTaxAssetsRollForward_83b3ff3b-730c-4d48-999f-8644472e04e8" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_811c1d70-65ac-4fe1-8762-f3120b645e94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_42f6c473-d15a-4d49-94d6-b096ec9fcd5d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_ChangesInTheValuationAllowanceForDeferredTaxAssetsRollForward_83b3ff3b-730c-4d48-999f-8644472e04e8" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_42f6c473-d15a-4d49-94d6-b096ec9fcd5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="exdx-20241231.xsd#IncomeTaxesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_312c6fd4-3fd5-4705-bfd8-ba07e64a6eda" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardTable_338c483e-8524-49bd-b36b-5035fd7fe0cf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_312c6fd4-3fd5-4705-bfd8-ba07e64a6eda" xlink:to="loc_us-gaap_TaxCreditCarryforwardTable_338c483e-8524-49bd-b36b-5035fd7fe0cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodAxis_8cfa3ad7-fa70-472f-9526-0056cd078e49" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_338c483e-8524-49bd-b36b-5035fd7fe0cf" xlink:to="loc_us-gaap_TaxPeriodAxis_8cfa3ad7-fa70-472f-9526-0056cd078e49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain_c0e0eeea-cf1b-44be-aee8-f0dacca7855f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodAxis_8cfa3ad7-fa70-472f-9526-0056cd078e49" xlink:to="loc_us-gaap_TaxPeriodDomain_c0e0eeea-cf1b-44be-aee8-f0dacca7855f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_TaxYearsThroughDecember312017Member_4438e1c3-7d8d-4ba4-8fbe-87766340cc73" xlink:href="exdx-20241231.xsd#exdx_TaxYearsThroughDecember312017Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_c0e0eeea-cf1b-44be-aee8-f0dacca7855f" xlink:to="loc_exdx_TaxYearsThroughDecember312017Member_4438e1c3-7d8d-4ba4-8fbe-87766340cc73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardLineItems_75aa7071-f14b-401a-b6fa-c35ffb02d7f8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_338c483e-8524-49bd-b36b-5035fd7fe0cf" xlink:to="loc_us-gaap_TaxCreditCarryforwardLineItems_75aa7071-f14b-401a-b6fa-c35ffb02d7f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_6958cd0e-32e6-48fe-9a93-ed79572bb6fa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_75aa7071-f14b-401a-b6fa-c35ffb02d7f8" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_6958cd0e-32e6-48fe-9a93-ed79572bb6fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_6b1fb19b-9e84-45c7-9087-b23cfcca2fbc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_75aa7071-f14b-401a-b6fa-c35ffb02d7f8" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_6b1fb19b-9e84-45c7-9087-b23cfcca2fbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_e2f2159e-5844-4895-b0e6-53c9baf8e715" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_75aa7071-f14b-401a-b6fa-c35ffb02d7f8" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_e2f2159e-5844-4895-b0e6-53c9baf8e715" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_1f585c21-6995-48e6-8051-6a624afd9518" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_75aa7071-f14b-401a-b6fa-c35ffb02d7f8" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_1f585c21-6995-48e6-8051-6a624afd9518" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_fe80efec-2d45-4cec-bf7a-f43adb6dc939" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_75aa7071-f14b-401a-b6fa-c35ffb02d7f8" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_fe80efec-2d45-4cec-bf7a-f43adb6dc939" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/A401kPlanDetails" xlink:type="simple" xlink:href="exdx-20241231.xsd#A401kPlanDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/A401kPlanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_84613045-b619-472e-8a99-e2040cb1e3ce" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_e19de81f-e18b-461a-9abb-cdf0605a76a4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_84613045-b619-472e-8a99-e2040cb1e3ce" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_e19de81f-e18b-461a-9abb-cdf0605a76a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_1244c7f4-ddbc-434f-9149-62bee5f53ce4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_84613045-b619-472e-8a99-e2040cb1e3ce" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_1244c7f4-ddbc-434f-9149-62bee5f53ce4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/SegmentReportingNarrativeDetails" xlink:type="simple" xlink:href="exdx-20241231.xsd#SegmentReportingNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/SegmentReportingNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_f604694d-471c-44b1-a1fc-34b9629efa23" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_b0f3cad1-a488-4b0c-864f-497c2a9f6ea6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_f604694d-471c-44b1-a1fc-34b9629efa23" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_b0f3cad1-a488-4b0c-864f-497c2a9f6ea6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_17b1314f-5434-4568-b3f0-5dff34ebbe53" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_b0f3cad1-a488-4b0c-864f-497c2a9f6ea6" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_17b1314f-5434-4568-b3f0-5dff34ebbe53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_f5263fac-e8f1-437b-a24a-33d894b47858" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_17b1314f-5434-4568-b3f0-5dff34ebbe53" xlink:to="loc_us-gaap_SegmentDomain_f5263fac-e8f1-437b-a24a-33d894b47858" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ReportableSegmentMember_cc74d210-578a-433d-bae1-728877e6eb97" xlink:href="exdx-20241231.xsd#exdx_ReportableSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_f5263fac-e8f1-437b-a24a-33d894b47858" xlink:to="loc_exdx_ReportableSegmentMember_cc74d210-578a-433d-bae1-728877e6eb97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_b559027b-ef1a-4cb1-9fa4-c199a9d9da1d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_b0f3cad1-a488-4b0c-864f-497c2a9f6ea6" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_b559027b-ef1a-4cb1-9fa4-c199a9d9da1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_a69bc961-a80f-4a6f-97d5-c15e2d70b4ae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_b559027b-ef1a-4cb1-9fa4-c199a9d9da1d" xlink:to="loc_us-gaap_NumberOfOperatingSegments_a69bc961-a80f-4a6f-97d5-c15e2d70b4ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_437e93a5-bae6-4700-8cbe-8add5b5325e6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_b559027b-ef1a-4cb1-9fa4-c199a9d9da1d" xlink:to="loc_us-gaap_Assets_437e93a5-bae6-4700-8cbe-8add5b5325e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/SegmentReportingDetails" xlink:type="simple" xlink:href="exdx-20241231.xsd#SegmentReportingDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/SegmentReportingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_c77f5b87-b0e9-434c-baba-f8f56b0632ac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_138644d9-1bb5-40d1-8a64-efd06f763448" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_c77f5b87-b0e9-434c-baba-f8f56b0632ac" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_138644d9-1bb5-40d1-8a64-efd06f763448" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_8bc7bcbf-d6f6-4a11-a1ab-49bf6009316d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_138644d9-1bb5-40d1-8a64-efd06f763448" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_8bc7bcbf-d6f6-4a11-a1ab-49bf6009316d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_2bb20a0d-4a2b-49a6-9a89-4a51662aa682" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_8bc7bcbf-d6f6-4a11-a1ab-49bf6009316d" xlink:to="loc_us-gaap_SegmentDomain_2bb20a0d-4a2b-49a6-9a89-4a51662aa682" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ReportableSegmentMember_132d92ed-f5f8-469f-a9f6-2d9ff55d49ec" xlink:href="exdx-20241231.xsd#exdx_ReportableSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_2bb20a0d-4a2b-49a6-9a89-4a51662aa682" xlink:to="loc_exdx_ReportableSegmentMember_132d92ed-f5f8-469f-a9f6-2d9ff55d49ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_a4d648b3-f934-47ec-9a49-a10cae9e2445" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_138644d9-1bb5-40d1-8a64-efd06f763448" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_a4d648b3-f934-47ec-9a49-a10cae9e2445" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_28ca31d4-4cb2-4755-93a2-8f70ed6342fe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_a4d648b3-f934-47ec-9a49-a10cae9e2445" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_28ca31d4-4cb2-4755-93a2-8f70ed6342fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_92254e6b-3248-4d9a-9e92-22215458348f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_a4d648b3-f934-47ec-9a49-a10cae9e2445" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_92254e6b-3248-4d9a-9e92-22215458348f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_f9df8820-bca0-4789-87cb-040a9d6f3f66" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_a4d648b3-f934-47ec-9a49-a10cae9e2445" xlink:to="loc_us-gaap_GrossProfit_f9df8820-bca0-4789-87cb-040a9d6f3f66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LaborAndRelatedExpense_d0648953-7860-4ed3-b5a1-e458c23705a8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LaborAndRelatedExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_a4d648b3-f934-47ec-9a49-a10cae9e2445" xlink:to="loc_us-gaap_LaborAndRelatedExpense_d0648953-7860-4ed3-b5a1-e458c23705a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OutsideServicesExpense_874bb7ce-5c71-4067-a14a-0967a8696508" xlink:href="exdx-20241231.xsd#exdx_OutsideServicesExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_a4d648b3-f934-47ec-9a49-a10cae9e2445" xlink:to="loc_exdx_OutsideServicesExpense_874bb7ce-5c71-4067-a14a-0967a8696508" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OccupancyNet_41cd9463-d21e-4355-a837-f7f6b3a0e49d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OccupancyNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_a4d648b3-f934-47ec-9a49-a10cae9e2445" xlink:to="loc_us-gaap_OccupancyNet_41cd9463-d21e-4355-a837-f7f6b3a0e49d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TravelAndEntertainmentExpense_aa911582-732f-4d8a-93d1-e78e17820b97" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TravelAndEntertainmentExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_a4d648b3-f934-47ec-9a49-a10cae9e2445" xlink:to="loc_us-gaap_TravelAndEntertainmentExpense_aa911582-732f-4d8a-93d1-e78e17820b97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_d388c035-03f2-4bc9-baf7-53bbb2b145a8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_a4d648b3-f934-47ec-9a49-a10cae9e2445" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_d388c035-03f2-4bc9-baf7-53bbb2b145a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_8841cb22-6f84-4343-8ea7-48eabb60fcfd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_a4d648b3-f934-47ec-9a49-a10cae9e2445" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_8841cb22-6f84-4343-8ea7-48eabb60fcfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingOtherItemAmount_5853c2d5-5ece-43b5-b626-1576e95c6118" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingOtherItemAmount"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_a4d648b3-f934-47ec-9a49-a10cae9e2445" xlink:to="loc_us-gaap_SegmentReportingOtherItemAmount_5853c2d5-5ece-43b5-b626-1576e95c6118" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_286c8669-b949-4f56-bd01-35d3b849825d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_a4d648b3-f934-47ec-9a49-a10cae9e2445" xlink:to="loc_us-gaap_OperatingExpenses_286c8669-b949-4f56-bd01-35d3b849825d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_410cb0e7-0ecf-45f4-9892-28226632deed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_a4d648b3-f934-47ec-9a49-a10cae9e2445" xlink:to="loc_us-gaap_OperatingIncomeLoss_410cb0e7-0ecf-45f4-9892-28226632deed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating_7d6d6b4f-9958-4a3e-8af1-461047c7702d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_a4d648b3-f934-47ec-9a49-a10cae9e2445" xlink:to="loc_us-gaap_InterestExpenseNonoperating_7d6d6b4f-9958-4a3e-8af1-461047c7702d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_ee874065-0a7b-4bd0-be6c-071c2a6e9cf1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_a4d648b3-f934-47ec-9a49-a10cae9e2445" xlink:to="loc_us-gaap_InvestmentIncomeInterest_ee874065-0a7b-4bd0-be6c-071c2a6e9cf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent_5fc852d5-a83e-44dd-9f79-df4cf5295f73" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_a4d648b3-f934-47ec-9a49-a10cae9e2445" xlink:to="loc_us-gaap_IncomeLossAttributableToParent_5fc852d5-a83e-44dd-9f79-df4cf5295f73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_5093e513-987b-4859-a1de-1fd333fbae88" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_a4d648b3-f934-47ec-9a49-a10cae9e2445" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_5093e513-987b-4859-a1de-1fd333fbae88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_2e002de6-f223-4e10-a4f7-3633f7029830" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_a4d648b3-f934-47ec-9a49-a10cae9e2445" xlink:to="loc_us-gaap_NetIncomeLoss_2e002de6-f223-4e10-a4f7-3633f7029830" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardTimingDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaap_AwardTypeAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_EmployeeStockOptionMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardExrcPrice"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardExrcPrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardGrantDateFairValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ErrCompDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompRecoveryTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompRecoveryTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_RestatementDateAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonNeosMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_ecd_NonNeosMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDeterminationDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDeterminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompAmt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_ExecutiveCategoryAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="loc_ecd_AllExecutiveCategoriesMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_PeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_NonPeoNeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_AdjToCompAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllAdjToCompMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="loc_ecd_AllAdjToCompMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtPnsnAdjsSvcCstMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsSvcCstMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="loc_ecd_PnsnAdjsSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsPrrSvcCstMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_EqtyAwrdsAdjsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_MeasureAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoTotalCompAmt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TabularListTableTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TabularListTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_us-gaap_NetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_OtherPerfMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAmt"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoName"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureName"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_MeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnBnftsAdjFnTextBlock"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjFnTextBlock"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangements"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrByIndTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TradingArrByIndTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_TradingArrAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllTradingArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrAxis" xlink:to="loc_ecd_AllTradingArrangementsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndTitle"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndTitle" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrAdoptionDate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrAdoptionDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrTerminationDate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrTerminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrExpirationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrExpirationDate"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrExpirationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrDuration"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrDuration" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingPoliciesProc"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>exdx-20241231_g1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 exdx-20241231_g1.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  (! 0$! 0(! 0$" @(" @0# @("
M @4$! ,$!@4&!@8%!@8&!PD(!@<)!P8&" L("0H*"@H*!@@+# L*# D*"@K_
MVP!# 0(" @(" @4# P4*!P8'"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@K_P  1" "1 8H# 2(  A$! Q$!_\0
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M&K]!J93POD--+&RYZCZ:W]4ELO7Y,^@AF7$6=5&\*N2'R2]&WN_3YGS9I?\
MP<I_\%';#Q7=>(;JV^'][9W"XBT&Z\,2K:6W&,HT=PDY]?GE;D^G%>Q? /\
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MG_"-Z]?:/'JEK8_\(WJ5YYEH\LL2R;[6VE09>"5=I8,-N2,$$^^5^#?_  =
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M+VRG5F6>>%0FVV<$AB<E>""2/L[_ (.NCE_@+C^[XH_]Q-?G3^PC^PC\7O\
M@H5\7]1^"WP5\0^'--U33?#LVM7%QXGO+B&W:WCN+>!E5H()F+[KE" 5 P&Y
M! !^LR6&%J<'QCB7:F^;F>VG.SP<XGB:?$[EAU>::LO/E1^NW_$41^P7_P!$
M?^+W_@ATK_Y8T?\ $41^P7_T1_XO?^"'2O\ Y8U\?_\ $+]^W[_T5GX1?^%!
MJO\ \KJ/^(7[]OW_ **S\(O_  H-5_\ E=7C?V?P3_S_ '][_P CU/K_ !?_
M ,^OP7^9]@?\11'[!?\ T1_XO?\ @ATK_P"6-'_$41^P7_T1_P"+W_@ATK_Y
M8U\?_P#$+]^W[_T5GX1?^%!JO_RNH_XA?OV_?^BL_"+_ ,*#5?\ Y74?V?P3
M_P _W][_ ,@^O\7_ //K\%_F?LQ^R)^U#X!_;._9Y\/_ +2GPPTC6-/T/Q)]
MK^PVFO6\45VGV>[FM7\Q8I94&7@<C#G*E2<'('SC_P %J/\ @F%:?M[? K_A
M-?A7X;T\?%CP?"9?#]]*WE2:O9#<TNE/)G;\Q8R0F0%4F&T-$D\SUZ]_P3)_
M9>\?_L8_L1>"OV;/BEJVCWVN^&_[2^W76@W$LMI)]HU*ZND\MI8HG.$G0'*#
M#!@,C!/N5]#/>+]DM-0N+619(I6FAC7YE$@8QY=&7#A2C8&X*Q(*L58?'1Q/
M]GYFZN$EI&3Y7WC?2_JMSZR6'^O9:J>*CK**NNSMK;T>Q_)S^SO\>OB%^R_\
M;O#/Q^^%6H1V^O>%=42]L?.W^3. "LEO*$9&:&6-GBD564LDC $9S7]/'[%?
M[6_PT_;;_9U\._M ?#/5+-EU2SC37-)M;PS/HFI"-&N=/E+)&V^)FP&*()$,
M<J@I(C'\EO\ @XH_X)K7GPG^)LG[=?P<\-7DWACQA>?\7 MK'385M=!U,B*.
M.[)BPPCO&+%W="!<AB\I:ZBC'C7_  1%_P""F-W^PM^T"OP[^*'B'4&^%_CB
MX2UUBT^V1K:Z+J#O$D6KE9!\JJB^7/L="T3!V$K6T49^_P YPM'B;*8YAAE^
M\BM5U\T_-;KO\SXG*L56X?S26"Q#]R3WZ>37D]F?T222+%&TCG"KR:_&?]L'
MXS>-_P#@J/\ MK:3\*_@=.MUH<-PVF>"5OHS;(4V"6[OI0Q9@K>4[\*'\F&,
M>4) RGZ:_P""TG[<MIX(\%R?LF?#'7;:;6O$%M_Q6,UM>2+-I5D?+=+?]WA0
M]PI.Y68D0Y#1E9T<;?\ P1A_8I;X.?#'_AI?Q]INWQ+XRT]?[$5;[>MKHL@C
MEC+*HVB29@)&RSE46(?NW\U#^537M*GLUMU/GN+,56XWXBI\,X*7[BFU/$37
M9--03VO]^O\ A9U_[=/QC\,_\$IO^"96I3_".>WL]3T?1X/#W@7[0T$<LVJ7
M&4%V5\EHIYXQY]\Z&,+,8) =H<D?SS_"SX:_&']K;X^:7\-_"*:AXC\9^.->
MV?:KR26XFN+F9R\UW<28=RJCS)IIFSM19)&. 37ZH?\ !U-\6YH[/X0_ C2_
M&4/ERS:IKVN>'XY$,@9!!;V-TZXWJN'U%$.0K$2]2G'F_P#P:\_ ;3?&O[3G
MCW]H'58]/N/^$%\+V^GZ;#=68DF@O-2EDQ=0N?\ 5,L%G<PL1\Q6[(S@L#^H
M9#R9+PS4S!)<TKV^_EBO2^I]!F5&.,SJCEM+W:=-122V22N[?*R/U*_X)[?\
M$]_@K_P3M^"L?PS^&,']H:QJ'ES^+_%]U:K'=ZW=*" S $^5!'N=8;<,5B5F
M)+R/++)[X*.V*0D@Y-?G-:O6Q%:52I)RE)W;9^@T:-+#TE3IJT5HDA:***S-
MCS/]K+]D[X*_MI_!34O@1\>/#7]H:3J&);6ZMV5+O3+M0PBO+64@^5.FYL-@
MJRL\;J\;NC?S'_M+?!/XT_L?_%KQ=^R7\5M2^SWFBZQ;2ZQI^EZH9=/OI$@=
M[.\ ! ?-O>.T9=5DC2Z=66-FD2OZNL$FOQS_ .#IK]GN6'7/AC^U5I6DW31W
M-K<^%->OFN4\B%D9KNPC$?WM[^9J+%AE<1*#M.-WV7!F92P^/^J3?N3VOTDM
M4UZVMYNW8^1XLR^%;!_68KWX;VZIZ6?I>_WGE/\ P:_$_P##?WBS_LD.H?\
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MN($3Q37L=TDN&*O:KM )#I_1![&MN-LSG"K#+Z+M&*3:6E^R]$E?MKY&7".
MC.G+&U%>3;2O^+]6].^@M%%%?GY]R&>:Y7XQ_!SX:?M _#'6O@Y\8O!]GKWA
MO7[-K;5-+O%)25,@A@00T<B,%=)$(>-T5T9652.JH&?6G&4H24D[-:IKH1.$
M:D7&2NF?RM?MU_L<^/\ ]@_]I;7OV=/'M]_:']F^7<Z-KT>GRV\.L:?,NZ&Y
MC60?[T<@5G1)H9HQ(_EEC[#_ ,$%.?\ @K'\*/\ >US_ -,-_7W'_P '2_P&
M\/WOPD^&G[3EL;.WU32_$DWA>\6/3$^T7]O=6\MW#ON 0VRW:SGV1$,,WLC
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MH$%I-JWC'5M/\G[19Z;!M5C$)6 +R3206ZL%D,9N!(8W2-UK^ESX0?"'X;?
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M /"@U3_Y74?\0O\ ^W[_ -%8^$?_ (4&J?\ RNK]Y/PHQ[5\O_KAGG\R_P#
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MX->?^3"?&'_97M0_]-6EU^DE?FW_ ,&O/_)A/C#_ +*]J'_IJTNOTDKP<_\
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MZNG>$_$VL*=OB2$K^X@GN.GVT$&(-)M-P?*&Z6>1M_U/_P %,O\ @F/\*O\
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MK>*,/!YL[1EHT!G&U%S'N:?[*_X)B_\ !,?2/V7])M_C-\9+&WOOB+?6Y\F
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MG]E4T?*_+3T6AT^VI:KF6F^JT.SS35('%?)?[ ?_  4;\&?M'GXV2_$GXY>
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MK,X6-7+$JJLQP. I)X!H+EB\+"RE-*[:5VM6G;OWT]3O#GM16/J_CGP7X?\
M$FD^$-=\6Z;9ZMKGG_V+IMU?)'<7_DH'F\F-B&EV(0S;0=H.3@5@_#_]H[X
M_%?7)/#/PQ^-GA/Q%J$<#3R6.B>(;:ZE6($ R%8G9@H+*"V, L/44!+&86-1
M0E.*E>R5U=NR=K=[-?>CMJ***#H/S1_9_N_^"A7Q-_;/_:F_:8_8HT;X.6NF
MZM\3X?!.K67Q0U+59)DNO#EDEHMQ"+&$+Y<PG\PJS%@?D_AWO<_:1\ ?M?\
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M6PIWH&0X#DCSNIXM6IF6%SZM7AA95%.,(QDG!15G)N_-)26LM;1=TE:YY/\
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M)GPQ^-NF^(H)/"?PI^/SVOA_QW>7PGO'\$M?S:<[O(1N"OYBPM%&JJ888B$
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M\;X(-:=CGCD.(I2K4'3E)2M&,KP:Y>5+5RO)-.[>C;?O6=V>,ZQX+UG]I/\
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(H4444&<C_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>exdx-20241231_g2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 exdx-20241231_g2.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X13T17AI9@  34T *@    @  0$2  ,
M   !  $      !H !@$#  ,    !  8   $:  4    !    : $;  4    !
M    < $H  ,    !  (   (!  0    !    > ("  0    !   4<P
M  !@     0   &     !_]C_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+#!D2
M$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_VP!#
M 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !X &(# 2$  A$! Q$!_\0 'P
M 04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%! 0
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MO38.XYP6)]!M0TV[D*VVN:LDRQLZXAE.%?!!V[,%1NX)&>1AAB@"W%-87MO
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ /2LCQ#XDL
M/".C7&HZM=VVG6-FADFNKB98H84'\3NV%4?C6L_W:^#?^"Z=QJ5Q\!O"VFZ=
M<LRWFL,]S81/F:ZCCAD;S-@Y9(_O'LN]:4I6BV>'Q'F[RS+JN-4.=P5[=^Q]
M*7?[7O@_7A!:>#M5T[QWKFH,T=GI^C7L4[,5ZO,ZL5AB7O(__ 0S;5:IX[_9
MNUSXVZ*Z>+/'/B72S<1X.G>&+W^SK6'*_,OFA/.F_P"!L%/]Q:_.O_@B7X-\
M57/[4KZSIUM=P^&;/3YX=5N"A^SR;U_=1!ONLWF;6^7YOD>OUWV%@.>F>**4
MKJY\_P (9Q6X@RYXS'4W"]URZI>OS/C/]C_Q5XR^ /[8_B/X'^)O$6I>*-"_
MLH:WX<O=1E,]W' &5?++GEE^\IYV[HN NZOM.OD62V3Q/_P6&BDB&1X<\ ?Z
M0W]V22\;:/\ OF6OKJFMCU.%HRA1JT7)R49R4;MO3HOEL%1]<5)63XD\26'A
M'0;W5-5O+>PTW3H'N;NZN'5([>)%W.[L>%4+UJ7%RT1].V:8 !)%/KYXTK_@
MH]\.-8\3BPFGO["W,IB>[NO(1;?'&Z>$2FYMT^9,M-"BKO7<1NKZ''2M9TIP
M=IJQE1KPJJ\'<****@V"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HKY
M^_:Q^,WC6T^)W@7X4_#.[T?2?&GQ!BO]3FUS5;)K^W\.Z18^2MS=BW#IYTYF
MNK2*)6=4W3;FRJ;6\GD_;6\:?L6_$#XB>#_BGJ%U\7CX;L?"VJ>'[W0M%AL-
M8U(ZYJEQI:6$EN)%MVE2XM]ZLICW1OR-R[J /MFBOD3XP_\ !3W4/A9X)\87
MX^#WCS4-1^&NBOK/C>"UO=-FC\'1F*2>*.=_M.+B4VZ+<-':^:R1.N3N95;F
M1_P5HA^"GP4T1O&&@:YXT\4^#_!ND^(/B;?Z1+IUA;^'I+BRCN9ML-S<1/-*
M(V:7R+=794V_Q,JD ^X:*\.^&W[83_&+]I'Q5X'\.>"?%%_HO@F]BT_6O%KR
M6L.DV\\NFV]_'#&CRBXF?;<1*VR+:C/\QKQ']L3]M7X@>#/B=\8?#W@O4+#3
M_P#A&;;P+X:T"273TN6BU_7M7FMY9"K?ZP1VKVCB,_+_ !?Q4 ?;]%?+GPQ^
M('Q1^"/[9?AWX6^._&FD?$K2/'GA?5-=T[4DT)-(U+2)]/N+..6.989&BD@E
M6]38VU&1H=OS[OE^HZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!KL$
M3)Z"OG?P+_P5B_9P^)_QR'PUT#XR>!=5\:37#64&G0:A_P ?5PO6&&7'E22?
M[*.S>U>I_'S3]"U3X%>,[+Q)K*>&_#E]H5]!JFJM<+;+I=JUO(LMP93@1^7'
MO;<Q"KMK\L9](\0_\$]/V1_A-X=^,O@'X-_'K]E[PWJ^B1>&_'O@^]?3=<TT
M27$:Z9J4EI]RXDW/$Q:UGW.K[OF^;< ?L+17Y5>&]"^+G[8_[1/[9EN?VF/B
M-\.-+^#?BGRO"^G:'<VL-OI9.EQSK-=^9$[R6FY>(-R+_KV)+;=OF'_#SCXS
M_MN_\,U>%3:?&C2X/&'PF?XA>*?^%16^G6VO:U>K?M8+LFOI$2WLPT7GLL69
M&^TQ+]WYE /VDK@OVA/VC?!W[*WPMN_&OCS5UT+PUI]Q;VT]Z]O+-Y<EQ/'!
M$NR-6?F25%^53UK\RM/_ &H/VE[OX&_"+X1^,-:\:_#/7OB7\9KSP);^.-7M
M].3Q,WAFWLVNX6D\DS6T>I2_/;;ES\T+-C<U=3^WX/BC^P#^P?\ &R#2_P!H
M[7_'SV&L^%9?#XUF6WF\6>%XKG5+6&YCNKB,+YL4RO\ N]\2LJ[^6H _4=7#
M*".].K\BOVI?%/QD^*'QF_X* :QI/Q\^)'@/2OV<]+T_7?">C:#-;I:_:1X?
M^VO'/YL3LT#M%S$I56:9V8GY=O1?!+XQ_%OX*_M5?LF^)-=^+GCGXB:=^TSX
M"UK7O%/AO5DM4TNQN[;1H=3A_LR&*)/LRAI?*V[FW+]XEFH _5.BOQ"_9E_:
M]_:E^.'PQ^'OQV\/6G[2?B;Q7XK\16][>Z1/%H,/PSNM'DO6AFL;:+[1]KC:
M.WWJD[+YK2IRM>@?$K5OC5\:/#/[=OCFP_:&^*7@QOV>/%&L7'@_2M&FM4L4
M^QZ3#>^3=+)$[S0'[@B5U5=[MAV;Y0#]?:*\T_8_^*>H_'/]E'X8^-M76!-4
M\8>%-+UN\6!=D:SW-I',^!_=W/Q7I= !1110 4444 %?.'QV_P""LO[.'[,'
MQ2U'P9\0/B[X0\*^*-*6(W>FWLKI-;^8BR)NPA'*NC#G^*OH^O@K_@X>T6S'
M[ -M=&TMOM+?$'PD#+Y0\QO^)S:K][K]V@#ZG_9D_:\^&O[9/@^^\0_"[QCI
M'C;1=-O#I]S>:<[/'#.$63RSD#YMKHW_  .O3J_-G_@J?^T9X^T[]NGX9_ G
MP9;?%_2_">L>%-0\8ZS_ ,*GATV'Q)JTD5S';101S7TD<4<$>[S)=F7;>B_=
MW,O!GX@_MD>)O^"?>IZ1:VWQ0CUSPY\54TW[5<7&C6'Q \0>"@GF.L++)):?
MVJC/L+*0S+#N4;FH _4?Q=XSTCP#H-QJ^O:IIVC:5: -<7M_<);6]N"=HWNY
M"KEFV\FM>*1)T#H58.,@C^(5^'G[;_C-?CQ_P1<_:9T!OBW\>K[5?A;XBT>Y
MO/#7C_38=+\3:#'<3VJQ:?J,R!EO[5V=[B)UVMNB3YF5=K?KGX"^'^L_!7]E
M:+0])\1^)/&6O:3HUP;+5/$-PESJ%].4DDB\YT1%;#.BC:H^5%% '#?%G_@K
M'^S;\#?C*?A_XO\ C3X#T'Q='*MM<:?<Z@/]#E;I'.XS'"Q_NRLK5] 66H0Z
MK90W5M)'/!<('BEB;<LB$9# C^$U^>7_  15^#_PB\;_ /!%'PY<^(=*\.ZQ
M8^,M-U*]^)%YJ\,4\MYJ33S?V@]\[Y;?&RO]_P"ZJ)C'RU\K_L8^,_B[\2OV
M>?\ @GO\+M&^*WCGX<Z!\1X_'5E>:CI+I_:%YHFG[FT[89D=586Z(L4A5MBN
MK*/E6@#]NKJ[CL[9YIG2..)2[NWW5 ZFN9^#_P 9/"_[0/PVTCQGX*UNR\1>
M%M>B,^GZE9N7ANT#,NY"V/XE8=*_.;PIX?\ B=^U/^T#^T9HP_:(^)'@+1OV
M9(]/\+>'K*"YLW_M.1-)CN9=6USS8#]M6X;=E?W:[4?:1]X?,_[,W[4'Q"T+
M]AG]A?X+^#S\6K/1/'/A#7?$&N3_  T2P3Q-J26=VRQ6EK+>R)%"@:7?*RDR
M;=FT?>:@#]WZ*_''XB?M&?M/>#?V0+;P]J6O_%/P'J#_ !\\-^$_"?BKQ3%I
MW_"27FAZ@Z[X=02UDDMY)(9'=3DCS(_*W#[U?JA^SY\';KX#?"K3_#5UXR\9
M>/I[&2:236_%5['>:I>&25I/WCQQQIM7=M150;555H [ZBBB@ HHHH *X7X]
M?M!^"_V6_A7?^-OB!XCT[PIX3TEXDO-2OWV0VYEE6*,-@'K(R*..]=U7P3_P
M<D7$ME_P2:\8316TEY)'XA\-.D";=TS#7;'$8R0NX]/F(6@#Z'_9E_X*'_ _
M]L?7K[2_AA\4/"'C35--B^T7%EIU\'NHHMVWS/*.'V;OEW8V^_->WU^;\7@'
MXI_M(_\ !0OX6?&_Q7\%4_9S\$? 31-?N=2U;5]6TZ_U+Q%]KL_)6V\JPD?;
M;0?/*=[_ #?PX:OG?X>_ML?%'PO\<OV<O'WA_P >_M)^-O"OQ@^)=IX:U/6_
M&NDZ7H_@GQ)IM_\ :/*_LO3$=KRW9%1'CD90K*C,S-N5: /UL\>?M&>!_AIX
M \9^*=6\3:9'HOP]MYKGQ%+;R_:9-'2*+SG6:*+<ZN(_FV[=VWM6]X#\<:;\
M3O!6C^(]#NEO]%U^SAU+3[I4*+<6\R+)%( P#?,K*W('6OQ_^!/PY\0?LX^#
M/^"G/CK1/BA\2[K7?!5QK\%D+W4H'AFNAH<-S%J$@$2[KN-DV(RD*J?+M/WJ
MTO'G[7GQ>_:!^.OP]^&5M>?M&-X>T+X,^&_%U\_PD_LF'6M8U34(OFN[NXOY
M(_\ 1DV;1'%G<[OO_A6@#]C*R?%7C#2? GAVZU?7=4L-&TNP3S+F]OKA+:WM
MT_O.[D*J_4U^3MK\;/VF?B?/^QG\._&WC?QW\*_$OC[Q-XOT+Q)JEK%80ZMK
MFFV-FTME<R)%YUM'<M#UV[E27<V&VK7FO[<$GCO5/^">W[?GP=\5?%7X@>,M
M,_9_U71[[0-9U.[@_M35+.]LX9SIVH2K$!<0)(^[HK,R+SM7;0!^W,%U'?VJ
M2Q.DD4BAU=6RK ]"#5FO-?V6/AC/\(OV?O#/A^X\3>)_&$MM:B0ZKK]VESJ%
MQYG[S:[HB+M3?L7:HVJBUZ50 4444 %%%% !1110!4O;^+3+.2XGEBAAA4M(
M\C[%11]YB3V%<;\./VFOAO\ &37;O2O"'Q!\%>*=3LL_:;32-;M;ZXM\==Z1
M.S+C_:%?&?\ P<M?L]?&3]I/_@F'J_AOX+6>KZMJC:Y9W6NZ1I;E;S6-*19O
M-@C0?-+^^:WD,8^\L3<'[I_-G]D/2_V&_'_[4/P/TKP[I/QD_8M^/G@W5+1T
M35X9_)\270,:BTFEN)'7;*V]=SQP^8LK(P;<JT ?T7T5^7?_  5 _P""D'[3
MW[/'[0'BO2?!;?LW_"WX?>#M)_M.QU?XG>*(4U#QM(L7F/#96T-QYL>6WHJR
M1KNV?>7=MKQSXS?\')?Q,C_X)4?!3X]^#O!?A*W\5^-?'<G@WQ#H]VD]S:LT
M*2,S6I\U&C\S:F-Y;;OVG=MW4 ?M/17XWW7_  5P_;N\ ?\ !0%_V;_$?PG^
M"4_Q*^(_A\Z_X)2VU6Y33="B_?.TE[-N+7"QQVMPK*BQLSHNT[6JO\(_^"^W
MQTD_8+_:[O\ QOX3\!Z?\;_V6]4M-.GDLX97T;4'FU%K1U>+S=VZ-H9?F20*
MV]&PNUMP!^S%<[%\3O#DWCE_"X\0Z&WBB.#[2VD"_B^W+%_ST,.[?M_VMNVO
MQG\;?\%U/VS_ -GW]E_X2?M,^//A9\)7^ GC$V%IJ%AIUQ<?V])YT;,;S)D*
M0K*R.T2XDVKL5_F;=6EHWQDT'0O^#JWQQ\1)[ME\+V?P.'B&2Y5?F^QKI]K.
M9,?]<_FH _:BBOP5O?\ @YK^/_BSX6ZW\=?#X_9=TWX9Z/JC6]O\-M7\4,GC
M[4K%95C:=8A*/G^?=\J#Y49EC=5W-^UG[-/QWTC]J#]GWP3\1M!$L>C>.M%M
M-<LXIMOF11W$2R"-\?Q+NVG_ &J .^HHHH **** "DX]J6HLX_*DW839G>*/
M%%EX-\.:CJ^HS);:=I=M)=7,[_=CCC5F=C]%6ORO_85_X+\>._VCOVT?"_@[
MQEX:\*Z'X"\<WMU9:-?P6]Q#=,XW?9U+O*R,Q950[5'S/_#7T/\ \%]OVEO^
M&>_^">/B:SM9C'K'Q FC\,V:AOFVS!FN&_[\JZ_\#6OB3_@H;^PCJ7[(7_!+
M[]FWQYH4;6OBWX47<-YJTJ)^\AFOY%N]Y/\ TRND1!_OU]7DF!PTZ/\ M2UJ
M-QB^UD]?OL?(YWF&)A7_ -FVII2DN]VOTN?J=^W_ /&/QE^SS^R'XX\<>!++
M2=2\1>%++^U$MM2B>6WE@C=6N-P1T;B'>P^;^&N4_P""5O[;US^WU^QYI'C[
M4X=+L]?6ZN=.UBUL-RP6\\4F1A79F7,+0ORQ^_7IOP7^(FB?M9_LS>'O$L<4
M5QHGCO0HKB6W;YUV7$7[R$_3<Z&OS1_X(*:[>?LF_MT_';]G#69BJVMW)J&E
M[WQYSVLOELR+_P!-;>6%_P#=BKSZ&$A4P-:+C:I3:?JMFOU/0Q&-E3QE&:?[
MNHK>CW3/U<\;^+;'X?\ @_5M>U*7R--T6SFO[N9O^6<4:,[M^"K7Y[_\$T/V
MUO&?[<^A_%WXW^)?!_A/38O!5A/I/AVZMXKHS3;$DN7A?S)VCVA?L^[RE0LS
M]:Z__@X9_:5;X#?\$^M2T"QN&AUGXCWD>@P;/O"W_P!;<M_NF-/+/_7:NP_8
MI_9@'[)O_!).W\*S6_V;6)_"=[JNK*?O_:[JWDF=6]UW*G_ *K#X:E3P7M:B
MO*<DEZ+=_H8XR<Z^,5%*\81NUY]/\RA_P19_;U\5?\%!_@+XH\3>+=(\-:->
MZ-KITR&+1H)886C^SPR;BKR.V[<Y[BO-OVJO^"O?Q$\3?M1ZI\$OV9? 5AX[
M\7>'F>/6=7U,M]AL71MLB@;XPJQM\ID=PN[Y55OO5RW_  :S#/['_P 0?^QP
M?_TBMJ^4M%^.NO?\$@?VV?VA_#?BS1;J&?XH"Y.A:\R?NXTENI)(;M6_BB,<
MKL^TEE=%7'RM7JQR^A]<Q'+!2<$N6+>^WWV['C5\RKT,LI55)I.]Y+?;;Y_H
M>T_L1_&3]LF?]H^Z^)=Y\-?"GC'1?'^N6GAW7=3@=0NGQ6[K \D/E2EEB1?F
M+>6ZMLZU]W?\%8OVR/$G["G['6J?$+PG9:+J&LV>HV=I'!JBN]NRS2[6R$=#
MGT^:NO\ V%=3\"+^S7X8TGX?>)M!\4Z/H=C';/>:9=I<J\Q^:1GVG*L\FYMK
M &OGC_@XZ8?\.Q=<_P"PWIG_ */KS*$EB<?2I5::C[R35FNO8[,%0J8+*)U(
MSO)Q<O23U=GZGD'PU_;T_P""@_QD^'VB^*O#OP+^&^I:#X@LX[_3[A9E3[1!
M(NY&VOJ 9<K_ '@*]H^ >L_M7_M7^%?'_@_XX> /"?PYT_4=#*Z+J&G.LZR7
MPE7;',JW,VZ+U7 W+NYJ;_@GI_P4,^!?@#]A;X3:'KGQ;^'VD:QI/A:PM+RR
MNM:@AFM9D@56C=6;*D-7U%\%OVGOAY^T<-13P%XT\->+_P"R?+^V_P!DZA'=
M?9?,W;-^PG;NV/C_ ':TS*I*$IPCAXQ2;2ERO9/S.O+J,9QA*=>3DTFX\RW:
M78^2X?V1_'NK>/\ 5-0?PQJ\.L^)[G6Q>KJFI13>'=#&I(L;W=JJ7)+2I'YJ
M?Z@-*LWSB+:S5][)]T4P(5ZG=4E>%5KRJ6YNA[V'PT*5W&^H4445D=(4444
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M4NL/(TFTW$[O*P#/M&6^50JCI7H%%% !1110 4444 %%%% 'R?\ \%<OV/\
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MO+:_:[/0RFO@HPA"%.T[*_NO>W>R/LHX2GU&0"G*U)7SO4^I04444QA1110
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M\0^#O$;_ /$E@:WMTAL-4M+>VCMEBGDWO'!Y\C+'9M*H3[U<A=_M"_'+X<^
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MH **** "J6KQW+Z5<I:NB731,(7?[JOM^4G_ (%5VL?Q9H0\4^&M2TIKO4+
M:E:RVIN+.5H;BW\Q"OF1NO*NO4,.C4 ?S ^"/@K\(OV58?BQX5_X*#_ OXUM
M\2_%VN74MM\7+'[3>6=N)554GA82I#)B;?*&43;PZJ5&W;7Z(>-?^"@^H_\
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M.>_UW3KAY[RX\Z!I)&:'8&3:\*KA?,.&/WJP_P!F[]H3]H7XF_!5_BAK5_\
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MXC_X*I?$2P_X7W\ / >M)\4+SPUK-_K?B'7;#P&NJ/J5Y;V5AY$2O_9I%SY
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M8>.M;^(/Q-T'QE\1M1ETU-'LY[#1(&DL;*SLH_,7_CZM[3=YLA9EWLS':JT
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M'P;>Z7;:A(@UZ.T%A#N>7;) NR.:1T"R*[["U 'ZV45\QW?_  4P\&^$]?\
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M\MT/]L[P%KW[8>M? F/4IXOB-HGAZ'Q//8/ R1O822^2LD<GW68-MROWEWT
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M$GB/]_XH\&MX:\.'QE,GB[P_=Z&UUH8W;M4@$Z+YEL.[+\R[TW ;EJ/X*?\
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M3#X$P>/A<>*Y(KGQ&_@^/P]'X<O'\1_VXN[?IG]GB/SEN0JNY5AMV#?NV\T
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M[U^4[2-U.D\(Z6_B@:V^FV,FM1VYLTOVMT^U+ 6W&$2XW["WS;<XW4 ?BO\
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MH6CPW]TBK'Q*^"O@WXT:;;V?C'PEX9\5VMK)YUO!K.F07\<+_P!Y!*C!6^E
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MZ'HZP>('>358ELHMFI.Z[7:<;?WC,ORG?G*T ?A[JW@33? GPE_;-3P9XO\
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M/B!X,^'/AZU\0:9/I6I:AI=G:_\ $WOGM)@LT<<EG%?*F]59EA1L;66O1_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%133+;0L[LL:("23T4"
MN:;XW>#E?:?%7A[</^HA%_C0!U5%<O\ \+O\&_\ 0U>'O_ ^+_XJC_A=_@W_
M *&KP]_X'Q?_ !5 '445R_\ PN_P;_T-7A[_ ,#XO_BJ/^%W^#?^AJ\/?^!\
M7_Q5 '445R__  N_P;_T-7A[_P #XO\ XJC_ (7?X-_Z&KP]_P"!\7_Q5 '4
M45R__"[_  ;_ -#5X>_\#XO_ (JC_A=_@W_H:O#W_@?%_P#%4 =117+_ /"[
M_!O_ $-7A[_P/B_^*H_X7?X-_P"AJ\/?^!\7_P 50!U%%<O_ ,+O\&_]#5X>
M_P# ^+_XJC_A=_@W_H:O#W_@?%_\50!U%%<O_P +O\&_]#5X>_\  ^+_ .*H
M_P"%W^#?^AJ\/?\ @?%_\50!U%%<O_PN_P &_P#0U>'O_ ^+_P"*H_X7?X-_
MZ&KP]_X'Q?\ Q5 '445R_P#PN_P;_P!#5X>_\#XO_BJ/^%W^#?\ H:O#W_@?
M%_\ %4 =117+_P#"[_!O_0U>'O\ P/B_^*H_X7?X-_Z&KP]_X'Q?_%4 =117
M+_\ "[_!O_0U>'O_  /B_P#BJ/\ A=_@W_H:O#W_ ('Q?_%4 =117+_\+O\
M!O\ T-7A[_P/B_\ BJ/^%W^#?^AJ\/?^!\7_ ,50!U%%<O\ \+O\&_\ 0U>'
MO_ ^+_XJC_A=_@W_ *&KP]_X'Q?_ !5 '445R_\ PN_P;_T-7A[_ ,#XO_BJ
M/^%W^#?^AJ\/?^!\7_Q5 '445R__  N_P;_T-7A[_P #XO\ XJC_ (7?X-_Z
M&KP]_P"!\7_Q5 '445R__"[_  ;_ -#5X>_\#XO_ (JC_A=_@W_H:O#W_@?%
M_P#%4 =117+_ /"[_!O_ $-7A[_P/B_^*H_X7?X-_P"AJ\/?^!\7_P 50!U%
M%<O_ ,+O\&_]#5X>_P# ^+_XJC_A=_@W_H:O#W_@?%_\50!U%%<O_P +O\&_
M]#5X>_\  ^+_ .*H_P"%W^#?^AJ\/?\ @?%_\50!U%%<O_PN_P &_P#0U>'O
M_ ^+_P"*H_X7?X-_Z&KP]_X'Q?\ Q5 '445R_P#PN_P;_P!#5X>_\#XO_BJ/
M^%W^#?\ H:O#W_@?%_\ %4 =117+_P#"[_!O_0U>'O\ P/B_^*H_X7?X-_Z&
MKP]_X'Q?_%4 =117+_\ "[_!O_0U>'O_  /B_P#BJ/\ A=_@W_H:O#W_ ('Q
M?_%4 =117+_\+O\ !O\ T-7A[_P/B_\ BJ/^%W^#?^AJ\/?^!\7_ ,50!U%%
M<O\ \+O\&_\ 0U>'O_ ^+_XJC_A=_@W_ *&KP]_X'Q?_ !5 '445R_\ PN_P
M;_T-7A[_ ,#XO_BJ/^%W^#?^AJ\/?^!\7_Q5 '445R__  N_P;_T-7A[_P #
MXO\ XJC_ (7?X-_Z&KP]_P"!\7_Q5 '445R__"[_  ;_ -#5X>_\#XO_ (JC
M_A=_@W_H:O#W_@?%_P#%4 =117+_ /"[_!O_ $-7A[_P/B_^*H_X7?X-_P"A
MJ\/?^!\7_P 50!U%%<O_ ,+O\&_]#5X>_P# ^+_XJC_A=_@W_H:O#W_@?%_\
M50!U%%<O_P +O\&_]#5X>_\  ^+_ .*H_P"%W^#?^AJ\/?\ @?%_\50!U%%<
MO_PN_P &_P#0U>'O_ ^+_P"*H_X7?X-_Z&KP]_X'Q?\ Q5 '445R_P#PN_P;
M_P!#5X>_\#XO_BJ/^%W^#?\ H:O#W_@?%_\ %4 =117+_P#"[_!O_0U>'O\
MP/B_^*H_X7?X-_Z&KP]_X'Q?_%4 =117+_\ "[_!O_0U>'O_  /B_P#BJ/\
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M/?\ @?%_\50!U%%<O_PN_P &_P#0U>'O_ ^+_P"*H_X7?X-_Z&KP]_X'Q?\
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M (*/?\% /"__  3*_9BO_BKXQTG7M;T2PO[:P>UT9(GNF>=]B,!*Z+@=_FH
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MJ[H4]6'\(KG_ (S_ !F\,_L\?";7_'/B[55T?PKX8LI-1U._=&=;>!!N9MJ
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M/MO^?>#_ +X%3T4 0?V?;?\ /O!_WP*/[/MO^?>#_O@5/10!!_9]M_S[P?\
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M_O@5/10!!_9]M_S[P?\ ? H_L^V_Y]X/^^!4]% $']GVW_/O!_WP*/[/MO\
MGW@_[X%3T4 0?V?;?\^\'_? KC;.U33_ ([W!BC2$76AH\HC39YA6X903]%:
MNYKC_P#FOW_<O_\ MS0!V%%%% '(?'+_ ))M<?\ 7Y9?^ED-=?7(?'+_ ))M
M<?\ 7Y9?^ED-=?0!^'7QW^%WQC_X*J_&?]KKQ?X ^%OA[QYX.UZ)/A-X/\0W
M_B]=*FT/^Q9UN9;FUA:WD:97U+9+N5H]WD[<_P 5>B_%;]LB._\ V9OV0/V^
M;F&Y%Q\/YW\'?%2.W7,T=C>JUA?[U&69;?4H4D1>6_?5^LWA+P7I'@;1TT_1
M-,T[2+&)WD2WLK:.WA5F;<[!$4#<6^8\=:SI?A%X4?P=?:$_ACP])H>HRM/=
MZ<VF0_8[J1G\QGDBV[&8M\Q8@_-\U 'Y _&?X6:MHG_!LA\<_B9XKMGM_''[
M0FH1_$O7%=/WD(O]9LVM(/\ =CLTMU"\;?FXKVG]JJ^^"Z?MT:K<VG[07B?]
MDKX\:5X0TO[7X@O9;"U\/^-M-*,T.8;[-O>_9VWH=I1T^[D[?E_2+6O NB>)
M?#1T34-'TR_T1E2+^S[FU26U=4VE%\H@IM7:N./EVUF_$WX#^!_C/;6L/C'P
M=X5\60V!WVR:SI,%^MNW]Y!*C;?PQ0!^+7[1_P"U_P"+/VN/V,?V7_%_CKQ[
MH7P_N=*_:.DT:S^*6GZ?#8:;JEE:V]Y'%XAAAN\PQI)_MY3<C?[M?I;_ ,$W
MO'NF>(H_%MI;?M::+^U%=1&VE)LY=$\SP['^\7E=- ^65OXI?^>/R_Q5[YXE
M^#'A#QQX<L]'UOPKX:UC2=-(-I8WVF0W-K:D#:OEQNI5<+Q\H%)X ^"G@_X3
MS7;^%?"?AOPS+?!1<-I6FPV9N N[;O\ +1=V-S8S0!\#ZK^TK\.?V:?^#@OX
MI7OQ'\>>#? =EJGP<T*WL[CQ#K-OIL-U(NH73-&C3.H9@OS;5S2?M,_M:?##
MP1_P5_\ V:OBOJ?Q"\(6OPM\2_#SQ5HVG>+FU6#^P[B[%U9MY(O-_D[OW3K]
M[[R;?O5]Y>-_V>_ 7Q)U@:EXD\$>$/$.H",1?:M2T>WO)M@Z+OD0MM'UI-1^
M!'@K6/"5AX=O/"'A6Z\/:5*+BRTN;2H'LK.0%B'CA*[%8;V^90/OF@#\'/BE
M\0/ GQ0_9+\0^)]6U6?_ (5IKW[>LE_>ZE;^;"S:3+;[GE#*!*JF%W;<H#;>
ME>U>/O"WPSM_VB?VJ/"?[)J:#J'PQU7]F/6F\5:9X*F6YT'_ (2)O.CT_P O
MR2T7VQ[=YE*I]Y?O#=7Z3?M;_L ^'OVF+3X;V]E<V/@^+P#\2=,^)$L=EI43
MKK5Q9^9NBD4%/FE5^9#N;Y.AKV'X<?"GPO\ "32KBR\)>&_#_AFRNY3<30:5
MI\5G'-(>KE8U4,Q_O4 ?DIX)_;%^&'Q_\7_\$O\ PQX)\:Z#XHU_PZ\3ZQ8Z
M;<+<S:.8_#,T#1W07/D2^8CJ(WPS;'8#:NZO*/@_J/PS_9S_ &J_!NOX^#?Q
M_F\1_&R:#3_$^C:Q?Z)\8-*O[F_FCVW]H^'N[2W_ -7)&Q2)HMK-'\U?MIX=
M^ ?@;PA>Q3Z/X,\*Z3-#>-J,<MGI%O"RW#!E,X*(/WA5G4M][#]:?8_ CP/I
MGQ$F\86G@[PK;>*[L$3:W%I-NFHS ]=UP$\UL_[U 'Q?_P '%-KJNH?L:^ ;
M;1KV#3-8G^+OA*.PO+BW^TPVLYO_ -U(\65\Q5;8Q7<-WW<BO [C1?C?IG_!
M4/Q_8_&/QO9^*_C-X(^#VLZC\ WT/0H]'T?6I+JW:.^9(C)(_P!LBFBA0QM(
MW[OY_N[:_63Q)X1TKQK9PP:MIVGZM;V\Z7445Y;I,L<R'<DBJX.UT;Y@WWEH
MU+P9HVM>(=.U:]TK3KK5M'\S^S[V:T1[BQ\P;7\MR-T>]?E.TC=0!^!_[ _@
MW1[Z]_9-\1Z!X[_9I\'_ !/N?%6FR:I>Z1J&LWGQ&\33,K?VMINKP^6[;I?W
MJRM.!%&Z)M=5VM72>/=0^&/[.'[4GBGQW<M\&_V@6U3XW"1)X=5O_#WQD\,Z
MC+?QQK901, ]S;6S?*(U,:21;N-K?+^VVA_ GP5X9^(5YXLTWP=X5T_Q1J&[
M[7K-MI4$.H76[[V^=4#MGOEC0?@'X&?XCKXP?P=X5;Q<@ &N-I-N=2P!C_CX
MV>;_ ./4 ?DC\1?VGOA_^SOX$_X*B> ?&OBK2/#OC;Q9J>L76AZ%>3*FH:U%
M>^'HX;=[6'[\RENNP'RU^9MJ_-4GP<^%^D?&C]H3P]X:UW1K/Q#INJ?L(Z&K
MZ==6ZS1W3I>^9%\C?>82(C#_ &DK];/$_P %/"'C'Q*=9U?PKX<U75S:O8&]
MN]-AEN/L[[E>+>ZEO+*LV5SM;TJ_H_@+0]$U6&_L=%TFSU&VL4TR*Y@LDCFC
MLT;<ELK@!EB#<B/.U?2@#\NO^"7GA3]DV]_X)!_LSMXIU7PAH;CQ9H=TQTO5
MGL)KKQS'$RPPW?V9E9KDKUCG^7;M8_PM78_\':V[_AS=XCQU_P"$GT7&?^OJ
MOT#TWX&>"-(B:*S\'>%;2)M176BD&E6Z*U\OW;O 3_7CM)][WK3\:> -#^(>
MB'3/$.C:3KFF.ZR&UU"TCN86=?NML<%=P[<4 ?F3X9_X)A?M.?&S]HSP1\>O
MCE\1OAOK'B#X+>&=1/P^\.>"=)N8;>34;BS98I+F6?#<2>4Q4!MVQ?NKNW?E
M?X;O/AI'^P#\,O%O@K7-<N?^"B=U\6-E^PU"\?Q--=&]N%>*>(G;Y!C\K.X#
M<VY2?OK7]3\<8C0!5VA1@*.U<G:_ GP1I_Q!F\86W@[PK!XKN%*S:U%I,":A
M(#US<!/,;_OJ@#^=W_@K9I?@;P+^W9^TCXY\2:_\(_B]?V\^G&_\*>,M5UGP
MWXT\+O&L>V'0)L+#-'N^8-%O_=[./O;O?(_!V@?M@_\ !4/XAV.M^$]<FTGQ
MC^QK97HT'6KF6;4HWWV$\,4\BD/).DBQ9;AF=.1S7[1^,/V?? GQ#\666OZ_
MX*\):WKNFX^R:C?Z/;W-U:XZ;)70NN/8BM:+P!HD7C*3Q&-%TF/Q!);BSDU1
M;1!>/ &W>49L;]F[G;G;0!_,;X5T;X86?_!O!\%Y_!K:3_PL"Z^-^CCQXMM<
M.]TMPLNK"S^T(2?+/V?9MV@;EKW[_@K7=^*/V"?VV/VG/@KX*TVX-O\ MXZ9
MH=SX7\E#Y,>JSZBMIJ,? ^]*LMVQ_P"NT7]ZOW4B_9J^'=K;W<47@#P6D5W>
MIJ-P@T6V"7%TN[;.Z[/FE&]L.?F^?K6YKOPR\.>*]>TS5M5T#1-2U;17WZ?>
MW5C%-<6)SG=#(P+1_P# 2* /Y[?^"@_[/=K\"_\ @I1X8^#?C^X^$%O\(?AY
M\(-.T[P&GQ7U#5K#PU=-%%#'>W-LUB1NU!IOM#'>?N_[7EU^HO\ P;RVFMV7
M_!*GPE9W_CJU\?V,%Y?P:!KEK:ZC#"; 2MY,:?;XHIF2)MZ*VTKM15!.VOL+
MXC?!?P=\9;"VM?&'A/PUXKMK23SK>+6=,AOXX7_O()48*WTK>TK2[70M/AM+
M.W@M+2V01Q0PH$CA0=%"KPH% 'R_^R-^Q1\</@)\96\0>/?VI_%GQ@\-FSFM
M1X>U'PIIVFPK([*R3>="=^Y-O_ M]?%?_!2W_E8M\%_]FZ>)/_1&L5^P5<[J
M?PR\/:YXK76[W0M&O-92T:R2_GLHGNEMVW;H1*07\L[VRN=OS]* /YE/#_[*
MOA#X-?\ !#_]E/\ :1\-PZMI7QFD^*L&G+XCBU:X\R&U%_J"K;1Q;_*C0?9T
M;Y4'S;\D^8U>M_M,6GP9\0?MO?\ !06^_:DU?5+'XLZ1;O#\(XI]0O(;F.U:
MUNEM/[.2,@2,5^R97F/:[Y&UI*_H!'P.\&R^$[30'\(>&FT'39Q=6>FG3(?L
M=G*&9O,CBV[%;<SMN4!OGI_B7X*^#_''B>UUO7/"?AO6-9L[=K6"_OM,AN;J
M&%MV8TE=2RH=[Y4''S4 ?S7:[)KFN?L;_P#!.SP_XJNO!-K\$K_0O$,T\?CR
M]O[/P?=:PFHWVQ=0EL\/N$?D^5N(7<[_ ,+/7IVC^'O ^@?\$3?VD[+7_B'X
M7\6>&].^(EO-\)+7P+#JUS;^&_%!+-%9:5-?Q*\T1;9_JGD58GE;=N;YOZ -
M5^!?@K7?A_'X4O\ PCX:OO"L?^KT:XTJ&33TY8_+;LA0??;^&EC^!W@F/0='
MTH>$/"XTSP]*MQI=G_94'V?39%^Z\";-L;#^\@% 'XR?\$T+7X;^+?V9/VV;
MS]L[4=;T?XPWM[%;_%V6ZWPWVGZ((H?[/^Q_9PS^06Z; =S>4K!EV[OUY_9M
M\+?#[5OV3_ 6E^#1;^(/AE+X:TZ/0&NMUW'>Z:MO']E9_.&YLQ[&^<;MW7YJ
MZ36/@MX/\0:QJU]?^%O#E]>:_:?8=4N+C38)IM2M]JKY,S,A,D?RK\K$K\@X
MK?TW3+?1]/M[6U@CM;6T18H(8D")"BC 50.%4+T% 'Y'?\$R?VEO!7['W[9G
M_!3+XB_$+6XO#O@WPS\1--DU"^:%YO(#RZA$BA(PSLQD=%"JIKR/]O?XW^&O
MBO\ \%PK[4)/C4O[(^B0_"BVFT3XGV44B7'Q&LKH6\Z1;Y9%M_*C\U]F%$NZ
MWVYW*H3]KK_X)^#M4T_7[.Y\*>&[BW\4N)-9BDTJ!H]7<'*M< IB9A_MYJ/Q
M]\!/ _Q8TZQLO%'@[PKXDLM,P;.WU32K>\CL\;?]6LB,J_=7[N* /@C_ (-7
MO%S^(O\ @EY'I\?A>UT/3_#WBS4]/LM7MEN%C\8Q QR?VIB<L^Z1G:,\[?W/
M&W[J_I36?I.CVGAO28+*PM8+2SMD$<-O;Q+%'"HZ*JK@**T* "BBB@ HHHH
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M!_\ !1[P#X^N=-G4:IH>CWUUJU@]QKNGW6FW"7%AJ]KI)Q"\7S0R7%W$/,W
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MXM_&ZO7?&_\ P2U^(>I_L7^+/B%\0OB#XF^+'Q#T3X"ZYX0\%>&+7PI!H_\
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MPLU>W9(#ITVUY%CC7;-;-\[Q)*F"S;: /HR/6[.33?M:W=LUK@GSA*ICP/\
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MCU&3PW+%JG]A)O:31;RXN8I[K?*[W<\_VAUFD>0;OO*$^[7V;10!\U_LO_\
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M-)&TZ3(9I%,B(!]G*LK;6?,>Y: /K"BO"?\ AYM\ ?\ HK7@S_P.6C_AYM\
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MXP\5?!#P]\0/&$EQX9;X?W7EVXNOL[:1?_V @FE6Q3=?+'&J2>0URC$+M^0
M_3S6OC1X7\/?$[0_!EYK%M#XH\26%UJ6F:<=WF7EO;-"LTB'&WY6N(NX9M_
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M?ADWASPUI[>%[S6Y/#NLQ:E=>:LD*QN]I//9_P!GK#=N$55MF7S$_BY[X?\
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MV>O NDZWJ&KZMJ^E>'K"SO[W5;9(;Z\GCMHU>6=$DD196;YF59'4-N^9OO4
M=_1110 5Q_\ S7[_ +E__P!N:["N/_YK]_W+_P#[<T =A1110!R'QR_Y)M<?
M]?EE_P"ED-;/CK_D1]:_Z\9__1;5C?'+_DFUQ_U^67_I9#6SXZ_Y$?6O^O&?
M_P!%M0!\M?\ !!;_ )0\_L^_]BI#_P"AR5]=U\B?\$%O^4//[/O_ &*D/_H<
ME?7= !1110!Y;^V7]BC_ &0_BHVI?V)_9R^$M4-S_;=E/?Z;Y?V.3?\ :;>'
M][-!M^_%%\[KN5?F:N^\-,CZ!8-%Y7E/;1E/*B9(\;5^ZI^Z/1:Y+]IR.]_X
M9P^(/]FG7UU#_A&]0-K_ &+J$.FZEYOV:39]FN9OW4$^[&R23Y$;:S<+77>'
M(G31+(2>;O%O'O\ -E$TF=O=QPQ]6_BH TZ*** "O'?VWI-.B_9UU)M3/AQ;
M)=5T8N=>T^XO['=_:UGLWPP?O&;=MV,O"2;&;Y5:O8J\R_:M74/^%*WO]DMX
MF%Z=0TP Z#J<&FWVW^T;??LFG_=JFW=YB_>DCW(OS,M 'IM%%% !1110!X[^
MU6=/?_A6O]H_\([C_A/M,^S_ -L:9/>?O_WVSR/)_P!3<_\ /.9_D7^+[U>Q
M5Y?^T3)??\4*VGGQ'_R.&G_:?[(U6"P_<?O-_P!I\[_76W_/2%/WC?P_=:O4
M* "BBB@ KQ_XVR6!_:+^"PG_ .$?^V'5-5^Q_;=*GN;W?_9=QO\ LEPG[NVD
MV[M[2\/'O1?F:O8*\Q^+ U%?C;\+/LA\0?9!J6H"\^PZQ!;6>S^SKC9]KMW_
M 'EVF[;M6+E)-KM\JT >G4444 %?&/\ P7B_Y,8TK_LI/@O_ -2&QK[-WBOC
M'_@O"P/[#.E?]E)\%_\ J0V- 'M_B1].7]N?PBC_ /"._P!J'P3K;1>9IMP^
MK>5]OTG?Y5R/W,=MNV>9&W[QW\IE^6-Z\$_X),?\G(?MJ_+_ ,UIG_\ 33I]
M?2&MKJ'_  U;X7:(^(_[-7PMJWG"+5;=-)\[[5INSSK0_OI+G;O\N9?W<:>>
MK?-*E?,W_!*?4+;3_P!HS]M0SW$%N/\ A=,Y^=@G_,)T_P!:/*P6OI8^XOF
MIF[)ZBN=O_B[X6TPGS_$6B0L.S7T0;_T*L'4OVHO 6E9\SQ/8/C_ )Y9F_\
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M:ZOXX%\=+^3]RPLX5FFWO]U<*_&>M=A'J$$S*B31R%XQ*%##YD/\7^[7Q?\
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MB_2L[Q5_R+=__P!>TG_H-:= EL>>?LD_\FH?#3_L5M,_])8Z[N3M7#_LD_\
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MNO -UXMM[Z&70;&&QU!M(ADC>]M4N%N%W)O5)'5]K>7N4 _5F*5;B-70JR,
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MN1OXJ /NS_AR[^S?_P!"+J__ (66N?\ R91_PY=_9O\ ^A%U?_PLM<_^3*^
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MJ?BK6/&E_P",-.\&:AJGB..Z6.XT^2ZO+>:*W6R^?_0D169?O,ZKN8 _1O\
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M?_T(NK_^%EKG_P F5]2T4 ?+7_#EW]F__H1=7_\ "RUS_P"3*/\ AR[^S?\
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MY:OQ?_8S^*>N_&SXJ?"_X2^.DU22'_@G?H'B36/&<L%BURUYJE@TVG:&T*,
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MPT_;[^.6G?LR?%/7M-^-7_"1-=_ Z]\877F^.M.\0ZMH^L)Y+0W]K%:6</\
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MV;?RIG3>ZBY6$;E^<!6VLH!^B/\ PY=_9O\ ^A%U?_PLM<_^3*/^'+O[-_\
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M /0BZO\ ^%EKG_R91_PY=_9O_P"A%U?_ ,++7/\ Y,KZEHH ^6O^'+O[-_\
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M-+FN--E&G6ZRQ%)G+1L&3:ZX'S)S7MS_ +3_ .R=<Z?I%D_Q _9YDM/#^_\
MLN%M;TCR]-W_ '_(7?B/=WV8W5Z1'^R#\)HT"K\,/AXJJ, #PY9_+_Y#I_\
MPR'\)_\ HF'P\_\ "<L__C= 'S(MG^QU-^U)J'Q0NOBW\%]2FO\ PI8^$H]
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M5\ M8U/1F\S3[N]\0:3<SV)_O1.\A:/_ ("17H7_  R'\)_^B8?#S_PG+/\
M^-T?\,A_"?\ Z)A\//\ PG+/_P"-T >>ZQ^UM^RSK_C"P\1:C\3?@%?>(=*&
MVRU2X\0Z3->68SG;',TA=?\ @)%6K']MC]FK2Y-2:V^+?P1M_P"V9&EU#RO$
MVEK]N<KM+2XD_>,5X^;/RUW'_#(?PG_Z)A\//_"<L_\ XW1_PR'\)_\ HF'P
M\_\ "<L__C= 'GW@']KO]EOX4Z9-9^%OB=\!?#=K-(998=+\0Z39QR.?XBL<
MBJS5G6O[1_[(]IXL/B&+QU^SG!KSSM='4UUO1DO&F;YC)YN_?N/][.ZO4O\
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M /#(?PG_ .B8?#S_ ,)RS_\ C='_  R'\)_^B8?#S_PG+/\ ^-T 8'_#P_X
M?]%Q^$7_ (6&G_\ QVC_ (>'_ #_ *+C\(O_  L-/_\ CM;_ /PR'\)_^B8?
M#S_PG+/_ .-T?\,A_"?_ *)A\//_  G+/_XW0!@?\/#_ ( ?]%Q^$7_A8:?_
M /':/^'A_P  /^BX_"+_ ,+#3_\ X[6__P ,A_"?_HF'P\_\)RS_ /C='_#(
M?PG_ .B8?#S_ ,)RS_\ C= &!_P\/^ '_1<?A%_X6&G_ /QVC_AX?\ /^BX_
M"+_PL-/_ /CM;_\ PR'\)_\ HF'P\_\ "<L__C='_#(?PG_Z)A\//_"<L_\
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M_1<?A%_X6&G_ /QVC_AX?\ /^BX_"+_PL-/_ /CM;_\ PR'\)_\ HF'P\_\
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M"PC\UY)7/R(JK]U0M?1W_#(?PG_Z)A\//_"<L_\ XW1_PR'\)_\ HF'P\_\
M"<L__C= '*:5^WO^SQH&FV]G9?&CX-6EG;QA(H8/%NFI'"@Z* LNU5%7/^'A
M_P  /^BX_"+_ ,+#3_\ X[6__P ,A_"?_HF'P\_\)RS_ /C='_#(?PG_ .B8
M?#S_ ,)RS_\ C= &!_P\/^ '_1<?A%_X6&G_ /QVC_AX?\ /^BX_"+_PL-/_
M /CM;_\ PR'\)_\ HF'P\_\ "<L__C='_#(?PG_Z)A\//_"<L_\ XW0!@?\
M#P_X ?\ 1<?A%_X6&G__ !VC_AX?\ /^BX_"+_PL-/\ _CM;_P#PR'\)_P#H
MF'P\_P#"<L__ (W1_P ,A_"?_HF'P\_\)RS_ /C= &!_P\/^ '_1<?A%_P"%
MAI__ ,=H_P"'A_P _P"BX_"+_P +#3__ ([6_P#\,A_"?_HF'P\_\)RS_P#C
M='_#(?PG_P"B8?#S_P )RS_^-T 8'_#P_P" '_1<?A%_X6&G_P#QVC_AX?\
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MZ+C\(O\ PL-/_P#CM;__  R'\)_^B8?#S_PG+/\ ^-T?\,A_"?\ Z)A\//\
MPG+/_P"-T 8'_#P_X ?]%Q^$7_A8:?\ _':/^'A_P _Z+C\(O_"PT_\ ^.UO
M_P##(?PG_P"B8?#S_P )RS_^-T?\,A_"?_HF'P\_\)RS_P#C= &!_P /#_@!
M_P!%Q^$7_A8:?_\ ':/^'A_P _Z+C\(O_"PT_P#^.UO_ /#(?PG_ .B8?#S_
M ,)RS_\ C='_  R'\)_^B8?#S_PG+/\ ^-T 8'_#P_X ?]%Q^$7_ (6&G_\
MQVC_ (>'_ #_ *+C\(O_  L-/_\ CM;_ /PR'\)_^B8?#S_PG+/_ .-T?\,A
M_"?_ *)A\//_  G+/_XW0!@?\/#_ ( ?]%Q^$7_A8:?_ /':/^'A_P  /^BX
M_"+_ ,+#3_\ X[6__P ,A_"?_HF'P\_\)RS_ /C='_#(?PG_ .B8?#S_ ,)R
MS_\ C= &!_P\/^ '_1<?A%_X6&G_ /QVC_AX?\ /^BX_"+_PL-/_ /CM;_\
MPR'\)_\ HF'P\_\ "<L__C='_#(?PG_Z)A\//_"<L_\ XW0!XA_P3/\ 'VA_
M$WXF_M2Z]X;UO2/$6B:A\7 UKJ&F7:7EI<!?"_A]3LD0E&PRLIVG[R5]!_\
M-?O^Y?\ _;FKG@+X:>'OA7ITUAX8T'1O#ME/*;B2VTVRCLX7D*JID*1@+N*H
MHW8_@JG_ ,U^_P"Y?_\ ;F@#L**** .0^.7_ "3:X_Z_++_TLAKKZY#XY?\
M)-KC_K\LO_2R&NOH **** /BK6?V\_%EA_P4T@\-13Z2_P $[748?AO>OY0^
MU+XLGLFU1)O-_P">"P^5:E<[?/N5_B7;743?\%,K=?B?=:;-\,?'$?@[2_B
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M_P""@WB/P[JDFF-\)/%-WJWA[P!+%$/M$FIZ#Y*ZGO<?>6XDEN_*_NKI<O\
M>KT;]J[]K23]F7]HOP(NK:C%I_@&7P?XM\2^)&:W5Y!%I46GS(Z'[WRK<3?*
MOWJXSP7_ ,$;?A3\*_!7PT/A/2M#\/\ Q%^'6I:;JO\ PGD&B0'6M<G@;_36
MNI5VO)]MC>X27<Y_X^-P^95KT7]KG]CK2/VF]9M-4UK[9J5GI?A+Q+X9FT&W
M=86UJ'5X+>-U6X9AY+C[+A6P?OY^7;0!Y5X]_P""M5S\*]!UN3Q9\&O'G@W4
M+7X=ZU\1=(BU2[L)H]2M-/6W_<.UM/+Y,[M=1*T;#Y/5NT7AOXL_%#X"?&?X
M96'Q%_:#^$>L^(/B!<0#6/ 6I166@S6\-RLBH^BGS#<W!CN-D06;S?-7?AD9
M=M>9_LY_LN?$C]I7]I"PN?BW8_$W4O NF?"[6_ FJ+XVTS2]*DD.I2Z>K6T*
M6$K_ &B7R[65IKOY8V_=>4%^:O</"O\ P3R\5:AXN\!K\0OC'J7Q"\%_#+4+
M?5O#^DS>';6SO[JZME9;234+Y'9KKR?OC9'#OD1&??MVD ZW]KCXA:Y:_'/X
M!^!-'U&ZT>'QUXRFN-6N;>8PS26.FZ==7[6P9>=LLT5NC\_-'YJ]&KP#]C7]
MLG6?CI^T%J>F^(_V@KJ/6;/X@^(]#@\!V_@VU^SR6=AJEY;V\)O!;E]QM[='
M+>:&W5]1_M(_ ?4/BEXQ^%GB?0[JSM=>^&OBM-9C^U.RPW5G-;7%E?0$J&.6
MM[IW7C_60Q9(7=7#?L__ +&WQ,_9W\5WEKH_Q>TFX\ W_BS5O$\N@S^"E^U;
M=1U&XOYK9;W[7VDN'4-Y7W>U &O^Q5\<_$?QE_8O3QGKMU%<:^]WK\33I;I"
MN+/5+ZVA^10!Q';Q \?-7S$_[<_Q*UWX4_ W7_&/Q(N/@YX-\7_"G1?%5]XY
MM_!J:K8ZGK]U%YES:74K1O;V$$<>R4;A%YGG,JRCR]M>_?LZ?L4_$;]GG3O^
M$7A^+6EZI\/%N]6N!HS^#UAO=M_<75RT?VS[4?N37&[=Y7S*FW"U4T']A#XC
M?"#X:^!/#?PV^.%YX;M_"G@C3/!%Y;ZOX:BUO3[U+&+RDOX;8S1BVNG5OF^:
M2-E1%93MW4 <?^VC^V!\6?A?^S/\*K#X?:AX$\1?&3QE8RZ_/<:;_I.BZIIV
MF6#7M]):[SNV73?9[:)LG:U\C;OEW5W?CK]HN74OC%^R[X]\*:U=77@3XQR7
M6A2V7G-]GNH[S1YM6LKO9G;YL?\ 9[INQNVW++6'\._^".?PHT*_\/)XSTW3
MOB?HG@KP?9^$O#NF^*-&M;R/2]D\T]W>C*%//N9)8MVU$5%MT51MK0^#W_!.
M]_@YXT^$FF6>LVUQ\-_@]J?B'7= L#"R7%G/?^=#9V2J,I]FL[6]OHE;=N;?
M$NT>7N8 ^K:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "OD9?CM\8_"'[?_C/PEKNH^"[[PK)\.M2\5^&-%L[=K;[/);7\=O"UW>R
M'+/*K[I-JI'%]T;]N]OKFO#OC#^Q?HOQN^,VM^)]9U6_6P\0_#W4/AU>Z;;K
MY+-;7DZRRSI,&W+(%7:/E_BW9H ^9?\ @F#^W]XK_:=^-_AG1+WX@Q?$&T\0
M> I?%GB"&7PNF@KX5U$7-K"EII[X'VVV_>W"&0-/M\F)O/\ WJJW4_M%_M%_
M&+6?$O[0WBKP)XKTSP]X;_9NMTCC\/7&BP7B^,KV+28=6NUN;ASYL,1AN(H(
M_)V,K;I&+K\E==X#_P"">_CS0]?T35M=^-D^L:QX!\)W_A;P)=6OA*TL?[!-
MW%#$U[<IYCK>3HMO#A<0Q?(W[KYN$^,/_!-K6OB9K_C067Q8U3P_X?\ B]IM
MGI_Q&TV#1(7?Q \-JMI-/:3>8OV"6XM46*3"RKM164!EW4 <A^WQ_P %"?%W
MA?PGX5A^$!LH]28>'_$OBS4;RW6YCT/1M0U&UMH+;8W'VF\:5U3^[%;W#_>\
MNO;_ -NKXT:_\"_!'@:_\.W$=K=:U\1?#'AV[:6)9O,L[_5;>VN%4-G:QCE=
M0WWE[5P'[4/_  1[^$'[2^G>(95M=<\,^(?$5QI<UYJ.G^(-42&8:?);^3&;
M1+I+=ML-JD2_)\GWA\RUZQ\>/V6[#XU?#OP9X:AU.[T>Q\%^)="\0VSMNO))
MAI5Y#<I [ROO;S/*VF1F9OXN6H \>T']K3QI=?\ !/W]H?X@27]H?$WP\U3Q
M_:Z)/]E39;QZ3>7T5EN3&&VK;Q9W [OXJQO%7[?^M_#77=1\6:I#JVN^$O 7
MP\\.7>MZ3I%O!]HU;7=?OXX85C+[5W0QQ;MN]5VWG.?EV[/Q!_X)G^)=>M/B
M'X3\._&+4?#/PE^+&J7VJ>)/#?\ PC\%WJ"'4&W:C#9:@TBM;I<LTK'?%*T;
M3/L*_+MTM/\ ^"?<_BCX0_%+PWK.HV>CW7C_ ,;V>NVT]BC7:6.FZ7-IZ:9;
M?/L_Y==-AWKGY6FEP6^\0#$U/_@JU=>&=<\36OB+X)>/M!C\ :WI>C^,+J74
M])N8=!34FM_L<X\JY9KA2MTC2+$"T:[OO?+N]1_8O^-7B#XU:W\9X=?N8+F+
MP7\2-1\-Z7Y=NL/DV4-O9R(AV_>8-*_S'YJQ?B]_P3\L_BNOQEBD\3W5E_PN
M'4=!U*7;9*_]F-I:VJJJ_./,63[*F?N[=_>JOPU_8V^(OP>^-GC#7?"_Q;TJ
MS\&^-_&,GB[4] NO!J7-QNE2WCF@2\^U+M5H[?:&\H[=^[!H ^F:*** /-OV
MM/'VH_"K]EKXE>*M%F2WUCPUX5U35;&5XPZQSP6<DL3,IX;#*ORM7R'\-?\
M@I+X[\4?L^?"RS\0G2_#_P 7XO'/A/P_XQLXH ]OJ6FZK(NS4;4./]1=0MN#
M+_JY4EC^]'7VI\<OA>GQM^"GC#P7)=-I\/B[1;W1)+I%WM;+<P20M(%R-S+O
MW=17A/Q@_P""8/AOXP:K\"-:DU[4=,\2? V]TMH]0LX0/^$BLK%HY!9729^X
M9HDE7DM$V[;G<V0"AX*_X*V^"/&WQKTK0HM$U&W\+Z_XBN?".E>*)=3T_P F
M\U*!IHV4V2SF\C@>2WE2.=X@K-LZ+(K&?X<?\%0+?XB^,_AC&/A;X[TWP9\9
M-6FT[PAXJN);)[/5$CLKJ\6=XHYVF@26&U9HE= SJ^["[6%9WP?_ ."5UC\%
M/B_9ZGI.N^&8/!.FZ[?:]:Z.? NG?VPTEU)<2FVDU9MTK6T<EP[)MB6551%\
MXJO/A?P6_94^*%[\>?@CX,BLOC#I/PV^"WB#4KF"'Q';Z3;6.AZ:-+U*PMHX
M+ZVE>:_E_P!*MU@;8OE1(_F_/0![W;?\%0I-7\;:WX/7X:Z]H_C,^&M6\1>&
MM-U+6-+:XU9+#RU>.XAAN7ELG/VB)@LP7<N_D,NVN+^&_P#P4F\5ZG\)_AG\
M0O%?ASQ'9:CK/P9U?XCZEX0T=+*:UU1+1M)9KF&7>\RN5O7:*#?]UV5_WBK6
MG^R]_P $@X_V=?'OA#4KOQOI.J:5X*\-ZGX6L;+2_!]KH]QJ$%\ENCW=]<I(
M[W=Y_HZYE8*K,[-L#,S-Z%^S3_P3_N/@=??#.;6O&7_"7I\+O VH_#ZP1]%2
MS^V:;<RZ:T7G;9'#2Q1Z:D98 +)YSMA/NT 1?&+_ (*A>!/A#J>LI]BU37K7
M2M)T*_@N[!X5AU"ZUJXDATZPC>5T199%B>5F=ECCBV.[*K5U_P"R#^V?I/[5
M\OBO3X]*N/#_ (G\$7D%KK.EOJ%IJ2PB>+SK>6.YM9)(9(Y%W?=;<K(ZL%VU
MXYX._P""-OA3P?\ LG:S\,6\2:EJUSJ'BFT\2Z;KFH:?!>2:6=/^SQZ7:/;R
M[HI[:VM;6&V,;X61/-^ZTE>T?L@_LNWW[-&B:^FJ:SX>UK4O$-\MU(=#\(V?
MAO3[.-(EC2&.W@+NW\;%I9I&W.VW:ORT >TT444 %%%% !1110 4444 %>1?
M%K]K[PM\-/B-;^";*WUGQIX]GACN/^$9\.VGVR_M8';:L]TV5AM(#\V)+B2-
M6V,J;V^6O7:\Q^,O[)_@GXW^(M.US5=.N+'Q5I&%T_Q#I%W+INL6:!MWEK<P
ME7:(MUB<M&W=30!Y[\4OVEOB3\,?VC/#&E7_ (7\*1^"?%?BN+POI4"ZA+-X
MAU)&M//EU*-$!B6"%EE\R-\,L4+2%EW*C<=\+?V]_B!XYU+P/K=[X+\.W'@C
MXR#58_ \6GZFZ:MY]K;W%W:1W;3 0K]LM;65PR8\AMJMOW;EZ]?V,?',?[:U
M[\6F^)VDWEK<I!I]GHU_X3^TS:+I:E6FLK2Z^UJL;3R)ODF\DNS;-V5C15K?
M!#]@&X^#_P 1O!\]WX\N=<\#?#&;4;CP1X<?2DADT9[Q9(OW]WYC-<K!;SS0
M0_)'M27YS(RJU '6_L8_M%^(/C]\(->UOQMI&B>&M:\.>)]9\/W]KIU])<V=
MNMA>20;Q/(D9;Y4W%MB_05W?PF^//@;X]Z//?^!_&/A?QC864WV>XN-"U6"_
MAMY-N=CM"[!6V\[6K*_9Y^!,'P#T'Q)I\>I2ZI%XC\4ZMXG9GB">2]_=R7+1
M=3N",^T-QN]*[VPTRUTM&2UMH+9'.2L2!-Q_"@#XK_9U_P""LMU\=?V=O!.O
MWGA2V\/^-=;\4^']%U309KEG6&PU>Y5+;4;=\ R0R0LV&_AEAEC;F-J]3TS_
M (*<_":ZN-3DO+_7-%T2ST[4M5M->U+29[?2]:M=.;%Y)93$?OO+^\%4!G7Y
MHPZ_-7)-_P $H_#:>#?@%9)XGU2UUKX$7>G>5JEO;A/^$CL[2=9_L5U%N*^6
M9HHI%;):-T^7[S!N+T3_ ((Q>%/AKX)\7:1:6WA?5M#N/#FL:1H]GIO@_3=*
M\22?:T;8L^MMO>22-?W<<GEQ??W3>;0![/X8_P""B7A'Q)<>)[,>%?B?8ZUX
M4L-.U.ZT6Z\)72:E<P:A<306C0P@%I%DDB?+<+'L;S"FUMN1I_\ P4MT'Q;\
M2OA?X?\ #W@[QKJ2?$/6-5T*\EET]K:3PS>:>O[Z*ZB;T;YCM;;Y?SJ76O"O
M!?[$_P 6OVL/&/Q$UCXG:EXA\.?VUI/A?3-/_P"$FTK2WCU!]+O]0NY;>XT_
M3KR2*>QD^U1+)ON%:5W?:$156O7O@5_P3';]GV'P9-HOC'3[74?"GC+4_%DB
M6GAB&STVXAU&'R;NPAM(Y0MN@7_5,KML_B$GS;@#;^%/_!1_P?XA^!X\3:_?
M,VI:=X<T7Q!>IIVGS)'?1:K/);69M(I3O;S+B)X@K'<K_*>M=5X'_;N\!_$'
MXOV_@ZP.NK+J-_>Z5I>L7&DRQ:1K5Y9>9]KMK:Y(V221^5<>BMY,NPOL:O/O
M#W_!+70= F^ <DOBC5+A/@E8)I]Q!';JD/BN.$QS6?VE=QV_9KR)+B/;GYMR
M_P 5,_9^_P""67AW]GK]H9/&&ER>"Y-,L=4U76K")? M@FO1SW\DTCQS:P=T
MTD4?VB58]B1R;=JO*ZKM8 ]?^'?QSN_&/[4GQ)\ RV-M#9^!M+T._M[I';S+
MHWXO-ZNOW?D^RIC']^O(?%O[;?CKX(_&![?XB^%_#&G>%K[2?$6O6]CI.I/=
MZ]I.G:2K2+?W:_ZEHKB-44;"/+DN(D)?YMOMG@OX%1>"OVA_'OC]-2EN+CQQ
MI^DV,EDT01;06'VK#!\_-O\ M7(P-NSONKQWX?\ [ 7B;3_BY\2=:\8?$32?
M&VB?%07=IK5G<>%3!J/]FR1R16^FQ7GVMQ';6ZR\*D(W-O=OGD9J *_PV_:Y
M^,5YXBL_#WB'P%X-N?%7C3P6?&GA*PTS6IX88UCN+6"YLKZ::,[6@^WVDAGB
M0[U\U5BW*N_TG]EG]J6'XN_L8^%/BQXS?1/",.JZ*NKZJQO=FGZ:!NWMYTNW
M]V-OWGQ7/_LU?L<ZU\&_B5IWB7Q=\0[KX@:EX:\,#P=X>9])BTW^S].,L,DK
M3['?[1=2M;VGF2CRU_<KMB7<:[[]F'X VO[-O[.WA?X>)?MKEMX9L1IZW4UN
M(3=("?F9,L/XO4T ;7@OXW>#?B3X$D\4^'?%WAK7O"\8E=]7T[4H+FQC$7^M
M8S(Y3Y._/R]Z\_\ "W[8*_'7PKXGO_A1X6UGQG;Z9IKW&BZS>)_97A_Q)=G_
M %4%K=3?/-$>IN8HG@V_<=V^6O88])M;>Q-JEM ELX.^(1*(V!ZY'3FO(+7]
MBCPSX!T;Q?#\.]2U[X9R^*;)H F@W3)I^EW1?>MY;6+[K:&7=]_8BK(OWP>M
M 'BO@W_@I)XHU?0/%NEV]G\.?&7BG3_&&D>"M#U?PSJ<TWAN^O\ 4%W2Q32D
M,ZR64:O),J%MR^4HV,S*O8>'OVHOB]XR\-^)- T_PSX!L_'G@/Q7+H'BK4[W
M4Y4\.Z;:#38]2AU%$XN&66.XMT\O(\MWE8NR1[FJW?\ P3?U7Q5-XH\1>)/B
M.EU\2==O]#U"PU[2/#L6FV>DS:/+-+:-]B\V3SF=KBX69GEW21OL4QJJXI_$
MO_@FUXG^(/P:UCPZWQ72/7/'/BU?%?CF_G\-":Q\5*EO#;1Z<;1;E&AL5AM[
M5#%YS^8L+*Y=9'5@#UC]G_\ :ELOB7^R1X>^*?C$Z1X)TW4-.^WWT]UJ*IIM
MN@D9//2>79_HTF%>-G"YCE3(%,^.?[7&B^$?V*/B'\8/ VI^'?'%AX0\+ZKK
MUA/9:@ESI^H2V5O-)Y9GA++M\R+:VT_+7>_#+PKJ_AWX;Z9I'B;4]+U_4[:(
MPW-U::4--M;@;FV*EMYD@C4+M7;O;[E8W[2'P)MOC_\ LV^.OAO'=)H=KXX\
M/:AX=:Z@MU?["MW;R0M*(LJ&V[]VW(W>M 'BOP=_X*"6C?#+5/$_BWQG\*_'
M2?;]/TG3+'X77,^MWDU]=;MEH\6]SYK[<K]U55)68A59E[WX-_MX^ _CKXSL
M] TI/$5CKMW?ZEI;66J:5+9S6MUI\-K-=PR!\;6C6\B7NK-NVEE^9N3U/]BW
MQ[XL\&V=KKOQ1\/'Q%X6UBPU[PMJFE>"$L(]+NK99HW^T0M=R?:XI8998BN^
M)E5V96#;67SWX2_\$_?B99>+_$OBB]^(3>'O'NG_ !!U?6-.\0?V%;7EKK&G
M:CI>FV]QBR\T^3B2UVQ;I&9/LZ[Q*K-N /1_A_\ \%%_!_CGQY920ZCO\+^)
M;+PW)HLO]FS0W$,NLRZA';M=.6V+'+)9+$F%#+(ZJV?,6KOB?_@I5\.]#:=+
M&U\:>))K.75#<Q:'X?GOY+>UTV\:RN[TJ@/^C)<(Z*RY:1HGV*^UJXWP'_P2
MFTSP;\#_ !!X*_X375[J?4_ ^@>$;/6!9)#=:7=:-->7%GJD:J^#*MQ=)+MX
M7=;KV:M5O^"=.I> ]#\,6_PW^(T_@W4M+\&+X&UB_NM$356UFS#M+]K53+'Y
M-X)Y;B429D3=<OOB?Y< ':1_M]> =5^(MCX?TE/$OB2&9].BN==T?1Y[W1],
MDU"..6RCGN4!56ECEA?Y0RHLT3.45E:N(^./_!3K0/AUX ^(,FE>'/%-OXD\
M)>&]4\0Z1;^(]%N-*M?$$-A+'%<- S@/L226+[RHS*ZL@9?FK1^%'[ FJ_LZ
M>)[>U^&OQ&O_  CX"N+C2+C5=!?1X+^ZO'T^RM;!5AO'<>3'/:V5NDRM%(WR
M,T31,VZO(=/_ ."(-E'<Z^U]X]LY7UCPIKGA/[?;^$H(=8OH]3GMY6N]1O?-
M:6_N8_L^T,WEIM?_ %8;<S 'U'\8_CK=_#;XZ_"7PE;V5M=0?$?5]0TZZGD=
MA):);:7=7JLBCAB6MT4Y_A>N7_:B_;^\&?L<?$/0=,\?V>MZ;HWB,1QV6N6Z
M07D+73NR_9C:12-?,WRHVY+=T^?[PVM7;?$SX%1?$SXO?#/Q;+J$MK-\.-4O
M=0BMUB#+?&YTZXLBI;(VX6XW]#]S%<Q\9?V+M(^,GQD@\=)XL\;>$?$<.EQZ
M.+KP[=6MG(]NDDTBJSO;O+]Z5_EW[?;[U '#?M8_MH>,_P!G/XL^&[1=,\ _
M\([XDUG2M%TG2[W6)$\3>,'N[B&&YDT^V POV19T=ED#;E1\F)=K-5T_]N7Q
MI<?$6'6Y?#GAQ/A%<_$6?X:QW0O9SK:W<=TVG"_*;/)\@ZA$\'E?>VNLN[^"
MNB_:3_8H\2_M&:Y?:;>?$VZM_AWK=S87&H:!<:%!>7EL]J\+?Z!?%U:U\UHD
M9F:.5E;<R%&;Y:EK_P $_P"YM_BW#,WCJZ;X:VWC27XA0^$?[)3>NL2.T[9O
MM^6M/MDKW0@\H-YO_+78NR@"Q\'OVF/B7=_M/:9X#\>^%?#&CCQ/H.H^(;2T
MTK4Y+S4/#<%K=6\$2Z@V/);[2MQE&B*JKPRH ^UG7UR/]H'P%+\6F\!)XT\)
M-XZ1?-;PZ-6M_P"UE39YN[[-O\W;Y?S_ '?N_-7D_P"RC^R-X]^ /Q6\5>(O
M$/Q-TGQS_P )A>27VJRR^$OL6I73_=MH_M(NY%6"WC_=QPK$JJO/WF9F^@/[
M%M/[0^U?98/M7_/?RE\SIC[W6@#Y"_:E_;\\=? SXH_%@:1I?P\NO"/P<T#3
MO$&HVNKZE<6>L:X+F*ZD>"T95:/S=MOLC5E.Z1U7BO5;+]OKP%=_%.'PF]OX
MJA$FLKX;;6Y-%G718=8,2R?V>]WC8L_S;/[GF?NMWF?)5F+]B'P/??M3^*?B
MQKNA>'/$GB'7;;2[2Q?4M'M[BXT/["+C#03N&=?,^T;CMV[=G>N3N?V ;V;X
MB2*/']Q'\-&\;#XA?\(NNCI]J75A-]KV_;C(?]%^W?Z5Y1A+>9\OF^7\E #?
M^'C'A_X@?#M-?\'VNMVNF7.L:%9:?K6N>'[Q-,UR#4=6ATY9+61,;B6?:-Q5
MEWI(R[.O.>"O^"GT'C?1K#6KOPEXA\,6$?B[Q1X>NK"^TJ6YOM4CT6WU"5FL
M]A4>:?L&XJX;YM\0RVUJS_!?_!)H>'/$.J:A>^-[!'O]3T+43!H/A6#1+>^D
MTS6;?5/M-[##*8KB^E:W6(W*)"JJ[_NFW5WWP_\ V#7\&?$O1M6F\6-J&D>&
M_'.O>-]-L)-*5)(WUB"^6ZMI)O,(D037\KHWEJRJB(0WWZ -;QE_P4(^&WA%
MECBO]7UZXN=.TC4;&+2+![Q]2_M5KC^SX(=GWI95MY9-N1MB3>Y5?FKO_@/\
M=M#_ &A_ _\ PD&@?VC##!>3Z=>6>H6KV=[IMW _ES03Q/\ ,LBM]59=K*65
ME:OFBV_X(U^$;7X"ZCX,_MR+6+F/QE%XLT6Z\0:+%JMGID-M;_8K'2Y;21PE
MQ9V]COMPI9&^=G!1_FKWW]E']G.V_9:^$,?ABV/A^21[VYOKM]$\.6N@V+23
M2;ML=I!E555V(-[R2%4^:1C0!ZK1110 5Q__ #7[_N7_ /VYKL*X_P#YK]_W
M+_\ [<T =A1110!R'QR_Y)M<?]?EE_Z60UU]<A\<O^2;7'_7Y9?^ED-=?0 4
M444 %8/C[XAZ%\*_!^H:_P")]8TW0=#TN(SWFH7]PMM;6J#^)W<@+^=;U?/'
M_!0/P1JWB#P#X%UVQ\.ZCXMT[P'XWTSQ+K.@V%N+FZU6R@\Y3Y4/_+62&26*
MZ$8^9C;;5!;;0!Z1\#/VD? ?[1^BWFH^!?%>B>*;6PG-M=&PN5D:TD(W*DB?
M>C)7D;@-R\UW]?#O[07CBY^/>D:KXH\)_##XFZ'X6EUOP_9^,]:M]%U'1/%'
MBO1H7NFN((+,1Q:BT5NTMNS,@$DL4TZ1!MOS<A\*_P!G?Q+\8_B]X2T76;;X
MOV7P3?4?%T^BVE_JNKZ;>0Z<8-%^Q1WSF1+E5^U?VF]M'=,'6/9QM7;0!]B_
M$W]JGP!\%_&0T'Q)XA@TW5CI4^NR6ZV\\S6]C#NWW,IC5A%'\CJ&<KO9&5=S
M+MKTF.42(I7H1D5^6=A^SA\1]3^#GC3QU?:#\26^*M]^S=H>F0WYGU%+ZXUM
M?[4BFAV;PK70C^SLR[=ZL^_ :1F;T[Q7^S/XL\41>,M2NHOBDNI^)/CC96$K
MVVMZI#M\,"_M6?R$24+!:%?-9I(@OR[_ )J /T!K*U_Q!9>%K-KS4KVVL+,3
M10>;<2K"GF2.L<2;F(&YI'51_>9U6OSS\)? [XB? FZT?Q+X>TCXN:]J\'B?
MX@Z2VF7'B/4W6ZT.&WU9M%M T\C)#&\D%BL$[#=N=6#-N^;R*V^"?C;XG?!_
MXHZ;J_AKXI:QX*L&^'_B2TT[^RO%5G<27=OKDTFL>0NHSO>7=REFB>8T2QK(
MR1,D6_:[ 'ZO>%O'^D>-+W6K;3+R*[F\/7YTW4 F?]%N!%'*8SD#YO+E1N,_
M?KH*_/'QWX>\23_%W5I/&>D_&/4/@=+XXOY)+/1(M:>^:,^'M#72V,-GB^:S
M69=04J@*K<[&<;E9EXR\_9\^+_C?X.>/=7\2CXO2>*O"/P5AO/ ZQ:Q?PW2Z
MS%?^();'S%@D5;G4TM5TQ95?>S,_S@^90!^DNO\ C;2/"FLZ)9:EJ-K8W?B*
M\;3=+AE?8U]<+!-<-%&/XF$-O,_^ZC5N5\A_\%*O!$GC.Q^ -WK&A>/M<\/:
M-X^%]XE7PI:WL^H6MHV@:M"TCBQ'VCRO.EAC?ROF97V_-NQ7SSXFC^+OP^^'
MW@J'0;GQ]I]M\:=6UWX6:#::W>W":QX=TR[OY+O2=4F2X)F66ST^+46&_P#?
MK&]JLOS1_* ?HM\3_B[X8^"/@N\\1>+O$&D>&=!L-OG7VI7*6\,98[4&YB/F
M9OE"_>9N *J_![X]>#?V@?"W_"0>"O$FD^)](%P]I)<V%PLRPS)]Z%U^]'(-
MRY5@&^9>/FKR#]M3P;>^$)/@KXHLO#VO>+?#'PH\5KJ6K:1I]O)J5^UL=,O+
M*&[CA&Z2XDMIKB&4JH:3:CNH9U56\P^*.A2?M@^/?!U[HGPV^(W@OPCKWQ)M
MH_$NK^5>^&]2\66%OX>U1?.NX4$-W#:I<?9[<-/L9VV;1MV;@#ZU\-?&#PQX
MUU2:STW6].GO(;Z\T_R/-"2R3VCB.Y1$.&;RF9=VT%?G7GYJ9/\ '3PE!\(!
MX_77K"?P:VGKJJ:O [36\EJPW"92@)92IXV@U\2>&?@5K,?[6OPK\7>+O#GQ
M OH]&\<?$#3K2]":C,NFPW.HK)I+3)$3MM'CB?;(Z^5MV*QV[:\P\/\ [+OQ
M*^!?[&G@NT\&:5\5;/7O$7P'U6'Q%9B]U*9H=:A?1_L,2PNY6VN4C>^CCCB5
M&V(ZX;;\H!^G_BOQYH_@9=/?6-2M--&J7L.F6?GOL^U74K;8HD_O._9:9X"^
M(6D?%+P?8:_H%[%J>CZDIDMKN/=LF4,R\9 /WE]*_/GQU\,O$&O_ +3_ (=D
MUOPW\9-4^(UA\;HM4EU".'5IO"]OX72XD:S9'_Y!ZQ1V[VZLJ?O5G25F&W<S
M>7?&2W^.;_!#P/:0^'?BO9^.O#G@S3+O2-02R\2ZE<7VH_;[IKB/9:R1V=I/
M%&D7F27WFM+',BK&RKM8 _5O5O'&DZ%XJTC1+O4+6WU;7A,VGVLC[)KOR55I
M=@_BV*VXUN5\??\ !3GX5>.?B-J6@-X$TW7+C5H?!?C>SM+G3]Z-9WUSI"QV
MG[Y<>4[S?*C%A\W0UY)\3/'_ (_^./CSQ!KVF^&/CEIOPS31_ UEX@M?[$U3
M2M4OK2*_UIM66RM]J7+2)YMCYWV<"5XD;9O5H]P!]U>/OCKX4^%FJ+:>(M=L
M-'F.GS:HWVI]BK:Q2PQ/*6Z*HDN(EY/\=:7@KQ_I'Q!M[VXT>\BOH=.U"XTN
MZ*9_<W5O(T<T;9 ^9&7;7Y[?'GX9^)?&'P];3?A[X:^-<G@6X\#^)H[73O$T
M-_-<-<-KV@R6RB*<M<*ODI=M!'< 2K$DORJM<]^U;I?Q6U#X=ZEHC^'?B1]K
MEUSX@7^C:M:V_B6_;[0VLR?V9 EMIDL.UGMW5[:YNI1!&B?*&W4 ?J57(>._
MBSHWPY\1>&=,U6Z>"_\ %VHMIFEPI$7::9+>:Y=CC[L:0V\K,QPJ^OS+7YUR
M>%/COXJ_:5T/4/$6I>/M+UR:[\)7'AZ:U\-:Y?V\=B++3VU.*2:&\ATRWWW"
M:@MRM[%YNUU9-_[I5^M?VH],NM/_ &R/@3KTEO+-HK6_B3P\77[MOJ%W9V\U
MJQ_WX[*[B#?WIE7^*@#H?%'_  4&^"G@R\T2+4OB7X6M9/$.D6^O:8AN]YOK
M"X9EAN4V@_NY&B?:W\6QJ]#TSXN^&-<^(VM>%+/7--O/%/AZRM]0U'2H;A7O
M+.WN/,\F1XOO*LGE/CUV5\'_ + W[+7Q4T[Q5X"NAKWC+X5VFC? ;P'I&I1?
M\([:S?VC>VT^L-<63M=0.T<L"RIO5-KK]H7=_#3/V=?AA\:?!7[4OA[]H+Q#
MX3TZSTSXH^(]4M/$5K$MZ_B#3M&U!88]+^VV[Q!(ULETW3U?G]TMQ=,=NY]H
M!]Y?"7XJZ)\;/AQHWBWPW=F^T37K9;JTEVE#M/571L,LB-N5E8!E9&4C<M=7
M7S[_ ,$TM/N+?]E*VU*6%[>S\4>)/$?B72X6_P"6>G:AK=]>V>T?W3;SQ,/]
M^OH*@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** ,7QGXQTOX=>$M5U_6[VVTS1-$M);^_O;AMD-I!$C22RNW\*JJL36;:?%
MWPQ?GPL8=>TN8>-HS)H+17"NNKH(&N"T##_6+Y*[_E_AYKA/^"@7A74O'?["
MOQJT31;"]U;6=8\"ZW965E:PM-<7D\EA-&D4:+DLSLP4*!RU?(GBCX;>*_V#
M_CU\+I$\.:EJ'P&\!67B'QQ:7L$3.O@DC0;S[7I,W_/.!IG22UZ;?.EBX6&/
M< ?<&H?M-> ]&\,/K-[XIT;3])7Q ?"JWEY-]FADU,77V3[(A?&Z3[1^Z^7/
MS(W]VO0J_-/XN?L7?%#]H'X2?"GX0VNA:']D\/\ @N_\4^+-2\0R75M8R>)M
M8BN(=]L\,3[KFVFN-3N.^QG@;AMM?</[)WC?Q-\1_P!G#P=JOC;1[WP_XSDT
MY(==LKJ%H6AOX?W-PR!N?*>1':-OXHW1OXJ /2Z*** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH *X_P#YK]_W+_\ [<UV%<?_ ,U^_P"Y?_\ ;F@#L**** .0^.7_ "3:X_Z_
M++_TLAKKZY#XY?\ )-KC_K\LO_2R&NOH **** "BORZ\2?\ !0.W@_X*V_\
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ME_P4:O\ 7?!OP7D\1^&_B!XZ\)Z_!MTC0M(T#^S=OB35KR6.WLH)/M=I</\
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M4 >3O^QM\.Y_V:KSX0OH)D\!WZS+-8F[F\Z1YKEKMYO.W^;YIN'>7S-V[?\
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MGP]XKC:'2O'\6J8O8EGN;F&:S2W9(8;2"*26X>7S_NH-RJF[!7=MT=8_;_\
MA%X?^%_ASQE)XSM[S0?%<\MKHYTZRNK^\U"6'=YT:6D$3W&Z+8WFKY8\K9\^
MV@#VNBO.OAY^TYX!^*>H^&K7PWXFTW6)O%VC7/B+2/LNZ1;ZQMY88)IE?;M7
MRY+B%&5B&5GVX^5L>>>+/^"H_P "?!&G:3=W_CN,V^M:)%XEM6M=*O[P_P!E
MR/)&MZZQ0,T< :*7?(X58]GSE=RY /HBBOGK]I;_ (*1?"O]FGP_>2ZCXGL;
MS6?^$=D\2V5C;17%S#):^6S6\T\T,<D=I!*R;4GF*(WS;2=M;?B_]L?3OA]^
MQ?8_&35M(O6M;W0;#58=(L76:XNKJ]6%;>RB9MJL\DT\42L=J[GYVT >U45\
M\_"/X_\ QFE^*^A^'OB;\(-.\-Z=XHMIIK#5_"_B*7Q#;Z3/$GF&TU/=:0?9
MW9?NR(98F=-N[YEW9WPT_P""A5I\6?\ @H%XB^#FCZ \WA[P[H-[?2>*VN]L
M-UJ5E=6<%[911;/F6'[;$KR[]OFI+'C=&U 'TO17S!X9_P""H7PY^)G[1OP[
M\ ^ ]1A\5?\ "=W6IQ-?K%<6L,,-G:23^?:M+$J7L#M%L\R%VC7^\?E6NW^*
MOQYU;P_^UA\,/AMH2VK_ /"16&L>)==GFB9VATVP2WA$<?("R275_:?,V[]V
MDO&YE90#VBBODS]C_P#;8^)/QY^#>@?%7Q7X,^&/@_X5ZKH,WB.XO+3QE>7^
ML:?:I"T@9[0Z='%QM^;$YVKTW?=JQ\+?VT/B]XSMO!WB[4/@>MG\+O']W:QV
M%QIWB%]0\3:3;W;*+:]OM.%HL4<1WHTOE7,C0*^YP=K[0#ZKHKQK]DWX[:K\
M8W^(FC>(8+:/Q%\-O&E]X8NWM4*0W4'EPWME*%)/S/8WMINY_P!9YN.*]EH
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M@U^RCU'2]+CUNW>\U&UD3>D\,6_?(CK\P9059?FJ74?C9H]E^T#I?P[>&_\
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MOKCYJ .A\1?!W0?%_P 0/#_BG4K(W.M^%8KR'39C*X6%+M(TN%*9VMN6)/O
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MY#$[;6_V6Q0!V%%%% !1110 5Q__ #7[_N7_ /VYKL*X_P#YK]_W+_\ [<T
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M(DFOM6NVT_R/,D1;"-]DTR*[;I3M_P!JOT?KS+P#^V%\)?BMX\E\*^&/B?\
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M>#?%WBCX@/X&G'VI[_\ MRSN;&'2[*6*RB^QM%>P*UD\XG2>-8/.G:4#^/\
M6ZB@#YY_:N_9*U#]H[]H'X4ZVFM:WH>@^#H-:34;C1=:GTK4M]U%;I"L<L.&
MVEHGW?,/X:\I^,'_  3_ -;^&^HZY8?"_P $^$/%7A7Q=\/7\!FU\2:U*DF@
MSO>7US-?N\D4[W:W,FH.]Q\PE=[:+E]VY/MRB@#X6TS]A;XF_#[]HW2[OPZF
MF1^'_.L9/$&KW^M)>0^(A;Z&NG&Y^PS6CRVFHLRH@EM[E(_*3YM[,R-A6/\
MP3K^)NB?!J]\)0V?A2XD\0?!/PEX'N;W^TF1K'5=&>X\U=GE'S()5NOED5@R
M^3\R_,M?H-10!\/?%;_@FCXM^)GQC^+T-OXATO2/ 'B70=>G\(K"'^U:+XCU
MVPCL+ZY9% 79&L4TJLK;F?5+K/W:ZW_@GK^R9XM^"?CSQ%XE\9Z7+IFJ7FA:
M9X>A9O%$6L?:([5KB1L)%8VJ1Q(TO[K=N?:[[@GRK7UA)((T)9MH49+'M0\H
MCY)P,@?G0!)1110 4444 %<?_P U^_[E_P#]N:["N/\ ^:_?]R__ .W- '84
M444 <A\<O^2;7'_7Y9?^ED-=?7(?'+_DFUQ_U^67_I9#737-XMI$\CAVC4%C
ML1G;CT49+?@* /FWX=_M7_$SQ5^WWXL^'&H?"O7-*\&Z/H.FW\&K2:EIKK"9
MKK5HS=OLN6D:*9;6%8XPGF1LCLZJK+7TW7BG_#>G@'EO[*^+>2,$_P#"I_%7
M_P KJ=_PWMX#_P"@7\7?_#3^*O\ Y74 ?(?P<\;_ +//@O\ 8X^+WA[X[W'A
M<^,9_%WB,^/=)O67_A)-6O9=2N/L36\0(NI))+5K3[(T/S;?*\HC;7E'[8^J
M7LOC7]M+1(?&_P %O#&C:IINCQWFD^/[<_V]?0GPO9JRVMP]QMAG*_(C/;S[
M9]K8;[M?>6J_M/\ P=USQG9^([[P/X_O/$.G#9::I/\ !?Q*]Y:C^ZDS:877
M_@)%5-8_:$^".O\ BT:]J'P]\;WVN91O[1N/@KXCFNLHNU/WC:87X7IS0!L?
M"+4?BUXOB\#ZUH=UX)TKX9ZEHNGW;Z5KNF7LWB:W1[2-C')<+<+#YH;KF(U\
MG_LY>-OV>-/_ ."<UAX5^+W]@W'Q$76&@\8Z"'1/&%YXN-_N>2&)'6[:[>XV
M2PR(=WE>4RG97V)_PWMX#_Z!?Q=_\-/XJ_\ E=7.M^T]\')?'(\3MX'\?R>)
M4C$2ZJWP7\2_;E0?+M\[^S-^W\: /BK]N7QSXY^)W[6OCOXU^#?ACXH\9:;^
MS!>Z=8Z!KEEJ&G0VMBUD_P!M\3Q^5-<+<3-/9W'V,^3$_P UMM7<U==K/AKQ
MG^U3^UC^U5H7PZ\*?"OQAX4^(>@>&+:76O%.JSHNGPW>BMLN(;6.SF%ROEOO
M"^;%N9%7*_>7ZTM/VR?AGI=A<VEMX;^*%O:WDTLT\$7PE\3I',\K,TK.!IVU
MF=F=CG[W>DT3]L#X7^&"_P#9GA?XE::TD<4+?9?@_P")X-T<2>7$IVZ</E1?
ME7T7Y5H M_LM>!-*^%/CC7?"4.L_$;7M<\,>'/#^EZC=ZT+S^Q[A8;62*.:R
M\S_1_-DV.T_E%FW;-Y^[7YM_M0>*+C3O#W[8-M>>,/@S%X=M/BE)J%[X7U2+
MR?&6L)#9:3,T6E7)G98[F78B0?Z)(WF_=.YE9?TO_P"&]O ?_0+^+O\ X:?Q
M5_\ *ZN6?]H7X(2>+SXC/P]\:MX@,GG'5#\%?$?VS?\ WO-_LS?N_&@#Q[X6
M>/OA%\//VCOVH)/CK>^"]!\3ZUK-M?#_ (3!X(&O/"G]D6:VB0^?Q);1S?;D
M=4SMG\W<-S+N\6_X*+>*K3QI^Q+HO@7PK\-/B^W[/.E_"R[\46\\6BW%RNH3
M+:S+I-A=F9_-@MK;8EY)YI+?):KC:LBU]I>,/VG_ (._$.\L+G7_  /X_P!=
MN-*D\VREU#X+^);F2S?^]&SZ8=K?[N*U]3_;?^'FKV$UK=:'\5KFUN4:.6*7
MX2^*'CF1OE*D'3L,I[T ?*-O\=5^(>N?#_0?%GQ/\8_ 3P7IGP8T_P 3Z+$]
MU!HEUJ^HB>:"YDF:8-YRVL-O:.+;)5EOU9U/R[?<?^"52:Y>?\$A/@Q_PCEW
MIT?B"3P%9?V?<:I;2/:K.8/D::)'1]F[JJLK>]=+XE_:@^#?C%=.76/ _C_4
MTTB19;%;WX->)9EL77[K1[],/EL/;%:VC_ML?#GP[I4%CIV@?%.QLK5!'#;V
M_P )?%$,,*#HJJ-. 5?H* .X^!]M\0K'PM./B7J'@[4=>-TQBE\-Z?<V=FMO
MM7:I2>:5]^[?EMP7&WBORB_9T\97-OX'_9U_M/Q=\(]:TK2OC'.MKX7T:+[-
MX\AGGUS4+9)#,T\OF01M<>?/&L$+-;(W[Q=K;OTQ_P"&]O ?_0+^+O\ X:?Q
M5_\ *ZN5\-_M#_!+P9K\FK:/\/\ QKI.KS%C)>V?P5\1PW$F[[V9$TP-SWYH
M \X_X*1>(?BSJ?["?QW@\;>%/ .B^&+?09O[+O=$\47FI7UT1<1[/.MY;"!(
M\Q_,=LLFUOE^;[U8WC#XX?$32OVX[K]G2+Q'K<>H^*?&ECX_T_5B_P"\L_!@
M@:>^M$?!V@:A9/9_WEBU&+I]ZO?]6_;;^'.O6,UI?Z#\4KRSG&R6&?X2>*'C
MD']TJVG$-7GGA3XM?#30/VD-?^*-Y-\>->\0ZSIL>BV27_PJ\0_9M T]9/.>
MVM4BTI#MDFV.[2M([,B?-M55H ^<_A?<?$CXBZQ\&;^]^-OQ8MT^+GQ*\:>$
MM:M;74H$AM],L)]:FMH;7,!:&1/[-B7SU/F['E7<%V[:?P\_:!U[X@_$3X*^
M"OB'\>_%O@GP]=V7Q'TZ[U2+5X-*O/$DNC>([>PT_P ^[* +.EJCL67:S['S
M_K&W?:%I^V!\+K(6?E^&?B7#]@GDN;;9\'_$R?9Y)-V^1/\ B7?*S[WRRXW;
MV_O5YYXQ\6? OX@_%_1/%VL>$?BCJ T/0]3T*/1I_@WXAFTN=+^\L;V:62%]
M+.Z836$3!LC[[LP+?,H!\[?LT6?B/]MK]I#X3S:W\2?&]F5^&WC.VL_%'A^X
MBTW4/%&G6OBBSM-/OWE2,KMFMTBG/E!5D;8WW&VM+\*?VH-=_:%\+?#^'XL?
M'C7OA'ID?P8T_P 66NKV&I6NB2>)-6:XO(+Z]DE>/;-]FCM[1VMD'E[K[<R;
M6CV_9-E^V5\,[&]@N;?P[\3H)[.V^QP2I\(O$R/#!E6\I#_9WRQ_*ORCY?E6
MLO7/VBO@GXFTK3+#4O 'CC4+'1G$FG6]Q\%?$<T.GN.C0HVF$1M_N@4 ?*OA
M#]J;Q-\>M*L;[XT?&K7OV?IM*^$OA[Q?I?\ 9]Q;Z.NI7UVETU]J4D,R,UTL
M316Z_8N57SMK*6D4KW'Q:^._Q'T#]J@_ JQ\4ZW/??&K5_#WB;PKKD4+0S:3
MH<<6[Q#''G'DJBZ;\JMED;6HE_NK7O?B[]J7X0>/KS3KC7O!?C_6KC1YO/L)
M;_X->)+EK&3_ )Z1L^FGRV^7[RXKC]/^*_PS7]J:Y^*NH3_'K6=8CTA]%T;3
M[SX5>(?[/\-VLK0O<_9532EE\RXDMX6D:621ODVKL7Y: /E+5?&^O?LL^#_V
MGIO!/C/6V\0ZC\>;'2-;_M#Q*D,GAO2;R+3=]^KS1R):-)YOD"[EB95CV-_R
MSW5[]^Q)\4?C?J?@?XBV'AV\^'WQ)?0?$MK;Z5:Z]\2CJLVCV\EDLES;W.IV
M>GR-(XFV21J\1;9<,K2?NU6O7[K]JOX2WFH:G>S>#_B)-=ZY;K::E,_P=\2M
M)J$"AE$4Q_LW,B!6<!6R*G\&_M;?"GX=:#%I6@>%/B/H6EPDF.ST[X.^)K:W
MC)^]A$TT+S]* /E_X[SVNK?\%-)X?B5\5Y?@3J#? _3KZ\;PYXE2SADNHM6U
M!GV7MS!&TT4&]WVE$W_>=2JLM<WX._:J\5?'OPKIM[\8?C5KWP+_ +-^#>C^
M,='ETZZM]$_MZ_G:^^UZE(LT9\Y8EM[3_1,>6OVGYD/F)7UMXQ_:8^#GQ#E1
M]?\  WCW77!B8'4?@QXCN64QLS1??TT_<9W8?W=[8^]4_BW]J/X/>/IM/?7?
M!/C_ %Q]+E\^Q:_^#/B2Y:SD_P">D>_3#Y;?[2XH ^0_%G_!1[Q7X+_9P^.N
ML?$/QO;^ ?'EY^S[X<\6>&])N+I+.:UUFZTO5/M$EC"YW,_VQ+=2JAMK(BM5
M_P".7Q'^)$&G?M+_ !$L/BKX\TNY^"VL>')/#FC6]U%_9+(VD:3=745S"8R9
MDG:XF5E9OEW[EPWS5]5>*OVH/@_XZO[>[UOP3X_UBYM8I+>"6^^#7B6YDACD
M&UXPSZ82JNO5?XJN-^UU\+;BUOX9_"_Q)DCU5UDO(V^$'B;;>%555:1?[-^;
M"HBC=GY46@#X9_;P^*1^)'PZ^--[XN^,.M^'_%GAOXKZ9X7T?P NIV\-C-IJ
M:IIOV;-B4\V9KB%VNO/R67^$A(V6OK7_ (*EMIEGX=^#NI>,1$_PLTKXDV%W
MXW^U+NL+>S%I>+:2W>>/LR:DVGL^\;%^5GPJL:Z'7?VD_@SXF\3KK>I> _'6
MH:R(A;B_NO@OXCFN1&&W"/S3II;:&YVYK;U+]N#X>:S836EUH?Q6NK:XC:*6
M*7X2^*'CF1OE92#IV&4]Z /*?'W[07PR\*^.OBEXS^ WA6#XH?&+0?!,$=W#
MX/\ ])T^^WW&W3[6[>W?RFG#.\H7!F6V\UE^5E#?(GP-^+6O?LMZ5^UU<^%M
M!^)&C^.8O!WASQ!KGB;Q'X=:VN&OY)[Q=1U21'++N"W$L\,; KY5IM^['MK]
M ?!'[5WPD^&VC?V;X:\'_$3P_I^XO]ET_P"#OB6SAWGJVQ-- W?A5N/]M3X;
MQWUU=CP_\4UGU!%CN)1\(O%&ZX1=VU7;^SOF WOC/]^@#Y\_8\/ANP_X*P:_
MI_AGXNZU\6["W^$EM<-=:EK$.L36$DNK,S)]IB &V1=CB-ON;_EPK*JXO[>L
M MM;_;X^WJWVVX_9YM'TIG_Y\5M?$2RJG^S]HWY_X#_LU]%>"OVFO@Y\.$QX
M=\$>/=!&67&F_!CQ';<,VXK\FF#JWS'_ &JC\1?M*_"'Q3XTC\0:GX0^)M]J
ML.DW.B>?/\)?%3^98W#1R36SI_9^V2-VA1MK@_=^7[S4 >,_M+_#WXN:5_P3
M@^(H\4CP)JD$FDZ5OM_ >A7EAJ$FCK=6[:M"[/<2-(6T]95"Q!2WS?WEKTGP
M7\2_V8_B%\?/@^/ 4W@W7O&-GIMY+X7?P=-$ZZ3I1M=LK77V9@L=F5V*JS#;
MYOE;5WKQZ%'^WGX"C4*-*^+:J!@ ?"?Q5_\ *ZN7T;]H;X+>&+35H=(\#_$+
M11KB.NHMIOP=\36;WF\;69WBTY69O]K.[WH K_\ !(R$Q_L.Z$R+MTJ;Q!XC
MFT91]U=-?7M0:RV_['V?RMO^SMKZ;KY^\#?M=?"WX;>#-(\.Z#X=^*>DZ'H=
MI%I^GV5O\)O%*16L$2*B1H/[/^ZJKMK8_P"&]O ?_0+^+O\ X:?Q5_\ *Z@#
MVFBO%O\ AO;P'_T"_B[_ .&G\5?_ "NH_P"&]O ?_0+^+O\ X:?Q5_\ *Z@#
MRS_@MC\(?#/Q(_X)P?%S6=>T/3]9U#PEX2U6^T66ZA\[^S;AK9E,\:M\JRA>
M V-R_-@C<U?/G_!0;6;+X9?%WXX.MS\'M<?X@_"W3;'4[+QS?RV&H:#!&E]'
M%)I\+6TBZG%,TKXMH9$=;E%5F'F+M^R=8_;7^''B#2Y[+4=!^*=]972&.:WG
M^$GBB:*53U5U.G$,OU%9WB+]JKX0^+]8TW4=6\&?$+5-0T9S)I]S>?!KQ+--
M8N?XH7?32T;?[I% 'RC\;M2\%VWP.\'_  2\33^#;']H+XM_"O1= \?:_P")
MKV)/^$5T>&U:.:[F\]MOVGSI;O[/ @#/._F/\D3-7LG_  5N^%7AOXK?L:?#
MSP7?O+JWA?Q!\1?!6CSNEVWF75I+J]K%N69#NW&-]P93_M"NZ\7_ ![^!GQ#
MUC^T-?\ AUXPUS4/+$?VK4?@EXAN9M@^ZN]],)VCZUM7'[9/PQO=/M+6?PS\
M39;>PDBEMH7^$7B9TMWB.Z-D']FX5D[;?N]J /AOXF?M!?%?X(_M3R>$]0LK
M_P 2?&#X%_ _Q[>:!J\MDSP^-K7S-'DTR_"J"K3G[.\4\:_\MX7P-LB5S>J>
M,_B#\8OV4?CKH=U\3)?$WAO7O@/K'B"[MX/B1:^)]6FOXXE:&Y@6VM(OLEK<
M*UQ%+#DHWR*BC:]?H6_[:7PWN]=AU)] ^*+ZC;1/;Q73?"+Q1YT<;LK.@?\
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M!3]CO5-)T/1M+U37/%OPXEU&[L[**&XU!Q?1X:9T ,K#<WWB?OU^D5I^U_\
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M)98I([B17=[9_G1=VSZPF_:K^$D_C:'Q(_@OX@MXBMX#:Q:HWP:\2F^CA/\
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MG\*-$\4WNO6?A#XC6NMZFBQWFH1?!WQ*EU>(OW5DE&F;V4=MQ-;?_#>W@/\
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M.KQWL4=IKUE'J-F+AUAD>%XEDW;2>R_,?[M>6_'']O#PG\%/B)=^$H]#\?\
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M>/?"?^N;?)_P"O<* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?PSXC_X1CPE<ZJVFW"6:W;2OY.=L A=/WK87=\M<_P##[_@M+\*/B'\*=/\
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MXA_$?7O&$?B?7+'0/ .G?&C4O&NG:&?#,L.J:E+;:E]KLIFOWN"GV5YDB?\
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MMW]U<'=701_\%#_@ZWQ?;P&GC*$^)DUIO#<D1L+S[-;ZF&PME)<^5]GCG?\
M@C:0,_R[ VY: +__  NGXN_]$3/_ (6%E_\ $T?\+I^+O_1$S_X6%E_\37F_
M@+_@IWX;^-JWG_")6YT^;1?B5;^ +[_A)K+4=-BNA),T?F6K_9BLD[['VQ-M
MVM\LK1[EW>Q?M8_M#67[*G[.'C3XCWVGW>L6G@[2YM2DL;9@CW&Q>%WM\L:[
MOO2-\J+N8_=H \&^+G[/J_'KXA#Q/XN_9;T;6]<\N"*>>?QA;(NH1PLS0QW4
M282Y6-G?:LRNJ_PUZZ/C/\7%X'P2X_['"R_^(KSK4/VWOB'\'?@GX[\=_$GX
M9Z"_A[PKX3N/%EAJW@CQ7_;>FZHD2_-:&6:WMGCE_B$BH\7E[FW#;MJGKW[<
MGQ3^%7[/?Q!^('C'X6>$)M'\+^!=0\;:5JGA3QM_:^DZ@UK%YG]GS2O:0O'*
MZ_,LD4<T;*C\AE56 /4_^%T_%W_HB9_\+"R_^)J./XQ_%J'.SX);<DL<>,++
MJ?\ @%<C^SS^V!XU\8?M#6'PW^(/@SPAHNJZWX8N/%FF7OA?Q7+KUJMO!/:V
M[Q70EM+9X7+72-'PZR;)>5:/YJW[-7[>=[\=?B_X5\.W'ANVL]-\;Z5XL\0Z
M1J$5VVYK#2-9L].MG*$?,;F.Z\_<&&U=HP=VZ@#N_P#A=/Q=_P"B)G_PL++_
M .)H_P"%T_%W_HB9_P#"PLO_ (FCXY_MU_"O]FKQO'X>\:>*TTG4WLEU.:)+
M"ZO$TZS9VC6ZNWAB=+2 R*ZB6=D3Y&Y^5JT/VF_VA_\ AGGPMX4U6'2TUI?$
M_B[1/"X47/DK"NHWT=K]H!VMN\OS=VWC=ZB@#/\ ^%T_%W_HB9_\+"R_^)J.
M3XR_%J=&1_@EN0C!5O&%EM;_ ,<K/C_X*-_!>X^*L/@F'QO;2:_+K?\ PC=N
M!87GV2\U0-M>RAN_*^SRSHW$B)(S1_-OV[6KSNT_;V^*7CWPWJ?Q%\$?!B#Q
M9\']*U&ZLX;B'Q$Z>*M>M[6>2"XO;'3!:M%)'YD3F*-[E)957<%&Y58 ]8_X
M73\7?^B)G_PL++_XFC_A=/Q=_P"B)G_PL++_ .)J7]M/]H*[_9L_9<\3^,M)
MM(;[6X(K>QT2UNRR17&HWEQ#:6<<@X;8;BXBW=&V[J\QU']K+XQ:Q^TAXY^&
M_@KP9\,->;X:6>C_ -J:QXC\776B2:A/>VK3;H;>'3[D*HV/]Z2@#TG_ (73
M\7?^B)G_ ,+"R_\ B:/^%T_%W_HB9_\ "PLO_B:N_ O]HF7XO_%_XL^$IM(B
MTU_AAK=EH_VA+OSEU#[1I=G?E]NQ=NQKKR^IW;-WR[MM>8? K]K;XM_'_P"*
MWBFWT3P'\-8/ WA3QUJ'A&[O]0\9WD6L21V5SY4T\=FFG-$S%?F13<#=W9:
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M\2V=S;Z3$V[;)<NDA$*G8^&<C[C4 ?(O_!07]CO]HG]L+2/&MC#96L>F^.?
M":-I^CV_Q*O='TWPIJC17BW?VI+2V1M5CD\VWV^:1'\C*8E5F9OI;]JG]GW7
M_C!\+/AWHFCO8&\\+^-?#&OWIGE9(VM].U"WN+C8=IW-Y<3[5P-S>E>G?"WX
MP>$_CAX3A\0>"_$_A_Q;H,[M''J.C:A%?VLCKU42Q,R[AWYJ_P"'O%>F>,K>
M6?2=3L=4AM+N:PN)+.X298;B%VCFA8J3MDCD5E9?O*R8- 'Y8Z#XNU32OB+\
M%_V?=%UCX;^*;7X>?&O^T4^Q:A=OXN^RQ7E]<RR7FEO;)]D6)97\R[:5HY5V
MLG^N^7U7XA_\$^_C#J7[.T_[/FG:-X0O/!-E?WQ\)^/_ /A,M1TK4O#%C=2S
M,GF:?!"/M-W;1SND?[\12,D3.$^9:^Y_B;\4_!_P/\,W/B?QGXA\.>$=&@*Q
M3ZKK-[#86T>X_*K32E5Y;IS5GX;_ !1\-?&'P?:^(/"/B+0_%&@WV3;ZEI%]
M%>VMQCKLEB+(V/8T >1?MX_ ;5_BI^Q+K?A?PG&^I^(]"73=9T."9\M?7>E7
MEO?6\+.2!NE:U1-S$??W5\]_%/\ 8>\0>,_VU/B!\4KW]G;X4?&#2/&]EH,F
MCR^+=;2QU+07M;1HYHO+>PN-N9&1OE<?<Z5]=^+OVJ?AYX U7Q7;>(?&&A^'
M8O D=B^NWFJW2V-CIK7N[[,DEQ+MBWOMSMW;OGBX_>+E/ '[7'PJ^+&E+?>%
M_B;X \262ZA#I'GZ7X@M;R/[9-_J;;='(1YLG\"_>;L* /$/!_@;XX? G]K3
MXP:WH?P[\'>+/"?Q1\0:9JT5[/XU;3;C3TATFQLIE,'V*7S,-;NP^==R]EK+
M^$/_  3?L/A1#\7/B#_PKSX<:Q\:M8\8>(_%/@[7+JTB>XA:Y>233UEN6C+Q
MX^17V[MJ],U]+?%_]H/P%^SUI%KJ'CWQMX2\$65]/]EMKK7M6@TV&XEV[O+1
MYG56;;SM!JMH?[3'PY\7^!],\3Z5\0/!>I>&M:U&/2;'5K76[>:ROKQY/+2V
MBF5RC2F3Y1&I+%OEQ0!\I?!7_@E3K_[)7B3X%>*O#/C_ ,7>+-<^'LD^F>);
M/7-5633[K3=1A9M4:U1(%?S#?+;W2JQ.XP[?O-NKW+_@GQ\(M;^&/P/U34/$
M]A)I/B/Q]XLUOQG>Z=+M\S3?[0OYIX;9\$C?';_9U?G[ZO7J$OQ5T&Q^*=OX
M+DO3'XFO]*EUBUM'B8?:;6*6.&9T?&UO+DEBW+G</.3CYJZN@ HHHH ****
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M7Z"M&@ HHHH **** "BBB@ HHHH *X__ )K]_P!R_P#^W-=A7'_\U^_[E_\
M]N: .PHHHH Y#XY?\DVN/^ORR_\ 2R&NOKD/CE_R3:X_Z_++_P!+(:Z^@ HH
MHH ^*-;_ &]/%=G_ ,%-(?#D5UI+_!*VU.'X:7K&)?M*^+9[)M32;S,9\A8?
M)LRN=OGW']Y=M=2__!318OB7>V,OPN\81^#=+^(*?#._\6_;;+[+;ZI+<1VU
MNPM_-^T- \UQ#&9 GR-+T*JS+C7O_!&7X7ZE\&M1M+JPT%_BU?ZQ-XF'Q1_X
M1^U_X2*'6&U%M12[25LOMCDV((O,V^4FS.VN[NOV!K*\\":SH1\1W>-;^*=E
M\3Y)S9+^[GM]3L]0^R!=_P!QFM=F[.Y5?I\M 'DW@7]OWQ_\1[&^;Q5X>U+X
M>Q:7\<+;X?V4NF2V%Y_:T!O&B-M.'>3:NW9YLB;6;?\ NL;6KU#]HG_@H_X$
M\#? GX@:W\.?&'P^^(7C3PC#% FB66OV]RT%[<74=E;K="%V>*$74\2R-@;5
MW?Q53;_@G8[>+M6F_P"$XNV\/WGQ+L?BA9Z8=*C\RPOHI?-N8/M <&2*9MN-
MR!H_5^WL/QT_9T\)?'_X3>)?!NOZ7$^E>*[*2QO7M56&X4-\RR)(!E9$D5)%
M;^%T5OX: /)_ ?@[XZ? 3Q;I&N>-/BUH7Q"\#?9;V;QBE]X?M]';P_Y=NTR7
M.GM; M)")$V-'<&1]K[O-RK*WGWA#_@M5X)\2Z3J&I7GA35M.L+CPEJOC+PW
M)_:^FWEQKUII]K]JDBDMX)WELIVA?>L=PJ_+NW%65EKT#P?^P]XUU;Q-IT_Q
M5^-'B'XF>'] LKJQL-&CT>WT2&\-Q;R6SSZB;=C]MF\F5U'$42L[/Y6[:5X'
MX=_\$BAX'\ :[X0D\=:7/X8N?!>H>"-*6S\"Z98:E!!=6_V9;F]O4!ENYXH?
ME#)Y"OO=G#LU #/B;_P5.\1Z%\&/B/J-G\(O$/A[QEH_PSNOB3X3M=;U"RFM
M]<L(@JO-)Y$Y\MH&EA>2!V5V1\(=VX+V'A7_ (*#>(KKQIX%\+ZK\+-:@U_7
M_"4'C3Q!<)K%DFG^&--:Z:"2>9VDS)A5\T1Q!VVOMZJS5O\ Q"_X)^Z-\4+]
M?[1U_45LS\+=3^%=Q!!$J--:WWV7S+E7).V0+;\+@K\_7Y:L_"/]B>;P;XTL
M=;\5^*_^$RU&'P$/ -Y_Q*4L(;ZV6ZDF24HLC;6\M_**@[6V[N-VV@#C_!?_
M  5(LM<M-"U;6_AIXU\*^%/'FBWVO>"=9OY;-U\20VEHU[Y9ACE:6TEEM4>>
M)9@-R(^2K+LKEM%_X*[ZYKUI!]A_9]^(LU[J_@M/B+I5L^L:0GV[0PJ^=.6-
MU^[F1GA40M\S><OW=K[=SP=_P2]U&VT[PYH7B7XI:OXG\&_#?0KW0/ ^EOHM
MO;3:.ES82:<L]U<!B;V6&SE>*-ML0^=F8.WS5VGA3]@*R\-:EX;N5\2WDS>&
M_A4_PL4-:K_I$3&W_P!-/S?*_P#H_P#J^5^?K0!Y]\5_^"RW@7P0B76BZ!JG
MBK2;#PMI_C37+A-5T[39M+TZ]@:YA6.WNIXY;NY^SH\I@A!^7:N=TBJ=OQ/_
M ,%3?#_AC7OB3=?\(;X@N?AW\*;*VOM=\81W=JMG)]KTVWO[2*UA:0332R_:
MHH_NJJLZ$M\W')ZK_P $<;/28=('A;QGI.CWC^$M&\(:Y>:IX)T_7KB\33+?
M[-#>V9N<BSN3#\IW":+Y(OW19=S>G>+_ /@G+X8\?^!_CAX:UC4[V;1?C8]D
M]PD5O%#)H[VFFV=E T/!1F5K**4;D"[OEVE: +'[)7[?&E?M/_$K7_!]SH,O
MA;Q3H.FV^M?8?[;T_6(;JQN))(DE2XL9945UDB=7C8AEWJWS*RM7RI^TE_P4
M$\7_  R^)O[2-W;?'_POX?USX4:]'9>#OA?>Z5IMS-XN']B:;>I;*GRZA))<
MW5U+ K1-\K=FVLM?6O[(W['^I?LX^*/$&K:QXD\.:]>ZQ;6]E!#HG@FP\-VE
MK#$TC%F$&^2661G^=FD"?(NV)._3?!G]EK2?A-\4_B;XL\ZWU34OB-XEC\2,
MTUBB/IC)IMC8+#&_+,NVRW[N/FF?B@#RSQ#_ ,%,X/"?B+XG?;_AIXO'A[X2
MWEOH^L:S%<6;K>:K<VNGSVVG6D)E$DDLLFH11;F"1JVW+?-\O&?M-?\ !4+Q
MI\(?@/\ $Z2#X2ZCX=^*W@#3M-UQ/#^M:G97=K=:9>736ZWJ36\^R14DBEC>
M/<KJ^SJK*S>J^./V M&\>^ ?C1H-_KNKQ#XO>*+?Q:EW9QI#<>'[ZVM--AM9
M(&;<K-%-I44XWC:S/M(VURWB/_@FM??&+PG\3/\ A9'Q'O/%'C'XB^'K7PM'
MK=AHL6E6^AV-M/)<PK!:>9(K2&XE>65G<^9\J@(J[: *'Q[_ ."L^B?L]^(M
M3TG5_!.I7&H>#M$M==\:V\>OZ5#)X=CGB:;R(DFN$:_G2%'D,=N&^79M+-(J
MU%??\%&H/!OQ%\566E:?XQ^)TFM_$#3/"'AW2[-+"VCMY+OPS'K">3*YCW6Q
M5'9I)F+*TS?\LU6F?%W_ ();WOQ-\>WWB]/'^A6/BGQ?H]AIGBW4+KP%I^J-
M?36B-$M[IZW+N+"=HWV'=Y\7R1'R]R[F[6#_ ()Y:98_'0>-(O$ETKQ>/K/Q
MXEDMBB1J]MX<;05MLJ0-IC;S=RJ-K?+C;0!W?[+/[2T'[3'@O5M2F\/:IX3U
MOPMKUYX9US1K^6*:;3[ZV9=ZB6%FCD1E>)U93\RNO ;Y:^#?V)?^"D7CSXG>
M+O@=]N^+S^,=>^)7B"ZTOQ!X2U/P;#H]CIMI&EXS366HK%"LL\?V>+$8DF:5
M7?:OR[E^_P#X ?L_V_P$O_'\\&I3:B/'GBVZ\5RB2$)]C>>*WC,(P3N4>1NW
M<??Z5\_?!G_@EUXA\$>%/AYX/\0_%Z[\2?#CX8Z_!XBTC0[7PO;Z;<375O=-
M<VWGW?F2NT<<S;BJ+&S;-I.W<K 'HW[7WQ"UFS^._P  / &CZE>:3!XY\7SW
M6KW%K,T,TUCIFGW%^;8,,-MEN(K=7Y^:/S5/RLU>8?#SQ5^T/^UI\/M?^+7@
M/XC>'O#-FNL:I:>$/ ]WX?@FTW5+?3[ZXM%_M.].;E9;EK=FW6[(L"NGRRLK
M;O=_VCO@-??%+QI\+/%&AW5G9Z]\-?%2:Q']J=DCNK.>UN+*^@)56.YK>Z=U
MX_UD,62%W5Y9KG_!.OQ19KXG\->#OC5XF\%_"OQCJEWJNI^'+/2H'U"S-Y*T
MU[!I^HY$MI%-(\S_ ')&C:9_*9/EV@'DOC_]L3Q%=_MT_%'P1KWQYUOX56OA
M6]T6TT?0]*\%V^MQW NM+M;F;?<O9RG_ (^)74;F7Y>PKL_A%^WGXSTC_@H'
M\5? ?CR*S;X:R^+X?"'@?6XHE0V&JIHFGW[Z?=L !_I/VIW@9OO/#*F?FC6N
M[NOV)?B%X-^/?CCQA\//BY9>$=-\>S:=/>:3>^$4UAH7L["&R39</<HW,<",
M=RGYO6MS5?V ?#/C7PG\:M$\17M[J=C\9_$,?B2<Q)]FN-#NHM.T^RAEMI02
M5EB;3XIXY.&5^WRT ?'W@G_@H7XS^(I^!D7C3]HGPU\$;/QA\(_^$PU+5+VR
MT:&'5M4%_'!L'VQ=JKY;.VV(K]RO6_V:?VK?'WCKQO\ LP^*/$ESB+XP:5X@
M\.:Q9VZRVVGWTUEYE[I^KP6[EC'Y]O:W#]?N7B*Q/EKCT?\ 9>_X)JZ%^S;J
M7PYGFUR7Q:WP[^'B_#^%=0T^+_3$6ZCN?MIY;;)\FW:H/W^M=_XZ_9_U#X@?
MM;^ O'%[=V<?AOX=Z/J::=9)N^T2ZG?>3"9F^7:J16J2HNT[F:Y;IM^8 \^_
M:D_;2?\ 9<_:AAAUV[F_X5_I?PQUOQ=J5I:VJS7EU=VNHZ7!;K#T9G=;IXPN
MX*S.N:XGXQ_\%6?$/PE\/^.M-UWX0>(?!_CS0/!R^*M(L]9U*SN-/U#S[^'3
MK2-YK623;_I4Z>:O#(J=]RLWHO[:7[$FF?M$W>O^);]=7UR9OA[K'A&#0]/E
MBL[B[>ZN+.[BEAN9#LCG2:RB\O>"FY]S?*NVOGSX _LB>-_VL/CGX\U'XRVW
MQ+OO!WB'X:'P--+XKT_2]$OGEEO5G/V2WL))-K1;-YN78;I75D&U5H ]/\"_
M$SXA? 7]JWP'X*\=?M&_##QWJOBR.8:YX0U2WL-"U:R+0226\^D10GSIHO,B
M>,Q7'F,R?/YJM&RMZ'^T5\0M7F_;.^ _P^T[5-0TO3=:;6_%>L?996A;4(--
MM[>&.T<C_ED]QJ$4K+_%]FVGY6:L/X>?L(^+)_B[X'\2_%'XPZI\3[7X8R27
M7ANR?P_:Z4WVUK>2V6]OI823=SI#/,J[5BCW3,^S=MV^@_&S]GN^\??'KX3^
M/]%O+6UU/X>W]]#>13.WEZAI5_:^5<PC:#^\$T5I*N[Y?]'V\;MR@'R?_P $
MT/VRM?\ VF-6\.WOB3X_Z]JWB:\NM7^U^"(O!%K;:?MMY[J-(_MRV8.U(XD?
M<LWS,FW/S;:]>^#O[4'C+QE_P1U@^,5_J$!\>2?#.[\3-=K:HD9OH[*297\K
M&S;N5/EQM]JTOV2_V+?B+^REI>D>%XOB_8:U\/='N;V1-&?P;%#>2)<2S3^6
M;L7+'Y9)=V[R_F5-N!7/_!K_ ()T^/\ X7_LRR_!O4?C/::Y\._^$5O/"=O9
MKX-BMKZ&&>VD@20W"W+;FCW[ON#=L[4 ><?LZ?M]#PS^S#XM^*VL_'+Q#\5I
M_#'@9=<N_#=UX-M]$AAOI$C:*.&:.TA,C/-^X5=[*WG;O[K5?\*_M"_%;QS_
M ,$T/C9;^+O$EK9_M ? Z.^EU/4=%Q9V]U=6L$>K:>ZHGR_9I[=X8I%Y5OWZ
M\\U[Y\8_V'-%^-_P"^'OPR\17YU#P=X/OM)N=7TZXLDFM_%4&G1?NK2X1R5\
MI[A+>5EPV[R=N/FW5YS\4/\ @E;H.C:)\4+/X.0>&OAAI_Q@\(P>#=?T;2=)
MBT_3U3[1(LNI1K H'VM;.ZNXA\GSMY&YE6.@#ZA^&/C:+XC_  W\/>)(4:&'
MQ!IMMJ,:-_"LT2R*O_C]=!6=X=\/VGA70K+3;"%+>STVWCM;>)?NQQHNU%_!
M:T: "BBB@ HHHH I:MJ4>CZ5<W4N[R[2)IGV_>VJNXU\-?L]?M/_ !A6S_9U
M^)GC#Q=IVM>$OVDK];9O"<>CP6T?A&.]TVZU/3FMKE/WTS)';I%-Y[/O:;<H
M3;MK[KN;=+R%XY$5XG!5E;[K U\I_![_ ()I7_PL\1^"+:Z^)^LZ]X#^$;W=
MQ\/_  [/I,"-H4TUO-;0O/<@DW:VMO<310JR)M5_FWLJM0 G_!2W6/B7\*/
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MKH_C,^&M6\1^&]-O]=TN6XU)+#R5>.ZAAN'>R<_:(659L;EW\JR[:Y'X<_\
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M:;!XHTJ[TN2:"(;H1<0-$T@7@,PW;J /F?\ 9G_X*20^,/@[?>./&'CSX/\
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M 4444 %%%% !7'_\U^_[E_\ ]N:["N/_ .:_?]R__P"W- '84444 <A\<O\
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MA1XZ^(_QE^%,_@..]M=3T[2O&,$6L11MY&BW=SH<D-G-+(.(_P#2&3#,1\U
M'U WB[24MKN8ZCIRQ6 D-U(;A-MN(QE]YS\NSOG[M> _#G_@J%\.?B1XK\.V
MEOI_C[2?#WC6\73O#'BO5O#=S9^'_$EP^[RH[>Y<?\M=I\II519?X"^Y<_"_
MAW]GOPW\2?B=\*/ /@GX0^(?@QXG\2?!KQGX8UC5M3TI+!=0U&;3M/A\PRHQ
M^WM')*[F[7<K>=\LA9F5?<)/B?\ %KXLS?!'P3X1\+?%;X?>)/"VH:+9>,M!
MU3P59OX1L;2SEA:]N5U2YMW2;]W$\=M]BG\QF>)MJ;6V@'V%^T3\?+7X!Z;X
M98Z?<:MJ_C/Q+8>&=)L8I?):YN+E_G8N0=J16Z7$[\'Y86Q\U<+X*_X*%>'_
M (D_%35/"_A[P)\5-8CT7Q)<>%KW7+?PX7T>WO;>?R)MUQY@^2-NK;?NUF_\
M% ;1]%^(7[//C216;1/!/Q*@;5WS\MK#J&F:AI<,Y_V1=7MNI;^%79OX:^=_
MV.-%O/A9^U!X[M_$6H?M.Z#?ZO\ %[7=0LM&L/"E[-X/OK6ZU%FMYY+D6#Q>
M1(K;FD^T*J_>RJT ?<?P5^//A_X^^"+WQ#X>>Z;2['5]2T:5KJ+R6^TV%Y-:
M7&%Y^430/ANZ_-7G7[+_ /P4!T3]K.;1)_#'@/XJVOA[Q':-?6'B'5/#GV/2
M;B$)N5_.,A^__#\OS5Y1_P $\OC#_P *K\(:[\+]?\%?%72_$MYX_P#&%S%<
M3^!-6_LEH;K7-0N[>7[=]G^S>7)#*C!O,V_/UKRW]G7]F?XK?LV_\$F?#DGA
M[Q!\8[SXFZYX,M/"]CX1U/8]CX9OK]X[;[2;=8$FA2S\UYRSR?+'"VXT ?5W
MPU_;O\*?M"_L\_$#Q_\ #*VN?&L?@*[U+3YM-'^ASZA=V:>:88RX/$L;(T3D
M;765&X5J]9^%OQ'TKXQ_#'PYXNT&Y%YH?BG3+;5].GZ>=;SQ+-$WXJZU\*_
M'X/^-O\ @EU\3?$4WB]_#NM?"W5?ADHGOO"OARZL+'1[OP[;K%#]J66XN/W]
MU8R[ VY%D:Q5=I9J^G?^";OPLUKX(?L#_!SPCXBA:UU[0/"&FVFH6[_>M)Q;
MKOA_[9M\G_ * /<**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHK'\5:/-XB\-ZCI\5_J&D7%];26Z7MD4^T69=&42Q[U9=
MZ?>&Y67=V- %37?B;X<\*ZS_ &=JFOZ/I]\;*;5/LMS>Q0S?9(=OG7&PD-Y4
M>Y-[8VKOY->5_L\_M_>"/VDO&MIH>DV7BW1KK6-*;7M!EU[1)=-A\4:<K1J]
MW9,_^L1?-A8JP5]LT3;=K9KP;P/_ ,$Y_'/PR^%_QC^'QA\'^+KKXE>#M5TN
M'XIW-Q.GBZ\N9K=H88-4\XRM,H\W<)89TC79_J$W50^'WC_7_BM\2_@EXG/P
ME^*'AF+]GOP7K-YXHM;[PU/;327TFG0VB:3IV\!;^1F25PUN6B_<Q?-ND5:
M/H#X_?\ !0CP+^SGXZU?1]:TWQMJ4?A>Q@U3Q+JFCZ!/>:;X5M)MVR>]F7A5
MVQ.Y5 [*B[V4+\U>B?%_X\^'O@EX;T+5M;N+C[%XBUS3- LGM8?.\RZU"YCM
MK?\ X 9)4RW\*U\@?\%0/&6K?M#?"/7_  &O@;]H?3+S4]#CO_"__"-Z.]YI
M?BVXN(%9=-U=41DMXDF_=3P7<D*-&[_O-K?+ZS^W=X \:^.?V1_!]_:>&WUC
MQ-X+\3^%?&&IZ#HVUYKE-.U&UN[RWLU) DD$<4WEKD;]BJOS-0![5J_QOT'0
M/CEHWP_N)[@>(=<T*_\ $5LJQ?Z.MI93V<$S._\ "WF7L.%_B^?^[57X&?M"
M^'OCW\)O#/C+2I9=/TSQ=;17NFQ:BR0W$\,N[R'V!S_K57>O)W+7PW^UQ\:/
M$/QP\?:W\0/!OA+QYX5TRT^&^H?#+2M2\5>'[K0;B\\0^)M7T>VM$MK6Z2.X
MD6W^S^9))L\OYU56.UMM']M+_@GK9^)[_P#:+33_ (;3^(&\-? ;0M#^&]U_
M9C7,UOJ5G_;6Q=/?!VW<;?86W18D7?%S\U 'WK\8?V@O#'P3^'=UXLUJ]>31
M['4K+2I7LD^TM'<7=Y#:1(54_P#/:XBS_=7FN^K\Q?VI?V1[GX*#XP0_#SX9
M:I8>%M0\.?#/5&L/#.@RNNJ:C9>*+J;4'2&%#YUTEG%;M)M!DV^5N_AK[S^!
MW[16D_'ZRU"?2]'\<Z.FFR1Q,GB7PKJ.@R2%U9AY:WD,;2 ;>60';WH ]'HH
MHH YOXH_$33_ (0_#3Q#XLU=I%TGPQIMSJU\T2;Y%@@B:5]J_P 3;4XKS?PU
M^WC\./%_P(^'WQ)T?5+C5/"7Q0U/3M)T.YM;=GD:ZO9?)BCF3AHV23Y)%;YD
M964CY:UOVUO#.H>+_P!C?XLZ1I=G=:AJFK>#M7L[.VMU9YKJ:2RF5(T4<LQ9
MMH6OACQ[^QS\1_@IJ/[/J>"/#&IZI\/_ !CXR\&Z_P",='BB;S/!>LV;0M<:
MB(L?+;7$:/\ :>FR=$D_Y:O0!^EHUVS?57LDN[5KZ)!));K*OG1H?XBO7;^%
M11>([&YU![*.]MI+J-Q')$LH+QL59@K#.=VU6/\ P U^5O[-'[)/CO2OVL/#
MK^(+3Q'IOQ-TGXB:QKFJ>(+'X52(;ZTDGO&$ESXFDNQ#<6,]O+"@ME#R)^Z5
M;=?)W+0^#OP_L/AK\3/V0M-N/@SKV@_&'1_&>H6WC'Q?=6D5M#XNU'_A'M::
M:8:@A/V];F9'G23Y_(7Y6V,VU@#]6=7\>Z-HEAJ=Y/J=FL&C1M+?,LJO]D15
MW'>!DK^5<CX+_:7\-_$F7PC<^'3J>K^'?'&@OXCT_P 0PV^W2UMQ]GV+([E7
MCED6X1E5D_@;.UOE;\U/V0/V</$/CCX_>&'NOA(_A:P\0_#WQ-I7C/1D^%]Q
MX>TNSOIQ9R16%W?7DDCZN_G>:RW+$QML9E/[S:O?_LN?L8P?%;X8?!#P#>_#
MK7?!/AU?V?O$O@;Q8ESX<ET?^S=:FG\/QRLV8U7SY)+>XGCG7/F^2TBLW6@#
M]+)=2MX7=)+B)'BC\UU+C*I_>/M2:7J5KJME'/9W$%U;R#*2PNKQM]&'%?E7
MXQ^ /QT_:/\ V6?&OCWQMX5UG3_'9U3PMX/U31)-):_FU3P]HD\;:I+#9^9'
M]I@O+Z6[N1 KC[3!#$F3NVU]+_\ !)GX177PXL/B=?6J:[I_AWQ#K-K+IVG7
M'P];P'IL,D=JL=Q/9:9),\T:R-L61GCAWR0LRAMV]@#[)HHHH **** "BBB@
M HHHH *CDD$:$LVT*,ECVJ2OEK]K;]F3Q]\4/C'I?B.&Z@^(?P\LE@6[^'%[
MJ<NB6[SH^[[6LT.4O6^ZWV:]!B^1=K(U 'I%Q^W)\)K'XO0^ Y_'6B0^+Y]1
M_LB'3)'=)IKOYOW"Y&UI/E]:]=KY_N?!.L?&[]N.UU'6-+O+7P3\&[/=HWVJ
MW9(]9UV]@VRW<>X89+6S;RE93M\R^G7[T5=]XR\ ^)_$'Q3TG6=,^(NN:#H>
MFJ@O/#EMIEA-:ZIAV9F>:2!KA=RG;^ZD7[G'.Z@#9U/XL>&M/^*-CX*GUS2X
M?%FJ:?+JUKI#W"K>75I%(L<DZ)]YD1G0'']^KG@KQWHWQ$TZXOM%U"TU.VL[
M^ZTR:6W?>L=S;3O!<1'_ &HYHG0_[25\H_M=_LI>(?CA^W3H?B7P\MUHFO\
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M$OX?:3\-O#-MJB)\3=1&B:YK%JC+'H.C[&DOYFE7'ERRPJ]O%SN\VY5A]QJ
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M5O\ A<<!3GP]XP3U']CR_+^5 ':45QG_  N6#_H >+__  3R_P"%'_"Y8/\
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M4VD&O2/^%RP?] #Q?_X)Y?\ "C_A<L'_ $ /%_\ X)Y?\* ///"7_!/;X?\
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MQ+-),(V5DD:;/F^:C(CB7<'#INW;OFJ7_A<L'_0 \7_^">7_  H_X7+!_P!
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M5NO,F6V9_->%/N+7U_\ \+E@_P"@!XO_ /!/+_A1_P +E@_Z 'B__P $\O\
MA0!YA\(/^":WPF^!_C?2==T#2->-_P"'M-N=%TE-2\2ZCJ5OH^G7"QK)96L-
MS/(D%MMB0"-%"KL7'2NB^#'[%?P]_9^O/#,WAG3-3MY/!FD7V@:']KUB\O\
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M^% '9T5QG_"Y8/\ H >+_P#P3R_X4?\ "Y8/^@!XO_\ !/+_ (4 =G17&?\
M"Y8/^@!XO_\ !/+_ (4?\+E@_P"@!XO_ /!/+_A0!V=8WB[P3I'CW0I]*US2
MM-UG3;L 36=];)<V\V#N&Y'!5L-STK%_X7+!_P! #Q?_ .">7_"C_A<L'_0
M\7_^">7_  H G\+_  HT/P7X\\3>)=/L6BUSQC);-JMU)+([7'V>'R8$&XD1
MHB[L*@"[G=L;G9FZRN,_X7+!_P! #Q?_ .">7_"C_A<L'_0 \7_^">7_  H
MEO?@_P"'[[XI)XTFL"_B*/2)-!%RTS8:SDG69H2F=G^L16W8W>]>3V7_  3&
M^#FB>!]$\-Z'H&K>$M.\.2ZDVG'PYX@U'1[BUCU&Y^TWEL)K:='^S23;6\@L
M8UV+M5=JX]3_ .%RP?\ 0 \7_P#@GE_PH_X7+!_T /%__@GE_P * /EW]JW_
M ()8R?'OQPL.B7/A7P_X-O-/TG3+\+_:J:AY5A*K)OBBO%M+V01JBPRW4+/
MWS#?\NWV;1_V!_AEX=^,EIXYM-*U9M:L-6OM<L[>7Q!?RZ7I][?17$=[/#9-
M,;:-I_M$S2;8QN9V;[U=Y_PN6#_H >+_ /P3R_X4?\+E@_Z 'B__ ,$\O^%
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M/<I\IE7:[KC:S"NM_P"%RP?] #Q?_P"">7_"C_A<L'_0 \7_ /@GE_PH ?\
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MQ_\ &J/M/C__ )\/!W_@=<?_ !J@#L:*X[[3X_\ ^?#P=_X'7'_QJC[3X_\
M^?#P=_X'7'_QJ@#L:*X[[3X__P"?#P=_X'7'_P :H^T^/_\ GP\'?^!UQ_\
M&J .QHKCOM/C_P#Y\/!W_@=<?_&J/M/C_P#Y\/!W_@=<?_&J .QHKCOM/C__
M )\/!W_@=<?_ !JC[3X__P"?#P=_X'7'_P :H [&BN.^T^/_ /GP\'?^!UQ_
M\:H^T^/_ /GP\'?^!UQ_\:H [&BN.^T^/_\ GP\'?^!UQ_\ &J/M/C__ )\/
M!W_@=<?_ !J@#L:*X[[3X_\ ^?#P=_X'7'_QJC[3X_\ ^?#P=_X'7'_QJ@#L
M:*X[[3X__P"?#P=_X'7'_P :H^T^/_\ GP\'?^!UQ_\ &J .QHKCOM/C_P#Y
M\/!W_@=<?_&J/M/C_P#Y\/!W_@=<?_&J .QHKCOM/C__ )\/!W_@=<?_ !JC
M[3X__P"?#P=_X'7'_P :H [&BN.^T^/_ /GP\'?^!UQ_\:H^T^/_ /GP\'?^
M!UQ_\:H [&BN.^T^/_\ GP\'?^!UQ_\ &J/M/C__ )\/!W_@=<?_ !J@#L:*
MX[[3X_\ ^?#P=_X'7'_QJC[3X_\ ^?#P=_X'7'_QJ@#L:*X[[3X__P"?#P=_
MX'7'_P :H^T^/_\ GP\'?^!UQ_\ &J .QHKCOM/C_P#Y\/!W_@=<?_&J/M/C
M_P#Y\/!W_@=<?_&J .QHKCOM/C__ )\/!W_@=<?_ !JC[3X__P"?#P=_X'7'
M_P :H [&BN.^T^/_ /GP\'?^!UQ_\:H^T^/_ /GP\'?^!UQ_\:H [&BN.^T^
M/_\ GP\'?^!UQ_\ &J/M/C__ )\/!W_@=<?_ !J@#L:*X[[3X_\ ^?#P=_X'
M7'_QJC[3X_\ ^?#P=_X'7'_QJ@#L:*X[[3X__P"?#P=_X'7'_P :H^T^/_\
MGP\'?^!UQ_\ &J .QHKCOM/C_P#Y\/!W_@=<?_&J/M/C_P#Y\/!W_@=<?_&J
M .QHKCOM/C__ )\/!W_@=<?_ !JC[3X__P"?#P=_X'7'_P :H [&BN.^T^/_
M /GP\'?^!UQ_\:H^T^/_ /GP\'?^!UQ_\:H [&BN.^T^/_\ GP\'?^!UQ_\
M&J/M/C__ )\/!W_@=<?_ !J@#L:*X[[3X_\ ^?#P=_X'7'_QJC[3X_\ ^?#P
M=_X'7'_QJ@#L:*X[[3X__P"?#P=_X'7'_P :H^T^/_\ GP\'?^!UQ_\ &J .
MQHKCOM/C_P#Y\/!W_@=<?_&J/M/C_P#Y\/!W_@=<?_&J .QHKCOM/C__ )\/
M!W_@=<?_ !JC[3X__P"?#P=_X'7'_P :H [&BN.^T^/_ /GP\'?^!UQ_\:H^
MT^/_ /GP\'?^!UQ_\:H [&BN.^T^/_\ GP\'?^!UQ_\ &J/M/C__ )\/!W_@
M=<?_ !J@#L:*X[[3X_\ ^?#P=_X'7'_QJC[3X_\ ^?#P=_X'7'_QJ@#L:*X[
M[3X__P"?#P=_X'7'_P :H^T^/_\ GP\'?^!UQ_\ &J .QHKCOM/C_P#Y\/!W
M_@=<?_&J/M/C_P#Y\/!W_@=<?_&J .QHKCOM/C__ )\/!W_@=<?_ !JC[3X_
M_P"?#P=_X'7'_P :H [&BN.^T^/_ /GP\'?^!UQ_\:H^T^/_ /GP\'?^!UQ_
M\:H [&BN.^T^/_\ GP\'?^!UQ_\ &J/M/C__ )\/!W_@=<?_ !J@#L:*X[[3
MX_\ ^?#P=_X'7'_QJC[3X_\ ^?#P=_X'7'_QJ@#L:*X[[3X__P"?#P=_X'7'
M_P :J3PIXLU2Y\3W.C:U965K>PVRWD3VEPTT4\99E/WD5E8-[4 =;1110!R'
MQR_Y)M<?]?EE_P"ED-=?7(?'+_DFUQ_U^67_ *60UU] 'S#KO_!8G]FWPSKL
M^F7_ ,4M,M+^UGDMY()-/O=RR1G:Z_ZGM[5[Q\+OBGH'QG\!Z5XH\,:A%JV@
MZU#]HLKM$=%N(\[=V' ;\P*^8_VQ[:+_ (>D_LBCRDPY\6[OEZ_\2R.OI7XU
M/JUG\&_%;>' RZY%HUX=-"?>^TB"3RL?]M-E 'E7C3_@J#\ /AM\4Y_!6M_%
M3PS8^(;6X%G<Q,\CV]K.?^6,UPJ&&-_57<,O>O>;2ZCO[9)8I$DAE4,CHV]6
M!Z$&OC#_ ()S^'OA-J7_  1W\,_V]#H-QX/O_#,T_C66\4?O+K:S:A)=-]_S
M1)O^8_.OR8_AKROXT?%K4/%7QM^%/P@^$2_%R^^$.G?#&#Q5IJ> ]8@TW6-6
MA:X^S6WF76HRQ2_9HHT3Y5/F,TR;OEH ^_\ QY\9/#/PO\1^&M,U[5X--O\
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MY8!6SL?[I/2N^K\_O^"5W_*3;]M[_L9]+_\ 0+JOT!H **** "BBB@ HHHH
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MWCKP9X1T.]T3488O -B=+T"^LM=O[/4M.LS\OV87<4RS-%M5%VN[+\O2JO\
M;/[5O_0O? #_ ,'VK?\ R)1_;/[5O_0O? #_ ,'VK?\ R)0!H:O_ ,$Y/@[K
M7PC\.^"%\)KI^C>$KJ2_T:33]0NK._T^XDW>;.EW%(MQYDF[]XS.=_\ %FFI
M_P $Y?@Z_P  M1^&,O@NWN/"6KW_ /:M['-?7$UY=7WR_P"EO=M(;AIQL7]Y
MOW?P_=JC_;/[5O\ T+WP _\ !]JW_P B4?VS^U;_ -"]\ /_  ?:M_\ (E "
M^&/^"8?P2\%^'/%6E:?X.:.U\<Z,N@:^SZI>3S:K:J[2?O)7F+M)N=OWF=_W
M5SM55KK?%7[&7P\\9_$;P9XOO=$N(_$OP_A2UT34+74+FVFAMT966"3RY%\Z
M+<N?+E#+[5R/]L_M6_\ 0O? #_P?:M_\B4?VS^U;_P!"]\ /_!]JW_R)0!Z9
M\$OV?_"G[/.@ZOIO@_2/[)L=<UBZUV[3[3+-YMW<MNFDS([%<M_"N%7L*S?@
M9^REX#_9NU_QAJG@W1WTO4/'NJ-K.OW#W<US)?73,S>8QE=BOWWPJX7YNE<+
M_;/[5O\ T+WP _\ !]JW_P B4?VS^U;_ -"]\ /_  ?:M_\ (E %37/^"5'P
M)\2^&=?T2\\$>;HOBCQ.OC#4+'^TKQ()-47S5^T!!)A?EE92JX1EV\?*M6/@
MO_P2X^!7[/<_BZ3PEX#M=-F\<:?+I&J2M>W,TC64J[7MHFDD9H8RO\*%?N+_
M '5I_P#;/[5O_0O? #_P?:M_\B4?VS^U;_T+WP _\'VK?_(E &I=?\$[/A#<
M_!CP/\/)/"SMX2^&^JQ:WX>LO[1NO^)?=QR22))O\S?)AI7^5RR_/TKG?CU_
MP28^ 7[2OQ6N/&WC#P#;ZAXAO3&;^:#4+JSCU+R]NSSXH9%23&S^)2WO5[^V
M?VK?^A>^ '_@^U;_ .1*/[9_:M_Z%[X ?^#[5O\ Y$H [6+]D3X>P?'K0?B3
M;^'8++QAX7T+_A&]+NK>:6*&RT_YL6Z0@B+:-[X^3Y:S+G]@_P"%=WJ?Q2N9
M?#.Z7XTP+;^,&_M"X_XFB+&T87_6?N_E=_\ 5;:YW^V?VK?^A>^ '_@^U;_Y
M$H_MG]JW_H7O@!_X/M6_^1* .A'["'PKM]1^%EU_PC.ZX^#=K)8>$F:^N&72
MX7B6)E(W[9<JBC]Z&KS%?^"*'[-<,DTR?#C8)+]=2AMO[;O_ +/8SB3S-T$7
MG[(LMU5 %;[OW:ZW^V?VK?\ H7O@!_X/M6_^1*/[9_:M_P"A>^ '_@^U;_Y$
MH [[X7_LM^!_@S\4?&_C'PWH_P!@\0_$:ZBO/$%U]KEE^W2Q;MC;'<K'C>_W
M *])KYX_MG]JW_H7O@!_X/M6_P#D2C^V?VK?^A>^ '_@^U;_ .1* /H>BOGC
M^V?VK?\ H7O@!_X/M6_^1*/[9_:M_P"A>^ '_@^U;_Y$H ^AZ*^>/[9_:M_Z
M%[X ?^#[5O\ Y$H_MG]JW_H7O@!_X/M6_P#D2@#Z'HKYX_MG]JW_ *%[X ?^
M#[5O_D2C^V?VK?\ H7O@!_X/M6_^1* /H>BOGC^V?VK?^A>^ '_@^U;_ .1*
M/[9_:M_Z%[X ?^#[5O\ Y$H ^AZ*^>/[9_:M_P"A>^ '_@^U;_Y$H_MG]JW_
M *%[X ?^#[5O_D2@#Z'HKYX_MG]JW_H7O@!_X/M6_P#D2C^V?VK?^A>^ '_@
M^U;_ .1* /H>BOGC^V?VK?\ H7O@!_X/M6_^1*/[9_:M_P"A>^ '_@^U;_Y$
MH ^AZ*^>/[9_:M_Z%[X ?^#[5O\ Y$H_MG]JW_H7O@!_X/M6_P#D2@#Z'HKY
MX_MG]JW_ *%[X ?^#[5O_D2C^V?VK?\ H7O@!_X/M6_^1* /H>BOGC^V?VK?
M^A>^ '_@^U;_ .1*/[9_:M_Z%[X ?^#[5O\ Y$H ^AZ*^>/[9_:M_P"A>^ '
M_@^U;_Y$H_MG]JW_ *%[X ?^#[5O_D2@#Z'HKYX_MG]JW_H7O@!_X/M6_P#D
M2C^V?VK?^A>^ '_@^U;_ .1* /H>BOGC^V?VK?\ H7O@!_X/M6_^1*/[9_:M
M_P"A>^ '_@^U;_Y$H ^AZ*^>/[9_:M_Z%[X ?^#[5O\ Y$H_MG]JW_H7O@!_
MX/M6_P#D2@#Z'HKYX_MG]JW_ *%[X ?^#[5O_D2C^V?VK?\ H7O@!_X/M6_^
M1* /H>BOGC^V?VK?^A>^ '_@^U;_ .1*/[9_:M_Z%[X ?^#[5O\ Y$H ^AZ*
M^>/[9_:M_P"A>^ '_@^U;_Y$H_MG]JW_ *%[X ?^#[5O_D2@#Z'HKYX_MG]J
MW_H7O@!_X/M6_P#D2C^V?VK?^A>^ '_@^U;_ .1* /H>BOGC^V?VK?\ H7O@
M!_X/M6_^1*/[9_:M_P"A>^ '_@^U;_Y$H ^AZ*^>/[9_:M_Z%[X ?^#[5O\
MY$H_MG]JW_H7O@!_X/M6_P#D2@#Z'HKYX_MG]JW_ *%[X ?^#[5O_D2C^V?V
MK?\ H7O@!_X/M6_^1* /H>BOGC^V?VK?^A>^ '_@^U;_ .1*/[9_:M_Z%[X
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MM6_^1* /H>BOGC^V?VK?^A>^ '_@^U;_ .1*/[9_:M_Z%[X ?^#[5O\ Y$H
M^AZ*^>/[9_:M_P"A>^ '_@^U;_Y$H_MG]JW_ *%[X ?^#[5O_D2@#Z'HKYX_
MMG]JW_H7O@!_X/M6_P#D2C^V?VK?^A>^ '_@^U;_ .1* /H>BOGC^V?VK?\
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M[: .=\8?\%>M=\8:)\)=3^&WP]N-8'BSX@W7@?Q%975]9N]K=6\3,UM;7"7
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MB1!?C3=29'A9+ZS^:6QFA=0\<NQ;@[6PRM;2J1NKV"@#YX_X9P^/G_1R3_\
MAO\ 3?\ XNC_ (9P^/G_ $<D_P#X;_3?_BZ^AZ* /GC_ (9P^/G_ $<D_P#X
M;_3?_BZ/^&</CY_T<D__ (;_ $W_ .+KZ'HH ^>/^&</CY_T<D__ (;_ $W_
M .+H_P"&</CY_P!')/\ ^&_TW_XNOH>B@#YX_P"&</CY_P!')/\ ^&_TW_XN
MC_AG#X^?]')/_P"&_P!-_P#BZ^AZ* /GC_AG#X^?]')/_P"&_P!-_P#BZ/\
MAG#X^?\ 1R3_ /AO]-_^+KZ'HH ^>/\ AG#X^?\ 1R3_ /AO]-_^+H_X9P^/
MG_1R3_\ AO\ 3?\ XNOH>B@#YX_X9P^/G_1R3_\ AO\ 3?\ XNC_ (9P^/G_
M $<D_P#X;_3?_BZ^AZ* /GC_ (9P^/G_ $<D_P#X;_3?_BZ/^&</CY_T<D__
M (;_ $W_ .+KZ'HH ^>/^&</CY_T<D__ (;_ $W_ .+H_P"&</CY_P!')/\
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M%:[_ .'GQ9TCXD^*/%NE6'VHWW@O4H]*U(31;%CG>UM[M50Y.X>7<1?\"W4
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M\/M2^"'Q%^(#WFH6.A_"O4-1TOQ$EU:[+JSN+'_71A,G<QW)LY^;>M<3JO\
MP5.\$VGCFX\.Z9X*^+GB;6+/2].UB^M]#\)3ZBVGQ7UNMQ;K-Y1/EN8_X6_B
M1E_AH V_^&</CY_T<D__ (;_ $W_ .+H_P"&</CY_P!')/\ ^&_TW_XNO=]'
MU(:OIEM<K#<6XN(DE$<Z;)H]RAMKK_"P[K6A0!\\?\,X?'S_ *.2?_PW^F__
M !='_#.'Q\_Z.2?_ ,-_IO\ \77T/10!\\?\,X?'S_HY)_\ PW^F_P#Q='_#
M.'Q\_P"CDG_\-_IO_P 77T/10!\\?\,X?'S_ *.2?_PW^F__ !='_#.'Q\_Z
M.2?_ ,-_IO\ \77T/10!\\?\,X?'S_HY)_\ PW^F_P#Q='_#.'Q\_P"CDG_\
M-_IO_P 77T/4<D@C0EFVA1DL>U 'SY_PSA\?/^CDG_\ #?Z;_P#%T?\ #.'Q
M\_Z.2?\ \-_IO_Q=>E7W[1?@>S^*0\#R^*-)C\5R.L0TUIOWOF-'YRP_W?-,
M?SB/.YE^;&*3PC^T;X%\>>/M3\+Z/XLT;4M>TGS6N;2"X#M&(65)L'HWELZ+
M)M)V,^UL-0!YM_PSA\?/^CDG_P##?Z;_ /%T?\,X?'S_ *.2?_PW^F__ !=>
ME_"K]HGP1\;KB_A\(>)M(\02Z>5:X2SFWE$=F5)!_>C9D?$BY5MC8)VUWE '
MSQ_PSA\?/^CDG_\ #?Z;_P#%T?\ #.'Q\_Z.2?\ \-_IO_Q=>N6OQA\+3WWB
MBVCU_3)+KP9M_M^)9P9-)W0>>OG#JF8?G&?X:W-%UFT\1Z1:7UE<175E>P)<
M6\R<K-&Z[E8>Q6@#P?\ X9P^/G_1R3_^&_TW_P"+H_X9P^/G_1R3_P#AO]-_
M^+KZ'K+US7K'PMISWFH7D%E:HZ1F>XE$4:L[*B#<<#EF51_M-0!X9_PSA\?/
M^CDG_P##?Z;_ /%T?\,X?'S_ *.2?_PW^F__ !=>V:-XMT[Q!J6JVME<F>YT
M.[6SO4V,GDS-%',%R0 W[N5&^7/W_6MN@#YX_P"&</CY_P!')/\ ^&_TW_XN
MC_AG#X^?]')/_P"&_P!-_P#BZ]OU3QGI>B^)-,TFXO[>#4M;\W[#;._[RZ\I
M=TNP?[*\FM-9D:1D4J73&1_=S0!\^_\ #.'Q\_Z.2?\ \-_IO_Q='_#.'Q\_
MZ.2?_P -_IO_ ,77IFK_ +17@G1_BI;^";KQ+I$/BBY*+'I[S?O-[HTB1D]%
MD=4W*K$,PY -'A[]HGP+XJ^)=YX/T[Q1H]YXDT\RB:PBN/WBM%M\U1_"S1[D
MWJ"63/(% 'F?_#.'Q\_Z.2?_ ,-_IO\ \71_PSA\?/\ HY)__#?Z;_\ %UZ9
M\+_VB? _QFUS4[#PKXFTO7KS2@KW,5K+O9$+,@<?WHRR. RY7<C<UW= 'SQ_
MPSA\?/\ HY)__#?Z;_\ %T?\,X?'S_HY)_\ PW^F_P#Q==WXF_:O^'/@SX@O
MX2U7QCHEAXACN(+62SN+G8T<TZJT*,Q^56D5TVJ3\V]?[U>F4 ?/'_#.'Q\_
MZ.2?_P -_IO_ ,71_P ,X?'S_HY)_P#PW^F__%U[9XL\8Z=X02Q;4K@6JZG>
MPZ?;MM9O,GE;;&GR@]6]<#GK5*T^*6@7VJZ7:6VJ6=U<:[]I%A]GD\Y+@VQV
MW"ATR@,;?*<D?-QVH \@_P"&</CY_P!')/\ ^&_TW_XNC_AG#X^?]')/_P"&
M_P!-_P#BZ^AZ* /GC_AG#X^?]')/_P"&_P!-_P#BZ/\ AG#X^?\ 1R3_ /AO
M]-_^+KZ'HH ^>/\ AG#X^?\ 1R3_ /AO]-_^+H_X9P^/G_1R3_\ AO\ 3?\
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M<FO^,)/'&N^-_$)\07NHR:5%INUOL5K:+&(HB4X6T3YAC[W2NP_YK]_W+_\
M[<UV%<?_ ,U^_P"Y?_\ ;F@#L**** .0^.7_ "3:X_Z_++_TLAKKZY#XY?\
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M.+PI\8;9YM*6;PV_AO3WN=+\3RRQ?+9:@H39#$)%V2Q731*T;M\WS?+]B44
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M#^QT[QKX2T]IO'6G:Y=?Z7#';S7,\;6-RDKDK(ODNC12(2NY&_BWU]W44 ?
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MO"/BSX:Z1X.GTQ[70= %N-)CL+J>SN-):!/+AD@GA=98W1?E#*P;;N4Y5FH
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M#MKQ'XJ?\$YO%OC77_B+8VFJ:')X+U/P[K%[X:TN1W1K/Q/JFF_8+B9_D*K
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MTW?+0!ZU??M1>"I]/GFT#Q#H/BF2PU:RT>_@TK6[)VT^6ZNEME\W?*H7#/\
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M_P#@XE_^1Z .QHKCO[=\<_\ 0O>'?_!Q+_\ (]']N^.?^A>\._\ @XE_^1Z
M.QHKCO[=\<_]"]X=_P#!Q+_\CT?V[XY_Z%[P[_X.)?\ Y'H [&BN._MWQS_T
M+WAW_P '$O\ \CT?V[XY_P"A>\._^#B7_P"1Z .QHKCO[=\<_P#0O>'?_!Q+
M_P#(]']N^.?^A>\._P#@XE_^1Z .QHKCO[=\<_\ 0O>'?_!Q+_\ (]']N^.?
M^A>\._\ @XE_^1Z .QHKCO[=\<_]"]X=_P#!Q+_\CT?V[XY_Z%[P[_X.)?\
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M"]X=_P#!Q+_\CT?V[XY_Z%[P[_X.)?\ Y'H [&BN._MWQS_T+WAW_P '$O\
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MHKCO[=\<_P#0O>'?_!Q+_P#(]']N^.?^A>\._P#@XE_^1Z .QHKCO[=\<_\
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M^.?^A>\._P#@XE_^1Z .QHKCO[=\<_\ 0O>'?_!Q+_\ (]']N^.?^A>\._\
M@XE_^1Z .QHKCO[=\<_]"]X=_P#!Q+_\CT?V[XY_Z%[P[_X.)?\ Y'H [&BN
M._MWQS_T+WAW_P '$O\ \CT?V[XY_P"A>\._^#B7_P"1Z .QHKCO[=\<_P#0
MO>'?_!Q+_P#(]']N^.?^A>\._P#@XE_^1Z .QHKCO[=\<_\ 0O>'?_!Q+_\
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MHKYZ_P"&0?B3_P!',_%;_P %/A__ .0*/^&0?B3_ -',_%;_ ,%/A_\ ^0*
M/H6BOGK_ (9!^)/_ $<S\5O_  4^'_\ Y H_X9!^)/\ T<S\5O\ P4^'_P#Y
M H ^A:*^>O\ AD'XD_\ 1S/Q6_\ !3X?_P#D"C_AD'XD_P#1S/Q6_P#!3X?_
M /D"@#Z%HKYZ_P"&0?B3_P!',_%;_P %/A__ .0*/^&0?B3_ -',_%;_ ,%/
MA_\ ^0* /H6BOGK_ (9!^)/_ $<S\5O_  4^'_\ Y H_X9!^)/\ T<S\5O\
MP4^'_P#Y H ^A:*^>O\ AD'XD_\ 1S/Q6_\ !3X?_P#D"C_AD'XD_P#1S/Q6
M_P#!3X?_ /D"@#Z%HKYZ_P"&0?B3_P!',_%;_P %/A__ .0*/^&0?B3_ -',
M_%;_ ,%/A_\ ^0* /H6BOGK_ (9!^)/_ $<S\5O_  4^'_\ Y H_X9!^)/\
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M'_\ Y H_X9!^)/\ T<S\5O\ P4^'_P#Y H ^A:*^>O\ AD'XD_\ 1S/Q6_\
M!3X?_P#D"C_AD'XD_P#1S/Q6_P#!3X?_ /D"@#Z%HKYZ_P"&0?B3_P!',_%;
M_P %/A__ .0*/^&0?B3_ -',_%;_ ,%/A_\ ^0* /H6BOGK_ (9!^)/_ $<S
M\5O_  4^'_\ Y H_X9!^)/\ T<S\5O\ P4^'_P#Y H ^A:*^>O\ AD'XD_\
M1S/Q6_\ !3X?_P#D"C_AD'XD_P#1S/Q6_P#!3X?_ /D"@#Z%HKYZ_P"&0?B3
M_P!',_%;_P %/A__ .0*/^&0?B3_ -',_%;_ ,%/A_\ ^0* /H6BOGK_ (9!
M^)/_ $<S\5O_  4^'_\ Y H_X9!^)/\ T<S\5O\ P4^'_P#Y H ^A:*^>O\
MAD'XD_\ 1S/Q6_\ !3X?_P#D"C_AD'XD_P#1S/Q6_P#!3X?_ /D"@#Z%HKYZ
M_P"&0?B3_P!',_%;_P %/A__ .0*/^&0?B3_ -',_%;_ ,%/A_\ ^0* /H6B
MOGK_ (9!^)/_ $<S\5O_  4^'_\ Y H_X9!^)/\ T<S\5O\ P4^'_P#Y H ^
MA:*^>O\ AD'XD_\ 1S/Q6_\ !3X?_P#D"C_AD'XD_P#1S/Q6_P#!3X?_ /D"
M@#Z%HKYZ_P"&0?B3_P!',_%;_P %/A__ .0*/^&0?B3_ -',_%;_ ,%/A_\
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M/^&0?B3_ -',_%;_ ,%/A_\ ^0* /H6BOGK_ (9!^)/_ $<S\5O_  4^'_\
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MHKYZ_P"&0?B3_P!',_%;_P %/A__ .0*/^&0?B3_ -',_%;_ ,%/A_\ ^0*
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M0/#$GA.>UTWPM+>RZ3+8ZQ>V=Y9_;)6DNHUN(Y5E\N5G?=&6*^U 'SW\9O\
M@I3\7]"\?Z/X)\/>'?#2>*].\%1^*M=?3]"U;QAI]]=/<R0):6SV&&AB+6[Y
MGEW;2^W!96:NI\ _&+7;O_@H9\%=?ETO6/#,OQU^&%W)XD\-W6]/[+OM/:&X
MCD=& *NGVB:#<0-R[<BO8/'G_!-SX,?$#1/#NEW7@Y=/M_">E_V%IW]CZE>:
M7)'IQ^8VDCV\B-+ 6^8I(64MN;[S-6AX0_8WTGP=^U+8?$.WN;>+3_"_A"+P
M9X7T&WM/)M]$M_-\R:3?O.YI-D2#Y1M5/XMU 'M]%%% !1110 4444 %%%%
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MV2:ZZ@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M6YWS7"QF%<PMN7Y_F^Z,LNVM7XT?%?5? ?PAF\3^$_#LWC2\EA%Q:VL5ZEG
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MJ&&WN3$K3112[TC<J-RAL#< W\6!]*T* /GO_AV)\*O7XC?^'#U[_P"3*/\
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M &@>)K[3+'6--\/ZAXAMUM_[/L;_ %!86M(&5IA<-O\ M%OEDB95\Y,G[VT
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M-'D\N_@TW4HKF2S?<R[9%0DK\R./FQ]R@#RK_AV)\*O7XC?^'#U[_P"3*/\
MAV)\*O7XC?\ AP]>_P#DROH2B@#Y[_X=B?"KU^(W_AP]>_\ DRC_ (=B?"KU
M^(W_ (</7O\ Y,KZ$HH ^>_^'8GPJ]?B-_X</7O_ ),H_P"'8GPJ]?B-_P"'
M#U[_ .3*^A** /GO_AV)\*O7XC?^'#U[_P"3*/\ AV)\*O7XC?\ AP]>_P#D
MROH2B@#Y[_X=B?"KU^(W_AP]>_\ DRC_ (=B?"KU^(W_ (</7O\ Y,KZ$HH
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M?L@3^$/VL]>^)1\:>+[VSU73+.TBTN?5I'A\R*>^=UD3: T 6Z3RH\_*R/\
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MZ\VTOD)CC;:)(H91_$K?+\WWJR_$7["_Q#CL/ WB**ZM]1\80P:Y-XJM+#Q
M^CQW%YJT]O<2R0W!MIMT47V=;?:8U9HMO/R[6^U** /GGQY^R?JM]^R7\-_A
MYHC6%O/X,U;PM=2+/=RS0QP:9J-G<S1I(4WMB.W=8]RC=\N<5<_;*_99U[]I
MT:';V&M>'[72=.$XU#2M<M-2O-/U3?Y>SSH+2_M$D5=C_+,)5^?H/FW>]44
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MA%9-A78S(JOP&9>XKK-.\$:-I7AM])L])TRUTJ0,K64%JB6[!OO*4 V\]^*
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M?6=9.@^%M-\*VWDZ9I]CIMOA5V6MND*X485< #IVK6H **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\._:8\?^*KOXJ>
M_AGX.UJ/PKJ7C5=0U&]UQK)+R;3[&Q6'>L$4F8O/DDN(5#.&55WMM)VU[C7E
M_P"T!^SX_P :+KP[JVE^(;_P?XN\)74ESHVMV<27+0"6/RYH)(9 4F@E7;N5
ML?,B,I5E5J ./MO'_CO]EFQ=/B+JL'CGPW>^(M+TG3?$,5O%9ZA;1WK>06OH
M8T6';'=-$HDB"[EFRRCRV9N:^+G[=/B>V\:>&K/P)X.76M-NOB1-X%O+N[O8
MH4OF@LI)9O(Y^7;,DJ;CGYK25<?,M6OB_P#LW^(-._9D^)ECJ5YXI^+_ (U^
M(EA]@?ROL>FQVKA&CMFMX7=(K>*"1_-+;GEW?-\[;5K3TO\ 8DEL?V<?AGX2
MMO$]QI/BCX>W]OKL>MQVR7BWFI^7,MW-+$^!(L[75RQ^ZVY]W\- "WG[=B6?
MBV[G_P"$)UYOA]8>)AX.N?%OVJW$,>H_:OLC,+;?YK6Z73) TN!M?=\NU6:J
M?AC_ (* 2:SJJ7UW\/?$&F^!F\93^"'\2O>V[QQWZ:C)IT4GV<'S?LTEPB)Y
MF/E:7D;59ZLWW[#+7?B:[T__ (3?51\.-0\4#QA<^%A91?O+_P"U+>M&+O[_
M -F:\7SS'M+;MR[PGRUQ7P*_8D\6WNE2VWC3Q9JEGX4A^(^K^,5\*?9;=_M#
MKK=Q>V+&[0E_LY;[/<&+&[=U8+\E %[PG^W#XB\(_L[:+XDU?08O$UW>ZKXA
MBN]1N-8T[0;&S@L=4NH(HV>9U#2F-$551#NV,S,/O-LO_P %%]+\0^(O!=CX
M4\*ZEXBF\6^%]/\ %\<4NI6>FW36-ZS+$MM%/(INYTV.9(T(5?E^?<RK69JO
M_!-:&.ZT"ZT;Q>;&_P!'AUBS:YO_  ]:ZE^XU'4I+]S LG%O/&TKHLJ[MR_>
M4\4WQG_P33'C/X+>$OA])X\G;PEX>\.Z?X=EM[OP_9WEQBU7;]KLYG&^RN9%
MVYD7?MV(RA67=0!H>-?^"AUWX3\;:W96GPQ\3:SHN@^+X? \NIV^H6:>=JEQ
M%"UO&D4DBGRVDN(HVD8A8]^[YEW;4@_;7'B'QAX1M]8M=?\  =]IOB_5/#OB
M/2_-M+RU5[71IM1W23;&+0>3Y4JM$4;=\K?=9:ZF]_8LTVZM-7A&NWRC5/B#
M8?$%AY2LT<UHUFRVW7YE/V1,M][YZ9??L.Z)JOQ-E\0WFJW5W'<^+KWQ5/9-
M;KY<QNM#71WMF;.=GEKYF[[V[Y: -+]G_P#:>UCXUZEIEQ/\.?$OA[PSXCTQ
MM5T/6+FX@FCNH/W;(MS$C%[662.5'17SN7?DAEVUXC^TE^U#J7A+]J;X@>'K
MSX]Z1\*--\+^&M*U31M.O;+3)?[6N)S?>;\LZ?:)E_T>)=D+!OGX^9EKVS]G
M_P#9G\2?!74-*M+WXE:]XC\+>&-,_LG0]&EL8+988!M5&NID^>ZECC1(U;Y%
M^\Q4LVZNF\/_  $TW0OC]XK\?/*;N]\4Z=INGM;RVZ;;,6373*Z-UR_VCG_<
M6@#Q/QG_ ,%$=0^"'P8\(>)O''@2XTZ*\\*Z?K_B&676;*P^QR3HK3VUK;32
MB>YEB;?F/:OR[5!9FVUG_%C]M_XE^#E_:7DT[P3I-Q:_"30DU30KE]03$S-9
M?:%:=,AF4KOEVC:VU/+^\VZMS]IO_@G':_M$>.?&NJP^+CH,?Q T:'1M84Z#
M:W]W''$DD:?9;J7Y[="K_O%4'=]Y2C-NKK?%O[&%OXO\1?$]I?$NHPZ#\6O#
M0\/:UIJV\1:.1;9K1+N&;[RL(693&P96;YN.E ')_$C_ (*+I\*Y]+TG5/""
M2>+5T"/Q)K.FGQ'I]HNFV\CR+%''+/(BW$\GE.RQI_<^9E^7=H+_ ,%!;?Q'
M?ZW=>&/!VKZ]X5T+PE:>-+W7OML%M"MG=65Q=V\:1.?-:5UM]NT+M7?N8_PM
M5\<?L"7_ (PUS3]=7QO9Q^+O["C\.ZQJESX4LK^/4K>&6:2WECADR+>>+SI5
M#*65M_S(=J[>SB_8_P!.M['XA6R:Q?LGC[PS9>&)FDBBW6L=M:W%L)AL"JS%
M;@DKM5=R?*!0!SW@#]MW5/%UW-:7WPN\5:7JFI>$9?&GAVP%[9W-QK]I$T*O
M"NV0)#<AKBW^5VV_OE^?Y659OV]/C!X]^&G[/.B:M\/EL]-\8ZOXGT/2[6WU
M6-'A;[7>PPO!-C=M5M^PLAW+]X&M[4/V691J6@:EHWBS4-#UGPSX&O?!FGWL
M5I%,T!N&LV6]V/E&DC:R3"L"IWM70?&'X&K\9O"GAK2M0U6ZCDT#7])U][J.
M)-UY-874=RJLO"JLC1<[?N[N!0!XH_\ P4'MKWQQX2UV:>XT/P=%X)\3ZWXM
MTFXMT>^T>_TJ?3UEMY/XEEA\VX7:IVOO5N5VM5OXA?MX^*/#'P[\6-<_#75?
M#'BZ/P=>^+O#-GJFH6LT.IV]L(_.\PQ.?*E@\Z)Y(2?F5]J.S;MN[\1?^"=W
M@GXE?M">(O'=Y)JMO_PF'A._\*:[I4#[+74%NUAC>['_ #SN?)MXHRR_>5(L
M_P"KJ70/V';G6+J_G^('CW5O'4[>&+SP?IS_ &"#3?L-C=K&MS(RQY$ES)Y4
M69,*OR?+&NYL@&S>?M':OX-_8@O?BOXDT%+;5-(\*S>(;G2X+A91(\=NTRJ'
M7C;)M7UV[^ORUY_K6N_%[]G'1/!WC?Q7\0K7Q?8:]KFE:1XBT+^Q+>SL]/&H
MW,=LDFGRQCSOW$UQ%_KGE\R-&^ZVVO9/ WP273_V>8?AUXMU+_A,K(Z5)H=]
M<2V268U"S9&B\MXD)7_4_(=OWNN!FO/_  O^Q3K*ZSX9MO%WQ/\ $/C7P?X'
MO(-0T31;S3[>VD:>W_X]9+VYC >[,'RLO";G16?>RT <G\'/VZ/$UNU_-XO\
M):M+X5C^(VK>"T\5I+:I#:O_ &W<65BIME(E:(?Z/ T^/OON(*JSUU'@']O[
M2_'&M^+9G\-W6G^$?!YU5+[63JMG--8_V>TBS-=622?:+=&\I_+W LWR[E3<
MM4=(_8$N;369;"]^(>LZGX$F\9W'CJ?PV^FP(9+Z346U&*+[2/G^S1W#(YCP
M69D^\JMLIVI_\$\K3QO\7IO$?C'Q,_BBQ%MJMC;PMHMK9ZA);ZA%)!+!=7L8
M#W,4<,K+&I5=NU&;>RAJ .>TC_@JSX?D\-^(=1U#PU<63Z9X0O\ QKIEG;Z[
M87]QJ5G9JK2Q2+!(_P!GN=LL3>6^?O\ WBRLJ^D>'_VO7L?$FA6'CCPI>> _
M^$DT?4M;LY;S4(+E5ALO)D>.3RR564V\OF[5+;5AEY^6N)T?_@G*8OAQXH\)
M:EXW6]TW6_"EUX2M&M?"^GV%Q;P3QK&US/+&F^YG"JBA@8T^]NC9FW+Z!^U=
M^R!HW[6'PSTGPUJ>HZEI2:7?1W*WEGM\Z2$Q26US;G_IG<6LTT3?[+[OO*M
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MT?5M>O?$^J:9916MUJ]Y%'#<:E(B[6F=$ 16;[WRB@#I:*** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M!K?Q"_9A\->#K":P&K:/J'ARXG>25DA9+#4+.>;#;2>8[=]O RVWI7"_#O\
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M#,NUF]GT+7++Q/HEGJ%A<PWEAJ$*7%O/$V^.:-UW*P/]TK7QUXD_8E\?Z/\
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MRKRWEC/+;E>)N-U<;\%/VZ_&WC#0_A3XE\7> _"^D>$OB[<I8Z5=:3X@GO\
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M2W@9V^54D*[?E5V^\JLU>Q>"KGQ)-J&O)KUEHUK:Q:@8]'ELKAYI+JT\J/\
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M\23WVG2:P^@Q06FE7D]]<:A&GF/;1VB1&X:55Y95C.W8V[&UJ\.^/'PSU/\
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M;1WD%G86-M+!)*L3^3([6\N&577[N?O?*D/[-GQ'TS]K:+Q/H5MH?A'1KSQ
M-5UJ_P!-\47KV^O67D>6T$^D/$;?[86V*;E'3Y45OO?)0![-\:/VEO"'P$O=
M.M?$5[J2WNK)--:VFG:5=ZK=/##M\Z;R;:.1UBCWIND8!5W=:YCQQ^WU\*O
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M616.G>&_!.G-K.JZSIVC>);V_L_%'F"22W\C2YHBEA/NV22-#)\S[E 99/E
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M)1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !3=H./;I3J*
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *9M"MG'S&GT4 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !2<-2T4 (JA>E+110 4444
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M>%OV<]=T;PY\?;.:;3O-^)^MWNH:25E;;''-I%G9)YWR?*WF6[YQN^7;_NT
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MC:>;JMTO_+Y?S,T]W/\ ]M+B65_^!UX9X _98^(7P*\,_!O5=#M?"WB3Q/\
M#[PYJ/AC5-*O-2EL[>Z@O);>;SX+H02%9(Y+6'.Z/YD=^0V-P!ZQ>?MK_#:V
MO?!T,'B"75)?'\$ESH,6FZ;=7\E]''+'#-)MAC8QK$TJ^9O"[/FW8VM6 /\
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MZI_9WB)DM='TZ?59+V]T^ZL[&XLX&VS7,%Q-&D5Q%&WWI(F=5]?FKP;X(_\
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M_ +1O%%EX=\.>#O!WAP7T.H6%]*^IZD]SHUQ80PFU:!5MO+CO7:1O-?<\*8
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MIK>L:_H@\.7^I0_%R'Q_I]A=7TMM'>68TF&P>)Y5B?RY=WFN/D=6V*N5W?*
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M$NK:%IMGX>TZ_P!4NKS[#<R1.HMT@,S21K%^]9$,2MT9EVLVGK_[:OPV\/\
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M&?@/)HB>&]8\8_!ZWFM[K2KJ_>ULM4BN+5H)O*N!$YCE7<C(S1E6^=6QNW4
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M3D\6'Q5-;?VOHC>"7\--J":0S/\ +XN;2?[)^T_<V_9O)^?H6\U]VT4 >_\
MBSX\7&D_LRZ+X]B31]-DUBWTB?RM2EG^RV_VV:WC\LM#&[L?W^U?DV[MN[:N
MYA9T3]K7P'X@^++^#+/5KN;6_MDNFJ_]F77]GR7D*-)+:)>>7]G:=%5V,:R%
MEV-Q\K5S7Q,_9VUWQ?\ L8Z#\/;2;3EUK3(_#\<TDLI%NQL+RSFFPVPMRMN^
MWY?[O2N,\+_LS_$3PW^URGB+28]'\'^&)?$%YJVL3:;XEO9K7Q-:S12*D4FC
MRH;>"[\QXFDN8I!N:'=AO,VJ >K?&+]K7P)\"_%MKH'B+4M277K^S?4K?3[#
M2+S4KJ:V1]KS"*VBD;RT_B;'RKUJ!/VT/AS=>)O#.C6.O2ZOJ/C.P@U72$TS
M3[J_6XLYI/+2Y+PQLL<0;[SN55/XB*\O^-DGCW2/^"B>BZEX%\/^'O$$\?PZ
MO+>XM]6U"73HV5M2M\,MPD,WS*RHQ79\R[N0RKN7]G/]AK6_A-JL2ZQJNEW%
MI<> 9O#=]-8;XWCOKG4KJ]F\A&'RP+]JVQ_-N^1>* /2? G[;?PR^(VL7=KI
MWB3:T%G<:C%=7=E<6=G?VEO_ *ZXM;B:-(KF*/\ B:%W5>N=OS4>&_VW_AGX
MH\(Z]KR:Y=Z?IGAVV@O[V35-(O=-D^SSLRV\\44\2/,DK+MC:)6WM\JY;Y:\
M _9\_P""?WB[P%#H>EZ_I'AV_'@GP[>Z+INI:IXWUS7;/4I9;,6B,-,G*PVL
M#P[_ #8U9_[J;1M:JA_8"^)WB_X6>)M N;VU\)Z2/[#O= \,KXUU36+6&_TZ
M]^TNT=\\<=U96TJHD2QQ%FC_ -8-K+M8 ^@Y/V[OA?!X.N-=NM>O-/M[75(=
M%N+6^T>]MM0MKR==T,+VCQ"X5I5_U?[OY_X=U<]XY_X*-^!/#'A;PWK6GVOB
MC7K?7/%,?A6XM[3P]J/V[2+HKN=;BV^S^='(%9&$;HK.K[DW5P7@G]B/Q3)?
MV>N7FD:9H.JGQIH6LW*77C35/$]U-8Z=YWRR7=X/O[IW\N-$557JQ;[N]\2?
MV3O&\VN>,=<T'_A';[4KOXGZ7X]TJRN[Z6VCNK>UTVQM)8))5B?RY"UO*PVJ
MZ_=S][Y0#VCXM?%&7X>ZEX&MX9M(A_X2OQ%#HY&H^>LDB/;W$Q6$1QM^_P#W
M7'F[$V[LMNVJW-_"/]MOX9_''Q5I^B^&]?N;RZUN&6XTR2?2KRSM=46'_7+;
MS31+',\?\:(Q9?FR/E:KG[0/P@U?XL>(/A?>6$MA"O@[QA!X@U#SY6^:!+.\
MA*QX0[FW7"8W;?EW<UYY\(?V0O$G@+P=^SII]Y/HS3?">:]DUCRI7*RB;3KR
MV7R?D&[]Y.F=VWY=U '??M"?$_QS\.[FT@\'>'O"US8K:SW^I:SXGU[^R]-L
MQ'MV0*4CDD:63+MN95C548EB?EKS[6_V\->/@CX.>)M*^'5ZV@_%"[T6&_O=
M1U*.V71_[2F6%(HT4,\\HW;_ +J)LVMNW-MKK/VJ_ 'C'XB26VGZ;X+^&OQ*
M\'7=L\.H^'O%<K6WEW08-#=I)]GN$90NY3&T:M]UE?\ AKFT_9$\61?LN?"3
MP7/KMEK&L^ _$NB:QJ-W<32^7)!9WJSO%"S!G;9'^[CWXW*B[B* ,GQ#_P %
M%)/!GQX\8^%=5\-P26VBBZATZWL[UGUB\NHVL8[:-X2@15O9+W9 P<_\>[LW
M\6SZ+\/ZU>P^!['4/$L6GZ/J,5FEQJB1W6^VLI FZ51*P7<B?-\S ?+S7B7[
M3_[-OCGXYZWJ>H6FIV=F/#<-M_PB-E%?RV327+2JU]<S7"(7AEDM_-M860,T
M2S2OG=)\O2>$/@)K_B#]C34OASXSUNZDU?Q!I.IZ5<WJ7LM_-9Q7;7"Q1BXE
M >9H(94C\QQN?RMS?>H H?\ #P/X=:KX1\0:MHE_J^JR:'HLVOPV?]B7\,VL
M64>U?/M%> &X@W.BF6$.J[U8G;4_[-_[2>L?$G]CZT^)_B32_+N;G29M<.FZ
M;IEY;2+"L7G+ B70661]ORB15"2?>3Y66O/]/_9N^*7Q,OM$?Q?9>"?#Z>!?
M!>J^&=+_ +&U.>Y&M75[;PP>>X>"/[-;!;=&$7[QMS]?W:[O:_AE\/\ 7OA]
M^S+X=\*6U[86?B;1/"]MI,5XT37-K#=Q6JQ+)M^4R1B1=VWY=R^E 'EGP;_:
MT\?>//!$7C6\\(>#;SP=JV@7&M6>H^'/%']I-I;QP><EM>J\4?S2+\NZ'?M=
M-K#;AJZCQ=^UA=^&_P!@&7XU)H<$UTG@N+Q8ND/=LD;.]JMQY'F["=OS[=VW
M\*\G\.?LA^.O%GQ-;Q'>^#/AK\,[T:%J6FZS=>%=5EF_X3:XN;5HHFN81;0J
ML22-YX9S+*K(J@[=S-/_ ,* ^,WC7]@[6/@IKOAGX?:6P^'_ /PB]AJ5KXHN
M+Q;JZ2UCMT\R(V4?EQOM=BP9V7T- 'N?P'\5_$+Q1-=/XQTOX?6-CY"26Q\/
M:]<ZE(SM_#();:$*NWI@GZ5D^*?VY_AEX*\?ZGX:U+Q%=6^I:#?PZ=J\@TF\
M>ST>>:..2%;JZ6(PP+(LJ;6E=5;U^5JR_P!D?X-WWPFU/4Q-\'OA1\,8;FVB
M1[KPA>B:74G1FPLRK8VWRC<[#YF^_P!*\3U?X2_$GXR>+?VI/!'A[2?"J^&/
MB%XICTF]UC4;V6VO-)CDT'2X[B6.%8'6Y_=O^Z^>/;(C9/S?* ?1^M?M>^ /
M#WQ8_P"$.NM9NH]86_@TJ1_[*NWT^WO)U5H;22]6,VT<\@=-D;2!FWJN-S+7
M">$_V\M-^*(NCI%C=:'+H_C^W\&W1\1Z9J-G'?J\WE[K=_LX5ISVC/RHWWRF
MY6KSSXJ?L7_%+XA?&V.>YN[;5M$TWQUHOB73-1O/&6HPPV.EV5Y9S-9+I,<0
MMFG"Q38F=FW;^JM]WJ9?V3/'3ZUJEBZ^'3H@^+%E\0;"]&H2_:)K4SK+<020
M^5A9(]NU<.ROO_@H ]2\-_ME?#GQ9\2SX5L/$$LFK/=7%A;RMI]TEA?7-N&:
MX@@NS&+>:6/:^Z-)&9=C<?*U8_@3_@H#\+_BG"6T#6M4O_,TF?7+ +H5^BZS
M;0KNF^QL\(6Z>/HT<.]U/:O&/@7_ ,$^O$OPS\>^&]+U.V@U;P[X*UJZU2QU
MRZ\=:W<M,&^T?9]FCDBTAG'VC;(VYH]N\JO[SY>Y^$/['7B7P/X2_9RL+ZYT
M;S/A/H]YI^LM#*[^8\VG?9E\CY!N7S/F.[;\M &QX _X*,^ O&7P'\&>.+Z+
MQ)HQ\<6+7EGI!T"_N]0V1QQR3.L,4!>2")94S.J>5\Z_-\U>JZ]\9/#7A_X6
M/XYNM8MH/"D=BFI_VB SQO;N%9'4 %FW*RX506;?@#-?+)_8W^)6E?L\_"[P
MU)X:\):AXB^&FFW.@6FJ:;XUU/0;^% D,=O>P7=O!G9(L7[ZT>-E^[AFV[6]
ME\>_"3XF:G^Q9;>$K#Q7;W'Q-@TJPMKS6_->P35)HFA^UXE1&>#SXTF02*A:
M/S=P'RT 6C^W=\+[?P9=:[>:]>:7;Z;J=OHUU:ZCHM[9ZA:W=PNZWB>TEB6X
M7S5_U?R;7_A+5/;?MM_#JX^&EQXG&M7ZV-MJX\/R6CZ->IJJZD0K+9?83$+K
MSRKJXC$>[9\WW>:\"^'7[ WCVV\:ZGKNH0:3I2:KXQ\*^(4L[CQ=?^(;J&#2
MVF^T+)=W4>^24[D95&$_A^7;N;L?&W[)'CK3_C9K?Q#\/+X<U+4[/X@0^+=*
MTJ]O9+:'4+4^'H])N(9)1$_DS[M[QML=?D3.-WR@'J/[,?[4&G_M0_\ "<76
MD0/'I?A+Q(?#]O.ZRPS76VPL[EVDBD1'A=)+IXC&PW*T//S<5R^B_M_>#/#_
M (5T>7Q9J]O)KVL1ZE=0VGAO2M3U7SK6SOI+:65(TMS-MCVKYFY %;=_#M8[
M?[(7PC\8?#>X^)6K>-(_#]KJOCWQ>_B*&UTBXDN(;.!M.L;98F=XXRSAK5\M
MM&[[W&[:O%_LQ?L<^)_@U\3M!UG5;O1Y[;3/#OB'295MY7=C+?Z]_:$++E!\
MHAX;D?-V/6@#T?XX?M*V7P^_9.UWXJ>'TL_$VE6&A'7=/\NXV0ZE"461&5\'
MY65O0TWQ9^V;\.O!7Q+;PIJ>O30:K#<6]C=RII]U-8:;<W 5H(+F[2,V]O+)
MO38LLBLV]>/F7/!?\,C>)C_P2_3X-_:=)_X2H>#UT#S_ #7^Q^>(]N[?LW;/
M^ ?A7.?$S]DGXC:[8_$[P#I</A";P)\5_$ URYUZZU"5-2T5)5MUN8A:B!EG
MD_T?]S)YR;=Z[A^[^8 ]HC_:S^'USJ7AFS_X22".]\7:U?>'M*@>"5)+F_LF
MF6Y@PR_*T;1.OSX7.W!;<N[6M/C]X3OOA1K'CJ'52WA304OY+Z_^SR[(DL7F
MCN6"[=S*C0R_,H.[9QNKYE^+_P#P3O\ &?BCXM?%#Q-X>UW0;661H->^'<%R
M)=NCZXT]C<WDD^$*K%+-IMO]W<VVXN,CYOF]'^,/P<7X*?\ !+/QAX(LV:\E
MT#X;:AIQ=-SM>3KITBN_JS22;F_WGH ['X>?MH_#;XCS:A%IWB%[=-*TQ];D
MEU+3[K3H;C3TV[[V![B-$GMAO3,L19%WIS\RU1T[]OCX57WA#7]>E\1W6F:;
MX8M;?4-0;4M'O;"2.TG?RX;M(IH4>2!VX$J*R>]>):U^Q[\1OVM_AW86'C-/
M"7@^RTOX=:AX5TN?1KV>\DU*XOXK5?M,B-%%]G@1;5/W"L[;G;Y_E5FIW7[
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M^)DGA1_$%TNKP:ROAVX?^R;S[':ZB^WR[2:[\K[/'+)O3RU=QYF]=N=RUA>
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M[DM)A>W_ ."FFGWVM_L5>*[735B;4)KS25M_-B,T:O\ VK9X9U'WE'WC_LT
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MMIMUH-V9IIFWAEF_M.R$DNY8;C#;M_W1)\H!]KQ2K<1JZ%61@"&'1@:EKE/
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MO+_Q#X#BT#4?"OBSP7?K%N^SPPW3R?;XD^=)),)MV;U++\K>&?\ !.G]I_\
M:#_8U_X)I?LB^-[C4?AIJGP;\3Z]I7@>X\+QZ5<?VY;VM]>S0)?_ &XS;&E$
MGS^3Y*JJ[5W,VYJ /VLHK\J/^"EW_!7_ .(_[(GQ/^)EYH'Q/^!4D?PWEADL
MOA[9Z%JGB#6-:MU6-KC^T+Z!DBTR?YWPK(5543<QW5Z7XI_:U_:._:,_;?\
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M=ISC /U' %2;QZCCWHW =Q0!"MJP;D@@G.<G^7TP/?K4OE^]#3*!D$'Z&G4
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MVW%W:20L<"12N?K7CO\ PL#]H3_HE7PC_P##FW__ ,HZ/^%@?M"?]$J^$?\
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M557V?_A8'[0G_1*OA'_X<V__ /E'1_PL#]H3_HE7PC_\.;?_ /RCH ^4+_\
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MV=FW4E>,_P#"=_M!?]$K^$O_ (<V_P#_ )1T?\)W^T%_T2OX2_\ AS;_ /\
ME'0![-17C/\ PG?[07_1*_A+_P"'-O\ _P"4='_"=_M!?]$K^$O_ (<V_P#_
M )1T >S45XS_ ,)[^T)_T2GX1?\ AS;_ /\ E'1_PGO[0G_1*?A%_P"'-O\
M_P"4= 'LU.WGVKQ?_A//V@V//PI^$?\ X<V__P#E'1_PGG[02C_DE7PE/_=3
M;_\ ^4= 'M&\^U&\^U>+_P#">_M"?]$I^$7_ (<V_P#_ )1T?\)W^T%_T2OX
M2_\ AS;_ /\ E'0![1YGM2AQ7BW_  GO[0G_ $2GX1?^'-O_ /Y1T?\ ">_M
M"?\ 1*?A%_X<V_\ _E'0![2&!I:\5_X3W]H3_HE/PB_\.;?_ /RCH_X3[]H3
M_HE7PC_\.=?_ /RCH ]JHKQ8_$#]H7_HE7PC_P##FW__ ,HZ;_PL/]H,=?A9
M\(\9Q_R4R_\ _E'_ /K]* /:Z3>*\6/Q _:%[?"KX1_^'-O_ /Y1T?\ ">?M
M!L>?A3\(_P#PYM__ /*.@#V@RJ!G.>_'-#/Z5XO_ ,)W^T%_T2OX2_\ AS;_
M /\ E'1_PG?[07_1*_A+_P"'-O\ _P"4= 'M*?=%+7BP\??M!K_S2KX1_P#A
MS;__ .4='_"P/VA/^B5?"/\ \.;?_P#RCH ]IHKQ;_A8'[0G_1*OA'_X<V__
M /E'1_PL#]H3_HE7PC_\.;?_ /RCH ]IHKQ;_A8'[0G_ $2KX1_^'-O_ /Y1
MT?\ "P/VA/\ HE7PC_\ #FW_ /\ *.@#VFBO%O\ A8'[0G_1*OA'_P"'-O\
M_P"4='_"P/VA/^B5?"/_ ,.;?_\ RCH ]IHKQ;_A8'[0G_1*OA'_ .'-O_\
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M_%_Q;\8M'\:I MO>W>E:?H]WH+PMYD4MLUG$@\Q)DAE#.&PT73:S TOV9_\
M@F/JGPS_ &B--^*OQ-^,WC+XW>./"NC3^'O"MSK.GV=A;^';2?;YSK#;(%DN
M951%>=_F9>U>H_\ "P/VA/\ HE7PC_\ #FW_ /\ *.C_ (6!^T)_T2KX1_\
MAS;_ /\ E'0!\O\ P(_X(K_$3]F_QYXM\1>%_P!K/XBV>I^/=9_MKQ)=3>%-
M$N;S6)O[LEQ- \NP+\JJK!47[H%>L?M:?\$:/V=_VNO#_CPZM\,?!%AXS\<V
M=U#/XMAT2"35K6ZFC9?MBN1\TJ-\PW'[R5Z1_P + _:$_P"B5?"/_P .;?\
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MR>R@_P"$4\8V/B&\^TLR^9;P),KJFT']Y^]7&<#WK*_:1^%OB[4?B?X#\?\
M@BST76-<\&)J-G)I&KZ@]A;W]K?)"KLEPD4WESQR6\17=&RLK2K\N[<H!VWP
MW^,WACXO>#M-US0=9MKS3=7DEAMY)5:VF::*1HY83%*%ECECD1T>-U#HR,K
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M:M=^&?%'AN$ZMY^FV/AN?4[^2YM]2M4\JX+2A6VR;?+==D2HV%9F /NWX?\
MQ7T3XF76N0Z1=/<2^&KU=/U!)(FB:"5K>&Y3Y6 ^5H;B)PW]UZXWXE?ME>#?
MA'\6;#P3K%OXW;7]77-E'8>#=6O[>Z 56=DN+>W>%MBLF_#_ "?Q8KB?A'H?
MB[X6?&[Q;J8\*W5Y9^,_$>D>'D>-VBCAM++1=TVJ/\A^0S(UNF[;OV1<C<M>
MB?$GX1ZGXN_:%^&WBNVGLUTWP?%JT=ZDCMYTOVJ"../RQ@JV&3G)'XT .^-?
M[5'@WX ZMI^G^(+O6)M4U2*6[@L-&T2]UF\6VB91+<O#9Q2NL",Z*9&4+N=5
MSNKJ?#'Q-\/>,?#>E:QI6L:=J&FZW8IJFGSP3*ZWEJZ>8LT8ZLI7YN!7EGQ@
M^''Q#\,?M"I\1OAYI/A/Q+=ZKX;3PUJ.FZ_J\VE?9?)N9+BWN89HK>XW+NN)
MEECV#=^Z8-^[VMX+X@_X)P_$+Q/^UCI7CG6]4\/ZHDLNAZA<7VFW,&E+HLUA
M:K'-;6L+V%Q<_9I9%E<*E["K+=SJX_B< ^M?@S^T7X/_ &A=(EOO".K'5K6"
M*SGDD^SRP[4N[.&]MV^=5^_;W$+_ .SOVG#?+5_X??&/P]\5H+Z70-3@U%=-
MO[S3+I5RCPSVEU):3J4;!PDT,J[L;6V<$U\X?L?_ + 'B?X,_#H:1K_C#4=#
MN8XO#P5_"U_Y*W1L/#^FZ9-',98OFC,UK*R[0/E=6^5N*\RU?_@E_P"/O%.H
M>,K*VL?A_P"#Y=5U7QMJ:>+=-OYWU;Q!#K<MY]FT^]1;=&6"/[1"\O[Z3YK:
M+8/XE /OC3]?LM5ABDM[RUN8YBPC>*5763;][##T[TR#Q+87-XEM'>6LES,-
MR1+*OF2#"MN S_=937Q?I7[$OQ+\)^.[/QOX4\)?##PK<1Z^]U%X(LM;GAT>
MSMI-%DTU[M+B*R \\R-$[1);JK1PK\^_FLGX/?\ !*?Q)X'\&^'Y;N3PA:^.
M='U/PK)'XAL@SWEC::=X<L]*NXX)C$'7?)%<,JY"LK_-MW;: /L_3OBWX=UC
MXB7?A*SU2WNM=L;!-2FMXMS^7 TK0ABX^7/F(P*YW>U-\#?&'PW\3/#-EK.C
MZM:W&GZG)/#:/+NA:X>"5H95"/M;Y)$93Q7S?^P)^Q9XH_9U^*DNLZWX5^'7
MA:W@\"Z7X0DD\-7LLTVO7=G/-)+J$ZM;P[6E\W/S-))_>8U\U?M'_LA^*?AC
M9/X5G\'Z-\0M?\5Z7:Z?I=U_96J7,GAN1?$>H7K265S%920JTD-[$9O.FM=G
MDJS-*GRJ ?>EG^VE\.]1^+ \&0ZS?MJO]IOH@NO['O?[)DU%%9GL5U#ROLC7
M*['!B$N_<C+C<K+6I\1/VE] ^&?C*?0;RU\1ZCJ-IHXUR[BT;1;G59K6V>X6
MVBS%;(\K-))YNW8C?+;RL<!:\)\-_LG_ !=\.^,/#7A:SU72-+\ >%_'%]XI
M76K+79TO-4L;K4Y-2-A<Z<UL8I)1)+Y7G_:-JIN=5WMM7V73_A?JVB?MJZSX
MS2 RZ#XH\%V&CS2JZ_Z#=:?>WDJ*RYW-YL>I/C:"J_9FS]Y: (_@K^V?\/\
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M*VM^&O L%SXTL-*N/!#^?#XFF@D\/-J+RR2BX7]P9)=OEB ?+$K>;N7;5/\
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M77B75]'@?Q;H^CW,^EV,-]I6M7LMIY(OFW7,7]E0L&\Y5:.[1FB7^+@O!_\
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M  I^#GPK1/%'_"->-O#EE8:-]GOO$UC9S6UG_9^G0V$5RCN"BL\<6XL"/O\
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MV]\.Z7CQ#XLFCT_7-%G>^ND?6=0DT^2.9;B-(T>%K=OGA?<OS$_-0!Z5X(^
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M+K3;/7KJWN)+6STRUL([B1-4L;]&NV3:EW(K62012.BR+',ZLTC-NJ+XM_\
M!.N)_ASHQ\/:EJFIZ_X(TZZ30(OM$%FSW4FN:?K44_FO'(FZ*;3X5"NA21?E
M<C=N7'^-7PQ\>:A_P3A^(/AF:'QUX@UVQ\4W,>CJSF\URXTV'Q"LELT;R9:1
MA:HC1LY+,J*Q)KS7QMXW^,/@>RMAX4U;XAPZ'X_\87?P]\)6_BMW36K.UU#3
MK.1=:9+G%PWV&^M]0:/S07\B9FQY:QT >X_L\_#?7OA%\$OB#'\3_',7@SQ/
M\4?$%]J]OJ4FIV2:AIGF6=K;(RG8+;S8_L^\(BR1JKJI+_,S-T'_ ()^SVET
MWBNP^(+V_P 09M?C\1VNO66@VD-@KC3Y;!E^PH=DBRV\[[WW[V?RFW!8U0<S
M_P %$?AKJVJ?';X+ZE::;J-[HV@:5X@L[V__ .$%G\;+;R3?V7Y*R6R?,K2>
M5+B1O[C?WJK+X8^)VE?&.7Q6MQ\3YO#L?CB33AHUGYMM9_\ ",?\(DLFZ&Q&
MWRY/[23:K<2++\BLJ_+0!T/B+_@D;\.O$OA_PY VM^/K/6]!DTE[C5[/Q%>6
M<FJ_8-4;4_WT,,D=ONENGN'++&-K3;EP56O3/VK_ -ES4_VF=(_LN'Q?_8>B
MWME/IVJ:5>:#::Q8WT4NW]\L4Z_N[F/Y]DF67YVW(_R[?D:T^*7Q3^$G[,EM
M\0=%OOBFGB[5/%JV \&>,OM_^BIJMO\ V=IUE"]_A[EK>\EL;B:1&9=WVK8-
MFU:[N?\ 9\^+=_\ %RVL;WQO\89M#A\<1>';BZMM5EMH;K0(_!\<CW8V?=:3
M6(N9U(D\QV165696 /3M!_8&O_">F^/O#^D_$345\%_$6V:UU+3;K2HKF\4G
M1+?21(+LN&W>7:PRG*?,V[^]7H?[+_[/]]^SYX6FTF[UG2=:@58%M_L'AVWT
M?RQ&FWYQ"3YC'Y/F/]ROD#X-7/[2^H?&OX8'Q?>^,M/;^S?"\DRG2KJ:QN+<
MZ;;_ -LK>^4Z6<=R;K[6I^T#S8_W#1!EW*WZ*T %%%% !1110 4444 %%%%
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MLF]F";=I],\'?L8?!O0KF^O-.T>UE2TGL[M5?6[JYM]'%M=QZC;QVR/,R64
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M'%GX;UJ:3X;SW5O?:7I;IJ4VI20V$-^JV3IA;AI(;B)5Z;I-R_=^9LRP\/?
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M^&WQ"\<6'Q"UN"-[RP-K)]J76KBVT^\-K.TUHUS"DJV]PT,S;XFF1]C?=VT
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M.R2W\0W^KW&O6ZRZI/M^W36K6UQ-#;M)L5I(7;?L0!C\Q&[YJ /$?"__  6
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M3K'B[7_#G_"MVU3Q%%XTU3PWH-C9:Q#"M]:6$,<TUW/++A8\++$NU0VYIE7
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M]XAUQ==_LO4+T7+>)G'B"'5'MIKA;!+B"WFA2:.2*>2]19)EV 11[7M?%/\
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M6^6D\-?MO_$KX[>$(/$5U!X?\.Z)!KOP^LTTF"WOX;YKC5[C29II7NH[N/=
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M2\71ZS),UO8:A&ML-L%LLJ*6\V7_ (\X-BHORK[O^VO^RSJWQ/\ @_X0\)^
M-"\&PZ1H&M1W=QI%S;VEM"MJEO<1HMJ9K*\A@99I8F/^C%O+\U49&;=7B_P
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M5L&N ^+O[0OBCP]_P4ENH;7Q/=1Z;I7C/1_#T6D_\)1+#=317&D+(]M'H/\
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M9+'+N"F3>R[N/E:N<\6_L3R7GC;4O%?AGQEJ7AGQ?=>*+CQ+;W_]GQ7D-O\
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MOGNY8])GM(DF5;C1)M)>R34,/+#9F.=Y1'$@VRNSG?\ =  WX#?%[]GCX?\
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M8!A/EB^R[)PW$;*\6#\R[N+\%_L3:3H'C>YO4\5WM^NGWGBJ2WL_L\6[3_\
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MYFU+38=:N+E[BW;PAJ2:@QMECDN+FYM/LWVB.*)986:>6,(JRQ,6^9:X^_\
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MJVO:KX\U#2O$5UXX76;75+MIM/T^&+7E_L/R8ONPYL7?9MPSQ_>SM7;]8T4
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
K %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>exdx-20241231_g3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 exdx-20241231_g3.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1.$17AI9@  34T *@    @  0$2  ,
M   !  8      !H !@$#  ,    !  8   $:  4    !    : $;  4    !
M    < $H  ,    !  (   (!  0    !    > ("  0    !   3 P
M  !@     0   &     !_]C_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+#!D2
M$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_VP!#
M 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !X * # 2$  A$! Q$!_\0 'P
M 04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%! 0
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M>?-<D''?G\\U)L9.GD-<S*,J5O(1D 'G:3[>ON:?;NN8")'RZV_.[L78C^M
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M10 5\Z?$71=6^('[4UCX3_X33Q/X:T.+P:^J&V\/:A]D#W OA$'8[3GY&(_
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MC/\ \GKV/_9/;C_TY0U[=7B,_P#R>O8_]D]N/_3E#7MU !7B'P@_Y.,^/?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MZ+?36VJ6"0W^OV_G6FE&2ZB0WLHR#LBSYA&Y0=HR0,D<O\%M<N-#^,,_@_\
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MJRG!Q^WW@&[AO_ GANZMUG6"?3;:6,77^N"F)2 _^U@\^^: .AHHHH ****
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M;&/PS@-9VDL\\,TTL'.8@YA4F,?+DEAMR<ZG[0?_  D7_"LKO_A&_P"U//\
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MTK_L*ZS_ .G6[KW"O#_V,/\ DW[2O^PKK/\ Z=;NO<* "BBB@ HHHH ****
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MZ\0_:@_X^/@[_P!E#TO_ -%W% 'M]%%% !1110 4444 %%%% !1110 4444
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M<6[@SL,E7\HQ@YP%W2Y(P<@'ZQZ-8V>FZ/8VFGHD=A;P)%;)&<JL2J @!],
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MWNC"?]7YT2QR;>V_CC%>JT44 %%%% !1110 50U>!;O2KRW>18$EA=&D8D!
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M_P!EZT\16^A:Q)J_B,>*].FDMGM-5%Y;W2W$_P!FC^UM"T/"P><6"(WS+AN
M,5[A7EWP6\ :GX5G\3ZYJL>B6%UXDNXKS^S/#NYK&W"0K&&#LJ&21]NYGV+G
MY1CY<GU&@ HHHH **** "BBB@#Q+]M7_ )-;^(7_ %XI_P"CHZ]JC_U:_05X
MK^VK_P FM_$+_KQ3_P!'1U[5'_JU^@H ?7B'[4'_ !\?!W_LH>E_^B[BO;Z\
M0_:@_P"/CX._]E#TO_T7<4 >WT444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %>=:U_R</X/_[%;6__ $KTJO1:
M\ZUK_DX?P?\ ]BMK?_I7I5 'HM?"W[1.D>#M)^*'B[2+GXXZ+X+.I7EIXPNM
M!OM&%W-%J=I!&;8^?N V,+6)S;X\QP&"$!Z^Z:^%?VB]"\)Z5\3O%^D3_'#P
MWX,_M2\M/&5SH.J:0+JYBU&S@C-N?.WC]TPM8G,&WS& 8(</0![-^Q_>6WBK
M0_&/C.7Q7:>*?$?B'6%DU<V&ESZ9#8RPVT,,=N+:?]ZA$:(Q+\MOSTQ7NVK7
MK:9I5[>1VTEX]O \RV\(R\I520B^YQ@?6O"?V0+ZV\6Z'XQ\;R>*].\5:_XD
MUA9=5.DZ?/86]E)#;0P1VXMY_P!ZI$:(Q,G+;P1QBO<M>$W]A:C]GNUL+C[/
M)Y=VZ[EA;:<.1W"GG'M0!Y)\'_CS=?$OQ<EG_P (Y!9Z;=::]S!J<%R\C.\/
MV=9E9&B3$?FSRQQMG+&VE^45X]\7O$]IXJ\<7<$DP\V[^T:0\-II^M"'Q!]F
MN95:T5;:54N?*5]C@C&3-SL!"ZG[.7Q0\/77Q L;6/Q?9P/<:9]ENK2Z\9/K
M!UG4'>,QW$"R.?+ $<X&-A?S -GR"M[5_"?PFTOQ7/,WCGQ5I>HV=]>S+!9:
ME>)%:S7$K/<B,*A4!G+9QQ0!]!^&_#ECX9TW['I]M]EADGFNW3<S%III&EE8
MEB227=CU[XZ"MFF1XV+@DC P3U-/H \E_:4O;.'X>0VMY;:S<-=:KIX@;1M(
MDU)HIDNXI(WEA13NB#*"RG&X @$$BN7_ &=_AG!!\-O$N@:HFKW=KJ$$.E3W
MFHZ4^CFZ@CL8[8>7;NS2)A%"EW.6;)'RA0.@_:?UW3M/^&4]EJ%Y=62WMQ;[
M633+Z[MIPEQ$S6UPUK&[1I,/W)SU\P@!N5//?L<6\UIX(U.UN=1%Q?V<MI87
M5@EI>VZ6LD%E!%G%W#%(6D5%<X0*-P')!) .@TCX7^([G5- TWQ'XYT_6]&\
M-W$-W:V-II(M;V>2-&$!NI?.=2%^]B../<5!X&5/L=?'GA3X?/>?M&W^KZ8M
MY?Z ^O//-K$'AUTD-W!<WA>-KPS ,J/<26Y<1G]W$(QQEJ^PZ /-_C]Y*?#2
M]N)]%U;7#;7-K/##H<R17D$JSILN(W<A1Y;8<YR-JMD$9!XG]GSX<ZKX1UB,
M:OHGBJ%-.T^6RTR\\2:KIUREI \L;/;PQV87:"8T.6!P(E4$# KU7XB^,I/A
M_P"$;W7(]"U?Q*]J%(TW0[<3W4F6 RJ$C(&<G'. < ]*\]^ GQJU7XS:[XHE
MG;P_I^G:-<+9+I>GW,EU>%VA@F\V21A'L \UHS'Y7WT;YSC% &!\</ ^KZU\
M8-(UJ?X6)\5?#5OH$]BEE-<V*I:74DZEY/+NI%&6C0+N4$XR,\FMC]EYO'F@
M^!-#\'^,/ NH>'1HNGB!-4NM5M+M)MC[8XE$4KOD1D?,PQ\G7)KW*B@ HHHH
M **** "BBB@ KXT_:I_8:\5_%GXIR?$/X8_$5_AYXAU32CH>NKL?9>VO0$,A
MR&V@*01SM4@J1S]ET4 ?#?Q _P"">^OZM\$/A?\ !7PMXXBT7X=Z7)+/XODE
MA/VK5Y3+'*C1J 0/G$N 7 7*??VU]KZ5I=MHFEV>G6<?E6EI"EO#&/X410JC
M\ !5VB@ HHHH **** "BBB@ HHHH **** "BBB@ K.UN,2Z/?HS-$KP.I9%9
MF4%3D@*0Q/LISZ<UHU5OI/*LKAS,MMMC9O.?!6/ ^\<]AUH ^1_A!\;O$.C:
MCX'\&:C\1]'UB!Y8-+B^V?#[7+.\OU5<;?M$LGEB4HI)=EQP6(ZU]A5\::)X
MPU'XD^,/ W_"8>-?$=WX.?6[6]T;4?\ A"5TK3]6NT)>U47)ED=4=@"N402<
M ,0P!^RZ "BBB@ HHHH \1G_ .3U['_LGMQ_Z<H:]NKQ&?\ Y/7L?^R>W'_I
MRAKVZ@ KQ#X0?\G&?'O_ *^M%_\ 3>M>WUXA\(/^3C/CW_U]:+_Z;UH ]OHH
MKXA^$?A#7=>^+^KKHVH:3?>3J]C>:KXCMO$1>\=[6]O9)1+:8$JO+!=1VYC<
M"-5#;20$H ^WJ*** "BBB@ HHHH **** /)/CUK]^?#=WH>GZ3=7DLXA\Z4^
M&CK,#Q.9 R)#YB*\B^7D[B0H925.<5F_LO>$-'\&^&-6L=(M?%MFC70EFB\4
MVJV:JQ7I;6R!8H8\<;8T4>N3S6?^TOX-N_%5WX;NVM[I8](O[>33Y+;QC+H0
MNKN;S83"WEHV6 :/:P^8F1@,#=F7]EFXTC4M.\57VFQV[WK7Z6]]=1^+YO$<
MLCQQ@*CS2J&0*#PHXPQ(ZT >G?$Q=,;P3J?]K1V,UJJHRQZG>FSMY)@ZF%7F
M )0&41C(!Y(X/2OD;X6:AIVL>,_# O-+^$V@^+SK"/>RVGCAKV^WK.2\<5F$
M ,K ;1^\."<X.-M?;ES:PW<;1SQ)-&V,I(H93@Y'!]Z^3?#DGQ+U#XFZ59WM
MZ+;5-(U6&.XT^.ZTPK?0R74\MY=21(3*($M?(CA&%D$C98'!:@#ZYHHHH *\
M/D_Y/;@_[)Y)_P"G)*]PKP^3_D]N#_LGDG_IR2@#W"BBB@#P_P"#?_)Q'Q__
M .PAHW_ILBKW"O#_ (-_\G$?'_\ ["&C?^FR*O8-7UFQT&R>]U.]M]/LT9$>
MXNIECC5F8*H+,0 2S*!ZD@4 ?*7@G]H_QMK/Q8N/#5Y>VT^KR:GIZMX9&CR1
MR6-L]S>PWB>83D^5#%;3F9LHQ("@"1:^O:^1_A[XKDN?C#;0^'_B7H?A/0'U
M)XI_".I>+H->O-1;>P*10$L;-BW(6.=\<@QCH/KB@#YZ_:<^,WB#X4:SX6^R
MZE!H'A^>:&2\U&XL#<+<'[;:Q/;>8?EA_<2SR[B"6\H[<;6KTSX,^)]7\9?#
MK3M7UN/9>7$MR(Y?L[6_VBW6XD2WG\IN4\V%8Y-IZ;Z\D_:1\:Z2=7T:'2/%
M6FZ!K\#7%N-=N/'$6CP6#J4,D4L!\S[2XRI\MX6 XRRYY]A^$%_>ZE\.=$N-
M1\6:9XYOGB83>(-'B2.UO&#L"R*C,HQC:<'JIX'0 %SXD:YJWAKX?>)=7T+3
MCJVM6.G3W-E8A2WGS)&61-J\MD@<#D]!S7A_[.7QS\0?$CQC)HLNNVWBZPLD
MU-=0U&#2FL_(>.YB6S)_A7S8WF_=G+ 0Y)ZY]E^)_B/0]$\':I'KD\*Q75G<
MJEDVII82W82%GD2.9Y(]A"*Q+;EV@%B0!FO&_P!F;Q%J6J^*+V%OBCH.N:,;
M,O:^#[?Q#%X@O[,AE_>O>A4D*@':482#)!$E 'TM1110 5X?^SS_ ,E#^/?_
M &.J_P#IJL*]PKP_]GG_ )*'\>_^QU7_ --5A0![A1110!X?^QA_R;]I7_85
MUG_TZW=>C?$^ZUZQ^'/B>?PNJ-XDBTVX?3A(%V_:!&?+^\0OWL?>./7BO.?V
M,/\ DW[2O^PKK/\ Z=;NNW^*_B'2M%\(ZA9ZG9VFJ'4+.Z2+3=1MY9;6[V0L
M[QS&.*4A"JG/R,3T 8X! /(?V</%'CO6_%LEGJ3>,)_#]DFII=7'C'2?L4DK
M&ZB-BR%HHR[^4;@/L'E@!.AQGZ7KYA_9<M;&U\7:DUCXRO)8I;,[/!VGZ9J-
MOH]B Z_O(VO0S;QD+B,Q(02?+[CZ9DE2"-G=@B*"S,QP !U)- 'RA\;OVBO%
M_@#XKZIHMOJ=OI40M[B'1=)ET:2Z?4Y?L*303!U.Z3?<L]N(X\8V$G.1CZHT
MV:>ZTZUFN8?LUS)$CRP9SY;D E<]\'(KY.^*7CVVO?BA<77@OXH^'_A]-+':
MSSZ[JOC.WN+._C:%&1H])8NC H5'F;H&/W@6&"?K.R9GM(&,R7!**3-&,*_'
MW@,G@]>IH M4444 >(?M#?\ )0_@)_V.K?\ IKOZ]OKQ#]H;_DH?P$_['5O_
M $UW]>WT %>(>(?^3SO!'_8D:Q_Z6Z?7M]>(>(?^3SO!'_8D:Q_Z6Z?0![9(
MN]&7ID$5\[^'_P!F'Q?X7'A,:?\ %R\C7PQI;Z/I@?0+1O+MG$(96S]XXMX^
M3Z'UKZ+KEY/",C_$B#Q2+]A''I,FF&PV_*Q:9)!+G/4;"N,=^M '1PJR1(KO
MYCA0&?&-Q]<5Y)\4/@9JWCKQ/JNKZ1XVN/"ZZMH::!?VT>FP70F@5YV!#2<J
M?])<<>@KV"N8^)'A.7QYX!\0>'8;]M+EU6QEM$OHU+- 74@. ",XSGJ* *7P
MO\&ZWX%\/II6M>*I?%7D+'%;32V$5J88D0*$Q'PW3.3S7:4U1M4#T%9VO:]I
MOAG3'O\ 5KV#3K%'CC:XN'"(&=U1!D]RS*H]R* /E;P%\;?B5JGQ7?P]?W&H
MW&I2:A8-<Z)+X=>&UL;=IKU+V-;CRQ\D<26LBRM(WF,5"\2;1]>5\>_#/Q+8
M3_&.R30?B=X;\$Z:VH212^![/Q(=<EU-MQ&P1RD)9L2,[8-WIGK7V%0!\\?M
M._$_Q9\.=?\ "TFG7U[I'AQIK>2[N;+2#??:F^W6R2V\C!'\E1;//(" &8H<
M,-N&]-^#.NZ_XF^&^EZEXDAFBU.=[@@W%J;662 3R+;RR0G!C=X1&[)@8+$8
M'2O&OVD_&GAJ]UK2H+/Q5X=\,ZU;FXM1XGOO%LFER:?)&RB2(01<W1!8$QR$
M(.YR:]I^#U[-J'PUT*>?QC;?$"9H2&\2V<,445^P9@75(R4&,;>#U4T =M11
M10!XE^VK_P FM_$+_KQ3_P!'1U[5'_JU^@KQ7]M7_DUOXA?]>*?^CHZ]JC_U
M:_04 /KQ#]J#_CX^#O\ V4/2_P#T7<5[?7B'[4'_ !\?!W_LH>E_^B[B@#V^
MOGC]IOXH>*_AQXA\+2:??7VC^&VFMI+JYLM(-\+MC?6T<UO(P1S"HMGGD! #
M,5.&&W#?0]?+_P"TEXU\-7NMZ5%9^*_#OAC6H#<6H\3WOBV33)-/DC91)$((
MO^/H@L"8Y"$'<Y- 'LWP9UW7O$GPWTK4O$L,T6J3M/S<6IM998!/(L$LD)YC
M=X1&[)@;2Q&!C%7_ (GZKKFA_#OQ)J/ANR_M'Q!:Z?/-86HC,ADF5"4 0$%S
MG^$$;NF1FJGP@O)=0^&VA3S^+[;Q_,T!#^)+.&.**_8,075(R4&,;>#U6F?%
MSQ/X?T#P5JL&O/8RI=V5UY6GW]\MFMX(X6D=/-8C8 JDE_X0">U 'D7[-_Q7
M\6^.?%DNG76J:EXDT6R35([W4]3T(Z<RR)>H+$@^5&"TD#R9C"G:(E)P3\WT
MM7S+^RYK@OO%.IPV_P 6-#\0Z:UGOM_!.E:RVMMIV'4>;]NF/GNN"%V%0HW#
M'2OI2>:.VA>65PD2*69V. H'))- 'R=\9_C/\1?"/Q;UC2;"]U.RB>UN(M!T
MFT\.M>0WT@LXI+>8S"-BS/<F:%DW($5,D#(>OJVR>>6R@>YC6&Y:-3+&K;@C
M8Y /?!KY ^*/CS0]6^)]Q?>&/BKX7^%TTR6ES)XAE\3FYDU*)X(G0G2F(M\&
M-@HDD.[ ! P17V%;,'MXV643 J#YBXP_'7CUH GHHHH **** "BBB@ HHHH
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M% !1110!XC/_ ,GKV/\ V3VX_P#3E#7MU>(S_P#)Z]C_ -D]N/\ TY0U[=0
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M%% !1110!X]^TO:6]YX.T6%'UI-??685T+_A'VMUNS>F.48!N 8@ODF<LS]
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M2\\57WQ*MM3.H):0:A9IX<CA$T-N92B*PF.PGSGRV#V]* /:**** "O#Y/\
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MN-#ETN+5=)OW$6IK)JDNGM!;!6<RI)&I8L'6/Y>,@G)QP0#Y\^"7P]'@#2?
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MNM0TN*\EB@0%V";E)QU.!W-=#X3\#>&_ UM-#X:\/Z9X?@N&$DL>EV4=LLC
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M@#+$DGZD]: ):*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*\ZUK_DX?P?_ -BMK?\ Z5Z57HM>=:U_R</X/_[%;6__ $KTJ@#T6OEK]I71
M=>^(6IZ=X1U#3_AW?7<NHW%[H<>LZQJ-C=QV\4$0,R36R;HI@TLH8!@"A3!;
MY@/J6OC']NGPOX/L/$?A_P 0GX5^$_&WC6;3-4NA=^*'=+=K6RMUFDA*HI\Z
M8K_JU/W0LA!'- 'J7[)&DP^$O#?B7PJ;/PE87VCZF!>0>$KZ[O@998(Y-]S/
M<J'DF967G+87:,C&!WWQKUN;PU\-]5U&!_$BM!Y9)\)V<5UJ)4N 1&DBLO0\
ML1\JY.1C->7_ +&6JQ?\(]XM\/1>&?!?A8Z-J<)^S^!E;[#<)<6D,Z3%F4$N
MRR '(R-H'3%>V>-?$DWA#POJ&L0:3<ZU]CC,SVEI+%'(R#EV#2NB_*N2<G/'
M&3Q0!X1^RKJ>F^-?%7BW7[#3=)B?3W729M0GUF76M9N"T4%P!)<N<11KYA4P
M("HD0X(V\\!\1_B1X%O-+\<^&KOPA<ZE\/;;6KA-0U ZE<)=V=U*9Q<2V06!
MDC&^*Z.TSH6+D!<2HK^Z?#GXA6/B_P ?V-Q>_#6\\(:[J^B/?VFKZE]A>:[M
M5DA#Q;X)9'&#+"Q5L#D>G'/>+_V0O!.K^*=0\17VJZAINC7$DMYJ.E"2%+20
ML7:4EV3>B,99B<,,>;)M*!CD ]]LS$;2 P,'A*+Y; YRN.#^56*CC5%C54 "
M  *%Z =L5)0!X?\ 'FTFF\8>$+PV?AK6[+3+'5-1FT?Q-J$EI!\@MQ]L!6WG
M4^2CR [@,>?D'K6Q\&O"^H^ [+Q?J.K:7H?AG2]0O1J=MIF@7KW5I;1BVC65
MP3!"%+M&SD*F,L3DDFI/CE\._#GBW2#K'B3Q1?\ A.QL+"[L+F]L[F&!&M;K
MRUFCD,L;C#>7&!C!ST/-:WPAFTE_#171?&MUXXLU,3+=WD\$KP*\,;QI^YC3
M ,;HX##.'!S@B@#SG2?$GPH\;_$G394^(VHZ_JAU,SZ?HDVIS?9$NU5F"K"%
M4$HNY@K$XQG'&:^A*^0=$\4V-Y\:9]%>[UD^%[+Q7]IM-+-Q9G.H2W5ZDDC*
M(A.(UN89'">83MD#'"#;7U]0 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 445\ 7&F>$#J^O+\;]!^+&I_$8ZE>&"ZT>/6);.2 SO]F_L
MXV1\E$\KRQ@X;=G=DY- 'W_17E?[,MOXMM?@KH$?C;^T?[<#7!5=8D62_2U-
MQ(;5;EEX,P@\H.?[P.><UZI0 4444 %%%% !5._E,%C<2B>.VV1LWGRC*1X!
M^9AD<#J>15RJE_?1:78W-Y</Y<%O&TLCXSM5023@>PH ^"OA+HTOB[X^:#XC
MUG2;KXN7\-]OA\=^%+5M'TVQ&[[TJ_9H5N$'&5%S<YQ]VOT KPNR_:L\/WFM
M^&+*W\.Z\+'6(-.FFU!H85ATS[>[QV"W \S<#*4X"!MH="VW=7NE !1110 4
M444 >(S_ /)Z]C_V3VX_].4->W5XC/\ \GKV/_9/;C_TY0U[=0 5XA\(/^3C
M/CW_ -?6B_\ IO6O;Z\0^$'_ "<9\>_^OK1?_3>M 'M4L27$;1RHLB,,,CC(
M(]Q7*^&M7T/7-?\ $FG66FK%>^';Z*RN)'MT4&1[>&X4QD<D!)T&3CD'ZUJ>
M+?%.F>"/#NH:]K%T;/3+"(S3R[&<@= %502S$D * 220 ,FO/]%^-VDPZ_:V
MVI>"O$_@\:[=QP0:KJ^EI%!=W# )$LCQN[1NP547S@I.%7K@4 >MT444 %%%
M% !1110 4444 >#_ +1OP]\,BWG\?:WK/B73WL8K&W;3_#QAD?4VAO!/:6ZQ
M21MND-PZA=I4Y8#(ZUWOPSTC0[L:CXWT;5+G6E\7B#4%O+AEVBW$8$$4:JJ[
M456/!!;+-N)/1WCVZ\$C4] ?Q9K.FZ==:9=_VG8P7^HI;@RA'C60HS .%#MC
M((# $<@&K'PV7PG:Z+/9>#M3LM0TR*ZFG9+"^6Z2"2:1I74$,=HW.Q"] #@
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MPZB^$?COP%J=UX<^%LD=[XCL].5]#>]:^A>5B%DB1YBK$$#/!VC+$$*:^WJ
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M<]!7L5 'A_Q0\<^'O@KXN%]9^&SJE[KK)J7B2:*7:ECI\ 2"34'4Y7*^9""
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M_P!EK6O$/B'X&^';[Q-/J%W?.UR+>\U:+R;RZLEN95M)ITP,2/;B%VR!DMG
MS7K=>._LG^+=:\=?!/3M=\0+J<>HWNIZLXBUF(Q744(U*Y$$;H>5*Q"-<=@H
MKV*@ HHHH **** "J&M&1='OC%:K?2B"0I:MC;,=IPASV/3\:OU3U0W2Z9=M
M9"/[:(7, E.$\S:=N[VSC- 'PO\ "C6(U\4^"?$WA;P)X/T/R[O2M%OX[#P2
M+&ZO;^[#OJ"0RG#P+90[23\P8I(&/05]Z5\,?"'QOX_N_&%EHPU#X@W/B:34
MM#O-3BU[3YQ91#9*NKHTC1"!( IS&(FPS"$J6Y-?<] !1110 4444 >(S_\
M)Z]C_P!D]N/_ $Y0U[=7B,__ ">O8_\ 9/;C_P!.4->W4 %>(?"#_DXSX]_]
M?6B_^F]:]OKQ#X0?\G&?'O\ Z^M%_P#3>M 'K?B"ZU2ST:ZFT>P@U/4T3-O:
M7-T;:.5O1I0C[1[[3]*\(\/_ +54VH?$>P\'ZA%X!L]0FOEL)K6S\<BZNXY-
MQ5D6#[&N]P58;-PY4C(P:^BZ^/\ 2?!.AVB>"?$VG:IKL'A.Z\36^E[)M/M6
M>?R=3N9=/D\P.'BB^T7#0E@K2.DB[U4%FH ^P**** "BBN,^,%A)JGPG\964
M6HSZ3)<:3=1+?VT,DTEN6B8;U2(%V(SG"#=Z<T =;%<17 W1NDB^J$$=<?S!
M_*IJ^2/V1O";7/BB37=/;P9IFBZ:FI6T>G>$M4:Z9C=3P2B.6,Q1>2L1A?:K
MJ7)E8D+SN^MZ "BBB@#R3]H[R#X3T5(8]5D\2OK, \/'1Y88KA-0V2%6W3@Q
M!!$)M^]6!3<,$D5G?L\K=0ZGXR@\2#56^("36IUB?5)[:421&(_9C ;=$C$0
M'F #8K;M^[.03H?M-1Z9+\,)%U74]'TN%;R%XGUJ&XD664$E(X3;R).DQ(RC
MQ$N,'"MR*S?V7%=_">JS2^ ]1\&7$UX'EO-4O;B[EU<[ !<>9=A;K  "A9T4
M@# !'- 'MU?&WA35([OQKX?^'1UGPRT>C>+I=4B\50W=X;R_N%GDEDMQNMQ
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MPKK/_IUNZ[3XYSZ-!\&O',GB&.YFT1-&NVO([)PD[1")MPC8\*^.A/ .">*
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M,.2 >H4444 >)?MJ_P#)K?Q"_P"O%/\ T='7M4?^K7Z"O%?VU?\ DUOXA?\
M7BG_ *.CKVJ/_5K]!0 ^O$/VH/\ CX^#O_90]+_]%W%>WUXA^U!_Q\?!W_LH
M>E_^B[B@#V^O"_BY^T!K?PAU?RM6TOP5IVEW,I73[K6_&GV":[4;02(39MC!
M8 @,V,CGD5[I7AGQ;\&:?X]^*6GZ1;7NIV/B)]$:Y%Q;0PR6ULMO?6]Q;2R!
MV5BPN(@ B?>!?<0 IH ](^&/C5/B)X%TGQ%&^G21W\;2*VD7_P!NM2 Q7]W/
ML3>..NT<Y':F?$;Q'K_A703J6AZ3I6J>1NDO#J^L'38;>!5+-*9?)E'&.00
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MPRB-K(;U)VPNPVG('2OH2R>X>TA-TD<=T4!E6)BR!\?,%) )&<X.* +5%%%
M!1110 4444 %%%% 'Q9^VK\+?!^F>//"GQ+\6?%[Q]X1BCN9+2UT7PQ=2R32
MRM:LG^@QQJS1.5!:1L,&7(.W(-4?V.]:^#_BKXSO?^&?%GQ0\<>,5T"22TO?
MB";F6.VT]Y8][0-(BJ!(XCYYSM..]>@?M,_$?X::#\8?A:VM_%+0_!GB_P -
MZDUW_9VI9E6XLKF(PSQR8XA9D(*.Y !'<&JW[/G[-GCSX>_$'P[J'B'Q+H&I
M>#/!^BWNA^&!I$4HO;NTN)HI$-XS?(?+2%%4)D$\\=P#ZJKY\_:V\+)K5IX+
MU74?#^F^+/#FCZE+-J>C:OK$6G6\RO \<;@S$1O(CL"H9@/O=R"/H.OFC]L#
M2M)\6VMC9PZIX6N_$>@6-_JTGAWQ)?)!&UE);26\EV68,(C$9 RR.NWAERN=
MP .Y_9YT?2M)TC5%TKP+X@\!1/)$S66LZ@EY#+\IP]LR7,Z!,<$*5[<5Z5XB
MV'P_J?FQ">(VLNZ)I/+#C8<J7_ASTSVKQ7]E'0];CTC5O$-];V.FZ5K%OIR6
M=EI^IQ:A'));VPAFN_-A)CS*5081CQ$">2:]QU5YHM,NW@@%U.L+F.!C@2-M
M.%)]SQ^- 'PA^R3\093X>^&.DP_$WX(Q6@CM+=/#L5L&UU%& +82"Y4-<@?+
MO$7S,,[3GG[\K\W/@?\ &V[U/XBZ-I<>L:+KGC*ZUC0IKCPY%X9MK:6P299Q
MJ=NH2,20BTPC^8[%MT2@D[\'](Z /$?VNM+T/Q'\)&\/Z[I&K^(4UO4K73K/
M2=%U'[!-=W+O\B-*6"B, ,S;\KA?NDXKR#X/>+Y?#7C/1_ ^F>,OB#9:KI>H
M0V&I^ =0T&RU*+3X?E8,][;VZ+% T;JRR&7.#PI/RU[+^U9:Q'X7#4I= \6>
M(&T?4(-1CC\$S)'J=NR!AY\0<X?:&.5&20>G%>&_L]^+Y+OQ='K7AWQG\1I]
M-\3:M!+J*^)O"=MJ,-S*D<5OY;7UBNRW81Q1H6=L*1EAG- 'VU7R(-#^)EEJ
M7C>?QA^TG_PAMAI.J2?9W2UT8P)8R$-;M)YB;XF ;RR).K(2"017UW7YUVGP
M&^(.A^+O#NKZA^SKI_B>\TGQ!K.J:MK-QKVFAM>BN9+AK<S"1B3Y7F0LHDSM
M\O@+0!]T?#*QN[#P/I4=[XL?QQ<-&TG_  D#QPQ_;$=BR,!"!'@*54%1R%![
MUUE>)?L>Z%?>&O@%HFFZA9VNFSPWVILNGV5[%>0V<3:A</% LL3%#Y:,J84\
M;<8&,5[;0 4444 %%%% !5+5;%-4TR[LI,>7<PO$VY=PPRD'([]>E7:Y?XD:
M7J&L>!M:L]-\0R>%;N2W.S6(HHY6M@.6;:X*XV@@G&0"2,$ T ><_#?X,?$/
MX>VGAW3'^+DNK^']'2&W&GS>'K9'FMXP%$1F#%A\H"[N3WY->W5\8^!/$:0W
MGPMT'Q#\8?&OB.T>'2;]8T\/PVEJ6=BEB+NX6$3(L\L)VJ[9D &XX;)^SJ "
MBBB@ HHHH \1G_Y/7L?^R>W'_IRAKVZO$9_^3U['_LGMQ_Z<H:]NH *\0^$'
M_)QGQ[_Z^M%_]-ZU[?7B'P@_Y.,^/?\ U]:+_P"F]: /;Z^*O"EUI<?C_0O&
M*VOAO^S]1\6O8P>"X=5O6O-/NWN9(6NQ;-<&V$ZG=-(JVZ%%+L')&X_:3NL:
MY9@HZ9)Q7S'X(T'QI'\:!K'A[11/X>FNWCU+6?'>G6EOJ7DYY6QE@ N' Z 7
M* 8Z,1B@#Z?KB_'?Q:\+_#B_T6QU_47MKW5YU@M((;:6=V+21Q;V$:ML0/-$
MI=L*"Z@GFNTKYN_:W\-22QZ1XF_XFVF6.FQ[;_6=&NK$20PI<07*K);WF$D0
M26\;Y1PXVD;6#$4 >[^%O%.F>--%AU?1KQ;W3YF=$E52I#([(ZLK %65U92I
M (*D&L;XHZ]J?A[PK?3Z=!(O^C7+2ZDMS;0#3PL#NDI-P0A^=54;LJ"V6^4&
MLO\ 9_E\-W?PET.]\*:E?ZSHU\;B]74M3B:*YNYI9Y))Y9%*)AFE>0X"A>?E
M&W%9_P"T?X2T_P 9?"[5K+Q!!HLWA:&UN;G5?[:2=D2-+>0HZ&%@P*OM)QD[
M0P')!H XSX*^$X]!^*#:EXA\':O9>-=2TR5!XE\2^(+.^O+J&-XM\<<,#[40
M%HR?+C51\N>HS]%5\K?LYVN@>'?B_JFD6VE>#=-U>+3W1I=#T&_M9Y /(DDB
M6>X)0[!+"9(U.Y2R;@,<?5- 'G_B7XY^!?!WB2?0=8\016FJV]JU[<0^3+(L
M$2H9"9'52J'8I?:Q#%1NQCFNZBF2XB22-U>-P&5E.00>A!KX\_:1T/3_  G\
M2K[Q!XEUGQ'X'\%ZG*#=ZOI\%G?VMQ++9K92G:<W%N[0[8\B.1/D##:Q-?76
MB06EKHUC!8#%C';QI;C)/[L* O7GICK0!YW\9_!NKZWITM[H.H7,6HN8(?L\
MGB6?1[9$0RL762*&4B0^9@X7Y@H!(V\\]^S7JVJB_P#&_A_6Y)9-4T:\MXY"
M_B>;74*R0^8I266&(IP>4QGC)QD9F_:S2.;X=:9#=KI,.E2ZU;)?ZEKNCQZI
M9Z= 5DW7$D,GR@ [4WG 4R D@9KE/V7+._.N^(;?P]XJT+5/A[I=TBVS^&_#
M5M86.H220Y?9)$=K-&^-SID'*C@@T ?0FO)JKZ7,NC3VL&H[D,<E]$TD(&\;
MP55E.2NX#G@D'D#%?*?@?6XO ?Q;M$^QZ=IL^MZS]B?4K[X=ZW'>W9=V(B_M
M*XF9<D X))3CA<<5]@U\32^(?&.J77A[Q9?Z%XD\4>%IO$L<>DPZEXMLX[-K
MD7)CM)FBCLEEV><%"AF."5+# W4 ?;-%4-(GNKG2[2:_M4LKZ2)6GM8YO-6)
MR,L@? W8.1G SBK] !7A\G_)[<'_ &3R3_TY)7N%>'R?\GMP?]D\D_\ 3DE
M'N%%%% 'A_P;_P"3B/C_ /\ 80T;_P!-D5>X5X?\&_\ DXCX_P#_ &$-&_\
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M3UR)]X^>:>V1$V@$C!\YLL,R<<_0] 'Q[\<;*'5_&7Q-UBWT_3[;0_#44/\
MPDUA<^*+[3F\0J+..8AH(2(MODNL(>0-YA1D;Y5%?6FDS17.EV4T$36T$D*/
M'"R;#&I4$*5[8'&.U?,_QG\+Z]K/QD_M'PGX.M_'FMV+V_[KQ=X:M1IFGC:C
M V^IOY<R_P!\^6+G:^X;5)P/I^$R-"AF54D*C<J-N /< X&1[X% $]%%% 'B
M'[0W_)0_@)_V.K?^FN_KV^O$/VAO^2A_ 3_L=6_]-=_7M] !7B'B'_D\[P1_
MV)&L?^ENGU[?7B'B'_D\[P1_V)&L?^ENGT >VD @@\@]J^'OCYX)U_0_%GB*
MXT+PS9:)HEK(;738-*^']IJ8N7:P6:WD9_(D<A[I9K=L!0G[HG&[)^XB< GT
MKX-^)&JS_$_XTZH_A34;/5;[5K:XL[1M1\0/HMYI$4ME' D;6<^R91'<K)<;
MHHV+%P#R!0!]RZ093I5D9X3;SF%/,A./D;:,KQQP>..*\D_:1\%W/B;2-&.C
MZ!IUYK%WJ,6G3:Q<Z'!J<UA;,LI#JDJL-GG>4K$@A%D=\<9KU[3H9K:PM8;B
M;[3<1Q*DD^,>8P !;';)YKP']K[Q7ID'A>Q\/WFHQVA>X2]N;+4+F73K/4[;
M;+'Y!OMHA1A(8Y/+=UW", X5LT ,_8W&M1^'-?35K":V3SK1E>;PW%HA$YMD
M-S#Y4<,?F^5+N7S<$'@ G:37T97@_P"R7H/B'3_!,^H:W+;QPWT5A';V5MJR
MZBB-!9Q02S>:A:,&5H]VQ"0  2=S-7NDDBQC+$*,@9)QR3@4 ?%W@.ZTV/Q]
MX6\8+;^&WL-9\2RVEMX-MM5O9;O2;IY)4:Y%N]P;<3)\[RJMO&4!D(8D9;[5
MKY@^'>@>-+?XPC6- T19?#-Q<2+J.L^.M.M+;5FB)^[9RVX$\@SP!=(./XCQ
M7T_0!\Y?M)6<7BGQ_P"%O#L5YH_AC5AIMW?P>)-5O[RSD$:R0I):PM:W%N[[
MMRLX,F %4[&SE?0OV=M7L-9^#GAVXTS2[/2+")9K6.#3I&DM9/*GDB,T+M\S
MQRE#*KMEF$@))))/&_M*Z)J7B6XT6UT/3=5US5461X;!M-L+S1201AKO[7M"
MD'@&)Q)@G (KU7X=)XC'@G1U\5P:1;>(5A"W<.@LYL48$@"+> VW;C@]#D=*
M .HHHHH \2_;5_Y-;^(7_7BG_HZ.O:H_]6OT%>*_MJ_\FM_$+_KQ3_T='7M4
M?^K7Z"@!]>(?M0?\?'P=_P"RAZ7_ .B[BO;Z\0_:@_X^/@[_ -E#TO\ ]%W%
M 'M]?.7[2-G%XJ^('ACP[%>Z1X7U9=-N[Z'Q)JE]>6<GEB2))+6%K6XMW?=E
M6<&3 "H=C9ROT;7@7[2FB:CXEN=$MM"TW5-=U9%D>&P?3K"\T4D'AKO[7M"D
M'@&%Q)@G (H [+]G;6+#6_@[X<GTS3+/2+&-);:.WTZ0R6K^5-)$9H7;YGCE
M*&17;)8."2223J_&C5K30?A-XQU&_P!(BU^RMM*N99]+G'[NZ01MF-^#\I'4
MX.!DX-7_ (=CQ"O@K2!XKM])M?$"P!+N'06<V2,"0!%O ;;C'!Z<U/XYD6/P
M;K7F3ZE;C[)+^\T5-]ZORGF!=K9D]!@\T ?/W[/=A:^#_BN-(>^T#Q9?:IH4
MM[!K.C:G>WKZ;;1S0@6K?:KFX*1.90R%&0,86RGR@CZAKY^_9L\/^-_#VJZM
M'J6@Z5H_@^>(2VLMU96EGKT\^1\US'9$VY7;GYOE?/517T#0!\9_'H:7J7C7
MXC:W+%X9L;;PPL/]J:!JVJWMM-XH"VL4R%XH;B.%E(801F6*?<T94@ ;:^PK
M"X%Q96\PA>W$D:N(9%VLF1G:1V(Z8KYN^*FA^+]4^,']I>!-'&MZI:/!FX\:
M:?9G0[5?+4G[+<X%XK%3D^5YB;RV0#NKZ6BW^6GF;1)@;MO3/?% $M%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %>=:U_R</X/_P"Q6UO_
M -*]*KT6O.M:_P"3A_!__8K:W_Z5Z50!Z+7SQ^U_86T^AZ#=#PYK.HZM:RRM
M9ZYIGB=?#T6D$A-SSW;2* K87";)-VP_+Q7T/7S9^U7X>?7_ !U\+S#X>TCX
MASVDVHW"^ ]7N4@74AY* W,;2JT1D@R"%DP")6(((H [#]F'2O'NF_#D/X]\
M;Z=XZNKFX:73[W372=8;7 "Q-<I'&+A@0V9/+7/IQFO3O$;6,.AW\^I6JWEC
M;PM/+ T0EW*@W<*>IXX'K7D/[+OPTUKP%IWC*_U3PWI_@2V\0ZP-0LO!VE7"
M3P:4@@BB;YD CWR/&TC",;06[G->G^/_ !!=^%_!^J:E8Z?<ZG>PPMY%O:Q>
M:Q<C"DKD?*"06YZ T >8?!'XR:+XZ\1+86GA"U\.7UQ:W%PDEE-!.#%$;8X=
MHU&-RW<)'5<JX#';D\!J&C_LW^)-=UVUN_B"^G7RO?P7VG7'C*[L%B^UW#F[
MA$+3(%626-BR 8X4XP1GI/V8_#</A_5[BXDTKQ#H^KZK8"ZOXM3\/Z3IMM-,
M"F]D:TA220@N0-S,-K<\X-2_&G0O%Y\<:I>^'],UQIY],@&C3^'X;'[/+?J9
ML_VBTWSF,;HL?P["^/FH ^@X%1((UCQY84!<'/&.*FJ&W\P6\?F[?.VC?M^[
MNQSCVS4U 'E7[17AJR\1?#^-[W0KGQ$+'4[&\%I:?:&E1%NHO,E6.!E>4HA=
MM@Y.,5D_LR:?JNFZ%K\>K>$[7PO<2WD-QBWMYXVD\RVB<QR-,[M*\.X1&0'8
M2A"@;2*T?VD=#AU#X>7ETF@6VO:@C06JI+I+:I+':RW=O]I:.V7F0JJ*X7IN
MC4G@4S]G7PUH_AWPGJ=OI%M=6T$MX6D6Y\-'0F)\M1D1&-"XQ_'SZ=J /+-,
M\)20?'1->_X1P1>()/$LZ3,WANQ72Q8^9(JW":@(1*UR5V$CSB_F%T,849'U
MA7Q5X0T)?!/QOTK3;;P=%:Z8WB&Y^PQ:@=4N[HDW5R);A&DF,&57RI]Q3A+@
M8)93G[5H **** "BBB@ HHHH **** /@37QXA\(>+_VA-*U3X >*O'R^-=6G
M:UURQLK>6"2T-G%#"FZ1PV$97(P.,Y'->P?L<?$CQC-X)\(?#[Q3\+/&'A6Y
MT#P];VUQKVMQQ+:7$L*1QE4(<L2W)&0.%-?3=% !7S/\2/"Q\+^,?B<?$7A'
M6_$_@GXB64%O<ZKX:M3=WVG[+86TEL\* R^457S$:-7PSR9 R"?IBB@#PG]F
M_3)4\1_$;6=,\-:AX0\$ZOJ%M/I.EZE9FQD>98 MU<K;-AH5D8)PRJ6*,Q'S
M9-[]J'6O$?AOPOX1U?PY8>(-4^P>*M.N=2LO#4,DUU-8JS&9/+0@NA&,J>#Q
MFO:** /E7X%?'W6[SQCXCLO$7PX^)$$VN>)I3I6H:CX:DC@L]/=8EB6:4G]V
MBLKDCG .:^JJ** .&^+_ (I\8>#_  1<ZEX&\&#QWKZ2*L>CG48['<ISN?S)
M!CCCY>IS7R[\/O\ A+=<^-^A>*?%5EK7PJUFXNT2\TOP[X/N_LFJ[CCRKZ^6
M26WD&< 2M&C#LRU]MT4 %?GI^TC\"_CMKD'B>3Q.FK_%G1+B]CFTNV\-:V+"
M&QM1<(S1S:6$C%RWE!EW&60Y/W1UK]"Z* .%^"]UX:O/AIHTGA#P]-X3\/!9
M8[;1[C2VTV2UVRNKHUN54H=X<].<YR<Y/=444 %%%% !1110 50UJ6T@T>_E
MOE#V*02-<*5W QA3N&._&>*OUS/Q!\07_A;P;JNJ:;H%YXHO;:$M%I-AY?G7
M!) P/,=%(&<D;LD XR< @'Q_\)+KPG:0:8MQX-\0Z?H[^(?#=U;2WWB(7\SV
M\\;IHYG4CB*)UAQ C-M+!F9BK _<U?%GPC^'6SQ!X.U_2_@1XL\.:A=2V%S=
M_P#"0Z^CZ+I:*I+O!9_;9&5XUDE6%#$-A?&$YQ]IT %%%% !1110!XC/_P G
MKV/_ &3VX_\ 3E#7MU>(S_\ )Z]C_P!D]N/_ $Y0U[=0 5XA\(/^3C/CW_U]
M:+_Z;UKV^O$/A!_R<9\>_P#KZT7_ --ZT >NZWH>G>)-.DT_5+*#4+&4JSV]
MP@=&*L&4D'T90?J!7QE;Z-X6TCXT^'+GPS=^ O$VM2^)XDN=/TKP)Y.H6\1E
M;S9A="5@K1?>:1@,@,1R0#]NLP098@#U-?&UMX&\6:OJ^FZ3=S?%6S\4/XC9
M]4N/[>NH-#73VN6+^3,)L%/(P(E0^9OVAQC=0!]EU\H?'#Q3HA^,%CI&L>)]
M%M?$.F0SZA8R:IX$GU=;.!C %1'68 2 DDR*.0<97&#]/Z3IT6C:5:6,4US<
M1VT2PK-=3M-,X48R\C$LS''))R37SC^T3K-MX+\4V-DFN>*$UK5(+F[TZ*SU
M];+[3<27%I;PV40,3EE,DJ,0/]6H=L-G@ ]F^#_B2]\6?#[3-4O[F:[GE>=/
MM4^E-IAG1)G1)!;,[LB,JJRY;)4AB!G =\9[_2=)^$7C.\U[37UC1(-'NY;W
M3XV*-<PB)B\88$;2PR-V1C.>U9O[/NO2>(_A1I=U-+=3W,4]Y9SS76H?;VDE
M@NI879;C8GFQEHR4;:N4V\"L']I7XAOX&T?PO9/XCL_!^GZ]JQTZ^U^^MXYT
MLX!:SS'"2 QEG:)(P7! \P\$XH XWX*:%+X)^)GA[2-<T;3DU"^T74=1TR_T
MSQ'<ZH0KW%N]TUQYZ*7>1I(<3C.1'MPH S]*.K%&"$*V."1D _2OFK]C[Q5\
M,-0L-1T_PR?",?C%+J]M[R3P]90VDM_:P73QPW)C0<(Z>6^!\N7)4 &OI61?
M,1E#%<C&Y>H]Q0!\3:K\4- LOB%XFUV+QQ\/Y/&FB"*PO;FZ\$W=[?SW,=K$
M9%M2+\%59C@1J%^;@[C\Q^S]+N);S3;6:56266%'=7C,9#%02"I)*GVR<>IK
MX_\ BKXRF\%>)]=T;1_%/C&XUG2FBCN8?[=L;+[5%!IB7-S>N6M';_5B)-QX
M>63:-BKQ]>Z%>IJ6BZ?=Q-*T5Q;QRJTX D(9006 XSSS[T >&?'O7/B7H>N>
M*8_!_A[Q'KD&I>$A:Z3-H\EMY5GJGFW&9'$TR8.UH?F ;A?:NN^$6L>)_$/B
MSQGJ6M>']<\,Z-+]BCTO3]::'<NV)A,R+#+(J@MCN"?2NN^)6MZSX=^'_B/5
M/#NG?VMKUG833V%@8V?[1.J$HFU2"<M@8!!KI4)9%)&"1R* .'^-?CZ7X7_#
M+6?%$/V;=IPA=C>DB%4:9$=F((P K,<YXQ7S1IOQ'^#S_%2ZF\*2^$]2UR+Q
MOIUCIEO:ZX]S%<)=I;O=7L%HLYB$JO<3CS$3@H2>=U?9TL231LDB*Z,,%6&0
M?PKE?#.N:)K^N^)-,L].\F[\.WT=C<RO BAI'MH;A3&022-DZ#)P<@^Q(!UU
M%%% !7A\G_)[<'_9/)/_ $Y)7N%>'R?\GMP?]D\D_P#3DE 'N%%%% 'A_P &
M_P#DXCX__P#80T;_ --D5>N:_P"'[#Q1I<NFZI;+=V,K([PN2 2CAU.00>&5
M3^%>1_!O_DXCX_\ _80T;_TV15[A0!\06)\,:'\9_#3Z#KWPO\5:I<^)([>;
M3-!TRZ;5;=&=M\V1?R*#'C+LT84 ,<9 4_;]?&.G:#XVUG5-+TI_$?Q6LO&,
MGB!AJ\ @:'1X+ SMYC179@\MD6':T>V1G9@H*\L!]?Z38'2]+M+,W-Q>?9XE
MB^T7;[YI=HQN=L#+'&2<=: /G+]H_P (>!],U/3GU'Q#\//"DUY)<WCIXSM9
MIGNI7*!Y(BMY!@?*H88;MT[^B_LOZD=6^!WARY^R6-DI:Z1%TNVEM[21%NI5
M66%)7=Q'(JB12S$D.#QG YC]H%-4'COPU-<ZCXYTSP>MA=K<3>![62[E:\WQ
M>4L\<<4KA-GF$,JXW##$< ]!^S?X5\1:+X(74?$^M^)M3U2_DFVV_B2=6EAM
MUGE%NQC51Y<CP^4SKV8D8&,4 =/\5?#FB:UX2U&]UAM-MAI]G=217^L!FM+3
M? \<CRJLD9*;&8,-R\9P0>:^>OV:Y]#T[XV_V;X=U+P!XIM)]"N;BXU/P3IU
MQ&UFZ3P*L4TCWDZ 2!R5'#'RVZ <_1?Q;BUV?X7^+4\,+*WB-M*N1IP@<+(;
MCRV\O:3P#NQC/?TKP/X:>%M9\3?$G1UTWQ=\61X<LM->;57\40/IRM>+)#Y,
M:B2WC\W<OG[P@9 %7##/(!]6T444 %>'_L\_\E#^/?\ V.J_^FJPKW"O#_V>
M?^2A_'O_ +'5?_3584 >X4444 >'_L8?\F_:5_V%=9_].MW7HGQ(T?3=3\(Z
MI+J,/_'M:3M'=1:8NH3V^Z-E9HH#')YC%21L"-NSC!SBO._V,/\ DW[2O^PK
MK/\ Z=;NN[^+^G:CK_PR\3Z)HMREMK^JZ;=6>FE[DVY:X:%]H5U.Y3P3D=,$
M]!0!X=^S_I\NG_&+&B-K&I^&WT6X-[>ZKX%@\/?9[D30>2BR"S@>;>IF)5<A
M?+!/45]0RPI/$\;J&1P593W!ZU\I?#7X/:?J_P 4-"O&\+>+O".BV6ERM);>
M(/&4MR]_>)+ 8I(4AOI=ZQCS=[-A6\R,;3V^LJ /A[]HS1_!/@?5=?-CK?PM
MCU+2=/A6T\*ZQI]U<:K*(K=!' #'?(6=U50@$6?F7.>2?M'1V9]*LV:(P,8$
M)B*%"AVCY=I)QCIC)QZU\L_&NV\6+XR^(/E:O\3;#5)XX1X2M?"EDT^FS$6L
M8!DE$+I$QN/,5Q*\8"A6!&2U?2/@#PW=>%?"]K8WVJZEK%YCS)KC5+D7$H=@
M-R!PJY4'('% '2T444 >(?M#?\E#^ G_ &.K?^FN_KV^O$/VAO\ DH?P$_['
M5O\ TUW]>WT %>(>(?\ D\[P1_V)&L?^ENGU[?7B'B'_ )/.\$?]B1K'_I;I
M] 'MK'"GG;QU/:OS^UBWU#QWK1MM?EN_VJ])%UNBAT=;G2K.W&[@8BC^P3;>
M/]9."<?A7Z!URQ\7K!\1+?PBMDP$FDOJ:W:MA%"3)%Y>W'7YP<Y[=* .@LE"
M6D"B$VX$:@1<?N^/N\<<=.*^</VJ=9URT\1:-::1\3AH:26I:;P19Z?-+>ZL
M"S#S%FM8Y;F)>-N4CQE3SUKZ8KE_B/XM3X>>!O$/BEK)K_\ LFQDNVMHV"/,
M(U+; V#C//;O0!YE^R9X>M- \%:J+;X87GPREN;XS3I?7SW<FIOM ^TEY<3<
MXQB9$;C[M>QZYH6G^)-/:QU2R@U"R:2.4P7*!T+(ZNAP>ZLJL/<"M!3N4'U%
M(S!!EB%'3).* /B/1]%\*Z/\:O"T_A:[\!^)]6F\1*EU9:/X#\B_M827,D_V
MH2L$,9 +.P&1G'. ?M^OC+2_ GBS6-4T/2+N;XKV7B8ZZQUNXEUZ[AT5;(RN
M7,$PFP4V;1$J$R9V[QC=7U_IFGKI.FVMFDD\Z6T20K+=2M+*X4  N[$EF..6
M)R3R: /G']I+P)\/HM4TQ]7U'P/X:FN6N+IE\1>$EU9[F1V7S)%;S$VDD#/7
M/'I7I'[,LDTGP0\,F?3;32GV3A8+'3#IMNR">0)+';$DQI(H60 G.'!/)KEO
MCWINHW/COP_>W(\=OX3CTZZAE_X0.\N$E%Z9(_+^T10N&*[ ^U@, Y#G!6M_
M]F[P3JWA;P+'>>(+SQ%<ZWJ#R-+;^(=8EOY885GE^SA@TCI'+Y1C\P1\;P1V
M% 'KU%%% 'B7[:O_ ":W\0O^O%/_ $='7M4?^K7Z"O%?VU?^36_B%_UXI_Z.
MCKVJ/_5K]!0 ^O$/VH/^/CX._P#90]+_ /1=Q7M]>(?M0?\ 'Q\'?^RAZ7_Z
M+N* /;Z^8_VDO OP^AU33'U;4? _AJ:X:XNF7Q#X275GN9'93)(K>8FTD@9Z
MYX]*^G*\!^/FFZC<^.M O;D>.G\)QZ=<PR?\('>7"2B],D>S[1%"X8J$#[6
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MQ<J#G )X% '1T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M5YUK7_)P_@__ +%;6_\ TKTJO1:\ZUK_ ).'\'_]BMK?_I7I5 'HM?%?[5'B
MI/&_B;7KN\^']YKG@[X3W"OJVN:?XMN='OH))[6*:=K6* #S?+@E0G>ZYRRK
MU-?:E>$?$+]C/X=_$SQ%XCU?6)/$L4GB)E;5+33O$5Y:6ET5A2'+P1R!#F.-
M%.1SB@#T+X8_"W1OA3I%U8Z'<:Q<V]U-]H<ZSJ]SJ,@;:!A7N)'91@#Y00,Y
M/>I?BH- E\ ZS!XHCOY- N(?)NUTV&YDGV,<?*+8&4>Y4<#KQFH/A9\*-)^$
MFD7>FZ1?:W?P7,_VAFUS5KC49%;:%PKS.Q5< ?*#C.3WKH/%3VT?AG5GO+9K
MVS6SF,]LGWIDV'<@Y')&1^- 'CWP+G^$+^((8O D>J_VQ_9.^"?5[;5%9K$O
M&"8GO%"[&819\L\X7T&*OQT\3?$G3=;UU/#&I6^EZ)IVEQZB^H"XL%%LZ1W1
M\N87!RHEE^RY8@)Y4<N&5^:Q_P!F"0^(->L]7N?$6DZ_'#H?E:3!#XMBU:ZT
MZUD:%C$8H[.#&0D0:1WD;**,\DG(^,'P_35?C%'>>)=7\=2IIJQ7NEW>D>&[
M2_M&#/*?LTFVQ;>(6".HE+X9E<$,": /JJT=WM86E*&1D!8QG*YQSCVJ>HX_
MN+R6X')&":DH \>_:>L+$_#6>]ET6QU>_-S9:9"+K2H]1D$=S?6R2)%#)\K.
M<(5#?+O1"W J3]G+PG!X1\+:E;6^BWFBK+>^88KW0[+26?Y%&1':#:PX^\W/
M;H*A_:ATW6-1^&<BV#:;+I@N[4:E::EHTNI(T)N8<S;(IHV A&93C<3L[8S6
M7^S+(=+\.>,/(CL]3T>UU#?8ZEHND3V*:@GV>-GV132R,[*^Y-RMM)&!R&H
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M* "BBB@#Q&?_ )/7L?\ LGMQ_P"G*&O;J\1G_P"3U['_ +)[<?\ IRAKVZ@
MKQ#X0?\ )QGQ[_Z^M%_]-ZU[?7B'P@_Y.,^/?_7UHO\ Z;UH [/XV^#]6\>_
M"_7-#T-[5-7NDC-L;V5HH2Z2I( [JK,H.S&0IZ]*\@B^&7QAUWQ7>W&M:7X/
MLM(U+Q;I7B*=[/Q!=W$UK':+:JT4:-9('+?9B>64 N?3)^FZY?PS;>(H?$7B
MZ36+A)M+FU&)M&C4KF*V%I K@X /,XG/))Y],"@#J*\&_:$U.\LO%WA5+_5M
M=\-^$5M[J9]9\-Z.NH727X:(0QL3;SF%#&TQ#!!N8 %AP&]YKY&\?>%_'=G\
M2M?\0V/P[\4Z[XBA\2V-WI&OV&M6D=LND1FV$]HL4EVF Z"[!1H\,\@8G."
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M^<FS_;QY?F>WXUU% !1110!XA^T-_P E#^ G_8ZM_P"FN_KV^O$/VAO^2A_
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M#CF6=/\ A%?[*9&@^7=]L\Y2K=,X\O<.N/:NFH **** "BBB@ HHHH ****
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MF*)* ^GY4D%-RY.&) )&#7OD0*1JK,9"  6;&3[G'% $M%%% !1110 4444
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M6\2ZK):WOPZ\2>$8D@W"]U=]/,3;2 (Q]GNI6S\Q(RN.#SZ]VV-IR,C'3UH
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M1% P H%U@ #H*]?A;S(D8J8\@':W4>QH EHHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ KSK6O^3A_!_P#V*VM_^E>E5Z+7G6M?\G#^#_\
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M=U,:M-80^$9H3):6>I/:S>(/.W#Y[A[-5@V[21SYCYQE^N0#W^BBB@ KP_\
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MPOJ7Q_\ %VL>&-)\0"/PEH]YI\XNM;5D216OKTPAGC5V=!&^W)C!/&!7UO\
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M#788KC/E&)"Q))/6OI6'?Y2>85,F!N*],]\>U $M%%% !1110 4444 %%%%
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M]G62Y!\9P:Q</J/BNWU.*/5M3_M".]AN6^S1-$(WC@@1=L;*I01*0>3NW D
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M'!!!!!%6JYKX<^#(?AWX!\.>%K>XDNX=&T^"P2>10K2B.,)N(' SC.!TKI:
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M4@_3'PF\:V?C;PJ'M=-OM'GTN=M+NM.U)D>>WEB"_*SQLZ."K(X96((<'KD
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MN].U-D:XMIHL*59D9T?(VL&5B"&![XH [2BBB@ HHHH **** "BBB@ HHHH
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ML^VOQ?\ $6A:Q?>,O$>AQZ(/-M]-T]K-[$S DBXDAN+>56E4'"L?NXRN#DD
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M\>_+::UXML]4TUHK:9E_?7"VL<Q\G=DDI$@(#D#BOH?]J#_CX^#O_90]+_\
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M\J\)_%Z.?QA=^$+GP?JVD:G'?W2A[>U5K1X?.<I=;P00L@*N25^\YZ]3ZK0
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M_#6I^-M?M-'L;::]M!!=6,EZUW'<6<L4JQQ1@OYB*?,#A3M"-G@DU[_7SO\
MM;)IMS)X)L9O$EGX.UO49M0L--UK5!&]BK2V4B2P3HSHQ61"0K*P*NJ=<[6
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MGU*V?Q1H6H,;:SU&)X'^TK$59K9I %F(29E)C+8WD'%>F4 %%%% 'B7[:O\
MR:W\0O\ KQ3_ -'1UWOQ$\2Z7H7ATV-]X@M_#=]K,4]CIUU.^TB?[/))E?4H
MD;O]$-<%^VK_ ,FM_$+_ *\4_P#1T=;OQ_\ A/X&^+GPRU"P^(.EMJ>AZ=$^
MI!X9'CGMGCB?][$RD$.%+8['.""* /BK]F?]G?XAV?C?P;/#\/\ 3_#/AZSU
M/2_$#^-+'7X[J+44BL'AG>%5)DD^VF178N!@,<]!7UM^U!_Q\?!W_LH>E_\
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MR#@UV_P[^%WAWX6:?>6N@6DL1OK@W=[>7=U+=W5Y,0%\R:>5FDD;  !9C@
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M.Q7CL,"@#E?@W_R<1\?_ /L(:-_Z;(J]+\?>#;3X@>%;S0;Z2:&VN6B=GMV
M<&.59%P2".2@'3IFO-/@W_R<1\?_ /L(:-_Z;(J]PH \%\.ZQX&^*7Q&\,ZO
M8>'+W3O&IM)KW4;RSF^RW%@+>;[.UK?-&P$X,PEC6-MZGRG88 !KWJN:\/\
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MQP.I/<U@R^ M N?'-MXQETJ!O$UM9/IT.HG/F+;LX<H.WWAUQD;F .&.>DH
M**** /$/VAO^2A_ 3_L=6_\ 37?USG[5GBWQ#XAU32_@]X6\$Z!XTO?$VE7F
MI:A!XINY+>Q2SMWA4KF,%S(SRH%(QM(#9XR.C_:&_P"2A_ 3_L=6_P#37?UJ
M_&7]E_X>?'S5=*U+QEI5W>WNF0R6]K/9ZG<V;+'(RLZGR9%W E%//I0!\]?\
M$^?#4%Q*_C3PO\(U\ >#]5TLQG5]9UZ;4]2OKGS0SI;AV;RK42><26P7;:V.
MM>X>(?\ D\[P1_V)&L?^ENGU/\%_V1_AE^S_ *Y)JW@C1[[3+J2U:S*S:M=7
M,0C9E<@1RR,H.5'(&>OJ:@\0_P#)YW@C_L2-8_\ 2W3Z /;6 8$$9!X-?*>@
M_#3X%^#-1?P4WPLT75-?A\0)I5O:ZEHUE-<RQ3JURMPLFS+6\</F_.V6'V=D
M)+#GZNKFY/ 6@7'CBW\92Z3 WB>WLFTV+42#YBV[.'*>GWN^,C+ '!.0#>BA
M2WB2.-%2- %55&  .@ KQ;XV_#KX<W_Q!\'^*_''A:TUTW#'PX;G4;.WNK.
M3$R0&=958K^]7RT=,8:?#9#<>WU@^,_!^C_$#PSJ'AW7[%-2T?4(_*N;:0D!
MUR".00000""""" 10!ROP+L_!Q\$QZOX(\(V/A'1=5E>XBBL+&&T%Y&K,D5R
M5C !$B*KJ3SM9<XZ5TOCSP?:^._#%SHMY)-'!++!,6MV"ONBF250"01RT8!X
MZ$UM6-G!IME!:6L*06T$:Q111C:J(HPJ@=@  *LT >"^%]7\#?%+XC^&M:TW
MP]>Z;XQ:QEU#4;VTE^RS60AF-N;2^,; 3YF6= C;U_<R$8P#7O5<UX=\ ^'_
M  EK7B#5](TJ"PU+7[A+K4[B('=<RJ@16/.!P.@P,ECU8D]+0!X#\19OA]X#
M7Q;H/C+19M9TW5(KCQ;&E]#',EU.&CB>WM@,,)E8V^SHV9AAN#CU[P/H4?AO
MPGIFFQ+?1Q0PC;%J5X]W/#GYO+:9V9GV9V@DGA1R:9XI\!Z!XVGT2?7-+AU&
M;1;]-3T]Y<YM[E 0L@P>2,G@Y&<'&0,='0 4444 >)?MJ_\ )K?Q"_Z\4_\
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MF\=0^,FTJ!O$\-DVF)J1!\Q;8OO,?I][G.,\D9P3724 %%%% !1110 4444
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MM?KXLTTV-YI.D7.EW^FP10ZC*V^35[JY"H=D,:$) ZE06C&-^_GZ^H ****
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M(?M0?\?'P=_[*'I?_HNXKV^O$/VH/^/CX._]E#TO_P!%W% 'M]%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7
MG6M?\G#^#_\ L5M;_P#2O2J]%KSK6O\ DX?P?_V*VM_^E>E4 >BT444 %?$7
MCF\\!R?M#?$R\^+OPS\2^.V@N+2P\.D^$;O6=/M]/%E"[F';&T2NUQ)/N8?-
M\H&>*^W:^,/VMO@_K^A^)K_XDVGQYU/PII$P7S?"FL^);G2M/<K&J[;6:!MT
M;MMSM\N3+,>.: .^_8RDC@TSXA:=HNC^(-"\"6OB$-X:L/$-A<6<EO;26EN\
ML44<X#+"MP9PHZ ' KZ1KY[_ &+==/B;X87FI?V=X\T[SK]O^1[U*:_>8!%
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M3?M*_P"PKK/_ *=;NO<*\/\ V,/^3?M*_P"PKK/_ *=;NO<* "BBB@ HHHH
M**** /$/VAO^2A_ 3_L=6_\ 37?U[?7B'[0W_)0_@)_V.K?^FN_KV^@ KQ#Q
M#_R>=X(_[$C6/_2W3Z]OKQ#Q#_R>=X(_[$C6/_2W3Z /;Z*** "BBB@ HHHH
M **** "BBB@ HHHH \2_;5_Y-;^(7_7BG_HZ.O:H_P#5K]!7BO[:O_)K?Q"_
MZ\4_]'1U[5'_ *M?H* 'UXA^U!_Q\?!W_LH>E_\ HNXKV^O$/VH/^/CX._\
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M]-D5>X5X?\&_^3B/C_\ ]A#1O_39%7N% !1110 4444 %%%% !1110 5X?\
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MJ_9W\5>)_#^K0:#J-H;5!JEQ )Q:1R7444DBQD$.ZH[%5/5L"@#VNO$/$/\
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M-"^)?A=_#UYKND>)IXK:QO\ 4M*:S,,6GW-_%;1^;'<QR"1A/*"OEJ"!YF6
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M -.4-<M^VQXWU+PAHG@F&3Q/?> O!>I:L]OXB\6Z98"ZN-.A$#M$JY1Q$))
M$,NT[>.F:ZF?_D]>Q_[)[<?^G*&O$/VM/B=X>^'GQ-T_PGK7Q7^)7AR?Q'<-
MJ3#PY:^=#I]NML46) +9_,1WB9BBDLI?<<+0!Z%^Q+XUO_%NE^.+>#Q/J'C[
MP5INIQ0>'O%^J6(MKC4(V@5YD8A$\T12$J)-HSG':NL^$'_)QGQ[_P"OK1?_
M $WK7+_L7>)8_$6E^,1IOB7QUXQT&UO8(;+6O&UL+?SR8=TBV\9AB8*K$!MP
MY/2NH^$'_)QGQ[_Z^M%_]-ZT >WT444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !7A\G_)[4/_ &3R3_TY)7N%>'R?\GM0_P#9/)/_ $Y)0!RW[;/C
M:_\ ".D^"()_%-]X \%:CJLD'B'Q=IMB+JXT^,0,T**2CB(2R *9-IVX'3-'
M[$OC74/%VC>-8(O$VH>//!>FZK';^'?%VJ6(M;C483 CS*Q")YHCE9E$FT9Z
M=J\Y_:Q^)_A[X>_$ZP\(ZW\5_B5X<G\0W#ZF_P#PCEIYT.GVXM]BPH!;/YB,
M\3,54EE+[C@&O2OV+O$T?B/2/&']G^)?'7B_0;6_A@L=;\;6PMS/^Y#2+;Q^
M3$RHK-M.X<D<4 =+\&_^3B/C_P#]A#1O_39%7N%>'_!O_DXCX_\ _80T;_TV
M15[A0 4444 %%%% !1110 4444 %>'_L\_\ )0_CW_V.J_\ IJL*]PKP_P#9
MZY^(/Q\YQ_Q6HY_[A5A0!XQ^UI\0TTGXW1:)XT^*6N?!WP0F@Q7>DZGHFG"3
M^U+\S2B:.2<PR?ZM5A(B&-WF$YKWW]E;Q+XE\7? #PAJ_BU7_MRZMY&DFDM/
MLCW,0F=8)VAP/+:6(1R%<#!<\5\?_$;XN>#X/B;J'@75_CI\8=*F\+VB6UQ>
MV.EF=+VY^TW.\LJ6;'<N%42#",H4+DJQK[#_ &8-7O-?^!WAF_OIO$=U+<+.
MZ7/BP*-2GB\^3RY)0J(!N3:RC:"%*YYH QOV,/\ DW[2O^PKK/\ Z=;NO<*\
M/_8P_P"3?M*_["NL_P#IUNZ]PH **** "BBB@ HHHH \0_:&_P"2A_ 3_L=6
M_P#37?U?_:P\3>)/!_P#\4:MX5,L>JPBW#74%G]LEM+=KB-;BX2'!\QHH3)(
M%P>4JA^T-_R4/X"?]CJW_IKOZXK]M;XB:9\(M#AUS5?'7C?PW_:\$6CVMGX5
MB#K&_P!M@>2ZW&&0)*(R5^8_,A95!8B@#D?V1O'Z:U\:M2T7P7\3]:^,'@0Z
M$UYJ&KZU8+&=,U#SHUBACG$,>[S$,K&/!V^6#7L?B'_D\[P1_P!B1K'_ *6Z
M?7D'[)'B_3=9^+MU8>'/B#\3_B'I"Z/-<7=QXLL#9Z=:3>=$(U"M;1,TS#>1
M@D!5;/MZ_P"(?^3SO!'_ &)&L?\ I;I] 'M]%%% !1110 4444 %%%% !111
M0 4444 >)?MJ_P#)K?Q"_P"O%/\ T='7J_B&YOK+PSJ5QI=LMYJ<=G+):VSG
M EE"$HA]BV!^->4?MJ_\FM_$+_KQ3_T='6C^TAXBL? WPW_X2S5/$VO^'--T
M&474X\/0^;+>;HWB2%U$;G9OD5L@#!0$G - 'Q[\"_C%J>J_$?X9'1_BSX@\
M=>/=:U!(?&7@74M"%O::/ 8G:Y=5$*FV,#JH4[SO_P"!5]7_ +4'_'Q\'?\
MLH>E_P#HNXKY6^!'Q4T?Q-X]^'5SX=^*OQD\:ZQJ]Y:M>Z'J5B([.&%HR\CW
M,YM$62*/&#L?YN-O%?5/[4'_ !\?!W_LH>E_^B[B@#V^BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KSK6O\
MDX?P?_V*VM_^E>E5Z+7G6M?\G#^#_P#L5M;_ /2O2J /1:^3?VG?$/@_4_&^
MB+KT/A/Q-HMM;3P^7=>+;?1+VROHKB-B$E\U'891=\>0%>.,]>GUE7R5K/CS
MPKXI\;>-(_$WQPT_X<3:3K$^GZ?H5O>Z7:O$(U0&XG6YC=Y6D?<W.%V[1@G)
MH ^@/@_>:5J'PS\/SZ'IVGZ3I1M]EM9:5>17=M$BL5 2:+*..,Y'<G/.:\!_
MX*$^/-1\(_#W3[07MCHF@7MOJ,]UJ^HZ5#J$7VJ"V,EI9[9E>.,SON =E/W-
MHY85[;\ /&4WC_X1>']:GFLKN>59H)+S3E"VUTT,\D)GC"D@)(8]X )&'ZU\
M=_M/?M"W?ASQK\6)V^+Q\,:_X0O;&V\.^!IHX'L-5B-O;33-=1-&7F#M/(N0
MZ[1'QS0!]%_LC^/#XWT+Q<FERZ??^#-.U5(- U'2[!+.VEA:VADEBC5 $=8I
MGDC\Q1AL=R#7O]>(?LK:_8>)/!>I7UK\48/BI>->?Z9>Z?#';V-C)Y:XMK>%
M!^[0#!Y+,2Q)/.![?0 4444 ><_'JYGM/AQ/)9W^H:?J7]H:>MC+IB(\[W)O
M(1#$%D=$*R.51M[!=KMGBJ_P4\4Z_K=IKVG^*I+@>(]*O$AN;:>V@B\I7B22
M/:T,CJZLK9SD$'((&,FQ\;/%NB>&/"JP>)/"^I>*M&U*6.SEM=/M([D>8\B)
M$K(SJ<M(Z!=N3D9XQFJ?P>N/#6HZ)XBT;PYX9U+P2;2[,-[:7D"V]T9I(E83
M9#N6)1EQ(2?NX'W: .%'PI^):?&.SUZ77+R\TI]6>XD5=>G2TM[59IRJ&SP%
M8O;RPQ8'1X-Y)#G.M^TY/IVEPZ#J.MZ-=WNB".\LKG4=/U.UL;BR:58S&5:Y
MGBC(+QJPY)#Q1D# -<'X23Q%I_Q=MO#8\3^)]0UC3?$+O>?;?$UI/IW]F/YK
MP1O )?M'FM"@(5HP=Z.V=@KT7]H%;U/$'@VY\.V3ZMXRA^V'3]-?38KV"2 I
M&+B1UEN;94*YB ?S0?G*@,&. #N/A#I]GI?PYT9+&WU"VMYEDNL:K-%+<N\L
MCRO)(\+-&Q=G9\H=N&&,#@=K7G?P#@LK;X3Z%%I\UQ-$IN!+]JMUMWCN/M$G
MGQ^4I98PDOF($5F"A0 S 9/HE !1110 4444 %%%% 'SM^V'::9HVC^$O'+_
M !"T7X;>)/"^H2R:1JGB%1)97)GA:*:VDCW!F#QDG*?,NS(Z5XG^PK:>';[Q
MEX;M[WXR>%/B#KOA#PU/I&A:'X5AD2.TM'DB,]S*\GS22,4B7H !T'->E?MG
MPZC+X]^!Q\,>%[7Q9XT&NWO]EV&LR+'IC)]BD-P9V(.&" .A4$Y0\'D'N/@J
MWQ9/BV;_ (3;X<>"?"6C_9'V7_A[4VN+EI=R;8RIA3Y2-Q)SU4<4 >YUY!\2
M_P!H/_A5?BZQT;4_ ?BO4[?4I1#I^H:%!;WHNG$9D=5@6;SQL ;<?+V@#.>1
M7K]>"?M6Z_8>%],\,:M%+KL'C&QN;FZT5_#]E#=S!4MG-WYL4SI$T'D[BP9U
M.0FT[L4 >@_#+XP^'?BW#JK:"VHQW&DW M+^SU33+BPGMIBH8(R3(ISM(/&1
MR.>:Y/\ :J^'NK?$?X7P6&EV-MK<-GJUGJ.HZ!>WGV2#5[.&3=+:O*>%###?
M-\I* -P35/\ 9R4:CJGC#7-1\5R>)_%.H-8?;T&E'3(;6'[,)+81P%WR&25B
M9-[!B"H/R8JY^U7\.]9^)?PNBTW2+&'78[75;/4-0\/W5Y]DBUFSBDW2VC2]
M%##!^;Y24 ;@F@#Q;4?@[*WBSP9I_P 'O$6BZGX!@\3Z7K.L^#4U2*<Z";>=
M9'FLR'.V-N0\'3=ADQDBOL^OBJP^&T_BWQW\/KWPS^S[:_!231M:M[VZ\5-<
M:;:N;93F2TB2S=FG$X_=X?"@-GFOM6@#!\7^-_#_ ( TH:IXFUS3_#VF&58/
MMFIW*6\.]L[5+N0 3@XYJ;P_XMT+Q7:BXT36M/UF _\ +73[J.=?S0D58UG3
M4UC2KRQD.T7$31;]H;:2"-P!XR.M?$/PV^&.E:CJW@/0_#/PT\*_\)5X(UFR
M34O'^@ZEI\]O(D+?Z0TRH_VEIYD1SY<J95WW;ODW4 ?=U?#MM\-/ GPZFUC2
MO$WC[P3\/?BUI^N7>IZ#XS@UB"/5KZ.XF:9?M\,A5I%.\1/"Q965 5*\8^XJ
M^*O#G@OQ1\-M0\5>$8?@GX0^+=_<:G=ZA-XB;7;**[NH[B9Y4-_%<1M*'4.$
MR-RD(-N.E 'O'[+7@S7_  '\%-)TOQ/-IL^N2WNHZC<2Z/*9;1_M5]/<JT3'
MDJ5F4C/ZUZ[7DW[+W@BY^'7P6T70+J]TV]GMI[QFCT>8S65F7NI7^R0.>3'!
MN\D9 (\O&!C ]9H **** "BBB@ II4,"",@]0:=5'5[:*^TJ]MYI6@AF@>-Y
M5;:44J06![8!SF@#POP%X-_9\3QQ%?>%KK0;K6],U%K2UM;?67GM[.]9)&,=
MO;&4PQR[$E.(T! 5NF#7T%7P'\.?#]O8>/?!/A:_\;^!V\.WIT&_T>YTB&Z^
MUW\6FM*MH0IC$-LUPZD%C*V_9(J!MW'WY0 4444 %%%% 'B,_P#R>O8_]D]N
M/_3E#7-_MEQ_$"ZL/!=GX N;_1[JZO+R.76M*TZ.[NK6464K6T89U80QRRJL
M;R < @9&:Z2?_D]>Q_[)[<?^G*&O*OVW)/%'@OQ9X-\=0_&^Y^''ANR::V71
M[+01J5S<7!@E+210@$S_ "?>60!(PF\'- &M^P7XU\3>-M#\9S:WXG\3^+K&
M"XLEM-0\2V'V.2*5K56NK95\M-QBF+*S8(/RX[Y[[X0?\G&?'O\ Z^M%_P#3
M>M9G[)P2XC\:WUU\4=3^)OB&>^MAJ,VH:>-.6Q MHVACCME^5 T;ARR\,6]0
M:T_A!_R<9\>_^OK1?_3>M 'M]%4=7-T=*O?L4D<5YY#^1)+]Q9-IVEO8'&:^
M)/A!;?$6/QG8:2NF_$:WUO\ M30[_5-4UV6=]/;RXI5U4M,[F&2*0.1''#D;
MFB95782 #[IHHKY1_:7;Q7I?Q<\/ZP+#QEJWA^QN-%GL(?"BW$\$+)?NVHFZ
MMX#N<O!Y00R*R85P,-G(!]745YO\ +'Q'IWPITF#Q0M_'J7FW3Q0ZM.)[R&T
M:YE:TCGD!.Z58#"K').0<DG)I?C]!XAN?A/K4?AAKT:H7MMRZ9.(;R2V^T1_
M:8[=R1MF:#S50Y!WLN"#@T >CT5\H?LLKXLN/%&FJ--\::1X<TNVURVOE\6B
MYC6?S-5,VFB-;@EY)$MVDW2_W652S$ +]7T %%?#/Q%3X@VOQ9\5JND_$/4=
M7U&TURQTV]T*:X?3%WR6K:48G5Q!;&/RY1*S[6W"3.X, ?M?15O(]'L4U%D>
M_6",7+Q_=:7:-Y'MG- %^BOG?]LBP\3WW@VQBT6+Q%>:68K[[?9^$YI([^2;
M[*XM'Q$RRM"LQ7>L9R<ID%016S^S7<^)]6B\2:IK%GK^FZ)>M9'3;/Q*'2Z6
M5+5$NG6)R7BB:11M5L'<'; ##(![?15'6#=-I%[]ADCAO?(D\B27[B2;3M+>
MP.,U\2_!VV^(D?C6PTE=,^(]MK/]JZ)J&J:GKTT[V#".&1-5W3.YAEBDWD1Q
MPY&YHV55"$@ ^Z**** "O#Y/^3VH?^R>2?\ IR2O<*\/D_Y/:A_[)Y)_Z<DH
M YG]LV'XA75GX,L_A_<ZCHUW<7%^LFLZ1IT=W=6\RV4KVT6YU;R8YI5"/(!W
M SS65^P=XT\2>-]!\93ZWXE\3>+[""\M%LM2\36'V.1':U1KFW5/+3)BF+HS
M8(/&.]8O[;<GB?P/XO\ !WCJ+XX77PZ\.6?GVR:+9: -3N9YS!(6DBA )G^3
M[PDPL83>#FO1OV4(DDB\;WEW\4-3^)OB*;4H4U.;4+ :>MB5MHS%%';+\J*T
M;*^Y>'W9Z@T 7_@W_P G$?'_ /["&C?^FR*O<*\/^#?_ "<1\?\ _L(:-_Z;
M(J]AUDW;:-??8)(X;[[/)]GDF^XDFT[2WL#C- %^BOA?X.6WQ$C\;6&E#3/B
M/;:O_:VBZAJFI:_+.]@1';R)JNZ9V,,L<A8B..'*[FC954)D?=% !17RA^TH
MWBO2?C!H&L?8/&>K^'[*XT6>PA\*"XG@B*7LC:C]JM[<[G9X?*"&163"N%VM
MG/M'[/\ 8>(]/^$^C0>*EOTU0/<LD6JSB>\AM6N)&M8YY 3NE6 PJQR3N4Y)
M.30!Z/17F_[0%OX@NOA3K$7AEKT:D9+7S$TNX$%Y+:BXC-U';R$C;,T'FJA!
M!W,N"#@UXO\ LK+XLN/$VG9TWQIH_AO3+36[6]C\6BYC6<R:JTVFB-+@EWD2
MW:0-+Z,BEF(PH!]84444 %>'_L\_\E#^/?\ V.R_^FNPKW"O#_V>?^2A_'O_
M +'9?_3784 >)?M?ZK\2-*^*MY?Z+XB\1^"/"&FZ3I=W=:EX9T6.YDO(&OWA
MOFDF,;L7MXY89%A ^ZTC8ZU[S^R3KNO>)?V>_">I>)K[4]4U>=;DMJ&KP^3<
MW<0N91#.T>U=@>(1N%(R%8 D]3\Y_&*?QOX _:9NK.7]I#4-!F\6):0Z5H=A
MX334C91/<SK$DJD>7$FZ38LI.^4A@1\@KZ;_ &84TM?@7X5DTCQ=>^.[*>&6
MX_X2#45*7%W(\SO(71N8RKLR>6?N;=O:@#$_8P_Y-^TK_L*ZS_Z=;NN@\9_&
MC_A$?BK9>#CI/VE;CPQJ/B(W@N-I7[+)"GE;=I^]YV=V>-O0YKG_ -C#_DW[
M2O\ L*ZS_P"G6[KS_P#;.^#TWCWQ!X6UV3X1W'Q2TS3;2XM[O^Q_$TNDZG;*
M[(V(D5T2=3MR5)!R!B@#T/X;_M()\1O%'P]TN'0FL8/%W@QO%R2O=;VM@)+=
M1 0% ;B?.[(^[TYKVVOC']CO2?V>]+^)E_:> ?#GB;P9\2;#27@NO#OBQK];
MNULC)'NVI,[Q[-ZQC*$]NQK[.H **^%OB%%\0[?XJ^*8TTKXAW^NZE::[9:=
M?Z+-<-I2,\]JVD&)U?R+?RUCD$I?:VX2;MP8 _;NE+=1Z9:+?,CWJPH)W085
MI-HW$>V<T 7**** /$/VAO\ DH?P$_['5O\ TUW]7OVK[SQ'8? CQ!<^%H9G
MU:*6T;S;6P6^N+:#[5%Y]Q# P(DEBB\R11@_,@(Y JC^T-_R4/X"?]CJW_IK
MOZQ_VV-#\1W_ ,)3JNB_%(_"_3]'NK>\U&[^Q?:!<QK<PLJ@J"X8%?E1 ?,+
M!&^5C0!Y1^R3XE^(B?M$:[X4\5>-_&/BY=*L=4AU.VUS3TM[2RECOXTL94E6
M)1*9[8EP%/&'ZCI[?XA_Y/.\$?\ 8D:Q_P"ENGUYA^RKK_\ PFGQ,AUS6/C9
MKOQ U>70+DZ?H6I>'5T..*W%\8)YFB7AY%FMMF&^9 W(^<5Z?XA_Y/.\$?\
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MYQGVKT2OG/\ 8OA^"W_")>(KCX,B_BMIK]1K5MJDEVUW!=K&%"2BY)=6" #
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M#IGQ9\$>)3X_^)5CJMU!>66G^%? 5I!=7$H"1F::(/$PC4 *9#(6!RFW:<Y
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MSG-?8O[0>N6'B:P^"&K:3>V^IZ9>^/-)N+:\M)!)%-&T5P5=&'#*0<@B@#Z
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M8_;%<W\9/%5W\./CU:7'A;Q5I-KXE\56.GZ3=:5K.AWFH10 7$R6D_G6S+Y
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M['_AZW\*_L\>%=+MM9TW75MVNP]UHY8V22&[F:2" L ?+B<M$O XC'% %?\
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M CQ)!X3MK.]UV)K:YAM]2DMX[618KF.203-.#&$V*^<X..A!P:H?M#?\E#^
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M[?%JY\#:3J/BW2[/Q[HT>I#4]<TK4'U7PMJ,OV6/5)HIB'EBC82W,,Z?N6R
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M>4"40DS)"EW('+;49V('3/.*X7PEJVC:Y\>['Q;IVEVSZQJ/B":Q.EMX:U"
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M_(\K?_M9SSFO5:YWP+X>U#PGX4L=+U/Q#J'BN^M]_F:MJ:1)<3Y=F&X1(B#
M(484<*,\Y-=%0 4444 %%%% !574+&'4["ZL[A=\%Q$T,BYQE6!!&?H:M53U
M3[2-,N_L;QQWGDOY#R_<5]IVEO;.,T >):#^SSXGM8O"N@ZS\1#J_@7PQ<6E
MQ8:5'HT=O>3?92K6J7%R)"'5&2,G9&A;:,GKGWFOA?X1M\1H_&%AH_V+XDQ>
M(&U/0[_5+_7OM#:?F-)5U?,SGR'A=7Q'%"2-QB9%&PD?=% !1110 4444 >(
MS_\ )Z]C_P!D]N/_ $Y0UY+^V_\ "'P?XI\>?#C4)?A7:?$3QYK5W+H]D-2U
M>33K 11V\LQ%PZ@YP-[(J@$MGDXP?6I_^3U['_LGMQ_Z<H:\[_:K^%'Q$^->
MOQ:0WPM\%>-O!VF2I<Z9<:QXEO=/N1*8P)&9(%'1MP'S'@ ]: .Y_9-^%^H?
M"KPOK.G7OPS\+_#59[M9X[;PSJ<E^+OY,%Y9)$5@1@ #D8]*M?"#_DXSX]_]
M?6B_^F]:R?V0/@[JWP>\/^(+/5? N@^!WO;J.5+?0==N]42<!""SM<\H1TPO
M!K6^$'_)QGQ[_P"OK1?_ $WK0!Z%\2_%-CX3\*7-QJ6DZQKEC<G[)+::'ITM
M]<%74@GRX@6VXSENV17Q7\/7T/3/C/X4\*:QXH\<2VE_<:8VE>'M4\"36%Q<
M#301:-/<MP8HB59W6- 2B[B!D'[#^,Q^(9\!7D7PP71/^$ME98X9O$$KI;0(
M<[I,(C%G'&U2,9ZY P?*O@IX"^)GP]UL7&I>"O"]U?:I*@UWQ;=>+;B^U6Y0
M'D_-8(NU>=L*E(UZ +0!])U\2_M%>+--U#Q)=^++"X\>>"'L)+"35;J]\ 7=
M]I\HTZZ>XMY=Q\O8%>23+!]K*PR. :^VJ^3?$?PX^.7C/XA7>K^+O#'@KQ=X
M?LKOS=!\/R^);FUL+8*?DFGA%D_GS]]SL50_<4'D@'K_ .S5_8TWP6\/7N@W
M.J7^GZ@;C43>ZU9M:75W-/<2333M"0-@>1W=0!C:RXXP:S_VD-:TM_"?_".:
MCIWB^>2_:*\M+_PKH4^I-97%M/'-#(VQ&4%94C;:_#!2.F:]&\'7.NW?ARSE
M\2:?8Z3K;!OM%GIMXUU;QX8A=DK1QELKM)R@P21SC)\T_:)TKXP^(;'2=,^&
M$NBV-A/(QUF\O-1DL[X1#&([6003+&6YS(5) 'R@$Y !X[^R5J6DZC\6=0TF
M^\2>(M?\4Z!;:E<QV=_X1FT2#3UU"]%U<&7>SYED?9L4L,(APIY-?7&MZNFA
M:/>ZE+!=74=I"\[064#3SR!03MCC4%G8XP% R37E/P#\+>+O <']@7O@'PKX
M1\.)&\WVC1O$%QJ-U<7)89:;S;6,NS98M(SEL@=<\>I^(Y-5BT'4GT*WM;G6
MEMY#907TK10/-M.P2.JL54MC) )QVH ^!/BGKN@:-XDNM9G\0?$3P7X3UB34
MK2;3[_X>7+R[M4>$W<5M<.!AI6A!4,DA4R-C/ 'W_H=K;6>C6%M9Q/#:0V\<
M<,4BE61 H"@@\@@ =>:^6O!7P[^.FE>)O^$O\7>#_!/C;QJ-RP:E=^*[F*WT
MZ-C_ *NRMOL#+ N, MEI&_B<C@?5]L9C!&9D6.8J"Z(^Y5;'(!P,C/? ^E '
MS/\ M5W]CXJN/[%@M?'6EZ]ID%S!#K.C>#[G5K)X;NV,4\9VJ%<%''*NI5D'
M/!!O_L8:UH?BOP]XFUW3M>U?Q/JKW4&FZAJ>HZ&^E0@VL7E1P01-GY8QNW'<
MQW,V2. &?'CP3\9_B'XW.FZ=8^'K[X61Q)OTG_A(+G2[O5)2 66ZECM9#Y .
M1Y4;+O\ XV(.RO5OA+!XGT_P]_9WB'PGX=\'V]GL@T^P\-ZB]W;K"%Z8:WA$
M>#P% (H O_$WQ18^%?"EQ/J6D:SKEC<_Z'-::%ITU]<%75@3Y<0+!<9RW;(]
M:^+?AS)HFF?&GPKX5UGQ3XXEMK^YTV32O#VJ>!)M/N+@::NVU:>Y/!BB)5G=
M8T!*KN(&0?L+XT?\+#;P%=Q?"]=$'BV5UBAG\02NEO ASND 1&+..-JD;<G)
MR!@^5_!/P%\2_A[K:SZEX(\+W-[J<J?V[XLN/%MQ?:K=*#R?FL$4JO.V%2D:
M]%"T ?25%%% !7A\G_)[4/\ V3R3_P!.25[A7A\G_)[4/_9/)/\ TY)0!Y+^
MV[\(?"'BGXA?#?4'^%=I\1/'>MW,VDV?]IZQ)IU@(HX))B+AU!S@;V15 ).[
MKC%>I_LG?#+4/A7X4UG3+WX:^&/AJLUX)X[3PUJ4E^MU\@!DEDD16W#  '/'
MI7!?M6?"CXB?&SQ#%I+?"OP7XT\'Z7*MQI=SK'B6]T^Y$K1J)&9(%&,-N Y/
M !XKL?V0?@_JOP>\-:_9ZKX&T+P,]Y=QS);:#KEWJD<X"8+NUQRA'3"\&@#3
M^#?_ "<1\?\ _L(:-_Z;(J]!^)_B>P\+>$KB;5-'UG7+&ZS9RVFA:=-?7!61
M6!/EQ L%QD%NV1ZUY]\&_P#DXCX__P#80T;_ --D5=E\9_\ A8C^ KJ+X7KH
M@\6S.L<4_B"5TMX(SG?( B-N<<;5(VY.3D#! /CWX;OHFE_&OPMX5UGQ3XXG
M@O[G3IM+\/ZGX$FT^XN/[-39:O/<G@Q1?*SNJ("57<0,@_H!7S;\%/ 7Q+^'
MFMK-J7@CPO<7FIRI_;OBRX\6W%]JUTHZM\U@BE5_AA4I&O10M?25 'Q'^T1X
MMTV_\27?BZQN?'O@9K"2PFU6ZOO %W>Z?*-.N))[>7<?+V;6DDRP<JRD9' -
M?1G[-8T9_@OX>NM N-5OM-OQ/J'V[6K1K2ZNY9YY)IIWB95V"221W4 8VLN.
M,5XWKWPY^.7C'X@W6L^+_"W@OQ?HEG=^;H.@R^)KFUT^T"GY)IH!9/Y\_?=(
MQ5#]Q5/)^E_"-UKMYX=LY?$FGV6D:TP;[19Z;=M=6\?S$+LE:.,ME=IY08)(
MYQF@#S?]I'6M,D\+)X<U'3/%\\MX\-]::CX7T&?4C97-M/'-#(VQ&4%9$1MK
M<, 1TS7C7[(^H:1J7Q5U+2KWQ'XB\0>*?#]MJ,R6M_X2FT2#3DU"]%U<>;O9
M\RR/LVJS#"(<*>37L'[16D_&'Q#:Z3I7PQET:RTZ=F.LWEWJ4EE?^6,8BMI%
M@F6,MSF0J6 ^[@_,)/@+X8\6^ [<:!?> ?"OA#PW'&\JSZ)K\^H7,]R6&6E\
MVUC+LV6+2,Y8D#KG@ ]FHHHH *\/_9Y_Y*'\>_\ L=E_]-=A7N%>'_L\_P#)
M0_CW_P!CLO\ Z:["@#YN^./[._A3Q!^TWK^F>$?@3HGC;Q%>Z3#KNKW_ (E\
M0S:?:EIKB==T"(K,[LP8NV<#Y!@=_L/X'^&[OPC\*_#VC7GA?2?!EQ90M$=#
MT*X,]G:@.VT)(54MD88DC.YCG/6OD[XT_L]?$_XU>.9?$/B;X)?#W7KRWC-E
M:7TOC+4[60VRNS("D0503NR??N<"OJ?]G[P9>?#WX/\ A[P_?:#8>&+NS257
MTK2[^:^M[?=,[ )--\[Y#!OFZ$D= * .7_8P_P"3?M*_["NL_P#IUNZX;]L+
M4'^$_BWP7\7=*\8>$O#?B/3+>ZT0:;XSG>&TU6UG:-W1'C!=)$:)&#!2,$[L
M"NY_8P_Y-^TK_L*ZS_Z=;NN7_:-^%GQ#UWXS^#/''@KPOX5\81:3HU_IDVG^
M*;QH8HWN)(6\U (WR=L3+VX8T 2_ ?P5XZ\??$V'XT^/]2\+%I- .CZ!IGA"
M>2ZM5M994FDGDN7 \QV*( %&T >I-?0&NZO'H&C7NIRV]U=1VD+SM!96[3SR
M!1G;'&H+.QQPH&2:^=_V-O!/QB^$_A>Q\#^-O#OA?3_"NF0W3VE[H^J2W%P9
M)+EI4A\MHU58U61E!!Z(O'-?0GB:36(/#FI2:#!:76N);2&QAOY6BMWGVG8)
M'5694W8R0"<4 ? GQ1UGP]I'B:XU.YU_XB>#O"&LOJ=C)I=[\/+EIV.JRPO>
M0VUPX&&E>'*@QNR^8^,\8_032;>WM=+LX+6-HK6*%$BC<$,B!0%!!Y! QUYK
MY7\#?#SXYZ/XE_X2WQ7X/\$^-O&Y#)'JEYXKN8X+",GF*RM_L#+;KC )!9V_
MB<]!]7P&5H8S*BI*5!=5;< >X!P,_7 H GHHHH \0_:&_P"2A_ 3_L=6_P#3
M7?US?[>/@;P7XC^"-QKGB_P4_CB?0[FV;3K&*[:T;SIKF&/#2C(2(DKYC$'"
M!NG4=)^T-_R4/X"?]CJW_IKOZJ?M5>%/'OQ%\,CPEX>\#^&/&OA;5(L:O;>(
M-:N=.;<DB/&J&!2Q&5R>1TQR": .,_9.^!FJ_"KQIJ=_<_!3P3\.+>[L#$=4
MT#79M0NY&WH1"1)&-J'EB0W5%X/&.^\0_P#)YW@C_L2-8_\ 2W3Z\S_9*_9R
MUSX1_$6^U;4_A9X3\$6TFFO;+?Z'XGU#4IG8R1D1F*X^0*0I.X<C:!W->F>(
M?^3SO!'_ &)&L?\ I;I] 'KFO:O'X?T:]U.6WN[J.TA>=H+&W:XGD"C.V.-0
M6=CCA0,DU^?_ ,4-9\/:1XEGU&YU_P"(?@_PAK+ZG82:5>_#RY:=O[5EADO(
M+:X8##2O%E<QNR>8^,\8^_/$TFL0>'-2DT&"TNM<2VD-C#?RM%;O/M.P2.JL
MRINQD@$XKY@\#_#OXZ:+XD_X2WQ9X0\$^-O&Y#)'JUWXKN8X;",GF*RM_L!6
MW7& 2"7;^)V[ 'U1I-O;VNF6<%I&T-M%"B11N"&5 H"@@\Y QUKXU^+_ (UU
M?]G/]I/7[WP9XS^'<U_\1!8RWGA3QEJ<EE=07448MXIH9(U8>7(BJ-LF,L#M
M/6OM& R-$AF54E*@LJMN /< X&?K@5\/?M ?LW?%SQ?XS^-R>&O"'@C7]$^(
M-O9V]OJVNW[QWNGB&R2$&-1$P&V0.Z_-UP: /H']G+X2^)?A^/&'B3QSJ-AJ
M'CCQCJ:ZGJ:Z,CK8VHCA2&&"'?\ ,P5$&7;EB?:NT^*OB33O#?@^Z.KZ/K6N
M:?>@V$UIH.G37UP5D1@QV1 L%QD%NV1ZUC? V[^)DOAB6'XG:-H6CZE;&.&V
M_L/4)+M9XP@!>1G12&+9X&:N?&L?$:7P#<Q?"P:(GBN>18X[C7Y72WMXB#OD
M4(C[G'&T$;<G)R!@@'R%\,I=&T_XW^&/"^M^*O&]TE_<V%UI>@:KX$FTZ>X.
MGQ>7;27%RW6.(;69E1 652Q R#]^=17SC\$O 7Q(^'>M*^I>!_#,MUJDJG7?
M%EQXMN+_ %:[ _B.ZQC! _AB5DC7HH6OH^@#X'\"^,/B!\)_&>L? CX4>-/A
M3XH-O>WL^F1:WJ4\6IZ6LLKSR0S0QJRSM$SN?E;=@?,!CCZR_9^^$R? WX/>
M&O!*WYU273(7\^],?EB>>21Y97"_PJ7D; [# KXVL/V:_P!H#PUIO@[3M)\#
M?#V2;PMXLG\3V^N2:O+'>WQ>:X<QS$0Y 99PIY/" 5]U?#^\\3WG@_3I_&6G
M:?I7B5U8WEGI=RUQ;1MO(4)(RJ6RNT\@<DT =+1110!XE^VK_P FM_$+_KQ3
M_P!'1UV/QH\"^&OB-\*]?T3Q?HSZ_H3VC3SZ?"6$DIB'F+LVD'>&4%??%<=^
MVK_R:W\0O^O%/_1T==7\9G\:GP*]OX$T'1O$6JW3BVGLM<OI+.W-LR,)#YD:
MLV[[H 'J3GB@#X\_9,^!DD6J_#SQWH7[/'@GP]H$T,-U:Z]-XHFO=4M[=X\"
M8QF/RS,5.2 1@D]"*^EOVH/^/CX._P#90]+_ /1=Q7SQ\$_V0_$?@7XI>&-:
MF^"/@7PY9V%ZL[ZCIGC/5;F>V')+I#)\CMST;@YKZ'_:@_X^/@[_ -E#TO\
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M #T!S7HE<1\+-2\=ZEHMR_C[0-&\/ZFD^R"'1=4DOXY(MH^9F>&,JV[<,8/
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MM)^7&23FN]H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M1K'_ *6Z?7M]>(>(?^3SO!'_ &)&L?\ I;I] 'M]%%% !1110 4444 %%%%
M!1110 4444 >)?MJ_P#)K?Q"_P"O%/\ T='7M4?^K7Z"O%?VU?\ DUOXA?\
M7BG_ *.CKVJ/_5K]!0 ^O$/VH/\ CX^#O_90]+_]%W%>WUXA^U!_Q\?!W_LH
M>E_^B[B@#V^BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ KSK6O^3A_!__ &*VM_\ I7I5>BUYUK7_ "</X/\
M^Q6UO_TKTJ@#T6BBB@ HHHH **** "BBB@#R_P#:,NK2P^%=]/=)<%TOM/\
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MC_TY0U[=0 5XA\(/^3C/CW_U]:+_ .F]:]OKQ#X0?\G&?'O_ *^M%_\ 3>M
M'M]%<WXY\57G@_1/[0L?#.K^*Y_-6/\ L_1/(\_!S\_[Z6--HQS\V>1P:\;\
M7_$+QM\0[OPII6F?"WQSX8">(]-N[S4=0DT^.!+2*X5Y@YAO'<@H"-H4YZ4
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M!M4444 >(?M#?\E#^ G_ &.K?^FN_KV^O$/VAO\ DH?P$_['5O\ TUW]=O\
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MM&L/$/P8\<:9JCZBFFW6C745RVCVWVB\$9B8,88L'>^,X7!R<5\>>#?B'/\
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M?L)0QZ#I/C[PM<^")O!?B/0]7A@U9;_Q#_;=[>2/;1O'++<;1D>48PH'R@#
MP016!^V?!XDUVY6/7_ 7A^[\":7.C6&OZE\1I?#9DEDC4.KA%'\08 %CG;D
M9KI?V$++0M/\$^)8=#\.^&-"5M166XE\.>,/^$E>ZD,8^:>X(W*P  "DGCD8
MYH ['X-_\G$?'_\ ["&C?^FR*NY^+.I:+I7A99]>\)7OC.Q^T(HTVPTC^TY
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M6OP(\)0:-H^BZ%ID4$D<.G^'=6&JV40$SC]W= #S22"S-UW%@>10!C?L8?\
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MGMVKHJY+X63BZ\ :-*LJSJT1(D35VU8'YCTNV ,W^\?IVKK: "BBB@ HHHH
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M##RC-"TB,I9AAE85Z'^Q;\'==^%OAWQ+?:W_ ,(C"FO7%K-;6_@K+6++#:I
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M'QG\&?"WQ,FC3_$L:/&(Y&MK&75;_P"Q^89-I> -O3S%?8NZ(Y5MHRIQ7/\
M[&'_ ";]I7_85UG_ -.MW4/QMT7PSI?Q1\'^*_%NK^#H-!DLKO0+G3O&,\<2
MR+,T4F^U,F5:7,05D(^96ZC'(!>\$?"/PS\*/B[;CP[IFG65IJ&C7"PBYUJX
MFO+=4GB8P65K(62*U'F*SB(J QC&W&*]6U[2-.U[1;_3=6MH;S2KR!X+NWN
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M723XMTN;[3!IG@?1(=+L@_=9I2&FN5Y/WR#_ "KT_P#:@_X^/@[_ -E#TO\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 5S_BO^W'MK2+1K2RO!+/Y5Z+ZZDM]EN4;<T;(C$ONV #C@DYR!705S
M?Q _X2=?!^J?\(<FGR>)/*Q9#5'9+??D9+%58YQG'&,XSQF@#YV^&O[.7B/P
M;XH\/SCP3H>DZ7I]U')_H?Q*UV[$"*V<I;2P+%)C^XQ"GH:^K:^4_A=\8?B#
MXZ\0^&?".I^/_A?!KUFUO)KEIH6JF\U2?R0#<P"(H(PS%65RA^3)(Z"OJR@
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M(S+:O_L2H?\ EF*]V@MHK."*""-888E")&@PJJ!@  = !5BB@ HHHH ****
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MXA\)ZMHT7@/6&\%SWXTI;Z&>VN=2ANV8N]U<*DGES)D'*HX=BY.W/'O?P2\
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M<.H^=W4?+TQS@4OPK\6Z?-:^*;4>"G\!W&A7*K>Z8D=O(TFZ!)5E46I</E&
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MOHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O#Y/^3VH?^R>2?\
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M -'1U[5'_JU^@H ?7B'[4'_'Q\'?^RAZ7_Z+N*]OKQ#]J#_CX^#O_90]+_\
M1=Q0![?1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M)%G>HP<E<<Y';%7*I:K#<7&F7<5E,+>[>%UAF89".5.UB.^#@T ?+G@WQO\
M&:/6;>/P)8:K\0?!8R7OOB/9)H=QL&2H@G4"67/0&2TP<@^8>:^D? WB*7Q=
MX/TC6;C2;W0;B^MTFETS44V7%JY'S1N/4'(SWZ]Z^,?"?P7\8^'OB!X)GN--
M\2W>N2W6C7MYJ=QXN>YM+6>%W354N(FNOG65526)5C;YG ^4*PK[MH ****
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M(?M0?\?'P=_[*'I?_HNXKV^O$/VH/^/CX._]E#TO_P!%W% 'M]%%% !1110
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MGM0_]D\D_P#3DE 'N%%%% 'A_P &_P#DXCX__P#80T;_ --D5>X5X?\ !O\
MY.(^/_\ V$-&_P#39%7N% !1110 4444 %%%% !1110 5X?^SS_R4/X]_P#8
M[+_Z:["O<*\/_9Y_Y*'\>_\ L=E_]-=A0![A17QE^TEX(\?_ !-^/TOA;1);
MC4?"FJZ1I=OJO]G>(8[632+%+V6>]#VP<2%[M8H8DE'9'7.,U[I^RWX:\3^#
M_@1X5T?QBES#KMM',&MKRZ%U-;0&>1K>&24$[VCA,2%LG)7J: ,C]C#_ )-^
MTK_L*ZS_ .G6[KW"O#_V,/\ DW[2O^PKK/\ Z=;NO<* "BBB@ HHHH ****
M/$/VAO\ DH?P$_['5O\ TUW]>WUXA^T-_P E#^ G_8ZM_P"FN_KV^@ KQ#Q#
M_P GG>"/^Q(UC_TMT^O;Z\0\0_\ )YW@C_L2-8_]+=/H ]OHHHH **** "BB
MB@ HHHH **** "BBB@#Q+]M7_DUOXA?]>*?^CHZ]JC_U:_05XK^VK_R:W\0O
M^O%/_1T=>U1_ZM?H* 'UXA^U!_Q\?!W_ +*'I?\ Z+N*]OKQ#]J#_CX^#O\
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M?_)Q'Q__ .PAHW_ILBKW"O#_ (-_\G$?'_\ ["&C?^FR*O<* "BBB@ HHHH
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M/?\ U]:+_P"F]: /;Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MKP^3_D]J'_LGDG_IR2O<*\/D_P"3VH?^R>2?^G)* /<**** /#_@W_R<1\?_
M /L(:-_Z;(J]PKP_X-_\G$?'_P#["&C?^FR*O<* "BBB@ HHHH **** "BBB
M@ KP_P#9Y_Y*'\>_^QV7_P!-=A7N%>'_ +//_)0_CW_V.R_^FNPH ^9/C)\
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M,2W[/YG^ER\;6/W>.*^W_"-[#J?AG2KJU6X%M+:QF/[7;/;2E=HP6B<!D/\
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M\JPH @_8P_Y-^TK_ +"NL_\ IUNZ]PKP_P#8P_Y-^TK_ +"NL_\ IUNZ]PH
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MF3V45Q("41W0A=X')7. 1W&:[BJM[>6^GVLUU=3QVUO"ADDGF<(B*!DLQ/
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M34=:\#Z7=:O*9M3(DCN680!A(DC(0P@DDC##;@['(R#TZ#K* "BBB@ HHHH
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M8CM[6UC$<42#HJJ. !Z"@#0HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MR$49(+ U]N>-==UKP]HINM#\-3^*K_S%3^S[>ZAMFVG.7WS,JX''&<\U\N?
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M\?\ _L(:-_Z;(J]PH **** "BBB@ HHHH **** "O#_V>?\ DH?Q[_['9?\
MTUV%>X5X?^SS_P E#^/?_8[+_P"FNPH \4_;,^%/B_QA\23KDL/B/5O"MCI^
MF/IVF>'O$!T][AUOF74;985D0R3RV\L;QL3_ ,L"H.3BO=_V1_#NM^%?V>O"
M>F^(;.]T_4HEN7^S:G=&YNTA>YE>'SI"S9D\IHRV#@$D#   ^>_VT? 'B:V^
M-NA?$.V\*V/CC2M)@TR[ACN==M["315M+UY;M]L[JGEW"21QM*,E2@!X(KZ*
M_90\&ZCX!_9\\&Z+JES;7%U%;R3*ME=_:X((I9GEB@CFZ2)%&Z1AAP0G'&*
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M>PN=%4SPAM/EDC^:5=LL9)?!+)TKZ \0_P#)YW@C_L2-8_\ 2W3Z /;Z***
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M[^*FO3>%=,TK4=(\:^&;7PO>:U?:@+>Y\/VJ7;R7C1QD9D2:*0 A.=RKGC%
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MV\)>&]=\=V6K>!?"US9W-A9P:+]GU&X^R%6M4N+CSF1@C(A)2)"^SG&37O=
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M!9D\D-YB6T4<*('+AQ*Q.W /L'Q=LO#I_LO4M6\83^"-3L([J2TU6SN((YA
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MWAWQ?X;B\2Z9K^O0:?%'*Y0VL_E32I<*P^967RB 5*L-W!K!^#?_ "<1\?\
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MXJ5!!.><XH NT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M5YUK7_)P_@__ +%;6_\ TKTJO1:\ZUK_ ).'\'_]BMK?_I7I5 'HM%%% !11
M10 4444 %%%% 'C/[3/@'3/$GA*T\07.E:CJ5]H-W:SK_9.L/IEQ]F^V6\EP
M!*LT2X A63#L!F)2"I -;?P,N=+O/#5W/I%GXBM+1[@,#XCULZI))F-&#1R&
MZN-J%64@;AUSCG)9^T/!9W/PLO([LW#2&^T\V<-O:I=-/=B\A-M$8G=$=7F$
M:L&=!ACEEZCC_P!D?PW)X1\-:WH^I_:X?$]A+9V>I6ES90VHC6*RACMV58IY
MT;=$BDOYK$G(PNT* #S_ $O6/$5G^U=?6=UJ%BNI7.H1 7,NH:7L^Q+)=_Z.
MD(;[5N-L]JNW9DRH6+;!SZ!^TUJ_]@:YX'U"SGO;?6HY+F*)[6TMIT6WD:".
M9G\\X !:$@("Y_W0U;_A7X<WG@WQ%<ZA!XSTV30;S7+N[^P2Z3#YIFGG=W@%
MSYFXL)&8#(+<;<< #G?VJ=.'BJ?PAX8GTI]9LKZ6ZNI;>TT2VU.[5H43:Z+<
M_NHU'F$,WWCE0."U 'IOPCU\^)OA]I=^UQ)<S%IK>:66".%C+%,\4@VQDI@.
MC %3@@ CK7:5R7PMT\Z5\/\ 0[(VUS9BWMQ$MO=V<%G)&JD@*88/W:8 & G&
M,5UM !1110 4444 %%%% !1110 4444 %%%% !1110!F>(I+"#0-2?5#C3%M
M96NB<@"$(=_3G[N>G-?F''\)? L7A%_B3#^RE>CX1&(ZE_:J^.;A=5:P/S?;
M/L7F]"O[S9OW8K]%?C'\2?"'PI\ :CKGCF_CL= (^R2*T;2M<M)E1#'&H+2.
M^2 J@GKV!KY"\<?"*/X:>"/"WA/Q-^T!XGT+X'>)'33;70KS08A-!;2+N2QG
MU$#?!&5(BRX&/NDB@#[C\-S6$_A[2Y=*?S-+DM8FM'!)W0E 4.3R?EQUYKY"
M_:K_ &D_$OPM^*'BCP[:ZNEE=7/A&VA\':"UB)?[9UB[NWA:8,5.3;A(SY>0
M/G).:^QM-T^VTG3K6QLXEAL[:)(88DZ(B@!0/8 "OD;]J#]IS4_A7\2?%.EQ
M3:%;7&C>$H+OPUIVH0+)>:OK%[<O;Q& DYV0^6NY$&3YF20 , '9?LC>(O$[
MZ[\4/!6N>,;CXB6'A'5+:QM?$EU D<KSO;A[JU8H K>3+D>H#A3TKZ2KYQ_9
M*\7^+;C6_B;X'\7Z_I?B_4?">IVP?Q#I-A'9)<2W-N)IH9(X_E\V*3<&;J=P
MW<YKZ.H **** "BBB@ KG/&6I7VFZ; ;31$UJVGG\F^66[CMTM[8HY>9B_#
M84%1S\V>QKHZP/%GB_3/!]I:R:E=P6DE].+.T6X8JLUPR,RQY .,A&YQVH ^
M5OA+X"UW5M9\(7'_  B_B+4_ &G7D-QI=G+X\L=0TK3O+/[J5%B023B+@HCR
M. 57 R 1]$_&#0/&VMZ!:2> M=M-&UZQN&G$6H0M):WJ&&2/R9-I#+@R+(K
M\-&N01FOEOX5GP'XA^+^B>(A\2?"GA#6YKU"GA;X:I-:P:G*Q $5[*^!= GT
MAB/3GBOM;5=/35=-N[*1WCCN8GA9XSAE#*02#V/- 'S#\&?CGXS\0^(O#GA/
M5_B)\+]8UF..*'4K33S<M>SR1H/M"Q2!_)>48?.P$ @G  Q7U77S?X=^!_Q"
M&C^!/!>MS>$8/!?@V]L;NVU/2DG&H7BV9!@7R641V[,5'F.LCY!< #=D?2%
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MJNNM649U.ZA(/WH8UM;8!O1C(,'L>E?2%_!+=65S!!=26<\D;)'<QJK-$Q!
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M5U_Q^\*ZKXX^"/CKP_H4(N-9U/1;JTLXFD$8>5XF5!N) 7DCD]* /DWQ/?\
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MRJ^&I?VEO ?CO1_AQX>^)MYHNO1S-J,?BB#6-',IM9(U?R#_ *O$;;@HRG-
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M3:86-XD0Y:$_>W''VC80S06-O'<RB>X2-5ED P'8#EL=LGF@"U1110 4444
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M_P"@MXN\%VWAZ#QUJ'P_U#5K^*TL]3TW(EFE*NPMR5*L%=5;.UT;Y>&%>&?
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M;L1RVD;3INN%60H)A)C([GUH ]!^#?\ R<1\?_\ L(:-_P"FR*NJ^-7C_5O
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M@/\ #>P\,>.=,U'PS\)/%GA2QM+&33CJ7C3Q,\WV:U;83%:VOVFYZM%%G(B
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M=T6WT^3Q[>^'=$N_#?P]U'5XY_#VF75H]F HMXUN)HK=PK0PR2AF52JY(9@
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M%NWE,4P)!+F,,<!L!>WV+0!\3_M"W/@_PG\9O#VAWVB?#[PWX?T]M(C\K6]
MLWDU*TN;N9+CRI90!%#;@ L$&09<DJ",_0G[,VJG6_@GX<NAI^FZ?%_I$4*Z
M/9BSM+B)+B5([F*$?ZM)D59@O./-ZGK7B_QF\6>,?!OQ)U./QAXQ^&$/A^[6
M*;0-+U_0;J_GA1&EWR^7'+N4X,8>4_(2HQMP<_0_PB^UO\.-$FO?%-IXSN+F
M-KHZW81+';7"R.TBB%59@(E5@B_,3M09).: .UHHHH \2_;5_P"36_B%_P!>
M*?\ HZ.L#]MKXF:A\,_A;X:EL?%B>!(M9\2V&D7OB9H$E;3;602/+,BN"N[;
M'C)'&XUO_MJ_\FM_$+_KQ3_T='7JWB!]+M]"N;S68H)-.LX6N9C<1B18U126
M;!!Z#- 'YP?"/]HNZU3XP>!+FV^/$OC?6;WQK)X6F\,QPPQ6=UHRQRQQ7YB1
M!B9V1)3(& )DP !Q7V/^U!_Q\?!W_LH>E_\ HNXKDO#'[6WPRUGQ]X0T*Q\'
MZO9/KT%G-#J\VC1Q6]C+=K*]E#.V=R23)"S+@$89<D9..M_:@_X^/@[_ -E#
MTO\ ]%W% 'M]>-77[3FB6=U+ _@WXBR-$Y1GB\%ZBZ$@XR&$6"/<<&O9:^.O
M!_Q0^(7AC_A6EEJ?@/XE7@T-M1CU^2*P\U+S>KBW()E_>@,5()Z4 >\_L\ZK
MKVN?"G3M0\2Q:G!JUS>7\OE:Q \%TD)O9_(#QN RXA\O (X&*P?B%XJOD_:"
M\">&[WQ%-X8\-RZ?=:E&(G2$:Q?1RQ*EH\C#.U8W:0QK@OQR0I%;?[.:Z]_P
MJ739/$MKJ5EJ\]YJ%P]MJ^?M444E[.\*ODG!$31\9.!@=JQ?VMS;CX*WWGZ=
MX?U!Y-0L+2)O%.G+?:=;-/=Q0>?,A9<*@D8E@010!QGP(B\1?#[XMV?@2]\>
M7OCYI/#$FI^(%N[TWJZ9?K<1I"T4C#>B3K)-B)NGV?*@#->]>/\ QI8_#GP1
MK_BG4Q*]AHUC-?SI"NZ1DC0L54=R<8'N:^0(O$_B_P#9C\07>BZ/J/PTFT"T
MTV'7+O3?#?AAM.>Y#745L82R73!)I/-S$Q#[RC @8S7U_P"//!>G_$;P5K?A
M?5_.&EZQ9R65S]GD\N3RW4JVUN<'!ZT ?-/P]\"76N?$O7M#UQ_'OPRUK6(Y
M?%4>GZ1XL2XL94DF"S[0D2B*17=-R8(.\$,Q)-?6<4?E1HFYGV@#<YR3[D^M
M>$/^RCH8\1PZJ_Q%^(?]M16K6L=PWB9_-6W9U9D'RYVET0_4"O=XHO*C1-S/
MM4+N<Y)QW)]: ):*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH *\ZUK_ ).'\'_]BMK?_I7I5>BUYUK7_)P_@_\ [%;6_P#TKTJ@#T6BBD-
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MD \8KN_B/XJT[P3X&UO6M7M+O4-,M;=C/:V-I+=2RJWR[1'&K,0=W) P!DG
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M)AIL0'K!)+Y 'L5Q7LNE065MIUK#IL<$.GI$HMTM558A'CY=@7C;C&,<4 >
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M)VG:EXC_ .%Q^'/A\MK=W,#^&WTNWN&TX12O&%O'FE5RY"ACM$8YXR.3Z_\
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M_"L7@GQ#+;XNM @F66.SVL5559>,%0IV_P .<=J .)_8P_Y-^TK_ +"NL_\
MIUNZ]#\<ZKX.@&DZ1XNETJ3^V+M;.QT_4T27[7.1D)'&P.X@<G X')P*\\_8
MP_Y-^TK_ +"NL_\ IUNZF^*^DZ]X9^*_AKXD:5X:E\9V6G:3>:/=Z99S0QWM
MJ)I8)!<6_G.B,?W11UWJ2"N,X(H W?@Y\0_A?XS@O[3X<7NBL+,@W5GIEN+9
MXP20':+:IVDJP#8P<'!KT:X6)[>59PC0%2)!)C:5QSG/&,5\\_!SPI<ZG\4=
M&\06G@N?X=^%?#OAZYT/3[#5+J"74+\W$\,Q+K%+*%BB\@[0SEB9F.% Y]7^
M-'@[4?B#\(_&7AK2;L6.J:OI%U8VMP[%5222)E7)'(&3@D<X)H \WMS^S5I7
MBC0;VVM?AO:ZYK;N^E7T5I9+)>,LAC8Q2A?F.\%>#R1@<U[Z!@5\A^/+:;XC
M^#=2\,Z=\#O$>D>,]0\.R>%8Q?Q01Z+ID3D'S?/64QND3@2*8U+G:  ,\?6&
ME6<ECIEG:SSFYFAA2-YVZR,% +'W)&: +M%%% 'B'[0W_)0_@)_V.K?^FN_J
M']H;]F:?XW:GIVKZ1XXU3P#K<&G7>B7=[IEO'.;S3KDH9H&5_NG* JZG*DGK
M4W[0W_)0_@)_V.K?^FN_KEOVY/@Y>>/_ (77/B#0D\47?B;15C%O9>&=6GM9
M9;=KB+[24BC=5EE6$2% V>0!ST(!V?@+]G:U\#?%*V\5+K4UWINC^'(/"_AS
M0_LZ1Q:79J(C*2XYE>1X4.YL8 P*J^(?^3SO!'_8D:Q_Z6Z?7AW[(VA6C?M
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MY_"@#X+^!?@,^'/B-X(T&X^#E]I"-JZZY%<W_P 4+/4Y3Y$)MXI3;CYYXK9
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M>PS>6&WG&W=[5S/[+_B!/%>E^(-;NKF]N]>U1[#4+^6XAAABQ-8020K$D1(
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MV%E?ZC=6.J"PM+.VDNRMFMT&<+/F=78*RL%&22!FOM/1D6/2;)5L_P"SU6!
M+3C]P-H_=\<?+TXXXKY#_;"U3X3^%_&NM/XGF\7W>M>)/"7]C:OI?A6V^T1P
MV#7.+:_N=V%B,4S2*CLPR6(P<4 =W^R)XBM-?U?XJ/+\.]1^'GBHZ\MSKMOJ
MVJI?W-Q/+$'1MRGY8EC*A /EVGY>]?2%?.7[)7AW2=#UKXGL_C76O'7CN/68
MM-\17^NV*64R&WA"6RI$H \HQMN609W[B:^C: "BBB@ HHHH *Y_Q7XJM_"M
MK:M.)S->S_9+;R;2:Y'G%'==XB5BJ?(<L< <#/(KH*X3XP7%\?!TNG:7J6K:
M-J6JRBQMM3T?3/MTEHQ#,7=-K!4(0J7(X+#!!(H ^9O 5IX3\<?&7P_XN\5:
MUKUQXT6[06L7AWP#J&@V&\D86YN'@,LR9Z^=,(^3E:^R-4%TVFW8L61+TQ.(
M&D&5$FT[2?;.*^1_A==:S?77@;0?$'CKXL:Q!I\]CNM[GP)-IMK/-#MV>?=?
M95<1;U!;>_S ?,3DU]<:I;SW>G7<-K/]EN9872*<#/EN5(#8[X.#^% 'QW\/
M=(U2/4_ 0TS1_B9:_%2._M#XLU'7Y+XZ9)#D?VAYCRN;.1&&\1+;@D$Q[0H!
MQ]H5\I^#O"'CN30_A?X-?P%J_AS4_">I6UYJ/B^XUJ&>SG5&W7C1,L[3SFZS
M(I66-0/-).-HKZLH **** /$9_\ D]>Q_P"R>W'_ *<H:X3]IWP[\0K[XY?"
MR3PU\9O^%>:?J$MU96VGMHBW<;W0MI79F8_)(73@1RD %-R9;BN[G_Y/7L?^
MR>W'_IRAKR3]KCXI?"7QWXP'PLUGX;:U\8/&^A*-130M-:2SALB\0<22W)DC
M504(/&_'IF@#W/X'_##Q-\/QXCOO%WQ%O/B+KFLW,4KW4MI'9V]LD<81(X;>
M-BJ9Y9B,;B<XSR<;X0?\G&?'O_KZT7_TWK7%_L!^$CIGPLN/%-GX(T+P#H/B
MW[-JNEZ7I&IW=_-]G,7RM<R3DC>01@1@ #KS7:?"#_DXSX]_]?6B_P#IO6@#
MT/XC_$72_A?X;;6=52[N@T\5I;6.G0&>ZN[B1@L<,,8^\[$^P R20 37%P?M
M)Z$OQ.F\&7^B:]I3QZA!I"ZU<V\1T]K^:TCNDM2Z2,R2&.50-ZA2WRJQ.,[G
MQJ\ W7CKPS8S:9JL.C:YH&HQ:YIE[=1&6W2>$.-LR @M&R/(C8((#9'(KYE3
M]H;PQ\0_$&@_\)I\1?A?X=T'3]6@UR>+PUJ4]W<ZO=VV#$7DEAB$2(R1LW$C
M$1JNX '(!]O5\G^&;"^^%^BV?A3Q%\)O$_BG4]#\07FN:9J_AU();;59II+@
MI<2R-,FR0I<NKK, ,\@D8KZCTS4K76].M;^PNHKRQNHEF@N;=P\<L;#*LK#@
M@@@@BOF'XY_#O1M3^-=QXE\7?#/4OB3H5QH5OI^G'0WB>2SN$EG:99HVFB/S
MK)#MDY"[&^[G) /8/V>/!&J?#OX2Z1HVM06]EJ/G7=Y)86DF^&Q%Q=2W"VJ-
MT*PK*L0(X^3CC%97Q^^(OQ(\$V^F6WP\^&<_CNYOMXN+W[;!%!IX&T O$\B-
M,3DD*K*#MY85P/[*GP6U[X4ZS [Z._A[1I]  O;07PN(I;QKR5H!@.V9H;;;
M'++P)&93EMN:](_:9\'WOC[X-:[H5A9)JL]S):/)IIN%@>[@CNHI)X8Y&("2
M/$CJK$@!BIR.H /+_P!F+X;7WAWXCZWXCUCPIXLT#7=4M&^U22VFFZ7H6[>I
MQ'9V=U*S2GC]Y*7;"GYAG!^D?$UAJ&J>'M2M-)U,Z-JD]O)%:ZCY"S?992I"
MR^6W#[3@[3P<5\0WOP!@\4:SJ&M_#7X3:QX%N+'1UMK&74[R.UN/[4-U!]GN
MHE%PY5($$[2DG]Z"%VOQ7WAG8F78<#DG@4 ?#6H? OQUX.^(7@SQ-\0_"=S\
M9;31KFXFU#7+/47U":97@9(V72+@K'"4DVOBWWGN!D5]O6<R3VL,B*R(Z*P5
MT*,H(X!4\@^QZ5\-?$_X'6FJW7Q-T^\^$FI>(O'?B/4[NZT/Q78W<*Z=&DAS
M:R2.TZ^3Y7'F(8SO*L<.&%?2_P"S_P" M3^'6G^+--N+-M+T(ZX[Z'IS7/GB
M"T%O C%/F;8DDZ3RK'GY1(!@=  >3?%C]J6#X;:U\3-(U/7;.#7-+U_2AH5C
M=V>\K9206)N77"_-CS;L[B<CGTQ7N'PC\;?#_P 8:3?#X=W6ESZ=;3YN$TFW
M\B-97&22H506.,Y[UB?$3]H[2/AKXLM_#^H>%O&&H7EU((;232=$DNHKM_+\
MPK$RGY]JY+8'R[3GI6[\+?C#I7Q7&MK8:9K>C76C72VEY9Z]I[6<Z2,@<?(W
M."K @]#GC- &-\?OB=)\)M/\&ZO-J2Z7HTWB.WL]6N9(O,5;1H)RV>"5&]8_
MF'/OS7GGP<_:-^&?C_QA?17^IZ#-XDAU^ZTWPVZ6&RX:S8KY7EOLR Y9\G(S
MWKW7Q[XUB\ : VK3Z3J^LQ+($:WT6S:ZG ()WE!T48Y/;BO,?"_[77A?Q5?>
M&(H?#/C.PM/$ETEIINJ:CH,EO93.X)0^<QVX8 E3_$/NYH ]THHHH *\/D_Y
M/:A_[)Y)_P"G)*]PKP^3_D]J'_LGDG_IR2@#SS_@H'K")X0\)Z$O@KPKXPO]
M0N[N\M!XP65K.&2TLY+@HBQ$,TTJJR(NX \@Y%6_V%_'5SXSM_B&U_9>"8-0
M.I6FH3W7@=)OL]W]JLXY5DE:1V/F!2$*<;-F,8P2[]O7XM:[\+/!7AU]'O\
M2/#@N[F\E_X236=/2]BL9X+.6:"*-7^199W7RE=NFY@ 214O[#OBK2_$.F^/
M;7PY8^'1X7L]5MY++5/#.G1V=M=236<,MQ&WEC9))%(2A=>V!QC% '8_!O\
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M)9"<!$DSL8D\  G-?5\,*6T211J$C10JJ.@ X H EHHHH \0_:&_Y*'\!/\
ML=6_]-=_63^UWH7A_1?AYX@\::M;^)-4O?L-MH4&FZ%KD^G^>TU_"80&1@L;
M&8QAI<9"9'0XK6_:&_Y*'\!/^QU;_P!-=_7-_MBZ^M_X.UKP+JNAZ1J>AZQI
M4<Z+?^,H=!FO+A+R+=;J7^8*(P9"XX.W9CYJ //?V2_#6H?#3XZ77AGQ=X.\
M0>&O$]]X?EU&QFF\;W'B"PEM5GB25663 CF5VCYP<@G!]?9O$/\ R>=X(_[$
MC6/_ $MT^OE3]FWX$>'?B%\3)3JFB7?A^>WLA.NH:-\8&UJXE\J1-D3PQ-N\
ML;B<GY1TQ\U?5?B'_D\[P1_V)&L?^ENGT >RWUC;ZE:2VMU;Q75M*NV2&= Z
M./0J>"*^$OB/\6O#EO<?$WQ'J7Q6\*^%_%OAO5;^ULO ]QIVF31W)A=E@6?S
M(S<2M/A69XY%V>81QL-?:7Q"349/!.MKI$^I6VI_9)#!+H\<$EX' R!"L_[H
MN<8&_"Y/)%?+WB&\^(.K^);RX@T_XMZ4+R9YXM.BTGPFXB4DG:IDE9V Z98D
M\<F@#Z=^'WCW0?B-X:M]7\/:OI>L6AQ#+)I%['=PPS!5+1>9&2N5W#CW'K7C
MG[4OB71_#.K^"=(U7Q)H?P_T;Q%>W)O_ !+?VMI),LD<*>7'&;A6C5G& 975
M@!&J\%EKW[2[6.SLHD2+R,J&9=BHQ; R6"\9]<<5\]?&6[\;+KVJV>GV_P 2
M)+".\%U#J.BV'AZ6T6)H(E\B/[9('VJZNQ+*&W.PR5 H K_LN_&;PEJ'B7Q5
MX(M/B'X7\72VNH)'I%[8R65M>ZFGV99)08;?:LIB(8>;&@4C/]TFOH3Q/<&R
M\,ZM.+%M4,-I-(+ +N-SA"?*P<YW?=_&O-/V>+/66T2_G\00^)FNQ< V\WBJ
MRTJ";84Y\K^SR4*=>6.[/M7J&OW%]9Z%J,^FVZW>I1VTCVL#G"RRA244GL"V
M!^- 'P_X*\/>$)YOAWKDT/PG\8_\)A?6UM<>#],\)V,4MDDR%I&@=2TI-OUD
M\T'*J_W#BON32])LM"TZVT[3K2"PT^UC6&WMK6,1Q11J,*JJH 4 < "ODOX>
M_$?0[G4OAJ?"U[8:G\5M1O(D\86D7AR.VO6AD4M=F[VQ*UMY!/R%F&XJ%.\M
MFOL*@#Y2^.>BZ)\0/C??Z%J][X&\'MI>C6M]'JOB?P_9ZA=ZH)))P51KD@"&
M'RQN"Y;,G5!C/HG[+6G>';[X8Z;XHTKPGX:\/ZCJ0F@N+SPWID=G!?I#<21Q
MW"!1N\J4()4!)P)!R>IYCXN^,O"VG_%Z^L/BO<:7IO@Z#18)- .KZ5%<07%[
M)+)]HE2:2-\31".$+$,9$F[#9&WTOX!:[KGB3X2Z!J/B&*6/4)1,J/-:?9))
MK=9G6VF># \II(5B<I@;2Y&!TH ]%HHHH \2_;5_Y-;^(7_7BG_HZ.O3?&L%
MO=^!M>@O#<BTETV=)C9KNG"&)@WECN^,X'KBO,OVU?\ DUOXA?\ 7BG_ *.C
MKU'Q=<V]EX.UFXN[)]2M8["9Y;)!EKA!&Q:,#N6&1^- 'QA\ /A7XT^(.B?!
M9=2\0_#Y_AQX0DM=7T6YT*SE@UN^\J%D@CGC8[("0W[T(6)92#WKWS]J#_CX
M^#O_ &4/2_\ T7<5\2?LYZAX(L?B5X)UI?AO\,H=2U'Q#I<5A%X::8WME#>V
M,EPCHS2'S)+=E"S':!][ '%?;?[4'_'Q\'?^RAZ7_P"B[B@#V^ODSXT/'JWQ
M_P!4L]3^('AOX<0:5H5I?6-SKVAZ=<RW;N\XDEBFN5!"1>6@958D%Q]W(+?6
M=>&^(_V?_%7BFX5]2^+.J7L,4QEMX+OPYH\ZVY)XV%[4D8X&>O% '._LJ_%+
MQMXPU :?XJUN/Q,ESX>M=;6[73DLY+5Y)YX@A"85HY4B$T>0&"YSG(-==\=M
M-^!U[J.E-\6KKPG;WRPN+#_A([^*V<Q[AOV!W7(SC.*]*\*:->Z#H-I9:CJ\
MVO:A$FR74KF"*&2?DD92)508!QA0.E<5^T7K>H^&?A=?ZGI2QPW<<]K#+J3V
M0O#IMK+<1QW%T(B#O\J)GDP>/DR00"* .>^"6F_ "R\3W;_"F[\&W&OFT83K
MX=U&&XG%OO7)94=B%W;.<=<5[E7S3\!_%]K=?%=]%\*?$4?%GPM)HTMY?ZJT
M5D[:7="6%88A<6D4:-YRM,QB8%E\G.0#BOI:@#X=\2>!K/XG?$[Q#XDM_"'P
M_P!.>QU>\T^6S\1^+;^TENVCF57FN;&%?((F,$4F&#;U$3-GC'VY 6,,98*&
MVC(0Y7..WM7P?KMOX=\$_%/Q3H.L:'\#_$FKZCK]S>)>>*KV:344^TS%XH;J
M4V4B(X#JJ(7&%V*,XR?N^W0QV\:[$C*J!LC^ZO'0=.* )Z*** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH *\ZUK_DX?P?_P!BMK?_ *5Z57HM
M>=:U_P G#^#_ /L5M;_]*]*H ]%HHHH \T^/'B/P'X-\ 7&O_$'3K#4]'L&#
M16UY:1W+23$$*D2.,;SR.W&<D &OD.7QIKT_B7P)J5W\!?!/A+P-XGUVUTNW
M.I:3#+?RI*V=V!MVY0$@E/3K7L7[2MG%XL_:3^ _AC5U5_#TUW>Z@\$@S'/<
M0QAHU8'@X( Q_MGUK1_;%XU/X*#H/^$[L/Y/7LX:U-0BU=R3>[T6JT\]#Q<1
M>HY23LHM+IJ]-_+4IZOK7PJ\)?'*/X>^)OA9H6C6^I+'_8NNR:/ ;:_D95W1
M$^7\K!R5')!XSC(S]+6=K#9VT-M!$D-O"@2.*-0JHH& H X  XQ7@7[=F@:?
MJW[-OB2_NPL=YI#07UA<YP\,XF105/8D,5_&O9/A[JMUKO@/PWJ5\,7MWIEM
M<3C&,2/$K-^I-<-:TJ4:BOU3UZJVOSN=M)N%24'Y->COI\CHZ***Y#M/-/VA
M)KQ?A-K$=GI[ZGY\EM!<V\.E_P!IR?9GN(UG=+8JPE=8B[*&4KE02" 17"_L
MLW]IH,>M^#=,T?6;+0;2<3Z1>WWA1]'$\/E1"3>4MXH2PD)"G:KL%.5PN3U?
M[2%Q%-\/GTA[?4;F2]GAF6*UT:[U&WF6":.5X+D6R,RQ2JIC;/56;AL$'-_9
MATU+70?$5]!I$?AFUU#45FBT"STNZL+.R @C4F%;B*(OO(WLZQJN3C&020#R
M>;Q%K=K\;7LM/FCU+Q=#XEN7,O\ PF;*MU89D=+$639A5A"5&S[R^7YGWLX[
M3]KB2PFL/"-K?7=MX<O[QYQ%K5]X@ATFWM@HBE>!II;>X5R[(C!/+Y\DG<,8
M/F-YJMYJ_P 5SX6TW7O$NE^'4\72WUM,+?2FMX+V2]ND+!&#3L@NHY>&Y^="
M0$88]7_:=U0>';[P'>Q7NIVNN0RS1)?636,2B!S#'.7^TV\RLV6C98T4$[6.
MX*IH ]-^"]M9VOPST,6$UE=02+).USIVI?VC#/*\KO+*+G8GF%W9V)"*,L0
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MW^(VI6/@-_AKX8U[5X;G2/#]Y=K<7L,:6ZI(TI5W"!G#,J%B5RW;%=S\(/\
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M4?,EEA\QKH* %5/LB@8SEY)"=I&#ZW\5O!L?Q$^&?BKPO+?'2XM9TNYL'O0
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M=-MO#NK7]M)\-O&&@ZYJ$)N=1\6^+Y].GNM3D4J-KO!=2N -V5C5%B0 A0O
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MJMM0O?A?H6G^%$\2VN@:5JUK+>1WZ7$MM$\=T%D=HY83.[P\8*E<_-@U]F4
M?//QTL?%MSX[A;X>6_CA/%HM(MUY:WD,7AT)O?:+E+K>C-RV?(C,F-N2/EKM
M?A'J_P 4%N9M%^)>EZ))>PV,%TFO>&GE%E<2,SK)"8Y1N5TVJV02&#CA<8KY
MK;X6VGQ*\.Z7XG\'?"7PP8O$GB*:WL9=4N+Z8)IR17#&[N_*<>2TDL*JH7<%
M$JYR3@?3/[.^L:7K?P@T&;1]%7PW:0FXM)-)28S):W$-Q)%<1K(>742I)ANX
MP>.E 'IE%%% 'B7[:O\ R:W\0O\ KQ3_ -'1UV'Q=MO&\_@X'P%KVA^'-6BE
M66>^\06CW-LMNJ,7&U74@YVG<3@ &N/_ &U?^36_B%_UXI_Z.CKJ?C=\0/"_
MP\^'MQ/XM%W-IVK2)HT=C80//=7LUP#&L$2)RSL"WT )[4 ?'7P&T8Z'\5/A
M]XYCUSX40P>.KV[CL]2TCP+<V%UJ?E,1,D-P[;8GDPQ4D#S "1NKZ:_:@_X^
M/@[_ -E#TO\ ]%W%?,'@0Z?I'[0/@CX4^)OBSXC\5^$_!&LQ6N@0/X5BM;!=
M5@MF-O8W&I*W[V:*)N%VKN( )SQ7T_\ M0?\?'P=_P"RAZ7_ .B[B@#VX]*^
M++'3?#_V>\3XL^'?BSJ7Q&-Q/]HO-(CUJ6VD/F-Y;6+V+?9XXMNW:/E(_CYR
M:^U*^7/A1\$_&WP]^'FA7^@^,+KPOXKN6D^V^'/$TS7^E7LYE=L!"_F0.R+G
M,#@=24;F@#V#X#0^*;?X2^'X_&0NUU\))YBZA(DETL/FO]G6=T)5IA#Y0<C@
MN&KR[]H[Q_8:1\4?#?AWQ+\0=6^'?A.?1[J_-YHTGD375XLT*1QM+Y;D*J-(
MVT8R<9R!BO>/"5[K=_X<L9_$6FV^CZVR$75G9W7VF%'!(RDA52RD ,,J#@X(
MR*@\8_$#PW\.]*.I>)]?T_0+ ' GU&Y2%6/95W$;B>P&2: /)OV5/C[H/Q4\
M"Z+IC:_;:GXSM[-Y-2ABMS!(_ER>7Y[*%"@N-C$#^_P,5[Y7F'PO^/6B_&35
MKQ/"NE:W=Z!:B1'\17-D;6RDG1PK01B4K*[#))(CVC:?FSQ7H>H27,%C</9P
MQW-TL3-#"\GEK(X!VJ6P=H)P,X./0T ?*MKX3\2^,_#GQ&\$^&]=\)+X(UW7
M-8M=1O-;AF75]/DFGD^U)Y&=DS!F8Q2.R?(8B58 9^K+"T6PLK>UC=Y$AC6-
M7D;<S #&2>YXKX@U+PEJNM1Z^WBKX'?!#2?&>H7U\RZKKVIVK2Q[IY!#<21&
MS+3878V2X,F,G86P/M^PB:"QMT8HS+&JEHUVJ<#J!V'M0!:HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ KSK6O^3A_!_\ V*VM_P#I7I5>
MBUYUK7_)P_@__L5M;_\ 2O2J /1:**0T >,?M-?!;4?BSX7TN^\-WJ:7XV\-
MW@U/1+U^%$HQF)CV5\#VRJYXS7RM\<_VC_$>LM\.+/QS\.->\.^(/#/B6UU6
M_,%OYEM=1Q;@Q@;(R3D$#)'^U7T)^V;K7B+PEX%T[7]!^($O@?[+,\+P6UD+
MJ?4Y9 OE0QH?XLJQ^A)/2O+_ (?_  =_:E\5Z&FH:]\6#X5FF0/%83VL<\ZY
MZ>8%4!#[ DCO7O811A2C4JRC9-VO=-=[63O^AX.*YIU)0IIW=KVLT^V[T+^L
M-X[_ &VM7TK2KCPMJ'@3X1V=TEY?2ZL/+O-6V'*QJF.%^F0.NXD 5]C0V\=K
M!'#$HCBC4(B*,!0!@ 5^?/B*#]HGX??$/2O#OB_XO/H=AK$GD:7XA6S2>QGG
M[0R'8#$Q[;A@^N.:]5T7XU?%/X >-](\/_&HV&M^&-9G%K9>,=,C$:PS$_*L
MX 4 >N5! R06 .(Q.'<XQ5.4;)-I*_S>N[+P]>,&_:1=V[-NWR6FR/KFBDZB
MEKQ#VSS;]H#19M?^%6K6L%K/?LLMK<&R@M#=BZ6.XCD:&2%2&DB<*5=5R2A;
M 8_*>+_8_P!*M-)\!WL%OXAT_6;F"2UL;JTTV&:!;&2WLX( DL4P61)66-78
M,B?>48XR>U_:!MKR\^%.KV]E92WS2RVR3I#%-,\=N;B,32B*%UDFV1[W\I3\
M^W:0P)4\Q^RAJNJ:K\.E-YX<A\.6*1VAMH(=%;2=TC6D37(\A@#A9S* ^T ]
M!G;D@&CHGB_PCX@\>);ZEX$U"P\5Z=J=W;VNH3^%KJ2)3N*?:([[[/Y:K+&B
M$MO'4*2<5S_[7<FGCPAHT>HM9JLEX1#_ &S+IXTLR[>/M*7:2%QC<0(8VD&&
MP5&318? K7;;XHKKCVVA!EUR75F\61W$W]LSVSLQ6P>/9M\I581?ZTKL0$1A
MN1I?'^[NM$\1>#=9LQK%C/:B]B&L:7H[ZLMJ)%BS'+;HA.V3;PX92I0#D,PH
M [_X5W%U<_#KP]+>W6AWMP]G&3<>&@1IKC'RFWR3^[QC'-=;7%_"31K+0?A]
MI-II\FHRVQ\V=I=6M&M;F2225Y)&>$HGEY=V(7:  0 ,8KM* "BBB@ HHHH
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M:1HU; R$!QS2?$CX-#Q]\2] UVZMM*U31(](U#0]3L-5BWLL-P8G$UL=K*)
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MV7&?FSU]\\2Z3/K_ (=U/3;74[K1;F[MI((]1LMOGVS,I E3<"NY2<C((R*
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M \::GX# ECF?5]+N1 V%/^KD;*GRVR P5D)XPPKD_@W_ ,G$?'__ +"&C?\
MILBK4_:/\(ZAXH\):'<6&FV>N)H>NVFL76BZA<)!#J,,6\&(O)\@8,Z2KO\
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M*_DE\7:_XGE)TN]MY5=KX&8N5NC)+L,0 ^08Q@"OH']J#_CX^#O_ &4/2_\
MT7<4 >WU\[?$+XEV_BO6?##R>!/B/&WAK7!JJ-!X::1+EDAG@V@[QA2)RVX?
MW1QS7T37SS\1M3U3X?\ Q5\0^-9_#<OC?PY=Z-!HB&SU>TM_[(D5Y'GBECN9
MHHPDV^ EP2_R $8VT >V^%M?_P"$HT&UU4:?J&DBY4M]CU6W,%S%@D8="3M/
M&?H17C/[26D?"VYU_P .:EXSE\0:/XIL8Y6T;7O#=C?RW5HI(#@/;Q2)@G'R
M2J0?2NY^ 'AO5_"/PB\/:7K<R2W\:2RB.*Z-TEM#)*\D-NLQYD$43QQ!_P"+
MR\]ZXC]JCQA\3/#MAHUEX%M=-M--OW:/5->N=8M;*ZMEX BM1<_N_-?G#L'"
MX^X3@@ Y+]E'QII]MX]\3>!])^(P\<6S?:?$,\.K>&KO2]8MYKB<,SRNT<<+
MQLSL1MC0YZ @''U57@W[/D-YX-U&;PQ=_#:'P0UW#)J4NH7/B6#5-0U28,BO
M+,1^]E8[N9&) X7C(%>X7EU#I]K-<W,L=O:PHTDLTK!410,EF)X  !))H ^)
M6LM/\(_$;QSH6H^!O@]XNUB36+S69+[Q#XDB75%MI[A?*^U*]G(4VF:*-1N
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MV1[%\&I]4N_A)X-FUO=_:\FD6K7>_P"]YAB7=GWS7:XZTR.-8T"J J@8  P
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M!#ZLN!(GTVMCUKZ:3Q37-1Y9KR2O]VYV1AAD^6LY0?FW;[]CE/\ AD[]J/\
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M*],_9P\6:WXLT76)M9^)_@[XG217")'=^#H4BBM1MR4E"S2Y8]1R..U>4?\
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M2:AX5MH/'NI^-1XEU?6EN89)-!L8<+'8&8-OD+VNR'9&#'F25C@8+?5M?/\
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MY'IFO'/'.M?$;XF_#+5/AD_PBET'5]9TU]*NM3N]2L9=%LXG3RWN(MDIGD5
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MCMHK:*ZW@;LM($4<\,2,?1%[>V^GV<UU<SQVUM"ADDFE<*D:@9+,QX  YR:
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M\L]<^(WB/PG:QSV3ZAXS@TVRA-VDB I';16T5T'&'!,@11@\$D$ 'TA1110
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M:MX(_P"%?S:'XU\9-X-34)8)+2YL98_[1,T,T<R&UC:.0NX>-?NQL1U&#@@
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M)Y#/ )VM@Y9=[([1,JA@VS9C ^V+V_M]+LI[N[N(K6T@1I99YG")&@&2S,>
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M\(>(K>]_X1S4-8^']Q>7D>H3IX?NBMG<7*3+.LDMG)N@8^8BL2$5CW:O>:*
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M_BAH#:+XJT>VUK3?-6=8;E3^[E7.V1&!#(XR<,I!&>#7FOP;_P"3B/C_ /\
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MFX\0:G>RR)LGFS;QCRR!%L9=PP"6+ Y 6OKG]E.*PC^ GA8:6/#(L2MPT?\
MPAL\TVDC-Q*2+=I?GV@D\'@'(' %? 'QO^)OP&U'XGZJOP1EM_!_Q!CNF74?
M$5SJ=MH^@>;YAWFXMKM7%SA@V1'!DY^]7Z)?L\:I/K'P:\+WEUKOAWQ-=26[
M>;JOA2(1Z;.XD8,85'& 00<8RP8X'0 ',_L8?\F_:5_V%=9_].MW7:_$7X+^
M$_BG/87>NZ=)_:VG!Q8:QI]S+9W]GNQN\JXB974$@9&<''(-<5^QA_R;]I7_
M &%=9_\ 3K=U[A0!Y'\'O@SK7P?U75+>W\:W?B/PI?SW%^;+6K1'OX[R6179
M_M:%=Z'Y\J\9;)'S<8/I>N:+8>)M'OM)U6R@U+2[Z%[>YL[J,2131L,,C*>"
M""00:BT'Q%IWB6"[FTRZ6[CM+J:QG* C9/$Y21#D#E6!'I6M0!\^ZG^R;!H6
MLZ)K7PZ\8:QX.O-#,S:=I5Z[:KI$7FQ^6ZBVF;?&I7^&*1 .PKWNW$JP)YQ5
MIMHWE 0I;'. 2<#\:GHH **** /$/VAO^2A_ 3_L=6_]-=_1^V5K'B#0/V=/
M%5[X8O-2L-61K11/HUJUQ?+$UW"LWV=%5CYOEE]K8PIP20!D'[0W_)0_@)_V
M.K?^FN_KEOVPOBE\8_ATF@+\-O#;W>@WBR_VUXDL]*.KW>E 8V-'9+*ADR"3
MD[@,=* .:_9(U+PS>_$*^71?%_QM\078TQV>V^(\=RM@B^9'ED\R)%\W. ,'
MH6KT[Q#_ ,GG>"/^Q(UC_P!+=/KPW]@/Q=8?$KQAXWU_7OBQK?CGQW9WUWIU
MMI>KS_8A%I@,)6X73,+Y+,PP3@XP!WY]R\0_\GG>"/\ L2-8_P#2W3Z /7M<
MT2P\3Z/?:3JME!J6EWT+V]S9W48DBFC889&4\$$$@@UX=J7[)L.A:WHFM?#O
MQCK'@Z\T,S-IVE7SMJND1>;'Y;J+>9M\:D?PQ2H!V%?05% $$*RB%!,RF;:-
MY084MCG .<"O,/'W[.'A#Q[K&HZZG]I^%_%&H0B"ZU[PW?/975P@38%F"YCG
M 7  E1P !CI7JU5KZ\ATVSGNIV\N""-I9'P3M51DG ]A0!PWP9^'^N?"_P (
M6_AG5/$D?B;3M,BAL])N&L%M;F*VCC5%CF*,4D8;1\ZJF>XSS6WX]^'/AOXH
MZ#_8OBK1[;6M.$RW"0W .8I5SMD1@0R.,G#*01DX-:VB:Q:>(M&L-5T^<76G
MWT$=U;3J"!)$ZAD8 \\@@\UHT >(>$?V=M2^&WQ&E\2^&/'FKSV-_%:V>IZ3
MXGSJF^U@:8QQP7+,LT94SR$%VD'/(/;V^BB@#P3QG^Q]X2UN"<^%]1UCX?SS
M7T.IR0Z%='[!-=13I<1R2V4FZ$GS45B556..37K_ (1L=<T_P_9VWB+4[76-
M8C#+/?V=H;6.;YCM81%WVG;MR-Q&<XP.*E\1>(M.\+Z<M]JMR+.T:X@M1*P)
M!EFE2&)< $_-)(B_CSQ6O0 4444 >)?MJ_\ )K?Q"_Z\4_\ 1T=>LZXVW0+]
MA?KI9%K(?M[A2MM\A_>$-P0OWN>..:\F_;5_Y-;^(7_7BG_HZ.LS]LGXB:K\
M.?AAH<NGZS!X7L-7\06.D:OXCN;5+F+2K&8MYLS(^4P=JQY;@>9]* /F+X8_
MM%7W@?Q'!IOA_P"'/ACXZ:%I$]S?-XJ^&?AR33'L)63$L[AXOLK2N@()AF!8
M<?7Z-^,?C33?B/X1^ 'BG1GD?2M:\::+J%JTR;',4L$[KN7L<'D5XKX+^.WC
M'4_B?X$\3Z)XR@'@OQ?XTN/#F@?#^#3H8X;C08$D1]31@HD!$D7F;N%PP'?%
M?0_[3<202_!J.-5CC7XA:6%51@ >5<< 4 >YUX)XT_8^\):S!/\ \(MJ6L?#
M^:6^AU22#0;H_P!GS744Z7$<DEE)NA)\U%8E54G')KWNB@##\(V.MZ?X>M+;
MQ%J=KK&L1AEGOK.T-K%-\QVL(B[[3MVY&XC.<8'%<_\ $7X+>$OBC<V-[KFG
MRKK&G!UL-9TZZEL[^SW8+>5<1,KJ"0"5SM..0:[RB@#R3X.?!K6?@]J6J6T'
MC2Z\2>%;Z>YO_LFLVB-?Q7DTHD=_M494.A)?*M&6R1\W&*])UW0]/\4:+?:1
MJUC!J6E7T+V]U9W48DBFB889&4\$$$@@UI44 ?/NI?LG1Z#KFBZY\.O&6L>$
M+W1/._L_2M0=M6TB(2IL=!;S-OC4@#B*5 ,<"O?80XB19"K/@;BHP">^!Z5+
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5YUK7_)P_
M@_\ [%;6_P#TKTJO1:\ZUK_DX?P?_P!BMK?_ *5Z50!Z'UKF?B#\1?#_ ,+?
M#<FO^*-172])BD2-[EHW<!F.%&$!/)]JZ7H:^9_^"B7_ ";%K/\ U_6?_HX5
MO0I*K5C3>S=CGKU'2I2FMTKG8?M _#CQ;\;?#N@Z)X5\5MX9\/WLAEUB]@R)
MIK8H"B(!@G<3R,J,=<]"SX >%OA9\,[O7/ _@ Q-KVBB,:R9(V-T[,/E:24J
M V<' 4[1V KU/P=_R*.B'_IQ@_\ 1:U\V?L\C/[8?[0/^_8_^@FNFFY2I5*=
M[1BKV[NZ6O<YIJ,:D)VNY.WHK7T/4?CY!X8TKPPWB[6=9/A+4=%*FVUZ.)FD
MMV9@JHZJ"9(V9@"N".:V?A-\2&\<:7);:E$EIX@L5C^UP1D^7*CC='<19Y,<
MB\CTY!Z5YK_P4"4']EGQ42!D36>"1T_TF.O4?AQX4TZ'2/#WB!86_M1]"M;(
MS%SCR@BN%QT^\>O6N:5)*C&HMVVON2_S,^2<<6W3LE97\[WU]59'>4M%%8'J
MGG'QN\=OX$\'RW-EJ^G:=JJ2P70AO;VVMGGM$NH%NA&UPRQABDFP,Q"AI$R0
M2#7-?LZ>*O$GB_PIX@FU+Q=I/B>[2:,6]]97%K=PV\[VT;RQ?Z*5!B29V5 Y
M$A5>3@J:T/V@=3U^31+'P_X6TV\U'7-3D65O[.O;.VN4LX;B!KK8;AUP61MF
MY0VTLI..#6K\%M)O-&T*^BO=)\1:/(]SN$7B35(+Z9AM4;D:&1PJ]L$@Y!XH
M \;^&^BW7A7Q-!K>H3>%]5M+_P 9WNGR:LO@UH[QKQII?,*7)OG=8Q.'@1V1
MB-H&-F&KT#X_C5&\1>#AX5:X@\;8O?L-PL]O#;I;[(S<+*9HY <XB*A5W94G
M(4/7!3:!);?M%6&I:182W]W)KLGVR&;P5=VL$$)1UDN$O780-(/E'FJ-T@)
M^]6_^U'\*Y/%4FFZIH_@?0-;U!8Y9+S4[OP[:ZI>A8@ICA03#^)#. >?F"*,
M;R: /1/@)]A/PHT4Z<+P1E[DSM?O&\SW/VB7[0Q:,!&#3>80R *005 &!7HM
M><_L_6]S9?"/0+6ZL(=+> 3PQVMO8I8JL2SR+$?LZ +"60*QCQE22#R#7HU
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M[HLQ/)).WDUT&EZ3\>=#L8K+3K/X5Z?9Q B.VM8[^.-,G)PJ@ <DG\:]THH
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@ 4444F 4444P"BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>exdx-20241231_g4.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 exdx-20241231_g4.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1%$17AI9@  34T *@    @  0$2  ,
M   !  8      !H !@$#  ,    !  8   $:  4    !    : $;  4    !
M    < $H  ,    !  (   (!  0    !    > ("  0    !   0Q
M  !@     0   &     !_]C_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+#!D2
M$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_VP!#
M 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !X * # 2$  A$! Q$!_\0 'P
M 04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%! 0
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M9;&1CN: *>I65S<W8:(#9B/GC/#Y/OTJMJ.G74[SF*)F#R.V-RC(,)4=3W-
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M 2(  A$! Q$!_\0 'P   04! 0$! 0$           $" P0%!@<("0H+_\0
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M&:O;Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %<K\5_P#DEWC'_L#7G_HAZZJN5^*__)+O&/\
MV!KS_P!$/0!A_LW?\F\?##_L6-,_])8Z]&KSG]F[_DWCX8?]BQIG_I+'7HU
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MROQ7_P"27>,?^P->?^B'H P_V;O^3>/AA_V+&F?^DL=>C5YS^S=_R;Q\,/\
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MF'WXS<>>4R2=I'; 'K= 'GWQ]M7OO@?\0+:-(999M!OHTCN'"QLQ@< ,2R@
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M P_V;O\ DWCX8?\ 8L:9_P"DL=>C5YS^S=_R;Q\,/^Q8TS_TECKT:@ HHHH
M**** "BBB@ KQ#XX?\EL_9__ .QBU#_TTWE>WUXA\</^2V?L_P#_ &,6H?\
MIIO* /;Z*** "BBB@ HHHH **** "OS%_:7_ &E_'G[5_CC3_ '[--QXMTSQ
M5X9DU"3Q!%%>PZ6LT220PJ1)]H <*Y;@D'#Y ZX_3JO&_AI^RS\+_@Y\0-:\
M;>$_#!TKQ+JT<T=[>_;KB7S5EE$L@"22,BY=%/ &,=A0!^6_[1W_  4*UKQ9
M\)_A7X?\">+_ !CX>\7Z!8_9_%-]]H-O]MN1# I;S(Y"TO[Q)3E@/O9[U:_X
M*4ZQ?^)?@Q^RMJFIW<NH:I?^$FNKJZF8M)/*\-BSNQ/))8DY]Z\]U3_@F?\
MM(7.J7\T'P[\R*:=W4_VS8#*EB1P9_YUL^*?V$?VOO&^FZ+I^O\ A?4M8L=$
MA%MI=O>^([&5+&':J^7$&N#L7")P/[HH X#QWXY_:&^&I\/>"/'/C3Q19:)K
M^D6\L&E/KK3P7&E39B4$1R, C*K+L)!QU R*]S_;=_81\1_"'QWJ'C7X4>#9
M-&^&^A:;!J,M_#JZLUO<(S&211+,9LJ=A^48XXKD]5_8,_:P\9:WH=YXH\,:
MAK+:7%!9V\FH>(+.<P6T;96)29R=JY; ]^*_4S]N"3?^R+\6AM(QH%QU^@H
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M_P 1(/CBFK7":7H=M!>'1GC%R1:J(Q']D:T: 1EY7.X9<E@XQ7VN,X&>O?%
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M.-E<>85(/(VGJ#7[9U^8G[<DSR_MT_LI.TC.S3Z468G)).HKDFOT[H ****
M"O.?B=_R/OPA_P"QEN?_ $S:E7HU><_$[_D??A#_ -C+<_\ IFU*@#T:N<\8
M>*K+P;9V5[>6%_?+/?06,:Z;9/=21O,X1794!*H"<L_0#DUT=>1?M'KXQB\)
M:'J'@ZRU#5I=,UVTO]3TK2KV.TNKZSCW%HDD=E7!D\HLI8;D5U[XH [30M8T
MFW\6:OX9T[1KK3[BS@AOI[A-.:&TF,Q<#9-M"22#RSN )(R,]:V=6U6'1-*N
MM0N5G>WMHFED%M \\A4#)VQH"SGV4$GL*^=/V4_!GQ#\)^*=>D\6ZCJ=]!>Z
M/876H?VCJWVZ%M9E>:6Y^R+N;RH8T>*$@!5)C&T'!)]N^*GBC4/!?PX\2:[I
M5J+[4=-L9;J"V,3R"1E7.-J?,?H.: /G;X/VJW?Q?TF2'3YK*ZAO+VZN?$S:
M3K%O>:[%(DVR"[%Q:1Q(J[T;YIG&Z%!&JYP/0?BW^RWIGQ!\42>+;#7+C1O$
MHFM)UFOK>/4;53;RQR(%CE^>%28E#""2+<"V<DYIOA;]I!?&OQ"L_#VD6DLL
M$WB"2S\V73+N+=IRZ8T_VC?(BJI^T@1<]>F,G->>?M#?#C0_B'XYU[1-&\=W
MD'B;6H5T^XT'5=5U*#3%F,*L@@DA811W'EX<P$/O!!V+G?0!]5Z2M\NF6@U-
M[>341$HN'M$9(6DP-Q0,20N<X!)..]7ZP/!-_I.I^$-%N]"N)+O19K.*2RGF
MDDD>2$H-C,TA+DE<<O\ ,>_-;] '.^/+K6[/P3K\_AR*&;Q!%83OI\=P0(VN
M!&3&&+$#&['4@>I%>9? CQWXL\9^*->EUF_M+K27MTN+6SCFLWEL"9YD2)C;
MR/EFA2*1]Q(5W*H2,@=O\:H],F^$'CB/6I;J'2'T6\6[DL4#SK%Y+[S&IX+8
MS@'@GKQ7FW[.'PTO?!_B;Q3JMQX;U#PS!?(HM[>ZAT^-65YY[AP3:SR[RLD\
MFW<$"HP49Y- "R?\*-T#XJ:]:ZEX,T'2_&":I#<&^N="222[GDAA=+B*81M@
MY(4G*D.C,1SN/T!7Q)\2?'4>M?'JXGT;Q]916ET\-@)9=5O[:32V:2S\N-;5
M83&Y\RWG<$LOF&X*-\J\_;= &/XG\.6'B[P_J.B:K;_:M.U"![:XBW%2Z,""
M P((//!!!!Y%<QX=^"_AWP[=:-<V_P#:$\^E7-S?127M]).TUW.GER7,Q8DR
M2>6612Q^57( '&._HH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH ***:S!1DD >IH ^59OAW\4+OQK=W/PPBU7X6:
M6U_))=S^*]774[*]RYWO#IF93&KG)!6>W/\ L\U] ?#J]\67GAL#QI865CKT
M%S-!(VFL3;74:R$1SQJ69D#IM;8S$J202<9KS#PS\1_BU\1?MFJ^'M+\$:7H
M4>IW=A';:O?7;WZB"X>%FE6.,*CMY98)DX#+R:][H **** "BBB@#Q#XO_\
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MA,)L$GRP/+^4ABP /1_@>VF-\'/ _P#8MK=66DG1;3[);WTGF3QQ>2NQ7?\
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M3XB:M936B)X7BTNTFM;LK\SW;2W(G3.>0J);GI_$>3G@ ZBBBB@ KQ#XN_\
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M%&$7 PN^2.6;8O"^=CL: /3Z*** "BBB@ HHHH **** "BBB@ HHHH ****
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M;;39(MPSE\W%K(^3D?Q8XX K;\$^'M2\-Z1):ZEXJU+Q?<&<R"_U.*UCE52
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M^O$/CA_R6S]G_P#[&+4/_33>4 >WT444 %%%% !1110 4444 %%%% !1110
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M#=BRUM=+NFL;EFC413")MCYD(08;!RWRCOQ7FG[,WB[3O%\6M7%A?:SJ+0K
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M110!X7^U+H$'C[P.EII'B/P]I_BCPMK>G:_;6VN7:I:/<0R>;%!=8.Y%E4,
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MQ#XX?\EL_9__ .QBU#_TTWE>WUXA\</^2V?L_P#_ &,6H?\ IIO* /;Z***
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M.4W9?&=P[YKU_5;*;4=,NK>"_N--FFC9$N[41F6$D<.HD5D)'4;E(]0:OT4
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MRNX#<,@&NE\)>"M)\$0ZFFE0RK)J5]+J5Y-<3/-+//)@%F=R3PJHH'1510
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M?]-",MU[UOUR'PH-^/AEX3_M2^M=2U'^R[;S[RQ=)()G\M<NC( K ]<J #U
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M>*O#U_K/Q<U-5TJRU^]#65GKMS8^'K]X4D*VTKH7_M&.,%DCMRVV-LHL:OO
MVU]8T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !117.>/RR^#-8D&MWOAL0VSS-JNG0)/<6RH-S,D;QR*QP
M",%&SG@9Q0!\5:EX4M/$'C75;;P[>_$/6?AS</?:-<6ND^$4EADAEOS->6\-
M\[J3%YZR(7\MB%+!7/##[V"A0 !@#H!7P7\/OB;X>T_P>T_A+XP?%6^EFO[J
M6W\-V_A>S=[FX:Z<.L;?V;Y:"23<^-ZA=YSM(('WM0 4444 %%%% 'B'Q?\
M^3C?@'_U]ZW_ .FUZH?MJ7&@Z3\$SK&N^(IO"AT?5['4].U>/3)-12WO89@\
M/FVZ EXR05;I][.<XJ_\7_\ DXWX!_\ 7WK?_IM>JG[:*:)'\$I=2UKQ@O@9
M](U6QU/3M7DLVO4%]#.KP1M;+EI@S#&P#/?M0!\R?L5?%;X>^$/'UG9>(_B6
M=9\6S6$'A72;:/PO>Z59V\+W$EQ'')).GS32R2';N*C@!02:^I[?_D]6^_[)
M_!_Z<9:^;_@QH4G[57C#6=3\0?$:?4O$*S:+/?6UAX/NM(LO[/L+M[F*%#<C
M+2O.X)?)*J" ,'CZ0M_^3U;[_LG\'_IQEH ]8\3P6-[X;U:WU*![G3I;2:.Y
MAC4LTD10AU '))&1@<U\A:+KR>._"&G:'_PD/Q1U_P"&][;Q10VL?@3:]W98
M&R*2\6'F,KA2RJK$9^8')K[*N[J&SMI;BXE2"WB0O)-(P5$4#)8D\  <Y-<5
MX,FN;CQ7>7&BRZ;-\.9M)M9-+DTMH6A>\:>Y:Y93'U!4P'/0DG'.: .^HHHH
M *\0^+O_ "<A\ O^OG7/_3<U>WUXA\7?^3D/@%_U\ZY_Z;FH S_VU9] TCX+
M#6=<\13>$VT?6+'4].U>/3)-12WO8I0T/FVZ EXV(*MT^]G.<5\U_L4?%;X>
M^$?'UG8^(_B4VM>+IK"W\*Z5;1^%[W2K.WA:>2>..22=/FFEDD.W<5' "@DU
M],_MHKHD7P3;4]:\8KX&?2-6L=3T[5I+)KU!?0S!X(VME^:8,PQL'/?M7SY\
M%]#?]JGQAK.J:_\ $:XU+Q"EQHMS?6UCX0NM(LOL&GW4EQ%"AN1DRO.ZEI,D
MJH*@8/ !]'6O_)ZVI?\ 9/[;_P!.,U>M>);&35/#NJ6<5Z^F2W%K+$E[$</;
MED($@/8KG/X5Y+:_\GK:E_V3^V_].,U>RW]E!J-G/:74*7%K/&T4L,JAED1A
MAE(/4$$C% 'Q=>_#^SB\.Z%X/D\)?"SPQK$\\-K;>.M/UQ6O5N$!D-U HMEF
M-P5B=\/*!G.YV&<_;=?,<'[$7A70/'7A*[T'3O#Z^#])U-]1FT74M&AGN$/V
M:>)(X+G&\Q;IE?RY=^#&I5E "U].4 ?/7Q6T7XDZM\0[K1],MM8E\&Z[=:0D
MVH:7K$-J]E;122?;E4&5)8RZM'EH06(4@8)S7;_ S0]<\.:9XFL-5;4$TZ'6
MYET6VU;4OM]Y;V(BB"B28N['=()9%#NS!)$!QC Q_%WP!M?''Q6U+Q#K4-K?
M6-QI=O#I^H)+)%JNB74+N0]G(!A%<2;F(93N0 AU; U?@A\//%'@&/QBWBK6
M;/7]0U?7/M\5_:0F$RPK9VMNC2Q]%E/V<E@IVY.1@': #U&BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "N5^*__)+O&/\ V!KS_P!$/755ROQ7_P"27>,?
M^P->?^B'H P_V;O^3>/AA_V+&F?^DL=>C5YS^S=_R;Q\,/\ L6-,_P#26.O1
MJ "BBB@ HHHH **** "O$/CA_P EL_9__P"QBU#_ ---Y7M]>(?'#_DMG[/_
M /V,6H?^FF\H ]OHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH *\Y^)W_(^_"'_L9;G_TS:E7HU><_$[_D??A#
M_P!C+<_^F;4J /1J*** "L3Q;9:AJ7AC5+/2YA;ZE/;21VTIF:$)(5.T[U5B
MO/< D>AK;KGO'.FW.M>#-<L+.PLM3N[FSEBALM2E:*VG<J0J2L@9@A/!(!.,
M\4 >%_"7Q7:0?%BW\+:SJ7B>3Q;;1RE[6/78M9TP#8<^8\2J\/3*B>.+) QD
MT[]IB_B\->-_#6HZ59M?^(KFSGL6LVT&WU.%XII[:)782W5L%D,K11J0[9#D
M%<#(I_ J'QEH7Q(BT7Q=INH>$-,@L8VTK1=!T6&UT&2Z/VC[0/-MS-N"QB$I
MYTJ%F+'R\@ 6OVBO'7ART^(>F:%J>J_#NX8Z/<B[TCQGJ/V&5%::W=)(IE@D
M9>4!VY7)5& RF0 >M_!!;!/@[X*CTF6\FTU-'M5MY+\()R@B4#S A*AL=0I(
M!X!XKNJY7X8W5G??#KPQ<:;9VNG:?+IMN]O:6*NL$,9C7:L8=$;8!C&Y%.,<
M"NJH \\^-^JQ6GP_OM(\O4I]1\0A]%T^'2&1+IKB:-\-&SLJ(457D+,0 (R>
M>AP/@EKWBF77=<T+QI>ZK_;MG;6]RMG?P60B,$C2*LT4ML 'RT;*58 J5Z88
M$[7QOMO!Q\*VFH>-;W4=,TS2[P7D-_I=Q=V\UM*(I$W^9:D.J^6\H)^[@\U@
M_!";X<7_ (BUJ[\':WK>NZS]DMTNY=<OM1N9([<M(T(4W9.%),A&WKS0!Y?\
M)='MO$-CI'B>3X5^/O[2U5XKFZU;3_%FRSF<-@2^6^J!R@ 'RLF=HQM[5];5
MYWXP^,?AGP=J!T"+5M)?Q(KP(FD371A*B1EQN*H^P["64$<X'0'(]$H ****
M "BBB@ HHHH **** .;\8^/]"\ PZ3+KU\+"/5=2M](LV,3OYEU.VV*/Y0<;
MFXR< =R*Z2O!OVS]-\&ZI\#[NV\<WWB*TTJ34+1;>'PHX&I7EX90+>" %6W,
MSD8'&,9R,9KPG]G:\\-0>/? >HW?C+XWVU_JNIZMI-MI'C+7DN[ 7MF&22UN
M@@(\P@2.BY/,)YR!D ^[Z*** "BBB@ HJI<7]O:36T,UQ'%+<.4ACD<*TK %
MB%!ZG )P.P-6Z "BBB@ HHHH **BBFCN(DDC=9(W&Y74Y!'J#4M !1110 44
M44 %%%% 'A>L?M6>"/"MG9R0:5K=SI\LVH/+-I^GCR[6UM+A8;J^D!8$0"60
M#< 6;YB%(!->Y @@$<@]Z^"/$WBGP3:VOBB^T;P$^H0WIU#4/$EG<>*9T-KI
M-IJNQXHHL,L3W-P9I/LJ[5<*P9CD ?>ZG(!'0^M #J*** "BBB@#Q#XO_P#)
MQOP#_P"OO6__ $VO6?\ ML6VG/\ !-;J_P#%P\%2Z=K6GW]AJR:.VK3K>1SJ
MT"0VRL#)(SX '/&<@C-:'Q?_ .3C?@'_ -?>M_\ IM>N/_;'^*GAC1O[&\(W
MVA>,_$.O6SP^+D/@FS2>YTJ&SG5A=2;V"["P9-O)8;AQQ0!D?L9?'+5OBQXG
MUZVU#XGWWCZ&#3HKN*WNO K: L*O(0LJR%V\T-A@ /0GM7I%O_R>K??]D_@_
M].,M>/?L2'PAKWQ'\3:[X'USQ=XJ\*1:;]CTC4=4TE;+2[&WDNGN&L8)"JO<
M.DDC9=A\H&T$U[#;_P#)ZM]_V3^#_P!.,M 'J?C'0W\3>$M<T>.40/J%C/:+
M*PR$,D;("1Z#.:\STC]F^Q\):=IDW@_6;KP1X@M[:"*\N-'538ZBZ(JLUQ9O
MF-RV#\X"R<_?KUR]M5OK2:VD:14F1D9HG*. 1@E6!!4\\$'(KP6Z^'_PFT/Q
M7+H=U\2/$-MKUFD5S-IMU\0]1$L2/)&D9>-KK@,\L2C(Y,BC^(4 ?0M%%% !
M7B'Q=_Y.0^ 7_7SKG_IN:O;Z\0^+O_)R'P"_Z^=<_P#3<U &;^VS;Z<WP5CO
M+_Q;_P (1-IVM:??V&K)HS:M.MY'.&@2&V5@9)&?  YXW9&,UQ?[&7QQU?XL
M>)M?MM0^)U]X^AM]/BNHH+KP*V@+"KN0LJR%V\T-A@ /0GM6M^V+\5_"^CG1
M/"-]H7C/Q#KUF\/B]3X*LTGN-*@LYP1=2[V"["P9-O)8;NG!KC_V(O\ A$=<
M^(GB;7/!&N>+O%?A2'3!9:1J6J:4MEI=E;/=/<&Q@D*J]P\;RMEV'R@;030!
M[!:_\GK:E_V3^V_].,U>RWMHMY:3VYDEB$L;1EX'*.N1C*L.01V(Z5XU:_\
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M !7G/Q._Y'WX0_\ 8RW/_IFU*O1J\Y^)W_(^_"'_ +&6Y_\ 3-J5 'HU%%%
M!1110!Y1#\6KKQQJMC9>"[:]CB-VZS:IJOA^Z.GW$4>X.(Y]\84EEPKX=3C
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MTPV.G72-;P2F14,CY<-*T;G/#1E?X: />:*** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH *Y7XK_\DN\8_P#8&O/_ $0]=57*_%?_ ))=XQ_[ UY_Z(>@##_9
MN_Y-X^&'_8L:9_Z2QUZ-7G/[-W_)O'PP_P"Q8TS_ -)8Z]&H **** "BBB@
MHHHH *\0^.'_ "6S]G__ +&+4/\ TTWE>WUXA\</^2V?L_\ _8Q:A_Z:;R@#
MV^BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ KSGXG?\C[\(?^QEN?_3-J5>C5YS\3O^1]^$/_ &,MS_Z9M2H
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M_P#A8G@SQMKU]X>L)] L#J-XFG6&A^#(;I;NZ5;1[4M/Y+L/M"O<!IR0D;Q
M'&/F^U:^)OB;\/8]:^)'C;P]<:9<WGB_5M4@U'3M<A\8):VMA8L\"+YUG]J2
M50&)0JL+"4R+AAN&T ^V:*X+X+>&]:\(^ H-+UMYC<0WEZUM#<7;7<EO9M<R
MM:PM,Q)<I"8UR2>F,G&:[V@ KQ#XN_\ )R'P"_Z^=<_]-S5[?7B'Q=_Y.0^
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MZM?CQ9H]CX?\5R7%C/J.K^'-4BU-'NY;%E2,FWV2R1&RQ"2Z[/,'!V?-^AE
M'C7[1UOK,MEX4GL[CQ1:Z#!J;/K4W@YY/[06#R)/+PB L\9E\L,%5F (('4C
MC?@#H_CS3/'J7,UWXRNO!E\-29%\83!I4A5[;[(S1L!)%*7-V N!F(*7 ;%9
MO[<.J^%_$'A*+PM>^+O"=KJT*3SOX;\2ZPMC'=K+:S0PRG(;)BD=94#*5)CZ
M@@,.[_95O[?6_"/B/6K36M#U6'5-<DN?LWAW5/[1M=/;[/ C0^;@ NS(9G
M :<XSU(![=1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7*_%?_ ))=XQ_[
M UY_Z(>NJKE?BO\ \DN\8_\ 8&O/_1#T 8?[-W_)O'PP_P"Q8TS_ -)8Z]&K
MSG]F[_DWCX8?]BQIG_I+'7HU !1110 4444 %%%% !7B'QP_Y+9^S_\ ]C%J
M'_IIO*]OKQ#XX?\ );/V?_\ L8M0_P#33>4 >WT444 %%%% !1110 4444 %
M%%% !16'!XKL;KQ5?>'(UNAJ-I:0WDI>TD6 QR,ZKMF*[&;,;94$D<9'-;E
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M_P"_Q_J?-_ISBNIH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MAJT4&I1SPJ-@CDDC,RVVXAF0 ["Y%?>BD%01P/IB@!U%%% !1110!XA\7_\
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MX,E^+G@;PWH5QJ('Q+TVXM8)+N*=8[#7+)F12X_A@N ISP?)?W<T >YT444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@DR1;X];OIYH8W:, G9IC*C$2Q':7'^L3)PP)^BJ^1/BC/X9\0_&[6M$GO\
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MN-=7X"\*+X%\':3H2WEQJ!L;=8I;VZ8M+<R=9)7/]YW+,>PSQQ71T4 %%%%
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MWX1ZE\3?%GBOX<ZC)+JNHVL2:E8P++'9Q_O7?S8XW0!&=V<ML."<DC))/O-
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M(11X(W!D<,6;)/L% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M<\+G:>6('O7 ?LO-IEQX1\17FEZMH^JI>:_<W$X\-JW]E6TK1Q;HK1R )4&
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M_P#^QBU#_P!--Y7M]>(?'#_DMG[/_P#V,6H?^FF\H ]OHHHH **** "BBB@
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MET9HY_)$7FB:%6"*BG8?+ W!3BOLP#  SGWH =1110 4444 >(?%_P#Y.-^
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M3/B#7-9U33=4U>?P]+IMK'':ZYXL37)VG669))X_+GE6.-BA3.06:-L*H7D
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M3;O;. _&10!]VUX+^U?X0TS7=&\):E=ZCXKM-4L]>M(=+MO"U_\ 9Y+FYDD
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M  )R?6@!U%%% !1110!XA\7_ /DXWX!_]?>M_P#IM>J?[:)6T^"KZJ?&NG^
M9-%U2RU2+6]2@EN(TDBE#(@AB(:5G;"A,,&R1M-7/B__ ,G&_ /_ *^];_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P"+)O$%UJ%KYDJ*HEEB0QQQL&^08Y?.WG)C^.KR1_%)/^$#E\:CXD/I4/\
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MT\=_%#4[?3=<\1^'H?\ A&U?POJNE7LD.G6>JK),93>QH?WFX-;8$BLI42
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M8:=O(C\MHU;;][;G:-N6^L:^:_V:? ,N@?$GQ?KFG>#9O ?AJ]TVRM8M*O\
M6HM1N9+I))FDF BGF6*,H\:XWY8J3M'4_2E !1110 5YS\3O^1]^$/\ V,MS
M_P"F;4J]&KSGXG?\C[\(?^QEN?\ TS:E0!Z-7SK^U3K6I>'Y]%O;_P 5^&=)
M\#O#.E]I&N>$[G7GN9%4OYODPR M&BC).%"8)+,& 'T57B'[1]OHLMSX67Q#
MX?\ $&KZ/<C4-/N[GP[:75U-;Q3VC1NLD4$3EHG!P2<$,L9&<' !J_LW:M!J
MW@.[DMM>CUR.'4IH-EOX>ET*"QV*B_98K.7YXU7&?F)RSL<]A%^TIX,\0^.O
M">@:5HDFI+82:_9G7(M'U$V%U)IQ+++LF#*5"LT<C ,"RQL!R:O_   T?2M,
M\)7]QIE]XDU62_U![F]O_%>GR6-[<3B../<8GAAPHCCC4%4 .WN<FO,/VR=*
M\8>.K30/#.E_#*^\:^%XM3LM2U,IKMGI]MJ"*[JUC*)94<@DHXP"K,$'/- &
M'^Q-\//%_@/Q)XBBU[1_$]A;1:196%W=>)-:DOTO=2BEG$T]F&FDQ#)&8G)P
MO)P!P0/KNOF[]D_P]X>T/5/%:Z%\%[+X52Q^5;WDMGK%E?-<2*7_ '3BWE<Q
MLF2</C[U?2- !1110!Y_\;IY[/X7>(;H7NG6FGVUE/-J(U32WU&*:T6)S+'Y
M*S0DEAQ][';'/'G_ .SMX!C^%OBS7] N/LG]J75A;ZI^[LKE)/+EEF+*99[^
MZ)"RF3*+L 9RPW;LU[%XVU?1_#_@W7-3U]$DT.TLII[]'A\Y6@5"9 8P#ORH
M(VX.>E<3\%M+\/Z8=4&A?#[6?!C2+%YL^LPJKW*C=L16\Z1]J9;"G 7=P.30
M!XA\7HM!E^,GBC3[K[++IEW<66IZQJ5QX;6[N+*2U^P P07/GJ0!'+;RM^Z<
M()9""2=H]&\963?"?X;^%M T_5)9[SP_=6^HR6L<-W;PW\*R/^XW6T4IBC#E
M2J888C5&&TDTWQ9\'-6UGXRW?BBX\#^&?$=IY]N]G?7>O7-C/%$(X0ZS6T=N
M\5P5DBWJTA)X09 1<:_[2U])+X9LK"T^U3S07MO>W5A&VHP17EMET,3SV4$L
M@&XJVT#JB[OE/(!K_ +4;_6O"VK:K?7#,=0U>XNHK(O<R+8(P4^2KW$<<C#=
MN?[@4>857Y5%>HUYG\ ;B&[\!;H-(&AQBZD'V075]<<X7YMU[!#+SZ;-OH3S
M7IE !1110 4444 %%%% 'C_[47@1/&GPN^T+XEL/"%_X<U&U\1:?K6K &RMK
MFVDWH;@$C,9Y4\Y^;(Y KY6_9,TZ^^+?Q)LO[8^)GPWUO3O#7B;5/&46B^";
MV:XN[B^O#,-SF4*1!']HDQM!R=N37O\ ^W)X8U+Q1\&M.33O"NH^.I+#Q%IN
MHS>&]/B$HU&&&;>\,H)'[M@.3S@[3M(R*\"\7>/-8USXM?"[Q7HO[+OC_P -
M)X2GN+FZNM/T:UCNKA'MWA%FH215,)+AB6/'E@!>20 ?H/7S?^U5X[_L>:+P
M]J=_X67P]J%FLL]GXIT[4HXFD64E9$U&V#1PLI52 5WJ5# C(KW'P5XEG\7^
M$],UJXT34O#L][")7TO5XUCNK8_W)%5F ;Z$UQG[1&N:[H'PY^UZ+>7NF0C4
M+5-5U+3+87-W9:>TH%Q/%&5<%E3DG:VU=S $@4 >2_L;:?X?M]2U-M*CT:_E
M@L5MXM4TKQ\_B5(X#*7,")(B/;J78N?EY.,DX%>M?M,Z9J>M_ GQAI^C:O;Z
M)JMW:""WN;F^^Q(S,Z@P^?D>691F,-G@N#7G7[/'B;2;SXLZYI?AGQE:_%#0
MGT=+UO$GD6KWEA,9MOV2>ZMXT602 ^8JL-Z^6V<@C'K_ ,9=>\*>%_ACXAU?
MQO80ZKX8L[?S+RQGLUNQ<#< D8B8$.S.550?XB.E 'R]\2_V</%^F_ ^]A^#
MVCR:3I?B?3H8M6^'&I:DLT=I(Q0FXM)S(R)*N,.H;RY!R,, 3]LU\$ZCI]O\
M.[<>(S\(_B-\"/"19?M&N>%O$]LT5BCD!9;C2UEDB5 2-V(F*C.1Q7W!X;L+
MO2M T^TOM4EUR\@A2.749XXXY+E@.9&6,! 3UPH ] * -:OBK6/ WA#7O"OC
M+XNZEH^K:=HT&KZA9ZOX<T;7V6"YL(KT)>27,#IA)'D@::2")EWC&69F.?M6
MOS_UW7]*UCQUXU\8^)_!7AC4(-/2]U:?1;.YNK2<?8-3CM6^W*)3#=7#18E1
M7A'/EC)!!H ^_4*LBE?ND<8]*^2K'X$O\0?C!\4=8GOKJR\50:DMSX:\?Z-K
M2SM81B)(QI\EJ)/E6.1)/,B=-L@<\[NGULK;E!&<$9Y&*^/?BK8>%/B!\1_$
MD7@SX"ZEXSU_1+K[)JWB[0=4@\.R1W919&B2[$L<LTBAU+'D G!- 'J'[+?A
M/Q[X<MOB1<_$73[+3]>UCQ4]ZKZ;-YEM=1"QLX!/%SN17:!R$;#+T.<9/NE>
M"?LM7LNL:=K\_P#PD?C:4Z?=?V7>^%O&\EO<76CWB(LC*+B-=\JM'+&P9I'!
M!!!!S7O= !1110 4444 %8WB7Q/IWA#19M6U6X:VL(7C1Y$B>0@NZQH-J L<
MLZC@=\]*V:R/$VAOXET&\TU-3O\ 1VN4V"^TR58[F'D'*,RL >,<@]30!\':
M_P"%?!=U?>)] U3QKI=S(DU_I^C%O"VH&:Q>]U$7%Y=R/Y;+)=JJ)''(FT?N
MU)."17Z# 8 &<X[FO@6_UG6=$\.:SIDOQ:^)3_%VVU:>'3_!YRXN46Z*V\?R
MVWSQ20[&:X#A1O+9&-M??0R0,C![B@!U%%% !1110!XA\7_^3C?@'_U]ZW_Z
M;7K-_;;N=*7X*QV6K>'=$\1QZIK6GZ; GB5W33;2::81I<W)0AA&FXG@C)(&
M1FM+XO\ _)QOP#_Z^];_ /3:]8O[8VH_$J+PMHVG^"?!7A[QAX?O;V-/$<?B
M.ZBCMQ:[TRCI*C+Y;#=NDZIM! )H \C_ & M0\)P^,;FQT3P9X1T34[_ ,)V
MFJWFH>%3*"CFZEA>WG1Y'V9,:R(,YVDY[5[O;_\ )ZM]_P!D_@_].,M>??L<
M:)JFA>)O$4<'ASX:^!?##646W0? NHQ7\\]UYC9N9Y516"A"$522,DXKT&W_
M .3U;[_LG\'_ *<9: /;J^"O$GQ UW4M-U*XD^-D]OX_MO%4UI8_#XZ1I$E_
M /MIBCBC5[1I3(8=LBSX*X()RH+5]ZU\"ZQ\7/&NG_$OQ/9-K^MK\1KBVGCT
MW0%T-6AAN(]406L$1\@[H);7!DF9S\KNVY2,  ^J_P!G[Q-KWB7P1>-X@O6U
MFYL-7O\ 3H-9:T%J=1@AG:..<QJ H) VDJ I*$@ $5Z?2#ITQ]*6@ KQ#XN_
M\G(? +_KYUS_ --S5[?7B'Q=_P"3D/@%_P!?.N?^FYJ ,W]MRXTH?!:&QU;P
M[H?B./5-;T_3($\2NZ:;:333"-+FX*$-L3<>A&20,C->.?L!7_A.'QA=6.A^
M#?".B:G?^$K+5KO4/"ID!5VN)8GMYT>1]F3&LB#.=I.>U>M?MCZA\28_#&BZ
M=X*\%>'O&'AZ]O$3Q''XCNHH[<6N]<HZRHRB-ANW2=4V@@$US7[&^B:KH?B3
MQ%'#X:^&W@;PN;*+9H/@74(K^>>Z\QMUS/*J*VT(0BJ21UQ0!W]K_P GL:E_
MV3^V_P#3C-7N%>'VO_)[&I?]D_MO_3C-7N% 'P7XA^(&NZGIM_<2?&VX@\?V
MWBJ6TLOA_P#V1I$FH0#[:8HXHU>T:4R&'$@GV[<$$Y4%J^IOV?\ Q-KWB?P-
M=2>(+YM8NK'5[_3H-8:T%J=1@AN'CCG,:@*"0N"5 4E20 "*^4]6^+OC:P^)
MGB:Q?7];7XC7%M,FG: NAJT,-Q'JJBV@B/D'=!+:@%YF<_*[MN4C ^^1TH ^
M>_VC/%M[H7Q$\#:9/\29/A9X8O[74)+O69+:R>"XN$, AMO,NH72)V629@<C
M<$88).1Q/[-_C?Q9#XZTC28_&<OCCPAJ-WJUM;2_V/:6EN;6V6)X[^W:VAC'
MEM+*8#N+!V^9"!Q6G^W-XS\1>%/#UJ+75=2T#PZ=+O[E[W3;!;C[1J49@-I:
MS.8Y/*C=3.V<+N,8&\=#ZC\ /%NH^,=*\5ZA//=WOAW^W[@>'+V]LOLLDVGF
M.)AM3:I,:S-/'&Q4%DC0_-]X@'J]%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %<K\5_P#DEWC'_L#7G_HAZZJN5^*__)+O&/\ V!KS_P!$/0!A_LW?\F\?
M##_L6-,_])8Z]&KSG]F[_DWCX8?]BQIG_I+'7HU !1110 4444 %%%% !7B'
MQP_Y+9^S_P#]C%J'_IIO*]OKQ#XX?\EL_9__ .QBU#_TTWE 'M]%%% !1110
M 5X?^T7;ZAI*:;J]CXS\:Z;>7DT6D:=X<\)_V>#?W;EW'S74+!3L#%F9U4+%
MGKU]PKQ?]J>VL=0\":-8S_\ "0/JMUKEK'HT/A>ZAM;Z2^&]T"SR@K$H5)&9
MO[JL.<X(!D?L\:MK]KXNU_P[XQU+QFOB2&RAO4TWQ3<:=<P&V9W43V\UG$@8
M[E*LK\KA>,$$[/[4B:E)X!TI++3_ !#K.FMK5J-9TSPLLGV^[L?G\R-&C960
M;MC,0RY567(W5YI\%_AY?/\ %[4CXFUWXAZ#XZM;2TOI;;4=<L=1M=1T]97"
M(LL=LI$8D$@>(!#\P/.[->E?M1Z=JFI^!=(BL-&UWQ)I_P#;=JVL:+X>D\JZ
MOK$!_,CW^9'A=VQF&X;@FPX#9 !YI\%?$Z^#/BYJ-AX?^'OQ)T#P+J=M:6\-
MIJVFW,MM%?F5Q)<J9'?R(_+,8<Y )7.T8);M_BU\7?'^A^/]:T+P1I>BZG)X
M>\/1>(9M+U$3->ZV'DG3[/9^6<(RB#EBK_-+&-H!S7&?!>]NO GQ<U&U\.?"
M7QWX2\!ZG:VELEE<Q0M:17OFOYEUL-RWD((V16V9W;<[?EY[3XB^,O%EY\;1
MX=\(:?X0&LZ+H<>JPGQ*C_:M2$\DR/;VDJ$&%5%N"\F'YDCRF.: $^#VK:_'
M\:?$NB^,5\,:MXJ/A_3]0FUK0--:TGMXGEG"V-QNDD9@C!GC8E=P9SM&*TOC
MKX+CT.R\0?%#3?%>O>#M6TC1)'U"?0XK:X%]:6RRS+&\%S&Z,REY=K#:1O(+
M8K*^#?QBL/'?QH\5:-8>'8/#=]'HUI?Z]97-H(M2AU+SI83'.ZG$JB*.(HXR
M&4@JV#BH?CCXV\5Z]XD\3> /#=YX1T6WT_PRNKZC/XRM'NX+^*=IXO)6)98P
ML2B!_,D8MCS$&WJ: .Y^%OPL3PMJ=[XJU+Q)K'C'Q+JMK#;R:IK/DQM%;(6=
M(8H8$2.-=SLQPN6)R2<"N&_:G\?^$- MM!M=4\9Z5X6\3:-J%MXAT^/7+:::
MSF*F2(+,(QPK;I "#E7"L < &?\ 9O\ C3X@\?2VVB^)(]+GO)O#>F^);>ZT
MBW>U\J"Z#[;>XMVDD,4B[."'(=3D 8-=U\8O &J^/-'T9M"O[2QUK1-5@UFR
M&I0M-9SR1AU\N9%(;:1(Q# Y5@C ';B@#S+]G+QE9_%3XF^+/%UQXI\-ZKXC
MBTVUTJ72O"\=SY-I;K)+*CS2SHC22,TC8&U0J@XSN)K5^(7CKPGX!^/MM=BR
M\;7GBZ70XVN['PUI$U]:WMDLLRQ&941OFBD>0@J5(\P!LA@*Z3X;> _%\'C[
M6O&_C:ZT6/5KVP@TJ#3O#JRFWC@BDDDWR2R@-+(6D('RJ% (&=Q->??'OXS7
MGP_^(^JR0:?X>CN?#WAF.^TZYUB)OM,\EW=&"5XG##;;VZQ++.%!8AE^[@&@
M#9^ _ACP6/B9XN\5>%_"_C#PG=ZG:Q1W=CKFDSZ?89\V20O;I*H"NSNS.$."
M3NP"Q)QOVAH[?Q'\7- \.?\ "JKKQ3K3:3+>V'B"S\2MH4VQ90L]M'/&RR,5
MS$Y3=C$F0#AB.L^#GQ$\3:E\1?$?@SQ!XAT'QJMAIMIJL6N^'K0VJ1>>\J_9
MYH_.E ;$8="'R5;D<9.W\5O%.LV<<EKIOA_QE-]@N;"[%[X:2Q8W:F1VD@'V
MB0#9B(+)PIQ,NT]< &1^SUX0N?"#ZW'+\,O^$%^U&.66_N/$']L76HN,@"69
MBTAV#IO8XW8'>H_VK=4L[+P#H]IJ$/AI+'5-<M=/FU3Q;9Q7EAI:N'_TAHI"
M%9LJ(UR0 TH). :VOAAXNU+QYXMUG6+C1/&/AS3S9V\$.GZ\MB++>KR%I(#!
M+(YD.X!MS;<*N!G-1_M%_P!A?\*_C_X2#Q7X?\'6!O8\:CXEL+>\M2^UL)LG
M(3<>2#G/!QUH \V_9Z\7^&_ ?Q%\0?#^U\2^!M8L6MK6^M]2\.V=GI;O<RO)
M&;26.!O+EDPBLI4!L/AA]TGH?C9\#(/'?C6+7I8O &M7(LQ#'I7C?P[%=,8H
M\L_E7*NLB*"^3E9%4L>!FN&_9HM/#'B'XK^);2ROO!?Q%TC2;&QOK'Q%X>\,
MV=I%9W3R2AH3-$&!E CC<;6R PR!P3H?M2?!_P 4^(_$&N:OX>TC2/%,WB#1
M+318K'4;];6XMC;W3W$D<6\;7@N581S*&5L(#\PX !T?[/":1I.K3IH'PJ\)
M:!:7@,-SXF\ :A97>G2-&"P24JL4P.2<#RV )Y(ZU]"5\]?LY^&Y[[QKXF\:
MQ:%X;\%6%W86FCGP[X:U&&]7S[=Y6>:X>!5B60"41JJ@G:OS'HH^A: "BBB@
M KSGXG?\C[\(?^QEN?\ TS:E7HU><_$[_D??A#_V,MS_ .F;4J /1J\(_:L^
MRV.A>'=9UV*VU+P=I]\YU?1;K6(M,6]#Q,L1\R62..38V3Y+N V<]4 /N]?-
MO[3FJZMX/\5>%?&%WXA\*Z/H^B33R6<&KZ9>WT\S/;LLS>7 21L7YA(J_( V
M3AC0!V?[,5H\'PXFO()H$T'4=0FO-&T^VU1=373[-@H6#[0K,K'>LC[59E3S
M-BDA16-^V%:11?#/2]=F\1^'?#K>'-<M-8B?Q8[KIMS+'O6.*79EB=SAUV@G
M?&AQQ5W]EF>'4?!WB+55U.RU*ZU+Q!=7-W_9VFW.G6\$VR)&B6WN%#H0$!;.
M<L6;.2:;^T^^A6NE_#^\\0:HVBPVOC'3Y;>_D@CEM8I2)%VW(=U"QNC/'OR2
MKNC <4 >1?L+Z-X)MO%GB"Y\&^-O#?BDP>'],L=1?0$=9KZ\WSS7%_=[E +O
M+,ZIU.Q1D] /LJOG#]EWX4#P#XAU>Y7XA:+XQM;72;30M.M=%C1'AL8)9G@:
MZ*R/YDP67RPP"C:G3GCZ/H **** .2^*R7$WPQ\6QVND_P!O7+Z3=+'I99Q]
MK8Q-B+*$-\W3Y2#SP0:\6_9$U.YO9=<@2SG>PMXV@;47AU&WC>2.\NHXU2.\
MFDP&@2&3"?=W88G*@>T_%9/-^&7BR/\ MD>'-VE70_MAF*BR_=-^^)!!&S[V
M00>..:\,_9#AO(]8\1)>3)IK0P8AT)?[14BWEO;NXBN-M[;P-M"S>4K(K9\L
M[FZ  &#\8]6\0Z?^T4UG:>+8K.'4%@M8ICK]Q;Q:5O>S,*2VRJ8MY>"X==Q!
MF%R$.%%>N_M">$K'5K#0]6O-"FU>&TU"*._EM8KFXGM[$DM*T<$#AI&)5%R
MQ4.S;3MQ6#K/P3M[FX\6W&H?%S68]+O]0@N-=L9(],2 R(D(2.5OLP9 T2VZ
MD!@2NTYR23Z/\6O$&J^&_"@OM$N)(M3^T(L,4>BS:I]H)!_=&*%E90V/]9N
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MI;VUM",)%&H"JBCL   !Z"M&@#S+]H[QYJ'PT^"?BOQ'I5Y!IVH6=N@AOKI
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M\/V?BZ.>ZU26?4]0\<V<UMJ>HW92/=.XE52R[?+12JA0$P!P:]IHHH ****
M"BBB@ HHHH \ N/VO-&@OO$,K>%==_L#1[>:[_MI1!LNK>"]6TNIXX_,W^7$
MY9B6 ++&Q56XS[Z"& (.0>XKX5\?>'?!GPV^*X;XG:;XAT#2-8OI8+.P\/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\0^+_P#R<;\ _P#K[UO_ --KU[?0 5XC;_\ )ZM]_P!D_@_].,M>W5XC;_\
M)ZM]_P!D_@_].,M 'MU%%% !1110 5XA\7?^3D/@%_U\ZY_Z;FKV^O$/B[_R
M<A\ O^OG7/\ TW-0![?1110!X?:_\GL:E_V3^V_].,U>X5X?:_\ )[&I?]D_
MMO\ TXS5[A0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7
M*_%?_DEWC'_L#7G_ *(>NJKE?BO_ ,DN\8_]@:\_]$/0!A_LW?\ )O'PP_[%
MC3/_ $ECKT:O.?V;O^3>/AA_V+&F?^DL=>C4 %%%% !1110 4444 %>(?'#_
M )+9^S__ -C%J'_IIO*]OKQ#XX?\EL_9_P#^QBU#_P!--Y0![?1110 4444
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M=$U7PQ>M!;6.H+),UP]V@.)"4^SA!*K1D!QC)KK_ (4^)+37+K48[7X9ZWX
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M8Z5]B>*HM:G\/WB>'I-/AUID MGU6)Y;8-D9\Q$96(QG@,.<5\G?%;X6^(_
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MH)K/3S%"N/);YH4:=;B18V *K(O &  #VVBBB@ HHHH **** "BBB@ HHHH
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M:?#(_$3/A*.]\1ZB^@1:M%XIU?5KC4Y_)FGEA:!&N'=X2&@.]!MYX(R#6/\
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M$D6UOED9D:56BQDHY.1U'3_!_P 7:C\1O$NL>)9]%U[0["6U@M88+K6]/O\
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MKG4;#P]9:MXNM3+::>EQ<;!),5^;RU9SP".7'- '&_L5_# >&_C!XT\3Z?\
M#?0/A5H5[H]I8)H>G>((-6N9ITFD=[C="S"-"K(I7/)0''6O8[?_ )/5OO\
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MY+9^S_\ ]C%J'_IIO*]OKQ#XX?\ );/V?_\ L8M0_P#33>4 >WT444 %%%%
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MEF')QZGTRW_Y/5OO^R?P?^G&6O;0 !@<"O$K?_D]6^_[)_!_Z<9: .Q^-_Q
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M "6S]G__ +&+4/\ TTWE>WUXA\</^2V?L_\ _8Q:A_Z:;R@#V^BBB@ HHHH
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MN<D ]CTKX=0V'Q,USQK/J5U?ZAJ-E;Z=!;RA%ALK:(L^Q H!8M([.6<D] ,
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M^RCXN^('Q1\(2^._&?B#1KJTU62>VL=#T&Q,=K9?9[J>%Y!<.[//YGE@@G:
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MI7C/PIXT^(-_XMUSXL?"[P9XRM=9NK%=.FT+3YM1M%AN7BB4W4LOF.[(JMO
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MR6S]G_\ [&+4/_33>5[?7B'QP_Y+9^S_ /\ 8Q:A_P"FF\H ]OHHHH ****
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M0 : .2_9BTQ?!GQ:\9>$I=*\'6E[#I%EJ N?"5U=W"R1R2SILF\^1MC QD@
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MX4\,:&EQ&=/N/$=DNIZ6^IG3VU.T^<20+(""2,B;RP?G$!7O0!L_"'X(Z?\
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MR2?M2@ HHHH **** /$/B_\ \G&_ /\ Z^];_P#3:]>WUXA\7_\ DXWX!_\
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MT"#2/ GB>]LK3PQHNGZQX@GU&V\/^$[V"]M=(1H85\AIH0$:0E#(P7A?- '
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MXJ?%SQ-XGE\.:1\2VT>?29H-!FUK[/<):_9YX[JQ*L0D.[S([I7)&Y@!_"*
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M?&VEZ#+%X\US2?$&L-<L\=SHNG/8PK#M7:A1Y9"6W!SNW#@@8XY[*@ HHHH
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MROQ7_P"27>,?^P->?^B'H P_V;O^3>/AA_V+&F?^DL=>C5YS^S=_R;Q\,/\
ML6-,_P#26.O1J "BBB@ HHHH **** "O$/CA_P EL_9__P"QBU#_ ---Y7M]
M>(?'#_DMG[/_ /V,6H?^FF\H ]OHHHH **** "OGW]J7XQ1^"XM#\.VOB#6/
M#M[?7]L^I7VBZ+-?7-OIS&17>$^1+$'WJ@.065"S 9Q7T%7B/[1%GXODU?P!
M+X<^(</@>VEUM+26.72FNUNY7BFV*S*Z@+QC:^%+;>=VT$ ;^SYK^@ZQJ6L+
MHWQ$\8^-W2&,R0^*-/-LEN"QPT9^QP9)Z'EN@X%<?^UMK>B:/XH\#C7OBEKG
M@<37T;Z=:Z3I=K<B&YC69OM3/+ [@%28BH."&QM(+&O6?AWX!\6Z!K^HZQXL
M\?3^+KBXM8[2"S@L$L+.W569BXB5WW2,6P7)^ZH&*/C9I?C&]TC0+SP/9V&I
M:QI>L07KV.IW(MH;B )(DB>;Y4A0X?(*@'('.,@@'&?L^^/1XH\4Z[86OQ"\
M0_$BSMK*"<ZAJ&BV]E9V\C.X\I)(X(B\N%W%3D!2IXS5?]J7XR1^"XM#\.6O
MB'5_#E[?WUN^I7VC:++?7,&FL9%=XCY$L0?>J Y!94+,!G%=7\)OB_JWCOQ3
MKV@:UIWAG2]3TF*.26UT3Q,-6FC+,PQ,@@C\K[O&22>>.*\?_:;\;16/Q/UC
M2M;\7>,/"EE8>%8;[P^/"\=XJ3ZE)-=J[2M;QL)-@AMP(Y/DQ(V0=U 'HO[.
M^L^']1O=7AT+XA>+O&8BBC+VWB33?LD5L"QPT?\ H<&2>0>6Z#@5O?'[P7K_
M (O\.:%<>&7T6/6M!UJWUF'_ (2&61+$B)75A)Y:L3\KG'3:VULY49X7]D?Q
MDGCO3IM9U;QOX@\6>-+K3K675+._TR?3;'32028;>!HT3(8L"^7=MHRV,"MG
MX]_LW3_&#Q%I>OP>(\2:=;^2/#/B"V.H>'[LARXDFM \9,G./,W'  ^7B@#@
M/A%XG\:>._C]KGB*PU/X:ZZ8K&STK5!X;U*]F2VMDFD<_O?LWES3Y=\*7&T8
MX&XD^V?';3['4O! BU'POXA\6VJW2/\ 8/#-^;.Z4@-^\,@N(/D'((W]QP>W
M-_LP^%/&'PR\&GP-XG\-:;IL&E27$UGJVAWBR6-VLUS+-L2$JDD)02!=I4C
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M?+C.>*\4_91T#4O#^LZ]:W?AX>'X%A90;[2;#3KZZQ?77DR%+5$+)]G:!22
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M=^G:A: :Y%#+>2/-;)*MSY>&=GV2F,L$=3@GFOO(#  '04 .HHHH \0^+_\
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M-7M/"_B?PIXE\/V5E!(LFC:J+J]2=GD#B6-<JL>U4VMNR3NXXK"_:BM[._\
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M[+XY:O\ "73-0LC\0M$@U6^6!IHYUT66^FM8 X3<TD4;-$C2.J#) 9C@9P<
M&Q\#M.O](T76[>^A;3$FU6:\L]"N+Q;FXTNUD"E8I65F +.)9 H9E42!0<+7
MIM>?_!R3P>_AFXB\&Z"GAFTM[MX+O2_[.^PS07 "DB6+ .XJR-DYRK*<\UZ!
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %?G9X?\"_%70?'NF0_"_1
MO!7Q)\/>'=2\2&VUR/Q%%$5;4Y 674(0K/YD#JRMMR7  ^7%?HD3BO@7XB_L
M_>+?CEX[U'5/A_\ !ZQ^">I17DB_\+$O=8ET_4+DJY#2QV=BPW[B-P,YPP(S
M0!]<? 'X92?!GX,>#_!4]XNH7.BZ?':S74:E4DDZN5!Y"[B<#TQ7DW[3_B?Q
M?#\6_AIX5\,>+](^&<>M6NI23>,=1TR"]F#0B%ELH1,0BF0,7.3R(^.F#[M\
M.O#NK>$_ ^AZ-KVO2^*=8L;2."[UJ:$1/>R*,&5D!(4GTR:^:/VZ?[%UG4?#
MF@I\,?#?Q%\71Z3JFM03>*Y'2STVQMEB:X;Y/F=W9HE5%QR,D@"@#U+X%>&_
M&VBZSJ;^*?C?;?%6V>W58;&#1K*R-J^[F0M Q+9'&#Q7M=?(G[)47@SPS\2I
M-%T3X8:#X&U'6_!>E^)[;4=#+8O+:8*)HI%/*&.?.WDY4@]<U]=T %%%% !1
M110 4444 ?#6L>%]-\9K<:?X0T[XE77AIKO5]&N[^PT:RDM;RRN+X2W-O#)-
M-&X2.>.4)-M) 9\;N#7V;XF\,Z9XPT"[T75[47FF7:".>!G9=ZY!QE2#U Z&
MOC[P?H&I:)J6K0:WHOQNCU&3Q!J%R?\ A';H6VDM')>2/&\,*3*$C*,I8;<E
MBY).<G[9H _-CQ#<:;I>H:GJ^E_#SP+9Z!8)?WT,-_JVHR7YAL=0%I<(5$BI
M]H&4D$7?>JY)YK])0=P!'0^M?%GB[XH>'M4\&:T=8?PC=_%[2_%ES=:/X-OM
M&AEO5E2Z\N*".$_O7:>*-'-TO_/0,#M08^TQD@9&#Z4 .HHHH \0^+__ "<;
M\ _^OO6__3:]>WUXA\7_ /DXWX!_]?>M_P#IM>O;Z "O$;?_ )/5OO\ LG\'
M_IQEKVZO$;?_ )/5OO\ LG\'_IQEH ]NHHHH **** "O$/B[_P G(? +_KYU
MS_TW-7M]>(?%W_DY#X!?]?.N?^FYJ /;Z*** /#[7_D]C4O^R?VW_IQFKW"O
M#[7_ )/8U+_LG]M_Z<9J]PH **8LBL2 P)'8&GT >3^*/CZOAC7[[2C\//B!
MJIM9/+^VZ7H#3VTO'WHW#C</>F_ +Q!K_BMO'NL:SI>OZ-97GB(OI%CXB@:"
M>*T%E:+\L9)VH9EG( XR6/>O'_%'B'XF^'=2UW2M/\ ^-]74>/H=;AU/3)[7
M[//I:RPL\*%[E6P55QL*A3GWKU_X S>(M3E^(.M>(-#U?PXFK^(_M6G:=K3Q
MFXCMA8V<72.2154R12D -ZGO0!ZW1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !7*_%?_DEWC'_ + UY_Z(>NJKE?BO_P DN\8_]@:\_P#1#T 8?[-W_)O'
MPP_[%C3/_26.O1J\Y_9N_P"3>/AA_P!BQIG_ *2QUZ-0 4444 %%%% !1110
M 5XA\</^2V?L_P#_ &,6H?\ IIO*]OKQ#XX?\EL_9_\ ^QBU#_TTWE 'M]%%
M% !1110 5X+^U-IM_%:>$M<MO'_B/PE'I^K1K'I?AS3;>^N=5N'CD2.**.2)
MR9/F/WCY84,S#Y0R^]5Q_P 1_AW;_$;1K6V?4+S1]0L+N/4-.U73RGGV=R@8
M+(H=61AM=U*LI#*[ ]: /+/V<];TOQ-XDNM8D\:^+?%6NZCX?L;V"+Q-:6UH
ML-A*\K(8DM8HXF;S ZNWS,"JC.,9ZK]HZ37(O!.G/I4NM6NGC5;?^V[GPY"T
MNIPZ?A_-:W559]V[RPQC!<(7*\@5!\"/V>[;X*P(\_B75/%FIPZ?!H]O>:DD
M,0MK.)F9(8XXD4#+.69FRS''. !7K^1G'>@#YA_8^\5>+O%L5M<ZE-XGN-%A
M\,:=;WDGB>UF@;^UD:02^3YZK(^8_+,C<J6VX).ZO3O'GPEU?6/&,?C'P;XL
M?P?XG:R33;MYK!+^SOK9'>2-982R'<C22%71U.'8'((QT&I>-M3LO&ECI%OX
M2U/5=&N4 D\0V-Q:M;VDVY@8Y8VE648 4[E1A\WL:^>OVF?%"6_Q/UC3=<U_
MQSH-C9>%8+SPZ?"4&H>7)J<DUV)'E:TC979!#; )+E,.?E.XT >V?#7X4WWA
M+Q#K'BCQ+XDF\7>,-5@ALYK]K5+2WM[:(NR06\"D[$W2.Q+,S,3RW  [^:QM
MYKF"XDMXI)X-WE2L@+Q[AAMIZC(ZXZU\^_LD>)H_&.G3ZSJ_BKQ7XE\;W>G6
MDFK0ZYI-SIEE8,5),%K \,<0"N6!92[M@$L1BK7[55EKFD6FA^)+#Q[XK\(:
M.NH6UEK$NAK!+!969,A>Z:-K>1RQ8QQEL[4#!B,*<@'L-KK^BW'C?4-&B'_%
M16MC!<7#&T=3]G=Y!&/.*[6&Y)/E#$CJ0,\^5_M&6X\-V%GKTEWXSDL-1U.Q
ML=0C\+7=Z9K*W59_W\,-LC-DM(OF< %57NH#8_[.?B*37/B9XKBT/XC:[\3_
M  1'IUK)#JVI&%X+:\,D@D@BEBAC64[%1CC.S.#R1B]^U%XSU6T@T/P[I6F^
M.Y89]0MKC5[KP7I=Q),UAF17BCN8QB-]XC9@&#; P'+#(!K_  #O/#%Q?ZS_
M ,(]KWQ UEQ%&95\:0ZHD<8RV##]LB0$GG.S)X&:J_&"YU_XG^,KWX5Z'9>&
M_P"SX](AU76[_P 4:>^HPB.::6.WBBM5DCWN6MI6+EQLVK@$D8G_ &?XM#BU
M#6!I%O\ $N%S%'YA\?/J31D9;'D_:V(W>NWG&,UM^//V?/"_Q!\7GQ+?WGB'
M3=8DLHM/>;0_$%YIPEAC>1T5U@D0-M::0@G)^:@#COV:_#D'PE\2>)OAG)X9
M\,Z+J%E:6FKQZGX6LWM(-3MI6EB0R1.[NDD;0.I!D<892",D5D_&CX>>(-:^
M+NMZQ_PJFR^)NAZAX7MM(M?MU_:1"RE$UVUP%2?.-ZRV^64<^6.>!7I7PL^#
M?A#X?ZWJNMZ!J.K:OJ=U"FGW-WJVO7.J.B1LSB(&:1]F&=B0,=:G^-7Q'NOA
MKI/A^XMFL+5=5URTTJ;4M5)%I812%BTDF"O79Y:98#S)4R<<$ Q_V<;GQ[9>
M M#\.>.?",NA7FB:39V3:G+J\-[_ &A-'$$D?"$LN2N[+==WUKH?'7QV^'7P
MOU./3/%_C?0O#5_)"MPEMJE_'!(T98J' 8@X)5AGU!K/\)?%*7Q%\9_%?A."
MYTS5M'T_3+/4(+W39"[VKRM(CV]P0Q7>3'YB8P=K$$< G*_:?M8(? >F:]+K
M.CZ/+X?UBUU.!/$&\V-[(I9%MY @+DL9,IL5F$B1D*V,4 :OPY^,NA_%/QIK
MD7A;QEX3\4:!96=NPAT:\\^^@G9I-YFVL5$94)MP,Y#9[5YG^UK\:/#'@S4?
M#WAWQ!IGC/3]1\^+5-%\5Z%96WV2SO!YD:J9[F18=Y5F5HWX99<=^-7]GK6)
MOB#X\U[QU?:IX9BOM1T33HX]$\,S33!;5C++#=7$DT43.S[V5?W:A50C)/2W
M^T-\4_B#X:U&W\->#?A1>>-;2_M@]WK<ZQS6%J"S QFWWJ\[X7.W<BX9?FZT
M 8?[(?@8>&;226[M/&LUW:Z3::79:GXJMK&WA^PQEVCAMDM97!^9B[,V2V5Y
MP !]+5\V?LC?#\^![CQ1*VE>+]'N-0,4TUIJ]A;:9H\39;(L+*":18>OS9))
M^7+&OI.@ HHHH *\Y^)W_(^_"'_L9;G_ -,VI5Z-7G/Q._Y'WX0_]C+<_P#I
MFU*@#T:O*_B=_P +H_X2"'_A7G_"!_V)Y"^9_P )/]M^T^?N;=CR?EV;=F,\
MYS[5ZI7A'Q7/QOO/BWI.E^!=6T'0O!MUI+RR:EJ6BOJ#0WL<GS1R;9XMBO&Z
ME3@\HX.,C(!+\(/A[\2[3XM^)?'7Q&N?"C7.H:)9:-:VWA;[3L18)[F4N_GC
M.2;DC@_P]*]FU"YBLK&XN+A7>WBB:218XFE8J 20$4$L<=@"3T K@_A/HWQ*
MTN747\>^,- \4V\BHMFNAZ*]@86!;>7+3R[L_* !C&#7<:V+0Z1??VA<?9+#
MR)/M%Q]H,'E1[3N;S 04P,G<"",9R,4 ?-?@3Q3^S!=_$&U71]/\+Z)XK2_N
M$M(;^P6RECN(60,T<<@7RV)D&WA6)S@9!KZ$\>>%H_'/@?Q#X;EG:TBUC3KC
M3WG1=S1B6-D+ 'J1NSBOCG3-*\+1?%SPVGP[\8^./&MU<W6I7\<-O!!>::\4
MLEJ9W^WWRE)%3:FXQO)(=RXVD<_:FN63:GHE_9@6Y-Q;R1#[5&9(<LI'SJ"I
M9>>0",C/(H X:_\ @OX5UG6;;7--EFT7Q/9E()-;T&X%O<3B/ ,5R%RDZ^J2
MJV,\8/->EU\ _!GX7:[<_%2UU;PE=Z#X@TC3=5U1KVY\'>.;A(K99GMS&K6Q
M,R(&$;X3.7"G<1M4U]_4 <_XY\3VG@KP9KOB&_ADN;'2K&>]GAA4,[I&A=E
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MTWQ'H_AB\L?$/F[+?4)HM--RT+3FS&T(9#%\IRWF%?XMA3?\VZO0J "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@#SCXZ:9X5N/ AUCQFNI/HWAR\M]<Q
MI9G\X2P.&C(2'YY!D\I@@^G%?G[H?CG]EKXAZ=J/B+6?#OQ(LM;N[Z]=['3K
MO7;B-V$\@4JZ;44N #LP-A;:?NU^I-?(?P?^*-[XA^#OQ9U.X^(/AWP!J5OK
M6JV]A81V5K"OA?R)Y%'GQ''FO(5\YRX^8R\4 >Y?LZ.S_ SP0[>'KWPGOTN)
MUT34KJ2ZN;-2,K')+( [, 1DL,\\UXK^W*_@34I_"&AZQIWCS4?'EY'??V+_
M ,*WBWZK':E%2\W9^0P,K(K*X(/&.A->T?LW?$+5OBO\"/ OB_7;5+/5]8TJ
M&ZNDC0HA<CEU4\A7QO [!A7A/[8VHZA8_';X/+I_Q"T;X02O9ZL/^$TU*.&=
M_NP?Z%Y<SK&4D^_E_P"*)<$'A@";]A_PQHOAG4];C@\%?%;3M;&G6UJWB+XG
M6RJ\EI"=L-G;E6VHB9)V*H]23@8^O*^?OV<;O6[K7=775/VB-$^,\0MUVZ?I
M5AI]N]DV[_6L;9V8@_=PW%?0- !1110 4444 %1R2)"NYV"KP,L<#TJ2L;Q5
MH6B^)-#GL/$%I:WVDNT<DL-X 8B4=70G/'#JI'N!0!\?:[\*M5N9->LI/AMK
M5Y\79]8N+C3?B7%>0"VA1KEGMIQ.9Q)'%%$45K81X/EE0K!LG["\2:)<:]H\
MUC;ZM>Z--(T;"]L-@F3:ZL0-ZLN&"E3QT8XP>:^&]>\.>'KS2_$7Q2;PC\(V
MM[/6[N,^$[C0%;5;LQW;Q8-WYPVW4I7>JB$C+J,D'=7VOX]\43>#O"=YK$,-
MG,;8Q%TU"_2RA5&D579YG!5=JL6YZD =Z /F"*Y\6^-/$]]KOA:7XPZOHG]I
M7-I!J5M<^'+:V=8IVCD6)9U6?R5='4%ADA<\]:^Q*^"X]4T_2_%>H+H>J?9]
M/NM6FNU6R^-B002-+,79UMP,+O+%B@[L>IYK[TH **** /$/B_\ \G&_ /\
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M2,&@#VZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MOX"^*_B7XRU.]T?P_I^OR:AH,6F:+K%[JK6<GA2\269GO(@JEB7$D1S'\Q,
M4_*:VOV.- FO_"5QX\EMO".E#7&FMH]*\&Z%#96D"V]S-%N\\9DN-VS(+%5
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M/AO%K,FDV^@'PSH4%]<WTEO',&63R(59QL#D!F4(H<DD#-?8E?''A?X:Z/\
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MM,$;7$QR!M3S'1<\YY8< T ?'^I^/]#TKP;XDTYDT"W^,T7B"?\ LOP@OAJ
MSM&EULM[5(O+WR02Q(KM<@\>:SAU"@#[7&2!G@UX]#\?-8GN(U_X4U\0(BS!
M?,>'3<*">IQ>YQ7L= !1110!XA\7_P#DXWX!_P#7WK?_ *;7KV^O$/B__P G
M&_ /_K[UO_TVO7M] !7B-O\ \GJWW_9/X/\ TXRU[=7B-O\ \GJWW_9/X/\
MTXRT >W4444 %%%% !7B'Q=_Y.0^ 7_7SKG_ *;FKV^O$/B[_P G(? +_KYU
MS_TW-0![?1110!X?:_\ )[&I?]D_MO\ TXS5Z5\1;'PKJ?@S5+7QM'I<OA:2
M,"_76C&+,IN!'F&3Y<;@O7OBO-;7_D]C4O\ LG]M_P"G&:N@_:3\8?\ "!?!
MK7-=8V0AM9K+SVU&)98%A>[A25G5N,!&8Y/3&>U '@/Q4TG]E[P9\/M=UWPE
MHWPFU'Q+90":PM8FLIGEE##: B/N8^@'-?9U?#_C;]I[X76L?Q3B\-ZS\/);
MS2K:R?PPULEI))=S21YE"#D2E7 & .,U]P4 ?-_[36M>1\0_ .E:IX]B^&WA
MBZM;^:?6;NQL)H)KE#;B&W$EY"Z1.5>5P<C(C88)P1S?[/WQ(\;ZA\1=+L;G
MQY<_$3PQJEUJMM!=S:9:V\3VMJD317\#V\2#RS)(;<ABP9AN0@<5ZUXR^">M
M^+M5O[D?%;Q9I>G74F]=)M[;2Y+:$<?*OFV;L1D9^9B?>NO\ >#[WP7H1T^^
M\4:IXLE\TNE[JT=LDJ(54"-1!%$FT;<CY<\GGI@ ZNBBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "N5^*__ "2[QC_V!KS_ -$/755ROQ7_ .27>,?^P->?
M^B'H P_V;O\ DWCX8?\ 8L:9_P"DL=>C5YS^S=_R;Q\,/^Q8TS_TECKT:@ H
MHHH **** "BBB@ KQ#XX?\EL_9__ .QBU#_TTWE>WUXA\</^2V?L_P#_ &,6
MH?\ IIO* /;Z*** "BBB@ KQ/]I"+2="T#3M:O?"NDZM8W6KV-OK]]>:#_:C
MPV"&1@QB52[X9O+4X/E_:&;'!KVRO&OVG[N;2? VD:O:^+H?!U]I>M6UW;7=
MQI]QJ"W#X=?L_P!E@=9)MX=AM&> 2!E00 <!^R=%J]CXTUM+[PQH^AQ:GHMI
MK,EOIGAJ/2VTEYI93%822(H\]A"(W.XEE;=G&X >I?M#^+[GP;\/Q<6FI6&F
M37EW'8AKW1;C6&F#AOW<-G RM-(<9 )V@!B>!7)_LU_&^]^+&I:Q!=>+]*\3
M+;6MO=Q)IWA+4M%*1REMDA:[=A*KA?EV>A.2*Z;]H34-&TK0?#%[J-OK=[JM
MOXAM)-#M?#HC-[<7P#XB7S2(]K0^>KER $+\@X- 'E_[&B?#F/5/$TW@S4?$
ME]J^IVMKJ=\=5T5]&L7AD+^3+:VBPQ0JKX?YU5F;'S,:^IB 00>0>U?.?[,7
M@"]\,^)=9O+[0/&FC06]A'IND0^*&TTPVEEY\DHMH3:2NS[6?[TO.T( >#GH
MOVA;C6/#::?K&G^.?&&D-=RQ:79>'?"FG:9=2W]TWF/E?M<#8;8K$DR*H6(G
MKG(!UGA;0?AYX<^)/B"V\/:=H^E^,I[."[U:+3X%AFE@9W$4DH4 -EED 8\\
M5R_Q=_9H^'_QD\<:7XE\3SZJNMZ/ L5F;+6I[1;8%G82+&C@*Y);Y\9.T#/R
M\<I^RK\4;_Q_J^IKJ&J^.K_SM)L]5LQXQL=(MEDMIFD"2P&Q4,V2K!@_W>!@
M$\ZW[46B>%K'1-.U/6/#?A:X@UC6=.TW6-;\2::ES;6=HC2E)9LD?=+M&C,0
MJ-<9/&: /0?AS\-],\"3WLEAXB\1:XURBJR:YK]QJ2Q@$X*+*[!"<\D=<"NT
MN;:*\MY(+B%)X)%*O%(H96!Z@@\$5\__  '3P'I/QF\:Z3\.-%\(#PZNF65R
MVJ^$K**/R)F:16M)YHB4E;Y?-4#!4.01]TG>_:!UGQ%X.AM-:L/'U[X>L9GC
MT^WT;3/#4>K75[=L78",$[B2H/'  C))ZT =+X#\!_#GP#XVU^T\(66E:'K]
MS!%=:GI.ES>4!&S/Y<S6JML0LRR#>$!;!R37EOQX\3:;\._BH-<T;Q[<>$?$
MUUI$$>LQ/X9GUS3Q8QS2_9[B[$)0VP5Y)U$AD4$%L@A,B;]EKXI3?$?Q!K,E
MYKNM:S<R:597\$FL^%8=&:2TE:7R9(W1B9D)#X[*<]R:]:E^&Z+\43XTM-4N
MK1[O3DTS5-,$<;V]_'&TC0,VY=R-&9I>5(W!\$' P <3\)]+BM/BCJUYKWC(
M>-O&]]H-I<+=6.GK9Z=!IAFF\I;=5=\[I!(Q9I')PN"!@5D_M3>)KVV@T+1/
M^$ UOQ'%>ZA;?V3JV@ZU;6-W;ZGF0H(?,8,&5$=F8C9L+ALC<*Z_X>?L^Z%\
M+OB/KWB?0;J[M[/5+&*SCT)F!M+ +-+,WV<=8T9Y6/ECY5).T ' G^/OA2Y\
M7>"8;?3_  _=Z]J=O?PW=H=/U==+NK*5-VVXBG8$!ER5VX(8.P(()! /*_V3
M/#\'@+Q5KWA*_P#"OB;0_$%AI%EY-WXIUFVU&673@\JQ16YMP$2-'$F0 "6;
M+9^4U[+XT^(^J>$IKY;;P'XA\116RVY273'M L_FF0,$\Z>/_5^6N[=C_6IC
M/./*?V<H[W2?BCXNTOQ3HFN6OC/^R[.Z?5?$/B"'5)KFR:298XX?)CCCBC61
M9,A5!+,"<\&NV_:"\/S^+]-\.Z=IITG4]8T_58=<3PQJMX($UB&WSOCZ,?D:
M2.0,5*AXX]V <T =#\//B-J?CJXU&&^\">(/!YM A#:VUF1,6S\J^1/*00,$
M[@.&&,UPGQ?^ WB/QWXHUVZT#Q'8Z-I'BW1H/#_B.*ZLWFN?LL4DS;K219%"
M.R7,T9W!@,JP&00:7[/^KM\2?B7XR^(41T#3H+JSM='GTK0M:AU222>!I"9[
MIX?D60*XC51N.Q>3C:!W'QR\0^)?#&@:'J7AZUU.ZMH-8MWUB/1;);R]:Q4.
MSK#$0=Q9Q$C8&X([D8(R !WA;X9WVD_%G7O%UY<64=@VDVFA:/IUA$RF&TA9
MY&:9C]YS)(0H4 *JCJ6./2:\ _9XN_B9)XGU,>-[C5KBVO=(L]4N(=3M8HH=
M,U">25FLK5T1?,2.'R5;)?:Z_>)8@>_T %%%% !7G/Q._P"1]^$/_8RW/_IF
MU*O1J\Y^)W_(^_"'_L9;G_TS:E0!Z-7A/Q7_ &:!\5OBWI7B>^\4>(;30(]*
M?3[S1M+UV]T]?-63?#<1_9Y%!;YI$<-G(V8QMY]VHH \Y^%GP/T#X0SZC/HM
M_P"(;U[Y425=<UV[U)5"$D;!/(X0_,<E<9XSTKK/%_ABR\:^%-9\/:B'.GZM
M936%R(VVMY<J%&P>QPQYK:HH \)OOA3\2O%N@6?@SQ1XE\.S>$8F@6\OM/TZ
M6/4=0AB=66,JTABA+[ '==W5MJKD$>N^,/#%EXU\)ZSX?U(.=/U:RFL+D1MM
M;RY4*-@]CACS6S10!X3??"KXE^+= L_!OB?Q+X=F\)1- MY?6&G2QZCJ$,+J
MRQE6D,4)?8H=UW=6VJN01[M110!QWQ?M&U#X4>,K9)K*W:71[M!+J<GEVJ9A
M;F9OX8_[Q[#->8?LPZII%_=:]!IV@6/AZ>&&W,D%OK=_>2NA+[&\J[@B*1G#
M;73(;!YXKK?VD-1U73_A/KOV#PTOBNQGLKJ#4K 7R6DGV=K:4;DD=E4'S/+!
MY!"EB,D 52^#'AO6[77]7UCQ+9>*O[6>UALX;[Q-<Z9(?LZL["*-;$A00S%F
M9URV1SQ@ 'E?Q9&OP?'^_%MX'@U%M0MX+>SG7PS]JBOA'+82QFYO0N(_G6Y0
MAV4(L$;88[:]T^,?B?Q+X4\/:?=>%M/CU;4I+](VL"\2RW*>7(WEQ>8Z*6+*
MF><A/,8 E:\+^+.KV<7Q5\7^'SJJPZ3J<UCJ6L:D^BRSSZ<]K]B BMYUF4 H
MLT$^?+(B\Z1\L3MKT3]J?P]IVJ>&?#M[>:!9:O-::O&B7E[I%SJJZ<DD;J\W
MV6W97E'W5(R%&[<?NT =9\&-0\5W>A:K;^,;N"_U:PU%[07,*Q(9%$<;$LD9
M(0;V?:#AC&(V89:O1*\S^ &G6&E^ 1!IRZ<L'VN5F.F>'9]#C+'!)-O,S.6]
M7)YX]*],H **** "BBB@ HHHH **** "BBB@ HHHH **** "OSAO?B++\ _%
M/BGPKI?[6G@KPU:#6;R]_L&3PB;S^S9)IFDDAWK(<$.S$KG@D\ <#]'J^%OA
M[=?%OX /K7A&P^!OAG6+2\UV_P!0TZZOO&EE;7MU'/<O(ID5HBTC?-@'@[0H
M/(S0!]:_!S7I/%/PO\,ZM+XCM?%TEY9)*VN65J;6&^)_Y:I$?N ^E?//[>:^
M"M8A\-:)K7PUN?B?XI2UU#5K.PMM6;2EMK"!$-Y)/<*0?*(:-?+PV\X&.,U]
M-^![W5]2\(Z3<Z[HD7AK6);=6NM)AN5N4M9.\8E4 .!Z@"O"/VL_ GAGQ[XE
M\%Z2WCC4O GQ OK;4[/2]0TRT6Z#V#0 WRW4;#9]GVK'EF*X<I@Y- $?[/7B
MGPCK7QEU>:#P7/X8\5Z[X0T36[>\>\^T07&EF%46"W7@0I#+E"@4;B0_<8^F
MJ^+/V!+OP/JVL:S<V7C3Q)XX\8V6BV>FV]_XBTC^RX_[$B9EMVL81\K0,RDF
M3)9F )QGG[3H **** "BBB@ HHK(\3^&M-\8:%>:/K%O]JTV\01SP^8T>\9!
MQN4AAR!T- 'R9\4_ \VOR:Q;^#O /Q>L_%LM^&M-3N?%-U#I7F><"SN#J) M
MR-Q*K&#MX4 XQ]:>)_"^D^,M!O-%URP@U32;Q/+N+.Y7='*N0<,._(!_"OAF
M_P#@);Z=X>UGPK;_  Q\7S?$I]7GDTSQ%!>RG1T3[47MIC*UQY:P)#Y8>%EW
MMM8;68[C]J?$+Q_H_P +O"TOB'7YFM=)@GMX;BY51L@$LR1"20D@+&I<%F)P
MJ@GM0!^?'B-="T74-2U>Q^&GPDTO1[,:C=VME?:?<2Z@RV&H"TF@W"9%-SAD
MD6,+SO5?]JOTM4Y ///K7A6G?';]GSXB06&H3>*/ MW-!?RS6BZI=V8N(KI)
M#&945SN5V* AQR1M.>E>[T %%%% 'B'Q?_Y.-^ ?_7WK?_IM>O;Z\0^+_P#R
M<;\ _P#K[UO_ --KU[?0 5XC;_\ )ZM]_P!D_@_].,M>W5XC;_\ )ZM]_P!D
M_@_].,M 'MU%%% !1110 5XA\7?^3D/@%_U\ZY_Z;FKV^O$/B[_R<A\ O^OG
M7/\ TW-0![?1110!X?:_\GL:E_V3^V_].,U>D>/= UKQ'H?D:!KP\.ZFD@E2
MYEL8[R"3 (\N6)\%D.<_*R-D###D'S>U_P"3V-2_[)_;?^G&:NO^.OQ O/A=
M\*=>\2V$-O-?6J11V_VLD0)++,D*22D<^6C2!VQCY5/(H X^+P=\:[Z1;:[\
M0_#W2[;(#W^F^&[F2Y([E$EN=BMZ$[P#V/2O8M+M)[#3;6VN+V74+B*%(Y+N
M9562=@ "[! %!)Y(4 <\ 5\[_%?7?B_\*5N/%S>*;'5/#/AW1=.DN[*7388T
MUV\:YF2[6/:QD@?RS;^6 64LP!#<U]+T ?+G[;?P_P#%/C;1[(Z1X?U#Q;IL
M>F:A FE:9>)#)#J3^2UK=M&\B"54$<RXR2ID#!3C(]*_9[M]7DT;Q3K6HVMS
MIEAKNOW&IZ7I=W>I=2V=N\<2LK-&[HI>=)Y=BL0GF[>,$#S?]LFRLK:XT'4M
M1\>>'?!=E>:;J/A^1]?N'CDCBNC )[FS"9W3I%&Z#(  F^\.AZK]DRT\,0^%
MO&%UX+U/0KSPQ>>);B6QL_#;,;/3XUA@B$(!5<2-Y?FN ,!YFZ\D@'N]%%%
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M=VT'#_9]UF>#XR>,?#E]'X%NKVTT'2Y8]0\$VTJ 6X:>**VFWS2",1B/*1C
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MB'KJJY7XK_\ )+O&/_8&O/\ T0] &'^S=_R;Q\,/^Q8TS_TECKT:O.?V;O\
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M'KP<=: /,OV>O&_AGP)\1=>^'UKXM\#:U8/:VM];:CX?M+/3'>ZEDDC-I)'
MWERR8164J P#X8?=)^HJ^2OV:8/#GB+XK>)K.QU+PC\1M&TNQLKVR\0Z#X:L
M[2*SNVDE#PF:$$-*!'&XVMD!AD#@GO/V@?AU\3_%^NZ?>>%_$;3>$8;8)?\
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MB@#B?V1/@S\1OAO\0M=UKQ=%>6_]N:+!=ZT]SJYO8[O69;F:9O)3<1&L$+I
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M.I6FDV_GWUU#9P%UC\R>01KN8A57).,DD #N30!=KE?BO_R2[QC_ -@:\_\
M1#UNSZI:6M[;6<]W!#=W6[[/;R2*LDVT9;8I.6P.3CI6%\5_^27>,?\ L#7G
M_HAZ ,/]F[_DWCX8?]BQIG_I+'7HU><_LW?\F\?##_L6-,_])8Z]&H ****
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MU=!%%X#T366UGP]H<^A:]::E;S^)UEDLWD7>@C,<?S2.PD(51R#AARHH ?\
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MB;"B%SM\PJ#@[23ZUX_\7^/] UF*W\*_#V#Q9I[PAWO9=?BL2DFY@4V-&Q.
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MU\4:9;:@FC /:B2!))C,S (L18?*Q;'(Z=>U?/?AWQ=^U5\9M/B\1Z':^&/
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M/J6MZ+\(M9O_  Y'J4FJVTUI*B:1"\MTT8NX3,$1 6;,?F9 !R,U\_\ CO\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MK%Q9:M?Z?;ZQ/:"U?4;>&X>..=HU55!(7!*J%;;N  (H \X^(L?[)I\;:O\
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MTGXQ^ -1F_9_^'W@&#5M1U;1[77]'O99;NWO+1)XYH%4Q@!F\J7!)P4#'.<
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MFW/YLCFYF\T,)-PX&"S'G<:TOC!\<[;X0ZOX6LI_#/B'7CKEX;7S-%TR>Z6
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M8Y70/%+YXW;&W!HER"", '70>--;\0^/I;;PO=^%];\-:;*+'6XC?2IJ=A=
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M#"X)Q^->_P! !1110 4444 %%%<!\<O'EY\,_A7K_B33XK>74+2...V6\)$
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M]F[_ )-X^&'_ &+&F?\ I+'7HU !1110 4444 %%%% !7B'QP_Y+9^S_ /\
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MSBOL^N+\!WG@34)KJ3P>=">=88))_P"R4B618IHUEA+A "%=&5USU!R*[2@
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M^)?Q&UC6?!%KX)OM,UOP5)X2NU\5R3B:U,DTKM- (T8!L.F">ZCCBO2_B_\
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M-4\":#HE]X>T3Q VMZ_::?;#Q(SC3[6=A(T<TNPACRFQ ",O(@R,T =/\.O
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M);V^\@#>KA=Q&<8 '0?IM7YB>)?&/AWP)KWCOPII/[7>M:%I]YJUX][I6A>
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M1D&@#\H3XN^ ^OZ/XNOK7XN:OJ;:U=S:5I'@^#0XY+^WL[C61<W4$!'$AN)
M"DK,&2,KQD8K]7P   . *_.#PE\:I)/%'B*WE_:3\%?")K3Q/J%K'X+T_P +
M64RPHMVX#><QR[R_?9A_$YZ$$#](: "BBB@ HHHH \0^+_\ R<;\ _\ K[UO
M_P!-KUYA^V_XDTKX?7>BW-]%\4[]O%=S9:4R^!M0GAALTCF)WIL4A9W\X@(,
M&4)C(QFO3_B__P G&_ /_K[UO_TVO6-^U'X?M-/T]=9G\4>/K*ZU^]TOP]9Z
M9X3UI+$+<-<-LD0NI6,GS&WL3RJ*,9Q0!QO['I4_$/Q+_9.E?&)/#Z:7%NU'
MXIWTY5[DRG]U;V\HZA!N,@;O@@<$^F6__)ZM]_V3^#_TXRUY%^Q+XPMM8^(/
MBFRCU?XDZE:36)O-%N?&WB./5+?4;".[DMFNHHU13 WFQ$;6)RK UZ[;_P#)
MZM]_V3^#_P!.,M 'MU>7>*;:Q^)_CW5/A[XATA[KP_8Z;IVN>:MQ+$MS,]S<
MKY,@0@.B_9T8H20V[# CKUWCZU%YX1U+?>:Q8I @NFET$$WI$3"0I$H5BQ;9
MMV@$L&('6OD72OB%<>.-)DU_1W^/,NK7=[.+718[:2&P+BY>-4-RUGLBC^7D
ML?D&022* /MVBBB@ KQ#XN_\G(? +_KYUS_TW-7M]>(?%W_DY#X!?]?.N?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M\$^ M+EM];_X1RPU#6;;3]3U=+!;Z6TM) ^]XX61U9B51<LC!59F(.* ,/X
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M.&7N?7?CW;>/)/%EO)X:'Q'&F+9)YC>$KK0(K02;WSN%^1+OQMR1\N-N.<T
M>??L,^)KI[[5/#JR^%WM(]'M=1O;#POH$>EC2=2:::&YM+E49LR Q?+NP2H)
MP!C/KG[3VNW&A> ].8W%II6EW.KV]MJFOWMC'>)HUJP?==>7(&0'<$C#NI5/
M-W," :R_V<K;Q+;ZCK[Z^/&P658V0^++C0Y49\MN:/\ LTEMV,9,G&,8[TW]
MI'Q!XAT;Q%X AT;XG>&O ,%UJ;)/:Z]8R7!O!]GG/\,\8,8QRK[5R%.\$!6
M.._8P^)LWQ"VRVEYI>N:<?#&EW&H:CIFG06XM]48RB:!Y(55'8J$D* ?N]W8
M.!7U57AWP4U9[KX@:[8WWQ/T;QMJ$&EVSKI'AC3#9Z=8PF67$K 3SJ9G8$??
M!VQCY>]>XT %%%% !7G/Q._Y'WX0_P#8RW/_ *9M2KT:O.?B=_R/OPA_[&6Y
M_P#3-J5 'HU%%03W$=I!)-+(L4,:EW=R%55 R22>@ H \$_;-^(6L^#_ (;Z
M9HGARZ:PUWQ;JT&A6]XGWK=9<[W4]C@;<]MV1R*])^%/PG\._![PK:Z'X?L(
M[>.-!YUUM'FW4F/FDD;JS$Y//3.!Q7DO[6_A.;XR?!^#5_ E];ZQKWAC48M9
MLTL95F,ICSN0;2?FP=P'4E .];_P=_:Y^'WQ3\.6L\^NV'A[7$0+?:1JEPMO
M+!*!\P7>1O7.<$=NN#Q7HN,I86+IJZN^:WRM?R/-52'MVY-:I6?EUL5OVKOA
M+8^)_A[JGB_2E&D>./#%L^JZ;K=I^[N%,*[VC9ARRLJD8.0"1[UWOP(^(4GQ
M5^$/A3Q5-&L=UJ-BDEPJC"B9<I)@=AO5L>U>%?M1_M/:%JGA&^^''P\O(O&/
MC7Q-&VF10:.XG2WCD&V1F=<KG:6  /&<G '/O/P2^'Y^%?PG\+>%'=9)],L4
MBG=/NM*?FD(]M[-BE4C*.&BJFCOI?>UOR'3<98ANGM;7U.\HHHKSST3$\7Q7
M<_A/6H[!KU;Y[*98&TTPBZ$A0[3%YW[K?G&WS/ESC=QFO&OV7?@UX@^&$_B>
M^\0Z7I=M<ZLT++?I<RS:I=[0V3>'<T*L,C @PO)X&!7H'QUN=1T_X0>++S2O
M$$GA>[M--GN1JL-H+J2!40LQ2,LH+8''(Q7'? [QM?>)O''B>TU3Q%J^LW%G
M$(;<7-A;6EE(L<\L,TD*Q2.6831O$S/M_P!6-H(.: ///BKXST;1?C;J.E:]
MI/A+Q%#)J-E>V[WUC?FZL66&WB*RR6]C)$Q#3(P\R3($\88A2F/9/V@KUK7P
M1;6\PU#^S;Z_BM-0FTS1QJLT,#*^7%N8I0PW! 28V SG%>!?'#Q'HT7QZOM"
MO-"MQ/.T=Q%9#4;NWO-<E"V",$1#L:*2)C%L"G<]CER E>O_ +4GB7P_H_AG
M0=/U[7]$TW[;JB,FE>(+]K.SU=(XW9[>:10Q6/E6)*LNY4# AL4 7O@#X \+
M^%-)^U>"]0\2KHCJ\$NFZZMU"AFW*WFI;W")Y'!(VQ(D9#<+\HQ[!7CW[,<]
ME=>!=2DTR]TVXTQM6G^SV>ASR7&G:>FV/_1[:=U3S4!RQ95"AW=5 "U[#0 4
M444 %%%% !1110 F*H:UK%EX>TB]U349TM+"SA>XN+B3[L<:@LS'V !-7\XQ
M61XJ\-V7C#PUJFA:BKO8:E:R6=PL;;6,<BE6 /8X)YH5KJ^Q$KV?+N?*WQ%_
MX*7?#KPZ[VOA2PU+QG?=$:*,VMN3Z;W&\_@AKS__ (6K^UC^T$5C\+>&4^'^
MB3'B]FA^SG8>A\V?+M]8T!KZZ^'/[/GPZ^$T:GPSX3TW39U&/MAC\VX/UE?+
M_K7/_%#]KGX6?"998]7\4VMUJ$9*_P!GZ8?M5QN]"$R$_P"!$5[=.K13Y<+1
MYGWEJ_N6AXU2G5:YL56Y5V6B^_<\"\-_\$Y+WQ7?+JWQ:^(NJ^)[X\FWLY6(
M'<CSI=Q(]@JU[O'\#M3^&7A?3M"^#^H6?A'3K>26:YM;V)KM;J1P@#EWW,I^
M7MQSTXKYVUK_ (*#^-_B7?3:5\'?AI>:C(#M%]>Q/<NN>A,<?RI]6<BOI?\
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M7*>P<K\3GU&+X<^*GTBWM+K55TRY-M!?!#!)+Y3;5D#D*5)P#N(&.I KQO\
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M&\8?#K7M?OX]2U[1]#_X1^WBT:?1[ W$!NGNF%^TA",!<);+&8!)A"Q;&XY
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MNP[T 8'[*TT5QX U6:U.G6]D^LW!M],TA;E+73DVQX@C2XAA=1U<C8%S(2N
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MNDV&G2NNUWM+9(F8=<$J!D5KT44 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 5#/#'<Q/%*BR1NI5D89# \$$=Q4U% '._\*Z\)_\ 0L:-
M_P""^+_XFC_A77A/_H6-&_\ !?%_\37144 <[_PKKPG_ -"QHW_@OB_^)H_X
M5UX3_P"A8T;_ ,%\7_Q-=%10!SO_  KKPG_T+&C?^"^+_P")H_X5UX3_ .A8
MT;_P7Q?_ !-=%10!SO\ PKKPG_T+&C?^"^+_ .)H_P"%=>$_^A8T;_P7Q?\
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-110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46061881132752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Mar. 07, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39049<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">EXAGEN INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">20-0434866<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1261 Liberty Way<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Vista<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92081<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(760)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">560-1501<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">XGN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,898,098<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Certain information required to be disclosed in Part III of this report is incorporated by reference from the registrant's definitive Proxy Statement for the 2025 Annual Meeting of Stockholders, which proxy statement will be filed not later than 120 days after the end of the fiscal year covered by this Form 10-K.</span></div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001274737<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46061880321696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_AuditInformationAbstract', window );"><strong>Audit Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">BDO USA, P.C.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">San Diego, California<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">243<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_AuditInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Audit Information [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_AuditInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46061880098384">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 22,036<span></span>
</td>
<td class="nump">$ 36,493<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">7,835<span></span>
</td>
<td class="nump">6,551<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">6,584<span></span>
</td>
<td class="nump">4,797<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">36,455<span></span>
</td>
<td class="nump">47,841<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization', window );">Property and equipment, net</a></td>
<td class="nump">5,283<span></span>
</td>
<td class="nump">5,201<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">2,401<span></span>
</td>
<td class="nump">3,286<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">550<span></span>
</td>
<td class="nump">616<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">44,689<span></span>
</td>
<td class="nump">56,944<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">4,137<span></span>
</td>
<td class="nump">3,131<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">1,096<span></span>
</td>
<td class="nump">976<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Borrowings-current portion</a></td>
<td class="nump">423<span></span>
</td>
<td class="nump">264<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued and other current liabilities</a></td>
<td class="nump">7,850<span></span>
</td>
<td class="nump">7,531<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">13,506<span></span>
</td>
<td class="nump">11,902<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Borrowings-non-current portion, net of discounts and debt issuance costs</a></td>
<td class="nump">19,822<span></span>
</td>
<td class="nump">19,231<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Non-current operating lease liabilities</a></td>
<td class="nump">1,664<span></span>
</td>
<td class="nump">2,760<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non-current liabilities</a></td>
<td class="nump">157<span></span>
</td>
<td class="nump">357<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">35,149<span></span>
</td>
<td class="nump">34,250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 6)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value per share; 10,000,000 shares authorized, no shares issued or outstanding at December 31, 2024 and December 31, 2023</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value per share; 200,000,000 shares authorized at December 31, 2024 and December 31, 2023; 17,640,328 and 17,045,954 shares issued and outstanding at December 31, 2024 and December 31, 2023, respectively</a></td>
<td class="nump">18<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">303,853<span></span>
</td>
<td class="nump">301,893<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(294,331)<span></span>
</td>
<td class="num">(279,216)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">9,540<span></span>
</td>
<td class="nump">22,694<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 44,689<span></span>
</td>
<td class="nump">$ 56,944<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46061880360992">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Preferred stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Shares authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Common stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Shares authorized (in shares)</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Shares issued (in shares)</a></td>
<td class="nump">17,640,328<span></span>
</td>
<td class="nump">17,045,954<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Shares outstanding (in shares)</a></td>
<td class="nump">17,640,328<span></span>
</td>
<td class="nump">17,045,954<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46061875321344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Operations - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 55,641<span></span>
</td>
<td class="nump">$ 52,548<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Costs of revenue</a></td>
<td class="nump">22,529<span></span>
</td>
<td class="nump">23,092<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross margin</a></td>
<td class="nump">33,112<span></span>
</td>
<td class="nump">29,456<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative expenses</a></td>
<td class="nump">41,373<span></span>
</td>
<td class="nump">47,428<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">5,375<span></span>
</td>
<td class="nump">4,865<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">46,748<span></span>
</td>
<td class="nump">52,293<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(13,636)<span></span>
</td>
<td class="num">(22,837)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest expense</a></td>
<td class="num">(2,234)<span></span>
</td>
<td class="num">(2,335)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">767<span></span>
</td>
<td class="nump">1,516<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossAttributableToParent', window );">Loss before income taxes</a></td>
<td class="num">(15,103)<span></span>
</td>
<td class="num">(23,656)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="num">(12)<span></span>
</td>
<td class="num">(33)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (15,115)<span></span>
</td>
<td class="num">$ (23,689)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic (in dollars per share)</a></td>
<td class="num">$ (0.83)<span></span>
</td>
<td class="num">$ (1.34)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted (in dollars per share)</a></td>
<td class="num">$ (0.83)<span></span>
</td>
<td class="num">$ (1.34)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average number of shares used to compute net loss per share, basic (in shares)</a></td>
<td class="nump">18,203,044<span></span>
</td>
<td class="nump">17,679,467<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average number of shares used to compute net loss per share, diluted (in shares)</a></td>
<td class="nump">18,203,044<span></span>
</td>
<td class="nump">17,679,467<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of income (loss) attributable to parent. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46061875359440">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Statements of Stockholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,549,984<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2022</a></td>
<td class="nump">$ 42,460<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
<td class="nump">$ 297,970<span></span>
</td>
<td class="num">$ (255,527)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesShares', window );">Issuance of stock from vested restricted stock units and payment of employees' taxes (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">273,042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93,335<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of stock under Employee Stock Purchase Plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">129,593<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of stock under Employee Stock Purchase Plan</a></td>
<td class="nump">279<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">279<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">3,617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (23,689)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23,689)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2023</a></td>
<td class="nump">17,045,954<span></span>
</td>
<td class="nump">17,045,954<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2023</a></td>
<td class="nump">$ 22,694<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
<td class="nump">301,893<span></span>
</td>
<td class="num">(279,216)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Issuance of stock from vested restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">413,202<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="nump">85,124<span></span>
</td>
<td class="nump">85,124<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">$ 22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of stock under Employee Stock Purchase Plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96,048<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of stock under Employee Stock Purchase Plan</a></td>
<td class="nump">176<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">1,763<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,763<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (15,115)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15,115)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2024</a></td>
<td class="nump">17,640,328<span></span>
</td>
<td class="nump">17,640,328<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2024</a></td>
<td class="nump">$ 9,540<span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
<td class="nump">$ 303,853<span></span>
</td>
<td class="num">$ (294,331)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance Of Stock From Vested Restricted Stock Units And Payment Of Employees Taxes, Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46061881491536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (15,115)<span></span>
</td>
<td class="num">$ (23,689)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">1,724<span></span>
</td>
<td class="nump">2,168<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt discount and debt issuance costs</a></td>
<td class="nump">154<span></span>
</td>
<td class="nump">156<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaidInKindInterest', window );">Non-cash interest expense</a></td>
<td class="nump">276<span></span>
</td>
<td class="nump">363<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Loss on disposal of assets</a></td>
<td class="nump">111<span></span>
</td>
<td class="nump">189<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_GainLossOnDispositionOfLeaseAssignment', window );">Loss on lease assignment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,470<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_NonCashLeaseExpense', window );">Non-cash lease expense</a></td>
<td class="nump">884<span></span>
</td>
<td class="nump">939<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">1,763<span></span>
</td>
<td class="nump">3,617<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable, net</a></td>
<td class="num">(1,284)<span></span>
</td>
<td class="num">(474)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(1,787)<span></span>
</td>
<td class="num">(654)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other assets</a></td>
<td class="nump">63<span></span>
</td>
<td class="num">(101)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(976)<span></span>
</td>
<td class="num">(1,010)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">308<span></span>
</td>
<td class="nump">67<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued and other current liabilities</a></td>
<td class="nump">600<span></span>
</td>
<td class="nump">2,497<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(13,279)<span></span>
</td>
<td class="num">(14,462)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(515)<span></span>
</td>
<td class="num">(828)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from disposal of property and equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(515)<span></span>
</td>
<td class="num">(804)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">22<span></span>
</td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Proceeds from common stock issued under Employee Stock Purchase Plan</a></td>
<td class="nump">176<span></span>
</td>
<td class="nump">279<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Principal payment on finance lease obligations</a></td>
<td class="num">(490)<span></span>
</td>
<td class="num">(697)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Principal payment on note payable obligations</a></td>
<td class="num">(371)<span></span>
</td>
<td class="num">(241)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Principal payment on long-term debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(10,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash used in financing activities</a></td>
<td class="num">(663)<span></span>
</td>
<td class="num">(10,632)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash, cash equivalents and restricted cash</a></td>
<td class="num">(14,457)<span></span>
</td>
<td class="num">(25,898)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, beginning of year</a></td>
<td class="nump">36,693<span></span>
</td>
<td class="nump">62,591<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, end of year</a></td>
<td class="nump">22,236<span></span>
</td>
<td class="nump">36,693<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest expense</a></td>
<td class="nump">1,719<span></span>
</td>
<td class="nump">1,737<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>Supplemental disclosure of non-cash items:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_EquipmentPurchasedUnderNotesPayableObligations', window );">Equipment purchased under notes payable obligations</a></td>
<td class="nump">706<span></span>
</td>
<td class="nump">250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Costs incurred, but not paid, in connection with capital expenditures</a></td>
<td class="nump">$ 717<span></span>
</td>
<td class="nump">$ 66<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_EquipmentPurchasedUnderNotesPayableObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equipment Purchased Under Notes Payable Obligations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_EquipmentPurchasedUnderNotesPayableObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_GainLossOnDispositionOfLeaseAssignment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) On Disposition Of Lease Assignment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_GainLossOnDispositionOfLeaseAssignment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Prepaid Expense And Current Other Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_NonCashLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-Cash Lease Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_NonCashLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for allocation of cost of tangible and intangible assets over their useful lives directly used in production of good and rendering of service.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaidInKindInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaidInKindInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowElementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowElementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46061880537552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock', window );">Organization</a></td>
<td class="text">Organization<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Description of Business</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Exagen Inc. (the Company) is a medical technology company primarily focused on the design, development and commercialization of a next-generation portfolio of testing products under our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> brand, which allow for the differential diagnosis, prognosis and monitoring of complex rheumatic, autoimmune and autoimmune-related disease including, among others, systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Liquidity</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company has incurred recurring losses and negative cash flows from operating activities since inception. The Company anticipates that it will continue to incur net losses in future periods. At December&#160;31, 2024, the Company had cash and cash equivalents of $22.0 million and had an accumulated deficit of $294.3 million. Since inception, the Company has financed its operations primarily through a combination of equity financings, debt financing arrangements, and revenue from sales of the Company's products. Based on the Company's current business plan, management believes that its existing capital resources will be sufficient to fund the Company's obligations for at least twelve months following the issuance of these financial statements.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">To execute its business plans, the Company may need additional funding to support its continuing operations and pursue its growth strategy. Until such time as the Company can achieve significant cash flows from operations, if ever, it may need to finance its operations through the sale of its stock, debt financings or other strategic transactions. Although the Company has been successful in raising capital in the past, there is no assurance that it will be successful in obtaining such additional financing on terms acceptable to the Company, if at all. The terms of any financing may adversely affect the holdings or the rights of the Company's stockholders. If the Company is unable to obtain funding, the Company could be forced to delay, reduce or eliminate some or all of its programs, product portfolio expansion plans or commercialization efforts, which could have a material adverse effect on the Company's business, operating results and financial condition and the Company's ability to achieve its intended business objectives.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/275/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 250<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/250/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46061881602672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Basis of Presentation and Use of Estimates</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company's financial statements are prepared in accordance with accounting principles generally accepted in the United States of America (GAAP). The preparation of the accompanying financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities as of the date of the financial statements, and the reported amounts of revenue and expenses during the reporting period. Actual results could materially differ from those estimates.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Significant estimates and assumptions made in the accompanying financial statements include, but are not limited to revenue recognition, the estimated incremental borrowing rate for the determination of the Company's operating lease right-of-use (ROU) assets and the recoverability of its long-lived assets and net deferred tax assets (and related valuation allowance). The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could materially differ from those estimates.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Concentration of Credit Risk and Other Risk and Uncertainties</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Financial instruments that potentially subject the Company to credit risk consist principally of cash, cash equivalents and accounts receivable. Substantially all the Company's cash and cash equivalents are held at one financial institution that management believes is of high credit quality. Such deposits may, at times, exceed federally insured limits. The Company has not experienced any losses on its cash or cash equivalents.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Significant payors and customers are those which represent more than 10% of the Company's total revenue or accounts receivable balance at each respective balance sheet date. For each significant payor and customer, </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">revenue as a percentage of total revenue and accounts receivable as a percentage of total accounts receivable are as follows:</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.707%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.768%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Revenue</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medicare Advantage</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United Healthcare</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">*</span></td></tr></table></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.847%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.724%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.129%"></td><td style="width:0.1%"></td></tr><tr style="height:8pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less than 10%.</span></td></tr></table></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.707%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.768%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accounts Receivable</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medicare Advantage</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For the years ended December&#160;31, 2024 and 2023, approximately 91% and 88%, respectively, of the Company's revenue was related to the AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD test.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company is dependent on key suppliers for certain laboratory materials. For the year ended December&#160;31, 2024, approximately 71% and 26%</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">of the Company's diagnostic testing supplies were purchased from two suppliers, respectively. For the year ended December 31, 2023, approximately 66% and 30%</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">of the Company's diagnostic testing supplies were purchased from two suppliers, respectively. An interruption in the supply of these materials would impact the Company's ability to perform testing services.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Disaggregation of Revenue</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table includes the Company's revenues as disaggregated by payor and customer category (in&#160;thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.707%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.768%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23,985&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,323&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,002&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Client(1)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,360&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,949&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other(2)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">358&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">612&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55,641&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52,548&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.24pt">Includes hospitals, other laboratories, etc.</span></div><div style="padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.24pt">Includes patient self-pay.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Cash, Cash Equivalents and Restricted Cash</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company considers all highly-liquid investments purchased with a remaining maturity date of three months or less upon acquisition to be cash equivalents. These investments are stated at cost, which approximates fair value.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company has an arrangement with a financial institution with which it has an existing banking relationship, whereby in exchange for the issuance of corporate credit cards, the Company agreed to obtain a certificate of deposit with this financial institution in the amount of $0.2 million as collateral for the balances borrowed on these cards. The Company has classified the value of this certificate of deposit (including all interest earned thereon) within other assets in the accompanying balance sheets. The Company has the right to terminate the credit card program at any time. Upon termination of the credit card program and repayment of all outstanding balances owed, the Company may redeem the certificate of deposit (and all interest earned thereon).</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cash, cash equivalents and restricted cash presented in the accompanying statements of cash flows consist of the following (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.707%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.768%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,036&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36,493&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,236&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36,693&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Property and Equipment</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Property and equipment are stated at cost, net of depreciation and amortization. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally between <span style="-sec-ix-hidden:f-296">three</span> and five years. Leasehold improvements are amortized on a straight-line basis over the lesser of the estimated useful life or the remaining term of the related lease. Maintenance and repairs are charged to expense as incurred, and improvements and betterments are capitalized. When assets are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the balance sheet and any resulting gain or loss is reflected in operating expenses in the statements of operations in the period realized.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Long-lived Assets</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company&#8217;s long-lived assets are comprised principally of its property and equipment and operating lease assets. The Company amortizes all finite lived intangible assets over their respective estimated useful lives. Operating lease assets are amortized over the term of the leases. In considering whether long-lived assets are impaired, the Company combines its long-lived assets into groupings, a determination which is made principally on the basis of whether the assets are specific to a particular test offered or technology being developed. If the Company identifies a change in the circumstances related to its long-lived assets that indicates the carrying value of any such asset may not be recoverable, the Company will perform an impairment analysis. A long-lived asset is deemed to be impaired when the undiscounted cash flows expected to be generated by the asset (or asset group) are less than the asset&#8217;s carrying amount. Management&#8217;s estimates of future cash flows are impacted by projected test volume and levels of reimbursement, as well as expectations related to the future cost structure of the entity. Any required impairment loss would be measured as the amount by which the asset&#8217;s carrying value exceeds its fair value, and would be recorded as a reduction in the carrying value of the related asset and a charge to operating expense.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Leases</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company categorizes leases at their commencement as either operating or finance leases. The Company recognizes operating lease ROU assets and operating lease liabilities for each lease arrangement identified. Lease liabilities are recorded at the present value of future lease payments discounted using the Company's incremental borrowing rate for the lease established at the commencement date. The incremental borrowing rate is the rate of interest the Company would have to pay to borrow, on a collateralized basis over a similar term and in a similar economic environment, an amount equal to the total lease payments. The Company primarily considers industry data, its credit rating and the lease term to determine its incremental borrowing rate. ROU assets are measured at the amount of the lease liability plus any initial direct costs, less any lease incentives received before commencement. Lease expense is recognized as a single lease cost over the lease term on a straight-line basis. The Company has elected not to apply the recognition requirements to short-term leases and not to separate non-lease components from lease components for its leases.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Clinical Studies</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">From time to time, the Company engages in efforts to scientifically measure and document the application and efficacy of its various testing products. These arrangements typically require the Company to pay a fee to a third-party scientific investigator (usually a physician or research institution) for each subject enrolled in a clinical study, and the Company accrues expenses based on estimated progress of services performed, including actual level of subjects enrolled and progress of the clinical studies. Payments made prior to the completion of clinical study services are capitalized as a prepaid expense. The prepaid amounts are expensed as the related goods are delivered or the services are performed, or when it is no longer expected that the goods will be delivered or the services rendered. Expenses associated with clinical study activities are recorded in research and development expenses in the accompanying statement of operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Revenue Recognition</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Substantially all of the Company's revenue has been derived from sales of its testing products and is primarily comprised of a high volume of relatively low-dollar transactions. The Company primarily markets its testing products to rheumatologists and their physician assistants in the United States. The healthcare professionals who order the Company's testing products and to whom test results are reported are generally not responsible for payment for these products. The parties that pay for these services (each, a payor) consist of commercial payors (healthcare insurers), government payors (primarily Medicare and Medicaid), client payors (hospitals, other laboratories, etc.) and patient self-pay. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company recognizes revenue in accordance with Accounting Standards Codification Topic 606, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> and follows a five-step process to determine the amount and timing of revenue recognized: (1) identify the contract with the customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to performance obligations in the contract, and (5) recognize revenue when (or as) the performance obligation is satisfied. The Company's service is a single performance obligation that is completed upon the delivery of test results to the prescribing physician which triggers revenue recognition.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Payors are generally billed at the Company's list price, unless a separate pricing contract is in place. Net revenues recognized consist of amounts billed net of allowances for differences between amounts billed and the estimated consideration the Company expects to receive from such payors. The process for estimating revenues and the ultimate collection of accounts receivable involves significant judgment and estimation. The Company follows a standard process, which considers historical denial and collection experience, insurance reimbursement policies and other factors, to estimate allowances and implicit price concessions. Adjustments are recorded in the current period as changes in estimates occur. Further adjustments to the allowances, based on actual receipts, are recorded upon settlement. Included in revenues for the years ended December&#160;31, 2024 and 2023 were net revenue increases of $6.6 million and $3.4 million, respectively, associated with changes in estimated variable consideration related to performance obligations satisfied in previous periods. The transaction price is estimated using an expected value method on a portfolio basis.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Variable consideration is included in the transaction price only to the extent it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainties with respect to the amount are resolved. The Company's portfolios are grouped per payor (i.e. each individual commercial payor, Medicare, Medicaid, client payors, patient self-pay, etc.) and per test. Consideration may be constrained and excluded from the transaction price in situations where there is no contractually agreed upon reimbursement coverage or in absence of a predictable pattern and history of collectability with a payor. Accordingly, in such situations revenues are recognized on the basis of actual cash collections. Additionally, from time to time, the Company may issue refunds to payors for overpayments or amounts billed in error. Any refunds are accounted for as reductions in revenues in the statement of operations as an element of variable consideration. The estimated expected refunds are accrued as a liability on the Company&#8217;s balance sheet.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Collection of the Company's net revenues from payors is normally a function of providing complete and correct billing information, along with any requested medical or other claims-related information to the healthcare insurers. This generally occurs within 30 to 90 days of billing, however, the amount and timing of any reimbursements or collections for the Company's billed tests may vary by payor and other circumstances. Contracts do not contain significant financing components based on the typical period of time between performance of services and collection of consideration.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Accounts Receivable and Allowance for Credit Losses</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We accrue an allowance for credit losses against our accounts receivable based on management&#8217;s current estimate of amounts that will not be collected. Management&#8217;s estimates are typically based on historical loss information adjusted for current conditions. We generally do not perform evaluations of the financial condition of our customers and generally do not require collateral. The allowance for credit losses was zero as of each of December&#160;31, 2024 and 2023. Adjustments for implicit price concessions attributable to variable consideration, as discussed above, are incorporated into the measurement of the accounts receivable balances and are not part of the allowance for credit losses. Accounts receivable was $7.8 million, $6.6 million, and $6.1 million for the years ended December&#160;31, 2024, 2023 and 2022, respectively. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Research and Development</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Costs associated with research and development activities are expensed as incurred and include, but are not limited to, personnel-related expenses, including stock-based compensation expense; materials; laboratory </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">supplies; consulting costs; costs associated with setting up and conducting clinical studies; depreciation; amortization and allocated overhead, including rent and utilities.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Advertising and Marketing Costs</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Costs associated with advertising and marketing activities are expensed as incurred. Total advertising and marketing costs were approximately $1.4 million and $1.5 million for the years ended December&#160;31, 2024 and 2023, respectively, and are included in selling, general and administrative expenses in the accompanying statements of operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Shipping and Handling Costs</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Costs incurred for shipping and handling are included in costs of revenue in the accompanying statements of operations and were approximately $3.1 million and $2.5 million for the years ended December&#160;31, 2024 and 2023, respectively.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Stock-Based Compensation</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company recognizes compensation expense for all stock-based awards to employees and directors based on the grant-date estimated fair values over the requisite service period of the awards (usually the vesting period) on a straight-line basis. Equity award forfeitures are recorded as they occur.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The fair value of each restricted stock unit (RSU) is determined on the grant date using the closing price of the Company's common stock on that date. The Company's RSUs generally vest in equal annual installments over four years from the date of grant or, for grants to new hires, date of hire. Vesting of the RSU is subject to the holder's continued service with the Company. The Company issues new shares of common stock to satisfy the RSUs upon vesting.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Comprehensive Loss</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Comprehensive loss is defined as a change in equity of a business enterprise during a period, resulting from transactions from nonowner sources. There have been no items qualifying as other comprehensive loss and, therefore, for all periods presented, the Company's comprehensive loss was the same as its reported net loss.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Income Taxes</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized as an expense in the period that includes the enactment date. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company recognizes net deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If management determines that the Company would be able to realize its deferred tax assets in the future in excess of their net recorded amount, management would adjust the deferred tax asset valuation allowance, which would reduce the provision for income taxes. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company records uncertain tax positions on the basis of a two-step process whereby (i) management determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (ii) for those tax positions that meet the more-likely-than-not recognition threshold, management recognizes the largest amount of tax benefit that is more than 50% likely to be realized upon ultimate settlement with the related tax authority. The Company recognizes interest and penalties related to unrecognized tax benefits within income tax expense. Any accrued interest and penalties are included within the related tax liability.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Net Loss Per Share</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Basic net loss per share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common stock outstanding during the period. Diluted net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">stockholders by the weighted-average number of common stock equivalents outstanding for the period determined using the treasury-stock and if-converted methods. The weighted-average number of shares used to compute basic and diluted shares includes shares issuable upon the exercise of pre-funded warrants at a nominal price. Potentially dilutive common stock equivalents are comprised of warrants for the purchase of common stock, stock options, RSUs outstanding under the Company's 2019 Incentive Award Plan (the 2019 Plan) and shares of the Company's common stock pursuant to the Exagen Inc. 2019 Employee Stock Purchase Plan (ESPP). For each of the years ended December&#160;31, 2024 and 2023, there is no difference in the number of shares used to calculate basic and diluted shares outstanding as the inclusion of the potentially dilutive securities would be antidilutive.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Potentially dilutive securities not included in the calculation of diluted net loss per share, because to do so would be anti-dilutive, are as follows (in common stock equivalent shares):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.707%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.768%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Warrants to purchase common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">325,330&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">409,108&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">489,296&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">986,819&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,710,373&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,387,459&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock purchase plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57,461&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,582,460&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,828,086&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Recent Accounting Pronouncements</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB), or other standard setting bodies and adopted by the Company as of the specified effective date. Unless otherwise discussed, Accounting Standards Updates (ASU) not included in the Company&#8217;s disclosures were assessed and determined to be either not applicable or are not expected to have a material impact on the Company&#8217;s financial statements or disclosures.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">In December 2023, the FASB issued ASU 2023-09,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%"> Income Taxes (Topic 740): Improvements to Income Tax Disclosures</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> (ASU 2023-09), which requires additional income tax disclosures in the rate reconciliation table for federal, state and foreign income taxes, in addition to more details about the reconciling items in some categories when items meet a certain quantitative threshold. ASU 2023-09 is effective for annual periods beginning after December 15, 2024 with early adoption permitted. This update will result in enhanced income tax disclosures, and the Company does not expect any impact to income tax expense.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">In November 2024, the FASB issued ASU 2024-03, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%">Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> (&#8220;ASU 2024-03&#8221;). This update requires entities to include more detailed information about the types of expenses, including purchases of inventory, employee compensation, depreciation, amortization, and depletion, in commonly presented expense captions such as cost of sales, research and development, and selling, general and administrative expenses. ASU 2024-03 is effective for annual periods beginning after December 15, 2026, with early adoption permitted. The company is currently evaluating the impact of this standard on its financial statement presentation and disclosures.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:107%">Recently Adopted Accounting Standards</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In November 2023, the FASB issued ASU No. 2023-07, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (ASU 2023-07), which requires public entities to disclose significant segment expenses that are regularly provided to the Chief Operating Decision Maker (CODM) and details of how the CODM uses financial reporting to assess the performance of a segment. The Company adopted this pronouncement in 2024 and retrospectively to all prior periods using the significant segment expense categories identified. The impact of the adoption of the amendments in this update was not material to the Company&#8217;s financial position and results of operations, as the requirements impact only segment reporting disclosures in the footnotes to the Company&#8217;s financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46061981368096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Financial Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_OtherFinancialInformationAbstract', window );"><strong>Other Financial Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock', window );">Other Financial Information</a></td>
<td class="text">Other Financial Information<div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Prepaid Expenses and Other Current Assets</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Prepaid expenses and other current assets consist of the following (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.707%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.768%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Diagnostic&#160;testing&#160;supplies</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,725&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,871&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">859&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,926&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,584&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,797&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Property and Equipment, net</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Property and equipment consist of the following (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.707%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.768%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Furniture&#160;and&#160;fixtures</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,248&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,312&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,113&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,185&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,286&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,316&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,543&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,295&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,970&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: accumulated depreciation and amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6,012)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,769)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,283&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,201&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Depreciation and amortization expense for the years ended December&#160;31, 2024 and 2023, was approximately $1.7 million and $2.2 million, respectively. At December&#160;31, 2024 and 2023, the gross book value of assets under finance leases was $2.0 million and $2.5 million, respectively.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Loss on Lease Assignment</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On October 24, 2023, the Company entered into an assignment and assumption (the Assignment and Assumption Agreement) of the Company&#8217;s previously executed lease agreement with Liberty Vista, LP (formerly known as Geiger Court, LLC) and Mindera Corporation (Mindera), pursuant to which the Company assigned to Mindera the lease of a building located adjacent to the Company's headquarters in Vista, CA. Under the terms of the Assignment and Assumption Agreement, Mindera assumed all obligations under the lease, effective October 31, 2023. As a result of the lease assignment, the Company derecognized the remaining balances related to the associated operating lease ROU asset of $0.7&#160;million, operating lease liability of $0.8&#160;million and leasehold improvements of $1.6&#160;million, resulting in a $1.5 million loss on lease assignment. The loss was classified within selling, general and administrative expenses in the accompanying statements of operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Accrued and Other Current Liabilities</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Accrued and other current liabilities consist of the following (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.707%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.768%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued&#160;payroll&#160;and&#160;related&#160;expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,046&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,738&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,804&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,793&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,850&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,531&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_OtherFinancialInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Financial Information</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_OtherFinancialInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid Expenses and Other Current Assets; Property, Plant and Equipment; and Accrued Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46061880546432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Borrowings<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Borrowings</a></td>
<td class="text">Borrowings<div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">2017 Term Loan</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In September 2017, the Company executed a term loan agreement (the 2017 Term Loan) with Innovatus Life Sciences Lending Fund I, LP (Innovatus), as amended (the Amended Loan Agreement), pursuant to which the Company borrowed $25.0&#160;million. At December&#160;31, 2024, no additional amounts remained available to borrow under the Amended Loan Agreement.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On April 28, 2023, the Company entered into the Amended Loan Agreement. The Amended Loan Agreement was treated as a modification. In connection with the Amended Loan Agreement, the Company repaid $10.0&#160;million of </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">the principal balance outstanding, for which the prepayment premium was waived. Pursuant to the Amended Loan Agreement, the interest rate on all borrowings under the Amended Loan Agreement is the sum (the Basic Rate) of (a) the greater of 8.0% or The Wall Street Journal prime rate (the Prime Rate), plus (b) 2.0%, which is paid-in-kind in the form of additional term loans (PIK Loans). Under the Amended Loan Agreement, an amount equal to 1.5% of the Basic Rate will be payable in-kind and capitalized to the principal amount of the outstanding term loan on a monthly basis until April 1, 2026, after which interest is scheduled to accrue at the Basic Rate. The maturity date of the loan was extended to December 31, 2026. The Company estimated the effective interest rate of this loan to be approximately 10.6% and 11.0% as of December&#160;31, 2024 and 2023, respectively. Accrued interest is due and payable monthly, unless the Company elects to pay paid-in-kind interest. The outstanding principal and accrued interest under the Amended Loan Agreement is to be repaid in ten equal monthly installments commencing in April 2026. Upon repayment of the final installment under the Amended Loan Agreement, the Company is required to pay an additional fee of $1.0&#160;million. This obligation is being accreted into interest expense over the term of the loan using the effective interest method. For the years ended December&#160;31, 2024 and 2023, the Company issued PIK Loans totaling $0.3 million and $0.4 million, respectively. At December&#160;31, 2024, $18.5 million in principal and PIK loans are outstanding, all of which is included in borrowings-non-current portion on the accompanying balance sheet.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Amended Loan Agreement is collateralized by a first priority security interest in substantially all of the Company's assets, including intellectual property. The affirmative covenants of the Amended Loan Agreement require that the Company timely file taxes, maintain good standing and government compliance, maintain liability and other insurance, provide prompt notification of significant corporate events, and furnish audited financial statements within 150 days of fiscal year end without qualification as to the scope of the audit or as to going concern and without any other similar qualification.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The affirmative covenants require that the Company achieve a specified level of revenue, as measured quarterly on a rolling twelve-month basis, however the Company is not required to comply with the revenue covenant for any quarter during which it maintains a minimum aggregate cash balance equal to fifty percent of the aggregate principal amount of the Amended Loan Agreement (excluding any capitalized interest paid-in-kind) at all times during such quarter. The consequences of failing to achieve the performance covenants, when applicable, will be cured if, (i) within thirty days of failing to achieve the performance covenant, the Company submits a new financial plan approved by the Company's board of directors (the Board) to Innovatus under which the Company is expected to break even on a cash flow basis prior to the maturity date, and (ii) within thirty days of the submission of such financial plan, the Company issues additional equity securities or subordinated debt with net proceeds sufficient to fund any cash flow deficiency generated from operations, as defined in the Amended Loan Agreement. The Amended Loan Agreement requires that the Company maintain certain levels of minimum liquidity and maintains an unrestricted cash balance of $2.0 million.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The negative covenants provide, among other things, that without the prior consent of Innovatus, subject to certain exceptions, the Company may not dispose of certain assets, engage in certain business combinations or acquisitions, incur additional indebtedness or encumber any of the Company's property, pay dividends on the Company's capital stock or make prohibited investments. The Amended Loan Agreement provides that an event of default will occur if, among other triggers, (i)&#160;the Company defaults in the payment of any amount payable under the agreement when due, (ii)&#160;there occurs any circumstance(s) that could reasonably be expected to result in a material adverse effect on the Company's business, operations or condition, or on the Company's ability to perform its obligations under the agreement, (iii)&#160;the Company becomes insolvent, (iv)&#160;the Company undergoes a change in control or (v)&#160;the Company breaches any negative covenants or certain affirmative covenants in the agreement or, subject to a cure period, otherwise neglects to perform or observe any material item in the agreement.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2024, the Company was in compliance with all covenants of the Amended Loan Agreement.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon an event of default in any of the Amended Loan Agreement covenants, the repayment of the 2017 Term Loan may be accelerated, and the applicable interest rate will be increased by 4.0% until the default is cured. Although repayment of the 2017 Term Loan can be accelerated under certain circumstances, the Company believes acceleration of this loan is not probable as of the date of these financial statements. Accordingly, the Company has reflected the amounts of the Amended Loan Agreement due beyond twelve months of the balance sheet date as non-current.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Equipment Notes Payable</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company has purchased laboratory equipment in the normal course of business using notes payable. At December&#160;31, 2024, the total notes payable balance related to the financed equipment was $1.1&#160;million, with </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$0.4&#160;million classified within borrowings-current portion and $0.7&#160;million within borrowings-non-current portion, net of discounts and debt issuance costs in the accompanying balance sheets. At December 31, 2023, the total notes payable balance related to this financed equipment was $0.8&#160;million, with $0.3&#160;million classified within borrowings-current portion and $0.5&#160;million within borrowings-non-current portion, net of discounts and debt issuance costs in the accompanying balance sheets. The financed equipment is subject to effective interest rates between 5.28% and 10.50%, and will mature between October 1, 2026 and April 1, 2028.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Future Minimum Payments on Outstanding Borrowings</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December&#160;31, 2024, future minimum aggregate payments, including interest, for outstanding borrowings are as follows (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.303%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.767%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ending December 31,</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,076&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21,400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">215&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23,758&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unamortized debt discount and issuance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(70)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,443)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total borrowings, net of discounts and debt issuance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,245&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: Borrowings-current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(423)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Borrowings-non-current portion, net of discounts and debt issuance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19,822&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/470/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46061881377456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Leases</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Operating Leases</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company leases office and laboratory space located in Vista, California. The lease expires in April 2027, with an option to extend portions of the lease for additional 5-year periods. The Company has not included the optional renewal periods in the measurement of the lease liability, because it is not reasonably certain that the Company will exercise these renewal options. The Company's payments under the lease are subject to escalation clauses.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company leases additional office space in Carlsbad, California, under a sublease which commenced in October 2021 and expires in April 2027. Monthly base rent under the sublease agreement is $72,143. The monthly base rent increases by approximately 3% annually, each October 1, through the remainder of the lease term.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Finance Leases</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company has entered into various finance lease agreements to obtain laboratory equipment. The terms of the Company's finance leases generally range from <span style="-sec-ix-hidden:f-420">three</span> to five years and are typically secured by the underlying equipment. The portion of the future payments designated as principal repayments were classified as finance lease liabilities on the Company's balance sheet.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Operating and Finance Leases Balances and Costs</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Operating and finance leases consist of the following (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.361%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.163%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.783%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.786%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Lease Balance</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Lease Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,401&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,286&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-425"><span style="-sec-ix-hidden:f-426">Property and equipment, net</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">486&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">810&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Lease Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,096&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">976&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-431"><span style="-sec-ix-hidden:f-432">Accrued and other current liabilities</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">201&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">490&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,664&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,760&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-437"><span style="-sec-ix-hidden:f-438">Other non-current liabilities</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">157&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">358&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Costs associated with the Company's leases were included in the statements of operations as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.794%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.783%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.785%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Lease Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease cost</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,345&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,463&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finance lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of lease assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">280&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">556</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest on finance lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">128</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total lease cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,709&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,147&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">(1) Includes variable lease cost of $196,000 and $129,000 for the years ended December&#160;31, 2024 and 2023, respectively.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Supplemental cash flow information on leases is as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.794%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.783%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.785%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating cash out flows from operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,240&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,405&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating cash out flows from interest paid on finance leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">128&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Financing cash out flows from finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">490&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">697&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Information regarding the weighted-average lease term and weighted average discount rate are as follows:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.783%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.785%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average remaining lease term (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.76</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.06</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Future payments under operating and finance leases as of December&#160;31, 2024 are as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.917%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.783%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.784%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Finance Leases</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,277&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">248&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,315&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">147&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">445&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total minimum lease payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,037&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">423&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(277)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(65)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,760&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">358&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,096)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(201)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Lease obligations, net of current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,664&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">157&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Leases</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Operating Leases</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company leases office and laboratory space located in Vista, California. The lease expires in April 2027, with an option to extend portions of the lease for additional 5-year periods. The Company has not included the optional renewal periods in the measurement of the lease liability, because it is not reasonably certain that the Company will exercise these renewal options. The Company's payments under the lease are subject to escalation clauses.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company leases additional office space in Carlsbad, California, under a sublease which commenced in October 2021 and expires in April 2027. Monthly base rent under the sublease agreement is $72,143. The monthly base rent increases by approximately 3% annually, each October 1, through the remainder of the lease term.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Finance Leases</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company has entered into various finance lease agreements to obtain laboratory equipment. The terms of the Company's finance leases generally range from <span style="-sec-ix-hidden:f-420">three</span> to five years and are typically secured by the underlying equipment. The portion of the future payments designated as principal repayments were classified as finance lease liabilities on the Company's balance sheet.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Operating and Finance Leases Balances and Costs</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Operating and finance leases consist of the following (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.361%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.163%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.783%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.786%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Lease Balance</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Lease Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,401&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,286&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-425"><span style="-sec-ix-hidden:f-426">Property and equipment, net</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">486&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">810&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Lease Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,096&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">976&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-431"><span style="-sec-ix-hidden:f-432">Accrued and other current liabilities</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">201&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">490&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,664&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,760&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-437"><span style="-sec-ix-hidden:f-438">Other non-current liabilities</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">157&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">358&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Costs associated with the Company's leases were included in the statements of operations as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.794%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.783%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.785%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Lease Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease cost</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,345&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,463&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finance lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of lease assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">280&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">556</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest on finance lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">128</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total lease cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,709&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,147&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">(1) Includes variable lease cost of $196,000 and $129,000 for the years ended December&#160;31, 2024 and 2023, respectively.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Supplemental cash flow information on leases is as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.794%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.783%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.785%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating cash out flows from operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,240&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,405&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating cash out flows from interest paid on finance leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">128&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Financing cash out flows from finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">490&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">697&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Information regarding the weighted-average lease term and weighted average discount rate are as follows:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.783%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.785%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average remaining lease term (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.76</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.06</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Future payments under operating and finance leases as of December&#160;31, 2024 are as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.917%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.783%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.784%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Finance Leases</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,277&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">248&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,315&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">147&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">445&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total minimum lease payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,037&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">423&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(277)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(65)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,760&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">358&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,096)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(201)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Lease obligations, net of current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,664&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">157&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46061983392960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Licensing Agreements</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company has licensed technology for use in its diagnostic tests. In addition to the milestone payments required by these agreements, individual license agreements generally provide for ongoing royalty payments ranging from 2.0% to 7.0% on net sales of products which incorporate licensed technology, as defined in such agreements. Royalties are accrued when incurred and recorded in costs of revenue in the accompanying statements of operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Supply Agreements</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In August 2024, the Company amended a supply agreement with one supplier for reagents, which includes pricing terms and minimum purchase commitments, through December 31, 2025, for new consumable products related to the Company's launch of the Anti-RA33 IgA, Anti-RA33 IgG and Anti-RA33 IgM biomarkers. The aggregate minimum annual purchase commitment related to such agreement for the year ending December 31, 2025 is $10.4 million.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Collaboration Obligations</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In May 2021, the Company entered into an exclusive license agreement with Allegheny Health Network Research Institute (AHN), pursuant to which the Company is required to pay AHN a collaboration fee of $0.4 million per year. Collaboration expenses under the master research collaboration agreement were $0.3 million for each of the years ended December&#160;31, 2024 and 2023. Collaboration expenses under the AHN collaboration are included in research and development expenses in the accompanying statements of operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Contingencies</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnifications; including for subpoenas and other civil investigative demands, from governmental agencies, Medicare or Medicaid and managed care organizations reviewing billing practices or requesting comment on allegations of billing irregularities that are brought to their attention through billing audits or third parties. The Company's exposure under these agreements is unknown because it involves claims that may be made against the Company in the future, but have not yet been made or that the Company believes to be immaterial. The Company accrues a liability for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Litigation</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">From time to time, the Company may be subject to various legal proceedings that arise in the ordinary course of business activities. The Company does not believe the outcome of any such matters as of December&#160;31, 2024 will have a material effect on its financial position or results of operations.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In October 2023, the Company resolved an investigation with the U.S. Attorney&#8217;s Office for the District of Massachusetts that was initiated by a </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">qui tam </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">lawsuit (the October 2023 Lawsuit). Pursuant to a settlement agreement entered into by and between the Company and the U.S. Department of Justice (the Settlement Agreement), the Company made a single lump-sum remittance to the government in the amount of $0.7&#160;million, including interest, in connection with specimen processing arrangements that Exagen historically had with </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">physicians. The U.S. Attorney&#8217;s Office dismissed this &#8220;covered conduct&#8221; in the October 2023 Lawsuit with prejudice, while non-covered conduct was dismissed without prejudice. The Department of Justice excused itself from the case in connection with the settlement. In November 2023, the complaint was unsealed by the court and served on Exagen by the relator. Exagen filed a motion to dismiss the complaint. In December 2023, the Company's insurance carrier provided reimbursement for certain defense costs the Company incurred in the October 2023</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Lawsuit. In February 2024, the relator filed a motion for leave to amend the complaint. Exagen opposed this motion, and all motions are still pending. The Company cannot predict when these matters will be resolved, the outcome of these matters, or their potential impact, which may materially and adversely affect the Company's business, prospects, and financial condition. The Company intends to vigorously defend against the claims being asserted in the complaint.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company's participation in federal healthcare programs is not affected by the Settlement Agreement.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46061881901376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">Fair Value Measurements<div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The carrying values of the Company's cash, cash equivalents and restricted cash, accounts receivable, prepaid expenses and other current assets, accounts payable and accrued and other current liabilities are determined to be a Level 1 measurement. The carrying values of these items approximate their fair values due to their short-term nature. The estimated fair value of the Company's long-term borrowings is determined by Level 2 inputs and based primarily on quoted market prices for similar issues. As of December&#160;31, 2024, the Amended Loan Agreement had a carrying value of $19.1 million and a fair value of $19.2 million. As of December 31, 2023, the Amended Loan Agreement had a carrying value of $18.7&#160;million and a fair value of $19.7&#160;million. The estimated fair value of the Amended Loan Agreement was determined based on a discounted cash flow approach using available market information on discount and borrowing rates with similar terms, maturities, and credit ratings. The aggregate carrying value of the Company's other long-term borrowings as of December&#160;31, 2024 was $1.1&#160;million and approximated its fair value.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Fair value is defined as the exchange price that would be received for an asset or an exit price paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The three-levels of the valuation hierarchy for disclosure of fair value measurements are defined as follows:</span></div><div style="margin-top:9pt;padding-left:94.5pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Level 1 -&#160;&#160;&#160;&#160;Unadjusted quoted prices in active markets for identical assets or liabilities;</span></div><div style="margin-top:9pt;padding-left:94.5pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Level 2 -&#160;&#160;&#160;&#160;Inputs other than quoted prices included within Level 1 that are observable, unadjusted quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and</span></div><div style="margin-top:9pt;padding-left:94.5pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Level 3 -&#160;&#160;&#160;&#160;Unobservable inputs that are supported by little or no market activity for the related assets or liabilities.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The categorization of a financial instrument within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table sets forth the Company's financial instruments that were measured at fair value on a recurring basis within the fair value hierarchy (in thousands):</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.432%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Money market funds, included in cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,144&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,144&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.285%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.579%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Money market funds, included in cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,386&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,386&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The fair value of the Company's money market funds is based on quoted market prices.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 107<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 940<br> -SubTopic 820<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46061881026304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">Stockholders' Equity<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Common Stock</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Shelf Registration Statement</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On November 17, 2023, the Company filed a registration statement on Form S-3, as amended (the 2023 Shelf Registration Statement), covering the offering, from time to time, of up to $150.0 million of common stock, preferred stock, debt securities, warrants and units. The 2023 Shelf Registration Statement became effective on November 29, 2023, and all $150.0&#160;million remain available for sale as of December&#160;31, 2024.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">At The Market Sales Agreement</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On September 15, 2022, the Company entered into a sales agreement, as amended on November 17, 2023 (the Sales Agreement) with TD Securities (USA) LLC as sales agent, pursuant to which the Company may offer and sell, from time to time, shares of Company common stock having an aggregate offering price of up to $50.0&#160;million. The Company is not obligated to sell any shares of Company common stock in the offering. As of December&#160;31, 2024, the Company has not sold any shares of its common stock pursuant to the Sales Agreement</span><span style="color:#008080;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Outstanding Warrants</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following equity classified warrants to purchase common stock were outstanding as of December&#160;31, 2024:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.432%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.783%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.788%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercise Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Issuance date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Expiration date</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">237,169</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.84&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">January 19, 2016</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">January 19, 2026</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">67,086</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.84&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31, 2016</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31, 2026</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">131</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.84&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 1, 2016</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 1, 2026</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,944</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 7, 2018</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 7, 2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock warrants (Exchange Warrants)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">804,951</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.001&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 22, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">None</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,130,281</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">No warrants to purchase common stock were exercised during the years ended December&#160;31, 2024 and 2023.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46061881159184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Option Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock Option Plan</a></td>
<td class="text">Stock Option Plan<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">2019 Incentive Award Plan</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In September 2019, the Board adopted, and the Company's stockholders approved, the 2019 Plan. Under the 2019 Plan, which expires in September 2029, the Company may grant stock options, stock appreciation rights, restricted stock, RSUs and other awards to individuals who are then employees, officers, non-employee directors or consultants of the Company or its subsidiaries. The options generally expire ten years after the date of grant and are exercisable to the extent vested. Vesting is established by the Board and is generally four years from the date of grant or, for grants to new hires, date of hire. The 2019 Plan contains an "evergreen provision" that allows annual increases in the number of shares available for issuance on the first day of each calendar year through January 1, 2029 in an amount equal to the lesser of: (i) 4% of the outstanding capital stock on each December 31st, or (ii) such lesser amount determined by the Board. As of December&#160;31, 2024, 2,189,228 shares of common stock remained available for future awards. Pursuant to the evergreen provision, on January 1, 2025, an additional 705,613 shares of common stock became available for issuance under the 2019 Plan.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Restricted Stock Units</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">RSU activity under the Company's 2019 Plan is set forth below:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.163%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.373%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.378%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Grant Date Fair Value Per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Value</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding, December&#160;31, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,387,459&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.24&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,761&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Awards granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,324,275&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Awards released</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(413,202)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.87&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Awards canceled</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(588,159)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding, December&#160;31, 2024</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,710,373&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.48&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,013&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December&#160;31, 2024, all of the outstanding RSUs are unvested. The fair value of RSUs vested in the years ended December&#160;31, 2024 and 2023 was $0.9 million and $0.6&#160;million, respectively. The weighted average grant date fair value per share for RSUs granted during the years ended December&#160;31, 2024 and 2023 was $2.11 and $2.39, respectively. As of December&#160;31, 2024, total unrecognized compensation cost related to RSUs was $3.4 million, which is expected to be recognized over a remaining weighted-average vesting period of 2.8 years.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Stock Options</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Stock option activity under the 2019 Plan is set forth below:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.367%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.888%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.918%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of<br/>Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise&#160;Price Per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term&#160;(Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Value</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding, December 31, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">986,819&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.87&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.44</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">228&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.99&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(85,124)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9,623)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.70&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(458,276)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding, December&#160;31, 2024</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">489,296&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.53</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">370&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested and expected to vest, December&#160;31, 2024</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">489,296&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.53</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">370&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Options exercisable, December&#160;31, 2024</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">468,706&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.65&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.42</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">332&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The weighted-average grant date fair value per share of options granted during the years ended December&#160;31, 2024 and 2023 was $1.44 and $2.17, respectively. The aggregate intrinsic value of options exercised during the years ended December&#160;31, 2024 and 2023 was $0.3 million and $0.2 million, respectively. The intrinsic value is calculated as the difference between the fair value of the Company's common stock and the exercise price of the stock options. The fair value of the Company's common stock was $4.10 and $1.99 per share at December&#160;31, 2024 and 2023, respectively. As of December&#160;31, 2024, total unrecognized compensation cost related to option awards was negligible.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">2019 Employee Stock Purchase Plan</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In September 2019, the Board adopted, and the Company's stockholders approved, the ESPP. The ESPP became effective on the day the ESPP was adopted by the Board. The ESPP permits participants to purchase common stock through payroll deductions of up to 20% of their eligible compensation. The number of shares of common stock available for issuance under the ESPP will be annually increased on the first day of each calendar year during the term of the ESPP through January 1, 2029 in an amount equal to the lesser of (i) 1% of the outstanding capital stock on each December 31st, or (ii) such lesser amount determined by the Board. During the year ended December&#160;31, 2024, the Company issued 96,048 shares of common stock pursuant to scheduled purchases under the ESPP. As of December&#160;31, 2024, 523,744 shares of common stock remained available for issuance. Pursuant to the evergreen provision, on January 1, 2025, an additional 176,403 shares became available for issuance under the ESPP.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Stock-based compensation expense related to the ESPP for each of the years ended December&#160;31, 2024 and 2023 was less than $0.1 million. As of December&#160;31, 2024, total unrecognized compensation cost related to stock purchase rights granted under the ESPP was less than $0.1 million, which is expected to be recognized over a remaining weighted-average vesting period of 0.2 years.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Stock-Based Compensation Expense</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total non-cash stock-based compensation expense recorded related to options granted, RSUs granted and stock purchase rights granted under the ESPP in the statement of operations is as follows (in thousands):</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.075%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">159&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">191&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,374&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,174&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">230&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">252&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,763&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,617&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Common stock reserved for future issuance consists of the following at December&#160;31, 2024:</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:77.408%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.784%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Warrants to purchase common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,130,281&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock option grants issued and outstanding</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">489,296&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock reserved for issuance upon vesting of outstanding restricted stock units</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,710,373&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock available for grant under the 2019 Plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,189,228&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock available for future issuance under ESPP</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">523,744&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,042,922&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46061881026304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The provision for income taxes consists of the following (in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total deferred</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The effective tax rate of our provision for income taxes differs from the federal statutory rate as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.660%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Federal statutory tax rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State income taxes, net of federal tax benefits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development tax credits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-deductible expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(15.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(18.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Significant components of the Company&#8217;s deferred tax assets at December&#160;31, 2024 and 2023 are shown below (in thousands). A valuation allowance has been established as realization of the Company&#8217;s deferred tax assets has not met the more likely-than-not threshold requirement. If the Company&#8217;s judgment changes and it is determined </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">that the Company will be able to realize these deferred tax assets, the tax benefits relating to any reversal of the valuation allowance on deferred tax assets will be accounted for as a reduction to income tax expense (in thousands).</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35,348&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32,479&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development tax credits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,360&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,353&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accruals, reserves and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">955&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,119&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,785&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,547&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Indefinite lived assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">276&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">598&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,391&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Lease liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">681&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">925&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Capitalization of research and experimentation costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,942&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,929&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total gross deferred tax assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45,945&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44,043&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: valuation allowance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(45,237)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(42,942)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred tax assets, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">708&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,101&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Right of use assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(592)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(814)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Basis differences in fixed and intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(116)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(287)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(708)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,101)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Changes in the valuation allowance for deferred tax assets during the years ended December&#160;31, 2024 and 2023, which related primarily to increases in net operating loss (NOL) carryforwards, research and development tax credits, and capitalization of research and experimentation costs were as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Valuation allowance at the beginning of the year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42,942&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38,567&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Increases recorded to income tax provision</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,295&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,375&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Valuation allowance at the end of the year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45,237&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42,942&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">At December&#160;31, 2024 and 2023, the Company had federal NOL carryforwards of approximately $141.5 million and $129.8 million, respectively. At December&#160;31, 2024 and 2023, the Company had state NOL carryforwards of $98.7 million and $91.0 million, respectively. Approximately $43.5 million of the federal tax loss carryforwards will begin to expire in 2025, unless previously utilized. The federal NOL carryforwards generated after December 31, 2017 of $98.0 million will carryforward indefinitely. The Company&#8217;s state tax loss carryforwards will begin to expire in 2030, unless previously utilized.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">At December&#160;31, 2024, the Company's deferred tax assets are primarily comprised of federal and state tax NOL carryforwards. The Company completed a formal study through the year ended December 31, 2019 and determined ownership changes within the meaning of Internal Revenue Code (IRC), Section 382 had occurred in 2003, 2008, 2012, 2017 and 2019. Based on the analysis, $58.4 million of the Company's tax attribute carryforwards through December 31, 2017 cannot be utilized under IRC Section 382. The Company's ability to utilize NOL carryforwards generated after December 31, 2017 will not expire under the Tax Cuts and Jobs Act of 2017. The Company adjusted tax attribute carry forwards and deferred tax assets accordingly. As the deferred tax assets associated with the tax attribute carry forwards were fully offset by a valuation allowance, a corresponding reduction in the Company's valuation allowance was also recorded, resulting in no income tax impact.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company is subject to taxation in the United States and in various state jurisdictions. The Company&#8217;s tax years for 2004 and forward are subject to examination by the U.S. and state tax authorities due to the carryforward of unutilized NOLs and research and development credits. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company recognizes interest and/or penalties related to income tax matters in its provision for income taxes. The Company does not have any material accruals for, and did not recognize any, material interest or penalties in these financial statements in any period presented. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Uncertain Tax Positions </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">At December&#160;31, 2024 and 2023, the Company had no unrecognized tax benefits. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company does not believe that the balance of unrecognized tax benefits will materially change within the next twelve months.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46061981708736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>401(k) Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">401(k) Plan</a></td>
<td class="text">401(k) Plan<div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company sponsors an employee savings plan that qualifies as a deferred salary arrangement under Section 401(k) of the Code. Participating employees may defer up to the Internal Revenue Service annual contribution limit. Additionally, the Company may elect to make contributions into the savings plan at its sole discretion. For each of the years ended December&#160;31, 2024 and 2023, the Company made contributions to the 401(k) Plan at 4% of qualified employee compensation. For each of the years ended December&#160;31, 2024 and 2023, these contributions totaled approximately $0.8 million.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480794/715-70-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480482/715-20-55-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/715/tableOfContent<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480126/715-20-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480266/715-60-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46061879997664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Reporting</a></td>
<td class="text">Segment Reporting<div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the CODM in making decisions regarding resource allocation and assessing performance. The Company operates in a single operating segment focused on the design, development and commercialization of testing products which allow for the differential diagnosis, prognosis and monitoring of complex rheumatic, autoimmune and autoimmune-related disease. Segment revenue is primarily derived from the sale of the Company&#8217;s testing products, most of which is attributable to its AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD test.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company&#8217;s CODM is its Chief Executive Officer. The CODM assesses performance for the segment and decides how to allocate resources based on revenue and net loss as reported on the Statement of Operations, after taking into account the Company&#8217;s strategic priorities, its cash balance and its expected use of cash. The CODM considers budget/forecast versus actual results on a quarterly basis when making decisions about the allocation of resources. The measure of segment assets is reported on the balance sheet as total assets and were $44.7 million and $56.9 million for the years ended December&#160;31, 2024 and 2023, respectively. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Segment revenue and net loss, including significant segment expenses regularly provided to the CODM are as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.876%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.184%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="12" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55,641&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52,548&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Costs of revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,529&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23,092&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross margin</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33,112&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29,456&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Segment operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27,753&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27,070&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outside services</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,253&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,920&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Facilities related</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,674&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,125&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Travel &amp; entertainment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,440&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,469&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,604&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,426&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,041&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,426&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">1</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,983&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,857&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total segment operating expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46,748&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52,293&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13,636)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(22,837)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,234)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,335)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">767&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,516&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(15,103)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(23,656)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Segment net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(15,115)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(23,689)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"> Other segment items included in Segment net loss include insurance expenses, trade show and conference expenses, fulfillment expenses, board compensation, clinical trial expenses, collaboration expenses and bank fees, among others.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46061880539936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (15,115)<span></span>
</td>
<td class="num">$ (23,689)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46061874758992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46061880658160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Policies and Procedures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingPoliciesProcLineItems', window );"><strong>Insider Trading Policies and Procedures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTrdPoliciesProcAdoptedFlag', window );">Insider Trading Policies and Procedures Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingPoliciesProcLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingPoliciesProcLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTrdPoliciesProcAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTrdPoliciesProcAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46061880337680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cybersecurity Risk Management and Strategy Disclosure<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems', window );"><strong>Cybersecurity Risk Management, Strategy, and Governance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock', window );">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We recognize the critical importance of maintaining the trust and confidence of physicians, patients, business partners and employees toward our business and are committed to protecting the confidentiality, integrity and availability of our business operations and systems. Our board of directors is actively involved in oversight of our risk management activities, and cybersecurity represents an important element of our overall approach to risk management. Our cybersecurity policies, standards, processes and practices are based on recognized frameworks established by NIST and other applicable industry standards, as well as the HIPAA Security Rule and other recognized frameworks. In general, we seek to address cybersecurity risks through a comprehensive, cross-functional approach that is focused on preserving the confidentiality, security and availability of the information that we collect and store by identifying, preventing and mitigating cybersecurity threats and effectively responding to cybersecurity incidents when they occur.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Cybersecurity Risk Management and Strategy; Effect of Risk</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We face risks related to cybersecurity such as unauthorized access, cybersecurity attacks and other security incidents, including as perpetrated by hackers and unintentional damage or disruption to hardware and software systems, loss of data, and misappropriation of confidential information. To identify and assess material risks from cybersecurity threats, we maintain a comprehensive cybersecurity program to ensure our systems are effective and prepared for information security risks, including regular oversight of our programs for security monitoring for internal and external threats to ensure the confidentiality and integrity of our information assets. We consider risks from cybersecurity threats in addition to other company risks as part of our overall risk assessment process. We employ a range of tools and services, including regular network and endpoint monitoring, audits, vulnerability assessments, and penetration testing to inform our risk identification and assessment. As discussed in more detail under &#8220;Cybersecurity Governance&#8221; below, our Audit Committee provides oversight of our cybersecurity risk management and strategy processes, which are led by our Vice President of Information Services.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We also identify our cybersecurity threat risks by comparing our processes to standards set by NIST, as well as performing intrusion detection and prevention. To provide for the availability of critical data and systems, maintain regulatory compliance, manage our material risks from cybersecurity threats, and protect against and respond to cybersecurity incidents, we undertake the following activities:</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">a.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:9.67pt">monitor emerging data protection laws and implement changes to our processes that are designed to comply with such laws;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">b.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:9.67pt">through our policies, practices and contracts (as applicable), require employees, as well as third parties that provide services on our behalf, to treat confidential information and data with care;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">c.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10.23pt">employ technical safeguards that are designed to protect our information systems from cybersecurity threats, including firewalls, intrusion prevention and detection systems, anti-malware functionality and access controls, which are evaluated and improved through vulnerability assessments and cybersecurity threat intelligence;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">d.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:9.67pt">provide regular, mandatory training for our employees regarding cybersecurity threats as a means to equip them with effective tools to address cybersecurity threats, and to communicate our evolving information security policies, standards, processes and practices;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">e.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:9.67pt">conduct regular phishing email simulations for all employees with access to our email systems to enhance awareness and responsiveness to possible threats;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">f.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:12.46pt">conduct monthly cybersecurity management and incident training for employees involved in our systems and processes that handle sensitive data;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">g.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:9.67pt">leverage internal and external resources to help us identify, protect, detect, respond and recover when there is an actual or potential cybersecurity incident; and</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">h.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:9.67pt">carry information security risk insurance that provides protection against the potential losses arising from a cybersecurity incident</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our incident response plan coordinates the activities we take to prepare for, detect, respond to and recover from cybersecurity incidents, which include processes to triage, assess severity for, escalate, contain, investigate and remediate the incident, as well as to comply with potentially applicable legal obligations and mitigate damage to our business and reputation. As part of the above processes, we rely on internal resources rather than consultants, auditors or other third parties, to review our cybersecurity program.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our processes also address cybersecurity threat risks associated with our use of third-party service providers, including our suppliers and manufacturers or who have access to patient and employee data or our systems. In addition, cybersecurity considerations affect the selection and oversight of our third-party service providers. We perform diligence on third parties that have access to our systems, data or facilities that house such systems or data.</span></div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We describe whether and how risks from identified cybersecurity threats, including as a result of any previous cybersecurity incidents, have materially affected or are reasonably likely to materially affect us, including our business strategy, results of operations, or financial condition, under the heading &#8220;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Failure in our information technology, telephone or other systems could significantly disrupt our operations and adversely affect our business and financial condition</span>,&#8221; which disclosures are incorporated by reference herein.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag', window );">Cybersecurity Risk Management Processes Integrated [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock', window );">Cybersecurity Risk Management Processes Integrated [Text Block]</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We also identify our cybersecurity threat risks by comparing our processes to standards set by NIST, as well as performing intrusion detection and prevention. To provide for the availability of critical data and systems, maintain regulatory compliance, manage our material risks from cybersecurity threats, and protect against and respond to cybersecurity incidents, we undertake the following activities:</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">a.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:9.67pt">monitor emerging data protection laws and implement changes to our processes that are designed to comply with such laws;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">b.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:9.67pt">through our policies, practices and contracts (as applicable), require employees, as well as third parties that provide services on our behalf, to treat confidential information and data with care;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">c.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10.23pt">employ technical safeguards that are designed to protect our information systems from cybersecurity threats, including firewalls, intrusion prevention and detection systems, anti-malware functionality and access controls, which are evaluated and improved through vulnerability assessments and cybersecurity threat intelligence;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">d.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:9.67pt">provide regular, mandatory training for our employees regarding cybersecurity threats as a means to equip them with effective tools to address cybersecurity threats, and to communicate our evolving information security policies, standards, processes and practices;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">e.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:9.67pt">conduct regular phishing email simulations for all employees with access to our email systems to enhance awareness and responsiveness to possible threats;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">f.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:12.46pt">conduct monthly cybersecurity management and incident training for employees involved in our systems and processes that handle sensitive data;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">g.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:9.67pt">leverage internal and external resources to help us identify, protect, detect, respond and recover when there is an actual or potential cybersecurity incident; and</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">h.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:9.67pt">carry information security risk insurance that provides protection against the potential losses arising from a cybersecurity incident</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag', window );">Cybersecurity Risk Management Third Party Engaged [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag', window );">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag', window );">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock', window );">Cybersecurity Risk Board of Directors Oversight [Text Block]</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Cybersecurity Governance; Management</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cybersecurity is an important part of our risk management processes and an area of focus for our board of directors and management. In general, our board of directors oversees risk management activities designed and implemented by our management, and considers specific risks, including, for example, risks associated with our strategic plan, business operations, and capital structure. Our board of directors executes its oversight responsibility for risk management both directly and through delegating oversight of certain of these risks to its committees, and our board of directors has authorized our Audit Committee to oversee risks from cybersecurity threats. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Upon detection of a material cybersecurity threat, our Audit Committee receives an update from management of the cybersecurity threat, risk management and strategy processes, as well as the steps management has taken to respond to such risks. In such sessions, our Audit Committee generally receives materials that include cybersecurity materials discussing current material cybersecurity threat risks, and describing our ability to mitigate those risks, and discusses such matters with our Chief Executive Officer. Our Audit Committee and board of directors receive prompt and timely information regarding any cybersecurity incident that meets established reporting thresholds. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our cybersecurity risk management and strategy processes, which are discussed in greater detail above, are led by our Vice President of Information Services, with support from our entire Information Services department. Such individuals have collectively over 10 years of prior work experience in various roles involving managing information security, developing cybersecurity strategy, implementing effective information and cybersecurity programs, as well as several relevant degrees and certifications. These Information Services team members are informed about and monitor the prevention, mitigation, detection, and remediation of cybersecurity incidents through their management of, and participation in, the cybersecurity risk management and strategy processes described above, including the operation of our incident response plan. As discussed above, these Information Services team members report to our Chief Executive Officer, and ultimately to the Audit Committee of our board of directors about material cybersecurity threats.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text">Cybersecurity is an important part of our risk management processes and an area of focus for our board of directors and management. In general, our board of directors oversees risk management activities designed and implemented by our management, and considers specific risks, including, for example, risks associated with our strategic plan, business operations, and capital structure. Our board of directors executes its oversight responsibility for risk management both directly and through delegating oversight of certain of these risks to its committees, and our board of directors has authorized our Audit Committee to oversee risks from cybersecurity threats.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text">In such sessions, our Audit Committee generally receives materials that include cybersecurity materials discussing current material cybersecurity threat risks, and describing our ability to mitigate those risks, and discusses such matters with our Chief Executive Officer. Our Audit Committee and board of directors receive prompt and timely information regarding any cybersecurity incident that meets established reporting thresholds.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskRoleOfManagementTextBlock', window );">Cybersecurity Risk Role of Management [Text Block]</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cybersecurity is an important part of our risk management processes and an area of focus for our board of directors and management. In general, our board of directors oversees risk management activities designed and implemented by our management, and considers specific risks, including, for example, risks associated with our strategic plan, business operations, and capital structure. Our board of directors executes its oversight responsibility for risk management both directly and through delegating oversight of certain of these risks to its committees, and our board of directors has authorized our Audit Committee to oversee risks from cybersecurity threats. </span></div>Upon detection of a material cybersecurity threat, our Audit Committee receives an update from management of the cybersecurity threat, risk management and strategy processes, as well as the steps management has taken to respond to such risks. In such sessions, our Audit Committee generally receives materials that include cybersecurity materials discussing current material cybersecurity threat risks, and describing our ability to mitigate those risks, and discusses such matters with our Chief Executive Officer. Our Audit Committee and board of directors receive prompt and timely information regarding any cybersecurity incident that meets established reporting thresholds.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</a></td>
<td class="text">Cybersecurity is an important part of our risk management processes and an area of focus for our board of directors and management. In general, our board of directors oversees risk management activities designed and implemented by our management, and considers specific risks, including, for example, risks associated with our strategic plan, business operations, and capital structure. Our board of directors executes its oversight responsibility for risk management both directly and through delegating oversight of certain of these risks to its committees, and our board of directors has authorized our Audit Committee to oversee risks from cybersecurity threats.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock', window );">Cybersecurity Risk Management Expertise of Management Responsible [Text Block]</a></td>
<td class="text">Our cybersecurity risk management and strategy processes, which are discussed in greater detail above, are led by our Vice President of Information Services, with support from our entire Information Services department. Such individuals have collectively over 10 years of prior work experience in various roles involving managing information security, developing cybersecurity strategy, implementing effective information and cybersecurity programs, as well as several relevant degrees and certifications.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our incident response plan coordinates the activities we take to prepare for, detect, respond to and recover from cybersecurity incidents, which include processes to triage, assess severity for, escalate, contain, investigate and remediate the incident, as well as to comply with potentially applicable legal obligations and mitigate damage to our business and reputation. As part of the above processes, we rely on internal resources rather than consultants, auditors or other third parties, to review our cybersecurity program.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementThirdPartyEngagedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskRoleOfManagementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskRoleOfManagementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46061880547616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk and Other Risk and Uncertainties</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Concentration of Credit Risk and Other Risk and Uncertainties</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Financial instruments that potentially subject the Company to credit risk consist principally of cash, cash equivalents and accounts receivable. Substantially all the Company's cash and cash equivalents are held at one financial institution that management believes is of high credit quality. Such deposits may, at times, exceed federally insured limits. The Company has not experienced any losses on its cash or cash equivalents.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash, Cash Equivalents and Restricted Cash</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Cash, Cash Equivalents and Restricted Cash</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company considers all highly-liquid investments purchased with a remaining maturity date of three months or less upon acquisition to be cash equivalents. These investments are stated at cost, which approximates fair value.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Property and Equipment</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Property and equipment are stated at cost, net of depreciation and amortization. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally between <span style="-sec-ix-hidden:f-296">three</span> and five years. Leasehold improvements are amortized on a straight-line basis over the lesser of the estimated useful life or the remaining term of the related lease. Maintenance and repairs are charged to expense as incurred, and improvements and betterments are capitalized. When assets are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the balance sheet and any resulting gain or loss is reflected in operating expenses in the statements of operations in the period realized.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Long-lived Assets</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Long-lived Assets</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company&#8217;s long-lived assets are comprised principally of its property and equipment and operating lease assets. The Company amortizes all finite lived intangible assets over their respective estimated useful lives. Operating lease assets are amortized over the term of the leases. In considering whether long-lived assets are impaired, the Company combines its long-lived assets into groupings, a determination which is made principally on the basis of whether the assets are specific to a particular test offered or technology being developed. If the Company identifies a change in the circumstances related to its long-lived assets that indicates the carrying value of any such asset may not be recoverable, the Company will perform an impairment analysis. A long-lived asset is deemed to be impaired when the undiscounted cash flows expected to be generated by the asset (or asset group) are less than the asset&#8217;s carrying amount. Management&#8217;s estimates of future cash flows are impacted by projected test volume and levels of reimbursement, as well as expectations related to the future cost structure of the entity. Any required impairment loss would be measured as the amount by which the asset&#8217;s carrying value exceeds its fair value, and would be recorded as a reduction in the carrying value of the related asset and a charge to operating expense.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Leases</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company categorizes leases at their commencement as either operating or finance leases. The Company recognizes operating lease ROU assets and operating lease liabilities for each lease arrangement identified. Lease liabilities are recorded at the present value of future lease payments discounted using the Company's incremental borrowing rate for the lease established at the commencement date. The incremental borrowing rate is the rate of interest the Company would have to pay to borrow, on a collateralized basis over a similar term and in a similar economic environment, an amount equal to the total lease payments. The Company primarily considers industry data, its credit rating and the lease term to determine its incremental borrowing rate. ROU assets are measured at the amount of the lease liability plus any initial direct costs, less any lease incentives received before commencement. Lease expense is recognized as a single lease cost over the lease term on a straight-line basis. The Company has elected not to apply the recognition requirements to short-term leases and not to separate non-lease components from lease components for its leases.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_ClinicalStudyPolicyPolicyTextBlock', window );">Clinical Studies</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Clinical Studies</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">From time to time, the Company engages in efforts to scientifically measure and document the application and efficacy of its various testing products. These arrangements typically require the Company to pay a fee to a third-party scientific investigator (usually a physician or research institution) for each subject enrolled in a clinical study, and the Company accrues expenses based on estimated progress of services performed, including actual level of subjects enrolled and progress of the clinical studies. Payments made prior to the completion of clinical study services are capitalized as a prepaid expense. The prepaid amounts are expensed as the related goods are delivered or the services are performed, or when it is no longer expected that the goods will be delivered or the services rendered. Expenses associated with clinical study activities are recorded in research and development expenses in the accompanying statement of operations.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Revenue Recognition</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Substantially all of the Company's revenue has been derived from sales of its testing products and is primarily comprised of a high volume of relatively low-dollar transactions. The Company primarily markets its testing products to rheumatologists and their physician assistants in the United States. The healthcare professionals who order the Company's testing products and to whom test results are reported are generally not responsible for payment for these products. The parties that pay for these services (each, a payor) consist of commercial payors (healthcare insurers), government payors (primarily Medicare and Medicaid), client payors (hospitals, other laboratories, etc.) and patient self-pay. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company recognizes revenue in accordance with Accounting Standards Codification Topic 606, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> and follows a five-step process to determine the amount and timing of revenue recognized: (1) identify the contract with the customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to performance obligations in the contract, and (5) recognize revenue when (or as) the performance obligation is satisfied. The Company's service is a single performance obligation that is completed upon the delivery of test results to the prescribing physician which triggers revenue recognition.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Payors are generally billed at the Company's list price, unless a separate pricing contract is in place. Net revenues recognized consist of amounts billed net of allowances for differences between amounts billed and the estimated consideration the Company expects to receive from such payors. The process for estimating revenues and the ultimate collection of accounts receivable involves significant judgment and estimation. The Company follows a standard process, which considers historical denial and collection experience, insurance reimbursement policies and other factors, to estimate allowances and implicit price concessions. Adjustments are recorded in the current period as changes in estimates occur. Further adjustments to the allowances, based on actual receipts, are recorded upon settlement. Included in revenues for the years ended December&#160;31, 2024 and 2023 were net revenue increases of $6.6 million and $3.4 million, respectively, associated with changes in estimated variable consideration related to performance obligations satisfied in previous periods. The transaction price is estimated using an expected value method on a portfolio basis.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Variable consideration is included in the transaction price only to the extent it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainties with respect to the amount are resolved. The Company's portfolios are grouped per payor (i.e. each individual commercial payor, Medicare, Medicaid, client payors, patient self-pay, etc.) and per test. Consideration may be constrained and excluded from the transaction price in situations where there is no contractually agreed upon reimbursement coverage or in absence of a predictable pattern and history of collectability with a payor. Accordingly, in such situations revenues are recognized on the basis of actual cash collections. Additionally, from time to time, the Company may issue refunds to payors for overpayments or amounts billed in error. Any refunds are accounted for as reductions in revenues in the statement of operations as an element of variable consideration. The estimated expected refunds are accrued as a liability on the Company&#8217;s balance sheet.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Collection of the Company's net revenues from payors is normally a function of providing complete and correct billing information, along with any requested medical or other claims-related information to the healthcare insurers. This generally occurs within 30 to 90 days of billing, however, the amount and timing of any reimbursements or collections for the Company's billed tests may vary by payor and other circumstances. Contracts do not contain significant financing components based on the typical period of time between performance of services and collection of consideration.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesPolicyTextBlock', window );">Accounts Receivable and Allowance for Credit Losses</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Accounts Receivable and Allowance for Credit Losses</span></div>We accrue an allowance for credit losses against our accounts receivable based on management&#8217;s current estimate of amounts that will not be collected. Management&#8217;s estimates are typically based on historical loss information adjusted for current conditions. We generally do not perform evaluations of the financial condition of our customers and generally do not require collateral. The allowance for credit losses was zero as of each of December&#160;31, 2024 and 2023. Adjustments for implicit price concessions attributable to variable consideration, as discussed above, are incorporated into the measurement of the accounts receivable balances and are not part of the allowance for credit losses.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Research and Development</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Costs associated with research and development activities are expensed as incurred and include, but are not limited to, personnel-related expenses, including stock-based compensation expense; materials; laboratory </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">supplies; consulting costs; costs associated with setting up and conducting clinical studies; depreciation; amortization and allocated overhead, including rent and utilities.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvertisingCostsPolicyTextBlock', window );">Advertising and Marketing Costs</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Advertising and Marketing Costs</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Costs associated with advertising and marketing activities are expensed as incurred. Total advertising and marketing costs were approximately $1.4 million and $1.5 million for the years ended December&#160;31, 2024 and 2023, respectively, and are included in selling, general and administrative expenses in the accompanying statements of operations.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfSalesPolicyTextBlock', window );">Shipping and Handling Costs</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Shipping and Handling Costs</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Costs incurred for shipping and handling are included in costs of revenue in the accompanying statements of operations and were approximately $3.1 million and $2.5 million for the years ended December&#160;31, 2024 and 2023, respectively.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Stock-Based Compensation</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company recognizes compensation expense for all stock-based awards to employees and directors based on the grant-date estimated fair values over the requisite service period of the awards (usually the vesting period) on a straight-line basis. Equity award forfeitures are recorded as they occur.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The fair value of each restricted stock unit (RSU) is determined on the grant date using the closing price of the Company's common stock on that date. The Company's RSUs generally vest in equal annual installments over four years from the date of grant or, for grants to new hires, date of hire. Vesting of the RSU is subject to the holder's continued service with the Company. The Company issues new shares of common stock to satisfy the RSUs upon vesting.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Comprehensive Loss</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Comprehensive loss is defined as a change in equity of a business enterprise during a period, resulting from transactions from nonowner sources. There have been no items qualifying as other comprehensive loss and, therefore, for all periods presented, the Company's comprehensive loss was the same as its reported net loss.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Income Taxes</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized as an expense in the period that includes the enactment date. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company recognizes net deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If management determines that the Company would be able to realize its deferred tax assets in the future in excess of their net recorded amount, management would adjust the deferred tax asset valuation allowance, which would reduce the provision for income taxes. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company records uncertain tax positions on the basis of a two-step process whereby (i) management determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (ii) for those tax positions that meet the more-likely-than-not recognition threshold, management recognizes the largest amount of tax benefit that is more than 50% likely to be realized upon ultimate settlement with the related tax authority. The Company recognizes interest and penalties related to unrecognized tax benefits within income tax expense. Any accrued interest and penalties are included within the related tax liability.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Net Loss Per Share</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Basic net loss per share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common stock outstanding during the period. Diluted net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">stockholders by the weighted-average number of common stock equivalents outstanding for the period determined using the treasury-stock and if-converted methods. The weighted-average number of shares used to compute basic and diluted shares includes shares issuable upon the exercise of pre-funded warrants at a nominal price. Potentially dilutive common stock equivalents are comprised of warrants for the purchase of common stock, stock options, RSUs outstanding under the Company's 2019 Incentive Award Plan (the 2019 Plan) and shares of the Company's common stock pursuant to the Exagen Inc. 2019 Employee Stock Purchase Plan (ESPP). For each of the years ended December&#160;31, 2024 and 2023, there is no difference in the number of shares used to calculate basic and diluted shares outstanding as the inclusion of the potentially dilutive securities would be antidilutive.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements and Recently Adopted Accounting Standards</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Recent Accounting Pronouncements</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB), or other standard setting bodies and adopted by the Company as of the specified effective date. Unless otherwise discussed, Accounting Standards Updates (ASU) not included in the Company&#8217;s disclosures were assessed and determined to be either not applicable or are not expected to have a material impact on the Company&#8217;s financial statements or disclosures.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">In December 2023, the FASB issued ASU 2023-09,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%"> Income Taxes (Topic 740): Improvements to Income Tax Disclosures</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> (ASU 2023-09), which requires additional income tax disclosures in the rate reconciliation table for federal, state and foreign income taxes, in addition to more details about the reconciling items in some categories when items meet a certain quantitative threshold. ASU 2023-09 is effective for annual periods beginning after December 15, 2024 with early adoption permitted. This update will result in enhanced income tax disclosures, and the Company does not expect any impact to income tax expense.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">In November 2024, the FASB issued ASU 2024-03, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%">Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> (&#8220;ASU 2024-03&#8221;). This update requires entities to include more detailed information about the types of expenses, including purchases of inventory, employee compensation, depreciation, amortization, and depletion, in commonly presented expense captions such as cost of sales, research and development, and selling, general and administrative expenses. ASU 2024-03 is effective for annual periods beginning after December 15, 2026, with early adoption permitted. The company is currently evaluating the impact of this standard on its financial statement presentation and disclosures.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:107%">Recently Adopted Accounting Standards</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In November 2023, the FASB issued ASU No. 2023-07, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (ASU 2023-07), which requires public entities to disclose significant segment expenses that are regularly provided to the Chief Operating Decision Maker (CODM) and details of how the CODM uses financial reporting to assess the performance of a segment. The Company adopted this pronouncement in 2024 and retrospectively to all prior periods using the significant segment expense categories identified. The impact of the adoption of the amendments in this update was not material to the Company&#8217;s financial position and results of operations, as the requirements impact only segment reporting disclosures in the footnotes to the Company&#8217;s financial statements.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The carrying values of the Company's cash, cash equivalents and restricted cash, accounts receivable, prepaid expenses and other current assets, accounts payable and accrued and other current liabilities are determined to be a Level 1 measurement. The carrying values of these items approximate their fair values due to their short-term nature. The estimated fair value of the Company's long-term borrowings is determined by Level 2 inputs and based primarily on quoted market prices for similar issues. As of December&#160;31, 2024, the Amended Loan Agreement had a carrying value of $19.1 million and a fair value of $19.2 million. As of December 31, 2023, the Amended Loan Agreement had a carrying value of $18.7&#160;million and a fair value of $19.7&#160;million. The estimated fair value of the Amended Loan Agreement was determined based on a discounted cash flow approach using available market information on discount and borrowing rates with similar terms, maturities, and credit ratings. The aggregate carrying value of the Company's other long-term borrowings as of December&#160;31, 2024 was $1.1&#160;million and approximated its fair value.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Fair value is defined as the exchange price that would be received for an asset or an exit price paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The three-levels of the valuation hierarchy for disclosure of fair value measurements are defined as follows:</span></div><div style="margin-top:9pt;padding-left:94.5pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Level 1 -&#160;&#160;&#160;&#160;Unadjusted quoted prices in active markets for identical assets or liabilities;</span></div><div style="margin-top:9pt;padding-left:94.5pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Level 2 -&#160;&#160;&#160;&#160;Inputs other than quoted prices included within Level 1 that are observable, unadjusted quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and</span></div><div style="margin-top:9pt;padding-left:94.5pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Level 3 -&#160;&#160;&#160;&#160;Unobservable inputs that are supported by little or no market activity for the related assets or liabilities.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The categorization of a financial instrument within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_ClinicalStudyPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Clinical Study, Policy</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_ClinicalStudyPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for advertising cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 35<br> -Topic 720<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483406/720-35-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478898/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfSalesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cost of product sold and service rendered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Topic 705<br> -Publisher FASB<br> -URI https://asc.fasb.org/705/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfSalesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeStockOwnershipPlanESOPPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for ESOP transactions, including the method of measuring compensation, the classification of dividends on ESOP shares, and the treatment of ESOP shares for EPS computations. If the employer has both old ESOP shares for which it does not adopt new guidance and new ESOP shares for which new guidance is required, these disclosures are required for both blocks of shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 40<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480489/718-40-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeStockOwnershipPlanESOPPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481569/310-20-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46061981580624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Schedule of Concentration of Risk, by Risk Factor and Significant Payer</a></td>
<td class="text">For each significant payor and customer, <div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">revenue as a percentage of total revenue and accounts receivable as a percentage of total accounts receivable are as follows:</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.707%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.768%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Revenue</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medicare Advantage</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United Healthcare</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">*</span></td></tr></table></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.847%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.724%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.129%"></td><td style="width:0.1%"></td></tr><tr style="height:8pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less than 10%.</span></td></tr></table></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.707%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.768%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accounts Receivable</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medicare Advantage</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of Disaggregation of Revenue</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table includes the Company's revenues as disaggregated by payor and customer category (in&#160;thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.707%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.768%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23,985&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,323&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,002&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Client(1)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,360&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,949&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other(2)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">358&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">612&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55,641&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52,548&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.24pt">Includes hospitals, other laboratories, etc.</span></div><div style="padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.24pt">Includes patient self-pay.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Schedule of Cash and Cash Equivalents</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cash, cash equivalents and restricted cash presented in the accompanying statements of cash flows consist of the following (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.707%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.768%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,036&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36,493&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,236&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36,693&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock', window );">Schedule of Restricted Cash and Cash Equivalents</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cash, cash equivalents and restricted cash presented in the accompanying statements of cash flows consist of the following (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.707%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.768%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,036&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36,493&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,236&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36,693&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Potentially dilutive securities not included in the calculation of diluted net loss per share, because to do so would be anti-dilutive, are as follows (in common stock equivalent shares):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.707%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.768%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Warrants to purchase common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">325,330&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">409,108&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">489,296&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">986,819&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,710,373&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,387,459&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock purchase plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57,461&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,582,460&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,828,086&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-16<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46061881381376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Financial Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_OtherFinancialInformationAbstract', window );"><strong>Other Financial Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">Schedule of Prepaid Expenses and Other Current Assets</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Prepaid expenses and other current assets consist of the following (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.707%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.768%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Diagnostic&#160;testing&#160;supplies</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,725&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,871&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">859&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,926&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,584&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,797&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Property and equipment consist of the following (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.707%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.768%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Furniture&#160;and&#160;fixtures</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,248&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,312&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,113&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,185&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,286&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,316&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,543&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,295&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,970&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: accumulated depreciation and amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6,012)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,769)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,283&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,201&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued and Other Current Liabilities</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Accrued and other current liabilities consist of the following (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.707%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.768%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued&#160;payroll&#160;and&#160;related&#160;expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,046&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,738&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,804&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,793&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,850&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,531&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_OtherFinancialInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Financial Information</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_OtherFinancialInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46061987456288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Borrowings (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of Future Minimum Aggregate Payments for Outstanding Borrowings</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December&#160;31, 2024, future minimum aggregate payments, including interest, for outstanding borrowings are as follows (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.303%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.767%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ending December 31,</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,076&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21,400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">215&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23,758&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unamortized debt discount and issuance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(70)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,443)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total borrowings, net of discounts and debt issuance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,245&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: Borrowings-current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(423)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Borrowings-non-current portion, net of discounts and debt issuance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19,822&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46061881599040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Lease Costs</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Operating and finance leases consist of the following (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.361%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.163%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.783%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.786%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Lease Balance</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Lease Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,401&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,286&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-425"><span style="-sec-ix-hidden:f-426">Property and equipment, net</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">486&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">810&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Lease Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,096&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">976&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-431"><span style="-sec-ix-hidden:f-432">Accrued and other current liabilities</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">201&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">490&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,664&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,760&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-437"><span style="-sec-ix-hidden:f-438">Other non-current liabilities</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">157&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">358&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Costs associated with the Company's leases were included in the statements of operations as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.794%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.783%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.785%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Lease Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease cost</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,345&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,463&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finance lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of lease assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">280&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">556</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest on finance lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">128</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total lease cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,709&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,147&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">(1) Includes variable lease cost of $196,000 and $129,000 for the years ended December&#160;31, 2024 and 2023, respectively.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Supplemental cash flow information on leases is as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.794%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.783%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.785%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating cash out flows from operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,240&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,405&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating cash out flows from interest paid on finance leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">128&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Financing cash out flows from finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">490&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">697&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Information regarding the weighted-average lease term and weighted average discount rate are as follows:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.783%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.785%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average remaining lease term (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.76</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.06</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Lessee, Operating Lease, Liability, Maturity</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Future payments under operating and finance leases as of December&#160;31, 2024 are as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.917%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.783%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.784%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Finance Leases</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,277&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">248&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,315&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">147&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">445&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total minimum lease payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,037&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">423&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(277)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(65)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,760&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">358&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,096)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(201)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Lease obligations, net of current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,664&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">157&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Finance Lease, Liability, Maturity</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Future payments under operating and finance leases as of December&#160;31, 2024 are as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.917%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.783%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.784%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Finance Leases</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,277&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">248&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,315&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">147&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">445&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total minimum lease payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,037&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">423&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(277)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(65)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,760&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">358&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,096)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(201)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Lease obligations, net of current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,664&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">157&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46061987456288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Fair Value, Financial Instrument Measured on a Recurring Basis</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table sets forth the Company's financial instruments that were measured at fair value on a recurring basis within the fair value hierarchy (in thousands):</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.432%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Money market funds, included in cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,144&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,144&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.285%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.579%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Money market funds, included in cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,386&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,386&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46061881901376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of Outstanding Warrants</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following equity classified warrants to purchase common stock were outstanding as of December&#160;31, 2024:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.432%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.783%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.788%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercise Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Issuance date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Expiration date</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">237,169</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.84&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">January 19, 2016</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">January 19, 2026</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">67,086</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.84&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31, 2016</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31, 2026</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">131</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.84&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 1, 2016</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 1, 2026</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,944</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 7, 2018</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 7, 2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock warrants (Exchange Warrants)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">804,951</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.001&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 22, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">None</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,130,281</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46061988112480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Option Plan (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Schedule of Share-based Payment Arrangement, Restricted Stock Unit, Activity</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">RSU activity under the Company's 2019 Plan is set forth below:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.163%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.373%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.378%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Grant Date Fair Value Per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Value</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding, December&#160;31, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,387,459&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.24&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,761&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Awards granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,324,275&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Awards released</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(413,202)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.87&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Awards canceled</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(588,159)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding, December&#160;31, 2024</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,710,373&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.48&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,013&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option Activity</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Stock option activity under the 2019 Plan is set forth below:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.367%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.888%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.918%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of<br/>Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise&#160;Price Per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term&#160;(Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Value</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding, December 31, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">986,819&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.87&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.44</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">228&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.99&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(85,124)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9,623)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.70&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(458,276)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding, December&#160;31, 2024</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">489,296&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.53</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">370&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested and expected to vest, December&#160;31, 2024</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">489,296&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.53</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">370&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Options exercisable, December&#160;31, 2024</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">468,706&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.65&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.42</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">332&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Non-cash Stock-based Compensation Expense</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total non-cash stock-based compensation expense recorded related to options granted, RSUs granted and stock purchase rights granted under the ESPP in the statement of operations is as follows (in thousands):</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.075%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">159&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">191&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,374&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,174&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">230&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">252&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,763&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,617&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock', window );">Schedule of Common Stock Reserved For Future Issuance</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Common stock reserved for future issuance consists of the following at December&#160;31, 2024:</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:77.408%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.784%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Warrants to purchase common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,130,281&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock option grants issued and outstanding</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">489,296&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock reserved for issuance upon vesting of outstanding restricted stock units</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,710,373&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock available for grant under the 2019 Plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,189,228&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock available for future issuance under ESPP</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">523,744&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,042,922&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46061993018144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Components of Income Tax Expense (Benefit)</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The provision for income taxes consists of the following (in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total deferred</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate Reconciliation</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The effective tax rate of our provision for income taxes differs from the federal statutory rate as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.660%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Federal statutory tax rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State income taxes, net of federal tax benefits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development tax credits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-deductible expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(15.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(18.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities</a></td>
<td class="text">If the Company&#8217;s judgment changes and it is determined <div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">that the Company will be able to realize these deferred tax assets, the tax benefits relating to any reversal of the valuation allowance on deferred tax assets will be accounted for as a reduction to income tax expense (in thousands).</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35,348&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32,479&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development tax credits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,360&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,353&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accruals, reserves and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">955&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,119&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,785&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,547&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Indefinite lived assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">276&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">598&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,391&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Lease liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">681&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">925&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Capitalization of research and experimentation costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,942&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,929&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total gross deferred tax assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45,945&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44,043&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: valuation allowance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(45,237)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(42,942)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred tax assets, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">708&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,101&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Right of use assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(592)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(814)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Basis differences in fixed and intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(116)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(287)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(708)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,101)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SummaryOfValuationAllowanceTextBlock', window );">Schedule of Valuation Allowance</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Changes in the valuation allowance for deferred tax assets during the years ended December&#160;31, 2024 and 2023, which related primarily to increases in net operating loss (NOL) carryforwards, research and development tax credits, and capitalization of research and experimentation costs were as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Valuation allowance at the beginning of the year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42,942&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38,567&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Increases recorded to income tax provision</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,295&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,375&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Valuation allowance at the end of the year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45,237&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42,942&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfValuationAllowanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfValuationAllowanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46061880004112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock', window );">Schedule of Reconciliation of Profit or Loss</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Segment revenue and net loss, including significant segment expenses regularly provided to the CODM are as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.876%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.184%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="12" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55,641&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52,548&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Costs of revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,529&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23,092&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross margin</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33,112&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29,456&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Segment operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27,753&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27,070&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outside services</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,253&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,920&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Facilities related</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,674&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,125&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Travel &amp; entertainment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,440&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,469&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,604&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,426&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,041&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,426&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">1</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,983&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,857&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total segment operating expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46,748&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52,293&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13,636)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(22,837)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,234)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,335)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">767&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,516&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(15,103)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(23,656)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Segment net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(15,115)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(23,689)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"> Other segment items included in Segment net loss include insurance expenses, trade show and conference expenses, fulfillment expenses, board compensation, clinical trial expenses, collaboration expenses and bank fees, among others.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46061879990656">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Organization (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 22,036<span></span>
</td>
<td class="nump">$ 36,493<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">$ 294,331<span></span>
</td>
<td class="nump">$ 279,216<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46061880389072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Revenue by Major Payers (Details) - Customer Concentration Risk<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=exdx_MedicareMember', window );">Medicare | Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="nump">34.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=exdx_MedicareMember', window );">Medicare | Accounts Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">13.00%<span></span>
</td>
<td class="nump">42.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=exdx_MedicareAdvantageMember', window );">Medicare Advantage | Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="nump">17.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=exdx_MedicareAdvantageMember', window );">Medicare Advantage | Accounts Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="nump">16.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=exdx_UnitedHealthcareMember', window );">United Healthcare | Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-20<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exdx_MedicareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exdx_MedicareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exdx_MedicareAdvantageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exdx_MedicareAdvantageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exdx_UnitedHealthcareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exdx_UnitedHealthcareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46061880350688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>installment </div>
<div>unit </div>
<div>segment</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportingUnits', window );">Number of reporting units | unit</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Increase (decrease) in revenue recognized</a></td>
<td class="nump">$ 6,600<span></span>
</td>
<td class="nump">3,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancingReceivableAllowanceForCreditLossExcludingAccruedInterest', window );">Allowance for credit loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">7,835<span></span>
</td>
<td class="nump">6,551<span></span>
</td>
<td class="nump">$ 6,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvertisingExpense', window );">Advertising and marketing costs</a></td>
<td class="nump">$ 1,400<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments', window );">Number of annual vesting installments | installment</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ShippingAndHandlingMember', window );">Shipping and Handling</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of revenue</a></td>
<td class="nump">$ 3,100<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Revenue | Supplier Concentration Risk | Supplier One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">71.00%<span></span>
</td>
<td class="nump">66.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Revenue | Supplier Concentration Risk | Supplier Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">26.00%<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Revenue | AVISE CTD Test | Product Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">91.00%<span></span>
</td>
<td class="nump">88.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Annual Installments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 720<br> -SubTopic 35<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483385/720-35-55-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 35<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483406/720-35-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-20<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancingReceivableAllowanceForCreditLossExcludingAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount excluding accrued interest, of allowance for credit loss on financing receivable. Excludes net investment in lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancingReceivableAllowanceForCreditLossExcludingAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476173/280-10-65-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476173/280-10-65-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-9<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-1<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477123/405-50-65-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482477/820-10-65-13<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482477/820-10-65-13<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479845/805-20-65-3<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479845/805-20-65-3<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479845/805-20-65-3<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-5<br><br>Reference 53: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 54: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 55: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 58: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 59: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 60: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 61: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 62: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 63: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 64: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 65: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 66: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 67: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 68: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 69: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 11.M.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480530/250-10-S99-5<br><br>Reference 70: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 71: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 72: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 73: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 74: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 75: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 76: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 77: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 78: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483194/926-20-65-2<br><br>Reference 79: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483194/926-20-65-2<br><br>Reference 80: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483194/926-20-65-2<br><br>Reference 81: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 82: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 83: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 84: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 85: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 86: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-6<br><br>Reference 87: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 88: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 89: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 90: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 91: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 92: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 93: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 94: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 95: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 96: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 97: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 98: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-3<br><br>Reference 99: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br><br>Reference 100: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportingUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportingUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ShippingAndHandlingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ShippingAndHandlingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_SupplierConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_SupplierConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=exdx_SupplierOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=exdx_SupplierOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=exdx_SupplierTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=exdx_SupplierTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=exdx_AVISECTDTestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=exdx_AVISECTDTestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46061879522080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Disaggregation of Revenue (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 55,641<span></span>
</td>
<td class="nump">$ 52,548<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=exdx_CommercialMember', window );">Commercial</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">29,600<span></span>
</td>
<td class="nump">23,985<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=exdx_Government1Member', window );">Government</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">14,323<span></span>
</td>
<td class="nump">18,002<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=exdx_ClientMember', window );">Client</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">11,360<span></span>
</td>
<td class="nump">9,949<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=us-gaap_OtherCustomerMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 358<span></span>
</td>
<td class="nump">$ 612<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exdx_CommercialMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exdx_CommercialMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exdx_Government1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exdx_Government1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exdx_ClientMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exdx_ClientMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=us-gaap_OtherCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=us-gaap_OtherCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46061881595200">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Cash, Cash Equivalents and Restricted Cash (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 22,036<span></span>
</td>
<td class="nump">$ 36,493<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">200<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents and restricted cash</a></td>
<td class="nump">$ 22,236<span></span>
</td>
<td class="nump">$ 36,693<span></span>
</td>
<td class="nump">$ 62,591<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46061881014240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Securities (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from computation (in shares)</a></td>
<td class="nump">2,582,460<span></span>
</td>
<td class="nump">2,828,086<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from computation (in shares)</a></td>
<td class="nump">325,330<span></span>
</td>
<td class="nump">409,108<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember', window );">Common stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from computation (in shares)</a></td>
<td class="nump">489,296<span></span>
</td>
<td class="nump">986,819<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from computation (in shares)</a></td>
<td class="nump">1,710,373<span></span>
</td>
<td class="nump">1,387,459<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember', window );">Employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from computation (in shares)</a></td>
<td class="nump">57,461<span></span>
</td>
<td class="nump">44,700<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46061875181488">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Financial Information - Prepaid Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_OtherFinancialInformationAbstract', window );"><strong>Other Financial Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Diagnostic&#160;testing&#160;supplies</a></td>
<td class="nump">$ 5,725<span></span>
</td>
<td class="nump">$ 2,871<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Other prepaid expenses and other current assets</a></td>
<td class="nump">859<span></span>
</td>
<td class="nump">1,926<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">$ 6,584<span></span>
</td>
<td class="nump">$ 4,797<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_OtherFinancialInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Financial Information</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_OtherFinancialInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46061880174304">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Financial Information - Property and Equipment Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Total property and equipment</a></td>
<td class="nump">$ 11,295<span></span>
</td>
<td class="nump">$ 10,970<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization', window );">Less: accumulated depreciation and amortization</a></td>
<td class="num">(6,012)<span></span>
</td>
<td class="num">(5,769)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization', window );">Property and equipment, net</a></td>
<td class="nump">5,283<span></span>
</td>
<td class="nump">5,201<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture&#160;and&#160;fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Total property and equipment</a></td>
<td class="nump">105<span></span>
</td>
<td class="nump">98<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=exdx_LaboratoryEquipmentMember', window );">Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Total property and equipment</a></td>
<td class="nump">4,248<span></span>
</td>
<td class="nump">5,312<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=exdx_ComputerEquipmentAndSoftwareMember', window );">Computer equipment and software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Total property and equipment</a></td>
<td class="nump">2,113<span></span>
</td>
<td class="nump">2,185<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Total property and equipment</a></td>
<td class="nump">3,286<span></span>
</td>
<td class="nump">3,316<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Total property and equipment</a></td>
<td class="nump">$ 1,543<span></span>
</td>
<td class="nump">$ 59<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation and amortization from plant, property, and equipment and right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=exdx_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=exdx_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=exdx_ComputerEquipmentAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=exdx_ComputerEquipmentAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46061874752880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Financial Information - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Oct. 24, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">$ 1,700<span></span>
</td>
<td class="nump">$ 2,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization', window );">Gross book value of assets under finance leases</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="nump">2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">2,401<span></span>
</td>
<td class="nump">3,286<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">1,096<span></span>
</td>
<td class="nump">976<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_GainLossOnDispositionOfLeaseAssignment', window );">Loss on lease assignment</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,470<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Building</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseholdImprovementsGross', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_GainLossOnDispositionOfLeaseAssignment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) On Disposition Of Lease Assignment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_GainLossOnDispositionOfLeaseAssignment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseholdImprovementsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseholdImprovementsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46061880629968">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Financial Information - Accrued Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_OtherFinancialInformationAbstract', window );"><strong>Other Financial Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedSalariesCurrent', window );">Accrued&#160;payroll&#160;and&#160;related&#160;expenses</a></td>
<td class="nump">$ 5,046<span></span>
</td>
<td class="nump">$ 4,738<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued liabilities</a></td>
<td class="nump">2,804<span></span>
</td>
<td class="nump">2,793<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued and other current liabilities</a></td>
<td class="nump">$ 7,850<span></span>
</td>
<td class="nump">$ 7,531<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_OtherFinancialInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Financial Information</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_OtherFinancialInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedSalariesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedSalariesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46061875407120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Borrowings - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Apr. 28, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>installment</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Prepayment of principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Borrowings-non-current portion, net of discounts and debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,822,000<span></span>
</td>
<td class="nump">$ 19,231,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=exdx_AmendedLoanAgreementMember', window );">Amended Loan Agreement | Innovatus Life Sciences Lending Fund | Loan payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Term loan borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity', window );">Remaining borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Prepayment of principal</a></td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Term loan, interest rate</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_DebtInstrumentStatedInterestRatePaidInKind', window );">Term loan, paid in-kind, interest rate</a></td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Term loan, effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.60%<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_DebtInstrumentNumberOfMonthlyInstallments', window );">Number of monthly installments | installment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFeeAmount', window );">Term loan, fee incurred upon payment of final installment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_DebtInstrumentCovenantRevenuePerformancePeriod', window );">Term loan, covenant, revenue performance period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_DebtInstrumentMinimumCashBalanceRequiredNotRequiredToComplyWithCovenant', window );">Debt instrument, minimum cash balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_DebtInstrumentCovenantNumberOfDaysToCureIfPerformanceMeasureIsNotMet', window );">Term loan, covenant, number of days to cure covenant if performance measure is not met</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance', window );">Term loan covenant, minimum unrestricted cash balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=exdx_AmendedLoanAgreementMember', window );">Amended Loan Agreement | Innovatus Life Sciences Lending Fund | Paid in-kind note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_DebtInstrumentPaidInKindLoansIssued', window );">Term loan, paid in-kind loans issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Borrowings-non-current portion, net of discounts and debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=exdx_Term2017Member', window );">2017 Term loan | Innovatus Life Sciences Lending Fund | Loan payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease', window );">Term loan covenant, increase to interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=exdx_EquipmentNotesPayableMember', window );">Equipment Notes Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Notes payable current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Notes payable noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=exdx_EquipmentNotesPayableMember', window );">Equipment Notes Payable | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Term loan, effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.28%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=exdx_EquipmentNotesPayableMember', window );">Equipment Notes Payable | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Term loan, effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.50%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant Compliance, Minimum Unrestricted Cash Balance</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant Non-Compliance, Interest Rate, Increase (Decrease)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_DebtInstrumentCovenantNumberOfDaysToCureIfPerformanceMeasureIsNotMet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Number Of Days To Cure If Performance Measure Is Not Met</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_DebtInstrumentCovenantNumberOfDaysToCureIfPerformanceMeasureIsNotMet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_DebtInstrumentCovenantRevenuePerformancePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Revenue Performance Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_DebtInstrumentCovenantRevenuePerformancePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_DebtInstrumentMinimumCashBalanceRequiredNotRequiredToComplyWithCovenant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Minimum Cash Balance Required, Not Required To Comply With Covenant</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_DebtInstrumentMinimumCashBalanceRequiredNotRequiredToComplyWithCovenant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_DebtInstrumentNumberOfMonthlyInstallments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Number Of Monthly Installments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_DebtInstrumentNumberOfMonthlyInstallments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_DebtInstrumentPaidInKindLoansIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Paid In Kind Loans Issued</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_DebtInstrumentPaidInKindLoansIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_DebtInstrumentStatedInterestRatePaidInKind">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Stated Interest Rate, Paid In-Kind</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_DebtInstrumentStatedInterestRatePaidInKind</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the fee that accompanies borrowing money under the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=exdx_AmendedLoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=exdx_AmendedLoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=exdx_InnovatusLifeSciencesLendingFundMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=exdx_InnovatusLifeSciencesLendingFundMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_PaymentInKindPIKNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_PaymentInKindPIKNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=exdx_Term2017Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=exdx_Term2017Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=exdx_EquipmentNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=exdx_EquipmentNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46061879838016">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Borrowings - Future Minimum Payments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtByMaturityAbstract', window );"><strong>Long-Term Debt, Fiscal Year Maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2025</a></td>
<td class="nump">$ 2,076<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2026</a></td>
<td class="nump">21,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2027</a></td>
<td class="nump">215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2028</a></td>
<td class="nump">67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_LongTermDebtIncludingUndiscountedInterest', window );">Total</a></td>
<td class="nump">23,758<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Unamortized debt discount and issuance costs</a></td>
<td class="num">(70)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_LongTermDebtUndiscountedInterestAmount', window );">Interest</a></td>
<td class="num">(3,443)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total borrowings, net of discounts and debt issuance costs</a></td>
<td class="nump">20,245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Borrowings-current portion</a></td>
<td class="num">(423)<span></span>
</td>
<td class="num">$ (264)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Borrowings-non-current portion, net of discounts and debt issuance costs</a></td>
<td class="nump">$ 19,822<span></span>
</td>
<td class="nump">$ 19,231<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_LongTermDebtIncludingUndiscountedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-term Debt, Including Undiscounted Interest</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_LongTermDebtIncludingUndiscountedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_LongTermDebtUndiscountedInterestAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-term Debt, Undiscounted Interest Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_LongTermDebtUndiscountedInterestAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtByMaturityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtByMaturityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46061880159664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=exdx_OfficeAndLaboratoryMember', window );">Office and Laboratory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating lease, renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=exdx_OfficeMember', window );">Office</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_OperatingLeaseMonthlyBaseRent', window );">Operating lease, monthly base rent</a></td>
<td class="nump">$ 72,143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_OperatingLeaseAnnualIncreaseInBaseRentPaymentPercent', window );">Operating lease, annual increase in base rent payment percentage</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeaseTermOfContract1', window );">Finance lease, term of contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeaseTermOfContract1', window );">Finance lease, term of contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_OperatingLeaseAnnualIncreaseInBaseRentPaymentPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Annual Increase In Base Rent Payment, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_OperatingLeaseAnnualIncreaseInBaseRentPaymentPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_OperatingLeaseMonthlyBaseRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Monthly Base Rent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_OperatingLeaseMonthlyBaseRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeaseTermOfContract1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeaseTermOfContract1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483359/720-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 27<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482395/460-10-55-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=exdx_OfficeAndLaboratoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=exdx_OfficeAndLaboratoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=exdx_OfficeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=exdx_OfficeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46061981645136">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Lease Balances (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">$ 2,401<span></span>
</td>
<td class="nump">$ 3,286<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Finance lease, right-of-use asset, after accumulated amortization</a></td>
<td class="nump">$ 486<span></span>
</td>
<td class="nump">$ 810<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList', window );">Finance lease, right-of-use asset, statement of financial position</a></td>
<td class="text">Property and equipment, net<span></span>
</td>
<td class="text">Property and equipment, net<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">$ 1,096<span></span>
</td>
<td class="nump">$ 976<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Finance lease obligations, current portion</a></td>
<td class="nump">$ 201<span></span>
</td>
<td class="nump">$ 490<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Finance lease, liability, current, statement of financial position</a></td>
<td class="text">Accrued and other current liabilities<span></span>
</td>
<td class="text">Accrued and other current liabilities<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Non-current operating lease liabilities</a></td>
<td class="nump">$ 1,664<span></span>
</td>
<td class="nump">$ 2,760<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Lease obligations, net of current portion</a></td>
<td class="nump">$ 157<span></span>
</td>
<td class="nump">$ 358<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList', window );">Finance lease, liability, noncurrent, statement of financial position</a></td>
<td class="text">Non-current operating lease liabilities<span></span>
</td>
<td class="text">Non-current operating lease liabilities<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes noncurrent finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46061881503264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Costs Associated with the Company's Leases (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 1,345<span></span>
</td>
<td class="nump">$ 1,463<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Amortization of lease assets</a></td>
<td class="nump">280<span></span>
</td>
<td class="nump">556<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestExpense', window );">Interest on finance lease liabilities</a></td>
<td class="nump">84<span></span>
</td>
<td class="nump">128<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease cost</a></td>
<td class="nump">1,709<span></span>
</td>
<td class="nump">2,147<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="nump">$ 196<span></span>
</td>
<td class="nump">$ 129<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46061880421072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Supplemental Cash Flow Information On Leases And Weighted-Average Lease Term (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_CashFlowInformationOperatingAndFinanceLeasePaymentsAbstract', window );"><strong>Cash paid for amounts included in the measurement of lease liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash out flows from operating leases</a></td>
<td class="nump">$ 1,240<span></span>
</td>
<td class="nump">$ 1,405<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestPaymentOnLiability', window );">Operating cash out flows from interest paid on finance leases</a></td>
<td class="nump">84<span></span>
</td>
<td class="nump">128<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Financing cash out flows from finance leases</a></td>
<td class="nump">$ 490<span></span>
</td>
<td class="nump">$ 697<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_WeightedAverageRemainingLeaseTermAbstract', window );"><strong>Weighted-average remaining lease term (years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating leases</a></td>
<td class="text">2 years 3 months 18 days<span></span>
</td>
<td class="text">3 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1', window );">Finance leases</a></td>
<td class="text">1 year 9 months 3 days<span></span>
</td>
<td class="text">2 years 21 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_WeightedAverageDiscountRateAbstract', window );"><strong>Weighted-average discount rate</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating leases</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent', window );">Finance leases</a></td>
<td class="nump">17.30%<span></span>
</td>
<td class="nump">12.20%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_CashFlowInformationOperatingAndFinanceLeasePaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash Flow Information, Operating and Finance Lease Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_CashFlowInformationOperatingAndFinanceLeasePaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_WeightedAverageDiscountRateAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-Average Discount Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_WeightedAverageDiscountRateAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_WeightedAverageRemainingLeaseTermAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-Average Remaining Lease Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_WeightedAverageRemainingLeaseTermAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestPaymentOnLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest paid on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestPaymentOnLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for finance lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46061874753552">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Future Payments Under Operating And Finance Leases (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Operating Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2025</a></td>
<td class="nump">$ 1,277<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2026</a></td>
<td class="nump">1,315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2027</a></td>
<td class="nump">445<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total minimum lease payments</a></td>
<td class="nump">3,037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(277)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total lease liabilities</a></td>
<td class="nump">2,760<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less: current portion</a></td>
<td class="num">(1,096)<span></span>
</td>
<td class="num">$ (976)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease obligations, net of current portion</a></td>
<td class="nump">1,664<span></span>
</td>
<td class="nump">2,760<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Finance Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2025</a></td>
<td class="nump">248<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo', window );">2026</a></td>
<td class="nump">147<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree', window );">2027</a></td>
<td class="nump">28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDue', window );">Total minimum lease payments</a></td>
<td class="nump">423<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(65)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Total lease liabilities</a></td>
<td class="nump">358<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Less: current portion</a></td>
<td class="num">(201)<span></span>
</td>
<td class="num">(490)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Lease obligations, net of current portion</a></td>
<td class="nump">$ 157<span></span>
</td>
<td class="nump">$ 358<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46061881974832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Aug. 31, 2024 </div>
<div>supplier</div>
</th>
<th class="th">
<div>Oct. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_PurchaseObligationAmendedSupplyAgreementNumberOfSuppliers', window );">Number of suppliers in amended supply agreement | supplier</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseObligationDueInNextTwelveMonths', window );">Purchase obligation, due in next twelve months</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=exdx_USDepartmentOfJusticeCaseMember', window );">U.S. Department Of Justice Case | Settled Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForLegalSettlements', window );">Settlement payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exdx_AHNCollaborationMember', window );">AHN Collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_CollaborationAgreementCollaborationExpenses', window );">Collaboration agreement, collaboration expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="nump">$ 0.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Licensing Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_RoyaltyObligationPercentageOfSales', window );">Royalty obligation, percent of net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Licensing Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_RoyaltyObligationPercentageOfSales', window );">Royalty obligation, percent of net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=exdx_AlleghenyHealthNetworkResearchInstituteMember', window );">Allegheny Health Network Research Institute</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_CollaborationAgreementAnnualCollaborationFee', window );">Collaboration fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_CollaborationAgreementAnnualCollaborationFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Annual Collaboration Fee</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_CollaborationAgreementAnnualCollaborationFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_CollaborationAgreementCollaborationExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Collaboration Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_CollaborationAgreementCollaborationExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_PurchaseObligationAmendedSupplyAgreementNumberOfSuppliers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase Obligation, Amended Supply Agreement, Number Of Suppliers</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_PurchaseObligationAmendedSupplyAgreementNumberOfSuppliers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_RoyaltyObligationPercentageOfSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty Obligation, Percentage of Sales</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_RoyaltyObligationPercentageOfSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForLegalSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for the settlement of litigation or for other legal issues during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForLegalSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligationDueInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of purchase arrangement to be paid in next fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligationDueInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=exdx_USDepartmentOfJusticeCaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=exdx_USDepartmentOfJusticeCaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exdx_AHNCollaborationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exdx_AHNCollaborationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=exdx_AlleghenyHealthNetworkResearchInstituteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=exdx_AlleghenyHealthNetworkResearchInstituteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46061881528832">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total borrowings, net of discounts and debt issuance costs</a></td>
<td class="nump">$ 20,245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Money market funds, included in cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds, included in cash and cash equivalents</a></td>
<td class="nump">15,144<span></span>
</td>
<td class="nump">$ 14,386<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level&#160;1 | Money market funds, included in cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds, included in cash and cash equivalents</a></td>
<td class="nump">15,144<span></span>
</td>
<td class="nump">14,386<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level&#160;2 | Money market funds, included in cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds, included in cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level&#160;3 | Money market funds, included in cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds, included in cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=exdx_AmendedLoanAgreementMember', window );">Amended Loan Agreement | Recurring | Level&#160;2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total borrowings, net of discounts and debt issuance costs</a></td>
<td class="nump">19,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Debt instrument, fair value</a></td>
<td class="nump">$ 19,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=exdx_A2017TermLoanMember', window );">2017 Term Loan | Recurring | Level&#160;2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total borrowings, net of discounts and debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Debt instrument, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,700<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=exdx_AmendedLoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=exdx_AmendedLoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=exdx_A2017TermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=exdx_A2017TermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46061981552848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 15, 2022</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Nov. 17, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet', window );">Exercise of common stock warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=exdx_ShelfRegistrationStatementMember', window );">Shelf Registration Statement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_SaleOfStockAuthorizedAmount', window );">Common stock offering, authorized amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_SaleOfStockRemainingAuthorizedAmount', window );">Common stock offering, remaining authorized amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=exdx_CowenEquityDistributionAgreementMember', window );">Cowen Equity Distribution Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Consideration received on transaction</a></td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_SaleOfStockAuthorizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Authorized Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_SaleOfStockAuthorizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_SaleOfStockRemainingAuthorizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Remaining Authorized Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_SaleOfStockRemainingAuthorizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Warrants Exercised, Net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=exdx_ShelfRegistrationStatementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=exdx_ShelfRegistrationStatementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=exdx_CowenEquityDistributionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=exdx_CowenEquityDistributionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46061880134112">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' Equity - Warrants to Purchase Common Stock Outstanding (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants issued to purchase redeemable convertible preferred stock (in shares)</a></td>
<td class="nump">1,130,281<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=exdx_ExpirationJan192026Member', window );">Warrant expiration January 19, 2026</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants issued to purchase redeemable convertible preferred stock (in shares)</a></td>
<td class="nump">237,169<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of warrant or right, exercise price of warrants or rights (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 1.84<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=exdx_ExpirationMar312026Member', window );">Warrant expiration March 31, 2026</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants issued to purchase redeemable convertible preferred stock (in shares)</a></td>
<td class="nump">67,086<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of warrant or right, exercise price of warrants or rights (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 1.84<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=exdx_ExpirationApr12026Member', window );">Warrant expiration April 1, 2026</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants issued to purchase redeemable convertible preferred stock (in shares)</a></td>
<td class="nump">131<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of warrant or right, exercise price of warrants or rights (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 1.84<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=exdx_ExpirationDec72025Member', window );">Warrant expiration December 7, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants issued to purchase redeemable convertible preferred stock (in shares)</a></td>
<td class="nump">20,944<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of warrant or right, exercise price of warrants or rights (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 14.32<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=exdx_NoExpirationMember', window );">No expiration</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants issued to purchase redeemable convertible preferred stock (in shares)</a></td>
<td class="nump">804,951<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of warrant or right, exercise price of warrants or rights (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=exdx_ExpirationJan192026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=exdx_ExpirationJan192026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=exdx_ExpirationMar312026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=exdx_ExpirationMar312026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=exdx_ExpirationApr12026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=exdx_ExpirationApr12026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=exdx_ExpirationDec72025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=exdx_ExpirationDec72025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=exdx_NoExpirationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=exdx_NoExpirationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46061875420320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Option Plan - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jan. 01, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance (in shares)</a></td>
<td class="nump">6,042,922<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Employee options, weighted-average grant date fair value per share (in dollars per share)</a></td>
<td class="nump">$ 1.44<span></span>
</td>
<td class="nump">$ 2.17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Intrinsic value of options exercised</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Common stock, fair value per share (in dollars per share)</a></td>
<td class="nump">$ 4.10<span></span>
</td>
<td class="nump">$ 1.99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock compensation</a></td>
<td class="nump">$ 1,763<span></span>
</td>
<td class="nump">$ 3,617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance (in shares)</a></td>
<td class="nump">489,296<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">Employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance (in shares)</a></td>
<td class="nump">523,744<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Stock options, cost not yet recognized, remaining weighted average vesting period</a></td>
<td class="text">2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate', window );">Maximum employee payroll deduction percentage</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of stock under Employee Stock Purchase Plan (in shares)</a></td>
<td class="nump">96,048<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock compensation</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation cost related to stock purchase</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">Employee stock purchase plan | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesAuthorized', window );">Increase (decrease) in number of shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">176,403<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance (in shares)</a></td>
<td class="nump">1,710,373<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested', window );">Grant date fair value of RSUs vested</a></td>
<td class="nump">$ 900<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Awards granted (in dollars per share)</a></td>
<td class="nump">$ 2.11<span></span>
</td>
<td class="nump">$ 2.39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Stock options, unrecognized compensation cost</a></td>
<td class="nump">$ 3,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Stock options, cost not yet recognized, remaining weighted average vesting period</a></td>
<td class="text">2 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Common stock, fair value per share (in dollars per share)</a></td>
<td class="nump">$ 2.48<span></span>
</td>
<td class="nump">$ 4.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=exdx_IncentiveAwardPlan2019Member', window );">2019 Incentive Award Plan | Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Stock options, expiration period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Stock options, vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=exdx_IncentiveAwardPlan2019Member', window );">2019 Incentive Award Plan | Stock options | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesAuthorized', window );">Increase (decrease) in number of shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">705,613<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=exdx_IncentiveAwardPlan2019Member', window );">2019 Incentive Award Plan | Employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage', window );">Annual percentage increase in shares available for issuance under the Plan</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Additional Shares Authorized, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Increase (Decrease) In Number Of Shares Authorized</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of vested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=exdx_IncentiveAwardPlan2019Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=exdx_IncentiveAwardPlan2019Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46061875465168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Option Plan - Restricted Stock Units (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted- Average Grant Date Fair Value Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding, beginning balance (in dollars per share)</a></td>
<td class="nump">$ 1.99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding, ending balance (in dollars per share)</a></td>
<td class="nump">$ 4.10<span></span>
</td>
<td class="nump">$ 1.99<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number&#160;of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, beginning balance (in shares)</a></td>
<td class="nump">1,387,459<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Awards granted (in shares)</a></td>
<td class="nump">1,324,275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Awards released (in shares)</a></td>
<td class="num">(413,202)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Awards canceled (in shares)</a></td>
<td class="num">(588,159)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, ending balance (in shares)</a></td>
<td class="nump">1,710,373<span></span>
</td>
<td class="nump">1,387,459<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted- Average Grant Date Fair Value Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding, beginning balance (in dollars per share)</a></td>
<td class="nump">$ 4.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Awards granted (in dollars per share)</a></td>
<td class="nump">2.11<span></span>
</td>
<td class="nump">$ 2.39<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Awards released (in dollars per share)</a></td>
<td class="nump">4.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Awards canceled (in dollars per share)</a></td>
<td class="nump">4.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding, ending balance (in dollars per share)</a></td>
<td class="nump">$ 2.48<span></span>
</td>
<td class="nump">$ 4.24<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract', window );"><strong>Aggregate Intrinsic Value (in thousands)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Outstanding, Aggregate Intrinsic Value</a></td>
<td class="nump">$ 7,013<span></span>
</td>
<td class="nump">$ 2,761<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46061880748896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Option Plan - Stock Option Activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number&#160;of Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, beginning balance (in shares)</a></td>
<td class="nump">986,819<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">55,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(85,124)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(9,623)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Expired (in shares)</a></td>
<td class="num">(458,276)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, ending balance (in shares)</a></td>
<td class="nump">489,296<span></span>
</td>
<td class="nump">986,819<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expected to vest (in shares)</a></td>
<td class="nump">489,296<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Options exercisable (in Shares)</a></td>
<td class="nump">468,706<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted- Average Exercise&#160;Price Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, beginning balance (in dollars per share)</a></td>
<td class="nump">$ 11.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="nump">1.99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
<td class="nump">0.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited (in dollars per share)</a></td>
<td class="nump">16.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Expired (in dollars per share)</a></td>
<td class="nump">16.46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, ending balance (in dollars per share)</a></td>
<td class="nump">8.39<span></span>
</td>
<td class="nump">$ 11.87<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested and expected to vest (in dollars per share)</a></td>
<td class="nump">8.39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Options exercisable (in dollars per share)</a></td>
<td class="nump">$ 8.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding, Weighted Average Remaining Contractual Term</a></td>
<td class="text">6 years 6 months 10 days<span></span>
</td>
<td class="text">6 years 5 months 8 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Vested and expected to vest, Weighted Average Remaining Contractual Term</a></td>
<td class="text">6 years 6 months 10 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Options exercisable, Weighted Average Remaining Contractual Term</a></td>
<td class="text">6 years 5 months 1 day<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding, Aggregate Intrinsic Value</a></td>
<td class="nump">$ 370<span></span>
</td>
<td class="nump">$ 228<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Vested and expected to vest, Aggregate Intrinsic Value</a></td>
<td class="nump">370<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Options exercisable, Aggregate Intrinsic Value</a></td>
<td class="nump">$ 332<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46061881489456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Option Plan - Stock-Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock compensation</a></td>
<td class="nump">$ 1,763<span></span>
</td>
<td class="nump">$ 3,617<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock compensation</a></td>
<td class="nump">159<span></span>
</td>
<td class="nump">191<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock compensation</a></td>
<td class="nump">1,374<span></span>
</td>
<td class="nump">3,174<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock compensation</a></td>
<td class="nump">$ 230<span></span>
</td>
<td class="nump">$ 252<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46061880744032">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stock Option Plan - Common Stock Reserved For Future Issuance (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance (in shares)</a></td>
<td class="nump">6,042,922<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember', window );">Warrants to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance (in shares)</a></td>
<td class="nump">1,130,281<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Common stock option grants issued and outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance (in shares)</a></td>
<td class="nump">489,296<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Common stock reserved for issuance upon vesting of outstanding restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance (in shares)</a></td>
<td class="nump">1,710,373<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=exdx_CommonSharesAvailableForGrantUnderThe2019PlanMember', window );">Common stock available for grant under the 2019 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance (in shares)</a></td>
<td class="nump">2,189,228<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">Common stock available for future issuance under ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance (in shares)</a></td>
<td class="nump">523,744<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=exdx_CommonSharesAvailableForGrantUnderThe2019PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=exdx_CommonSharesAvailableForGrantUnderThe2019PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46061880542704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Components of Income Tax Expense (Benefit) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract', window );"><strong>Current:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="num">(12)<span></span>
</td>
<td class="num">(33)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current</a></td>
<td class="num">(12)<span></span>
</td>
<td class="num">(33)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total deferred</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="num">$ (12)<span></span>
</td>
<td class="num">$ (33)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46061880113200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation of Effective Income Tax Rate (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal statutory tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State income taxes, net of federal tax benefits</a></td>
<td class="nump">2.20%<span></span>
</td>
<td class="nump">2.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">Research and development tax credits</a></td>
<td class="nump">0.10%<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock compensation</a></td>
<td class="num">(5.90%)<span></span>
</td>
<td class="num">(3.40%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense', window );">Non-deductible expenses</a></td>
<td class="num">(2.50%)<span></span>
</td>
<td class="num">(1.40%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(15.20%)<span></span>
</td>
<td class="num">(18.50%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent', window );">Other</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="num">(0.10%)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="num">(0.30%)<span></span>
</td>
<td class="num">(0.10%)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of reported income tax benefit (expense) from difference to income tax expense (benefit) computed by applying statutory federal (national) income tax rate to pretax income (loss) from continuing operation, attributable to other reconciling items. Excludes state and local income tax expense (benefit), federal tax expense (benefit), statutory income tax expense (benefit) outside of country of domicile, tax credit, nondeductible expense, deduction, income tax settlement, income tax contingency, and cross-border tax law.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46061879635808">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Reconciliation of Deferred Tax Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGrossAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 35,348<span></span>
</td>
<td class="nump">$ 32,479<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development tax credits</a></td>
<td class="nump">2,360<span></span>
</td>
<td class="nump">2,353<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves', window );">Accruals, reserves and other</a></td>
<td class="nump">955<span></span>
</td>
<td class="nump">1,119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Interest expense</a></td>
<td class="nump">2,785<span></span>
</td>
<td class="nump">2,547<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Indefinite lived assets</a></td>
<td class="nump">276<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock compensation</a></td>
<td class="nump">598<span></span>
</td>
<td class="nump">1,391<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_DeferredTaxAssetsLeaseLiability', window );">Lease liability</a></td>
<td class="nump">681<span></span>
</td>
<td class="nump">925<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCapitalizationOfResearchAndExperimentationCosts', window );">Capitalization of research and experimentation costs</a></td>
<td class="nump">2,942<span></span>
</td>
<td class="nump">2,929<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total gross deferred tax assets</a></td>
<td class="nump">45,945<span></span>
</td>
<td class="nump">44,043<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: valuation allowance</a></td>
<td class="num">(45,237)<span></span>
</td>
<td class="num">(42,942)<span></span>
</td>
<td class="num">$ (38,567)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Deferred tax assets, net</a></td>
<td class="nump">708<span></span>
</td>
<td class="nump">1,101<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_DeferredTaxLiabilitiesRightOfUseAssets', window );">Right of use assets</a></td>
<td class="num">(592)<span></span>
</td>
<td class="num">(814)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets', window );">Basis differences in fixed and intangible assets</a></td>
<td class="num">(116)<span></span>
</td>
<td class="num">(287)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Deferred tax liabilities</a></td>
<td class="num">(708)<span></span>
</td>
<td class="num">(1,101)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_DeferredTaxAssetsLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Lease Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_DeferredTaxAssetsLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCapitalizationOfResearchAndExperimentationCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Capitalization Of Research And Experimentation Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCapitalizationOfResearchAndExperimentationCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities, Fixed Assets And Intangible Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_DeferredTaxLiabilitiesRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities, Right Of Use Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_DeferredTaxLiabilitiesRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGrossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGrossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from loss reserves other than estimated credit losses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46061881526736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Change In Valuation Allowance (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_ChangesInTheValuationAllowanceForDeferredTaxAssetsRollForward', window );"><strong>Changes In The Valuation Allowance For Deferred Tax Assets [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance at the beginning of the year</a></td>
<td class="nump">$ 42,942<span></span>
</td>
<td class="nump">$ 38,567<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Increases recorded to income tax provision</a></td>
<td class="nump">2,295<span></span>
</td>
<td class="nump">4,375<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance at the end of the year</a></td>
<td class="nump">$ 45,237<span></span>
</td>
<td class="nump">$ 42,942<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_ChangesInTheValuationAllowanceForDeferredTaxAssetsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Changes In The Valuation Allowance For Deferred Tax Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_ChangesInTheValuationAllowanceForDeferredTaxAssetsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46061875136144">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic', window );">Federal net operating loss carryforwards</a></td>
<td class="nump">$ 141,500,000<span></span>
</td>
<td class="nump">$ 129,800,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal', window );">State net operating loss carryforwards</a></td>
<td class="nump">98,700,000<span></span>
</td>
<td class="nump">91,000,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration', window );">Federal tax loss carryforwards, subject to expiration</a></td>
<td class="nump">43,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration', window );">Federal net operating loss carryforwards, carryforward indefinitely</a></td>
<td class="nump">98,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=exdx_TaxYearsThroughDecember312017Member', window );">Tax Years Through December 31, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration', window );">Federal tax loss carryforwards, subject to expiration</a></td>
<td class="nump">$ 58,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are not subject to expiration dates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=exdx_TaxYearsThroughDecember312017Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=exdx_TaxYearsThroughDecember312017Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46061881620288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>401(k) Plan (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Qualified employee compensation, employer matching contribution, percent of employees' gross pay</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Qualified employee compensation contribution, amount</a></td>
<td class="nump">$ 0.8<span></span>
</td>
<td class="nump">$ 0.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480794/715-70-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46061875369792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Assets</a></td>
<td class="nump">$ 44,689<span></span>
</td>
<td class="nump">$ 56,944<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=exdx_ReportableSegmentMember', window );">Reportable Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Assets</a></td>
<td class="nump">$ 44,700<span></span>
</td>
<td class="nump">$ 56,900<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=exdx_ReportableSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=exdx_ReportableSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46061879735616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 55,641<span></span>
</td>
<td class="nump">$ 52,548<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Costs of revenue</a></td>
<td class="nump">22,529<span></span>
</td>
<td class="nump">23,092<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross margin</a></td>
<td class="nump">33,112<span></span>
</td>
<td class="nump">29,456<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock compensation</a></td>
<td class="nump">1,763<span></span>
</td>
<td class="nump">3,617<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">1,700<span></span>
</td>
<td class="nump">2,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(13,636)<span></span>
</td>
<td class="num">(22,837)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest expense</a></td>
<td class="num">(2,234)<span></span>
</td>
<td class="num">(2,335)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">767<span></span>
</td>
<td class="nump">1,516<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossAttributableToParent', window );">Loss before income taxes</a></td>
<td class="num">(15,103)<span></span>
</td>
<td class="num">(23,656)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="num">(12)<span></span>
</td>
<td class="num">(33)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(15,115)<span></span>
</td>
<td class="num">(23,689)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=exdx_ReportableSegmentMember', window );">Reportable Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">55,641<span></span>
</td>
<td class="nump">52,548<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Costs of revenue</a></td>
<td class="nump">22,529<span></span>
</td>
<td class="nump">23,092<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross margin</a></td>
<td class="nump">33,112<span></span>
</td>
<td class="nump">29,456<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LaborAndRelatedExpense', window );">Employee expense</a></td>
<td class="nump">27,753<span></span>
</td>
<td class="nump">27,070<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_OutsideServicesExpense', window );">Outside services</a></td>
<td class="nump">4,253<span></span>
</td>
<td class="nump">5,920<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OccupancyNet', window );">Facilities related</a></td>
<td class="nump">3,674<span></span>
</td>
<td class="nump">5,125<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TravelAndEntertainmentExpense', window );">Travel &amp; entertainment</a></td>
<td class="nump">2,440<span></span>
</td>
<td class="nump">2,469<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock compensation</a></td>
<td class="nump">1,604<span></span>
</td>
<td class="nump">3,426<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">1,041<span></span>
</td>
<td class="nump">1,426<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingOtherItemAmount', window );">Other</a></td>
<td class="nump">5,983<span></span>
</td>
<td class="nump">6,857<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total segment operating expenses</a></td>
<td class="nump">46,748<span></span>
</td>
<td class="nump">52,293<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(13,636)<span></span>
</td>
<td class="num">(22,837)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest expense</a></td>
<td class="num">(2,234)<span></span>
</td>
<td class="num">(2,335)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">767<span></span>
</td>
<td class="nump">1,516<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossAttributableToParent', window );">Loss before income taxes</a></td>
<td class="num">(15,103)<span></span>
</td>
<td class="num">(23,656)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="num">(12)<span></span>
</td>
<td class="num">(33)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (15,115)<span></span>
</td>
<td class="num">$ (23,689)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_OutsideServicesExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Outside Services Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_OutsideServicesExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of income (loss) attributable to parent. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LaborAndRelatedExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LaborAndRelatedExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OccupancyNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of net occupancy expense that may include items, such as depreciation of facilities and equipment, lease expenses, property taxes and property and casualty insurance expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(14)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481161/840-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OccupancyNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingOtherItemAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other expense (income) and loss (gain) calculated as difference between segment revenue and separately disclosed expense category to arrive at segment profit (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingOtherItemAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TravelAndEntertainmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expenses incurred for travel and entertainment during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TravelAndEntertainmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=exdx_ReportableSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=exdx_ReportableSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>84
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M76-NO*<W"D-03R[V!^@7N _]RO1CSBSI>CT7X@$]"'_#6RU#J^F_+;4RP\(
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MW@#NEA7Q*;38W8V7T-HDB$.KZME"?CC0NY&6*<DI3/D"/F+SH!_BH$^7+K&
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M  #V"@  &    'AL+W=O<FMS:&5E=',O<VAE970T+GAM;*U6:V_3,!3]*U9
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M_; 'OAP.#[IP5]MLO/J-5]_R!4?X5OJ$@!"0(KVLR4.?GXH@["<P*74M2Y+
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MJN\Q415954?QTM8I]USIJL<V,UV8@C !>G[#N7KJF-*G*77C/U!+ P04
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MB+VDJXZ9/!XS_%1[5T?3P%Z+GYWD$H&ATH[U$[Q;XC3; QD0[+%)UK;I=UB
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M6@N(1]'>I79IV^,4JN%SV6Y@.!=?9J)=RX>RP$,YY[G#S'^<H3X6Z[27F3Z
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MY#/7AO;(@@H.+2#CM&^%62&$/>4<("#=7:ZXP-A->I#")@'!1.:V\HP$0L-
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M#VGO>0\/\Z:D.3<E3\5E#UEAA'X4O:L__2$>1W\Y@7S8(A^>XOYU[CG)XC#
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MYH/&VZCEDLFU*(U4)=-B>36X"2_>3&B_V_"[%%MS\)^1)@NEOM#+N^QJ,"9
MHA"I)0X</P_B5A0%,0*,/VN>@U8D$1[^;[B_=;I#EP4WXE85?\C,YE>#V8!E
M8LFKPGY4VY]$K4]"_%)5&/=D6[\WC@<LK8Q5ZYH8"-:R]+_\L;;# <%L?(0@
MJ@DBA]L+<BCON.77EUIMF:;=X$9_G*J.&N!D24ZYMQJK$G3V^EV9JK5@G_BC
M,)<C"X[T?936U&\\=72$.HS8+ZJTN6$_EIG(N@Q&@-+BB1H\;Z(7.=Z)-&!Q
M.&31.)J\P"]N]8L=O_AO]6-WTJ2%,I46[+\W"V,U(N)_?3I[CI-^CI0E%V;#
M4W$U0!H8H1_$X/J'[\+S\>L7\$Y:O).7N/^M/[Z>FGW*!=MH]2!= B%_F?3+
MUBVG"IEEK&%JR2RV+E6!#)7EBIW*$E]497B9F;,+]A_!M7<P@WO$>B%TZR)Z
MQ.RVTEJ4]H*]%9G0O& G[(?O9E$8O3[X=V^Y%>PTC,[8:1R?L4_*8F?J20^^
MWXFEP+=LSZWAT.7T]*OGE]74SY;?M<HS\8B:9@2P.:DG-1X802R7PM4)MT^3
M&)A'5?HE2V825-JPI59K;\H:MP'.RBJ]\YRXJ8ULOL:F;Y\Q:2%%83!FWS<_
MWAJ'B(:L1#D'\ 8(42Y$*982_HZ"B(C=\R,"F.LT9W U3/> (KU9DSN((H49
MB6 <A-CJG_=6I5\0.VNR('>%]30)YF=8.HV#"?V^5^4KZ%7!CHM"-,8V[#0*
M$K<O]/MN<UZN"#A[X$7E>7$R#R]3BI,DB/SVF:?[%:;5K3NQ $3T_<?G/L-2
M?':PY5ZN2KF4*8=FA%V5T+&-_%M\X>7.<9Z^-OL0(G[<&(&MW/;XB8SF?,51
M4TRNMB6L# 6>9%# ;GI5S!$0"R%*)N#C12%1Q3,*$C370O[E=W\#1&)7*LO6
M\#W1K!50%?*+*':O+&S]BA9MCIJ5JR*#E#\KJ05Y.V#O^L5\KK*5"X?4^<HX
MC:5EDA!8H=&0"$/.[2$Y6EA10#/&R?]6U0H)VH.LZ\$^=.2=*-6B@ 50C4!/
M/#6"4QO$<FV1/H/BI<\P+9PT555IL4@I#&MQ<'5Q"D*(D<\KQ%-''LG5N^=2
M+]A[RL$-\L^I@<Z#FLNUWD'XENO,H.[$R3">S.A/-)Q,YU^7CM$P/A_3,XG9
M39KJBA<P8-V*O(N42Y5YDK!P&(9SU#XX"U'6ZA4-I[,$SV0RQ2*,)DMI*5H>
M7 @ZLT73<Q:/QWTIG\QGX!S/0_:SP$@$.KZ0A;0[=CX+V3Q*V"W?2-L)8WVH
M&^'0--Q9OYXJXS2;3R)Z1O.ZFJ\TF:W/J9,$FQ,VF0S'DQ@P#"S>6T>P,8JG
MZ"T3Q_ZLSUF^8$['I%4X#KM;&N6D@ @WM9(ZE1$-E--D3KUK%J*LO>%&-AU!
M0+ZA^K:4CV16RATH7*Y<76R(P_ <Q-%L>G94+#L%-&QRX,Y<8/69I*_IWM:)
MZ^*X/VLH&?K8995V^0>R'3QGF#C2KIHR.&3;7,+!+G6Q<P,/<RV+79U<FF+%
M02F?I\;I^U]_/NLFR+ ;,T?R8>@6TW\2;UOXZ* K/QM\CF3[[SU&K"O@0JQD
M69)2=9DBR\$=/O8HT6?#Y)QRKK&&%JG29-=N =J/&]$PFB/.A_$T>4FRH+3O
MRG2!OQ=^\U(+&W8*>,ZS=G: 7Y[4+8CA&P!\A'LMN@L["2=AD.!X4A0.&WB>
MA-$\F#6?G"<WODL7N^!;H1@WX?0".9G/@FE7\IS&HF."N[@G\0'L9@X^F)EZ
MBG;=3%;2M0S$%7HHA320)T-6E04J$;PG'B3B"#(J*ZGW98&;+X\;=87&IUW:
M\"6*]5/[A--&VU8W#^60"W TI9R4_=33T;TIOUFW>/RR;GT.[?CQ7T?&*BT.
MR@3U&"V-R YG5_+I'O4SPW74=!P*X:S(W(T%S<]5MJ.Y1U6K?)\?O<4,K=)7
MFG:VP4R'L2.7FW8$VDJ;U]5T+7B3ZZ[#EA#W$56JK A1AN;S[N/MV9#=UU<0
M\2QR\:Q2=^K)O&W',8D>SQR J':V3X9P'E!'(1Q>(H>('3K,D)TDLV#R-';W
MQG8VME;+107+==W<V.)YB&% IB$1LU+C6G@=;F#0XU"+CM$AK>G^B)J:\!]%
MN(L_ E"'GI=-BM'Y_;:R?KKYMUH83#ZN#1-=-P1X]KDRM@FSK@E8"\:[N2<@
M4RK'<*JK%L8)[]UGC$JETX8"HIU?CPITO699%0ASM5R"!UL :U]#1D-#'&LJ
M7*HD* =3:AUX>\OW-?0MC;:%46UO<56P*ERSI>[;Z302K%+;M2%&&%,M/L/A
MY%+LXH?2?Z,"D_ES9WTDH#.<IJI0I^IGS XFDPZTZ:]$)-O/%32 ( %\!VA*
MF3M2[3&(1XZ$]# 6.P\CN ^>5 =>H7UK/S-EE3M[T,Y.C:39K6S#&V'J53@Z
M:M1C1M= 9%D<*?]RXTP]6X-P!$TP)?/"(6CFH&YG1^^Q=%L F]$T?_Q>H2LQ
M4\(?[W+^(-R)B)J8EE0AZT, <?#34"8SM[>%203#/46+N8/7NQ=S+5H( DG6
MEP_NB.A622K-48IF.VRDLU2 <$B%MASKE*4?E)'.Z]_:Y!&55=D"SCJGP2.F
MP&%;"CKW-P?0!2_\07!YG)>O,HTIJ.OX>XB#NEZ*1_#;BN*!3M%TOQGT7>V-
M#JY=UT*OW.4R7:SAD.EO8-NO[?WUC;^VW6_WE]^_<(VN:U@AEB =!]-DP+2_
M4/8O5FW<)>Y"6:O6[F\N.,HC;<#Z4BG;O)" ]E;_^O]02P,$%     @ L4IK
M6MNK=1/\ @  V@8  !D   !X;"]W;W)K<VAE971S+W-H965T,3@N>&ULI57K
M;]HP$/]73ME#FU21$&A7=8 $[:;U0R5$]_@P[8-)+L3"C]1VH/SW.SLAI5W+
M)DU"Q';N]SC[?!EMM5G;$M'!O13*CJ/2N>HBCFU6HF2VIRM4]*;01C)'4[.*
M;660Y0$D19PFR5DL&5?19!36YF8RTK437.'<@*VE9&8W0Z&WXZ@?[1<6?%4Z
MOQ!/1A5;X2VZ;]7<T"SN6'(N45FN%1@LQM&T?S$;^O@0\)WCUAZ,P6>RU'KM
M)]?Y.$J\(128.<_ Z+'!2Q3"$Y&-NY8SZB0]\'"\9_\<<J=<ELSBI18_>.[*
M<70>08X%JX5;Z.T7;/,Y]7R9%C;\P[:)'9!B5ENG90NFN>2J>;+[=A\. .?)
M"X"T!:3!=R,47%XQQR8CH[=@?#2Q^4%(-:#)'%?^4&Z=H;><<&XR3/KOUN]A
M+I@:Q8X(_7*<M>!9 TY? /=3N-'*E18^J1SSQP0Q.>GLI'L[L_0HXQ5F/1CT
M3R!-TN$1OD&7WB#P#5[@6Z#C!JF(',Q08<&=A9_3I76&RN'7<QDW?,/G^?P5
MN; 5RW <T1VP:#883=Z^ZI\E'X^X'79NA\?8_W88_PR&KR7"I9854SNPE596
M&PNTCK(2>H<(EFVX6EFH?+0KF8.[F@E><*0X^OG"1F,PITA!EQ68,4RMFIVL
MZ; -W+;WJM75!?%XU1Q[,&?&\8Q7S)%*IVJI<'<-,]05.!T0U\JA44S  C>H
M:B1BL^$9DE]%GB"C"C-\60<QP25W/9CF.?=S)L3NI-5MLO4*X<I[>LG6^ AO
M@:M6]M$.4/Z^,JP6"#FWF4$?W0.Z^( L*_?9[9#11J(O=J!21;FD5/;E2H9S
M/Q@\=90_-=%:.#PQ<C!\XV7VYY _'%9&3-0&V7][LG\:<4P0CE65T?><FAR*
M';Q.>N?4:X3P>L^5=7S0;R2:5>BJEKAKY9K6TZUVC7O:]*N'\*;KWS"SXN1$
M8$'0I/?A- +3=-)FXG05NM=2.^J%85C2QP>-#Z#WA=9N/_$"W>=L\AM02P,$
M%     @ L4IK6OUDCKA$!@  BPT  !D   !X;"]W;W)K<VAE971S+W-H965T
M,3DN>&ULE5=M;]LV$/XK!S<H6D"+;4FVXS0)T*;=5F!%BJ;;, S[0$LGFX@D
M>B05)_OU>XZT%&=-B^Z+38G'N^>>>Z/.=L;>N VSI[NF;MWY:./]]G0\=L6&
M&^6.S99;[%3&-LKCT:[';FM9E>%04X_3R60^;I1N1Q=GX=U'>W%F.E_KEC]:
M<EW3*'O_AFNS.Q]-1_V+3WJ]\?)B?'&V56N^9O_K]J/%TWC04NJ&6Z=-2Y:K
M\]'KZ>F;7.2#P&^:=^Y@3>+)RI@;>7A?GH\F HAK+KQH4/B[Y4NN:U$$&'_O
M=8X&DW+P<-UK_S'X#E]6RO&EJ7_7I=^<CTY&5'*ENMI_,KN?>>_/3/05IG;A
MEW91-EV.J.B<-\W^,! TNHW_ZF[/P\&!D\E7#J3[ VG '0T%E&^55Q=GUNS(
MBC2TR2*X&DX#G&XE*-?>8E?CG+^XYC4H]O2)M\9ZW:[/QAYJ97-<[%6\B2K2
MKZB8IO3!M'[CZ%U;<OE8P1AX!E!I#^I-^DV-;[DXIFR:4#I)\V_HRP8GLZ O
M^UXGZ<_7*^<M4N*OI_R-VO*GM4F9G+JM*OA\A#IP;&]Y=/'\V70^>?4-K/F
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M(ANO_O'!FVVX;J^,Q^4]+#?X6F(K MBOC/']@Q@8OK\N_@502P,$%     @
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MFM*?O->BA!L%+E"\L=VTX4KWIEV6>GJ", GZ?,NY.@2FP#"/L]]02P,$%
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M+"J7MW$ . 49F:D)N<;TD2K&;#21BAC8V(V\O XAOT*2-+<,[(E)/1%RWH8
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MZ4IJ@R# AZK:22@M-@V-V$D[* ;[S"J 8!]?(')>4!!#1#8:!>2%6,^1EXA
MK-4>,H1]8>HL -=&%;5H7$I(LS8F9S%D9@EH@TXR2J.)Y",8-!>;L%>#N0TA
MF(^(,0[+%SS19DZP8;?[22&^ 5-CN_11R_5!N<T'!.W=ND2HN035CC5,("+W
M2,-U;GH338[)"NPI,X:""5X=BLPN95!B"3G%M!27#'E79Q1"/;6-X%D_6S'
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MKSRP%.?V_G1#.$V-AXBXZY+TA-8VU0LX:8[_XN03[?O(;NCTPFY$+4O1]>F
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M3BCM5?>YZ"9&UNV#OI:&O@?M<$?_,53V .UOI#2'B248?GC+?P!02P,$%
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M4#L'NB^4LIN-2]!]O-)?4$L#!!0    ( +%*:UI5#18;] (  )@&   9
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M0!L<:'UKC#\888/Q8[3Z'U!+ P04    " "Q2FM:]<NS S,%  !S#0  &0
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MC03;30I^/T!1=WTP,OF.&,^IT[;0K!OWISU<ZD;](=T_R^)GS*O$.B(WUJ!
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MQSWGGG/AWKCAXD$6  H]E93)F5,H54U=5Z8%E%B.> 5,W^1<E%CIK=BZLA*
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M719Z[((P ?H^YUSM-Z:S^T&>_ -02P,$%     @ L4IK6KG8<#". P  QA$
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MHNHHJX'B&]N4W7.E6SQ[F>LN'(0)T/?7G*O'@7E T]<G/P%02P,$%     @
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M!-\B8:(UFUG8VEBTSH8P<XH+);27:)Q*OZ@"!+HE#+.,8(KN6-,9IL3OT5Q
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MP;C2AN9:TCGM:R)9UZVZ@Z*LKOZ90%U(JF:F2SU($Z#GYT+@IF,6:/\\Q'\
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M#3Q(5MK(HDXF!@47U3_[51NQDQ#UCR1$=4)T:D)<)\1.:,7,R;IEALTF2FY
MV6A"LP?.&Y=-:KBPV_A@%-WEE&=F?R-YH.$#/*S*,D?:(,-RF#.=P1UM,7P2
M5:E8R[\(J,.O10H_G$.8?KA>HZ(=K^[!-U0%O+]%PWBN+PCX^\,MO']W >^
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MXQ_L_/@6HN:,L&BE9KVM!3TIR'FQ]$J16"PS72ZQJ(_6R[LNBT5-.\>OZ'E
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M2I;FEVL@$7#=03U?,B9?&OI\N_H_8_8O4$L#!!0    ( +%*:UK@EKO2P ,
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MS^:@[ *\OY;2/$_L<;$[[<?_ 5!+ P04    " "Q2FM:^0VG:N\"   $"@
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M> L<7:(9S7)*@ B.:(3>%]'M5B8.!W0^!0)1(B[0^1P$3E)^(64OBSDZ/[M
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M,&4@UR-*Q6Z@-J@:/_\_4$L#!!0    ( +%*:UI2;!&!8@,   D+   9
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M(+\@>MJI)CQ/^6#8B>BK5O350-)E]D0PY7@/:5=DNB3V<XPF_BQ\TU5VE@/
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M5%&?H=<72FRK8^A;H93(JJ\;'B]Y41KHWU="J,>+<H#V/QFS_P!02P,$%
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M::(!G!>'Y!N<3$6;-)@LN#!<UKTY3U,F7QQGK+RA$_NGS):^'9^RC"Z$>6S
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MW&,EC'%BM/XU@LD/['X 4$L#!!0    ( +%*:UI-['=L5@4   0L   /
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M?#;^(V[Q E!+ 0(4 Q0    ( +%*:UH'04UB@0   +$    0
M  "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ L4IK6N_96C+N
M    *P(  !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L!
M A0#%     @ L4IK6IE<G",0!@  G"<  !,              ( !S $  'AL
M+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " "Q2FM:I"5XZ/0'  "Z,
M&               @($-"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L!
M A0#%     @ L4IK6GC.=4TW @  M@4  !@              ("!-Q   'AL
M+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    ( +%*:UJIM$V#K@4
M .H7   8              " @:02  !X;"]W;W)K<VAE971S+W-H965T,RYX
M;6Q02P$"% ,4    " "Q2FM:?/ICB],"  #V"@  &               @(&(
M&   >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ L4IK6@Y'
M?HZ"!   $!$  !@              ("!D1L  'AL+W=O<FMS:&5E=',O<VAE
M970U+GAM;%!+ 0(4 Q0    ( +%*:UJ#DVI1> 4  #<B   8
M  " @4D@  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4    " "Q
M2FM:[C?0X#8'  "4(   &               @('W)0  >&PO=V]R:W-H965T
M<R]S:&5E=#<N>&UL4$L! A0#%     @ L4IK6F>XP[L1!@  DPT  !@
M         ("!8RT  'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0
M   ( +%*:UI'\<R2A1X  %E;   8              " @:HS  !X;"]W;W)K
M<VAE971S+W-H965T.2YX;6Q02P$"% ,4    " "Q2FM:0\'AV:\%  #=#0
M&0              @(%E4@  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+
M 0(4 Q0    ( +%*:UK>?5P*!@P  #0A   9              " @4M8  !X
M;"]W;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @ L4IK6JU4X3FZ
M!@  /QT  !D              ("!B&0  'AL+W=O<FMS:&5E=',O<VAE970Q
M,BYX;6Q02P$"% ,4    " "Q2FM:/LRW:@8)  "[%0  &0
M@(%Y:P  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( +%*
M:UH10HEH! 8  /</   9              " @;9T  !X;"]W;W)K<VAE971S
M+W-H965T,30N>&UL4$L! A0#%     @ L4IK6L;)]I][!   #PL  !D
M         ("!\7H  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4
M    " "Q2FM:J72O@_ (  !H&@  &0              @(&C?P  >&PO=V]R
M:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( +%*:UHCF3%'V @  .$7
M   9              " @<J(  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL
M4$L! A0#%     @ L4IK6MNK=1/\ @  V@8  !D              ("!V9$
M 'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4    " "Q2FM:_62.
MN$0&  "+#0  &0              @($,E0  >&PO=V]R:W-H965T<R]S:&5E
M=#$Y+GAM;%!+ 0(4 Q0    ( +%*:UIR/80^0@(  )L%   9
M  " @8>;  !X;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @
ML4IK6BQU:+Y# @  B@8  !D              ("! )X  'AL+W=O<FMS:&5E
M=',O<VAE970R,2YX;6Q02P$"% ,4    " "Q2FM:/*4S.!$"  #=!   &0
M            @(%ZH   >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4
M Q0    ( +%*:UHD;?SCQ@X   M%   9              " @<*B  !X;"]W
M;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @ L4IK6JIXJMV8'
M9UD  !D              ("!O[$  'AL+W=O<FMS:&5E=',O<VAE970R-"YX
M;6Q02P$"% ,4    " "Q2FM:B(&5Y#P%  !-#@  &0              @(&.
MS@  >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( +%*:UJ$
M=6LER@,  .T)   9              " @0'4  !X;"]W;W)K<VAE971S+W-H
M965T,C8N>&UL4$L! A0#%     @ L4IK6GH,I! & P  N 8  !D
M     ("! M@  'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( +%*:UK]QV=E[04  +(/   9              "
M@73L  !X;"]W;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @ L4IK
M6OVJ21 9!   C@@  !D              ("!F/(  'AL+W=O<FMS:&5E=',O
M<VAE970S,RYX;6Q02P$"% ,4    " "Q2FM:I[#;760"  #4!0  &0
M        @('H]@  >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0
M   ( +%*:UJYV' PC@,  ,81   9              " @8/Y  !X;"]W;W)K
M<VAE971S+W-H965T,S4N>&UL4$L! A0#%     @ L4IK6KVV-OKR!0  >B4
M !D              ("!2/T  'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q0
M2P$"% ,4    " "Q2FM:D\/7$G,#  #C#P  &0              @(%Q P$
M>&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( +%*:UI)N11V
MI0(  " (   9              " @1L' 0!X;"]W;W)K<VAE971S+W-H965T
M,S@N>&UL4$L! A0#%     @ L4IK6K(2JVVP P  ^1   !D
M ("!]PD! 'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q02P$"% ,4    " "Q
M2FM:03=!.H "  "D!@  &0              @('>#0$ >&PO=V]R:W-H965T
M<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    ( +%*:UJ$_TZI_P,   H4   9
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M970T-2YX;6Q02P$"% ,4    " "Q2FM:(#$6$6,#   ($   &0
M    @('5)@$ >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    (
M +%*:UKU+&YF70,  "H,   9              " @6\J 0!X;"]W;W)K<VAE
M971S+W-H965T-#<N>&UL4$L! A0#%     @ L4IK6N7N%]CN @  2 @  !D
M             ("! RX! 'AL+W=O<FMS:&5E=',O<VAE970T."YX;6Q02P$"
M% ,4    " "Q2FM:6!OE%9<#  "U#   &0              @($H,0$ >&PO
M=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0    ( +%*:UK+8CN3PP,
M %D1   9              " @?8T 0!X;"]W;W)K<VAE971S+W-H965T-3 N
M>&UL4$L! A0#%     @ L4IK6LWENPQ"!0  ,"<  !D              ("!
M\#@! 'AL+W=O<FMS:&5E=',O<VAE970U,2YX;6Q02P$"% ,4    " "Q2FM:
MMR-&H30$  #;&   &0              @(%I/@$ >&PO=V]R:W-H965T<R]S
M:&5E=#4R+GAM;%!+ 0(4 Q0    ( +%*:UK@EKO2P ,  ,42   9
M      " @=1" 0!X;"]W;W)K<VAE971S+W-H965T-3,N>&UL4$L! A0#%
M  @ L4IK6J]-<CG/ P  \Q(  !D              ("!RT8! 'AL+W=O<FMS
M:&5E=',O<VAE970U-"YX;6Q02P$"% ,4    " "Q2FM:P5+>_Z$'   J-0
M&0              @('12@$ >&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+
M 0(4 Q0    ( +%*:UJRBHWU3 0  .H3   9              " @:E2 0!X
M;"]W;W)K<VAE971S+W-H965T-38N>&UL4$L! A0#%     @ L4IK6EV#/R!9
M!0  Y!H  !D              ("!+%<! 'AL+W=O<FMS:&5E=',O<VAE970U
M-RYX;6Q02P$"% ,4    " "Q2FM:'.RUK5T#   _#@  &0
M@(&\7 $ >&PO=V]R:W-H965T<R]S:&5E=#4X+GAM;%!+ 0(4 Q0    ( +%*
M:UJ=O;]U@0,  /D/   9              " @5!@ 0!X;"]W;W)K<VAE971S
M+W-H965T-3DN>&UL4$L! A0#%     @ L4IK6OD-IVKO @  ! H  !D
M         ("!"&0! 'AL+W=O<FMS:&5E=',O<VAE970V,"YX;6Q02P$"% ,4
M    " "Q2FM:4FP1@6(#   )"P  &0              @($N9P$ >&PO=V]R
M:W-H965T<R]S:&5E=#8Q+GAM;%!+ 0(4 Q0    ( +%*:UIT^J:JK@0  .T4
M   9              " @<=J 0!X;"]W;W)K<VAE971S+W-H965T-C(N>&UL
M4$L! A0#%     @ L4IK6KKMD@G: @  =@<  !D              ("!K&\!
M 'AL+W=O<FMS:&5E=',O<VAE970V,RYX;6Q02P$"% ,4    " "Q2FM:W4",
M-0\#  !2"P  &0              @(&]<@$ >&PO=V]R:W-H965T<R]S:&5E
M=#8T+GAM;%!+ 0(4 Q0    ( +%*:UJ$#*+6F@(  *@&   9
M  " @0-V 0!X;"]W;W)K<VAE971S+W-H965T-C4N>&UL4$L! A0#%     @
ML4IK6DG0RWG' @  !PD  !D              ("!U'@! 'AL+W=O<FMS:&5E
M=',O<VAE970V-BYX;6Q02P$"% ,4    " "Q2FM:E>&E#FT%  #5&   &0
M            @('2>P$ >&PO=V]R:W-H965T<R]S:&5E=#8W+GAM;%!+ 0(4
M Q0    ( +%*:UHS1L>Z.@,  .P3   -              "  7:! 0!X;"]S
M='EL97,N>&UL4$L! A0#%     @ L4IK6I>*NQS     $P(   L
M     ( !VX0! %]R96QS+RYR96QS4$L! A0#%     @ L4IK6DWL=VQ6!0
M!"P   \              ( !Q(4! 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0
M   ( +%*:UK(7,%2( (  - G   :              "  4>+ 0!X;"]?<F5L
M<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( +%*:UKB(3)"\0$  !DG
M   3              "  9^- 0!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@
0  !+ $L A!0  ,&/ 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>136</ContextCount>
  <ElementCount>370</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>69</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>8</UnitCount>
  <MyReports>
    <Report instance="exdx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="exdx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="exdx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>9952151 - Statement - Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/BalanceSheets</Role>
      <ShortName>Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="exdx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>9952152 - Statement - Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="exdx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>9952153 - Statement - Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/StatementsofOperations</Role>
      <ShortName>Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="exdx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>9952154 - Statement - Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/StatementsofStockholdersEquity</Role>
      <ShortName>Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="exdx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>9952155 - Statement - Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/StatementsofCashFlows</Role>
      <ShortName>Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="exdx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>9952156 - Disclosure - Organization</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/Organization</Role>
      <ShortName>Organization</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="exdx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>9952157 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="exdx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>9952158 - Disclosure - Other Financial Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/OtherFinancialInformation</Role>
      <ShortName>Other Financial Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="exdx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>9952159 - Disclosure - Borrowings</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/Borrowings</Role>
      <ShortName>Borrowings</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="exdx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>9952160 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="exdx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>9952161 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="exdx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>9952162 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="exdx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>9952163 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="exdx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>9952164 - Disclosure - Stock Option Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/StockOptionPlan</Role>
      <ShortName>Stock Option Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="exdx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>9952165 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="exdx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>9952166 - Disclosure - 401(k) Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/A401kPlan</Role>
      <ShortName>401(k) Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="exdx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>9952167 - Disclosure - Segment Reporting</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/SegmentReporting</Role>
      <ShortName>Segment Reporting</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="exdx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="exdx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="exdx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>995447 - Disclosure - Insider Trading Policies and Procedures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc</Role>
      <ShortName>Insider Trading Policies and Procedures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="exdx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure</Role>
      <ShortName>Cybersecurity Risk Management and Strategy Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="exdx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>9955511 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.exagen.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="exdx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>9955512 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exagen.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="exdx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>9955513 - Disclosure - Other Financial Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/OtherFinancialInformationTables</Role>
      <ShortName>Other Financial Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exagen.com/role/OtherFinancialInformation</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="exdx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>9955514 - Disclosure - Borrowings (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/BorrowingsTables</Role>
      <ShortName>Borrowings (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exagen.com/role/Borrowings</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="exdx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>9955515 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exagen.com/role/Leases</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="exdx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>9955516 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exagen.com/role/FairValueMeasurements</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="exdx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>9955517 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exagen.com/role/StockholdersEquity</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="exdx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>9955518 - Disclosure - Stock Option Plan (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/StockOptionPlanTables</Role>
      <ShortName>Stock Option Plan (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exagen.com/role/StockOptionPlan</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="exdx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>9955519 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exagen.com/role/IncomeTaxes</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="exdx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>9955520 - Disclosure - Segment Reporting (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/SegmentReportingTables</Role>
      <ShortName>Segment Reporting (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exagen.com/role/SegmentReporting</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="exdx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>9955521 - Disclosure - Organization (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/OrganizationDetails</Role>
      <ShortName>Organization (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exagen.com/role/Organization</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="exdx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>9955522 - Disclosure - Summary of Significant Accounting Policies - Revenue by Major Payers (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Revenue by Major Payers (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="exdx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>9955523 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="exdx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>9955524 - Disclosure - Summary of Significant Accounting Policies - Disaggregation of Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Disaggregation of Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="exdx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>9955525 - Disclosure - Summary of Significant Accounting Policies - Cash, Cash Equivalents and Restricted Cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Cash, Cash Equivalents and Restricted Cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="exdx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>9955526 - Disclosure - Summary of Significant Accounting Policies - Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesSecuritiesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="exdx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>9955527 - Disclosure - Other Financial Information - Prepaid Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/OtherFinancialInformationPrepaidExpensesDetails</Role>
      <ShortName>Other Financial Information - Prepaid Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="exdx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>9955528 - Disclosure - Other Financial Information - Property and Equipment Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/OtherFinancialInformationPropertyandEquipmentNetDetails</Role>
      <ShortName>Other Financial Information - Property and Equipment Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="exdx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>9955529 - Disclosure - Other Financial Information - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/OtherFinancialInformationNarrativeDetails</Role>
      <ShortName>Other Financial Information - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="exdx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>9955530 - Disclosure - Other Financial Information - Accrued Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/OtherFinancialInformationAccruedLiabilitiesDetails</Role>
      <ShortName>Other Financial Information - Accrued Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="exdx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>9955531 - Disclosure - Borrowings - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/BorrowingsNarrativeDetails</Role>
      <ShortName>Borrowings - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="exdx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>9955532 - Disclosure - Borrowings - Future Minimum Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/BorrowingsFutureMinimumPaymentsDetails</Role>
      <ShortName>Borrowings - Future Minimum Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="exdx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>9955533 - Disclosure - Leases - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/LeasesNarrativeDetails</Role>
      <ShortName>Leases - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="exdx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>9955534 - Disclosure - Leases - Lease Balances (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/LeasesLeaseBalancesDetails</Role>
      <ShortName>Leases - Lease Balances (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="exdx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>9955535 - Disclosure - Leases - Costs Associated with the Company's Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/LeasesCostsAssociatedwiththeCompanysLeasesDetails</Role>
      <ShortName>Leases - Costs Associated with the Company's Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="exdx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>9955536 - Disclosure - Leases - Supplemental Cash Flow Information On Leases And Weighted-Average Lease Term (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/LeasesSupplementalCashFlowInformationOnLeasesAndWeightedAverageLeaseTermDetails</Role>
      <ShortName>Leases - Supplemental Cash Flow Information On Leases And Weighted-Average Lease Term (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="exdx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>9955537 - Disclosure - Leases - Future Payments Under Operating And Finance Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/LeasesFuturePaymentsUnderOperatingAndFinanceLeasesDetails</Role>
      <ShortName>Leases - Future Payments Under Operating And Finance Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="exdx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>9955538 - Disclosure - Commitments and Contingencies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/CommitmentsandContingenciesNarrativeDetails</Role>
      <ShortName>Commitments and Contingencies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="exdx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>9955539 - Disclosure - Fair Value Measurements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/FairValueMeasurementsDetails</Role>
      <ShortName>Fair Value Measurements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exagen.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="exdx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>9955540 - Disclosure - Stockholders' Equity - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/StockholdersEquityNarrativeDetails</Role>
      <ShortName>Stockholders' Equity - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="exdx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>9955541 - Disclosure - Stockholders' Equity - Warrants to Purchase Common Stock Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/StockholdersEquityWarrantstoPurchaseCommonStockOutstandingDetails</Role>
      <ShortName>Stockholders' Equity - Warrants to Purchase Common Stock Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="exdx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>9955542 - Disclosure - Stock Option Plan - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/StockOptionPlanNarrativeDetails</Role>
      <ShortName>Stock Option Plan - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="exdx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>9955543 - Disclosure - Stock Option Plan - Restricted Stock Units (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails</Role>
      <ShortName>Stock Option Plan - Restricted Stock Units (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="exdx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>9955544 - Disclosure - Stock Option Plan - Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails</Role>
      <ShortName>Stock Option Plan - Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="exdx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>9955545 - Disclosure - Stock Option Plan - Stock-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/StockOptionPlanStockBasedCompensationExpenseDetails</Role>
      <ShortName>Stock Option Plan - Stock-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="exdx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>9955546 - Disclosure - Stock Option Plan - Common Stock Reserved For Future Issuance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/StockOptionPlanCommonStockReservedForFutureIssuanceDetails</Role>
      <ShortName>Stock Option Plan - Common Stock Reserved For Future Issuance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="exdx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>9955547 - Disclosure - Income Taxes - Components of Income Tax Expense (Benefit) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails</Role>
      <ShortName>Income Taxes - Components of Income Tax Expense (Benefit) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="exdx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>9955548 - Disclosure - Income Taxes - Reconciliation of Effective Income Tax Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails</Role>
      <ShortName>Income Taxes - Reconciliation of Effective Income Tax Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="exdx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>9955549 - Disclosure - Income Taxes - Reconciliation of Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails</Role>
      <ShortName>Income Taxes - Reconciliation of Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="exdx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>9955550 - Disclosure - Income Taxes - Change In Valuation Allowance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/IncomeTaxesChangeInValuationAllowanceDetails</Role>
      <ShortName>Income Taxes - Change In Valuation Allowance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="exdx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>9955551 - Disclosure - Income Taxes - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/IncomeTaxesNarrativeDetails</Role>
      <ShortName>Income Taxes - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="exdx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>9955552 - Disclosure - 401(k) Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/A401kPlanDetails</Role>
      <ShortName>401(k) Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exagen.com/role/A401kPlan</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="exdx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>9955553 - Disclosure - Segment Reporting - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/SegmentReportingNarrativeDetails</Role>
      <ShortName>Segment Reporting - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="exdx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>9955554 - Disclosure - Segment Reporting (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/SegmentReportingDetails</Role>
      <ShortName>Segment Reporting (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exagen.com/role/SegmentReportingTables</ParentRole>
      <Position>67</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="exdx-20241231.htm">exdx-20241231.htm</File>
    <File>exdx-20241231.xsd</File>
    <File>exdx-20241231_cal.xml</File>
    <File>exdx-20241231_def.xml</File>
    <File>exdx-20241231_lab.xml</File>
    <File>exdx-20241231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>exdx-20241231_g1.jpg</File>
    <File>exdx-20241231_g2.jpg</File>
    <File>exdx-20241231_g3.jpg</File>
    <File>exdx-20241231_g4.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="621">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="15">http://xbrl.sec.gov/cyd/2024</BaseTaxonomy>
    <BaseTaxonomy items="38">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="5">http://xbrl.sec.gov/ecd/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>91
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "exdx-20241231.htm": {
   "nsprefix": "exdx",
   "nsuri": "http://www.exagen.com/20241231",
   "dts": {
    "inline": {
     "local": [
      "exdx-20241231.htm"
     ]
    },
    "schema": {
     "local": [
      "exdx-20241231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-af-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-af-sub-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "exdx-20241231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "exdx-20241231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "exdx-20241231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "exdx-20241231_pre.xml"
     ]
    }
   },
   "keyStandard": 336,
   "keyCustom": 34,
   "axisStandard": 29,
   "axisCustom": 0,
   "memberStandard": 34,
   "memberCustom": 32,
   "hidden": {
    "total": 15,
    "http://fasb.org/us-gaap/2024": 11,
    "http://xbrl.sec.gov/dei/2024": 4
   },
   "contextCount": 136,
   "entityCount": 1,
   "segmentCount": 69,
   "elementCount": 678,
   "unitCount": 8,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 621,
    "http://xbrl.sec.gov/dei/2024": 38,
    "http://xbrl.sec.gov/cyd/2024": 15,
    "http://xbrl.sec.gov/ecd/2024": 5
   },
   "report": {
    "R1": {
     "role": "http://www.exagen.com/role/Cover",
     "longName": "0000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.exagen.com/role/AuditInformation",
     "longName": "0000002 - Document - Audit Information",
     "shortName": "Audit Information",
     "isDefault": "false",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:AuditorName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:AuditorName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.exagen.com/role/BalanceSheets",
     "longName": "9952151 - Statement - Balance Sheets",
     "shortName": "Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:PrepaidExpenseAndOtherAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20241231.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.exagen.com/role/BalanceSheetsParenthetical",
     "longName": "9952152 - Statement - Balance Sheets (Parenthetical)",
     "shortName": "Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.exagen.com/role/StatementsofOperations",
     "longName": "9952153 - Statement - Statements of Operations",
     "shortName": "Statements of Operations",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SellingGeneralAndAdministrativeExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20241231.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.exagen.com/role/StatementsofStockholdersEquity",
     "longName": "9952154 - Statement - Statements of Stockholders' Equity",
     "shortName": "Statements of Stockholders' Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c-8",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-8",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.exagen.com/role/StatementsofCashFlows",
     "longName": "9952155 - Statement - Statements of Cash Flows",
     "shortName": "Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20241231.htm",
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.exagen.com/role/Organization",
     "longName": "9952156 - Disclosure - Organization",
     "shortName": "Organization",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.exagen.com/role/SummaryofSignificantAccountingPolicies",
     "longName": "9952157 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.exagen.com/role/OtherFinancialInformation",
     "longName": "9952158 - Disclosure - Other Financial Information",
     "shortName": "Other Financial Information",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "exdx:PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "exdx:PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.exagen.com/role/Borrowings",
     "longName": "9952159 - Disclosure - Borrowings",
     "shortName": "Borrowings",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.exagen.com/role/Leases",
     "longName": "9952160 - Disclosure - Leases",
     "shortName": "Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.exagen.com/role/CommitmentsandContingencies",
     "longName": "9952161 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.exagen.com/role/FairValueMeasurements",
     "longName": "9952162 - Disclosure - Fair Value Measurements",
     "shortName": "Fair Value Measurements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.exagen.com/role/StockholdersEquity",
     "longName": "9952163 - Disclosure - Stockholders' Equity",
     "shortName": "Stockholders' Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.exagen.com/role/StockOptionPlan",
     "longName": "9952164 - Disclosure - Stock Option Plan",
     "shortName": "Stock Option Plan",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.exagen.com/role/IncomeTaxes",
     "longName": "9952165 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.exagen.com/role/A401kPlan",
     "longName": "9952166 - Disclosure - 401(k) Plan",
     "shortName": "401(k) Plan",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.exagen.com/role/SegmentReporting",
     "longName": "9952167 - Disclosure - Segment Reporting",
     "shortName": "Segment Reporting",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20241231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R21": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ecd:NonRule10b51ArrAdoptedFlag",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ecd:NonRule10b51ArrAdoptedFlag",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc",
     "longName": "995447 - Disclosure - Insider Trading Policies and Procedures",
     "shortName": "Insider Trading Policies and Procedures",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure",
     "longName": "995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure",
     "shortName": "Cybersecurity Risk Management and Strategy Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "longName": "9955511 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ConcentrationRiskCreditRisk",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ConcentrationRiskCreditRisk",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesTables",
     "longName": "9955512 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.exagen.com/role/OtherFinancialInformationTables",
     "longName": "9955513 - Disclosure - Other Financial Information (Tables)",
     "shortName": "Other Financial Information (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.exagen.com/role/BorrowingsTables",
     "longName": "9955514 - Disclosure - Borrowings (Tables)",
     "shortName": "Borrowings (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.exagen.com/role/LeasesTables",
     "longName": "9955515 - Disclosure - Leases (Tables)",
     "shortName": "Leases (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.exagen.com/role/FairValueMeasurementsTables",
     "longName": "9955516 - Disclosure - Fair Value Measurements (Tables)",
     "shortName": "Fair Value Measurements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.exagen.com/role/StockholdersEquityTables",
     "longName": "9955517 - Disclosure - Stockholders' Equity (Tables)",
     "shortName": "Stockholders' Equity (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.exagen.com/role/StockOptionPlanTables",
     "longName": "9955518 - Disclosure - Stock Option Plan (Tables)",
     "shortName": "Stock Option Plan (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.exagen.com/role/IncomeTaxesTables",
     "longName": "9955519 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.exagen.com/role/SegmentReportingTables",
     "longName": "9955520 - Disclosure - Segment Reporting (Tables)",
     "shortName": "Segment Reporting (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.exagen.com/role/OrganizationDetails",
     "longName": "9955521 - Disclosure - Organization (Details)",
     "shortName": "Organization (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20241231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R35": {
     "role": "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails",
     "longName": "9955522 - Disclosure - Summary of Significant Accounting Policies - Revenue by Major Payers (Details)",
     "shortName": "Summary of Significant Accounting Policies - Revenue by Major Payers (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c-24",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-24",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
     "longName": "9955523 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)",
     "shortName": "Summary of Significant Accounting Policies - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:RestrictedCash",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "us-gaap:RevenueRecognitionPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20241231.htm",
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails",
     "longName": "9955524 - Disclosure - Summary of Significant Accounting Policies - Disaggregation of Revenue (Details)",
     "shortName": "Summary of Significant Accounting Policies - Disaggregation of Revenue (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-39",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20241231.htm",
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails",
     "longName": "9955525 - Disclosure - Summary of Significant Accounting Policies - Cash, Cash Equivalents and Restricted Cash (Details)",
     "shortName": "Summary of Significant Accounting Policies - Cash, Cash Equivalents and Restricted Cash (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20241231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R39": {
     "role": "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesSecuritiesDetails",
     "longName": "9955526 - Disclosure - Summary of Significant Accounting Policies - Securities (Details)",
     "shortName": "Summary of Significant Accounting Policies - Securities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.exagen.com/role/OtherFinancialInformationPrepaidExpensesDetails",
     "longName": "9955527 - Disclosure - Other Financial Information - Prepaid Expenses (Details)",
     "shortName": "Other Financial Information - Prepaid Expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:OtherAssetsCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:OtherAssetsCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.exagen.com/role/OtherFinancialInformationPropertyandEquipmentNetDetails",
     "longName": "9955528 - Disclosure - Other Financial Information - Property and Equipment Net (Details)",
     "shortName": "Other Financial Information - Property and Equipment Net (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.exagen.com/role/OtherFinancialInformationNarrativeDetails",
     "longName": "9955529 - Disclosure - Other Financial Information - Narrative (Details)",
     "shortName": "Other Financial Information - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20241231.htm",
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.exagen.com/role/OtherFinancialInformationAccruedLiabilitiesDetails",
     "longName": "9955530 - Disclosure - Other Financial Information - Accrued Liabilities (Details)",
     "shortName": "Other Financial Information - Accrued Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:AccruedSalariesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:AccruedSalariesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.exagen.com/role/BorrowingsNarrativeDetails",
     "longName": "9955531 - Disclosure - Borrowings - Narrative (Details)",
     "shortName": "Borrowings - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RepaymentsOfLongTermDebt",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-70",
      "name": "us-gaap:ProceedsFromIssuanceOfLongTermDebt",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20241231.htm",
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.exagen.com/role/BorrowingsFutureMinimumPaymentsDetails",
     "longName": "9955532 - Disclosure - Borrowings - Future Minimum Payments (Details)",
     "shortName": "Borrowings - Future Minimum Payments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.exagen.com/role/LeasesNarrativeDetails",
     "longName": "9955533 - Disclosure - Leases - Narrative (Details)",
     "shortName": "Leases - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c-84",
      "name": "us-gaap:LesseeOperatingLeaseRenewalTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-84",
      "name": "us-gaap:LesseeOperatingLeaseRenewalTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.exagen.com/role/LeasesLeaseBalancesDetails",
     "longName": "9955534 - Disclosure - Leases - Lease Balances (Details)",
     "shortName": "Leases - Lease Balances (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:FinanceLeaseRightOfUseAsset",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20241231.htm",
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.exagen.com/role/LeasesCostsAssociatedwiththeCompanysLeasesDetails",
     "longName": "9955535 - Disclosure - Leases - Costs Associated with the Company's Leases (Details)",
     "shortName": "Leases - Costs Associated with the Company's Leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.exagen.com/role/LeasesSupplementalCashFlowInformationOnLeasesAndWeightedAverageLeaseTermDetails",
     "longName": "9955536 - Disclosure - Leases - Supplemental Cash Flow Information On Leases And Weighted-Average Lease Term (Details)",
     "shortName": "Leases - Supplemental Cash Flow Information On Leases And Weighted-Average Lease Term (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OperatingLeasePayments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OperatingLeasePayments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.exagen.com/role/LeasesFuturePaymentsUnderOperatingAndFinanceLeasesDetails",
     "longName": "9955537 - Disclosure - Leases - Future Payments Under Operating And Finance Leases (Details)",
     "shortName": "Leases - Future Payments Under Operating And Finance Leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.exagen.com/role/CommitmentsandContingenciesNarrativeDetails",
     "longName": "9955538 - Disclosure - Commitments and Contingencies - Narrative (Details)",
     "shortName": "Commitments and Contingencies - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c-89",
      "name": "exdx:PurchaseObligationAmendedSupplyAgreementNumberOfSuppliers",
      "unitRef": "supplier",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-89",
      "name": "exdx:PurchaseObligationAmendedSupplyAgreementNumberOfSuppliers",
      "unitRef": "supplier",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.exagen.com/role/FairValueMeasurementsDetails",
     "longName": "9955539 - Disclosure - Fair Value Measurements (Details)",
     "shortName": "Fair Value Measurements (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:LongTermDebt",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-96",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20241231.htm",
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.exagen.com/role/StockholdersEquityNarrativeDetails",
     "longName": "9955540 - Disclosure - Stockholders' Equity - Narrative (Details)",
     "shortName": "Stockholders' Equity - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "exdx:StockIssuedDuringPeriodSharesWarrantsExercisedNet",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "exdx:StockIssuedDuringPeriodSharesWarrantsExercisedNet",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.exagen.com/role/StockholdersEquityWarrantstoPurchaseCommonStockOutstandingDetails",
     "longName": "9955541 - Disclosure - Stockholders' Equity - Warrants to Purchase Common Stock Outstanding (Details)",
     "shortName": "Stockholders' Equity - Warrants to Purchase Common Stock Outstanding (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.exagen.com/role/StockOptionPlanNarrativeDetails",
     "longName": "9955542 - Disclosure - Stock Option Plan - Narrative (Details)",
     "shortName": "Stock Option Plan - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20241231.htm",
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails",
     "longName": "9955543 - Disclosure - Stock Option Plan - Restricted Stock Units (Details)",
     "shortName": "Stock Option Plan - Restricted Stock Units (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-117",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20241231.htm",
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails",
     "longName": "9955544 - Disclosure - Stock Option Plan - Stock Option Activity (Details)",
     "shortName": "Stock Option Plan - Stock Option Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20241231.htm",
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.exagen.com/role/StockOptionPlanStockBasedCompensationExpenseDetails",
     "longName": "9955545 - Disclosure - Stock Option Plan - Stock-Based Compensation Expense (Details)",
     "shortName": "Stock Option Plan - Stock-Based Compensation Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-124",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20241231.htm",
      "unique": true
     }
    },
    "R59": {
     "role": "http://www.exagen.com/role/StockOptionPlanCommonStockReservedForFutureIssuanceDetails",
     "longName": "9955546 - Disclosure - Stock Option Plan - Common Stock Reserved For Future Issuance (Details)",
     "shortName": "Stock Option Plan - Common Stock Reserved For Future Issuance (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-130",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20241231.htm",
      "unique": true
     }
    },
    "R60": {
     "role": "http://www.exagen.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails",
     "longName": "9955547 - Disclosure - Income Taxes - Components of Income Tax Expense (Benefit) (Details)",
     "shortName": "Income Taxes - Components of Income Tax Expense (Benefit) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://www.exagen.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails",
     "longName": "9955548 - Disclosure - Income Taxes - Reconciliation of Effective Income Tax Rate (Details)",
     "shortName": "Income Taxes - Reconciliation of Effective Income Tax Rate (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R62": {
     "role": "http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails",
     "longName": "9955549 - Disclosure - Income Taxes - Reconciliation of Deferred Tax Assets and Liabilities (Details)",
     "shortName": "Income Taxes - Reconciliation of Deferred Tax Assets and Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R63": {
     "role": "http://www.exagen.com/role/IncomeTaxesChangeInValuationAllowanceDetails",
     "longName": "9955550 - Disclosure - Income Taxes - Change In Valuation Allowance (Details)",
     "shortName": "Income Taxes - Change In Valuation Allowance (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:DeferredTaxAssetsValuationAllowance",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SummaryOfValuationAllowanceTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SummaryOfValuationAllowanceTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20241231.htm",
      "unique": true
     }
    },
    "R64": {
     "role": "http://www.exagen.com/role/IncomeTaxesNarrativeDetails",
     "longName": "9955551 - Disclosure - Income Taxes - Narrative (Details)",
     "shortName": "Income Taxes - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R65": {
     "role": "http://www.exagen.com/role/A401kPlanDetails",
     "longName": "9955552 - Disclosure - 401(k) Plan (Details)",
     "shortName": "401(k) Plan (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R66": {
     "role": "http://www.exagen.com/role/SegmentReportingNarrativeDetails",
     "longName": "9955553 - Disclosure - Segment Reporting - Narrative (Details)",
     "shortName": "Segment Reporting - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:Assets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-133",
      "name": "us-gaap:Assets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20241231.htm",
      "unique": true
     }
    },
    "R67": {
     "role": "http://www.exagen.com/role/SegmentReportingDetails",
     "longName": "9955554 - Disclosure - Segment Reporting (Details)",
     "shortName": "Segment Reporting (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-135",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20241231.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "exdx_A2017TermLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.exagen.com/20241231",
     "localname": "A2017TermLoanMember",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2017 Term Loan",
        "label": "2017 Term Loan [Member]",
        "documentation": "2017 Term Loan"
       }
      }
     },
     "auth_ref": []
    },
    "exdx_AHNCollaborationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.exagen.com/20241231",
     "localname": "AHNCollaborationMember",
     "presentation": [
      "http://www.exagen.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "AHN Collaboration",
        "label": "AHN Collaboration [Member]",
        "documentation": "AHN Collaboration"
       }
      }
     },
     "auth_ref": []
    },
    "exdx_AVISECTDTestMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.exagen.com/20241231",
     "localname": "AVISECTDTestMember",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "AVISE CTD Test",
        "label": "AVISE CTD Test [Member]",
        "documentation": "AVISE CTD Test"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.exagen.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Accounts Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r808"
     ]
    },
    "us-gaap_AccountsReceivableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableMember",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts Receivable",
        "label": "Accounts Receivable [Member]",
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold."
       }
      }
     },
     "auth_ref": [
      "r745"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.exagen.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/BalanceSheets",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable, net",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r984"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.exagen.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.exagen.com/role/OtherFinancialInformationAccruedLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.exagen.com/role/BalanceSheets",
      "http://www.exagen.com/role/OtherFinancialInformationAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued and other current liabilities",
        "totalLabel": "Accrued and other current liabilities",
        "label": "Accrued Liabilities, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "us-gaap_AccruedSalariesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedSalariesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.exagen.com/role/OtherFinancialInformationAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued\u00a0payroll\u00a0and\u00a0related\u00a0expenses",
        "label": "Accrued Salaries, Current",
        "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r753"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional 402(v) Disclosure",
        "label": "Additional 402(v) Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r878"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://www.exagen.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r808",
      "r1114"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.exagen.com/role/StatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Paid-In Capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r684",
      "r974",
      "r975",
      "r976",
      "r977",
      "r1053",
      "r1115"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation, Amount",
        "label": "Adjustment to Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r891"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation:",
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r891"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote",
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r891"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment To PEO Compensation, Footnote",
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r891"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.exagen.com/role/StatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r44",
      "r399"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:",
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdvertisingCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdvertisingCostsPolicyTextBlock",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Advertising and Marketing Costs",
        "label": "Advertising Cost [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for advertising cost."
       }
      }
     },
     "auth_ref": [
      "r118"
     ]
    },
    "us-gaap_AdvertisingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdvertisingExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Advertising and marketing costs",
        "label": "Advertising Expense",
        "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line."
       }
      }
     },
     "auth_ref": [
      "r435",
      "r793"
     ]
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table",
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r936"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Amount",
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r849",
      "r860",
      "r870",
      "r903"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined",
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r852",
      "r863",
      "r873",
      "r906"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Pension Adjustments Service Cost",
        "label": "Aggregate Pension Adjustments Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r937"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Adjustments to Compensation",
        "label": "All Adjustments to Compensation [Member]"
       }
      }
     },
     "auth_ref": [
      "r891"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Executive Categories",
        "label": "All Executive Categories [Member]"
       }
      }
     },
     "auth_ref": [
      "r898"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Individuals",
        "label": "All Individuals [Member]"
       }
      }
     },
     "auth_ref": [
      "r853",
      "r864",
      "r874",
      "r898",
      "r907",
      "r911",
      "r919"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Trading Arrangements",
        "label": "All Trading Arrangements [Member]"
       }
      }
     },
     "auth_ref": [
      "r917"
     ]
    },
    "exdx_AlleghenyHealthNetworkResearchInstituteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.exagen.com/20241231",
     "localname": "AlleghenyHealthNetworkResearchInstituteMember",
     "presentation": [
      "http://www.exagen.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Allegheny Health Network Research Institute",
        "label": "Allegheny Health Network Research Institute [Member]",
        "documentation": "Allegheny Health Network Research Institute"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.exagen.com/role/SegmentReportingDetails": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/SegmentReportingDetails",
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails",
      "http://www.exagen.com/role/StockOptionPlanStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock compensation",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r428",
      "r433"
     ]
    },
    "exdx_AmendedLoanAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.exagen.com/20241231",
     "localname": "AmendedLoanAgreementMember",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails",
      "http://www.exagen.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amended Loan Agreement",
        "label": "Amended Loan Agreement [Member]",
        "documentation": "Amended Loan Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "crdr": "debit",
     "calculation": {
      "http://www.exagen.com/role/StatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of debt discount and debt issuance costs",
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r349",
      "r777",
      "r778",
      "r967",
      "r1064"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Anti-dilutive securities excluded from computation (in shares)",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r189"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities [Axis]",
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities, Name [Domain]",
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://www.exagen.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r493"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.exagen.com/role/BalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.exagen.com/role/BalanceSheets",
      "http://www.exagen.com/role/SegmentReportingNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "terseLabel": "Assets",
        "label": "Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r115",
      "r136",
      "r159",
      "r192",
      "r199",
      "r217",
      "r221",
      "r265",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r494",
      "r496",
      "r545",
      "r627",
      "r708",
      "r765",
      "r766",
      "r808",
      "r827",
      "r1009",
      "r1010",
      "r1069"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.exagen.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.exagen.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r143",
      "r159",
      "r265",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r494",
      "r496",
      "r545",
      "r808",
      "r1009",
      "r1010",
      "r1069"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.exagen.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets:",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsFairValueDisclosureAbstract",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets:",
        "label": "Assets, Fair Value Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "exdx_AuditInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.exagen.com/20241231",
     "localname": "AuditInformationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Audit Information [Abstract]",
        "documentation": "Audit Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://www.exagen.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Firm ID",
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r832",
      "r833",
      "r856"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorLocation",
     "presentation": [
      "http://www.exagen.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Location",
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r832",
      "r833",
      "r856"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorName",
     "presentation": [
      "http://www.exagen.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Name",
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r832",
      "r833",
      "r856"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise Price",
        "label": "Award Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r914"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value as of Grant Date",
        "label": "Award Grant Date Fair Value"
       }
      }
     },
     "auth_ref": [
      "r915"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r910"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing, How MNPI Considered",
        "label": "Award Timing, How MNPI Considered [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r910"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Method",
        "label": "Award Timing Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r910"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Considered",
        "label": "Award Timing MNPI Considered [Flag]"
       }
      }
     },
     "auth_ref": [
      "r910"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Disclosure",
        "label": "Award Timing MNPI Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r910"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Predetermined",
        "label": "Award Timing Predetermined [Flag]"
       }
      }
     },
     "auth_ref": [
      "r910"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanCommonStockReservedForFutureIssuanceDetails",
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails",
      "http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Axis]",
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Securities",
        "label": "Award Underlying Securities Amount"
       }
      }
     },
     "auth_ref": [
      "r913"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r912"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures",
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "auth_ref": [
      "r911"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table",
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r911"
     ]
    },
    "us-gaap_BuildingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BuildingMember",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Building",
        "label": "Building [Member]",
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities."
       }
      }
     },
     "auth_ref": [
      "r90"
     ]
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Costs incurred, but not paid, in connection with capital expenditures",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r19",
      "r20"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.exagen.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/BalanceSheets",
      "http://www.exagen.com/role/OrganizationDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash and cash equivalents",
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r134",
      "r752"
     ]
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Money market funds, included in cash and cash equivalents",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1055",
      "r1056"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash, Cash Equivalents and Restricted Cash",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash, cash equivalents and restricted cash, beginning of year",
        "periodEndLabel": "Cash, cash equivalents and restricted cash, end of year",
        "totalLabel": "Total cash, cash equivalents and restricted cash",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r81",
      "r155"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.exagen.com/role/StatementsofCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net change in cash, cash equivalents and restricted cash",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r81"
     ]
    },
    "exdx_CashFlowInformationOperatingAndFinanceLeasePaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.exagen.com/20241231",
     "localname": "CashFlowInformationOperatingAndFinanceLeasePaymentsAbstract",
     "presentation": [
      "http://www.exagen.com/role/LeasesSupplementalCashFlowInformationOnLeasesAndWeightedAverageLeaseTermDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities",
        "label": "Cash Flow Information, Operating and Finance Lease Payments [Abstract]",
        "documentation": "Cash Flow Information, Operating and Finance Lease Payments"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changed Peer Group, Footnote",
        "label": "Changed Peer Group, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r889"
     ]
    },
    "exdx_ChangesInTheValuationAllowanceForDeferredTaxAssetsRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.exagen.com/20241231",
     "localname": "ChangesInTheValuationAllowanceForDeferredTaxAssetsRollForward",
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesChangeInValuationAllowanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes In The Valuation Allowance For Deferred Tax Assets [Roll Forward]",
        "label": "Changes In The Valuation Allowance For Deferred Tax Assets [Roll Forward]",
        "documentation": "Changes In The Valuation Allowance For Deferred Tax Assets"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year",
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r886"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested",
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]"
       }
      }
     },
     "auth_ref": [
      "r884"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityWarrantstoPurchaseCommonStockOutstandingDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Line Items]",
        "label": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r139",
      "r140",
      "r141",
      "r194",
      "r358",
      "r359",
      "r360",
      "r362",
      "r365",
      "r370",
      "r372",
      "r678",
      "r679",
      "r680",
      "r681",
      "r779",
      "r941",
      "r969"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityWarrantstoPurchaseCommonStockOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Warrant or Right [Axis]",
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityWarrantstoPurchaseCommonStockOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Warrant or Right [Domain]",
        "label": "Class of Warrant or Right [Domain]",
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityWarrantstoPurchaseCommonStockOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of warrant or right, exercise price of warrants or rights (in dollars per share)",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r373"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityWarrantstoPurchaseCommonStockOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants issued to purchase redeemable convertible preferred stock (in shares)",
        "label": "Class of Warrant or Right, Outstanding",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "exdx_ClientMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.exagen.com/20241231",
     "localname": "ClientMember",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Client",
        "label": "Client [Member]",
        "documentation": "Client"
       }
      }
     },
     "auth_ref": []
    },
    "exdx_ClinicalStudyPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.exagen.com/20241231",
     "localname": "ClinicalStudyPolicyPolicyTextBlock",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Clinical Studies",
        "label": "Clinical Study, Policy [Policy Text Block]",
        "documentation": "Clinical Study, Policy"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Amount",
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r890"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Name",
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r890"
     ]
    },
    "exdx_CollaborationAgreementAnnualCollaborationFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.exagen.com/20241231",
     "localname": "CollaborationAgreementAnnualCollaborationFee",
     "crdr": "debit",
     "presentation": [
      "http://www.exagen.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration fee",
        "label": "Collaboration Agreement, Annual Collaboration Fee",
        "documentation": "Collaboration Agreement, Annual Collaboration Fee"
       }
      }
     },
     "auth_ref": []
    },
    "exdx_CollaborationAgreementCollaborationExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.exagen.com/20241231",
     "localname": "CollaborationAgreementCollaborationExpenses",
     "crdr": "debit",
     "presentation": [
      "http://www.exagen.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration agreement, collaboration expenses",
        "label": "Collaboration Agreement, Collaboration Expenses",
        "documentation": "Collaboration Agreement, Collaboration Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "exdx_CommercialMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.exagen.com/20241231",
     "localname": "CommercialMember",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commercial",
        "label": "Commercial [Member]",
        "documentation": "Commercial"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.exagen.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and contingencies (Note 6)",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r108",
      "r628",
      "r695"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.exagen.com/role/CommitmentsandContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r308",
      "r309",
      "r746",
      "r996",
      "r1001"
     ]
    },
    "exdx_CommonSharesAvailableForGrantUnderThe2019PlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.exagen.com/20241231",
     "localname": "CommonSharesAvailableForGrantUnderThe2019PlanMember",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanCommonStockReservedForFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock available for grant under the 2019 Plan",
        "label": "Common Shares Available For Grant Under The 2019 Plan [Member]",
        "documentation": "Common Shares Available For Grant Under The 2019 Plan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanCommonStockReservedForFutureIssuanceDetails",
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock reserved for future issuance (in shares)",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r64"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.exagen.com/role/StatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r818",
      "r819",
      "r820",
      "r822",
      "r823",
      "r824",
      "r825",
      "r974",
      "r975",
      "r977",
      "r1053",
      "r1113",
      "r1115"
     ]
    },
    "us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract",
     "presentation": [
      "http://www.exagen.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock",
        "label": "Common Stock, Number of Shares, Par Value and Other Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.exagen.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Par value (in dollars per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r64"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.exagen.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares authorized (in shares)",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r696"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.exagen.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares issued (in shares)",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r64"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.exagen.com/role/BalanceSheetsParenthetical",
      "http://www.exagen.com/role/StatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares outstanding (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r64",
      "r696",
      "r714",
      "r1115",
      "r1116"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.exagen.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, $0.001 par value per share; 200,000,000 shares authorized at December 31, 2024 and December 31, 2023; 17,640,328 and 17,045,954 shares issued and outstanding at December 31, 2024 and December 31, 2023, respectively",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r630",
      "r808"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure",
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r895"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Net Income",
        "label": "Compensation Actually Paid vs. Net Income [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r894"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Other Measure",
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r896"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return",
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r893"
     ]
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Comprehensive Loss",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for comprehensive income."
       }
      }
     },
     "auth_ref": []
    },
    "exdx_ComputerEquipmentAndSoftwareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.exagen.com/20241231",
     "localname": "ComputerEquipmentAndSoftwareMember",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationPropertyandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Computer equipment and software",
        "label": "Computer Equipment and Software [Member]",
        "documentation": "Computer Equipment and Software"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskBenchmarkDomain",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Benchmark [Domain]",
        "label": "Concentration Risk Benchmark [Domain]",
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r26",
      "r46",
      "r47",
      "r227",
      "r745"
     ]
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Benchmark [Axis]",
        "label": "Concentration Risk Benchmark [Axis]",
        "documentation": "Information by benchmark of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r26",
      "r46",
      "r47",
      "r227",
      "r674",
      "r745"
     ]
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskByTypeAxis",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Type [Axis]",
        "label": "Concentration Risk Type [Axis]",
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r26",
      "r46",
      "r47",
      "r227",
      "r745",
      "r945"
     ]
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration of Credit Risk and Other Risk and Uncertainties",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r119"
     ]
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskPercentage1",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration risk percentage",
        "label": "Concentration Risk, Percentage",
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r26",
      "r46",
      "r47",
      "r227"
     ]
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskTypeDomain",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Type [Domain]",
        "label": "Concentration Risk Type [Domain]",
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r26",
      "r46",
      "r47",
      "r227",
      "r745"
     ]
    },
    "us-gaap_ConstructionInProgressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConstructionInProgressMember",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationPropertyandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Construction in progress",
        "label": "Construction in Progress [Member]",
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "crdr": "credit",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (decrease) in revenue recognized",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due."
       }
      }
     },
     "auth_ref": [
      "r377"
     ]
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostOfGoodsAndServicesSold",
     "crdr": "debit",
     "calculation": {
      "http://www.exagen.com/role/StatementsofOperations": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/SegmentReportingDetails",
      "http://www.exagen.com/role/StatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Costs of revenue",
        "label": "Cost of Goods and Services Sold",
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r72",
      "r620"
     ]
    },
    "us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostOfGoodsAndServicesSoldDepreciationAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.exagen.com/role/StatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation and amortization",
        "label": "Cost, Depreciation and Amortization",
        "documentation": "Amount of expense for allocation of cost of tangible and intangible assets over their useful lives directly used in production of good and rendering of service."
       }
      }
     },
     "auth_ref": [
      "r962"
     ]
    },
    "us-gaap_CostOfRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostOfRevenue",
     "crdr": "debit",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of revenue",
        "label": "Cost of Revenue",
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r159",
      "r265",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r545",
      "r765",
      "r1009"
     ]
    },
    "us-gaap_CostOfSalesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostOfSalesMember",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of revenue",
        "label": "Cost of Sales [Member]",
        "documentation": "Primary financial statement caption encompassing cost of sales."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostOfSalesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostOfSalesPolicyTextBlock",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shipping and Handling Costs",
        "label": "Cost of Goods and Service [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cost of product sold and service rendered."
       }
      }
     },
     "auth_ref": [
      "r950"
     ]
    },
    "us-gaap_CostsAndExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostsAndExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.exagen.com/role/StatementsofOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/StatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Costs and Expenses",
        "documentation": "Total costs of sales and operating expenses for the period."
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostsAndExpensesAbstract",
     "presentation": [
      "http://www.exagen.com/role/StatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating expenses:",
        "label": "Costs and Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://www.exagen.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Axis]",
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r161",
      "r162",
      "r331",
      "r360",
      "r585",
      "r603",
      "r626",
      "r754",
      "r756"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "exdx_CowenEquityDistributionAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.exagen.com/20241231",
     "localname": "CowenEquityDistributionAgreementMember",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cowen Equity Distribution Agreement",
        "label": "Cowen Equity Distribution Agreement [Member]",
        "documentation": "Cowen Equity Distribution Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentFederalStateAndLocalTaxExpenseBenefitAbstract",
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current:",
        "label": "Current Federal, State and Local, Tax Expense (Benefit) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentFederalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.exagen.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Federal",
        "label": "Current Federal Tax Expense (Benefit)",
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r949",
      "r972",
      "r1052"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.exagen.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Total current",
        "label": "Current Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r464",
      "r972"
     ]
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.exagen.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "State",
        "label": "Current State and Local Tax Expense (Benefit)",
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r949",
      "r972",
      "r1052"
     ]
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CustomerConcentrationRiskMember",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer Concentration Risk",
        "label": "Customer Concentration Risk [Member]",
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r227"
     ]
    },
    "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r841",
      "r930"
     ]
    },
    "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r841",
      "r930"
     ]
    },
    "cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Expertise of Management Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r843",
      "r932"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]"
       }
      }
     },
     "auth_ref": [
      "r843",
      "r932"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]"
       }
      }
     },
     "auth_ref": [
      "r845",
      "r934"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r843",
      "r932"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r836",
      "r925"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r837",
      "r926"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r837",
      "r926"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r835",
      "r924"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceLineItems",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r835",
      "r924"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceTable",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Table]"
       }
      }
     },
     "auth_ref": [
      "r835",
      "r924"
     ]
    },
    "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Third Party Engaged [Flag]"
       }
      }
     },
     "auth_ref": [
      "r838",
      "r927"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]"
       }
      }
     },
     "auth_ref": [
      "r840",
      "r929"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r840",
      "r929"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r841",
      "r930"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r844",
      "r933"
     ]
    },
    "cyd_CybersecurityRiskRoleOfManagementTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskRoleOfManagementTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Role of Management [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r842",
      "r931"
     ]
    },
    "cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]"
       }
      }
     },
     "auth_ref": [
      "r839",
      "r928"
     ]
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://www.exagen.com/role/Borrowings"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowings",
        "label": "Debt Disclosure [Text Block]",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r157",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r316",
      "r317",
      "r327",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r343",
      "r350",
      "r351",
      "r353",
      "r554"
     ]
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails",
      "http://www.exagen.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Axis]",
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r52",
      "r53",
      "r105",
      "r107",
      "r163",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r334",
      "r339",
      "r340",
      "r341",
      "r342",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778",
      "r806",
      "r970",
      "r997",
      "r998",
      "r999",
      "r1063",
      "r1065"
     ]
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable rate",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument."
       }
      }
     },
     "auth_ref": []
    },
    "exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.exagen.com/20241231",
     "localname": "DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance",
     "crdr": "debit",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term loan covenant, minimum unrestricted cash balance",
        "label": "Debt Instrument, Covenant Compliance, Minimum Unrestricted Cash Balance",
        "documentation": "Debt Instrument, Covenant Compliance, Minimum Unrestricted Cash Balance"
       }
      }
     },
     "auth_ref": []
    },
    "exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.exagen.com/20241231",
     "localname": "DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term loan covenant, increase to interest rate",
        "label": "Debt Instrument, Covenant Non-Compliance, Interest Rate, Increase (Decrease)",
        "documentation": "Debt Instrument, Covenant Non-Compliance, Interest Rate, Increase (Decrease)"
       }
      }
     },
     "auth_ref": []
    },
    "exdx_DebtInstrumentCovenantNumberOfDaysToCureIfPerformanceMeasureIsNotMet": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.exagen.com/20241231",
     "localname": "DebtInstrumentCovenantNumberOfDaysToCureIfPerformanceMeasureIsNotMet",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term loan, covenant, number of days to cure covenant if performance measure is not met",
        "label": "Debt Instrument, Covenant, Number Of Days To Cure If Performance Measure Is Not Met",
        "documentation": "Debt Instrument, Covenant, Number Of Days To Cure If Performance Measure Is Not Met"
       }
      }
     },
     "auth_ref": []
    },
    "exdx_DebtInstrumentCovenantRevenuePerformancePeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.exagen.com/20241231",
     "localname": "DebtInstrumentCovenantRevenuePerformancePeriod",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term loan, covenant, revenue performance period",
        "label": "Debt Instrument, Covenant, Revenue Performance Period",
        "documentation": "Debt Instrument, Covenant, Revenue Performance Period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentFairValue",
     "crdr": "credit",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument, fair value",
        "label": "Debt Instrument, Fair Value Disclosure",
        "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable."
       }
      }
     },
     "auth_ref": [
      "r341",
      "r544",
      "r775",
      "r776",
      "r1056",
      "r1057",
      "r1058",
      "r1059",
      "r1060"
     ]
    },
    "us-gaap_DebtInstrumentFeeAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentFeeAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term loan, fee incurred upon payment of final installment",
        "label": "Debt Instrument, Fee Amount",
        "documentation": "Amount of the fee that accompanies borrowing money under the debt instrument."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term loan, effective interest rate",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r356",
      "r554",
      "r555",
      "r806"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term loan, interest rate",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r329"
     ]
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Line Items]",
        "label": "Debt Instrument [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r163",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r334",
      "r339",
      "r340",
      "r341",
      "r342",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r352",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778",
      "r806",
      "r970",
      "r1063",
      "r1065"
     ]
    },
    "exdx_DebtInstrumentMinimumCashBalanceRequiredNotRequiredToComplyWithCovenant": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.exagen.com/20241231",
     "localname": "DebtInstrumentMinimumCashBalanceRequiredNotRequiredToComplyWithCovenant",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument, minimum cash balance",
        "label": "Debt Instrument, Minimum Cash Balance Required, Not Required To Comply With Covenant",
        "documentation": "Debt Instrument, Minimum Cash Balance Required, Not Required To Comply With Covenant"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails",
      "http://www.exagen.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Name [Domain]",
        "label": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r163",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r334",
      "r339",
      "r340",
      "r341",
      "r342",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778",
      "r806",
      "r970",
      "r997",
      "r998",
      "r999",
      "r1063",
      "r1065"
     ]
    },
    "exdx_DebtInstrumentNumberOfMonthlyInstallments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.exagen.com/20241231",
     "localname": "DebtInstrumentNumberOfMonthlyInstallments",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of monthly installments",
        "label": "Debt Instrument, Number Of Monthly Installments",
        "documentation": "Debt Instrument, Number Of Monthly Installments"
       }
      }
     },
     "auth_ref": []
    },
    "exdx_DebtInstrumentPaidInKindLoansIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.exagen.com/20241231",
     "localname": "DebtInstrumentPaidInKindLoansIssued",
     "crdr": "credit",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term loan, paid in-kind loans issued",
        "label": "Debt Instrument, Paid In Kind Loans Issued",
        "documentation": "Debt Instrument, Paid In Kind Loans Issued"
       }
      }
     },
     "auth_ref": []
    },
    "exdx_DebtInstrumentStatedInterestRatePaidInKind": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.exagen.com/20241231",
     "localname": "DebtInstrumentStatedInterestRatePaidInKind",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term loan, paid in-kind, interest rate",
        "label": "Debt Instrument, Stated Interest Rate, Paid In-Kind",
        "documentation": "Debt Instrument, Stated Interest Rate, Paid In-Kind"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentTable",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "documentation": "Disclosure of information about long-term debt instrument or arrangement."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r36",
      "r39",
      "r48",
      "r96",
      "r97",
      "r163",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r334",
      "r339",
      "r340",
      "r341",
      "r342",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r352",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778",
      "r806",
      "r970",
      "r1063",
      "r1065"
     ]
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.exagen.com/role/BorrowingsFutureMinimumPaymentsDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/BorrowingsFutureMinimumPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Unamortized debt discount and issuance costs",
        "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net",
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r339",
      "r354",
      "r553",
      "r554",
      "r555",
      "r775",
      "r776",
      "r806"
     ]
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Prepaid Expenses and Other Current Assets",
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]",
        "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.exagen.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Federal",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r972",
      "r1051",
      "r1052"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.exagen.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Total deferred",
        "label": "Deferred Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r122",
      "r972"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred:",
        "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Deferred tax liabilities",
        "label": "Deferred Tax Liabilities, Gross",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r61",
      "r106",
      "r457"
     ]
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.exagen.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "State",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r972",
      "r1051",
      "r1052"
     ]
    },
    "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Indefinite lived assets",
        "label": "Deferred Tax Assets, Goodwill and Intangible Assets",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill."
       }
      }
     },
     "auth_ref": [
      "r1049"
     ]
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total gross deferred tax assets",
        "label": "Deferred Tax Assets, Gross",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r458"
     ]
    },
    "us-gaap_DeferredTaxAssetsGrossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsGrossAbstract",
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax assets:",
        "label": "Deferred Tax Assets, Gross [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "exdx_DeferredTaxAssetsLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.exagen.com/20241231",
     "localname": "DeferredTaxAssetsLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liability",
        "label": "Deferred Tax Assets, Lease Liability",
        "documentation": "Deferred Tax Assets, Lease Liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "calculation": {
      "http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net deferred tax assets",
        "label": "Deferred Tax Assets, Net",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r1047"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Deferred tax assets, net",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1047"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating loss carryforwards",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1049"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsDomestic",
     "crdr": "debit",
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal net operating loss carryforwards",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Domestic",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1049"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration",
     "crdr": "debit",
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal net operating loss carryforwards, carryforward indefinitely",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are not subject to expiration dates."
       }
      }
     },
     "auth_ref": [
      "r1049"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal",
     "crdr": "debit",
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State net operating loss carryforwards",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, State and Local",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1049"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration",
     "crdr": "debit",
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal tax loss carryforwards, subject to expiration",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates."
       }
      }
     },
     "auth_ref": [
      "r1049"
     ]
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOther",
     "crdr": "debit",
     "calculation": {
      "http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest expense",
        "label": "Deferred Tax Assets, Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other."
       }
      }
     },
     "auth_ref": [
      "r1049"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "crdr": "debit",
     "calculation": {
      "http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development tax credits",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1049"
     ]
    },
    "exdx_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCapitalizationOfResearchAndExperimentationCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.exagen.com/20241231",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCapitalizationOfResearchAndExperimentationCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capitalization of research and experimentation costs",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Capitalization Of Research And Experimentation Costs",
        "documentation": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Capitalization Of Research And Experimentation Costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock compensation",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r1049"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves",
     "crdr": "debit",
     "calculation": {
      "http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accruals, reserves and other",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Loss Reserves",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from loss reserves other than estimated credit losses."
       }
      }
     },
     "auth_ref": [
      "r1049"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesChangeInValuationAllowanceDetails",
      "http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: valuation allowance",
        "periodStartLabel": "Valuation allowance at the beginning of the year",
        "periodEndLabel": "Valuation allowance at the end of the year",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r459"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilitiesAbstract",
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax liabilities:",
        "label": "Deferred Tax Liabilities, Gross [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "exdx_DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.exagen.com/20241231",
     "localname": "DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Basis differences in fixed and intangible assets",
        "label": "Deferred Tax Liabilities, Fixed Assets And Intangible Assets",
        "documentation": "Deferred Tax Liabilities, Fixed Assets And Intangible Assets"
       }
      }
     },
     "auth_ref": []
    },
    "exdx_DeferredTaxLiabilitiesRightOfUseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.exagen.com/20241231",
     "localname": "DeferredTaxLiabilitiesRightOfUseAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Right of use assets",
        "label": "Deferred Tax Liabilities, Right Of Use Assets",
        "documentation": "Deferred Tax Liabilities, Right Of Use Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedContributionPlanCostRecognized",
     "crdr": "debit",
     "presentation": [
      "http://www.exagen.com/role/A401kPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Qualified employee compensation contribution, amount",
        "label": "Defined Contribution Plan, Cost",
        "documentation": "Amount of cost for defined contribution plan."
       }
      }
     },
     "auth_ref": [
      "r395"
     ]
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercent",
     "presentation": [
      "http://www.exagen.com/role/A401kPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Qualified employee compensation, employer matching contribution, percent of employees' gross pay",
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay",
        "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.exagen.com/role/SegmentReportingDetails": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationNarrativeDetails",
      "http://www.exagen.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation and amortization",
        "label": "Depreciation, Depletion and Amortization",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r192",
      "r204",
      "r221",
      "r765",
      "r766"
     ]
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisaggregationOfRevenueLineItems",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disaggregation of Revenue [Line Items]",
        "label": "Disaggregation of Revenue [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r376",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisaggregationOfRevenueTable",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disaggregation of Revenue [Table]",
        "label": "Disaggregation of Revenue [Table]",
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r376",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Disaggregation of Revenue",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r1012"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlan"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Option Plan",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r397",
      "r401",
      "r429",
      "r430",
      "r432",
      "r791"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Common Stock Reserved For Future Issuance",
        "label": "Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block]",
        "documentation": "Tabular disclosure of share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r41"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Annual Report",
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r832",
      "r833",
      "r856"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Financial Statement Error Correction",
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r832",
      "r833",
      "r856",
      "r899"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r877"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Documents Incorporated by Reference",
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r830"
     ]
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year",
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r888"
     ]
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.exagen.com/role/StatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per share, basic (in dollars per share)",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r150",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r182",
      "r184",
      "r186",
      "r187",
      "r188",
      "r191",
      "r483",
      "r492",
      "r520",
      "r521",
      "r625",
      "r637",
      "r758"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.exagen.com/role/StatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per share, diluted (in dollars per share)",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r150",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r184",
      "r186",
      "r187",
      "r188",
      "r191",
      "r483",
      "r492",
      "r520",
      "r521",
      "r625",
      "r637",
      "r758"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Loss Per Share",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r23",
      "r190"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://www.exagen.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Effective tax rate",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r444",
      "r795"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "calculation": {
      "http://www.exagen.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Federal statutory tax rate",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r160",
      "r444",
      "r470",
      "r795"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "calculation": {
      "http://www.exagen.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in valuation allowance",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r447",
      "r795",
      "r973",
      "r1043"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpense",
     "calculation": {
      "http://www.exagen.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-deductible expenses",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r448",
      "r449",
      "r973",
      "r1043"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "calculation": {
      "http://www.exagen.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock compensation",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent",
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r795",
      "r973",
      "r1043",
      "r1045"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent",
     "calculation": {
      "http://www.exagen.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Effective Income Tax Rate Reconciliation, Other Reconciling Items, Percent",
        "documentation": "Percentage of reported income tax benefit (expense) from difference to income tax expense (benefit) computed by applying statutory federal (national) income tax rate to pretax income (loss) from continuing operation, attributable to other reconciling items. Excludes state and local income tax expense (benefit), federal tax expense (benefit), statutory income tax expense (benefit) outside of country of domicile, tax credit, nondeductible expense, deduction, income tax settlement, income tax contingency, and cross-border tax law."
       }
      }
     },
     "auth_ref": [
      "r1044"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "calculation": {
      "http://www.exagen.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "State income taxes, net of federal tax benefits",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r446",
      "r795",
      "r973",
      "r1043"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch",
     "calculation": {
      "http://www.exagen.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Research and development tax credits",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit."
       }
      }
     },
     "auth_ref": [
      "r795",
      "r973",
      "r1043",
      "r1045"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "crdr": "debit",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock options, unrecognized compensation cost",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r431"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock options, cost not yet recognized, remaining weighted average vesting period",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r431"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized compensation cost related to stock purchase",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r1041"
     ]
    },
    "us-gaap_EmployeeStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockMember",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanCommonStockReservedForFutureIssuanceDetails",
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee stock purchase plan",
        "verboseLabel": "Common stock available for future issuance under ESPP",
        "label": "Employee Stock [Member]",
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanCommonStockReservedForFutureIssuanceDetails",
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock options",
        "verboseLabel": "Common stock option grants issued and outstanding",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockOwnershipPlanESOPPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOwnershipPlanESOPPolicy",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-Based Compensation",
        "label": "Employee Stock Ownership Plan (ESOP), Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for ESOP transactions, including the method of measuring compensation, the classification of dividends on ESOP shares, and the treatment of ESOP shares for EPS computations. If the employer has both old ESOP shares for which it does not adopt new guidance and new ESOP shares for which new guidance is required, these disclosures are required for both blocks of shares."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r829"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r829"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r829"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r939"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Public Float",
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r829"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Shell Company",
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r829"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Small Business",
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r829"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r829"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Voluntary Filers",
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Well-known Seasoned Issuer",
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r940"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments, Footnote",
        "label": "Equity Awards Adjustments, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r882"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table",
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r935"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments",
        "label": "Equity Awards Adjustments [Member]"
       }
      }
     },
     "auth_ref": [
      "r935"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table",
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r935"
     ]
    },
    "exdx_EquipmentNotesPayableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.exagen.com/20241231",
     "localname": "EquipmentNotesPayableMember",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equipment Notes Payable",
        "label": "Equipment Notes Payable [Member]",
        "documentation": "Equipment Notes Payable"
       }
      }
     },
     "auth_ref": []
    },
    "exdx_EquipmentPurchasedUnderNotesPayableObligations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.exagen.com/20241231",
     "localname": "EquipmentPurchasedUnderNotesPayableObligations",
     "crdr": "debit",
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equipment purchased under notes payable obligations",
        "label": "Equipment Purchased Under Notes Payable Obligations",
        "documentation": "Equipment Purchased Under Notes Payable Obligations"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.exagen.com/role/StatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Component [Domain]",
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r126",
      "r147",
      "r148",
      "r149",
      "r164",
      "r165",
      "r166",
      "r169",
      "r176",
      "r178",
      "r180",
      "r193",
      "r269",
      "r275",
      "r295",
      "r374",
      "r465",
      "r466",
      "r479",
      "r480",
      "r481",
      "r484",
      "r491",
      "r492",
      "r501",
      "r503",
      "r504",
      "r505",
      "r506",
      "r508",
      "r519",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r557",
      "r560",
      "r584",
      "r635",
      "r663",
      "r664",
      "r665",
      "r684",
      "r734"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Valuation Assumption Difference, Footnote",
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r892"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneous Compensation Analysis",
        "label": "Erroneous Compensation Analysis [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r849",
      "r860",
      "r870",
      "r903"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneously Awarded Compensation Recovery",
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r846",
      "r857",
      "r867",
      "r900"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Executive Category:",
        "label": "Executive Category [Axis]"
       }
      }
     },
     "auth_ref": [
      "r898"
     ]
    },
    "exdx_ExpirationApr12026Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.exagen.com/20241231",
     "localname": "ExpirationApr12026Member",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityWarrantstoPurchaseCommonStockOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant expiration April 1, 2026",
        "label": "Expiration Apr 1, 2026 [Member]",
        "documentation": "Expiration Apr 1, 2026"
       }
      }
     },
     "auth_ref": []
    },
    "exdx_ExpirationDec72025Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.exagen.com/20241231",
     "localname": "ExpirationDec72025Member",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityWarrantstoPurchaseCommonStockOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant expiration December 7, 2025",
        "label": "Expiration Dec 7, 2025 [Member]",
        "documentation": "Expiration Dec 7, 2025"
       }
      }
     },
     "auth_ref": []
    },
    "exdx_ExpirationJan192026Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.exagen.com/20241231",
     "localname": "ExpirationJan192026Member",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityWarrantstoPurchaseCommonStockOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant expiration January 19, 2026",
        "label": "Expiration Jan 19, 2026 [Member]",
        "documentation": "Expiration Jan 19, 2026"
       }
      }
     },
     "auth_ref": []
    },
    "exdx_ExpirationMar312026Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.exagen.com/20241231",
     "localname": "ExpirationMar312026Member",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityWarrantstoPurchaseCommonStockOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant expiration March 31, 2026",
        "label": "Expiration Mar 31, 2026 [Member]",
        "documentation": "Expiration Mar 31, 2026"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r525",
      "r526",
      "r527",
      "r799"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r525",
      "r526",
      "r527",
      "r799"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r341",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r522",
      "r524",
      "r525",
      "r526",
      "r527",
      "r533",
      "r534",
      "r536",
      "r590",
      "r591",
      "r592",
      "r775",
      "r776",
      "r787",
      "r788",
      "r789",
      "r796",
      "r799"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Frequency [Axis]",
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r523",
      "r524",
      "r525",
      "r527",
      "r796",
      "r1058",
      "r1061"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements",
        "label": "Fair Value Disclosures [Text Block]",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r529",
      "r531",
      "r532",
      "r533",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r624",
      "r796",
      "r800"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level\u00a01",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r341",
      "r381",
      "r386",
      "r524",
      "r534",
      "r590",
      "r787",
      "r788",
      "r789",
      "r796"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level\u00a02",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r341",
      "r381",
      "r386",
      "r524",
      "r525",
      "r534",
      "r591",
      "r775",
      "r776",
      "r787",
      "r788",
      "r789",
      "r796"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level\u00a03",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r341",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r524",
      "r525",
      "r526",
      "r527",
      "r534",
      "r592",
      "r775",
      "r776",
      "r787",
      "r788",
      "r789",
      "r796",
      "r799"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Frequency [Domain]",
        "label": "Measurement Frequency [Domain]",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r523",
      "r524",
      "r525",
      "r527",
      "r796",
      "r1058",
      "r1061"
     ]
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r341",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r522",
      "r524",
      "r525",
      "r526",
      "r527",
      "r533",
      "r534",
      "r536",
      "r590",
      "r591",
      "r592",
      "r775",
      "r776",
      "r787",
      "r788",
      "r789",
      "r796",
      "r799"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recurring",
        "label": "Fair Value, Recurring [Member]",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r796",
      "r1055",
      "r1056",
      "r1057",
      "r1058",
      "r1059",
      "r1061"
     ]
    },
    "us-gaap_FinanceLeaseInterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseInterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.exagen.com/role/LeasesCostsAssociatedwiththeCompanysLeasesDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/LeasesCostsAssociatedwiththeCompanysLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest on finance lease liabilities",
        "label": "Finance Lease, Interest Expense",
        "documentation": "Amount of interest expense on finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r564",
      "r570",
      "r807"
     ]
    },
    "us-gaap_FinanceLeaseInterestPaymentOnLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseInterestPaymentOnLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.exagen.com/role/LeasesSupplementalCashFlowInformationOnLeasesAndWeightedAverageLeaseTermDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating cash out flows from interest paid on finance leases",
        "label": "Finance Lease, Interest Payment on Liability",
        "documentation": "Amount of interest paid on finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r566",
      "r573"
     ]
    },
    "us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilitiesPaymentsDueAbstract",
     "presentation": [
      "http://www.exagen.com/role/LeasesFuturePaymentsUnderOperatingAndFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance Leases",
        "label": "Finance Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.exagen.com/role/LeasesFuturePaymentsUnderOperatingAndFinanceLeasesDetails": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/LeasesFuturePaymentsUnderOperatingAndFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total lease liabilities",
        "label": "Finance Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease."
       }
      }
     },
     "auth_ref": [
      "r562",
      "r576"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.exagen.com/role/LeasesFuturePaymentsUnderOperatingAndFinanceLeasesDetails": {
       "parentTag": "us-gaap_FinanceLeaseLiability",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/LeasesFuturePaymentsUnderOperatingAndFinanceLeasesDetails",
      "http://www.exagen.com/role/LeasesLeaseBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance lease obligations, current portion",
        "negatedLabel": "Less: current portion",
        "label": "Finance Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r562"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://www.exagen.com/role/LeasesLeaseBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance lease, liability, current, statement of financial position",
        "label": "Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes current finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r563"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.exagen.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Finance Lease, Liability, Maturity",
        "label": "Finance Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r1068"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.exagen.com/role/LeasesFuturePaymentsUnderOperatingAndFinanceLeasesDetails": {
       "parentTag": "us-gaap_FinanceLeaseLiability",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/LeasesFuturePaymentsUnderOperatingAndFinanceLeasesDetails",
      "http://www.exagen.com/role/LeasesLeaseBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease obligations, net of current portion",
        "label": "Finance Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r562"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://www.exagen.com/role/LeasesLeaseBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance lease, liability, noncurrent, statement of financial position",
        "label": "Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes noncurrent finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r563"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.exagen.com/role/LeasesFuturePaymentsUnderOperatingAndFinanceLeasesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.exagen.com/role/LeasesFuturePaymentsUnderOperatingAndFinanceLeasesDetails_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.exagen.com/role/LeasesFuturePaymentsUnderOperatingAndFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total minimum lease payments",
        "label": "Finance Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease."
       }
      }
     },
     "auth_ref": [
      "r576"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.exagen.com/role/LeasesFuturePaymentsUnderOperatingAndFinanceLeasesDetails_1": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/LeasesFuturePaymentsUnderOperatingAndFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Finance Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r576"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.exagen.com/role/LeasesFuturePaymentsUnderOperatingAndFinanceLeasesDetails_1": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/LeasesFuturePaymentsUnderOperatingAndFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Finance Lease, Liability, to be Paid, Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r576"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.exagen.com/role/LeasesFuturePaymentsUnderOperatingAndFinanceLeasesDetails_1": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/LeasesFuturePaymentsUnderOperatingAndFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Finance Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r576"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.exagen.com/role/LeasesFuturePaymentsUnderOperatingAndFinanceLeasesDetails": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/LeasesFuturePaymentsUnderOperatingAndFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Less: imputed interest",
        "label": "Finance Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease."
       }
      }
     },
     "auth_ref": [
      "r576"
     ]
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeasePrincipalPayments",
     "crdr": "credit",
     "calculation": {
      "http://www.exagen.com/role/StatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/LeasesSupplementalCashFlowInformationOnLeasesAndWeightedAverageLeaseTermDetails",
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Principal payment on finance lease obligations",
        "terseLabel": "Financing cash out flows from finance leases",
        "label": "Finance Lease, Principal Payments",
        "documentation": "Amount of cash outflow for principal payment on finance lease."
       }
      }
     },
     "auth_ref": [
      "r565",
      "r573"
     ]
    },
    "us-gaap_FinanceLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseRightOfUseAsset",
     "crdr": "debit",
     "presentation": [
      "http://www.exagen.com/role/LeasesLeaseBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance lease, right-of-use asset, after accumulated amortization",
        "label": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization",
        "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease."
       }
      }
     },
     "auth_ref": [
      "r561"
     ]
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseRightOfUseAssetAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.exagen.com/role/LeasesCostsAssociatedwiththeCompanysLeasesDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/LeasesCostsAssociatedwiththeCompanysLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of lease assets",
        "label": "Finance Lease, Right-of-Use Asset, Amortization",
        "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease."
       }
      }
     },
     "auth_ref": [
      "r564",
      "r570",
      "r807"
     ]
    },
    "us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization",
     "crdr": "debit",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross book value of assets under finance leases",
        "label": "Finance Lease, Right-of-Use Asset, before Accumulated Amortization",
        "documentation": "Amount, before accumulated amortization, of right-of-use asset from finance lease."
       }
      }
     },
     "auth_ref": [
      "r942"
     ]
    },
    "us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://www.exagen.com/role/LeasesLeaseBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance lease, right-of-use asset, statement of financial position",
        "label": "Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes finance lease right-of-use asset."
       }
      }
     },
     "auth_ref": [
      "r563"
     ]
    },
    "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.exagen.com/role/LeasesSupplementalCashFlowInformationOnLeasesAndWeightedAverageLeaseTermDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance leases",
        "label": "Finance Lease, Weighted Average Discount Rate, Percent",
        "documentation": "Weighted average discount rate for finance lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r575",
      "r807"
     ]
    },
    "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.exagen.com/role/LeasesSupplementalCashFlowInformationOnLeasesAndWeightedAverageLeaseTermDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance leases",
        "label": "Finance Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r574",
      "r807"
     ]
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instrument [Axis]",
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r352",
      "r370",
      "r509",
      "r541",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r636",
      "r771",
      "r796",
      "r797",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805",
      "r809",
      "r951",
      "r952",
      "r953",
      "r954",
      "r955",
      "r956",
      "r957",
      "r986",
      "r987",
      "r988",
      "r989",
      "r1054",
      "r1057",
      "r1058",
      "r1059",
      "r1060",
      "r1061"
     ]
    },
    "us-gaap_FinancingReceivableAllowanceForCreditLossExcludingAccruedInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinancingReceivableAllowanceForCreditLossExcludingAccruedInterest",
     "crdr": "credit",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Allowance for credit loss",
        "label": "Financing Receivable, Allowance for Credit Loss, Excluding Accrued Interest",
        "documentation": "Amount excluding accrued interest, of allowance for credit loss on financing receivable. Excludes net investment in lease."
       }
      }
     },
     "auth_ref": [
      "r991"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r853",
      "r864",
      "r874",
      "r907"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount",
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r853",
      "r864",
      "r874",
      "r907"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r853",
      "r864",
      "r874",
      "r907"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery, Explanation of Impracticability",
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r853",
      "r864",
      "r874",
      "r907"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r853",
      "r864",
      "r874",
      "r907"
     ]
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year",
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r887"
     ]
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationPropertyandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Furniture\u00a0and\u00a0fixtures",
        "label": "Furniture and Fixtures [Member]",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnDispositionOfAssets1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainLossOnDispositionOfAssets1",
     "crdr": "credit",
     "calculation": {
      "http://www.exagen.com/role/StatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Loss on disposal of assets",
        "label": "Gain (Loss) on Disposition of Assets",
        "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee."
       }
      }
     },
     "auth_ref": [
      "r967"
     ]
    },
    "exdx_GainLossOnDispositionOfLeaseAssignment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.exagen.com/20241231",
     "localname": "GainLossOnDispositionOfLeaseAssignment",
     "crdr": "credit",
     "calculation": {
      "http://www.exagen.com/role/StatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationNarrativeDetails",
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Loss on lease assignment",
        "label": "Gain (Loss) On Disposition Of Lease Assignment",
        "documentation": "Gain (Loss) On Disposition Of Lease Assignment"
       }
      }
     },
     "auth_ref": []
    },
    "exdx_Government1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.exagen.com/20241231",
     "localname": "Government1Member",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Government",
        "label": "Government1 [Member]",
        "documentation": "Government1"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GrossProfit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GrossProfit",
     "crdr": "credit",
     "calculation": {
      "http://www.exagen.com/role/StatementsofOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/SegmentReportingDetails",
      "http://www.exagen.com/role/StatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Gross margin",
        "label": "Gross Profit",
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r73",
      "r114",
      "r159",
      "r265",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r545",
      "r760",
      "r765",
      "r978",
      "r980",
      "r981",
      "r982",
      "r983",
      "r1009"
     ]
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ICFR Auditor Attestation Flag",
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r832",
      "r833",
      "r856"
     ]
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-lived Assets",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r91"
     ]
    },
    "exdx_IncentiveAwardPlan2019Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.exagen.com/20241231",
     "localname": "IncentiveAwardPlan2019Member",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2019 Incentive Award Plan",
        "label": "Incentive Award Plan, 2019 [Member]",
        "documentation": "Incentive Award Plan, 2019"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeLossAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://www.exagen.com/role/StatementsofOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/SegmentReportingDetails",
      "http://www.exagen.com/role/StatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss before income taxes",
        "label": "Income (Loss) Attributable to Parent, before Tax",
        "documentation": "Amount, before tax, of income (loss) attributable to parent. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r149"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement [Abstract]",
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Income Location, Balance [Axis]",
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r296",
      "r303",
      "r305",
      "r528",
      "r530",
      "r535",
      "r658",
      "r660",
      "r719",
      "r749",
      "r798",
      "r1083"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Income Location, Balance [Domain]",
        "label": "Statement of Income Location, Balance [Domain]",
        "documentation": "Location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r303",
      "r305",
      "r528",
      "r530",
      "r535",
      "r658",
      "r660",
      "r719",
      "r749",
      "r798",
      "r1083"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r160",
      "r439",
      "r444",
      "r450",
      "r451",
      "r452",
      "r454",
      "r461",
      "r471",
      "r473",
      "r474",
      "r475",
      "r683",
      "r795"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.exagen.com/role/StatementsofOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      },
      "http://www.exagen.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails",
      "http://www.exagen.com/role/SegmentReportingDetails",
      "http://www.exagen.com/role/StatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Income tax expense",
        "negatedTotalLabel": "Income tax expense",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r117",
      "r123",
      "r179",
      "r180",
      "r192",
      "r207",
      "r221",
      "r443",
      "r444",
      "r472",
      "r638",
      "r795"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r146",
      "r441",
      "r442",
      "r454",
      "r455",
      "r460",
      "r463",
      "r677"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.exagen.com/role/StatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Accounts Payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://www.exagen.com/role/StatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accounts receivable, net",
        "label": "Increase (Decrease) in Accounts Receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.exagen.com/role/StatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued and other current liabilities",
        "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities",
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other."
       }
      }
     },
     "auth_ref": [
      "r966"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in assets and liabilities:",
        "label": "Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.exagen.com/role/StatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r948",
      "r966"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.exagen.com/role/StatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other assets",
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r966"
     ]
    },
    "exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.exagen.com/20241231",
     "localname": "IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.exagen.com/role/StatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses and other current assets",
        "label": "Increase (Decrease) In Prepaid Expense And Current Other Assets",
        "documentation": "Increase (Decrease) In Prepaid Expense And Current Other Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "presentation": [
      "http://www.exagen.com/role/StatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Individual:",
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r853",
      "r864",
      "r874",
      "r898",
      "r907",
      "r911",
      "r919"
     ]
    },
    "exdx_InnovatusLifeSciencesLendingFundMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.exagen.com/20241231",
     "localname": "InnovatusLifeSciencesLendingFundMember",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Innovatus Life Sciences Lending Fund",
        "label": "Innovatus Life Sciences Lending Fund [Member]",
        "documentation": "Innovatus Life Sciences Lending Fund"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r917"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r834",
      "r923"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Adopted",
        "label": "Insider Trading Policies and Procedures Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r834",
      "r923"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted",
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r834",
      "r923"
     ]
    },
    "us-gaap_InterestExpenseNonoperating": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpenseNonoperating",
     "crdr": "debit",
     "calculation": {
      "http://www.exagen.com/role/StatementsofOperations": {
       "parentTag": "us-gaap_IncomeLossAttributableToParent",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/SegmentReportingDetails",
      "http://www.exagen.com/role/StatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest expense",
        "negatedTerseLabel": "Interest expense",
        "label": "Interest Expense, Nonoperating",
        "documentation": "Amount of interest expense classified as nonoperating."
       }
      }
     },
     "auth_ref": [
      "r203",
      "r965"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for interest expense",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r151",
      "r153",
      "r154"
     ]
    },
    "us-gaap_InvestmentIncomeInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentIncomeInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.exagen.com/role/StatementsofOperations": {
       "parentTag": "us-gaap_IncomeLossAttributableToParent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/SegmentReportingDetails",
      "http://www.exagen.com/role/StatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest income",
        "label": "Investment Income, Interest",
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r192",
      "r202",
      "r221",
      "r765",
      "r964"
     ]
    },
    "exdx_IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.exagen.com/20241231",
     "localname": "IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesShares",
     "presentation": [
      "http://www.exagen.com/role/StatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of stock from vested restricted stock units and payment of employees' taxes (in shares)",
        "label": "Issuance Of Stock From Vested Restricted Stock Units And Payment Of Employees Taxes, Shares",
        "documentation": "Issuance Of Stock From Vested Restricted Stock Units And Payment Of Employees Taxes, Shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LaborAndRelatedExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LaborAndRelatedExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.exagen.com/role/SegmentReportingDetails": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee expense",
        "label": "Labor and Related Expense",
        "documentation": "Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit."
       }
      }
     },
     "auth_ref": [
      "r963"
     ]
    },
    "exdx_LaboratoryEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.exagen.com/20241231",
     "localname": "LaboratoryEquipmentMember",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationPropertyandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Laboratory equipment",
        "label": "Laboratory Equipment [Member]",
        "documentation": "Laboratory Equipment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseContractualTermAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseContractualTermAxis",
     "presentation": [
      "http://www.exagen.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease Contractual Term [Axis]",
        "label": "Lease Contractual Term [Axis]",
        "documentation": "Information by contractual term of lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r578",
      "r946"
     ]
    },
    "us-gaap_LeaseContractualTermDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseContractualTermDomain",
     "presentation": [
      "http://www.exagen.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease Contractual Term [Domain]",
        "label": "Lease Contractual Term [Domain]",
        "documentation": "Contractual term of lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r578",
      "r946"
     ]
    },
    "us-gaap_LeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.exagen.com/role/LeasesCostsAssociatedwiththeCompanysLeasesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.exagen.com/role/LeasesCostsAssociatedwiththeCompanysLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total lease cost",
        "label": "Lease, Cost",
        "documentation": "Amount of lease cost recognized by lessee for lease contract."
       }
      }
     },
     "auth_ref": [
      "r569",
      "r807"
     ]
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://www.exagen.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Lease Costs",
        "label": "Lease, Cost [Table Text Block]",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r1067"
     ]
    },
    "us-gaap_LeaseholdImprovementsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseholdImprovementsGross",
     "crdr": "debit",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leasehold improvements",
        "label": "Leasehold Improvements, Gross",
        "documentation": "Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r90"
     ]
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationPropertyandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leasehold improvements",
        "label": "Leasehold Improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r577"
     ]
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeFinanceLeaseTermOfContract1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeFinanceLeaseTermOfContract1",
     "presentation": [
      "http://www.exagen.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance lease, term of contract",
        "label": "Lessee, Finance Lease, Term of Contract",
        "documentation": "Term of lessee's finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1066"
     ]
    },
    "us-gaap_LesseeFinanceLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeFinanceLeasesTextBlock",
     "presentation": [
      "http://www.exagen.com/role/Leases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Finance Leases [Text Block]",
        "documentation": "The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r559"
     ]
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Leases [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r568"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.exagen.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Lessee, Operating Lease, Liability, Maturity",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r1068"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.exagen.com/role/LeasesFuturePaymentsUnderOperatingAndFinanceLeasesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.exagen.com/role/LeasesFuturePaymentsUnderOperatingAndFinanceLeasesDetails_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.exagen.com/role/LeasesFuturePaymentsUnderOperatingAndFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total minimum lease payments",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r576"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.exagen.com/role/LeasesFuturePaymentsUnderOperatingAndFinanceLeasesDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/LeasesFuturePaymentsUnderOperatingAndFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r576"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.exagen.com/role/LeasesFuturePaymentsUnderOperatingAndFinanceLeasesDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/LeasesFuturePaymentsUnderOperatingAndFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r576"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.exagen.com/role/LeasesFuturePaymentsUnderOperatingAndFinanceLeasesDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/LeasesFuturePaymentsUnderOperatingAndFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r576"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.exagen.com/role/LeasesFuturePaymentsUnderOperatingAndFinanceLeasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/LeasesFuturePaymentsUnderOperatingAndFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Less: imputed interest",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r576"
     ]
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "presentation": [
      "http://www.exagen.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease, renewal term",
        "label": "Lessee, Operating Lease, Renewal Term",
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1066"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://www.exagen.com/role/Leases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Operating Leases [Text Block]",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r559"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.exagen.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r52",
      "r53",
      "r54",
      "r57",
      "r58",
      "r59",
      "r62",
      "r159",
      "r265",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r495",
      "r496",
      "r497",
      "r545",
      "r694",
      "r759",
      "r827",
      "r1009",
      "r1069",
      "r1070"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.exagen.com/role/BalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.exagen.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and stockholders' equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r109",
      "r632",
      "r808",
      "r971",
      "r990",
      "r1062"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.exagen.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities and Stockholders' Equity",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.exagen.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r133",
      "r159",
      "r265",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r495",
      "r496",
      "r497",
      "r545",
      "r808",
      "r1009",
      "r1069",
      "r1070"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.exagen.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LicenseAgreementTermsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LicenseAgreementTermsMember",
     "presentation": [
      "http://www.exagen.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Licensing Agreements",
        "label": "License Agreement Terms [Member]",
        "documentation": "Terms of the license agreements under research and development arrangements accounted for as a contract to perform research and development for others."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCreditFacilityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditFacilityAxis",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lender Name [Axis]",
        "label": "Lender Name [Axis]",
        "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r56",
      "r970",
      "r1007",
      "r1008"
     ]
    },
    "us-gaap_LineOfCreditFacilityLenderDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditFacilityLenderDomain",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Line of Credit Facility, Lender [Domain]",
        "label": "Line of Credit Facility, Lender [Domain]",
        "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r56",
      "r970",
      "r1007"
     ]
    },
    "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditFacilityRemainingBorrowingCapacity",
     "crdr": "credit",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remaining borrowing capacity",
        "label": "Line of Credit Facility, Remaining Borrowing Capacity",
        "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding)."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r56",
      "r317"
     ]
    },
    "srt_LitigationCaseAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "LitigationCaseAxis",
     "presentation": [
      "http://www.exagen.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Litigation Case [Axis]",
        "label": "Litigation Case [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_LitigationCaseTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "LitigationCaseTypeDomain",
     "presentation": [
      "http://www.exagen.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Litigation Case [Domain]",
        "label": "Litigation Case [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LitigationStatusAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LitigationStatusAxis",
     "presentation": [
      "http://www.exagen.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Litigation Status [Axis]",
        "label": "Litigation Status [Axis]",
        "documentation": "Information by status of pending, threatened, or settled litigation."
       }
      }
     },
     "auth_ref": [
      "r997",
      "r998",
      "r999",
      "r1002"
     ]
    },
    "us-gaap_LitigationStatusDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LitigationStatusDomain",
     "presentation": [
      "http://www.exagen.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Litigation Status [Domain]",
        "label": "Litigation Status [Domain]",
        "documentation": "Status of pending, threatened, or settled litigation."
       }
      }
     },
     "auth_ref": [
      "r997",
      "r998",
      "r999",
      "r1002"
     ]
    },
    "us-gaap_LoansPayableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LoansPayableMember",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loan payable",
        "label": "Loans Payable [Member]",
        "documentation": "Borrowing supported by a written promise to pay an obligation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.exagen.com/role/BorrowingsFutureMinimumPaymentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.exagen.com/role/BorrowingsFutureMinimumPaymentsDetails",
      "http://www.exagen.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total borrowings, net of discounts and debt issuance costs",
        "terseLabel": "Total borrowings, net of discounts and debt issuance costs",
        "label": "Long-Term Debt",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r107",
      "r340",
      "r355",
      "r775",
      "r776",
      "r806",
      "r1079"
     ]
    },
    "us-gaap_LongTermDebtByMaturityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtByMaturityAbstract",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsFutureMinimumPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Term Debt, Fiscal Year Maturity [Abstract]",
        "label": "Long-Term Debt, Fiscal Year Maturity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebtCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.exagen.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/BalanceSheets",
      "http://www.exagen.com/role/BorrowingsFutureMinimumPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowings-current portion",
        "negatedTerseLabel": "Borrowings-current portion",
        "label": "Long-Term Debt, Current Maturities",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r137"
     ]
    },
    "exdx_LongTermDebtIncludingUndiscountedInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.exagen.com/20241231",
     "localname": "LongTermDebtIncludingUndiscountedInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.exagen.com/role/BorrowingsFutureMinimumPaymentsDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/BorrowingsFutureMinimumPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Long-term Debt, Including Undiscounted Interest",
        "documentation": "Long-term Debt, Including Undiscounted Interest"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.exagen.com/role/BorrowingsFutureMinimumPaymentsDetails": {
       "parentTag": "exdx_LongTermDebtIncludingUndiscountedInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/BorrowingsFutureMinimumPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Long-Term Debt, Maturity, Year One",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r163",
      "r345"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.exagen.com/role/BorrowingsFutureMinimumPaymentsDetails": {
       "parentTag": "exdx_LongTermDebtIncludingUndiscountedInterest",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/BorrowingsFutureMinimumPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Long-Term Debt, Maturity, Year Four",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r163",
      "r345"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.exagen.com/role/BorrowingsFutureMinimumPaymentsDetails": {
       "parentTag": "exdx_LongTermDebtIncludingUndiscountedInterest",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/BorrowingsFutureMinimumPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Long-Term Debt, Maturity, Year Three",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r163",
      "r345"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.exagen.com/role/BorrowingsFutureMinimumPaymentsDetails": {
       "parentTag": "exdx_LongTermDebtIncludingUndiscountedInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/BorrowingsFutureMinimumPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Long-Term Debt, Maturity, Year Two",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r163",
      "r345"
     ]
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.exagen.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/BalanceSheets",
      "http://www.exagen.com/role/BorrowingsFutureMinimumPaymentsDetails",
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowings-non-current portion, net of discounts and debt issuance costs",
        "verboseLabel": "Borrowings-non-current portion, net of discounts and debt issuance costs",
        "label": "Long-Term Debt, Excluding Current Maturities",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r138"
     ]
    },
    "exdx_LongTermDebtUndiscountedInterestAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.exagen.com/20241231",
     "localname": "LongTermDebtUndiscountedInterestAmount",
     "crdr": "debit",
     "calculation": {
      "http://www.exagen.com/role/BorrowingsFutureMinimumPaymentsDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/BorrowingsFutureMinimumPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest",
        "label": "Long-term Debt, Undiscounted Interest Amount",
        "documentation": "Long-term Debt, Undiscounted Interest Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermNotesPayable",
     "crdr": "credit",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Notes payable noncurrent",
        "label": "Notes Payable, Noncurrent",
        "documentation": "Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongtermDebtTypeAxis",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term Debt, Type [Axis]",
        "label": "Long-Term Debt, Type [Axis]",
        "documentation": "Information by type of long-term debt."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r997",
      "r998",
      "r999"
     ]
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongtermDebtTypeDomain",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term Debt, Type [Domain]",
        "label": "Long-Term Debt, Type [Domain]",
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r33",
      "r997",
      "r998",
      "r999"
     ]
    },
    "us-gaap_LossContingenciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingenciesLineItems",
     "presentation": [
      "http://www.exagen.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss Contingencies [Line Items]",
        "label": "Loss Contingencies [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r310",
      "r311",
      "r312",
      "r315",
      "r434",
      "r773",
      "r1003",
      "r1004"
     ]
    },
    "us-gaap_LossContingenciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingenciesTable",
     "presentation": [
      "http://www.exagen.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss Contingencies [Table]",
        "label": "Loss Contingencies [Table]",
        "documentation": "Disclosure of information about loss contingency. Excludes environmental contingency, warranty, and unconditional purchase obligation."
       }
      }
     },
     "auth_ref": [
      "r310",
      "r311",
      "r312",
      "r315",
      "r434",
      "r773",
      "r1003",
      "r1004"
     ]
    },
    "srt_MajorCustomersAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MajorCustomersAxis",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer [Axis]",
        "label": "Customer [Axis]"
       }
      }
     },
     "auth_ref": [
      "r227",
      "r782",
      "r811",
      "r815",
      "r1012",
      "r1082",
      "r1084",
      "r1085",
      "r1087",
      "r1088",
      "r1089",
      "r1090",
      "r1091",
      "r1092",
      "r1093",
      "r1094",
      "r1095",
      "r1096",
      "r1097",
      "r1098",
      "r1099",
      "r1100",
      "r1101",
      "r1102",
      "r1103",
      "r1104",
      "r1105",
      "r1106",
      "r1107",
      "r1108",
      "r1109",
      "r1111",
      "r1112"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails",
      "http://www.exagen.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.exagen.com/role/LeasesNarrativeDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r311",
      "r312",
      "r313",
      "r314",
      "r396",
      "r434",
      "r527",
      "r619",
      "r657",
      "r659",
      "r673",
      "r686",
      "r687",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r747",
      "r748",
      "r770",
      "r779",
      "r790",
      "r799",
      "r800",
      "r804",
      "r805",
      "r812",
      "r1011",
      "r1071",
      "r1072",
      "r1073",
      "r1074",
      "r1075",
      "r1076"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measure:",
        "label": "Measure [Axis]"
       }
      }
     },
     "auth_ref": [
      "r890"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Measure Name"
       }
      }
     },
     "auth_ref": [
      "r890"
     ]
    },
    "exdx_MedicareAdvantageMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.exagen.com/20241231",
     "localname": "MedicareAdvantageMember",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Medicare Advantage",
        "label": "Medicare Advantage [Member]",
        "documentation": "Medicare Advantage"
       }
      }
     },
     "auth_ref": []
    },
    "exdx_MedicareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.exagen.com/20241231",
     "localname": "MedicareMember",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Medicare",
        "label": "Medicare [Member]",
        "documentation": "Medicare"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails",
      "http://www.exagen.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.exagen.com/role/LeasesNarrativeDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r311",
      "r312",
      "r313",
      "r314",
      "r396",
      "r434",
      "r527",
      "r619",
      "r657",
      "r659",
      "r673",
      "r686",
      "r687",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r747",
      "r748",
      "r770",
      "r779",
      "r790",
      "r799",
      "r800",
      "r804",
      "r812",
      "r1011",
      "r1071",
      "r1072",
      "r1073",
      "r1074",
      "r1075",
      "r1076"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MNPI Disclosure Timed for Compensation Value",
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]"
       }
      }
     },
     "auth_ref": [
      "r910"
     ]
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Money market funds, included in cash and cash equivalents",
        "label": "Money Market Funds [Member]",
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": [
      "r1014"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Material Terms of Trading Arrangement",
        "label": "Material Terms of Trading Arrangement [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r918"
     ]
    },
    "srt_NameOfMajorCustomerDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "NameOfMajorCustomerDomain",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer [Domain]",
        "label": "Customer [Domain]"
       }
      }
     },
     "auth_ref": [
      "r227",
      "r782",
      "r811",
      "r815",
      "r1012",
      "r1082",
      "r1084",
      "r1085",
      "r1087",
      "r1088",
      "r1089",
      "r1090",
      "r1091",
      "r1092",
      "r1093",
      "r1094",
      "r1095",
      "r1096",
      "r1097",
      "r1098",
      "r1099",
      "r1100",
      "r1101",
      "r1102",
      "r1103",
      "r1104",
      "r1105",
      "r1106",
      "r1107",
      "r1108",
      "r1109",
      "r1111",
      "r1112"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Named Executive Officers, Footnote",
        "label": "Named Executive Officers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r891"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.exagen.com/role/StatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r152"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract",
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from financing activities:",
        "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.exagen.com/role/StatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r152"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract",
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from investing activities:",
        "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.exagen.com/role/StatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r82",
      "r83"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract",
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from operating activities:",
        "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.exagen.com/role/StatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      },
      "http://www.exagen.com/role/StatementsofOperations": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.exagen.com/role/SegmentReportingDetails",
      "http://www.exagen.com/role/StatementsofCashFlows",
      "http://www.exagen.com/role/StatementsofOperations",
      "http://www.exagen.com/role/StatementsofStockholdersEquity",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss",
        "terseLabel": "Net loss",
        "verboseLabel": "Net loss",
        "label": "Net Income (Loss) Attributable to Parent",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r83",
      "r111",
      "r131",
      "r144",
      "r145",
      "r149",
      "r159",
      "r168",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r179",
      "r180",
      "r185",
      "r265",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r483",
      "r492",
      "r521",
      "r545",
      "r634",
      "r716",
      "r732",
      "r733",
      "r826",
      "r1009"
     ]
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]",
        "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r125",
      "r126",
      "r127",
      "r128",
      "r129",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r174",
      "r181",
      "r191",
      "r228",
      "r229",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r294",
      "r295",
      "r304",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r542",
      "r543",
      "r556",
      "r557",
      "r558",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r621",
      "r622",
      "r623",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r675"
     ]
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounting Standards Update and change in Accounting Principle [Table]",
        "label": "Accounting Standards Update and Change in Accounting Principle [Table]",
        "documentation": "Disclosure of information about change in accounting principle or amendment to accounting standards or both. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards and other change in accounting principle."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r124",
      "r125",
      "r126",
      "r127",
      "r128",
      "r129",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r174",
      "r181",
      "r191",
      "r228",
      "r229",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r294",
      "r295",
      "r304",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r542",
      "r543",
      "r556",
      "r557",
      "r558",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r621",
      "r622",
      "r623",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r675"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recent Accounting Pronouncements and Recently Adopted Accounting Standards",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "exdx_NoExpirationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.exagen.com/20241231",
     "localname": "NoExpirationMember",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityWarrantstoPurchaseCommonStockOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "No expiration",
        "label": "No expiration [Member]",
        "documentation": "No expiration"
       }
      }
     },
     "auth_ref": []
    },
    "exdx_NonCashLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.exagen.com/20241231",
     "localname": "NonCashLeaseExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.exagen.com/role/StatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash lease expense",
        "label": "Non-Cash Lease Expense",
        "documentation": "Non-Cash Lease Expense"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-GAAP Measure Description",
        "label": "Non-GAAP Measure Description [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r890"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-NEOs",
        "label": "Non-NEOs [Member]"
       }
      }
     },
     "auth_ref": [
      "r853",
      "r864",
      "r874",
      "r898",
      "r907"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r881"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount",
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r880"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO",
        "label": "Non-PEO NEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r898"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted",
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r918"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated",
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r918"
     ]
    },
    "us-gaap_NotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NotesPayable",
     "crdr": "credit",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Notes payable",
        "label": "Notes Payable",
        "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r107",
      "r1079",
      "r1080"
     ]
    },
    "us-gaap_NotesPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NotesPayableCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Notes payable current",
        "label": "Notes Payable, Current",
        "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r53"
     ]
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://www.exagen.com/role/SegmentReportingNarrativeDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of operating segments",
        "verboseLabel": "Number of operating segments",
        "label": "Number of Operating Segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r766",
      "r979"
     ]
    },
    "us-gaap_NumberOfReportingUnits": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfReportingUnits",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of reporting units",
        "label": "Number of Reporting Units",
        "documentation": "Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OccupancyNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OccupancyNet",
     "crdr": "debit",
     "calculation": {
      "http://www.exagen.com/role/SegmentReportingDetails": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Facilities related",
        "label": "Occupancy, Net",
        "documentation": "Amount of net occupancy expense that may include items, such as depreciation of facilities and equipment, lease expenses, property taxes and property and casualty insurance expense."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r110",
      "r116"
     ]
    },
    "exdx_OfficeAndLaboratoryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.exagen.com/20241231",
     "localname": "OfficeAndLaboratoryMember",
     "presentation": [
      "http://www.exagen.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Office and Laboratory",
        "label": "Office and Laboratory [Member]",
        "documentation": "Office and Laboratory"
       }
      }
     },
     "auth_ref": []
    },
    "exdx_OfficeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.exagen.com/20241231",
     "localname": "OfficeMember",
     "presentation": [
      "http://www.exagen.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Office",
        "label": "Office [Member]",
        "documentation": "Office"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.exagen.com/role/SegmentReportingDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.exagen.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total segment operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.exagen.com/role/StatementsofOperations": {
       "parentTag": "us-gaap_IncomeLossAttributableToParent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/SegmentReportingDetails",
      "http://www.exagen.com/role/StatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss from operations",
        "terseLabel": "Loss from operations",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r760",
      "r978",
      "r980",
      "r981",
      "r982",
      "r983"
     ]
    },
    "exdx_OperatingLeaseAnnualIncreaseInBaseRentPaymentPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.exagen.com/20241231",
     "localname": "OperatingLeaseAnnualIncreaseInBaseRentPaymentPercent",
     "presentation": [
      "http://www.exagen.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease, annual increase in base rent payment percentage",
        "label": "Operating Lease, Annual Increase In Base Rent Payment, Percent",
        "documentation": "Operating Lease, Annual Increase In Base Rent Payment, Percent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.exagen.com/role/LeasesCostsAssociatedwiththeCompanysLeasesDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/LeasesCostsAssociatedwiththeCompanysLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease cost",
        "label": "Operating Lease, Cost",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r571",
      "r807"
     ]
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "presentation": [
      "http://www.exagen.com/role/LeasesFuturePaymentsUnderOperatingAndFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Leases",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.exagen.com/role/LeasesFuturePaymentsUnderOperatingAndFinanceLeasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/LeasesFuturePaymentsUnderOperatingAndFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total lease liabilities",
        "label": "Operating Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r562"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.exagen.com/role/LeasesFuturePaymentsUnderOperatingAndFinanceLeasesDetails": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.exagen.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/BalanceSheets",
      "http://www.exagen.com/role/LeasesFuturePaymentsUnderOperatingAndFinanceLeasesDetails",
      "http://www.exagen.com/role/LeasesLeaseBalancesDetails",
      "http://www.exagen.com/role/OtherFinancialInformationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities",
        "negatedLabel": "Less: current portion",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r562"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.exagen.com/role/LeasesFuturePaymentsUnderOperatingAndFinanceLeasesDetails": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.exagen.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/BalanceSheets",
      "http://www.exagen.com/role/LeasesFuturePaymentsUnderOperatingAndFinanceLeasesDetails",
      "http://www.exagen.com/role/LeasesLeaseBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-current operating lease liabilities",
        "verboseLabel": "Lease obligations, net of current portion",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r562"
     ]
    },
    "exdx_OperatingLeaseMonthlyBaseRent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.exagen.com/20241231",
     "localname": "OperatingLeaseMonthlyBaseRent",
     "crdr": "credit",
     "presentation": [
      "http://www.exagen.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease, monthly base rent",
        "label": "Operating Lease, Monthly Base Rent",
        "documentation": "Operating Lease, Monthly Base Rent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.exagen.com/role/LeasesSupplementalCashFlowInformationOnLeasesAndWeightedAverageLeaseTermDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating cash out flows from operating leases",
        "label": "Operating Lease, Payments",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r567",
      "r573"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.exagen.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/BalanceSheets",
      "http://www.exagen.com/role/LeasesLeaseBalancesDetails",
      "http://www.exagen.com/role/OtherFinancialInformationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease right-of-use assets",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r561"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.exagen.com/role/LeasesSupplementalCashFlowInformationOnLeasesAndWeightedAverageLeaseTermDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating leases",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r575",
      "r807"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.exagen.com/role/LeasesSupplementalCashFlowInformationOnLeasesAndWeightedAverageLeaseTermDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating leases",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r574",
      "r807"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.exagen.com/role/Organization"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organization",
        "label": "Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r85",
      "r86",
      "r101"
     ]
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.exagen.com/role/OtherFinancialInformationAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other accrued liabilities",
        "label": "Other Accrued Liabilities, Current",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "us-gaap_OtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.exagen.com/role/OtherFinancialInformationPrepaidExpensesDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationPrepaidExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diagnostic\u00a0testing\u00a0supplies",
        "label": "Other Assets, Current",
        "documentation": "Amount of current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r142",
      "r808"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.exagen.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other assets",
        "label": "Other Assets, Noncurrent",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r135"
     ]
    },
    "us-gaap_OtherCommitmentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherCommitmentsLineItems",
     "presentation": [
      "http://www.exagen.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Commitments [Line Items]",
        "label": "Other Commitments [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCommitmentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherCommitmentsTable",
     "presentation": [
      "http://www.exagen.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Commitments [Table]",
        "label": "Other Commitments [Table]",
        "documentation": "Disclosure of information about obligations resulting from other commitments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCustomerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherCustomerMember",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other Customer [Member]",
        "documentation": "Customer classified as other."
       }
      }
     },
     "auth_ref": [
      "r1082",
      "r1110"
     ]
    },
    "exdx_OtherFinancialInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.exagen.com/20241231",
     "localname": "OtherFinancialInformationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Financial Information [Abstract]",
        "documentation": "Other Financial Information"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.exagen.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other non-current liabilities",
        "label": "Other Liabilities, Noncurrent",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Performance Measure, Amount",
        "label": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r890"
     ]
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherPrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.exagen.com/role/OtherFinancialInformationPrepaidExpensesDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationPrepaidExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other prepaid expenses and other current assets",
        "label": "Other Prepaid Expense, Current",
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r960",
      "r992"
     ]
    },
    "exdx_OutsideServicesExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.exagen.com/20241231",
     "localname": "OutsideServicesExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.exagen.com/role/SegmentReportingDetails": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outside services",
        "label": "Outside Services Expense",
        "documentation": "Outside Services Expense"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount",
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r851",
      "r862",
      "r872",
      "r905"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Amount",
        "label": "Outstanding Recovery Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r854",
      "r865",
      "r875",
      "r908"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r854",
      "r865",
      "r875",
      "r908"
     ]
    },
    "us-gaap_PaidInKindInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaidInKindInterest",
     "crdr": "debit",
     "calculation": {
      "http://www.exagen.com/role/StatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash interest expense",
        "label": "Paid-in-Kind Interest",
        "documentation": "Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r879"
     ]
    },
    "us-gaap_PaymentInKindPIKNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentInKindPIKNoteMember",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Paid in-kind note",
        "label": "Payment in Kind (PIK) Note [Member]",
        "documentation": "A payment in kind note accrues interest over the term of the note and is repaid at maturity or upon refinancing. A PIK loan is typically unsecured."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForLegalSettlements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsForLegalSettlements",
     "crdr": "credit",
     "presentation": [
      "http://www.exagen.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Settlement payment",
        "label": "Payments for Legal Settlements",
        "documentation": "The amount of cash paid for the settlement of litigation or for other legal issues during the period."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.exagen.com/role/StatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of property and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r79"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Issuers, Footnote",
        "label": "Peer Group Issuers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r889"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Total Shareholder Return Amount",
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r889"
     ]
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "presentation": [
      "http://www.exagen.com/role/A401kPlan"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "401(k) Plan",
        "label": "Retirement Benefits [Text Block]",
        "documentation": "The entire disclosure for retirement benefits."
       }
      }
     },
     "auth_ref": [
      "r378",
      "r379",
      "r380",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r789"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Actually Paid Compensation Amount",
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r881"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO",
        "label": "PEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r898"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Name",
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r891"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Total Compensation Amount",
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r880"
     ]
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Axis]",
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1015",
      "r1016",
      "r1017",
      "r1018",
      "r1019",
      "r1020",
      "r1021",
      "r1022",
      "r1023",
      "r1024",
      "r1025",
      "r1026",
      "r1027",
      "r1028",
      "r1029",
      "r1030",
      "r1031",
      "r1032",
      "r1033",
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039",
      "r1040"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Domain]",
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1015",
      "r1016",
      "r1017",
      "r1018",
      "r1019",
      "r1020",
      "r1021",
      "r1022",
      "r1023",
      "r1024",
      "r1025",
      "r1026",
      "r1027",
      "r1028",
      "r1029",
      "r1030",
      "r1031",
      "r1032",
      "r1033",
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039",
      "r1040"
     ]
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Adjustments Prior Service Cost",
        "label": "Pension Adjustments Prior Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r882"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Adjustments Service Cost",
        "label": "Pension Adjustments Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r938"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Benefits Adjustments, Footnote",
        "label": "Pension Benefits Adjustments, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r881"
     ]
    },
    "us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract",
     "presentation": [
      "http://www.exagen.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock",
        "label": "Preferred Stock, Number of Shares, Par Value and Other Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.exagen.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Par value (in dollars per share)",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r358"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.exagen.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares authorized (in shares)",
        "label": "Preferred Stock, Shares Authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r696"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.exagen.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares issued (in shares)",
        "label": "Preferred Stock, Shares Issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r358"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://www.exagen.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares outstanding (in shares)",
        "label": "Preferred Stock, Shares Outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r696",
      "r714",
      "r1115",
      "r1116"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.exagen.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, $0.001 par value per share; 10,000,000 shares authorized, no shares issued or outstanding at December 31, 2024 and December 31, 2023",
        "label": "Preferred Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r629",
      "r808"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.exagen.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses and other current assets",
        "label": "Prepaid Expense and Other Assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.exagen.com/role/OtherFinancialInformationPrepaidExpensesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationPrepaidExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Prepaid expenses and other current assets",
        "label": "Prepaid Expense and Other Assets, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r961"
     ]
    },
    "exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.exagen.com/20241231",
     "localname": "PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Financial Information",
        "label": "Prepaid Expenses and Other Current Assets; Property, Plant and Equipment; and Accrued Liabilities [Text Block]",
        "documentation": "Prepaid Expenses and Other Current Assets; Property, Plant and Equipment; and Accrued Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "crdr": "debit",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term loan borrowings",
        "label": "Proceeds from Issuance of Long-Term Debt",
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r678"
     ]
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://www.exagen.com/role/StatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from disposal of property and equipment",
        "label": "Proceeds from Sale of Property, Plant, and Equipment",
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r78"
     ]
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "calculation": {
      "http://www.exagen.com/role/StatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from exercise of stock options",
        "label": "Proceeds from Stock Options Exercised",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r12"
     ]
    },
    "us-gaap_ProceedsFromStockPlans": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromStockPlans",
     "crdr": "debit",
     "calculation": {
      "http://www.exagen.com/role/StatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from common stock issued under Employee Stock Purchase Plan",
        "label": "Proceeds from Stock Plans",
        "documentation": "The cash inflow associated with the amount received from the stock plan during the period."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ProductConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProductConcentrationRiskMember",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product Concentration Risk",
        "label": "Product Concentration Risk [Member]",
        "documentation": "Reflects the percentage that revenues during the period from a specified product are to a specified benchmark, such as total net revenues, segment revenues or product line revenues. May also reflect the percentage contribution the product made to operating results. Risk is materially adverse effects of a loss of sales of a significant product or line of products, which could occur upon loss of rights to sell, distribute or license others; loss of patent or copyright protection; or technological obsolescence."
       }
      }
     },
     "auth_ref": [
      "r88"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Axis]",
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r224",
      "r620",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r751",
      "r780",
      "r810",
      "r812",
      "r813",
      "r816",
      "r817",
      "r1005",
      "r1006",
      "r1012",
      "r1082",
      "r1084",
      "r1085",
      "r1086",
      "r1087",
      "r1088",
      "r1089",
      "r1090",
      "r1091",
      "r1092",
      "r1093",
      "r1094",
      "r1095",
      "r1096",
      "r1097",
      "r1098",
      "r1099",
      "r1100",
      "r1101",
      "r1102",
      "r1103",
      "r1104",
      "r1105",
      "r1106",
      "r1107",
      "r1108",
      "r1109",
      "r1111",
      "r1112"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Domain]",
        "label": "Product and Service [Domain]"
       }
      }
     },
     "auth_ref": [
      "r224",
      "r620",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r751",
      "r780",
      "r810",
      "r812",
      "r813",
      "r816",
      "r817",
      "r1005",
      "r1006",
      "r1012",
      "r1082",
      "r1084",
      "r1085",
      "r1086",
      "r1087",
      "r1088",
      "r1089",
      "r1090",
      "r1091",
      "r1092",
      "r1093",
      "r1094",
      "r1095",
      "r1096",
      "r1097",
      "r1098",
      "r1099",
      "r1100",
      "r1101",
      "r1102",
      "r1103",
      "r1104",
      "r1105",
      "r1106",
      "r1107",
      "r1108",
      "r1109",
      "r1111",
      "r1112"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization",
     "crdr": "credit",
     "calculation": {
      "http://www.exagen.com/role/OtherFinancialInformationPropertyandEquipmentNetDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationPropertyandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: accumulated depreciation and amortization",
        "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, Accumulated Depreciation and Amortization",
        "documentation": "Amount of accumulated depreciation and amortization from plant, property, and equipment and right-of-use asset from finance lease."
       }
      }
     },
     "auth_ref": [
      "r943",
      "r947",
      "r995"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.exagen.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.exagen.com/role/OtherFinancialInformationPropertyandEquipmentNetDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.exagen.com/role/BalanceSheets",
      "http://www.exagen.com/role/OtherFinancialInformationPropertyandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net",
        "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization",
        "documentation": "Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset."
       }
      }
     },
     "auth_ref": [
      "r947",
      "r993"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.exagen.com/role/OtherFinancialInformationPropertyandEquipmentNetDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationPropertyandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total property and equipment",
        "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, before Accumulated Depreciation and Amortization",
        "documentation": "Amount, before accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset."
       }
      }
     },
     "auth_ref": [
      "r942",
      "r959",
      "r994"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationNarrativeDetails",
      "http://www.exagen.com/role/OtherFinancialInformationPropertyandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment, Type [Axis]",
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r577"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationNarrativeDetails",
      "http://www.exagen.com/role/OtherFinancialInformationPropertyandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Line Items]",
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r577"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and Equipment",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r120",
      "r121",
      "r633"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Property and Equipment",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationNarrativeDetails",
      "http://www.exagen.com/role/OtherFinancialInformationPropertyandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment, Type [Domain]",
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r577"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, plant and equipment, useful life",
        "label": "Property, Plant and Equipment, Useful Life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "exdx_PurchaseObligationAmendedSupplyAgreementNumberOfSuppliers": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.exagen.com/20241231",
     "localname": "PurchaseObligationAmendedSupplyAgreementNumberOfSuppliers",
     "presentation": [
      "http://www.exagen.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of suppliers in amended supply agreement",
        "label": "Purchase Obligation, Amended Supply Agreement, Number Of Suppliers",
        "documentation": "Purchase Obligation, Amended Supply Agreement, Number Of Suppliers"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PurchaseObligationDueInNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PurchaseObligationDueInNextTwelveMonths",
     "crdr": "credit",
     "presentation": [
      "http://www.exagen.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase obligation, due in next twelve months",
        "label": "Purchase Obligation, to be Paid, Year One",
        "documentation": "Amount of purchase arrangement to be paid in next fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure",
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r879"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure, Table",
        "label": "Pay vs Performance [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r879"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails",
      "http://www.exagen.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.exagen.com/role/LeasesNarrativeDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Axis]",
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r311",
      "r312",
      "r313",
      "r314",
      "r379",
      "r396",
      "r424",
      "r425",
      "r426",
      "r434",
      "r527",
      "r593",
      "r602",
      "r619",
      "r657",
      "r659",
      "r673",
      "r686",
      "r687",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r747",
      "r748",
      "r770",
      "r779",
      "r790",
      "r799",
      "r800",
      "r804",
      "r805",
      "r812",
      "r820",
      "r1000",
      "r1011",
      "r1058",
      "r1072",
      "r1073",
      "r1074",
      "r1075",
      "r1076"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails",
      "http://www.exagen.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.exagen.com/role/LeasesNarrativeDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Domain]",
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r311",
      "r312",
      "r313",
      "r314",
      "r379",
      "r396",
      "r424",
      "r425",
      "r426",
      "r434",
      "r527",
      "r593",
      "r602",
      "r619",
      "r657",
      "r659",
      "r673",
      "r686",
      "r687",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r747",
      "r748",
      "r770",
      "r779",
      "r790",
      "r799",
      "r800",
      "r804",
      "r805",
      "r812",
      "r820",
      "r1000",
      "r1011",
      "r1058",
      "r1072",
      "r1073",
      "r1074",
      "r1075",
      "r1076"
     ]
    },
    "us-gaap_ReceivablesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReceivablesPolicyTextBlock",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts Receivable and Allowance for Credit Losses",
        "label": "Receivable [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable."
       }
      }
     },
     "auth_ref": [
      "r231",
      "r232",
      "r233",
      "r234",
      "r985"
     ]
    },
    "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
     "presentation": [
      "http://www.exagen.com/role/SegmentReportingTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Reconciliation of Profit or Loss",
        "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r32"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r846",
      "r857",
      "r867",
      "r900"
     ]
    },
    "exdx_RentalPropertyByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.exagen.com/20241231",
     "localname": "RentalPropertyByTypeAxis",
     "presentation": [
      "http://www.exagen.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rental Property, by Type [Axis]",
        "label": "Rental Property, by Type [Axis]",
        "documentation": "Rental Property, by Type"
       }
      }
     },
     "auth_ref": []
    },
    "exdx_RentalPropertyByTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.exagen.com/20241231",
     "localname": "RentalPropertyByTypeDomain",
     "presentation": [
      "http://www.exagen.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rental Property, by Type [Domain]",
        "label": "Rental Property, by Type [Domain]",
        "documentation": "Rental Property, by Type"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RepaymentsOfLongTermDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.exagen.com/role/StatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails",
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Principal payment on long-term debt",
        "terseLabel": "Prepayment of principal",
        "label": "Repayments of Long-Term Debt",
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r681"
     ]
    },
    "us-gaap_RepaymentsOfNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RepaymentsOfNotesPayable",
     "crdr": "credit",
     "calculation": {
      "http://www.exagen.com/role/StatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Principal payment on note payable obligations",
        "label": "Repayments of Notes Payable",
        "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation."
       }
      }
     },
     "auth_ref": [
      "r80"
     ]
    },
    "exdx_ReportableSegmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.exagen.com/20241231",
     "localname": "ReportableSegmentMember",
     "presentation": [
      "http://www.exagen.com/role/SegmentReportingDetails",
      "http://www.exagen.com/role/SegmentReportingNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reportable Segment",
        "label": "Reportable Segment [Member]",
        "documentation": "Reportable Segment"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://www.exagen.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Domain]",
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r161",
      "r162",
      "r331",
      "r360",
      "r585",
      "r603",
      "r626",
      "r755",
      "r756"
     ]
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "presentation": [
      "http://www.exagen.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]",
        "documentation": "Information by form of arrangement related to research and development."
       }
      }
     },
     "auth_ref": [
      "r438",
      "r1042"
     ]
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "presentation": [
      "http://www.exagen.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]",
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others."
       }
      }
     },
     "auth_ref": [
      "r438",
      "r1042"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.exagen.com/role/StatementsofOperations": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/StatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development expenses",
        "label": "Research and Development Expense",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r437",
      "r749",
      "r765",
      "r1077"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r436"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date:",
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r847",
      "r858",
      "r868",
      "r901"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date",
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r848",
      "r859",
      "r869",
      "r902"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement does not require Recovery",
        "label": "Restatement Does Not Require Recovery [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r855",
      "r866",
      "r876",
      "r909"
     ]
    },
    "us-gaap_RestrictedCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedCash",
     "crdr": "debit",
     "calculation": {
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted cash",
        "label": "Restricted Cash",
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r958",
      "r968",
      "r1078",
      "r1081"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanCommonStockReservedForFutureIssuanceDetails",
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails",
      "http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted stock units",
        "verboseLabel": "Common stock reserved for issuance upon vesting of outstanding restricted stock units",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.exagen.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/BalanceSheets",
      "http://www.exagen.com/role/OrganizationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "negatedLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r98",
      "r631",
      "r667",
      "r672",
      "r682",
      "r697",
      "r808"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.exagen.com/role/StatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Deficit",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r126",
      "r164",
      "r165",
      "r166",
      "r169",
      "r176",
      "r178",
      "r180",
      "r269",
      "r275",
      "r295",
      "r465",
      "r466",
      "r479",
      "r480",
      "r481",
      "r484",
      "r491",
      "r492",
      "r501",
      "r504",
      "r505",
      "r508",
      "r519",
      "r557",
      "r560",
      "r663",
      "r665",
      "r684",
      "r1115"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://www.exagen.com/role/StatementsofOperations": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/SegmentReportingDetails",
      "http://www.exagen.com/role/StatementsofOperations",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r113",
      "r192",
      "r200",
      "r201",
      "r215",
      "r221",
      "r224",
      "r226",
      "r227",
      "r375",
      "r376",
      "r620"
     ]
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueRecognitionPolicyTextBlock",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue Recognition",
        "label": "Revenue [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources."
       }
      }
     },
     "auth_ref": [
      "r717",
      "r750",
      "r757"
     ]
    },
    "exdx_RoyaltyObligationPercentageOfSales": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.exagen.com/20241231",
     "localname": "RoyaltyObligationPercentageOfSales",
     "presentation": [
      "http://www.exagen.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty obligation, percent of net sales",
        "label": "Royalty Obligation, Percentage of Sales",
        "documentation": "Royalty Obligation, Percentage of Sales"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Adopted",
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r918"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Terminated",
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r918"
     ]
    },
    "exdx_SaleOfStockAuthorizedAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.exagen.com/20241231",
     "localname": "SaleOfStockAuthorizedAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock offering, authorized amount",
        "label": "Sale Of Stock, Authorized Amount",
        "documentation": "Sale Of Stock, Authorized Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "crdr": "debit",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consideration received on transaction",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "documentation": "Cash received on stock transaction after deduction of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock [Domain]",
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "exdx_SaleOfStockRemainingAuthorizedAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.exagen.com/20241231",
     "localname": "SaleOfStockRemainingAuthorizedAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock offering, remaining authorized amount",
        "label": "Sale Of Stock, Remaining Authorized Amount",
        "documentation": "Sale Of Stock, Remaining Authorized Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SalesRevenueNetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SalesRevenueNetMember",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue",
        "label": "Revenue Benchmark [Member]",
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation."
       }
      }
     },
     "auth_ref": [
      "r227",
      "r944"
     ]
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Accrued and Other Current Liabilities",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Cash and Cash Equivalents",
        "label": "Schedule of Cash and Cash Equivalents [Table Text Block]",
        "documentation": "Tabular disclosure of the components of cash and cash equivalents."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Components of Income Tax Expense (Benefit)",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years."
       }
      }
     },
     "auth_ref": [
      "r1050"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Deferred Tax Assets and Liabilities",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r1047"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Effective Income Tax Rate Reconciliation",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r445",
      "r795",
      "r1043"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Non-cash Stock-based Compensation Expense",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Fair Value, Financial Instrument Measured on a Recurring Basis",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r1055",
      "r1056"
     ]
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Future Minimum Aggregate Payments for Outstanding Borrowings",
        "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]",
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationNarrativeDetails",
      "http://www.exagen.com/role/OtherFinancialInformationPropertyandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Table]",
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r577"
     ]
    },
    "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Restricted Cash and Cash Equivalents",
        "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]",
        "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r103",
      "r1081"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "presentation": [
      "http://www.exagen.com/role/SegmentReportingDetails",
      "http://www.exagen.com/role/SegmentReportingNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r29",
      "r30"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanCommonStockReservedForFutureIssuanceDetails",
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails",
      "http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails",
      "http://www.exagen.com/role/StockOptionPlanStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r398",
      "r400",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share-based Payment Arrangement, Restricted Stock Unit, Activity",
        "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year."
       }
      }
     },
     "auth_ref": [
      "r99"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock Option Activity",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r11",
      "r99"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityWarrantstoPurchaseCommonStockOutstandingDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock, Class of Stock [Table]",
        "label": "Stock, Class of Stock [Table]",
        "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r35",
      "r36",
      "r37",
      "r38",
      "r39",
      "r94",
      "r96",
      "r97",
      "r98",
      "r139",
      "r140",
      "r141",
      "r194",
      "r358",
      "r359",
      "r360",
      "r362",
      "r365",
      "r370",
      "r372",
      "r678",
      "r679",
      "r680",
      "r681",
      "r779",
      "r941",
      "r969"
     ]
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Outstanding Warrants",
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]",
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Concentration of Risk, by Risk Factor and Significant Payer",
        "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]",
        "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r25",
      "r26",
      "r27",
      "r46",
      "r102"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r828"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r831"
     ]
    },
    "us-gaap_SegmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentDomain",
     "presentation": [
      "http://www.exagen.com/role/SegmentReportingDetails",
      "http://www.exagen.com/role/SegmentReportingNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segments [Domain]",
        "label": "Segments [Domain]",
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r113",
      "r114",
      "r115",
      "r192",
      "r196",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r221",
      "r222",
      "r223",
      "r227",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r306",
      "r307",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r762",
      "r765",
      "r766",
      "r772",
      "r814",
      "r1082",
      "r1084",
      "r1085",
      "r1086",
      "r1087",
      "r1088",
      "r1089",
      "r1090",
      "r1091",
      "r1092",
      "r1093",
      "r1094",
      "r1095",
      "r1096",
      "r1097",
      "r1098",
      "r1099",
      "r1100",
      "r1101",
      "r1102",
      "r1103",
      "r1104",
      "r1105",
      "r1106",
      "r1107",
      "r1108",
      "r1109",
      "r1111",
      "r1112"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://www.exagen.com/role/SegmentReporting"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting",
        "label": "Segment Reporting Disclosure [Text Block]",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r192",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r211",
      "r213",
      "r214",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r227",
      "r761",
      "r763",
      "r764",
      "r765",
      "r767",
      "r768",
      "r769"
     ]
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingInformationLineItems",
     "presentation": [
      "http://www.exagen.com/role/SegmentReportingDetails",
      "http://www.exagen.com/role/SegmentReportingNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting Information [Line Items]",
        "label": "Segment Reporting Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingOtherItemAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingOtherItemAmount",
     "crdr": "debit",
     "calculation": {
      "http://www.exagen.com/role/SegmentReportingDetails": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Segment Reporting, Other Segment Item, Amount",
        "documentation": "Amount of other expense (income) and loss (gain) calculated as difference between segment revenue and separately disclosed expense category to arrive at segment profit (loss)."
       }
      }
     },
     "auth_ref": [
      "r192",
      "r213",
      "r214",
      "r221",
      "r765"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SellingGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.exagen.com/role/StatementsofOperations": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/StatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Selling, general and administrative expenses",
        "label": "Selling, General and Administrative Expense",
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc."
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Selling, general and administrative",
        "label": "Selling, General and Administrative Expenses [Member]",
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SettledLitigationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SettledLitigationMember",
     "presentation": [
      "http://www.exagen.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Settled Litigation",
        "label": "Settled Litigation [Member]",
        "documentation": "Agreement reached between parties in a litigation that occurs without judicial intervention, supervision or approval."
       }
      }
     },
     "auth_ref": [
      "r1002"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.exagen.com/role/StatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.exagen.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Annual percentage increase in shares available for issuance under the Plan",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Additional Shares Authorized, Percentage",
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Additional Shares Authorized, Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock options, vesting period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r791"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Awards canceled (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r418"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards canceled (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r418"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r416"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails",
      "http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards granted (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r416"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding, beginning balance (in shares)",
        "periodEndLabel": "Outstanding, ending balance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r413",
      "r414"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number\u00a0of Shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails",
      "http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, fair value per share (in dollars per share)",
        "periodStartLabel": "Outstanding, beginning balance (in dollars per share)",
        "periodEndLabel": "Outstanding, ending balance (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r413",
      "r414"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted- Average Grant Date Fair Value Per Share",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://www.exagen.com/role/StatementsofStockholdersEquity",
      "http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of stock from vested restricted stock units (in shares)",
        "negatedTerseLabel": "Awards released (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r417"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards released (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r417"
     ]
    },
    "exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.exagen.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesAuthorized",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (decrease) in number of shares authorized (in shares)",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Increase (Decrease) In Number Of Shares Authorized",
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Increase (Decrease) In Number Of Shares Authorized"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanCommonStockReservedForFutureIssuanceDetails",
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails",
      "http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails",
      "http://www.exagen.com/role/StockOptionPlanStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r398",
      "r400",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum employee payroll deduction percentage",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate",
        "documentation": "The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.exagen.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of annual vesting installments",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Annual Installments",
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Annual Installments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Expired (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period",
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements."
       }
      }
     },
     "auth_ref": [
      "r412"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Forfeited (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r411"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r409"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee options, weighted-average grant date fair value per share (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r419"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding, Aggregate Intrinsic Value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding, beginning balance (in shares)",
        "periodEndLabel": "Outstanding, ending balance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r405",
      "r406"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number\u00a0of Options",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding, beginning balance (in dollars per share)",
        "periodEndLabel": "Outstanding, ending balance (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r405",
      "r406"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted- Average Exercise\u00a0Price Per Share",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options exercisable, Aggregate Intrinsic Value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r422"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options exercisable (in Shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number",
        "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r422"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options exercisable (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r422"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested and expected to vest, Aggregate Intrinsic Value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r421"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested and expected to vest (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r421"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested and expected to vest (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r421"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanCommonStockReservedForFutureIssuanceDetails",
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails",
      "http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Domain]",
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercised (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r410"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expired (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired."
       }
      }
     },
     "auth_ref": [
      "r412"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forfeited (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r411"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r409"
     ]
    },
    "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplier [Axis]",
        "label": "Supplier [Axis]",
        "documentation": "Information by supplier."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplier [Domain]",
        "label": "Supplier [Domain]",
        "documentation": "Specific identification or general nature of (for example, a construction contractor, a consulting firm) the party from whom the goods or services were or are to be received."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Intrinsic Value (in thousands)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding",
     "crdr": "debit",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding, Aggregate Intrinsic Value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding",
        "documentation": "Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested",
     "crdr": "debit",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Grant date fair value of RSUs vested",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested",
        "documentation": "Intrinsic value of vested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock options, expiration period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r792"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intrinsic value of options exercised",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Outstanding, Weighted Average Remaining Contractual Term",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r100"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options exercisable, Weighted Average Remaining Contractual Term",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r422"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested and expected to vest, Weighted Average Remaining Contractual Term",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r421"
     ]
    },
    "exdx_ShelfRegistrationStatementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.exagen.com/20241231",
     "localname": "ShelfRegistrationStatementMember",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shelf Registration Statement",
        "label": "Shelf Registration Statement [Member]",
        "documentation": "Shelf Registration Statement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShippingAndHandlingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShippingAndHandlingMember",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shipping and Handling",
        "label": "Shipping and Handling [Member]",
        "documentation": "Packing and transport of product."
       }
      }
     },
     "auth_ref": [
      "r1013"
     ]
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Significant Accounting Policies",
        "label": "Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r156"
     ]
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementBusinessSegmentsAxis",
     "presentation": [
      "http://www.exagen.com/role/SegmentReportingDetails",
      "http://www.exagen.com/role/SegmentReportingNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segments [Axis]",
        "label": "Segments [Axis]",
        "documentation": "Information by business segments."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r113",
      "r114",
      "r115",
      "r130",
      "r192",
      "r196",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r221",
      "r222",
      "r223",
      "r227",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r297",
      "r306",
      "r307",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r762",
      "r765",
      "r766",
      "r772",
      "r814",
      "r1082",
      "r1084",
      "r1085",
      "r1086",
      "r1087",
      "r1088",
      "r1089",
      "r1090",
      "r1091",
      "r1092",
      "r1093",
      "r1094",
      "r1095",
      "r1096",
      "r1097",
      "r1098",
      "r1099",
      "r1100",
      "r1101",
      "r1102",
      "r1103",
      "r1104",
      "r1105",
      "r1106",
      "r1107",
      "r1108",
      "r1109",
      "r1111",
      "r1112"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.exagen.com/role/StatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Components [Axis]",
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r64",
      "r67",
      "r68",
      "r126",
      "r147",
      "r148",
      "r149",
      "r164",
      "r165",
      "r166",
      "r169",
      "r176",
      "r178",
      "r180",
      "r193",
      "r269",
      "r275",
      "r295",
      "r374",
      "r465",
      "r466",
      "r479",
      "r480",
      "r481",
      "r484",
      "r491",
      "r492",
      "r501",
      "r503",
      "r504",
      "r505",
      "r506",
      "r508",
      "r519",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r557",
      "r560",
      "r584",
      "r635",
      "r663",
      "r664",
      "r665",
      "r684",
      "r734"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.exagen.com/role/StatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Line Items]",
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r164",
      "r165",
      "r166",
      "r193",
      "r560",
      "r620",
      "r676",
      "r685",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r696",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r715",
      "r717",
      "r718",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r734",
      "r821"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Cash Flows [Abstract]",
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Financial Position [Abstract]",
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Stockholders' Equity [Abstract]",
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://www.exagen.com/role/StatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Table]",
        "label": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r164",
      "r165",
      "r166",
      "r193",
      "r230",
      "r560",
      "r620",
      "r676",
      "r685",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r696",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r715",
      "r717",
      "r718",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r734",
      "r821"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Price or TSR Estimation Method",
        "label": "Stock Price or TSR Estimation Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r850",
      "r861",
      "r871",
      "r904"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "presentation": [
      "http://www.exagen.com/role/StatementsofStockholdersEquity",
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of stock under Employee Stock Purchase Plan (in shares)",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r63",
      "r64",
      "r98"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.exagen.com/role/StatementsofStockholdersEquity",
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of stock options (in shares)",
        "negatedLabel": "Exercised (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r63",
      "r64",
      "r98",
      "r410"
     ]
    },
    "exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.exagen.com/20241231",
     "localname": "StockIssuedDuringPeriodSharesWarrantsExercisedNet",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of common stock warrants (in shares)",
        "label": "Stock Issued During Period, Shares, Warrants Exercised, Net",
        "documentation": "Stock Issued During Period, Shares, Warrants Exercised, Net"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "crdr": "credit",
     "presentation": [
      "http://www.exagen.com/role/StatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of stock under Employee Stock Purchase Plan",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r63",
      "r64",
      "r98"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://www.exagen.com/role/StatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of stock options",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r64",
      "r67",
      "r68",
      "r98"
     ]
    },
    "us-gaap_StockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockOptionMember",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock options",
        "label": "Equity Option [Member]",
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option)."
       }
      }
     },
     "auth_ref": [
      "r820"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.exagen.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/BalanceSheets",
      "http://www.exagen.com/role/StatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders' equity",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r67",
      "r68",
      "r89",
      "r698",
      "r714",
      "r735",
      "r736",
      "r808",
      "r827",
      "r971",
      "r990",
      "r1062",
      "r1115"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.exagen.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders' equity:",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders' Equity",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r158",
      "r357",
      "r359",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r371",
      "r374",
      "r510",
      "r737",
      "r738",
      "r744"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event",
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r552",
      "r586"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event Type [Axis]",
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r552",
      "r586"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event Type [Domain]",
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r552",
      "r586"
     ]
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsidiary or Equity Method Investee, Sale of Stock, Type [Table]",
        "label": "Subsidiary or Equity Method Investee, Sale of Stock, Type [Table]",
        "documentation": "Disclosure of information about sale of stock made by subsidiary or equity method investee to investor outside consolidated group by type of sale. Includes, but is not limited to, stock issued in business combination in exchange for share of acquired entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock [Axis]",
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiarySaleOfStockLineItems",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsidiary, Sale of Stock [Line Items]",
        "label": "Subsidiary, Sale of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SummaryOfValuationAllowanceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SummaryOfValuationAllowanceTextBlock",
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Valuation Allowance",
        "label": "Summary of Valuation Allowance [Table Text Block]",
        "documentation": "Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance."
       }
      }
     },
     "auth_ref": [
      "r1048"
     ]
    },
    "us-gaap_SupplementalCashFlowElementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalCashFlowElementsAbstract",
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental disclosure of non-cash items:",
        "label": "Supplemental Cash Flow Elements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental disclosure of cash flow information:",
        "label": "Supplemental Cash Flow Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplierConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplierConcentrationRiskMember",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplier Concentration Risk",
        "label": "Supplier Concentration Risk [Member]",
        "documentation": "Reflects the percentage that purchases in the period from one or more significant suppliers is to cost of goods or services, as defined by the entity, such as total cost of sales or services, product line cost of sales or services, segment cost of sales or services. Risk is the materially adverse effects of loss of a material supplier or a supplier of critically needed goods or services."
       }
      }
     },
     "auth_ref": [
      "r87"
     ]
    },
    "exdx_SupplierOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.exagen.com/20241231",
     "localname": "SupplierOneMember",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplier One",
        "label": "Supplier One [Member]",
        "documentation": "Supplier One"
       }
      }
     },
     "auth_ref": []
    },
    "exdx_SupplierTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.exagen.com/20241231",
     "localname": "SupplierTwoMember",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplier Two",
        "label": "Supplier Two [Member]",
        "documentation": "Supplier Two"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tabular List, Table",
        "label": "Tabular List [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r897"
     ]
    },
    "us-gaap_TaxCreditCarryforwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxCreditCarryforwardLineItems",
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax Credit Carryforward [Line Items]",
        "label": "Tax Credit Carryforward [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r462"
     ]
    },
    "us-gaap_TaxCreditCarryforwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxCreditCarryforwardTable",
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax Credit Carryforward [Table]",
        "label": "Tax Credit Carryforward [Table]",
        "documentation": "Disclosure of information about tax credit carryforward available to reduce future taxable income. Includes, but is not limited to, description, amount, expiration date, limitation on use, and related deferred tax asset and valuation allowance."
       }
      }
     },
     "auth_ref": [
      "r462"
     ]
    },
    "us-gaap_TaxPeriodAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxPeriodAxis",
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax Period [Axis]",
        "label": "Tax Period [Axis]",
        "documentation": "Information by period subject to enacted tax law."
       }
      }
     },
     "auth_ref": [
      "r1046"
     ]
    },
    "us-gaap_TaxPeriodDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxPeriodDomain",
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax Period [Domain]",
        "label": "Tax Period [Domain]",
        "documentation": "Identified tax period."
       }
      }
     },
     "auth_ref": [
      "r1046"
     ]
    },
    "exdx_TaxYearsThroughDecember312017Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.exagen.com/20241231",
     "localname": "TaxYearsThroughDecember312017Member",
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax Years Through December 31, 2017",
        "label": "Tax Years Through December 31, 2017 [Member]",
        "documentation": "Tax Years Through December 31, 2017"
       }
      }
     },
     "auth_ref": []
    },
    "exdx_Term2017Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.exagen.com/20241231",
     "localname": "Term2017Member",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2017 Term loan",
        "label": "Term 2017 [Member]",
        "documentation": "Term 2017"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Amount",
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r889"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Vs Peer Group",
        "label": "Total Shareholder Return Vs Peer Group [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r896"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangement:",
        "label": "Trading Arrangement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r917"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangements, by Individual",
        "label": "Trading Arrangements, by Individual [Table]"
       }
      }
     },
     "auth_ref": [
      "r919"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instruments [Domain]",
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r352",
      "r370",
      "r509",
      "r541",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r636",
      "r796",
      "r797",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805",
      "r809",
      "r951",
      "r952",
      "r953",
      "r954",
      "r955",
      "r956",
      "r957",
      "r986",
      "r987",
      "r988",
      "r989",
      "r1054",
      "r1057",
      "r1058",
      "r1059",
      "r1060",
      "r1061"
     ]
    },
    "us-gaap_TravelAndEntertainmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TravelAndEntertainmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.exagen.com/role/SegmentReportingDetails": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Travel &amp; entertainment",
        "label": "Travel and Entertainment Expense",
        "documentation": "Expenses incurred for travel and entertainment during the period."
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adoption Date",
        "label": "Trading Arrangement Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r920"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Arrangement Duration",
        "label": "Trading Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r921"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiration Date",
        "label": "Trading Arrangement Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r921"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r919"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title",
        "label": "Trading Arrangement, Individual Title"
       }
      }
     },
     "auth_ref": [
      "r919"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Available",
        "label": "Trading Arrangement, Securities Aggregate Available Amount"
       }
      }
     },
     "auth_ref": [
      "r922"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Termination Date",
        "label": "Trading Arrangement Termination Date"
       }
      }
     },
     "auth_ref": [
      "r920"
     ]
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://www.exagen.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r493"
     ]
    },
    "exdx_USDepartmentOfJusticeCaseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.exagen.com/20241231",
     "localname": "USDepartmentOfJusticeCaseMember",
     "presentation": [
      "http://www.exagen.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. Department Of Justice Case",
        "label": "U.S. Department Of Justice Case [Member]",
        "documentation": "U.S. Department Of Justice Case"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Security Market Price Change",
        "label": "Underlying Security Market Price Change, Percent"
       }
      }
     },
     "auth_ref": [
      "r916"
     ]
    },
    "exdx_UnitedHealthcareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.exagen.com/20241231",
     "localname": "UnitedHealthcareMember",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "United Healthcare",
        "label": "United Healthcare [Member]",
        "documentation": "United Healthcare"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized tax benefits",
        "label": "Unrecognized Tax Benefits",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r440",
      "r453",
      "r794"
     ]
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesChangeInValuationAllowanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increases recorded to income tax provision",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r456"
     ]
    },
    "us-gaap_VariableLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VariableLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://www.exagen.com/role/LeasesCostsAssociatedwiththeCompanysLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable lease cost",
        "label": "Variable Lease, Cost",
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases."
       }
      }
     },
     "auth_ref": [
      "r572",
      "r807"
     ]
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year",
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r885"
     ]
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantMember",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanCommonStockReservedForFutureIssuanceDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants to purchase common stock",
        "label": "Warrant [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r818",
      "r819",
      "r822",
      "r823",
      "r824",
      "r825"
     ]
    },
    "exdx_WeightedAverageDiscountRateAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.exagen.com/20241231",
     "localname": "WeightedAverageDiscountRateAbstract",
     "presentation": [
      "http://www.exagen.com/role/LeasesSupplementalCashFlowInformationOnLeasesAndWeightedAverageLeaseTermDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average discount rate",
        "label": "Weighted-Average Discount Rate [Abstract]",
        "documentation": "Weighted-Average Discount Rate"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://www.exagen.com/role/StatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average number of shares used to compute net loss per share, diluted (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r183",
      "r188"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.exagen.com/role/StatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average number of shares used to compute net loss per share, basic (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r182",
      "r188"
     ]
    },
    "exdx_WeightedAverageRemainingLeaseTermAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.exagen.com/20241231",
     "localname": "WeightedAverageRemainingLeaseTermAbstract",
     "presentation": [
      "http://www.exagen.com/role/LeasesSupplementalCashFlowInformationOnLeasesAndWeightedAverageLeaseTermDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average remaining lease term (years)",
        "label": "Weighted-Average Remaining Lease Term [Abstract]",
        "documentation": "Weighted-Average Remaining Lease Term"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested",
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]"
       }
      }
     },
     "auth_ref": [
      "r883"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-4"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(g)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "470",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-1"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "250",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-16"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-21"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-5"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "40",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480489/718-40-50-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-20"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "250",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/250/tableOfContent"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/275/tableOfContent"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480091/360-10-S99-2"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/470/tableOfContent"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(14)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "840",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481161/840-30-50-1"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "35",
   "Topic": "720",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483406/720-35-50-1"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-7"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-6"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481569/310-20-50-1"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477123/405-50-65-1"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-3"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/715/tableOfContent"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(o)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(p)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(r)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(r)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480126/715-20-S99-2"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480266/715-60-50-3"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "70",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480794/715-70-50-1"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "35",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483406/720-35-50-1"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-10B"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.1.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482477/820-10-65-13"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482477/820-10-65-13"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-5"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/842-20/tableOfContent"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-2"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-1"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "940",
   "SubTopic": "820",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column J))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column K))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-3"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478785/954-310-50-2"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-8"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482395/460-10-55-27"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "720",
   "SubTopic": "35",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483385/720-35-55-1"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "217",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-217"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "101",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r873": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r874": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r875": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r876": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r877": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r878": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r879": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r880": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r881": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r882": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r883": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r884": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r885": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r886": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r887": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r888": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r889": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r890": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r891": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r892": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r893": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r894": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r895": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r896": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r897": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r898": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r899": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r900": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r901": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r902": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r903": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r904": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r905": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r906": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r907": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r908": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r909": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r910": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r911": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r912": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r913": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r914": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r915": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r916": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r917": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r918": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r919": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r920": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r921": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r922": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r923": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r924": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106"
  },
  "r925": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r926": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r927": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r928": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r929": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r930": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r931": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r932": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r933": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r934": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r935": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r936": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r937": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r938": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r939": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r940": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r941": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r942": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r943": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4"
  },
  "r944": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r945": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "SubTopic": "825",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r946": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r947": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r948": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r949": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r950": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Topic": "705",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/705/tableOfContent"
  },
  "r951": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r952": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r953": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r954": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r955": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r956": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r957": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r958": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r959": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r960": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r961": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r962": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r963": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r964": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r965": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r966": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r967": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r968": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r969": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r970": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r971": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r972": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r973": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r974": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r975": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r976": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r977": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r978": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r979": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r980": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r981": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r982": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r983": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r984": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2"
  },
  "r985": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r986": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r987": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r988": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r989": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r990": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r991": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-1"
  },
  "r992": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1"
  },
  "r993": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r994": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r995": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r996": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r997": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r998": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r999": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1045": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r1046": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r1047": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r1048": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r1049": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r1050": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r1051": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r1052": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r1053": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r1054": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r1055": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1056": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1057": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1058": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1059": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1060": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r1061": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r1062": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r1063": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r1064": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3"
  },
  "r1065": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r1066": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r1067": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r1068": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r1069": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1070": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1071": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1072": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1073": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1074": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1075": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1076": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1077": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r1078": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r1079": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1080": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1081": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1082": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r1083": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1084": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1085": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1086": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r1087": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r1088": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r1089": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1090": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1091": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1092": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1093": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1094": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1095": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1096": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1097": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1098": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1099": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1100": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1101": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1102": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1103": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1104": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1105": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1106": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1107": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1108": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1109": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1110": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1111": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1112": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1113": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r1114": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1115": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1116": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>92
<FILENAME>0001274737-25-000019-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001274737-25-000019-xbrl.zip
M4$L#!!0    ( +%*:UJ-,F[FN0(  (4)   8    97@R,S$M,C R-&)D;V-O
M;G-E;G0N:'1MW59;3]LP%'[?KS@K&@RI*;FT31M")59 FJ8Q1#?Q.#F.TW@D
M=F0[E.[7[R1.-1 P(6 7+0^63\[%YSLW.\Y-6<SBG)%T]BI^[3AP)&E=,F&
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MBRX1XG".: ?75F>N$LU*'GT<$[?H"%UKV^"93L9C48_8'K;GG$-(=9CESB+
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MOY3>QQ^MA: ?4V$QIWA"FA/8]#L#*Q=(^%52?XO+5C/O-4;YE[?/[@NM70Y
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MW4*17B*,+4LRO4FE]:4S-F*,$A /R+I6SJLYLEWZ9A1G0P*@AM6X=CY=]YQ
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M9B+9P>/4C"9>F\<4,Y)$-T=%+$@!0J.$Q:UJ/7PP/T1&H9:&7$-CM\11'Q%
M<$C-O08C[ST>U<K<]2U_;)?QYD2%'<:]5>K(M+1V_.8/Y]I]6^H/M5OF$CBT
MO+YQA-^"DY7B86B8*+S_K>[LL"</VRN;Z5269DR (^NJW;,E-IP?00#_8!/
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MA<AYP' #3#Q3E,R9+N;$;0P[VM\HC['@R^_;B'\F41YG0E$^F4IMPGK[=6S
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MQ7LY7OA7N$GBYL(/TC'P&;Q%F8,(>S&&E4\;*+Q@.#CU2)BA-U3)338R'[=
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MWQ7),7.<Q/$=Z\@@C[7VJ0_S,&"T*9H<%1+55UTEK[H/&D<K!<J*D&J +%!
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MBH)+VT[ PP"4Q1^R. $$5T1::@G'6\0$E"Y\E:2D7R/:O!?GXSX"T@ZL'DK
M50@L;YN+1E-& ; 9$W!HG9L!7CT67S5>_8"\88VB\)Y$ B-!%TZV /V)W"^\
MOM,?W-22A2LBPH?4*DA2>H2?IZD^OX83B 6MW:&!XD/R>F8Y7P(@[N$^IO8H
MU,((4V-0Q'JIP X^A@]!18CJ;5IYF_0.A:6+ZJCN/.9$V/?7)L+^?";9TQ^P
M1>^M+B3X8BKA 6.[]1O,5LOSX7CHI<K_:4/>!K=-;$C5Z6YW_G?8;?T^&6[
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M!;!]),%TT$%>B!AC%2MZ#RT2];\PYLB+B4DX[$ZK_!NR/3K^\3W:=>)/.6P
M=!4^7U+TWIGUNGX,RMR'>P@,"+Z;;/ZT25778FV))"7UTUX1[@E6TE)?Y,-Q
MR:C42;4X&@*WD$4+G\*]B(H I@>&6"@02)0=;!:?\[VYY'.//$&H,Z+:Q*!F
MC.GCC_BJM5(&=DK&([(B>2%R@*H948_$#IS;!.YM^!34\@$3DCP=M&4D[2A
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M&3*0G!'?O7UTB(:D- '2FQ6)_<^LY$Q5VEL5$\O?!'8ZIK[EQXILW;*]JC@
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M-@S]5UEL@F=M2053Q,7R(]LHB /9G9=6XCC)L\L8ON(*&@L/Q"^JLU_/$'-
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M7A'DM6M_>P0Y"7Z8*)E5-#KK:,4/O',P>./;?]]@<-8/!J_Q[-\Y'H\R &U
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ME5VY9%KJ8GP39KG1L.I@63&JR$=BA3&#Q.B>"'8VB:OR.@\<->K[<)$.0PU
M4-O$A#^VRQREK8EA?C3*F1^8?IZG^JI=763'"5HBVZ$]VPUGI$/:TFD\653$
M@@$P1DR<2S>J& F? \' ;<BE>*7\/"X72SUM%C?.L[IHV^9ZB ;/[ \>:"ZC
M%%1?-R]Y$$P-1.,\H8%*V4BW]E8^DM^@6()FMA(L*!W>@F;)),@5JV7Y[1R%
M.*42,%=7 @[A#Q3\9]KNJXH. ]?_7^ +H7-[1_[4K&C%E9$;A<P^.P#QN!6N
M/:Q0G[.7!/9R0?]([)UOT9P[;\BSF8'@HOM.V_MJ9%VHGU/B34>O&4<6,!X"
M3=7O,%"7YDM_N#!HKE68X6-T(12>YQZ:J]D2'TZF\]SH263PDX9V@#D9>"E+
M[MJT-(%S$V<0:H3L HXOR[D4-0D^0'D7A"J)!SQJ)KCC7WA])2\/7-T"A17'
MD X,R09A?+3DA([24D0*"[]US/O?9-_?"&@PGO;UPR&C6KLN N.7 J!RTCNI
M[!6[7$H4G.%HU_$]O4=G.Z=_?;6+LVXCR-V1M\YEBFCZ[6?)G^I).< \HYGS
M:7:)A%LN\0_ ZIOT_)5Z^OS)\R_G[>C(&Z.+5=+J?V1#F;WCN#ZQ#:JM;==?
MGZ1M*NQ>TJ\&F:&E6V-&XS4<W_RI\_:W#_UNB\-\O"9*<F$I<:1H+$#%+V$+
MP02B-"D):CDN=U0)J%P+58LAB4BW=#6EJ[P2J(3HZYQU,YM8_!M:3EK@->2=
M4\0D.TE$:]6#Q31RYW\I*F_>A'BEE!?)O>-@S6AE![)WS_SQY;W/[?QKK2'P
M##@<(<X%+2</"<<HO(6^,FGF/'M)@@)$1I,V$T4!_BIUJC;>O]4P9=_Z*DLM
M[,!<W&+'\H>U><!;K"T1*(MH2$*]L(FPB#+D4R74.4$$=*NY4-_$$CPE4%2C
M=2T"&LU,$D_]X:NA)5=:PF0>F,4KD>(QU\!K%G21$:K23ZYJ")8M2/Z/*VN4
MP>C1R4K[59&2EWH(O^5<2T=3&FO5KD&S--';K=@&9F$32K2$@R,)V?(2.V.Y
M9YS<6[K\;\3-'#YZP,W<U:Z'+!]K<72Y?M]0#\)%KKCVW/O4(;='A30'U))D
M[J1!#VK&51%(4L7,%\-:?23DIB5;(:".Q%=21+-GS:)GKMK@G";>G(A* 3IJ
M -%PFPJ-8(G C^4>0/SS!2I&NR7&F\M%+5C'3\N]CC;!\NKZBP7+48&QFFF/
M,=GZ-&WXI[Z7+4HR#M@O60H!&%]4TD:E:- "1DO5K#KZTY.#1SN?=D5[L5I0
MQP=VGZ[SWT40HH ].ST]M?Y>]MKES4+UB,6@Z>WSJ@N(@!#AAX_%S7]$98;?
M^R:#.V?OCG?7UM(6<-9<,X$ \U(,#+&L(%)UI+PT/-H?@"RF!;<91+5:>&W4
MBC3'X)VI09:&K5(<.I>C!7"ZFRZO@%IOSB"8^E,XE7H? \,GJG]('9*1S=U]
M:.9[F'=_%MHGK9PO^#M:IU=U7CQS<R3.M-Q]'O'[DUSCR'=9IR\_>%*2?2<N
M.P(:Q=*O#;WVFTU']YMP=B=2TV%GU5RI[U"!6=BS1"'RS2HO\"@9&6HCE3(2
MG-[/\^S@Q;.G.39&GD5',!Y.]='B<J PLUA_K']O:)5)!J/)-MV<<(]X!&$S
MFW!L74EF42LQ7^]5>7#@!]]IE]D3K/I[CD.IM2C[Z^<)?,*<AAZEI07LZA6S
M&&$RR>6#=RZ92_=U:<8QRA*JV4PB%'"!5B1C62.(GR^%!619R%TVRYLL/G=Q
M!TZ\+.GMQ]K;*7E&-TW\J3!O!&C"ID39D%96J,\6IA\E-YE$,0B%$J=*_8K4
M$/0.A>0[3+1OI9\6"I)Y.ZUD*]Z^1BHZ-XFZ/*O)=J?SN=%AA5:X,66C$/OO
M\,:_Z+J>BX$=RP<#HZXQ&'BQ!<="*MJS4HU^EB*<O'+.H&YP3B[2&.Y%W%BY
MC;:KT2IPEOEDU<;4F_,J[;Z]#(? ^P4O;2$#2L".&WWMLAI)B+*XX,K]I7F1
M/D* N$@=2F+HIV^:Z70/[_H&7MO+8/ZL6?3Q&&Y<1W$HD\64[WGY7TW57=0G
MLR"19GP%?"XHOCJXH!#G$S*&+K5_!ILD*$60U.&\F$U1E=#4XBD6),YO5*ZC
M H7O,0=1 '!-GG[[PV6@_@5"?[WD<-AXU6HL5U, H[8I)HDX<]E*J[LIN3OA
M6")S"S92$J<]PFE#39$V&UJ7CV2P%-5L)</QKN4RY65&0/QNWID6[ 1@RE#
MEK:\D+3QK%PN,?ZIB&<K#D%,1;L-T O';1D+2%R1" .JJU;^P3YJ\-"99!__
M8&-1^]M4?\>M<0PYW.QSR;:B*@4F. AE->Z#/O80;@V_I"M \0%F(J,,BIHA
M*,#.QVEX]K3$D[:X+G1HX9V=,D6@1"^TT(T6JX8J8[U,VW#+R&UB>3KVN3@Y
M]I.,;$B.B8AE'\%;,;\E581KX::-,:O[19G2-%R,F)+>)VW2:;;-7SON<MF6
M05BST:9_GOA[DUX5;'"?RY@3;[X+,>*M(68B&H.ML"24A6X0+K14*"44+>3%
MY9["*7C=.&NYI_5=OH+P!G$?5@[EE:XIS=AX7QY2TG=)25N9=<2VR%X6\@/8
M=4@ ['$"(%M4"XR7FP9/*M28(.OAF@I7H?'/XW@@M8"G8 ') .L5AP@J=E.+
M '_A8\^O=M0\)D-Z,GO:%O/RVC!A"SKMPK>SE /^68S)32<=$<(;O43DJJA'
M?-.#^V!>+Y4_)@QZ1*)X[BE=Z($_K3@J( VZ1 _2-'KJ#:_DD99[/$XU;80@
MIQF/T:R7!3"WVF71P36CR(87*MPCS="4MP15R;E5((>0^E!\0$P=7"EXPYK5
M-6=%^1DU]$*G=(^?#37+O@1H[$KYII 17/O']#N.C_H!4O56'\>GYA'(8+)*
M"92K/F,02(!$>&W:S;4&-C%G72A\U5P2:,(R.ECF8;N/&W>)8 2"41.TI3^^
M$E_F&,MD8&>KSO!@&<"&-"<]S9;VD_03XW(;,A9*YM&Z@@$K*739.>,0<K9)
MW\B9KFC)-ELUT?N2G"GH3!<: +0$?587T/H:=^'S&^ 1ZW"40 T%P"D_$(X=
M?\NRC72<)"L(=@,-$+8N3C^B$<H8;,7HW24=W97%.?R]BZS #?/' !TW7Q2Q
M=OI!UM];UN=KW!O6Y<\*T044'0R)K0&_2!UHDJO&V8R7E_W!Q5)Y7H_)JV8@
M9C;$1W.LP7$$6H]/WA[ORC))>)WUS1ST0;R<JOE>6*]&!Z?">]RC^)Z\:V8E
M CC,BG0IK59WCM^=W?H&;69[$%["'CJW<8=(8-!2%[S>H'WEHKTN&.Y59Z\0
M5!"!^+'\7(0,779.$NQR\".YR5@ZXWP2OB='*'DE=S L8W12A5L BPCS@3>$
M(S1L:(.$5[#\Q)^\*L;V*2^+!4@B&IJ).L;<7T^\4@Z(<E@9&#3VOQI4O02N
M++,S%8L2&:MN7R>:=ELQ4.,"PJ^^:-RWDM?P6,*JTJ*BVSQ:#&DJ4U2+/6(6
M8#KJ=P8QQZEF(8GH3Y_S&I+XM6R^HH.9_(17,PWBS8M/)E;#%Y2^ANPPV'0=
M#?(:;5-ME%%3,\\=R3@X;,#,F(,;8ZAJXS&3%YA8CL><^.>%3A4>?\$T? ^/
M( ,BXZIIEP)!U .G&H1GP&%0L2QX>:W(FG7BFJ("4U'-I*5]G=E3E_U()6=
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M3F[-IA"Q"+,GCY(B;.V_J2R<B=^?)$>*B!  G FQ_(HCRM@9\I)J]%'RPU4
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MQ^.(AH6\#Y'J0B/X=MK7TI*N&6T U,LAYEK@0" 6F-=6+:#&LL5#=PB!G('
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M,K$Y9QM1D O_]-G73V=O2LJR[&:_YKML]K>R(V&=4X*F-VU=Y@?X> (??WJ
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ML^+;YU___T^__N+J;?1L$DCZ64T ?.NG)\>S7\KN RDAWK<<V,W!'9+AO9"
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MW\HN!>]+D/@5+LKY4;X.O V@Q%)27G*RVBY2V>P]?B8<^N46:320HJR5R1J
MG%+UU/VM" ^*^FP<$:2[A\]Y.(?NT-&^="/7<P.IR<*MD7(21U6R5F-[)"&A
MF"N)1Z>^U:D:;IIOE#.-W!77'F;Z,\XT100.GF(,-C+=T8EO$DGH2>"O0P#.
M_)7L6*+X/!$][Y_._TCXQ+,' I\X;*[;;:Y7S-U%!H]4&$;&SU3+*E>?]ZM=
MH-:LW,<H:+#_0(TNIG]4YK\3Z0'PCC+\HZ>J1Z;,G,.'D.U?A&<]V-J[L[5
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MX4;-[X?3\ XGFO"1IK@:B%4 B*?#*9&>1*W?Y2TQ71CNW$R9[X@E26O!(]X
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M7$J =I\&[EJ$BV%MXZ&2LZ)O>O"E%61AX#,,QU";JKF;2@O2>P0V6/ /A_L
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MS9,((6>B.KBN$]&"']0_N<:_2?[),0-'[OMN,* 88 03I3CAFX(?@4[!^6[
M7'N44M=:*[^$I&UD)35TO<+@"VPE<7. @C<2#DG=Q+]&CZRS]("",]C_C3F
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MZ1+TS1PR(85Z^OW1Z<D[^!L+AWA2,J\\0SK<W+"^]SX<-4V->%>N(>/L&,\
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ME(-Z_3@EO.\N^%G@9J8'#L93T!W^D #83%!@M[J6[KJK?SE[9'RP?+:(< C
M:2EV)OED "O,&RNQXNU>UE2KN/]OCI,AN$8Y,ZP)A!(@%9U#+K/24OORB3UY
M&)=]T53^2X18X+IE^*>WQ8UWU^K%SK!H" YNO,XPY9WZ$6D/J)P,XC'2DKI^
M&4573\J1(3PEY<K?.BC9;]*UQRC=K'XW-6W;7$*GCEJGN0H27)\NG@-L#.Q
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M/GMC/SNXB01C/E0QS8$L?2)^C#DL4[/]XCB;'V<VO__V;'I[<1V(I+R8616
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M_U7-WZ.D]);C9S66";<?C<AE=4[*U<3/'J\HH1,EVACLH-2N$+7#_SL@CJ5
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MV7^_>OO=[QC0/Z?^JWL\^X2[2*-\\@S7H_0=&2D9[/,8D-,%J.GLR5=?_,'
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M4@);J72I4)_E7U'MN[Z0CLU:#^5,1X%&_27(9Y6P%7X/H>8M9?B?90U^^2<
MX7U>S"[B#HY!8!SH.*UU5:8-0^#_$O&\!"^@GYMK534>N8$M;S6=]*#:?8\8
MA5:8#.!D?K^[+%OKW1>-$NJ49>!-YKF=(^8A>-?>^VH$R?D-&I#4Q@''<U":
M&Q)F.S]^_VX%80$Y*.+^=Q:\^I:):"Q;T$ZYCV9)/HM-,'=O?CX;3UH<-#<[
M2+%H&(QW2Q5.N9<F@02$G&Q; @0Z:2,8:3IP4ROIH#JG01C;O'JF(@UZ: Y5
M4>TZ*I6DZT?\EP#.695DPB5QQRW^0K#&,EZJGXUZ]*C1!5?KWO,W^&R.EDX6
MFLRO+#5H(M(YD+E%T5_I!2]G^'.ZYU2?M4Q+&GU-/[F$TAE#'#]]^>;-V6=%
M(HJS8XP7 B$ETXEZ%48)ZJ%'J].9QR"Y5K48&%?<&@CY^>9NYX21[5>GZ'SG
ML^HOC;L:B]&2 $9B[1]FN$Y@Z#Y=)I,T^^^*3'I5_M_@R.;%\"U]RP^@4+SF
M5(>X%AZ?[ &POU,[@W*>O;%>NVCJE[Z,3NA+.B*BG:9_L=S'?-L7LV_C<1X=
M@&@ROX]_KQ;15Z8T9%G3/YKK^-^?XOF 'U_'>2)3]B[46.L"^V586GS37PFN
M7U_T31W?\9.?=II(C/^B%_V$7N\SE3I2R@NT:^QQQ@9M.4KJJXW]!S OC[A8
M'1?M=UOBW.:U]Y=OW_P\.=W<R?CD:R4T@N42%/?(7(BY,3BT'A58MEG@WGE6
MJ^^^.SL5[1+K+M86CVR6\)00:4A[U=E=;S6/!6-?,'Y^+!C?MF!,9YT_7>$*
MMLTYK4=W8F6(L.7(,(](NI(GP)R?\.B;VJ_>Y6R[(=L4XZ!GS[]X\?3SF0IF
MQ<]^\6_6:EO7E!&]6#7GR'?&8V<;C(G<75/I_G=R1A(8F\[)"YS"[>GLS)'2
MYCT-MMD<D897@LYW]H![$U^$C55! Z72EV>,^YTW.9QZ"M40,ID.O:;VRT5\
M*'(%W<!J]BU[ IS!T4H]YR?_[A<,^4#SCUAA%BQXIN_B^JG-N]2_M;[)+UY1
M7FY0&*54._/ F*?R]K(*JT4!%.#X]P)\ORI3_PRW1U-LH&4\A,U>6DL'[A>\
MJ7[^64%^N6+L@QATZJQJUIK TY")(G ,)W4WA7G5J4O-OM@Z$*5*U7'C@8T!
MBPK'4;EI)-"6^(2Z#_&9DU_>JM?!+_^]#K3Z:Q8?Q N.2CC:0 LO$9[LL!S%
MP4$BV4K]"!RE<#J.G"G^N^9.>#,AD++:G_R-NS'CD<\ =^@XAX6LKW>787+\
M*(,@\P^H 2NH4T;\ R#65T'XP"IJ>EELY_0)>JUSH2!R1;+H5[?N]*3S#5#(
M$,_)Q0WKPGH[;&FYWH_H<%T@_9,O17ZKJ47C>\"1DI/>2ZE+KKWRQF"7K1K%
MD%(68S1DJ85K/)J6O(38(:>6Z4J+MKQ&X(;.9DUL4UGYEY'='5(PCKJR@(O3
M^"?9-'#L5@30I6" VWF(S>ZQN',_<[J,$B>\*$WIAZ?GO^+/,:*P9:+CZNGH
MOOO%^X*E:QE+FG#YY33!]<OI?YWB:[RD[,>X)WI9$R:EHH@%?&@J,B%OTZ(Z
M?8)4K(F;J5$G3_W'7_AN<%UQW;B+AX^RKMJ6JH(]M^D&S[9!'X@6YC2<%OJW
MC4E;\FE)ZVU\,']*TD'/7CSYZO1+_=UGZ;3.3^JX>FN*X\6$<T=KM.)/]AMO
M(PU)VT?R3+1!.ZJ@<HJ)KO;TJX);EU6T<<F9#MDQQ<R:7 >3&&K&@MH10; H
MVNE<CK#)63;MX.#W9V4:39V._6>&W/FQ;*YW>8]9<AH2OG:(C"*"INA.)_23
M)-Q\8BXOHQJIZFKGXLH4ID_G^Z([UY:;BC*7X:I973&%*_JUB,QL)62/J4TQ
MKPU9%ZJ D*[*=L<)<1&2TG:G/#<KT1=]DN@PXAATFB<<0TPT?P%GSU(+!&K:
M"(6>%>\=HM@R.-:*VG.W'OP5D+''^4>O&(XFY:SW!,F30$/=!>;"(SU5=8ES
M3S^A"0"I4'EQ+:3!"%S/EI$*>76-Y<\927(JXL-UO4$X,A+>#22:YJHG=#-H
MO! ]K!Q.QE<VJ;!%XXJ7@QP']VOP1"B0J& :/1 &(8.JZ5A;2=(. !3:!)A0
M6D-3^:-)X'/T*+AX/#Z//2B5-KD8Z%^FY!'@T49WMRS48J"<9!Z J1I(#=QZ
M2FC0,MW[H$ MA_Q4^2CD[CZ@8UVI4S)MI@8\#4:QJN&2*EQKY4U88=@I\[!3
M'"A%CCX5W71)3TWK=)OTU,@\B#$%.S22C>C*M_#I')MFQ74F7SQKG7RVD^.R
MFAQWMPIB.H=+WZ:I8R(;)JOF8<NG'BY*:7,^*+NCS=_?8C-JGF'#GV AOCEC
MN#_2TF(9-/>W0HS1J%R<67RMHX,]AO%[^^U5G5LHL5XLUAY=B;]MVZI;5!9Q
M*S.JWH>@,"LH$\.VU,$^D=;V\"T&QLKE]VYK!+6_Q>G!Q04:5Q?WNE^%H3 <
MJB$KVLCX(=.&LP<=*0)F@&#:@WENN#4G"2W#"-FFJY!Z-"8ANFV-31H6Q:CX
MD!5Q.L[/I_0U'=5$_'2_K?DH=N$=V^!>4_J=(\*+MKGN+Z6[D>PX<(>BQU0/
MF:_YY=%)KF!YD0$NF)_(D_-G.F!IAIPS>+Z-X7VNV0A"MQ*<Z.I=P<(_G+$^
M3-ISWY'UJ.4QO_B(8'X\ >!:(L,&\7.(94I55]E0M>DT:/?.Y)6%_OTZ6&5[
M0D=3!$Q'XCR^'"EBK*-U J _]]/6R*KJ?<1>C$4[.=6V_YECM&JYK"Y RVSZ
MJ;4!0O6<),4*]!?6X'8HU,HVJ04'B\$;Q_656KM*?!RP3W8B_KYL+7\EP4.@
M](E:00N-IK3/BK%LJJ/G[\H5'*:VFNOAM@!QT/E6LUK30\AX;AG%J<';MV"P
M6:-SMF:K?J_%6]S&;DR;AJR87S/--!/,(SC2?,XWM[8@&[IG?7&R"LO^FV?/
M)VT*_ZJ"JMHW)T^^_OVYO0]:&;#5/?_#^9?SH7GR!7%$?_(?E/D+K? -[Q4*
M\\L(ZEQN$=A&?'&<I(\T26V(6P_@C"PC16XN\BY;IC:)YT:T1UPU.$[&QYH,
MCC\1/G#$ZZP</.H3\A)VIF_-<*1FFC)4FG/573TP:_^2Q?NO'DGQ_KB'[K:'
MO(A%&:^ZI$B_):[7\[*-9TF;)=V&1]+1MGVL>2%*SF9=S:-#5[[GU%;RSZIZ
MN5*L;8M4*N0E0,"GL5#E-=+,19#+6J<%O,;C+'ZTW34@!>[+#X6DCE@5N5JO
MJXLVI5 0,G'&'X!*S3+-5A62;(R+N K0U"N!%S_.WL>:/?.K.:F^FRU76W+Q
MM+O6D79, 7@3A9V(]*@I91=20%,N:>,3E?$R@.-S4RP3>DDB#;E3'WKOCDO@
M8RT!L[0@-:0T*S>)YITQ*-%S@5V21$38;^3H-/WQ**WGR$3PLN%6DB&&GT'[
M$*9)7&;=%DESY47F+$KWXCCE'W?7Q_^NS[=M%]A2^TQ056L+)4D#K8\!]\>;
M#2IWH4*>P00JE^R0A#F?G-N:Z$)%+V/=U,>)^5@3(UE([N-J6M:WX6,05,1(
M;-<[[DCQU$IM>9U:CF';=EQR5TEY(#K*C96ES<^AK7><SH\SG<Z[B%,# FYR
M0P83>A&:%&T8:T!&"RS\*X1SJ[JUXSD06E MV\*/^>4]T;H'0TG^5"T6*Z;J
M?\$J,H3RJCI0]W<Y3WCX4$:#< [\\H)Q1?,5LN>BS.@?+,10Z/)_M^5[.D;[
MW>:R8>:T5:,TM4NB=7E!*'$D,%B.JJ-3^<7LO-G-FYX"):O8VGAY>N+;E=>>
M//TCZVO3E<N?403X.?4W4^[KE<]BOM$LYL.I&-ZQ.LN5&"KE;6OE#3<BH^F,
MK><FU7[*T',7H36U&T28"."IW_3AC-"--557*54N)"XMS2]KTNVH<N<V'.4T
M;R6G^>-VLX5F1T^0PT).NVY"\'H3A"0/7=67D#?NXF(@,XBRPK+2% XJT2W5
M BDY0%\^%Y8[,DZ_G+X]S=CV.,NM+"S(>'MJ<ZIN;G;:R( 4'\4JG7*)\(^#
MKPAEGH&%O+$;KJ%#-1"\BL@FQXVCX%,# ^><SA?1MX86EW\CZ7^>>#/N3%:"
MV>."O<V"'=62 >8^9[T;*L[;\,-R4BJ*@:KX43J$\JZ+-S(SU"9KR^DUZ,9G
MG^+C;]^\>_T9$UE,=VX@G7EN!1OE*I<^Z;:?KG9JS9UP6K=:E,4 ;R4.A9X1
MNDO1=&=*DX1J2MA.![Y@;AJ/ULRT?KK>UK47#VD#5BVS:$@KJ_!2[7WN1W/2
M$((&?CW0^K*+LUTZB7[PIQ #%#IF@&M#LQ2"AMDBA#57P6-$'B]M[6<Z'[H,
MQD] S0SK#<4J0D]_^ F J89HTL[DV:@"3SP"*RS5&^\(QL2D\R35QC[#-G;^
M4G.C<G "&8F",=3:I7FG.YS.7B:U2-6/1W]8](]9ZB1NM)JY_$EG2WH^<,;(
MG0I +-UOO V6DT+,.GK9NDW#%CO;KZ&E39>N:<\K+NC1>M_'>N-X);:W)<WE
MY.3UEVU(2JM[IK&[YSP>I_'WFD902%USGX?T(1,E7_#0ALEYJR;:1V!&#OA-
MP.P2ZEF:&OW? "N$]KH5-GA9R92?SKX3/#%W0LM"6#1.E8J($>E+4^>M:?#
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MMQ?/C, IJDTSPW-;4W=XF)S](B/H:%I_ROF%X;QBRSTD56^W,#MUY 8<2EB
M+K>R!=!.N^N0-"62*Z3_56-[6!_UM^& DL]8M'&[7O!!M[?U@3N49[FXJNA[
M,%G;&ID>935AMJG5BI,GJH-C4@]I#V;R.0.!)^U]A?&+-^*.5JX]#%_,3XP;
M?Q(BB>8KX)*(1^AD%5*69KSEXPWKICYQ E7."B3JD<EQ<D/C!LQ7#.&IA]FN
MV69<<T:0DMU+1 K.@RFT%&9,DOMN'$/4R+!0.F@R#\I:WFI 8>.8+DY+>$;)
M*+1^<5<R0SUI!!H\WVC93+^1Q!L< =L-!A>5GF87S!"JU$[,;!8'F^H\#!)W
MPFQ:[BS\!F5-N0K[#L)B" \0!"I=WDQY8^R-LC,4*\D!SDYS7ADI2>"+M,U.
M6$F88H'*9>"KX\5*<.E;/!B+5?"C.8;MZX.%YQ@$;3HKB?0Q*!?B.3\XZZI+
M!2?O,63&)UO&MCUR&9A'XBS\U-2TXFFLM[5CM';[.QIG,[/6BRX2+]@>UY=!
MFJVG1YGI[3#&,&_>=K3L TA-NK#=JI5>4,WXHUU$#$30)%E#RDDL9O$R1 1"
MYO5<@!9X8&B=644R-_%5G_JH&;Y?"6 ;)#S,<6[D]2 XE/C9OK:MA;^/D\Q9
M(D#*V<I).@[YI29-Z@H8!T373L LMRQ34"<=W6P&#7B9:PG>9S6/SIU"Q:Y<
MWU'\*:M$)G8+2TTLP?:?JJ89"$L)#GC[ZJLE!3X 1P72569PK7C,1AM#3"52
M?6=D?MZVX05?#O,*I68.Y3!AT."8>_L!;?([ N9>BG7<%Q!M^PID!'%A8Z;"
M8LIG8V4S&L>KLEIARN"0L&\&29+S78:NPW'_<$;MH&D<C-$Q;+A/V) @AL?Q
MN\WXO7SW;6&[[SR:Y=G4!@1,;KSY]H1564K#$#*:RKX1S'<>QX2PB[@DGZ*F
M]7+P&9#+5OW,AB@O2#TL]+U2>U':F2Q#&R[EU!TL'Q_^788;;F=<7TAE;#>L
M$P,A$)@B55,31C%/46E_3R Y.3H8'V9QS7$1WZ^&^SH_ P1--Q7YR*>("+PJ
M+^I&-$E<$L*"$J\U&+T5J"<]#DC=74_KU+GOX3RK\EIA"A44<B\58;$= L=$
M5ZW@A&LT T1-71E&;P]6_".N]CN-P,-;_W><P(D=\7 6XXV=!(*7(6MZ&<JK
M:J7T; CT]S18##A$(3)%9X8F"SB@2\5N,A*'/Z XXF07ND0**^G'CL_,E"Q0
MF6CFAT23?O@ ^)'0%J<"*)4B"35)4=^)17T2Z5P&Z?!U9=)WHU".=(Y#7<Z5
M S/K#39R<;1/Q3CKI!4Z7&6M"1!\C8]:=2M)(_S,9>2WVPVEKX21O]VN4''E
MP$K@3SD?\2C <F<FX?T4]U>U\^V:4DV*OB82BE#+Y1R/CN"TKVO*7KDKQ(VY
MG2B .VTTSBVDCDXIT!"CFX*N/%\BTZD-YIQQ:T"7=</V"&D[I+%7P:^)VV7U
MH*&)),3K/%C.X'3V;5 H!G'W"QMZ9R@$,L(OF_JB9>YC1RDMT;YF"H!7*/:S
M0R=&[QQWQK !>OLLM3"C"J+D./$YGJT]8TBZ#\[=<UF4G!UZU$VBMU"TB5PO
MFPN?XY0GQ%\IJ;KH@6B15@_+0D)J@04L4I?!0H-V]Z2XT9#4B9U131$8^:,#
M2[K4: H_UJ&_U,:_+(?(&:0VN'+40[+*=SQAWHK8Y/[V'--@U\0U]G@+LF%'
MA+X$82Q][:(MU[J2MY:F<DR# PUT+&B-]M#Q^OF+-=5R3ZH:/SYY8>HJ:CW:
M@-(L<BT#!2/2V0B*):*<$>VZDW.K]T*\BW6\/.^*I\0T>"O$"&75YQ#.0IAO
M]>]9"Q>7*(2OLJE/L.]3]W)X1,D,71^,0]L?\:6>@;EH,C=: .-_0\>4_^;^
ME-N&!!'#@F/GLW?KK4_2[!C3P?KS'-/I?,X7GZZ@B44X$$WMW*L3>S/@!<-J
M)KBVV[Q)=@*30XEDV2$9YWNZ,)!:1+2?$ M%.C3<-VR,;"_P!.#@=!-TA-YX
MZ,V?CM";VVQWV]5A?=XLJG3*CJ$OU'0@_1RT3/]<[BY/OFVBKW%&^9=W*+L.
MUZXL554*+V$=S;06^%'%6ACG444O^*IAYN.XUU8+<H!]+](V YI:C3:358C/
M2H*0@P++U.:ZE)YF/&@A8C&ZT6#MZ13QSF_!K7ILV#AEQ:!+]UJ(:+@B:\<(
MZ^J=C/JK6$RYGH31BBJ<JUU52RI#&1"7O9-O9I]6GZ7Z-9?6<IRG%=AR#N$,
M;?PB7B9>QXV.*!Q7OH&!@,J!(#_(L:FP"A5:F7&Y#F'!K CQ:K>_W%BSDZ]/
MT\VS,N5%?(JL'8[_5D3T1BZ%+$+Q+#Y3_:5\'> ZV6+ .@<BN^JYQ#2:'6XO
MD.EOH_._J1BV6;%>NX$ULF$V :=T]_BZ]B7 LDGR*$&&><5=$*MI>^!@%N52
M"F @M<!E22QBQ%Q3WTE'+@]RN=_%LR3IQ.$Z[9X5LR'9G>_4\3N(=4XR:+8I
MF=QB%\O%U%>ODU_/=FUG#-83>XS)VYF ;<+OV/<UTK1('MYB@,28:F6FE5=U
M4]YJ2D^(\WQ=0F9"PDA=^24+3.,EI?U$=(K$%Y(%B> ;?:D=82O"#0X=E>$Z
MP]XYY!,I16YKUP6E4*CDLJVI0&PFT$P:,0")?#-9*@9/.<UQ?"QD$2I5MDT9
MRHWL+0;6D#E)ZRO/5YAFM;^N8<D<[&M):0@$>+>;JKO$ [(D\[A Y8EYL3I<
M&\*3/?GI=YG.CF/O%Z]Z>IIU^]['RRX4'7HE"0Y94)D3@!&1:5_MN/7Y(<4]
M=XR4?YW$&=R6WD('MQ&U5?@R#VDT#KJ%WU<KS+IUG*O>0=P/OO.H4[F-8[WK
M7EA9@JA TE2)ZZ9633*0\7N7U7DEW!.&03J=_13C7L887@_JL"F9/B2%,6&F
M'!U]6?H,O%G.U$H[+\56J#K!G"M.OF6I)$F6<CYO(,9!R7+7/F6]29HIZMNF
MO@CMM&W' S'=VX0GH U2B-U'-"!:]--->W##RMV[<AU4>$I(>>S7:G$[ON_T
M(?_?TH^5GH)/"5Q%7*=UV?<JRR<H&"O?ISP3?<.ZGI>4Z'+)=9^F'23!";ZJ
M]0R5A>.$Q9+T==41V7N 21J7N!,%8,"<INDV\>$YKTZG)J;%T)G<GL7'4;;B
M7 O7LIEO83K,F3,D5A"7@NHW*L +1[/LM.WP( G&/ ?CW)()Z>:,CBF_=@H"
M.-J]WU#G?QD'/3KMB7]D\JA5O*U'LJ/;380JM2SM8[*A1=V+I^24L <:;#L%
M%>>4+S?!%0U".BZF.?DI::F\KG.4PE)1R?0$T:0W;>_D$ 6ND!T:9)%( YW@
MN&'X/!. 27+CQ5(8Y#JQ(_BG%9<XVC>VR<SXAJ:-Z7!&6COYN1@O<P3"_%Y-
M-(-BU\TH++^)4IL<5$WI>$=R(MM78<W;R; TC\9!_8FB'JON\-*/G@CST% T
M[GH*XBA%B\)<<KK81_[L3:Z!'B0#$B7*)3%DH-MU/=W$G4%.!2W#."3)<%@&
M .721\5G69970A4RV+N)OV</.OMF'LM<M15G.^\31I2?5XTK9:02:0Z3?A^0
MBC3/D2)9SN9T/9L[ UMY=A.WHOG0KT1]VO!<WCLVF5C[NBO>RNP(9HD<D3>^
MVSTO8^>*/_MF]$:V .EOJ\B&<*%0<B(H1?;2N"62I=S<!42!=14F_#C?:K/-
M.N&)2XSDV.CC3%LS(*OQ\JD,Z5CME)41UXM!>@,BB8%^:-EU],PC4>*L7$ZV
M@:C+("BP@YN[K5R=/T8%?57VB9Y71'J3@;+NJ?*Z;"$I6B&)5GCKE"5=UJ&D
M6&.Y79W.SH8Q@^N^\[-Y<+L*34@*H$PIVW+DR<LM!S0#)O>7N@5,,'[ZKCHV
M>M"G:N<#Z@2^8_+CW>6$*^&]9^^&T\[O'*Y@=)K)^&=@L&Q]/IISY]>@:K_6
M[)GQ_7%7S'+GP"+> #A'%6&.^%4$!I*8VI6:AWJE(@E#ISJ3H(N>*/-\]4TS
M6^5+>SR!''*M<6YQM=R<[W5%>L&6HR4*D;;?UI6:C^@1AOHB?KN>BN6GQ>KI
M>)4W!V)-7C<:&2B)2C_B$LFFB?-A*E!C+[GJ^L) !FTUQ!44K)3#A?T1L(LW
M;J)K88M8R.3$&;VL-H6TCPE.CCL9@RIQR(-1:CN:"5J':P8>B=+G8(44UOFF
MC.=-FYY45HXU,!6I?8ESPTA=9'QF-YWU"EEAC$OR#<^#2<W0^%#P#XX0/'B^
MJ%7NEMN.YXTT.[$_2?3KU&#+0TO<IXFX)MF%(H_-VZ$C@SJ-/Y6++"Z1YS9J
M;30 -'&9RO,"\('G3!ULLMYT,8!XV:VV(C-;XR>Z>?T5^430H!YQ%PYW\?SS
M(^[B-N<(O!'X=;29_QTR)8Y_4'1]@)$;43"*LK-ZJ+A*D9$Q&Q#RS!<OI1M5
MMQ0C^\>P?@X./5.*^#]97V>JY"ISK'1+XKKS7@L#ZNX^FA,>>"RM4/+@Y2_N
M*%"&+K;4[A=F9J8)UBQMZ0',9M.1][&FWLN04'73QIZ+GM[_&G,])6(H)H3C
M++-$FDI>MJ:8"L7+9L4<9L*ED#P..OP&&=8;SNO;'56'R.!Y%SBO9S<8^%2-
M3@WB:+[= E^/0#R'(3AU]4FTM5YGL,E<NT&VSV[;(_=F *'BTKB44B<(NABG
M.II8>!3I*^J"<B.]AZ_H7$Z<<K:FW"L@&9) #QHH(FP4)C<U6AGMGU_!2KLI
MK><;@BGUDE@7VEK,9_9(=NO"&#D4'L+>L3@?*0M@;WYHX>0.#2Y+L/(Y,%(I
M(V9 $W:WX!0*-JIJU9?;GS\=#AW^I(CV<;VX#5UR4(:SD!AT9?R0C17HER&0
M.-]D4CO.]"K? !MXTB+);+ 5[RIA^\#L&%.AF;$LB;MEM]:A#-*8"O8N1Q]D
M?Y;?19,-,:X2N79'CJZ4[4RH)39SPC[Z(&:20=X]Q[BU>'#&64_ (,#2.M>^
M^'7(!Z"D$0>K%[Z;$0?INGR/VOK6^%#B)5><!!RFP![-J9D59F$$\K+$I%V:
M2"6X;L1]I;J#P/-)5X7G)PX*'PT3T\C,LW_;+JHYPV]D=W'"S7[0%&18 +\H
M:]P%3<:<2?G<> LV1#$T?T]*,'/A"&48*QA_UCSO[LP=#\JC602OMQECU_X)
M4LK22<T-!R]L@Q36] 1]?7#XFQA+U/*E(5K>H&%Q<H9'[#83+,N6ZE:JSOCZ
M"CA"S[S)H%Z?-)R3S$DU%Y="L/Y;.MIP C)%B62L9QU.(,H]$FT(IZTQ0/9-
M5Y=FCR%K[5?2X'F<[ ;NF[LB+,O\LN$L?R)WD414(FWQJ?_\)IK5R=C3ULP$
M9#F-PUO"D Q5JQBSP8O8N4;2'L8;)#'*2$C%=','">'4%)&Y-SF!&:HI5W*&
MKZMNVSVH5J[#%M:< H6E5Z-^/H5K3.Z\G+&+#!NN"(!R/H+SUL3#3R9&TBSJ
MN><6RCC^Y82ED[?72Q0JA*M'WI[#VE>9#C+PL#DPYX:H@/MPH3W'AB]Q^-4!
MV;Z]&VHW.F:#ZG^&F7<'L\N@HE)"DZ+AP]Z)X86>W0$,!Y.A^-0@IK+9X6%\
MO)6'7+@)D=LNP0ER/6Q&2"5KSD;>^#U2S]F!8M'88[!P#I&XXZ..-M14,,70
M.,U'"1XOJXWC-_0Y8#5JV''Z;(86E293IT;4/,X$RJ]LI5S84L[J[?J<CHKE
M5)@[F#7ZLLJ]W8"PO7G,L@8_MR2,F";+-6,MG/WP5^RM__SA%[8PU@ ]\>QT
MZRZ80R-)A*;=:5K/V8Y%W-D7@?O';147G@DQSD'<QTW-+?;_GO$@3FK"#W7.
M#FT7;? 8O44QG7]0$Y^HQ,E+DGGB4_1:J>T&L<] W,09+1WW(RSH?KBY,VMC
M'^#F.(.>@BV6>3 _5L/I(CE-DK58Y [3X<(Z8+VK&"53VX#-OO1MC ,]1#C\
M.U<**K)LBL%P7/KD,!AGF(7@-.8XRH\^2:.+V!6/E&K.+D"=8<1S7XH&"7T,
M70X/Z! ]N$Y^-'95>/:'QH[Q2>;?B>&<A]%YQFPFPI4B="B<>2KR#[F( ZRR
M<9%^6W6;K3)6<GGV//37E*'=)FA;FD#F^+@1A>4"PTDKEH=PQG"B*"$Y4E*/
MT-CBY<EJH&Q@/$\T#.,WE"!%XA]%P@@X/#X=F\AF$ US64"HL!,-U3[=X42I
MXE.]Z="C3>]&)'T(625])1P0"YT/)!AN/E,UPY+2DZK*T^YQ55/%>IN*W.YQ
M6F*P479UPC#,PZ877K9V+1FZA(Q2/DU*N&CJEZ2YQ]2:5FUAB,7>1)V!G% <
M9;?>48)8XUI.3X!-L/^ '1VNG#Y,[H%S^BCAS$S?R-3.%?],#8['"K*O(#\Y
M5I#O%SGEM%BZ)14C/\ZCNSAY6" S32$R6(LM&.$6S7P+*QFMCIR0!?%UFP/K
MVTU<,S>[R ,>#*=92"ZQ405//ZEA0";1*YJ&.QF^!4?;_F$>31#USC2L:%1T
M.A2R>F@<K70V*GJZ*&QJ7LMVMV\^M9?7-8#&+^M)F^9KCICK37SE9H%NVP3_
M68+C/YX+X3H^,_]4UO46LGE!XAM]3[YK]I9,#,^HU %[O81*>=F9FMJ,MC,>
M699"3:,Z:$^R 234+V$L*$';,[CURER&94!7O1S+!QZ!8T?M/M%Z %$,*%*<
MPD\4!5Q2=1'*Q8J)'4C;1)5E;(20%(_K?B%*D^G/:?\,[\D:"_1]^U.,#M83
M=Y 1RX>)XKD](\4D2Y+N(CAQNU5@_"M-SER0=]>#DLWN(RUO4%]S/8U"YC$+
ME+$^P=@+QG\W0 9KFUB9?(+XC44+N3;?-^;JN6Q:+-8>#RQ+J@W@#=FJZ@EB
MN>G" $$_!!@R?Q1W?8M?E=<_(-9U<\\9MQ=0E;:LN;5RTPV;W/@U!G?+I5"G
M6B\96G[KSLO$SNS;&F:.&JW509U]MR6?,GY5Y,1>-@IZ56+\WRBTGCW"WO8N
M'P_@]9HN#!_]/*R:5/?8_^"CN/M22#H(44YI@S0[J#0V:U@)D$3,MZ948VNO
M9*0N&5M6MV>#1T!X[F##6L\.,H]9:;>KT!4. )FX%5.&ANM2>@+0CDLKHCR/
M$]$8]XBM*V?-)^$\ZIG+F K-S8S37#%"[%%.\#R0>6_MI!0Y; 4OKYKS2L60
M"E[H!3W=?ZU<*))8(IM1<4LMV"S(84A)W%P"<UX":L()1X%*4$$Y 4G530]2
M=7BX6+;?1&K@2B.5[_IV$@H03C:VGE0C4C8+FJ6F3@7[3(:+!BV3@JHV2*EI
MFSL77=@D:<I!*QT/:I0/^FIOJ%H+YE8-G ^CLO7E+>B<*$'06'!,.63:;*ZQ
M#;.CXYA-O5\V]<]*9L"-94QDR93C+%*6LX9*^RVSY"1\FI2U)SK3H.XYQ"MR
MNOVB;:Y[T_.UC!I0:I)/Y?A,#>U$55%*EH7;-6C:[[30.'XDRX-DM5O'T^@N
M-?%"U@:F;2ZEB:MG"N?'17G_13F  .H<6;N:X\)C&.)HF@H%^)V'(>%>+[3N
M%]65)@;\.5LR@;?GO,B*U0D-P)K)KP1J*<=VP@7(_EAX<B_79H<82B R KYT
MN#Q'%]H&A$AK;K=)CO$C.1K>70ZUS]R)9^!RI2\>[S?B;,HEC-I0:K>G-#][
M++[RN5@S$;3N6SZ5+D!ZW?HQ)V<)(EW<G0E^*(J7":DK 0)A*@07ZFR,6HP;
MGM_HH5E*@SSUUID*NE#/"LY7+,JD+"*C"N+1H-S;H/PT6!&N;S[U;^P1RD+F
M8^LS Q6E@_X>34GTHB_=6J(UJ2ML'I\+!::;VQGGY89/M,?4!3K0;=/19&*^
M^'Z!!I%[X<_]V$K'(LY>I^#&-'V9V3,_F[")H>*Z?^W)^;1P0EN(4A<LZ;E*
M)<]TO-^P;P_7GVIE\$M4?9PHX?<#_I#I*A7+30C,;5NGO-!5X ;)[&FG].DR
M#)D<>&DHTIERAX??I^KJZD[.HSJ:G=^=P215]6XNWY'K*(ZQKYH])+MPYS[Z
MM%2UH8:D)_<7NS/.#*_)BNSPJMR-HFJA2'A(HW0C3-S!HE0U1LM1PWCGJJDD
MB9>3B0SR[U/NQ[![3U";[%9Y5'&YIL0@X]-Z*>H6+!$CK+J\G _D&BE@'*ID
MW(*RYX!634'1U34A/$G5?@'EIEZ:L#>.Z 1->9>TK+Q*S" !&NV=4IFRWTVH
M.!5'\5<34H%4 Z!P;J/6*%<!75-C-1KAW 4.D^7\&,K+W<G;-:4US^(2B%8L
M1A&LS'+&%'U*Q@M9$BE4A6[X-IA3E+NNJOA!K "J)R@;,_V6;VEZ.F7RNB4Z
MUFN?MTP90TL*# 9&NN?/&AWD8/!//]F]$WRU/K#TC2&Q3"FITE987$84"!:Q
M/[[TZ%^W<6:ID(>BA*^UC4MWLTW&*#KHMN>G("^!2 ^GDBE 9QIN _R&*0DN
M'H8C6CJ>Z+\!?-CMM544Y)>UR.<@!+4I;E5NO!!P8/=^)HI/ZC/#SJ<.WV-V
M\_=PP,AWN& !&\X6B?_!W3][CE)W<K( _0&OXE\2G?3TB$ZZ91. =&43!CB:
M@%VSG1D[OYQS(S:<XU:_WU9'U2!3-[6>A32VB13$ ;BMR?RZ;*WS?W!(<^1/
MMS#]>&ME-@*_HYV^M_ UU_&UVV*L9T?3DKDS22IR6_/$ 2602 ?446.611&V
MH_X2)W\PZ"S=:F]9^L11S_PW>4M$FC#SVCWLZER;^)UYO&#8Z*AHDR7 %/+2
MU.%H,7_O33?5PBJQDE2#Z8-#SE/>5NAU&7)KD..K_!I3M 6$P(&>T)I,["X&
M9"SA1K;61.R8N&;)Y55"/<:)?O(UH0/[2][,Y%K#IQ#:O('Y2*9!PZJQ01G0
M*5CQ:*75(8E0IXZ!HT&X]R$M9?%Q\Z^<V<B.\VS /N2 $*8C1# EGS=Y(,$?
M#"_^:/*!;PP*^!YL&$."6NR"/&1IJ7L_E1Q26J>Z!4-V%\)[3F.I7.W?MK5Q
M97-NBTH-W*#2DIK&,C<$'IAXOFKF[V^L(]3!=N_Q6/U-Q^JWJ5>0TWA*W\E=
M9*O0=6DM4(*1C+B023"H9Y). AU=VF:0)X=!]MS)&F,P=0BN\LE<SUD"[-6
M:Z+T4#O>RL,P/*UW.YRXH9)1VMD#,>=RUO'6!EJLRL8L9-1-6X>=]3<"ZYR
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M/K;;M_ "&(M<TX!J:9+KX&QGUOZ]SU4\SMG'F[/=;%W^S5P$#;)2!N@X]G^
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M>7]H%5*&4G:>1WII7,.M8(I-FUM2 =@AXIO0BE'VW]U&JX,)7]>P:(.(MHK
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MWN3/JVBS[/F_^B1E",YZ_A4]0.CFY8:*.NTV?/* CZ)? V03HTF6\'7>BLA
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M)$N,1)&,ZAO= I;WHKFA(:^"F*GSW(<W5X277"CEB.;_L>$PBGU7*OU@[4&
M5?:<IVEK..(*2KP$O2U[!@#[BVER#T.<2F[JNTQ0\?=$QUF*T-X2$FG60$K:
MTHSL_<6<AJQ..%ZGVJ4:5'?.Y8-$7K]$[GQ:$2*ZR[NQI=O]E=NS7+@^6V'8
M'03M.O*I9AR@,H<05&?K;[=^M41A4WG7]C_S/3[,==)OE[E.GM\YZQRTG/_W
M::-?Y9/YJCC(\$,!4\I?_?\]FAOM)?M^.X_A^^WWZH2V55[-PY:EAOTUIC!*
M2N4'I**=4 ] CYCT!V,(G6I#B'[S-;.%OAA;:(LR!C:,F/\K3)UX*JW8W'$!
M[WB<[8_8.27VH<::6S81)9#ZAP!G9I'4;)0X 2TV0[[$+\&29N0=,&'#K,&F
M\F/%R7AD01>U]99S@4U^2QJWY(Q$>G"</W;7''M$&-GP*&(SWOX^.S?9?ANM
M,:)>?":)F!3X?,ZSJ8@LK\R?9YJQ?I&B,DILN=3TP_ [=7W/-L]@IYIF0#J_
MC!+4)@CX:&:!J?6CQ (-D!0B7<8"Y\6FC#0O)<#\=#9G6G?*:&;O@IL/TNE9
ME2>KI[Q' ^]1QY /[!;8,X96N4%&B8X%HLSJ4S/?@JN["V8--P4_39,I.5(F
M8#;9&!4F"4#_*DM'QXI#Z@KM>YD#X);C*-#<BCME$]^]8]C]@PUCV,^A_V)A
M& (P;0^?O#,-%1W?#E9(($IQAM5AVF;,(P\F[2'=9!VGR/M&I<>F]L34.V3)
MF-Y_C"L1V[G#4KG,C:U](&>@%B\DZ@Z"\(JS/G6'BWD48O)++.X)<C[]X^/%
MV2,J?0>MP5HP>4M*&1Y?LT=/7V'6.&R=G"*R)1Q@[^>__-0Y[/\8;);;4[2&
M$9R"*9RB;O$ZVXUY@>#Q24M4CS%R^9]VC0VY2B><?:)NG&BJ4N3](P0B2T(/
M@7DYE3'[LZD=N'#Y%6<8F:)R%X:]9/<HO/'BTQFK&2>Y[&(I*P^)HXY2S<83
M:9 S=$??+Z,P#3)^XV'8 V,S/#W!F8%)#XDMF01GKN2<23*HNAFIN60=PVM
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M*RUZBC[J)..LQZ#IGV0#K=5@J9O+HX;-B+GSI^U;0P]!X,74#7 %6<2&+H
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M4_$"71- @!>1,OR@5'2M'#POK[C^U]%T3]U]3#S@#AE684WU(S4GBXU$JHA
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M:M?PUASCH-OHWC?3HS[&K3G&5X/&H+^YS5Q[]S?;YD\8'^;&XLNEAL]@-^\
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M1M>#\QB'*8+/;@Q'MTM@+H^X*UMX<\D*ZMP[M^01=N69M.OZ,M27H=22/-K
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ME[FR.1=Q-E,1FO/>?Z0<6'@H?EWST1](0)S&FX6,,6(58^ZZAYZO+*D'-<T
M[+>I-Z=\'MAW\:HVLE1/G=]MLCU((*)'1#O=.!DH$Z*WDHEQP^5>#A2QGYM
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M!)>N. @ 6 ,-,88/%ZX73($27=+-8C;2PG/-T A\<5CIAIYR\X^['Y\EE$L
M6+_9VP)B.;H>,7FET=W+X03=9_@ [*?4'G0_E+C:+=&K3#P O:H\SRQCIN@V
M)GQB[A[AR9I.F0?8L2B_07]T8&N^BK#FOQ+6YJYC!:XG*@$1^39[4;P9"S%G
MU% 5/0Q<:SX/'4;7QW]>$82 +L"XI(ZTEBPCA9O@L?! 6(8';_1??1#6(.SL
M<!'Z"O->X0MXO.O#7Q<_OGZ^Y#4L_*6N!6_Q@ID'>("OO]]<;J6G#L-L!87'
M5^L_H65:P6MU=K"6GG[&$D*9Z?%YBN(Q_ 6IQ'9]'$B,"'/8([%(G&TL&MJ[
M<F1YHC>. G+3(")A)$R;2O)E.I I=IHC13_3 \4*E&?+MB.UA.J?5@-O#>0B
ML U/B$%(94&%S7Y3N0F43\Q@\PGS>&11:ZM*I]7IJDJ0VAPOE.*2:[FB"CCA
M+V^OB>GE)>:#)E[*N+\);G7/0P?F'[H=QMT-^[%:[F)Y2S-[<*@ PFU<%*X>
MMP+T 1Y1. \%1[(I0#/8?1\K:M"_LT 'VC$_ZQ[6$/LW\;L_\5?G[0:+=4;=
M9K9@0&ZGJ?Q(T\@RSGS9 ]L$^O EF8%9E-!6(#C<\!$0B\)L I=+580(#E[C
MODV^2@T,DXV</ ^KW\FL5$59W1-#XB.J]F%#OO HY:+^RX]T5U/YJ"?49'P!
ML1 HR8DP'11PQ6%KX'KI_&7*!-0(O"DB?9"1+Q;7C/*8$NP\T(H&7$-L,6&*
M'TX1U'@_\,84-.?2>Q-)/J04X-'8.APN?V8V<"W(Z&"&7Z':P'?A[3A^@KJ,
MK_6<*R21U\LS%V<N&>!_$U13&/#3U#777T&T /[P9 &!!AM&H!)@7(#V BT7
M>HR02:0S8Q)$>EF$GA_R=SUZ[G,P@VW"]^SQM:G\@IL AB$HZ@ \<$7W4^\W
MB(=G2 ?$=A8@%Z3B*MGJXOHMH&JP2524EM'ZD1A$I_@E)I&L@:]%8D8<XR4T
M>&29&^!.CVMPN0=0X/"+XW.N15EK![/H@4DNG3"P.6&G0*[^-+113GNZY2?I
MV>)<L@!Z)#QX2'J*XP)8_-"CU:?T !%\\H'N!&40/I) FL1:Q-#(BLR;^R@<
M0:)0ZAN )[%<@B&\!DPGKI#X]6BY.@E90=#538 U6'SP&_7&H.?,7-N4T,*_
MZ=PI1TH0C/%B>$13N4M]C3L/';DZOC%)>VDB!5?.-A$6P,\&Q[4)5AAL Y1T
MB%SK*2!+YBCV &#NG#Z!S4E4H_'GZ7-N!J+82MCC[ 7>X9.-CNR!=V9M>C:%
M5Z-XY"8G7]!,!Z(%;P)>BCPK(847(YPR$E'RH9JP%$# A;:H9HY%#K :QRM]
MGGZ*/K%LE.@ !,DX%N6 ! R\"#/F=G?R;\S\  &[)+?^NN2F%HOU: 5C/4>+
M.G2*1AU^Q/)GJ_!!/R=\T,^&#WZ$<P#/*])BX@U*_ I%ON-MP05Z9<Y".B<6
M<J#8#D(I&=TA!OC%9P=^AE4BLYU*%.)GBF_S# J*WB\\MM ]WEX3 _R>27J
MTK7TF$@6O"LU&F,\KF"C2"8)S^]%,?$+S%SXB^*$!,L;HB1=N?C[S<W#)1?V
M_(61A1@L'RSDKM1#0Q(0DS3@0 3-]3] X$G$<%\95-E\(74O:IE8;\";08ZB
MN3''?7&5 TZ-D("VQ:4;\((JO/E4>2<1^2.%7G)O0NM"[,A$52!^S]N0&HG6
MO#5)"QBO$86 OF*&GK07^3V$%G+!P"HP@I ;K"3/N8:0J@$PQ>,2W)@!^\%/
M0.U4S,JD]%J-\KEN,DF.F\F*1T\8SUQ$;L#L153E =?S$A'@B;OP]M@]D@M
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MO;(MV"=.G7Z"_?%1M'$1!1_:#F[*7+<<S&8'Z1]Z6.@0SR/W&%/FL(Z9C\-
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MS=7V3FKNKKG[K?[-X;B[2WY/OVR_YTC<O:+M?S)W:*>TN0?/7<"[7Q]LW0D
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MY"7I3$[WH\H)AY]XU'-,[;G=K*LSEQN4$Y44&G<RI/C+D0<9<8N*PG;H")2
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MM]'E)'[B@A;P%Q3.8,-0[@V&F8^^>6Y"8HC)7DQ18TL\T";QJ55JD1GU![+
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M>YJ\F7-T%S+YPGWI7N18S A#L8^H#U('EDOENL1^)V\V%TH250=0?H)]'\P
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MT?U!T/, V/^;$=C!FJFDXW&['$!,GM*R!C9>D<N0<+ZBR)?A09Q,@3F__)2
M"L*<Z8-VC!]##M'"#K+HD[DTQ9^-@TLO<FJDUAT-R[^J.J"QU]6U:D]:MZAQ
MMZ\.Q)K:NB9-K6.V9F,['I37U&_827D[)*5-(S!7W83]*E,PK^1$,_U#UG5(
MZ!6;)#3QM&E/T%W:&NVRSPN'%57Y&0(I F150:8*D%4%F5:%]=8U*PD =\KM
M,G/HTR[(L5<OPAWNKP7KQ.+:O;@ZFQPJXS.26;G>\[OGDO<DI!'14K9L(28-
M_=%(W$H61K-:'EYGI[1+ZH<V'FQNB'8'^(<-J^"_+RD6EB2"5>QCJ/=P\*$N
M*_W3-#)L?;M"06JM)[7AN4A-$:0F2.VJ2&UT%%*;V6_$NOD/\4LF^>H]%=U9
M(U51?Q5D)LCL*LAL? 8RT]I%9EL,V3@("=L@ZZE27+7N*@'>XX,WWQ>Z/!8_
MV)X4E*^RVH&9[5ANK>Y4;IWG#6W)$%!'>N.BS/IP<Y19K*G):QJ+#($+SQ"H
M%*:ZDA.]G'BDR! 0&0(B0Z"A(!,9 @T,)8O%7>3B1(: R! 03M[C.WGACG/%
M+;'O0U_61L5YO$WT] I:$[1V,*TIYZ(U7=":H+7KHC7U#-'+0;NBEX+.!)T=
M3&?:&>ALV"XZ$V%LD270WJO63(_.-?$47>/KZAH_;D/7>-YZM=E],#9TZ5P4
MW&]IAY,UC3=WZCZ\:Q/A?EN:"(^J-A%^"CWSS[GG@#0-4-Z'[_B<#4/0]=ZH
MT-H7/BLV%,X^^2\2>_8^W839P]LUY@D'P,,&* B:TWUH[2;*B?)ICF,.?I!G
M'.3#3N0IGBW8G$UMW,)C9N2",I1+IAW%S?7][#:3$8K(7+Z"EBL]W6AT0'<\
MEYF.QJ$C*#9!Z:,LT?D3M+D/=L6?S>@??%!>?JP6MAY<XI^5FFXJO7ZY/D\G
M9N(4\\<91</;*)QC8RF@63ISI]AD4^^-L3*E5S+</&GM"XLT&6X'^%#:7!KV
MA%V'^ <6F892@.V&> =3/H>0-5S$K? .IENA1X?C 838."[LL.=E)VB,X^.,
M1QI4A)N^&]Q^D(5ANW!H10!6:F&J*[UUT,TW,?7I"S-=96F+.0.;<6]HU]J@
M)F<5V<QM2-'A=R:\$?)!VIJW.;O:QF>>R#+DC$:G1Z)NFJ%,#S1(QW;EF(M7
MPK7X,*X\=#ZR]L$_/\/;8X*3/OSQ=/M1^O;M#A\9OX:^8O.(99R[01D4'S?C
M.*5L*I@;/FO7GLP(R3 $G*5'>R*[F0[%,=OCW6?W972#S>V%,S1[Y[F!;?&I
M?#]X3]Q']V?:@[8R\8(&LIUV5X:+L%$9'IL#SH>W UC9B,+-8(P')'+([=(R
M/G[.W&#O!<O+6GD5MD/.O2:+$27XM7$DS@C^52"DK7GAE)!:/-KS,0JQ"RB=
M ?=/+O,*^NT^S1'+5?3X%8_^#UQ$<?*'KJAM;81(Z"YQZ$X0V#.;6*D2@</?
M(]^<&W3(5 :5:0M$+W,&FZ3EIU95'JBCK;WD=GV4HG5U97/2^>D3X16U.QR-
MFK:H$2Q*:^*B-D-JQPSS+5EA+4CT?*)BK;Y4]!9L^<L;\4V<G_P=%:FKVOI]
M@(H*SHP$5>JJ=O[E;6EST[BP]Q/E-)\^I'F7$^VKVM0>2<YKLUDWP:+I\5VF
MV1<MI5QKD_N'KX48+RI6CS.N0G(-,J._[F8=]5)-4^M,5&TH*X-QP4"J.S.]
MGH.^B.2%:CMN$V*#_?^=^%3"UX3=L>BDDC/Y,K&>E#*LQH37[NC@-CU5.=#1
MTH*.71C0 E;Z=\.E4W85ZCU6!HVLFVD='-7!85I)>2U(\UAS?5K)]ATWY* K
MZQZC4^L>>F<R&,J]DE3INFMODOO5:B=;JFPT_7PWBN"]#GD?$3RH1P1O*#8[
M<?[M97&'WW%:#.]TL*<PO4I8'2HPK]:,;_XQ5Q:8XX,%9I%MXKA<K3@M]6C:
M[B:!6')RER<0]SK$?03BJ%:;M&669_.I_W;IVXYTB#R\1E )^U'8CYR3*KU3
MVX_CSD3MR>.2=MS"?CR2N-SOD/<0ERKF7/:[FBH,R&:B3](MCZ8Y*B-A0NX.
M+56_8B-2^O#ES9P;[C-)DNT^"L,RQV25$TM25>E,1KV^/-:%Y7DZ4;K7*>\C
M2M7.!+,7BV<K3,]&H,_?(Y=(6'4 DF&G_IK7"ZH'SSTPCZHFE:/-(>"*\D@_
MM3320/67%:TGJZ.:Y%'->J:X/]L[<G/#@L86+E35RM90 :LZ1 T7$UV)]3G"
MLA^0^K9GL43G6$;'HMMZ(.'6%BP9<NA77NNZ/*OCKU5'%EU"LZM5J3M6A9!X
M&9(5);6X[\3P XD5W)47B= Z.*R]J[.5P*#7EE8"XZJM!-*F 8\S+$8C;L +
M\!PL?[OS@C"@^/$;]FWX;KQCB5E)W9(Z*#884 =K&@Q(CTN*R]\=P]VKNP![
M<LG[UC?,:&;]F=I3QM*]BVGK6"M]"\1A<;!L+ZEK ">]S];0XF986>-O'N[#
ML#SXRF+%WOG>($&F/$XREDO?>\$+68$^@ 1!T)7^ $+W\Q_*O B68((]";#F
M,KL =2P7ZF.?D=UPUN)1Q MD_B>^&;@EPRVJHL%7\-@0,#%,R^-_//W!*N$]
M>+8O&7A*E'_9H.6\V%8$W!;6Y4E )_AZ5R*+I>.]$RRE]V8SL-=\^ VP_";^
M0K)@^6;HP?8]'S$YB)R0LL5\'Q7\%BM @V@:V)9M^#;AI?A\*](S<8EO.,X[
MA\D6!H %ABM%BTC>M"U+E@'<(I=^IA6EO[VGEW .0!$U+7)@<B0G+0"CS$_
MNE]!6PZ(FS**86<2 H0H*U\E?HDVVJ'[MU@1,C\]VBX@E0JT )"7O\+>L._
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M&,Q^$$ $X')?/?]KA.7F]YPP*H.LWYGH(':'92;<&IBQ26]TV&,9;791^"1
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M[IU$+UE9WZY%5=!:T3%R6NGR?M=;4N(&]=_T*+Y;ZZFAMV)BY);6F*@_]-T
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ML$8;0*LW5! C$Z(.J,GV1\= T70G2DD).3DC/2;EL75OH*N7-[L*]:LXR$Q
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M!I4CK=-J*QY&(Q6UQRAYZ]7S@1"'%"P,BG#'J/!Q>+;V2D5PHXN#[+& BCE
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MM*F0 <0@R#NVOFKZ 4A#JNUHRY*6NM@SO7#Y>?TCDAW[Q]_^+U!+ P04
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M-VR'<0%B6:QE Q@-K_>OO/KP%_H["O^F^O:07!>S=@$GTQHAB'8@?*$-(HM
M)WZE: 51]%-;,MDF#T&!=]S-M]7?-@)KK+??2%)GYV=+(B66?<X&#--U!^&L
MUE_2-"(?37%"I[11,N=]A3NOOO2PE[,[BWW40F:- ^=^"]^O %$AJQ"B ?0H
M@0Q^"\'5C3L4521+QL@V55>_/VCE[2RS0]QP74W84[Y$;P0G1+Y&"T@#D<4$
MA@N5N->8N[\\/VJNY'$3A9KIIH/[CLL^DR_"Y$O/Z6)XY:Y*,M?6V9)6'YM
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M?H'"B&*,DA"\XK3\NPB.B5K-"6.IT74F/:'NJ%LI].[NJ-L(MG$8S?J69IN
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MN,E:MD6;_;B/8UKXO-8BZ40BX!J4<A9<RIX,8BS,2LZMUQL186<(CX(?AU%
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MA:*-VS J^/;#'X4J]Y19!XOSA6'S_,>5$_'K,9)Y,DP_9HN22DF)6@%79,Y
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MKT[(A%-(' V\7O\9)JHOP6FV68W-.UYR!(6W/^$TE63KB7X%UP>L$JJ.S9L
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M4#)#JW1PB19MEVF]]@C)9)>=P:2:WZ:M!7,TEWPK;=^\LVXB]0YLY97 %EZ
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MPZN2PX*.5+&=@6^:NDJ:-;0DS,[(L$5:ZGL*53_OF/Y<SRPL;JAV/P0/3G8
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ME?:>EH[QP$RNDP8(G"N=7),H'!=5*D,@I]0@WP$!.,U,[@>X\9E6!U_\'#W
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M -=+F"N&Z?"!KK1/N^+. TM/56@.0H^5JFMW%*E,/TR/?>!QC4LJ?/^19L*
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M]<95]<N:ZOW*;G=]QAV$5%4D6]C-59WX*67P9D%'HLQ!#9C[#/W*"MT.@9W
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M*^9"5[9!#[_3/Z;VR;\H1^F<H(8IK,0H6NHFF(T:V]@CDRV7L501,!$YQ[O
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MP \1X)YD!']]X(<E0T],5]P$(2/BH28%+_NFW;_Y;)+'M;RZB7Y!*Q )>LF
MB5;?@'0*%_4M&4*RI#G$3.<Q!92&Y4D@:]-V8E^+?'T*LWAM\5W^5O,L__J3
M]5-&H=+A/&ZN[%7)7;T/XXR?7U/'WP'"B8.9(<>@C"X9H&(Y,*7!3UC\7?'Z
MG_!XNE2@CT:'L';2R($##QJC&Q[\PT0Z(OMK4K]8FV'KHI2>=N5$16*Y&2[X
M<1DUJCDW^\E6]NQPE)B@\[5R]]";:%4UL] &A_9&>-C,RY]8LEV-CUTF576N
M@YWHYNRKJ[_":7OO6\=-&#QXU>S##U?W'O&)\X;(+_9>7K(<A=U?I!V^B8,G
M0@+9@+#A7MSYW,#R=5STZS!J6-B+:JN%GA0^C[M6?-SW3[.!0*#3D3ZD0IHR
MD$HM)><GA*#.TNW%N69T%5=T(-RPMNYO<U;S00C1*L'= N-IXD^N/7[P9;87
M$40H5>NHD>Z*)F?0'?XVU@,I![US8 J3JA(A+(Z^!<_B#[._=B:U]R:>=6$+
M?^NI?=YXKZU(V?E5GH!>C;N@TWW;-"DAV=-\/I=W1F5DJILP;I/VK3^9+NB(
MT=A)1F$.2*CRB'?[A:H@@,TRL8ASSM]+<\F[Y./HX_3V [1O!L,LHOCE'</N
MN8!=K8RJY?*M.LHD5P*X<=(%J3C!D(3AV9%ZRG0$>8GFF"(7"B^;(F R?/M[
M1&#./XZ*#6"F15\>_\R$ 34T0;HR\ZJW:HY!'(E$$2]RW?/Y_?U=S/?PCC#J
MP<=%XQ37M='\X7^\HTE=ME+)(I+Y _@379J#E)Z]%4@W-+W-(J6@)6%K/QU^
MBR(0[SE=\TMS;US:08ZRV"UM416DL&5;W\+SN5G(X3> IV>J("'IKAL8+PU%
M4S),0\O&3L9+63C5RA[NN'3P_9#*E8KGT)6B7:<''C5#/.LXX<[@-+I=K=-_
MSL>@1+H9'%'^ALO59'+(T_<-AYD$G!*J^N]V[=;=>)$1NX/,DXS/X ;+>.35
M\Z]JD +?D.8?]-:;++DCVLT2;::;%/-U2C\5+8=X1TH_'OLN>5O6[\-G/G74
M=RUBZ>#6Q#)T?F%9#UL)GXS88+BY#'1)[YUNZF?42 U*=J2HCX01/5,NBBJ4
M:3CFNIKDJ]JHSF]29Z<[3H%[P7PQ"\+(O)IFQ9V+, B705EK4(#G9>/)P&:-
MSHXBI]U)K]A7,0[=CYS0T,U@?Q6WM-[IM'IM.[LH#=]:,\, FYSM0I/K2\I-
MH2'TNC4P7Q<O'%+O\'G!<GZ<H-7W)F#.#*B@/!DW().(TT'!A$WV5:YPONJL
MO#T0_X&>NVXK7VU+0F0^LJC)AYG/I*.D_?$3+;'OC@J0<OX% V;!P7H%#4OQ
MC^8O4?8>B0;H>/($6&@VD 1+E^L V9V>JIWY9\RJW B-#1UUN'T,>JYEE6A'
MAB;S$$9#R_TFAJ2KD!O&3LEY3DXKDE;)@A)I2?,*P";5[JB,H1YQ'OP<+(2"
M#X>3?\SBO2B\1>?)5I._S?W LC G%>FV3RD7=A^\=WQK%_H#K7#=*NS;A]4F
M7PM70"^$R'>V7$ P<)1W%:[8WIQ7;V;.HP<C'PTFZ\K0+B.O @ME0,HY75ER
M^<H>#D -AN?W1 V2S:"CY3H=SP/8& ][)@PKRP0?2H*L,_V/RKHD%NDFP$+D
M@\IUW'L\NQ[K?X\CZI9EO\_DAHX^E#N]F)=W2OV./LM#G4F6K#MCW]Y7)L+J
M7($AFBQ=#RBG*4!CA@HBHL&WLV^W3(6$&V9Y/*!&)\PP?+CDTI?34QI_W7JN
MANR;POKLS(<SJP%+S&FM;H3SJJX5[ET;>D"XJ^X!-^J"VZ*:QLB<8IPTOGVX
M]Y7@W0]I.RU!E[I('#!/IU+Y(VN7>>W;7QV6'ID_7HAQ\/7;"7GMOC8.;11/
MK :&>_,@&&S_^/>Y?CQWA]<*NW:H(]TL4C7Q?=-4C9=]'OO-:R*=]X=@<&&+
MSYY*#?P^V2S/S6+.?P1>T:[2'9CPC>U!-[I7$,#/7R"56V="+<^9?( I<LXE
M*8W=_7C;*_11\X"9QN[\BTLZ1FT&WF<'.P$'FGS,+/24GL@0V8.()J%*1XFT
ML$^IO2U=<F1VO%^!<A7'[9.F^1/]D!R]]2SE$I$[D0\NF;4-;EW98XQU:0).
MQ<A_.E('\-PE4,"\2V;CB6MX^)-"'OZ[5[;O9G U'N91;HLHW!:AOT*,#&J]
M?"-:#A95UG.VM9-X7;NH$;F+F?3;=AW=#,MMB3ZOQ3BW3N-!GB0/;L43\!>
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M.V\6'<0UPTS#=4.+,(SH3S3B9T!32(V@^1Z[9;2P&(?;7<6 Y6,N71IQVFM
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MCJ-</%_4V JBXU,C+T>Y <R)L4"^5^&OA85.+ZGBYG[!2+T1[M7L/,?3@[0
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M<"2=-US8WUC E&1B@ZW4;H[=.33-1XP=D. KTXV9&UKO>3,&$A>N2-VR!6?
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M^6!#N^RB7'[V)O.F<'C'1CDO7"2IQ5-N1QZ&':?I)$.2FJ5Y.>VJX?'!AMI
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M_&B 6 ;8>;[GW7I"?>!JR;)'([B<F:4$IBO$-,=G&.)M>7"O58;.1@*M\JW
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MA<I]RY\8,6B.04/-,;17[SVQV;3U>M!&L;DS(</IH?4&;^R+*]+L*G:ED-%
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MWE?=_D]^]MQ>:](^1[6\U.TP-GN6_8%:[JK2"AM4X&^H4(D?$<[%25S,LB(
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MIN7-8=&[LZ_-EX^YYYP]/=;ZH830<(#A[_086LX03//1^YI(2N&P+5A;:^W
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M9/.]M:CS34E!+E1A[D(YIVP54MI%N,.(V"7-J--CL3G-6G<M-9]Y#1?D_OG
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M'TY2F;QS[C6M,V\XK_K%5!C'!KV^).>1IZ>6^/!B8&[$2W]7QX;K??DTB7H
M#]W_>$]WCUMOW$M&'+NY' 7+Y>Q-TWOM:1\BI+? 4\?V)CZMK[=>A;S0E5V
M+&<8-H>L0C"PN/ZHD[;EV/O+@I^<9DY)[8- CR2DS9Y7-%1^]@!S A'M$!$J
MF-AU,._C((M=E'!O%3+RFJ HVRG70)')?'9-3>T5!RR:+M!RIL:EM$6G/N[^
MM#;OUA#E9[K>_<XR^NLQC[M6XTD )HX .,/BN=L/2XX69$5N1FX#GW<ZO1<?
M<EV.,C.K\![<,[--E[OG#^YNHVJKF91]0.E,B5L_8R0/NCD\]F#W_/!<$ZN1
M@SKIG_)] (NZ'!.'/N=N4/EA/F-]9-6SUVEJKP+9/D5:F-2[UO=>T[F\58C
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MUASZFZ&Q8+>D*D&H)KK\K>Z(K)M52N+#UTZQ^A]4P5DWE>_,&Y8<<RNC]QB
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MN@HJ7<E9.8?S#IL7-@:#<%FVQ FXK:[% W-NU_R+_=1>JN@3.8&[RG8GM,-
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M%GY<IZFHG>(V#4Z,-0"UUN(!ZE#.RKDL.;Z7=35QBC8RATKT#MYT<5Z@QR#
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M\D@8=LY$?S6)C@;'\!LDH$Y$ZFPG83?6FR?;(3[57T44RRU%.L?I&SD.^-B
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MT$R]CXO>ALZ5J3E3L0 ]3;H.Q,TFU+V5@'PARBU*'#F>P@6N03O*WOV>!(0
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MZ8QKB9>&;C1F=766F8I^+4AWY8Z%K_?XZAIU<K]GDP%HB"(C[3A%K1D3\A!
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M.FFW[(N<GZZ6%X.P%1[(K(B:/@?EH9*^CU)/](&N&9[DR_KN6BOZB50#\.+
MMMZV;/N4-J/YZY!NWU)/4J--GW)FVVQ)J@QD,.C!Z&+@1;!Q8@\O45-!H/J
M<H!2^0JC6X_8AH$!KUAHQ<X8%C0ANN@AT=H^8*^)Q_BE?(VG5?FH"K+WK:SO
M*F%CU0YV-0WR, 9;VPD8PH+W D<9J 6_WQ5P\ 96W\XL> ")+8N,J!QK CBK
MR<@_X9QD5/%3O@OOU"K!9W-L]RE($+9GW ! A?#U+P[9J'L%[ %VS7OD%I]
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M(+=2X&.KTZ%!N2[JX5^V_H"UPE*P:H C7]2J>92VG(N"M8SOK<P1N9"AC:'
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MH7]U$G+NV:0"B8+*9M@F4]0NZ=HM!Y@2D##0(D3=^/G9+2JE=F' "D;5PO0
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M=S-:HG@_[OD/"^=N?XW.(;V!X#S"A60W1=>'06>LWY2\6AD2^OZ[N%>/V I
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MA+=V_4S!R_EGNW-3ZL-AYNK2GS,$-"HWMQ0O>NT.7Y^-7O&>C9P,7,_4+ %
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M,M 9(Z)<8V7)@;HS<W5$+C;F) W87S%1@(3/N") MWEX>% U9RV%N1ST-@3
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M4)?+QZ2J,6BKB[.<H9+GX=N]L#,C>[16]WA$.?L%>-GP _21;#AW6K"Q=?R
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M52*EHDNXIM-2F(- U"$4XI0/ [A8_JP]OX"RNW+(^D;1[1QLJ;!AA]MD7?W
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M#O8<D8*JI*#Y[.#"&65'_D9!>&H?369G*R:0*-O%Y5$I"/\)#A#"HEZ,>J:
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M+N^]2:[+G-S&L-><.?RI[V*E3OE8V?!%;#UF5$6R5?$MQJLY23N>KV;-X\I
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MI2'1W=N!N!97U1OTS&0B2^'JH1=^B["U4UD7ZNQ#AQ7>7: >_;P:]X4\!]:
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M;EU#F"P-YC>SD%#6=$MV0!MXEP%1S9>X=_-H =GGWH3SEEQQEN9]*U1!:[B
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MAD"+0_AF_3J3J+?H6\8,@;CF$[X'-RI)F]QG'TZ$9$V*GH.8 *8]3G(0:^J
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MY1K?N_SVV(6@6Z[N+VV7])$O!QF3,(O;:[O?BZ6@C@WKKZUP6.QV64H6B>R
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MRO'=\ITQO,7%DXVH!</>6@BCD)C&A>K[=Z65707[]'@^%#EBFXW-/016PI<
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M MFLX$;9A0$SO/TWQPO(D\;'"Y;HTXCW/$]")\ 6M@-V_&[NKO_8N3;:7+K
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MKX03&]!TMC%[O.!'H029.;6S :(DI;564A[(7-PWM]&1^<%7Q:.^D3Q4M3#
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MS)NZ>K3[R9=&JDKT8W7VZX93GZU"U!H;-:X_^L&+21TR-EZP^9G ?*_P@ZV
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M($:E_LKZH&Q*_12C.Z.7Q6R/W'%PVS*UHW<T$PJDBJQ0*6VT#,SAH;HF=T[
MAXE?\ZOM:7"S\F\+&4[)TP=;C6JKND_2QDD)RUN@T;?"7;J5XBNX=LPV/K6E
M=Q?0T&U+2&G&R IVM!E3 VHBBW+N7& 45F4LA_>U$W:ZZN[_)P-1+K0^N&UB
M(VZ^/:Q,' 4\\_PC'_#@Y_R9MFQ;DR>,["[O\;M$ZW<X_W?M!3?&>N.1\:P"
M\O@6Z&QZ>3?:1*0,)(.95I<%Z:36JAC*;]&MK%/#JSVV'9XJGWU#H"KW6)>#
M2Q^&(*=V+N^A[^LUL#<HSH+5'PS/N3-?=FI[K]A.9(JZTPY1#J:JLABSBUR+
MPV=#:ZWQK-: LL;JAM&32DM10I$ )PYV247[;T;G")]OUAB!#\,9O?&&BS(>
M*"5F*Q+Y'DB>N_:9DH4,*,JX*/EQ*UM?[V[G#TO$\ KOX#8^NPTZHMBQ'Y72
MP=K'Q\625<$OR(%<A;UPE;#7 48FL:)FYXV[*F@YF#PIK<-1U]^$Z9]^R'-J
M;1*.G"1C_^=8I9ZK!1 X/#E'/CU.?(+;I-/V#0X/JRPJW$-GI(O#SCL^]NP)
M\#_@R+;X[A"HY>E55A#IY(JU]GVOD+R:,L+L=*$>%=N&9JB#H0I0\<-^BJ8[
MM/(]*YB6"CLW>O\+?QUZ-OX$A;-<T] C-G,C][I+9>\M8/$. !=H6SOX_+D%
MBD=,YQ2*C5_JT..^\5?S2)M$FN+U_FO'8:X#O:'?G+P^$1[AET]@8AMWJ&81
M$U0N%028/7MJ\6O[3_V11*$_7;(7D.'N86SFTG*J4,MN43?N59*MU:L-8_SQ
MO#37PF0&Z\2[35SZ56]&:<:3<7?(-LOM*#K'1ZRXQF&WVGOX7.U#(SC4'3/J
M:I^'O*LEP[6$/+E[#SX'OR9CPKK2>&-7%ACW+BPXKT6<VCXUYSCR;%$8M9E.
M=IU(>65*_.#-=03/;B.H/9/,')?TFC@>=2$)A7T=Q#Y[-6JVH!VY)["NT3YJ
M.J)]$X]]= IM-=&[$Q76 OF=HH"^VF>NR\G![9FYB?K(J5@07W!%T%CN,'(\
M-5A)G^7OE/GLZE=V!*7QXW/S'*O-;(34G2Z@[#F+;?+V=P5W-_12BT=G3=^9
MY@['=!2&('_K6,YZD'81$^KLM8QFKI>QZ_2;$Q.E81,PV8PYR*]Z)?9"(-0*
M/P*1[<L]1LFE/@>KUS]9M*XGU_X]3*X?LR-ZO&DN'Y%*^5<KCB.]W)Z4%_@%
M;G]=HSM$ 6TS8.[*Z?UMUO-" TW9OI;TXGUC4LB1B2=)A3!/IQ=6;3G&Y0KG
MB0L*(XD=F-_Y<7$A2=I7^56OC;9 N\50@4G;D6"=Q*I:]SEB=OJ/"N)Z3M<#
MTLU6[)[2)E>G#Z.I2S6;'ZQ!Z/-\DD2VEYL+AM8/B2\7H:Q"JS@0U='<"RRH
M*=VJD4Z 1XY4O/=Y$Q"O:>NJQ6C,"56&(Z!Y$%]'$) X$1='0+XR8*!,VEFG
M@.>2G?]$E2YN@4AG%_P?#LP7)G3I5]>Y?-)Q-><&YQE%_\@MW YL@=REL\W#
M^BV.ZMS<S*?Z@F-,&7 W5MQ[P%0>9J2:I.R&NSY$&K<.^*OB66LLPTU[?%F!
M4W4::/Z?!K$TB>JLZ53<?ST? *MVST."L%8Z_PA!<))PQN[]C[5,N@&T\=O!
MQ5#2!;^]:^!SZ2R&'C3T7]&S!!#@_N=F#.6DV'(S/[B1NK<H"QPGGCMB?KF<
M/6<7KO ZAA+;$%@ODB9-W:*/WTM>ND>^2^ERS(DTT'QX3RI(3"4G?^%V5J%/
MR.-B]+0$,LT0693Z])K(+K4BQ./(@OGPZ!3X@JSSW%3JO0OKD OB;NC[H9LR
MK>Q#U(EL2UT@2Y#"73&6'!]820&A,B_3B_D)+6">F_[K5>:N>?U*UX,[1E7:
M#<NZF%FK]A6;C#GL1!ZUQB<1(PLLMWF>$.1EZF65>?JZ^<1]>"*XZM;)T"3
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M:Y[OYT/544EB6'MT;3TD0N3F<C1@V?0P.:$X^%8ZU:6B!N,-6G=V$U);Q,8
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M6U%ZTUN*E[![TA47]2'*-H)#>&I1]?N?A<X5<D30U6O,.5,4,LUV-FF3%.6
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M:X!_ ?IJ74U=VLV'$RIR@^'(2?,(*3PV^^Y8PO=7;BK:F$':=LSA6:&7W"Z
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M57>WT(207#I02=GRVI;VS.;\34].'K^ ;"D<99DR3@8^-Z_5,W4_DHL]*C9
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M$[X*GWKTS08Z6KW)4H[1X)\</]LYZ^$_?=9DR4I]/D/0U:HR(N:"Z?%QG7L
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M?(L4H^= B_(PB_RYD+;0 "MX6RMW[G*ID= OC)$E9V^ VMJZ-T I15-XWK"
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M<=VIB[6/-EYDYM-B,/R:7=&L9MXT:%)7D4#QR@7 [OR5E<'70>RPV6'/)(>
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M_/R_+QC_K]3BELA2_$?W)L@7'TT:._5MO"_PAW9=736ELN_=?A:"G%;S&16
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MO7WVIITKO9GLFMK]?->2$C0347KL:EM*.8_D8E*-4J6N8%VXZ)AW.&^6'#9
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MU7_Y]JYG6<_P1G<@\_?+CL%*TZA?SDEFCNZAI8;2>#M$^I\%Z5=ZCWX3WZO
M6N"O-V2LT:IT2_5105*9"QL%C,4Q7V]SZA]?GJ5*'GZ3VMK#:E;KAGF;N@FP
MC4M+M#2$*V/V]=X!DO-_;(E<T]1]>"VB>H,:-5WWRR7ZWHJ"%NR?\WMHH7<F
M_=:A$NEP@7HO1[O%(&G5S.>%Q8Z<X8(&3V$G^N/8T0_]6 A'#SH7YJ\"/KO[
MO@LG4:_'.^I:C;B\A>LGW 0]W^JX(BIBCWAG#+LO>!%3<MEP9,Q/CK,S?A%U
M?V9F!EJ?F9"Z.* 5JG\B=%^?@_LFZ'1Q<?PR6 [C8\</3MB%ST,(73TRO3./
M$FO(SO>B<'6Q3T\GOWTK]P7/<)WA6@/R(BL".<,DG>,+0;#VN-F'EFN)#MTS
MI1Y&'BZ_LJSW,$UR(V(KPZPICD;TP!7%"Y$TF16X(O8" *[02A;4-%6/S*CO
MW@19]08"%L(V1@;TC9#,0GV9J0]S8KKB/^*D9CTT!X-@77M_K YFGXKN83F9
M.LX:/4EQ)>!]EHYC<XTBD.SX^=;^KO;ZJS0?UC97S),IVYA&2_F8:PVOM#Y4
M)U\E0\/BY.<-"SI+Z21K$/:=*!333S7#8C;2"P![3G),QF2.14 IC!X>N@F2
M;] ZK$S/B+0(.$'XX4(ALT,22W^P@BFO)7MDQL%Q."(Z*1 <">:_8(HO]4>H
M83Q$+:YS8[LS!B_W+N/VP\M:"IX]/BCA12 QG/H/S$ES]&+FGGKDLF?3EG"E
MG!GO@&&6X?M\S2R4R')!!YVG!3!=0[-0]/'B;<0ON%/^]9BR,+M]/?1;]11R
M#2EZ9A/DZ?;UU6GHHZK@ N',D,>N)S>EZ!)I8,V4YR* "C4%[ZLEG8*(=UL
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M-577B*0S%%Q7.N*T^KB]'&BMFX9-;=ZMADSDV14130\4\8>D"W*8>G0:4K-
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MF]FOQMD:>HD?JT*2#PU3IN8ZW>R]H;J[\G_VK"*BN&;S&TB!TDW *<B@.#2
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M=7F#_M7J),)Z>; =@.-&.C[/9AW!<_=0(SCE?WTZSW$U;OZYEHA,;,Z:.&<
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MO^Y23I;D:6>HL7CC*:3*1J6'$4%_>L'QZ$R8_^8Z+T?X )&+FB\6."^V0U2
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M@H<'(E*J<O("-T-*[T:'XW/!5SL[*=99I=\_:CL4VZF[H3X"_KXA+N\+GXW
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M:>P%%W;WMY&ZPHP$KYA9>S'7<:X77-KTSG0ZX+;B>)")OIS07_G1I&8C ^G
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M;3GAUJ:T:/^^D$+T-6&R0#;[*#>U\,,$4-R6+5--X!YXS9;XFF807Q<S''J
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M,3S4L)4HIW_/0DBH>UC?,MY>%#[[]]>>^D=E>Y;3!AON\_W0YSDVB4M&AH5
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M-M$;P&U=O>F\ZC!]M8AV[Z-A>O'\D;N'=RN*[7P&_H]TXO_]$$M#(X%P%OT
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M<T0;[6)4U)W!O 1S!V</[HLPFY4/=N!N9.U*N.#!KXYO@-IH.Y1BR%0ERWM
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M]GM/D[F[R_"L4+$V/?W497AA8[B7/23352_+=4?M!;/I;]9V/@G?_5=G7+_
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M1PAMGPVVP'KJ2+]5_7CY&>$<2$ #8O0_$* /V< ?2_/2\X52C51!^3#70GK
M)GX=]/0(2E;LCIR9F%"]_P.Z'RE[0? I2RBW8>-OAXRN\:-AX.KF?G2)WW,/
M[45MZ$J0]DK$]Y08WN 0R@6H?_.=7>M%Q_TRK;45L:?E#<RR@J#ZO/>+S^MC
M61?R_/G&O%;^'Z62H.R[)R#_OA,&&$$PCS?AECYL)Q\N 8_W_,Q+FX'2L$N/
ML*NCN-C\;1ZJ/!##<K?V?)*SK[9^TK,!D[8.(N&7FS#IM%W6&GADS*>IY9;(
M5NGAQGZB2G8/_1<NDF?X55ZH??YI@,NDGH?ME1B[F+N&_]G<P/^M2?@GIPOO
MN]>M54;30&&N,-VDMA0CBL/+CM1J!UGK[.$_:/HQ0V*KY/?KH*N=$K.99_^E
M-?U#5^G_K_?_RGJH-?%EZ6>THNUV@$8W7Y6Y+Y$CA&PP(IZU76!D*3)SYL.,
MU9L^QS$=Y^"C%8$=Z.<G$&&@X'^^L].$!:\Q6FSVW59W (5X/6UR%0FE,VX2
M8HN0=V \Q^D@<D/#_?D\![<:<(VD^@_FX\%GJ"0RY$ B<QTD9WM@S-L>/SO<
MD-#"QZF4Z]SZODRN)3O[9!E#3J:OR<EJ5\YB('R[9=^[)_YAZ1N\&:*%LY-9
M&L*25%-UPFY*K%2!&,^+[G=MB/?74R;ZY2]>-;RIW&54GXC.XS^JYN&A&6#E
M)>@FR:&\9JFB8(YE2LG>$PF#*<_XO.]]%KPXF>U&WDOHBBFGC6UR!?UA]P_^
MUD%0*,H'*]KN1UIY8NBY$S#;7P7G$X_=^] W-D54YR:[51LQDU*ZC8X?-:CF
M0_,V>91G;:"2-S#DEJ:6\H 2-)ZOR?9SVSF*K/[42?>=#:O;77&\3=';WZ!E
M;]LMWM'MHFRG&UC<&/]W6?"_[XFG\]H[E+.@>#; +8TJUX>R9GC=JZ3$[@UI
MH,^XV\,BA(6,J^5-JMA;OE>N,'QT;F!EEM$6KH)@4;HPN5 8ZR9 -"-DOE.5
M!RG.+UVX&ONF[]!G+M5>;-\5J])?TZ0RPA6?<5V(</0*!V.G0#W_" /4!Z_N
MVL;_8[5&$U$24 AYWW.WP$)8&W-LQAWI=)HZE)3G\A7?6U?W!&%(E1^=8Y)E
MIJ$F*,,-<O,"2.OQ$QP&J@3BLP+'^T*+#UBJD4"*?XU,%WMX,OK:$3<SI_3N
MZ6<DD?F[R-B?QX+R_AFQXYQ2-N2CILU; >Z!K0[0-OXU8!^@/Y$GMO+3"$4Y
M8BU)V*U?T[*Q==D%%SWNN4[G/S'16Q(/OHS<(,HZ0G8ZU0KX9B\ ?VB$M.2"
MZ=#=&'F8RK>6'7 N[(,US9P_[!8BJMTQQ=^U 'E>"FC=M0'_)RL^_-\/U-=H
M'+..J_#PU<]H]]LMZ 1YV&44^.=1[869@G]_5#M'8H\826G"*:/<!#5TWPM)
MPLU^ FG>RZ8@[AN$L4ZZ.ZXSKMBSUB'CE?\C52/R8,CF#6GPW\X+YK]==966
M8NG.*)D'Z&!H)LM(J)JLU2=Q$5A<;?A<:6HZ8+$."G,6T^96]DC>=F #PKU7
MY-EY\_ *\XV^W$?Y"^TV5.]>Y&8Z6Y:RQ0RZ[?NJ<6&%1E2;0O&*R8Q*0?RI
M?6+UE8++,J='T;*_1[Q0</UGJ^D_5\"?<"/%EUZKJS]FX*KD/G]VM'3TY5L+
M$+OESQ_XG:"5^7\>X=6]:?^3ZFWH9IP*Q420XE+7*+2M+PDA#1_'-]8W9%VJ
M+$:0#X0NO_Y+=&5K8^GFC_\T+[FS(KJ FB<,;$E4'3PX;/H;1?V5;6-"Q8RG
MW<W^&W49HG.]5G\M&,('[X4C.(')9;8Z:\0?;@JHBPF@$$T]:K]A=(8%?37E
M(7R(+;9M70==]/;MV^;Y_.K&U-7Z33[1\UA\JC\/![7]%VB?MOC&=]8Q("_P
ME1-G7LGW.V.($,]9 S?7."#6L.70D51J[Y;X(!.()'X4'IQZ2?I)[+P2&^\/
M0BW_\_J,2=1;*[.&<"",P-. SQL7=#!78>\TO"RTQEI[+E;='SO'BDCT26LQ
M2+JV>-16?I)Y:1I,I-TUME:$<S4"F^_$/@B'$!/L'4B62TN-Z?Y7?0)<0P^[
M]L$1K--=YOG,F*^0<Z"O=O]VJ GGA%X\A7'P%J!LF+[Z+8.B6SCK5=6FVYC$
MQV^QN*R30=Q_:=3$P&)S9IB&EP@+Q+]&WK_:-RDL2?*Z+.A^79>+QXIJP:']
MKQY&Q#XQ$C^#=/[]9]V==="=N];_!9N9M567?K'=";R13XI_/:MV-5<AU;3<
M_P+='>M.=,CA1U@_Q%,()MV+YW'ZH\RIQ'DKJ2]+6++17[N4F,51F-1<4)DB
MES\OBF[&KE:H="*B)PVI]O.1)#>C7A$N#U8>" ?%$?X9]#?TO:KTQ,;G5HEZ
MT>PR=_EB_Q(\T*47S^B\P?PZ #E4>\\M)PM%.\[9\;M;YV>+<] T7*W7/>JV
MF3LW-(\)MV*2+_L$N_CEGZDU#\)&3,8G:UZ!+U8JC\3&=(/B:/_<_@BR3O3B
MLT1;"'TO55)1FRI&)?R:1O>H)BJ\;O9ES$Q:C*IN9TX0L;(J(G%%DT=6IFHS
MAAE%#U B56/M^X@]&D6?<M"5YQA[ZIBP:X%'6Z+^\(V[+E?MR%"6M;(X=7(_
M]-]CK,?/QQ\K4!-0BW2&5BU2HPGRT]DQJJM3C4%*X&L"B6H9/J*_O*/&@C^F
MBSAZPMQ1G*?,K_TO$346*@Z8PVWVHN^!I)BQE<,"C(;LJF[/RFG/E9L^E?5+
MKVZI#$[6O:1106M;)@E]$@^L54MD8L>O#$OL*T> G<?>C'ZO4TD\W$AZ^XY(
MK8-7O^^>,CU/GT=ESG1TO.?>/8'^!QHUL 3.#)#KI2"*@+#%E@(UHE"^NDRD
M%M[P]Y$X5 89YK 'SB\)# PY,1(0"^9]&T\85MD+];'G/I= HKC-GYD^;X^[
MPA1R%O#O_V;R;2^;3QST@.;D>/B!E/YA6?G6 F\XXL[#P7"$\T/G.[D^E^,5
MPQL3WM6.5GKUK+1]?%T34TK9+*QI6@<I+1F=:Z,'& CF'T),XZS)@.G8.8,<
M0W:4\8CR#H-%;4P>^-9=Z_+_E3W__W?J+1)&UD&B&P+L7,N+F=7@!T9FZG[P
M6'>X[](\T0I_+CZ].&V?KV-VG,8Z:+!I[]K\.,'A_[C91=B1^%$1L!?5#%-U
MP6I(JJC'H]^0I]7W;? U$O6QA!KKHQ@B!_)[O5#8T[&!@BQ"],:O@+)YZ8XF
M;B=[&QN@217E?,'I3X'W@$A6@7=S'?0@&C'Q;JUYZY9X44+2WH&ZY=C(NLG*
M\H"U%.*\(M*":_U7F&],RH3?.D@C -G9U-!L523M?N+BA_0\(;V(>N-YY'JN
MV:?O;#$S9LW+ 82""1:E._JYX#T^$MLJ85OJDI&J&Q E&'85W,2I)BUY)E4:
M%^CZ>SK+MDG?2'M"4ENGKJ F8AA+=DE@D,25H_ E<9D341(?G% ^S3!^R<'K
M_>CZ5#.2E"MGZYSYWD/:\[7B;W".^M. ^8VVXL=Q(^Q6H]!Q']M?O0&%4P)$
M4\]VZ+0J5D7M65TZP7#H&,-%N[!)C<F41>;G'N\[!O^;Y]]=LP[:@@="\2&X
M;42P,I"]X.IU66@H#&7XSWVFF%P-\0U+2'=]/"A-Z'=\,G9@':0\X35H>E&F
M.Q<B45QL8ND!."&LF6HM@&PP3)4 H+_9H#1D.3?SZ=:U 97THB],PXB%5I](
M,TJ%LC,4%\L*$XZ!I3MFN;3MZZ /E98$NL(#FC)'@*%;@67&?)&8B][7JAKO
MW7P\=3_AF?@9H9.\?7 9K[1)>/Z.6W.CK.B=<*WNGD1V/-!FGHZ6"XTU5\VE
MD(8L#:DW*TK?=F3COYU2_51L=G8$&_'+#T(PX"S>BW3CT!Y0P2W(:*/+4,&V
MI)(0T?)L&8MI?ZSFST G\^G#*?DY*W^)IQJI&V8+$X4!P<)TE[671,P^R3E!
MR7V$F6MD<0W&JUIXI@;]>VA8U^<17U^SW(PBDFE%7_)CZ4TK3U/H::!$L.CG
MQFCCH#-^E%M0WU95#5),*AY$CP7#D4;\P'I&<\2ER&L[#P31$LCJ'N5?OK]0
MR*#^_*O<XE"*-^!+4[2V&$?L"PW8+I#K2=$C#A@INF=:K4"N9=U,U<.HHVJC
MQ^@H<:0[L"S=\60=I(9(/#P&T]0;0NFA7#2HJ9PQ"SJV'%X\S?!XL+/A5J<J
M=M$T5C-<?(I!%A'&"%6'7RB  &=!?^N=;SR(S"-)4" \,/8%L*V-7BGJ1]11
M!R)TQ1=>" K4VQW3QCQR[(^QVSHWENC_GC[\_[+<RJ:I2(Z4(O?.MNP&GIYZ
M2C>G!KI5Z$K< K=GC(!-(KZ0??:[V1E<E/%RT)=S.;E5&</!*8<6F/8%#MS.
M.#U\I;_8N&K,YU.-PR'/$";LS=$_.F;BQ)U^/V\=Q\;8A4&3T3M1[KDR:;:'
M &VZ[]>'3_3RRV D4NSY3.:E!^Z_P4OJE#9]SYJTJR4T\;RX/]9!"F"7^-^&
M/U!-W@JW?BN8R\._\,D:_%7^V\JPABUQYM>NNE_+"PT?CN]V<MQ6YEHYTB37
M[QP%5_LBMZQ;!/T1F<'$B6F0[D^'-W]#,S B1R&DE;9;XM?09WP[Q"G#6J[P
MNQJ44?3X6'P0NM3?(I\H_P7#..3?64]=[ER0C"JTN7TI;$/OE>HCL<WEA;[L
M%J'%F>K:P1\TP+NA%1/\<M0A8FBA3<OG565AN) F-$20[ZR-V$)K)ZYI_2(_
M/GK?[87"%L!# &Y>!VV> NCH0M\0WXQOJ<9X8XE%<'2L8<QB0IYC3?59/C20
M$G:S#KWRG9F(: PHYS:JK8-:[.3-Y&Q/P1"E,VKAV9.71CB9P:G8Y/?PEQC6
M^PGB[<''W)Y]TP&;!).L*D)8MIIM5DEK4$-CXSL76/QM<#/_ZU'"P&>9IQ(U
MX,C$.BB)_8NU'*<3JAPR9)&X#T KI-RH?GI>'%0UI%67_!L!Q?O.4PK/W(54
M'UPM]]HL((R#F^$F$Z1"H9;;5HF9P+:RX "UFE;[V<SG)J;-L@*_ZZ]1EL7(
MJSVOX8J\FSY!ZZ"SB3%K\R^H*I+K EPK;].2FPP2>TKH^?S)/LW9<]2TA7U?
M-2X^TX<I\'-GOF^><$M"5ULT$]0E.D AAY"FIIIL*'$6>CG4UPU97[O&/1)]
M)'?R:2?IGKIC[4/[X%_(*Y&IZA$]>?%G>P(>"YYRW)HQ^Q(_6X(SI3I?D'[V
MZ&U S.SI?OQMUPL;;IQGD%X/9TPM=3:I9FDRO3U_H\:LL"-7/*GW*^()BJ$D
M3=V:ON !0^[ TO:BW+Y>OG*$<6$Z(O=[SFA'05CPYDD6M793E4,@G0NWA"I=
M#=W#'J'B80B-KZ+K0>(S%\_V'3W7^^U68:U[:?BU''4QL>JD9JSX,LIL(-%$
MVK4.VBW1+FQ\.R#QX."=SM98&+?O[+:I>*PGNGCN9P2Z'P3YM?QUT/A3M)QT
M'VHGJ=_,7\T/HQ96(+,!5$[>@Y-#$#.].F>>BCJQ5GSFT=M6OQCSHRB:\2\2
MXH\U3)KI6*#7@.DL_/2G;Y?Z<O:*&$>RIFJ,"ZX;/I3WNB6A'XSP'7JA<)>'
MOL9F;.:Z-:&WHG8*QY;I2*DRTGSQO-_\GNDZ"[<*9/J_XL?!$-64:X<>4YY[
M.ENWBG&'S5Q$E UICD(%KA5*M6"]&NKCH]A8WSDOJ090@+'-XQ)V?JD0?C2B
ME!Y<!SEG_S;8ZU.\LV,=]"OA<^[AS5.0^W;5JFE4,)I^3I:9;XP _.Z,?7KY
MRO+"I\X#N>$Q])Z5;4.+BG]'K, RAFF_T]1FT (W\)_KH)W<^G\%=HLJ!R*6
MK\34HZO;-7&6%-;EE?B<M/\([":VW0!YM.CYST190-Z$*F_Y)=#O//##SRWI
MSMH4IAQ8=GX79SM8!@V5^V/(50UTZ?%R<W6$@;0DUNQ38N]&.PIJR#;1-R!%
M>"AQKT0)J'H!-/0XU_7WMZI5D(;57!A^*[>JM1CG:10$>MQW;?.KNR:WE=ZI
MZ>(8XS^#JCWM299A*T'JLAS?CV[^5U"U_Y3IEZ .Y(B/^@'8";FZ9H+\K"(R
MN&V(!"M9JX2=&:C@XSWJXA2V4%I+Q$/SLCBN?E&\KM*F":HU8,*%^XGN#:)\
M7K*GU;SK!=8%FM7U9!*LIYJM7IRC$Q]]9.J,:ME*.KD(N0YJQGTI:=4T7BO:
M '6]/$YZ]^G%YCN.A!)DA[\GE[%(%V6'1E2/Z!54F;HC1F)>YEZJ1]@BEF#D
MN:.'-T^R4V@U8,QMJ"K@0K=\EG@ \QZL(+GV!EES8?#E@&Z"RQ4_3)U98R'3
M]%1@2.X2I=UZB/6V\K-U*Y,?<! XPNE11#GT2[P20B/-ZXI>X2MF2Z_J1);5
M_-KE<C"#*DZ8M(&]?7776G$B>"Z;?4!J.L.@OKQ%RG7X]F"\KP(!OWECP#3_
M@JR(G,S7-"\_P]QGGK@ /UANAM2HDR@.<TD8#D0^(( ]?6<YE58CL2^"Q:PB
M'NKV&GZUS"28K7["B$)S7D5CP]_RY)9C:N"$Q@VL_43+A"I$(^X3RB7&?14_
MW';W<!L#/UB\->H(,X&IK(,"_<U'"NNZ:QPB?S%Z2BOH+\FB)DS$LG[,*R1^
MA"HN*3"\S@GE:5&OG0N_,TH>5JIP;:#+)J=*3T5K--!+VD+5'#]6MTS5=&J3
MM<VG"%6E+Q0P$C.Q I+6;"<[=QN]VSRU<$8-03> R/B.>K/:HT3^GA]FNVNI
MIP,S2*E:R9<DY]B0[N5R2#/T+:WYMSEK.>[A2OP2>)_]MGJ+-+RA]<E5ZUC5
MW%K1\MYVN292WNU+"?EPT?/!7".*A.S'.[<!5SC-Q/95_/(<5L#F3#T<4ED$
M3#P%Q(%TF]$:^P-J-PN#HTQ##[GR'O+& D<+8SO_]NAA&HA\AFFAO2^97V !
M8&+?;<YO Z;X6_WNE/XE5VE CZ6LB_C,8Z] 2<T.KV_?;>&L)0<0,KM<;#7#
M'J%M@1OV?R!%2GX;'KY$2W&N@INX>6][6NH+KR6-Z6=3@P:\']4SR-2P10BC
M7'1"B&D=0Y]K&#;%R4C<7!(4+O8.]2VZ-PC&J'F149%3L@/>[C%/EX_L/9X]
MUJ#1OIR'&+YR4>9C@.[:7U*]-HZ",F!N-2\/I+L"A%>AOK&IT6+R&T-^+?.A
MX<NWC>\RQZX'Y7U*U@D91L7?&/L9WC-13Z(HF&]9,^\;;C;W4OW+N_Z)<MHJ
MEPE39K8G?:Z;R)W;X$,'UDIIP3 <IH% /QO8V-A_F[T3^9*8OA(>?>+';,M]
M,>0B27;7Y[_$E,Z'-8N03C*.8QV<A@Z"NW%D,DUMHC@E*=8VW! C4W\OI\9^
MBDOYIR?.-FM=%@JH9<B!>1.K,[/FZZ"<X9OJDTRHRZ638'7 0J0-_"DH:=G@
M*-<^Z_52.SEK=G1&8ET%J6Q>_HU\_D)'=>@3YL>,P_ZS6X0N2H_G_=N6T:9[
M$YOM=IMN.!2ZZ VG_(T9.ND.[4^";OS*(;'<:(\I:>'% B9'L9:LGG5#_"4Q
M2Y2@M&E1OD:L.)MX<.VUWB":.#<GD8D+7"/85.QBAV&:/S35$LD.[Z&&/M46
M7;%Q;\L#&R^M)=%N0)11VX7)>7'<A]>-. A9A9TC_OJI00.%#6[F*C>3Q_!<
M/R1FI/=>S=D.?ZQ=7-Y,QW\MI_G_R$)H-^!9>:[E;L AUO;@4/@AV@!ED]#K
M_*"161YRV74=M%U:C8C0KFMTD.XS]MA[!$V&/-MP@TNK3!^:("-TNI"(^5(A
M??_^/F(2\N3]W[BGZNAS(*!F@L:+LZ#'(S*IF@W"89%;.@\5_\(/@+G&#[I,
M]E?^WALE0DK%9WBBN>I[M-E;, 1GOGD6O%L2,4A4V& OPY03$WF0A\.V!ZH$
M=Z"0$59+< C/B%9SU_;Z*&/NG=C9O_-;!$O%AKBT(7SOWTX(O.S';#2XT$"Y
MLF='"='I\44-9NR>?#(5@3\AT7Z-VUM<?;OQ!/%!^D>_Q7!<F/<ZZ)UN*X\V
M-W77SM1:6QC8DNOVIU0=\#?# (X2S=5MY'*'VZS?H#+XR=59["7:ZJ5[4)./
M*8$K^ST05E$R'BNW::$81GFKBMW6%^1Z8>,D(4-B)*#V-U^>,:>:I9_J11A/
M^24G\X?&X%V,OZN)U'YUK:9EC].U.,AW4LVXG*Q?WT0-I;<VCWQ6=Y&;''_F
MR;ZOGWB<<W_AI4-'HMF;0A+U**2& 5,XY.*[&D^7V'=$9]^MU^Z5-FN\6&X!
M(67F6HSKA'ZB$B"#  LX*CQ#*MB7H&5C8I^V]++OFH6O1D7_B0>;IHX]\;I&
MR?)<>;9M["HBXP=8 TD030.#A8 =G:9 _&@&E4'&#$FA2F&*=(WG,8/*/H?2
M&%";1*E'@=V[<ES>K;6$X-?,T/YV4Y7/]H:3YRL>*K]FF%=&+K^E[+P3^KFE
MU.76X^8ZDR1G70_UKQYC1&?1Z)<7"MT$Q@2W@" ^@E1;_J"I(>QY:+1$NV<+
MZCMX;V:#3;_]GAWKY2P;7B!G?4JGX>\G*W[^0;;N:X.'ZLPB4 E ?#%,E48:
M(P,IS;VSJ[@_7PX:_7A''.FM/&1I][S/"4&;>NBJFK5PKZQ2N#;$A*)F [9\
MECB_<8HO#5D->!F]Q75+U"A#IT\'OERX]1FI?RRL'YG83?PS,1SO*SD#I_;U
M0O*_9H\&LC.8L5%U5B&;%[]-X%I=$>>%!3F<1@7N9A] X3R0 ,>'^'YE[QT^
M(_U,CN-G3TU6,G9(V2+T4>6%_91:KY5G?/_&?&R:==3$5J"0ZQ_?YOOC3LD]
M6^5IM6YB9DJI#2E][4W4ZQFYR%MODD*5/J;UEG.\KIN/,6/6,J(%3#J6$93Q
MNF%;JEEEGGY>\*[L2Z8QA+7OP_L\UT&QRB_U,D(61\G,DZW36Z*R'=86Y)@>
MZR *S61I0]I*U&/+)">$\DFP2I2_,#\S8P+SP$*J-T1LA%Y.0\Q9,6_V>_%$
M4S>.^7$00=?)*-IC6V@C>7 =!$\P^4#56?O;U%OB.N$&.-4"2PE:BQ>$9BVO
MH"-M\4K"3I@1X_?3GYVU]-9:M%>D"ZCBQNI9NF7">%!NZ]!%.*,']KZ"Z@+O
M\K?E,.JAY,LSOO[%1<4NH5'PK2U_]ZZXGSHJDWG&&GX4V0)*O"-Q62OB5TA.
M3/Q%U1,$I%1X(\E-),V#P-/Q;0OA2[)6Y>L@74[6U0[M^GL:TNLK3\I>]]Y8
M!\FY"-TFEM.DX- ""\'R7>OH-T =9XV0AK(H:>?">I3T<UX5<:^:+96(:G18
MOLEI+:A6^=Z$^GIH%G9N7B/QDZV*</G^C_P=%:]Z31M5K[X=OD;JXZ2Q+ KZ
MIJP>>+HFQ9AHE0OV8]]5UEP0.&84(>$_\FSTSQ/[7N_"!VTMTR5O$W=<E*,L
M<^_:*@H(K78JD*0?^3+-Z+U&/P@IOKAFQUZ$M7T10!=?7W2JE;;#'O1/#4I*
M2;78CZE345H5[:K/]V=72VU03D+P?4F0H.TBX,S-<.%V3J]Z/>(Y-MZ:CDLH
M^5(TA!7E'.1X72H8B:VX*EUZ'&O"@[/13N-&\G:[\O?<]M>];0_.OBT,P04Q
MU]@&ZN929:.29%/>"?A68@:^X8OC[R3O5U?$EAKU5]ZO7.$%/'^A\"?U!.H:
M5:"\G"%Q$_0W+_ORB&UTQ.86U=0(R."4OVU"_)7DJ15^@(7WR*&XJQV]U2W+
M%-H8K[06\TAJVFNM30CU N_F\:QE+=(E-L4SOL243#N.SH"U?NCMF@1"8O&0
M<"740/=5\O5N5480_",Y9FT-QG&U.)_F0'Q;4Y=Y9J'@-WRO\E-#Y@69L5$^
M6V"^5%K+WO0]%Y(\V3OW WZ\Y]S?OS[I4+^2R3K)CC^\C14O/ DV60<UV93T
MIK31&#LU-K<L2W_KJUCJUF.QW1L&;-G:\+Z)+FCH.BB;Y1?AVN5#=:UP,4H(
M]K%42*IE[V3&6=[$!18S.5Y!^(;3[RXE7059QN##_F^]U?<_NQC0-W $#)3-
M<TON2O<#5KZ8#PW8#*^+ XCHUFJ7]EJQNG+*G2:EG/2>)RX/KY@D>_CS:O.)
M?+/)=5"MS!RP#E(SIEB5AR8>H@G0Z13=:-U/&?B19JP1*-O..$0G^:1[B*X_
M.:MJ4>MX5I#G"WE;9IO4:BT[W-]6:^8M\AL]EJK5]R/?HOF87TMPJ9_3'=8I
MV/= AY3P6->]J5JR]3<[#R^,Y.4"]>+;0 &SM4"M1J!_'^O;'T'5<1WWZR23
MO[QTF;K7X7QSX<1*3->3X@E<;I]'6Q<1QET'S;&Y<E:B&T!.X)L 9,G&%QF)
M6MX)?TH(5=-5C'>.F2-X3NQ9//>>TZ)+1%PLBFT%]^WO6P===PY'!X.3$_>2
MA#:M3[F8E#K1ZMR=T9AV9%TN#GM\K-O0[4^M3\->AHFS$0EL^DG9.'&,+BX]
MXMN&;M</0*0,:>IIRM<+$0Q\\[$9NS"Q]J\D]A2QP?_XR;YQ> +;>/!F6>*^
M#?UZU[EBYDU"K&"Y60WQ9U[K9>"0Y-PR:?Y ['1I>XF#_DC38F*W[@>MN.<K
MO@&.@\'E%NRWG?Y [KS;1CML#["\F8*2PKZK@+>/@[AS'40TFG4TEJZ#1G*%
MJ$7-/F:=L0!G% G]A7;=384U[<Y$]K?D%N&2#@$;&KD%=43D%RNVKZR+C+_>
MRMN!KLD6VS2EJ]=%_T[3!04(<#PZ%[)=^HD!235+V 91]&?-4 ^ES5]Z-V3*
MV];Z25;#?69[87#.@&FQJ8/'&2N2B8D"A0E9!VU5[9/8<R%;OP"7-VSH8;$0
MD?1C':3:IM2059!W>\BBHG,OT\$Z+>*;:^:-C.T>*XD)7>4^N02)HN\^?JTL
M7KUEJG4=Y)3B70/+VZ#2OC/0=P/11R"C[ZLC$=9P@U<=Y#H(ZW*+12M:X'IL
MPNX>:R^0H(_11^Q QM,;T"E!=63!6OYDJY$7@C$W%4GMF')@YJ@FCCWL4,9&
M@T*0P]*=&K$<.W58C"=N%\JUXGN#0CI'8-V03WUYLR#F3:22$4+-02<-17K"
M/<QP/!3()D_Y,]T5F%>1*:V:>^J&C*+709O8H53(H+45UP;274LA>A%[BP=B
MG<U;C62>3I[#[W$<6Z@;"ZHL7A89]D?@S9".9%3A%>#^->'6E&<5O=TA0^&D
ML<0@NQOGZU@KTUCV6WYJF<05VVR1BQ\<C;4U;A1>$;E&4*^VSMK[:_!R:O(+
M?%?RJ*+Y[+NFM.!U$"/>&QA^$XI5W(!?2 K%A&MSC.BOX%W_[EX(_\4:4VNT
M^5' D(]VEH;R8GWLUV1_(M>N%LNS?X-T$14#?W)F>S!WG#YD6'R0JO417=4O
M-%;WZTJ'WOW-CJ,93HM2L6N:NB.RVU: E1P8TVZCN1%<,VYKM-S1OF6N9R/7
M3A89>%[:_OE':/B&__]=W4-MYL8*ORC3].P@U4'<=:4FHC*/OC% IF.R&P J
M02WDD=E*TXR(@J$%9C'SV(WA\Y49PQ!1)GK4%R2TV_\S?V.TPCWP-NM#7,0!
MY-Z)"VF+'QH2:=S]04/A%;9M.M_Q-D1\;5\J/RBU;LJF?(%WT2</'BSQ7JN3
MZ@(GT*%QIO-;IBU4:#M,=09-#; #BHHF/@DO?6]_O.E.GF28DP86I(L1^!X&
M0KJC#28^@_S6VE!A:VRY"[W;-.0V_-J%^S!T[(%(G<<E(Q%%*[S/Y5+A%0UV
MW#F3B,JZ%EI5$BU=XB"T*1(:%\K?%\+H]G3&4"Y)J)+I0(*=(2<C*!6';EY6
MW^:)R,M\MJE=<G9C.:>7?*C_T:A_17#/F3OX65NH5U.,VS,M2B]F?EPPO-1F
MN* UZJ;_;*ZJ9-GV)A0;<V]C!$[!)4YH_!@RL(E!;>3XRW[P+#!M'*8RM]8:
M!$<'1<8BU,Y\ZP[UAXMXLL18?J#$R*L-_%9W'?3(K-O.'ZH^TL:=GSLLL:H(
MP]HJ5=,P[G7)/J_KLG^[\;&N &+IL:LHJT[R,::2]0GR91UTH:X*2 K/;1'K
M8R@F09S4W+.OQF :1'S+V^?A.RM:(G88$+UNH5Y<E+$95V#&7A%&CPYAV;(4
MCZ*97.R#(&%)2OA67GYW*RU4\31A)^\O'8M#E492+SB-"L5-!OG0$&Z/-&V
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M]Y/^E0MW-S#<))6AW+_8:^K7;<MB.!:PI38W&NL?R9!_1550]+XY!+,Z3Q[
M-?4P"YN'>.@-KJ=;[L+QEFJ'L63=E%^3WLAMD'+XJ(_W&Y*[;DC*JK6<K:V8
M?["L9OC2.)@I=A&VUG%'</187_0#E&;T%>K0A?)@TR&[$9Y6U["GLS[#J)=2
MLK#\2_<"_\HHT>GLVI_&<+.<<$CBH5E+W)]ZPORVS!(!<_KMH2>KK@[$?:_$
M9U>DW1IT[><"GQS;A?+PDC"TP,W 35T2D-><>$QH KQJ]@LCF0M(Z;#@4F=$
MJ8/.WJ;H^'T*44I_='2J9?F3+^7%'PX#?:O% $=[4KX*V ^C->SI7BINQ<C3
MZZ#6AJ!\*OD:.O*-STA9;=79MQL^(KB>:>@Z24U<![$,*\JG-<%KA("VYESE
ME$SK(W'C=H"S:8*+7TWVXL5[DY[J$#VG3#?#+!]7"C5BT(AX#8O+?I</EN[H
MN Y$<C$[P@(L_,8L_ 1%PP_P:L,?5A.26BB*K57$KH76/'[PSM*7?V;8BKZ/
MY-U:E>'YBP^&L(DI=!M]NF]!X9M0YR*VTZVZ['C4]*%CSO"H"/1T?DM%_QGV
M''6>4GY2TX<+!HY2TU^&Q&#9@C36RF,@8K@E=S!_JN[:M>BBD:MM.I^=#D2=
MQ4?=NN8ZI0,V]HB-"%*B$14D2C)>O8FRDLN#B?N1?K["+9K;!9VL463N#GQB
M3Q'+K00_5MD9=V$V*?,$?!*;48:1!-\:]A>6B^1)0*K0ZN(&J"V)(3M8L-5H
M$K8\13"9778CC=WE?8-D\D9LS3WA8W&M/TR?+_7M MK_%6^A02C-G^"!3P&8
M2J0+':SXXT>M4 \GGX.X-:RHFSL2)S@7LV)[X]CIZE+WBBH4-8 WL.D'(H5_
M@]IK6/2XSCI;^+%[;<J@&UJ6&Y0VO0HG5I,X"+76'5*C<A+^\[_+6_;_5)'I
MI)%*6@D/+7"U$#KXOMTN8J?"MMD &^( ,>-R\[#O'6A[T1<?PSB_D*L/GOCH
M9*E^6_%(#.O"B5* E^+=J!,#_1-;2#0E0K3"WB] _'ML[M;7GFK8M"D*](EL
M.NHA_&M&UN)!> 7-W!::UTN#0;[P[1A. 0)LJBE.!095D"2,GRC!GA*JY.RZ
MW!Y64X*-W/)7UZ[+]EJ\CK=2>>*W7(QD+[^_F2T'X0Q+=8#AJ\#C>*X?6+5M
MPJ=O3V3@&V\"-N2S[Q:Q]1].ZI8KZN=(HO8?H$_#=N,50P'*O0',*T PEPE]
M:*YI\5:@6<A1(A-S9UC\598S3S<S&JUUMN@*IPY"'2.ZO*<)O*X(]=-,98T"
M.:H9$JN@A D"X,EH+;3A/?O\_8[8]@N>U'8HKI?J>/S5G/^:+^D'#M#-_YN1
MG]S(!6O.)NH(RR6G^J0'9WV_BBZ>CO;Y >C<8_0>.J_SJPZB%C[*6L)';5A0
M;Y\^J?XA@+N,KI5<3^>*P=4EG;<PZ@GIA%7"T_F$^3 0IY8-&"S.6HHRX"62
M?<*AHF N9D]8P=Y>R+4!P[TV+I[5V4&_@A;*'3.KK.(P2="<1#CQNAM@F))<
M!/B/KSFRFU9K-WQ)#+[L^RP'[^3]MA]=$]ROLS#O&\],51F[M/_QY5 C;<M2
M<#SBVC@!T*M\/$ZV2Q&T<!,N7!.L@]H:2C+'C<)PTT^A9OVF"CT=J:+*?2BV
M[JT[/9*]"F?\Y,SGG83Y_#PN7J&9,?_P]MB%68>: ?R@69QU9[HSWGBS@Y;<
M&R+5T]-U -0 E2BWN0&8T'%OJ:;$3(C(-&-KAEI6%B**F*P1/^= X[P_2,L7
M70V?Q%TU,=^_/XOJ_X)?@9%'-[E;NPDQ$^RY:=@X]!>WZ''HHSN>)0FE-KSF
MW>P1YU#(4TL,"PZM.6Y%DYLJ+ROI;FCT&F^;VUHB.0KD"19;<()G83\SJ=C(
M7NG-XYE["C0N$;YEAMX,>J#E1'S%*$NO0T0MEV.!R(T9::@%[ ,%)RAV$V/7
MVRX#!I%E<1:N)4W'9SUS'_&,QFH?CBPLT X^EI\4L^_<U5G+M1LOR=[P/ ^C
M/03?Z#V*5[\/"<+<1UA^,W>BNP=Z;O#4[2-O/%T9<C- 5<6]B%B)5284;OBF
M#[-M-(7;KA'+]H,HD[BRD998\Z=OPL4W"_CD1\?##<G]_/S7PUVL;3\#-N%D
M$S__(7&@ 3GX&08? ROS^UX'>^7M&^8YCWJ$-QH;O91""\FBQ51GE'^'36.2
M-54'*/L%RV=ZE^!WEIM7BW."E/%#A#BE/T;#W+5XH?F[MW@B&A?20-,A_PMH
M___A>PE:RRT,3QQ7W5\SX<('#5^1>3:CP^6!2_H#*.5CSFB'U;AG(ZI=&"C=
MD3X^GXZN:[MO%V*P%M4\Q#HL"'KEUU3B=R$U\';@HKG)I"QA=;BC?"M"//N'
M#$D"!^[K?\#<MS42GO=,3]!/_@'K]H"/B&3O;Y$S_O#%*JH&81^@+2"+IH:#
MA>8I,.'FDX+DU&M<MQUC2"ICD<[2PGK U..O)#MG\RU(#]H6/N7YN)0?/SY<
ML\'<?J$"A0+M5I9:__D=I4#Z*6J_T2.^NUDV+$[;=6[32JR=M=I*X'B/1)'I
M[1]()ZW6T=G)T%VF\6"Y ""^^3A@?SF.8'U-HQL[0B$_\[.Z_45G#0@^?KS!
M>#0B\*1FD>";" O@N4S$3J#P(N!S#3&NH-H3GMW[!7:+A;SO7%<?M! Q;T3]
M=&A!5&U:]M3D#)X,(9*^H]S6:B8$7KRH<402(^"^^5OJP7J8?Y2GJN852R5"
M4'0L7'ZLI"O[[%S1]7JHD?DQ.XIO!^#/<6-L_K#J]0"EG,C:TG\;+.L,0R1P
M.ZU&(A#$6?6$,BU76Y<_LONZWI <%_,O1QU'R[.<W#?,/!9)IK/WH?97AH"5
MESHSS.G<K>P,LX=F&G9NBR8V^5\ADQTDYE=X]>M-_J37T%@YM8LRT<)@Z4ZY
M<4(*U;A:('IJW3!5%\4=,_EPRTGD5QKNSIU:50\M=&$?9K9;&QB03U9"OX;S
M&,P$ ^Y\&T(>M:L_W%CB%!NO'C;L^.G#$-WMW0 "4K2][W@; G'@"6G0*3!I
MY704](2;^##J,K'W-B)%Y)FX_6E3(AC(D<FX/EPT,"G]W% M94H'X@/AHEOE
MM_+&4#VFY660S?'P)0C3A!.,D>JY<;8)HNG^(8SH03HL]XRF?H.@N_6%IJZW
MCLML",O#.R\NI-4B97:!][ML@=8:A:J,C#\KX(F1:;,7TUL\5=6RLU2PA>PP
M5=5L$;]J].S;)L4.ZF7S$>5GQU',NXS!P%8<B49WV_:=(5]D\1!ZD2@TQZ[5
ME6A W!H&*)V[(*M7<<$97>9LRYL^ITMH'8-3[*J2N2 N[2YCGC[;?<=?#DO7
MU!0Z8I$D;/^85.P^;#3/^;)X,$[)7K'<))]):UPNWSP^/)<CO"P*[T>=B'PQ
MS=HIU'L9/>X"V18F8,]4C[04=<(BXTR]?JUFTO+WB&$5C[GF\-3:M1G0,O0^
M5(W8@\%5IR11T!R>JB,F0!B1!"MG3&-7'Z0&JW>KM4\V?C@S7QLA[MR_ZI4-
MR(B8PI:2>U1M)+V-NEN0C.&X)0\W9&)+S3.XLN5KIV?X_6%EIV1'FA]5U[RJ
MG%:NLSNWA!C9S#$N$BB*/(&X\?P(V DB6A:9V'.>$N\9G%24IIN18P&*X1_X
MP^">VQ>NN 6ZR?8X$N)'JZM%/)3J#9KE6RX,W^Z^7D.YY7=VYK1$V+[WV%7>
MBN7G;6SZ?#I;U2GSMBST@,2TM[91L<5P6OE;RE)]M'/M_BVNQ]M*M9G-995O
M:KI2\SU=RR7G!OTNK-5Z->-(?9+#?3]4&_I^[YL/:A J,$B.#4GEOK6D2\7]
M4W&18V=NP.DPVRX53Z;%/;<VC J2;$\2WDC<)HC(>+WC0E'LRQE(V55DFKVB
MDRI62?215!6768W+^3J:EL/HZIY"R]F-_YUH"-@(R9Q)*4YX^>J0M3;'%>)'
MI*1)Z6XNG:F0R;K'4B0^ZW7H#:<XG5AVO:K,5!B(S[<;?T&5&Y8> Q2;I/NS
M_6\A]LTN6YX@Q_N5NUP^H&*!W=L#,_F@1;[R9% +<:2#D#?,Y_^ /%H'U=+N
M2W\)"!45Z-!HF8N7TV#I\?YVY\@#E=8/8U;Z:SU[/\XJQ????O1+)9\X#MV!
M#F*G%8 ';#<!".\J@0TM2;J530DM8X2Y-TXUAN7Z3R91[HTRR]Z+@U)?0X_5
MF7-+PB1C&%Z*P(1KUX(#3YL@[Z!YD)WKH!NC/E=#7;C,>;FU I&3/_:6S=\W
M_9Y3&F=^#_98Y:^<M(H4!TI^0X!#;37JA& FT1_A3!J&9W_JX$ZQQ9;CSI,!
M[<<=KV=NGK2;U\A*Y+MU$8/'V3SXN!W&\D=#<+)97CJ97:UQ>LN[_HB*C:<T
MVGQTK7BD)&-KLWJ^:M?#:LEL3Q=Q KIY0Q6S=R,1G$]X#GI/F(K*T.IP$TY!
M8E$P>R&'!8LGGS7;'G'S_"OI_-J1_>I6><#=DL0V7#4XC:J"NMA+)"A_%WD2
M.$;;_%6&UD%2Q3%8LU&<3K)R[#W6]PKS/RR9A?L$/'+8/>787V7>;'C<^L1]
M*%5A]W(*Q97KU1]M9# W7\KOYQ?7]7'?K8,N&W6U[T_;GD^]I%-13G[4-XTF
MS=/]+S<Q^%2S67*\G=S8J: $N2%,/+S4P8P.&>F%:^J^>_J)5>#YL2='8E5^
M#Q"*P0".>P,-]G+#.;H!/JN>&8%%<8N6<8B0:D-JS&X>%/<H0G(4C%D'U>@W
MHW>C[(52VOB:^Q +HM3.Z1JA5[@5^8?%#,G%B<@(8IMZ8[D=3F5DM\J*^:3M
M$BC6DL!C"\AG!1[)C5$$:,NVHO+V%_;!:^GHM5?12DG%YC=[VL6G>R8KQS/V
MW5R)7,[.$]!%[9\I?H193[4R=."8_<1^E&ZAW]9L&-Z_;XCUK7O!TT;(B;!-
MH(>'Y>5G4U)$B6LID@T6>"#D#JLXU^SO&+0BPCK4C"!:FZHR-8]"PL1F@19>
M1Z9Z[!BVUWN2F(M'Q.5>$K!X)[*&@^9Y<3'IN4;2?/,J+EII%"_-CX[59HXB
M$Z=D?V.VZRJ,S&OECDVJ;QOQ^AJU:'!0I@KI(NH#(B?<-%Q>3*^*VQ/V->SN
M6$T8,+^#&:E+>.$[2KFN7J/2-O;5BO=E$//ZY[Y/HLJL=',_Q>4:'F:9F54Q
MEI#G G.3#[OL6O%K2L]-8M+!XZ..CR4].N<^DM5U8?0-14X ]#%I5-6P#7UB
MYB)K8W]6L,7B\31C<AACEK=$B27F,EAG;V.U&+T2<HJ/;:AR(OS^U$H\1$7:
M+CU"6L-299$!"@K?"[2&J9HAI-R$KP)D@9@^/&32=DV#[!)8ZG<HR+^3F-4/
M:V-.,D^"3_E*?A=T+W^HFK@R-*?Z(<5-.@ _Y[3 FR#NF#+-;%._ O%_#^<;
MM%%U?T; E.5@[H)W4T)?V!+P+*2J@R7]^[*ET5K&X ?+*E)>1_8FR,CKH'40
M)LM>K7+*:&&H@"PV1[9Q8^?V1 OZ6ZCZ=50AZ>7+A.1O/E_Z3P^?BSW3LZ#M
MO.^&PTU&Q6S]V_WE/5+#Q$ZTDETH'LR5)W!AX.U(/^B0[0$VH.K47V$6BN#Q
M]<A!3_QRIF#(CK:&P]EFV[O*%I[\S#W&6P?)4H_-K_UM9!TYD3X&<<HTLG5U
MN=( <\&;#WW2'>UJ-7A;X_CRSOSF6-9FF%%D;AM/R)&SIW^&(OTKE](Y7 T9
M1W+_DJP!7G-F2,-3JGZV4D)^[L$PJN17J(;GF?,KZT1Y@':<L%,4-BQ1#49O
M37Z##MK+N'HN0[=A]+2P6_5YHZ^VSEF"M-,L;CE=JH'R ]9!G/(0BD<AH/BA
MIP2)HUL6->*3BVPD"TXE,W^Q_"E8O7VM0U>82B[@CM@(=-[.32P@6-0,1'-I
M:7(<=;D[/F;)E/K^ZY!B?X? Z.CPBF&5SV.4ZRSG0H^$WM=)V,#(!:*[H(?7
M+2"WW+E9@P[EHO5=/_\8B7XSCS 5EUOYI>_+@XTQ74S#L,<,4.27QN0<-(5,
ML?NP#JKJ:4E?!S'TFP*TA0Z#!7B%!RC_-S OWT9V^OR\]@!>GSAPL"Z3Z;PP
MU-=;Z%>:)7#1P"1;Y44*^D5F0 ZG6[NY0?N[5*[/&AS'\>L^@#R-4 KS9:<L
MI:]HFBCUVIO"]'+"E8.@1U43J+%N8^6_RM38\=)?  UR<A)(0ECU&%#00U\>
M8AWJ7](XNC!Z5?MLV5_M$;J+.AYCZI85KFNK_0(:KU PW K=C:-[:NKXF&W)
MG=E>'&_P/!SQFC0F>CY.1K90>E2&655GN\CJ8GR D6!9Y P4>)U3&_P:8RF/
MF?!7A_;],%@'*?LCG\#UAH:.9']3'=YCB)\R*?[XO/I5"6N%1+ 7>(VS6W]&
M49(WG4^.<1[7L*.SE*MH-?T4SV%%5IAJWJN<\-<J >ZO]Q:>RS QK2X/C[XD
M[N[85#,!!0X3[AE)99'L9JE2]H3_@+4NIU[BBBAA??&?=JGP;:49"ERL7;Z=
M]+N^4B4#S4=3B+/0O=)C2/0X^T]F<X'^@.KY?GN'G:3A7.>@K*SKR;_]9=)N
M4 /W<#!D90EOT 1N=FE2\SZ*F][;7/_*\G+)L4'*O@B(!%$ZVP<-LSC^Y6.-
M5*KKXA(HBD/'[I0CKX*QB %H[8;+64-S+1Y(P/$<S%PG9@]2MMF3JEU=/1 4
M$K[DF';D)5+GF<'SQ0/\3KU6QO>,^R=W6/#(@C[(+_9<[<J 6L69%/O,]R'+
M/>5FJR7/AW C4B\&2@C^Y-4Q5C,EIIDYX!/'<+*U"+D0-3HRD[O0W_(+K_9=
MA6GY;&=G<4V07ZFT9Y?K\7:5^0+SDYU5"[:>;>I<1#)-5>+!!<M(SN;9"PX*
M$0^(_@X3 HI:Q30LLB3 MVW;,/57C>&'O=JI6W;F:4RL@^!E$H6UQRCH>,\C
MEHJPLM[VOJAU@'()/^N9[?Y1\*6GC(A[NI5\?+/6*X9DX5?7KCEFX@:AH6B(
M[Z"."!='-Z@"\+(2/]YW<[BP 7Y\0=UO]K!J=#.IW_J4L35A):3*Y+A%QWNS
MZS"<X&(/: 8L:QU<B72[A T8L#;C^,TKCXR,^?B'5LUFDWH1H?#B7&6?5V-5
MN_Z:]V#16+X+-%7I1\VC0*SX5Z2F[)O;]4% J&"QQ3>B-+N/7-OO/W*TY:OD
M?FS7W_RV"9]LNQJ9%C>&W[A3\DOA5NQ]BI5"2J)J6*)FKV:/>T&H67FCBVOR
MB&[.KATB[[UFH[U3GJRUF-:*]V![&)K41F=O"V/<S"/,S!?/J'J28F/S#"LK
MPW^@B1"^PUB?XS42BQW;<V-LN8R03D/,)VEN%A87O9A)U"]@+3O2+#UFC3'Q
M9HU$?LMC([4;#UJ^?22(WRU'/.6_, K8\S,;*Y/;Z-(J-<YD= PWYRHT>\^I
M7A0[8:+S]PZ[AE08_6]LG7L\T^W_^-?=Z2Y)412A@W*7TYVP0MO=74B23HXS
MJYS-+ F3V3HYQVZ$&Q^6Y%#,<MB&L>5<EO-YL\TF*HP-S=C!U_W[^_?'^\_K
M\;ZN]_5Z7Z_G\[JN]_6>KSR1VS&XWZM-Q"HRZ=9"+[R*$ 2M&#F(@:*+W?$)
MA7&(PS=*12_L1<,-I%990_C[P=5R=/PJ]T<U+PI&7;ZY\RU10!&R:4?TDS2@
MC=(]#>4!#OYR7+3\ S,II=O'$$VL7>-AD"9=;,I_@>4RM $(Z8U=CXPW4[Z+
MBIM=T#VHU3X@F#>+9C'FWAN.N\SHUMBH7:]NZU[N^'P8$XS++.\$F6*:,<8B
MD]1P[,&?-39AT2IM5K@#[H%DFEY3GP^]JJ[?<.6G-YQU:Z;U?#K[?P\_,Y8H
MW+4GL'&I&#B*T9)=E6#Y5LF.)QPLK219RVXDQXA5M[S>H=SN^\A:]HP['D%<
M/$PV7FRHW3)F(EB<)-CQZ:W(O8%*%7,C7+5Y8^)*MTOK-6INEWGL%"XXM6H?
MH9X-"X49^"]&A'C,TTPQ UYJDEV@G)V)QK]^)YJ'9\[/K\C/S-UIK+OJ[!&X
MS:+_L\(SZ&<]60!EP]L5FI@NCJ7D,E%V;(CPML_<18@IY?\;_J^R[*.@9L3<
MA*0G!+[F^*2=.>5]CTHACZS!2^0?0?O05R2%4\0]GBB_R"'KLW#_2$19P)=-
M1-YS#OJY;TT#&>JOY6AVZ\.U$N4N CW2*F!KB2A[\WUG?'IB^Z*,@TI;J)#9
ME"@'?5EA6\YM6G=B*$N1=Y3R_PQ1(?ZK?'&)] AD*J>O*)D<1-_H,POPBUZ,
M5Z@DMR=6S*J[TL<B;W[9WM;5&[I'15KL1@EQE*Y6O_%+>1VU ?@$&[?B?Y\O
MXA&5)B3>CD)@$HDBB2E!G7,A#_V*SK.*L9CM@+P_7I_2IEK;!V3F^^!^YQZO
MSJ@O+Y3T2L_(+HE(&X#V?RO46FH@:!>)J^[+=W60]\&CCD.3S]?-QE6R3\T%
M:JXN1N45W?VQLF7^CF+02WD0;40,HJQ/[&OF.=JR[$8B(#T81M1#LF#/)0MD
MQE>I,ZW[0V040S'L]Y-.SFYM@O&O< Y21I"^PU/U#1]MH6>6Y[-=(SX/>'I<
M"IN..N>D633S1S[^6PC(8Q*-E6K O4[**V0G^<EP@:GNMJMD35Q2[12UASYL
M]B[G\<^,E IJY?YW$Y>Q;YHIDO)DX>I\E AR6UXL.\Q'JK)9LR,%^T7%"JI%
M3>B4@3235IW+O1G'U$+H=T$<;%.MRKPC;KN3SX58Y3W<68A6EU-KN;@&Y#-S
M(_5>J?I@>\&QH16#9,2C 47/+*S:)NK4W.T1GIZW..9[J+,SA]K8/@YU?4$/
MP<4JP(VT^.NB<Y_)'C$]'S(<2M@0R*Q%U@9@KK0VZ^JP\12."JD934?YBXU$
M_\O5>&YM3M#>/>H@A"5;VZ-&Q9%+ULRX_/?,V>0#+>=4U\+>9?\HN?B5?N)/
M[]6@@CSI"?1M$?$Y6HU'5!U'Z=N3).Z\?(<K@^':P-M9@=8VH:#L4SE[XD[\
M%I-N8K3ZF?H.>2Z(V$4MV\JF[5&,TE4V  $JJN1,7DQ0]-S(8 <A6'_3M$9O
MUAB6B_/\<\T@"2\L3Z.2SV1[87S+_]/,CB]@_]Z7KEZG'2^&^Y&&S.; U3F-
M^2VS"DY_'D9K(4K:@%6.ZLB0@E"CS:"C$B0Q0!0 ;,A^2CL<!%*'0,HI<5J$
M:[!Y\E.DVWB6\LCMQ> 06,9N.$%>AE%%O9@:G9]4:-=J0@NH45'OO&Y4W]@
M^*8(2$J0G$R8WPRTZCSL=<@:1@ XNYF0%N/2T#>1NU7V]3 ;GW3*3@P"Q8CO
M8X)?JEVJ PYX@WE1EU1AX[]G V \L>"!%\?+/Y@YC=/;O7X;($&!L*8,_H[:
M=6O50"9BF,_,).7RWF%/ 3< !9 ((=<*S$ZU/;*7(-5#Y4H_Z9P>/)YG#\GW
MY\_@I_ZUSQ$37FF6X"-F,4Z_:-!R7A24%54Y)WXGN<]'ZG#0%T;0IW>DE05Y
M_2;R>3*?I1D[-]X9L]7=R_U:^9G.4^._<:)>/-K'LIB.#'FS-XQ'EQU0:M'Y
M0Y)<(7&%1JT8P6Z(PKDO!9!YUSMN$XY'\HZZ&[?!_..BZ,\U_CF'W2M@0*$X
MP3/AHKND@J9$&2W)@,+7'O_K)(X9'?.C)6K:(U2%G6*_.AN[KP['PL<FT 2O
MZ"CI"506,MY#\?K4 &;X ]JK1O3-\3N(^[&]8IQ33?FBH'RAA"NM1B)FZE1B
MZ1]W)C;N%\&</M(_QKL)*W%36O@#S*!5'?!(Q)F+WT8_OOW1JEX>>F1 8$1G
M^-K&4/,0@!@M49ZX6 C[Y(BU&T#;E7$[R^%]$]# $75-9TYQ>-01Y4,Y14G,
M"]KDJ#(GW<BPF.&@KR(-08UPM)6C(EP@HZ^LIV0G\;.FKN'L!T-(!N6?[V\
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MLEC\5ZVA<5-]\=6].#.59QBE_S:A_$YL-7E5H-HG,_(M^H+D4W."_6J'!/P
M# ?WS3/D50?K[S)[[_$E:LC:7\:23L7N/ZS/\8GQ5K*+R)(?!>?[:_-#7(87
M/9CKYQ>GE]CWD^_;PO_8 &##ZD=]8.;1KI^(B9'TP^BM&HG^_<7]P>91W_+L
MDR*0M9YN_JM U<*MC$#7[_N725#3R!#GY?W2LZ@:+XF^<)#70>>?-R?L_'N
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MU1IM )*.YEU5]-1)8M^B" >GL<!YLL=E]ZMUX[AS/6N98:O1!$!T9/,&(*5
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MX> -84A*92<1RAV7)%:ZM"A;V3;1:?^P+%CY(_^TC>Y?,UIB-&DPD)D?AY?
M+=AQ1@>L=C3VEU.BA9)O>)D'^N;P+X8#U*#M"2Y^/GQ.*]]BI,NE=NBH3=ZW
M='WGM*)=QE\BM[N#8+;#]/N+ZC\V 'MD9@W^+\T.-]H@WP<QB[^2Z?M^494A
M]O6- 6+'O157TB=\'\AECSI4;9G-&&C%EE\6Q2)\JZ932Z>HO8=T'\DS&^RH
M"+?7E>O.%ULW6RPN9/[LB"GO )ECFVVM=2>QX[V=.A;";T]*Z.62&QP@0GW9
M;LC0.,N>$I,_$RN0228SD&I1& AB[08\K)-;0WE%.XEI6\<^#:>KN05Y7:1\
M'-3#NV:I2W4*R\8=D8\T;6YJ=:4[Q!"?Y5=V4R3P'MH?"@96#1P@L.+;UO.M
M5'9)7+U$KK&&,OWB0!>/6HKPP^6HDXS>L$=]=E\"(SK*#S.IU6&GA@&KOX,N
M!G+W8OVC3;1E?P\;/H;HU5+P=YHT8X;SF^HS1\S]XD+%"=EA;_'FETW0+B'Q
MTF"TV4CC"?Y%7_3E4&]_WI4XQ.V+=M<:JQHIJ7XLY%%*[LE<FTR:V_A^"J6+
MFEM/EYRNS(NNP+1C_B /M-?3<Z57U17HZ\+R#0#<G9=OQ[G$E>?RK;'2B^@@
M":4"Q>A(Y1P1NB8A'^<;M#9@LHM0SR/A<U8(F\I%Z^[+\Y_%BZ%:C;=,KW2K
MTN87-CF++'FQ =B^7ZCR''0$@LKM8;5KMB'XT2I*7FXV/+FM]F6'NH:L0YN"
M&"R,ZN=?<+%QN30C^Y"7DT7!BQLVT3\.S#O;*-(IO@\O#="4DV-]M3,)@I[B
M4&NQR^KI8#'MK[1*)R;P=YXJ.O^J;YIK"]I ND]FUR]3$OTVZ1Z0M3Y#F8(I
M2UKM!Q8;(=B*J,3BIM<X1&C91,<@,F.^LE!L6OGK$Y-4+(H4'Q3A<-;.E:AJ
M]GS/9NN5?C/1&/L903O5-* YRVX$(XLG+HGG?-SOO;Z:7OW1Q>4N\Y-A2NW6
M,9(NB\*+P<4]ONC>>"D\5#<QQ+CB,0,2H[..^'MV9A._C&B?_\F++0")3'?"
M\G"9Y:9SBMV[)LOI"9OW6$$<-N_=YXZ^ ZDI#7+1=/PV(A9L&6-8' =!=@$K
MDJ0>1CDQY9ZNGS8)K+--9YLD;5)%M;<T4-.:Z4*IG+-DUXFT%=2'O=&^RK6&
M(8M;TJ,BV@J\T4G@E[K\R.<; !_Z$;2IR*D5X3>,OO#>G@<[+"'>'$+XT+*.
M_&0._VI[;^8T;?'S04K_J^"#D!GHU.+-G1]E9O(*M)((V9$AB6Y=)W7/%.W+
MYT69L<KAT$OW,K[D$T).IMROW_]EB9*^2,[@.PE\-WMI4DY)7FATXE\UBT;^
M1LB8>^2XC?[# ,5"Y+VTRK)=L^WFFI)#2>5?P'[8<3Q?OX6.>X\6;@J+T//L
M[(E; [7X UZS'B$DZX&*K"7FF&<GY09KN3'Y0*P[/F2W;!@K+I$G^,DWP2,0
MJ03/UK",E!T=S86/208=\9'YY4KW'ZX_>-,,K>J.?"BHP]75;N'(;.1EM;B]
MDN7K0D7.^T"@QD\B*]"R%K@?:IV6.&]L<ML*>TK?7?_/UD:#?=3H!1^79:B:
M8G<DCQ#&(SY#>YCI[AO_J6,@RN>^#%%==&Q*Y0_S7MQ,T_F=UDL3O(/K73IR
M+:*6Y;:8DE4-^DW1BK$4:CP#::JHSC*-J_ARC<YN/E=M]K39OXV)9E2"*9=Q
M$G@N&5M]^O9!C-T,Z;_-%QASX4R>D&4W-"7DCZ//2S+*4>E69>&[3B*NM2QP
MW<8X[HGH^A%'^P.=]=E!YZ+PK7_IB(2X*6 \R!)E;GV9!U\=,ELM@+A;,Z(0
M)<]1>)^/C#UEU7;'_V0Z#YFNNZ8H>K"D[ZGT "VV5ILF]KG,)'Q2^]%ZM$:T
MBNH:\WN\V"PI'0:QOIJ<Y5A])=TL[1Q191FQHC(^R%,O%[Y7'%.V=0!+WLON
M8RO'#WE^(>\:..BXMG5F I?Y?<Y+%>N/U39I[]V+FFOG:$E<)ZD;@-]@]N4H
M'']G/-$_3MHV<M;&0J)7N^_4V#=7]O%NLP]YP%,SS*XMLSHZ\@9KW4*9B;"
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MNI^PZBBR<L3W9B]]BF*@3HB,K_5M$OUE&W<Q^G;6:=KH=/O',Q^B;MDO56T
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M#KW%ANQ2^,PQF? EO$9@[H(2;0Z+09-&6K0_D1BP,/;9) NS102M;B7BBDW
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MP5R3).G=G:*B;,PSP^EFNM%R70_>?&541?UMQ*7'AQ_)5VQNDO@A';D2'?0
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M($=YCO'!DW#+CM%[_L@I0RX>:E07(AD/85(P'_I?0-71*DA/&K?I"U(3L2-
MX4:*4O1R:8[S"+Y$0RD$Z[N2]OM_IN4SW4.?*LN^0/I7G@;(^ZF"FX0XCI;\
M4."3T5Y^7USY':0#"AH=:(-%OL?77#B<!8<]$!Z%X)ML.@(B4.R6(#:(3*#M
M$.3EX-MQL C7)^-#[:6V"&[O51C^YKTK7S-YBJ%/>XQJ#,NN?8LUR5EV>PO#
M5"LD$5H4I :"\5L!SS<!'S&*1,1.SJEZC!$AI*[)RIUISLI,^DQ&U0)8X4*(
M.5E@T$G=AX()9CMT]@VCSO"<P*UR)8Q"4*-KZ4_W_&^]L*/C%QZ\=US3(S.[
M/UGH_AAO"MB.%_KSN0)<JRO3>@B9#7$(D^E+,&"([E7*Z/W&]\K$I8M>MKJ1
M 9SH>"U0TH$X48V GD%8R&*@=05MWKN'K0V*Q05&=G]4Z?"NF/C6I_SA<1E]
MRU[_GR25-KZN^333XO@24.0O>R6U%8 [&EWSRSC?&$D:+\V,C-<6^4=/SELP
M*=E)E2=[-@$Z73.-Q@]8-VT\)[^;B/6Q*76(6,MC-5 Q3!)!T]DC,,_Q/4Q6
M:<ZEE[\+LG"KZ3QC&)7)!)OK[7U7(^TE3Z\_M7DGMO@I?8#:WR7KUE8187K,
M<Q^((X:$4$FRI>3Z/U63M5[C1QUUW&:TWNS2WEVU1)%,MG-2S=Z,$I4/!\@/
M"OCM;<(D+:6C(LC%*W=OKR>W]W2J?.JX^.7VJY.$<*.5#:7_H_'H0Q!0KN\H
ML)^$)J/\M?^S?)FG,K <]BQH-=(@%,[_FM5C\H)L9;[T<<--EP=F(;: [KF9
MEY(%A*$W;':(#S=>#@]<<S-_<J(1V* 1<;/C+HDCM7E<LMR\!BN2E<BU.-)[
MLO]L?D<Z7DUGG@.WZQP>,4VRKW_T3^4PJTM%PW<'?UPJ0&=,ZEC*TN3'.KG4
M1&\EP0_RBS#E?=+ VN?:]A[4D6.Q"[2JT*;HT[/WCRIX$5?@@]SU*99N#;EG
M]88"4=PD:A='3"(2]3]NI#0;6K;>\?(8KPE<N^4^MZ9AA>[?V<NT@_.GLYX$
M>]QWA2]T?F[**4!_ 2JC'(3!2.-AC\9H^/+L4$'XL/%0QXR(K>F UZ4$M%->
M=Y0M^G@HHGXNJ9B5[Q>?$EZ:+&W#JLUY:PQ+U2K$H(X\O1=M2K@%BUI9[;5+
M:I46?YXKL"5Q1:RE!.E7%\ZJ,ELZ?CQ7HH5R'=T$!)HHB)/:R/1L(N&E%!')
MVQV6@ST$_4S./'TA6INBS@2_(642#D?\UO&YJ#;2BJS]>63;-^@N$.+7EB-B
MM^O"?=7^L)(YLLV>:J%31VYI>U3%_,"Y]O$!5#4MY'(:>B'Y[>MP:47%4E7<
M)5D+6@,F5QH-8\$1M[V<M-Q3S]>3L;2-5Y8OLU^F528$JA5^,#[^IH-%*C@#
M7V_A([<B#CRF.J6P*!&([XCMIEI5D?0>+AH[R?^+/=$C<@\[2%@JB62MZ8<&
M:G=,KZ/]G"I_D8Z"G66)J#""5%-@&R?5;31_@4>=%:HNG/IX5[C]9NQ4^_$9
M.D^K:W8$SG^7K5@:*&5_A'C-./]"[MZVG,4A==*\0'$;_@E9=YH::NC+Q4.+
M>,/ON)Y<9]Z2T408]8NS[J.:GPTN ;3C_3EJ)HL$R=4O\F&H4ACFP%B[6DM6
MZ0*S) UQPB^L\?D0[XHKZG2Y:QBD_>'*=X*&P'XQ;HKP@BQ7%7;&H4#<<HI7
M2=!&^]9;!Q63;U*]OID=Q-];O5X:=KB&. [S16#9OXZA1B'4R.9+HNMB"U[J
M"]!.RDU_GF@ 0S9;5H&ACV:89D808Q A1?7N-$L#<PN^U9N0=XJ<W9@01"SP
M,+'7O(?6<C23^Z/)KGEHMF'8Q) ?YCX8X2@*+$DX^K80^B/QE8<-_ ,\J'V$
MBL!NW^)H1A)1>0\LLV9>1T? GDV LSR&P[04#18<P]:KIC+P:W<\"X-=T]F^
MDI_!2C$1G=X*/D<>=I$AL;X4'<A%[/F&5:YSH7_O]63.>Q (5<6#2T9&A5'V
MSUR53?A50TMI:W4&=7=S0E _I^>3O,_4,HH9V&NI;B-H=63<1^<)CIASDY%S
M>X0P-.K\56_0T-6U'<^FU+M-<P;XD'= QR L&4Q+W8,<PNR;EQ])-_)KG1^B
MW0JHRV%4#RT9%\0ZAN5]L_W:6O.S6=V7O89>(49!4/BI_B^=[=[Z8E\AQXZ,
MO2R!MC7?<J(,,1VP/<E&E::LB-64_@Q*C\?#.HN>VN)HQ<DF['['"O&S,):V
MSA!=^WS5*Y$%PC1+'7T;F1X6"C7^WU.JY[6/';AY?N?_[;$(^$LT=[W@Z9X3
M_Y?';P#_'ZH#^W^V8?[__?QG9G0 D)C_Q'GP_]L'U5++D#2'8>L+L,([08VA
MEAWY6H[P>VN_9FG\2HU,/QUQ.D6\BV0P@_BY^>$:9I?42]:,.B2Y %U 'R<)
M[5\8J4PHV4R$.FJ]!KZMQIZ 8.@M+NZ[-@$M9$#T-E[G:(&@7?(M7*2Z<'27
M^3^<<6OS&L?4C/NA]KY0U]N(?$(>6A,]BE5#.80)3T]Y"_R?ALKTN6&]2]BR
MYKCX9>,0XZK?A^\V@X_I])FML/C[__#[NV?U 1K" 3-BD%ZBQXQ0Q#Y4=&TV
MW*I7C,5/S&LZ>'@%/^PM\AC3SUU!X6>\6AXV3;/D?, EH/0 D+L<1]G-S;W5
M[IG1D8JI0GH/MUO0,TD:GF^>:!<)(Y][E=]-R#Q(1MS4:U(CW;9<X]_D41.P
MO_D*UC[V*XMA;>4E<^:6]&+<PD;E!OQ5X)/D8\44Q\,JW4-=FHBS+K?=[DSG
MP%&#PO^".-41L5)[+D%\Q7H/D_!*KA'H>3S?'W]NXQK9-=Q-'2HT&@N9P\R$
M;(D1^& CB>Y#NOH#J(#^S/D-#41>[%NCM6@*R(EUFP!ML?ZE0:D'%_M;$%G3
M.C,B,]S[?/;9@N?P;A_?E"MC+EE=KJYR3<"&(U>A+6D3 )2:U3',-@'[YG7V
MCJPYZ>07S^^KHI^^R-?*>/.WP_ZQAF,WMA?B_@ZITM]*TRUJXA<7&6;N%-LP
M1"D28Y_5YJ8*#5@CP1Z6M*\MPZ7?LOA_*K]>^V?Y?W8E Q>')>8+F-I-P"+Q
M(5<+[LGDM*TEET./L4GKE=^;FAKN9^@^=<@*,%HK.+X)>)MI;-^;N$Z6:W.%
M7AW9;@D<+TU("PXG-:935-;<Y'^-$.?,E.R$BQXA&(Q*<7&UQ!H_W?HB1!XW
MS=SV0R'F?QK&O?\8M 9C-!(T.QBMZC?GLW."LN'T[$&/GJ;NALOUR9H!1<SY
M],N'("TNQRI2/X)8!K9BB7"Y+4]%(,-OL,2/S[\?+<7>J&X<1NAFSO#F0<<=
MO?XM3+MM'Y*^2W?&H[[JC"A[BZL<A;A.RQ9<$32 #M-_68>WI/&==/6R8[&X
MJE+-:_F8J3%IT<5N1^.U=<]&Q#/07KDN!#UB8R!.GLHU:&T!QMT1=&3E>\PU
M7L<9%YL>I\]O^ <>0QYQ[6?6MTKKMFUQOBA&W"18%3T3$%[407>A+$<JI6$/
MHW52(R-Y7CV!+D9PZ5K@H.&6'%RWZ\#@0[SD8YJ(E])+0I7^CCD85P*-6\N^
MGK=FOM*#9":W_R@Z8_AG6]IZ#>BM269BHH=<-#A$DANAU$>DT9++4GTAI))T
MR4E@S:S+?GYU\7A:2&7VK]+JYUHS"^DV4$\!AYDTF5(LX+3)K<3%894!EL'F
M<E/!<L)W.ZIC>>4X\XO1RVJ.Z2FKC_M7?>^>QE4Z5;.F73T!WS !0/%)Y9<M
M:E*M>F%<;/ /977[?'%FYT7AOEPC?%].=&'1W.S5_KU"@_5JVNIZ<*&DP7,!
MM*4%67X]D_[MP)<V:L.AHT(U3KN3GX&3\$ZPD^5'$L[[OUWC+?=)WW =?'Y_
MC_=N >@#<XT?,P4ZC-S"5EOCNI[4A,9][X<#A_K-7V,"?8MI.]O"R2J7DR-B
MX;%.\:]8C&D61)D&%.O;OY+^$54"KH0UFA-!+REN!2PDG.G&]N4Z&4<6DY_U
M]8LEH(!HR7G7E7OK+9Z #<24<N?R7M0>TG!_?$@8$.2>D5]=.UR':[ZZ(DRS
M:.F)"OB:D:$QX\<BNBUKQGW$U,4]1^O.6Z(L=9H19>:E!9N 5MN 0=LC'I4[
M6FXY-FD7K5_][W1>0;T)2Y5KT09*F- 5O)DXD+M,.5=*9,(T#;U/4@1M6>E7
MJF5Y&"*S8Z7N87"&)S K(K=)/P@?:?(1^X7!8RRRN?UQ*P'[D<J>HW6</?-H
M%?K?+71C+KE60S/)FQ:QM^5RJF7I9X+6HM\Z)G(M^^FYI%8HF?K"&B'LN2Q
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MJ_OC39IKBT8\?;&!D-::'2;*>B _5SWT7:;"F_>WN^M?-#:F7L\LA1TR8K=
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M,P-W(]VF/50SQZW3_HVI.W[D .M*_9\27$VGM<&:3#\._"E<4WY"P+TTX.K
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M)EB]-+#?,+X9YNV#^REK,&@R51W2:U[$5^);^;&EP?GX0.P%AL3S2];!_U9
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MZ30=:CQ9.\MA=AN]9\(EE!;5M<PKT#_C/AJS4R_L92-%5'*BY@1>R=7R_1]
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M)(YY5]LI0?<DPE.C)Z1X@7BNO0]U?[2"G.1ANSS0N"GKKO_BX_4ILWO8'=<
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M2HX140]^L]:606*3"EH3H[84;,F5_&FI@]Q:Z^YE.ES2D[0",AZ>\?A!1ZR
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M.K-\>^4.D::D>*)/P@6W_)ZQ9YPF]+B5X_[.:RI=6Z9U.*ZYRY7,N]G7I<^
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MSN^6-GQ? 9U-'[?$QR;/S.=8+&<P]@XK6+$M7NJQMF)BM**A:#*BL.ZV,!'
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MI@+Y39O-66[U6M-A+_W[=O[J**JDUJ>9IAGX&[-.H';/:N?]S3O=64['=MR
M^A(H<LO^=X"G:JQWW_\J:3?23(X&7'&P]!B^:3%L*WVQB6IIMSU48C;^,FOQ
M<R&=W[("JG9J/HQ'> N3-W_,P[@Z,27KGQ>4(#S"$B#797<:=PKLB223T"1B
M8=W+.YCH3R$^CDF+>>P/ND]&()Q205CS"DC;S<\"$E=4V] _,V,R=>I[+VEO
M):W^2><\48^&2=/(MBKR5F.L@%(*/,6QHG3Q5%N.C:YVK_R,(3NQ/7A]37(A
M]YQWL3VR7K2-S;6ZHY26[#WCYCD4"EWT8 0LOU8H8^V )C%*H(@O]E=H]6"W
M"9)UX, [4S=2D:*/IO&;_.LE+.I%<^GNF'M+!?,)-?BFNM(JP%^F)[_09X*/
MQOW%RA-GDYXPMDQ"BMT1:9E/9]]C'MHAT$C_792C1SAF'&*?>=:!<<<2L_95
M<M/6B.>0!/A6H@>;T\3;EP:G3B27N=_D35!#-:C2EZ+Y>X_]1R^.NU%Q\]XZ
MA):$[RF*S<XC1MY"K_A"?]7W7GYA; V24+OK4I3Q[X&\FDJ'\'72'GL0HE;?
M':YVK@YW^02M[B+^ENI6!/0OQ28 <JW?I,-4[/08#=\\1=4(MJQJ&']%\?*A
MC&E7'NR:1Q)5_\+N K(.MN!C/59 S=80@3110(KF:0R86+;UH4_-:M^8SR7#
M:TJLMI4=1=:L!L>6C+#E4<I#ZXW2V.4JNJ48+FC-*YT(A@%/7&.;?%O,S/Z>
MTP]+VX>Y/?_LW2YGAYL'3LR;=]7H$*G7FZ$4>!-!27X5O\D+T6=7VA2Y(3UH
MW__N$?&<J.TUF1)O,W'W@>\<[4]EG,'D#,08?*A)ZC"(,U9\PF_O_:S@S2O4
M3%= 3T]\,*=.&%618D(XQ3:-;8>9B-E4ZCK=._F.\\8LDCWP2*:/O3!X'XL6
M2QNA2M"'-GLQ==BK04+MI+,A R:?[M92ZVHI&H_W53F,GQ<>QHXYN_Y3_GWI
MH75,GY0N5N&W](U\+/-,"IKE7TSB7*([VCCTV[XDJHG;I/?JMN55/K.O_S[1
M\B]_*WZD$*QJ=4J<,]]JL=WKD"0T^7:IFU^O0^%/S5DE1S1:ZEWEM*<L21W%
M*R5DW8E:V@;K)I.^_1"V)3+]N.J>K!D16@?:M/H_@@.)-^HD:;D2RAM=U(%>
M%1UOC1<=VQ_D[MIT+RJKFF;+8=G+]@*4-L6F^2*L&3GK3$JKEO4RHQ0U/GPQ
MS5R-,V7P/M]HSS-::<E]HPJ1[T^_M:Y75T"/$P'(1_Q..ES WTY6Q-X6? LI
MK26#ISO^5*W?F#'.*_E3M9[2SSWFS!T,9)5WNRQ7*[0 5)ONH:\DTR6C6;GF
MFKK!<:3-U'2$U1VVY8L^;CCNTFQT3SJD3O%S?0Q[?@6DJ_B<<W253$/9AI]-
M''0<1B%/B35$"S"%WC/$+4\WK2Y+'DOFEO6*/Q<]D'/LN/D2U>G;0O .0'4T
M)G6Y*/\;5WYVT$0$.T]83+'3'G+SK\P=+M\XPQ.V#Z0&RZC_.PH@4T4",06^
M#GC2? *(B0)?%M?61#FCD4?F'6F5SR>=$WCWJ+7Q^^?NWEO2=S[$-X<:.&=K
M2SE 4 E@UQPQBAATT<A1GX.2C19T#LPU2OG=2,J/Z;[SU4<S&&Z4O?]+"\(*
M9'?D^X#44=58A0GP1!AET)@#'BPWE)L+&@Y>[$,5#+Q;LCJ'>+!H?KQF:QK\
M6/JV$IWBNL1 9.F0_/1R#LY$?F/0RGOT7OI9L5."J><)VZ^&OY*TFZ^O@ K=
MW/E=8:&D]\NINCQ8="TFSR_72$T^--Q5LY8"K"JR]3O%!Q\SP/Z*O=5DB1=9
M93#AOGQ_N/?&V(5U_2;UQ3SH@K1K8[;VWV-VSG=5C'_=Z#C>=Y\Y\DZAVF=S
M[$\[]OT([GKZL?(A/[%7MLT<PD4SU(6ZM1U]_..8^^PK02[\U&#P_G!H#/YV
M=QP;\M@*&;6#%"L81$-U 7PK[7)ZF+!^V5D_V='!6CIHD=3I9)YQ<(B_F+7+
M-6($Z3&+TU=\TCTB&6S")_^.<'C'X<M=!Z;)*D9>X;J602HQA#7N61VB_66U
M'Z#&?7/+ R 17\H4SSXUDCM $\B>5BJ6+2D PI'<8P1!*TVU7_M[?,[FR\M=
M=^LV?^FL*,U]RZV?19*)BF&\\B_"AI\1PQ'+O'>^0J<:\E./P.1(?/@>,I)J
M*/W:W&=;8=YA_ MNQ'!I<HW'.BX_DON48BCS+5I1+0W2//_1+EBS&=N3E "1
M6PVR-*4NE&DFLD;W_HD\V(Q2C*WGY[;QX<I5T5NY,>$7))JAZ0ANQ.U.:4Y+
MSVQ]%V1-:E8);+K6,T,J>'[&T.*=6E=HD>_L:-K1*@;+63NT8N.@8J?$.C91
M;GZ[9"+]7[[_[VQZ6"AU&Y@[?&'?C!UX.G6<\2] D/G*SXAC$W!'AW_F;!27
M5PK 3S:<*&E'"T]-+QC\7(V"MYFI;Q.GNS7&GGN^\W(>;N\/)-DN$ZSL1ZT-
M7)Y\P!DFRP)F&VW4>\;ZZ2XE7]N( 2E1N99QHXFWP/LX^=&O5T =G^6E-TT)
M<O71)J\3R^\8AS!-;1'6I#A#.:S,C3<1FE3,C<I^^\2)_"BZZSWZL1/_O&B^
M5%Z/>[UF^./JZ*QK):T$0;<(,=:_L-87W%'@:4W\;S'(D,+JX^K?X^WZ[FKK
MQKMPC[<:Z.M5KRQ7"RN7:XUP:I0847[7'<JL< =A\=\I)^7T^,+7;3RS8U:R
MZN6!MJZ;J.;9H62A[CO9=8(Z8*.BWDBALK]DX-]C'C<U4[]2WGD'[H4E.G#U
M.A"(8M[)G$,_AI]5TJ)8R>-CL_B1_W0/]V.U\4(^\ _ZHL)X&/,!F#,X5V:_
M OJ;/7DX6/;FG[/6"K?*\V2C)$Z8&33FH4TG[<6YM="NI^O^,QZ7EXXE/UH!
M47,J):7-*J&43+/XMSSYZ?2/;#2EM"" I3EXK$DZ%J9J^-<I8_ T["G&.3[,
ML P<,$C#Z@.)Q5A;A@0&_WG"C\+>PC1+*>K0JZ84;S]VCO']KT3R/]W'E7T?
M--5#S0;FC#2E]A*CF*R16J\I._ZJ,*=U/R\/_;P",DT:_EWS<A^6,!7*:TD5
MX%9 G?BXM>>DKJO@&P,82)_UR$^LZW/(!=*;'8/6::#\T=)=,WO]K3A^**_]
MU,R0)/,:O['!\=&Q %8/<^0M?_,"?_W!N&DR]]J\?5U]0F/C12ST/3VSI3E1
M[^_[N5M1]2\,G>INN0Y54N_0"2.NTQD2V#EQ>F/R7T#)X >6S4[ 5V@FT9[\
M'5A@-9B98N!IKU(%J_F[DC*5S',8-QN[K+F81$4UPJMBDW'J\EV ZH&X'&V6
ME;<X@H>()!Z97!;=)U\L-_+81"]]I/YFS//3IZY=+DL#E?5H4(19D2Q,#NFS
M,G@[N0(2O_#B<H""V7V]HNF:2$['5#%1&]D/OI>@D>&3"(S>5:X'ZXT%%.>N
M@#Z>8VR;DH9IFND>R4':#-K5#;K,RG07C%!&1NGH#MBEGG49[^ ++YO=^X"'
M[(%6N>YR\FJ\PB?A-"5?ZFP>0N">$G <N=3@\'=,R)*I=J3;WL=#"9"L2J0B
M?'-;738'U>5LHX/[9,%L1*V3[T2I>V&P$U EHM5Y['GL(.;[8^EARO1GE<\[
M%%$<_,B--=,*T^7W]+7B<?\^%XE*0Q7'KU1X:M>M-!^81L8=>]P%RV>O+,K\
MZL)0-)4'F>DBJF#9JZ])#0@PX)Y9@/^I^'N]II]H7%,JVF<O?(7LA75K72*2
MK\:,;?[,/TPB0'U(0]UMBKW+K[ ^)4 P/-,ZS*.A^BOV(-ZD:B),D[>MUYA>
M?]&FI[* &EF*)U-SBNMPO>5Y,V24_/#R4WE8'L"8A_6/]H;4,($G[X!\=V;\
M[,+4>Z3AM#XY]2Z]WLG,OL-,T(-_ZHWJ7#-C82<:%'? @:3;@D0=W#C2U:W?
MI^<7%7E$8FB*J$VS3;-$5&NFF*>/G;R7-.2Z(RE7P;=1%L\V=F^>PAFSB&GS
M\-XM5 -,Y#_]9 /+R M1Q-!IBDQ T?F>[0UO6&8O)0N\&DI6"7X/H"K&.PQ@
MP4(C<P$\R?=%UOH&QPA+2X3*I1V$*S69ZV!&.0%[4<?D2SJA6*(G))YYBYDX
M)U<1+SX2S=:(8/8U8DVY'LI7,PEMO:'-OK\Z:)S[*:TRD)EP<2SZ_(.JDB5K
MLT]=I\%H_\QG6@W/S$.K[(+6=R(,K^4%NF^+&?FP @H9[,2KXP-5=3!J/X0_
MXHQ6&;K1N0^$C:;0RH!Y)^%A$1KQOK?QB]3_5NQTDM+1YU,!!O_4#YF-A1E%
M^$[SRQ&T[5TC*@X7-%A>(+$TT7NY(L6RK=B+7!^5>ZC_[=*=&]'4NS/S-&/V
MJIQY!A;_$PV\)&*O2%ZY P]0X,D<DRJ)[],9E$\:XI1>377?*,SA6V7UW2J/
M80.D*[M:KWBX_L;:/H4UCBU= 6VPL<):B1/\4@(L\ GT.C+7J>L;0YM:EV/I
ML$OG:%CXXJM\3]L!N_MR\NS '+@%#!RT*9+9(< :IK,[ 9+75S)J]Y(%+M7W
M[619FEFHV0O(-^S"L>3CYVF1\=WB4L>62+O5SQ&'.SI(/Q<IX&O\_->#A_$^
MUZLE<R;7AI'[34\)7Y8+8T,0LEI*\\?J^?#A:,[I340%:P6D6H-*1(Q,$>],
M6OM#!+WYZ;(CDE\ ZH"S'U'WERTR+^?T1!S[=%>#JW9&0.Q3?" XQL8:2$0*
MHBSA]>G7Z?TSOQ!A4<9SVJ=((H\S07[ID*W114Z'.1W\^H# O^A.PK;I,(F3
M,+;M251DF$^)GU07VFOE6#1IKGNT_S:UNL\(@O0UL\^WVTF9'[B3>GZFJWX
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M48J(-=HVKRZS]5ZD+KP(_).O-(B?#X!8E376UX<-+1?6#)<2)OGQ50&,L\C
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M;N]=;FQ=]67<9%3NA>&_!E80,,L6FTMF&VF>*1]=#L50;]J/K<,/(Y&9%8W
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MBDZ+G6)0JP7)FMO?158=_&GF"T'* #HNS2.Z(;TX-7B8WAED?52!=\KU^MA
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M''\/E.J+074_;:"6I!S&2!7=0_?K\XV')QBU.AS?AH!'%6Y8*I(V](&B)$1
MX^JE'19616?-J+K-7B/X_-=',[I?505X)M]O6OVVX=H=1G>_/)4Z;M I!DD+
M';G3+G42,Q%T.[>-;,1S+W[KTAVE:U;/\=]D>V69K.8&\ZY][S3>YDPP^,?B
MIY4 (NK#'A I"B/<K*8&S,%3;Z>'L?7!+>!V BTKMZK/Z!U_E>YTKZONYO@:
M*?_N\W,6$[\:)HQBM#"C6%FRS#C0O-C..!YMU< ]/F[1=(*_*@85EDPC&@(.
M;"1IH(N]5UZY_DX;N<PVX5PN!I!=FSYQ]2UVU@6W;0^XS*O4*\NYF:=5\I65
MR]4H&0J5&?\@UF,>*"/MFM)<GV^50^\OIM+ _"QN:8O>YSPQ:,_YSCS-U&2C
M\?5PVOL&!:O2T_L5Z4?&'&7H\2*56?).3)L(PI6EKL3"V0CXM5&25S'ZHH4>
M[UI1AE6#Z- />I7AY --DW-)V%HOI]/"]+6M*>EDL&A?"(L3Q$I]2G+)V1W_
M,!BG" RNM)GL#2^!:8X0+^\J/&ZU ^;##/6$G[A0<XHVA/ @&[NLR\:"CZ A
MO-P/TFRLC-N$OXNGH>V.#\ZVTB.D+^=TWUL%?*\[\;:WOO.C:IB_!$1C8;4%
MR23(?>ZTU8@"->D^=XY]LX+M&\!JR?PV7"\@1GEXA'O+S7RN];]>>OX3\78N
MECOV3O09NR<$&N,2UVX\K%F;AKX]K3J)Z5\:/+=$>'7,WO&C*BS8]E^?Q0OJ
MMTLDBG93:%:%-N(J)RE<X&FF9++%H$,,U(T9 Z.*;\T$7\3/O?+7CPLL! UI
ME6F_M9?!_^SI0C_$?^<(D&@3V]AF;.*#45Q Y<_D2VY:GS\SKY-R[1I)26%Y
M#W7O: 3-=M6L%[XP7-JH<0_D4OEV/$J<+EG%S_1OS!%7@UBF'!XI;QFV<PFG
M57(_#%GQ$*G;3K[+MK$ZV-64[7\.*5*9$6EB6LD&PT(GD=906?0MRGM>0U/U
MQ3<TX)T81.V+NE]^&0X68EUDC4]-PX,11!=CQQ#M6>D+X)NHR]..L6@DERA2
M0&C;IZQ3CS/@V<3K!<%^,BL0MSTR.%6-"HV37IY>&B&![KNWR.2#PBLI"PB#
M]HQNI$RJ<8MTW^?,<(1,R?U]RSF1EEF:KO6I "E= %?]0-FQ3-XK:B?K?PE8
M0CP,<26J^=@1"77#*R%7G9>O#(%_5!0-_3F'[=?8.2'XYR1.";@J^%VBZJ_%
M()_4F)?P40MIKBAW2@R*RW90.=]1M31T#ZYLLFGRM="OR%=AJ>;$X^4T^Y()
M0:BPX@+X I8:B3Z7T9H30)0IP[DY+=I9*V5EB52&2YM'[IPLSG+F< :WZXYV
M'WG;&7Q966#_Q1>+1_Z"&9J_29:Z=EUCW>"//6C[H$?O1#?F'V_0]>UK8F$_
MPN]R>D_9O-F%.P",2-(%[LZ(A2)\\S@6[F\AQ<T%'.T&.6BO<I3C9T=7!_F.
M,&^IVC=9PLYY?.;ZHQY\[K0!H*U%J$)# *_"[QFH2.HB?#]--@7QH)E(BA5<
M(9%2-OE[M J":Z][)SVH;]P(\$%FA]) /P5@NC;5Y0&*Z# :DGP:+#VO,'_;
MKQ>.C-0O?[0^6M._W];_@<Q0]RPN^\@Q.I(A4<Z6W<^A_LS?4 O]5[.HSMG8
M^)!7YN<1\,"R"5<WR[==2,U>NNV.FLKWUX\E,!^^H^@S5_0E).FXE#"MBDL2
M'>-U/D%#0]XZ _U6/.^84N8]<^/U;GBQ\2LC!=-.D;5BED-R)@Q^XD]+1F6>
M'=\9* S"8=NZ$_M;L=Q\0OLA<P^);C#YE?.E5941)W*@XV0Z/TH4G@(SZOZ&
MF%SU^-5@H8N-I2NPUJ,?JEO]=!5T9S@0O\3DYQ8S_)7KW&C28V=+2'+FE<=A
MK\;O%N$BJ+9TG[8Y=LCGO, @)#A&]>(72)):H/F8:SD$+N@]^<!SKZ!FUK5C
M[:RJ"S(W@,:;%X,\L/'K[KO/+;@?X;HWL<UP*G!W34,_C-YPO53?$7?.:G)6
MX7Y7@-Y@C^+W$%W!5 ?A;8'1 D8>L)N.LIZV?&%$K)"&L0(R6'IVKC8KCYIC
M6D8+M6F*Z)JF-!Q"V+ =G:[%*7R[?0$JB[8:(-E-G\=2:2&LQA'A:?[BNRLU
M%G3'? -C"./:J >X#V]%JV[JG,'IYHKV0;F):@$V1J@XNRRNNYO?2UUU\+"W
MZR+=S^549=6KHSKG>PS7]E]]0U^3W"5+H0*3]:O.O;; U E._CVN&XB>%L3Q
M;!,4BSQ]JZL50R_8D[U6$8,,O3="LDT0!K3UTMR&Y811*NE@O.AJQ<J1KK)[
MM]*[!;W68A G5=-C8]<<&!GWN$$1$^"*_+2- <-,0*671&!44'L@W&0S)BXQ
M)V20-?0CDDX7% =\(H"_OVP?D_I6R\D^FZK7^/"N^NFM%HP2ZB;]1A9,SLW?
MJLI/P[U.]'%@)<0AUY8Q@/],]\W+,O+:&'\R+G3"[>7M%BJ(09TT:+P15,Y)
M-V*TL'0A7U=9!9&='&*PWV@TIZ&6EDQ*"//.%7X<D?-,'BY&3BTG_ZKCZX/]
M*G $+K(G#7_0OV<9AS)V%%#7:#1_9<<D->'FB^S:VMZ@9N<#];A7:H1SV'U;
M(R#:* 4I*YV:E*TN,_C7,-(KM[6K4\ET:@BI-3#[O-A*71#/]EQ-K%XYZX3C
MRA;,E#/Y:US99Z0_6.-H1_:>8\,AYW?UPH;!5D,KR*5@>N1SR>S+/ ;U;O!F
MUEJG&LS8YJJZD%8^4&H(J1CP=_*NH6+8?F:''S<4&J?2FW?)*:=S^9"%U13L
MY,: ><&Q"0\O6.ZL '_99BO=XK30D&O<PNJ7IJ.TG:/9RM%&.!G_=9?_:MV5
M.DF;I_R5[COPUW^U[FI_.&"\-<').+UMB0'9:B(?$IKR^M;C\#"YB<O8DGLN
MK>76ZAGAD/RL@/0_]/HZ>JY\:4O7+<?GC42)'*ID#XJ^,F7--7D7@$N"=GEJ
M15<XLNR>E7I!""0Y>;*364>W#4W+1?ED1"!2G!5S(WAK^BO'1L6@^]@#)JW0
M%'7Y(>0/8H)Y9,E\A'="8(A.\9GZ0<3#I'L(._R+K&6F_C*^#Z#_*I;MYCAM
MDG1AB$.Z*!%C-50I6*X[,&1Z$FD39WMIE&-D.&_\S77B=]^P*_0AP"0U8Q;T
M4S:Y@'L+N4MH*'$9,CEC*K,MVHG!.*D;13WSNAI-Q!8"(4LN<D8UM"GQ#]KE
MW:\HWV@7-AHV?3JQ*8S#@'21$PR5LHIR="1:2UN,?NZ)%- %L?M[#RIQ-7HU
M$);(M)N*A\8^YZPOY?(<I-70.TO' 2WD[LL\8V97S6*VRM_S6,WRL6R'K($J
MTC-RA/%/^? 2Y]NH_4R#:M$0=)_0D0T^(H3R*-%'!T,081],QAYCO?RSTYWI
M"P[KH7W(TPGI?Y@WV7WS1,1@-O\-F+QPI+\-2:\=F@;'!W<-%5#Y+IIS23]3
M9<+',NZ5='PS-K8)FKM&ON4T@=CZ%G20]G9B>0->R4WE-'%[.QG@47P%4JX7
M_L;7]-&HOCY>SW"U[7"EZ_+DAZ'V M^GY.\H0H5:+F9U>14;"ZNAM$N;=$1<
MH["UN??">*C%=@O=EGI\5GCEJ)ZU=3KMI&.P[R B30P*;]2:F6!V-#3V045[
MMW@Z'3 I<]>I\>IZ,6@;X+)H61MM\T57""N'1V#Y)24_3/S,I0U/T$(*G<QQ
M6GL/O>MMW.D[]FCW0+./9)#T.]R;1)P8])#QE8[RMT;]5'7=4N?WWR)$QM(#
M*)Y9FHW(/\A._$YTIX!8;L>?!((9((MCHK$1\Z<5LK*YVU\SQ2 XUO<?TDIM
M5'2/P#%W1K2&S%ZW0!+7'&.=11_!"I5"-?8DS*HANHU\<A1V'8^R;8_R<1J&
MV)@.LJVJ]63*'\<LC=H:VR>_CGN,#-5;0S>)#F\]%P85 KL[=PFH[BJC!I"5
M(W2@M-\FN\N%PH\MV.=W9CS\Y:*9Q2 AX3CTT]V*:\L%I_&@J)UL63J2U1##
M.K_=,<I;Q)=5T%WSXS>H:/Z<+3SAP&E@6]8G:C4FWT=F74.-]2(SWP^C"'PV
MX#5%C%)A8^4A,]7$DJYJUPF_',1HR7[3X&2\@4\D:O*O)X3>V1OVF&MS,P]1
M,N6"_4('NZE4A047DH3^+3+>++AHE7CG6XR0SANZ]F/YN3;-R6_N+POC^5>U
M\^0WB(J %^TS;WWIU'3+[@\,I4'AMA*4!Y7&SV:EO;G*UM/IV&S(#7D]^:KT
M%2'6F5*_]#Q]V2G@#)VP-:#=LXU/NE/5[O_=/NW)L;AKNTJJ[3ZDHTI"W-R9
M[<82$D)XQYX_O3S(8K WH<>AQE;LDTI*:P36[;Q0SFQS,^AD4>+_Z^/JK993
MOO^]PNX B)*L=_#6MJO___$?'5:D6UNG_@9ML9/9.0=RI)L5_O5,M2NPY8(S
M06:H8E3IH93KG 5;Z(T[S_>!0GG7>'\6/0&3;I/L3K[>O7(0>;#GY#9!AVK'
MT1MNT8PGTI*3O.S<^]EV[J+M#9";Y%-N_>:=6]O7$TT2O0[U@:"_3CBUJ7(F
M2OJ_3W[[@OQM";3?^?+_]67MNEDR+:UM.:H7+.BSN]E :?F=T)#%DH>GKA_(
MZP/V^?&\L\C:-@<6C.%5JMB&I%V-MGBC;:0Z@^P\D?M*=JCQ\@HL%5J?O115
MBCX($'B"=FS]^M+<-.P%XPBO*W[EYR1X>G=TM8+]"$FUV-!@O*JC[CI!"7;?
M?N)$S&$+FZ]F\+$0'-VDE5F7S4%XL*M4Z->!3!9LAZC;#L6\R<-SFOO8J7(N
M=%AGS55-OO)Z$.YS[PQNQ>T?SD;6$^@M7USOI"M_?*L:(X/"\CUX!<EX:#0M
M.Q;J6Z &!%UI&0S.V[>@BMM+7[ ZP?2VRF>-SIT1EEZS7_UF^[<IH?<I3U;"
M< +[?JXM/QN@L*JL68J4:(HW,WZ3']LL+8H)@:PGU&^9^JY?&]O[J"*@39GU
M[)Q9P&1-:!4(\WX EL7$4X1*<?>2^!7- &*J7QU0G>+$Q:$U2E I8I CS_(Y
M'JI@4^&^<&NKB-%SJ+*G\JRES&BZHR;!8AB66>'X <9U@+V -2"CL=X2R$8;
M#Z*UN0*V3Z>U7I@=3ZL"-T]0WD3&<8S\1'U&60VEU[U>57M_'=!Y3U<5C@N&
MMVW>EOYQ;J)O_^..$Z/ FMR]@%3S9"H0=".;:Q.BV6RC:B,S=%Q'>F"NU+(%
M@\*V'K'KVBL&[=R^1?  TK3CELW]$&RPU,6W]WP#K60*PNNN>26BV&FOIM<T
MOLX:>W_]W-O4,-MT.!B:+-(5@YZQ1,,T9&LR]@-&OLE"CAO265@!9%L5V-_U
M;&@6G*\/Y?4J;W:&>6>^:M"%G:XSZ=FVF785$_"K2P#7T2"^0.ZG&#1>9\]+
MR6"U_-IX9'Z9+1MK\7OBN-N8%<\M^KJ>"NV!&+2@[\*PWT<G;ZYMK5S:^IL"
M!]-D^9\! RQ/]4,H3+H_#H)-'%/!Q@W=2UP8]^;:E_2ZVH2F2IF\"M=-,[-\
MJ4'_^F4W;3.V<%=VP-!$OR+IU M2M9RCQ6S1$)ZNYZ56B=,S^.W1[%Y[_E9@
M#F GDKD7Z26Y-%/T#<'C\"PLS526IN!A 8A!#0_7]4=FR+ ;7-AXUP>8-!X*
MG%IODY7'?,3N$_IQZ:UD\% (E6=])Z/-I2#62.W.0)7Q5YJY8V G0?GXXIRJ
MPF-<7T'V#&@KN(AR#NL!IN/X&4"3&+2#,4+Q@ZJ@*%.[XW[T<G[[X:L26H<,
M*?%K"'NT8/.0T!S#3>LIO)MYE71;V#>#60LRGA"#OHZ)]K%X.FQ;CAQ/F35L
MNA(-]95*UF9YK;0;R"RX'^:6%K-2&V#TF^^-TX\WARGO/9'>48M*%>BM17V1
M'3Y=Y16FN%4?=/%$D.71GF:+G_>7X&L2LNB0A((^\*MZ65-P@3+Z+J!7Y;ZH
M+D^B\&2?L+] P/N NM:P1:65.JKT4#<?R)BS.M&&&&^Q-NAA')9<R/Q6F1CD
M"Y6,;6^)X#C F+X-^+W[U0*BI02E/MW&FW<$T[/XA+&Z"]EB4,"YAWY7"J 9
MW]Z]X[A]HN<\@<)/XGI2@5-A0D4QB U=2N!!V5ZS3WG0J;MI0I.LP[ID]?'O
M+F7QD&3_20?C1M$7\M-T/4-L'K<RQOZVR=E)]VQV 6V,G[)5#$5(/!5,RD(&
MCI4V5RM&!7W(V?T"@0?+?;=;($A!-N^9C!M;FELW7+NRQ>K/>LO4J1.^!A=F
MIGJP)TWL1G]*&S+MWC</_T@UX(RFW4P-])G5_TYJW_TX /9/P/8P?^$S@""X
M+PS;:L0<QGPHD$?K38-EA9!AL@;0,W=C^,?W^MZD7BC'-7CX6/@W^Z87?=Z]
M 4MZ_PHKOS,\$+A:"8Z+0:IE\=BI,EB#4KQ(C9M?$,Y*$!X[TDQ^59J$N'SO
MW+S\];YP?;;G5Z9NE#$.YP+:I DZFAUR'X^NFV;&D!9?=.BU:00MV?AI[/XS
M)99R$(J0CN1'<+%")2@_3\+[OK;1# V@ZO4\9C^WGE\[3Y9O&O/@"N%^P6,*
M?_)8"/M,A?64WG75@LQW_1]LZ<RN JZM+:#M^,%VGW'A_:EQD2E0X-;"=:^8
MOEY-ND26X@9CYT.3C8Q3!B?ZO_7NZY#OQJ-G)BY5W-K-N6J?SC\9<$?AA+71
MZ[\OB4'GMHUMIU%."T])(ND+;_F5P!CM&GL2K<G3Z6+(\0SBA'I3E(,NOCDI
MOQJX*=I4]7ZC=Y_'=ZT4POV4O#)O]S2TTZYQ1CPZ3"F=ML_ 7*>5)^L4-8@D
MME"=8%GT[[SJ&K\JE,_U[!M^&DZZWYH;TFE67AM%JQF>B=,1O3T5!I^V;6:'
M1"D^M_#L/W*J4?JS0%FS 3?GL,C3X4\ &P(KT8A$>ZP-]J$]>,G]5"EL+/@@
MVIF5M(B4\FOV^F1*B*W,=<>G=WJWA#OK?XN*K^V:.0HS>UR0C8B"\=9$^PK9
MS'&#=BQ^-GK:#*$RYP@X%LV+3@,/TUSK]7#."U9\N&]>F(A7/$QY].F?24H)
M"!-M?ZZ<+GW!-9P;55G*DOFY9HR-1-YSU!- H4G]K> ]E%3W-EO5WF):-VXK
M$:PUCLS1]!LUFJ#?LFJR_ 1?A8NDCK%3Y84'?JFM$ KTLX9"C&"_811:V9R(
MMH/ZM*Q8VIJ3OR^%HUFU5+LN!ME= -?08LN09?')[=PVG\ CD5^U_YDK>B&Y
MVXY();_ !;"G:5[BY/+X-WQ;^"O1\L0LY3!E"@=6T9<X C!PRN"#'UJG0G.N
M30QZPI0GR4I/=E3HT!=HRTU1:FTGD>S58$$PDN\RAU2M&!:#/ T ;>U6,#V2
M/["%7Q&=1IMRUY/PU@:)VVWK*$1+Z]Y#-U_YT^^_VD?"G@O8_\9X ;3E4D36
MDER,&K#6KM*U]&M[R <:H^4=ZEW7%*7#X  :^B4D[P:K&FE07W%* PXSE61!
M)UXEV6%ETP/V\#]BG=_.?'QS_7G4N8P%O^'__:7:::UFJ<]C7=70_@VA[S:!
M+/[8'>F3:3<R7H(6\X>)P]L^SCWM YGL_C(4^N\T:,L2=#>WZ^TT(_E#V,%M
M^VCO ZX?_7=.>R/JS/G-83*L1=KPZ<N+FRHAH(.WK_Z/8X=WCMU@WE70\:@!
MZ_\,S^R1/_<8$8,@GP9<V__YE-YX]9X@!P_;@VWM;AA8@'(M;1-O_9ETPL[=
M-["9P#LU^O!Q_;9UF>QJ9_A)CD\X'%5.-3*LF%Y,;(%E2SPX]FL!JT H#PBU
M@ &N+#5+#))"V\%YRA>YLV5E ,99KQ+M5KJ@;(T(] I$$'O2&L@_$,3,C"IO
M;*LU=.H]3 [J:9L DU\QA_(LI_Y,$_Z>?DHBO#3?_Q;>G4ZT:<&ES=_2_#*$
M*S&>7O97O3V:GT#MW^(^T6U5T3!>E_#(WB*;4O35P1^4W_QA.Y:$=V@[/Z>9
M#VAET=[ (13E8Q9?/1EM*SZ]X&4AA8W;/X2=8DN27^H5,2@&5X**9OT<BU5M
MC^UALOZTD!WUYNT<32$PO>$%G/NB9'Z_ 5ITI].#OII!# %A!D?.7[8C#+5C
M??-/HN?DNEJ>;:1$G.SG.>8+]4E 63B/T,7D9EZ<^D>DNOTOQMZHL\O0!JW+
MNS=A]$PQ*+@Q=PN6*81&D.4DT4C#]$;8E'&."8S0KN0Q<\=WBT/"2.[-A%*_
M,9=<29A_-RX-]<NBC3_*]QR\DGHB1>7:QMT#%0U/H#<@_0?]\@]>=[4;?FC$
M>L3^/7FD[=*)(*%.8W+?S=$0(E1J/MMQ?3V4[Z!T&]+1U[[Z/)%AI)HWF?+;
M6]@_-9 -*HLR#I<PWQTQ"-"!<6SAO#IJEKOI .; //D(E_#\!\(V:'S^#-/)
M*BPH3,5'RCP]^*5T3WDK3H/KV+FBB*H0[9$.Y];\[+-SX4&3,,?<T3NX_*K
M<S8A47[&>,WTC_?277N'A#.3&:O4T2=0%RC+$Q5JHVPSHNPZB*T+^3O%QH++
M:#]*MMSW\0LY\'AM ZL^;P3W;E$I1_-]^NH"X[-A:%R._56/^2Q</Q(XN;(4
M*( (=P]!8(D%AX-U"A)U#.*"Q2"0$,J5_F:->M\O;WC9[XWK22:?F& <D)%U
MU6;<W@&G U E"CX-<*9_->T96X)SQ: ."]"@".(/E?X95 E,7^7MCF<WX+V4
M'&_37._=LVGYEB*+/_'GQW1C.F;;Y 5P1;-[G4_5%<^Z9D)SLHS4Y9,A=H"#
M12[/A.I"CHLJ'P?BKC0/&1'+'Z[HL\F)U_5\$A*M#Z:H^C>;]/2T&Q)< !V^
M\E8)^0CFHQCT&]0OZJS%+A2<'\XK^^#J@4/U4W,@2V$Y 6^2[VMV9$XHGTS;
M2-(-1*@6.SAL!#I3=E&F_J5(>TC"Q!^]FZ?,4:W\1ZC!G;,D S'3>K)W,NTN
MCD+<[%WXD7E7]WSJ0VJV,USF N;H>++]:]E!Z7-W",,_@&J$3^("+43V2,T9
MU#>[B3/3BHX7>==>L4LR?[1<HMZQ#M__&%_5]F=-XT*9GYD+Y1"D3[8#ND,,
MFDH3@PXNHS6]<&AMP%9P">T^6"\&;9_?Y=A XN)B(&859GYE5[SU? DW:AOC
M-'I=\Z-#HJ39T''DAP*N#130<5RJ\^)>IO+)NP;(9_P8&EQ"DA$",JX7$J^K
MJT&L)V8=OU'/LQ*#]'@MF?P:L[?;?_BA74LH\3=?0G1VC5P*+^WE[.7'V*X\
M_,RAQ+B2*='6>+^Y'!V4W4JWSG/[S0Q86D$]0:@@8)6UK4B2S'X+!>&QZ-L\
M)">P'#4XUM4\UY[[*FR1#!Z,$8,*PK'EDUJ*#]+51FM</> K]PP>KP &!IV-
M%$3!?J$?\$<QD#]D!6"YX%9'T2E>^\#"WOTY$I3;^6^&GZDN>MGK:5I F7W_
MI[1K=)<G4#=VFO:%[_;1+YY!X^]F?H.^KV[RPV$ZL'NK=:NK ECJLH,>S/WO
M%EL>%CJX]>9??@0?>_N_6SY4A<WJZGOL&WP26D'N\*#K10M3!Y]8'.;-">4(
M[1G^&/,!]';!#?0M()!+8(>6A+T%HEOY$5$QFYWK!;QUM>3)=@0DW;I)9#^A
MC%6D64IB.P<(GX(=ZJB:SXI(J6)QP%.2A[2K2JBRG'^SI*1^T:3_T3>37*U^
MW;H#% LV?)C"^@OSI>#'C5_:P^JCB$$S:F#N>ZBO[:8F;(\$4&:98M!JRA/H
M:?(A42_V /F,\,[6/Q*W[ O%]_-]6OOC56SCR]X#A:7.7X&P#Q%7GW63::H?
MBU,%-X,$;PLS@G,]KM$4@AR_NV);3Z/-Q:#:+HXLMQ(HNZ<2QI%ENP6U-R=+
MG!=[K?X5Q-8 ?0LWZ97JHTK^&>$HU)6X'5&"8QM4^ =!#!(6%XN4=G,D#O%*
M!0LL.D(7@T2WO^S.0$L"YIF;?S$[*CO%0D["4K:MS,-]K$CP'E0LO^MZS0@"
M;>7GF8LHR6',[*OZY/^YW/1 #XZPTQ^:!.7>T&"+0;N%1YNYZYT&">Y@H(I[
M=S)9F:TH'(!'5*VZZ],;<7=F_K3K,.@6D$Z7=MBWC56+06T?M@JAWS/1&F(0
M-1<K!O680O_G300%,M_'"15*F7Q-()IGUY&!6FEG0'G@CJUKU+MC!C_?OK92
MF:5-%OE<3;"W=WOU]?23MT3[:R/5)M..0GEBN[K.5A4IDE?!FNN"J0JU>66I
MP55FEXFB_J&'N"6'P5&M5+]GP7\-*GEZ9IP>,#0VK#4<J_E/1X:VEQ"QTJ^M
M*+@V T"3$(OUPD5;[ &RI[&*BZ8DT]BG[+>W80)9I]3;L<L(C[O#>R]*07,?
MT?]60KXZ:- +N^<DHO9/%8P'L0RHLMM0Z^T4F1_,F# 7,\AH;$UXSDQ5(B>K
M!VMDLERM.IL!-EZ!O7(-^Y_/;D"" ]OYS\6@(GMNJA@D(S%*8M#)[[\9T 7\
M<T-0)&X\PP6X7['HR  /_202I9H,$,>MO%_0&)<?OU,4N;NHE6UM\B/I@6%^
M)W0?G;C3M#F6\I_>@' UG%!>JDT2>#N:!RG>>]'.;-NE/)FKI"'AE9<?LD?7
M Q=LRB]#LRY?H6L]1/QEGPE5265AA?(XYT&)HZE"LG'MLBED"]YZ,NDB=W.-
M-4$8'74@@]V,/T?&SRDXZ^7@QDN2BR94=>F3N= 0QZ__ES'\W^:8N1T++)2'
MVP^2SZ-,V+(=X&0&!"!6H,\.K-3;[A*#_/V,E>3]:ABN6_E^U:6$BWI+(EB/
MB@/8>+;5>]*E.4PH;T8-!;^/:Y7P\CR;@ZC'1HN.#I(N^KR+RC>H]Y=W<H?0
M+(]'C3CZT$+%(.D(PG\VQ3XQ5:!3<7>$5D/D<X"ME21U%NP1&@"<2G<@HUU=
ML69@22M#<',1;G.<:>X]O=1YY=H93P/N\KY/53^@K="O,"M 6V +U+$1I4WE
M,!B :W/1CM&JS3*Z7L4>VM&3'@LVWC!G8..^51D 3N!Z[2UYW',L$(04@S8L
M+?_'"%_+;A>#XG3\3,%+/MQH5FJL2 M50577 ,!L*Y(="ZM,=W;I"Y&>&)R\
MOJA97UB8;D@((&*_NF/X*\' 7L%A9^&>K1+1&>%--XP$YD=$AA9)6L5(H[W[
MC1&EXY"B^DCL7"FGZ[R9?>I_,IA]^=);L:3SK%0:97IWAUF%(-E99.B;<S/F
MG>_8+>UQ/<[2@\:D5#82$@ .7>"I;1?MJ2D!%/AHKG(T^AS/NC-'AL)%MH=M
MCE&QBE>12,AZ#")@76>^.CTV<6&L-^Q%Q=L)8@0"%RX!TJ>"2]B!TX!$X>.,
M?\V4OX.Q_S/80:LPB3MK/06>-ECJYFW_ %,BGQ5: MF5Z MD_$ANNXGTSE2A
M!B'T1:V+50GMBD6_;\W'^)F[:AQBH!G9!;9;DN3_5BE-$MQ%V;'7V_N3&6>
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M^6M#.'TYS&'GCZ3E%:YKZ>&)MLJN]+<3Y1WJDA=%/G6]Q,EG:B^3&)B]SY4
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MG9$0G,_-H> ML ]MQ:?^GHOI<EF>S\;CW@X8$[Q35%$4M4SDIG&'_QP0RM,
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M_D;+X@!NR!QIUB[>1TL.O'-[J>J]2Y!Z1&PTQVH&FV1V$!N7/3G?N@V*&XU
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M[ZB+[+;+5=1]E>VU)GU>$!G!V@;YDUT!);X&ZBJ'W8:/S2+K#D/O_<<JQ9C
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M>++*_IOB1-D&0:Y[7YZ((68H.:'N$4VVND6-A0FN&TA,H6S?C0)/J8[+[]+
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MU>#:B9^Y:R 7$DI*[:Y\H]4@Y,GV+6#W2:Y+;=GIP2G$@U+;_A6_1F9#0XI
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M2(?Y;'KH32T#?R5MSS^QN7TN3D:W(E^:;HY/=[]1C!+.296V0?_B#DHC?,N
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MWO&<RF$P(ST3UL\U);/58]657%);U4Q9A'8"O:_=65O3-%4F#_#:P18B9JM
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M.#=%IYU@ZFSTC2ME]D2%$Y*B /F%R],(+E:B)721CV1R]&%36*)8A^>TF6J
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M/(J_^W>>'#]B)+'DCKK/X@24E/N",%5WD9<F.K$]3&4>,*$H!Y&/4[AV::A
M5IU"-[S*Z<2N%-T$ +R;2@_\'701GN^V4JN*R%=RG4S&E=D++R'UAT\76#J_
MSG%](FA?80 'H:MPB6-V1U4&/DV:G)P<7_BGSWH<LUH$7=,^4_6I-]9#Z2G$
M1O)2W[K]"^JR$?B6EL&?SH<#-XDN*X7%2RHIJ6G%[MXKA(Q%=Q\X(56U.F**
M7U2#D:GF8BZK/!T0G7"[_-7ZC #<OCDM3X.N;KS%HJM'0$L>M2;C&\"TT\/'
MM.KS7RQGP\YD)6K,!49\P!0^8^)IK3PA_PW7+PO*.FME,^.L'*EWGQ>2B8JV
MNN<5])4:5=8)/7,_[%M"ZL)DUPQ^+/F?WMZ+X/T@<;^BC8I)O_3UEQU$LW)6
MJZ>AG*>CU%B-E24\&F;Y@!'("5U;V+2^GT%)WT.J@DW(<[8@@ZC'L&?,@QD!
MUCJ1,I='34A;F-6??[!;1VKGQ=0KT>+<<BI$?T"VJ'2N[GS[^Q.9<UL!>]HY
ME!")!<G*@C9V(@SCIW$$EW9T8L'SUY\.,-;PK*)%3?;13Z:(G.7U&P^%O<_,
MORRM<8+X-K]J]3L@S6=2CG2M+5&W-]I&:JWL_0/WD6SG'SP(5)FT,/S7W")E
MS-SMZ%;T:Q>WK=XQ6QB4BW+C&2;'[JEHB+G*_X)2A.0IH2U,_F%.]^NO;S6+
M+1,BSM4>BJILKP;<!H\GS"!>6_EC@HP"\$_CW[-A'#W(:YVQD'*":TNV)7H.
M3S!^BYEV+(J/LGIEMWX,;$D.DOI>AYHIUKK!^\#M*I\!@)UY1S(-2L0Z"<);
M4YR?JB 9+S,^I- T-G"$ONBZDI38C'YRE/*T*<9&?&B*I9$(/HA+\00GT#$;
M;YS+$D\1FW%H( BXT10PW]J\]9ZP)NY=.H=?!90]>YQH;DA$VNSD6BLBS8DY
M=X>#_R*VU,=<E<'8WZ7ICM2617?@0!2<4ZA>RV<>G:Z[ZI%[]_B=.';]\JZ4
MC\8KLCKWU5,7[/9&2OR[KUZ!Z[JIIM>).&! B;M/0Y/0#;WW&%5_/%7)G4\*
MQ3\[(T#Q-_"\>XM/"_)G6OV$;=Y*.$)A1]X.OMPW]$BZ-O'!TX(1AU(8MB1B
M4U'X+2X7<9-D7M5HN(<[*S[$*!=Y)]S$<[]3.8B[8\@KE>[C@?CD"L\M><Q<
MP7N$ A#>U'DRO;;0$*WQN:?5; M=C>-I?)2;V)S12,9&P6IJ?JIB-*CKWIZ!
M!RN]8[+7NF\V@OP*@,=.Q:\ H]VNRP-5^P@A!^DDA/4Q\1>4-%*+M:/1X:UA
M[!5(=!DE5Y9-+ZIKM5+2;IRG]^\]J-R<+WH[&\_W/2JJ(".FIO#/C&S\"AE@
MMYUBL95341M+H5CP(%+/B7>&U$2R;R&0FEO(^.R)P8.N]R&ZM_MVNH(YOG4V
MSH)SBN4L/:<84^??%[UUT=3M\M<ZY$+[)@(>=,F@NP.A<O."XS?UQW-W3^ME
MN6ZA]=8P3W,Z8BQGQI8![\T[U0(+VUU5]N=M.Q)?+/+G0@">4;6B8JBJ#=U#
M.SK1[0Q'OJ6F5"$F+*\L06C=QDNXR]6FNPQ#O+6,W8..9.>AQTVVXZ@0N4!3
M]DN8[.=&&_IU)\T>W%C H=Z2/=+=*.Y]IN *EN/,L3EL!817"FX-@$=$SCZ0
MJ@E41]F8?;0-MD>55#5IW!VMT%4<LIKKZ+G8<E$2)&4;B3SKYG=+!4=H6#44
MU75[[DNIWUC$IIX2W[<@YVFOSC5<G@,<A$3!,UQLX!Z8 )2<]5Y1L*"?Y];&
M=S7S[$XV63I88P4)RIQZ=,&T(Z7L-7D&7>YEK;]L6;R&>HGH_\Y4-$5-A+$+
M,+,@BL(US/,RQYJE;7S=<<]Y-*0J)N.+)<#S@N'#-79K"F"Y* D2X#5('EC7
M,FJ\O?]7+\V*'T3D>I GX87(ME2@26<MEX[E+4Y#"8ZL58&#FO47C?YQ *)L
MQ282'8HC %;E46V.C[B*R16&B58R<%;A\<M$ERE\3I4@P1F?RAZ^*W2;F!->
MR83EJ?2RU/=ZZ$PF8RW,-@8%!!;E.:JQ*-+_"DT$J ;;O(8?W,C7NSGTT^F>
M=]YB=(S!):/ FV8]9\?Q1B7VD6M\BM,D+3]GV9X;V]T688PK?!U>41N",55U
MNK7:J8(KJ_?CM9FX<KL1.A^;G\NK5K^.:X*[>)1Z48QO2YO.2#SI]$N>:F?L
MP88/W()FV?(4D3F4K:K;2L(U$HD*GOVAWSQ!O8LPW[3>"<WVSJS\V+NDW"=:
M$FM@ QI%LL[*:3)M)X<6_9U5'I#UAN\N&@&L1WPR#(V_@/ZAG,*OO7GAO.TO
MI*]LK(Z/S:2URQU:V)Y:2;^4^IPK$5+93(C;>B#_ ]WS9O4I[/K->\XG2$YX
M.[LLMY7"K @VBJHLVC^"35%:IJ,2<;8\ZR+HNY%ED3WFP>)A[[:L=TVMP)>A
M:M6>;7-O2T.5)N^:&WW=_[W=67!&+L':)'+]*G<EO22(2<^;&S]/M=1LL8 $
M*F[G!=TR0OW=!X=);[9,1.Q*R:BLR]$3^)T\)A7VVMLXC4I_,3Z^X'V!N_H<
MP'8^TE?G%$*P@ 29FX?2+[L&EJ!PH(X3H" ,>3EF<2/MY:Y4H^%+\3$DC!:K
MTU85D'*B,.[GZN\!"[]'G?_AZ9+9HYNNO:JW-=224>:!1W[H("'TC(W92A\'
M7FDHB_4$9%GPO5R<X-0@+O\1K<^[::ALN/0E!^A3<1!0DN0^%T"_;] @.TB5
M3U_#2!GS_Q8LL%$JR  R-Y40::H'T=B[8'U**>.'DHKL-X(28KOD2(/GS65N
M16KOB4-,,PZG$#VWM6DG6:=TP?#5'33RUT6"HY%I=@TMP,J?&G+T(+%TZZ )
MR,D.ZH$5GM6XGX<ZO7) +"*[,M-U@E-P/UN8];M2U&BHCSWO2BL/J;3M\L;L
M?XO5LU-^RH: 1P60M\7-63!I^N#CIJR$_QYO>>6L\+R.Y'.!K)6TTDACYY?.
MP]D2_J^A,^-GS&MYI9,]H>2 T?^V4O"+K'C$N=5)4D3M5[E3.P44J-ZN5)I2
MX6^F#."4Q9*](+=H2246!_UKP;2UMO$OK4!O93O$]0P0TW8S"2] [TC2?PTQ
M4P5!'7BMTIK?_0K>EW;H1]Z82'/3^E0JF]DG'C4#0X\"FD/U[%PD?JBQ! XQ
M6WG*09[GRGRT/B'HMTG"4F7)C7ZFRF58T%>N9S^2UN UN76]\.PWH?Y%1IR0
MDS)D::[*4V"9?Z0)<$J)<#B!R--(?-<RRED^-;HR1Z!I$QJ%)F.AX]VG"-D<
M *A70=_/BW+&QE!*CB?-&87,:(ROWQ!0V:A#X!__$SQS-T"7 "M K1V%(=D7
M.%83S]>*!_(D2:1QL!<SBGSO&X+"=;]D"&Q6Z9]/!-0^-TL_J<B7.Z<]'-1?
MTU-N8- X%_-O5531 U3U5CWI6UUIK?AHI (;];%?M]UHX?.TO"+_3B"M(*8S
M?S0=?ZP'6D_5Z3"FSFGM/]Q0+(D7#YP3;7QM7O(+#\$V9/+U[M&P4UHWTQFW
M<313-7O7\!<+=:)/*W?]B)!2HBL\_60?:4Y:$+ GFXL0G5"BDO6'?FYFMF]O
MY/-; .\&@Z?=<W'H<AK(L2EI@O#H>KQSXQ=?(69?KTW?^KDU\:]^Z_5FY3:O
MPYG2 HLQ]S$3)S=;P@OC.OHD?=H3#*E?,.B"(,)3X?YVQU:@Y"<A-OI)Y.^L
MM D2ZP7$6CI#S0A@#Q)$;.:E/K<NKGC@'>3J'%F3<\]A_=.PPQ!L*^\)TVSZ
M377:@28!1&@F4)C=QVRO9X$3=Z6X_RQEWW&G'EH0GVLF8.MQK80"PWJO9X.>
M()#7)5)-]IKF=6%$UCM9+S?QH9V9?(5NLN'08RZ? (>Q/$PEP<@=N*]CS"W/
MQP1QU,22>K7.Z$:ZXUD7/V>TW]P4362X4X6$L4DV:0"VQB%&)/BNX"]-J(US
M-MOR"\@A=3,\\[KP\3V)'A[PHB $"%=*W*Z4GYQ$&8YJ-8^R!U>_); -TB]U
M;!M45BX>I9HH?<*$G1\^_:^V<=^N%.#Q,6T2(<0REP!\R)UER2U7<E]V6W1D
M3MJSIN#/> ;OHVO $$1>\18P(+TEP]&T(^.MJ"+K=@XL_7X,78H'>UF(=^Y@
M:H@4N=K=(%QF)^K$AI>Q_?"J:6&"9^K+<D'4_+ !3B8Q^^QWV8JZG* %]9YC
MR.YD78@KA0,1/H[<E>)?W'F+=(160\!'<*O)M^@O(KWG3:,M59-!$!U2]AI_
M8AX@TZG*.:_=/T]B_%5>B+NDRW)>3N2B.RE2^OI8'9Y=_0Q,WGV!F)UA* +5
M3)O^=Z>HS]\4/?!DV,-"3VO_JZZ^M5VI"%PX2J+^*]5<O)"JP4W^4:#[%>;7
M(OZ:<Z\)^FAM,?J5^\KCO#5$!JO<]_X]+<=6EV-/WKL%2/\G<MXA;Z#U,$;,
MMFE%+X0SGN<69V5>*T@%OK:F0LSJPLH;NP\_NKSVB,8_O:XTYY9GH 'A+.U*
M!3 98]=W_K.VB 2W(;9!S#ZV7HK9M"-K%+JOLSI(:>EA2/MP5%- 1S_145G>
M%$S\TOL)OT&1#)%,8:/EY,F9OK]Q1VF%H7,3$#?%IT$/ OM5/8"7L'<Q+1D,
MSN64<XHN]&8&UK6N(VT"P<KI9"9N.R?!A?Y-M&]F\O0:"\XHCEQ!C^EF!)=D
M3)]UU<,3<EO&)P;YJ^_D# =1,Q5F]/@X7Q2<N]X18<A&7S! ZH; 9=PR.^0,
M*F&E-= $!DR<#@]A_+<K517#C/(X1R8)H8*5,?ZYG7>Q?S[XX1JKP;-O%_8'
M#=P:GD_F\-II$?4.!;!,W=6USYRU$Y.D2+LM"%0DQ]W3K:XPA#U?S+Q)O)56
M[L$(##U=>@13-+'X]%\CSQL^=PT :$YV^@W=K<<OEX6;FNM>4VG+]5Q"^Z[4
M[U;W9L 2^>]4F]4F-H]EKWL1\Z#W. Z5H58Y3V[X3>GVY2I>64=.3%U6_VW&
MF0%C(]Z([OTJ1D#?O)[0^;0\&8.]9 ,>LU*-*<+E9RXH>?[7V%/2_[>.WZ[4
MU;PSH/[KZ00SF[\7Z6!\.:=OECD^P/>B<3;40"QR(R_JS]':G]&OF/[E/0\?
M!A.,IB<95J6S_^IU*OV3@=\*^8M^]5-O03E;;D*:91./E#5MG4YC>]VUD5\D
M1I/K=G#5B\0AK_UK4%VG:P,9*U./UL'RVA7I^@UX%X]-KTS^58$.!JDXBM2*
M9M4=AI#_R+/\M'$6+H%/;&V).42<J4_(M)R,:M +TW.DK*Q+ F^HS3$;&-3#
M6G-!!?S*RGBG\EUY2KC-@2"Q=G23-^WB:A&A.9*5\%G>*#FZ(M1H#MGC$M%0
M;30AH IA$-0^FT"82D!>VJL5.$HJTOX*EU]7L<C/.5J2=WG$T%0F\'$X@FF1
MUMAY>N0.3M[;(ZDX4 ":D?Y8EU1@V,#KRH$H%98*GD,Y&4R7E@_#8->A;T)Y
M!WW:=4)&)'E@3K\ 9&R7U*R')PZ\1C684VV2"Q6U>/&-I7VHNKX3F)9YV: U
MU1@[/9G$TR_TD@/FW$-\7K#=H W%YQK7SOQ>N+PC] T$8VU2-2Y+R-)UX/:P
MR<+*QFC38\;[2?N*R< EWU.NEJ51-75OH5L1H!6Q:5U![''Q%%.^Q9X[^X '
MYY?+MH,$#<S++YUR/KIM0]^<![*;PC-XBT]Z'Y(>AJR**^3R-V-&Z$P[\1>)
M1V%1SZUU!+F8GNH%E?)$JS#V_C'1%3@L1'\6]_N!F1>&>I__Z:H\#$HV1JY9
MU<4Q<1'W9@:HGV*5 \E'DH9O@66G%@.KQR=VFOF37H"U1: VC!*-*HW=G-.)
M]H'U75:_:"XZ7GQYY&>KT>P#KG4CA"6G"@),)Z,0H1!3<F6IVJUNIR92P:7O
M/:DV'+VH7C+B\G(W1._<3YOZ- Z#!:,W1$,5VKU51DW<PZ=..UT-\$LZXS/$
MB:5]#5RJE^OC5SR*?IVS)_A&LW"T6&G9AVMSJX$'+Z';OLE6UQVN;;&I\O""
M$!0\)R:\2::=I2W.%X%GYM,1)PC'5AZ#M^9)T6F_(X]PI9>W).SO_17K94B]
M)_C7O;-JZJ"'XD(PAT8;O+6.0S:YW(9VLT=^FT4=B+40@00IK!AC-A3S_3E<
M;M]2(W,'W5;M"RC#[&L!AN/[U'CY&9"QC+T>IP*T;*<7__@#X>@)%IP1%1ZU
M\N#R#1,*?G58>$F=UN,IYA1[+^8@'DU .U<20VN,NEJ1XQC:%!HAXOMV+?Y,
M,>8["* LF^0T-E2S7<]9,7<%EV)-BW%=^>Y<W]+DH1@M,*']!^K6+X!L9=BJ
M6,)RYG=F0[Z3#\1V[4H=(:N+3GVU4M-9*:R>#A2?(_*"IA<(<J4.])%&IS"3
M#_KRJRE7)ZVNJBU7P_!FTY3(/3E-$DPH!MFR4E3OV<A9 ><BYX>H=[GW-?EC
MGWDZ^=.5/F4EY=\90>U.-WJ]&@J;S;UZ>[&G)<\T+) 5N2OEE8)RUNIKD;F_
MS_XJ?"E.5:^0X+V0UU^;# \V<WP]QAG#+YU,O=H \SM("/PY(!W;I;'_IQYZ
MJ=_2'I<%T&TDN<2$+,XS[17'0A?-> RMSSV^4DU)9T6OKUYG*#QIJ'I>6A/;
M!S[0<JV4"HLI6C!7)'X8U<)/50#%&7#@.%R5%M?R>35C<5J9>FKR3=*GN\^L
M[MV0#.Z=([M0Z8=2GO^S;*BFFF''^M)FRM,TTSK^?45SR^"YCZ#7I:"*V!!K
MV+]Q 732)5W^VG#+65BQ)T3]=S)WNGX6=,G<_2OV;2UG'NT> [PKU#*X)_/]
MNB^A(-;#Q<"X&8_SX.:TH5YH')VF4GWA:(R/[<O[(U8I_J#1>VX9TW/?/K1F
ML+[_ZV0BOP6*Z.U7/7>]UZP&ZG6K7FCX WS4VE1TGM<+#AS^47@(*_QD==%7
MMBY?.VSR.G[@+,G([,?0<;K6Q*8X(AU?5;$GUBQV_*GSQX'$'I;3-<>1$+B7
MW9A3SC6'$F=!03^B$O"R[:@/"4X"0K5K8EV *<SV4;9866(!0H G.%%DR8JQ
M=QHUG7(5@^Y4>3-*%*$!!&)69Q8A)W#>LK^QEVE 7>M>1_8W*PW:!)"<]WJ)
MARE[1/YLIY"QVV8J^?.9,U/FSD-Y:^PE%Q(AW>^_2:W_N6OBDOQ\U]JK-4G6
M<[;%W1K2L7M%6H)A+M-Q1'Z)*C[+ WS.GE9KD!"M:@"\O#'#Z5I?<]+9ZVYZ
MQS-(=?1KY[ ,MU7H.[FSR>)#8;, R(Q?<M4/\9'D^Z.86J2EG 3OL\^$[^@O
MYF'-VB]PIITM[(26*_KE05&#Y@/KYWYXHMK<Q.JBFS1#P%B;DOA/%9<Q- O!
MA(2=?H\DEI(S#\W\YP$$="Y[W[.4F[*J85CA;]#P$D(%"'KUDON@&8S(/9U/
M$<]AR\L;7K?^>#@Z,ZHE'B"TX!U__S+H_4#+5KMWD;2YGS%<R05_''B&.F9]
M#NG,5?\W1R6[N>B 6\>V')]6RO<ZS"0NGN%_4$:B[3,",F)HSY4?7P^.=WDG
MP]Q/@3C!/+E*777RD0PJ3:P&CB/NC#X;!MW&V;G_.10<\F6ITA>$RJ_5D+?L
M('DAENDCNU+/"PGQF3SJC'2'W$D/ <PSSSE^?0K$#'P**BLU*]4V.\JLFK!X
M&*+B$*+ILD!TZMN,]?O\@;OY$19'=$Z./?HELS0G!1?JRSX^:@BKD\1.G-Z4
MF6-O?Y1)JCBJL6$=&/4R:,OIGR^X']Y2.[G(W[CKK+$DJXME5Q!FN;/1\4UC
MI90QF.$*SK&<$#_V.6,^L "Z>OCV.]_0326H5*1Y$F6F/O8$E_ <JV8'/H+F
M@-V=;JP*K:D=BF[G\/S?F5\FSE'Z+T(JBD'^]V.$F\$N;B&U5/&A._Y1;&":
M'FLU><7*C)[%3_2M!)DH> 6Y\8DF>6TO+ %BQ"J G>468?,4_8<!9S1AMO 5
MN%'BNN*S5[CS2XZ"K)C9@Z.FZ#Z.FLBY,DCV2 GS\51,%4@)I>D[[&JLUC'M
MW6<RHQ\$(1$EIFB-9AE%U@+=OW%KB]D]+KI@O":^/G(M,I3[+,&+\S=_:B^$
M$MG-?"?WIR!E5VH?: 3-VL=,;CG+6I))YAA2O75&O[R!ZX$$?NB;R4[HX+&C
MO>I3Q2!F@?0;A\]O*.>V0G;F,;_.C1H%MFRPJOULC/%='/8K;#5X%,-.F<61
M<%P^NAJ?EWH2G>B;RN840RN;,;FAFQZ-8CFD]0Z:K"F@>G)CTTJ7Z/.EU0R(
MF9O2]G?^2!_[#VT@2-;N ERUW77CKB7(02Y+;]G=S6]T,NC+*THCI1/VLD"1
M%JS/[%*7XX'3EE4 GNS%Q>\6&QG=#P/#PO37#N8FNX,8*] ^O1OHES6?/_]V
M#;C3(@K5[08+[ !61^G?CHBU,A:G:C4;6X:_#>MC2:\:THXL&"L;(ANUH'T6
MW*J:T07FD5VI$.>#2 <!;!:EZB'3Q84]QZ)CO)=<'QA-ZN<%/_VOOBL?80L#
MD%%T-&S:M<+: FDE\.$JW&H2%%9/3/_83DVIL7X/JY@X71QE'&11./%SIXPV
ML3G9;5+X^![TQ9M/*<_ZFI'"&=TW9 7Q)V;#ET267C+X./@*>RG?DSWK"$[8
MQEIDXTR&L?175,>CESHBJL8.O7SR=C:ER.G[W.1OZ;QR_A9O8XZ<P$+)"30W
MV\@7QN #1TK2%]TB$"C_P0T/@VS+5[X C4)B+_MT2ML:8QYL&C$&E"R8R@YI
M!>5[ 2LKU[[IK:2N-U(+A5^ZO(3X[<_A<)?6>)G$B-6[0Y^&MNX8H+Y7KWUH
M&"P*H#0BVB@'1#9CF-4A-I6M^QK[&JF+BJH.LL!TO8_1>$L,/]8RY*C_]Y7Y
MWB(SQG$0\V]7OSI' 6-&XY6-B@CT<(:I'C"MQ%-OQER=I]/71IS"*X,')T^L
M7V8>U="*TR>10UJ^2K\.0!'<TEH"A:Z+3\UR?:"0F6\\@](9S%E8N(=U7V60
M&3$\Y^RNE,+QIMX^[?200[1V0[TG6].P/D]*/8J3SUY-I)Q ?Z0<7;%293&/
M_TA&G."\<#H$ABA%3] N:"9%W7']XU%6J6^&4_^:"+.7!8FT87]?'JL5#UJ
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M!D])0P)Y:-; <Y/" TXLV2?KW8GO!&2]:A)HH&%"5@7JH3+MHJ/:GPHHQ:^
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MO-+S6DSEK>TWGN'RIHU-V:J!95GJEMFRJK;K\AB<RB4-\:'&]TO'(@%IK^#
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MX$F<?4#*EI;@)"[-:/4U^R_8PHSY V/.\)%!#/ H'=J-_)-,D[_%V<-T* W
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MU5T3^Z67!6TW7JHT[5HW1JG;7Q,=K3O?ZLS0[F=O- X(+!!!W",=XA:$=^#
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M4.MT<3K2"2X%WFEM.\ K+HZNSJR(5@&DA9#4U^[Q^4JC2?\"";:7&(^$P9-
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M'KJNH-J$7'U1)>HF'T<HU?I(Q;!<NJ1.*B%/T-V;:]26VG0K2JK<T:NY-0O
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MH@SW5.\26O($E]$/G@ID/-W@&\%:"8P^L+X3K+;P'\UEP.(6D@ZF@+DT.J4
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MI7(VLMH^!M3430"+V3\A$AY\(=S;8R#3:WY:(BC_X1JM=CJO@S$E?W?O'2@
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MP)9.6A_J><=4:LD84K[7F+'!CN=3PAPET8 &^/DF:VRDM5EN0/SSF''F_?Z
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M$PT?Z)-46:9\VL08=K IENY]*Z.M9U]TCP+>01Q,HQ([VEC*V7Y(9[HV8C5
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M443Q<\QXB69A":Z.I7N@IU9>%MK_5&(-CI8O44?R3X2B[GE&?>PW[_'?OIO
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MKJ:]+4W29/!GG[C39=;XZCGO"BH'_@RG G2*CZ;O*_Z?F(VVMSH4?FQ\R=<
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MX!$%8 (,"'\8X#TLS4]2*J!E(7K&$\9QD8L%)-1H3)Z+(?RJ#AHR);XUQ@<
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M/;\*/7C8C!J'/M_?W734KK*6J:YJX7.ZTTX7I1613E7,3]#KGLI1/M1/K/K
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M\7M;;L(UOMBL$$J/ZK0 \TC@A.VTMF.^VA/3O!16E=R)>&EZ!Y&1;ON<]\>
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MRZF[G^:_)G*Z_Z&  UJV@XL2@5H4!:;I 1;0TK*< )]5GY$#O_,\7 8,!I/
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MG5#;IVTB8;"B3N[X-R4[VJ99^0*AX;MW5Y%$^5[NUPJS)HLWBDBWY#((K)-
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MA;U@5#YB_T:K:ES89&Y5AI9JQ[74]K@;>/V2N@-R,"J.8T4B%$"X\;*AB_:
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MUX 4D'I@Q81+2I:FZ_C'2<YIJ^G:]( Q^4^8R7Q.Y/:;%,^?<+$I!(B>_'J
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M3C(XN[-PI<!(3HU$&58[B;LB5R&9K!\:Q</GKYKU/N)6!&NI\6WB=J_1]-%
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M\H.US,<Z-E9:.VP.-&8J_4^B<5A;O7+@OG0V0+PV%M3F^'S/,H[KX]J,5XM
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MTUOEH?ZY-1I[F6X)X4SQ@J9\9TWN5MQB.[I9OOKNM\D?"B!L8B'V.8%*]#X
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M;-I_-.5RXI9^FGQUVZA8Q/O(C;7NAB'1#6@C0OA"?&U$OY!?H8PN$.OE0"7
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MM$X$^I0N@,)4\562FQK#J+@K4W"6'*+M"O"[HG$BOF*HM^$<,P(<<N\R'O]
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MYSU+_,9C07Q=3_4@9'NF3 M@Z=*K&FRX<.UQ9,%I3VPXIQG*?5JRO"_ BH[
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M<Q*L\E>W LN5J>6+O'='IR@<&08/,']-ZP^$5#+=233#  4>C?(? #;Z &Z
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MD>,L67XO.=!+JI_<Y0J)C_!2@'1X+YR\>_R)C'Q+LPT0JW$MH5-F81%R-"1
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M@0,_SYBW"I?RJWGA1*PU2_6/6;#\QY 9.6M[:)[?PE'TL197N0F1#S,0T+;
M^+J2('X7#)%U4DH@#8-G/_WUSL(:I*1YB;8U^<5U+6NC-7";"P"-Z(RR] 6
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MF=,TOLC(X7G [BWRG;@'W\NW!.I#VY/[XT1<E&12DH.%+:@2@FZMFZO%=D7
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M_=^K-;#6_\%,(]81#+4^EF^.MC[ YIPH*1U^OP!,E ^_(-]H5W-B)!*)#RX
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M>R6+.O&V.?A602WB1I")@]U;@[ZS10;J4M=_)B'W-U>:=#3S. 1S5%E?<[P
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MDX.J'DA4UY*,_*?NF;#H.0WG3Z9:*$5>X?)UOJDH4Z?1POK_4MW?/O4@N1)
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M&^J>5].HTL1BS&187;RT476_OSU\[L]OLW@!Z!#;"L:^QA]F$>CTB.487,&
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MH]+:T^]]?U)$\)W]Z%=E@&EIZH*#6?]D2Q&LHS>E2J>%+#V-LU?$75M?\WY
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ML/04'6]6CSZ1Y]0.DPH>)%Y)K-(+JK3S[LOGC(A1O4UZ6(WOV(F72XIF=W=
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MM#AN&.6DA5I9GS[]>(,8@Q5+8BY\)^$B%R@MY0PMJVY4!^58A$:,0YR%8HW
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M;4A5T+%*K=IFMLX%H%#D"P/'X0XQ2O2=5PZ9PSTKZ1$X.::9Q:G2?!V]_:L
M571\FZ]!A[L4^27O:O*==(&MWGV**?53'B>T:A&&SYP>^#?4O!UL6WX3B?MO
MJ!GN2:/^&VK(FFD+3QV=K)F%1^"B!; KNSBM3X9UC3K58#TA%4WMU<1!,^@K
M,:&*SLJGH9<0UH*33S@EA^V!"0M12'O50BP4U*F@<%03XUB\KB1G_MH8HCT?
M (UA#<CF,AM)$M[&\0Y3!?YCV,QRJ%.-UXITG^CY@QBG]RO<H+F:69P=85"E
MK[W[+"5DL+A#:^ASB+^7/.H_]#"_$WMU3>'2@1+G"?>BH7DOMKZ!9R3:TY);
M0G[](HL68$Z;D2-;F:<@1N0Y6$F/[R^P_+DW?X40'..*R]8^X%(^E7B*>95(
MR9X!.46H6DB'<DW?U'QJFWD8N\<'Q G#HDPJQG(P.PG.[%@[4+43MX$(TV?\
M]KQC"]7GQ?WRYU\8L[V38DW,N^+D;R-U%L5.%VAA:NTEZ?XKH;*6 Z[*/K]E
M9LV*8Q0HZ]P_(!<,\KC*7?!#L7+E7'^,,SNCOC\J7O-]:L[SPWXV*>P1U^8C
M"B8_"B8W#;=Z1 ==\%4(NB B!Y7$/I?F]C;[2&L$YR"9?^=+-["?<O!*6+O]
M<I?3MK)HB63S%[ 37?Z"0^YBPR>)IV24[?9^/5X4(3I]WJN*.P]YDSJ:H\TO
M *'ERH)VF"'&&5CJ!<!R?*GB5&+@:%J:VWS(K0-H0T\,!RB0B:9;Y6:T!G,3
MG_V>(4KI5HW#I7ZL_4268DI]%&(/;_4M9^G<>!LOFS3_9##G+D^#B1Z!W+(:
MWU'SL1B$"01U<"@<B8"U\DU+)SHJJUR^/:J+;*VJ8*=24U6Z_A+.0;B-A)0T
M5A*EVD_H-.BTI>0;503BN%[HFVIWN2_B@*BMAWQ;_Q^"G1:M:SC:(687  <Z
M5PKB#VQ79! [T:/K(6)B4V0"K@@IT?/U%-G-_[B'HO8IT<=Q2J3Z=0'USX?0
M$=^J\3D/QTOA]E "D\63C0L C5[U7SZ0H"*QXO-MZ>K'-F^IC@(W5IIGQ#JL
M6>2&8O:"[8@Y^GBML/U J6>-M>-R._2H(IK%]+,O31_S4^^AP'DMV!M<=P;G
MR.2W+W^MP.CJ<K;SP7/F">^-F2Q#PRP77R<.'T>'(_>X(N/;I+^,J,LYM8PZ
M?7[VB(J$&/_#FI:$ W4^L ZW;SO*_)R>CE;X&JA2NCRWE&W0QC[H=\G&V'1U
M6!W3<:MEGO^VX%&LB_]6,[[F$UM'5(1\,'N/>).AV9\MIPK-6M& P%R'#%?.
MQ;34^YUZ -C0YAX!:%TW3A+%;'0C[WHE^**HVB?357D0F3='<OV$I%$/E!-O
ML/CMU#P4GAWNB>@"Y=I"HP?B%Z_'8N#,N%)P>WU).J*9 :F#X4RE;SLR"51N
MG]&^(GT84 16DQ862V14;9RQ<>SN[@*9 XXK6ZSY)%Q+D=($#JS4.TEEKIL_
MOG;6S M5U4&V!*'VMU5[\HV,$:^,9$9SORC3<#<E)[[,EOL[OR_D5:\'M0JU
M_!([D NZGZ!*+].%T4J$>FTX1" 5:DY8=:ZY?T=_+[X!N$4.((LW*9NIA0G9
M)>12/F+^V6JEQ#S#2J;RGX;C\L]^-0FL-],%VZNQ$Y.TFGZ-26YU5-$'%CVL
M1$&O34FKBT?>Q!H4"3-%/8@FI[HO?3Z\L/OB_$KP[_6%$TAS*1!=:460BFRB
MA"6]P']Y[PU#3YACZ<@")4H;+-H1'#0NCUBJW#[R2C**/>07/>5U:F*O(WS[
M6N  !'H!8WY6IUFI1<GET)DY/KYG)MPQQLG*\C*Y5FWAL/R2,).R?</4-K4G
MU?81H'+JLV1E:US!V=>#(6IB3B<:$6<W)G=FP/>\=P-U>,CL.(KZKL67'VF*
ML9;=8E_2_J) -?1YT6:.I'X!$,U:3#IED4\ZDQC[0SZC3<'D[SL XXA ,I\J
M$=6T+25_PU7K$+%F5K+^:'B%)K^F.^<;&2-?Z N/QR$R[E:DO]=S6BO#^CHO
MJ8$R%[81I-Y ]*/'K:7O#04$V&!._206'4I'5[0KW 8$PIZD41<"XI.U6<GV
MV6J3>D"BKN^KG*<3&MP[I=%(!!84WL1F1=Q[1N!(!*+RP(BQI8I8"1]=:"6X
M*C32P*7!$@RY9A.0A)5?.S1ALD _DJ\4F]'A1C[/\?K*11%@P[:ZP.4-I"3:
MZ" F2?H8F+*>GTA8;R=:14:LH2$*O>NGO]/"^3)E<,6(S#3U%KDK9HG_:EC;
M&IP.&(6KW'M4R\_/1$WJ=V_NQ?FH^'48$P=P>KJ8(U26H<7(5JGD@;;5/(^#
MZ\?T*[NS6M3S)BLM>[)=!?8D'H)O.%R_T"JX33CO9MCW] Q9-!U%M3B"O4=9
MYK6J,260BX+4C:KV#I)"ZJFA,C(,'!"J@J9&MMQVG]U[Y);N"@AU]^:'A\EH
M/07L!5/ 3J90V1*-8W__>39$3LQK]RV2RU"UL7+TS^J.O,71W:!?;9HO_3U1
M(V9PGG475#'UP0'(Y4T?8%;Y,P,3E;#_O4R$>@H=49K;2G7Z_)(<DVWFGYH4
M#E,-F4>U)W@:$YX7!981K^H%MV6S$%A__792Y?VXTER9^< CTJR$*%,V$P6L
ME_2[ )AT0F:4I;"!LIWF;&75>58WSC]YT41Z47I&WFF)!!1=HQ8(>43!G&*A
M4$<P7FTSW_Y:. T7)P05</=;[NS_T%6KG*TCE[D-B;#YS=++R#9+-#%/:S?G
MJ\F33 O^JN/&]0DT/L*"%>),^BPLLX13EEZ,!4S_U_Q%\[\8]@[46)WN<:N]
M.X ^'NN^9YPN"V*J#TQQ->V3/-RL(Q<=DU_.^1?;GW]S=)G4EK)TT5#!C,1\
M(=OG<LBE/O,Q"V.)#HQ[%21'=KQW*D[2'($[XD#4&XCF*ON(;;@95B'AP)K*
ME*C0B087V7*E]L_>B>&\\G2[9U!V$++>C/9[XDGB-0+<(D84A  6&26Q38^)
M&@0>[/ORSIPH=BL1PO;?6\"/_.UV2,)Z&#J(2/JHP\U3QST*KFCSV2=&H:\Z
M%)(?*9:77P#^83ID)=LZV)LX:B]U-29H%GZ'S).E6>,+WY&TY'RXDZ)N^NV4
MK,1>C2G('(I\[V.AK>9EL7=>'C\U7+V<N="A6TZSD1F98X<O[^2.ARCZ-H^6
M;)X/>2Q=ZRXH8TOTO[SKK&1S,.OV$_MX+S$]>TVD[IG"G^O7_M"N7C,*I;B2
M?U<@C(R"25/#O9D#&8!-HG;*IA\CB>6MU4^<5W_7<[U14^!UV/LF<=+LMTAL
M:?70^Q"SIWN#2HE#;>CQ;,'A4F\NKT];#+HA9B7R<D]JWVT+,S!_]'#/YL1K
MV%S2K?:HMO0:[E28KC'!N_>YP:TJ".Q&]LRMEI[3::9;PG>T%8]_Q;\-45P(
MGU? 'R.B6A4R;Q8NSMD\18C#57ZTM3V)ODN)_<">"$/=Y\'YK,LFOE_+D/D@
M49!\[:_'+<#7%EJAYS>MB$-&Z8.K+5:W\6U:-!E;_DOL/72\H3\Y5SUK5U6D
M0_S*5IZQ.I<1PE,V+G7,?2(YSFAD]+*JT&'5PG+4E3JCZ#JP@;1FKOM_H(4T
M]Q,Q@#V)[AN/?#2?,^X L$T)B2\SY5,XE>Y>*RD4"!^.W:6S3D"@ ZL4:IJO
MD@)=76FCL;$\/&Q/7MR]$NH= O@C-H5QE1%Y\TTYQ >AO^EPQ?S_9P]CW06
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MKA+CVHS- XA2*+2(9[#]NJ$<G5SGFL%-'5]9"M1/@,F4[ 6@9^/WI394J;T
MC/TE7W"J'C2L$ R J]C O/BT.LP[O[BH=N2O%3 O:0OXK:8L>;"QW!_YD)8V
M#-#YPB!Z>,EO,G#-=+!PTW!L9#E!W:JV+N8 TG!*(W<*N?V4Y2=Z1N96XEW9
M,1^0R$J]VC_;KSKX<)Q5#L$E,&APX5GCR $?6VG0"-2O:B=Q94Y2\#V7#J69
M1:*;1Z%07?._A7<AIGKY6<Y*Y;?LL<_.@77!]/+]]359$,8HB?[PEXA(2,,&
M)")-AF^TK69X5GIWXHDSZO./J?&C>R^F'X]9/$M^DD\N$L^F^9Q*=#;46@%V
M9ZA+C. G15(3K,!_SDC@_WJI:2<&"@;V1UQ>UW1U]Z\K04^?%9(3;Y&OU1_O
M'7XBCI3!;TZ0[DAX\X 8'63[>#,RL[8^9HFJ0:MC2M671$1[,OU\[XI$)\Z^
MRCQA:'([RU>V*50HRE?/@Z6//2%0T+N[U/=GRX=K5__R_FVEB'&5L[C7'V7S
M<-'6MLP/<& ==BX^3G+%[W:938QH#+0?Z;+VN!QN>#MGL-QH;$DXMV5I^]43
M?G8R1_A<!'PG'Q60H#E.IP/*RD.M6HEV^X5>:5I3JU>H>7Y?/@4?>7(!>$'T
MS1TJ)I8_(S3ECOS\9#5BH[WE\N'!M=P\&4)"(55J_J(7[P5@BPVSI65.M"N>
M<P@"X@\;RW_/6*ADPM*#A2;Y\#J\B=:.0/??3#,OPSQ:/!_R6F].8UPY8?;M
MW%UHY(V"/]F,]7$#<?K(T5*Y 9]MG%MK-H_,< 5TUO=N3*OPTD92KM@RXW0N
MB&J>],(/+I=#7=63.[IJMJ5,4Y+P_ 0GHQ'YYG5<7P+MS_OTM?7[,T,3\1C6
M2J;BJSJB(;?(EZ42+B5^3!,?_.7XOOX/1^X;)3Y[E\<2@?9* Q7UG>6L=BC)
MU,J(65P \J)Q7+V?<S[0GB1IUV8?/:VL;4 H^,H^3M4E4Y16?&'FN>FA1GOL
MB<V)<_%FC#&8(S)VU=N'V\.V5C+,)TEF$-4,GP26]PY>G3+IQ[1AO= X&\%/
M12?I/6CP?:Z5Q&6T_$V'2.9!U=WX;$;]GI-AJ@RX_]3.4.1VE<J#I_7(]&#1
MP;^(CM4?^$5EKCZ)ZM?PX^CKF=5^\?*]8L?;\[YSIA$2#R;!O$^[F@#-51E.
M=T :.M0XE9@45%?<Z;AF>LXYH54&DM<Z+!N6.SV3;<V,7\/2#;R9 9MZ9:EI
M$"CJ'UO,]EQ#ZM[AO45='@FH<?MQU"UW ;"%>G1951+89LTI#^.*K+0*G60&
MBF#I4(^ !K\MQ,RO3/V_:!LR^C;5^1>3&7/%L,UDOV%6J,,8L/>P+2&A/S,V
MU'>QT6GW2&?4-E%G*6$'*J*J]TOGYL>P&""D^VEN=HXY<9#&'C_X==G"R:><
M-0@6R"EL6=,&M'W=2E$S5RN<W.X^V00E6F)!K!N929$[XI??*8[][KP3]1&W
M<3GDF_F:SS 7Z(/5(^<*F0B*",ZW]WGJ!@"!-G__U_6O/M._0^A[+O4W@NHL
MK4=M?^DOLMU[6\&$E5,4D%/USL[?F$8-RV@S/O&$2:'JE3TN /9.,G(T<BM_
M@QI"UAGULZ7\6_.;'?8UJ_OX\FCY -=8I>8."9> VAFCQN:?J6WSHP8?3:'0
MCZQ:G%QK#:(BGS,W@QURT.Q]BXQ1FRY)40= -@AW%-IJ2'OLJ3#2!R]WQ(),
M?)RKQ<T"$ED",$# &*G.0#5LQT+TYI<QJ:H$K<?9\V*? @8*_4$N::@[,JFT
M,FIPWJ+N+PS6_UP)VH;\MRVAN>OK//>?5?8FMU-3+KTJEG%35,T/)0Y3]9XS
M_ UM 5A=HO\R4N'(T"DSL,J*OT:&_CF:J\SU2ZV.S*K73XDJV;K=B<>R#!Z)
M03_+/RK3V^%2"-Y2^S3T&>]L&VR;^97JJNK&;\:)*_S^!!_\,>:*MKL/;+76
M&Z8*.Q\)YO>V?L<OC"_(JCJYF?%M88!N;F%CYG P\A ]M[4H.&*LSX?J-XM[
M_49-D$ML@<1)F%AHSXGR#XZ6$JYAF=7S9NFS:]@\DNYP%]&?U6C(2LV'".W"
MW'LV+*BV&#+3ZP+R9V#VI^8X<'0WVV+C+TNAF]>0UEI>O"RR*<N=HX#GU-WE
M("+T$F4Y2 +U]PF6@RG>6$&&F9Y]2N^*MQ2ARU0W?L4S!(2W\+X@;[I!_+;1
M<@%@A.MBQ<2N3DA6E2IA#\5$NF61[I44B]?#M%Z!?I7S$"E/-9V:KY-LV$/=
MBXC6[1&"X_/;IZ@';>J' 1_R$,E%Z<]$>L2@?5>>/=/4?'QJDB19ND42+2Y%
M+4A]<I3)][>8-]I\I]D>S>.!?7;E47>GC#9@*N5\\"0X26[+UY"[:I*)J.GP
M+#W=/PT]@&5\X':\S3]@3-^@PWN<]-GN9(E\X4]N+$ ,=7DB<XYO!5^6JDUO
MZS-YT[]/]#]BP;XPAARXHJT-*R?VS_R"5(@H5)/B!!STW7%>>-2EJJ>\*H%#
M=T^2Y;;$UK4'=,5=5VE_*::)\'*? <\^;^];JB].16[#5;!9X,Z3ET5B7>4;
MG\ZG89WV>WRHXI2];0 4< O@1NF9PWH!<-Q0BU)CK9(B-R."7Q+XSI8.F=<Y
MTLMYC=%OY@?Q8"ZN0;,L7!IM7FZJ=MD&AJI]2PT'1,V)=M1#2R<B&HDI5H,'
MCP>@<@9(PR=$$3N1A"F!19Q0R'WK?POT3XI1%1HGW<:?MM=/)A3R69N,[:]M
MEXH_EO7;S;=[KU#>[_%PT<.? 3)P ?C7=:;#03<V_#53,/0&$E9OF6?-9L5]
MW)QNVWAZL=_TU;9S%/[=RI:XN%%U10?P-D39_M"+>%9*TB,$_$DJ<U25JJQ.
M,CP-RBOX75U; RO+TWV\\.#.\0BR-J$I>'9[D*:\ +(J-8TP(;!-Q4AA&PB'
M<<6PP*WX]&Q.I5GN^1_.,QDR.KXLFD]#DXV0N%2U '13G#@KRW/ NAX _HL0
M=5@R&<1+ DU5W6C -WUR+ 0_EW#V#KW5V/S>V6#E]HL85LZEE,QI(_T/W0GA
M.>E-V6,N5D>@ZMI4JNITAW3-,% CEP!+X:Q7^6?56^HX"4-L2A/1[X&&+W.8
M5C,!.O>Y"8BV4?_D@#]Z'8M3U8FA8]&]/A HZKKB)WW<\:Q!<S<D8B[1/7O\
M/W=@D5&'L\0$^URX$1X82=(G #O4KI&8/?/7N=^=)+U[UN/MZ9_Z,/G)#JM+
MZQ5D H)3Q!/=&/!/*ZAO,+OJS;4%*B35=UCARYJ&9D2UP^O8WE;R64N07-&U
MNYTT@,H>H5L]Y)_3'@(OT;E5]5Q*A^!J5#.N;$;PM2!$)6)'^-GQ[?46Z0H*
M3.*_BMX/I;,'1,YP[='9,[0PZ 4L1 <O[2&9+P!O-']=  KJ ^\M(K;4( 1K
MJS$OL1TZIVRV2=?]C0WB5V2J8NY ]M<;"?VJ;X 'T1L\_'>?Y%%@L_ZYPF#!
MFN-\A#LX4FXG(74.XN^]$VU,$DA#S5,3*% F=28(4UM(EAS9BIAFP[48H>O<
MQ3_OEU<4)A3$I-C"S$+)QKBLW9,U@W*;'M825&M.5N,Z4]P)J2K6S]/%&(D9
M1-]G3R96$P?I*Y"CIGR1CQ^*][_TYC&A!:@B*TQ'!REC@97MPB]2V&9^VD1T
M.7MU^&EM/2HT7U>[%C<W]^?$WVQ>RP.1.5A],U%0T-*3'BW&N2P8&_]#3$PI
M^9'\>@V]= 7B'FV?HH;,58'DWTLL7ZYX_I&VXCO57$]=4QJ*W$);\SS/+%W2
M;[T 4-<D0>#U7LD='BNO5\&Z>[6OWGFWA36XS81P'*I? -X%G@/G%2(P"RP.
MK3=CT> %YH;G1QNLMWE!KHI=GZYT%G\W,M)D8&7QW/%>MK[B>M W(^%Y:N#*
M,6^NY1%G[X<3@X#!'Z/2Z38CJ87NA";*+*9Z/.KPAT[T&[MSV:<(1C/1=;>^
M9'&["BH2")(CV^T*O0! ]'S;K5E,4%,2F"))%V\QZNNHR6^/BM#J<I>26:0N
M>3N=L5)=+$?BI?#=[?B@\O*/0?S3Q+4@":W K]J308SIRZEG<$]/1\\B/4YQ
M0(7"\0<INJ2J7C>UL*;,+XP49[E!JDXYU,H@#%@L((%1>TSJ+0+2L!40)"D<
ML 'Q$PR)TC!C49Q_TP^FS7'[?UA[KZ@FM[Y[- B""DB37D(35)ITD*[211"D
M0Q !:88B+;2 (+V#@!0!Z3U20N^]]R*A)O2>@,0H 0[[_=K9^WO/./\SQKEX
M;G*79R6_->=<<\T9T^M/LC8>*R3/A9>:PC_SI6UQ6Y;KNLW??4N06GHC1I"3
M?#SU4>Y (^_F]58$\C]_IEJR[X50;@\)+9&' [_0KE]O14P2!B AJR:*1!'7
M315K0BFNR#/M,-X>!?0G>R Z><F>'L1!2> M'U19]V(MX3QGHTXXMO6T8U>1
M5>[?6SQ%SST@?XX[ FZW2$WBDEZCH<EED/1NS3F/42JC%83]$;?W"G7I2$5X
MQU*IVJC[ZM_566Q1J<F.C_A*@3=[T-C8\A'OYQ-J,=V1   Y .H.';5@_'E,
MCW\?UO4G]1HVT#NR,4SY*7*A4^*\B\8$X7!K=5H8[ 5'EKBG.U7;TI=.V3>&
M<U> ?QH]-Z&LT$4?PUB/KR(KQYU,5X P]T-3@YJI R'8B$ +R 3>FSFE$OW"
M4:02L!'4[<E7>E&LL+Z^=GSQ64[H"J"\I'--MH*@DT"@N,(G>5XT_#,]$UM2
M(6CT_2\O!!9OIO)K#GORS.E9;GD$RZ'P.X$0[0855-LO$,GYL\*BBM4=["7M
MY4RV2=0(8M?[;9/8^W*IUM@=>;5MMM?O%$6#I'(HGN%$UZ/&PZ\ =]UAE*!>
M9Y9YK2?>*1\_T=]F.5%)ZF'F'4Y^96V6=-*P<5:V>D_6V&/-(@S*C:'-RO*0
M:>73SCKAT\Z@KN9X<W?BI=0V(-,6,)-]-Z.'I--$ 7]?=)<>RDY)X"OQ*?9Z
M.;//E ;?6['Z;A=I6 !73$UQV@:Q7NWD IF=G%.\E*OJG[BC//D;XN\J#1"6
ML/]KQX%>Y)YI1T(%S6_LZZ+'(XAT')R]BB'64K'$=:UJ;SSU^#-T(4O5-M4O
M!%54M?/X.MIMS17ZTYUJ2@IK!+/I/Q6$C537MOL:>UP!) -6&WW%3?V;M<^=
M$T4N'%<6NAZ^8W_ R(W-H4B&"EW._EGMAD5<<DZD;'=AZ=(]*OH7Q)9-1^E_
M3=_/E!16^Z1&$&N;<#BISY :?9J=V)97_?6HO&(KD;X^46T607\^H#:H=_3$
M<'25AA.358#1AU.$U?R6%&;@3KP"]/XR2-QA)K-S<V0@]V2H%-UDB*_B3IIK
M2PX+^)QEJ<=#C&H5766;(1#X/[FZZST'OP;H%&O7*)86WG[!-U4VZ3@&A_V6
M"B"Y!C@5%5> 75"R(EO47^#>J(U?HAT=N4_\>T-3H6ITNU:0JL?W+JK<A:#/
M10MLX-3*/;GC$VQJPO/-I>Z$X9 EL*9N^I/T.AD$;T>XGAV8GHM_C/N8-XZ2
M(^V9<]F;"Y)C\_[I2_J H[XII8]\^C?]M&BVA(QX5^XG4>K7Q$,751:<T-%+
MFAE#E%@*B .=G&NJ;,GZ4U<^K-B4E/@96+Q4^?[RR$!96B';"R5/=0=UPLW^
M>?=_925L9S/*6JW!2.WHRM;3!-].\S2&VJV0RI0$:=V;;'EALLSPC?H6)E$$
MPKAA8-'!%P!X5NC8WZ%KH7X#5$X?47P?H>ZT2^WM\FBIM)KSN<ZCCX$4K487
MN3SP.IRQSSS?XWB+W7U;64E'._#1Z ;GRKNTA#GQ6-W8D8%UA\PR6Q(@UB-Q
M \C866XFGX=J]G_YX RL??Y4YH>3Z<&DV%/)V%M4GGU#!40:2AM'2[<!)XOJ
MXHT!=CT1?EZL^,G]9L'R7 Q9!!C,F+*GMB;1<.M$KL$(*Z@QZ& <-Z;T9ZM-
M:,IV(NZ0L6GX_)TO%8H'WC:YJE-/B0#YUYUH>E%%!8C7CSA51K^SK)-0E[=Y
M%'SX/\:^_WI^:V*/,,# VA"<51%>S7W*3[1X7^\A1J#PFT!A0:[9_68Q2;I1
MX&C0*E<F)6&0JJLA]K5V(!!=+<X,N^&GU8;+P]Q=?VF=^GK^+,V##U>>/%/-
M]21$[=>],6+U7B.,4"3T(71RE;K%%@D+\RD*:Z%%"MU<C>$YMI@3"YEU.O:@
M$& S0H8,Q' I[I&R)/KXVN-I,5XQ+808^"6MGV8=^JBDU,+NQ.$/,!(O]X8?
MNDBDRZE-A/Y K2P8<_(U7X=D^O,K$ 4FN%?A7LM##%^7C]<GCVQ2,R-<UIZF
MD=@QY6X-YR(#&&%\JRG2KZ:N&RZ;AS<+K"4XIEU7@.MC/])W[=1>>'73X/K
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M_R.L4.<BOHUN7^&.+$>%??IXD+LSR=+22E2>8%JE=MEHL;0BDVG$ELYFZ#V
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M\'3#Z*YQ:@8J+F_]=1U:Z)L?O$>Y(A12OV  =/M!D5"PN);)N0:N>;WX3,O
MRLW?5VJJJ+%!>DVLVJCF,R@R#9$7<B-0;OYEA$ Y.%?M9KEK7_'WAT0J ,"#
M_B(-3 #"W8$>Q/+:^>ZH8%R1$#8-(\;&43>5K9EFH#9,*%*=L-E<LG0G.3Z(
MW/?]@T&F/!F-(8#@CV'?3(#"HY.X:(N:0UCO%8#*SJ3W5W2+ZK?^7 J)5:UI
MQ.C!BXY$0>Y0U(J^_6L6/F!S=.5==<!FP-L+\1R<AX>/GS1*@-4VD4'@C()F
M15EN+ ],Q'?O;A2+:SCJM4ZQ+'Q)9.EH"1I6:=IQ237CQV7C1IR'.G3L/=%D
M=V^82YP%<42#+6HZ*?NA2O)G0G%'4]V=3?"1+.ZX+JIG! EG"\_OO__\)HTB
MDPS2P;7%L!4H+X:FB)25J\"K1<K$4*^>RV\;PJ.TT6?MD<[YE^.2U0YTIT],
M4D_R&J,&1)[DPCY7:[P.(E!PWO$1B L3<R3GU:K3E'O2=>L07)'+8)2K?"?R
M&GU#:4\".L<I<%%]0/I#6<<\7.5DR^.>WW_&8,A1D7D]S(V$K@[.$-Y8FLY3
MZS>C^(=!3&T=.12I[8ZL/L/:F/Y@ ::;W]M<&9),M#[L:S1*)%D@3(:)R)UV
M;+C&C8UDP*^8,JD_R%%@7:9;9#S6F(%4.SZT=0ER(R0:7O#&1-3#;[4-65(K
M#UDV\SQ%ABIF\8<CZMSSB9<3J^\Q15''?LS?<$-"]_87YY!^T@%YNWJ[30R6
M)X->KG+-7\[C@]W+Y??6MX J^,=3'N:D'28\V96.=9?<L^##'K>]%,\$A)+H
MC8#97N!0)/$]@@4[PK)_$XYRC0,8S!#&.%&3AAF!E:,NOML;C?51,IO1*KVS
MKF-J PQGL,?_4/=;G@N9=IND[X;TY8/OT_72,GYJOCM"PJ&^',NP/A\)P$]<
M9!ZTW,SU>X9^V29/"[%533GO,3%CLL *A9^19F2H'1_D-P8]Y?[<+YHG>)_Y
M:;' /"VV_1]MZVV0BQ2\ 'VHK&_.B@.PA@@*Q!P/VU= ZL9?3YOPV:<%^+O4
M58WX?5W@SE>[=5<1U1;V;[3ZX78XM-W&<AU&O-#"9^FWHI-DK/7A^*]56D4@
M_F.5^C/OOSF$WWC8R<NU]^@W,S;DW"*FQ=)W[9"T[Q6D#'2WGK![_H]$LGS:
M-V(@?^HU@FB,:[PE^:([=WT+P%9_+F6_PM*$OIN-DJ-0K)O<;JZ_'/:L;?0-
M+PB=0D'6[?+=4B)^##^J-SBMEU#G:;*(:8K-SO?CP"1OE>7'^+X(5F_T_2H^
M-ML8K;*8D%%:PFKT@5AMU_"2T=ZD,FQ-CEY[[FPX@-JA#HN2B=$=FY(Q>O=&
M>RE2(?D>V0/"ZGE)S&F/"T2OT[[$#'?B3*"82@I$")2_:4T_^T&K:8=,D10\
M4.O*39'Z.0J *!S\!B./Z2$3=NFS,>T1'B21)RHS-#VIB&*XN:1NN&+P(;4T
MI4;?0_IXUASPD(LP5MQO_IP/0M,KSS8G/FJJ-_-S5$%Q)LD_.XQ]RGW1]&0Q
M[(_^XD)?9*6*8CC]8G/J^)!\0CQU3"C"]5?K T(4$$'2@V!1H&NQJ_=1SC2@
MPTY+%!2-HTP7J2K'P98W>][YVF4^GVR2JM<=VGI&I=?UT>(-[IGBM#OK_=!4
M:RS5JA9/GMB'&K%0^R^#'!]ZOBZ\MY(% #H A@--?0DPO"'F, JBBM(/"R^8
MK/0K@S$[0EDF5^;ZK?S0"(6$-F^E@8O%1QQC%BX(Z&R(,9?.:&L@H(IAR?__
M_T"5_]M#P8M;6'>FAPA> 9YG="/T+RO>8><7#W_N$[K/TZ^8"'RFCK\=2F>;
MD X""#_@)V"?P%EZET.8M7 1Q;A2QPJ#U1<-]-2.SOD%\+EOFPM]3K=B'TR/
MO;:QCL$FZC\-6OS@HQ!E\O,/"Y.C$H:B^Y) 1"QP$&:J^KBI T3CAWE3Z=T'
M1>\:60#\M'@CG/!.XR7V;/<=_0T>7*/:>^]DS-4N4FABVMY'L@ER@6,-/W:
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M]D]B_S7-.*LCX^/L&VT>[O-Z@IE//VOXI@E)E)K4%2/0?_T&\ 3 -];&Z&>
M\\+$8N6\NA#)%9>5*1R>XZ2+JZJ.'(9$O8_*@R0XC"0DZ@B(Y@O^9:_XIXY<
M?KT7_SGJ[U6X(ZN^YF@>H%F#$>BADUQ=>!+S:X'NS\QJ-W!A16E(H)O0N?E\
MZJ,)L%82_UDA,!O[I/XR_7@_YJ)9_BY>%!/6_0[C%8T7\*C<-WE=YVGB:)\:
M.K9ES],2\K;.'KH3L>E!9L3Z+2V5/%B1Q>O !JW=GT6-.7',8D<3*9"YF_-I
MSOPL=O\Y@VKR/6N<M6ZM-X]/C&"M5MO)/WD1$WC3%_C/O!:(UX%M(0[8#:0I
M!Q_(,UX!NFA1_J;/9XV637&)^WJ?F 7TRX]R%D5=AQ3W>2:;W0BBW8[D.:ZA
MW1A:]2+B/PO[#L]&U-?.;7%Q))%M<Z@] 1XM?A-,;=Z+1.>S@8=Q?4T/];-X
M7X-CE0BJ,H$FN";M8*_@+N=OFNA^]29<T(08$%VC'<%N3+Z@JU!+MM@V5]'\
M*TOG*<%O@L51@'^%V7A/W*U%O"*:(EQ6W,,3*X& ?Z[3->LCL$N>*;',$A$U
M3:'2NIE<ZT7CG^L>8Z#N>7C*<->4M=J[%R+9KT"H68Y_7CTG[DQLA'^!GK)W
M=*8(@WD\8)?PXC2T;3 2O-,M]"4ZTOB+B+<L8<,$R<0C@ X)%^TSLXG:51I[
M0R90U?_%VWM'-=5M[:-!4$!Z;P)*$97>1#JH-)$JO46D$XKT )$BTIN @(#T
MJH 1*:'W*M)[J E(#R34" $NGO?[G>][]9S[G7O'N'<,]A]98[-W]MQ9<S[/
M7',]L]C4L=[YV_9_^7+)#LXK1+VL2KZNVUM+E^2$> :;8C>*P@GG;3+T":0A
M_,T?6Q2]CZ;.Q_7O*5L_-^MBNM.DR!WKQQ#7Z%P(D4)7'T=XU=V.?OJ5R!;D
M[Y.EE39!^\O5\WT3RLFRQX]& SLHWI0B8_5QLDOLI$:@ .86=>//Y9X/;J9<
MNGK:3:N701> TBS1.BU=%<=#DQ4Y=G!X.YM@Y;C7$-&BD2/5)H.<\\'14XGJ
M?WIZU5"C*U< *G13PX0IX%T$M-T60Y_A@PR\ K;3F911*B%A_+QS\$" .VNY
M+U&GZ1O-\<T M>VK/B>$X54MUQWH3PRBB^ .S.9?.%AX&>D97Q D/LP+NJ;&
M$SR>CD!@R]%;W7*R<@S9NC6!M/8F(2P@666>X//1"CK;&@> <81:FEI,C<1;
M-XNTOTC,G\(J_AB:SGJ+4,28U2LD22#9(DA8RZK87/-4-7M[3RWY\$Y"PQGE
MU-7?_VUR]W).OSF_AJU#]VM_P884UA3G;HS(%; QL4FBLAYD'U>(O'T4RA_7
M\^!F% !;>F1WEGE^:P:[V%;9<>G4M=!#X66'LH*=%,OJK '2)=6T46V(3(3^
M;34YN+7ABZ7GPD.*0-. <78,!NUS_HTM]0*0M\.['#]3K(0%(8#T8(IGKB%3
MZ;0=1J.>*%%].8':IMH8BQGQKN3OZ-<5H@^>2MV$9]2[19VR'^5< .+C0UJ.
MM ]:SAC<%-@6+8R7H6&!Q-F=?C9#D8V$B$P5(PQ;[M&OEZ#*D^(?SZ$6X'-'
MZZ26?97G"^O6^-9WU#GO)01+C=<*NSU>;MK%3']Y2=O*<0XP.XJ721ED=9-$
MF%CTKG!*-Y+\#G[=L(QL(=90[1=2FS7G?%ISU?)K1;!EV$TUKGMW .YJ2SZ?
MY/C1[&&-KVS(BB,;+\^-&B666<^9<%JN>PRAJM,?#WJIVGLH/CS%@J% #H6>
MTW85#B!C%0_6Q7E3JE];.O/ULEHY,-;%FO8KE'0V6"I+<@2)-%-CI1&-4C;9
MT3+$"%::1QI/9HE]BQV$C0>XE.H,[N4LWR.GR($JV9 6&ETA:B-L>H&5L0<A
MRN7/J<*_)BGLA4_/:GKY>["_B"EX+750'LEEE&]G%:IME&VIP*:\>+7Y>CP]
M-#S^'\Y</&&<(! =;_J\G8LJZ9<KI^HQ.>Q=-M+FN*.G$ZK/"/"[OG]I7;H
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MQ$8\QO4E;/$;K+%IS$YXP^_=7G<2O9%.(RR!*N][@^+W0O?+KUF6&TQPA8*
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M>&U/W6]VPI@U585-FRE/$27F\+.(/50B;7RMPEFR+&\'!8 ;6L]O3(I= )B
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MBC8K9K$^7?#"B.K:<4LASN]E#WG2.9/3'F<H^WE#)<_* GBP_HC=SBT*HJU
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M :('XI<6_OH5^W6Y$^[MN<AL?\XRQB_>8#J-,Q&P,OZ>7JI1%#&ZE.I+/5]
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MW,\%H'0=813@X!]30OUHX@*09(J]?"D6=R\ ^?G09QB)67D$W41+I?.+IO&
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MME3)FT=<;8OR59GK\@-,+J=N\YA2A<70)GL06/5P?WX_S/6M=H 8 /#,HC+
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MQ*,N!D-OOW2PBX7,A*,Y3W*/37- Y_N;K0+AJ[?6*+6(^ FX7R_]VP/*K2M
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M357!:XO%1QFWQ9X%][?/JV1(Z1'%S?!US\9%PAZA?'Q-K@ ]M28_OOX4:L)
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MPA4#C)8'H1N?.C-+1T.J06&#_B@R>M%!WJ\^M)OWZA+U_WS>N"O[R:GE9;S
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MF,J>GVW^9'=[Q$'R%\RXX&O&>0V0+$\V$+)OF%\_\"?^>GM3-B1FHN@G*&]
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M(KT?0N%1&<0Z]PEGCN> NWNR8R.#DJ.U$?>.]D&P"@C R6,?P<17#V?#A;@
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MS.J-<8R;,)1;,G,8:!FXN<WK!>EX6+/;$8XJO5-%K>/XD$<KSGLB>QU.4E<
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M 6<&L.TS,/H^D+7UXDYERYAW;+;.RR:7!WIV:6@RNY;Z9*(WZMZ]T<LLE,H
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MXIK:;/N7VCY>BGV4-TJL :)\40V" #I_75(/BYMH[M^*>T1!TTEE01MNN?I
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M;,D73&N?(BW[Z$2E(!V]%>&"LDDSM/86%K:.O#7]!,!C*=HTLROS%7!D_'M
MZ]^BRXS_:#VM&CQ[KQ '.WH@@D_;ODVT H^J:Z%IL8^+:1S(*81$M4GC):JJ
M1\N<Y82P=]HT!3IG0TY[7ZDF>=8T?W_Z/6YEER=\@+S?+^Q4\DQZ#$]_=@TS
M'^*1*KDVYI3LE2!_4[TJ0%,NH51TF?"IU+L;/(1*RX=P.EP&AG^)?T?7Y2"+
MD_\ME&@!?3>^]0JK,:BQO;,^8,Y]087 @HB(^:[$CKGR&1-.KP!*@[/*QK&I
M(EK&W&<YF4+9,K3U>-M#/=T: HA*Z "7CQU%=IT_0\[N7"QG+)BZCIY<'>Q=
M>VSX,@C$XF%R :CX%:J5OT#=+-?I%]7(G>2<>\?UY07@S[]6QM:I8 92L&JM
M>$&L"WQA79+E;OD!5<:#+HENAF]5DD_!->(VQB\[&-_%I9H4==^XCJ#'Q+4K
M4 *%I^-H-M(\D@IR<E_>O;5F7)^V/_L4\J'5!G33.G+,.W+@UATBYJZ95\TF
M9B.2.[XJ+:,>('NP9,DW3JHFWX K;Q[U*I<0_0AT,[N^,!A\G8L6J0!Q,=%A
M0IE!9.?;3S[;^W,UQV?BAVTS._/5K=>^U\3U1;DL-2I("AMY[AS"(_VI8.&_
MIYWIH0WWLC3]0%KU7Z['"R]1)(BG5\2_D_AV^<BFO8XM[- )Q-_!>;AA^I2P
MX) S3??:X2E#G/]2IS/A/.(1\XY-(\W 9J=G9<+*VQM!B>:JQB6\U0\_J3/?
M)KT_\()&ENCMUQ/*7^V=9F2XBJ6],)^P]I(] JC<\$')--]HWH30H49A(/F4
MI_<7([\D=0\N\>)W)!9 JUC_J%&GW]WX6R96=Q-_T=\U<RH4/E5D^W#RT7J(
MI/=?"A:ZSM<9Q"&X;3!K>#KPM2VB=GXS7]\F>1/]4;N&X31-4)'MJ=12!\U8
MHL53-D ))Z2\^\__8 ]UAT6E13?Z!V$FE3 ?CZX/]9SGET%J'7@"QZP!42#F
M60G1N]XW(:U;BIPBIWQ0$DY&7-5GR&!["IZH"4.)VM1OM#D.5D]8TXW=/719
M,OE44N$_T/1)L51[A Q >1CW9]7MBH)MUH_&P85[<8=PKGE<XJE=9V-_3G5C
MT..1LH,,@6N-#0(@RO.SPGE;?F)LOX?_GSVX6XU',860L$<M(X>^AF#WDA^<
M<[LH],-8PU1U#PM?.FW02E2_R!'45*2#DP73'2ZGL 1C-#?)CT&&E.)V'=+6
M56Y #K"2B>H]--B?2MDE[C92!^:=,%(M+!>Z,!(J""Z23@%6%<P8\BX&0A-Y
M;)3IR'G<+H]%/X0VTAW, ;D$2$_FR!LP"NWR5Q^-Y>"[=>A:X:G;.4(?@I-K
MV\8UDDQVU5:OR+YMB@2<)$P9"2U2LRJV L1R>N$<!%\7_$B\PZ*@#IB4A<$8
ME\.LJY"LAYBL\)KU3QJ3NN-,I A#O.&R:!4ZU;7N^_1'@$0 X*!?=NC'#Q,3
M%C-T3H25>.^;O0#2I5W7M%]VBQ> =JTW/SNY& Y*J%J(-"R7JEQ&-T]V\RS&
MJF\E#RO*U0<[K^[LGZTC(4??EC,;LFFM<6)6>;\RA2>@"C1);KF@M(HQH</9
M!T;.&C6FPS<<>-Z0QUD1,725]A:S+G$(CO EW[_EP.L1*\5B^P9 -).V'_<6
M3^U'9((]JCK/R=4"EV_VN%+'AHBD7J%@%V#HXP809.J^76X+H $(Q73.5]L%
M2-&&<](/+U9_&?68UKIG&/1T3)+Z%8QO]$6MBH<]SZO2>I()79;'R1$/%Y8!
M^D'H>V% IK.'%=BP((04Z^S6TY@[)\Q2O#65-76I9U/"K]XBE;DUV+T-OXI\
M/"3.LH*GG3T[!6XAV;$Z04X("F\[VH!<+&,RW!L=U?#X F 3SN768^&K.D60
M?9K]KJ>.5V?D/<%/?,[I R@S=C 6;EW9F#;?8>P^,NA1B//JO.=IB]((EY"8
MGA[X)'&SZP+PWN7^@);/O=8HPVTDRWJMJZ%]XW-]D-"G*8CG]JR1(G?2J./C
M%YJBTS^MK8$+;U1!:S'\;5PT"(*%6?UV8^P%( @JLD1+YIAX'M9Y(G6F6?QP
M3=W:?(=\FB13U=;(\E7?#18V;>E3\/8X>FO^"I1E6$B*VD1C4KB<KWG,1&\H
M3]SH)55Z0SDCVFI@YK&\ZZ;/.]KG_R*\/(>[ &#YV^>O )GGS7$%SD\'5<8(
M1E9;1DJMFWQ%I/DY?>]:5'Y:6/GRVG7+4*$6?G;YG45.L#KG'!P>%X#K-3I<
M#F;TP6?20]5EOAV),SQL4DU=M=6UX24NF4K952$W53N7=X^R:<-;[,RGEK0G
MH<Z8GQU<M'+*F#K3H>J449$:/Y.'2HT?GTVU\C;EZ3GWEO5*"O%_>$C#T<##
M>E+U9[^WY0+7#[>G#;B>3V?&N(A%4QY<G6;ZCJA#)MGPS9'MH&.C_)L%#68Z
M\Y<D^<[!!>!?R16F8-G:856D&4M3TR98O[I0Z$,'5XE!AWQ<Y9Y.),HAUG:>
M_>K=U]5A)#C3&:9!XY/O^X*K"F0;673^U#@K8TQ<V Z0'1+V<-BF'I1A_G22
M[TOF+,\L<$>)I/8]B[0Z2]9WMM;9$-( ^:R%E;>C0!:(YY!#FG3<%?U6BRK,
MX7!#A;H7U]U.@1?"+-(53F\,]WT^[H5GWL?0MLW3;2!O8J50QJ!C_1&'B5OD
MMHV(^K W/;?4P)15]5>*-,A=N]0'I8&D$ HDZ]G=(000E83\C"E-H7:SN9[D
M]&0$T6GQ).-+<:*CL#;]<P,Q;%A[8WG,$IP&LM3NSSMT(.^O'A?&--B1O*]I
MYU^ESA/+8S]K)N#5W<H69.?PU/,=P;T /"\.O CO%!"1D_?(U3S/RJTVT#7?
M\&+R.;O[4\ \V5V5J4-@L/?A:YG%9JJN1NV(<IRRT2CB\3N%L'(AWCA=D]0G
MKGX?BW_>J^=VW!G05B7QAK7#:$!I>YVG%X"KD.Z.3,XQJ!IZ1Z;ZQ8B<A/-=
M5\/\/I4'+,M)4\OQP6*,+V^_X%E([O?A[[@ $!J?Z>+\%D4HYEYJ.H!+?_19
M'],%F EM*EK0DET^@J)9 ?L*K/ZC,!JH$5I>36.D)D;6R(,<V6_EM=A/BK._
MSE!!&6B$XHT8^DC#11;->GQJ>!9E;W4G\@7A3K2E*IGEAAG%8EQH"PO^!DY!
M%Z/=LFA.;(R#/:WQ YX^'W7W3?06:A+NWD<G/+OV5#PQ4#.$_P8[Y7&ZX/,O
MU8&H6UWWK0S'&GJ^,K/(#UXCL/T_J548"92V1]EU9D7YBXW9X(3R<:,:F$>U
M)V8UOG8E@W:+@MD3V!FFNDB.0,,EC10*G@ D,[^%_R0\&B\)U;^$&0AOK$ZW
M.:V<P *(:,'>N7J0;FONED1M;M&C5Y'+I7I*SP18GS1Y50A_#>EF 1P,3HET
M95)@J<-B)'7"6,T2"R%L[2<9S<ATOO?1!6L#%77U2:LS7MZ?-$S9O+Y+6S:0
M(@/@5\Y3#YM I_/A*(_)$'<P%:Y;>S(0$G(F?S.A3Z\^ <7R=(6"($A2^VU2
MZ(J-#+\,<$V1Y/4\JYQ,&:0$G5E7@//?V3Z429#6URRH<; RTEL)?H+HL(XQ
M4Q!]T_03U93V$XXB:L?@<M'7P[>%#[44U*OW<^O3UO13^BK%.N\\'IZY9V]-
M;@4[,FT\R*8EP'F@]Y@<LYC<3Z-:KFP!F;$,H"K'IR#9PHBRM=BU1^<+L2,/
MU,NMYSZ7L2LO4U)Z-QVS&_SPV.</E>/&A$.5,1XM[3MNK5\<4U![9SS:3L)+
M"8OD(U,IV]*DD@"E%5L^:9NVZKR;@WV'LP#OP:XR0S6TX [?H(D6[<O,$2TE
MU,YNYN0V9EKCJLYK4[W*"C+]VZKL'&&A/+HX1H>R#<\YWE&HYJ(]U*3<9)/R
MI^-KEPAKC9L:MRX :BB&^67+_:X!VCFAAG *[/17SNM88*Q4W#5<BAZF/,O*
MQJU@QMSH93<A&ZB*09.]%%M/V74?[R(V>:L6>!7'KXXI3_7UR\5%'G?J@1C4
M7J,R5L8,..W5)WC(L;>*=8O(E ^S:>E&I632C][&/<;/D74(++)%\(YW1PAS
MHGQ%YF0WHJS5$O@,(XNCWQ1("._,&.1"H8T3.QZ#%/RA-FE;YN_,F ^L1Y9:
M8G<OT7R";)^7,ZNW=7>HR,>> *"5&:@0HOVSPTP$,92'Y>K@H@R'&OD5HPQ5
MT$5VHPS@ZKY;3U+ M@]C^KRS'[QCJ4@ E$<M&80BGI6>J6!VXUW+<&^65!L#
M%U<[/4(;*YI"(;EOV=7<'/60%@,K7N5>7]J)F0&'\R&L6"Q_@'O)<0)_1D?\
MP*V*4[I8ZZ01]>] ZW064R-UFO8[ZCRLVR4I.(^<.!H(O_JH"C+=7BAGOT,6
MN%<9JS,CE"RSJ<&3H,$S^6^DC_Y<;GA!_(PO2+T:I"G8>A?_8AW9F#!OTZ Z
M,US)S7!:"[B_D/CQK2F)&XQ. <UO3K:9A0GCR^*/D"LUHM:;$CI>MJYX8?71
MCMWJ_B!+-FT&DA4_8,:- 4?**=S':(?E;?CXC;V!Y9P]GG3I("_[F%_]Y>Y3
MJ]-HI<Q09!G\/?XZU!(7M'1)X^S:9+/B\-=;X48UB+25@I#/Z?U/83Q$;H#P
M[&@)1ILW8<L]W-GPDG_.&>NPN[QD)BLN )6^KA> PMN@Z9*_FXH ?Y,Q_"W6
M]]> M#W1]/J_2!3L#\;.4U_Z?;8-6;/BA0SM467L;L0#S7Q'@\_]  W=3M=K
M.0_OQK"Y$)UB'\%"&R\ 87/DHW@VG* J9B"!:UO6IO)KW,V9_?@^];6F)B9;
M^;ZKIKS_5<?PO[8I)^W^4=\(^$=E%R?7'X&8W\&IOYG^0_.,"!NWX!4N9[I4
MAN=H#.UKYQ2MB]+$5CL+]W"B2.<2E "K&MSBJ)93AIP+0/*K9A25?>E")#FW
MH66$$H^]Z.=L"P"9(HGA);>__3_7O\?Q9WYOU>5+_RRV6C^SP93#Z,X,,,=1
MM_#?$15UH\+5ICK:XV71GS0=,F6HVGP$=\,%28G%ZYQSY=;^9,R^(0"(P=L6
M.]_!,!B+Y*R;YN1W)-&H>X92GS;F?*2JKZ#'0ZH$\5IS;L;OO7-,@U*'@&
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MFT O#RZ1)VYO-3'PSD;H!%*@AI,21C!C;W"GKO&5&IA;HY$XR4;/\250+P
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MI(45FFL0FHCQ]2Z>@33L.@O9A<Q*/:^/*$=Z)+W@C="7_O61]KT@Y6GM__/
M_\\#_Y_PP#_Y=QB7'L1C06W&)(-?Y^G.5$8MJY$9'L[W>B@+U(G%'X441CM;
M)XU/O"1*0C%'QQ5LK<RCMIY/[A9@#O<"$9HYO+L?4,D9\AD7@ CN4::1H\5Q
MJ]"=_1_OIDNCNZ[V7"5E?ZO((;*=N) *94-? *[=QM 4+P@!UY[&E.9@:8H\
MJ/4W>6HCY7_VK#UF?%X<*TG;=F/!MOD(Z7$>!Z6__E:RA<WA1+78P0]M,\&M
MQ4=E"CK5_<Q;*M;W 'BT_WV_I&\E,6DV$P?_5 0HC;NJ6::<,ZL05E8J?!A
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M+7;3Z6/2ICW1W_12F]L0"G^W_86)_;WV\'?B<8?ZMT[# O]Y;-EOG8:3HQ.
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M7VV;[R#BCFS&\..8QMX)^:M&(\Y.*VF\B4:^"M+>T%]R&(8)-<,VS6;IU]<
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MT&'1>U!>]-;IJ9:G\]5NIB-99_QRN+E,G?WWSRRWX@;HXS-B/F9,G7/!^R\
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M,Y75TF:C )-DI>43P]EA8BH\#!# &W46J0T/_:-]:ND1WY+BI;J:$%8CV_C
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MKC-5_Z;NS*AK;V!BO47']DES''(>;*K#GR '[4S;QX<-#)YE;N]M'RHS"'U
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M8>414GX#9$4^#%,U&52N3PH.Y+8@FN& L:W/<!DPWOE%#7_[TJ6-.<&1$D^
M*?8.6R++[8<\W6NKKG^TECJN16UOX4IZEFE;S7BS/Q"?-^%WDXH6!N&8 '(C
MP97);QGGWC5F; >":D78KZW?J"1V 55/"8?-#D01D4%O>-..Z$Y5W>E[%S#Q
M3W&&XG=0[-4D 4_=&X6VN96T=N<CXBM\!'6WIP3?E99ETE_CUG(YMO[H/W61
M&3:Q#T+O&IH1YN0.CMUS1=RP]<,)F5W*3(O.N9PM>-<<-_CZ:.'W]DQ(:3Q[
MW0N*VX,)*Q]IJ.S]+A>4<>B<;Q14Z%=682X []NEO).-)\F8V^P];-/W?=0@
M,N0HG&Z;@O,98+#P(4E+!E80':;J*P30/W\OA=E"/_CQ])9D.[DXBA5F3"W>
M$TNWX=\3(A5G'RV16>6C)7)46"+:N^<RJE?R.#=E6??CXD1&Z0ESM/<G>EY?
M=S UMEV[8WS=+.SS8K+J6EL2EC<3HP1']U4[H,V*HBR2-7Z>Y:Y8#(/4'DMI
M,9=$KR+"HZOZ9IYZ2&0!]H$4B \8N@H,$+B%MR3$+@T]Q@O.9*$86G"$NNK:
M<8S#XR\^"%;'POV9NZ2*P=].620&3LQ1UKBH</$"_'JD,"XH!.F_$L/?Q@A7
MB(KQWJLS&W6J;ATP%_!7SA%@;#$S^:DLBR,AW^0$["?-J:VM+:-'ODM3_A[(
M,ZR1TKE60I=[1.)J:]]D9F]/\N%I>9NFRH  _UK@MW.@&SG"TW*R]W6&I,6B
MNAUT\5-WZ5((;9UVS-UP"NSW?+6^+W\";8=2?=L=S<#7"<^\CD60!PGJ^J<4
MD\0\N9UVEZCM]JWH)+><G[M+[HW0Z?[ KU 1-RXGJ-!L%;;=*LBPN:ZEU7^O
M5HRP-,(:7&"1\=B0@TJ=\32]D=OE/9U%ES)#JZX+=E% ;19UW7K+>*?*JE<Z
MRS<2VQ!OLX]X&FF6Y6,?4Y2 MJI.?0!.9:,+L,#^936F5JMIG?7. SKZ#/E1
MM*99[U=[VO%Y'?VJ++=L#KT2,EC%-9;6TW !J!,K34+?!*.;9]$MIZ:X0TH[
M0U!;1!';YOO!NR$K06_G5 6:R0R;F]V2+@ 4%4@WC)7:[FA'(/C+C'C=>,DP
M!D:SF170E'J%ZQC(,MUA0BJ<QA;(&:PTVW62$UE[B2R&;R_!762U.QHC_>^"
M.>B1[_TD;]?0T)$8]BD:#WL$T=3K:9GCH)G>95^?3PVD*F8\ SR[H3V@3@%*
MO=/M2M<OP'_X2^'K?X/A%C"*:#^D-P7<7T\&JI_P?0T6+"@P2UD<MS*;Y'K-
M:Z(D9?3OZ>TD9LV'.F)QI: T71<NBX$*:<!; 3)],_<1+</$WT6623U#X%=[
M728.W;F7>";<S2A,ZJQV6\(J0\/([(KVUU;\(,0F&"I'", =70"Z3Y*"5Z:\
M@5<L"%I&4Q"(EYZ#:DL&?-A8E_:4<VE*#=+P1O:YYW6*8LNT=TD54 F";J_U
M+=S9!X)BKQ-:R5/_"[QTK2FDN*[I$4WUFQ*-%$K8DANY[]=?"6'Q)D-!M1DA
M*S.$B&*DZCA*$?%\RP*O-C^H'&6A/UG03#;RQ\5&]1;<#^0#?1I-.R)';R"\
M#>3:DC6W3LW("C?Q%"K?*>&OK\[Z=0VQ\'.&_WXQ\\\84A!-J 8 6873PH0O
MX]((-A-83%)W@K]%L^R,>?B)5E@5[5K!RNTOG,%--[=[^);2;QLHNO<&Y,#X
MB/2$$"SX6M U@CRA&',!N%<C.^=<U-_EXMJYM C0,&Y.A=T6J"-94UBQ%4)U
M_/^GN+CW8TL9]SD0^NH"T.4LD7=*9FKR9?:?Q1+)%P"G"P#[1A"]&-,Y$XS^
M?+1YMPQ]LS>CO#E>H7S69]9%^FWL]1?GMEIU_'9_/F/TOE=]"7(0J0W J7>Q
M73&@T:')4*V8[ZS684U;W84^;-2!VC_,5B7/F2];K:(-',KC(U)C^,B7-CC9
MNK+W"/=^@Y\??=T_W\59+L;]$7Q^\+5S^EX8NW*7PNQ47DUC-ZW;RFQ''BU!
MJ\?!0&$XSDJI8R(G]\>#1J-O91SVCX)K2 9X;I**_X^HJI\&_EBZ@:<M"<Y6
MJ\$IS;3E;P8^S+:JQ=M7AHF]]6EDR#9*U9O^5B#Y9269.>P=SP7@;Q!S;YX5
M"(0%CO+>K,$K;I456[:]H^2+?*!NE(6N1+/BY]\RE_ID#EFF].E<94@FP5X
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M+[&?JZ4>IL(Y]7\0%_];3>2?-(15&E4*,^VK:"+?!<"FH?$"4/3J"> 5&)F
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M?N)!IHTU'M=U5B=]_I0I7KE#V9F<"-^] -#/+<$<%7(:<CR/E-3@3K:-7RX
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M)9R6>/'22WJHPHD?$-%QZ,P5#-\=75ZMYWT*TTG?\^YG&S03TJ$?2PE(0D:
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MU'M^ NS>HT=EBG9Q)1CLG#RH-N-.1J[&_EY5N^/1(@>\?WR?L(P^#H688"X
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M*IW(Q@7@/XFZ]T3=(42@W:)F=/PP>0P;4*XZSWJ'Z:J">DUH< L 7E"5=ZZ
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M.2ZY'1[.NQ,?*(//ZP:2$[T(@RNT3'TS6<==>73S\(PA?];D7*"<YK!%"M.
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MGKD)@XY9J+Y?F:]47E\&K\/J(I7$MD?]\%63&D^$42,@J'E<;A_\GUBKX6L
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MM/_3[X?N7+._P$I*#8WQAL20=[[OR8K[-_$D"#2" ;PL%Q'#/!%S3!M^:?0
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M1.#VP.X*8 $0Q,@*<]'36I,"O(W=[_USY^Z&R>POLPJP;(X*4X#E/0/6>+P
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MTC)%NB0UEUJ\>J_6Z\U]RK-S499^R:[[?&\_X 8Z8'_WLQ[L),"%?L*N#=Q
M("#['B<][E8YQ+4[)P_>B@\)[6U-KJXJ&R7786]],CW '47=U3%S0C-A>D'V
MC["7P2_&9BY-C Q&;S1]';U9515IO]BE,5&/=*%5"".4]C<Y&4)^L+S[  ,R
MH?FC&W1OZ3J7F_P<=MTP"1F&] 0-H13WW404)6M%LSD]T_">37>,U,247);
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MP'35:8W2IX#&)9\1$YO DXE<,YG^]?,(5(<2'E'J_]:C6DM=<QC)AB@F)$@
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M[/H5C[NZDA&$Z1'FIQ=%)IE(]KM_P+K8"RU>)W]N3_C]I7=L^9Y=FY/$O=<
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M^R7,GEOT=LYFI\')^&*[MVB/IZ?5[!;P=MP B'%59G'3'GQK:5PIOTS>-E(
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M$6X @7"%<-. :-&%:/&)(\Y*F3\^;N9G:")%R!UA8%H=5U+^8;GWV<O M^X
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M]4?>EX3?;[DJXC57O0;=;Y#XJ]^Y/[H5GBS,/JI7<#CX <))O!S;ATG9H2N
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MU$=YQ=!L\,01!<!-8-+E&8/UG+$[6^0NJ4X.S=V+%!!H4YD!2/%U*[9BWC%
MLJ[:1UKP==T#;8)%%CAKD%Y05$:<^.R<TKC5^!-,#'_\]?S-5,7MSD:C.N\<
MLTC:<PV/-\Y.^9GL0JK,'TO+N_B2>!$RV1E X]QM.HL.:S><6Y_'NTI)=8J!
MWZ5Q1(B"'UY!;I+!\>HJ7/<1>(/N5DG,1K<K"=[5$I.$Y[6<D8ZVU#PT#[.9
M.CJ]FV50(Y"8F?S UIH^;N" .=((8+<]1*'QHZJN)G;I89ATK)7FPC"@5V</
M6A$A+4;NV#CI>P8M6?'NH!+H]0T]/A0MJ7#T*A/V*TQ0=^?3'(;/6L8FK0S$
M9(;^ "W_B,RIK-,4'*[\GAKK5=R^3?8*K<)8].],YO_M"/UC7<LJVLJS+'"@
M"Z],Z'%VO03H'GT'')D)YDL1K7+!9SJ<M5 CH4=-^U1+W])67:F6J P>M@30
MZXI_^H0S;L<-ED-_PLJP([AX+&?5,K7PN0=FU0JS'P&41)E;&IUWN*Z;6VHQ
MKO22]@_(DU F$J;\R<]L=ZQX,&D?WJ$#5?$?Q#X0AB0[,>:F%,7'\F\H?JNS
M<J$&*__0&>@>7 +"+P%D@8Y@ADV'(L@R(TVH[6?BGE=*I1Z_&K;6KS^Y=79-
M>]\*1ZM)G_>L-._-8L6[&3]314)X<-1ZIHY:NK=72^D$NFFTK50V[JKJR\"Z
MX^5 D2+H;21'YK@56*^$1O30:/9MY7?KT#]OJ)LB <:SH_-]$!*W[J]R>4\B
MHA[0$[V_'@##1]$@!) GW4I"75> W/R'(ZQ2(+$ '^HT[L>R@:8,?RDNCJY_
M^6<U_=B2:=6X1_D]I^PX4!E;- L)8)ZV8ZRU$I_@I2V5O'U0NG(=X/M;E9B/
M$8 2E_.6ZS'\Z)3L('2^U%2%.5XEO<BWG*]V6>;_UO]G/>KQU]1F]7G@/.[]
MF.T,@<%Q^H?92,"02%E'5=#H8G1!'$J>E>7.,U;M+_>,7PP(FA/%#T+;9J_^
M.O@XC,SO>EO$NPO;=7(1)Y<RJ5G;#TYOZJJ# $D]#TSIC$RF9B4$EI[&2?B!
M$:2(@T/DXPI7&QN10SV1JL<)/5(C' WU,?J"44RF=^<X3PX^GI]Y);2G /MV
M<[]OIU=T%<AFL8=WI=[CR*T-XF" 9XY+Y^N_!88!D'82[\]4E$B]UM[;;V:)
M8>(C@-#4/VD?I"EH&+80F8LMY;G*H>7YD8]1V?9Q9[L$L]+*KW3S?4_ROQ@K
MGUD.%,;?L!_;%K$MX4=><52GH<)8X:&Z>'@!0MO"VOT:,T(UK.-ILD9X>YG7
M/"IJ)]XYE]3RK:5ILRE']_*\Y+RBN#E9O.WRO1<AX!W=796'KQI8P5Q[>W #
M6JBL:35K3PSN*^Y.J8.OXO:0(Y])-7OM9@@ZV96:1?<C<<*P('$;WMC=TP.S
MTS6^M&CO74=CQR++R4KB4"Y^D %+/FNV9I\QMP!WZK,.J>+]\Q$.!XX2\UPR
M7FE&<(CY9[XDXR1-J*Y 6IK7':_W1 #*UTVZ_ZDTVP6LU6WL6:=L&QW,?P5\
MP]+RIQW2;[G&PLH_2ZU"LOM[IV2OPNWX$L[.EH4@2#8V(/1NF<WUGY^>EC@<
M7'P?U)+C?$E"+W!67MKOGZ&DDEN2%2!+72G%(>^$</;6^38SO.84:%L1ELH8
M[9)UZT<BH'?K8_\&@:0[>[K5^Z(VT+:- NJZ(AOA>0FXN67H,%/K2E)':[Z@
M.P8$.88)AR3VJOM92Q_-XG\B*?1Y$"=&T[M'IGQ>H6C7=9/UL!=RT#F/A.?'
MZ-$CGD93ZW&8'7+KJVOU-@)4X#)6_XPO"OKEEJ86R2WMLB+]IR6LD4X3<IP4
M8MVJ$P7,A^8%Y<U'4UP/8'38BM@CFJ  -BQC>(5]@"PFM/PS6::-UY:U]VO>
M&/([AY+5]^#QV5E"W00:?+SF1>E5D5)DLT!#D76C\ BF,U[=23[#]<:7#]]S
M,N^)W2-N%1J%Z5\"2)HQ/W%U0 17K*<^DT:Z/OJ;4M6",\M9R1W/%:\%\A/I
M(Z[@0)O]\"P*O"=9<!E<;@^^9BVTL+"RJ"<.8'D4'<3VX<0- ""*.BXPIPE_
M(:#Y^%E6M)ZI$B$@G/*!25.O&#(V,Z/1V<NKT:HT$*V%U!?HR:X^B4/71/"D
M4OC?1>&8$BB[I)Y6]V[[W1I4EE!@/9UHYY1-Y\(+9(<73@I_G2Q_%%MHYE]#
MDE@^7\PHV[&R^Z)]Q)-A,YLC@/Y<)1KIU8!48K-JF#X7*M*LU#Y0Q<4^'KS5
M7B4PW.I["\"=,/M+TE+V X@6;]C35DV:LD(E:61^1N$G]7ZY,\-2-*6N"6[W
MT?5!TI/#X'C?%4_>8ZW'A!-I])SY,>6SXFA/ATY@M9OC+T1=3=8(@7S+=QX:
M-H),&5+W<P3J,W[1;J3E$ABA7:L=QDC(;9P+":UPQ>^#[L+NC1Y?J A."FC%
MK>1T?N;U4FOW6JR3XY"TDA7K"D3<O 1H@*@;L'<3TFD-JG5*RO6[.D;CFYH4
MH;O^YBW^9)B-=EP@-9 A'^]A8)N$Z!3)LK[88DX:WEBH%,"6D\S;SK+.?GG,
MK]_Y),3:MF#:V*BJM<53/C"^C>X;WGTEU2^0 M_6/;$=I'=%Y$)D]<\\?^9)
M.4=^]BZGYPQ7<@=3GW-.!##AC9&%X?!XIH"^ - ,T,#.\<>V0FGK#;UO+5_\
M3X>3M)G3Y)TX/_<Y7G!C*4^F&TD+1#_?J)]<K4U!OPYL/ CAIS]C;*\85.):
M3<GZG(<O-VT5QY>[1IBU?2C;RZ]))1CZDT4E/[$](V$,"=@DC9,;UJT73TX.
M^P[Z<F%25U,Y"9-F@*=>XY#Q4V4SL>BDYWOT25SA';,AO ())NU9\=?")536
M8)FZXN?VD<^7:8[JYW5'*YH]UBG*-'^1<ZC6Q3'W1_$07EEN9,[M@SWM=XJW
MLVY6L98Z.)=:;/6+KG)YR2/$F_V);X/OP^[C!<X,8>QX[URHF"HVK?-4RI]U
M>7?ZIT_!,K!'PF"XHUT@>?0FX$AL=ONP4PQ90>_0*-#EKXQTC7KG;W@FV[W$
M-9$(A#=J3R4]3 30:6XB$W_("4P(;/IBXN>:D$SQ0")48,22 #ZR=%.AM0UU
M-J_X[:_<6_)7=1&J3MS$3I_E[T?Y9AWO'?TG&,SX(V'4BAPK$/N.ANIJPA-[
M5>"8]D<K0D3:>^*XI+"VMB'NUH:#9YS:C=<Q(/7!>-UCQS@=1BD[KYO?)4R^
M )3LB3?B0ULY\#U(<*25X)0G%QE4M.\A]G$!Q,^W,3!BCR]IQ*;937LS;.!A
M>2?W0LK 2M;QCC+#D;.Q)8:S!)*SY2M37<Y\8FJVLRJ39>O>T*K5 :@%/9-\
M[T8N_7H>%1@B]JZ%YGD=]G&\3$:Y1;22Z('B9HSQ1.9L%.-B)/MN8,K; ,,M
MRQ< V,@*35@VPS+AUI;G/B5,"C,\'>_@\7V;%4@*.9EE*(AEVMUAE4QX7B4[
ME&0LQW#40_]_5_%F/A+FN"AAO#[%4#N-2@Q-J&<\$_[$RLM2O2?-^('#Z C5
MYT7A5KT2J3#!5&D-7O>-.E"9\GE62_Q%\GS\A;RZE<?9FZ'5D=O0C"[.6W \
M?_ZY =['LW7U2?:+*9X: R7KY->1S+:SQ8B'#:<G],Q21*XXUC'X,DEV)"=%
M?&< "V:I#7GQ#"'R>*.3R?BVPPS!ICY) *ST>6S*I.0.D-UWQO/OWHKQ0-YR
MJ&0GX4YU*X8FC,!JKWG*IHO!?0A(.^ ^",\4Z1G$\C8="21\)]H4,O^OU3HX
MD1TN#SY1@.%,]O$KW6D4(627(18<J) E]BYB>V(14%20X+J1ILBZC#< 0)($
MN%O/(=F>UD86(+2I$%>)5>SSIEJU5*.IT?$K=+#M1.W)O>"!-T!SJ&X#'2IU
M7XI;N"QH^BOBXL>%14&<?66+^/2)CA,KUK9@LQ_38A/#M6'K2OV1PB^#>;3Y
M[ ?O4<)&TM9[W-*R,6GXC;X DM%6/D@KS:A3SS:DT2LEEZU8U+,!'>C'?"CP
MT"2%S:F,-=SCQUMZ&1508L47H"2&6 5O7;!%N(-]A3GR)E!->IHO<IDF3D\K
M1KC4_8!L\:E'$B56#7;;J)_<!\571("$ H80N!:4O\56*Q_F$M#C[^Q)X?Q"
M:IEI6;OQ6PJEM_NCU[5=S;1Y]WVL3VB_R(J^M2?>=)T+Z)WN6BF/Q2D9/YI&
M-3:VM4):&#Z7/DQ>&I'L<QDFLL]S8)5VH@PA8Q^':>.E@/Y8,949ES)XF>'#
M>.U)*:7'72^B_81E205NFW.4?E49#7W9?JUBDJ%C-X =7TVX'4@VN[VAE_S0
MA_+'0*$>\'9-4P_OPX%6,N@LJ7ILV00+8(U&^J(P@,D 2ZP_7A[?38ND8!-X
MEZ$WN<<7K3,5O>KD#7H^VG^%,\E<XH,RUP'6,!"F+Q2FA%WM)'!B"&TY4IP4
MF'<(C=;/=N\$INSH])Q;]=JC&*7!=VZN_5YRH":5Q]%$!5"X1EP"J("&R(<M
MSM(U+1(;!DSV$J\D>@>:6%AZ]SZO-]OA+#!+E1@/P^EF\C*HHL:H,GQ?S'.'
M8I_*JA-'IS;"?)!Z=TXA94G\TYQ[=H:2_V%WXZ,_5VS?4TEFQK!QS,4%G1^D
MI#GDFNTTG$]NZ";4H-/?S\OS'N2,K\9T=8%(\:]0BV"CM';"+:QWU+F2,W)H
MO>V+:KX:T[!6ZB*PDK=U3H<\IB&,87#5TU\(.0]%OZ.2N%%N=B!8]OIA?6#+
M_1" _(E2("L^[Q%>J.Q<'/LK>!4M#Q/'!DUTGLB^=4P_\LW5#WCAYQ7_9L1;
M*B$I)*P]]4[?#2'T!0CK2<'F5]0E[-%;5<1W.XR%@YSCC$Z0>-T5L:.!V4M&
MN5+B&W'S?0J_&ASLBJ1;DY%@VJ%O6CC[EQ(+C[H-6'.?KZZ=K@E_5P>(CP<,
MGIBI#ZT*BC2+E4.]34UW-UJ3NWVQTZ(5UDD+TLU?O5+5?^\B-7>O,;^\!3''
MA4Y=KZU<40+-=S8J1WA&#^UD_UB$_,G8PGG9.%MHLSZ/T[1-DGU'B[X3A@I
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M,YE.B[CD0C*MGV29^Y!G2?%W: ;9B8B20X+A_JLJ7+IC_Q+2"2/*!T\(2I>
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MQLY5E$,A]9>C>?C?HY[RSNP7MPB,>+8*:,V1*^62(\*MKJYN\ES?FFI8P=?
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MHCT/G3;#)U+_>6\Z '"F?&8X2PCOBJ7HR+J',0I&#F6TT9^#KF;VN,Z+UOF
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MKK8"ML,N[5W7\LBDKUCP_UBT,F@99T'T[^+\_%QK%K2(F[TN 8=304E,6&"
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MP27 /C;YB^4K_WJS3!T <7^=N7O9729OG'NFD+48HF;OUHG>FH>HM1_YBX<
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M=<7%3ZX.J?$T1%B.^:27HKZ5/8J&CJ#'W"OF;;)K$SA#[L 4Q76H6))O]U4
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M[+&:I@V[^;6!K9N0!UH=-'&%X100!A<)8*>5_YM'3>GW&ZV_[4I^J?R<+>B
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MZ:+@T<>OY$FEYM<3%"N$SFL1*Q,7_(C)&,3&QO8M7!_^30E!$?\XYU?A]HT
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MWN]G J27(!'3Q(P_4?$PRU_&"<&]:\U$>3QK%]]R/$<4%N90W^)'A3\N6-X
M+@37Q]__H<YJ/ 6I!JZ]F;$>P]X=<*$:DP_.Z.IX0X7-=1)MOX58"PXN&AD9
MC35PMO S>&1(F1T!@KRHX"&(0R_+S$;JUU4?J9#BZD2<)_.Z_6/OKUV<PTD.
MTBBF5Z\MV&6OJO4"?!!KGTAG#2GE!ZIP$,F^5A>JGI' G?PJ<7SQQS>M!/K
MAM(-2*/>89[_>=CC5@1;Z0X[)V6A@<F/T.9W5F?(!:<CAULQ*+?BCEN28"GL
M.L^FH.D#? NZG OCQ0@8A[W652KKWZDW65N7M?TE=#?+T(\BK"^)/GV(WO63
MGM5>=R,:$_+;1-DM87&SL9]L/)W$'XY'X*:. +^C8PW"'[WJO\JPO< %7@?
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M9$_1P()*=]CD5B)5@T:37"9SEOOU&&A7:^*OB=F$&EE7;9T2YPR^(?0[B*9
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M&8C7?]SZ3H'13V.<?/(($/2VA3@PL-HJRE':8#XG:VV%6Y\K0Z<0+4LJNGA
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MZ@O F2D72$TM/C5-658K(NH#,2$A[=$)?"73:[\Y73]4.=_H6?%_"&-$(XA
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M.=G#M-\JT;VLQ24N\;D?N*YAQ:J=$)ADFMPQU]J>.0(<' '>' $ZI*? D"-
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MT, ."=WI$N=YY?SHEZV^^3<Q^S,";0?V(J8K5LJBJ@S;9IG"&RZI&'6C,)7
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M\?*R^^:4RR*_F)\5&\VZ>2O4L.% []X Y@'L.?^SYO28HG[O@I\X B#3/8X
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MY,,22.6H GP.OUS-9#'CE(*>Y>7"++J,\XN$QD&HS?LPB^?7,(\SOSP_^>#
MK8QVUA*C2& EH@&K&'2EK:7@X'HLG=6BF$S1YR,V377EWH*-AKO'H/-H90HA
M'OB@!67YC6V>LC/DT)KQ.9\-H8(W)H#]OZ?BVOT+<+,84X,#1U_0%&ZCP$%
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M(5?L@=2=I4![N\-C?'NHCL-3T\1<,J,TS8)6#!Z:K <(C#CX4"_]]!&C\7F
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M1X,;O@1YTHC<SGARR](QT?;NH>5WD]@B!+B4\P;LI3%2G[-:.M-*83HH,V?
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M:]?$V72P&\XNH&!#VORL@N=@FAD(8UH41/3LE9;#OB"46"I^EFM8PO'!Z_P
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M:YW#M6D^]_W3_H>]1-/4K[42=C*I.]P0ER@&:/CA_H'1*=WAR5Q=P[2)X<N
MAF'.$,/&Y*W CV;:P8\,OP8#OQ#&Y;M(K,=Z0$.P5N48&ZN4/IG"P=Y.CAYS
M;=_*:B+C@ =-C4VSSN$55 P?W'OR7\1K<H@*-"#I$W&KFJG/\Q(-R;M^O_I_
M22!K6S@;#(S5*0FT<^PD.7&-5B0\3=C#N'HL+46N^=F;+2__"ON0JJ[+$]7=
MQT7XJIWO[X,Z4B[>P)9>P^\*> S7ZY \Y)KGKXP/A>Z@MZM J%Z9M@9\$[8
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MZN?.$%K<.,X+,>.(VT@8)1<EHE:3(D@N._FOV>#_^F'R[O]>L8$Q6Z<[.(U
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M8SSA98?A\U$>MV,'+WNW"=8*__O_:<<,]#4 -HB@C6T#HIM #8KX;P*$,%Y
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M)'9AV9:G1ZP/7E%P?.8N!5P26).C<8VR F2[KP%WU$,R^ZSE9CQ,E_0[6Q:
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M+X.(TT;T056+[_>V=]I[J(/HQ_PNW$!A6I ]YX_0HYV ,07FJ<T;"*M(CK%
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M.T52B ;>+?=S#;TO@$<$2GSK\NIGM@MLJ-7&-0O2, 7R9.2%<?;1 I(U!\_
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M[%9J4K<9<^CX%),-ODD,^D)K1I?2]+G2= WGP!,)!'308IZ.[U[1%(=50.O
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M;CI7NL#T9,Z4Z%4@^Z0"7F3GOPMX^2%R(;^<G*V&?#TZLG3QS'C2I?D\I9@
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MY*-]PUG$1:4I##YWCWY.XLO(M_D='DL-N"XJCZ'KX64]>T H_M0#K(*D:[:
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ME>AJQZ^K-Q;@HAC)A+;,E$K@D@P'HLBUDO!:>V'Q^9?:^%^"&UE22B\$ OB
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M NK[^YZU3B BV(AI-?9%4?:\$/^N0AJ$:#0AOXP0HSXMF[#]O*'V+[J[Z4O
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MR=G]^!Y+W/E!;]*S,F!-4\*73/5Z9IL^EK5VCO7G=X73]+:J?W8V7 )Z))E
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M(Q[H\> ?2/VYE%F.R94D$YQMQG71?(]&M[+2?A[U>W1$_8Y]$(#5@ZD1CC^
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M=]Q/^:^2L=P8D.4' J]:KAG^2@FL 'J;F<EJ_9% M/*GZZYVW>P"*0,(O\W
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M[Z_^%V]!&EY5;N9D;KE34+K:Y_#,D7K5PF+U]B-,G.IS;[MN *G66;5F]R\
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M4-[BV]9GF\R7VR8[<\;5SLD2B*I8,!LA9VFB7KU@_U(XTP^2(6"SW\85?-.
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M#%:5[B)OSDH4SLG1JFAW ?NPJBZ!+[]^5&WU_)UJ#9M%4VQJI1MQWR6;^9V
M9NL!Z>!JC_!DV:#5W=<?]&DXXC//>[=\#2*B&&6A9"_$+]+9&)+UIIS(U,Y\
MTUQR*:PLN/6XU?2R##)."'P+74VT<<@YTK7#NG6[*W1+JRL/@U7Y56O^J";;
M_!PU&0V2]A ;*E;S@,'/CE4+>\2E!U>>#AJK&X^8:$S<-GH;XF'Y\]^G79(P
M?A(\%VKM^O2J=NX%@Q_\4N>2.-:,97C]CK[?-\BO>PV;=%XL__VA<V:I-U_M
MXQYH&+9+8T]4?/0O_]V7JGG '!%\[M<N_P)+>"N:X ?OA=HG+>K7)_^ IAEK
MB+',BK4KOK=A7"9WY%N<D</-5U?G7,,UU6)_LO"&_Y +#ZU:AT (P(LKX -*
MIQK[F-$+DZP=B=5"UONU_Q]S[QG4Y-NV^P90$.E%.H0J*DVD*80 (DU$>B^1
M)B72I 4(O?<FH"!%:=)KB/3>13I()PF(] 0$H@38_I]WK;WVX_OAW6O/NV?6
MAWRY9W+-W#/)=9V_ZSR/X]B_/O,B"7IP_S71@'PB0/9_QCO3XCNO (+L6)K+
MCI/."^GV?XW/_L6N2S\ -71_-7==_WY20.-:N>1"H]TP*^8M%$#A*,4^F^A:
MC8DU,IV[_\3Z&V73Q!=2?SMTXZ?_L9_]U]U2&K=_5*6]_]YU[&G[6_FX_-_'
M$__G<45OIU.5YD +.+70\D=6!WD=-L+W(8ZQ0RIGM EV4S8B<,3@P^MW))3F
MK@_' A+]F/>YLF]U1L%E*F'AYDV3(HUNM MK?:*5>2=B'&[*KMS:>6JPC?07
M.D\_&W4O*7($[R%J%G9E!UJ9TM$U4;YL*NV-YB I[(3JBS!5'Q%O"4KI+78=
M2EORO!)DL#.%G. 4B$_(L8.C?;;:^]Q%>MH8)YI_.FHI4F+*^'2(5=/UU9.*
MS\1')=JWNB^'9%6J:N*DHNKGF74:IGX&N-"/W"$\"BX>%BG2?SJA^?I,O'SX
M044,CDL1D(\&^"OL*V$2U;JL2*=<]Q#SV)7VU68GVX"R)9.JDXW[CUQ=7$84
M<D1Q+ .#/+ZU^DTAH*U3.7Q.!;["8L8K_E<;^^U]^GF#SXW8S(17P.=M$IJ4
MITC;\?2SN$G:YIOJE.[B<3N7_+#"?O^LP1PW*IB5VPTG_X'T#Z(5)?D,)FWS
M; V:_&4@IJFB&.LG)GS'K$:/*3\]?4&Y<)'K;?D'ZXQP#":P^;[+>YFZ'&<4
M:!KRD@22-+6WG*]<VN;DJ35M28IU\ T82[UCC#TR/#JI,3^*R6<1Y)];4N5G
M[R9U4"R<-LI19RX_?I#RI&[ XKH#^/5/CA0J[<A@SII+/H+=/.BN=XE6P6BA
M(Q-2-BD^@/9<)?=X^5DUJ/MHE(%7=6CWJ/;1^@:U+Z:=X',%8"R,'VQ!)C1"
MHC!/(RMO8TN7;,*@Q\(=_BMC=I0CCRD"0^,^C!YIDT#7'9*\J<S1;G%M,A[H
M=B&T5M.[TL4O(--24Q7*VJ&CIU2)O3W/GNTPJA/O<S]:+@SS ?/#Y?"1Z+78
M1?NO\3@*$VQI./LSF*M+(VRO[5L-D]8PS[E*6_'<D]=%Q-)OWZP?/ 1L!3MH
M/4;O#@3Q1_=F78K.=K .VKYZ54VP0MY6"K*"2(D4M>B"4GX%Z0H<?>C8?L0=
M2/J<#&1,@3U&G2+61W,6I" Q5CRX<@O>2@^HKBGO4LIS4_"X&]WP5VJTOT?<
M$22I@]E2&=T"P6-ZP(*X\=ZY*9ZHGL'>2Y<^)M\>TV>'GDX,%2.6;(!D1,\O
MU_O-PX!3>2'4C#2006J<;;S,$K+#EIC1D7N][0,3NY!C/+CO)I'-E-PC!_Z?
M) #CN,O)M<;HF$L&6(5ETU0-7*34W!$,C+9@XN*AOZB I&F\U*Y?>..].+H1
MFEO/.56P2#3VZO*K%4?S%-P6#1VG@;GU@:GP;O*YC3[^,K'\J78!FWZ@A75D
MZLH^6OSMFW"DI^AC2GKW8,?.!&30==QJ&<,2["51 =Z?2O]INE7#L</GSWG;
M!9FP?/>E6T7. AGZHLH)&2S\) [K8G'>5! T,D8$D:O=DW=_]@ D5^KLT+?*
M-MW?VL^8]IQIQ(A>W9(Q*NV!"3WGD2S;]$61I*-+9]W)';$V6X48*?-/C?)"
MJA,@+7"ZBX<<.?_*764$\4?UL=MS+I\ E.Y"P%/G-FUJV''_*F5]*S8YYA5?
M V*N:![$4Z12JBHJZ&=8\%G=<C*?+O960RN4L_>#O-N^A AB,/1G.YLVU16@
M1_L3U*P?$95+-+,QS;2X2\-KP?YY-H\X3)HGA4G84&VU@))FX41*FPJV!,$B
M8]?G74#JF4R_PVY_0"^<G-^M,M.@!8D]4)W\[,T3FA!,3<[)@/9-M,$.[A-]
M["\BB,W!#3%D$WG00/WGLRZ5MGDS3T?Y*1NTV;[:.A@OCBR!UD<3TLT@#5N]
M"K0P=MWY&I ::I2=\_'E0T.$)[IU+.CW#QZ7NK:L^ZJVB3+TY44)#1S$&J"U
M@4-."F!\YB)S')A?"YO5XU2LXEVZ,R'2*%)N"4JKQ 56?Q=4;VM4U\XLD/!K
M_DIZAZ0"K_1!9+Q/^Q:LXPPE<-A;0^L\=XJS<I:132S"Z-TP=]5;=2":!S7K
MJ'/;89*T,?G12VAD_Q/L?#1<L-0*G_]DZD-[,T[@+$;,RTG$Y8 _PS9,II[+
MJSNQ+4'I1?R@WK+3Y3@7J!5'DTC0_>@4!,I!9X6]$JXJ:<))XA3-V)%^3S+S
M'4/IA1)X!WX9CKCV,J2:YG,0P&NW.NX)1K7)H>1ES_I^W\Z@VA^/%6M3"BC4
M@+IY\%=PT+6G')=0NFS84%RSDLU<_U,7>4]/=X$E< IAWMHW31VM[C)E+K;]
M1D0A/"L2]59635*+\G[XH0KMO+]MA+#?\\?\D/UU_+__G?\XJKX&"08/G6.C
M+P?,\R\DG W_R4G_2]8'^.G\:_PTYJ)J?CTK23*8U SF(3@G%6"?MV:.8RK(
M?AY)O65'+K!$^B6D&H[0<U?CD_II[T<3 _+V18\G8E"1R&BO,6.EABF^V38-
M[XHZ;Y-2I\*F,!:?5+Z&GKW^I(E"CK3[1+'G=_"M:+)^X U-3"<K/ERUI7'6
M+F]Q4'GBU3.?)HA#2QYSBH5<P_AWOQ=A/B'BH<,U?C4Y5P"'<4I8,"IY4"PV
MCV*ZC=UZ?;?;#5JQ2'7S2+]T=?MH5%9%<,%D#YEK]>A6#X!]DR_N]^.0FX5E
MJQVY)2LK,6VG8<PI3SCU_72>RXC?;![44^0<LZH48]V1_JT6(35ZWEEWD3DW
MX+=Y.<EO_LKD6[[,S<&71"N1@JSK/PMHF+%9^] _KVGJ\F$'3(03317H/SEY
M[ZO3DYV@O#=&*QPT,L4!?.1+=U1#YD$F]5,$[HNJ63C=#N)=<&Z!A(+9?OQN
MRA<\S>C!!_=E1U9N<RZ1?+^5-$E-L[!DD\:\Z9'PLJ.O@!J((8N4.N0@R,_!
M'Z$N'@]JMLRZ;-9G[OQFY:?KY7^5H,-7MC;$G9Y$K51MBV+ND7?HNA2>/6DW
MOJ2#*OF6FFWC%F#Z&H%@FA50XG?U*KX#MU5KCP2BN!4\;OU"82"?G*!I_VFU
MO[C(B&%9N<SB&4[-_E[?N</+Q]0SPX+?C#,N1^F<?*UNSR.TV%9'GS3F/&L*
M/V>B,CK]K>I8+6H3$"6CJSJ9B!OF(DX; #6!+4)DT"7I.,X@'GRTP>0_%W-Z
M:/*]I=ZS%G"5M5LI/^]#PD;>*C3"R3PX-VWG=?'CC %HP44Q(E'V?/WT#4C#
MB2S*=K9FO1&:&T18$DTXXL]O3]-T\GM(Q46OPS[6*SWUY[=)!Q:"%78I,!S\
MC&FS1FONR_9L,VT?'/R,MQ=T::QB] AVD$RC$=WV(:#R1]Z(":7_%.Q/!HZM
M4U'WH.>^?CTXN@+HQ#\/1<AUUIOV'+!$Y[DDZ0;ID3)FOE0!!G"3C"O8C;/@
M-76P7^M0[62FDP@738T9?O.**@F]@(9/5'6AON<+7#JEO&+OWI(P,6906)U;
M 'L@0 W,!;ONYQ9$':)CVIO<:REZJOIRWD'B8R%SE$V,:9#[C7LWZUO>[X_Y
MOOFOK>S&F5=%\34X3S19HN1X=,MA=!LS:IQ\K3I5Y+2J:+C,8H?YXXV2E&L,
MJG5//MI9'/5%R8M#E.>WR/8Y?@>'7#Z$96LYK&_%_%P1,VH_5\?%XF,_.;')
M$THD+0]>&,6MU'[PX($TSX6 O^+)<8*6^/ /L+#Q?B,CHR A[  "'%G.>1^Y
M()A!_TC/43EM))EQ4GJ.OXS?#B.U\T^_5"Q\GR"(7;W8;Y.BB4HWG.6?8;7&
MZ>,3K!@8-4Z3$9V"O/=;_0:Z/,<"<O^-L. BQ;#QGCQ)?'@P>L43/=AS2 H;
MF3=MJ;.4=:'0SM%M-'&UNO-F15/L[<%0^5(7R587A_&*U(8[P0L?P!Q;/ E2
M8<?+F)TKJS!:W:F5ONO3E<)&ONRG3SJ@.B@X0V)5QQ'/*U1(ILI*6<J=; 9(
M^_^#DOX?-/!?*Q?_ 0'L.>27?*+FY? %\O+]RQKW&II_]Y4_N_G?HF#[/U;-
MMOC[R$6B:Y6Y(^RW"UT57-->".KC#]UAEG5V29&<Z"I?6B*S7BY^K+YU+41H
M%?KU\B&[ %8OYQ?<FI%X1R&GF_SU_*]>VWAWB$,-RW8V8*/3H8:5AG''K,\6
M[=. N0+<OK,T/ N2E"QN&E9X4(N,]Y,73T\P*MWG*[""YE%,E4P;]X4;3GO#
MQ/8.0$(.3MX!UV*J9:ZU\,H7FV:THNH2&/YQPJ:N^R= H+]A2:%/@\"XZ)*]
MI(F[?D"OTDZO];VJS1,U\NHHUJ8S($3](>?@/E659A%>YGEC?0N.DFVNK%S9
MNJ0;%?]6Y*#:P=[GZ$MZH6IJA)H/OSM#0MX-,J%S.=A:']M\0IMF 2S=$(?X
M6FSKX.(CW 8IW,YDY\O8,$QC<-1(86 /TR9QE9V%)!BW;"6#Q01[EZ U-TV6
MN@M5*KZ9P&I4V"+\?W[_U_5S8BS]D\@X4H^M"EL Z?A%IK<(T!@GV=)WB(Z_
M MS:[6"=/GDR ](J4_&[#)MZ"HJ!%R7JJ(GNK[5>CR\;WO]9J,P^E#3".BU@
MDI Q3L;UANCXL"L_C@$*8?*N(59#O250D887F(T'HC[M86)%W/+0]KYQ3W3J
M>W"5]IPP[B,25Q(DO@[W<KP[9=B-NGI1:S]Q+&*^7K/ :D<<45D/WE B/CI(
M&2$A]N%@XD@X-5KEF3Z VP9_*&Z?VLELTEG1<)_3$Q9A3.;]6+GI(T><\)24
MWXZ>%!IQ450RA\)*A4YMSNW_;"@W3_1WHU(]+"O)B3K6^IS *M$Z0FG+WL,L
M-,1(9(LJ[6\5B^-Z,-=9)Q7=.E%5N?_%1X;M^GYBGSYS^A=/R9T*WMIOQ.6;
M/FG:O,W!,9T4W@J<<+?$DQJ\^GQ/3>&3;-6*@EUMNVSI#QP-H"E--O7B516H
M>X*1RL62$(!\Q?C4M]4/[H%^2!#WQE!< :+0/=^6QC!T,$MO$OX.YR6I'\Q4
MP*S-S*\ZTM)YYHS@1WA^9\BM:5-<5N^8.3HKY,]F88VLG99<$]T1D3VQ?U>:
M9GZ77^EN*AMM/6 37O\/ZRSBM3\0GM;A5VK&,79)5P!-!/8D+\<6S:Y!K%3^
M8/GY=Z,0X/(88N8AB1/WK8<\JI"!G!7HGZ+("<RY: YC,JF2-$'D:$D,M.AV
ML&TD"@_SZ^3N\)ID\J_NU#]XEY(Q: YI0(97>XFQP;+T)@BL97 9?*"WO0MG
M:;2WAJZ9YJP?)5)\L2A-I)[1<2*AS.;=HGAF'8ZAW^K^+%A."06DWO4GBW+=
M:S0YL121&KN_W(04&GZP_#B-3)]--56M<W0T^9%) H"%.+D+&#,G&]W/Z=F5
M+1-1!2)Q^/C#!^D?'86J35K8.R$7? ?\GG M4SJ1SRX5]L)SGMMGK5$AE*P/
M KB=-F?%W@EIZE=(1Y<):CXK0=^X7]^$=5=[N'YN+(1-Q]PNQE%@2F/:%,H<
MTV!NNI,$N9>+F5G>Q.^L6Z$Y(4\MB,Y_L!(_>)!;)(XR=V<*AH[I]3[#.Y50
M6<WW#*JWS.V[N)Z(L7Z+7Y'35*.^/MIC*9.[9 M\L#Z:ID@:\DAL(?X9A!1N
MALN**)YJXW0*H$ZU_T213VYIN2R<.BR\7>\&5OW6-: .>,W"D:?8CEL:F!S$
M:8'$T%> F'KX/:RFDXZEZ5J13UVBU7;Q&RVZEI8X=<Q1!@_8A"AG[*N[N%&G
M_5VXD.LE=QT6F0AFQ6<NWRC.GD:=1G-E6]N8D.7;SRQU;U"&)G ]=ZX9=&-7
M _9+8COC+WF'L17=(L5*W@Y!J8L#4@$EF;J2JCL[=_F21PPB?KT@=9-YU-4/
M< SZ:B63;X++BFVD8AZDP<ETM7AG-#;E\:7=D+@^W?914QN\^A"=?Z.NP_!U
M3FW?AF'^8G3/(E<A6918<"W]%6# +*F0*[+(6:C2TO'[\D@-G]^\467]+\4G
M@Z-;GK=TPQ;*UQJR$K?F0/9H%Q(57"]!"RN::^\B4AJS$4;9[75X)VUZ')GT
ML+1'V"W#HF1/_-&M14)@_I/@:\59,:X$/K<B2ZNE8C3LZ[JR\RE:T?YHB8\A
M\MJ 9R\ MJO(97_.!UU4>YMIE,>*G$+(>_::.<16(R1G#J0HXM/O9DHP'BU+
MC!X]D,EJ_G;+-H$6NMV"$PMA8PYID_NTR[1& >FF6D<V(>^M<K2=:QU;E+GW
MH'KOBY?[69.^!EMW]0>X_.\9DO@I](N%9%X!:$'Z]NAV8+_984B;-=31ZPJP
MGTNLCK0P.USER;M;"-M4L?G2;%'VLGMCOM(XX7)ZE;P9'XG2IG1T\F"=/@"I
MV;7D9?Y^-[VDW_BK+T4X)$Q]*&>4;(OVUJ$BN\*-H!O;5X";!X@J,RU/8YQO
M'*(I^5RSC^WGL,#,, OOG3>\Y6KTKJ_I&"D;N#RM<B"<EWU7 %*$6_BJ+$XT
MYQ/,'TBE01UI;?^Z?O=N@'25!^/\3>\;A?02*I2Q#8>1HV'$B25_^("X62QN
MSLRU%-O9?^H_N[O=(C60ZG=K?P_:7!#ZP8,_Y,5&>9I'TNS<G&""I+Q<WRK]
M7&/@B[TI;XJ[56(L&IMHYH2*W+7>H_1Q9\"O]/6F>'0G+5QYQG43AXQODZA:
M=C+SVK>M<935B[]X</?V$2OE;:VW#T8JR4V9_3>\:JHJMBSY4&*]2PJWONU*
MKS&#E#TJE.E-^R#].^<H:H['QBV9))N'$!4=LENXS-UG=7@5C'GNR_X3D=N<
M;$>:K0^+C[)A$<*6)%< <FZZ5J394?""N3*B;@:N['N!+(1%_;9?.ZU2Z*_;
M?=V7MJPE5RCLD[G+UE@_M)3TW<;].:-Q.=SVK0E<!D==:=>^4+1]YEOE9NN>
MDI/2-)4L\BXC!"A]H-1[[SW'BU]9>XBRQ9T_!:09/E\)=_-M@4V+3"QI^20Q
MY/J,F?G>N.VQ UEHDN*C/V?&+1<QD'?9CPE8M&)'\ZQ;8\4XM;-(M5,\Z=M/
M=?FKRD*Q\:V-@^*%61JZ2L\X B#]R<2['7+(*1')_%O]J*4[KFQ:CQ<#I86^
M':+%ZV,6[+A?B%.%W7C(X2[4VZ:%DU/-PA@N^^;=R3Q^]KFYUH5)GF^@R1].
M3J+,9%@%W_ C3VFUVZA]40 @#<A?7.H%,[1A?;+00-H?O\%E@84[=*,.;N5.
M6G Q]^JQ5T\<IZYSLU)/*-Z/>F' !OAY& VFSNGFXI3U'JC_W?LN(9Z[*6[Q
MCK'SI[@[-D2VBLP/.1>2_*J;VMQ.;29_CC%WFWTQL_.WC!NK'/< IWY<D*HJ
MR>4;9/ 3K[C70%PLL*I(]7T#\)EDX:];]L\U"6#Y=%1TKWQPW\2":*&WM5M.
M@ ;_T9Q3;MB3A&]R!JV?!,E(I+9DYQ,[A G<TVB<6!(_MC06?I>CCLKD!Y.O
MM+&9Q?-N,[MC@0Q7OH1:87%V%\HN>ND)LO9)%9Z'K*"; +.[!5& \)2 .&\
MH[$<9MC[4QL=FAPD_5&;3C3??='YC?'84&+;!\0[ \(Y["7)3!P:#"1XIO>=
MM3Q/K(;Q#8!OS;MBB%5FO'S3)@7H#KS/#;CLN-V_"8_FR:7<(9G[5\351G!2
M)W8Z2!C74?$![];;$IC5JP,O:IWRAII(63Y^4.BS+4JO$D%O8FVS\J.GXW,-
M _X81S%X!:!LTT>Y0'KS6-T8\>I+*_U5BU2JO=I'Q;>!#>JW6S(>L;QY946]
MEYY"!( L**"RX;?Q#N"8/&)(=-\._;)\\NG::<.*'*]KLU\MX"5W6 % &DOJ
M835O >FE8=G->S0AV#E/ /JNYPP=Y*V\$A/;=^.<?7QY'-B6%.(JW*HQ=.>U
MK+'3OUDI 4GP-8.RSQO06E!#G'9(FSY.L[>IQKNLWQ/M$C0K.?1J_U"KL4&M
M9.":/:_'^Z%$T5FJF?F%?.H.H..?EP')>HE<TZ).0DHLFYO)127-VGOR1-$"
M*.@SY?0_)I$1=QBW8+,))BW91VO=5L13DO%:OOJZ]N6PCLN1DV\K^RW,]Y68
M>M(UB$=>V P]GU(:%MQ_^G\CPW^CK>?_1(J_)P.-_UG0\L^"*?CK?Q:4W;K,
MR0Z1[_@'_/X3:OT-8__[@0#_U>=OI=;)[-^F]"'WKP!_Z[3\QO^S+?V_K_N?
M_>8S_FFZ_27H^H^NVW\ JN!%H:06M(^+?'I]:N]$2_]YM"$RWWSJIWE^@]6:
MTV[K6)P@=;1<PBN#!UD&]F3?:TQJ<A6@=T]6;(#4^-?SW<:7 A-%,RXU8FDB
MKT>?(V<*]7D1\;_FZ896;-.)GC;-ZG<_!(Q>)'NYL?:Z.'A7.?X^BY:L@%!N
M_S8X!?.\_94E&R%R^Q<ZHI51EYV764XSA9IZ.5_IHMA5> /[/+U$$W6>3[N3
MW=3@XE#4#?W4E(VU0FTD!2,^B9!VL^?ND"MXD:Z$IYZ#__PK+UEPI AH"8$'
M2.&V@8S3 (TNL1:U)GL2'2V-\P&H_5X0C5]#?U98#.^E(SS&QP9;.ZR/TM"O
MP!QZ4Z M"=G(& 056"9BS'-#Z9K/H%M.R^K+8PMXIZ!5%V?I7C?65Q>OQ?6!
MM! E%,B:6,E4ZRR&;CY9RHIZL"1R+-)F9:#Q.:6L6UB#]7OEY93L$R.,VLQZ
M!RZBY;+,FSJZV+$#B!->-$3T[7_7:-$K=0;$\TGFF#85 !A"32'U>:%\YBNP
MIL%N3YA8K^QF9&.+2T<9FB)77[?Y,46LO7$J.O1I[6)Y?[(1WT&B]F*P26O:
M:&\>)Y"R306S(F<P0SON6Z#-0;_])>X@;5 LGZ'_OKU>34J!'=.U$,5[E^.C
MY3"'@=]7@$B"+FF[ UJE-EPG25ZYOV'W5-^L,2D'Y:<GK49==%\\J2),3;W3
M.3\:*=O>%(W6M%0>.,6:K9DK5:JAJ,Q.[Z8_)U5-4Z]ZX<X?N,]B0Y<_NA+R
MM,KD(J]-)K (7]-G?(2GZ<OC1#8W(!-/\MEVA<J<YZ<JAF/"1?K.N1/5N>V#
MG%C6CZ!K=TBV:!9ZQHS1D'@QD(PGIDJYJWZ[*99S/+%T!FR.XN^P,5?S?Q()
M:F!]N92P3@H*K<&1K9_,]XDE#GO7?-M!7C(%LMWQ:M?4G&.;;&3';[S;S!DU
MO14_Q :HOP-GB4MA?/][I:.N; S=NB*M11\0>(]"O23>U DC;O'T"PI%%][&
M>+.H#L")(0LW!=_']Z\K1/]^;Q8<2W J@/G\5N_;AI;ON"\]G4Q3=*_NRA P
M<2@EFPH!+:& X6 !QV V@I(?QI1[3K+"C<;,R<PW9MU;=:;)8OSV=@%PI\0P
M53F#G9THBW6Q(Q7GN/,:+H^C0D:+?D#@ K^^\V6*.-+D<#N=IKC1Q(R1BSOW
MQYE>7L<CB^"JN*@:**J3#F_<9T:5^YZ^\K=H?99OO!PHM*^.^UXJ2A_JRI_6
M2W*K!_X,+_,1/XCQFR'8%O_@XL:N%J-P#L#3JJV,@$+YQK11_M,X-2+"#^10
M0E(4XR,^%L!I.U@]%17F9RU;OS@P_<G^P?Z&W=E2JP_-L^]M6:<527,*I#!/
MO:P^HU6VSJDV)6A J87%#\]=L/>0*9VUICJKE9&][WGS/2+K,!)*[9 @CMDU
M]'@,7+5#>@K,@W\N3S^O,H48%1HZ$&-1\P"5"#5P&18IW>%Z,8 +4WRUI7_:
M)),*D^E!^GCNM/@NP#6=)!>;PHLURIS9X-8"5)*TE:^)_;[UIV:-ICTGYZ:E
M4 "  FOP<V>FR:;S#,;JO(F%!EBN4M181.;PFA\?N6=HSXOJ!_YQG>>:SK\S
M4]<M'RZN6&[[JPQ4N9$V5SB=:OIZE'ZC/?^NOL /A#^)')'N]X'#FQDOB6#)
MYZ_/32%X;;@+!BC"!X;$$40NDE+LD.(RWUS:>@(2FNX_9/T^/R 6F^V:XP<M
M,*M).*'R6=Q9O-2$7-L>!WV@ZXW9>E.3ECI$.F?L+:#-U4CT!PWJQOO6:.&J
MTY6;Z0;M\Y(L</&2^(K641[BW@J2>^,<;G6@+P6)[RDC7@%4T87&Z,+510*L
MKG'RD@KO.2#;?YGDNHX3C/%6: @N3[?+G&2 @GM",7#BUHB($)\Z3F#HY3VG
MQ:V^9J/+^4'PK1EO39-]$4D%!J=$TCPK/OX$K'KHQV-3\^]<KNHJ/5AH)GX>
M8TF!.DPJ3KP".)+B/2I6N[+2',T:?>9/!R3>F-HF&1[S71M8%@[5(-O\ZDA2
MA?=;CU_1[P_OXQ+!&Z*TR79E7V]ISWK)/[-:[E@?Y96@,+EA6>2N29(7$@+]
MMML-)H8EJ^"V8MR\*2")64!&;_8;'@*);\.F!F;M'E*^B"2R\4FA3,)OL=0$
M_._-L>4$0]>B.BAP@5N].5< 1I6:Y34@W9)3$YWC[XT6KQ=#]0UMQ98&UQ+M
M GOIX1\,HS#Y116;P8OI TVR'<T!V%&KV4LV->H*JL35=\7XR]6CAPX\WX\U
M<DUM15EYOGWJCA[_#!]-H;P"?$.:8",/X]J>>HE=<\[C:)F5'+4TZC6>)2A+
M-X#+BMX=\")?3TM(=7Y)NC12[PO9R,NW,(Z# _#>Z)H;SOX#96@M"=1%06=#
M/:+I,]:P?>85MBN2-_'+E][1)]R\)8!1KI-]+X"13U/S9,UQ*:<%NY\"&G(4
M7$0H/8,\(C\.7'L;.BYXJ_!/&9+<N&)NBI6)J91D7]O;=]U]_CFLY_CAN7RO
MZBC'NWU$C$(D -Z^OB+S/!D3U?ZG#*#\Q2ANN;"=.;&H)A:]Z@)6%VAV<G#,
MW*L/$XS95++=_+EN_$T*1\BCF3Q)OHD/Z.5BQ,M5P+31MQ+'WE=4C1<5491H
M<<0X- <^\7"_&2M1EUN\$@:V3:Z]0Q*/'RX>KR((X/+RW6Q%2SU\"RU[.=]0
M5O#O3=3>B,P(L8%=*V/EXVU.#FVI&JC.FM*HP@\:A]HF\.!4JB*>1@O39,[5
M\;P<25F*I\F:EZK!'1M,_0P.!TMDF67IA3_+TOR,S+;D'3NHMC5.3'^M&I*F
M&H!2>TVJY>>P5XJ*:830PF(GO[^/?UTW[(32K+K9SYMYNK/QA&GC('6RU)TX
M\=-;CDQ)H@P,ZZLV/DPRK4FB<=^@9>.,,'7L1PM8CL$#J/B0K=\J/SVCW?75
M^X![44P/K+79.Q$.\3\WI<$T\U84%"(6JJ\.#UX=/JT:$%RK#S"]E1'A%%;X
M7C.\V21T&MH)K(8#<<[!I,Z+_,Q:@1YDIY)SBP.YUZ9Z< 4N6.W7:9GTOPI<
MM-\" /R>RJ<%F5M*4R(G:_LO:VL-C]A8!&:#IOGCN)0VBB,FFQX+%R>?&6RL
MZY">[<V7?'."4,UQRN[,75 M)XILEJ^$2^SKMBC[C F!B1/2$^Z%A@!JS&KX
M+K)/&JKAX'=YZ-. ^(!?UF\@B%_OV)WOD^W7:TA+UZ<>N_"$DI"VO_ZW@.6'
MA_%63%> B"747.O'8)L%?,RJ(JV3[UF]J;*[,NG-Z8%*W,\A>STEX@Z]^0X&
M?/:N:BOVLF9]+7X1'/M)<.' &KN5) )7>FGK6J[W6UM2[+R<6FA_!YM/1?#$
M"491G;[#K!'!NBS-G65TE2NW_1]#S)87WWU;&FZ:W/"ZF%3TO;.I(>](LE*Q
MH4UW^85MO#\X+DBN&2<UT%QZ."]<+2(5XVVJDE2(.HUE"KS[(DF']OLCY;20
M=-Y:V_<TU;L88"P8B%6)'G3CRF>_G/"?CZXJ:HPV0DY(7@%8M:W!V1_OWU8F
M)I1(]ZCG! 7G1DW==R29Z[2G(=GA(L8.QN_EJ+1C.Z->XCB_K').(,C;ABLK
MKWG<!A^_4GLGF*JO<&](UHMKVTKK7%HF0A#_V@W$@+%T&/3GG-VH#W:"MKQ'
M_JE(B0M[GA6 K'T<K$FNQQY:-2ARJ/6?+RG@%:6J;D,836'*NG.5U9+[<KKM
M+2:@UG<\[@F1,0)O<K]9!9G]BC\-PKK%$^0Q >R<P"[9TM#&3VV:%\6^DFP1
M$D[TWSBYV/TF9)\.H(I:(^WT]-W/]PPRR7Z,)\UQ 7' $"D()52V)+%XAVTS
M<;,I2[J>URYIW5Q]U;GR/0-;.,^@8M'\URL .9AUVQUVB*J:#^N@7H;=/'Z2
M.V\^NU>SGZ_^&7$N7%>K%N8C\WQ*\EDE+HHC<Y W!#Q1DQ D/>SG@;L"].'P
M]?,8U0^H3Y65JA&=U)CVN!Y>W<2NU*J1PZR@Z59^P&.L4<?7FMA.)S%J?,_@
M:=0T2,-C?9P9CWF<M#.QO89-6&&*FIO>\]6U7!JFR0X5\-N,[?M",YKPX$TW
MX#<2Y?L'*5!6L( ]#VB*6;PDW2#:]NY,AD?7YV.-8(EYCS$XXCS 4;J3MFKO
MX[0;@0^MN2+Q?*9Q&R13N7LZI[=HN5QDI?+3QHC\>_]F/>HTI4%</_NWPCI3
M-%J;"LZ"]<E _UK%]#5EO])9;<P".GJ[@W<UKP BK*J,G7(Q@H)2Q_/[<JAD
MHC]5!'8^:9\@AET:B!K1>CQJ.G$2?R';L[.S5\GN<.S ;I])6TSYFNO:K]TX
MP EP0>%YLS8UK->R-5VMR8T.GQ1HX;C(5)(=P68-LS:*+4G>>-#*]PP%6Q$?
M>*UQYOSK\%1\@GL*1(X.6!+2IG1L":I#DY^PN]'@GY]2+%GRL+$8#SE](&)[
MK#/4#8-($G7=^BGP[XW+^(]!8ZNW)T[DGZP0!/%:Z))\D[9.+5_SEDRMIR;?
MF_UT1L9LEHH,W0N_#S!2SY[,PCW0V@G!+-73)I?CEII/9^ R\GMG1O&H:!B"
M(KK31')%6L8+;*=]PXD+EL/W154XA YB$Z;.NG[&2)2(W@\*IOS!+)O1E!A8
M,T:NV.+S]I.KP/).J:./X;JX;2;'W:H6?*$J5@51$X>@ ++"6><)YNB%D_C1
MXCE^G&J>U0%I<^IZBN+OL/I[?;J/KW613[\W7OSY3UN9" W\VUSH7QX@?_='
M ;?0TG\PUA^Y=JJ]_D]:&V)_]J\GC43[_]/IZ-;?PY__6O/?VZ/_82K"]9]"
MX&[]G1/WWY/A\']>GH/0Y<0:%2*9$:XS?UB"5[T",#3&'][H+=K.(OW>;?RL
M5<*R<:_"\]X#"3*$W(3#F6V>T$[<<6="/F,A7KOHAUG$FC6R?D:JPD5Z5W=6
M%!2OR0+Q!$TI*/4P6JRS\BMJ2Q)MY==KAQ["*5#?D7,=;#MYMW 2"^94YGW9
M7RM<RBQVF>]]?OU28S/+D3O#:+& EI$Z8P&N@R?!;J%%$7_V*)KX2@&9*7/E
M8L04E-E(2-C*]I=.;9R!T>C7=6+RV\]\^STA#6>#-;1P YS*212BQ,G'Q]=,
MOC.FL7AZ(V79W'1<LHS2-^Y" #8I<-W]QDN67Z\MSY_NRGK/O7-RXRKU+(%V
ML,SL>7_F<J.".,^Y\9%/B?/[;+\C93+ZQ2[>,C#(84=2@!?!;J&20\2\*Q2B
MD;H:\N^T%'0:HZWR=<Y9G^W'%J8Y7>/W'&#$)<V*[9.@**X ;'C(D[HPC>>I
M7 BH-!)*_7&.RM/Z6#A^2^@ND6F:7C-[GTIP7-OXJ0%V/JIQG-%J^0=;U?ZO
M.NQ)7H:$)?[EF4;FD:YD@[:OW+)JO%!;??/-3G?Q8;D&2^;]2#LIX'7\XXEM
M_Y>-4_CR/I&H3IF,HB\^H_T8%[>5DWO2[T=XUW\64 N=/L1[EN&!_6PC8Z4:
MMBYN'Q>W?;,DH/&?JLO\**>#2Q0_.E%Z#-,]7NJA[Z/JO"NHAHG'LW:(Y%+T
M<['@XW$41BW3\X;(:4F_ERZRB\LR:=T\28ZI,?;7XX5JCXV%2>Y4+ZT#(XJQ
MJQ\J07ED>!<4G;#NIZRN]%]I8V&PG LVCCO[PQMY&31))V+,9G!C307JG37J
MDWT[LYQ6*I*^A%/_JC?4TNH38\QOQQD:M?)7J)6NQY  &#N(8 %*2!S5WB4;
MMK-/F\A4B?;8JY->4^S4>_)5B&V<:?'B;D(ZU]>%,6C0=$LK'MK=XEJ0MO C
M<WK'YU2V-$Y4$G^PI%KOLEE-/%19N'4CY_T#P9SF4,"\RGH ),Y8=J@=5WP6
MY77QR##,\9(KRF_A6Q*;9ED3]M$O(X']8ZZ,X<MIXTLA[$EIU,D^'_IV^+H8
MS;<=BHO2BX82+9CK&7],ZL?!!ZROOW0VDP@KNO2ZWB 5W%M#/Q0E!*)S:7I7
M)>/1QA$NDN?F$3@.GZ8/50>K&LJ+4OV5'OTR0V6WB0^TEO/?04E.R_&0:B@7
M]RQ"A!Y( _4-$IRLDKPC.>:F9RX4\0>(FQW75V^.4G5Y)SEVZQDJC7IQ"NY-
M8LX58KCXYT77\1]L,5'AV@B3GU44O6=L\HE%SX\>C&^.\N>L/@_M)4+(^I9U
MW";(89L*<5___!39KP ]/.4_@@0F"R=M:G&<BVJ!4,D'6K=W&=U]?T5Y4=46
MEB6R,'0!F, W\')&]?A<- W=KA47]BQ$S,T+*L2#TKIY(6IWES&=SO>1"<:J
MVE:K'*:<";J^'\1-$*C#?46X?++$-_1G,^;I+0DT1:/)][A3PL;R1:6)WF\<
MS]^4%XK&JV$'(5C@H!@=IWG_:9[@M"UV/S<I+4LOO5+%&2E#?7V>)85X+U[&
MF.*8JJM!^=P(K_UT)JOK-V)V/O'E[(NYM"6-R39@^462YE)65!"Y$QUM#&'N
M0>:U>[5?62;("@GR>*@M]N WSH6@A;;T"7@[T0CFF;_=>?2&(4HE-6DY/4S-
M@N8IAA#\$?X4Y]8/=83SX*C@<NOXGV=1EW(4[$+->R?7W$>_QX:ZU*MP=T%:
M;%E9X'%7@(:S<(=)N%+U3DM^.,CVHS.2J=8\V!G6V9<*I1^[*5<;Q9M%_W;6
M="&F9P,)]^B[G)(!TNP3;*LL=_(IQ$#ZOJA]+D[;OB">23?27%][F_T[SV0U
M.)"4U]O&:KEN^6^$*,KG=/TIU9C#$4XN;<8X40B+-CS_AY&Q?V!Q>LF7+#O:
M\@:LJF>*^*$F9H672J[?BA.GFE/ZS0+_84N+22*PC%T@<\KT6OHG(I-G/U+;
M8EE91YIN;E:,*;R\D%#";B5*!7*Y1<[E$>.LI_9/U \5&K]6>?C:2K1$!I0Q
MJE<G<W&!ZL,,HJS'K"[*VHA0D%N6!(76N4;H&,0D'1*M-6T;;?YY^H51YB/-
MQG&Z'WRF-[J6O]"1  9"Y('ZN""D/8YKL/>4C2G_T[;>8G'_RH9_CUJ (^N*
M+Z+PMIG8&^O>C=Q>M]%Q3RL@-J>7BP'O@LOIOV28A#^0W/T^58G@GP/JYUT&
M5!CYZ8^D?/F">Y5AQT-RZ\5YM%S(_Q@Z^G\Y]8F#)/E< 6@)D#_@>B,Z"LR%
MU[>8J';)-*\*&$#RFM]8;K@;8\HKF5:K0ZVA\BMD^'M[>3--+(3^9TTDF$O+
MT[QI]O8T>")%2S2K5,M_#A5ZL1=+WW!CX-$+Z@=W2+Y< 5X"%P(['3QJM 7C
M7+V=I#(3<]0;P_?\P7G&ODR9K?DC7_<8VK:(VP_:XGN!]*X=]V"EVG,=G+#=
M[DL>[)U8VQFOS<C-SB2ML>8Y@S=^#NQJ6?RF(WE^F-G-=R)H/WYO]0FFE[8A
M@!V- O**=_ATCTHS@ASNR2I7XG?<-7_+Z>W)@0_OJI\\LP%PD:\UU8H$.VI'
MR9QE6U:5)A/D?#W*GKM48I S'U/&[[QH)9T#'=CKYA6'L/(;G?6]=77MX,1_
M9)>W4J!9U2BVY)=M'*\3?M_7_?+E'BTJ=C\.\,M(F]HQ6S6V<'S],"+HX50'
M[^*X R\L#Z-YU].3=Q28YUI-65RLP?"%&NC.DTQ" G2<'Q)<'XPEN*#.M>Q@
M>IQBA@U:0IK8]QZ[XLM4U'>*'BSOV-C;L(_9)MQU2.53[")] >XHH";!!,?L
M@QYA6_OH+6$A,,N#RM+&IMD%?FNH1-\Y_^W[IH\Q/JAI3NA@L.V*F:6Q/HXQ
M>&DN2\>L][SJ]K1AVPRQBM3^,G9DW)/1/MB7.X:6W(-.&*8##L5]32V&Q7>;
M7;ZK_BKBI3E*OM[QY^2C4YRL33W+8[ZIL0QC&?,(IF@<NP6W1E-\ON31P!PR
MF)N;;Y\%><WE[%E?WWCBN%^H2,'\4K@K/8&2* Z ^WZYA(]$)],O06"0_@[6
M::G<QWV[+5[9PLPYI7&K2R)N =_%LE@6XYX/GB?\T$%RK>#&1/*[:S4]O:WM
M3P-^E,1A="8/O!].#NS9L/OQP5/4O^Z]2%&BLM)&U_S93AA  A@1!_7/..;H
ME^V-G8U:$BI_N-IHSQ(J??3+?I&<::]FM$/][$6DX]O/AE([5P".MEOEL*V>
M)J86.P47Z>PW,D@VW].$%K_V2!+2& N58]77(ZN)#4Y=-HID\N?WMC&:^, R
M<X&4L!LG?E,4_?7M"&;</=6R^YK#]CD (A;A;WV*8B.,^4XU?'@Z[$=,%RU4
M-JK812#I0YF5AC"3H%G+3.;7F8@E\C3;*)>1PY0VMT7RFU3^F__&&B]W_0]R
M4;GW,/JS)Q0N0EI(HI*V]G?64=SJK XV %9NN[P3[/M\&I"^/<:-07-]G'IE
M=[$)"0T2@0>CQFQ64,TM67IQ!R,!S2 <;R5=F6I"Q5V3TT_VKVC:J_>Y.YO2
M5G=8#EZDN,"*%8=Z)\*[:\(.+LFVS:(C3O85>A7(_L @#\[R !'H\9'P9*((
M@40^"&QYW.GL*>RI6DNWJ4&3.3)*1_X^ 1!X%!+)'B.2I,[RO5/A"N!$ :0A
M*.#S*[;/UI@(9 44:_2+,/2\QMS/LNH3QIF/25)QK'FWY5SR1\CDE$/Z1%6"
M0D1]$K^))'E,2^%H!FANYM(, NE _$$\<.E)+R"CLPZLP:1E[O!9$/<4;^R+
M59L$CH?$ %L?H0:_]00=LN:@D1:#\?6+@/ZS(%[L6<P)#1N4IFI<(9+?27)(
M.Y6JI9]"YDN?0$NF,-&R.5_<Z6_L^(+:L^DB;%8<W+ $EOX8)] 9WZ;B77F(
M_1K4[7*D=B-6XNM%K9"Z^K763L[QY@FR1YB< /9\LETUW7;DE$O:P'I'J0>'
MGD@VRUO)/O6;U@9IRL1%Q-2JT$U@B%ERZ!*&*=W>=IV3HL_WW#Y (>:2"$N8
MDP;Q$8L!E.@E1-V'^<M-HXCMC&?SZ4KFN?'!:%.X!+TV6OWG:.8T[UOB9"]>
MMSOW0;00-RNA[VM1"@Q\C;BS4*\U*H(6CB;)F],*M0_70$'H'^=#IPW,-?@L
M6>985J?M/L48=OKT*#(Z.'$#S>?[((V"W55"NO@M#*?O@,)UQ%KLJ=GW=TXN
M'R!XUTW]O:34>DV.]7'FS,W3VAQ*XG6/\'PD%!V\*'CJFH4N[1]G@.5!J)V
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M6UB9F$O>'XNEX:ZS+C4U46$XJ(Q1,SO:Z=JENB^@+,.&4^,F%2"0!,+G"*0
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M^,1Z?(!AU!4#ZIB'0A=2K%&A_VDGPS!(9C-;9"IZ+]^RD#5I1'"I=NA]N$?
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M974=1/63E5:2:Z"!>LRCJ+]P9[[>81.2JDG]X#7G6X;4)KS7$0\(Y%A!EZ
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M_$OW24RK2G*!8/C%%S3>3^/"V'HFB@_ZLBR-Z/[98@N9%@W9<CL_R'68T4*
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MQ:+> Z*J@PH.?#\?[I.D""L[8*]M=>"BN)U&J?B"T+4)L8 7)K>6>7(>A/7
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M.-W!":N'XA37LZBQ NZ7XO6=F(+/3HQ2/<<1N1&L".*/3H:?&Y;(YX<.?MX
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M2?GKO*5"0D'AU2*:H>O1+*8\;'W1GC;H YRIO#R_CNY.!TU=>VB\M4!]G@0
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M8AI"U_9B)'](00*8]UZ9+_E5F[N(]C*GB%#'643Q]]U;&&08S,=NK]^*"_2
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MKB.9]=[<QX3>5G8@.X.JDVK9Z1V%JFU"=(Q>X.]_FUSECA)^'287<N*6X)%
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MPI@WUW<;1YCJY?#G -'%]M[)-LW&6[.U-,O\"<KQ&9:#VS-'PVA7FY\2[C\
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M6V>"TK7NA:4"[<7;C;?%&>N2UZZE<@K[(Y3/TT(X79>9B-'8&CL3HC]VY=J
MM^O+J<Q>D&##M/NKU:"<@GU)N\AW4R/I\*TQ&SI H.0_"3UB3N^I0212N<;-
M:KK&)UAP0MT28CU4I\Z< 9 84247I@]V&ZP)72?(2Y^)$59.O?*^HB;LC:J+
MWOZ^:F](V<EA?1>7? F(0:7&^"W+$+5\BW>Y>T\JUNYAH?T?(]P:[K]%Q\4'
M(9?J+)^0W4E.3T:=7H-0NO$SP=2E\BLE(#=\K<!819)PQ@\+DG+BD\ED; ]A
MC?EAW*R[N".MMIA *<@NZ^K<-*3A$A"'.F0B<F\:,*[H5EN:N<Z=!K?7J7Q
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MA;Y_D9;HDY ;.-V=0BY\:8E8BL2'LR=/C&V;\AQX$HH@!7<UV1)O>.4=CT6
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MHQ/JS3OLV0\<Z.9>(0DMB^7-=S2@1.-%&$<>6%952=$K9#Q?E;TO;)H'#<7
MDPY*D$U?B?O8'[Z]J(A?1YIGH'BA;D1ZS(+M]8>#@K&<E"Y=V#"5EN_?>:B
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M\B+3I<3*W.JG>#DE^Z]%[91J1[WF,]TK,H'TSE>:(MJ>UL TB8E>A!KUWA#
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M_RU#<-1GWB'J8_+#T9N 6JK1>]3(-7-ZYAUU%R^Z):2W1<L@;0*7L'J6@Y!
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MT;\. ,B];NF32TL+K"TMJKF>3^S=^.GKY>>]@=']UXG>N%KZ?P!02P,$%
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MVU3E.F<W>2W>DDSL;^U7*\=//>(Z(20))1#%'H=Q%%"8^K['O(2[*'57P\&
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MF2Q;;^KLF7^1N1Q-Z&O@'(\\!\NF=5)TJ=CD(PYCS! D7N!ZE"0!QUJ=KJ8
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M3U9/=S9(PP9K,*1LJ$RE*AU>UY$'&OID:+Z;+=C2V!A2/9722RB_O@(#2J]
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M8.JS2/P28D2T6I[H@9]9&7P83E6[()M#@8^*QL!LW-'3"0>9'D='M"TR[15
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M$@FEERYI7[HC5)1?O(\"WI]!)A5I$VL3*H97BKTMS'BK9MG89Y6-65Q;3*[
M$!?0(F/=3#%BP@RCN*9AO]HD+F6VC WB4E_$3/G</#[AK)2[PFWY+JN>B@JO
M;]./1?[P41@WK$WT:"8HO>Q*<Z/83:/8P=!-$Q^B-/!@@HGX%'MNXG(:$^;I
MG--,D)C9.)' X5I"[RH&]?2.$5O5U,_<S-+30CMLQ&L'>GSD8:GAX,<!!Z_:
M*6DOX+?N?ZN%TS;88TD_&:&PJ)JZA$F'VNJBM0S./N^_/65E8\+^C)N8I1=V
M)K3#44!0Y,,D$E81<BF").:N^,&(2^* ^+'23-)Q,#,KGK_@LDE&XEOX0"!
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MXS@,?15I'X4RL]QW</=#HRUD1:D9Y]&X5K!&N9Y^,"):69J4B!H["H@%!L<
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M5%I2$5/0%M4)BJ0?*@'5V\RDONM6TT6+HM2E2 @S= (G@8@*:<<.8A S&M&
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MW\L#5_0B?]>/\?6\T .Z)H?!@]^N2=7,*OP>)NA>_&!>>XJN.0'_&)-T+WY
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M^+I=BL"G<:"^7=_*Q]6&?UR2!Z-BS(MW3QP?::*>IHJ" Q /#4U5K(@Q(,N
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MRQ&E,D5IB%,6T"3V0U#.9YSDC-%JQ\QALM-1\A<:?[K5C-/D[X01H[G44Z>
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MU;EKKFO=:='!5'B[?A3?R(^VJNLGL1*RV"RBE%%"6(PR%E*$4Q*B3"0^8CC
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M6KTJM5LR;Z\'+#FQ8;><>!TK'M\*73_5M>RMI=?CYP;<DP]1WGBZ:B*]P7R
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MNMMOS:5'1YNWR=F==2<XE_*/MY6ST;5%I=)?GF4'EAKQ7$8DBU >^BJZE6F
M<IPFB.<<"Q9&S ^,JES.+S]U>4L#TU13M,60/=#&L'N\7D:8,P.)9X% =4Z*
M*^"G#I:;&7OJG"BGP%-GK[(U(_4-69=/ZU[P]DX#&Y0O[]9<+$CBQ])/* K2
M6"(L>(JR+!"(TCQ+./83' 'M:I#>/(9VP,)-LR_PZB]HS8BG.8':W[ :30W2
MF7*L+/0JO5@8KI&T5UCR\/HSF[:1L*>V;G:;]6#=IU)\5]_MXEEH0H^BF5I_
M-+M^D25!+@AAB.:!VB3)+$04J[_)),=^'&!.8] FR93PQ.[@@ U/M\Z#A_&:
MZ<]LNS*%5F!^X% A#0LW7D/>^Z/]<ZIA\2#9W0W[-2,[]PQ@D#+.C :&W0\_
M)OI6<K43_;3BWXK-4IB>"1W>-;%UUS3,3WJ.)!H_UK$7!F:4WTJB)W4=[_QY
M\5SP+5EZPW*"SF_.BV1U6'.TU&PG,^=%Z!_#7+C"MI&RS79^T_C?"YP)$0=<
MQ<>8QBI<S@4B(HC5?Q@/0XJC/)6P;LG^\I/G_G:G!S4Y8!7FD2K,OGGV @(/
M2XQEL^AK/">"L^;%@\5G[E \)]AI&^+9JRP+GDE1UMFA%L%1K_NQ%/_:BA5[
M:?MU6$JB/)<Y2D3J(YP(@J@,!<JC5 :$X0CGH"I* YH3&UZ/L+>C;-GC9*)!
M,]-TK!>8O5JJ!%XF;2ZDJY)I XKSED^;J^"DE!IP*\PA5.5F46]T1?E$RLW+
M%_(HFM8''$>Q9 GB04#5%U9W2#&J]J,TI G/@R#.C;ZPEPA,ON7<D_0T35##
MPT6M#%NT"UFA&TF@F,:&.R;+D)6J>WL6JOZUM\Z+R\YBBF-"=78W>IUEX_#C
MTW+](D1]^'OWYTJ]UM^+)XU(\N'7N_MFT[CP,YKXG":(L%2C<3$?T8RG&@E5
MDH@1/PR,]H$0HK,<=I_.)@=V%9MHS^R3ZUHGP"QP2[UI2/1V]&O (^]OFH6_
MSY,-@NC!5:>R"<EY&Y<!2CCI8X;<:[GS+1Y6A2R8ABUB3#NE8O50KWR()"9Q
MFD:$(,8E0SB- T32.$8)3QG%F2_C%-36;$9V:L>Q?7PDY8L><]OCQ]LSY'4<
M ;?09CHUW%H[UQ1PRSVLF:D:HT!2N]JEFQ&==_<.4L3)KAYVMYT+^6U5-D4A
M_Q;\&_GQDU@)66RJ!<U#R6D>:T7'",<^1GFN'(<,HE2$/(TC"<(1OD!G8B?1
MI^IMR ^/MG1A/N&2DLR<@ /1859_(+6BZ/TT)C78Q$=D<F33EZC,:L0CHAY;
M[=CE%GT%OPBNO$ I;OFS\@7D0;3%X+$?4!9)@=(TD @G28!R'@OD9YGT<8A3
M2<S;"2X0F3SMUE#U=F0!U?*7]#)R;N1(6F@R[5A0F_Z 2Q(#V@(<2&[7#0!X
MU+ >@!&)!DO_+]T[7\7_"/<'A?YCU\+KS]X5FY?;4I"Z0HIE64X%ERA(,=8P
M91P1)BD*DSA+(N8G-#*"-#E>>.I\GJZ;TK2 16,'L@_[C&LD F;MS(0!57J=
MX]RJI.M@H=EJM\ZQWR_2.OM[2\B /<QOAQ#<#7W.!*9A&H>(B4@@Y49RE*D8
M&44TE*F?24XD*/=VF=34YM)VA2_W#/PGL!W^LI;,(F(WLL,,JT=SWQD_Q7SL
M<>%<-<A?)C1OG_RHP"?M\N-WP#]EMUM>J"?S63\@'051SG":J,UKDL0IPKE@
MB.21CV(F(YDG*EI.(M.OV=':$UMH2\WKR)E_THYU,/Y5NT(RF/T9"P7ZM%U@
MW^KK=KS6;!^X"T+TOW&7+K'83;Y;/SZN5W7;4'7[3(JEKAGYN"Y_+E5,^=M*
MK?+MNPC](->IZG9_0:7/4BE3)..8(2RC'%$2<!3D81KZF$2$F!4@6C(P^8FP
MYLBKZC,7TK%4=_0]:*:\K>;*VWP7GN:K/HP![-IL-&ZPAYU8C\"XM5%APXVW
M8\=3_'@U0U[-D?>MKT.;+;"-,@';XXF5:K=UME*NH]WU%0H9W'G;K#O?KOP*
MJ0]V[->L8^';-?[0'E+QW?I9K(C&6%-_UH"H]<"J5=<.NB#9_]_=N_<XCB-[
MHO_OIQ!P+L[M!LR%'I1$G0,LD/6:S3W5E8FJG!G,[3\,/K,\[91R)#NK\GSZ
M2^IARVE;(FE*F;W [IGJ*HGQD",8#$;\(LQHE"4 1?(X VF2@(PP'_  QY@%
M,!50JXS/@O;$'KU&P5H7.%]XM.5DX94-+PK[N&-&_5ER8^!_#%6LX<>G4YR9
M"U=\].!0Y2EII[F6&:_'C7<[L>8,G/9T&K3SUVXU:>:O[70QZ*H-EYS/2]O)
M>N"@+9>P2R]=JZHQ7FU4 _\7OEF*)(0<^0'P4\( C#(U6#$B@&=!0*,4AR@(
M3')*+]:?.FK&U7>O'MVF N552]OCS:@MLY322\WHY9$ND-?,-7:$ZK'S"^_C
M3[K>U@U!+0A#?=/:/;3P;N2N@NM*BRNZ63TYAEX\([6CK-++U6=-)9T1[67^
MZ-QCML,ASH]_&YC6^H[+GSWOC=7]P!]+3E?U5J$FQ_6&["X9@QRG60;"D&,U
MQPT"G%(,".(B%B@(16*$.SL#SU-':(6T&^^QE:.>W<@[(4Q'4DS__?3\T1O[
M*F8^[L5PS<7A=,WZOPZ&39^<-4UJ40Z&3?>%:49T3C)]>D;=.QO(,3W',T_S
MF.T3'(\"F8^TW2[3AI0]"*:7" 4P80@A&LA $"J<%Y\ S'$""$Q4/,Z24!A-
M"1NE.+&'[XXZ.GAHEBK3<\M.%6'F5#L=3%JJKRV?(\<U3F]6MZ,M_DNGH?^B
M.3C#=3/6\:YD7<6N=%'T2[&Y8L5CC69OB.6MO>#$5MWRX760"+M:<K6U*Y8X
MVZHLM>3,:UG3!X#0U]I(7FTJA9D>&XUU-0$BN+$BK, F]*G,AD-A+'@?HL+\
MY0O;[:_SQ^VF^BQ]TCIH[ZT"P<)4U$7X,AB 4< !1@C*_^09)#1#+#0JPA^@
M-;'7J$G]^[\%B?^?@64S_0G]Z&W_CJ0V,WU%M!D@J(!B%-V%5U/V@O%;3_L6
M^O,BNFZ=/T'I=5KFSXM\ME5^X!5;%#?)<]ZB;W]=57^\>W['<_K] 9=_U,WA
M.(P)14D,HH D )(@ TB$*>"9@O['B*%4JQA)E^#D!1,]\IZB[^W(6XT/'%6@
MGJF[5(N9O5^B$0ND-CTQG2&TC9";&9E-3_AC1#;-]^Q<P%_P*E?PA3?YAU7U
M6%3U>>)&U&F&*EBJ+9M#)AT C2"0)_H((-7)CPA+:!@E**+$8K36,%6MG_O%
M4[84?4_^Z%G- 5ZKEEQ<,V#F T8TJ.<!'"C$ROX57>\71?E7I8L><:6.JV%U
M&#L /2D=F?\(L5F-7T_PEZ:O^9;E>(QZE6XL' O]C,:8 R%W? !QI,":PPB0
M,$"0ITG"<+;<J+L//0,_6-UH5]_1,+R2Z2;EV9CPH2[T+-9:0C,#;<CL2O\=
M3F8XQ;^K,0H':\\[\^"46$<#"DX^="&,XXU0E06?UL6/:M=7$H8L$Q@B@' F
MS8H&<N>,4]7TRD42XB1 S"A^'B(V<>R\AT&4&T-=0U%3U^E%,=>;G@FZTH:9
M15Z@"'N R $)7<-%GB+U.N"1 T*?A9(<>L?.P._PSZ:*JH5 #..88AJ'@/D\
M M!/I'6C. -!%+,$I4%"0JUVTS/K3UV_@'^VA7N6*)$OU:%GJA<(:6:=)O(9
MF^,9*1Q9X,O59S6Z,Z*]M+-SC]GVK>9<&FS)V6KS"5/56_?\E:N%5_G];@KR
M>_PH_VWSO,11'#,.,[F'BAA B *  QJ "!,"*68T(H:]K";D)[]V;@E[I*/L
MT9:T:9^KD5;U#'@Z79G9M^*CWGAK3KR.%56AW.EOQXWW?DQ_%EVR-FIPUCEK
M1'SF;EH;Q1QWV%JM8NE]>M.O][/&O_+'9EY>=2-NRU5.5X]X?9W_@^/R3GY'
MOF11PD*FRB$SZ8H@0S'(D@"J"4=Q1")?B,@HIK=C8V)O)'][J?VP>0-M:GJ?
MR75DZ(5>C*QO>9)N2!'W:NK3#*TWEWZ"N?8&3,SKA"Y2U)$SNFPU.Z=TV-C1
MS$,@$4N@'ZCAA#Z3_X= 0$0< ,)"$4 8QDE@Y'%.T)@Z>4"_<[9=USMW;3N;
MSG9Z_4:5W?"(4QK3\RH7ZL$P;?!2!7=6*C!V'@-".O(,IRC,:O8#(KZTZ:%'
M+X\BODA^VR0RC!G*8B2CA#!+9&P B3RUH R$3/BAG\(L\F/;*&%/9F*SW45<
M%<B+''0I]D=57:S&_.6\3H*Q557C?#8%8DS]I%=5M:UK[FE1F6;CSV@T35&2
M<*+@4*C*I?H89&F$ $RB)&0$TU!$RR=>DF(^G?;)_3FU:AY_V6GJLOBJU[G6
M:FN_(4\39QU+.4$<U2/R:G'2L:!#<=")IVW["BA?/2G_6[VLCH_#,! X08!$
M1!IZ$*GAD5$ ?(YC%F<!X[YA0\$Y4A.[SQ;^N/+V'#2=1.MU\:.VXWKX>I/)
M4!>]IJ#? TK4LVLWJC&S[9XR)FXO&)/-65_!64(S-Q2,"7S<23#ZAN6E:!OL
MWHAO_%Y%6O+4I+:W_/XZKUO3U4[W[KG]QR9FCR*5.TE#P&D2 \BR3.[T'($,
MRW,.#"G*,#.Z*S7G8<934$O6VS'E];A:>.1Y]X3=1#V+#Z#G,B96J_VARIU&
MS:]I[77BZO;6@H-Y+W7M571TUWO!4I;N3 $AU<-^^K-^>E-5);7=([=->NCJ
M!R[K?DXUB'MWOK_9?%?823B_>51+5#*>>N+5AK._<]7BR=F5/%+@>UX#+7W
M&[XK_OY:K->?BE*MNN0H\6%$.* !41B1 0:8LQ10"@-Y&E(ADIFK?%OR3>R&
M.U: US+3@I$I=KQ] X2Z1FZPRPQ=[]M2IJY;?UM<3[AE*"E.3.[J#TFN-XO>
M<ZV\7BWPPFM$/DC;U4)[&RFUUXJ]\':"+[Q.])%?W"0E1&_SP[K:]]Z8=//N
MJ6],^'/[]1ME<^98H.6YYJVZSILRFE'&ETPD4< ) 2Q..(!^A $)$ 0!C1 ,
M,>8^,@+;FIG_B??RW>#!HO.Z/[K=';>NMH'"9<K5"N5JGVI7^RC==:7D]'Y9
MY1Z3/P]<5ON__76F/=_R1S'QGC[]IYY]S][MRHU0GOSHC5BZF_,;V)$O^RRO
MO>-:<O_GV%$O^S3.=LP+V3"?7O QW\@M^N]\O?ZOO/B1?^.X*G+.KJMJR\NE
MCR-5MX!!  .Y=\$T!%DB3ZPI%0%F(8MIHI7)'Z4T]2Y3T_84<?"'HNYUY+V&
MOOZH@V&%#?MUIVHP\\#V&C":BZ EG=64A.&59YN9H"5@?X*"W@N6H>R65/Q?
M6^D\/CZI3)E<I6Y:3RB*4JY&9U+?!S!$6)JM0 K_D4%$0C^F1O@=9^A,G6W?
M4?5JLIZB:]7E?TY/FE'8Y=(;1DLV@IM',<-BN8HVSE"9-RH8%O5H]QYYW!:$
MF18/_ [__+"JZ+JHMB7?W_8&,*4(1@S0F$:J)AD!G"80"*KJC1A-PE@+$5^'
MV,1FVY!6\U]-;\,'-:1GJZ[D-C/8O<C>GNY$0ZYU)'0&R3Q :F9\YG&AC\&:
M-=ZQ,^4FKV78['KXTH217I/<GB(5?5H$1[^V%XO/^OLZ+=C+7]29IVSKIS9X
M)0/!C[A4O3'5 1BL6-'59DFBS.<<1T $J=P4*/0!%@R!. OC@/A(4&14@CI.
M<OIZJAT\,VLHFM9+C2HM8C3&F&# HIC)V#<A(",) R&3?TPI5-/D.\";6=5V
MB'?S]A2GY\7<_H;,/%M'V^N(>[\< G[7],]G?BTJT'2%=5:)-DIPYHHT704<
M5Z9IOVF)7WD>7;N')= \M<+KVQ9]Y^//#<^K%5GSSZM*3=?E"-.$@RR-,P Q
MD7%WF*6 ^HE(*>99'!FY6"=<3>R%.S3]M6)RX94=G/ZVX@WXSL*K^A 9HN/6
MZR",#)$TG7PI/?<TN_[-/-C!((/%R4D&!^@D.T:]CE/O]SVOWL=\^\ ;8#F7
MH)XN=>@*_M,)3_,"A;I4XQ&DJ-/%+2;^74D*3(8Q!<ZO[DM>$VS1<7F*$(YH
M"% <Q]*G9A @B@( T\!G 410<^;,")VI8]6&L*<H>SO2!F/G!C0T[,L<RFWF
MG4Z+;#,L=4!V@_%Z;G1@-TK/\/.;S<H;%VQP+M[ Z_/-P!N7X6#>G<;C%E[(
M^I[URU:1OA%7>;Y5W=\RX%FOZQ*E)65) JG/@$^HNC)!!$B7%8!0I#!DE!"J
M5YL[%8,3^[V&<(VE6I/V5(&6*L9?]7@P< 53?"(-__G*BC>\\-$ICWDW6![3
M?K8;X36,>]=OYW,9N/Q7_FQV>\6K?3ZS76="W0YN5U/0G6^?FU!K!QODE'1L
M,]05ER]]O\K9!S6RH&@&F^TY>E_D=2;\KF@'UGXJRKK"MWKWO+MC]S$,&(0<
M)#2A "8B TCNHD"D.(1)*G!@AOGFA*N)]]".Q[I9N,=EWR&HX<P-H]ZFZ,8R
MU_W$#;,+^W('-Q].-Q\\\^<P31G/]24LDLL.-><L_^R"IYE3U [5>)S%=KFX
M;9'7X^.Z)H;7'33NQ^8O]GC+<90BF 889/*8 F"<,(!AK*8YH@C[69J%S+#B
M:YSHY.5?>Q9J+)6VK$*>3&K4%07<O-KPA^H_3(O!-/2IY_Q<:\GPU-!7T ['
MVNL8F*89S4!B9Q5D&B1G+B?35\)Q;9G!NW/!8OXHEM@GP@]# 3 /0@!A*,.T
M($J 'S ?14F8(#@Q*.:/8F*'(G]9R=20F%*3>JYC:OV8N9(Q.,P?Q6N"8>XE
M?S4H3,G"&P?"W"OI<AC,WEIV+NBFO,=Y.[]:ADA5L5ZQ;K;UK?P==BF6WA75
M[MK*=!-V0FLZT^JS5Y\T]@RVXUCW+!Y>^>ZYG&0K=ZHW1X;IAJ=9+=6I&E^:
MKMO%#2]8*%O>E4P>=KYQVCJ-J_O[JR>\6E\];'3G1P\L,?4-[OU]61?;>35!
M!2.C/Q%Z2/*1ZP=W0IMYFF[:\T%J8\^#=T(?WM6# KAS,^]90VBK"<]#Z\XV
MTUE#N/X49YW'S<WQX[\VSU<_2E9=L7]6[7VZIAF>>'5B\VOKT.L<M?SQL7]N
MJXW);=09><>-[T)1S8SNK)0.IRV/"&5E5*?6F\V8!H3I&]'08Y9QZ6-=+I??
MUX53+_JJ/[1XO5^EB[SEI1K:NN0H#H(HC8! *51C%2G(< @5Q&$0L9 E*2,F
MQV)3!B:VT1T[33&H8;^6L38U _H)=608N^_4TQ9L'B%-=.QXBI^%UW+D,$BW
MU(6K>-R4_+RAMZ5RCJ)LVW5<.*'/*TSJ,3E+'T(6A01)-Q-CE;D/ "(B 'Y
MDXS&012FJ<D(US-TC%R*[3#7VIUXZY;F$,BWD8IL'(B5X!?ZB1W-J3S!D5"3
M&/R>RBO:]9&HP^9[_+A%7>$7>=S&U?=ZP8\_534&7R(.&8E#7\V)C %$, 4$
M!;XT3TPSEB2!B+7&1IXC,'5=7W=GUI@F;X@:5(:=TLE(,.Y 4C-#5$+6-V$U
M.>^C$R$-RM<N%-:N_,Q0:+.BL0&)!HN^3KTW7]'6 -<'15=#S[D8__2)\R;#
MLH0T11 2"A),J?0>"DF)H S@A$0QCV/*LLQ^!-2.SL1.I+XB6A<X7WB"<V_5
MS))@WO:QR+WV/J%K&5OW*X8OF0BU5Z+>]N] -69>Y\4,J(4G:3K+K&E*-<DH
MJ#V55QP'=23J\$BHX\?M#/D+WRC7<%L63RO&V;OGOU:<7>=MGCV_OZ*;U5,=
MVBY%DL4\@0Q(#T@ C#("<"BC=^&3V$\2S @A)H&[/NF)8WG)B%?'#%M5LKS*
MNU90&>CB'0]FIFV@5CUKGT99AF&'U%.] W=<*"S+7_[:*.U7;\>+=S6N-6/'
M8*X 1[["@/"L[L-<(2\]BL4*YLG\.F7\UYR5Z^?[WD6!_LW:V04F#@(D22YI
MJM_SGJQ^4O^\W..I?2<BF]EV3=([*;/3V[-1T:S2_.=7G2W9/RI8/^4__K#=
M;GXKE<=5J/IM4] _NI:)NJ&BNL4-BNI5SNK2W3U>U+X4A?N<\C01($B" , 8
MI2!#$0.$!DSP-(5Q8H3/=B$_$UOXCCNO4NR9[?"7JEIOVY]1@6;^8J^[FK-=
M:Y<:<%1SM_ D?^V\"%4 U$R>Z./&35#LXTA=CB*'2[F9-9QPI+J7,8:K9<TA
MG^M6[/JHM,;W2Y]0#B-Y>,E\&@,(,Q]D/ H!9#CT"0Q9&FJU.Q^M/'5U3T?+
M4\3T\9L/I1]V-A?)9!AFZ(EC!,9\DG4K\.7#E68#6SXI0!]<^?0#-G F?[O^
M]O']W8<[7G5 %33F#*<*^YQ!N>4K!!,DY)]( "E'/*0,)_HP)D?K3VT>BJ G
M*7J*I ETQ[$F-++\E\EG:"H'HEG!DQS+: )+<I&LEG D>I_3$(;DK"##\"/'
MK\T(.W*6YT.XD?./V<Y(^,KO5VKOS3=?\ -?H@Q&S(\IB-., ,A] @@)?8!0
M2G"8X!!"K>O <P0F]@\-26]/TU-$3<<@O-#)^&YZJ:1FGL)02(M)!Z<EN6#
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MM;0D=.1]AVG-ZF>UQ'[I4?5>LO.=TDN_E\YZM>D[YKNZ#R#C?A;Z\OB6P%@
MF*40D @%@.$H"JF4/HF,S/T\J8EM7<4>#>6#6,/[O29NB+\XH# ]VW:C!C/#
MMM6 L5F/"^?(I@<(S6K0XP*_M&:--^Q,^3U^7&WPNCX2LF;\Z'5>)RK8N^WF
M2['Y!]^HIMXE#)/43V(&& E3 "&* 48T @$.?(1]/\XRH_X(7<*37Z=6FTI-
M]:PI+SPB]_2\V'CJG*RF?7KRD^:<UJG;'ZO-=[GSUWPW^9V6<3-GH*UR/=<P
MA2+-'$7+@==GP>MXJ#4JN?">Y5%8\>'.;YA*[LB+:).=U:>8*N.EAS%^WZ(
M]?Y^<YM7^17[9_7MB;ZOND9<W?K3,^]/77YZ?U_69R[OEN=571*U*XNN.F!/
M3SD2@V+4<ZH8MGE76C"S;WT%.)Z0.":J74WJN47G*TD=$>N@(G7LV<LF%#;)
M%OF'[N^ZW'"_:BMG[WC.Q6I3M4ZBO1.Z$5]YQ27M[^K*Z:<JQ-SUNM?[ZE+
M.*.JE9+&ZL@?9"G &$*0)3Y7C94LR;00VN=E>^J0XX ;-2*Q;/EIJ@ ..9(!
M2&4[&'#BKSOBJ][L-W.0C59_WOW#_F*K7S>KOF4GC/RGPX]^([Q.(.\J;Y;H
M?_3W;_:CVPV4?#L?W\%,RK?Q([ ><#G/M]"=D3DQ-Z\R9G,>#9^;U#D3=4O(
M0B'4:?J)[^">U;CYKUQI>+5N2D^^%#GC;"L?(VO>8?W#A/! 9!B0+ H %)D
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MI]Z;+P4TP/5!LF;H.<L^=_I='F;6_$;4+;WOGM^O<54U%491R".49#X($8(
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M'Q:I7X8_\N0%>!UDO%&;G('*:M&P5(/<=;XI5WFUHG5'7;!$H1#$APA$48(
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M@:,[DG$1K>Y)!I:=[:YD7+3^?8G&TQ8]4_N=[>JQ#*2*D@XBG=,X@4R  +%
MH6HQD,59"!B2FQ*+.<NH/A3_.2H3;SI_Q^JWN?'XCKPGZ:_67K#P%!,&'2MG
M]31BI*ZD-[/1CP<"=^+: .J?_WWH-]FXD-^N/^:T'ARULHR)-=B%<O;E^1I(
MQO@_Z/T8??B2^]I^I86JQ)9;;9'7&-W!DA.:,JD[$ B. 51SS5$2"N#3D+ P
MQ2)!@5$</$9QSDJQA2=7>% !(&W)VUS2#JG/Y';6D5+LKF5?5$#=M7IY/Z87
MR_M8#5F=7L0.T7N%&U@-\4]?O>J\:!X$]^Y_KN[O-Q_+4IW3KQXVNF519Q>8
MV)I[=#U)N*RSCYXD7^2\V%8OLEP/Q59[W,^@5L9/!DX48F;)+G5A=$08E=7J
MA'!^U=D."*."]<\'XP]/6U*EYH3=24WS)2/JOAM3$#"4 !B+!.#$)P"E+ QA
M&(B$&>'X&7,PL='+GTDZ33'57H<F^_9$FK';Q_7*JQ;-T+Z:I_E+K8[4,7/-
MU9[^FRR^.E*/;176\4+FH<$M+Z[H9HO7ZV?UPS&,"TZ_/;%_N/UXXW54FVGU
M%X4!9S0P'@-<+KR9"[A,;J,M?U@TJ_W^S)*S;?;#(O5W^I$G+:=I%-7F1GSE
M3SS?\B6DW&>JE1*C1  (10A0$*8 IV$D".,9)4:8^@>K3VQ^BI8Z.I8--<,9
M&0=JT-N%K84S,Z].KJ\C<IE/NCC%OZNY%@=KSSO%XI181S,K3CYD:T+-2?CO
MJ\WW]]MJ4SSP<K<MMB04#N9]KJ!/EA@A@;+(!UQ-I8$R8@88QUCEVE,,TS06
M*#&S,1/R$QOA'HB9]8&86YN4_]OQ86J>1BK6M=^I%&=JX T?W@_)B-=Q<A!!
MM]QX7\?U9^$&;-3@S$\8$9_9D=@HYMC36*UBT6#(_GE7U$&!:OC7[2OLOS2Q
M;Y"TI/QU59<\$?9CQ/\PZ"8\D'(\&+86T,R&S\OF#-/@K#1V#8,'*\W7)WA*
M@(/VP),/V,Z$Y(\R4&['476P[E?R$+O9S51!60B3E$.095)%, @5[G/F@UC^
M \MB%@1I8-(0J$'3R,S,>P%;#M3MMV*A.C%H M?LF Z+'%>FWK[K6$6&A]56
M.]T$N?TXB(:!"3KO#>1U-D%RG.+,8R2U57 \2U+_53LW<46IRE!4<A?FJR<%
M7MO6.D0!%$D0(< )DZ?A2#H(S*"JBI$Q.O4Q%8$6CM<8H:GWW9:LMZ=K9OIG
M%:1G[R[$-MR-CR6>8"CLF%R.C/DLF5DM>$S8EV8[^ORE*& W9=.'\QO??"_8
M==-QPWLP1N^>CQ_N'KM3#"TA32(:^3$@/ [54.@4$*IPB1 F!*69'U%H!QQV
M.7,3^X0]=:G^KCFOX=;K^%AX!^!<"^].KNK]7K-G#4SFX+/I>9W7^AAFGFJZ
M[W !5IH[A3F'5W/ VBLALKE3ZGD0-X<T[+%0[TJ<5S7N\U>NT+R6&8'2DR8(
M!(Q+-^M'F72X7%48)Y@$:<AXI#5:9XC(Q.YR!Q2ZI^LUA,TQ48_T,^S/7$EM
MYI<L!+;"1CTGT47PJ$>+SHZ0>DZL4R"I9Y\U,\%*_I(^RV4: ,+WJDY/+M#V
M0S$_R9(P3 "+J#S)^%D&4"0R(/R8A2F#0G"M>[TA(A.;X)ZLI^@:=HX-:F?8
M %W);&: QN)JFY^./$/[MGR_MV?+_]H;X>#2LQBACG"=$6H]:VZ$:L[=C?@-
M_[,HNWQ_^SN+TC3EF9IL&R8$0,@)P%AE'9%(<1#S& JM>9"#5*:^96^)6=C?
M><6,&Z 3<0VOY;0E-3*]44DNL+WS:\]F?*/B]:UO_&'S,/1COMGC=38[ZBJ_
M_[;!FVVU9 R)B&40("AW/^BK;'\J(!#,ST+H$Q''OFXH.D1H8B-L2'>9:F]'
MW&NHZ\>D@\H:CTM=J<#,,&VE-PI0=42S"E('%YXM4-41KQ^L:CUOE]+[RC?2
MXCG[B$N%[U:UN>4L$E'"(@YB@CB &(4 !P*!%..48XQ1PHR2<Z?)3)]ZWSYL
MUPJ:QOO Q8JN##N]SBA'+P5VN<AFAMG1\SJ"$R3=AV5RE&\Z0V36S-&PH"]S
M0"-/6]1?YU5^Q?Y9?7NB[ZM-^[/3K;X^\>[$AG;+Y1E:%1OOZC J[QLOGU:4
M>ZK6SZ#L^I3@P_;F0F8S2QL3UZ'AC0EG5W1]:L'Y2JX'Q#DHN!YZSA;_ISMO
M-GMG>P!*0KG545]N<1#+N)3$"""6RKC4#TB21"(@OE%-Z&DR\V5H&JK6Z#XG
M=:2WYUTNN76>1E=H"^R>(9F<(?:<)#(S3L^0H,?H/(-/VQGHBW%Q#8+CC6@&
M6/9Z+=_A:D6762($"Q@'H8 "0*&"U"Q!@"0\%92@+(XR$[LUHCZQ.7>\ -R.
M1LQK;M0]9#OL>:N ^C:%1XN'Q^U&/L WWKJH*C4CNGEFX1'%J3W"HMGGT',1
MDRG9S',<C9[\LM-O.Y'W !ZYYL:=3[%2@B-78T9[5@]DI9:7CLEN$?,8_=OF
MC]N2WI1W5?FQVJP>:E_8W/W>\9^;=U*P/W1C=IVUIJY)J4? W98JB"U*[^[;
M5V_/2EL4H1_':REG/*YWK1<S'Z&C$N]WQ8A7<^(HWC<1VBK^UR(PVWG 1-S^
M^<#H/8=3+S_OH *1GV20T@!@@J&,/T@(2" @"&%"DS!,<<",^C6'R4UM_SOB
M+RJ>]. %;?2G%S"XTXJA]5^F$#?3,H_DG')DYN=YT1C-!-<:GGG\EFU6O-I(
MMR^CB'K9O^:K3?7UVU_;?)0?1RQ5<Z6#($0 <A$#(KB"6HD8#J(@3#@Q2XX/
M4)O8[/>TO:K^<6\5==,T^9"VE#Y\'R: 0S\&D) 4D#2+0$ 3*G@04(SBI8S5
M2#&[OOI4]6^FBX<'N?TWVI+/\?))*D_( &%55=L:3FW[*!]0=7WJ7DRZC:('
MTE1.KG#=ZPE'2C2]I=B)WSC3FK#WBR1=_3K)C86&F,XN+H9HS7Q_H2'V\36&
MSDN6;3X/ZM+RO^L@[48T@';2'%2ZO+K*V8=5U70L++&?P1#'"8@XX0 &\D^$
M^ PDB:J4@RCCPJSM1Y/PU'>1/3:42V"<;#S6$J_[X.J_V;D0JO@S;!325;&>
M@YA"<6:^XJ7./B@-77<:JAFI-;=CQ6%WD:'PKKJ-=,G.VWUDJ(RC;B33]^U<
M3(=^\:'%OKC.:S?VO5C+-:JFW/YKL5Y_*DHU96*)XI@$L2# CZ@,3 0C@$20
MRH NBP,_C-(,&H5QAO0G=CA[+) /?2R0/DO_;]?R\KMBRVOY,CSCF6I=S_E,
MJ$LS'S2!&HV=D:4R'/DD4^JSNB9+U;ST4+;+F&>-/_[D=+M9/?'W>,/OB_+9
M!"_DY,L3^Y$=3:\C:H 7<EK:\;SOQ8*:&?FQC$YQ0P:EL<K@GEYQMI3MH$#]
M'.WP@Q8H.\KZJO=K>6B_*]0,<Q4[7.=,E3)K@^X,K#&Q+2D2!F [0\*.VY K
M.0UC]IJJ5Y-5&^7=ZH&K6^K?OMQ>UX&Z_(>M?'_A25963RNVQ6MO4"]F$#T:
M0MLA]@PM/!^ CX9X!W@^.L];X^ZI$9Q4!?77^6U9W,NOVE7(A@EE(@@$2"!)
M "2J,H.B $19$@9QRF(?:36=ZA";V&;[I-4/^K$E;@RA=UY;>B&Q*QV8V?-+
M\3NZ$Z3J= 1T!WQWGM3<,'>C0I\ M1M_Q_+&$Z]YU>+B?>%= 2[U,8\#D8'(
M5Z"9- T!PJHV2019G*0X3;$95,<I*I-?=%@ TYY6AYZ]7BRD:6*] :E\QW/Z
M_0&7?TQ@H8,BN;J9/$ECW@O)(3&/[B$''[:TP@LGI\ICJN"KC8JS=I.-_<3'
ME H,2$!3  /! <91 D@8<@;3@. $S3MT^@276N9QR=#IEN9KCIT^]7$T/<HK
M*?S5QT[W&'^+8Z<']/I&QDZ?XO!/-79Z0,6NQTX/D;)TY_0[9UM5I*(X*G+5
M,'0CKG-:// [_+,%5Y0;-Q>K30T$M*^13)*(Q!GSY6\BD6Z;$34=(&  9B@0
M 24L\XTF4E_ R]0%:"UGS0"ZCC?U7PUWGF1O!QSZ2\NAJ>^^X$MH^NAY]&OH
MBZU4VX*<>4X+7!WJR95OO8"3>7WHY2H[\I4.EK0%B?BT6O.RRPLO>9ID41R&
M($Y$ F 8,4 H#D&&*<2<A#2,M<:7G5E_ZDN2!A2A)KF[0S %@CA4R+"[<2"F
MX16)D8068 \GY;@ X^%PO9FA'4X*<XSH</HQNR#C Q>\+#F39MO ,^\GA155
M]1Z7Y;-H;B^K;UOR3TXW=\5^OO RBE-&TSA4M>P8P#A-0!9R'V1QE&91$F?$
M-TKQ7,;.Q.;ZB4N]XK6WD=M>W3)'^_PLO*KA2-U;[*>8FT4:%WX.O6!C/B6;
M.8N.KSJNZ)#=>S,*E<K?'ZK\VU[E'\=5;AQNN-&4HXCC0F9F#3K<*.YEW.%H
M5>LZ,1G>J*[E^CCX6?UXY*IMHSM*HBA-&0:$,0Z@'R" (8U &O%84$%A1HSF
MJ Y2F_I(U5'MA?H= ZJG=5T74MKA! QK4<]_.=.-X7'(C5ILZKC&Q757M35
M:^X:K7&Q3U1D:;QD"0.B?$R1*W?#<[KBU>==2QK#. Q$Z ."8P1@IFZZ..8@
MI0F. HI9@K0*3<9)36SZS1[;IWQ!']^ PO0,W8T:S*S<5@/F "&CPKD""3E/
M:%Z@D%&!C\!"QM\P+P9[7WSC:Z[:57[C6!45F52!G7QY\E*2AT></WL=9:\E
M/5S_I"GWL"$Z$=G,_NRD-:KV&I3(JLSK](JSU7<-"M0O[!I^\)PM];4N+?"/
M__4_NK^1_X?@BO^O__'_ U!+ P04    " "Q2FM:XBIHXB.B  ""GP< %0
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M!<8;P^8!<L9MX3 $?%K)_NDP\EL8S?%S/31N!*2OQ$J5S594%\Q-,B]>!1M
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MU>H77*7E]/2B3^_V#F<=?$>_G*:X^D2:?4DO^>=$>)F*4!Z"TC5H)A?$Y5*
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M,U9TD+QU)+F#E'&=GP;ZO^WXM!!YGW9A<PW@()MP_IL-[,%]-#2R!=M'7V)
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MX[4M@L)JW_PZ8QO*.QWZ_!2$W3/%Y+E5VJ<Y>[?\'.;3?VV>\@NNPW1V6*N
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M\Q&,["1@'*BTT.BBM7C''BG^5\RT^2_QKW@2<3EQS#"=R(W+G'-0V1KP+%I
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M!4SWQP1F,SWU@+G\E>*SZ8JD]/K;*<Y7.$E<!),# I-,DVAT 5<$2<JP.M-
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MR3KGR3#O=9RQW_OV0H[YP9 SE+R//9#_-$HS&7(?EV=$Z+DM/JX+_0%O&?(
M<D_>GN<DDK,0.,6+$%P,H+)!<):@Z@4WB05$?WO.W5@GD>=B^QAF85EG+UTT
M.J%@PI,!!1MJ%T*N-$2L_7D3L]HFAEXV[WY\+R5=GS(^1<UW.E\=+_@.W*)M
MRXD[2^^R_832*2A-LK&ULD07XL8K#U)YEXTK3,O6]3P/4]1UIYECX-10$1W
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MB^GTJMP"N1[%\VYZP]+ZXOUZ'OJ(96>]5XY$(TO_&7,H,IE)$!IBTCYJ*@^
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M7WH!1DE[[B@8 C2XDC4P$BPF$3[IG*/F-L3:9X;WO]](::@)9#P>UW"HFAJ
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M@2@=R\D1320$"239R#QE(#6OW0KS4NKB@B?/G0!T!8!F&[TEMC2#*"U=I-(
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M$%8+KO26U.H.=>O*PPT&.<:O/B>HP?M\KL;+G^5IDVM18GKS;?6$V^MQ1F(
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M8-S>H/IT,+)5&&F$"O/"V,VG:-($:GP*LM'4ZGL3-GV03!WCC3?4F18BPVO
M)\.PN=,OOP3J5.J,]Q-ORR 9_J<PGO&$'^U+=*@$B$A*+$ZUXP( 4$L#!!0
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M\#04>02;P.H":$K .5=B0C) S;+$LD>(.0T*!.HG4X-I$;>&2[9'+M !V)<
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M$&R#X!,$ >6 YQDV, - <HVIR;Z46S 5H$4)IA+PFDFB##+KAHP90\!&C!F
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M:*]L_P)02P$"% ,4    " "Q2FM:C3)NYKD"  "%"0  &
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M,C,Q+GAS9%!+ 0(4 Q0    ( +%*:UJ/DH[UKB$  #)- 0 5
M  "  5=M P!E>&1X+3(P,C0Q,C,Q7V-A;"YX;6Q02P$"% ,4    " "Q2FM:
MY .P&N1+  "*40, %0              @ $XCP, 97AD>"TR,#(T,3(S,5]D
M968N>&UL4$L! A0#%     @ L4IK6N/G=QYQ<0  DW0  !0
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M &5X9'@M,C R-#$R,S%?;&%B+GAM;%!+ 0(4 Q0    ( +%*:UKB*FCB(Z(
M (*?!P 5              "  ;8Y$0!E>&1X+3(P,C0Q,C,Q7W!R92YX;6Q0
M2P$"% ,4    " "Q2FM:0.')(S8(  #"+@  $0              @ $,W!$
M>&=N,S$Q+3$R,S$R-"YH=&U02P$"% ,4    " "Q2FM:%EX< # (  "\+@
M$0              @ %QY!$ >&=N,S$R+3$R,S$R-"YH=&U02P$"% ,4
M" "Q2FM:"W/[7;<$  "Y'0  $0              @ '0[!$ >&=N,S(Q+3$R
>,S$R-"YH=&U02P4&      \ #P#A P  MO$1

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>exdx-20241231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:cyd="http://xbrl.sec.gov/cyd/2024"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:exdx="http://www.exagen.com/20241231"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="exdx-20241231.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
        </entity>
        <period>
            <instant>2025-03-07</instant>
        </period>
    </context>
    <context id="c-4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:MedicareAdvantageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:MedicareAdvantageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:UnitedHealthcareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:MedicareAdvantageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:MedicareAdvantageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exdx:AVISECTDTestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exdx:AVISECTDTestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">exdx:SupplierOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">exdx:SupplierTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">exdx:SupplierOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">exdx:SupplierTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:CommercialMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:CommercialMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:Government1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:Government1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:ClientMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:ClientMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">us-gaap:OtherCustomerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">us-gaap:OtherCustomerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ShippingAndHandlingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ShippingAndHandlingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exdx:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exdx:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exdx:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exdx:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-24</instant>
        </period>
    </context>
    <context id="c-70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:AmendedLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-09-01</startDate>
            <endDate>2017-09-30</endDate>
        </period>
    </context>
    <context id="c-71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:AmendedLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:AmendedLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-28</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:AmendedLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:AmendedLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:AmendedLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:AmendedLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:PaymentInKindPIKNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:AmendedLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:PaymentInKindPIKNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:AmendedLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:PaymentInKindPIKNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:Term2017Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:EquipmentNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:EquipmentNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:EquipmentNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:EquipmentNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">exdx:OfficeAndLaboratoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">exdx:OfficeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-31</instant>
        </period>
    </context>
    <context id="c-86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">exdx:OfficeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-31</endDate>
        </period>
    </context>
    <context id="c-87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
        </entity>
        <period>
            <startDate>2024-08-01</startDate>
            <endDate>2024-08-31</endDate>
        </period>
    </context>
    <context id="c-90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">exdx:AlleghenyHealthNetworkResearchInstituteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="c-91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exdx:AHNCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exdx:AHNCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">exdx:USDepartmentOfJusticeCaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-10-31</endDate>
        </period>
    </context>
    <context id="c-94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:AmendedLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:A2017TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">exdx:ShelfRegistrationStatementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-17</instant>
        </period>
    </context>
    <context id="c-105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">exdx:ShelfRegistrationStatementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">exdx:CowenEquityDistributionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-15</startDate>
            <endDate>2022-09-15</endDate>
        </period>
    </context>
    <context id="c-107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">exdx:ExpirationJan192026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">exdx:ExpirationMar312026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">exdx:ExpirationApr12026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">exdx:ExpirationDec72025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">exdx:NoExpirationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">exdx:IncentiveAwardPlan2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">exdx:IncentiveAwardPlan2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">exdx:CommonSharesAvailableForGrantUnderThe2019PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">exdx:IncentiveAwardPlan2019Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-01</instant>
        </period>
    </context>
    <context id="c-116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-01</instant>
        </period>
    </context>
    <context id="c-123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">exdx:TaxYearsThroughDecember312017Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">exdx:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">exdx:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">exdx:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">exdx:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="installment">
        <measure>exdx:installment</measure>
    </unit>
    <unit id="segment">
        <measure>exdx:segment</measure>
    </unit>
    <unit id="unit">
        <measure>exdx:unit</measure>
    </unit>
    <unit id="supplier">
        <measure>exdx:supplier</measure>
    </unit>
    <dei:DocumentFiscalYearFocus contextRef="c-1" id="f-32">2024</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="c-1" id="f-33">FY</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag contextRef="c-1" id="f-34">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-35">0001274737</dei:EntityCentralIndexKey>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-47" id="f-296">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:NumberOfOperatingSegments
      contextRef="c-1"
      decimals="INF"
      id="f-334"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NumberOfReportingUnits contextRef="c-1" decimals="INF" id="f-335" unitRef="unit">1</us-gaap:NumberOfReportingUnits>
    <us-gaap:LesseeFinanceLeaseTermOfContract1 contextRef="c-47" id="f-420">P3Y</us-gaap:LesseeFinanceLeaseTermOfContract1>
    <us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList contextRef="c-5" id="f-425">http://fasb.org/us-gaap/2024#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList contextRef="c-6" id="f-426">http://fasb.org/us-gaap/2024#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList contextRef="c-5" id="f-431">http://fasb.org/us-gaap/2024#AccruedLiabilitiesCurrent</us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList contextRef="c-6" id="f-432">http://fasb.org/us-gaap/2024#AccruedLiabilitiesCurrent</us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList contextRef="c-5" id="f-437">http://fasb.org/us-gaap/2024#OperatingLeaseLiabilityNoncurrent</us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList contextRef="c-6" id="f-438">http://fasb.org/us-gaap/2024#OperatingLeaseLiabilityNoncurrent</us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:NumberOfOperatingSegments
      contextRef="c-1"
      decimals="INF"
      id="f-729"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <dei:DocumentType contextRef="c-1" id="f-1">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="c-1" id="f-2">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-4">2024-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-3">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport contextRef="c-1" id="f-5">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c-1" id="f-6">001-39049</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c-1" id="f-7">EXAGEN INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-8">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-9">20-0434866</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-10">1261 Liberty Way</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-11">Vista</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-12">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-13">92081</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-14">(760)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-15">560-1501</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c-1" id="f-16">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-17">XGN</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-18">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="c-1" id="f-19">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="c-1" id="f-20">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="c-1" id="f-21">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c-1" id="f-22">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c-1" id="f-23">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c-1" id="f-24">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-25">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="c-1" id="f-26">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="c-1" id="f-27">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany contextRef="c-1" id="f-28">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat contextRef="c-2" decimals="-5" id="f-29" unitRef="usd">27000000.0</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-3" decimals="INF" id="f-30" unitRef="shares">17898098</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock contextRef="c-1" id="f-31">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Certain information required to be disclosed in Part III of this report is incorporated by reference from the registrant's definitive Proxy Statement for the 2025 Annual Meeting of Stockholders, which proxy statement will be filed not later than 120 days after the end of the fiscal year covered by this Form 10-K.&lt;/span&gt;&lt;/div&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag contextRef="c-1" id="f-36">false</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag>
    <cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock contextRef="c-1" id="f-37">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;We recognize the critical importance of maintaining the trust and confidence of physicians, patients, business partners and employees toward our business and are committed to protecting the confidentiality, integrity and availability of our business operations and systems. Our board of directors is actively involved in oversight of our risk management activities, and cybersecurity represents an important element of our overall approach to risk management. Our cybersecurity policies, standards, processes and practices are based on recognized frameworks established by NIST and other applicable industry standards, as well as the HIPAA Security Rule and other recognized frameworks. In general, we seek to address cybersecurity risks through a comprehensive, cross-functional approach that is focused on preserving the confidentiality, security and availability of the information that we collect and store by identifying, preventing and mitigating cybersecurity threats and effectively responding to cybersecurity incidents when they occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Cybersecurity Risk Management and Strategy; Effect of Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;We face risks related to cybersecurity such as unauthorized access, cybersecurity attacks and other security incidents, including as perpetrated by hackers and unintentional damage or disruption to hardware and software systems, loss of data, and misappropriation of confidential information. To identify and assess material risks from cybersecurity threats, we maintain a comprehensive cybersecurity program to ensure our systems are effective and prepared for information security risks, including regular oversight of our programs for security monitoring for internal and external threats to ensure the confidentiality and integrity of our information assets. We consider risks from cybersecurity threats in addition to other company risks as part of our overall risk assessment process. We employ a range of tools and services, including regular network and endpoint monitoring, audits, vulnerability assessments, and penetration testing to inform our risk identification and assessment. As discussed in more detail under &#x201c;Cybersecurity Governance&#x201d; below, our Audit Committee provides oversight of our cybersecurity risk management and strategy processes, which are led by our Vice President of Information Services.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;We also identify our cybersecurity threat risks by comparing our processes to standards set by NIST, as well as performing intrusion detection and prevention. To provide for the availability of critical data and systems, maintain regulatory compliance, manage our material risks from cybersecurity threats, and protect against and respond to cybersecurity incidents, we undertake the following activities:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;a.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:9.67pt"&gt;monitor emerging data protection laws and implement changes to our processes that are designed to comply with such laws;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;b.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:9.67pt"&gt;through our policies, practices and contracts (as applicable), require employees, as well as third parties that provide services on our behalf, to treat confidential information and data with care;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;c.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10.23pt"&gt;employ technical safeguards that are designed to protect our information systems from cybersecurity threats, including firewalls, intrusion prevention and detection systems, anti-malware functionality and access controls, which are evaluated and improved through vulnerability assessments and cybersecurity threat intelligence;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;d.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:9.67pt"&gt;provide regular, mandatory training for our employees regarding cybersecurity threats as a means to equip them with effective tools to address cybersecurity threats, and to communicate our evolving information security policies, standards, processes and practices;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;e.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:9.67pt"&gt;conduct regular phishing email simulations for all employees with access to our email systems to enhance awareness and responsiveness to possible threats;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;f.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:12.46pt"&gt;conduct monthly cybersecurity management and incident training for employees involved in our systems and processes that handle sensitive data;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;g.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:9.67pt"&gt;leverage internal and external resources to help us identify, protect, detect, respond and recover when there is an actual or potential cybersecurity incident; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;h.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:9.67pt"&gt;carry information security risk insurance that provides protection against the potential losses arising from a cybersecurity incident&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Our incident response plan coordinates the activities we take to prepare for, detect, respond to and recover from cybersecurity incidents, which include processes to triage, assess severity for, escalate, contain, investigate and remediate the incident, as well as to comply with potentially applicable legal obligations and mitigate damage to our business and reputation. As part of the above processes, we rely on internal resources rather than consultants, auditors or other third parties, to review our cybersecurity program.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Our processes also address cybersecurity threat risks associated with our use of third-party service providers, including our suppliers and manufacturers or who have access to patient and employee data or our systems. In addition, cybersecurity considerations affect the selection and oversight of our third-party service providers. We perform diligence on third parties that have access to our systems, data or facilities that house such systems or data.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;We describe whether and how risks from identified cybersecurity threats, including as a result of any previous cybersecurity incidents, have materially affected or are reasonably likely to materially affect us, including our business strategy, results of operations, or financial condition, under the heading &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Failure in our information technology, telephone or other systems could significantly disrupt our operations and adversely affect our business and financial condition&lt;/span&gt;,&#x201d; which disclosures are incorporated by reference herein.</cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock contextRef="c-1" id="f-38">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;We also identify our cybersecurity threat risks by comparing our processes to standards set by NIST, as well as performing intrusion detection and prevention. To provide for the availability of critical data and systems, maintain regulatory compliance, manage our material risks from cybersecurity threats, and protect against and respond to cybersecurity incidents, we undertake the following activities:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;a.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:9.67pt"&gt;monitor emerging data protection laws and implement changes to our processes that are designed to comply with such laws;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;b.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:9.67pt"&gt;through our policies, practices and contracts (as applicable), require employees, as well as third parties that provide services on our behalf, to treat confidential information and data with care;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;c.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10.23pt"&gt;employ technical safeguards that are designed to protect our information systems from cybersecurity threats, including firewalls, intrusion prevention and detection systems, anti-malware functionality and access controls, which are evaluated and improved through vulnerability assessments and cybersecurity threat intelligence;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;d.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:9.67pt"&gt;provide regular, mandatory training for our employees regarding cybersecurity threats as a means to equip them with effective tools to address cybersecurity threats, and to communicate our evolving information security policies, standards, processes and practices;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;e.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:9.67pt"&gt;conduct regular phishing email simulations for all employees with access to our email systems to enhance awareness and responsiveness to possible threats;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;f.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:12.46pt"&gt;conduct monthly cybersecurity management and incident training for employees involved in our systems and processes that handle sensitive data;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;g.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:9.67pt"&gt;leverage internal and external resources to help us identify, protect, detect, respond and recover when there is an actual or potential cybersecurity incident; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;h.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:9.67pt"&gt;carry information security risk insurance that provides protection against the potential losses arising from a cybersecurity incident&lt;/span&gt;&lt;/div&gt;</cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedFlag contextRef="c-1" id="f-39">true</cyd:CybersecurityRiskManagementProcessesIntegratedFlag>
    <cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock contextRef="c-1" id="f-40">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Our incident response plan coordinates the activities we take to prepare for, detect, respond to and recover from cybersecurity incidents, which include processes to triage, assess severity for, escalate, contain, investigate and remediate the incident, as well as to comply with potentially applicable legal obligations and mitigate damage to our business and reputation. As part of the above processes, we rely on internal resources rather than consultants, auditors or other third parties, to review our cybersecurity program.&lt;/span&gt;&lt;/div&gt;</cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag contextRef="c-1" id="f-41">true</cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag>
    <cyd:CybersecurityRiskManagementThirdPartyEngagedFlag contextRef="c-1" id="f-42">true</cyd:CybersecurityRiskManagementThirdPartyEngagedFlag>
    <cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock contextRef="c-1" id="f-43">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Cybersecurity Governance; Management&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Cybersecurity is an important part of our risk management processes and an area of focus for our board of directors and management. In general, our board of directors oversees risk management activities designed and implemented by our management, and considers specific risks, including, for example, risks associated with our strategic plan, business operations, and capital structure. Our board of directors executes its oversight responsibility for risk management both directly and through delegating oversight of certain of these risks to its committees, and our board of directors has authorized our Audit Committee to oversee risks from cybersecurity threats. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Upon detection of a material cybersecurity threat, our Audit Committee receives an update from management of the cybersecurity threat, risk management and strategy processes, as well as the steps management has taken to respond to such risks. In such sessions, our Audit Committee generally receives materials that include cybersecurity materials discussing current material cybersecurity threat risks, and describing our ability to mitigate those risks, and discusses such matters with our Chief Executive Officer. Our Audit Committee and board of directors receive prompt and timely information regarding any cybersecurity incident that meets established reporting thresholds. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Our cybersecurity risk management and strategy processes, which are discussed in greater detail above, are led by our Vice President of Information Services, with support from our entire Information Services department. Such individuals have collectively over 10 years of prior work experience in various roles involving managing information security, developing cybersecurity strategy, implementing effective information and cybersecurity programs, as well as several relevant degrees and certifications. These Information Services team members are informed about and monitor the prevention, mitigation, detection, and remediation of cybersecurity incidents through their management of, and participation in, the cybersecurity risk management and strategy processes described above, including the operation of our incident response plan. As discussed above, these Information Services team members report to our Chief Executive Officer, and ultimately to the Audit Committee of our board of directors about material cybersecurity threats.&lt;/span&gt;&lt;/div&gt;</cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock>
    <cyd:CybersecurityRiskRoleOfManagementTextBlock contextRef="c-1" id="f-44">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Cybersecurity is an important part of our risk management processes and an area of focus for our board of directors and management. In general, our board of directors oversees risk management activities designed and implemented by our management, and considers specific risks, including, for example, risks associated with our strategic plan, business operations, and capital structure. Our board of directors executes its oversight responsibility for risk management both directly and through delegating oversight of certain of these risks to its committees, and our board of directors has authorized our Audit Committee to oversee risks from cybersecurity threats. &lt;/span&gt;&lt;/div&gt;Upon detection of a material cybersecurity threat, our Audit Committee receives an update from management of the cybersecurity threat, risk management and strategy processes, as well as the steps management has taken to respond to such risks. In such sessions, our Audit Committee generally receives materials that include cybersecurity materials discussing current material cybersecurity threat risks, and describing our ability to mitigate those risks, and discusses such matters with our Chief Executive Officer. Our Audit Committee and board of directors receive prompt and timely information regarding any cybersecurity incident that meets established reporting thresholds.</cyd:CybersecurityRiskRoleOfManagementTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock contextRef="c-1" id="f-46">Cybersecurity is an important part of our risk management processes and an area of focus for our board of directors and management. In general, our board of directors oversees risk management activities designed and implemented by our management, and considers specific risks, including, for example, risks associated with our strategic plan, business operations, and capital structure. Our board of directors executes its oversight responsibility for risk management both directly and through delegating oversight of certain of these risks to its committees, and our board of directors has authorized our Audit Committee to oversee risks from cybersecurity threats.</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock contextRef="c-1" id="f-45">Cybersecurity is an important part of our risk management processes and an area of focus for our board of directors and management. In general, our board of directors oversees risk management activities designed and implemented by our management, and considers specific risks, including, for example, risks associated with our strategic plan, business operations, and capital structure. Our board of directors executes its oversight responsibility for risk management both directly and through delegating oversight of certain of these risks to its committees, and our board of directors has authorized our Audit Committee to oversee risks from cybersecurity threats.</cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag contextRef="c-1" id="f-47">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag contextRef="c-1" id="f-48">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag>
    <cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock contextRef="c-1" id="f-49">In such sessions, our Audit Committee generally receives materials that include cybersecurity materials discussing current material cybersecurity threat risks, and describing our ability to mitigate those risks, and discusses such matters with our Chief Executive Officer. Our Audit Committee and board of directors receive prompt and timely information regarding any cybersecurity incident that meets established reporting thresholds.</cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock contextRef="c-1" id="f-50">Our cybersecurity risk management and strategy processes, which are discussed in greater detail above, are led by our Vice President of Information Services, with support from our entire Information Services department. Such individuals have collectively over 10 years of prior work experience in various roles involving managing information security, developing cybersecurity strategy, implementing effective information and cybersecurity programs, as well as several relevant degrees and certifications.</cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="c-4" id="f-51">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-4" id="f-52">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="c-4" id="f-53">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="c-4" id="f-54">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:InsiderTrdPoliciesProcAdoptedFlag contextRef="c-1" id="f-55">true</ecd:InsiderTrdPoliciesProcAdoptedFlag>
    <dei:AuditorFirmId contextRef="c-1" id="f-56">243</dei:AuditorFirmId>
    <dei:AuditorName contextRef="c-1" id="f-57">BDO USA, P.C.</dei:AuditorName>
    <dei:AuditorLocation contextRef="c-1" id="f-58">San Diego, California</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-5" decimals="-3" id="f-59" unitRef="usd">22036000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-6" decimals="-3" id="f-60" unitRef="usd">36493000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-5" decimals="-3" id="f-61" unitRef="usd">7835000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-6" decimals="-3" id="f-62" unitRef="usd">6551000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssets contextRef="c-5" decimals="-3" id="f-63" unitRef="usd">6584000</us-gaap:PrepaidExpenseAndOtherAssets>
    <us-gaap:PrepaidExpenseAndOtherAssets contextRef="c-6" decimals="-3" id="f-64" unitRef="usd">4797000</us-gaap:PrepaidExpenseAndOtherAssets>
    <us-gaap:AssetsCurrent contextRef="c-5" decimals="-3" id="f-65" unitRef="usd">36455000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-6" decimals="-3" id="f-66" unitRef="usd">47841000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization contextRef="c-5" decimals="-3" id="f-67" unitRef="usd">5283000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization contextRef="c-6" decimals="-3" id="f-68" unitRef="usd">5201000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-5" decimals="-3" id="f-69" unitRef="usd">2401000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-6" decimals="-3" id="f-70" unitRef="usd">3286000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-5" decimals="-3" id="f-71" unitRef="usd">550000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-6" decimals="-3" id="f-72" unitRef="usd">616000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets contextRef="c-5" decimals="-3" id="f-73" unitRef="usd">44689000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-6" decimals="-3" id="f-74" unitRef="usd">56944000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="c-5" decimals="-3" id="f-75" unitRef="usd">4137000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-6" decimals="-3" id="f-76" unitRef="usd">3131000</us-gaap:AccountsPayableCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-5" decimals="-3" id="f-77" unitRef="usd">1096000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-6" decimals="-3" id="f-78" unitRef="usd">976000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LongTermDebtCurrent contextRef="c-5" decimals="-3" id="f-79" unitRef="usd">423000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent contextRef="c-6" decimals="-3" id="f-80" unitRef="usd">264000</us-gaap:LongTermDebtCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-5" decimals="-3" id="f-81" unitRef="usd">7850000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-6" decimals="-3" id="f-82" unitRef="usd">7531000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-5" decimals="-3" id="f-83" unitRef="usd">13506000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-6" decimals="-3" id="f-84" unitRef="usd">11902000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-5" decimals="-3" id="f-85" unitRef="usd">19822000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-6" decimals="-3" id="f-86" unitRef="usd">19231000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-5" decimals="-3" id="f-87" unitRef="usd">1664000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-6" decimals="-3" id="f-88" unitRef="usd">2760000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-5" decimals="-3" id="f-89" unitRef="usd">157000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-6" decimals="-3" id="f-90" unitRef="usd">357000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities contextRef="c-5" decimals="-3" id="f-91" unitRef="usd">35149000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c-6" decimals="-3" id="f-92" unitRef="usd">34250000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies contextRef="c-5" id="f-93" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies contextRef="c-6" id="f-94" unitRef="usd" xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-5"
      decimals="INF"
      id="f-95"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-6"
      decimals="INF"
      id="f-96"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-6" decimals="INF" id="f-97" unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-5" decimals="INF" id="f-98" unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued contextRef="c-6" decimals="INF" id="f-99" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-5" decimals="INF" id="f-100" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued contextRef="c-6" decimals="INF" id="f-101" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-5" decimals="INF" id="f-102" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue contextRef="c-5" decimals="-3" id="f-103" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="c-6" decimals="-3" id="f-104" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-6"
      decimals="INF"
      id="f-105"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-5"
      decimals="INF"
      id="f-106"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-5" decimals="INF" id="f-107" unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-6" decimals="INF" id="f-108" unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-5" decimals="INF" id="f-109" unitRef="shares">17640328</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="c-5" decimals="INF" id="f-110" unitRef="shares">17640328</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued contextRef="c-6" decimals="INF" id="f-111" unitRef="shares">17045954</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-6" decimals="INF" id="f-112" unitRef="shares">17045954</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="c-5" decimals="-3" id="f-113" unitRef="usd">18000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c-6" decimals="-3" id="f-114" unitRef="usd">17000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="c-5" decimals="-3" id="f-115" unitRef="usd">303853000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="c-6" decimals="-3" id="f-116" unitRef="usd">301893000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-5" decimals="-3" id="f-117" unitRef="usd">-294331000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-6" decimals="-3" id="f-118" unitRef="usd">-279216000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="c-5" decimals="-3" id="f-119" unitRef="usd">9540000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-6" decimals="-3" id="f-120" unitRef="usd">22694000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-5" decimals="-3" id="f-121" unitRef="usd">44689000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-6" decimals="-3" id="f-122" unitRef="usd">56944000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-1" decimals="-3" id="f-123" unitRef="usd">55641000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-7" decimals="-3" id="f-124" unitRef="usd">52548000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-1" decimals="-3" id="f-125" unitRef="usd">22529000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-7" decimals="-3" id="f-126" unitRef="usd">23092000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit contextRef="c-1" decimals="-3" id="f-127" unitRef="usd">33112000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c-7" decimals="-3" id="f-128" unitRef="usd">29456000</us-gaap:GrossProfit>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-1" decimals="-3" id="f-129" unitRef="usd">41373000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-7" decimals="-3" id="f-130" unitRef="usd">47428000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-1" decimals="-3" id="f-131" unitRef="usd">5375000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-7" decimals="-3" id="f-132" unitRef="usd">4865000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:CostsAndExpenses contextRef="c-1" decimals="-3" id="f-133" unitRef="usd">46748000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses contextRef="c-7" decimals="-3" id="f-134" unitRef="usd">52293000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c-1" decimals="-3" id="f-135" unitRef="usd">-13636000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-7" decimals="-3" id="f-136" unitRef="usd">-22837000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpenseNonoperating contextRef="c-1" decimals="-3" id="f-137" unitRef="usd">2234000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating contextRef="c-7" decimals="-3" id="f-138" unitRef="usd">2335000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InvestmentIncomeInterest contextRef="c-1" decimals="-3" id="f-139" unitRef="usd">767000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest contextRef="c-7" decimals="-3" id="f-140" unitRef="usd">1516000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:IncomeLossAttributableToParent contextRef="c-1" decimals="-3" id="f-141" unitRef="usd">-15103000</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeLossAttributableToParent contextRef="c-7" decimals="-3" id="f-142" unitRef="usd">-23656000</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-143" unitRef="usd">12000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-7" decimals="-3" id="f-144" unitRef="usd">33000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-145" unitRef="usd">-15115000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-7" decimals="-3" id="f-146" unitRef="usd">-23689000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-147"
      unitRef="usdPerShare">-0.83</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-148"
      unitRef="usdPerShare">-0.83</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-7"
      decimals="2"
      id="f-149"
      unitRef="usdPerShare">-1.34</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-7"
      decimals="2"
      id="f-150"
      unitRef="usdPerShare">-1.34</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="0" id="f-151" unitRef="shares">18203044</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="0" id="f-152" unitRef="shares">18203044</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-7" decimals="0" id="f-153" unitRef="shares">17679467</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-7" decimals="0" id="f-154" unitRef="shares">17679467</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-8" decimals="INF" id="f-155" unitRef="shares">16549984</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-8" decimals="-3" id="f-156" unitRef="usd">17000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-9" decimals="-3" id="f-157" unitRef="usd">297970000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-10" decimals="-3" id="f-158" unitRef="usd">-255527000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-11" decimals="-3" id="f-159" unitRef="usd">42460000</us-gaap:StockholdersEquity>
    <exdx:IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesShares
      contextRef="c-12"
      decimals="INF"
      id="f-160"
      unitRef="shares">273042</exdx:IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesShares>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c-12"
      decimals="INF"
      id="f-161"
      unitRef="shares">93335</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-13" decimals="-3" id="f-162" unitRef="usd">27000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-7" decimals="-3" id="f-163" unitRef="usd">27000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="c-12"
      decimals="INF"
      id="f-164"
      unitRef="shares">129593</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-13" decimals="-3" id="f-165" unitRef="usd">279000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-7" decimals="-3" id="f-166" unitRef="usd">279000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-13" decimals="-3" id="f-167" unitRef="usd">3617000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-7" decimals="-3" id="f-168" unitRef="usd">3617000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss contextRef="c-14" decimals="-3" id="f-169" unitRef="usd">-23689000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-7" decimals="-3" id="f-170" unitRef="usd">-23689000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-15"
      decimals="INF"
      id="f-171"
      unitRef="shares">17045954</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-15" decimals="-3" id="f-172" unitRef="usd">17000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-16" decimals="-3" id="f-173" unitRef="usd">301893000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-17" decimals="-3" id="f-174" unitRef="usd">-279216000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-6" decimals="-3" id="f-175" unitRef="usd">22694000</us-gaap:StockholdersEquity>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c-18"
      decimals="INF"
      id="f-176"
      unitRef="shares">413202</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c-18"
      decimals="INF"
      id="f-177"
      unitRef="shares">85124</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-19" decimals="-3" id="f-178" unitRef="usd">22000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-1" decimals="-3" id="f-179" unitRef="usd">22000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="c-18"
      decimals="INF"
      id="f-180"
      unitRef="shares">96048</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-18" decimals="-3" id="f-181" unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-19" decimals="-3" id="f-182" unitRef="usd">175000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-1" decimals="-3" id="f-183" unitRef="usd">176000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-19" decimals="-3" id="f-184" unitRef="usd">1763000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-1" decimals="-3" id="f-185" unitRef="usd">1763000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss contextRef="c-20" decimals="-3" id="f-186" unitRef="usd">-15115000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-187" unitRef="usd">-15115000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-21"
      decimals="INF"
      id="f-188"
      unitRef="shares">17640328</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-21" decimals="-3" id="f-189" unitRef="usd">18000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-22" decimals="-3" id="f-190" unitRef="usd">303853000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-23" decimals="-3" id="f-191" unitRef="usd">-294331000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-5" decimals="-3" id="f-192" unitRef="usd">9540000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-193" unitRef="usd">-15115000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-7" decimals="-3" id="f-194" unitRef="usd">-23689000</us-gaap:NetIncomeLoss>
    <us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization contextRef="c-1" decimals="-3" id="f-195" unitRef="usd">1724000</us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization>
    <us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization contextRef="c-7" decimals="-3" id="f-196" unitRef="usd">2168000</us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="c-1" decimals="-3" id="f-197" unitRef="usd">154000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="c-7" decimals="-3" id="f-198" unitRef="usd">156000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:PaidInKindInterest contextRef="c-1" decimals="-3" id="f-199" unitRef="usd">276000</us-gaap:PaidInKindInterest>
    <us-gaap:PaidInKindInterest contextRef="c-7" decimals="-3" id="f-200" unitRef="usd">363000</us-gaap:PaidInKindInterest>
    <us-gaap:GainLossOnDispositionOfAssets1 contextRef="c-1" decimals="-3" id="f-201" unitRef="usd">-111000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:GainLossOnDispositionOfAssets1 contextRef="c-7" decimals="-3" id="f-202" unitRef="usd">-189000</us-gaap:GainLossOnDispositionOfAssets1>
    <exdx:GainLossOnDispositionOfLeaseAssignment contextRef="c-1" decimals="-3" id="f-203" unitRef="usd">0</exdx:GainLossOnDispositionOfLeaseAssignment>
    <exdx:GainLossOnDispositionOfLeaseAssignment contextRef="c-7" decimals="-3" id="f-204" unitRef="usd">-1470000</exdx:GainLossOnDispositionOfLeaseAssignment>
    <exdx:NonCashLeaseExpense contextRef="c-1" decimals="-3" id="f-205" unitRef="usd">884000</exdx:NonCashLeaseExpense>
    <exdx:NonCashLeaseExpense contextRef="c-7" decimals="-3" id="f-206" unitRef="usd">939000</exdx:NonCashLeaseExpense>
    <us-gaap:ShareBasedCompensation contextRef="c-1" decimals="-3" id="f-207" unitRef="usd">1763000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-7" decimals="-3" id="f-208" unitRef="usd">3617000</us-gaap:ShareBasedCompensation>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-1" decimals="-3" id="f-209" unitRef="usd">1284000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-7" decimals="-3" id="f-210" unitRef="usd">474000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <exdx:IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets contextRef="c-1" decimals="-3" id="f-211" unitRef="usd">1787000</exdx:IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets>
    <exdx:IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets contextRef="c-7" decimals="-3" id="f-212" unitRef="usd">654000</exdx:IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets contextRef="c-1" decimals="-3" id="f-213" unitRef="usd">-63000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets contextRef="c-7" decimals="-3" id="f-214" unitRef="usd">101000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-1" decimals="-3" id="f-215" unitRef="usd">-976000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-7" decimals="-3" id="f-216" unitRef="usd">-1010000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-1" decimals="-3" id="f-217" unitRef="usd">308000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-7" decimals="-3" id="f-218" unitRef="usd">67000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities contextRef="c-1" decimals="-3" id="f-219" unitRef="usd">600000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities contextRef="c-7" decimals="-3" id="f-220" unitRef="usd">2497000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-1" decimals="-3" id="f-221" unitRef="usd">-13279000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-7" decimals="-3" id="f-222" unitRef="usd">-14462000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-1" decimals="-3" id="f-223" unitRef="usd">515000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-7" decimals="-3" id="f-224" unitRef="usd">828000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="c-1" decimals="-3" id="f-225" unitRef="usd">0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="c-7" decimals="-3" id="f-226" unitRef="usd">24000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-1" decimals="-3" id="f-227" unitRef="usd">-515000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-7" decimals="-3" id="f-228" unitRef="usd">-804000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-1" decimals="-3" id="f-229" unitRef="usd">22000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-7" decimals="-3" id="f-230" unitRef="usd">27000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockPlans contextRef="c-1" decimals="-3" id="f-231" unitRef="usd">176000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockPlans contextRef="c-7" decimals="-3" id="f-232" unitRef="usd">279000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:FinanceLeasePrincipalPayments contextRef="c-1" decimals="-3" id="f-233" unitRef="usd">490000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments contextRef="c-7" decimals="-3" id="f-234" unitRef="usd">697000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:RepaymentsOfNotesPayable contextRef="c-1" decimals="-3" id="f-235" unitRef="usd">371000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable contextRef="c-7" decimals="-3" id="f-236" unitRef="usd">241000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfLongTermDebt contextRef="c-1" decimals="-3" id="f-237" unitRef="usd">0</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt contextRef="c-7" decimals="-3" id="f-238" unitRef="usd">10000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-1" decimals="-3" id="f-239" unitRef="usd">-663000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-7" decimals="-3" id="f-240" unitRef="usd">-10632000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-1" decimals="-3" id="f-241" unitRef="usd">-14457000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-7" decimals="-3" id="f-242" unitRef="usd">-25898000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-6" decimals="-3" id="f-243" unitRef="usd">36693000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-11" decimals="-3" id="f-244" unitRef="usd">62591000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-5" decimals="-3" id="f-245" unitRef="usd">22236000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-6" decimals="-3" id="f-246" unitRef="usd">36693000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet contextRef="c-1" decimals="-3" id="f-247" unitRef="usd">1719000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c-7" decimals="-3" id="f-248" unitRef="usd">1737000</us-gaap:InterestPaidNet>
    <exdx:EquipmentPurchasedUnderNotesPayableObligations contextRef="c-1" decimals="-3" id="f-249" unitRef="usd">706000</exdx:EquipmentPurchasedUnderNotesPayableObligations>
    <exdx:EquipmentPurchasedUnderNotesPayableObligations contextRef="c-7" decimals="-3" id="f-250" unitRef="usd">250000</exdx:EquipmentPurchasedUnderNotesPayableObligations>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c-1" decimals="-3" id="f-251" unitRef="usd">717000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c-7" decimals="-3" id="f-252" unitRef="usd">66000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock contextRef="c-1" id="f-253">Organization&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Description of Business&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Exagen Inc. (the Company) is a medical technology company primarily focused on the design, development and commercialization of a next-generation portfolio of testing products under our AVISE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; brand, which allow for the differential diagnosis, prognosis and monitoring of complex rheumatic, autoimmune and autoimmune-related disease including, among others, systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Liquidity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company has incurred recurring losses and negative cash flows from operating activities since inception. The Company anticipates that it will continue to incur net losses in future periods. At December&#160;31, 2024, the Company had cash and cash equivalents of $22.0 million and had an accumulated deficit of $294.3 million. Since inception, the Company has financed its operations primarily through a combination of equity financings, debt financing arrangements, and revenue from sales of the Company's products. Based on the Company's current business plan, management believes that its existing capital resources will be sufficient to fund the Company's obligations for at least twelve months following the issuance of these financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;To execute its business plans, the Company may need additional funding to support its continuing operations and pursue its growth strategy. Until such time as the Company can achieve significant cash flows from operations, if ever, it may need to finance its operations through the sale of its stock, debt financings or other strategic transactions. Although the Company has been successful in raising capital in the past, there is no assurance that it will be successful in obtaining such additional financing on terms acceptable to the Company, if at all. The terms of any financing may adversely affect the holdings or the rights of the Company's stockholders. If the Company is unable to obtain funding, the Company could be forced to delay, reduce or eliminate some or all of its programs, product portfolio expansion plans or commercialization efforts, which could have a material adverse effect on the Company's business, operating results and financial condition and the Company's ability to achieve its intended business objectives.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-5" decimals="-5" id="f-254" unitRef="usd">22000000.0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-5" decimals="-5" id="f-255" unitRef="usd">-294300000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c-1" id="f-256">Summary of Significant Accounting Policies&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Basis of Presentation and Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company's financial statements are prepared in accordance with accounting principles generally accepted in the United States of America (GAAP). The preparation of the accompanying financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities as of the date of the financial statements, and the reported amounts of revenue and expenses during the reporting period. Actual results could materially differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Significant estimates and assumptions made in the accompanying financial statements include, but are not limited to revenue recognition, the estimated incremental borrowing rate for the determination of the Company's operating lease right-of-use (ROU) assets and the recoverability of its long-lived assets and net deferred tax assets (and related valuation allowance). The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could materially differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Concentration of Credit Risk and Other Risk and Uncertainties&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Financial instruments that potentially subject the Company to credit risk consist principally of cash, cash equivalents and accounts receivable. Substantially all the Company's cash and cash equivalents are held at one financial institution that management believes is of high credit quality. Such deposits may, at times, exceed federally insured limits. The Company has not experienced any losses on its cash or cash equivalents.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Significant payors and customers are those which represent more than 10% of the Company's total revenue or accounts receivable balance at each respective balance sheet date. For each significant payor and customer, &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;revenue as a percentage of total revenue and accounts receivable as a percentage of total accounts receivable are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.707%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.765%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.768%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medicare Advantage&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;United Healthcare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:2.847%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:3.724%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:90.129%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less than 10%.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.707%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.765%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.768%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accounts Receivable&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medicare Advantage&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;For the years ended December&#160;31, 2024 and 2023, approximately 91% and 88%, respectively, of the Company's revenue was related to the AVISE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; CTD test.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company is dependent on key suppliers for certain laboratory materials. For the year ended December&#160;31, 2024, approximately 71% and 26%&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;of the Company's diagnostic testing supplies were purchased from two suppliers, respectively. For the year ended December 31, 2023, approximately 66% and 30%&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;of the Company's diagnostic testing supplies were purchased from two suppliers, respectively. An interruption in the supply of these materials would impact the Company's ability to perform testing services.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Disaggregation of Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table includes the Company's revenues as disaggregated by payor and customer category (in&#160;thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.707%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.765%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.768%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Commercial&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Government&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Client(1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11,360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,949&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other(2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;55,641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;52,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:31.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.24pt"&gt;Includes hospitals, other laboratories, etc.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:31.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.24pt"&gt;Includes patient self-pay.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Cash, Cash Equivalents and Restricted Cash&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company considers all highly-liquid investments purchased with a remaining maturity date of three months or less upon acquisition to be cash equivalents. These investments are stated at cost, which approximates fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company has an arrangement with a financial institution with which it has an existing banking relationship, whereby in exchange for the issuance of corporate credit cards, the Company agreed to obtain a certificate of deposit with this financial institution in the amount of $0.2 million as collateral for the balances borrowed on these cards. The Company has classified the value of this certificate of deposit (including all interest earned thereon) within other assets in the accompanying balance sheets. The Company has the right to terminate the credit card program at any time. Upon termination of the credit card program and repayment of all outstanding balances owed, the Company may redeem the certificate of deposit (and all interest earned thereon).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Cash, cash equivalents and restricted cash presented in the accompanying statements of cash flows consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.707%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.765%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.768%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22,036&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;36,493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;36,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Property and equipment are stated at cost, net of depreciation and amortization. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally between &lt;span style="-sec-ix-hidden:f-296"&gt;three&lt;/span&gt; and five years. Leasehold improvements are amortized on a straight-line basis over the lesser of the estimated useful life or the remaining term of the related lease. Maintenance and repairs are charged to expense as incurred, and improvements and betterments are capitalized. When assets are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the balance sheet and any resulting gain or loss is reflected in operating expenses in the statements of operations in the period realized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Long-lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company&#x2019;s long-lived assets are comprised principally of its property and equipment and operating lease assets. The Company amortizes all finite lived intangible assets over their respective estimated useful lives. Operating lease assets are amortized over the term of the leases. In considering whether long-lived assets are impaired, the Company combines its long-lived assets into groupings, a determination which is made principally on the basis of whether the assets are specific to a particular test offered or technology being developed. If the Company identifies a change in the circumstances related to its long-lived assets that indicates the carrying value of any such asset may not be recoverable, the Company will perform an impairment analysis. A long-lived asset is deemed to be impaired when the undiscounted cash flows expected to be generated by the asset (or asset group) are less than the asset&#x2019;s carrying amount. Management&#x2019;s estimates of future cash flows are impacted by projected test volume and levels of reimbursement, as well as expectations related to the future cost structure of the entity. Any required impairment loss would be measured as the amount by which the asset&#x2019;s carrying value exceeds its fair value, and would be recorded as a reduction in the carrying value of the related asset and a charge to operating expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company categorizes leases at their commencement as either operating or finance leases. The Company recognizes operating lease ROU assets and operating lease liabilities for each lease arrangement identified. Lease liabilities are recorded at the present value of future lease payments discounted using the Company's incremental borrowing rate for the lease established at the commencement date. The incremental borrowing rate is the rate of interest the Company would have to pay to borrow, on a collateralized basis over a similar term and in a similar economic environment, an amount equal to the total lease payments. The Company primarily considers industry data, its credit rating and the lease term to determine its incremental borrowing rate. ROU assets are measured at the amount of the lease liability plus any initial direct costs, less any lease incentives received before commencement. Lease expense is recognized as a single lease cost over the lease term on a straight-line basis. The Company has elected not to apply the recognition requirements to short-term leases and not to separate non-lease components from lease components for its leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Clinical Studies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;From time to time, the Company engages in efforts to scientifically measure and document the application and efficacy of its various testing products. These arrangements typically require the Company to pay a fee to a third-party scientific investigator (usually a physician or research institution) for each subject enrolled in a clinical study, and the Company accrues expenses based on estimated progress of services performed, including actual level of subjects enrolled and progress of the clinical studies. Payments made prior to the completion of clinical study services are capitalized as a prepaid expense. The prepaid amounts are expensed as the related goods are delivered or the services are performed, or when it is no longer expected that the goods will be delivered or the services rendered. Expenses associated with clinical study activities are recorded in research and development expenses in the accompanying statement of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Substantially all of the Company's revenue has been derived from sales of its testing products and is primarily comprised of a high volume of relatively low-dollar transactions. The Company primarily markets its testing products to rheumatologists and their physician assistants in the United States. The healthcare professionals who order the Company's testing products and to whom test results are reported are generally not responsible for payment for these products. The parties that pay for these services (each, a payor) consist of commercial payors (healthcare insurers), government payors (primarily Medicare and Medicaid), client payors (hospitals, other laboratories, etc.) and patient self-pay. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company recognizes revenue in accordance with Accounting Standards Codification Topic 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; and follows a five-step process to determine the amount and timing of revenue recognized: (1) identify the contract with the customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to performance obligations in the contract, and (5) recognize revenue when (or as) the performance obligation is satisfied. The Company's service is a single performance obligation that is completed upon the delivery of test results to the prescribing physician which triggers revenue recognition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Payors are generally billed at the Company's list price, unless a separate pricing contract is in place. Net revenues recognized consist of amounts billed net of allowances for differences between amounts billed and the estimated consideration the Company expects to receive from such payors. The process for estimating revenues and the ultimate collection of accounts receivable involves significant judgment and estimation. The Company follows a standard process, which considers historical denial and collection experience, insurance reimbursement policies and other factors, to estimate allowances and implicit price concessions. Adjustments are recorded in the current period as changes in estimates occur. Further adjustments to the allowances, based on actual receipts, are recorded upon settlement. Included in revenues for the years ended December&#160;31, 2024 and 2023 were net revenue increases of $6.6 million and $3.4 million, respectively, associated with changes in estimated variable consideration related to performance obligations satisfied in previous periods. The transaction price is estimated using an expected value method on a portfolio basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Variable consideration is included in the transaction price only to the extent it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainties with respect to the amount are resolved. The Company's portfolios are grouped per payor (i.e. each individual commercial payor, Medicare, Medicaid, client payors, patient self-pay, etc.) and per test. Consideration may be constrained and excluded from the transaction price in situations where there is no contractually agreed upon reimbursement coverage or in absence of a predictable pattern and history of collectability with a payor. Accordingly, in such situations revenues are recognized on the basis of actual cash collections. Additionally, from time to time, the Company may issue refunds to payors for overpayments or amounts billed in error. Any refunds are accounted for as reductions in revenues in the statement of operations as an element of variable consideration. The estimated expected refunds are accrued as a liability on the Company&#x2019;s balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Collection of the Company's net revenues from payors is normally a function of providing complete and correct billing information, along with any requested medical or other claims-related information to the healthcare insurers. This generally occurs within 30 to 90 days of billing, however, the amount and timing of any reimbursements or collections for the Company's billed tests may vary by payor and other circumstances. Contracts do not contain significant financing components based on the typical period of time between performance of services and collection of consideration.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Accounts Receivable and Allowance for Credit Losses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;We accrue an allowance for credit losses against our accounts receivable based on management&#x2019;s current estimate of amounts that will not be collected. Management&#x2019;s estimates are typically based on historical loss information adjusted for current conditions. We generally do not perform evaluations of the financial condition of our customers and generally do not require collateral. The allowance for credit losses was zero as of each of December&#160;31, 2024 and 2023. Adjustments for implicit price concessions attributable to variable consideration, as discussed above, are incorporated into the measurement of the accounts receivable balances and are not part of the allowance for credit losses. Accounts receivable was $7.8 million, $6.6 million, and $6.1 million for the years ended December&#160;31, 2024, 2023 and 2022, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Research and Development&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Costs associated with research and development activities are expensed as incurred and include, but are not limited to, personnel-related expenses, including stock-based compensation expense; materials; laboratory &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;supplies; consulting costs; costs associated with setting up and conducting clinical studies; depreciation; amortization and allocated overhead, including rent and utilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Advertising and Marketing Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Costs associated with advertising and marketing activities are expensed as incurred. Total advertising and marketing costs were approximately $1.4 million and $1.5 million for the years ended December&#160;31, 2024 and 2023, respectively, and are included in selling, general and administrative expenses in the accompanying statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Shipping and Handling Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Costs incurred for shipping and handling are included in costs of revenue in the accompanying statements of operations and were approximately $3.1 million and $2.5 million for the years ended December&#160;31, 2024 and 2023, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company recognizes compensation expense for all stock-based awards to employees and directors based on the grant-date estimated fair values over the requisite service period of the awards (usually the vesting period) on a straight-line basis. Equity award forfeitures are recorded as they occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The fair value of each restricted stock unit (RSU) is determined on the grant date using the closing price of the Company's common stock on that date. The Company's RSUs generally vest in equal annual installments over four years from the date of grant or, for grants to new hires, date of hire. Vesting of the RSU is subject to the holder's continued service with the Company. The Company issues new shares of common stock to satisfy the RSUs upon vesting.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Comprehensive Loss&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Comprehensive loss is defined as a change in equity of a business enterprise during a period, resulting from transactions from nonowner sources. There have been no items qualifying as other comprehensive loss and, therefore, for all periods presented, the Company's comprehensive loss was the same as its reported net loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized as an expense in the period that includes the enactment date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company recognizes net deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If management determines that the Company would be able to realize its deferred tax assets in the future in excess of their net recorded amount, management would adjust the deferred tax asset valuation allowance, which would reduce the provision for income taxes. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company records uncertain tax positions on the basis of a two-step process whereby (i) management determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (ii) for those tax positions that meet the more-likely-than-not recognition threshold, management recognizes the largest amount of tax benefit that is more than 50% likely to be realized upon ultimate settlement with the related tax authority. The Company recognizes interest and penalties related to unrecognized tax benefits within income tax expense. Any accrued interest and penalties are included within the related tax liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Net Loss Per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Basic net loss per share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common stock outstanding during the period. Diluted net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;stockholders by the weighted-average number of common stock equivalents outstanding for the period determined using the treasury-stock and if-converted methods. The weighted-average number of shares used to compute basic and diluted shares includes shares issuable upon the exercise of pre-funded warrants at a nominal price. Potentially dilutive common stock equivalents are comprised of warrants for the purchase of common stock, stock options, RSUs outstanding under the Company's 2019 Incentive Award Plan (the 2019 Plan) and shares of the Company's common stock pursuant to the Exagen Inc. 2019 Employee Stock Purchase Plan (ESPP). For each of the years ended December&#160;31, 2024 and 2023, there is no difference in the number of shares used to calculate basic and diluted shares outstanding as the inclusion of the potentially dilutive securities would be antidilutive.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Potentially dilutive securities not included in the calculation of diluted net loss per share, because to do so would be anti-dilutive, are as follows (in common stock equivalent shares):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.707%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.765%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.768%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Warrants to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;325,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;409,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;489,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;986,819&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,710,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,387,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee stock purchase plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;57,461&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,582,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,828,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB), or other standard setting bodies and adopted by the Company as of the specified effective date. Unless otherwise discussed, Accounting Standards Updates (ASU) not included in the Company&#x2019;s disclosures were assessed and determined to be either not applicable or are not expected to have a material impact on the Company&#x2019;s financial statements or disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;In December 2023, the FASB issued ASU 2023-09,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%"&gt; Income Taxes (Topic 740): Improvements to Income Tax Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt; (ASU 2023-09), which requires additional income tax disclosures in the rate reconciliation table for federal, state and foreign income taxes, in addition to more details about the reconciling items in some categories when items meet a certain quantitative threshold. ASU 2023-09 is effective for annual periods beginning after December 15, 2024 with early adoption permitted. This update will result in enhanced income tax disclosures, and the Company does not expect any impact to income tax expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;In November 2024, the FASB issued ASU 2024-03, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%"&gt;Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt; (&#x201c;ASU 2024-03&#x201d;). This update requires entities to include more detailed information about the types of expenses, including purchases of inventory, employee compensation, depreciation, amortization, and depletion, in commonly presented expense captions such as cost of sales, research and development, and selling, general and administrative expenses. ASU 2024-03 is effective for annual periods beginning after December 15, 2026, with early adoption permitted. The company is currently evaluating the impact of this standard on its financial statement presentation and disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:107%"&gt;Recently Adopted Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In November 2023, the FASB issued ASU No. 2023-07, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; (ASU 2023-07), which requires public entities to disclose significant segment expenses that are regularly provided to the Chief Operating Decision Maker (CODM) and details of how the CODM uses financial reporting to assess the performance of a segment. The Company adopted this pronouncement in 2024 and retrospectively to all prior periods using the significant segment expense categories identified. The impact of the adoption of the amendments in this update was not material to the Company&#x2019;s financial position and results of operations, as the requirements impact only segment reporting disclosures in the footnotes to the Company&#x2019;s financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="c-1" id="f-257">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Concentration of Credit Risk and Other Risk and Uncertainties&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Financial instruments that potentially subject the Company to credit risk consist principally of cash, cash equivalents and accounts receivable. Substantially all the Company's cash and cash equivalents are held at one financial institution that management believes is of high credit quality. Such deposits may, at times, exceed federally insured limits. The Company has not experienced any losses on its cash or cash equivalents.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock contextRef="c-1" id="f-258">For each significant payor and customer, &lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;revenue as a percentage of total revenue and accounts receivable as a percentage of total accounts receivable are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.707%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.765%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.768%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medicare Advantage&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;United Healthcare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:2.847%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:3.724%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:90.129%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less than 10%.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.707%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.765%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.768%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accounts Receivable&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medicare Advantage&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-24" decimals="2" id="f-259" unitRef="number">0.25</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-25" decimals="2" id="f-260" unitRef="number">0.34</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-26" decimals="2" id="f-261" unitRef="number">0.20</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-27" decimals="2" id="f-262" unitRef="number">0.17</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-28" decimals="2" id="f-263" unitRef="number">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-29" decimals="2" id="f-264" unitRef="number">0.25</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-30" decimals="2" id="f-265" unitRef="number">0.16</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-31" decimals="2" id="f-266" unitRef="number">0.13</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-32" decimals="2" id="f-267" unitRef="number">0.42</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-33" decimals="2" id="f-268" unitRef="number">0.91</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-34" decimals="2" id="f-269" unitRef="number">0.88</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-35" decimals="2" id="f-270" unitRef="number">0.71</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-36" decimals="2" id="f-271" unitRef="number">0.26</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-37" decimals="2" id="f-272" unitRef="number">0.66</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-38" decimals="2" id="f-273" unitRef="number">0.30</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:DisaggregationOfRevenueTableTextBlock contextRef="c-1" id="f-274">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table includes the Company's revenues as disaggregated by payor and customer category (in&#160;thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.707%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.765%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.768%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Commercial&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Government&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Client(1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11,360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,949&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other(2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;55,641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;52,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:31.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.24pt"&gt;Includes hospitals, other laboratories, etc.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:31.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.24pt"&gt;Includes patient self-pay.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-39" decimals="-3" id="f-275" unitRef="usd">29600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-40" decimals="-3" id="f-276" unitRef="usd">23985000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-41" decimals="-3" id="f-277" unitRef="usd">14323000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-42" decimals="-3" id="f-278" unitRef="usd">18002000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-43" decimals="-3" id="f-279" unitRef="usd">11360000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-44" decimals="-3" id="f-280" unitRef="usd">9949000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-45" decimals="-3" id="f-281" unitRef="usd">358000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-46" decimals="-3" id="f-282" unitRef="usd">612000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-1" decimals="-3" id="f-283" unitRef="usd">55641000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-7" decimals="-3" id="f-284" unitRef="usd">52548000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="c-1" id="f-285">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Cash, Cash Equivalents and Restricted Cash&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company considers all highly-liquid investments purchased with a remaining maturity date of three months or less upon acquisition to be cash equivalents. These investments are stated at cost, which approximates fair value.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:RestrictedCash contextRef="c-5" decimals="-5" id="f-286" unitRef="usd">200000</us-gaap:RestrictedCash>
    <us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock contextRef="c-1" id="f-288">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Cash, cash equivalents and restricted cash presented in the accompanying statements of cash flows consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.707%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.765%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.768%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22,036&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;36,493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;36,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock contextRef="c-1" id="f-287">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Cash, cash equivalents and restricted cash presented in the accompanying statements of cash flows consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.707%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.765%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.768%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22,036&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;36,493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;36,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-5" decimals="-3" id="f-289" unitRef="usd">22036000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-6" decimals="-3" id="f-290" unitRef="usd">36493000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCash contextRef="c-5" decimals="-3" id="f-291" unitRef="usd">200000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash contextRef="c-6" decimals="-3" id="f-292" unitRef="usd">200000</us-gaap:RestrictedCash>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-5" decimals="-3" id="f-293" unitRef="usd">22236000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-6" decimals="-3" id="f-294" unitRef="usd">36693000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="c-1" id="f-295">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Property and equipment are stated at cost, net of depreciation and amortization. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally between &lt;span style="-sec-ix-hidden:f-296"&gt;three&lt;/span&gt; and five years. Leasehold improvements are amortized on a straight-line basis over the lesser of the estimated useful life or the remaining term of the related lease. Maintenance and repairs are charged to expense as incurred, and improvements and betterments are capitalized. When assets are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the balance sheet and any resulting gain or loss is reflected in operating expenses in the statements of operations in the period realized.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-48" id="f-297">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="c-1" id="f-298">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Long-lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company&#x2019;s long-lived assets are comprised principally of its property and equipment and operating lease assets. The Company amortizes all finite lived intangible assets over their respective estimated useful lives. Operating lease assets are amortized over the term of the leases. In considering whether long-lived assets are impaired, the Company combines its long-lived assets into groupings, a determination which is made principally on the basis of whether the assets are specific to a particular test offered or technology being developed. If the Company identifies a change in the circumstances related to its long-lived assets that indicates the carrying value of any such asset may not be recoverable, the Company will perform an impairment analysis. A long-lived asset is deemed to be impaired when the undiscounted cash flows expected to be generated by the asset (or asset group) are less than the asset&#x2019;s carrying amount. Management&#x2019;s estimates of future cash flows are impacted by projected test volume and levels of reimbursement, as well as expectations related to the future cost structure of the entity. Any required impairment loss would be measured as the amount by which the asset&#x2019;s carrying value exceeds its fair value, and would be recorded as a reduction in the carrying value of the related asset and a charge to operating expense.&lt;/span&gt;&lt;/div&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="c-1" id="f-299">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company categorizes leases at their commencement as either operating or finance leases. The Company recognizes operating lease ROU assets and operating lease liabilities for each lease arrangement identified. Lease liabilities are recorded at the present value of future lease payments discounted using the Company's incremental borrowing rate for the lease established at the commencement date. The incremental borrowing rate is the rate of interest the Company would have to pay to borrow, on a collateralized basis over a similar term and in a similar economic environment, an amount equal to the total lease payments. The Company primarily considers industry data, its credit rating and the lease term to determine its incremental borrowing rate. ROU assets are measured at the amount of the lease liability plus any initial direct costs, less any lease incentives received before commencement. Lease expense is recognized as a single lease cost over the lease term on a straight-line basis. The Company has elected not to apply the recognition requirements to short-term leases and not to separate non-lease components from lease components for its leases.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <exdx:ClinicalStudyPolicyPolicyTextBlock contextRef="c-1" id="f-300">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Clinical Studies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;From time to time, the Company engages in efforts to scientifically measure and document the application and efficacy of its various testing products. These arrangements typically require the Company to pay a fee to a third-party scientific investigator (usually a physician or research institution) for each subject enrolled in a clinical study, and the Company accrues expenses based on estimated progress of services performed, including actual level of subjects enrolled and progress of the clinical studies. Payments made prior to the completion of clinical study services are capitalized as a prepaid expense. The prepaid amounts are expensed as the related goods are delivered or the services are performed, or when it is no longer expected that the goods will be delivered or the services rendered. Expenses associated with clinical study activities are recorded in research and development expenses in the accompanying statement of operations.&lt;/span&gt;&lt;/div&gt;</exdx:ClinicalStudyPolicyPolicyTextBlock>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="c-1" id="f-301">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Substantially all of the Company's revenue has been derived from sales of its testing products and is primarily comprised of a high volume of relatively low-dollar transactions. The Company primarily markets its testing products to rheumatologists and their physician assistants in the United States. The healthcare professionals who order the Company's testing products and to whom test results are reported are generally not responsible for payment for these products. The parties that pay for these services (each, a payor) consist of commercial payors (healthcare insurers), government payors (primarily Medicare and Medicaid), client payors (hospitals, other laboratories, etc.) and patient self-pay. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company recognizes revenue in accordance with Accounting Standards Codification Topic 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; and follows a five-step process to determine the amount and timing of revenue recognized: (1) identify the contract with the customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to performance obligations in the contract, and (5) recognize revenue when (or as) the performance obligation is satisfied. The Company's service is a single performance obligation that is completed upon the delivery of test results to the prescribing physician which triggers revenue recognition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Payors are generally billed at the Company's list price, unless a separate pricing contract is in place. Net revenues recognized consist of amounts billed net of allowances for differences between amounts billed and the estimated consideration the Company expects to receive from such payors. The process for estimating revenues and the ultimate collection of accounts receivable involves significant judgment and estimation. The Company follows a standard process, which considers historical denial and collection experience, insurance reimbursement policies and other factors, to estimate allowances and implicit price concessions. Adjustments are recorded in the current period as changes in estimates occur. Further adjustments to the allowances, based on actual receipts, are recorded upon settlement. Included in revenues for the years ended December&#160;31, 2024 and 2023 were net revenue increases of $6.6 million and $3.4 million, respectively, associated with changes in estimated variable consideration related to performance obligations satisfied in previous periods. The transaction price is estimated using an expected value method on a portfolio basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Variable consideration is included in the transaction price only to the extent it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainties with respect to the amount are resolved. The Company's portfolios are grouped per payor (i.e. each individual commercial payor, Medicare, Medicaid, client payors, patient self-pay, etc.) and per test. Consideration may be constrained and excluded from the transaction price in situations where there is no contractually agreed upon reimbursement coverage or in absence of a predictable pattern and history of collectability with a payor. Accordingly, in such situations revenues are recognized on the basis of actual cash collections. Additionally, from time to time, the Company may issue refunds to payors for overpayments or amounts billed in error. Any refunds are accounted for as reductions in revenues in the statement of operations as an element of variable consideration. The estimated expected refunds are accrued as a liability on the Company&#x2019;s balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Collection of the Company's net revenues from payors is normally a function of providing complete and correct billing information, along with any requested medical or other claims-related information to the healthcare insurers. This generally occurs within 30 to 90 days of billing, however, the amount and timing of any reimbursements or collections for the Company's billed tests may vary by payor and other circumstances. Contracts do not contain significant financing components based on the typical period of time between performance of services and collection of consideration.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized contextRef="c-1" decimals="-5" id="f-302" unitRef="usd">6600000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized contextRef="c-7" decimals="-5" id="f-303" unitRef="usd">3400000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ReceivablesPolicyTextBlock contextRef="c-1" id="f-304">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Accounts Receivable and Allowance for Credit Losses&lt;/span&gt;&lt;/div&gt;We accrue an allowance for credit losses against our accounts receivable based on management&#x2019;s current estimate of amounts that will not be collected. Management&#x2019;s estimates are typically based on historical loss information adjusted for current conditions. We generally do not perform evaluations of the financial condition of our customers and generally do not require collateral. The allowance for credit losses was zero as of each of December&#160;31, 2024 and 2023. Adjustments for implicit price concessions attributable to variable consideration, as discussed above, are incorporated into the measurement of the accounts receivable balances and are not part of the allowance for credit losses.</us-gaap:ReceivablesPolicyTextBlock>
    <us-gaap:FinancingReceivableAllowanceForCreditLossExcludingAccruedInterest contextRef="c-5" decimals="-5" id="f-305" unitRef="usd">0</us-gaap:FinancingReceivableAllowanceForCreditLossExcludingAccruedInterest>
    <us-gaap:FinancingReceivableAllowanceForCreditLossExcludingAccruedInterest contextRef="c-6" decimals="-5" id="f-306" unitRef="usd">0</us-gaap:FinancingReceivableAllowanceForCreditLossExcludingAccruedInterest>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-5" decimals="-5" id="f-307" unitRef="usd">7800000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-6" decimals="-5" id="f-308" unitRef="usd">6600000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-11" decimals="-5" id="f-309" unitRef="usd">6100000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="c-1" id="f-310">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Research and Development&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Costs associated with research and development activities are expensed as incurred and include, but are not limited to, personnel-related expenses, including stock-based compensation expense; materials; laboratory &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;supplies; consulting costs; costs associated with setting up and conducting clinical studies; depreciation; amortization and allocated overhead, including rent and utilities.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:AdvertisingCostsPolicyTextBlock contextRef="c-1" id="f-311">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Advertising and Marketing Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Costs associated with advertising and marketing activities are expensed as incurred. Total advertising and marketing costs were approximately $1.4 million and $1.5 million for the years ended December&#160;31, 2024 and 2023, respectively, and are included in selling, general and administrative expenses in the accompanying statements of operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:AdvertisingCostsPolicyTextBlock>
    <us-gaap:AdvertisingExpense contextRef="c-1" decimals="-5" id="f-312" unitRef="usd">1400000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense contextRef="c-7" decimals="-5" id="f-313" unitRef="usd">1500000</us-gaap:AdvertisingExpense>
    <us-gaap:CostOfSalesPolicyTextBlock contextRef="c-1" id="f-314">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Shipping and Handling Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Costs incurred for shipping and handling are included in costs of revenue in the accompanying statements of operations and were approximately $3.1 million and $2.5 million for the years ended December&#160;31, 2024 and 2023, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:CostOfSalesPolicyTextBlock>
    <us-gaap:CostOfRevenue contextRef="c-49" decimals="-5" id="f-315" unitRef="usd">3100000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue contextRef="c-50" decimals="-5" id="f-316" unitRef="usd">2500000</us-gaap:CostOfRevenue>
    <us-gaap:EmployeeStockOwnershipPlanESOPPolicy contextRef="c-1" id="f-317">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company recognizes compensation expense for all stock-based awards to employees and directors based on the grant-date estimated fair values over the requisite service period of the awards (usually the vesting period) on a straight-line basis. Equity award forfeitures are recorded as they occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The fair value of each restricted stock unit (RSU) is determined on the grant date using the closing price of the Company's common stock on that date. The Company's RSUs generally vest in equal annual installments over four years from the date of grant or, for grants to new hires, date of hire. Vesting of the RSU is subject to the holder's continued service with the Company. The Company issues new shares of common stock to satisfy the RSUs upon vesting.&lt;/span&gt;&lt;/div&gt;</us-gaap:EmployeeStockOwnershipPlanESOPPolicy>
    <exdx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments
      contextRef="c-1"
      decimals="INF"
      id="f-318"
      unitRef="installment">4</exdx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="c-1" id="f-319">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Comprehensive Loss&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Comprehensive loss is defined as a change in equity of a business enterprise during a period, resulting from transactions from nonowner sources. There have been no items qualifying as other comprehensive loss and, therefore, for all periods presented, the Company's comprehensive loss was the same as its reported net loss.&lt;/span&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="c-1" id="f-320">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized as an expense in the period that includes the enactment date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company recognizes net deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If management determines that the Company would be able to realize its deferred tax assets in the future in excess of their net recorded amount, management would adjust the deferred tax asset valuation allowance, which would reduce the provision for income taxes. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company records uncertain tax positions on the basis of a two-step process whereby (i) management determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (ii) for those tax positions that meet the more-likely-than-not recognition threshold, management recognizes the largest amount of tax benefit that is more than 50% likely to be realized upon ultimate settlement with the related tax authority. The Company recognizes interest and penalties related to unrecognized tax benefits within income tax expense. Any accrued interest and penalties are included within the related tax liability.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c-1" id="f-321">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Net Loss Per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Basic net loss per share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common stock outstanding during the period. Diluted net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;stockholders by the weighted-average number of common stock equivalents outstanding for the period determined using the treasury-stock and if-converted methods. The weighted-average number of shares used to compute basic and diluted shares includes shares issuable upon the exercise of pre-funded warrants at a nominal price. Potentially dilutive common stock equivalents are comprised of warrants for the purchase of common stock, stock options, RSUs outstanding under the Company's 2019 Incentive Award Plan (the 2019 Plan) and shares of the Company's common stock pursuant to the Exagen Inc. 2019 Employee Stock Purchase Plan (ESPP). For each of the years ended December&#160;31, 2024 and 2023, there is no difference in the number of shares used to calculate basic and diluted shares outstanding as the inclusion of the potentially dilutive securities would be antidilutive.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="c-1" id="f-322">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Potentially dilutive securities not included in the calculation of diluted net loss per share, because to do so would be anti-dilutive, are as follows (in common stock equivalent shares):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.707%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.765%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.768%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Warrants to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;325,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;409,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;489,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;986,819&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,710,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,387,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee stock purchase plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;57,461&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,582,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,828,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-51" decimals="0" id="f-323" unitRef="shares">325330</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-52" decimals="0" id="f-324" unitRef="shares">409108</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-53" decimals="0" id="f-325" unitRef="shares">489296</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-54" decimals="0" id="f-326" unitRef="shares">986819</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-55" decimals="0" id="f-327" unitRef="shares">1710373</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-56" decimals="0" id="f-328" unitRef="shares">1387459</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-57" decimals="0" id="f-329" unitRef="shares">57461</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-58" decimals="0" id="f-330" unitRef="shares">44700</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-1" decimals="0" id="f-331" unitRef="shares">2582460</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-7" decimals="0" id="f-332" unitRef="shares">2828086</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c-1" id="f-333">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB), or other standard setting bodies and adopted by the Company as of the specified effective date. Unless otherwise discussed, Accounting Standards Updates (ASU) not included in the Company&#x2019;s disclosures were assessed and determined to be either not applicable or are not expected to have a material impact on the Company&#x2019;s financial statements or disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;In December 2023, the FASB issued ASU 2023-09,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%"&gt; Income Taxes (Topic 740): Improvements to Income Tax Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt; (ASU 2023-09), which requires additional income tax disclosures in the rate reconciliation table for federal, state and foreign income taxes, in addition to more details about the reconciling items in some categories when items meet a certain quantitative threshold. ASU 2023-09 is effective for annual periods beginning after December 15, 2024 with early adoption permitted. This update will result in enhanced income tax disclosures, and the Company does not expect any impact to income tax expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;In November 2024, the FASB issued ASU 2024-03, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%"&gt;Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt; (&#x201c;ASU 2024-03&#x201d;). This update requires entities to include more detailed information about the types of expenses, including purchases of inventory, employee compensation, depreciation, amortization, and depletion, in commonly presented expense captions such as cost of sales, research and development, and selling, general and administrative expenses. ASU 2024-03 is effective for annual periods beginning after December 15, 2026, with early adoption permitted. The company is currently evaluating the impact of this standard on its financial statement presentation and disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:107%"&gt;Recently Adopted Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In November 2023, the FASB issued ASU No. 2023-07, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; (ASU 2023-07), which requires public entities to disclose significant segment expenses that are regularly provided to the Chief Operating Decision Maker (CODM) and details of how the CODM uses financial reporting to assess the performance of a segment. The Company adopted this pronouncement in 2024 and retrospectively to all prior periods using the significant segment expense categories identified. The impact of the adoption of the amendments in this update was not material to the Company&#x2019;s financial position and results of operations, as the requirements impact only segment reporting disclosures in the footnotes to the Company&#x2019;s financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <exdx:PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock contextRef="c-1" id="f-336">Other Financial Information&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Prepaid Expenses and Other Current Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Prepaid expenses and other current assets consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.707%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.765%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.768%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Diagnostic&#160;testing&#160;supplies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,797&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Property and Equipment, net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Property and equipment consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.707%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.765%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.768%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Furniture&#160;and&#160;fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less: accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6,012)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,769)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Depreciation and amortization expense for the years ended December&#160;31, 2024 and 2023, was approximately $1.7 million and $2.2 million, respectively. At December&#160;31, 2024 and 2023, the gross book value of assets under finance leases was $2.0 million and $2.5 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Loss on Lease Assignment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On October 24, 2023, the Company entered into an assignment and assumption (the Assignment and Assumption Agreement) of the Company&#x2019;s previously executed lease agreement with Liberty Vista, LP (formerly known as Geiger Court, LLC) and Mindera Corporation (Mindera), pursuant to which the Company assigned to Mindera the lease of a building located adjacent to the Company's headquarters in Vista, CA. Under the terms of the Assignment and Assumption Agreement, Mindera assumed all obligations under the lease, effective October 31, 2023. As a result of the lease assignment, the Company derecognized the remaining balances related to the associated operating lease ROU asset of $0.7&#160;million, operating lease liability of $0.8&#160;million and leasehold improvements of $1.6&#160;million, resulting in a $1.5 million loss on lease assignment. The loss was classified within selling, general and administrative expenses in the accompanying statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Accrued and Other Current Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Accrued and other current liabilities consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.707%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.765%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.768%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued&#160;payroll&#160;and&#160;related&#160;expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</exdx:PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock>
    <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock contextRef="c-1" id="f-337">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Prepaid expenses and other current assets consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.707%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.765%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.768%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Diagnostic&#160;testing&#160;supplies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,797&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
    <us-gaap:OtherAssetsCurrent contextRef="c-5" decimals="-3" id="f-338" unitRef="usd">5725000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="c-6" decimals="-3" id="f-339" unitRef="usd">2871000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent contextRef="c-5" decimals="-3" id="f-340" unitRef="usd">859000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent contextRef="c-6" decimals="-3" id="f-341" unitRef="usd">1926000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-5" decimals="-3" id="f-342" unitRef="usd">6584000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-6" decimals="-3" id="f-343" unitRef="usd">4797000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="c-1" id="f-344">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Property and equipment consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.707%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.765%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.768%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Furniture&#160;and&#160;fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less: accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6,012)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,769)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization contextRef="c-59" decimals="-3" id="f-345" unitRef="usd">105000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization contextRef="c-60" decimals="-3" id="f-346" unitRef="usd">98000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization contextRef="c-61" decimals="-3" id="f-347" unitRef="usd">4248000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization contextRef="c-62" decimals="-3" id="f-348" unitRef="usd">5312000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization contextRef="c-63" decimals="-3" id="f-349" unitRef="usd">2113000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization contextRef="c-64" decimals="-3" id="f-350" unitRef="usd">2185000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization contextRef="c-65" decimals="-3" id="f-351" unitRef="usd">3286000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization contextRef="c-66" decimals="-3" id="f-352" unitRef="usd">3316000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization contextRef="c-67" decimals="-3" id="f-353" unitRef="usd">1543000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization contextRef="c-68" decimals="-3" id="f-354" unitRef="usd">59000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization contextRef="c-5" decimals="-3" id="f-355" unitRef="usd">11295000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization contextRef="c-6" decimals="-3" id="f-356" unitRef="usd">10970000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization contextRef="c-5" decimals="-3" id="f-357" unitRef="usd">6012000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization contextRef="c-6" decimals="-3" id="f-358" unitRef="usd">5769000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization contextRef="c-5" decimals="-3" id="f-359" unitRef="usd">5283000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization contextRef="c-6" decimals="-3" id="f-360" unitRef="usd">5201000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-1" decimals="-5" id="f-361" unitRef="usd">1700000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-7" decimals="-5" id="f-362" unitRef="usd">2200000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization contextRef="c-5" decimals="-5" id="f-363" unitRef="usd">2000000.0</us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization contextRef="c-6" decimals="-5" id="f-364" unitRef="usd">2500000</us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-69" decimals="-5" id="f-365" unitRef="usd">700000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-69" decimals="-5" id="f-366" unitRef="usd">800000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LeaseholdImprovementsGross contextRef="c-69" decimals="-5" id="f-367" unitRef="usd">1600000</us-gaap:LeaseholdImprovementsGross>
    <exdx:GainLossOnDispositionOfLeaseAssignment contextRef="c-7" decimals="-5" id="f-368" unitRef="usd">-1500000</exdx:GainLossOnDispositionOfLeaseAssignment>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="c-1" id="f-369">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Accrued and other current liabilities consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.707%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.765%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.768%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued&#160;payroll&#160;and&#160;related&#160;expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccruedSalariesCurrent contextRef="c-5" decimals="-3" id="f-370" unitRef="usd">5046000</us-gaap:AccruedSalariesCurrent>
    <us-gaap:AccruedSalariesCurrent contextRef="c-6" decimals="-3" id="f-371" unitRef="usd">4738000</us-gaap:AccruedSalariesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c-5" decimals="-3" id="f-372" unitRef="usd">2804000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c-6" decimals="-3" id="f-373" unitRef="usd">2793000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-5" decimals="-3" id="f-374" unitRef="usd">7850000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-6" decimals="-3" id="f-375" unitRef="usd">7531000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DebtDisclosureTextBlock contextRef="c-1" id="f-376">Borrowings&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;2017 Term Loan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In September 2017, the Company executed a term loan agreement (the 2017 Term Loan) with Innovatus Life Sciences Lending Fund I, LP (Innovatus), as amended (the Amended Loan Agreement), pursuant to which the Company borrowed $25.0&#160;million. At December&#160;31, 2024, no additional amounts remained available to borrow under the Amended Loan Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On April 28, 2023, the Company entered into the Amended Loan Agreement. The Amended Loan Agreement was treated as a modification. In connection with the Amended Loan Agreement, the Company repaid $10.0&#160;million of &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;the principal balance outstanding, for which the prepayment premium was waived. Pursuant to the Amended Loan Agreement, the interest rate on all borrowings under the Amended Loan Agreement is the sum (the Basic Rate) of (a) the greater of 8.0% or The Wall Street Journal prime rate (the Prime Rate), plus (b) 2.0%, which is paid-in-kind in the form of additional term loans (PIK Loans). Under the Amended Loan Agreement, an amount equal to 1.5% of the Basic Rate will be payable in-kind and capitalized to the principal amount of the outstanding term loan on a monthly basis until April 1, 2026, after which interest is scheduled to accrue at the Basic Rate. The maturity date of the loan was extended to December 31, 2026. The Company estimated the effective interest rate of this loan to be approximately 10.6% and 11.0% as of December&#160;31, 2024 and 2023, respectively. Accrued interest is due and payable monthly, unless the Company elects to pay paid-in-kind interest. The outstanding principal and accrued interest under the Amended Loan Agreement is to be repaid in ten equal monthly installments commencing in April 2026. Upon repayment of the final installment under the Amended Loan Agreement, the Company is required to pay an additional fee of $1.0&#160;million. This obligation is being accreted into interest expense over the term of the loan using the effective interest method. For the years ended December&#160;31, 2024 and 2023, the Company issued PIK Loans totaling $0.3 million and $0.4 million, respectively. At December&#160;31, 2024, $18.5 million in principal and PIK loans are outstanding, all of which is included in borrowings-non-current portion on the accompanying balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Amended Loan Agreement is collateralized by a first priority security interest in substantially all of the Company's assets, including intellectual property. The affirmative covenants of the Amended Loan Agreement require that the Company timely file taxes, maintain good standing and government compliance, maintain liability and other insurance, provide prompt notification of significant corporate events, and furnish audited financial statements within 150 days of fiscal year end without qualification as to the scope of the audit or as to going concern and without any other similar qualification.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The affirmative covenants require that the Company achieve a specified level of revenue, as measured quarterly on a rolling twelve-month basis, however the Company is not required to comply with the revenue covenant for any quarter during which it maintains a minimum aggregate cash balance equal to fifty percent of the aggregate principal amount of the Amended Loan Agreement (excluding any capitalized interest paid-in-kind) at all times during such quarter. The consequences of failing to achieve the performance covenants, when applicable, will be cured if, (i) within thirty days of failing to achieve the performance covenant, the Company submits a new financial plan approved by the Company's board of directors (the Board) to Innovatus under which the Company is expected to break even on a cash flow basis prior to the maturity date, and (ii) within thirty days of the submission of such financial plan, the Company issues additional equity securities or subordinated debt with net proceeds sufficient to fund any cash flow deficiency generated from operations, as defined in the Amended Loan Agreement. The Amended Loan Agreement requires that the Company maintain certain levels of minimum liquidity and maintains an unrestricted cash balance of $2.0 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The negative covenants provide, among other things, that without the prior consent of Innovatus, subject to certain exceptions, the Company may not dispose of certain assets, engage in certain business combinations or acquisitions, incur additional indebtedness or encumber any of the Company's property, pay dividends on the Company's capital stock or make prohibited investments. The Amended Loan Agreement provides that an event of default will occur if, among other triggers, (i)&#160;the Company defaults in the payment of any amount payable under the agreement when due, (ii)&#160;there occurs any circumstance(s) that could reasonably be expected to result in a material adverse effect on the Company's business, operations or condition, or on the Company's ability to perform its obligations under the agreement, (iii)&#160;the Company becomes insolvent, (iv)&#160;the Company undergoes a change in control or (v)&#160;the Company breaches any negative covenants or certain affirmative covenants in the agreement or, subject to a cure period, otherwise neglects to perform or observe any material item in the agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2024, the Company was in compliance with all covenants of the Amended Loan Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon an event of default in any of the Amended Loan Agreement covenants, the repayment of the 2017 Term Loan may be accelerated, and the applicable interest rate will be increased by 4.0% until the default is cured. Although repayment of the 2017 Term Loan can be accelerated under certain circumstances, the Company believes acceleration of this loan is not probable as of the date of these financial statements. Accordingly, the Company has reflected the amounts of the Amended Loan Agreement due beyond twelve months of the balance sheet date as non-current.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Equipment Notes Payable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company has purchased laboratory equipment in the normal course of business using notes payable. At December&#160;31, 2024, the total notes payable balance related to the financed equipment was $1.1&#160;million, with &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$0.4&#160;million classified within borrowings-current portion and $0.7&#160;million within borrowings-non-current portion, net of discounts and debt issuance costs in the accompanying balance sheets. At December 31, 2023, the total notes payable balance related to this financed equipment was $0.8&#160;million, with $0.3&#160;million classified within borrowings-current portion and $0.5&#160;million within borrowings-non-current portion, net of discounts and debt issuance costs in the accompanying balance sheets. The financed equipment is subject to effective interest rates between 5.28% and 10.50%, and will mature between October 1, 2026 and April 1, 2028.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Future Minimum Payments on Outstanding Borrowings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As of December&#160;31, 2024, future minimum aggregate payments, including interest, for outstanding borrowings are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.303%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.767%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23,758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unamortized debt discount and issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(70)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3,443)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total borrowings, net of discounts and debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less: Borrowings-current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(423)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Borrowings-non-current portion, net of discounts and debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19,822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt contextRef="c-70" decimals="-5" id="f-377" unitRef="usd">25000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity contextRef="c-71" decimals="0" id="f-378" unitRef="usd">0</us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity>
    <us-gaap:RepaymentsOfLongTermDebt contextRef="c-72" decimals="-5" id="f-379" unitRef="usd">10000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-72"
      decimals="INF"
      id="f-380"
      unitRef="number">0.080</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="c-73" decimals="2" id="f-381" unitRef="number">0.020</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <exdx:DebtInstrumentStatedInterestRatePaidInKind contextRef="c-73" decimals="3" id="f-382" unitRef="number">0.015</exdx:DebtInstrumentStatedInterestRatePaidInKind>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="c-71" decimals="3" id="f-383" unitRef="number">0.106</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="c-74" decimals="3" id="f-384" unitRef="number">0.110</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <exdx:DebtInstrumentNumberOfMonthlyInstallments
      contextRef="c-75"
      decimals="INF"
      id="f-385"
      unitRef="installment">10</exdx:DebtInstrumentNumberOfMonthlyInstallments>
    <us-gaap:DebtInstrumentFeeAmount contextRef="c-71" decimals="-5" id="f-386" unitRef="usd">1000000</us-gaap:DebtInstrumentFeeAmount>
    <exdx:DebtInstrumentPaidInKindLoansIssued contextRef="c-76" decimals="-5" id="f-387" unitRef="usd">300000</exdx:DebtInstrumentPaidInKindLoansIssued>
    <exdx:DebtInstrumentPaidInKindLoansIssued contextRef="c-77" decimals="-5" id="f-388" unitRef="usd">400000</exdx:DebtInstrumentPaidInKindLoansIssued>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-78" decimals="-5" id="f-389" unitRef="usd">18500000</us-gaap:LongTermDebtNoncurrent>
    <exdx:DebtInstrumentCovenantRevenuePerformancePeriod contextRef="c-75" id="f-390">P12M</exdx:DebtInstrumentCovenantRevenuePerformancePeriod>
    <exdx:DebtInstrumentMinimumCashBalanceRequiredNotRequiredToComplyWithCovenant contextRef="c-75" decimals="2" id="f-391" unitRef="number">0.50</exdx:DebtInstrumentMinimumCashBalanceRequiredNotRequiredToComplyWithCovenant>
    <exdx:DebtInstrumentCovenantNumberOfDaysToCureIfPerformanceMeasureIsNotMet contextRef="c-75" id="f-392">P30D</exdx:DebtInstrumentCovenantNumberOfDaysToCureIfPerformanceMeasureIsNotMet>
    <exdx:DebtInstrumentCovenantNumberOfDaysToCureIfPerformanceMeasureIsNotMet contextRef="c-75" id="f-393">P30D</exdx:DebtInstrumentCovenantNumberOfDaysToCureIfPerformanceMeasureIsNotMet>
    <exdx:DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance contextRef="c-71" decimals="-5" id="f-394" unitRef="usd">2000000.0</exdx:DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance>
    <exdx:DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease contextRef="c-79" decimals="3" id="f-395" unitRef="number">0.040</exdx:DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease>
    <us-gaap:NotesPayable contextRef="c-80" decimals="-5" id="f-396" unitRef="usd">1100000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableCurrent contextRef="c-80" decimals="-5" id="f-397" unitRef="usd">400000</us-gaap:NotesPayableCurrent>
    <us-gaap:LongTermNotesPayable contextRef="c-80" decimals="-5" id="f-398" unitRef="usd">700000</us-gaap:LongTermNotesPayable>
    <us-gaap:NotesPayable contextRef="c-81" decimals="-5" id="f-399" unitRef="usd">800000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableCurrent contextRef="c-81" decimals="-5" id="f-400" unitRef="usd">300000</us-gaap:NotesPayableCurrent>
    <us-gaap:LongTermNotesPayable contextRef="c-81" decimals="-5" id="f-401" unitRef="usd">500000</us-gaap:LongTermNotesPayable>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="c-82" decimals="4" id="f-402" unitRef="number">0.0528</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="c-83" decimals="4" id="f-403" unitRef="number">0.1050</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock contextRef="c-1" id="f-404">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As of December&#160;31, 2024, future minimum aggregate payments, including interest, for outstanding borrowings are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.303%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.767%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23,758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unamortized debt discount and issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(70)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3,443)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total borrowings, net of discounts and debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less: Borrowings-current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(423)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Borrowings-non-current portion, net of discounts and debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19,822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths contextRef="c-5" decimals="-3" id="f-405" unitRef="usd">2076000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo contextRef="c-5" decimals="-3" id="f-406" unitRef="usd">21400000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree contextRef="c-5" decimals="-3" id="f-407" unitRef="usd">215000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour contextRef="c-5" decimals="-3" id="f-408" unitRef="usd">67000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <exdx:LongTermDebtIncludingUndiscountedInterest contextRef="c-5" decimals="-3" id="f-409" unitRef="usd">23758000</exdx:LongTermDebtIncludingUndiscountedInterest>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet contextRef="c-5" decimals="-3" id="f-410" unitRef="usd">70000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <exdx:LongTermDebtUndiscountedInterestAmount contextRef="c-5" decimals="-3" id="f-411" unitRef="usd">3443000</exdx:LongTermDebtUndiscountedInterestAmount>
    <us-gaap:LongTermDebt contextRef="c-5" decimals="-3" id="f-412" unitRef="usd">20245000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebtCurrent contextRef="c-5" decimals="-3" id="f-413" unitRef="usd">423000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-5" decimals="-3" id="f-414" unitRef="usd">19822000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="c-1" id="f-416">Leases&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Operating Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company leases office and laboratory space located in Vista, California. The lease expires in April 2027, with an option to extend portions of the lease for additional 5-year periods. The Company has not included the optional renewal periods in the measurement of the lease liability, because it is not reasonably certain that the Company will exercise these renewal options. The Company's payments under the lease are subject to escalation clauses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company leases additional office space in Carlsbad, California, under a sublease which commenced in October 2021 and expires in April 2027. Monthly base rent under the sublease agreement is $72,143. The monthly base rent increases by approximately 3% annually, each October 1, through the remainder of the lease term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Finance Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company has entered into various finance lease agreements to obtain laboratory equipment. The terms of the Company's finance leases generally range from &lt;span style="-sec-ix-hidden:f-420"&gt;three&lt;/span&gt; to five years and are typically secured by the underlying equipment. The portion of the future payments designated as principal repayments were classified as finance lease liabilities on the Company's balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Operating and Finance Leases Balances and Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Operating and finance leases consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:25.361%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.969%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:29.163%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.969%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.783%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.969%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.786%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Lease Balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Lease Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Finance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-425"&gt;&lt;span style="-sec-ix-hidden:f-426"&gt;Property and equipment, net&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Lease Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,096&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Finance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-431"&gt;&lt;span style="-sec-ix-hidden:f-432"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-current operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Finance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-437"&gt;&lt;span style="-sec-ix-hidden:f-438"&gt;Other non-current liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Costs associated with the Company's leases were included in the statements of operations as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:56.794%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.969%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.783%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.969%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.785%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Lease Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Finance lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amortization of lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;556&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest on finance lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;128&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;(1) Includes variable lease cost of $196,000 and $129,000 for the years ended December&#160;31, 2024 and 2023, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Supplemental cash flow information on leases is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:56.794%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.969%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.783%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.969%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.785%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cash paid for amounts included in the measurement of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating cash out flows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating cash out flows from interest paid on finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Financing cash out flows from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Information regarding the weighted-average lease term and weighted average discount rate are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:56.940%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.408%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.783%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.785%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.76&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.06&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Future payments under operating and finance leases as of December&#160;31, 2024 are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.917%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.408%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.783%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.408%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.784%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Finance Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,037&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(277)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(65)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less: current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,096)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(201)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Lease obligations, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeFinanceLeasesTextBlock contextRef="c-1" id="f-415">Leases&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Operating Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company leases office and laboratory space located in Vista, California. The lease expires in April 2027, with an option to extend portions of the lease for additional 5-year periods. The Company has not included the optional renewal periods in the measurement of the lease liability, because it is not reasonably certain that the Company will exercise these renewal options. The Company's payments under the lease are subject to escalation clauses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company leases additional office space in Carlsbad, California, under a sublease which commenced in October 2021 and expires in April 2027. Monthly base rent under the sublease agreement is $72,143. The monthly base rent increases by approximately 3% annually, each October 1, through the remainder of the lease term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Finance Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company has entered into various finance lease agreements to obtain laboratory equipment. The terms of the Company's finance leases generally range from &lt;span style="-sec-ix-hidden:f-420"&gt;three&lt;/span&gt; to five years and are typically secured by the underlying equipment. The portion of the future payments designated as principal repayments were classified as finance lease liabilities on the Company's balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Operating and Finance Leases Balances and Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Operating and finance leases consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:25.361%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.969%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:29.163%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.969%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.783%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.969%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.786%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Lease Balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Lease Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Finance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-425"&gt;&lt;span style="-sec-ix-hidden:f-426"&gt;Property and equipment, net&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Lease Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,096&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Finance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-431"&gt;&lt;span style="-sec-ix-hidden:f-432"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-current operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Finance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-437"&gt;&lt;span style="-sec-ix-hidden:f-438"&gt;Other non-current liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Costs associated with the Company's leases were included in the statements of operations as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:56.794%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.969%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.783%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.969%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.785%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Lease Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Finance lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amortization of lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;556&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest on finance lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;128&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;(1) Includes variable lease cost of $196,000 and $129,000 for the years ended December&#160;31, 2024 and 2023, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Supplemental cash flow information on leases is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:56.794%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.969%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.783%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.969%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.785%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cash paid for amounts included in the measurement of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating cash out flows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating cash out flows from interest paid on finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Financing cash out flows from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Information regarding the weighted-average lease term and weighted average discount rate are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:56.940%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.408%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.783%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.785%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.76&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.06&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Future payments under operating and finance leases as of December&#160;31, 2024 are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.917%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.408%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.783%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.408%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.784%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Finance Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,037&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(277)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(65)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less: current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,096)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(201)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Lease obligations, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeFinanceLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseRenewalTerm contextRef="c-84" id="f-417">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <exdx:OperatingLeaseMonthlyBaseRent contextRef="c-85" decimals="0" id="f-418" unitRef="usd">72143</exdx:OperatingLeaseMonthlyBaseRent>
    <exdx:OperatingLeaseAnnualIncreaseInBaseRentPaymentPercent contextRef="c-86" decimals="2" id="f-419" unitRef="number">0.03</exdx:OperatingLeaseAnnualIncreaseInBaseRentPaymentPercent>
    <us-gaap:LesseeFinanceLeaseTermOfContract1 contextRef="c-48" id="f-421">P5Y</us-gaap:LesseeFinanceLeaseTermOfContract1>
    <us-gaap:LeaseCostTableTextBlock contextRef="c-1" id="f-422">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Operating and finance leases consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:25.361%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.969%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:29.163%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.969%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.783%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.969%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.786%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Lease Balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Lease Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Finance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-425"&gt;&lt;span style="-sec-ix-hidden:f-426"&gt;Property and equipment, net&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Lease Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,096&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Finance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-431"&gt;&lt;span style="-sec-ix-hidden:f-432"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-current operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Finance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-437"&gt;&lt;span style="-sec-ix-hidden:f-438"&gt;Other non-current liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Costs associated with the Company's leases were included in the statements of operations as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:56.794%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.969%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.783%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.969%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.785%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Lease Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Finance lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amortization of lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;556&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest on finance lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;128&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;(1) Includes variable lease cost of $196,000 and $129,000 for the years ended December&#160;31, 2024 and 2023, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Supplemental cash flow information on leases is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:56.794%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.969%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.783%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.969%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.785%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cash paid for amounts included in the measurement of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating cash out flows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating cash out flows from interest paid on finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Financing cash out flows from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Information regarding the weighted-average lease term and weighted average discount rate are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:56.940%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.408%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.783%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.785%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.76&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.06&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-5" decimals="-3" id="f-423" unitRef="usd">2401000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-6" decimals="-3" id="f-424" unitRef="usd">3286000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset contextRef="c-5" decimals="-3" id="f-427" unitRef="usd">486000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset contextRef="c-6" decimals="-3" id="f-428" unitRef="usd">810000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-5" decimals="-3" id="f-429" unitRef="usd">1096000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-6" decimals="-3" id="f-430" unitRef="usd">976000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent contextRef="c-5" decimals="-3" id="f-433" unitRef="usd">201000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent contextRef="c-6" decimals="-3" id="f-434" unitRef="usd">490000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-5" decimals="-3" id="f-435" unitRef="usd">1664000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-6" decimals="-3" id="f-436" unitRef="usd">2760000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent contextRef="c-5" decimals="-3" id="f-439" unitRef="usd">157000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent contextRef="c-6" decimals="-3" id="f-440" unitRef="usd">358000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseCost contextRef="c-1" decimals="-3" id="f-441" unitRef="usd">1345000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c-7" decimals="-3" id="f-442" unitRef="usd">1463000</us-gaap:OperatingLeaseCost>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization contextRef="c-1" decimals="-3" id="f-443" unitRef="usd">280000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization contextRef="c-7" decimals="-3" id="f-444" unitRef="usd">556000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseInterestExpense contextRef="c-1" decimals="-3" id="f-445" unitRef="usd">84000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense contextRef="c-7" decimals="-3" id="f-446" unitRef="usd">128000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:LeaseCost contextRef="c-1" decimals="-3" id="f-447" unitRef="usd">1709000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost contextRef="c-7" decimals="-3" id="f-448" unitRef="usd">2147000</us-gaap:LeaseCost>
    <us-gaap:VariableLeaseCost contextRef="c-1" decimals="-3" id="f-449" unitRef="usd">196000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost contextRef="c-7" decimals="-3" id="f-450" unitRef="usd">129000</us-gaap:VariableLeaseCost>
    <us-gaap:OperatingLeasePayments contextRef="c-1" decimals="-3" id="f-451" unitRef="usd">1240000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments contextRef="c-7" decimals="-3" id="f-452" unitRef="usd">1405000</us-gaap:OperatingLeasePayments>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability contextRef="c-1" decimals="-3" id="f-453" unitRef="usd">84000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability contextRef="c-7" decimals="-3" id="f-454" unitRef="usd">128000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeasePrincipalPayments contextRef="c-1" decimals="-3" id="f-455" unitRef="usd">490000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments contextRef="c-7" decimals="-3" id="f-456" unitRef="usd">697000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-5" id="f-457">P2Y3M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-6" id="f-458">P3Y3M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-5" id="f-459">P1Y9M3D</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-6" id="f-460">P2Y21D</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c-5" decimals="3" id="f-461" unitRef="number">0.080</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c-6" decimals="3" id="f-462" unitRef="number">0.080</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent contextRef="c-5" decimals="3" id="f-463" unitRef="number">0.173</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent contextRef="c-6" decimals="3" id="f-464" unitRef="number">0.122</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="c-1" id="f-466">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Future payments under operating and finance leases as of December&#160;31, 2024 are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.917%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.408%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.783%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.408%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.784%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Finance Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,037&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(277)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(65)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less: current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,096)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(201)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Lease obligations, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock contextRef="c-1" id="f-465">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Future payments under operating and finance leases as of December&#160;31, 2024 are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.917%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.408%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.783%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.408%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.784%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Finance Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,037&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(277)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(65)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less: current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,096)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(201)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Lease obligations, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="c-5" decimals="-3" id="f-467" unitRef="usd">1277000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="c-5" decimals="-3" id="f-468" unitRef="usd">248000</us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="c-5" decimals="-3" id="f-469" unitRef="usd">1315000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo contextRef="c-5" decimals="-3" id="f-470" unitRef="usd">147000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="c-5" decimals="-3" id="f-471" unitRef="usd">445000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree contextRef="c-5" decimals="-3" id="f-472" unitRef="usd">28000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="c-5" decimals="-3" id="f-473" unitRef="usd">3037000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:FinanceLeaseLiabilityPaymentsDue contextRef="c-5" decimals="-3" id="f-474" unitRef="usd">423000</us-gaap:FinanceLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="c-5" decimals="-3" id="f-475" unitRef="usd">277000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount contextRef="c-5" decimals="-3" id="f-476" unitRef="usd">65000</us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability contextRef="c-5" decimals="-3" id="f-477" unitRef="usd">2760000</us-gaap:OperatingLeaseLiability>
    <us-gaap:FinanceLeaseLiability contextRef="c-5" decimals="-3" id="f-478" unitRef="usd">358000</us-gaap:FinanceLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-5" decimals="-3" id="f-479" unitRef="usd">1096000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent contextRef="c-5" decimals="-3" id="f-480" unitRef="usd">201000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-5" decimals="-3" id="f-481" unitRef="usd">1664000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent contextRef="c-5" decimals="-3" id="f-482" unitRef="usd">157000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c-1" id="f-483">Commitments and Contingencies&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Licensing Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company has licensed technology for use in its diagnostic tests. In addition to the milestone payments required by these agreements, individual license agreements generally provide for ongoing royalty payments ranging from 2.0% to 7.0% on net sales of products which incorporate licensed technology, as defined in such agreements. Royalties are accrued when incurred and recorded in costs of revenue in the accompanying statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Supply Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In August 2024, the Company amended a supply agreement with one supplier for reagents, which includes pricing terms and minimum purchase commitments, through December 31, 2025, for new consumable products related to the Company's launch of the Anti-RA33 IgA, Anti-RA33 IgG and Anti-RA33 IgM biomarkers. The aggregate minimum annual purchase commitment related to such agreement for the year ending December 31, 2025 is $10.4 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Collaboration Obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In May 2021, the Company entered into an exclusive license agreement with Allegheny Health Network Research Institute (AHN), pursuant to which the Company is required to pay AHN a collaboration fee of $0.4 million per year. Collaboration expenses under the master research collaboration agreement were $0.3 million for each of the years ended December&#160;31, 2024 and 2023. Collaboration expenses under the AHN collaboration are included in research and development expenses in the accompanying statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Contingencies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnifications; including for subpoenas and other civil investigative demands, from governmental agencies, Medicare or Medicaid and managed care organizations reviewing billing practices or requesting comment on allegations of billing irregularities that are brought to their attention through billing audits or third parties. The Company's exposure under these agreements is unknown because it involves claims that may be made against the Company in the future, but have not yet been made or that the Company believes to be immaterial. The Company accrues a liability for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;From time to time, the Company may be subject to various legal proceedings that arise in the ordinary course of business activities. The Company does not believe the outcome of any such matters as of December&#160;31, 2024 will have a material effect on its financial position or results of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In October 2023, the Company resolved an investigation with the U.S. Attorney&#x2019;s Office for the District of Massachusetts that was initiated by a &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;qui tam &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;lawsuit (the October 2023 Lawsuit). Pursuant to a settlement agreement entered into by and between the Company and the U.S. Department of Justice (the Settlement Agreement), the Company made a single lump-sum remittance to the government in the amount of $0.7&#160;million, including interest, in connection with specimen processing arrangements that Exagen historically had with &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;physicians. The U.S. Attorney&#x2019;s Office dismissed this &#x201c;covered conduct&#x201d; in the October 2023 Lawsuit with prejudice, while non-covered conduct was dismissed without prejudice. The Department of Justice excused itself from the case in connection with the settlement. In November 2023, the complaint was unsealed by the court and served on Exagen by the relator. Exagen filed a motion to dismiss the complaint. In December 2023, the Company's insurance carrier provided reimbursement for certain defense costs the Company incurred in the October 2023&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Lawsuit. In February 2024, the relator filed a motion for leave to amend the complaint. Exagen opposed this motion, and all motions are still pending. The Company cannot predict when these matters will be resolved, the outcome of these matters, or their potential impact, which may materially and adversely affect the Company's business, prospects, and financial condition. The Company intends to vigorously defend against the claims being asserted in the complaint.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company's participation in federal healthcare programs is not affected by the Settlement Agreement.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <exdx:RoyaltyObligationPercentageOfSales
      contextRef="c-87"
      decimals="INF"
      id="f-484"
      unitRef="number">0.020</exdx:RoyaltyObligationPercentageOfSales>
    <exdx:RoyaltyObligationPercentageOfSales
      contextRef="c-88"
      decimals="INF"
      id="f-485"
      unitRef="number">0.070</exdx:RoyaltyObligationPercentageOfSales>
    <exdx:PurchaseObligationAmendedSupplyAgreementNumberOfSuppliers
      contextRef="c-89"
      decimals="INF"
      id="f-486"
      unitRef="supplier">1</exdx:PurchaseObligationAmendedSupplyAgreementNumberOfSuppliers>
    <us-gaap:PurchaseObligationDueInNextTwelveMonths contextRef="c-5" decimals="-5" id="f-487" unitRef="usd">10400000</us-gaap:PurchaseObligationDueInNextTwelveMonths>
    <exdx:CollaborationAgreementAnnualCollaborationFee contextRef="c-90" decimals="-5" id="f-488" unitRef="usd">400000</exdx:CollaborationAgreementAnnualCollaborationFee>
    <exdx:CollaborationAgreementCollaborationExpenses contextRef="c-91" decimals="-5" id="f-489" unitRef="usd">300000</exdx:CollaborationAgreementCollaborationExpenses>
    <exdx:CollaborationAgreementCollaborationExpenses contextRef="c-92" decimals="-5" id="f-490" unitRef="usd">300000</exdx:CollaborationAgreementCollaborationExpenses>
    <us-gaap:PaymentsForLegalSettlements contextRef="c-93" decimals="-5" id="f-491" unitRef="usd">700000</us-gaap:PaymentsForLegalSettlements>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="c-1" id="f-492">Fair Value Measurements&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The carrying values of the Company's cash, cash equivalents and restricted cash, accounts receivable, prepaid expenses and other current assets, accounts payable and accrued and other current liabilities are determined to be a Level 1 measurement. The carrying values of these items approximate their fair values due to their short-term nature. The estimated fair value of the Company's long-term borrowings is determined by Level 2 inputs and based primarily on quoted market prices for similar issues. As of December&#160;31, 2024, the Amended Loan Agreement had a carrying value of $19.1 million and a fair value of $19.2 million. As of December 31, 2023, the Amended Loan Agreement had a carrying value of $18.7&#160;million and a fair value of $19.7&#160;million. The estimated fair value of the Amended Loan Agreement was determined based on a discounted cash flow approach using available market information on discount and borrowing rates with similar terms, maturities, and credit ratings. The aggregate carrying value of the Company's other long-term borrowings as of December&#160;31, 2024 was $1.1&#160;million and approximated its fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Fair value is defined as the exchange price that would be received for an asset or an exit price paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The three-levels of the valuation hierarchy for disclosure of fair value measurements are defined as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:94.5pt;text-align:justify;text-indent:-72pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Level 1 -&#160;&#160;&#160;&#160;Unadjusted quoted prices in active markets for identical assets or liabilities;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:94.5pt;text-align:justify;text-indent:-72pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Level 2 -&#160;&#160;&#160;&#160;Inputs other than quoted prices included within Level 1 that are observable, unadjusted quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:94.5pt;text-align:justify;text-indent:-72pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Level 3 -&#160;&#160;&#160;&#160;Unobservable inputs that are supported by little or no market activity for the related assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The categorization of a financial instrument within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table sets forth the Company's financial instruments that were measured at fair value on a recurring basis within the fair value hierarchy (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:53.870%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.426%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.426%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.426%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.432%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Money market funds, included in cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:53.285%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.572%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.572%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.572%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.579%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Money market funds, included in cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The fair value of the Company's money market funds is based on quoted market prices.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="c-1" id="f-493">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The carrying values of the Company's cash, cash equivalents and restricted cash, accounts receivable, prepaid expenses and other current assets, accounts payable and accrued and other current liabilities are determined to be a Level 1 measurement. The carrying values of these items approximate their fair values due to their short-term nature. The estimated fair value of the Company's long-term borrowings is determined by Level 2 inputs and based primarily on quoted market prices for similar issues. As of December&#160;31, 2024, the Amended Loan Agreement had a carrying value of $19.1 million and a fair value of $19.2 million. As of December 31, 2023, the Amended Loan Agreement had a carrying value of $18.7&#160;million and a fair value of $19.7&#160;million. The estimated fair value of the Amended Loan Agreement was determined based on a discounted cash flow approach using available market information on discount and borrowing rates with similar terms, maturities, and credit ratings. The aggregate carrying value of the Company's other long-term borrowings as of December&#160;31, 2024 was $1.1&#160;million and approximated its fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Fair value is defined as the exchange price that would be received for an asset or an exit price paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The three-levels of the valuation hierarchy for disclosure of fair value measurements are defined as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:94.5pt;text-align:justify;text-indent:-72pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Level 1 -&#160;&#160;&#160;&#160;Unadjusted quoted prices in active markets for identical assets or liabilities;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:94.5pt;text-align:justify;text-indent:-72pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Level 2 -&#160;&#160;&#160;&#160;Inputs other than quoted prices included within Level 1 that are observable, unadjusted quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:94.5pt;text-align:justify;text-indent:-72pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Level 3 -&#160;&#160;&#160;&#160;Unobservable inputs that are supported by little or no market activity for the related assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The categorization of a financial instrument within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:LongTermDebt contextRef="c-94" decimals="-5" id="f-494" unitRef="usd">19100000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentFairValue contextRef="c-94" decimals="-5" id="f-495" unitRef="usd">19200000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:LongTermDebt contextRef="c-95" decimals="-5" id="f-496" unitRef="usd">18700000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentFairValue contextRef="c-95" decimals="-5" id="f-497" unitRef="usd">19700000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:NotesPayable contextRef="c-80" decimals="-5" id="f-498" unitRef="usd">1100000</us-gaap:NotesPayable>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="c-1" id="f-499">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table sets forth the Company's financial instruments that were measured at fair value on a recurring basis within the fair value hierarchy (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:53.870%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.426%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.426%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.426%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.432%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Money market funds, included in cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:53.285%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.572%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.572%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.572%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.579%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Money market funds, included in cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-96" decimals="-3" id="f-500" unitRef="usd">15144000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-97" decimals="-3" id="f-501" unitRef="usd">15144000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-98" decimals="-3" id="f-502" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-99" decimals="-3" id="f-503" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-100" decimals="-3" id="f-504" unitRef="usd">14386000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-101" decimals="-3" id="f-505" unitRef="usd">14386000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-102" decimals="-3" id="f-506" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-103" decimals="-3" id="f-507" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c-1" id="f-508">Stockholders' Equity&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Shelf Registration Statement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On November 17, 2023, the Company filed a registration statement on Form S-3, as amended (the 2023 Shelf Registration Statement), covering the offering, from time to time, of up to $150.0 million of common stock, preferred stock, debt securities, warrants and units. The 2023 Shelf Registration Statement became effective on November 29, 2023, and all $150.0&#160;million remain available for sale as of December&#160;31, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;At The Market Sales Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On September 15, 2022, the Company entered into a sales agreement, as amended on November 17, 2023 (the Sales Agreement) with TD Securities (USA) LLC as sales agent, pursuant to which the Company may offer and sell, from time to time, shares of Company common stock having an aggregate offering price of up to $50.0&#160;million. The Company is not obligated to sell any shares of Company common stock in the offering. As of December&#160;31, 2024, the Company has not sold any shares of its common stock pursuant to the Sales Agreement&lt;/span&gt;&lt;span style="color:#008080;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Outstanding Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following equity classified warrants to purchase common stock were outstanding as of December&#160;31, 2024:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:28.432%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.783%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Issuance date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Expiration date&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common stock warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;237,169&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;January 19, 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;January 19, 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common stock warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;67,086&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;March 31, 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;March 31, 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common stock warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;131&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;April 1, 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;April 1, 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common stock warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20,944&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;December 7, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;December 7, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common stock warrants (Exchange Warrants)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;804,951&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;June 22, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;None&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,130,281&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;No warrants to purchase common stock were exercised during the years ended December&#160;31, 2024 and 2023.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <exdx:SaleOfStockAuthorizedAmount contextRef="c-104" decimals="-3" id="f-509" unitRef="usd">150000000.0</exdx:SaleOfStockAuthorizedAmount>
    <exdx:SaleOfStockRemainingAuthorizedAmount contextRef="c-105" decimals="-3" id="f-510" unitRef="usd">150000000</exdx:SaleOfStockRemainingAuthorizedAmount>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-106" decimals="-5" id="f-511" unitRef="usd">50000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="c-1" id="f-512">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following equity classified warrants to purchase common stock were outstanding as of December&#160;31, 2024:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:28.432%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.783%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Issuance date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Expiration date&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common stock warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;237,169&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;January 19, 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;January 19, 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common stock warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;67,086&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;March 31, 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;March 31, 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common stock warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;131&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;April 1, 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;April 1, 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common stock warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20,944&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;December 7, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;December 7, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common stock warrants (Exchange Warrants)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;804,951&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;June 22, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;None&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,130,281&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-107"
      decimals="INF"
      id="f-513"
      unitRef="shares">237169</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-107"
      decimals="INF"
      id="f-514"
      unitRef="usdPerShare">1.84</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-108"
      decimals="INF"
      id="f-515"
      unitRef="shares">67086</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-108"
      decimals="INF"
      id="f-516"
      unitRef="usdPerShare">1.84</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-109"
      decimals="INF"
      id="f-517"
      unitRef="shares">131</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-109"
      decimals="INF"
      id="f-518"
      unitRef="usdPerShare">1.84</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-110"
      decimals="INF"
      id="f-519"
      unitRef="shares">20944</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-110"
      decimals="INF"
      id="f-520"
      unitRef="usdPerShare">14.32</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-111"
      decimals="INF"
      id="f-521"
      unitRef="shares">804951</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-111"
      decimals="INF"
      id="f-522"
      unitRef="usdPerShare">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="c-5" decimals="INF" id="f-523" unitRef="shares">1130281</us-gaap:ClassOfWarrantOrRightOutstanding>
    <exdx:StockIssuedDuringPeriodSharesWarrantsExercisedNet contextRef="c-1" decimals="INF" id="f-524" unitRef="shares">0</exdx:StockIssuedDuringPeriodSharesWarrantsExercisedNet>
    <exdx:StockIssuedDuringPeriodSharesWarrantsExercisedNet contextRef="c-7" decimals="INF" id="f-525" unitRef="shares">0</exdx:StockIssuedDuringPeriodSharesWarrantsExercisedNet>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="c-1" id="f-526">Stock Option Plan&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;2019 Incentive Award Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In September 2019, the Board adopted, and the Company's stockholders approved, the 2019 Plan. Under the 2019 Plan, which expires in September 2029, the Company may grant stock options, stock appreciation rights, restricted stock, RSUs and other awards to individuals who are then employees, officers, non-employee directors or consultants of the Company or its subsidiaries. The options generally expire ten years after the date of grant and are exercisable to the extent vested. Vesting is established by the Board and is generally four years from the date of grant or, for grants to new hires, date of hire. The 2019 Plan contains an "evergreen provision" that allows annual increases in the number of shares available for issuance on the first day of each calendar year through January 1, 2029 in an amount equal to the lesser of: (i) 4% of the outstanding capital stock on each December 31st, or (ii) such lesser amount determined by the Board. As of December&#160;31, 2024, 2,189,228 shares of common stock remained available for future awards. Pursuant to the evergreen provision, on January 1, 2025, an additional 705,613 shares of common stock became available for issuance under the 2019 Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;RSU activity under the Company's 2019 Plan is set forth below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:54.163%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.373%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.378%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&#160;of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Grant Date Fair Value Per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Intrinsic&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding, December&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,387,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Awards granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,324,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Awards released&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(413,202)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Awards canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(588,159)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding, December&#160;31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,710,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As of December&#160;31, 2024, all of the outstanding RSUs are unvested. The fair value of RSUs vested in the years ended December&#160;31, 2024 and 2023 was $0.9 million and $0.6&#160;million, respectively. The weighted average grant date fair value per share for RSUs granted during the years ended December&#160;31, 2024 and 2023 was $2.11 and $2.39, respectively. As of December&#160;31, 2024, total unrecognized compensation cost related to RSUs was $3.4 million, which is expected to be recognized over a remaining weighted-average vesting period of 2.8 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Stock option activity under the 2019 Plan is set forth below:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.367%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.911%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.888%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.918%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&#160;of&lt;br/&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&#160;Price Per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&#160;(Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Intrinsic&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding, December 31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;986,819&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.44&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;55,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(85,124)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(9,623)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(458,276)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding, December&#160;31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;489,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.53&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest, December&#160;31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;489,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.53&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Options exercisable, December&#160;31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;468,706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.42&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The weighted-average grant date fair value per share of options granted during the years ended December&#160;31, 2024 and 2023 was $1.44 and $2.17, respectively. The aggregate intrinsic value of options exercised during the years ended December&#160;31, 2024 and 2023 was $0.3 million and $0.2 million, respectively. The intrinsic value is calculated as the difference between the fair value of the Company's common stock and the exercise price of the stock options. The fair value of the Company's common stock was $4.10 and $1.99 per share at December&#160;31, 2024 and 2023, respectively. As of December&#160;31, 2024, total unrecognized compensation cost related to option awards was negligible.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;2019 Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In September 2019, the Board adopted, and the Company's stockholders approved, the ESPP. The ESPP became effective on the day the ESPP was adopted by the Board. The ESPP permits participants to purchase common stock through payroll deductions of up to 20% of their eligible compensation. The number of shares of common stock available for issuance under the ESPP will be annually increased on the first day of each calendar year during the term of the ESPP through January 1, 2029 in an amount equal to the lesser of (i) 1% of the outstanding capital stock on each December 31st, or (ii) such lesser amount determined by the Board. During the year ended December&#160;31, 2024, the Company issued 96,048 shares of common stock pursuant to scheduled purchases under the ESPP. As of December&#160;31, 2024, 523,744 shares of common stock remained available for issuance. Pursuant to the evergreen provision, on January 1, 2025, an additional 176,403 shares became available for issuance under the ESPP.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Stock-based compensation expense related to the ESPP for each of the years ended December&#160;31, 2024 and 2023 was less than $0.1 million. As of December&#160;31, 2024, total unrecognized compensation cost related to stock purchase rights granted under the ESPP was less than $0.1 million, which is expected to be recognized over a remaining weighted-average vesting period of 0.2 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Stock-Based Compensation Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Total non-cash stock-based compensation expense recorded related to options granted, RSUs granted and stock purchase rights granted under the ESPP in the statement of operations is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:69.075%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cost of revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Common stock reserved for future issuance consists of the following at December&#160;31, 2024:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:77.408%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.408%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.784%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Warrants to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,130,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common stock option grants issued and outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;489,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common stock reserved for issuance upon vesting of outstanding restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,710,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common stock available for grant under the 2019 Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,189,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common stock available for future issuance under ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;523,744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,042,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="c-112" id="f-527">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-112" id="f-528">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <exdx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage contextRef="c-113" decimals="2" id="f-529" unitRef="number">0.04</exdx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-114"
      decimals="INF"
      id="f-530"
      unitRef="shares">2189228</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <exdx:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesAuthorized
      contextRef="c-115"
      decimals="INF"
      id="f-531"
      unitRef="shares">705613</exdx:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesAuthorized>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock contextRef="c-1" id="f-532">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;RSU activity under the Company's 2019 Plan is set forth below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:54.163%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.373%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.378%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&#160;of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Grant Date Fair Value Per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Intrinsic&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding, December&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,387,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Awards granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,324,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Awards released&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(413,202)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Awards canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(588,159)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding, December&#160;31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,710,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-116"
      decimals="INF"
      id="f-533"
      unitRef="shares">1387459</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-116"
      decimals="2"
      id="f-534"
      unitRef="usdPerShare">4.24</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding contextRef="c-116" decimals="-3" id="f-535" unitRef="usd">2761000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-117"
      decimals="INF"
      id="f-536"
      unitRef="shares">1324275</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-117"
      decimals="2"
      id="f-537"
      unitRef="usdPerShare">2.11</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c-117"
      decimals="INF"
      id="f-538"
      unitRef="shares">413202</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-117"
      decimals="2"
      id="f-539"
      unitRef="usdPerShare">4.87</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c-117"
      decimals="INF"
      id="f-540"
      unitRef="shares">588159</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c-117"
      decimals="2"
      id="f-541"
      unitRef="usdPerShare">4.11</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-118"
      decimals="INF"
      id="f-542"
      unitRef="shares">1710373</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-118"
      decimals="2"
      id="f-543"
      unitRef="usdPerShare">2.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding contextRef="c-118" decimals="-3" id="f-544" unitRef="usd">7013000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested contextRef="c-117" decimals="-5" id="f-545" unitRef="usd">900000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested contextRef="c-119" decimals="-5" id="f-546" unitRef="usd">600000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-117"
      decimals="2"
      id="f-547"
      unitRef="usdPerShare">2.11</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-119"
      decimals="2"
      id="f-548"
      unitRef="usdPerShare">2.39</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="c-118" decimals="-5" id="f-549" unitRef="usd">3400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-117" id="f-550">P2Y9M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c-1" id="f-551">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Stock option activity under the 2019 Plan is set forth below:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.367%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.911%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.888%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.918%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&#160;of&lt;br/&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&#160;Price Per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&#160;(Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Intrinsic&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding, December 31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;986,819&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.44&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;55,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(85,124)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(9,623)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(458,276)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding, December&#160;31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;489,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.53&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest, December&#160;31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;489,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.53&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Options exercisable, December&#160;31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;468,706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.42&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c-6" decimals="INF" id="f-552" unitRef="shares">986819</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-6"
      decimals="2"
      id="f-553"
      unitRef="usdPerShare">11.87</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-7" id="f-554">P6Y5M8D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-6" decimals="-3" id="f-555" unitRef="usd">228000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c-1" decimals="INF" id="f-556" unitRef="shares">55500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-557"
      unitRef="usdPerShare">1.99</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-1" decimals="INF" id="f-558" unitRef="shares">85124</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-559"
      unitRef="usdPerShare">0.26</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="c-1" decimals="INF" id="f-560" unitRef="shares">9623</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-561"
      unitRef="usdPerShare">16.70</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod contextRef="c-1" decimals="INF" id="f-562" unitRef="shares">458276</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-563"
      unitRef="usdPerShare">16.46</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c-5" decimals="INF" id="f-564" unitRef="shares">489296</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-5"
      decimals="2"
      id="f-565"
      unitRef="usdPerShare">8.39</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-1" id="f-566">P6Y6M10D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-5" decimals="-3" id="f-567" unitRef="usd">370000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="c-5" decimals="INF" id="f-568" unitRef="shares">489296</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="c-5"
      decimals="2"
      id="f-569"
      unitRef="usdPerShare">8.39</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="c-1" id="f-570">P6Y6M10D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue contextRef="c-5" decimals="-3" id="f-571" unitRef="usd">370000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber contextRef="c-5" decimals="INF" id="f-572" unitRef="shares">468706</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="c-5"
      decimals="2"
      id="f-573"
      unitRef="usdPerShare">8.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 contextRef="c-1" id="f-574">P6Y5M1D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue contextRef="c-5" decimals="-3" id="f-575" unitRef="usd">332000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-1"
      decimals="2"
      id="f-576"
      unitRef="usdPerShare">1.44</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-7"
      decimals="2"
      id="f-577"
      unitRef="usdPerShare">2.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="c-5" decimals="-5" id="f-578" unitRef="usd">300000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="c-6" decimals="-5" id="f-579" unitRef="usd">200000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-5"
      decimals="2"
      id="f-580"
      unitRef="usdPerShare">4.10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-6"
      decimals="2"
      id="f-581"
      unitRef="usdPerShare">1.99</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate contextRef="c-120" decimals="2" id="f-582" unitRef="number">0.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="c-121"
      decimals="INF"
      id="f-583"
      unitRef="shares">96048</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-120"
      decimals="INF"
      id="f-584"
      unitRef="shares">523744</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <exdx:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesAuthorized
      contextRef="c-122"
      decimals="INF"
      id="f-585"
      unitRef="shares">176403</exdx:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesAuthorized>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-123" decimals="-5" id="f-586" unitRef="usd">100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-121" decimals="-5" id="f-587" unitRef="usd">100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions contextRef="c-120" decimals="-5" id="f-588" unitRef="usd">100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-121" id="f-589">P0Y2M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="c-1" id="f-590">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Total non-cash stock-based compensation expense recorded related to options granted, RSUs granted and stock purchase rights granted under the ESPP in the statement of operations is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:69.075%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cost of revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-124" decimals="-3" id="f-591" unitRef="usd">159000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-125" decimals="-3" id="f-592" unitRef="usd">191000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-126" decimals="-3" id="f-593" unitRef="usd">1374000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-127" decimals="-3" id="f-594" unitRef="usd">3174000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-128" decimals="-3" id="f-595" unitRef="usd">230000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-129" decimals="-3" id="f-596" unitRef="usd">252000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-1" decimals="-3" id="f-597" unitRef="usd">1763000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-7" decimals="-3" id="f-598" unitRef="usd">3617000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock contextRef="c-1" id="f-599">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Common stock reserved for future issuance consists of the following at December&#160;31, 2024:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:77.408%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.408%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.784%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Warrants to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,130,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common stock option grants issued and outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;489,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common stock reserved for issuance upon vesting of outstanding restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,710,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common stock available for grant under the 2019 Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,189,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common stock available for future issuance under ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;523,744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,042,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-130"
      decimals="INF"
      id="f-600"
      unitRef="shares">1130281</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-131"
      decimals="INF"
      id="f-601"
      unitRef="shares">489296</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-118"
      decimals="INF"
      id="f-602"
      unitRef="shares">1710373</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-114"
      decimals="INF"
      id="f-603"
      unitRef="shares">2189228</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-120"
      decimals="INF"
      id="f-604"
      unitRef="shares">523744</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="c-5" decimals="INF" id="f-605" unitRef="shares">6042922</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c-1" id="f-606">Income Taxes&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The provision for income taxes consists of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:65.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.823%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.823%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.545%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(33)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(33)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Deferred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total deferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(33)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The effective tax rate of our provision for income taxes differs from the federal statutory rate as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:69.660%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.823%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.823%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.498%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Federal statutory tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;State income taxes, net of federal tax benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Research and development tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Stock compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-deductible expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(15.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(18.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Effective tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Significant components of the Company&#x2019;s deferred tax assets at December&#160;31, 2024 and 2023 are shown below (in thousands). A valuation allowance has been established as realization of the Company&#x2019;s deferred tax assets has not met the more likely-than-not threshold requirement. If the Company&#x2019;s judgment changes and it is determined &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;that the Company will be able to realize these deferred tax assets, the tax benefits relating to any reversal of the valuation allowance on deferred tax assets will be accounted for as a reduction to income tax expense (in thousands).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:65.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.823%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.823%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.545%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;35,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32,479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Research and development tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accruals, reserves and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Indefinite lived assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Stock compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Capitalization of research and experimentation costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total gross deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;45,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less: valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(45,237)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(42,942)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Deferred tax assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Right of use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(592)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(814)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Basis differences in fixed and intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(116)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(287)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(708)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,101)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Changes in the valuation allowance for deferred tax assets during the years ended December&#160;31, 2024 and 2023, which related primarily to increases in net operating loss (NOL) carryforwards, research and development tax credits, and capitalization of research and experimentation costs were as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:65.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.823%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.823%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.545%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Valuation allowance at the beginning of the year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;42,942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;38,567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Increases recorded to income tax provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Valuation allowance at the end of the year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;45,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;42,942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;At December&#160;31, 2024 and 2023, the Company had federal NOL carryforwards of approximately $141.5 million and $129.8 million, respectively. At December&#160;31, 2024 and 2023, the Company had state NOL carryforwards of $98.7 million and $91.0 million, respectively. Approximately $43.5 million of the federal tax loss carryforwards will begin to expire in 2025, unless previously utilized. The federal NOL carryforwards generated after December 31, 2017 of $98.0 million will carryforward indefinitely. The Company&#x2019;s state tax loss carryforwards will begin to expire in 2030, unless previously utilized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;At December&#160;31, 2024, the Company's deferred tax assets are primarily comprised of federal and state tax NOL carryforwards. The Company completed a formal study through the year ended December 31, 2019 and determined ownership changes within the meaning of Internal Revenue Code (IRC), Section 382 had occurred in 2003, 2008, 2012, 2017 and 2019. Based on the analysis, $58.4 million of the Company's tax attribute carryforwards through December 31, 2017 cannot be utilized under IRC Section 382. The Company's ability to utilize NOL carryforwards generated after December 31, 2017 will not expire under the Tax Cuts and Jobs Act of 2017. The Company adjusted tax attribute carry forwards and deferred tax assets accordingly. As the deferred tax assets associated with the tax attribute carry forwards were fully offset by a valuation allowance, a corresponding reduction in the Company's valuation allowance was also recorded, resulting in no income tax impact.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company is subject to taxation in the United States and in various state jurisdictions. The Company&#x2019;s tax years for 2004 and forward are subject to examination by the U.S. and state tax authorities due to the carryforward of unutilized NOLs and research and development credits. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company recognizes interest and/or penalties related to income tax matters in its provision for income taxes. The Company does not have any material accruals for, and did not recognize any, material interest or penalties in these financial statements in any period presented. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Uncertain Tax Positions &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;At December&#160;31, 2024 and 2023, the Company had no unrecognized tax benefits. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company does not believe that the balance of unrecognized tax benefits will materially change within the next twelve months.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="c-1" id="f-607">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The provision for income taxes consists of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:65.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.823%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.823%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.545%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(33)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(33)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Deferred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total deferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(33)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-608" unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit contextRef="c-7" decimals="-3" id="f-609" unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-610" unitRef="usd">12000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="c-7" decimals="-3" id="f-611" unitRef="usd">33000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-612" unitRef="usd">12000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c-7" decimals="-3" id="f-613" unitRef="usd">33000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-614" unitRef="usd">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="c-7" decimals="-3" id="f-615" unitRef="usd">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-616" unitRef="usd">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="c-7" decimals="-3" id="f-617" unitRef="usd">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-618" unitRef="usd">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-7" decimals="-3" id="f-619" unitRef="usd">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-620" unitRef="usd">12000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-7" decimals="-3" id="f-621" unitRef="usd">33000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="c-1" id="f-622">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The effective tax rate of our provision for income taxes differs from the federal statutory rate as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:69.660%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.823%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.823%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.498%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Federal statutory tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;State income taxes, net of federal tax benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Research and development tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Stock compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-deductible expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(15.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(18.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Effective tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c-1" decimals="INF" id="f-623" unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c-7" decimals="INF" id="f-624" unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="c-1" decimals="3" id="f-625" unitRef="number">0.022</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="c-7" decimals="3" id="f-626" unitRef="number">0.022</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch contextRef="c-1" decimals="3" id="f-627" unitRef="number">-0.001</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch contextRef="c-7" decimals="3" id="f-628" unitRef="number">-0.001</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="c-1" decimals="3" id="f-629" unitRef="number">-0.059</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="c-7" decimals="3" id="f-630" unitRef="number">-0.034</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense contextRef="c-1" decimals="3" id="f-631" unitRef="number">-0.025</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense contextRef="c-7" decimals="3" id="f-632" unitRef="number">-0.014</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-1" decimals="3" id="f-633" unitRef="number">-0.152</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-7" decimals="3" id="f-634" unitRef="number">-0.185</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent contextRef="c-1" decimals="3" id="f-635" unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent contextRef="c-7" decimals="3" id="f-636" unitRef="number">-0.001</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-1" decimals="3" id="f-637" unitRef="number">-0.003</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-7" decimals="3" id="f-638" unitRef="number">-0.001</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="c-1" id="f-639">If the Company&#x2019;s judgment changes and it is determined &lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;that the Company will be able to realize these deferred tax assets, the tax benefits relating to any reversal of the valuation allowance on deferred tax assets will be accounted for as a reduction to income tax expense (in thousands).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:65.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.823%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.823%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.545%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;35,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32,479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Research and development tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accruals, reserves and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Indefinite lived assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Stock compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Capitalization of research and experimentation costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total gross deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;45,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less: valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(45,237)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(42,942)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Deferred tax assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Right of use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(592)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(814)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Basis differences in fixed and intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(116)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(287)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(708)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,101)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c-5" decimals="-3" id="f-640" unitRef="usd">35348000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c-6" decimals="-3" id="f-641" unitRef="usd">32479000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="c-5" decimals="-3" id="f-642" unitRef="usd">2360000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="c-6" decimals="-3" id="f-643" unitRef="usd">2353000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves contextRef="c-5" decimals="-3" id="f-644" unitRef="usd">955000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves contextRef="c-6" decimals="-3" id="f-645" unitRef="usd">1119000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves>
    <us-gaap:DeferredTaxAssetsOther contextRef="c-5" decimals="-3" id="f-646" unitRef="usd">2785000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther contextRef="c-6" decimals="-3" id="f-647" unitRef="usd">2547000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets contextRef="c-5" decimals="-3" id="f-648" unitRef="usd">276000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets contextRef="c-6" decimals="-3" id="f-649" unitRef="usd">300000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="c-5" decimals="-3" id="f-650" unitRef="usd">598000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="c-6" decimals="-3" id="f-651" unitRef="usd">1391000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <exdx:DeferredTaxAssetsLeaseLiability contextRef="c-5" decimals="-3" id="f-652" unitRef="usd">681000</exdx:DeferredTaxAssetsLeaseLiability>
    <exdx:DeferredTaxAssetsLeaseLiability contextRef="c-6" decimals="-3" id="f-653" unitRef="usd">925000</exdx:DeferredTaxAssetsLeaseLiability>
    <exdx:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCapitalizationOfResearchAndExperimentationCosts contextRef="c-5" decimals="-3" id="f-654" unitRef="usd">2942000</exdx:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCapitalizationOfResearchAndExperimentationCosts>
    <exdx:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCapitalizationOfResearchAndExperimentationCosts contextRef="c-6" decimals="-3" id="f-655" unitRef="usd">2929000</exdx:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCapitalizationOfResearchAndExperimentationCosts>
    <us-gaap:DeferredTaxAssetsGross contextRef="c-5" decimals="-3" id="f-656" unitRef="usd">45945000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross contextRef="c-6" decimals="-3" id="f-657" unitRef="usd">44043000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-5" decimals="-3" id="f-658" unitRef="usd">45237000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-6" decimals="-3" id="f-659" unitRef="usd">42942000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet contextRef="c-5" decimals="-3" id="f-660" unitRef="usd">708000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet contextRef="c-6" decimals="-3" id="f-661" unitRef="usd">1101000</us-gaap:DeferredTaxAssetsNet>
    <exdx:DeferredTaxLiabilitiesRightOfUseAssets contextRef="c-5" decimals="-3" id="f-662" unitRef="usd">592000</exdx:DeferredTaxLiabilitiesRightOfUseAssets>
    <exdx:DeferredTaxLiabilitiesRightOfUseAssets contextRef="c-6" decimals="-3" id="f-663" unitRef="usd">814000</exdx:DeferredTaxLiabilitiesRightOfUseAssets>
    <exdx:DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets contextRef="c-5" decimals="-3" id="f-664" unitRef="usd">116000</exdx:DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets>
    <exdx:DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets contextRef="c-6" decimals="-3" id="f-665" unitRef="usd">287000</exdx:DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets>
    <us-gaap:DeferredIncomeTaxLiabilities contextRef="c-5" decimals="-3" id="f-666" unitRef="usd">708000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities contextRef="c-6" decimals="-3" id="f-667" unitRef="usd">1101000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="c-5" decimals="-3" id="f-668" unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="c-6" decimals="-3" id="f-669" unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:SummaryOfValuationAllowanceTextBlock contextRef="c-1" id="f-670">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Changes in the valuation allowance for deferred tax assets during the years ended December&#160;31, 2024 and 2023, which related primarily to increases in net operating loss (NOL) carryforwards, research and development tax credits, and capitalization of research and experimentation costs were as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:65.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.823%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.823%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.545%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Valuation allowance at the beginning of the year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;42,942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;38,567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Increases recorded to income tax provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Valuation allowance at the end of the year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;45,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;42,942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SummaryOfValuationAllowanceTextBlock>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-6" decimals="-3" id="f-671" unitRef="usd">42942000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-11" decimals="-3" id="f-672" unitRef="usd">38567000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="c-1" decimals="-3" id="f-673" unitRef="usd">2295000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="c-7" decimals="-3" id="f-674" unitRef="usd">4375000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-5" decimals="-3" id="f-675" unitRef="usd">45237000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-6" decimals="-3" id="f-676" unitRef="usd">42942000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic contextRef="c-5" decimals="-5" id="f-677" unitRef="usd">141500000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic contextRef="c-6" decimals="-5" id="f-678" unitRef="usd">129800000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal contextRef="c-5" decimals="-5" id="f-679" unitRef="usd">98700000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal contextRef="c-6" decimals="-5" id="f-680" unitRef="usd">91000000.0</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration contextRef="c-5" decimals="-5" id="f-681" unitRef="usd">43500000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration contextRef="c-5" decimals="-5" id="f-682" unitRef="usd">98000000.0</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration contextRef="c-132" decimals="-5" id="f-683" unitRef="usd">58400000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-6" decimals="INF" id="f-684" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-5" decimals="INF" id="f-685" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock contextRef="c-1" id="f-686">401(k) Plan&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company sponsors an employee savings plan that qualifies as a deferred salary arrangement under Section 401(k) of the Code. Participating employees may defer up to the Internal Revenue Service annual contribution limit. Additionally, the Company may elect to make contributions into the savings plan at its sole discretion. For each of the years ended December&#160;31, 2024 and 2023, the Company made contributions to the 401(k) Plan at 4% of qualified employee compensation. For each of the years ended December&#160;31, 2024 and 2023, these contributions totaled approximately $0.8 million.&lt;/span&gt;&lt;/div&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent contextRef="c-1" decimals="2" id="f-687" unitRef="number">0.04</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent contextRef="c-7" decimals="2" id="f-688" unitRef="number">0.04</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <us-gaap:DefinedContributionPlanCostRecognized contextRef="c-1" decimals="-5" id="f-689" unitRef="usd">800000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized contextRef="c-7" decimals="-5" id="f-690" unitRef="usd">800000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="c-1" id="f-691">Segment Reporting&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the CODM in making decisions regarding resource allocation and assessing performance. The Company operates in a single operating segment focused on the design, development and commercialization of testing products which allow for the differential diagnosis, prognosis and monitoring of complex rheumatic, autoimmune and autoimmune-related disease. Segment revenue is primarily derived from the sale of the Company&#x2019;s testing products, most of which is attributable to its AVISE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; CTD test.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company&#x2019;s CODM is its Chief Executive Officer. The CODM assesses performance for the segment and decides how to allocate resources based on revenue and net loss as reported on the Statement of Operations, after taking into account the Company&#x2019;s strategic priorities, its cash balance and its expected use of cash. The CODM considers budget/forecast versus actual results on a quarterly basis when making decisions about the allocation of resources. The measure of segment assets is reported on the balance sheet as total assets and were $44.7 million and $56.9 million for the years ended December&#160;31, 2024 and 2023, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Segment revenue and net loss, including significant segment expenses regularly provided to the CODM are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.876%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.180%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.184%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="12" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;55,641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;52,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Costs of revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gross margin&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29,456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Segment operating expenses:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27,753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outside services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Facilities related&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Travel &amp;amp; entertainment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Stock compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total segment operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;46,748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;52,293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Loss from operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(13,636)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(22,837)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,234)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,335)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Loss before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(15,103)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(23,656)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(33)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Segment net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(15,115)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(23,689)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt; Other segment items included in Segment net loss include insurance expenses, trade show and conference expenses, fulfillment expenses, board compensation, clinical trial expenses, collaboration expenses and bank fees, among others.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:Assets contextRef="c-133" decimals="-5" id="f-692" unitRef="usd">44700000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-134" decimals="-5" id="f-693" unitRef="usd">56900000</us-gaap:Assets>
    <us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock contextRef="c-1" id="f-694">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Segment revenue and net loss, including significant segment expenses regularly provided to the CODM are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.876%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.180%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.184%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="12" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;55,641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;52,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Costs of revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gross margin&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29,456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Segment operating expenses:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27,753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outside services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Facilities related&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Travel &amp;amp; entertainment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Stock compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total segment operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;46,748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;52,293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Loss from operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(13,636)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(22,837)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,234)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,335)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Loss before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(15,103)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(23,656)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(33)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Segment net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(15,115)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(23,689)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt; Other segment items included in Segment net loss include insurance expenses, trade show and conference expenses, fulfillment expenses, board compensation, clinical trial expenses, collaboration expenses and bank fees, among others.&lt;/span&gt;&lt;/div&gt;</us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-135" decimals="-3" id="f-695" unitRef="usd">55641000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-136" decimals="-3" id="f-696" unitRef="usd">52548000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-135" decimals="-3" id="f-697" unitRef="usd">22529000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-136" decimals="-3" id="f-698" unitRef="usd">23092000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit contextRef="c-135" decimals="-3" id="f-699" unitRef="usd">33112000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c-136" decimals="-3" id="f-700" unitRef="usd">29456000</us-gaap:GrossProfit>
    <us-gaap:LaborAndRelatedExpense contextRef="c-135" decimals="-3" id="f-701" unitRef="usd">27753000</us-gaap:LaborAndRelatedExpense>
    <us-gaap:LaborAndRelatedExpense contextRef="c-136" decimals="-3" id="f-702" unitRef="usd">27070000</us-gaap:LaborAndRelatedExpense>
    <exdx:OutsideServicesExpense contextRef="c-135" decimals="-3" id="f-703" unitRef="usd">4253000</exdx:OutsideServicesExpense>
    <exdx:OutsideServicesExpense contextRef="c-136" decimals="-3" id="f-704" unitRef="usd">5920000</exdx:OutsideServicesExpense>
    <us-gaap:OccupancyNet contextRef="c-135" decimals="-3" id="f-705" unitRef="usd">3674000</us-gaap:OccupancyNet>
    <us-gaap:OccupancyNet contextRef="c-136" decimals="-3" id="f-706" unitRef="usd">5125000</us-gaap:OccupancyNet>
    <us-gaap:TravelAndEntertainmentExpense contextRef="c-135" decimals="-3" id="f-707" unitRef="usd">2440000</us-gaap:TravelAndEntertainmentExpense>
    <us-gaap:TravelAndEntertainmentExpense contextRef="c-136" decimals="-3" id="f-708" unitRef="usd">2469000</us-gaap:TravelAndEntertainmentExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-135" decimals="-3" id="f-709" unitRef="usd">1604000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-136" decimals="-3" id="f-710" unitRef="usd">3426000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-135" decimals="-3" id="f-711" unitRef="usd">1041000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-136" decimals="-3" id="f-712" unitRef="usd">1426000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:SegmentReportingOtherItemAmount contextRef="c-135" decimals="-3" id="f-713" unitRef="usd">5983000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:SegmentReportingOtherItemAmount contextRef="c-136" decimals="-3" id="f-714" unitRef="usd">6857000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:OperatingExpenses contextRef="c-135" decimals="-3" id="f-715" unitRef="usd">46748000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-136" decimals="-3" id="f-716" unitRef="usd">52293000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c-135" decimals="-3" id="f-717" unitRef="usd">-13636000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-136" decimals="-3" id="f-718" unitRef="usd">-22837000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpenseNonoperating contextRef="c-135" decimals="-3" id="f-719" unitRef="usd">2234000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating contextRef="c-136" decimals="-3" id="f-720" unitRef="usd">2335000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InvestmentIncomeInterest contextRef="c-135" decimals="-3" id="f-721" unitRef="usd">767000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest contextRef="c-136" decimals="-3" id="f-722" unitRef="usd">1516000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:IncomeLossAttributableToParent contextRef="c-135" decimals="-3" id="f-723" unitRef="usd">-15103000</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeLossAttributableToParent contextRef="c-136" decimals="-3" id="f-724" unitRef="usd">-23656000</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-135" decimals="-3" id="f-725" unitRef="usd">12000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-136" decimals="-3" id="f-726" unitRef="usd">33000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss contextRef="c-135" decimals="-3" id="f-727" unitRef="usd">-15115000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-136" decimals="-3" id="f-728" unitRef="usd">-23689000</us-gaap:NetIncomeLoss>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
